## Contents

Editors ................................................................................................................................. 5  
Dedication .......................................................................................................................... 8  
Preface ............................................................................................................................... 8  
Acknowledgments ............................................................................................................. 9  

### Part I - Overview of Syndromes

Section 1 - Introduction .................................................................................................... 9  
Pathology of Familial Tumor Syndromes ........................................................................ 9  
Clinical Diagnosis and Management of Familial/Hereditary Tumor Syndromes ............. 22  

Section 2 - Syndromes ..................................................................................................... 32  
Ataxia-Telangiectasia Syndrome ..................................................................................... 32  
Basal Cell Nevus Syndrome/Gorlin Syndrome ............................................................... 36  
Beckwith-Wiedemann Syndrome .................................................................................... 44  
Birt-Hogg-Dubé Syndrome .............................................................................................. 51  
Bloom Syndrome ............................................................................................................. 58  
Carney Complex Including LAMB Syndrome ............................................................... 61  
Costello Syndrome .......................................................................................................... 71  
Denys-Drash Syndrome .................................................................................................. 75  
Dyskeratosis Congenita .................................................................................................... 82  
Familial Acute Myeloid Leukemia .................................................................................... 89  
Familial Adenomatous Polyposis ..................................................................................... 96  
Familial Chordoma ........................................................................................................... 104  
Familial Chronic Lymphocytic Leukemia ....................................................................... 108  
Familial Gastrointestinal Stromal Tumor ......................................................................... 111  
Familial Hodgkin Lymphoma .......................................................................................... 116  
Familial Isolated Hyperparathyroidism .......................................................................... 122  
Familial Non-Hodgkin Lymphoma .................................................................................. 129  
Familial Nonmedullary Thyroid Carcinoma ..................................................................... 133  
Familial Plasma Cell Myeloma ......................................................................................... 140  
Familial Testicular Tumor ................................................................................................. 144  
Familial Uveal Melanoma ................................................................................................. 148  
Familial Wilms Tumor ...................................................................................................... 152  
Fanconi Anemia .............................................................................................................. 156  
Hereditary Breast/Ovarian Cancer Syndrome: BRCA1 ................................................ 159  
Hereditary Breast/Ovarian Cancer Syndrome: BRCA2 ................................................ 166  
Hereditary Diffuse Gastric Cancer .................................................................................. 173  
Hereditary Hyperparathyroidism-Jaw Tumor Syndrome ................................................ 177  
Hereditary Leiomyomatosis and Renal Cell Carcinoma ................................................ 184  
Hereditary Multiple Exostosis ......................................................................................... 191  
Hereditary Cutaneous Melanoma .................................................................................... 195  
Hereditary Neuroblastoma ............................................................................................... 203  
Hereditary Pancreatic Cancer Syndrome ...................................................................... 209  
Hereditary Papillary Renal Cell Carcinoma ................................................................... 213  
Hereditary Paraganglioma/Pheochromocytoma Syndromes .......................................... 217  
Hereditary Prostate Cancer ............................................................................................. 230  
Hereditary Renal Epithelial Tumors, Others ................................................................... 233  
Howel-Evans Syndrome/Keratosis Palaire and Plantares With Esophageal Cancer ...... 240  
Juvenile Polyposis Syndrome ......................................................................................... 245  
Li-Fraumeni Syndrome/Li-Fraumeni-Like Syndrome .................................................... 251  
Lynch Syndrome ............................................................................................................ 258  
Melanoma/Pancreatic Carcinoma Syndrome .................................................................. 264  
Multiple Endocrine Neoplasia Type 1 ............................................................................ 268  
Multiple Endocrine Neoplasia Type 2/Familial Medullary Thyroid Carcinoma ............. 275  
MYH-Associated Polyposis ............................................................................................. 287  
Neurofibromatosis Type 1 ............................................................................................... 291  
Neurofibromatosis Type 2 ............................................................................................... 303  
Peutz-Jeghers Syndrome ............................................................................................... 312
Diagnostic Pathology: Familial Cancer Syndromes

PTEN-Hamartoma Tumor Syndromes ................................................................. 315
Rhabdoid Predisposition Syndrome .............................................................. 325
Schwannomatosis ....................................................................................... 333
Tuberous Sclerosis Complex ....................................................................... 339
von Hippel-Lindau Syndrome ................................................................. 349
Werner Syndrome/Progeria ........................................................................ 362
Wilms Tumor-Associated Syndrome ...................................................... 369
Xeroderma Pigmentosum ......................................................................... 373

Part II - Diagnoses Associated With Specific Syndromes .......................... 380

Section 1 - Breast ....................................................................................... 380
Breast Carcinoma, Female .......................................................................... 380
Breast Carcinoma, Male ............................................................................... 391

Section 2 - Blood and Bone Marrow ....................................................... 398
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma .............. 398
Diffuse Large B-Cell Lymphoma ................................................................. 408
Follicular Lymphoma ................................................................................. 418
Hodgkin Lymphoma .................................................................................. 433
Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia .......... 445
Mantle Cell Lymphoma .............................................................................. 452
Myeloid Neoplasms ..................................................................................... 458

Section 3 - Bone and Soft Tissue ............................................................... 474
Chondrosarcoma ....................................................................................... 474
Chordoma .................................................................................................. 483
Malignant Peripheral Nerve Sheath Tumor ............................................... 493
Melanotic Neuroectodermal Tumor of Infancy ......................................... 503
Osteosarcoma ............................................................................................ 510
Rhabdomyosarcoma ................................................................................ 519
Schwannoma ............................................................................................ 529

Section 4 - Head and Neck ....................................................................... 539
Squamous Cell Carcinoma, Head and Neck ............................................. 539
Endolymphatic Sac Tumor ........................................................................ 549

Section 5 - Endocrine ................................................................................. 556
Adrenal Cortex ............................................................................................ 556
Adrenal Medulla ......................................................................................... 589
Pancreas ..................................................................................................... 638
Parathyroid ................................................................................................. 647
Pituitary ...................................................................................................... 671
Thyroid, Nonmedullary ............................................................................. 684
Thyroid, Medullary ................................................................................... 708

Section 6 - Gastrointestinal ..................................................................... 727
Gastrointestinal Tract ................................................................................. 727
Hepatobiliary and Pancreas ....................................................................... 777

Section 7 - Genitourinary ........................................................................ 812
Collecting System ....................................................................................... 812
Genital Tract .............................................................................................. 828
Kidney ......................................................................................................... 861

Section 8 - Gynecology ........................................................................... 908
Cervical Carcinoma ................................................................................... 908
Endometrial Carcinoma ........................................................................... 912
Fallopian Tube Carcinoma ........................................................................ 918
Ovarian Carcinoma ................................................................................... 922

Section 9 - Nervous System ................................................................... 928
Astrocytoma ............................................................................................... 928
Choroid Plexus Tumors ........................................................................... 949
Ependymoma ............................................................................................. 955
Medulloblastoma/CNS-PNET ................................................................. 961
Meningioma ............................................................................................. 971
Pineoblastoma .......................................................................................... 977
Retinoblastoma ......................................................................................... 981
Editors

Editors
Vania Nosé MD, PhD
Director of Anatomic and Molecular Pathology
Associate Chief of Pathology
Massachusetts General Hospital
Professor of Pathology
Harvard Medical School
Boston, Massachusetts
Series Editor
Gladell P. Paner MD
Assistant Professor
Departments of Pathology and Surgery
Section of Urology
University of Chicago Medical Center
Chicago, Illinois
Joel K. Greenson MD
Professor of Pathology
Director of Gastrointestinal Pathology
Department of Pathology
University of Michigan Medical School
Ann Arbor, Michigan
Fausto J. Rodríguez MD
Assistant Professor of Pathology and Oncology
Johns Hopkins University School of Medicine
Baltimore, Maryland
Christine J. Ko MD
Associate Professor of Dermatology and Pathology
Yale University
New Haven, Connecticut
Elizabeth Morgan MD
Instructor, Harvard Medical School
Department of Pathology
Brigham and Women's Hospital
Boston, Massachusetts
Matthew R. Lindberg MD
Assistant Professor of Pathology
Department of Pathology
Directory of Immunohistochemistry
University of Arkansas for Medical Sciences
Little Rock, Arkansas
David G. Hicks MD
Professor
Director, Surgical Pathology Unit
Department of Pathology and Laboratory Medicine
University of Rochester Medical Center
Rochester, New York
Susan C. Lester MD, PhD
Chief, Breast Pathology Services
Brigham and Women's Hospital
Assistant Professor, Harvard Medical School
Staff Pathologist, Dana Farber Cancer Institute
Boston, Massachusetts
Fabiola Medeiros MD
Assistant Professor of Pathology
University of Southern California
Los Angeles, California
Contributors

Cesar A. Moran, MD
Professor and Deputy Chair
Chief, Thoracic Pathology
Department of Pathology
University of Texas MD Anderson Cancer Center
Houston, Texas

David S. Cassarino, MD, PhD
Consultant Dermatopathologist and Staff Pathologist
Southern California Permanente Medical Group
Los Angeles, California

Lori A. Erickson, MD
Associate Professor of Pathology
Department of Laboratory Medicine and Pathology
Mayo Clinic
Rochester, Minnesota

Elizabeth A. Montgomery, MD
Professor of Pathology and Oncology and
Orthopedic Surgery
Johns Hopkins University Medical Institutions
Baltimore, Maryland

Mari Mino-Kenudson, MD
Associate Professor, Harvard Medical School
Department of Pathology
Massachusetts General Hospital
Boston, Massachusetts

Michiya Nishino, MD, PhD
Department of Pathology
Beth Israel Deaconess Medical Center
Instructor in Pathology, Harvard Medical School
Boston, Massachusetts

Arthur S. Tischler, MD
Professor of Pathology
Tufts University School of Medicine
Tufts Medical Center
Boston, MA

Carla S. Wilson, MD, PhD
Professor of Pathology
Department of Pathology
University of New Mexico Health Sciences Center
Albuquerque, NM

Carlos E. Bueso-Ramos, MD, PhD
Associate Professor
Department of Hematopathology
University of Texas MD Anderson Cancer Center
Houston, Texas

Qian-Yun Zhang, MD, PhD
Associate Professor of Pathology
Department of Pathology
University of New Mexico Health Sciences Center
Albuquerque, New Mexico
Jessica M. Comstock, MD  
Assistant Professor  
University of Utah Department of Pathology  
Division of Pediatric Pathology  
Primary Children's Hospital  
Salt Lake City, Utah  
Soheil Sam Dadras, MD, PhD  
Associate Professor of Dermatology and Genetics and Developmental Biology  
UCONN Health Center  
Farmington, Connecticut  
Cyril Fisher, MD, DSc, FRCPath  
Consultant Histopathologist  
Royal Marsden NHS Foundation Trust  
Professor of Tumor Pathology  
Institute of Cancer Research  
University of London  
London, United Kingdom  
Aliya N. Husain, MD  
Professor of Pathology  
University of Chicago  
Chicago, Illinois  
Grace E. Kim, MD  
Professor of Pathology  
Department of Pathology  
University of California San Francisco  
San Francisco, California  
Gregory Y. Lauwers, MD  
Vice Chair of Pathology  
Massachusetts General Hospital  
Professor of Pathology  
Harvard Medical School  
Boston, Massachusetts  
Ozgur Mete, MD  
Assistant Professor  
Consultant Endocrine Pathologist  
Department of Laboratory Medicine & Pathobiology  
University Health Network  
University of Toronto  
Toronto, Canada  
Joseph Misdraji, MD  
Associate Pathologist  
Pathology Service  
Massachusetts General Hospital  
Boston, Massachusetts  
Alexandros D. Polydorides, MD, PhD  
Associate Professor  
Department of Pathology  
Icahn School of Medicine at Mount Sinai  
New York, New York  
Steven S. Shen, MD, PhD
Dedication

To my wonderful sons and best friends, Gustave, Erick, and Philip, for making my life complete.
To my dear parents, Dalva and Antonio, for their teaching, continuous support, and guidance.
To my brothers, Dalton and Walton, and their families, for their tremendous support and invaluable friendship.
I would like to thank my coauthors, Drs. Joel Greenson, Gladell Paner, Fausto Rodríguez, Christine Ko, Elizabeth Morgan, Matthew Lindberg, Susan Lester, David Hicks, and Fabiola Medeiros, for their contributions, wonderful work, and dedication in completing this project.
To Dr. J. Aidan Carney, for sharing his knowledge on familial cancer syndromes with us.
To Dr. A. John Iafrate, for his careful chapter review on the clinical and molecular aspects of familial cancer syndromes.
A special thank you to Dave Chance, Kellie Heap, and Laura Sesto from the Amirsys team for their patience and careful work in helping us make this book a reality.

Preface

Welcome to Diagnostic Pathology: Familial Cancer Syndromes!
Diagnostic Pathology: Familial Cancer Syndromes features a comprehensive review of the top inherited tumor syndromes. It is becoming increasingly well recognized that a given familial tumor syndrome may be very heterogenous in clinical appearance and that unrecognized patients may present initially with an apparently isolated tumor. Therefore, it is crucial for surgical pathologists to be aware of the specific gross and microscopic findings that suggest a possible syndromic association.
Written by well-known experts in the field, this book with over 164 chapters will help surgical pathologists, clinicians, fellows, and residents understand the critical aspects of diagnosing familial tumors and differentiating these from their sporadic counterpart. It includes detailed gross and histologic features of syndromic-associated neoplasms with associated manifestations and clinical implications.
The book is organized in 3 parts:
The first part, “Overview of Syndromes,” has the detailed description of the major syndromes within 56 chapters, genes involved, associated tumors, and diagnostic criteria. This part also contains tables that may be helpful in better classifying the diseases and the associated syndromes. Each syndrome discussed includes all benign and malignant tumors occurring in that specific syndrome as well as the differential diagnosis.
The second part, “Diagnoses Associated with Specific Syndromes,” discusses in detail the diseases occurring within the syndromes described on part 1. The diagnoses are conveniently grouped according to the gland/organ/tissue involved. Distinct diseases are described, highlighting the characteristics of the tumors according to the different syndromes. The book points out some of the distinct characteristics of tumors found in inherited tumor syndrome that distinguishes these tumors from tumors in a sporadic setting.
The third part, “ Syndromes by Organ Location,” is also divided by organ/subspecialty and distributed in 26 chapters. This part has tables with “easy to find” possible syndromes by organ, including the differential diagnosis.
We hope that Diagnostic Pathology: Familial Cancer Syndromes will guide pathologists and clinicians to master diagnostic criteria when diagnosing tumors associated with inherited tumor syndromes.

Vania Nosé, MD, PhD
Director of Anatomic and Molecular Pathology
Associate Chief of Pathology
Massachusetts General Hospital
Professor of Pathology
Harvard Medical School
Boston, Massachusetts
Part I - Overview of Syndromes

Section 1 - Introduction

Pathology of Familial Tumor Syndromes

Vania Nosé, MD, PhD
Graphic representation of abdominal lesions seen in patients with von Hippel-Lindau syndrome shows the bilateral and multiple renal cysts $\rightarrow$, renal tumors $\rightarrow$, pancreatic cysts $\rightarrow$, and pheochromocytoma $\rightarrow$. 
The characteristic lesions of tuberous sclerosis in the CNS include cortical tubers, subependymal nodules identifiable in the walls of the lateral ventricles, and a subependymal giant cell astrocytoma.

**INTRODUCTION**

Hereditary Syndromes: Practical Guide to Pathological Recognition

- Diverse neoplasias are a common finding in patients with a genetic predisposition to cancer
- It is becoming increasingly well recognized that a given familial tumor syndrome may be very heterogeneous in clinical appearance
- Patients without overt clinical signs of their underlying syndrome may present initially for treatment of a tumor
- As molecular diagnostic testing for these familial diseases has become more readily available, the heterogeneous clinical appearance seen in many syndromes has become better recognized
- Awareness of important manifestations associated with each syndrome that might provide additional clues to a hereditary/familial neoplasia syndrome is also important
- Identification of hereditary cases and early diagnosis makes preventive surgery and adequate treatment possible
- Most of the patients with familial disease are asymptomatic and are discovered through genetic screening in predisposing families
- All patients identified as having familial tumors should then be screened for the familial disease’s associated mutation
- Vast majority of tumors occurring in a familial setting are multiple, bilateral, and involve multiple organs
- Many surgical specimens are received from patients who have a known syndrome diagnosis at time of surgery
  - Pathologist may be 1st physician to suggest possibility of a syndromic association based on presence of unique pathologic findings in a tumor resection specimen
- Gross and histological features that are evaluated in routine tumor resection specimens might suggest each individual syndrome
In their pathological examinations, it is important for surgical pathologists to be aware of specific gross and microscopic findings that suggest a possible syndromic association. Some tumors frequently display characteristic clinical, biochemical, and histopathological features that, although not pathognomonic, can be helpful in suggesting an inherited disease as the underlying etiology and distinguishing these tumors from sporadic cases.

Recognition of Morphological Characteristics That Indicate Familial Tumor Syndrome
- Awareness of pathologic features of neoplasms seen in a variety of hereditary/familial neoplasia syndromes is crucial for diagnosis.
- Pathological findings suggestive of a familial or inherited tumor syndromes or findings specific for a syndrome are:
  - Tumors occurring at a younger age than the sporadic counterpart
  - Multiple tumors
  - Bilateral tumors
  - Tumors involving multiple organs and systems
  - Tumors associated with multiple lesions
  - Tumors associated with multiple hamartomatous lesions
  - Specific location of a tumor
  - Unique morphological features of a tumor
  - Presence of precursor lesions
  - Presence of multiple benign lesions
- Characteristic and distinct pathology findings in some of these syndromes should alert the pathologist of a possible familial cancer syndrome.

Pathology Reporting
- If the constellation of pathology findings strongly suggests a potential syndromic association:
  - Consult medical records for the diagnosis of a potential syndrome
  - Contact clinician to discuss possibility of a genetic syndrome
  - Pathologists should notify clinicians about this possibility, considering appropriate molecular testing.
- For reporting purposes, diagnosis of a lesion or a neoplasm should use same criteria and terminology as for sporadic lesions and tumors:
  - Comment suggesting a possible association with a genetic disease is recommended.
    - To document possibility of specific genetic association
- Final diagnostic commentary to highlight differential diagnostic issues that frequently arise when these diagnoses are considered.

HEREDITARY SYNDROMES KNOWN TO BE ASSOCIATED WITH NEOPLASIA

Hereditary Syndromes
- Some hereditary syndromes are known to be associated with neoplasia and have unique &/or characteristic pathological features.
- Characteristic and distinct pathology findings in some of these syndromes should alert the pathologist of a possible familial cancer syndrome.

ENDOCRINE SYSTEM

Hereditary Syndromes Known to be Associated With Thyroid Neoplasia
- Medullary thyroid carcinoma (MTC)
  - Multiple endocrine neoplasia 2A (MEN2A)
  - Multiple endocrine neoplasia 2B (MEN2B)
  - Familial medullary thyroid carcinoma (FMTC)
- Cribriform morular papillary thyroid carcinoma
  - Familial adenomatous polyposis (FAP) syndrome
    - Cribriform-morular variant of papillary thyroid carcinoma (CMV-PTC) was described originally as FAP-associated thyroid carcinoma
- Numerous adenomatous nodules, follicular adenomas, and follicular carcinoma
  - PTEN-hamartoma tumor syndrome (PHTS)/Cowden disease
    - Presence of numerous multiple adenomatous nodules (MANs) or follicular thyroid carcinoma (FC) in younger patients should raise suspicion for diagnosis of PHTS
  - Carney complex
- Oncocytic tumors
  - Li-Fraumeni syndrome
  - Familial oncocytic neoplasms
  - McCune-Albright syndrome
  - Tuberosous sclerosis complex

**Hereditary Syndromes Known to be Associated With Adrenal Neoplasia**

- Adrenal cortical tumors
  - Beckwith-Wiedemann syndrome
  - Li-Fraumeni syndrome
  - Multiple endocrine neoplasia 1
  - Carney complex
  - Lynch syndrome
  - Congenital adrenal hyperplasia

**Hereditary Syndromes Known to be Associated With Parathyroid Neoplasia**

- Multiple endocrine neoplasia 1
  - Hereditary hyperparathyroidism-jaw tumor syndrome
  - Familial isolated hyperparathyroidism syndrome
  - Multiple endocrine neoplasia 2A
  - Neonatal severe primary hyperparathyroidism

**Hereditary Syndromes Known to be Associated With Pituitary Neoplasia**

- Multiple endocrine neoplasia 1
  - Familial pituitary adenoma syndrome
  - Familial isolated pituitary adenoma syndrome

**Hereditary Syndromes Known to be Associated With Endocrine Pancreas Neoplasia**

- Multiple endocrine neoplasia 1
  - Familial adenomatous polyposis
  - Tuberosous sclerosis complex
  - Von Hippel-Lindau syndrome

**Hereditary Syndromes Known to be Associated With PGL/PCC**

- Multiple endocrine neoplasia 2A
  - Multiple endocrine neoplasia 2B
  - von Hippel-Lindau syndrome
  - Neurofibromatosis 1
  - Familial paraganglioma type 1 (PGL1)
  - Familial PGL2
  - Familial PGL3
  - Familial PGL4
  - Carney-Stratakis syndrome
  - Familial pheochromocytoma (PCC) 2q
  - MAX-related
  - SDHA-related

**GENITOURINARY TRACT**

**Hereditary Syndromes Known to be Associated With Renal Neoplasia**

- von Hippel-Lindau
  - Hereditary papillary renal cell carcinoma (RCC)
  - Hereditary leiomyomatosis RCC
  - Birt-Hogg-Dubé
  - P.I(1):4

- Tuberous sclerosis complex
- Succinate dehydrogenase (SDH) germline mutation
- Lynch syndrome
- Heritable sickle cell hemoglobinopathy and medullary carcinoma of kidney
- Hyperparathyroidism-jaw tumor syndrome
- PTEN-hamartoma tumor syndrome
- Constitutional chromosome 3 translocation
• Wilms tumor syndrome

Hereditary Syndromes Known to be Associated With Testicle Neoplasia
• Carney complex
• Li-Fraumeni syndrome
• Peutz-Jeghers syndrome
• Renal cell carcinoma and leiomyomas
• Xeroderma pigmentosus

Hereditary Syndromes Known to be Associated With Bladder and Ureter Neoplasia
• Lynch syndrome

GASTROINTESTINAL TRACT
Hereditary Syndromes Known to be Associated With Esophagus, Stomach, and Intestinal Neoplasia
• Familial adenomatous polyposis
• Juvenile polyposis
• Familial gastrointestinal stromal tumor
• Hereditary diffuse gastric cancer
• MYH-associated polyposis
• Peutz-Jeghers syndrome
• Breast/ovarian BRCA1 and BRCA2
• PTEN-hamartoma tumor syndrome
• Li-Fraumeni syndrome
• Bloom syndrome
• Dyskeratosis congenita
• Gastrointestinal stromal tumor syndrome
• Neurofibromatosis 1
• Multiple endocrine neoplasia 1

Hereditary Syndromes Known to be Associated With Pancreas Neoplasia
• von Hippel-Lindau syndrome
• Breast/ovarian BRCA1 and BRCA2
• Li-Fraumeni syndrome
• Familial adenomatous polyposis
• Dyskeratosis congenita
• Juvenile polyposis
• Familial melanoma
• Multiple endocrine neoplasia 1
• Peutz-Jeghers syndrome
• Carney complex
• Tuberosclerosis
• Hereditary pancreatic cancer syndrome

Hereditary Syndromes Known to be Associated With Liver Neoplasia
• Breast/ovarian BRCA2
• Familial adenomatous polyposis
• PTEN-hamartoma tumor syndrome
• Beckwith-Wiedemann syndrome
• von Hippel-Lindau syndrome
• Lynch syndrome

CENTRAL NERVOUS SYSTEM
Hereditary Syndromes Known to be Associated With CNS and PNS Neoplasia
• Ataxia-telangiectasia
• Familial uveal melanoma
• Hereditary retinoblastoma
• Neurofibromatosis type 1
• Neurofibromatosis type 2
• Rhabdoid predisposition syndrome
• Schwannomatosis
• Tuberous sclerosis complex
• von Hippel-Lindau syndrome
• Multiple meningoma syndrome
Diagnostic Pathology: Familial Cancer Syndromes

- Pleuropulmonary blastoma

**SKIN**

Hereditary Syndromes Known to be Associated With Skin Neoplasia

- Carney complex
- PTEN-hamartoma tumor syndrome
- Basal cell nevus syndrome
- Beckwith-Wiedemann syndrome
- Birt-Hogg-Dubé syndrome
- Dyskeratosis congenita
- Hereditary multiple melanoma
- Howell-Evans syndrome
- Melanoma pancreatic carcinoma syndrome
- Werner syndrome

**BREAST**

Hereditary Syndromes Known to be Associated With Breast Neoplasia

- BRCA1 hereditary breast &/or ovarian cancer syndrome
- BRCA2 hereditary breast &/or ovarian cancer syndrome
- Li-Fraumeni syndrome
- Familial gastric cancer and breast lobular cancer syndrome
- PTEN-hamartoma tumor syndrome
- Peutz-Jeghers syndrome
- Ataxia-telangiectasia syndrome

**GYNECOLOGIC**

Hereditary Syndromes Known to be Associated With Uterine Neoplasia

- BRCA1 hereditary breast &/or ovarian cancer syndrome
- BRCA2 hereditary breast &/or ovarian cancer syndrome
- Lynch syndrome
- PTEN-hamartoma tumor syndrome
- Peutz-Jeghers syndrome
- Hereditary leiomyomatosis and renal cell carcinoma
- von Hippel-Lindau syndrome

Hereditary Syndromes Known to be Associated With Ovarian Neoplasia

- BRCA1 hereditary breast &/or ovarian cancer syndrome
- BRCA2 hereditary breast &/or ovarian cancer syndrome
- von Hippel-Lindau syndrome
- Peutz-Jeghers syndrome
- Lynch syndrome

**LUNG**

Hereditary Syndromes Known to be Associated With Lung Neoplasia

- BRCA2 hereditary breast &/or ovarian cancer syndrome
- Hereditary retinoblastoma syndrome
- Familial pleuropulmonary blastoma
- Tuberosis sclerosis complex
- Carney triad
- Bloom syndrome
- Li-Fraumeni syndrome
- Xeroderma pigmentosum
- Peutz-Jeghers syndrome

**HEAD AND NECK**

Hereditary Syndromes Known to be Associated With Head and Neck Neoplasia

- Dyskeratosis congenita
- Fanconi anemia
- Xeroderma pigmentosum
- Bloom syndrome
Hereditary retinoblastoma
- Neurofibromatosis 2
- Basal cell nevus syndrome/Gorlin syndrome
- Hyperparathyroidism-jaw tumor syndrome
- Familial adenomatous polyposis
- von Hippel-Lindau

Hereditary Syndromes Known to be Associated With Salivary Gland Neoplasia
- von Hippel-Lindau syndrome
- Ataxia-telangiectasia syndrome
- Hereditary retinoblastoma syndrome
- Brooke-Spiegler syndrome and familial cylindromatosis

Hereditary Syndromes Known to be Associated With CNS Neoplasia
- Neurofibromatosis 1
- Neurofibromatosis 2
- von Hippel-Lindau syndrome
- Gorlin syndrome
- Lynch syndrome
- Familial adenomatous polyposis
- Tuberous sclerosis complex
- Li-Fraumeni syndrome
- Constitutional mismatch repair
- Melanoma astrocytoma syndrome
- Familial uveal melanoma
- Rhabdoid predisposition syndrome
- Hereditary retinoblastoma
- PTEN-hamartoma tumor syndrome
- Multiple meningoma syndrome
- Pleuropulmonary blastoma

Hereditary Syndromes Known to be Associated With Bone Neoplasia
- Hereditary multiple exostosis
- Li-Fraumeni syndrome
- Hereditary retinoblastoma
- Familial chordoma syndrome
- Tuberous sclerosis complex
- Hyperparathyroidism-jaw tumor syndrome

Hereditary Syndromes Known to be Associated With Soft Tissue Neoplasia
- Basal cell nevus syndrome
- Li-Fraumeni syndrome
- Hereditary retinoblastoma
- Hereditary multiple exostosis
- Familial adenomatous polyposis
- Renal carcinoma with leiomyomas
- Neurofibromatosis 1
- Neurofibromatosis 2
- Carney complex
- Beckwith-Wiedemann syndrome

Hereditary Syndromes Known to be Associated With Blood and Bone Marrow Neoplasia
- Congenital amegakaryocytic thrombocytopenia
- Diamond-Blackfan anemia
- Dyskeratosis congenita
- Severe congenital neutropenia
- Shwachman-Diamond syndrome
- Fanconi anemia

P.I(1):6
SELECTED REFERENCES


Image gallery
Pathological Features in Familial Tumor Syndromes

(Left) The presence of unusual tumors is 1 of the characteristics of inherited tumor syndromes. Axial graphic of temporal bone shows the typical appearance of endolymphatic sac tumor seen in VHL patients. When diagnosing this tumor, VHL syndrome should be highly considered. (Right) Hemangioblastoma is the most frequently occurring tumor in VHL syndrome patients and is usually multiple. The main locations involved are the cerebellum and spinal cord.
The presence of multiple lesions, including multiple and bilateral tumors, is a characteristic feature of inherited tumor syndromes. Axial graphic depicts sphenoid dysplasia with arachnoid cyst, optic nerve glioma, buphthalmos, and multiple plexiform neurofibromas, features associated with NF1. The combination of multiple meningiomas and schwannomas is characteristic of patients with NF2.

This graphic depicts a squamous cell carcinoma of the maxillary sinus. These tumors may be present in patients with dyskeratosis congenita, Fanconi anemia, xeroderma pigmentosum, and Bloom syndrome, presenting at an earlier age than the sporadic tumors. Lateral graphic of the mandible illustrates features of a classic keratocystic odontogenic tumor (KOT), displacing the inferior alveolar nerve. The diagnosis of KOT should prompt evaluation for Gorlin syndrome.
(Left) Nonossifying fibroma shows a large, well-demarcated maxillary mass that obstructs 1 side of the nose and compresses the eye in a patient with hyperparathyroidism-jaw tumor syndrome. These patients present with hyperparathyroidism and also have distinct renal tumors. (Right) This lateral graphic depicts a carotid body paraganglioma at the carotid bifurcation. The main arterial feeder is the ascending pharyngeal artery. The vagus and hypoglossal nerves are in close proximity.

(Left) This coronal graphic shows a highly vascular glomus tympanicum paraganglioma filling a portion of the middle ear cavity without involving adjacent structures and bone. The head and neck paragangliomas are mostly associated with succinate dehydrogenase (SDH) mutation. (Right) This coronal graphic shows a glomus jugulare paraganglioma centered in the jugular foramen with superolateral extension into the middle ear. The ascending parapharyngeal artery is feeding this vascular tumor.
This graphic shows both adrenal medullary hyperplasia and MEN2 pheochromocytoma. The presence of adrenal medullary hyperplasia should alert the pathologist for a MEN2-associated pheochromocytoma. (Right) Example shows an algorithmic approach for genetic testing in pheochromocytoma and paraganglioma for the evaluation and diagnosis of the most common and known pheochromocytoma/paraganglioma-associated syndromes.

Chordomas classically occur in the midline of the body, and 1 of the more common locations is at the base of the skull in the region of the clivus. In familial chordomas, there is an increased incidence of chordoma in patients with tuberous sclerosis. (Right) Atypical teratoid/rhabdoid tumors (AT/RT) form variably sized masses that may appear well circumscribed. Multiple foci of necrosis are common in these extremely aggressive pediatric tumors. They occur throughout the neural axis.
Axial graphic shows retinoblastoma with lobulated tumor extending through the limiting membrane into the vitreous. Punctate calcifications are characteristic. Hereditary retinoblastoma patients may develop carcinoma of the nasal cavity. (Right) Renal manifestations, including bilateral angiomyolipomas, are also typical of tuberous sclerosis complex. These are usually benign, but large tumors are associated with risk for life-threatening bleeding.

The presence of renal cell carcinomas in a young patient with specific histopathological features should alert the pathologist for the diagnosis of 1 of the familial renal tumor syndromes. (Right) Algorithmic approach for evaluation and genetic testing of patients with possible familial renal cell carcinoma by histopathological diagnosis is shown. The presence of extrarenal lesions and tumors help guide the proper testing and proper selection of candidate genes.

Clinical Diagnosis and Management of Familial/Hereditary Tumor Syndromes

Clinical Diagnosis and Management of Familial/Hereditary Tumor Syndromes

Clinical Diagnosis and Management of Familial/Hereditary Tumor Syndromes

Vania Nosé, MD, PhD
Mucocutaneous involvement in Carney complex is extensive and includes the characteristic pigmented skin lesions around the eye and in the inner canthus. (Courtesy J. Carney, MD, PhD.)
Patients with multiple endocrine neoplasia 2B (MEN2B) develop medullary thyroid carcinoma, pheochromocytoma, and present with multiple neuromas of the tongue and lips.

INTRODUCTION

Hereditary Cancer
- Characterized by mutations associated with a high probability of cancer development, vertical transmission through parents, and an association with other types of tumors
- Often have early age of onset
- Usually multiple and involve multiple organs
- Familial cancers may be associated with (or by combination of these)
  - Chance of clustering of sporadic cancer cases within a family
  - Genetic variation in lower penetrance genes
  - Shared environment
- Molecular genetics have identified a number of genes associated with inherited susceptibility to a specific cancer
  - Also provides a means of characterizing specific gene mutation or mutations present in certain individuals and families exhibiting an increased risk of cancer

Background
- ~10% of all cancers are attributable to a cancer predisposition gene
- Learning the clinical features that suggest possibility of an underlying genetic predisposition to cancer is another easily mastered diagnostic tool
  - It is crucial to raise awareness among oncologists and other health care providers about the importance of inherited cancer risk in the practice of oncology and cancer prevention
- Study of rare familial clusters became a remarkably productive scientific and clinical enterprise
  - These data have
    - Identified multiple new susceptibility genes
Informed understanding of pathogenesis of hereditary and nonhereditary cancers at individual, population, and laboratory levels

Defined clinical phenotypes of specific disorders more precisely
- Much of the data that form basis of understanding of hereditary cancer syndromes are derived from evaluation of highly selected families
- Single-gene hereditary syndromes account for only a small fraction of familial clustering on a population basis
- Accuracy of reports from 1st-degree relatives is substantially better than for 2nd-degree relatives

Diagnosis accuracy varies considerably, depending on
- Age, gender, and cancer status of individual
- Primary site of cancer origin
- Degree of relatedness between individual and relative
- Vital status of affected relative
- Recentness of reported cancer diagnosis

Need has never been greater for clinicians to be well grounded
- In knowledge of biological and molecular bases of diseases they encounter
- To become familiar with related new clinical issues, including predictive risk assessment, genetic counseling, and germline mutation testing for clinical decision making
- To warn at-risk relatives vs. their high-risk patients' right to privacy and confidentiality, and the need for evidence-based, safe, and effective management recommendations for high-risk individuals

Identification of At-Risk Individuals
- Accurate identification of patients at increased risk for developing cancer is essential
- Assessment of an individual's risk of familial or hereditary cancer is based on a thorough evaluation of the family history

In the process of focusing on molecular biology of human cancer susceptibility, importance of taking a thoughtful family history cannot be emphasized sufficiently
- Recording an appropriately focused family history must be performed in course of daily practice

It is now increasingly routine to undertake a cancer genetics risk assessment, which includes the option of germline mutation testing for 1 or more relevant genes

Identification of individuals at risk for cancer has become an integral part of medicine
- Will allow health care providers to intervene with appropriate
  - Counseling and education
  - Increased cancer surveillance
  - Cancer prevention

Genetic risk assessment in the context of childhood cancer represents a specific setting
- Meticulous clinical evaluation often provides essential information upon which to base a syndromic diagnosis

The National Comprehensive Cancer Network (NCCN) has established criteria for those individuals who need further genetic risk assessment
- Multiple algorithmic approach for tumor syndromes are available at their website

CANCER SUSCEPTIBILITY TESTING

American Society of Clinical Oncology (ASCO): Indications for Testing
- ASCO recommends that genetic testing be offered when
  - Individual has personal or family history features suggestive of a genetic cancer susceptibility condition
  - Test can be adequately interpreted, and
  - Results will aid in diagnosis or influence the medical or surgical management of the patient or family members at hereditary risk of cancer
- ASCO recommends that genetic testing only be done in setting of pre- and post-test counseling, which should include discussion of possible risks and benefits of early cancer detection and prevention modalities

ASCO: Policy Statement
- Advent of syndrome-specific germline mutation testing represents a major advance in the care of cancer-prone individuals
- ASCO reaffirms its commitment to integrating cancer risk assessment and management, including molecular analysis of cancer predisposition genes, into the practice of oncology and preventive medicine
Genetic testing for cancer susceptibility has become an accepted part of oncologic care.

- According to ASCO guidelines
- Germline testing for inherited predisposition is well established as part of the care of individuals who may be at hereditary risk for cancers of the breast, ovary, colon, stomach, uterus, thyroid, and other primary sites
- Germline genetic testing is distinct from somatic genetic profiling of cancer tissue to predict prognosis or treatment response
- Germline testing involves analysis of DNA from blood or saliva for inherited mutations in specific genes that are associated with the type of cancer seen in the individual or family seeking assessment
- When identified, such high-penetrance mutations usually result in a significant alteration in the function of the corresponding gene product and are associated with large increases in cancer risk
- Other mutations result in less dramatic increases in risk (intermediate penetrance)
- Identification of a high-penetrance mutation often justifies an adjustment of clinical care through the modification of surveillance or through preventive surgery
- Germline testing for certain high-penetrance predispositions is now part of clinical guidelines and is reimbursed by most 3rd-party payers
- Impact of intermediate penetrance mutations on clinical care is less clear

ASCO: Clinical Utility of Genetic Testing

- Genetic tests may benefit individuals by providing deeper self-knowledge and motivation to pursue healthy behaviors, even if the results do not inform clinical decision making
- Tests for high-penetrance mutations in appropriate populations have clinical utility, meaning that they inform clinical decision making and facilitate the prevention or amelioration of adverse health outcomes
- Genetic tests for intermediate-penetrance mutations and genomic profiles of SNPs linked to low-penetrance variants are of uncertain clinical utility

ASCO: Informed Consent

- Proposed elements of informed consent related to testing for inherited cancer susceptibility are set forth
- Basic elements of informed consent for cancer susceptibility testing
  - Information on specific genetic mutation(s) or genomic variant(s) being tested, including whether range of risk associated with variant will impact medical care
  - Implications of a positive and negative result
  - Possibility that test will not be informative
  - Options for risk estimation without genetic or genomic testing
  - Risk of passing a genetic variant to children
  - Technical accuracy of the test including, where required by law, licensure of the testing laboratory
  - Fees involved in testing and counseling and, for direct-to-consumer (DTC) testing, whether the counselor is employed by the testing company
  - Psychological implications of test results (benefits and risks)
  - Risks and protections against genetic discrimination by employers or insurers
  - Confidentiality issues, including, for DTC testing companies, policies related to privacy and data security
  - Possible use of DNA testing samples in future research
  - Options and limitations of medical surveillance and strategies for prevention after genetic or genomic testing
  - Importance of sharing genetic and genomic test results with at-risk relatives so that they may benefit from this information
  - Plans for follow-up after testing

Special Issues Related to Genetic Testing Research

- Prospective clinical trials, large registries, and retrospective reviews are the most accurate methods for
  - Deriving relative risks of genetic variants
  - Measuring response to and effectiveness of clinical interventions based on genetic cancer risk assessment
- Tests with uncertain clinical utility become commercially available
  - It will be crucial to establish an evidence-based algorithm for clinically responsible use of these tests
    - For patient safety and effectiveness
Wherever possible, genetic tests with uncertain clinical utility should be administered in the context of clinical trials.

Research should include basic studies of the functional significance of the genetic variants linked to disease risk.

As well as prospective, randomized controlled trials of individual genomic markers.

At a translational level, it is important to establish criteria for technologic assessment of genetic and other diagnostic tests.

Research should focus on the extent to which personal benefits accrue to individuals who receive tests that have uncertain clinical utility.

As well as the appropriate mechanism for measuring personal utility.

Establishing an evidence-based test for personal utility is particularly important for tests that would not be recommended based on clinical utility.

Research is also needed to demonstrate validity and reproducibility of some commercially available tests.

Because the algorithms used to convert genotypes into absolute risk estimates are empirically derived, prospective research is needed to confirm calibration of these estimates and to measure the effectiveness of interventions based on individual genomic profiling.

If genetic and genomic tests for cancer risk are going to be offered or justified on basis of personal utility, an effort should be made to establish evidence-based tests for these claims.

Genetic Counseling

- Genetic testing should be conducted only in the setting of pre- and post-test counseling.
  - Pretest counseling:
    - Allows for advance consideration of medical options and the impact test results may have on family members.
  - Post-test counseling:
    - Provides a valuable opportunity for health care providers to interpret test results, recommend appropriate follow-up, and emphasize the importance of continuing regular prevention activities.

**DIAGNOSIS**

Established Diagnostic Criteria

- Some examples of diagnostic criteria to characterize a syndrome present in individuals with multiple lesions and tumors.

- Diagnostic criteria for basal cell nevus syndrome:
  - Diagnosis is established if 2 major or 1 major and 2 minor criteria are met.
    - Multiple (> 2) basal cell carcinomas, or 1 basal cell carcinoma in patient < 30 years, or > 10 basal cell nevi.
  - Major criteria:
    - Any odontogenic keratocyst (proven on histology) or polyostotic bone cyst.
    - Palmar or plantar pits (≥ 3):
      - Ectopic calcification; lamellar or early (patient < 20 years) falx calcification.
      - Family history of basal cell nevus syndrome (BCNS).
  - Minor criteria:
    - Congenital skeletal anomaly: Bifid, fused, splayed, or missing rib; or bifid, wedged, or fused vertebrae.
    - Head circumference > 97th percentile, with frontal bossing.
    - Cardiac or ovarian fibroma.
    - Medulloblastoma (primitive neuroectodermal tumor [PNET], most often of desmoplastic histology).
    - Lymphomesenteric or pleural cysts.
    - Congenital malformation: Cleft lip &/or palate, polydactyly, eye anomaly (cataract, coloboma, microphthalmia).

- Diagnostic criteria for von Hippel-Lindau (VHL) syndrome:
  - Diagnosis is established if there are
    - VHL mutation.
    - ≥ 2 CNS or retinal hemangioblastomas or
    - Single CNS or retinal hemangioblastoma, plus 1 of the following:
      - Multiple renal, pancreatic, or hepatic cysts.
      - Pheochromocytoma (any location).
      - Renal cancer.
      - Endolymphatic sac tumor of inner ear.
      - Papillary cystadenoma of the epididymis or broad ligament.
Neuroendocrine tumor of the pancreas or
- Definite family history of VHL plus 1 of the following
  - CNS or retinal hemangioblastoma
  - Multiple renal, pancreatic, or hepatic cysts
  - Pheochromocytoma
  - Renal cancer < age 60 years
  - Epididymal cystadenoma
- Key diagnostic points
  - Multiple retinal and CNS hemangioblastomas
  - Multiple clear cell RCCs (bilateral), multiple renal cysts (bilateral) with clear cell lining, multiple pancreatic and hepatic cysts
  - May suspect possibility of syndrome based on constellation of pathologic findings

- Diagnostic criteria for Carney complex
  - PRKAR1A gene mutation
  - Patient must have at least 2 of the following
    - Spotty skin pigmentation with a typical distribution (often vermillion border of lips, conjunctiva and ocular canthi, vaginal or penile mucosa)
    - Myxoma (cutaneous: Often on the eyelid, external ear, nipple)
    - Cardiac myxoma
    - Breast myxomatosis or fat-suppressed MR findings suggestive of this diagnosis
    - Primary pigmented nodular adrenocortical disease or paradoxical positive response of urinary glucocorticosteroid to dexamethasone administration during Liddle diagnostic test for Cushing syndrome
    - Acromegaly due to GH-producing adenoma (somatotropinomas)
    - Large-cell calcifying Sertoli cell tumor of testis or characteristic calcification on testicular ultrasonography
    - Thyroid carcinoma or multiple hypothoic nodules on thyroid ultrasonography in a young patient
    - Psammomatous melanotic schwannoma
    - Blue nevus, epithelioid blue nevus (multiple)
    - Breast ductal adenoma (multiple) (or mammary tumor with intraductal papilloma)
    - Osteochondromyxoma of bone (histological diagnosis)
  - Diagnostic criteria is also satisfied in a patient meeting any of these criteria and having either affected 1st-degree relative or inactivating mutation of PRKAR1A gene

- Diagnostic criteria for neurofibromatosis type 1 (NF1)
  - NF1 mutation
  - Diagnosis requires 2 or more of the following
    - Café au lait macules
      - In children, ≥ 5 that are ≥ 0.5 cm in diameter
      - In adults, ≥ 6 that are ≥ 1.5 cm in diameter
    - ≥ 2 neurofibromas of any type or 1 plexiform neurofibroma
    - Multiple axillary or inguinal freckles
    - Sphenoid wing dysplasia or congenital bowing or thinning of long bone cortex (± pseudoarthrosis)
    - Bilateral optic nerve gliomas
    - ≥ 2 iris Lisch nodules (iris hamartomas)
  - 1st-degree relative with NF1 by these criteria

- Diagnostic criteria for Li-Fraumeni syndrome (LFS)
  - Population to be screened
    - When strict criteria are met, TP53 mutations are found in 60-80%
    - If less strict criteria are used (Li-Fraumeni-like [LFL]), TP53 mutations are found in up to 40%
  - Chompret criteria for screening
  - Individual (proband) must have 1 of the following tumors before age 46: Sarcoma, osteosarcoma, premenopausal breast cancer, brain tumor, adrenal cortical carcinoma, leukemia, or lung lepidic pattern carcinoma, and at least 1 of following 3 criteria
    - At least 1 first- or second-degree relative with an LFS tumor before age 56 or with multiple tumors
- Breast cancer is not included if proband has breast cancer
- Multiple tumors (not including breast cancers), 2 of which belong to LFS tumors and 1st of which occurred < age 46
- Adrenal cortical carcinoma or choroid plexus tumor, irrespective of family history
  - 30% of individuals fulfilling these criteria have a germline TP53 mutation

- Diagnostic criteria for Lynch syndrome
  - Mutations in genes coding for mismatch repair proteins (MLH1, PMS2, MSH2, MSH6)
  - Clinical features
    - Multiple epithelial cancers occur at average age of ~ 20 years younger than expected
  - Several guidelines have been proposed to help identify patients who should be tested for Lynch syndrome
    - Amsterdam criteria II
      - ≥ 3 relatives with a Lynch-associated cancer
      - ≥ 2 successive generations affected
      - ≥ 1 relative diagnosed < age 50
      - 1 should be a 1st-degree relative of the other 2
      - Familial adenomatous polyposis must be excluded
    - Revised Bethesda guidelines
    - Colorectal carcinoma (CRC) diagnosed prior to age 50
    - Presence of synchronous or metachronous CRC or other Lynch-associated tumor, regardless of age
    - CRC with histologic features suggestive of microsatellite instability in patient < age 60
    - CRC diagnosed in ≥ 1 first-degree relative with a Lynch-associated tumor, with 1 of the cancers diagnosed prior to age 50
    - CRC diagnosed in ≥ 2 first-degree or second-degree relatives with Lynch-associated tumors, regardless of age
  - Neither of these guidelines is foolproof; hence, many studies recommend testing all CRCs for Lynch syndrome

Future Perspectives
- Progress of recent years in understanding pathogenesis of familial tumor syndromes is expected to continue to improve patient screening
  - Also become, in the long term, a catalyst for development of new therapeutic options for surgically untreatable tumors
- With the fast-moving field, a new syndrome is frequently identified
- Awareness of possible syndromes when dealing with patients is critical for proper patient management
- Hereditary cancer syndromes in children and adolescents are becoming more recognized in the field of pediatric hematology/oncology
- Recently, germline mutations of DICER1 have been identified in patients with rare neoplasms, suggesting existence of a discovered syndrome involving cancer predisposition
  - Familial pleuropulmonary blastoma tumor predisposition (DICER1) syndrome
  - Additional manifestations of syndrome have been identified, including cystic nephroma, medulloepithelioma, Sertoli-Leydig cell tumor, and others
- Importance of learning about them for the practicing physicians
- Of particular use for identification of genetic testing resources and regularly updated clinical management information for many of these disorders
- There are now a number of additional online resources available that provide more comprehensive information about these conditions
  - GeneTests website, a resource to those seeing individuals with genetic disorders: http://www.genetests.org/
- Pathologist plays a crucial role; important for surgical pathologists to be aware of specific pathology findings that suggest a possible tumor syndrome

SELECTED REFERENCES
5. Kalkan E et al: Endocrine tumors associated with neurofibromatosis type 1, peutz-jeghers syndrome and other familial neoplasia syndromes. Front Horm Res. 41:166-81, 2013

### Tables

#### In Individual Patient
- Age at diagnosis younger than usual
- Associated with other genetic traits
- Neoplasms with rare morphological features
- Associated with congenital defects
- Multiple primary neoplasms within same organ
- Multiple primary neoplasms within different organs and tissues
- Bilateral primary neoplasms in paired organs or lobes
- Multifocal neoplasms within same organ or tissue
- Neoplasms occurring in gender that is not usually affected
- Associated with an inherited precursor lesion
- Associated with another rare disease
- Associated with cutaneous lesions known to be related to cancer susceptibility disorders

#### In Patient's Family
- 1 first-degree relative with same or a related tumor and 1 of the individual features listed
- ≥ 2 first-degree relatives with neoplasms listed
- ≥ 2 first-degree relatives with neoplasm types belonging to a known familial cancer syndrome
- ≥ 2 first-degree relatives with rare tumors
- ≥ 2 relatives in 2 generations with tumors of the same site or etiologically related sites

P.I(1):15

Image gallery
Clinical Features
Pigmented skin lesions are present in Carney complex and also in McCune-Albright, Peutz-Jeghers, Birt-Hogg-Dubé, neurofibromatosis, and PTEN-hamartoma tumor syndromes. (Courtesy J. Carney, MD, PhD.) McCune-Albright syndrome consists of a triad of polyostotic fibrous dysplasia, pigmented skin lesions, and sexual precocity. These patients may develop hyperplasia and adenomas of endocrine glands.

Patients with multiple endocrine neoplasia 2B (MEN2B) develop medullary thyroid carcinoma, pheochromocytoma, and present with multiple neuromas of the tongue &/or ganglioneuromatosis of the intestine, a marfanoid habitus, &/or medullated corneal nerve fibers. (Right) Bilateral vestibular schwannomas involving the vestibular branch of CN8 are pathognomonic of NF2. They present as a cerebellopontine angle mass and may be multiple.
Patients with MEN2B may present with multiple neuromas of the tongue and lip &/or pigmented skin lesions. The presence of multiple lesions, including multiple and bilateral tumors, is a characteristic feature of inherited tumor syndromes. Graphic representation of abdominal lesions seen in patients with von Hippel-Lindau syndrome shows the bilateral and multiple renal cysts, renal tumors, pancreatic cysts, and adrenal pheochromocytoma.

Section 2 - Syndromes
Ataxia-Telangiectasia Syndrome
Fausto J. Rodríguez, MD
Cerebellar atrophy is a hallmark of ataxia-telangiectasia, particularly in the vermis. However, this may not be evident in MR until late childhood.
This diffuse large B-cell lymphoma developed in an ataxia-telangiectasia (AT) patient. AT patients have an increased predisposition to various cancers, particularly of B- and T-cell lineage.

TERMINOLOGY
Abbreviations
- Ataxia-telangiectasia (AT)
- Ataxia-telangiectasia mutated (ATM) gene

EPIDEMIOLOGY
Incidence
- 1 per 40,000-100,000
- Occurs in all geographic regions with variable local prevalence

Gender
- Similar frequency in males and females

CLINICAL IMPLICATIONS
Clinical Presentation
- Ataxia of gait, stance, and trunk most frequent
  - Progresses to affect extremities and eye movements
- Dysarthria
- Late cerebellar tremor in variant AT rather than profound ataxia

Imaging Findings
- Atrophy of cerebellar vermis and hemispheres in older children (not evident in early childhood)

GENETICS
Autosomal Recessive Disease
- Caused by germline inactivation of ataxia-telangiectasia mutated (ATM) gene
- Chromosomal region 11q22-23
- Encodes for ~300 kDa serine/threonine protein kinase with sequence homology to PI3K family
• Predominantly a nuclear protein
• Major function is regulation of DNA repair secondary to double-strand DNA breaks
• Normally in the form of inactive dimers
• Activated ATM protein monomers recruited to areas of DNA damage
• MRN (MRE11A/RAD50/NBS1) complex required for optimal activation of ATM in areas of double-stranded DNA breaks
• Several protein kinases (e.g., CHK2) and p53 key substrates phosphorylated by ATM
• Other functions include regulation of cell cycle, apoptosis, telomere maintenance, response to oxidative stress, mitochondrial homeostasis, insulin signaling
  • In classic AT, ATM is almost completely absent secondary to severe/truncating mutations

Heterozygous Carriers of ATM Mutations Predisposed to Cancers
• Contributes to small subset of familial breast and ovarian cancer

CLINICAL IMPLICATIONS AND ANCILLARY TESTS
Hypersensitivity to Ionizing Radiation
• Most characteristic biologic feature
↑ α-Fetoprotein in Serum
• Useful biomarker
• Rising serum levels typical
• Not a feature of other ataxia and immunodeficiency syndromes in differential diagnosis

Early Diagnosis
• Allows genetic counseling and avoidance of extended medical work-ups
P.I(2):3

NONNEOPLASTIC MANIFESTATIONS
Central Nervous System Degeneration
• Progressive ataxia starts early (6-18 months of age)
  • Wheelchair bound by 1st decade of life
  • Cerebellar atrophy, particularly vermis
  • Extensive Purkinje and granule cell loss
  • Cell loss in inferior olives (retrograde)
  • Ectopic Purkinje cells may be found in molecular layer
  • Peripheral nervous system may also be affected and contribute to symptoms
• Mental deficiency
• Posterior spinal column dysfunction

Skin and Eye
• Telangiectasias
  • Involve bulbar conjunctivae and eventually bridge of nose
  • Appear between ages 2 and 8 years
• Seborrheic dermatitis common
• Cutaneous granulomas
• Café au lait spots
• Gray hair, skin atrophy

Deficiency of Cellular Immunity
• Hypoplasia of thymus, tonsil, and adenoids
• Lymphopenia
• ↓ IgA, IgE, IgG2

Respiratory Infections and Bronchiectasis
• Important cause of death in AT in addition to cancer

Endocrine Abnormalities
• Hypogonadism/infertility
• Insulin resistance/type 2 diabetes
• Short stature

ASSOCIATED NEOPLASMS
Hematolymphoid Malignancies
• Predominant neoplasms affecting AT patients (> 100x risk compared to general population)
• T-cell and B-cell lineage
• Myeloid leukemia very uncommon
Solid Tumors
- More evident as patients are living longer
- Ovarian carcinoma, breast carcinoma, thyroid carcinoma, salivary gland tumors, gastric carcinoma, melanoma, and leiomyomas/leiomyosarcomas may develop

CANCER RISK MANAGEMENT
Lifetime Cancer Risk
- 30% in AT patients
- Avoid x-ray-based tests if possible given characteristic radiosensitivity of AT

DIFFERENTIAL DIAGNOSIS
AT-Like Disorder
- Usually caused by hypomorphic mutations in ATM or mutations in genes encoding related proteins (e.g., MRE11A)
  - Missense or splice-site rather than truncating mutations in ATM more common than in classic AT
  - Milder phenotype

Nijmegen Breakage Syndrome (NBS)
- Caused by mutations in NBS1
  - Encodes for another component of MRN protein complex
- Patients also demonstrate immunodeficiency, radiosensitivity, and cancer predisposition
- Microcephaly and mental retardation, but lack progressive ataxia and telangiectasias

Disorders Associated With Defects in DNA Single-Strand Break (SSB) Repair
- Ataxia with oculomotor apraxia types 1 and 2, spinocerebellar ataxia with axonal neuropathy type 1
- Neurodegenerative syndromes and neurologic features overlap with AT
- No manifestations outside of nervous system

SELECTED REFERENCES

Basal Cell Nevus Syndrome/Gorlin Syndrome

Basal Cell Nevus Syndrome/Gorlin Syndrome
Christine J. Ko, MD
Multiple crusted pink plaques on the scalp represent basal cell carcinomas in this patient with Gorlin syndrome. (Courtesy K. Hoffmann, MD.)
Multiple pink 1-2 mm depressions are shown on the palm, consistent with palmar pitting characteristic of Gorlin syndrome. ( Courtesy K. Hoffmann, MD.)

TERMINOLOGY

Synonyms
- Nevoid basal cell carcinoma syndrome
- Basal cell carcinoma nevus syndrome
- Gorlin-Goltz syndrome

EPIDEMIOLOGY

Age at Presentation
- From birth (may not be detected until later)
  - Bony abnormalities
- 1st decade
  - Jaw cysts (of mandible/maxilla)
- 2nd decade
  - Palmoplantar pitting
- Childhood but more often late puberty/adulthood
  - Basal cell carcinomas (sometimes resembling skin tags)

Incidence
- ~ 1 in 19,000 births

GENETICS

Inheritance
- Autosomal dominant

PTCH1 Gene
- Mutations in this gene found in ~ 60-75% of those tested
- PTCH1
  - Located on chromosome 9q
Part of sonic hedgehog pathway
- PTCH1 encodes patched protein
- Patched protein inhibits smoothened
- Mutated PTCH1 leads to disinhibition of smoothened and tumor growth

No clear genotype/phenotype correlation

CLINICAL IMPLICATIONS AND IMAGING FINDINGS

Clinical Findings
- Triggers that should prompt evaluation for Gorlin syndrome
  - Keratocystic odontogenic tumor if age < 20 years old
  - Basal cell carcinoma if age < 20 years old
  - Palmar or plantar pits
  - Lamellar calcification of falx cerebri
  - Medulloblastoma, desmoplastic
- Characteristic facies
  - Frontal bossing
  - Hypoplastic maxilla
  - Broad nasal root (and hypertelorism)

Imaging Findings
- Head
  - Calcification of
    - Falx, tentorium cerebelli, sella turcica
  - Jaw cysts
    - Panorex (digital if possible)
  - Cleft lip/palate
- Trunk
  - Ribs
    - Bifid, missing, splayed
  - Spine
    - Scoliosis, vertebral anomalies
- Long bones
  - Bone cysts
- Hands/feet
  - Flame-shaped lucencies

ASSOCIATED NEOPLASMS

Skin
- Basal cell carcinoma
  - May look like skin tags in children
  - Often sun-exposed skin
  - May be non-sun-exposed areas
  - Typical clinical morphology
    - Pearly, pink, telangiectatic papules or nodules
    - Erythematous, scaly, thin macules or plaques
    - May be eroded/ulcerated
  - All histopathologic subtypes
    - Superficial multicentric with buds of basaloid islands off epidermal base
    - Nodular with islands of basaloid cells with peripheral palisading in dermis
    - May be pigmented
    - Micronodular, morpheaform, infiltrative, infundibulocystic, etc.
- Palmoplantar pits
  - Several millimeters in diameter
  - Pink in color
  - Histopathology: Basaloid proliferation
- Epidermal inclusion cyst/milium

Musculoskeletal
- Odontogenic keratocyst
  - May become secondarily infected
Thin capsule with lining of stratified squamous epithelium

- Sites
  - Mandibular molar/ramus (~ 40%)
  - Mandibular canine/incisor (~ 20%)
  - Maxillary molar tuberosity (~ 10%)

Central Nervous System
- Medulloblastoma
  - Especially desmoplastic
- Meningioma
  - May be consequence of radiation treatment of medulloblastoma

Genitourinary
- Ovarian fibroma/fibrosarcoma

Cardiac
- Fibroma

**CANCER RISK MANAGEMENT**

**Multidisciplinary Care**
- Dermatology, surgery, dental/oral medicine, orthopaedics, ophthalmology, neurology, genetics
- Regular skin examinations necessary
  - Every 6 months to 1 year (every 4 months in adults)
- Medulloblastoma
  - Baseline MR of brain with contrast and epilepsy protocol
    - Annually until age 8
  - Minimize ionizing radiation exposure, as it can induce basal cell carcinomas
    - Consider MR over serial CT scans
- Treatments/interventions to prevent new basal cell carcinomas
  - Oral retinoids
  - Sun avoidance/sun protection
- PTCH1 gene testing: Not mandatory for diagnosis
  - Scenarios in which testing is recommended
    - Prenatal testing if known mutation within family
    - Cases highly suspicious for Gorlin syndrome but not yet meeting criteria
    - Predictive testing for patients with affected family member

**DIFFERENTIAL DIAGNOSIS**

**Early Onset Basal Cell Carcinomas (Sporadic)**
- Increasingly, patients < age 40 are developing basal cell carcinoma
  - May be linked to tanning
- No other stigmata of Gorlin syndrome

**Bazex-Dupré-Christol Syndrome**
- Similarities to Gorlin syndrome
  - Multiple basal cell carcinomas (may have earlier onset than in Gorlin syndrome)
  - Milia
- Distinguishing features from Gorlin syndrome
  - X-linked dominant inheritance
  - Hypotrichosis
  - Follicular atrophoderma
  - Hypohidrosis

**Rombo Syndrome**
- Reported in 1 large Swedish family
- Similarities to Gorlin syndrome
  - Multiple basal cell carcinomas
  - Milia
- Distinguishing features from Gorlin syndrome
  - Multiple trichoepitheliomas
  - Atrophoderma vermiculata
  - Acral cyanosis

**Brooke-Spiegler Syndrome**
- Multiple facial papules, often clustered on central face (previously termed multiple trichoepitheliomas)
- Papulonodules may predominate on scalp (previously termed cylindromatosis)
**Histopathology**
- Trichoepithelioma (not basal cell carcinomas)
  - Basaloid islands, often with advanced follicular differentiation (e.g., horn cysts)
  - Peripheral palisading
  - Clefts between fibrotic stroma and unaffected dermis
- Cylindroma
  - Jigsaw puzzle arrangement of islands with ductal differentiation surrounded by thickened basement membrane
- Spiradenoma
  - Blue islands in dermis with alternating pattern of light and dark cells

**Familial Multiple Basaloid Follicular Hamartomas**
- Multiple facial papules
- Presenting in childhood
- **Histopathology**
  - Basaloid follicular hamartoma (not basal cell carcinoma)
    - Interconnecting cells with squamoid appearance with interspersed horn cysts, mucinous stroma
    - CK20(+) cells present

**Generalized Basaloid Follicular Hamartoma Syndrome**
- Reported in 1 large North Carolina family
- Similarities to Gorlin syndrome
  - Palmoplantar pitting
- Distinguishing features from Gorlin syndrome
  - No basal cell carcinomas
  - No jaw cysts
  - Multiple basaloid follicular hamartomas
    - Depicted in this syndrome as buds of basaloid islands arranged around 1 follicle or small cystic structure

**Hereditary Infundibulocystic Basal Cell Carcinoma**
- Distinguishing features from Gorlin syndrome
  - Multiple small papules on central face
  - Absence of palmar pits
  - No jaw cysts
  - Histopathology shows infundibulocystic basal cell carcinoma
    - Squamoid, ramifying appearance superficially, often with more typical nodular basal cell carcinoma at base

**Other Syndromes With Basal Cell Carcinoma**
- Defective DNA repair syndromes (e.g., xeroderma pigmentosum)

**CRITERIA FOR DIAGNOSIS**

**Major Criteria**
- Basal cell carcinoma
  - 1 if patient < 20 years of age
  - 2 or more if patient > 20 years of age
- Palmoplantar pitting
  - 3 or more
- Odontogenic keratocyst
  - Patient age: < 20 years
- Calcification of falx cerebri
  - Sometimes the tentorium cerebelli or sella turcica
    - Patient age: < 20 years
- Family history of Gorlin syndrome
- Medulloblastoma (primitive neuroectodermal tumor)
  - Patient age: ≤ 2 years

**Minor Criteria**
- Tumors
Diagnostic Pathology: Familial Cancer Syndromes

- Cardiac fibroma
- Ovarian fibroma
- Lymphomesenteric cysts

- Skeletal/developmental abnormalities
  - Bifid/fused/splayed/missing rib
  - Bifid/wedged/fused vertebral kyphoscoliosis
  - Short 4th metacarpal, postaxial polydactyly
  - Macrocephaly
  - Cleft lip/palate

- Ocular abnormalities
  - Strabismus
  - Congenital cataract
  - Hypertelorism
  - Glaucoma
  - Coloboma

Number of Criteria Needed

- 2 major, or
- 1 major and 2 minor, or
- 1 major and molecular confirmation

SELECTED REFERENCES

Image gallery
Graphic, Clinical, Imaging, and Microscopic Features
Lateral graphic of the mandible (buccal cortex removed) illustrates features of a classic keratoctytic odontogenic tumor, splaying roots of the 1st and 2nd molar teeth, displacing the inferior alveolar nerve. (Right) This patient with Gorlin syndrome had multiple basal cell carcinomas of the skin as well as several odontogenic jaw cysts. The photograph shows a scar from where 1 of the jaw cysts was surgically excised. (Courtesy K. Hoffmann, MD.)

Axial nonenhanced CT shows beaded calcification of the falx cerebri. Basal cell nevus syndrome should be suspected when multiple jaw cysts and/or precocious dural calcification is detected. Dural calcification is unusual in patients < 10 years of age. (Right) This is a typical basal cell carcinoma, with islands of basaloid epithelium that have peripheral palisading situated in a myxoid stroma.
Beckwith-Wiedemann Syndrome
A term infant with Beckwith-Wiedemann syndrome has a protuberant abdomen, secondary to enlarged liver and kidneys, and a large mouth with macroglossia. (Courtesy J. Byrne, MD.)

Photomicrograph shows adrenal cortical cytomegaly, a characteristic finding in Beckwith-Wiedemann syndrome. There are large polyhedral cells with hyperchromatic nuclei. (Courtesy E. Klatt, MD.)

**TERMINOLOGY**

**Abbreviations**
- Beckwith-Wiedemann syndrome (BWS)

**Synonyms**
- Wiedemann-Beckwith syndrome

**Definitions**
- Disorder of growth regulation
- Predisposition to embryonal tumors

**EPIDEMIOLOGY**

**Incidence**
- ~ 1 in 14,000

**Gender**
- M:F = 1:1
  - Exception is monozygotic twins
    - F:M = 3:1

**Ethnicity Relationship**
- All ethnicities

**Age Range**
- Increased growth
  - In utero
  - 1st few years of life
- Associated malignancies
Generally present by 8 years

Other
- Associated with assisted reproduction
  - Risk is 1 in 4,000 for in vitro fertilization

CLINICAL IMPLICATIONS

Clinical Presentation
- Highly variable presentation
  - Ranges from mild to severe
- Somatic overgrowth
  - Classic triad
    - Exomphalos
    - Gigantism
    - Macroglossia (can cause abnormal feeding/breathing/speech)
  - Initial increased growth
    - In utero
    - Through 1st few years of life
    - Height and weight are often above 90th percentile for age in initial years of life
    - Normalizes by childhood
  - Overgrowth may be unilateral (hemihyperplasia)
  - Visceromegaly can involve
    - Liver
    - Spleen
    - Pancreas
    - Adrenals
    - Kidneys: May be associated with renal medullary dysplasia, nephrocalcinosis, or medullary sponge kidney
    - Heart
- Characteristic facies in early childhood (often normal by adulthood)
  - Prominent eyes
  - Midfacial hypoplasia
  - Macroglossia
  - Prominent mandible
  - Anterior earlobe creases
  - Posterior helical pits
  - Nevus flammeus may be present
- Abdominal wall defects
  - Umbilical hernia
  - Omphalocele
  - Diastasis recti

Clinical Risk Factors
- Pathologic factors and risk
  - Associated with assisted reproduction
- Prognostic factors and risk
  - Worse prognosis with perinatal hypoglycemia
    - Hypoglycemia in 30-50% of BWS
  - Higher risk of tumor development with
    - Hemihyperplasia
    - Nephromegaly
    - Nephrogenic rests
- Risk of malignancy
  - Estimated at 7.5%
  - Range: 4-21%

Imaging Findings
- Ultrasonographic findings
  - Ultrasound can also detect large kidneys, large abdominal circumference, omphalocele, and polyhydramnios from obstructed swallowing
o 3D/4D ultrasound can delineate facial features in utero; protuberant tongue or hepatomegaly may be detected

GENETICS
Inheritance
• Sporadic in ~ 85%
• Familial in ~ 15%
  o Heterogeneous transmission
    ▪ Sometimes autosomal dominant maternal transmission

Molecular Pathology
• Involves chromosome 11p15.5 in ~ 80% of cases
  o IGF2 and KCNQ1OT1 are normally expressed from paternal allele
    ▪ KCNQ1OT1-associated imprinting center (IC2) is usually methylated on maternal allele
  o H19, CDKN1C, and KCNQ1 are normally expressed from maternal allele
    ▪ H19-associated imprinting center (IC1) is usually methylated on paternal allele
• Different molecular pathology is associated with different clinical phenotypes
  o Epigenetic
    ▪ Altered methylation: Loss of methylation at IC2 occurs in 50%; gain of methylation occurs at IC1 in 10%
    ▪ Loss of methylation at IC2 is associated with decreased risk of renal findings compared with gain of methylation at IC1
  o Genetic
    ▪ Microdeletion
    ▪ CDKN1C mutation
    ▪ Uniparental disomy of 11p15.5 (~ 10-20% of cases; usually paternal allele) is associated with high risk of Wilms tumor
    ▪ Duplication, inversion, translocation of 11p15 in < 1% of cases

ASSOCIATED NEOPLASMS
Embryonal Tumors/Malignancies
• Wilms tumor (nephroblastoma)
  o ~ 60% of all tumors in BWS
  o Histopathology: Often characterized by 3 elements
    ▪ Blastema (embryological structure related to kidney development)
    ▪ Mesenchyme (may be composed of striated muscle, bone, cartilage, fat, fibroblastic tissue)
    ▪ Epithelium
• Adrenal cytomegaly
  o Hyperplastic adrenal glands
  o Characteristic cytology
    ▪ Large, polyhedral cells with eosinophilic granular cytoplasm and enlarged nuclei
• Adrenal cortical carcinoma
  o Cells with eosinophilic cytoplasm
  o Often with numerous mitoses and invasive growth pattern
• Hepatoblastoma
  o High levels of α-fetoprotein (100,000-300,000 µg/mL)
  o Different histologic variants
    ▪ Epithelial (fetal pattern)
    ▪ Embryonal and fetal pattern
    ▪ Macrotubular pattern
    ▪ Small cell undifferentiated pattern
    ▪ Mixed epithelial and mesenchymal pattern ± teratoid features
• Rhabdomyosarcoma
  o Subtypes reported
    ▪ Embryonal: Dense foci of rhabdomyoblasts with areas of loose, myxoid stroma
    ▪ Alveolar: Small blue cells in aggregates floating in spaces lined by fibrous septae
• Neuroblastoma
  o Round blue cells, sometimes forming rosettes

CANCER RISK MANAGEMENT
Tumor Surveillance Protocol
• Abdominal ultrasound
  o Every 3-4 months
Until age 8
- α-fetoprotein assay
  - Every 3-4 months
  - Until age 4

Differential Diagnosis

Maternal Diabetes Mellitus
- Can cause macrosomia in fetus
- May be associated with polyhydramnios
- Omphalocele is uncommon

Isolated Hemihyperplasia
- May be associated with Wilms tumor &/or alterations on 11p15
- Diagnosis of exclusion

P.I(2):10

Isolated Omphalocele
- May be associated with normal growth or growth restriction

Simpson-Golabi-Behmel Syndrome
- X-linked recessive
- Mutations in GPC3 or CXORF5
- High mortality in infancy
- Macrocephaly, coarse face, macroglossia, polydactyly, heart defects
- Increased risk of tumors
  - Wilms tumor
  - Hepatoblastoma
  - Neuroblastoma
  - Gonadoblastoma
  - Hepatocellular carcinoma

Sotos Syndrome
- Autosomal dominant, mutation in NSD1
- Overgrowth, advanced bone age, mental retardation
- Characteristic facies
  - High forehead
  - Inverted pear-shaped head
  - Sparse frontal hair
  - Pointed chin
- Cardiac/renal anomalies
- Increased risk of tumors
  - Examples
    - Teratoma
    - Neuroblastoma
    - Acute lymphoblastic leukemia
    - Wilms tumor

Perlman Syndrome
- Autosomal recessive
- Mutation in DIS3L2
- Similarities to BWS
  - Macroglossia
  - Overgrowth
  - Neonatal hypoglycemia

Hemihypoplasia
- Underdevelopment of 1 side of body
  - Relative to underdeveloped side, normal side may be misdiagnosed as being hyperplastic

Syndromic Wilms Tumor
- Syndromes related to WT1 mutation
  - Examples
    - WAGR (Wilms tumor, aniridia, genitourinary anomalies, mental retardation) syndrome
    - Denys-Drash syndrome (gonadal dysgenesis, nephropathy, Wilms tumor)
Diagnostic Pathology: Familial Cancer Syndromes

- Frasier syndrome (pseudohermaphroditism, glomerulonephropathy, gonadoblastoma, rarely Wilms tumor)
- Genitourinary anomalies syndrome (abnormal external genitalia, Wilms tumor)

Nonsyndromic Wilms Tumor
- Wilms tumor not associated with any syndrome (e.g., BWS, WAGR syndrome, Denys-Drash syndrome, Frasier syndrome)

CRITERIA FOR DIAGNOSIS

Major Findings
- Abdominal wall defects
  - Omphalocele
  - Umbilical hernia
- Macroglossia
- Macrosomia
  - Height to weight ratio > 97th percentile
- Anterior ear lobe creases &/or posterior helical pits
- Visceromegaly
- Embryonal tumor in childhood
- Hemihyperplasia
- Cytomegaly of adrenal fetal cortex, usually diffuse and bilateral
- Renal abnormalities
  - Medullary dysplasia
  - Abnormality of medullary sponge kidney
- Positive family history of BWS
- Cleft palate

Minor Findings
- Pregnancy-related findings
  - Polyhydramnios
  - Enlarged placenta
  - Thickened umbilical cord
  - Premature onset of labor/delivery
  - Preeclampsia
- Neonatal hypoglycemia
- Nevus flammeus
- Cardiomegaly/cardiomyopathy/other abnormalities
- Characteristic facies
- Diastasis recti
- Advanced bone age

Criteria Based on Findings
- 3 major or 1 minor + 2 major findings support BWS diagnosis

SELECTED REFERENCES

Image gallery
Gross and Microscopic Features
(Left) Total nephrectomy specimen from a Beckwith-Wiedemann syndrome patient with Wilms tumor shows an area of relatively intact residual kidney and ureter. Wilms tumors often weigh > 500 g. (Courtesy L. Erickson, PA.)

(Right) Typical triphasic morphology of Wilms tumor is shown. Note the blastemal, epithelial, and stromal components. (Courtesy A. Putnam, MD.)

(Left) Adrenal cortical cytomegaly is usually present in children with Beckwith-Wiedemann syndrome. The adrenal cortical cells are composed of a mixture of small cells and large polyhedral cells with markedly enlarged nuclei.

(Right) Adrenal cortical carcinoma in a child with Beckwith-Wiedemann syndrome shows that the tumor is composed of large cells with nuclear pleomorphism, prominent nucleoli, and numerous mitotic figures.
(Left) This is a metastatic adrenal cortical carcinoma to the lung in a 6-month-old child with Beckwith-Wiedemann syndrome. (Right) The cells of this embryonal rhabdomyosarcoma have ovoid or spindled nuclei and moderate amounts of eosinophilic cytoplasm. Nuclear atypia is mild to moderate. The prominent myxoid stroma, a common feature, imparts a reticular or filigree pattern in this part of the tumor. (Courtesy C. Fisher, MD.)

Birt-Hogg-Dubé Syndrome
Smooth, skin-colored to slightly hypopigmented papules are seen on the cheek and nose in a patient with Birt-Hogg-Dubé syndrome. (Courtesy B. Goldberg, MD.)

This fibrofolliculoma shows characteristic reticulated, lace-like, thin strands of epithelium extending away from hair follicles. The reticulated epithelium is embedded in a loose stroma.

TERMINOLOGY

Abbreviations
- Birt-Hogg-Dubé syndrome (BHDS)

Synonyms
- Hornstein-Knickerberg syndrome

EPIDEMIOLOGY

Age Range
- Cutaneous lesions tend to present after age 30
- Pulmonary cysts generally present by age 20
- Renal cell carcinoma generally occurs after age 50

GENETICS

Inheritance
- Autosomal dominant

Gene Defect
- Caused by mutations in gene coding for folliculin (FLCN)
  - FLCN mutation in ~85% of families with BHDS
  - Exact role of folliculin unknown
    - May be involved in WNT, mTOR, &/or AKT signaling
    - May have role in determining polarity in cilia

CLINICAL IMPLICATIONS AND ANCILLARY TESTS

Clinical Presentation
- Cutaneous
Papules
- Multiple
- Smooth
- Skin-colored to white
- Occur in adulthood

Sites
- Face/ears
- Neck
- Sometimes upper trunk

- In ~ 80% of adult patients with BHDS

Pulmonary
- Cysts
  - Rupture can lead to pneumothorax
  - In ~ 80% of adult patients with BHDS
  - Multiple cysts usually detectable on CT scan
    - Tend to affect middle and lower lobes toward mediastinum
    - Often intimately associated with interlobular septae or visceral pleura

Renal tumors
- Present in adulthood
- In ~ 15-30% of patients with BHDS

Imaging Findings
- CT scan of chest
  - Pulmonary cysts
    - Middle lobe
    - Lower lobe
    - Associated with septae/pleura

ASSOCIATED NEOPLASMS

Cutaneous
- Fibrofolliculoma/trichodiscoma
  - Most experts now consider fibrofolliculoma and trichodiscoma a histologic spectrum of the same entity
    - On step sectioning, most tumors showing features of trichodiscoma have foci compatible with fibrofolliculoma
  - Fibrofolliculoma (as originally described)
    - Interconnecting epithelial strands, forming lace-like patterns, extending from hair follicles
    - Epithelial strands embedded in loose stroma
  - Trichodiscoma (as originally described)
    - Loose stroma
    - Often with hair follicle at 1 border

- Skin tag (acrochordon)
  - Some (but not all) skin tags in BHDS have microscopic features of fibrofolliculoma/trichodiscoma on step sectioning

- Perifollicular fibroma
  - Some experts consider perifollicular fibroma equivalent to angiofibroma or fibrofolliculoma/trichodiscoma
    - Supported by microscopic findings of perifollicular fibroma and fibrofolliculoma in same tumor
  - Formerly associated with Hornstein-Knickenberg syndrome
    - Perifollicular fibromas and GI polyps
    - Currently, this syndrome considered synonymous with BHDS

- Angiofibroma
  - Histopathology
    - Stellate fibroblasts
    - Fibrotic stroma
    - Sometimes with concentric fibrosis around vessels/follicles

- Rare reports of
Diagnostic Pathology: Familial Cancer Syndromes

- Lipoma
- Leiomyoma
- Dermatofibrosarcoma protuberans
- Leiomyosarcoma
- Malignant melanoma

Renal
- Renal cell carcinoma
  - Previously, chromophobe or oncocytic subtypes considered overrepresented in BHDS
  - Recent studies suggest that any histologic subtype is possible
  - Risk of development is 15% by age 70
- Renal cysts

Pulmonary
- Pulmonary cysts
  - Rupture can lead to (recurrent) pneumothorax in ~ 30% of patients
    - When ruptured, may be misdiagnosed as blebs or bullae or other cystic air space disease
  - When intact
    - Cysts lined by friable, cuboidal, nonatypical pneumocytes
    - Pneumocytes resemble type II pneumocytes
  - Cyst wall may connect to
    - Interlobular septae
    - Pleura

Thyroid
- Nodules
- Cysts
- Carcinoma

Colorectal
- Some families may be at increased risk of colon carcinoma

Parotid
- Oncocytoma

Rarely Reported Neoplasms
- Squamous cell carcinoma of head/neck
- Hodgkin disease
- Uterine cancer
- Prostate cancer
- Breast cancer
- Squamous cell carcinoma of cervix
- Rhabdomyoma
- Adrenal mass

CANCER RISK MANAGEMENT

Renal Cell Carcinoma
- Some experts recommend screening with annual MR
  - From age 20
- Annual ultrasound is alternative to MR

Colorectal Carcinoma
- Colonoscopy
  - Especially in families in which colon cancer seems overrepresented

DIFFERENTIAL DIAGNOSIS

Familial Multiple Discoid Fibromas
- Facial/ear papules
  - Multiple
  - Variable size
  - With surface telangiectasias
  - Histopathology
    - Features similar to trichodiscoma
    - No evidence of interconnecting epithelial strands
    - Some authors suggest the term “discoid fibroma” to avoid confusion with trichodiscoma and BHDS
- Age
Facial/ear papules develop in childhood
- No association with renal carcinoma
- Very low risk of pneumothorax

**Genetics**
- Absence of FLCN mutation
- Mutations in folliculin-interacting protein 1 (FNIP1)
- Autosomal dominant inheritance

**Tuberous Sclerosis**
- Facial papules
  - Tendency to cluster on central face
  - Multiple
  - Pink-red to skin colored
  - Histopathology
    - Angiofibroma/fibrous papule
- Other skin findings
  - Hypomelanotic macules
  - “Confetti” macules
  - Periungual fibromas

**Cowden Syndrome**
- Facial/ear papules
  - Multiple
  - Verrucous to smooth
  - Skin colored to pink-yellow
  - Histopathology
    - Trichilemmoma: Lobules of pale cells bordered by peripheral palisading and thickened basement membrane
- Oral papillomatosis
- Acral keratoses
- Other skin lesions include tumor of the follicular infundibulum, sclerotic fibroma
- Other associated neoplasms
  - Breast carcinoma
  - Thyroid carcinoma

**Genetics**
- PTEN mutation
- Autosomal dominant inheritance

**Brooke-Spiegler Syndrome**
- Autosomal dominant inheritance
- CYLD mutation
- Multiple trichoepitheliomas, spiradenomas, cylindromas

Lymphangioleiomyomatosis
- Can lead to recurrent pneumothorax
- Renal angiomyolipomas
- Tends to affect women

Pulmonary Endometriosis
- Women
- Median age: 36 years
- Often present with pleural pain, shortness of breath
- Sometimes with history of pelvic endometriosis
- Histopathology
  - Proliferative or secretory endometrium

**DIAGNOSIS**

Criteria
- Patients should fulfill 1 major or 2 minor criteria for diagnosis
  - Major criteria
    - At least 5 fibrofolliculomas/trichodiscomas
    - Adult-onset
    - FLCN mutation
  - Minor criteria
    - Multiple lung cysts
      - Bilateral
      - Basal location
      - No other apparent cause
      - ± spontaneous pneumothorax
    - Renal cell carcinoma
      - Early onset (< age 50)
      - Or multifocal/bilateral carcinoma
      - Or mixed chromophobe/ondcocytic histology
    - 1st-degree relative with BHDS

**SELECTED REFERENCES**

P.I(2):15

Image gallery
Gross and Microscopic Features

(Left) This is a high-magnification view of a typical fibrofolliculoma, with a loose stroma in which there are reticulated, thin strands of epithelium. (Right) This lesion, previously termed trichodiscoma, has the same loose stroma as fibrofolliculoma, but absent reticulated strands of epithelium, often with a hair follicle bordering the loose stroma. On step sections, reticulated epithelium is often present, evidence that fibrofolliculoma and trichodiscoma are the same lesion.

(Left) This perifollicular fibroma (PFF) has the same loose stroma as in fibrofolliculoma/trichodiscoma. The stroma is concentric around hair follicle epithelium, with clefting from the surrounding normal dermis. On step sections, some PFFs show changes of fibrofolliculoma, suggesting they are related lesions. (Right) Angiofibroma (fibrous papule) has ectatic thin-walled vessels and dense collagenous stroma; there may be perifollicular fibrosis. (Courtesy S. Billings, MD.)
Chromophobe renal cell carcinoma is typically well circumscribed, with a tan-gray, multilobulated cut surface. Hemorrhage and necrosis are grossly identified in > 1/4 of cases. (Courtesy S. Tickoo, MD.) Typically, a chromophobe renal cell carcinoma shows solid sheets of clear and eosinophilic cells, separated by thin and incomplete vascular septations that do not completely encircle cell nests. (Courtesy S. Tickoo, MD.)

Bloom Syndrome
This image depicts the results of sister chromatid exchange (SCE) analysis performed on cells from an unaffected patient. Note that only a few SCEs are present in this control patient.

This image depicts the results of SCE analysis performed on cells from a Bloom syndrome patient. Note the markedly increased number of SCEs.

TERMINOLOGY
Abbreviations
- Bloom syndrome (BSyn)

Synonyms
- Bloom-Torre-Machacek syndrome
- Congenital telangiectatic erythema

Definition
- Rare autosomal recessive disorder resulting from mutations in the BLM gene; 1st described by dermatologist Dr. David Bloom in 1954

EPIDEMIOLOGY
Incidence
- Exceedingly rare (265 reported cases from 222 families in the Bloom Syndrome Registry as of 2009)
- Parental consanguinity common
- Cases have been described in North and South America, Europe, Asia, Africa, and Australia
- ~1/4 of people with BSyn are of Jewish descent, particularly Central and Eastern European (Ashkenazi) Jewish background
  - Seen in 1 in 48,000 live births in this population
- ~3/4 of people with BSyn are of non-Jewish background
  - Founder mutations have been described in many human populations, including
    - Japanese
    - European (Italian, Portuguese)
ETIOLOGY/PATHOGENESIS

Molecular Pathogenesis
- Caused by biallelic mutations in the BLM gene, located at 15q26.1 (most commonly homozygous; less frequently compound heterozygous)
  - Described mutations include missense, nonsense, insertions/deletions, and splicing defects due to intron mutations
- BLM is a tumor-suppressor gene and belongs to family of RecQ DNA helicases
  - RecQ helicases are important for repair of DNA damage
  - Protein product (BLM) permits unwinding of DNA in order to resolve disruptive structures that have developed during replication
  - Mutations in other RecQ helicase genes result in additional DNA repair deficiency syndromes
    - Werner syndrome (WRN gene on chromosome 8)
    - Rothmund-Thomson syndrome (RECQL4 gene on chromosome 8)

Immunodeficiency
- Pathogenesis of immunodeficiency is not well characterized
  - Hypogammaglobulinemia
  - Decreased or absent delayed hypersensitivity
  - Abnormal functioning of αβ T cells

CLINICAL FEATURES

Consistent Features
- Short stature and microcephaly due to growth retardation, pre- and postnatal, otherwise normal proportions
- Paucity of subcutaneous fat in infancy and childhood
- High predisposition to hematolymphoid and epithelial neoplasms

Variable Features
- Photosensitivity with development of erythema or telangiectasias in sun-exposed areas
- Patchy areas of hyper- and hypopigmentation
- Characteristic facies (long, narrow face with malar hypoplasia, small mandible, and prominent nose)
- Affected males experience infertility and affected females undergo early menopause
- Average intelligence; some patients with learning disabilities
- High-pitched voice
- Diarrhea and vomiting at an early age
- Immunodeficiency leading to recurrent infections
- Increased risk of chronic obstructive lung disease and diabetes mellitus (adult-onset type)

ANCILLARY TESTS

Confirmation of Diagnosis
- Cytogenetic testing
  - Diagnostic test: Evaluation for increased number of sister chromatid exchanges (SCE) in any cell (typically peripheral blood lymphocytes)
    - Cells are cultured for 2 cell cycles in a medium containing bromodeoxyuridine (BrDu) and arrested at metaphase
    - Upon fluorescence-plus-Giemsa coloration, differential staining of the 2 sister chromatids is apparent (1 appears dark, 1 appears light)
    - In BSyn, sister chromatids show an increased number of exchanges (at least 10x increase compared to control)
  - Increase in random chromosome breakage seen on metaphase spread including chromatid gaps, breaks and rearrangements, chromatid interchange configurations such as quadriradial interchange configuration, telomeric associations, anaphase bridges, and lagging chromosomal fragments
- Molecular testing
  - Targeted mutation analysis (e.g., evaluation for blmAsh [c.2207_2212del6ins7] in patients of Ashkenazi Jewish descent)
  - Sequence analysis of entire coding region
  - Deletion/duplication analysis

Prenatal Testing
Can be performed via SCE analysis or by specific mutation testing if familial mutation is known (chorionic villous sampling or amniocentesis)

**ASSOCIATED NEOPLASMS**

**Increased Cancer Risk**
- Up to 50% of patients with BSyn will develop a malignancy
  - ~10% have ≥ 2 primary cancers, with fewer numbers reported to have 3, 4, or even 5 primary neoplasms
- Mean age of cancer diagnosis: ~24 years
- Hematolymphoid malignancies predominant in first 2 decades of life
- Carcinomas predominant after first 2 decades of life
- Increased cancer incidence shortens overall lifespan

**Hematolymphoid Malignancies**
- Leukemia (both acute myeloid leukemia and acute lymphoblastic leukemia)
  - There may be preferential occurrence of monosomy 7 (-7) and deletion of long arm of chromosome 7 (del[7q]) in myelodysplastic syndrome/acute myeloid leukemia in BSyn patients
- Lymphoma (predominantly non-Hodgkin lymphoma, less frequently Hodgkin lymphoma)

**Carcinomas**
- Arise in varied sites including skin, head, neck, lung, uterus, breast, and gastrointestinal tract (including esophagus [both squamous cell carcinoma and adenocarcinoma], stomach, and colon)

**Rare Tumor Types**
- Medulloblastoma, Wilms tumor, osteogenic sarcoma

**Carriers**
- BLM mutation carriers do not have an increased cancer risk

**CANCER RISK MANAGEMENT**

**Patients With BSyn**
- Markedly increased risk of a variety of malignancies, which occur earlier compared to general population, necessitates careful and broad cancer surveillance throughout patient’s life
- Exposure to radiation or DNA-damaging chemicals should be avoided

**SELECTED REFERENCES**


**Carney Complex Including LAMB Syndrome**

> Table of Contents > Part I - Overview of Syndromes > Section 2 - Syndromes > Carney Complex Including LAMB Syndrome

Carney Complex Including LAMB Syndrome
Vania Nosé, MD, PhD
Myxoid lesions associated with Carney complex (CNC) are located in different sites, including skin, heart, and breast. Cardiac myxomas may occur in any chamber and at any age.
Gross findings of PPNAD include decreased, normal, or slightly increased weight, presence of small black-brown and yellow nodules, atrophy of the cortex, and loss of normal zonation.

**TERMINOLOGY**

**Abbreviations**
- Carney complex (CNC)
- Lentigines, atrial myxomas, mucocutaneous myxomas, and blue nevi syndrome (LAMB)

**Synonyms**
- Nevi, atrial myxoma, myxoid neurofibroma, and ephelides (NAME) syndrome
- Carney syndrome

**Definitions**
- Multiple neoplasia syndrome featuring cardiac, endocrine, cutaneous, and neural tumors, as well as variety of pigmented lesions of skin and mucosae
- CNC may simultaneously involve multiple endocrine glands, as in classic multiple endocrine neoplasia syndromes 1 and 2

**EPIDEMIOLOGY**

**Age Range**
- Mean age at diagnosis is 10-20 years

**Gender**
- M = F

**Incidence**
- > 400 patients have been diagnosed with CNC
- Cardiac myxomas are most common primary cardiac tumor and occur in 7 per 10,000 individuals

**ETIOLOGY/PATHOGENESIS**

**Etiology**
Autosomal dominant disorder characterized by complex of myxomas, spotty pigmentation, and endocrine overactivity

- Several patients described in earlier years under acronyms NAME and LAMB probably had CNC
- CNC is not only multiple neoplasia syndrome but also causes variety of pigmented lesions of skin and mucosae

Genetic mutation in PRKAR1A gene (17q22-24) and chromosome 2p16

- PRKAR1A encodes regulatory R1 α-subunit of protein kinase A

**CLINICAL IMPLICATIONS**

**Clinical Presentation**

- **Skin**
  - Multiple facial lentigines and mucosal labial pigmentation
  - Subcutaneous myxoid neurofibromas
  - Epithelioid blue nevus

- **Endocrine organs**
  - **Adrenal**
    - Primary pigmented nodular adrenocortical disease (PPNAD)
    - Cushing syndrome
  - **Thyroid**
    - Thyroid nodules
  - **Pituitary adenoma**
    - Acromegaly/gigantism or galactorrhea, depending on tumor type

- **Heart**
  - Atrial myxomas are most common primary tumor of heart
  - Majority of tumors arise from left atrial septum near fossa ovalis
  - Lesions arising from right atrium or in young adults are more likely to be associated with familial syndrome
  - May present with tumor emboli

- **Testis**

**Treatment**

- Depends on main pathology
  - Bilateral adrenalectomy
  - Removal of cardiac myxomas
  - Surgery with removal of testicular tumors
  - Surgery with removal of other tumors

**Prognosis**

- Most tumors associated with CNC are slow growing with no malignant potential
- Sudden death due to cardiac myxoma may occur
  - Decreased lifespan expected

**MACROSCOPIC FINDINGS**

**Atrial Myxoma**

- Mobile, pedunculated, ball-shaped mass

**PPNAD**

- Small to normal-sized adrenal glands
- Multiple bilateral, small cortical nodules (0.1-0.3 cm)
  - May be pigmented, brown, or black; some may be pale to bright yellow

**Large Cell Calcifying Sertoli Cell Tumor**

- Ranges in size from microscopic to large tumor replacing entire testis
- Usually multicentric, bilateral, and calcified
Psammomatous Melanotic Schwannoma
- Black, multiple nodules that occur simultaneously or asynchronously at different sites

**MICROSCOPIC FINDINGS**

**Histologic Features**
- Atrial myxoma
  - Composed of plump, stellate, or spindled cells arranged in cords and primitive-appearing vessels in loose, myxoid stroma
    - Stroma often contains hemorrhage or hemosiderin with variable numbers of inflammatory cells
  - Heterologous elements such as glands or extramedullary hematopoiesis can be found in small minority of cases (2%)
- PPNAD
  - Nodules composed of cells with compact eosinophilic cytoplasm, with abundant brown granular pigment (lipofuscin)
  - Cell nuclei are vesicular and may contain prominent nucleoli
  - Intervening cortical tissue is atrophic
- Large cell calcifying Sertoli cell tumor
  - Tumor has ill-defined periphery
  - Multiple cellular arrangement patterns of distribution: Usually solid or trabecular
  - Large tumor cells with abundant granular and eosinophilic cytoplasm
  - Laminated calcospherites are characteristic
    - May be only few or multiple, and often with confluence
  - Mitoses are rare
  - Neutrophilic infiltration is usually present
- Pituitary adenoma
  - Adenoma with solid growth pattern
  - Round and polygonal cells with granular eosinophilic cytoplasm and round to oval nuclei
  - Usually growth hormone (GH) &/or prolactin-producing tumors
- Psammomatous melanotic schwannoma
  - Peripheral nerve sheath tumor affecting posterior spinal nerve roots, alimentary tract, bone, and skin
  - Spindle and epithelioid cells intermixed with melanin, psammoma bodies, and adipose tissue
  - ~ 10% are malignant and metastasize

**DIAGNOSIS**

**Criteria**
- Definite diagnosis of CNC is given if 2 or more major manifestations are present
- Major diagnostic criteria for CNC
  - Spotty skin pigmentation with typical distribution on such sites as the lips, conjunctiva and inner or outer canthi, or vaginal and penile mucosa
  - Myxoma (cutaneous and mucosal)
  - Cardiac myxoma
  - Breast myxomatosis or fat-suppressed MR imaging findings are suggestive
  - PPNAD or paradoxical positive response of urinary glucocorticosteroid excretion to dexamethasone administration during Liddle test
  - Acromegaly due to GH-producing adenoma
  - Large cell calcifying Sertoli cell tumor
  - Thyroid carcinoma or multiple adenomatous nodules in young patient
  - Psammomatous melanotic schwannomas
  - Blue nevus, epithelioid blue nevus
  - Breast ductal adenoma
  - Osteochondromyxoma
- Supplementary criteria
  - Affected 1st-degree relative
  - Inactivating mutation of PRKAR1A gene
- Cutaneous manifestations constitute 3 of the major disease manifestations
  - Cutaneous or mucosal myxoma
  - Blue nevi (multiple) or epithelioid blue nevus
- Findings suggestive of, or possibly associated with CNC, but not diagnostic
  - Intense freckling (without darkly pigmented spots or typical distribution)
- Multiple blue nevi of common type
  P.I(2):20

- Café au lait spots or other birthmarks
- Elevated IGF1 levels, abnormal GTT, or paradoxical GH response to TRH testing in absence of clinical acromegaly
- Cardiomyopathy
- Pilonidal sinus
- History of Cushing syndrome, acromegaly, or sudden death in extended family
- Multiple skin tags or other skin lesions, including lipomas and angiofibromas
- Colonic polyps (usually in association with acromegaly)
- Hyperprolactinemia (usually mild and almost always combined with clinical or subclinical acromegaly)
- Single, benign thyroid nodule in young patient; multiple thyroid nodules in older patient (detected on ultrasound)
- Family history of carcinoma, particularly of thyroid, colon, pancreas, and ovary; other multiple benign or malignant tumors
- Relationship between cutaneous and noncutaneous manifestations of CNC appears to be essential clue to molecular etiology
- > 1/2 of CNC patients present with both characteristic dermatological and endocrine signs
  - Significant number of patients present with skin lesions that are only suggestive, not characteristic, of CNC

- Classification based on both dermatological and endocrine markers has subgrouped CNC patients as
  - Multisymptomatic (with extensive endocrine and skin signs)
  - Intermediate (with few dermatological and endocrine manifestations)
  - Paucisymptomatic (with isolated PPNAD and no cutaneous signs)

**Diagnostic Criteria for Clinical Diagnosis**
- Patient must have ≥ 2 of the following
  - Spotty skin pigmentation with a typical distribution (often vermillion border of lips, conjunctiva and ocular canthi, vaginal or penile mucosa)
  - Myxoma (cutaneous: Often on the eyelid, external ear, nipple)
  - Cardiac myxoma
  - Breast myxomatosis or fat-suppressed MR findings suggestive of this diagnosis
  - Acromegaly due to GH-producing adenoma (somatotropinoma)
  - PPNAD or paradoxical positive response of urinary glucocorticosteroid to dexamethasone administration during diagnostic test for Cushing syndrome
  - Thyroid carcinoma or multiple hypoechogenic nodules on thyroid ultrasonography in a young patient
  - LCCSCT of testis or characteristic calcification on testicular ultrasonography
  - Psammomatous melanotic schwannoma
  - Blue nevus, epithelioid blue nevus (multiple)
  - Breast ductal adenoma, or mammary tumor with intraductal papilloma
  - Osteochondromyxoma of bone
  - Additional criteria is satisfied by a patient meeting only 1 of these criteria, but having either
    - Affected 1st-degree relative or
    - Inactivating mutation of the PRKAR1A gene

**Similar Clinical and Pathological Features**
- Peutz-Jeghers syndrome (PJS), with which it shares mucosal lentiginosis and unusual gonadal tumor, and large cell calcifying Sertoli cell tumor
- McCune-Albright syndrome: Sporadic condition also characterized by multiple endocrine and nonendocrine tumors

**ANCILLARY TESTS**

**Immunohistochemistry**
- Atrial myxoma
  - Cells stain positive for CD34, CD31, and S100
  - Calretinin is positive in 74-100% of cases and can be useful to distinguish this lesion from myxoid thrombus
- PPNAD
  - Increased expression of glucocorticoid receptor
Large cell calcifying Sertoli cell tumor
- Positive for vimentin, inhibin-α, NSE, S100, desmin, and smooth muscle actin
- Negative for α-fetoprotein, HCG, PLAP, podoplanin, OCT3/4, and cytokeratin (may be focally positive)

Molecular Genetics
- Genetic heterogeneity with ≥ 2 main loci for candidate genes
  - Chromosome 2 locus at 2p15-16
  - Mutations of PRKAR1A gene on chromosome 17 (17q22-24)

DIFFERENTIAL DIAGNOSIS
Other Syndromes
- Share clinical features and molecular pathways with several other familial lentiginosis syndromes, such as
  - McCune-Albright syndrome
  - Peutz-Jeghers syndrome
  - LEOPARD (multiple lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth, and sensorineural deafness)
  - Noonan syndrome
  - PTEN-hamartoma tumor syndromes (e.g., Cowden disease [CD] and Bannayan-Ruvalcaba-Riley syndrome [BRRS])
  - In all of these conditions, skin lesions accompany underlying endocrine &/or other abnormalities, and, similarly to CNC, are considered important diagnostic sign

McCune-Albright Syndrome
- Probably the closest to CNC in terms of molecular pathway link
  - P.I(2):21

- Patients have characteristic lesions that affect predominantly 3 systems: Skin, endocrine system, and skeleton
- Café au lait spots in McCune-Albright syndrome patients are similar to those observed in CNC
  - Tend to be more intensely pigmented
- Caused by post-zygotic activating mutations of GNAS1

Peutz-Jeghers Syndrome
- Autosomal dominant familial lentiginosis syndrome characterized by melanocytic macules of lips, buccal mucosa, and digits, multiple gastrointestinal hamartomatous polyps, and increased risk of various neoplasms
- Lentigines observed in Peutz-Jeghers syndrome patients show similar density and distribution to those in CNC patients
- Peutz-Jeghers syndrome was first mapped to chromosome 19p13.3, and gene-encoding serine threonine kinase 11 (STK11 a.k.a. LKB1) was found to be mutated in most patients

LEOPARD
- Multiple lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth, and sensorineural deafness

Cowden Disease and Bannayan-Ruvalcaba-Riley Syndrome (PTEN-Hamartoma Tumor Syndromes)
- Cowden disease and BRRS share clinical characteristics, such as mucocutaneous lesions, hamartomatous polyps of gastrointestinal tract, and increased risk of developing neoplasms
- Both conditions are caused by mutations in PTEN gene
  - PTEN is located on 10q23.31 and encodes phosphatidylinositol-3,4,5-triphosphate 3-phosphatase
    - Tumor suppressor gene that has been found mutated in a number of tumors
- Thyroid is usually affected by numerous adenomatous nodules, follicular adenomas, and follicular carcinoma
  - Findings are similar to those familial syndromes characterized by predominance of nonthyroidal tumors
    - PTEN-hamartoma tumor syndrome, Carney complex, Werner syndrome, and Pendred syndrome

SELECTED REFERENCES

Image gallery
Tumors and Lesions Associated With Carney Complex

(Left) Lateral radiograph shows densely calcified left atrial myxoma. This patient had multiple transient ischemic
attacks, a clinical feature associated with cardiac myxoma. (Right) Axial CECT shows myxoma involving the interarterial septum and extending into the right atrium. A tumor embolism is seen in a right lower lobe pulmonary artery branch. The tumor is of decreased density compared to contrasted heart chambers and has a different density than adipose tissue.

(Left) Gross cross section of an adrenal gland from a patient with Cushing syndrome, CNC, and primary pigmented nodular adrenocortical disease (PPNAD) shows presence of small, nonpigmented nodules, most of which cannot be appreciated grossly. (Right) On low-power magnification, the normal adrenal gland architecture is replaced by multiple nodules, most of which are unencapsulated but some have a thin fibrous capsule. There is lipomatous metaplasia and the adjacent adrenal is atrophic.

(Left) In PPNAD, there is loss of zonation of the adrenal cortex, which has multiple small cortical nodules composed of enlarged globular cortical cells with granular and eosinophilic cytoplasm. Note a variable amount of lipochrome pigment deposition. (Right) The adrenal cortex shows loss of zonation and atrophy of cortex adjacent to nodules in PPNAD. The nodules are composed of enlarged globular cortical cells with granular eosinophilic cytoplasm with lipochrome pigment.

P.I(2):23

Tumors Associated With Carney Complex
Pituitary adenomas, microadenomas, or macroadenomas, which are usually GH-producing adenomas, are some of the findings in Carney complex. (Right) Photomicrograph shows a sparsely granulated somatotroph adenoma composed of chromophobic cells. The nuclei can be centrally located but also tend to be eccentric, pushed to the cell periphery, and indented by the fibrous bodies.

(Left) CAM5.2 reveals diffuse paranuclear keratin aggresomes (fibrous bodies) in sparsely granulated somatotroph adenomas. Occasional fibrous bodies can be seen in aggressive acidophil stem cell adenomas as well as in intermediate-type somatotroph adenomas. (Right) GH in a densely granulated somatotroph adenoma shows numerous GH-containing cytoplasmic secretory granules that correlate with the cytoplasmic eosinophilic appearance on H&E.
Large cell calcifying Sertoli cell tumor (LCCSCT) shows cords and small nests of large epithelioid cells embedded in a fibrous background with dense neutrophilic infiltrate. A psammoma body is also seen. The neutrophilic background is an important diagnostic feature. (Right) LCCSCT is shown with nests of large epithelioid cells with abundant eosinophilic cytoplasm. A large area of calcification is seen in the loose fibromyxoid stroma.

Costello Syndrome
This young girl with Costello syndrome has the characteristic facies, with thick lips, a large mouth, and prominent epicanthal folds.

This is a hand of a patient with Costello syndrome. Deep palmar creases and ulnar deviation are apparent.

**TERMINOLOGY**

**Synonym**
- Facio-cutaneous skeletal syndrome

**Definitions**
- Syndrome of delayed development, intellectual impairment, heart defects, loose skin, flexible joints
- Cumulative incidence of cancer ~ 15% by age 20

**EPIDEMIOLOGY**

**Incidence/Prevalence**
- Very rare; several hundred reported cases
- Estimated prevalence: 1 in 300,000 to 1 in 1.25 million

**GENETICS**

**HRAS Mutation in 80-90%**
- H-Ras protein is relevant to cell growth/turnover
  - H-Ras is overactive in Costello syndrome
  - Most common mutation is p.G12S

**Inheritance**
- Autosomal dominant transmission
- Almost all reported cases secondary to new mutation (no prior history in family members)

**CLINICAL IMPLICATIONS AND ANCILLARY TESTS**

**Clinical Presentation**
- May be large for gestational age, secondary to edema
- Characteristic, coarse facies
Large mouth, thick lips, low-set ears, epicanthal folds, depressed nasal bridge, anteverted nostrils
- Curly or sparse, fine hair
- Redundant skin over neck, hands
- Deep palmoplantar creases
- Palmoplantar keratoderma
- Difficulty feeding, slow growth, short stature
  - Failure to thrive
- Hypotonia, joint laxity, ulnar deviation (splayed fingers)
- Tight Achilles tendons
- Chiari I malformation
- Skeletal malformations
  - Short stature, relative macrocephaly, kyphoscoliosis, positional foot deformity
- Dental issues
- Vision problems (e.g., nystagmus)
- Cardiovascular system complications (e.g., hypertrophy, pulmonic stenosis, arrhythmia, aortic dilation)

ASSOCIATED NEOPLASMS
Skin Papillomas
- Tendency to be perinasal/perioral/perianal
- May be present in young children or absent until > 10 years of age

Rhabdomyosarcoma
- 19 of 268 patients (7%) in 1 review
  - 9 embryonal, 1 alveolar, 1 mixed histology, 1 pleomorphic, 1 spindle cell type, 6 unclassified
- Median age: 2.3 years

Bladder Carcinoma (Urothelial Carcinoma)
- 4 of 268 patients (1.4%) in 1 review
  - 3/4 with transitional cell carcinoma
  - 1/4 with low-grade papillary bladder carcinoma

Neuroblastoma
- 5 of 268 patients (1.9%) in 1 review

  - 4/5 with ganglioneuroblastoma
- Mean age: 13.5 years

Fibrosarcoma
- 1 of 268 patients (0.4%) in 1 review

CANCER RISK MANAGEMENT
Rhabdomyosarcoma
- Abdominal/pelvic ultrasound: Every 3-4 months until age 8 years

Transitional Cell Carcinoma
- Annual urinalysis, beginning at 10 years of age

DIFFERENTIAL DIAGNOSIS
Cardiofaciocutaneous Syndrome
- Associated cancers/tumors
  - Acute lymphoblastic leukemia, non-Hodgkin lymphoma, hepatoblastoma, embryonal rhabdomyosarcoma
- Autosomal dominant
  - Germline mutations in BRAF, MEK1, MEK2

Noonan Syndrome
- Associated cancers/tumors
  - Neuroblastoma (8 of 1,051 patients in 1 review)
  - Acute lymphoblastic leukemia (8 of 1,051 patients in 1 review)
  - Low-grade glioma (6 of 1,051 patients in 1 review)
  - Rhabdomyosarcoma (6 of 1,051 patients in 1 review)
- By 20 years of age, ~ 4% cumulative incidence of cancer
- Autosomal dominant
  - Germline mutations in PTPN11, SOS1, KRAS, NRAS, RAF1, BRAF, SHOC2, or MEK1 in 70-75%
- Short stature, developmental delay, congenital heart defects
LEOPARD Syndrome (Noonan Syndrome With Multiple Lentigines)
- Associated tumors overlap with Costello syndrome
- Autosomal dominant, germline mutations in PTPN11, BRAF, RAF1

DIAGNOSTIC FEATURES
Frequency of Major Features
- Short stature (97%), abnormal palmar creases (99%), loose skin (94%)
- Characteristic facies (98%), thick lips (95%)
- Dysphagia/feeding difficulty/gastrostomy tube (95%)
- Developmental delay/mental retardation (100%)

Frequency of Unique Features
- Congenital heart defects (65%)
  - Examples: Pulmonic stenosis (20%), hypertrophic cardiomyopathy (40%), atrial tachycardia (30%)
- Benign (44%), malignant (16%) tumors
- Stretchy skin with hyperpigmentation
- Kyphoscoliosis, engaging personality, normal head circumference

Frequency of Other Features
- Polyhydramnios (62%), birth weight > 50%, hernias (50%), vision: Ptosis, strabismus

SELECTED REFERENCES

IMAGE GALLERY

(Left) This embryonal rhabdomyosarcoma has ovoid/spindled nuclei with eosinophilic cytoplasm set in a myxoid stroma that imparts a filigree pattern. (Courtesy C. Fisher, MD.)
(Center) In this urothelial carcinoma in situ with microinvasion, the small cluster of neoplastic cells fociy invades the lamina propria (p.T1). (Courtesy S. Tickoo, MD.)
(Right) This is a low-power view of a poorly differentiated neuroblastoma. (Courtesy J. Comstock, MD.)
Axial T2WI MR of a baby shows presence of an undescended testis in the right inguinal area. A vagina is also demonstrated, however, confirming internal genital organs of both sexes.
PAS stain shows glomeruli with mesangial sclerosis characterized by an increase in matrix deposits. Diffuse mesangial sclerosis is a primary feature of DDS seen in ~95% of patients. (Courtesy S. Meehan, MD.)

TERMINOLOGY

Abbreviations
- Denys-Drash syndrome (DDS)

Definition
- Disorder characterized by ambiguous genitalia or pseudohermaphroditism, early-onset nephrotic syndrome, and ↑ risk for Wilms tumor (WT)

EPIDEMIOLOGY

Incidence
- Very rare, ~200 cases reported

Gender
- Karyotype
  - Most tested are male (46, XY)
    - Including >80% of patients with ambiguous external genitalia and >60% of patients with female external genitalia
  - Few female karyotype probably due to underdiagnosis of DDS in both genotypic and phenotypic females with nephropathy
- External genitalia
  - Male: 13%
  - Female: 42% (most are male with pseudohermaphroditism)
  - Ambiguous: 43%

Age
- Onset of nephropathy
  - Range: 1 month to 17 years
  - Average: 1.4 years
• Onset of WT
  o Range: 1 month to 13 years
  o Average: 1.6 years

GENETICS
WT1
• Located at Chr 11p13
• Transcript critical in early and late stages of genitourinary development
• DDS is caused by germline point mutation in zinc finger region of WT1
  o C to T transition missense mutation at amino acid 394 in exon 9 involving 3rd zinc finger of WT1 most common
  o Also G to A transition at +5 of splice donor site within intron 9

GENITALIA
External Genitalia
• Most are male with pseudohermaphrodism having external female or ambiguous genitalia
Internal Genitalia
• Most have dysgenic gonads
  o “Streak gonads” composed of fibrous tissue without epithelial structures
  o Immature, infantile, or rudimentary gonads
  o Wolffian structures present in phenotypic female
  o Both Wolffian and müllerian structures present
• May also have both testicular and ovarian tissues present or ovotestis (true hermaphrodites)
• Only in few cases is internal genitalia appropriate to external genitalia

RENAL FEATURES
Nephrotic Syndrome
• Present in 95% of cases, a primary feature of DDS
• Early onset that progresses rapidly to end-stage renal disease (ESRD)
P.I(2):27

• Presents usually in 1st year of life
• Microscopic features: Diffuse mesangial sclerosis
  o Fibrillar expansion in mesangial matrix
  o No mesangial cell proliferation
  o Podocyte hypertrophy with vacuolations
  o Glomerular basement membrane thickening due to subepithelial apposition of thin layers of basal lamina
  o Tubular dilations, which may contain casts
  o Tubulointerstitial inflammation and fibrosis
  o Fully developed lesion shows glomerular basement membrane thickening and massive enlargement of mesangial areas
  o Mesangial sclerosis may eventually contract glomerular tuft into a sclerotic mass within Bowman space
  o Focal mesangial sclerosis may also occur in a smaller subset
• Nuclear expression of WT1 in podocytes absent or decreased, suggesting decreased binding capacity of mutated protein

ASSOCIATED NEOPLASMS
Wilms Tumor
• Malignant immature tumor of nephrogenic blastemal cell origin that may differentiate into epithelial or mesenchymal cells recapitulating renal embryogenesis
• Present in 74% of DDS patients
• Age of onset similar to that of nephropathy
• May also present as an abdominal mass
• ~ 20% of WTs are bilateral
• No distinct histologic features from sporadic WT cases

Gonadal Malignancies
• ~ 4% of DDS patients develop gonadal malignancies
• Most common is gonadoblastoma, a tumor composed of seminomatous/dysgerminomatous elements and immature sex cord-stromal elements
• Juvenile granulosa cell tumor also reported

OTHER ASSOCIATED FINDINGS
Structural and Functional Abnormalities
• Overall present in 10% of DDS
• Can be an isolated abnormality (e.g., hernia, contractures) or multiple abnormalities (e.g., cleft palate, mental retardation, nystagmus)
• Renal abnormalities include unilateral hydronephrosis, renal pelvis or ureter duplication, double kidney and horseshoe kidney

CANCER RISK MANAGEMENT
Wilms Tumor
• Bilateral nephrectomy for children with ESRD suggested
• For DDS children on dialysis, unilateral nephrectomy suggested, followed later by contralateral nephrectomy at time of kidney transplantation

Gonadal Malignancies
• Elective gonadectomy proposed

PROGNOSIS
Outcome
• With limited cases followed, 32% of patients alive with age range of 3 months to 21 years
• 38% of patients died at an average age of 2 years (range: 1 month to 7.5 years)
• Most common cause of death is renal failure (80%) followed by sepsis (3.5%)
• < 2% of patients died from WT

DIFFERENTIAL DIAGNOSIS
WT, Aniridia, Genitourinary Abnormalities, and Mental Retardation (WAGR) Syndrome
• Rarely, aniridia and retardation may occur in DDS
• WT and genitourinary abnormalities in absence of nephropathy in DDS (~5%) can make distinction difficult
  • Diagnosis of DDS made if external genitalia are female and internal genitalia show both wolffian and müllerian structures or karyotype is male

Frasier Syndrome
• Phenotype: Ambiguous genitalia, streak gonads, and segmental glomerulosclerosis
• Nephropathy similar but usually of a later age of onset

Diffuse Mesangial Sclerosis
• Rare occurrence as isolated finding (nephropathy) without other phenotypic features seen in DDS

Nephrotic Syndrome in Infants
• Consider congenital nephrosis, idiopathic nephrosis, diffuse mesangial proliferation, minimal change or focal segmental sclerosis, and isolated diffuse mesangial sclerosis

SELECTED REFERENCES

SELECTED REFERENCES

SELECTED REFERENCES

SELECTED REFERENCES

SELECTED REFERENCES

SELECTED REFERENCES

SELECTED REFERENCES
High-power view shows a glomerulus in DDS with early mesangial sclerosis shown by an increase in matrix deposits. (Courtesy S. Meehan, MD.) Silver stain shows a glomerulus with an early increase in mesangial matrix deposition. Glomerular capillary loops are open. Mesangial sclerosis eventually causes rapid decline in glomerular filtration rate and progresses to ESRD. Nephropathy and its complications are the most common cause of death in DDS. (Courtesy S. Meehan, MD.)

H&E of kidney from a DDS patient shows multiple nephrogenic rests. Nephrogenic rests are considered to be precursors of WT. DDS increases the risk for WT, which is encountered in 74% of patients. (Courtesy S. Meehan, MD.) H&E shows a dysgenetic gonad in DDS, composed purely of ovarian-type stroma without any epithelial cells (“streak gonad”). The majority of patients with DDS are karyotypically male (46, XY) and most have female or ambiguous external genitalia.
(Left) H&E shows a dysgenetic gonad containing both müllerian-type structure (fallopian tube) and wolffian-type structure (epididymis/ductuli efferentes). (Right) H&E shows an ovotestis containing both testicular and ovarian elements. Seminiferous tubules containing mostly Sertoli cells are present. In addition, ovarian follicles are clustered nearby. Note the presence of interstitial steroid-producing cells. Ovotestis increases the risk for the development of gonadoblastoma.

P.II(2):29

**Associated Neoplasms**

(Left) H&E shows WT with classic triphasic histology consisting of blastemal cells, epithelial cells, and stromal cells. WT may also have biphasic or uniphasic histology. Although DDS has a high risk for WT, only a small subset of patients will die from this malignancy. (Right) Low-power view shows WT consisting purely of blastemal cells. These are tightly packed primitive cells with high nuclear to cytoplasmic ratio, giving the appearance of small round blue cells.
H&E shows WT containing some glomeruloid epithelial structures admixed with blastemal cells. Note presence of mitosis. WT is a primitive neoplasm that recapitulates renal embryogenesis. (Right) Gonadoblastoma is characterized by nests containing large seminomatous germ cells located in the center, and sex cord-stromal cells forming Call-Exner-like structures at the periphery of the nests. (Courtesy S. Shen, MD, PhD.)

Gonadoblastoma shows smaller sex cord-stromal cells forming Call-Exner body-like structures and large seminomatous cells with abundant clear cytoplasm and prominent nucleoli. Gonadoblastoma usually occurs in dysgenetic gonads such as in DDS. (Courtesy S. Shen, MD, PhD.) (Right) Juvenile granulosa cell tumor is composed of multicystic follicular spaces lined by multilayers of granulosa cells containing basophilic fluid. (Courtesy S. Shen, MD, PhD.)
Dyskeratosis Congenita

Squamous cell carcinoma on the posterior lateral border of the tongue presents as an exophytic, firm, indurated mass with rolled borders. (Courtesy S. Müller, DMD.)
Well-differentiated squamous cell carcinoma extends from the overlying epithelium into the lamina propria with keratin pearl formation. (Courtesy S. Müller, DMD.)

**TERMINOLOGY**

**Definition**
- Syndrome with 3 characteristic features
  - Oral leukoplakia
  - Abnormal nails
  - Reticulate hyperpigmentation
- Secondary to defective telomere maintenance

**Synonyms**
- Zinsser-Cole-Engman syndrome
- Hoyeraal-Hreidarsson syndrome
- Revesz syndrome

**EPIDEMIOLOGY**

**Prevalence**
- ~ 1 in 1 million
- ~ 500 reported cases in literature from 1910-2008

**Gender**
- Male predominance for X-linked form

**Natural History**
- Phenotype variable
  - Severely affected patients may die early from bone marrow failure
- Median overall survival age: 42 years

**Age of Onset**
- Variable, but classically
1st decade
- Skin hyperpigmentation
- Oral leukoplakia
- Nail changes

2nd decade
- Bone marrow failure
- Median age: 29 years for development of cancer

GENETICS

Germline Mutations
- TERT, TERC, DKC1, TINF2 genes; documented in ~50% of cases
  - These function in maintaining telomeres
  - TERT and TERC encode telomerase, which maintains telomere length; telomerase is a ribonucleoprotein with 2 components
    - TERC encodes RNA component of telomerase
    - TERT encodes telomerase reverse transcriptase enzyme
    - TERT and TERC mutations also described in cases of idiopathic pulmonary fibrosis &/or aplastic anemia
  - DKC1 encodes dyskerin, which stabilizes telomerase complex
    - Dyskerin: 58 kD nucleolar protein, associates with small nucleolar RNAs
    - Dyskerin binds to telomerase RNA
  - TINF2 is related to shelterin complex, which helps protect telomeres
    - Shelterin made of 6 proteins
    - Shelterin protects telomere ends from destruction &/or DNA repair
- Other genes (also involved in telomere maintenance)
  - NOLA2 (encodes NOP10), NOLA3 (encodes NHP2), RELT1, CTC1, TCAB1, WRAP53
- Patients with dyskeratosis congenita have short telomeres
  - Exception is subset of dyskeratosis congenita with mutations in USB1 (C16orf57)
    - This subset has overlapping features with poikiloderma with neutropenia and Rothmund-Thomson syndrome
- Telomeres are noncoding sequences at chromosome ends
  - Telomeres become shorter with each cell division

Telomerase adds genetic repeat TTAGGG to 3' end of DNA after replication, to prevent shortening of telomeres
- Rapidly dividing cells are most at risk for telomere shortening; these cells (germ cells, stem cells) have telomerase
- Cells with shortened telomeres become apoptotic through p53 pathway

Genetic anticipation
- Disease presents at a progressively earlier age in subsequent generations
- Seen in families with TERC mutations

Inheritance
- X-linked recessive
  - When secondary to DKC1 mutations, located on X chromosome
- Autosomal dominant
  - When secondary to TERC or TINF2 mutations
- Autosomal dominant or recessive
  - When secondary to TERT mutations
- Autosomal recessive
  - When secondary to CTC1, WRAP53, NHP2, NOP10

CLINICAL IMPLICATIONS AND ANCILLARY TESTS

Clinical Presentation
- Variable severity: Ranges from mild skin findings with normal bone marrow to early bone marrow failure and death
  - Hoyeraal-Hreidarsson syndrome more severe
    - Cerebellar hypoplasia
    - Microcephaly
    - Severe immunodeficiency
- Aplastic anemia
- Enteropathy
- Intrauterine growth retardation
- Developmental delay

Revesz syndrome
- Bilateral exudative retinopathy
- Developmental delay
- Oral leukoplakia, abnormal nails, reticulate hyperpigmentation
- Cerebellar hypoplasia
- Bone marrow hypoplasia

Phenotypic variability correlated with genotype
- TINF2 mutations cause severe disease with early death; age of onset often < 5 years, aplastic anemia often before 10 years
- Disease secondary to TERC mutations less severe than DKC1 mutations, but bone marrow failure may present earlier with TERC mutations
- Cancer more common in disease secondary to TERT and TERC mutations (may be because patients with TERT and TERC mutations live longer)
- Cancer less common in disease secondary to TINF2 mutations

Classic triad
- Appears in 1st decade
- Oral leukoplakia (~ 80% of cases)
- Abnormal nails (~ 90% of cases)
- Reticulate hyperpigmentation (~ 90% of cases)

Associations (% generally based on London registry)
- Bone marrow
  - Failure (~ 85%): Most common cause of death by 3rd decade (~ 60-70%), presents in 2nd decade
  - Aplastic anemia (in up to 86% of patients)
  - Myelodysplastic syndrome
  - Leukemia
  - Immunologic abnormalities may be the initial presentation (i.e., lymphopenia, low B-cell counts, hypogammaglobulinemia, decreased T-cell function)
  - Cancers of head/neck/skin/anogenital region (52/552 patients on literature review)
  - Lead to mortality in up to 60%
  - Cumulative incidence of cancer 40-50% by age 50
  - Head/neck squamous cell carcinoma: 40% of patients on review

- Pulmonary fibrosis (~ 20%)
  - Leads to mortality in ~ 10-15%
- Narrow/blocking tear ducts causing epiphora (~ 30%)
- Mental retardation (~ 25%)
- Short stature (~ 20%)
- Dental problems
  - Extensive caries (~ 17%)
- Esophageal stricture (~ 17%)
- Alopecia
- Premature graying (~ 16%)
- Palmoplantar keratoderma
- Osteoporosis, avascular necrosis (hip/shoulder) (~ 5%)
- Liver disease (~ 7%)
- Cerebellar hypoplasia (~ 7%)
- Hypogonadism (~ 6%)
- Microcephaly (~ 6%)
- Urethral stenosis (~ 5%)
- Deafness (~ 1%)

Management
- Bone marrow failure
  - Consider treatment if Hgb < 8 g/dL, PLT < 30,000/mm³, neutrophils below 1,000/mm³
  - Mainstay of treatment: Stem cell transplantation
- Less severe cases: Treatment options
ASSOCIATED NEOPLASMS
Based on 552 Reported Cases of Dyskeratosis Congenita

- Squamous cell carcinoma of head/neck (especially tongue)
  - 24 cases in 22 patients
  - P.J.[2]:32

  - Metachronous cancers documented

- Skin cancer
  - 8 cases

- Anorectal carcinoma
  - 6 cases

- Gastric carcinoma
  - 2 adenocarcinoma (2 unspecified)

- Lung carcinoma
  - 2 bronchial, 1 adenocarcinoma, 1 unspecified

- Esophageal carcinoma
  - 3 cases

- Hodgkin lymphoma
  - 3 cases

- Colorectal carcinoma
  - 2 adenocarcinomas (1 unspecified)

- Other
  - 2 pancreatic adenomas, 2 liver adenomas, 1 retinoblastoma, 1 cervical squamous cell carcinoma, 1 non-Hodgkin lymphoma

CANCER RISK MANAGEMENT
Prevention
- Avoid radiotherapy
- Avoid smoking
- Limit sun exposure, use sunscreen/sun protection

Leukemia
- CBC annually (or more often if abnormal)
- Consider annual bone marrow aspirate after baseline examination

Squamous Cell Carcinoma (Head/Neck, Anogenital)
- Monthly self examination (oral/head/neck)
- Annual skin examination by oncology &/or dermatology
- Biannual dental examination
- Annual gynecologic examination

DIFFERENTIAL DIAGNOSIS
Isolated Aplastic Anemia
- Can be secondary to mutations in telomere maintenance genes like dyskeratosis congenita
- Other features of dyskeratosis congenita absent

Fanconi Anemia
- Pigmentary changes
- Short stature
- Eye abnormalities
- CNS malformations, developmental delay
- Urogenital/cardiac/gastrointestinal/oral abnormalities
- Acute myeloid leukemia and other hematologic malignancies
- Solid tumors, including Wilms tumor and squamous cell carcinoma (head/neck, gynecologic)

Other Inherited Bone Marrow Failure Syndromes
- Diamond-Blackfan anemia
- Shwachman-Diamond syndrome
• Severe congenital neutropenia
• Amegakaryocytic thrombocytopenia
• Thrombocytopenia absent radii

Idiopathic Pulmonary Fibrosis
• Can be secondary to mutations in telomere maintenance genes like dyskeratosis congenita
• Other features of dyskeratosis congenita absent

CRITERIA FOR DIAGNOSIS
Suggested Criteria
• 2 of 4 major with at least 2 minor
• Major criteria
  o Oral leukoplakia
  o Nail dystrophy
  o Reticulate hyperpigmentation
  o Bone marrow failure
• Minor criteria
  o Epiphora
  o Short stature
  o Dental caries/loss
  o Premature hair loss/graying
  o Hyperhidrosis
  o Intrauterine growth retardation
  o Pulmonary disease
  o Liver disease
  o Esophageal stricture
  o Hypogonadism, undescended testes, urethral stricture/phimosis
  o Osteoporosis, aseptic necrosis, scoliosis
  o Mental retardation, developmental delay
  o Microcephaly, cerebellar hypoplasia, ataxia, deafness
  o Malignancy

SELECTED REFERENCES

Image gallery
Microscopic Features
Hematoxylin & eosin shows well-differentiated squamous cell carcinoma. Note the extensive keratin pearls and large, pale, eosinophilic carcinoma cells. (Courtesy S. Owens, MD.) (Right) This invasive squamous cell carcinoma has a broad, pushing border and is adjacent to mucosal epithelium with little cytologic atypia. (Courtesy S. Müller, DMD.)

This squamous cell carcinoma of the lower lip has an acantholytic appearance characterized by tumor nests with a pseudoglandular architecture. (Courtesy S. Müller, DMD.) (Right) There are few features to distinguish this poorly differentiated squamous cell carcinoma from other poorly differentiated neoplasms. When present, intercellular bridges (desmosomes) can be helpful. (Courtesy S. Owens, MD.)
CK5/6 stains a squamous cell carcinoma beneath normal squamous mucosa. Note the positivity of the normal squamous cells as well as the carcinoma. (Courtesy S. Owens, MD.)

Positive p63 nuclear staining in this invasive squamous carcinoma nest differentiates squamous cell carcinoma (positive) from other possible neoplasms, including adenocarcinoma and neuroendocrine tumors (negative) in the anal canal. (Courtesy S. Owens, MD.)

**Familial Acute Myeloid Leukemia**

Elizabeth Morgan, MD
Peripheral blood smear shows thrombocytopenia with 2 platelets per high-powered field. Thrombocytopenia is characteristic of familial platelet disorder with propensity to acute myeloid leukemia (FPD/AML).
Bone marrow aspirate smear shows erythroid precursors with dysplastic changes. Dysplasia in 1 or more myeloid lineages is morphologic hallmark of myelodysplastic syndromes (MDS).

**TERMINOLOGY**

**Abbreviations**
- Myelodysplastic syndromes (MDS)
- Acute myeloid leukemia (AML)

**Definitions**
- **MDS**: Heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, clinical cytopenia(s), dysplasia in 1 or more myeloid lineages, and increased risk of evolution to AML
- **AML**: Heterogeneous group of clonal hematopoietic neoplasms characterized by ≥ 20% blasts or blast equivalents in peripheral blood or bone marrow
  - Exceptions include AML with specific recurrent genetic abnormalities (t[15;17], t[8;21], inv[16]/t[16;16]) or acute erythroid leukemia
- Familial MDS/AML is defined as > 1 first- or second-degree relative with MDS/AML; some cases are genetically defined but most familial clusters are of unknown etiology
- Familial MDS/AML syndromes with defined genetic lesions include
  - Familial platelet disorder with propensity to develop acute myeloid leukemia (FPD/AML)
    - Rare AD disease characterized by RUNX1 mutation, platelet dysfunction, clinical thrombocytopenia, and increased risk of MDS/AML (incidence of MDS/AML in affected patients is > 40%; no specific subtype)
  - Familial CEBPA mutation
    - Rare AD disease characterized by AML ± maturation including frequent Auer rods, aberrant CD7 expression, and no abnormalities detected on conventional cytogenetic analysis (near-complete penetrance)
Familial GATA2 mutation
- Rare AD disease characterized by MDS/AML and poor clinical outcome (highly penetrant; no specific MDS/AML subtype)
- Recently described GATA2 mutation in MonoMAC syndrome
  - MonoMAC syndrome (a.k.a. DCML deficiency) is an inherited (AD transmission) or sporadic immunodeficiency
  - Characterized by disseminated nontuberculous mycobacterial infections (typically Mycobacterium avium complex [MAC]), human papillomavirus (HPV) infections, primary alveolar proteinosis, opportunistic fungal infections, profound monocytopenia, decreased/absent NK and B cells, decreased circulating/tissue dendritic cells
  - Predisposition to MDS/AML in 50% of patients (few myelodysplastic/myeloproliferative overlap cases also reported)
- Recently described GATA2 mutation in Emberger syndrome
  - Inherited (AD transmission with incomplete penetrance) or sporadic disorder
  - Characterized by primary lymphedema secondary to lymphatic hypoplasia and predisposition to MDS/AML
  - Patients may also have immune dysfunction as evidenced by disseminated cutaneous warts, as well as sensorineural deafness
- Other well-defined syndromes with variable predisposition to MDS/AML include
  - Bone marrow failure syndromes: Congenital amegakaryocytic thrombocytopenia, Diamond-Blackfan anemia, dyskeratosis congenita, severe congenital neutropenia, Shwachman-Diamond syndrome
  - DNA damage repair deficiency syndromes: RecQ helicase deficiencies (Bloom syndrome, Rothmund-Thomson syndrome, Werner syndrome); Fanconi anemia
  - Cell cycle and cell differentiation defects: Neurofibromatosis type 1, Noonan syndrome, and Noonan-like syndrome (juvenile myelomonocytic leukemia)
  - Li-Fraumeni syndrome
  - In most cases, gene defects underlying these syndromes do not appear to be responsible for sporadic cases of MDS/AML

Epidemiology
Mutations in RUNX1, CEBPA, and GATA2
- All are rare; reports of different entities range from 5 to > 20 affected families

Genetics
General Points
- Underlying genetic cause of many clusters of familial MDS/AML have not yet been elucidated
- Given variable penetrance and latency periods, single germline mutations that have been described likely predispose to MDS/AML by rendering families highly susceptible to additional, somatic mutations

Transcription Factor Mutations
- RUNX1 mutation in FPD/AML
  - Runt-related transcription factor 1 (RUNX1), a.k.a. acute myeloid leukemia 1 (AML1), a.k.a. corebinding factor subunit α-2 (CBFA2)
    - RUNX1 (21q22.3) encodes α-subunit of core binding factor transcription factor, which plays a role in normal hematopoiesis and myeloid differentiation
    - Number of RUNX1 mutations have been described in FPD/AML (large intragenic deletions, Runt domain mutations) and tend to be specific to families; mutational heterogeneity may be reason for variable phenotype
    - RUNX1 mutations/translocations also occur in sporadic cases of MDS/AML
- CEBPA mutation
  - CCAAT/enhancer binding protein α (CEBPA)
    - CEBPA (19q13.1) encodes a transcription factor (C/EBPα) that can act as a homodimer or a heterodimer with C/EBPβ and C/EBPγ and plays a role in myeloid differentiation
    - CEBPA mutations also occur in sporadic cases of AML
    - CEBPA point mutations are commonly biallelic (2 acquired in sporadic AML, 1 germline and 1 acquired in familial AML) manifesting as a dominant-negative N-terminal mutation and a C-terminal mutation (in familial AML, germline mutation is always N-terminal mutation)
- GATA2 mutation
GATA binding protein 2 (GATA2)

- GATA2 (3q21.3) encodes a member of the GATA family of zinc-finger transcription factors (named for promoter consensus sequence to which they bind) and plays a role in hematopoiesis and other nonhematopoietic processes
- > 30 mutations in GATA2 have been described in sporadic and familial MDS/AML, MonoMAC and Emberger (e.g., missense, nonsense, frameshift, small and large deletions)
- Aberrant activation or overexpression of GATA2 has also been described in de novo AML
- 3 mutations have been seen in multiple families with varying phenotypes
  - C.1-200_871 + 527del (Met1_Ser290del) has been described in familial MonoMAC and in familial MDS (1 MonoMAC patient also demonstrated unilateral lymphedema)
  - C.1061 C > T (Thr354Met) has been described in familial MonoMAC, familial MDS, and familial MDS/AML (no evidence of lymphedema in these patients)
  - C.1187 G > A (Arg398Gln) has been described in familial MonoMAC and familial MDS and familial AML (no evidence of lymphedema in these patients)
- GATA2 has been shown to play a role in lymphatic vasculature development
- Lymphedema may occur secondary to significant GATA2 gene abnormalities (nonsense or frameshift mutations, partial or complete deletions) causing haploinsufficiency, as have been described in Emberger syndrome and de novo MDS/AML with lymphedema

Additionally Reported Genetic Abnormalities

- Telomere maintenance mutations: Telomerase reverse transcriptase (TERT) and telomerase RNA component (TERC) mutations have been described in 5 families with MDS/AML (most also with aplastic anemia [AA]) but lacking phenotypic characteristics of bone marrow failure syndrome dyskeratosis congenita (variable penetrance; no specific MDS/AML subtype)
  - Telomerase is a ribonuclease that maintains telomere length by addition of telomere repeat TTAGGG
    - TERT (5p15.33) encodes reverse transcriptase protein component of telomerase (hTERT)
    - TERC (3q26) encodes RNA component (hTR), which provides template for telomere repeat
  - Mutations in TERT and TERC underlie a subset of dyskeratosis congenital cases and have been described in de novo MDS, idiopathic pulmonary fibrosis (familial and sporadic), and AA; TERT mutations have been described in de novo AML
- Aplastic anemia/myelodysplasia with SRP72 mutations: Case report of AD transmission of heterozygous SRP72 mutations in 2 families with AA &/or MDS
- Monosomy 7: Described in families with early onset of MDS (pathogenesis is poorly understood)
  - Apparently AD inheritance pattern
  - Occurs in sporadic MDS/AML as well as in syndromic MDS/AML
    - P.I(2):36
  - Children with early onset MDS and monosomy 7 may represent children with MDS/AML-predisposition syndrome that is otherwise phenotypically silent
  - Alternatively, these families may have as of yet unidentified gene mutation(s) rendering affected members vulnerable to loss of a chromosome 7

CLINICAL IMPLICATIONS AND ANCILLARY TESTS

Familial vs. Sporadic MDS/AML

- Younger age of presentation in familial MDS/AML
- Relatives of AML patients < 21 years old at diagnosis have 6.5x increase risk of MDS/AML and 3x risk of any myeloid malignancy

FPD/AML

- Patients often present with mild to moderate bleeding
- Platelet aggregation study shows impaired response to collagen and absent 2nd wave of epinephrine-induced aggregation; decreased aggregation with arachidonate is also seen (author observation)
- Subset of affected patients (over 40%) develop MDS/AML at a younger age than sporadic AML (median age 33)

CEBPA Mutation

- Eosinophilia common
- Favorable prognosis of AML, even with relapse
- Wide range in age of onset (as young as 4 to over 35), consistent with evidence of secondary mutations in addition to germline mutations in affected families

GATA2 Mutation
• In families with GATA2 mutations and early onset MDS/AML alone, prognosis is poor
• In MonoMAC patients, some morphologic features of MDS are different than those commonly observed in de novo MDS
  o Frequent marrow hypocellularity, frequent marrow fibrosis, presence of CD56-positive plasma cells, consistent trilineage dysplasia, and frequent hemophagocytic histiocytes
• No clear genotype-phenotype correlations

ASSOCIATED NEOPLASMS
FPD/AML
• Increased risk for T-acute lymphoblastic leukemia
• No increased risk for other non-myeloid neoplasms
MonoMAC
• Reported malignancies (some due to HPV infection): Vulvar carcinoma, metastatic melanoma, cervical carcinoma, Bowen disease of vulva, Epstein-Barr virus-positive leiomyosarcoma

CANCER RISK MANAGEMENT
Stem Cell Transplantation
• Genetic screening is advised when evaluating relatives as potential donors for patients undergoing allogeneic stem cell transplantation

SELECTED REFERENCES
P.I(2):37
Aspirate smear from a patient with AML shows intermediate-sized blasts with slightly irregular nuclear contours, fine chromatin, and distinct nucleoli, and 1 cell with distinct Auer rods. Auer rods are frequently seen in AML with CEBPA mutation. Patients with familial MDS/AML may also have cytogenetic abnormalities, frequently monosomy 7, as depicted in this karyotype. (Courtesy P. Dal Cin, PhD.)

Bone marrow aspirate smear from a 26-year-old man with MonoMAC syndrome shows erythroid hyperplasia, ↑plasma cells and myelodysplasia in the erythroid (nuclear budding) and myeloid (hypogranularity) lineages. Koilocytes (large squamous cells with pyknotic nuclei and abundant clear cytoplasm) are present in this urethral condyloma biopsy from a 26-year-old man with MonoMAC syndrome. HPV infection is common in MonoMAC.
Thoracic lymph node biopsy from a 26-year-old man with MonoMAC syndrome shows nonnecrotizing granulomatous inflammation. Necrosis was identified in other sections. (Right) High-magnification view of acid-fast bacilli stain from a lymph node of a 26-year-old man with MonoMAC syndrome shows that numerous red-staining mycobacterial organisms are present. PCR studies identified the species as Mycobacterium kansasii.

Familial Adenomatous Polyposis

> Table of Contents > Part I - Overview of Syndromes > Section 2 - Syndromes > Familial Adenomatous Polyposis

Familial Adenomatous Polyposis

Joel K. Greenson, MD
Gross photo of the colon from a patient with familial adenomatous polyposis (FAP) shows hundreds of small sessile polyps carpeting the mucosal surface. (Courtesy A. Polydorides, MD.)
Photomicrograph shows 3 adenomatous crypts that stand out from the adjacent normal mucosa. Microscopic foci like this are common in the flat colonic mucosa of FAP patients.

**TERMINOLOGY**

**Abbreviations**

- Familial adenomatous polyposis (FAP)
- Attenuated familial adenomatous polyposis (AFAP)
- Congenital hypertrophy of retinal pigment epithelium (CHRPE)
- Colorectal carcinoma (CRC)

**Synonyms**

- Adenomatous polyposis coli (APC), familial polyposis coli, Gardner syndrome, Turcot syndrome, Crail syndrome, Bussey-Gardner polyposis

**EPIDEMIOLOGY**

**Age Range**

- 1st adenomas detected between ages 10 and 20 years
- Mean age of diagnosis: 34-36 years if not in a known kindred undergoing screening
- Mean age of CRC: 40-42 years, but can occur in teenagers

**Incidence**

- 0.003-0.015% of population
- Most common genetic polyposis syndrome
  - FAP accounts for < 1% of all CRCs

**Natural History**

- Adenomas increase in size and number with age
  - Polyp count and patient age predict cancer risk
  - As in sporadic adenomas, only a small percentage progress to cancer
- AFAP: Fewer adenomas at a later onset (~ 15 years later than FAP)
Diagnostic Pathology: Familial Cancer Syndromes

- Upper GI lesions almost always present, but extraintestinal manifestations rare
- Lower risk of developing CRC
- Phenotype identical to MYH-associated polyposis, which is autosomal recessive
  - Requires genetic testing to differentiate the 2

Gender
- M = F

GENETICS

Germline Mutation in APC Gene
- Tumor suppressor gene that downregulates β-catenin (Wnt signaling pathway)
  - Controls cell cycle and stabilizes microtubules
- Located on chromosome 5q21-22
- Specific APC mutations correlate with phenotypes
  - AFAP associated with mutations at 3′ and 5′ ends of APC gene, whereas CHRPEs, osteomas, desmoids, and epidermal cysts are associated with mutations in middle of gene
  - Hot spot for severe polyposis phenotype at codon 1309
    - More polyps and earlier onset of CRC in families with mutations near this hot spot
- 30-40% of FAP cases arise de novo (no family history)
  - Cause of these spontaneous mutations unknown

- APC I1307K mutation
  - Autosomal dominant mutation that imparts a 10-20% lifetime CRC risk
  - No polyposis or extracolonic manifestations
  - Affects 6% of Ashkenazi Jews

- Ren\(\text{ders}\) APC gene susceptible to further mutations that lead to CRC

CLINICAL IMPLICATIONS

Clinical Presentation
- Rectal bleeding, diarrhea, colicky abdominal pain, mucous discharge, intussusception
  - P.I(2):39

- Rarely, severe electrolyte depletion can occur with diffuse polyposis
- Acute pancreatitis due to adenoma obstructing ampulla/pancreatic duct

Imaging Findings
- Polyps can be detected in both upper GI and lower GI locations, especially with fluoroscopic-guided barium enema
- Osteomas of jaw in Gardner syndrome can be identified on radiographs
- Desmoid tumors in Gardner syndrome can be identified on CT

MACROSCOPIC FINDINGS

General Features
- Diagnostic criteria for FAP (any of the following)
  - ≥ 100 colorectal adenomas (classical FAP)
  - < 100 colorectal adenomas in AFAP
  - Germline APC mutation
  - Family history of FAP plus at least 1 of the following
    - Epidermoid cyst, osteoma, desmoid

Endoscopic Findings
- Hundreds of small sessile adenomas carpet the colon
  - Similar location as in sporadic adenomas with predilection for rectosigmoid
  - Some larger pedunculated polyps
  - May have rectal sparing in AFAP
- CRC distribution follows adenomas (70-80% left-sided)
  - Often multiple CRCs, either synchronous or metachronous

Specimen Handling
- Total resection
  - Aside from taking sections of all large polyps to look for invasive carcinoma, face-down sections of the flat mucosa can be taken to show unicryptal adenomas that are pathognomonic of FAP (so-called Bussey section)

MICROSCOPIC FINDINGS

General Features
Colonic adenomas look identical to sporadic counterparts

Presence of unicryptal adenomas in flat mucosa diagnostic of FAP

ASSOCIATED NEOPLASMS

Other GI (Extracolonic Lesions)

- Small intestine
  - Mostly duodenal/ampullary adenomas
    - Possible cocarcinogenic effect of bile
    - 10-15 years later than colonic adenomas but 30 years earlier than general population
    - 50-100% of FAP patients have these on routine screening (50-100%)
    - Cumulative cancer risk: 2-10%
    - Common cause of death in patients who have had a prophylactic colectomy (20%)

- Stomach
  - Mostly fundic gland polyps (40-60%)
    - More numerous, occurring at a younger age, and more likely to have dysplasia (up to 25%) than sporadic
  - Antral adenomas (6%)
  - Gastric cancer is rare, but cases have been reported

- Liver
  - Increasing rate of hepatoblastomas in male infants
  - Rare hepatic adenomas and hepatocellular carcinomas
  - Rare malignant embryonal tumor

- Pancreas
  - Adenocarcinoma
  - Rare reports of intraductal mucinous neoplasms

- Biliary tract
  - Adenocarcinoma and dysplasia of bile ducts and gallbladder

Extraintestinal Manifestations

- Soft tissue (10-30% of FAP patients)
  - Fibromatosis (desmoid tumors)
    - Locally aggressive (even fatal) but “benign” tumors: Do not metastasize
    - 2nd most common cause of death in FAP patients (after CRC)
    - Unencapsulated
    - Hereditary desmoid disease: Rare APC mutation that causes multiple desmoids and other extraintestinal manifestations without colonic disease
    - Most common in small bowel mesentery
    - Often post surgery/trauma
    - Hormones may affect growth (pregnancy, estrogen); tamoxifen sometimes used for treatment

- Bones
  - Multiple osteomas of the skull, long bones, and mandible

- Teeth (70-80% of FAP patients)
  - Impaction, supernumerary/absent, abnormal roots

- Eye (75-90% of FAP patients)
  - Congenital hypertrophy of retinal pigment epithelium (CHRPE)
    - Pigmented fundus lesion
    - Earliest manifestation of FAP; can be seen in young infants

- Skin
  - Multiple epidermal inclusion cysts of face and scalp
  - Lipomas, fibromas, sebaceous cysts

- Endocrine system
  - Papillary thyroid carcinoma, cribriform morular variant, in women
  - Adrenal cortical neoplasms
  - Pancreatic islet cell neoplasms
  - Rare reports of parathyroid and pituitary adenomas

- Brain (Turcot syndrome)
  - Hereditary CRC & brain tumor
    - FAP patients: Medulloblastomas
    - P.I(2):40
Lynch patients: Gliomas

Head and neck
  - Nasopharyngeal angiofibroma

**CANCER RISK MANAGEMENT**

**Surgery**
1. Prophylactic colectomy with ileoanal pouch anastomosis is surgical treatment of choice
2. Goal is to do this when patient is in their teens (if diagnosis can be established this early)
3. Patients will still require surveillance of pouch to remove adenomas
4. Upper endoscopy with biopsy of gastric and duodenal polyps
   - Most duodenal/ampullary adenomas can be excised endoscopically, but some may require a Whipple procedure
5. Surgical excision of desmoids (when possible)

**Medical Management**
1. Chemoprevention of polyps with indomethacin and other NSAIDs
2. Medical treatment of desmoids includes hormonal therapy, imatinib, and NSAIDs

**Genetic Testing**
1. Protein truncation test (PTT)
   - Looks for abnormally shortened APC protein in exon 15
2. Gene sequencing
   - APC gene is very large; hence, sequencing is difficult
     - Sequencing is done to try and predict phenotype of affected family members (likelihood of desmoids or severe phenotype)
     - Latest techniques are about 95% sensitive in detecting mutations in classic FAP, < 30% in AFAP
     - Important to test for MYH-associated polyposis if these tests are negative
   - Multiplex ligation probe amplification (MLPA) is used to look for large deletions and duplications
3. Sequencing of exons 1-14 coupled with PTT of exon 15 is one commonly used testing strategy
   - If PTT is positive, then exon 15 can be sequenced

**SELECTED REFERENCES**

3. Claes K et al: The genetics of familial adenomatous polyposis (FAP) and MutYH-associated polyposis (MAP). Acta Gastroenterol Belg. 74(3):421-6, 2011

**Tables**

<table>
<thead>
<tr>
<th>Variant</th>
<th>Phenotype</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Attenuated familial adenomatous polyposis (AFAP)</td>
<td>Fewer adenomas and later age of onset, lower risk of colorectal carcinoma (CRC)</td>
<td>Need to exclude autosomal recessive MYH-associated polyposis</td>
</tr>
<tr>
<td>Gardner syndrome</td>
<td>FAP with extraintestinal manifestations (desmoids, osteomas, epidermoid cysts)</td>
<td>Significant mortality from extraintestinal lesions, especially after colectomy</td>
</tr>
<tr>
<td>Turcot syndrome</td>
<td>FAP with medulloblastoma</td>
<td>CRC with glioma is likely Lynch syndrome, not FAP</td>
</tr>
</tbody>
</table>
### Extraintestinal Features in FAP

<table>
<thead>
<tr>
<th>Benign Lesions</th>
<th>Malignant Lesions</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHRPE (75-90%)</td>
<td>Papillary thyroid cancer (2-3%)</td>
</tr>
<tr>
<td>Epidermoid cysts (50%)</td>
<td>Brain tumor (medulloblastoma) (&lt; 1%)</td>
</tr>
<tr>
<td>Osteoma (50-90%)</td>
<td>Hepatoblastoma (1%)</td>
</tr>
<tr>
<td>Desmoid tumor (10-30%)</td>
<td>Hepatocellular carcinoma (&lt; 1%)</td>
</tr>
<tr>
<td>Supernumerary teeth (70-80%)</td>
<td>Pancreatic adenocarcinoma (2%)</td>
</tr>
<tr>
<td>Adrenal adenomas (7-13%)</td>
<td>Pancreatic islet cell neoplasms (rare)</td>
</tr>
<tr>
<td>Lipomas and fibromas (prevalence unknown)</td>
<td>Adrenal cortical carcinoma (rare)</td>
</tr>
<tr>
<td>Juvenile angiofibroma (prevalence unknown)</td>
<td>Biliary tract adenocarcinoma (rare)</td>
</tr>
</tbody>
</table>

P.I(2):41

Image gallery

**Gross, Microscopic, and Genetic Features**

(Left) Gross photo shows a colectomy specimen from a case of familial adenomatous polyposis with rectal sparing. Polyps carpet the more proximal mucosa, but the rectal mucosa at the top is flattened and atrophic. (Courtesy A. Polydorides, MD.) (Right) Gross photograph shows a colectomy specimen from a case of attenuated familial adenomatous polyposis with only a few colonic polyps. (Courtesy A. Polydorides, MD.)

(Left) This medium-power view shows a duodenal adenoma in a patient with familial adenomatous polyposis. Note low-grade dysplasia involving the surface epithelium. (Courtesy A. Polydorides, MD.) (Right) This high-power view of a fundic gland polyp shows low-grade dysplasia. The nondysplastic epithelium shows dilated oxytic glands typical.
of a fundic gland polyp

(Left) This medium-power view of a mesenteric fibromatosis (desmoid tumor) shows spindle cells, collagen, and evenly spaced blood vessels. (Courtesy A. Polydorides, MD.)

(Right) This drawing shows the location of various mutations along the APC gene and what phenotypic abnormalities have been associated with each mutation site.
Familial Chordoma

Sagittal T1WI C+ MR shows a classic expansile chordoma of the clivus. Note the adjacent pituitary gland. Given the delicate location, symptoms are common.
This image shows the classic histology for a conventional chordoma: A mixture of eosinophilic cells and bubbly physaliferous cells within a blue myxoid matrix.

**TERMINOLOGY**

**Definitions**
- Chordoma occurring in at least 2 blood relatives

**EPIDEMIOLOGY**

**Incidence**
- Extremely rare with few families reported so far

**Age**
- Wide age range reported (30-50 years most common)
- Very rare in people < 10 years

**Gender**
- M:F = 2:1

**Site**
- Most familial chordomas appear to arise in sacrococcygeal (~ 50%) and clival (~ 45%) locations

**GENETICS**

**Currently Under Active Investigation**
- Familial Chordoma Study (National Institute of Health)

**Inheritance Pattern**
- Possible autosomal dominant inheritance pattern
  - Male-to-male transmission reported in some families

**Genetic Alterations**
- Similar to sporadic cases
  - Duplication of region on chromosome 6q27 containing T-brachyury gene
  - Reports of loss of heterozygosity of 7q33
Possible tumor suppressor gene locus at 1p36

Other Associations

- Chordoma presenting in infancy can also be seen in tuberous sclerosis complex (TSC)
  - Autosomal dominant disease
  - Mutation of TSC1 on 9q34 and TSC2 on 16p13.3

ASSOCIATED NEOPLASMS

Chordoma

- **Etiology**
  - Thought to arise from notochordal remnants
  - Supported by characteristic midline location

- **Clinical presentation**
  - Cranial tumors
    - Headache
    - Visual complaints (e.g., diplopia)
    - Other cranial nerve defects
    - Evidence of pituitary dysfunction
    - May present as a nasal polyp
  - Sacrococcygeal tumors
    - Longstanding lower back pain
    - Regional neurogenic issues (bladder dysfunction, constipation)
  - Nonsacrococcygeal spinal tumors
    - Symptoms related to compression of spinal cord or spinal nerve roots
    - Lumbar vertebrae may show compression fractures

- **Imaging findings**
  - Cranial tumors
    - Consistent involvement of midline structures
    - Destructive lesion in clivus, sphenoooccipital region, or hypophyseal region
    - Mass effect on adjacent brain tissue
    - May show calcific densities
  - Sacrococcygeal tumors
    - Lytic, destructive bone tumor
    - Often shows anterior soft tissue extension

- **Macroscopic findings**
  - Soft, lobulated, translucent tissue
  - May appear mucoid
  - Sacrococcygeal chordomas that show anterior soft tissue extension are often covered by periosteum
  - Recurrent tumors in any location generally show multiple nodules

- **Microscopic findings**
  - All tumors characteristically lobulated
  - Conventional chordoma
    - Cells with clear to eosinophilic cytoplasm
    - Heavily vacuolated physaliferous cells
    - Typically prominent myxoid stroma
  - Chondroid chordoma
    - Contain areas of chondroid matrix or frank cartilage in addition to more conventional areas
    - Almost all occur in skull base
  - Dedifferentiated chordoma
    - Defined as a high-grade sarcoma arising in association with or at site of a previously documented chordoma
    - Dedifferentiated areas usually show up in recurrent tumors
    - Most occur in sacrococcygeal region

- **Immunophenotype**
  - Strong nuclear expression of brachyury
Generally strong expression of cytokeratin &/or epithelial membrane antigen (EMA)
Variable expression of S100

Astrocytoma, Pilocytic
- 2 cases have been reported in association with familial chordoma

CANCER RISK MANAGEMENT

Screening
- No current screening protocol in place
- Detection of T-brachyury gene duplication may confer susceptibility to chordoma development
- MR of entire craniospinal axis at the time a family aggregation is identified

Treatment
- Complete resection with wide tumor-free margins is mainstay of therapy
  - Depending on site, only incomplete resection may be possible
- Radiation therapy is debatable but does not appear to be effective
- Most chemotherapies are ineffective
  - Recent discoveries of overexpression of tyrosine kinases and transcriptional regulators in chondomas raise possible utility of tyrosine kinase inhibitors (TKI) and other drugs

Prognosis
- Indolent but locally aggressive
  - Most morbidity is due to local recurrence
  - Most mortality is due to local extension of tumor (brain, upper respiratory tract, genitourinary/gastrointestinal tracts)
- Metastases in up to 30% of cases
  - Skin, lungs, other bones
- Age < 40 may be good prognostic factor
- Chondroid chordoma may have better survival rate than conventional chordoma (controversial)

SELECTED REFERENCES
Familial Chronic Lymphocytic Leukemia

CLL/SLL involves a lymph node with proliferation centers. Note the vaguely nodular, irregularly distributed, pale-staining areas in a dark background of small cells. (Courtesy L. J. Medeiros, MD.)
CLL in the peripheral blood. Marked lymphocytosis is seen; lymphocytes have scant cytoplasm, clumped “soccer ball” chromatin, round nuclei, and indistinct nucleoli. (Courtesy C. Bueso-Ramos, MD.)

TERMINOLOGY
Abbreviations
- Chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL)

Definitions
- CLL/SLL: Neoplasm of mature B cells occurring in peripheral blood/bone marrow &/or nodal/extranodal tissues (hereafter referred to as CLL)
- Monoclonal B-cell lymphocytosis (MBL): Monoclonal or oligoclonal expansion of B cells, often with a CLL-like phenotype, detected at less than 5x10^9 cells/liter in peripheral blood and without evidence of extramedullary tissue involvement
- Familial CLL: Occurrence of CLL in a relative of a patient with CLL (more strict definitions define familial CLL as occurrence of CLL in ≥ 2 first-degree relatives)

EPIDEMIOLOGY
Incidence and Risk
- Age-adjusted incidence rate of sporadic CLL/SLL in USA is 4.3 per 100,000 persons per year (2006-2010 SEER data) with a median age at diagnosis of 71 years
- 13% of CLL patients report family member with lymphoproliferative disorder
- 6-9% of CLL patients report family member with CLL
- Population-based studies demonstrate 1st-degree relatives of CLL patients have 8.5x relative risk for CLL
- Some studies indicate lower mean age at diagnosis in familial CLL whereas others do not find difference in age of onset between sporadic and familial CLL
- Incidence of MBL ↑ in unaffected relatives in CLL families (overall rate of 17% vs. 3-5% in general population)

ETIOLOGY/PATHOGENESIS
Environmental
- No consistent environmental risk has been identified through epidemiological studies
Geographic variation is marked, with highest incidence in Caucasian populations of North America/Europe. Familial aggregation could reflect at least partial contribution of a common environmental factor. Alternatively, incidence of CLL in Asian populations is similar regardless of country of residence (United States vs. countries in Asia), suggesting genetic rather than environmental predisposition.

Genetic

- Genetic basis of familial predisposition to CLL is poorly understood
- Some factors suggest that CLL is a genetically heterogeneous disease
  - Only a small number of family members (often only 2) are affected in CLL families
  - Linkage studies performed in high-risk CLL families have identified few regions of interest but have not identified germline gene mutations
- Familial risk may be secondary to multiple varied susceptibility loci, each conferring small relative risks
  - Genome-wide association studies have identified multiple single nucleotide polymorphisms (SNPs) at 22 susceptibility loci to date
  - Coinheritance of several of these low-risk variants may contribute to familial predisposition for CLL
- Some studies indicate evidence of anticipation in familial CLL whereas others do not

CLINICAL IMPLICATIONS

Comparison of Sporadic and Familial CLL

- Large study showed no adverse prognosis in patients with familial CLL vs. sporadic CLL
  - No significant difference in stage at diagnosis or 10-year overall survival
  - No significant difference in need for treatment
- Small studies have suggested differences in familial and sporadic CLL, but findings require further investigation/confirmation
  - Higher frequency of mutated immunoglobulin heavy-chain variable genes in familial CLL
  - Higher frequency of deletion 13q in familial CLL
  - Higher frequency of deletion 11q in sporadic CLL
  - Higher serum levels of B-lymphocyte stimulator (a.k.a. B-cell activating factor) in familial CLL
- No difference in expression of CD23, CD38, or ζ-chain-associated protein kinase-70 (ZAP-70) between familial and sporadic CLL
- No difference in serum levels of β-2 microglobulin between familial and sporadic CLL

ASSOCIATED NEOPLASMS

Familial CLL

- Relative of a patient with CLL has a 2.6x relative risk for developing any lymphoproliferative disorder (absolute risk is very low)
  - Increased risk is for other (mostly indolent) B-cell non-Hodgkin lymphomas, particularly lymphoplasmacytic lymphoma and hairy cell leukemia
  - Not influenced by gender, type of relative, or age at diagnosis
- Risk of Hodgkin lymphoma variable in different studies
- No increased risk of aggressive B-cell or T-cell lymphomas or plasma cell myeloma

CANCER RISK MANAGEMENT

MBL

- Natural history of progression of MBL to CLL in CLL families is unknown
- Currently, no intervention is advised if a family member is found to have MBL by peripheral blood flow cytometry

CLL

- Screening of asymptomatic relatives is not recommended at this time given low absolute risk of development of lymphoproliferative disorder

Stem Cell Transplantation

- Screening for MBL/CLL may be advised when evaluating 1st-degree relatives as potential donors for patients with CLL undergoing allogeneic stem cell transplantation

SELECTED REFERENCES

Familial Gastrointestinal Stromal Tumor

> Table of Contents > Part I - Overview of Syndromes > Section 2 - Syndromes > Familial Gastrointestinal Stromal Tumor
Familial Gastrointestinal Stromal Tumor
Joel K. Greenson, MD
Low-power view shows 2 epithelioid gastrointestinal stromal tumors (GISTs) from a patient with Carney triad. These patients often have multinodular or multifocal gastric GISTs.
This high-power view shows an epithelioid pediatric-type GIST from a patient with Carney-Stratakis syndrome. Despite the numerous mitoses, these lesions have a relatively good prognosis.

**TERMINOLOGY**

**Abbreviations**
- Gastrointestinal stromal tumor (GIST)
- Familial GIST (FGIST)

**EPIDEMIOLOGY**

**Incidence**
- Most common mesenchymal tumor arising in gut
  - 6.8 cases per million per year in USA, 14.5 cases per million per year in Sweden
  - Vast majority are sporadic, not familial
- Sporadic GISTs are typically seen in middle-aged to older patients
- Familial GISTs tend to occur in younger patients and there are often synchronous or metachronous tumors

**SYNDROMES/GENETICS**

**Germline Mutations of KIT**
- Patients have multiple GISTs, hyperpigmentation, urticaria pigmentosa, and dysphagia
- Autosomal dominant
- Most mutations are in exon 11
  - Mutations in other exons tend not to be associated with hyperpigmentation

**Germline Mutations of Platelet-Derived Growth Factor Receptor Alpha (PDGFRA)**
- GISTs are typically epithelioid or mixed
- Patients have multiple GISTs without hyperpigmentation, urticaria pigmentosa, and dysphagia
  - 1 kindred also had large hands associated with multiple GISTs, and intestinal neurofibromatosis
  - 1 patient from a different kindred with a unique PDGFRA mutation also had multiple lipomas and fibrous tumors of small bowel

**Carney-Stratakis Syndrome**
Germline mutations in succinate dehydrogenase (SDH) complex B, C, and D subunits

- Patients have dyad of GISTs and paragangliomas
  - Autosomal dominant
    - GISTs are typically epithelioid or mixed, and are often multinodular
      - Histologically, these tumors appear malignant with high mitotic rate and increased cellularity, but they often behave in a benign fashion
      - May have lymph node metastases, but still have a good prognosis
      - Respond to sunitinib much more than imatinib
    - Dyad GISTs are wild type for KIT and PDGFRA mutations (also referred to as pediatric GISTs)
      - Loss of SDH immunostaining may be used to screen for tumors with SDH mutation

Carney Triad
- Gastric GISTs, paragangliomas, and pulmonary chondromas
  - Also may have adrenal cortical adenomas and esophageal leiomyomas
  - GISTs are typically epithelioid or mixed, and are often multinodular
  - Histologically, these GISTs appear malignant with high mitotic rate and increased cellularity, but they often behave in a benign fashion
    - Up to 29% have reported lymph node metastasis (nonsyndromic adult GISTs rarely spread to lymph nodes)
    - Even with these metastases, patients still have an excellent prognosis
    - Respond to sunitinib much more than imatinib

- 85% of patients are young females
  - Originally thought to be an X-linked trait as all of the 1st reported patients were all women, but now not thought to be familial
  - Genetic defect unknown
    - Losses of chromosome 1p have been found in tumors (not germline)
    - Immunostains for SDH subunits may be negative, but germline mutations are not found in Carney triad patients

Neurofibromatosis Type 1 (NF1)
- May have multiple small intestinal GISTs (as well as the usual neurogenic tumors and other stigmata of NF1)
  - NF1 patients 150x more likely than the general population to get GISTs
  - Autosomal dominant due to mutation in NF1 (tumor suppressor gene)
  - GISTs in NF1 often wild type for KIT and PDGFRA
    - Overall good prognosis and respond to sunitinib much better than imatinib

CLINICAL IMPLICATIONS AND ANCILLARY TESTS
Unique Features of Syndromic GISTs
- Presence of synchronous or metachronous stromal tumors or tumors in young patients should alert pathologist to possibility of familial syndromes
  - Epithelioid or mixed histology gastric tumors in young people should prompt work-up for paragangliomas and pulmonary chondromas
    - Immunostains for SDH subunits may be helpful to triage germline sequencing
    - Germline sequencing of PDGFRA may also be helpful if family history is positive and no paragangliomas are found
  - Multiple small bowel GISTs should raise the question of NF1
  - Presence of multiple GISTs in patients with hyperpigmented skin should prompt germline KIT sequencing

SELECTED REFERENCES
5. de Raedt T et al: Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA. Gastroenterology. 131(6):1907-12, 2006

### Tables

<table>
<thead>
<tr>
<th>Syndrome/Disease</th>
<th>Gene Affected</th>
<th>Associated Lesions</th>
<th>Pattern of Inheritance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carney-Stratakis syndrome</td>
<td>Succinate</td>
<td>Paragangliomas, epithelioid GISTs</td>
<td>Autosomal dominant</td>
</tr>
<tr>
<td></td>
<td>dehydrogenase</td>
<td>(SDH), subunits B, C, and D</td>
<td></td>
</tr>
<tr>
<td>Carney triad</td>
<td>Unknown</td>
<td>Pulmonary chondromas, paragangliomas, epithelioid GISTs, adrenal cortical adenomas, esophageal leiomyomas</td>
<td>Female predominance raised question of X-linked trait, but ~ 15% of patients are male; now thought not to be familial</td>
</tr>
<tr>
<td>Neurofibromatosis type I</td>
<td>NF1</td>
<td>Café au lait spots, neurofibromas, neuroendocrine neoplasms of gut, malignant peripheral nerve sheath tumors, GISTs, gliomas, pheochromocytomas, rhabdomyosarcomas, leukemias</td>
<td>Autosomal dominant</td>
</tr>
<tr>
<td>Familial GIST syndrome</td>
<td>KIT</td>
<td>GISTs, hyperpigmentation, dysphagia, urticaria pigmentosa/systemic mastocytosis, nevi</td>
<td>Autosomal dominant</td>
</tr>
<tr>
<td>Familial GIST syndrome</td>
<td>PDGFRA</td>
<td>GISTs, large hands, small intestinal fibrous tumors</td>
<td>Autosomal dominant</td>
</tr>
</tbody>
</table>
Familial Hodgkin Lymphoma

Lymph node biopsy from a patient with NSCHL demonstrates a diagnostic (bilobed) Reed-Sternberg cell in a background of reactive small lymphocytes, eosinophils, plasma cells, and histiocytes.
Lymph node biopsy from a patient with NLPHL demonstrates neoplastic lymphocyte-predominant (LP) cells in a background of reactive small lymphocytes and histiocytes.

**TERMINOLOGY**

**Abbreviations**

- Hodgkin lymphoma (HL) is classified into 2 categories
  - Classical Hodgkin lymphoma (CHL), which is composed of 4 subtypes
    - Nodular sclerosis classical Hodgkin lymphoma (NSCHL)
    - Mixed cellularity classical Hodgkin lymphoma (MCCHL)
    - Lymphocyte-rich classical Hodgkin lymphoma (LRCHL)
    - Lymphocyte-depleted classical Hodgkin lymphoma (LDCHL)
  - Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)

**Definitions**

- CHL: Lymphoid neoplasm composed of neoplastic Hodgkin and Reed-Sternberg (HRS) cells in reactive inflammatory background (95% of HL)
  - Bilobed Reed-Sternberg cells and mononuclear Hodgkin cells display large eosinophilic nucleoli; express CD30 and CD15 (variable); do not express CD45 or uniform CD20
  - 4 subtypes (NSCHL, MCCHL, LRCHL, and LDCHL) demonstrate distinct morphologic and clinical features
    - NSCHL (70% CHL)
      - HRS and inflammatory cells form nodules surrounded by fibrous bands
      - Peak incidence age: 15-34 years
      - Often arises in mediastinum or cervical lymph nodes
    - MCCHL (20-25% CHL)
      - HRS and inflammatory cells form diffuse or interfollicular pattern
      - Median age of presentation: 38 years
      - Often arises in cervical or supraclavicular lymph nodes (mediastinum uncommon)
o LRCHL (4-5% CHL)
  ▪ HRS cells are surrounded by small, reactive lymphocytes (eosinophils and neutrophils rare) in a nodular or diffuse pattern
  ▪ Median age of presentation: 43 years
  ▪ Often arises in peripheral lymph nodes (mediastinum uncommon)
o LDCHL (< 1% CHL)
  ▪ HRS cells may be scant, frequent, or pleomorphic in a variably fibrotic background depleted of small lymphocytes
  ▪ Typically presents in 4th decade
  ▪ Often arises in retroperitoneal or abdominal lymph nodes

- NLPHL: Lymphoid neoplasm composed of neoplastic lymphocyte-predominant (LP) cells in reactive inflammatory background (5% of HL)
  ▪ LP cells are large with multilobated “popcorn” nuclei; express CD20 and CD45; do not express CD30 and CD15
  ▪ LP cells are confined within follicular dendritic cell meshworks, resulting in a nodular appearance at low magnification
  ▪ Most common in 30-50 year age group
  ▪ Typically presents in peripheral lymph nodes
- Familial Hodgkin lymphoma is defined as ≥ 2 first- or second-degree relatives with HL (either CHL or NLPHL)

EPIDEMIOLOGY
Incidences
- Age-adjusted incidence rate of sporadic HL in USA is 2.8 per 100,000 persons per year (2006-2010 SEER data)
- Familial HL is rare but well recognized
  - Incidence is difficult to determine
    P.I(2):49
- Majority of studies (case series, twin study, population registry studies) represent CHL (± subtyping), with examples including
  ▪ Grufferman et al (1977): Siblings of young adults with HL have ~ 7x excess risk of developing HL, and show strong gender concordance
  ▪ Kerzin-Storrar et al (1983): 4x excess of HL cases among 1st- and 2nd-degree relatives with HL (predominantly MCCHL)
  ▪ Chakravarti et al (1986): Concordance for histological types of HL between affected relatives (out of 34 cases, 23 pairs concordant for NSCHL and 4 pairs concordant for MCCHL)
  ▪ Mack et al (1995): HL found in 10 of 179 pairs of monozygotic twins (0.1 cases would have been expected based on national age-specific incidence rates); no concordant HL found in 187 pairs of dizygotic twins
  ▪ Goldin et al (2004): 2.5-3.5x relative risk of HL in relatives of patients with HL, higher in males vs. females and in siblings vs. parents/offspring
- Few studies have evaluated NLPHL independently
  ▪ Saarinen et al (2013): 19x relative risk of NLPHL in 1st-degree relatives of patients with NLPHL, most prominent in female relatives of young patients

Inheritance Pattern
- Uncertain; some studies suggest autosomal recessive pattern of inheritance

ETIOLOGY/PATHOGENESIS
Environmental/Infectious
- CHL in general
  ▪ Some clinical and morphologic/genetic characteristics of NSCHL suggest at least partial contribution of common environmental factor
    ▪ Young age at presentation
    ▪ Increasing risk at higher levels of economic development
    ▪ mRNA gene-expression profile similar to that of tissue repair
  ▪ CHL can be associated with Epstein-Barr virus (EBV), particularly in
    ▪ Immunocompromised patients (HIV infection)
    ▪ Resource-poor populations
    ▪ Children or in older populations (e.g., 50 years or older)
    ▪ Males
Some studies have described geographic clustering (localized increased incidence of HL described in New York state, UK, Israel)

- **Familial HL**
  - Excess risk in young adults and in siblings (as described in some studies) could suggest that a common environmental exposure or prolonged close contact at an early age may contribute to risk of familial HL

**Genetic**
- Genetic basis of familial predisposition to HL is poorly understood
- Some studies have identified underlying immunodeficiency in family members of patients with HL
- Susceptibility gene(s) may predispose host to develop HL (in some cases, possibly in response to an environmental agent such as EBV)
  - Correlation between major histocompatibility complex (MHC)/human leukocyte antigen (HLA) loci and HL
    - Numerous HLA loci have been implicated in susceptibility to HL, e.g., individuals carrying HLA-A*01 allele have an ↑ risk of developing EBV(+) CHL and individuals carrying HLA-A*02 allele have a ↓ risk of developing EBV(+) CHL
  - Genome-wide linkage analysis
    - Studies of CHL families have suggested susceptibility genes on chromosome 4p and possibly additional regions on chromosomes 2 and 11
  - Genome-wide association studies
    - Study of patients with CHL identified 3 susceptibility loci at 2p16.1 (REL), 8q24.21 (PVT1), and 10p14 (GATA3) and confirmed a strong HLA association
    - Study of patients with CHL identified 2 loci in MHC region (1 adjacent to MICB, 1 at HLA-DRA) regardless of EBV status, and confirmed association between EBV(+) CHL and genetic variants within class I HLA region
    - Study of patients with NSCHL identified risk loci at 6p21.32
  - Evaluation of familial chromosomal abnormalities/gene mutations
    - Chromosomal analysis revealed inherited translocation [(t(2;3)(q11.2;p21.21))] in a family with multiple affected members (NSCHL), resulting in disruption of KLHDC8B and loss of protein expression
      - 5′ untranslated region (UTR) variant that reduces KLHDC8B translation was found in 3 additional CHL families
      - In vitro, reduced expression of protein product (which participates in cytokinesis) results in ↑ binucleated cell formation
      - KLHDC8B-associated variations were not detected in multiple NLPHL families by direct sequencing of all exons, exon-intron boundaries, and 5′ UTR
    - Whole exome sequencing and linkage studies revealed truncating germine mutation in NPAT gene in a family of 4 cousins with NLPHL

**Clinical Implications**

**Clinical Features**
- Male patients have higher familial risks vs. female patients
  - Risk of HL is higher in relatives of HL patients with early age of onset compared to late age of onset
  - Siblings of patients with HL have a higher risk of developing HL compared to parents or offspring
    - Relative risk is highest in brother pairs and sister pairs

**Comparison to Sporadic HL**
- Patients with familial HL present at earlier age of onset compared to patients with sporadic HL
- No specific laboratory or morphologic features distinguish familial HL from sporadic HL

**Mortality**
- 5-year and 10-year mortality is similar for patients with HL ± family history of HL

**Associated Neoplasms**

**Familial HL**
- Relative of patient with HL
  - 1.65x relative risk of development of any lymphoproliferative disorder
  - 2.11x relative risk of development of chronic lymphocytic leukemia

**Familial NLPHL**
- Relative of patient with NLPHL
Diagnostic Pathology: Familial Cancer Syndromes

- Registry-based standardized incidence risk of 1.9 for all non-Hodgkin lymphoma
- Registry-based standardized incidence risk of 5.3 for CHL

CANCER RISK MANAGEMENT

Familial HL

- Overall, familial HL appears to comprise 4.5% of all HL cases
- No consensus guidelines on screening of asymptomatic relatives of patients with HL

SELECTED REFERENCES


Image gallery

Microscopic Features
(Left) Lymph node biopsy from a patient with NSCHL shows effacement of lymph node architecture by neoplastic nodules surrounded by dense fibrous bands. (Courtesy C. Yin, MD.) (Right) Lymph node biopsy from a patient with NLPHL shows a large nodule with a “moth-eaten” pattern due to the presence of admixed larger cells in a background of small lymphocytes. (Courtesy P. Lin, MD.)

(Left) Lymph node biopsy from a patient with MCCHL shows a few scattered Hodgkin cells in a background of small lymphocytes, eosinophils, and histiocytes. (Courtesy L. J. Medeiros, MD.) (Right) Lymph node biopsy from a patient with LRCHL (nodular variant) shows HRS cells in a background of numerous small lymphocytes. Note absence of eosinophils and plasma cells. (Courtesy L. J. Medeiros, MD.)
Familial Isolated Hyperparathyroidism

Vania Nosé, MD, PhD
Graphic shows both an enlarged parathyroid gland (due to adenoma) and a normal-sized parathyroid gland. This helps differentiate this from hyperplasia, which usually shows enlargement of all glands.
In addition to a solid and nodular growth pattern, a variety of different growth patterns can be seen within an individual gland and among glands in an individual. This parathyroid gland has a follicular growth pattern.

TERMINOLOGY

Abbreviations
- Familial isolated hyperparathyroidism (FIHP)
- Familial isolated primary hyperparathyroidism (FIPHT)
- Parathyroid hormone (PTH)

Definitions
- Familial isolated hyperparathyroidism is defined as hereditary primary hyperparathyroidism without the association of other diseases or tumors
- FIHP is an inherited condition characterized by overactivity of parathyroid glands
  - 1 or more overactive parathyroid gland releases excess parathyroid hormone, which causes hypercalcemia
- Parathyroid hormone stimulates removal of calcium from bone and the absorption of calcium from the diet
  - Production of excess PTH is caused by the parathyroid glands
- FIHP is mainly due to 4-gland hyperplasia or single-gland adenoma

EPIDEMIOLOGY

Age Range
- Age at which familial isolated hyperparathyroidism is diagnosed varies from childhood to adulthood

Gender
- F ≈ M

Incidence
- 90% of hyperparathyroidism cases are sporadic
- 10% of hyperparathyroidism cases are familial
  - In 1% of cases of familial primary hyperparathyroidism (e.g., FIHP), parathyroid is the only endocrine organ involved
o Remainder of cases are associated with MEN1, MEN2, HPT-JT, and familial hypocalciuric hypercalcemia

GENETICS
Autosomal Dominant
- Mutations in parafibromin gene CDC73 (also HRPT2) on chromosome 1q25 have been found in a small proportion of FIHP cases
- FIHP phenotypes have been associated with mutant multiple endocrine neoplasia 1 (MEN1) and calcium sensing receptor (CASR) genotypes
- Genomic screen of 7 familial hyperparathyroidism families has identified a suggestive 1.7 Mb region on chromosome 2
- For majority of cases of FIHP, genetic cause is unknown

CLINICAL IMPLICATIONS AND ANCILLARY TESTS
Clinical Presentation
- 1st indication of condition is elevated calcium levels identified through a routine blood test
  - Even though the affected individual may not yet have signs or symptoms of hyperparathyroidism or hypercalcemia
- Because the production of excess PTH is caused by abnormalities of parathyroid glands, FIHP is considered a form of primary hyperparathyroidism
- Typically, only 1 of the 4 parathyroid glands is affected, but in some people, > 1 gland develops a tumor
  - Tumors are usually adenomas
    - P.[J(2):53
  - Rarely, people with FIHP develop parathyroid carcinoma
- Disruption of normal calcium balance resulting from overactive parathyroid glands causes many of the common signs and symptoms of familial isolated hyperparathyroidism
  - Kidney stones
  - Nausea
  - Vomiting
  - Hypertension
  - Weakness
  - Fatigue
  - Osteoporosis
- In contrast to sporadic primary hyperparathyroidism, FIHP is characterized by earlier onset of disease, higher incidence of multiglandular involvement, and higher recurrence rate

Treatment
- Parathyroid surgery is treatment of choice, especially when disorder is complicated by symptomatic hypercalcemia, bone loss or fractures, and hypercalciuria and nephrolithiasis
- Subtotal parathyroidectomy is recommended for multiglandular involvement

ASSOCIATED CONDITIONS
Parathyroid Hyperplasia
- 4-gland hyperplasia is often seen in familial isolated hyperparathyroidism
- Hyperplasia may be either chief cell or oxyphil cell variants

Parathyroid Adenoma
- Common occurrence in familial isolated hyperparathyroidism

Parathyroid Carcinoma
- Exceedingly rare in patients with FIHP
- Accounts for < 1% of all cases of FIHP
- Patients with the CDC73 (also HRPT2) mutation have a greater risk of developing carcinoma

CANCER RISK MANAGEMENT
Screening and Guidelines
- There are no published guidelines on surveillance
- Based on phenotype, annual screening with serum calcium, phosphorous, and parathyroid hormone levels
- Every 1-2 years, reassessment of renal status
- Annual palpation of thyroid and parathyroid glands is recommended beginning at age 10-12 years
  - Adenomas and carcinomas have been reported in adolescents

DIAGNOSIS
Clinical
Familial isolated hyperparathyroidism is essentially a diagnosis of exclusion

Clinical picture is of familial primary hyperparathyroidism in absence of sufficient clinical, radiological, or biochemical evidence for diagnoses of

- Multiple endocrine neoplasia type 1 (MEN1)
- Multiple endocrine neoplasia type 2A (MEN2A)
- Hyperparathyroidism-jaw tumor syndrome
- Familial benign hypocalciuric hypercalcemia

Laboratory Tests
- Elevated PTH in context of hypercalcemia in a patient with no renal disease

Genetic Tests
- CDC73 (also HRPT2) mutations
  - Tumor suppressor gene located on chromosome 1q25, which encodes the 531 amino acid protein parafibromin
  - Almost all mutations in this gene inactivate parafibromin expression or function
  - Relatively high incidence of parathyroid carcinoma is described in patients with CDC73 mutations
  - Studies report CDC73 mutations in 0-5.3% of all cases of FIHP
- MEN1 mutations
  - According to current studies, MEN1 mutations have been reported in up to 17.6% of unrelated FIHP families
- CASR mutations
  - Located on chromosome 3q
  - Current studies show up to 11.8% detection rate of CASR mutations in FIHP families

Surgical Procedures
- Parathyroidectomy

DIFFERENTIAL DIAGNOSIS

Sporadic Parathyroid Adenomas
- Predisposing factors poorly understood; possible association with prior ionizing radiation
- Later onset of disease than FIHP
- Lower incidence of multiglandular involvement than FIHP
- Lower recurrence rate than FIHP

Multiple Endocrine Neoplasia Type 1
- Autosomal dominant familial tumor syndrome in which patients develop tumors of the parathyroid glands, enteropancreatic neuroendocrine system, pituitary gland, and skin
- Primary hyperparathyroidism, caused by an adenoma or hyperplasia, is the 1st manifestation of MEN1 in > 90% of patients
- Parathyroid adenomas occur in ~ 90% of MEN1 patients
  - Cause hyperparathyroidism and hypercalcemia

Patients with MEN1 inherit a mutation in tumor suppressor gene MEN1 on chromosome 11q13

Multiple Endocrine Neoplasia Type 2A
- Rare familial tumor syndrome caused by the RET proto-oncogene
- Parathyroid tumors are found in 35-50% of affected family members
- Virtually all patients develop medullary thyroid carcinoma
- ~ 50% of patients develop pheochromocytomas, which are bilateral in 60-80% of cases

Hyperparathyroidism-Jaw Tumor Syndrome
- Autosomal dominant disorder characterized by adenomatous or carcinomatous parathyroid tumors, fibroosseous tumors of jaw bones, renal tumors and cysts, and uterine tumors
  - Penetration of each of these phenotypic features is variable
- Gene responsible for HPT-JT is tumor suppressor gene CDC73 (formerly HRPT2) located on chromosome 1q25

Familial Benign Hypocalciuric Hypercalcemia (FBHH)
- Most difficult of familial hyperparathyroidism syndromes to distinguish clinically from FIHP
- Usually caused by heterozygous inactivating mutations of CASR on chromosome 3q
- Characteristic features include
  - Mild to moderate hypercalcemia with nonsuppressed PTH
  - Relative hypocalciuria while hypercalcemic
  - Almost 100% penetrance of gene for hypercalcemia since birth
Persistency of hypercalcemia following subtotal parathyroidectomy

- Atypical presentations with severe hypercalcemia, hypercalciuria, normocalcemia following parathyroidectomy, and pancreatitis have all been described
- General recommendation is that if FBHH is suspected, kindred should be investigated to resolve diagnostic uncertainty

SELECTED REFERENCES
10. Simonds WF et al: Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab. 89(1):96-102, 2004

### Differential Diagnosis of Familial Isolated Hyperparathyroidism (FIPH)

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Clinical Characteristics</th>
<th>Pathological Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sporadic parathyroid adenomas</td>
<td>No associated findings; later occurrence, low recurrence rate</td>
<td>Parathyroid adenoma</td>
</tr>
<tr>
<td>Multiple endocrine neoplasia type 1 (MEN1)</td>
<td>&gt; 95% of patients with MEN1 develop hyperparathyroidism</td>
<td>Majority are parathyroid adenoma</td>
</tr>
<tr>
<td>Multiple endocrine neoplasia type 2A (MEN2A)</td>
<td>Parathyroid tumors may be present in up to 50% of patients with MEN2A</td>
<td>Usually all 4 glands are enlarged; hyperplasia or adenoma</td>
</tr>
<tr>
<td>Hyperparathyroidism-jaw tumor syndrome (HPT-JT)</td>
<td>Associated with fibroosseous tumors of the jaw, and with renal and endometrial tumors</td>
<td>Parathyroid adenoma or carcinoma</td>
</tr>
<tr>
<td>Familial benign hypocalciuric hypercalcemia (FBHH)</td>
<td>Difficult to distinguish from FIPH</td>
<td>Normal parathyroid size, weight, and histology</td>
</tr>
</tbody>
</table>

Table P.II(2):55

Image gallery
Diagrammatic and Microscopic Features
A symmetric hyperplasia or pseudoadenomatous variant of hyperplasia with marked variation in size of each parathyroid gland can be confused with adenoma. This example of parathyroid hyperplasia shows chief cells in a microfollicular pattern mixed with nodules of oncocytic cells, a common pattern in parathyroid hyperplasia. The nuclei of parathyroid cells are round with dense chromatin.

Parathyroid chief cells are the predominant cell type in parathyroid hyperplasia. Parathyroid cells have small amounts of cytoplasm and small dense nuclei. This hyperplastic parathyroid shows prominent parathyroid oxyphil cells. The nuclei are mildly pleomorphic, but markedly increased nuclear to cytoplasmic ratios and mitotic figures are not identified.
This parathyroid shows prominent oxyphil cells, which are not typically present in the normal parathyroid in children but develop with increasing age. Oxyphil cells can form small nodules in the normal parathyroid glands of older adults and should not be mistaken for parathyroid disease. (Right) Foci of clear cells are identified in this hyperplastic parathyroid. Note the characteristically well-defined cytoplasmic membranes of parathyroid cells.

Familial Non-Hodgkin Lymphoma

Elizabeth Morgan, MD
Giemsa stain of a bone marrow biopsy from a WM patient shows morphologic evidence of LPL (discrete lymphoid nodule and many dark purple mast cells). WM/LPL can occur in familial clusters.
Lymph node biopsy from a patient with follicular lymphoma (FL) shows multiple lymphoid nodules extending into extranodal adipose tissue. Risk of FL is increased 4x in relatives of patients with FL.

TERMINOLOGY

Abbreviations
- Non-Hodgkin lymphoma (NHL)

Definitions
- NHL is umbrella term to describe mature B-, T- and natural killer (NK)-cell neoplasms and consists of > 45 distinct entities
- Familial NHL is defined as ≥ 2 first-degree relatives with NHL (any subtype)

EPIDEMIOLOGY

NHL
- Age-adjusted incidence rate of all NHL in USA is 19.7 per 100,000 persons per year (2006-2010 SEER data)
- Median age at diagnosis: 66 years of age

Familial NHL
- Rare (< 5% of NHL cases are associated with familial clusters)

Risks
- Relatives are at highest risk of developing the same lymphoma subtype as the proband, although other subtypes can also occur
- Including all subtypes, family history of lymphoma is associated with 1.5-4x relative risk of developing lymphoma (based on various epidemiological studies)
- Studies incorporating classification information show that risk is increased for some subtypes
  - Relatives of patients with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) demonstrate 20x increased risk of WM/LPL
    - 5x increased risk for monoclonal gammopathy of undetermined significance
    - 3x increased risk for chronic lymphocytic leukemia (CLL) or any NHL
o Relatives of patients with diffuse large B-cell lymphoma (DLBCL) demonstrate 10x increased risk of DLBCL
o Relatives of patients with CLL demonstrate 8.5x increased risk of CLL
  ▪ 2.6x increased risk for any NHL (particularly hairy cell leukemia and WM/LPL)
  ▪ Relatives of patients with follicular lymphoma (FL) demonstrate 4x increased risk of FL
  ▪ Relatives of patients with multiple myeloma (MM) demonstrate 1.7x increased risk of MM
o Reports of familial mantle cell lymphoma are rare

ETIOLOGY/PATHOGENESIS

Genetics
- Linkage mapping studies in NHL families have not identified germline gene mutations
- Evidence of highly penetrant genes has not been found in twin studies
- Familial risk may be secondary to multiple, varied susceptibility loci, each conferring small relative risks
  - Genetic susceptibility studies have identified loci associated with increased susceptibility to NHL, including areas involved in immune function regulation, inflammation, oxidative stress, metabolism, and DNA repair
  - Genome-wide association studies have identified single nucleotide polymorphisms (SNPs) at > 20 susceptibility loci in familial CLL
  - Polymorphisms in IL10 and BCL2 have been found specifically in familial NHL cases
  - Possible association of SNPs within the 6p21.31 locus with mantle cell lymphoma and T-cell lymphoma has been described

Environmental Exposures
- Viral exposure may account for some familial clustering of specific subtypes
  - Human T-cell lymphotrophic virus type 1 (HTLV-1) in families with adult T-cell leukemia/lymphoma (Japan, Caribbean)
  - Epstein-Barr virus (EBV) in families with Burkitt lymphoma (Africa)
- Risk of developing WM/LPL is increased in context of parental gastric carcinoma, raising the possibility of association with H. pylori infection

Immune Function
- Patients with autoimmune disorders or other immune-related conditions (some of which may be hereditary) are at increased risk for lymphoma
  - Congenital immunodeficiency syndromes such as ataxia-telangiectasia, Bruton agammaglobulinemia, Chediak-Higashi syndrome, common variable immunodeficiency, and Wiskott-Aldrich syndrome are known to be associated with development of lymphoma
  - Autoimmune disorders are associated with increased risk of WM/LPL (both sporadic and familial)

CLINICAL IMPLICATIONS

Familial NHL Vs. Sporadic NHL
- Family history of NHL is associated with younger age at diagnosis
- Some studies find differences in risk based on gender (M > F) or type of relation (highest in siblings) whereas others do not find significant differences in these areas
- No differences in site or nodal vs. extranodal presentation in familial vs. sporadic NHL
- No differences in histologic subtype in familial vs. sporadic NHL
- No differences in survival, 5-year mortality, or 10-year mortality in familial NHL vs. sporadic NHL
  - In small sample, breakdown by lymphoma type showed worse 5-year mortality for patients with T-cell or anaplastic lymphoma and family history of NHL vs. sporadic T-cell or anaplastic lymphoma, but equivalent 5-year mortality for low- and high-grade B-cell lymphomas
- Retrospective study demonstrated that familial WM is associated with inferior treatment outcomes compared to sporadic WM

ASSOCIATED NEOPLASMS

WM/LPL Families
- No increased risk of myeloid neoplasms or solid tumors

CANCER RISK MANAGEMENT

Cancer Screening
- Currently, screening of asymptomatic relatives of patients with NHL is not recommended given the low absolute risk of developing lymphoproliferative disorder

SELECTED REFERENCES

Familial Nonmedullary Thyroid Carcinoma

> Table of Contents > Part I - Overview of Syndromes > Section 2 - Syndromes > Familial Nonmedullary Thyroid Carcinoma

Familial Nonmedullary Thyroid Carcinoma
Vania Nosé, MD, PhD
Gross cut surface from a thyroid of a young patient with PTEN-hamartoma tumor syndrome shows multiple well-circumscribed gray-white nodules compressing a small amount of uninvolved thyroid.
This histopathological picture of a thyroid from a patient with familial nonmedullary thyroid carcinoma shows a thyroid carcinoma with oxyphilia, an unusual type of thyroid cancer.

TERMINOLOGY

Familial Follicular Cell-Derived Carcinoma or Familial Nonmedullary Thyroid Carcinoma (FNMTCT)

- Familial nonmedullary thyroid carcinoma or familial follicular cell tumors derived from thyroid follicular cells can be subdivided into 2 subgroups
- Familial tumor syndromes characterized by predominance of nonthyroidal tumors
  - PTEN-hamartoma tumor syndrome (PHTS)
    - Cowden syndrome (CS) and Bannayan-Riley-Ruvalcaba syndrome (BRRS) are major entities comprising PHTS
  - Familial adenomatous polyposis (FAP): Characterized by hundreds of adenomatous colonic polyps that develop during early adulthood
    - Develop diverse tumors
  - Carney complex: Consists of myxomas, spotty pigmentation, and endocrine overactivity
  - Werner syndrome: Rare premature-aging syndrome that begins in 3rd decade
  - Pendred syndrome: Most common hereditary syndrome associated with bilateral sensorineural deafness
    - Also called deaf-mutism and goiter
- Familial tumor syndromes characterized by predominance of nonmedullary thyroid carcinoma
  - Characterized by 3 or more 1st-degree relatives with follicular-derived nonmedullary thyroid carcinoma and occurs regardless of presence of another familial syndrome
  - Pure familial papillary thyroid carcinoma (PTC) ± oxyphilia: Mapped to chromosomal region 19p13
  - FNMTCT type 1: Mapped to chromosome 2q21
  - FPTC with papillary renal cell carcinoma: Mapped to chromosomal region 1q21
  - Familial PTC with multinodular goiter: Mapped to chromosomal region 14q
  - Others
EPIDEMIOLOGY

Syndromes Characterized by Predominance of Nonthyroidal Tumors and Syndromes With a Predominance of Nonmedullary Thyroid Carcinoma (NMTC)

- Criterion of FNMTC families is that ≥ 3 first-degree family members are affected with NMTC
- Benign thyroid lesions such as multinodular hyperplasia (MNG) and follicular thyroid adenoma are associated with FNMTC
  - Personal or family history of benign thyroid conditions is present in ~ 45% of patients with FNMTC
- Age range at which each affected individual is diagnosed is broad; but usually < 35 years
- F:M reported ratio varies from 2:1 to 12:1

GENETICS

Syndromes Characterized by Predominance of Nonthyroidal Tumors

- PHTS
  - Caused by germline mutations of PTEN gene and inherited in autosomal dominant fashion
  - PTEN (phosphatase and tensin homolog deleted on chromosome 10) is tumor suppressor gene located on 10q23.3
  - > 90% of PHTS patients manifest a phenotype by 20 years of age
- Familial adenomatous polyposis (FAP)
  - P.I(2):59

Syndromes With Predominance of Nonmedullary Thyroid Carcinoma

- Although NMTC is mostly sporadic, evidence for a familial form, which is not associated with other Mendelian cancer syndromes, is well documented
- To date, no FNMTC predisposing genes have been identified
- Linkage analyses have mapped 6 different chromosomal regions that may harbor FNMTC susceptibility genes
  - 6 potential regions for harboring an FNMTC gene have been identified: MNG1 (14q32), TCO (19p13.2), FPTC/PRN (1q21), NMTC1 (2q21), FTEN (8p23.1-p22), and the telomere-telomerase complex
- Important genes reported to have been excluded are RET, TRK, MET, APC, PTEN, and TSHR
- Based on current evidence, FNMTC is likely to represent a polygenic mode of inheritance
- Putative susceptibility genes identified appear to account for only a minority of FNMTCs
- Identification of genes for FNMTC could be utilized in the screening, management, and surveillance of NMTC

Pure Familial PTC ± Oxyphilia

- “Thyroid carcinoma with oxyphilia” locus (TCO; MIM 603386) was mapped to chromosome 19p13.2 in a French family with an unusual form of NMTC with cell oxyphilia
- Speculated that TCO locus is associated only with this unique form of FNMTC with cell oxyphilia
- There are suggestions that TCO might be a tumor suppressor gene
- TCO locus may account for NMTC in a minority of cases
- Rare type of thyroid cancer with distinct morphology

FPTC With Papillary Renal Cell Carcinoma

- Locus predisposing to FNMTC was identified on chromosome 1p13.2-1q22 in a USA family with recurrent PTC and papillary renal neoplasia (PRN) (FPTC/PRN or PRN1; MIM 605642)
- To date, no further families with a PTC and PRN association have been reported
2 studies that performed linkage analysis on a total of 29 FNMTC families (without PRN) did not find an association between FNMTC and FPTC/PRN locus.

- These findings suggest that FPTC/PRN locus may harbor a susceptibility gene for a unique FNMTC phenotype where PTC is associated with PRN.

**FNMTC Type 1**
- Susceptibility locus named “nonmedullary thyroid carcinoma 1” was mapped to chromosome 2q21 in a large Tasmanian family with high frequency of PTC (NMTC1; MIM 606240).
- Extensive genome-wide scan followed by haplotype analysis revealed that the majority of subjects with PTC shared a common haplotype on chromosome 2q21.
- Studies suggested that the 2q21 locus, NMTC1 locus, has a more significant association with familial PTC follicular variant (FV) than with familial PTC.
  - NMTC locus is also associated with some oxyphilic tumors.

**FPTC With Multinodular Goiter (MNG)**
- MNG susceptibility locus (MNG1; MIM 138800) was mapped to chromosome 14q32 in a large Canadian family with MNG and low occurrence of NMTC.
- Additional studies failed to find linkage between the MNG1 locus and FNMTC.
  - MNG1 locus has shown evidence of linkage only to FNMTC in original Canadian kindred with multiple MNGs.
  - Linkage analyses in a further 124 families have failed to confirm an association between MNG1 and FNMTC.
- Therefore, this locus may not be involved in FNMTC, or it may account for only a minority of FNMTC cases with MNG.

**Other Possible Candidates**
- **FTEN:** Mapped to chromosome 8p23.1-p22.
  - Linkage to the 8q23.1-p22 locus was confirmed in a family with 11 cases of benign thyroid disease and 5 cases of carcinoma.
- **Telomere-telomerase complex**
  - Study of the telomere-telomerase complex in a series of patients with FNMTC revealed significantly shorter telomere lengths, higher telomerase reverse transcriptase (TERT) gene amplification, and TERT mRNA expression in patients with FPTC when compared with sporadic PTCs.
  - This study did not report any mutations of TERT gene or the telomerase RNA component.

**CLINICAL IMPLICATIONS AND ANCILLARY TESTS**

**Syndromes Characterized by Predominance of Nonthyroidal Tumors**
- Diagnosis of thyroid cancer is usually in younger patients than their sporadic counterpart.
- Multifocal and bilateral PTC.
- FNMTC is 1 component of a defined cancer susceptibility syndrome with preponderance of nonthyroidal tumors.

**Syndromes With Predominance of Nonmedullary Thyroid Carcinoma**
- FNMTC is a clinical entity characterized by an earlier age of onset, more frequent multifocal and bilateral disease, and recurrence compared with its sporadic NMTC.
- Familial cases of PTC are reportedly more aggressive than their sporadic counterparts.
- 10x increase in risk of thyroid cancer in relatives of patients with thyroid cancer.

**ASSOCIATED NEOPLASMS**

**Syndromes Characterized by Predominance of Nonthyroidal Tumors**
- **Thyroid carcinoma** is usually bilateral and multifocal.
- **FAP**
  - FAP, GI manifestations: Colonic polyps, colonic adenocarcinoma, duodenal/ampullary adenomas, fundic gland polyps, liver lesions.
  - FAP, extraintestinal manifestations: Desmoid tumors, osteomas, congenital hypertrophy of retinal pigmented epithelium, brain tumors, and papillary thyroid carcinoma cribriform morular variant.
- **PHTS:** Breast carcinoma, endometrial carcinoma, renal carcinoma, and multiple other tumors including papillary and follicular thyroid carcinoma.
- **Carney complex:** Multiple facial lentigines, myxomas, epithelioid blue nevus, neurofibromas, primary pigmented adrenal cortical nodular disease, atrial myxomas.
Less common: Large cell calcifying Sertoli cell tumor, psammomatous melanotic schwannoma, and multiple thyroid nodules and follicular adenoma

- Werner syndrome: Multiple malignancies occurring at a younger age such as melanoma, soft tissue sarcoma, osteosarcoma, and thyroid carcinoma

**Syndromes With Predominance of Nonmedullary Thyroid Carcinoma**
- Thyroid carcinoma usually bilateral and multifocal
- Papillary renal cell carcinoma in association with familial PTC/PRN

**CANCER RISK MANAGEMENT**

**Screening**
- Family history of individuals with FNMT should be reviewed carefully to rule out syndromes characterized by a predominance of nonthyroidal tumors and risk of renal cancer
- If a familial predisposition exists, annual screening of thyroid by ultrasound and physical examination
  - Screening should start no later than an age 10 years younger than that of youngest relative diagnosed with either benign or malignant thyroid tumors
- Renal imaging is recommended for individuals from families with history of renal cell carcinoma
- Surveillance for other cancers according to their syndromes
  - Screening for other tumors is advised by the American Cancer Society

**Prophylactic Surgery**
- Role of prophylactic surgery in most of these conditions is still undefined

**SELECTED REFERENCES**
1. Mazeh H et al: In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease. Thyroid. 22(1):3-8, 2012

Image gallery

Microscopic Features
(Left) This photomicrograph from an 18-year-old woman with PHTS shows multiple well-circumscribed, nonencapsulated adenomatous nodules surrounded by a small residual compressed thyroid parenchyma. (Right) Immunohistochemistry for PTEN in an adenomatous nodule of a patient with PHTS shows loss of staining of the follicular cells with preservation of staining of the endothelial cells.

(Left) This image in a follicular thyroid carcinoma in a patient with PTEN-hamartoma tumor syndrome shows a characteristic vascular invasion. The thyroid from this patient also had multiple adenomatous nodules and a papillary carcinoma. (Right) Papillary thyroid carcinoma with oxyphilia is also usually present in other family members with this familial syndrome. This tumor is characterized by large cells with granular cytoplasm and with the nuclear features of papillary thyroid carcinoma.
This photomicrograph shows the characteristic appearance of the cribriform morular variant of papillary thyroid carcinoma, which is present in about 12% of patients with familial adenomatous polyposis (FAP). Nuclear features of papillary carcinoma and colloid are absent. (Right) There is strong nuclear and cytoplasmic staining for β-catenin in cribriform morular variant carcinoma, which distinguishes these tumors from other variants of papillary thyroid carcinoma that are negative.

Familial Plasma Cell Myeloma
A diagnosis of MM requires identification of a clonal plasma cell population in the bone marrow even when the immunologic or radiographic studies strongly support the presence of disease.

Homogeneous sheets of plasma cells displacing normal bone marrow stroma indicate MM. Infiltrates may be widely spaced and irregularly distributed with considerable areas of bone marrow sparing.

**TERMINOLOGY**

**Abbreviations**
- Monoclonal gammopathy of undetermined significance (MGUS)

**Definitions**
- Occurrence of MM in > 1 family member
  - More than expected due to rarity of disease
  - Multiple myeloma (MM): Classified as plasma cell myeloma (PCM) in 2008 WHO classification of plasma cell neoplasms

**EPIDEMIOLOGY**

**Incidence**
- 20,000 cases of MM diagnosed in USA in 2008
    - Main effect on incidence of MM is race
    - Sex, age, year of diagnosis, and geographic area are not as important
  - African Americans diagnosed with MGUS and MM 2-3x more than European Americans
    - African Americans have fewer IgH translocations
  - > 100 cases of familial MM have been reported
    - Effects of genetic factors, environmental factors, or both are currently being studied
  - 40% of 1st-degree relatives of patients with MM have cancer
    - 10% are hematologic neoplasms

**ETIOLOGY**

Genetic/Environmental
Hypothesis that 1st “hit” is germline and inherited; 2nd “hit” is somatic and environmental
  - Environmental factors linked to familial MM
    - Many family members are born and raised in rural areas
    - Increased exposure to pesticides, insecticides, herbicides
    - MM develops in some spouses of MM patients
  - MGUS is precursor lesion to MM
    - Asymptomatic, premalignant condition
    - Progression to MM of 1% per year

Putative Autosomal Dominant Transmission of MM
- Families with probable myeloma syndrome
- Dominant allele is on a non-sex-determining chromosome
  - Affects females and males
  - Does not skip generations
- Significant association with other malignancies
  - High frequency of breast cancer in some studies
  - Increased incidence of lymphoma, leukemia, pancreatic cancer, melanoma, and prostate cancer
- Genotypically and phenotypically heterogeneous
  - Genetic causes may overlap with those for other hematopoietic and solid tumor malignancies
  - Genetic differences vary between MM families

Genetics
- Genome-wide association study
  - Single nucleotide polymorphism at 3p22.1 (rs1052501), ULK4 gene
    - C allele associated with 30% increased risk of MGUS and 40% increased risk of MM
- Potential myeloma-prone germ-line mutations
  - Germ-line CDKN2A mutation in melanoma-prone family
    - Mutation associated with development of MM in 1 family member
- Sequencing studies have identified novel loci in MM DNA

Role of Immune-Mediated Conditions
- Hyperresponsive B cells in families with MGUS/MM
  - Increased IgA, IgG, or IgM production after pokeweed mitogen stimulation in vitro
    - Suggests role in familial monoclonal gammopathy
- Hyperphosphorylated autoantigen targets of paraproteins more prevalent in familial MGUS/MM
  - Possible role in development of MGUS/MM by chronic antigen stimulation
  - Paratarg-7 (P-7)
    - Target of 15% of IgA and IgG paraproteins; 11% of IgM paraproteins
    - Hyperphosphorylation of protein is inherited in a dominant manner
    - Carrier of P-7 is at increased risk of developing MGUS/MM (odds ratio = 6.5)
  - P-8, encoded by ATG13 gene
    - Hyperphosphorylation of protein is inherited in a dominant manner
- Patients with giant cell arteritis and polymyalgia rheumatica have
  - Increased risk of MM (odds ratio = 7.8 and 1.9, respectively)
  - Increased risk of MGUS (odds ratio = 11.3 and 2.9, respectively)

CLINICAL IMPLICATIONS

Familial Aggregation of MM
- Family-, case-, and population-based studies
  - Primarily white populations examined
  - Families of MGUS probands have increased
    - Relative risk for MGUS of 2.6-3.3%
    - Relative risk for MM of 2.0-2.9%
1st-degree relatives have 2-4x increased risk of lymphoproliferative disorders
  - Families of MM probands have increased
    - Relative risk for MGUS of 2.0-2.4%
    - Relative risk for MM of 2.1-3.7%
    - 1st-degree relatives have relative risk for MM of 5.64
    - Standard incidence ratio for MM in offspring is 3.33 (2.1-5.0) in Swedish study

- African Americans or people of African descent
  - Scant data
    - Rare study supports role for genetic factors

**Familial MM or Myeloma Syndrome**
- Rare disorder
  - Increased risk of MM in 1st-degree relatives of patients with MM
- Excess cases of solid and hematologic cancers
  - Important to document extended family pedigrees
  - Examine both genetic factors and environmental exposure

**ASSOCIATED NEOPLASMS**
- Familial MM
  - Breast cancer, pancreatic cancer, melanoma, bladder or prostate cancer, lymphoma, and leukemia may be part of syndrome
- MGUS or MM
  - Increased risk of chronic lymphocytic leukemia
  - Increased risk of acute lymphoblastic leukemia (MM)

**CANCER RISK MANAGEMENT**
- Myeloma Susceptibility Loci Testing
  - Linkage analysis studies of family members
    - Find markers specific to familial disease
    - Monitor at-risk family members
- Test for M-Component in Family Members
  - MGUS is single best marker of familial disease

**SELECTED REFERENCES**
Familial Testicular Tumor

Image shows mixed TGCT that consists of seminoma ➔, embryonal carcinoma ➔, and mature teratoma ➔. In young adults, mixed TGCT is the 2nd most common testicular tumor after pure seminoma.
Large-cell calcifying Sertoli cell tumor shows distinctive large cells with abundant eosinophilic cytoplasm & calcifications; it is associated with Carney complex & Peutz-Jeghers syndrome. (Courtesy S. Shen, MD.)

FAMILIAL TESTICULAR GERM CELL TUMORS

Terminology

- Abbreviations
  - Testicular germ cell tumor (TGCT)
  - Familial testicular germ cell tumor (FTGCT)
  - Hereditary testicular germ cell tumor (HTGCT)

- Definitions
  - FTGCT
    - Affected individuals from families with ≥ 2 cases of TGCT
  - HTGCT
    - FTGCT with consistent passage of susceptibility gene via Mendelian inheritance
    - No definitive human susceptibility gene identified so far
    - Existence not yet firmly established

Epidemiology

- Incidence
  - In USA, there will be 7,920 cases of testicular cancers estimated in 2013
  - Incidence increased 3-6% annually since the 1970s
  - 95% of testicular tumors are TGCT
  - ~ 1.5% of patients with TGCT reported positive family history of TGCT
    - ~ 120 FTGCT cases per year

- Age range
  - 3 distinct age groups of TGCT
    - Mostly young adults between 20 and 35 years (pure and mixed germ-cell tumor [GCT])
    - Neonates and infants (mostly pure teratoma and yolk sac tumor)
    - Older men (spermatocytic seminoma)
Most reported FTGCT cases under 1st group
Diagnosis of FTGCT is 2-3 years younger than in usual TGCT

Risk Factors for TGCT
- Family history, prior TGCT, cryptorchidism, and testicular microlithiasis
- Syndromic associations such as Klinefelter syndrome (47 XXY) and XY gonadal genesis
- Testicular microlithiasis more common in FTGCT family members
- Incidence of cryptorchidism similar in FTGCT and sporadic TGCT

Family History as Risk for TGCT
- 4-6x ↑ risk of TGCT in sons of affected individuals
- 8-10x ↑ risk of TGCT in siblings of affected individuals
  - Represent highest familial risk for any human cancers
  - Higher risk among brothers suggests recessive or X-linked inheritance
- 88% of FTGCT have 2 affected individuals; highest incidence is up to 5 members
  - Indicates very low penetrance for HTGCT
- Risk in twins: 37x higher for dizygotic, 76x higher for monozygotic
- Also ↑ risk of ovarian GCT in female family members (familial ovarian GCT)
  - TGCT 15x ↑ than ovarian GCT

Genetic Factors
- Several candidate genes reported
- Most either showed conflicting results or needed further investigations
- KITLG, SPRY4, and BAK1 confirmed by genome-wide association studies

Clinical Implications
- Bilaterally in FTGCT slightly ↑ at 6.5-9.8% vs. 2.8% in TGCT with negative family history
- Clinical behavior of FTGCT likely similar to usual TGCT, which is dependent on stage, specific GCT component, and treatment type

Pathological Findings
- Similar to usual TGCT in younger adult patients
  - TGCT in this age group associated with intratubular germ cell neoplasia (ITGCN)
- Seminoma and nonseminoma diagnosis at 1:1 ratio in FTGCT

FAMILIAL SEX CORD-STROMAL TUMORS
Terminology
- Abbreviations
  - Sex cord-stromal tumors (SCST)
  - Familial sex cord-stromal tumors (FSCST)

Epidemiology
- < 5% of testicular tumors
- Most SCST are sporadic
- FSCST very rarely encountered in Peutz-Jeghers syndrome and Carney complex

Syndromic Associations
- Large cell calcifying Sertoli cell tumor (LCCSCT) and Sertoli cell tumor associated with Peutz-Jeghers syndrome and Carney complex; LCCSCT a component of Carney complex
  - Carney complex caused by inherited mutation in PRKAR1A
    - Autosomal dominant inheritance characterized by cardiac or cutaneous myxomas, lentiginosis, endocrine tumors or overactivity, and schwannoma
    - 1/3 develop LCCSCT within 1st decade and in almost all adult males
    - Clinical testing available for PRKAR1A, detecting ~ 55% mutation
  - Peutz-Jeghers syndrome caused by inherited mutation in STK11
    - Autosomal dominant inheritance characterized by gastrointestinal polyposis and oral pigmentation
  - Juvenile granulosa cell tumor associated with sex chromosomal abnormalities, ambiguous genitalia, and ipsilateral cryptorchidism

Clinical Implications
- LCCSCT is benign
- Juvenile granulosa cell tumor mostly have indolent behavior

Pathologic Findings
• Similar to usual SCST

SELECTED REFERENCES

Tables

<table>
<thead>
<tr>
<th>Genomic Region</th>
<th>Gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xq27</td>
<td>Unknown</td>
</tr>
<tr>
<td>2p23</td>
<td>Unknown</td>
</tr>
<tr>
<td>3p12</td>
<td>Unknown</td>
</tr>
<tr>
<td>3q26</td>
<td>Unknown</td>
</tr>
<tr>
<td>12p13-q21</td>
<td>Possible KITLG</td>
</tr>
<tr>
<td>18q21-23</td>
<td>Unknown</td>
</tr>
<tr>
<td>4q12</td>
<td>KIT</td>
</tr>
<tr>
<td>5q31.3</td>
<td>DND1</td>
</tr>
<tr>
<td>Yq11.2</td>
<td>Y gr/gr</td>
</tr>
<tr>
<td>2q31.2</td>
<td>PDE11A</td>
</tr>
<tr>
<td>12q22</td>
<td>KITLG</td>
</tr>
<tr>
<td>5q31.3</td>
<td>SPRY4</td>
</tr>
<tr>
<td>6p21.3-p21.2</td>
<td>BAK1</td>
</tr>
</tbody>
</table>
Familial Uveal Melanoma

Axial T1-weighted MR image post-contrast demonstrates a well-circumscribed intraocular mass centered in the uveal tract. Histologic examination confirmed the diagnosis of melanoma.
Uveal melanomas arise predominantly in the choroid and form well-circumscribed masses. Serous detachment of overlying/adjacent retina is common.

**TERMINOLOGY**

**Description**
- Malignant intraocular neoplasm with melanocytic differentiation arising in choroid, ciliary body, or iris

**EPIDEMIOLOGY**

**Uveal Melanoma**
- Most frequent primary intraocular neoplasm in adults
- Annual incidence: 5-6 per 1 million in United States
  - Predominantly disease of adults (mean age ~ 60 years)
  - Predilection for whites, light-colored eyes; no gender predilection

**Familial Uveal Melanoma**
- Families with multiple members with uveal melanoma very rare (< 1%)
- If cancers other than uveal melanoma are considered, familial predisposition for uveal melanoma is much higher (~ 10%)

**GENETICS**

**BAP1-Associated Tumor Predisposition Syndrome**
- Autosomal dominant syndrome associated with mutations in BRCA1-associated protein 1 (BAP1) located in chromosome region 3p21.1
- Encodes for a nuclear ubiquitin carboxy-terminal hydroxylase
  - Binds BRCA1 and ASXL1
  - Plays role in DNA damage response, apoptosis, senescence, chromatin modulation/stem cell biology, and regulation of cell cycle
- Inactivating somatic mutations in 1/2 of uveal melanomas, particularly when metastatic
- Inactivating somatic mutations in a small subset of lung and breast cancers
- Monosomy 3 (containing BAP1) strongly associated with metastatic risk in uveal melanoma
Germline mutations associated with increased risk in families for uveal melanoma, cutaneous melanoma, malignant mesothelioma, renal cell carcinoma, and other cancers
  - Frequent epithelioid/rhabdoid cytology
  - Protein loss may be identified by immunohistochemistry in tumor tissues

**CDKN2A**
- Encodes tumor suppressors p14ARF and P16
- Best known high-risk melanoma susceptibility gene
- Germline mutations strongly associated with cutaneous melanoma, but rare in uveal melanoma (< 1% of patients)

**GNAQ and GNA11**
- Somatic mutations frequent in uveal melanoma
  - Early genetic events leading to MAPK pathway activation
- Germline mutations not a feature of familial uveal melanoma

**BRAF**
- Somatic mutations frequent in cutaneous melanoma but very rare in uveal melanoma
- Germline mutations associated with cardiofaciocutaneous syndrome but not with melanoma predisposition

**ASSOCIATED NEOPLASMS**

**Uveal Melanoma**
- High propensity for metastases (~ 50%), particularly the liver
- Composed of 3 main cell types in various proportions
  - Spindle A: Narrow nuclei, inconspicuous nucleoli
  - Spindle B: Oval, plump nuclei with prominent nucleoli
  - Epithelioid: Abundant cytoplasm, prominent nucleoli, associated with poor prognosis
- Gene expression profiles
  - Class 1: Low metastatic risk
  - Class 2: High metastatic risk, frequent monosomy 3
- Other prognostic factors include tumor size, extracellular matrix patterns (i.e., vascular mimicry), mitotic activity, extraocular extension, necrosis, and lymphocytic infiltrates

**Cutaneous Melanoma and Atypical Melanocytic Lesions**
- Melanocytic BAP1-mutated atypical intradermal tumors (MBAIT) or nevoid melanoma-like melanocytic proliferations (NEMMP)
  - Terms proposed for a subset of tumors with spitzoid features and high prevalence of somatic BRAF (V600E) mutation in patients with germline BAP1 mutations
    - Terminology not uniformly accepted
  - Combined somatic BAP1 and BRAF mutations also found in a subset of atypical Spitz tumors/nevi

**Astrocytoma**
- Melanoma-astrocytoma predisposition recognized in rare families
- Associated with CDKN2A mutations, particularly when exons coding for p14ARF are involved
- Astrocytomas pathologically high grade (i.e., glioblastomas)

**Mesothelioma**
- Genetic factors important
  - Some patients develop mesothelioma after short exposure to asbestos whereas others do not, even after heavy exposure
- Recognized component of BAP1-associated tumor predisposition syndrome
- BAP1 mutations also occur in sporadic mesothelioma (up to 60%)
  - More frequent in tumors with epithelioid morphology

**Renal Cell Carcinoma**
- Recognized component of BAP1-associated tumor predisposition syndrome
  - Clear cell histology
- Somatic BAP1 mutations in 8-14% of clear cell renal carcinomas

**Others**
- Meningioma, lung adenocarcinoma, neuroendocrine carcinoma, paraganglioma

**CANCER RISK MANAGEMENT**

**Uveal Melanoma Families**
Members with uveal melanomas and other possibly related cancers (e.g., cutaneous melanomas and mesotheliomas) should be screened for BAP1 mutations.

Ophthalmologic and dermatologic exams; avoid environmental insults (e.g., sun exposure).

SELECTED REFERENCES
5. Abdel-Rahman MH et al: Cancer family history characterization in an unselected cohort of 121 patients with uveal melanoma. Fam Cancer. 9(3):431-8, 2010

IMAGE GALLERY

(Left) The majority of patients with metastatic uveal melanoma have hepatic involvement, as demonstrated in this abdominal CT scan. (Center) Most uveal melanomas are characterized by spindle cells. Melanotic pigment is variable. (Right) The presence of epithelioid cells in uveal melanoma is a negative prognostic factor and is associated with class 2 (high-risk) tumors and BAP1 mutations. These cells contain ample cytoplasm, round nuclei and macronuclei.
Familial Wilms Tumor

Coronal T1WI MR shows a huge, homogeneous mass occupying the right flank, displacing the bowel and liver. This Wilms tumor compresses the vena cava along the left margin of the mass, without venous invasion.
Gross image shows a very large WT replacing the kidney that was eventually resected from a patient after several rounds of chemotherapy were given to shrink the mass.

TERMINOLOGY

Abbreviations
- Wilms tumor (WT)
- Familial Wilms tumor (FWT)

Definitions
- WT: Malignant embryonic neoplasm arising from undifferentiated renal mesenchyme that exhibits triphasic histology of blastemal, epithelial, and stromal elements
- FWT: Individuals affected by renal WT with positive family history of WT
  - Familial predisposition occurs outside the context of congenital anomalies, genetic syndromes, or WT1 mutation
- WT-associated syndromes are grouped separately

Synonyms
- Familial nephroblastoma

EPIDEMIOLOGY

Incidence
- WT diagnosed in 1 in 10,000 Caucasian children and comprises ~ 85% of childhood renal malignancies
  - Majority of WT are sporadic (up to 99%)
  - FWT comprises ~ 2% of cases
    - Very rare cases of familial extrarenal WT cases have been reported

Age Range
- Sporadic WT
  - Average age of diagnosis for unilateral tumors: 42-47 months
  - Average age of diagnosis for bilateral tumors: 30-33 months
  - ~ 80% of cases diagnosed before 15 years of age
Diagnostic Pathology: Familial Cancer Syndromes

- **FWT**
  - Younger patients than in sporadic WT
  - Average age of diagnosis for unilateral tumors: ~ 35 months
  - Average age of diagnosis for bilateral tumors: ~ 16 months

**Gender**
- Males and females equally affected
- No gender bias in obligate carrier parents of children with WT

**Site**
- Sporadic WT
  - Bilateral involvement in 5-10% of cases
- FWT
  - Higher chance for bilateral involvement seen in ~ 16% of cases

**ETIOLOGY/PATHOGENESIS**

**Genetics**
- Etiology of WT is heterogeneous and may vary in sporadic, familial, and WT-associated syndrome settings
- Sporadic WT
  - WT1 at Chr 11p13 acts as a tumor suppressor gene and is inactivated in individuals with constitutional WT
    - WT1 is a member of zinc finger transcription factors and encodes a 449-amino acid protein containing 4 zinger motifs and a regulatory domain
    - Most mutations in WT are deletions or truncation mutations
- FWT
  - WT1 mutation occurs rarely in FWT
    - Considered not the predisposition gene in most WT families
  - 2 FWT genes mapped
    - P.I(2):69
      - FWT1 at Chr 17q12-q21
      - FWT2 at Chr 19q13.4
      - Specific genes in these 2 regions have not yet been identified
      - Lack of linkage in some families to FWT1 and FWT2 suggests the existence of at least 1 additional FWT gene
  - WT predisposition suggested as result of an autosomal dominant allele that is incompletely penetrant (25-60% penetrance)
- Other WT genes
  - Mutations in P53 and β-catenin observed in 5% and 15% of WT cases, respectively
  - Other genes at Chr 16q, Chr 1p, and Chr 7p
  - Alterations are mainly somatic

**CLINICAL IMPLICATIONS**

**Clinical Risk Factors**
- Positive family history
  - Majority of affected families have 2-3 members with WT
  - Hallmark of FWT: Affected individuals are either siblings or cousins, related through an unaffected obligate carrier

**Clinical Presentation**
- Most commonly, abdominal mass detected by parents
- Abdominal pain, gross hematuria, fever, or hypertension
- FWT rarely presents with features of genetic syndromes associated with WT (e.g., Wilms tumor; aniridia, genitourinary anomalies, and mental retardation [WAGR]; Denys-Drash, Perlman, Beckwith-Wiedemann syndromes)

**Prognosis**
- Similar for WT in sporadic, familial, and WT-associated syndromes settings
- High cure rate for WT; estimated survival of 90% for localized disease and 70% for advanced disease

**Treatment**
- Similar therapeutic approach for WT in sporadic, familial, and WT-associated syndromes setting
- Children Oncology Group (COG) and National Wilms Tumor Study (NWTS) advocate primary tumor resection & further chemotherapy &/or radiotherapy determined by stage and histology (favorable or unfavorable)
MACROSCOPIC FINDINGS
General Features
- Majority of WT are unicentric and solitary but with higher chance for bilaterality in familial setting
- Tumor macroscopic findings similar for WT in sporadic, familial, and WT-associated syndromes setting
  - Cut surface usually shows homogeneous pale graytan appearance
  - May vary in consistency depending on proportion of components; firmer and fleshier with predominance of stromal component

MICROSCOPIC FINDINGS
General Features
- Tumor histologic findings similar for WT in sporadic, familial, and WT-associated syndromes setting
  - Characterized by triphasic histology consisting of variable admixture of undifferentiated blastemal cells, epithelial cells, and stromal cells
  - Monophasic or biphasic WT may also occur
  - Blastemal cells
    - Tightly packed small cells with high nuclear:cytoplasmic ratio, overlapping nuclei, even chromatin, and brisk mitotic activity
  - Epithelial cells
    - From primitive to well-differentiated tubules and glomeruloid bodies resembling those found in normal kidneys
  - Stromal cells
    - Most are undifferentiated spindle cells or have muscle or fibroblastic differentiations
    - Occasionally may contain ganglion cells, neuroglia, bone, cartilage, or fat cells
- Immunohistochemistry
  - Nuclear immunoreactivity for WT1 of blastemal and epithelial cells
  - CK7 positivity in epithelial cells
  - Pax-2 often positive
  - Blastemal cells usually negative for pankeratin and vimentin

CANCER RISK MANAGEMENT
Screening for WT
- Clinical and genetic testing and surveillance for WT recommended for children in families with FWT
- Screening for FWT similar with other conditions considered high (> 20%) or moderate (5-20%) risks for WT, such as WAGR, Denys-Drash, Perlman, and Beckwith-Wiedemann syndromes
  - Regular ultrasound ~ every 3 months

SELECTED REFERENCES
Fanconi Anemia

Clinical photograph of a hand of a child with Fanconi anemia (FA) shows the dramatic “classic” finding of an absent or hypoplastic thumb. (Courtesy C. Clericuzio, MD.)
Bone marrow biopsy from a patient with FA shows marked hypocellularity with trilineage hematopoietic failure. Stromal elements, lymphocytes, and plasma cells remain. (Courtesy D. Czuchlewski, MD.)

TERMINOLOGY
Abbreviations
- Fanconi anemia (FA)

Definition
- Described by pediatrician Dr. Guido Fanconi in 1972
- 1 of several DNA damage repair deficiency syndromes including ataxia-telangiectasia, Bloom syndrome, Cockayne syndrome, Nijmegen breakage syndrome, Rothmund-Thomson syndrome, trichothiodystrophy, Werner syndrome, and xeroderma pigmentosum
- FA is a clinically and genetically heterogeneous inherited disorder characterized by
  - Autosomal or X-linked recessive pattern of inheritance
  - Congenital abnormalities in majority of patients
    - Low birth weight/short stature
    - Classic finding of hypoplastic or absent thumbs &/or radii
    - Pigmentation abnormalities
    - Renal malformations
    - Duodenal atresia or other gastrointestinal malformations
    - Microcephaly &/or microphthalmia
    - Congenital heart disease
    - Ear abnormalities/deafness
    - Hypogonadism
    - Neurologic abnormalities
    - Endocrine dysfunction
    - 25-40% of patients are phenotypically normal
  - Bone marrow failure presenting in 1st decade of life
Diagnostic Pathology: Familial Cancer Syndromes

- Pancytopenia with marrow aplasia (patients present with sequelae such as anemia, bleeding, and easy bruising)
- By 5th decade, cumulative incidence of bone marrow failure is 90%

**EPIDEMIOLOGY**

**Incidence**
- 4-7 patients per 1 million births
- Most cases are autosomal recessive in inheritance
  - Mutations affecting FANCB are X-linked recessive
- Increased incidence of FA in the Ashkenazi Jewish population due to specific FANCC mutations (IVS4 + 4A > T) (carrier frequency of 1.1%)
- Heterozygote frequency is 1 in 300
- Accounts for ~ 20% of cases of childhood aplastic anemia

**ETIOLOGY/PATHOGENESIS**

**Molecular Pathogenesis**
- Biallelic mutation in any of (at least) 13 separate genes composing the Fanconi anemia pathway
- Collectively, proteins encoded by these genes serve to sense DNA damage and initiate DNA repair
- FA pathway proteins fall into 3 separate groups, encoded by the following genes
  - Fanconi anemia core complex
    - FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCM
    - FANCA is the most frequently mutated gene in this complex (mutations account for ~ 65% of FA cases)
  - ID complex
    - FANCI, FANCD2
  - Downstream effectors
    - FANCI, FANCN (a.k.a. BRIP1 and PALB2, respectively)
    - FANCD1 (a.k.a. BRCA2)
- Functional interactions of FA proteins
  - Core complex detects DNA damage and ubiquitinates the ID complex proteins
  - ID complex colocalizes at site of DNA damage with FA downstream effectors and other DNA repair proteins, including
    - RAD51 protein, which binds and promotes accurate DNA repair via homologous recombination
    - BRCA1 protein, which binds to facilitate repair and mediate cell cycle checkpoint control
- Genotype-phenotype correlations
  - Some FANCC mutations predispose to early-onset bone marrow failure
  - Incidence of acute myeloid leukemia (AML) and severe cytopenias is higher in patients with some FANCG and FANCA mutations
  - Patients with biallelic inactivating mutations in FANCD1 have a 97% cumulative incidence of midline brain tumors, Wilms tumor, and AML by age 6

**ANCILLARY TESTS**

**Confirmation of Diagnosis**
- Cytogenetic testing
  - Diagnostic test: Chromosomal breakage (typically tests peripheral blood lymphocytes)
  - Cannot detect FA carriers with this test
- Molecular testing
  - Sequence analysis and targeted mutation analysis (nontargeted approach difficult given number of large genes that would require evaluation)
  - Carrier and prenatal testing can be performed by specific mutation testing if familial mutation is known

**Evaluation for Hematologic Malignancy**
- Bone marrow biopsy: Morphologic evaluation is gold standard for diagnosis of myelodysplastic syndrome (MDS)
- Cytogenetic analysis: Clonal amplification of chromosome 3q26-q29 often precedes progression to MDS/AML

**ASSOCIATED NEOPLASMS**

**Hematologic Neoplasms**
- By age 45, cumulative incidence of hematologic malignancy is 25%; median diagnosis age: 11-14 years
- Predominantly myeloid malignancies (600x increased risk of AML; 5,000x increased risk of MDS)
  - In ~ 25% of cases, leukemia (or cancer) diagnosis precedes recognition of underlying FA

### Solid Tumors
- Squamous cell carcinoma (head, neck, esophagus, anogenital), hepatocellular carcinoma, brain tumors
- By 5th decade, 30% cumulative incidence

### Breast Cancer Risk
- Heterozygous mutations in downstream effectors FANCI (a.k.a. BRIP1), FANCN (a.k.a. PALB2), FANCD1 (a.k.a. BRCA2) confer breast cancer susceptibility

### Cancer Risk Management
Patients With FA
- Increased surveillance for commonly associated neoplasms
- Exposure to radiation or DNA-damaging chemicals should be avoided
  - Special protocols required for patients undergoing stem cell transplantation

### Selected References

### Image Gallery
(Left) Peripheral blood shows mildly macrocytic RBCs and profound leukopenia and thrombocytopenia, typical of FA presentation. (Courtesy D. Czuchlewski, MD.)
(Center) Bone marrow aspirate from a child with FA shows bone marrow failure with essentially empty spicules. (Courtesy D. Czuchlewski, MD.)
(Right) FA patients are at high risk of myelodysplastic syndrome/acute myeloid leukemia. Progression may be accompanied by clonal cytogenetic abnormalities, frequently monosomy 7. (Courtesy D. Czuchlewski, MD.)

### Hereditary Breast/Ovarian Cancer Syndrome: BRCA1

> Table of Contents > Part I - Overview of Syndromes > Section 2 - Syndromes > Hereditary Breast/Ovarian Cancer Syndrome: BRCA1
Hereditary Breast/Ovarian Cancer Syndrome: BRCA1
Susan C. Lester, MD, PhD
David G. Hicks, MD

159
The majority of BRCA1 cancers are poorly differentiated, negative for hormone receptors, and cluster with basal-like carcinomas. However, 20-30% are ER positive and are of luminal B carcinoma type.
Hallmarks of BRCA1 cancers are a solid (syncytial) growth pattern, a high mitotic rate, and an associated dense lymphoplasmacytic infiltrate, which are features of medullary carcinoma.

**TERMINOLOGY**

**Synonyms**
- BRCA1 syndrome
- Breast cancer 1 syndrome
- Early-onset breast/ovarian cancer syndrome
- Online Mendelian Inheritance in Man (OMIM) #113705

**Definitions**
- Hereditary breast &/or ovarian cancers resulting from inheritance of a germline mutation in BRCA1
  - Early-onset and multiple primary breast tumors
  - Family history of breast or ovarian cancer

**EPIDEMIOLOGY**

**Population Incidence**
- 0.1-0.3% of individuals
  - Slightly less common than BRCA2 mutations
- Specific mutations are found at increased frequency in ethnic populations
  - Finns, French Canadians, and many others
  - Ashkenazi Jewish population
    - ~1% (1 in 40)
    - 185delAG and 5382insC
    - There is also a common BRCA2 mutation

**Modifiers of Risk**
- Parity decreases risk of breast cancer
- Low-dose ionizing radiation to chest before age 20 increases risk
- Mutations in other genes
None yet well defined

Genome-wide association studies (GWAS) are investigating possible associations

Cancer Incidence

- ~2% of all breast cancers are related to BRCA1 germline mutations
- ~50% of all cancers related to a germline mutation are due to BRCA1 germline mutations

Genetics

BRCA1 Gene

- Located on 17q21
- Large 81 kb gene
- 23 coding exons
- Transcript 7,094 base pairs
  - Protein 1,863 amino acids (210 kDa)
  - No sequence homology with other proteins
- Autosomal dominant inheritance
  - De novo mutations are rare
- More than 1,000 different mutations identified
  - Majority are small deletions or insertions
    - Results in frameshift mutations, nonsense mutations, or splice site alterations
    - Protein may be truncated or absent
    - Less common are full-length proteins with missense mutations
  - Inactivating mutations impair conservative DNA repair and genomic stability functions

Protein Function

- Central role in DNA repair, cell cycle control, transcriptional regulation, as well as many other functions
- Regulation of repair of DNA damage
  - Repair of DNA double-stranded breaks by homologous recombination
    - Cells that lack BRCA1 rely on other less reliable mechanisms for DNA repair
    - Increases replication errors and genomic instability
    - Chromosomal instability contributes to tumor formation
  - Cell cycle regulation, checkpoint control
    - Accumulating DNA abnormalities enable mutations in genes essential to cell cycle checkpoint activation
  - Transcriptional regulation
    - Required for transactivation of the estrogen receptor promoter
    - May explain why ~90% of BRCA1-related cancers are estrogen receptor negative
  - Also functional in chromatin remodeling and protein ubiquitination

Clinical Implications and Ancillary Tests

Population to Be Tested

- American Society of Clinical Oncology recommends that patients with >10% mutation risk undergo testing
  - 85% of mutation carriers will be detected using a 10% cut-off
- National Institute for Health and Clinical Excellence in United Kingdom recommends testing individuals with >20% risk of having a mutation
- Counseling should occur before testing to ensure patient is aware of implications for self and family

Clinical Criteria

- Personal history of breast cancer in a woman <40 years of age
  - Risk increased if cancer is negative for estrogen receptor
    - Risk is 35% for women <30 if cancer is poorly differentiated and estrogen receptor negative
- Breast cancer in 1st-degree relatives (mother, sister, daughter)
  - Risk increased if cancer diagnosed at young age
  - Risk increased if individuals have multiple cancers
- Risk increased if ovarian cancers are also present in family
- Risk increased if a relative has known mutation

Calculating Risk
There are multiple models to predict probability of an individual carrying a germline BRCA1 or BRCA2 mutation

- Empiric models
  - Do not make assumptions about genetic risks (e.g., mutation frequency, mode of inheritance, penetrance)
  - Examples include Penn II model, Myriad II (Frank model), and National Cancer Institute model
- Genetic risk prediction models
  - Make assumptions about the number of genes and allele frequencies
  - Include information about relationships among individuals in a kindred
  - Accuracy depends on validity of assumptions
  - Examples include BRCAPRO and the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA)
  - BRCAPRO available at http://www4.utsouthwestern.edu/breasthealth/cagene/
  - BOADICEA available at http://astor.som.jhmi.edu/BayesMendel/brcapro.html

Genetic Testing
- Full sequencing required to detect all mutations
- Additional testing required to detect deletions and amplifications
  - 18% of genetic changes are not detected by standard analysis
- All testing is performed by Myriad Genetics in USA

Interpretation of Results
- Mutation associated with breast cancer risk in other families
  - Patient classified as having BRCA1 syndrome
  - Testing of additional family members should be considered
- Mutation linked to a relative with breast cancer
  - Testing of additional individuals in family may be helpful to establish linkage
- Mutation known to be benign or have low clinical significance
  - Mutations that do not change amino acid type
  - Mutations known to occur in individuals without cancer
- Variant of uncertain significance (VUS)
  - Not yet linked to an individual with breast cancer
  - Detected in 7% of individuals (> 1,500 identified)
  - More frequent in populations of non-European origin as fewer individuals have been studied

Immunoperoxidase Studies
- Majority of BRCA1-associated carcinomas are negative for hormone receptors and HER2 (triple-negative breast carcinoma [TNBC])
  - These cancers group with basal-like carcinomas by gene expression profiling
  - There is an 80% overlap between TNBC and basal-like carcinomas
- Identifying a cancer as TNBC increases likelihood that a cancer is associated with BRCA1
  - However, > 10% of BRCA1-associated cancers are not basal-like cancers

ASSOCIATED NEOPLASMS
Female Breast Cancer
- Risk
  - 40-90% by age 70
    - Varies by mutation
    - May be modified by mutations in additional genes
- Macroscopic findings
  - Carcinomas typically have pushing borders that are evident grossly and microscopically
- Histology
  - Predominantly high-grade, poorly differentiated carcinomas
    - Dense lymphocytic infiltrate (predominantly T cell)
    - High nuclear grade, syncytial pattern
    - Foci of geographic tumor necrosis
    - High proliferative index
  - Medullary features (syncytial growth pattern, lymphocytic infiltrate)
    - 13% fulfill criteria for medullary carcinoma
60% have medullary features
- 70-80% negative for estrogen receptor, progesterone receptor, and HER2
- > 95% poorly differentiated
- TP53 mutations common (> 90%); ~ 55% positive by immunohistochemistry
- 50-80% positive for CK5/6, CK14, or EGFR
- BRCA1 regulates the expression of estrogen receptor
- 20-30% positive for estrogen receptor and negative for HER2
  - ~ 45% poorly differentiated
  - ~ 50% positive by immunohistochemistry for p53
  - < 20% positive for CK5/6, CK14, or EGFR
  - Majority show loss of wild-type BRCA1 allele
- Majority (~ 90%) classified as basal-like carcinoma according to mRNA expression profiling
  - ~ 15% of basal-like carcinomas are related to germline BRCA1 mutations
  - ER-positive subset are classified as luminal B

Male Breast Cancer
- 1.8% lifetime risk (compared to 0.07% risk in general population)
  - < 4% of male breast cancer cases associated with BRCA1
  - Lower than risk associated with BRCA2

Ovarian, Fallopian Tube, and Peritoneal Carcinoma
- 40-50% lifetime risk
- 60-85% involve fimbriated end of fallopian tube
- Serous tubal intraepithelial carcinoma (80%) and endometrioid tubal carcinoma (20%) are found in ~ 8% of prophylactic surgeries
  - Entire tube should be examined microscopically
  - Immunohistochemical studies for p53 and MIB-1 (Ki-67) can be helpful to identify early neoplasia
  - If no invasion is seen, risk of recurrence in peritoneum is 4-5%

Other Cancers
- Prostate: Relative risk = 1.8% (age < 65)
  - Risk of prostate cancer may vary depending on location of BRCA1 mutation
- Pancreas: Relative risk = 2.3% (age < 65)
- Cervix: Relative risk = 2.6% (age < 65)
- Uterus: Relative risk = 2.6% (age < 65)

CANCER RISK MANAGEMENT
Chemoprevention
- Oral contraceptives
  - Reduces risk of ovarian cancer by 50%
  - Breast cancer risk may be increased by some types of oral contraceptives (results of studies have not been consistent)
- Tamoxifen
  - Reduces risk
    - Evidence derives from observed 50% reduction in risk of contralateral cancer among mutation carriers treated with tamoxifen
    - Protective effect observed in BRCA1 and BRCA2 carriers
- BRCA1 carriers appear to benefit despite predilection to develop ER negative tumor for reasons that remain unclear

Screening
- Mammography
  - Should begin at age 10 years younger than youngest affected person in family
  - May have limited sensitivity because young women often have dense breast tissue
- Magnetic resonance (MR) imaging
  - MR detects cancer due to blood flow and is more sensitive for detecting cancers in dense breasts

Prophylactic Surgery
- Bilateral mastectomy reduces breast cancer risk by 97%
  - However, not all breast tissue can be removed and achieve acceptable cosmetic results
  - Greatest benefit for patients before a diagnosis of cancer
- Bilateral salpingo-oophorectomy reduces breast and ovarian cancer risk
  - Breast cancer risk reduced by 50%
    - Mechanism not well understood but may be due to decreased estrogen production
Ovarian and fallopian tube cancer risk reduced by 70-96%

- There remains a 4-5% risk of papillary serous carcinoma of peritoneum

SELECTED REFERENCES

Image Gallery
BRCA1-Related Cancers

(Left) BRCA1-related invasive carcinomas often present as circumscribed masses that may be mistaken for benign lesions. Associated calcifications are unusual. Young women often have dense breast tissue that can obscure masses and make detection difficult. In addition, cancers grow rapidly and can present in the interval between screening.

(Right) The typical BRCA1-related carcinoma has a solid growth pattern, a dense T-cell rich lymphocytic infiltrate, and a pushing border.
Screening by MR is an option for young women. MR detects cancers by vascular uptake, which is not affected by dense breast tissue. A common MR finding for DCIS is linear clumped enhancement. (Right) The DCIS associated with BRCA1 cancers can be limited in extent and difficult to detect. In this case, the cells in this lobule are highly atypical and are associated with a dense lymphocytic infiltrate. The cells were negative for estrogen and progesterone receptors and HER2.

(Left) This needle core biopsy from a palpable breast mass in a 34-year-old woman with a positive family history of breast cancer shows a poorly differentiated cancer with a high proliferative rate and a brisk inflammatory response. Subsequent genetic testing revealed a BRCA1 mutation. (Right) BRCA1-associated cancers are usually negative for ER, PR, and HER2. Tumor cells often show strong cytoplasmic expression of basal cytokeratin CK5/6, consistent with a basal-like carcinoma.

Hereditary Breast/Ovarian Cancer Syndrome: BRCA2
Breast cancers associated with BRCA2 are generally moderately to poorly differentiated with a high mitotic rate. Unlike BRCA1-associated cancers, they do not have a characteristic appearance.
BRCA2-associated breast cancers, in contrast to BRCA1 cancers, usually express hormone receptors (as seen here for estrogen receptor). HER2 overexpression is very rare in either type of cancer.

TERMINOLOGY

Synonyms
- BRCA2 syndrome
- Breast cancer 2 syndrome
- Early-onset breast-ovarian cancer syndrome
- Online Mendelian Inheritance in Man (OMIM) I #600185

Definitions
- Hereditary breast &/or ovarian cancers resulting from inheritance of a germline mutation in BRCA2
  - Early-onset and multiple primary breast tumors
  - Family history of breast or ovarian cancer

EPIDEMIOLOGY

Population Incidence
- 0.1-0.7% of individuals
  - Slightly more common than BRCA1 mutations
- Specific mutations are found at increased frequency in ethnic populations
  - Ashkenazi Jewish population
    - ~1-3% of individuals
    - 6174delT
    - There are also 2 common BRCA1 mutations
  - Icelandic population
    - 0.6% of individuals
    - 999del5 detected in 38% of males and 10.4% of females with breast cancer
    - BRCA2 mutations found in 90% of families with male and female breast cancer

Modifiers of Risk
• Parity may increase risk (whereas it decreases risk for BRCA1 carriers)
• Low-dose ionizing radiation to chest before age 20 increases risk
• Mutations in other genes
  o None yet well defined
  o Genome-wide association studies (GWAS) are investigating possible associations

Cancer Incidence
• ~2% of all breast cancers are related to BRCA2 germline mutations
  o ~50% of all breast cancers related to a germline mutation are due to BRCA2
• ~7% of ovarian cancers are related to BRCA2 germline mutations
  o ~27% of ovarian cancers due to a germline mutation are related to BRCA2

GENETICS
BRCA2 Gene
• Located on 13q13.1
• Large 84 kb gene
  o Does not share sequence homology with BRCA1 or other genes
• 27 coding exons
• Transcript is 10,930 base pairs
  o Protein is 3,418 amino acids (390 kDa)
• Autosomal dominant inheritance
  o De novo mutations are rare
• >1,000 different mutations identified
  o Majority are small deletions or insertions
    ▪ Results in frameshift mutations, nonsense mutations, or splice site alterations
    ▪ Protein may be truncated or absent
    ▪ Less common are full-length proteins with missense mutations
  o Inactivating mutations impair conservative DNA repair and genomic stability functions
• Central portion of gene designated “ovarian cancer cluster region”
  P.I(2):77
  o Mutations in this region are 2x as likely to be associated with ovarian cancer as are mutations in 5’ or 3’ region
  o Risk of breast cancer associated with mutation in this region is lower

Protein Function
• Central role in DNA repair, transcription, gametogenesis, and centrosome duplication
• Regulation of repair of DNA damage
  o Repair of DNA double-stranded breaks through homologous recombination

CLINICAL IMPLICATIONS AND ANCILLARY TESTS
Population to be Tested
• American Society of Clinical Oncology recommends that patients with >10% mutation risk undergo testing
  o 85% of mutation carriers will be detected using this 10% cut-off
• National Institute for Health and Clinical Excellence in United Kingdom recommends testing individuals with >20% mutation risk
• Counseling should occur before testing to ensure patients are aware of implications for themselves and their families

Clinical Criteria
• Personal history of breast cancer in women <40 years of age
• Breast cancer in 1st-degree relatives (mother, sister, daughter)
  o Risk increased if cancer diagnosed at young age
  o Risk increased if individuals have multiple cancers
• Risk increased if a male with breast cancer is in the family
• Risk increased if ovarian cancers are also present in the family
• Risk increased if a relative has a known mutation

Calculating Risk
• There are multiple models to predict probability of an individual carrying a germline BRCA2 or BRCA2 mutation
  o Empiric models
Do not make assumptions about genetic risks (e.g., mutation frequency, mode of inheritance, penetrance)

Examples include Penn II model, Myriad II (Frank) model, and National Cancer Institute model

- Genetic risk prediction models
  - Make assumptions about number of genes and allele frequencies
  - Include information about relationships among individuals in a kindred
  - Accuracy depends on validity of assumptions
  - Examples include BRCAPRO and the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA)
  - BRCAPRO available at http://www4.utsouthwestern.edu/breasthealth/cagene/
  - BOADICEA available at http://astor.som.jhmi.edu/BayesMendel/brcapro.html

Genetic Testing

- Full sequencing required to detect all mutations
- Additional testing required to detect large deletions and amplifications
  - 18% of genetic changes are not detected by standard testing
- All testing is performed by Myriad Genetics in USA
- Targeted mutation analysis may be population or family specific
  - Individuals of some ethnic backgrounds are at higher risk for certain mutations
  - Specific mutation may be sought if there is an affected relative with a known mutation

Interpretation of Results

- Mutation associated with breast cancer in other families
  - Patient classified as having BRCA2 syndrome
  - Testing of additional family members should be considered
- Mutation linked to a relative with breast cancer
  - Testing of additional individuals in family may be helpful to establish definite linkage
- Mutation known to be benign or have low clinical significance
  - Mutations that do not change amino acid type
  - Mutations known to occur in individuals without cancer
- Variant of uncertain significance (VUS)
  - Not yet linked to an individual with breast cancer
  - Detected in 7% of individuals (> 1,500 identified)
  - More frequent in populations of non-European ancestry

ASSOCIATED NEOPLASMS

Female Breast Cancer

- Risk
  - ~ 45% lifetime risk
  - Varies by mutation
  - May be modified by mutations in additional genes

- Histology
  - Moderately to poorly differentiated
  - No specific histologic type
    - Pushing margins
    - Lack of tubule formation
    - Some studies have suggested a higher incidence of tubulolobular and pleomorphic lobular carcinomas
    - Other series have not shown significant differences between BRCA2 carcinomas and sporadic carcinomas
  - Majority are positive for estrogen receptor
    - HER2 overexpression is rare (< 5%), lower than the incidence in sporadic breast cancer

- TP53 mutations (30-65%) are less common than in BRCA1-associated cancers (> 90%)
- Majority classified as luminal B by gene expression profiling

Male Breast Cancer

- Risk
  - ~ 7% lifetime risk (compared to 0.07% in general population)
  - 8-16% of male breast cancers are in individuals with BRCA2 mutations
60-75% chance that BRCA2 mutation exists in families with ≥ male with breast cancer
Association with BRCA1 is less common (< 4% of all male breast cancers)

**Ovarian, Fallopian Tube, and Peritoneal Carcinoma**
- ~ 11-18% lifetime risk
  - Risk for ovarian cancer lower than that observed in BRCA1 mutation carriers (40-50% lifetime risk)
- Age
  - Average onset is 55-58 years compared to 63 years in general population
  - Young women (< 40 years) with ovarian/tubal/peritoneal carcinoma are unlikely to have a BRCA1 or BRCA2 mutation
    - These women tend to have borderline tumors and cancers of more favorable histologic types
- Fallopian tube
  - Serous tubal intraepithelial carcinoma (80%) and endometrioid tubal carcinoma (20%) are found in ~ 5-7% of prophylactic salpingo-oophorectomies
    - 60-85% involve fimbriated end of fallopian tube
  - Entire tube should be examined microscopically
  - Immunohistochemical studies for p53 and MIB-1 (Ki-67) can be helpful
- Ovary
  - Carcinomas are usually high-grade serous carcinomas
    - Only ~ 2% of tumors are mucinous or borderline
    - Endometrioid, clear cell, and papillary carcinomas occur but are rare
  - Primary peritoneal carcinoma
    - Women have ~ 4% risk after bilateral prophylactic salpingo-oophorectomy

**Other Cancers**
- Prostate: Relative risk is 4.6%
  - 1-2% of cancers diagnosed before age 65
  - Increased prostate cancer risk is not a consistent finding across all studies
- Pancreas, gall bladder, & bile duct: Relative risk is 3.5%
  - Presence of pancreatic cancer in a breast cancer family may be predictor of a BRCA2 mutation
- Gastrointestinal
  - Stomach: Relative risk is 2.6%
  - As with BRCA1, initial reports of increased colon cancer risk have generally not been replicated

**CANCER RISK MANAGEMENT**

**Chemoprevention**
- Oral contraceptives
  - Reduces risk of ovarian cancer by 50%
  - Breast cancer risk may be increased by some types of oral contraceptives; results of studies have not been consistent
- Tamoxifen
  - Reduces risk
    - Evidence derives from observed 50% reduction in risk of contralateral cancer among mutation carriers treated with tamoxifen

**Screening**
- Mammography
  - Should begin at 10 years younger than youngest affected family member
  - May have limited sensitivity as young women often have dense breast tissue
- Magnetic resonance (MR) imaging
  - MR detects cancers due to blood flow and is more sensitive in detecting cancer in dense breasts
  - Highly sensitive but not very specific; false-positive results are frequent

**Prophylactic Surgery**
- Bilateral mastectomy reduces breast cancer risk by 97%
  - However, not all breast tissue can be removed and achieve acceptable cosmetic results
  - Greatest benefit for patients before a diagnosis of cancer
    - After cancer has been diagnosed, there may be no benefit if distant metastases are present
- Bilateral salpingo-oophorectomy reduces breast and ovarian cancer risk
  - Breast cancer reduced by 50%
    - Mechanism not well understood but may be due to decreased estrogen production
  - Ovarian and fallopian tube cancer reduced by 70-96%
    - There remains a 4% risk of papillary serous carcinoma of peritoneum

171
SELECTED REFERENCES
4. Rhiem K et al: The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res. 14(6):R156, 2012

Image Gallery
BRCA2-Related Carcinomas

(Left) A 70-year-old man was discovered to be a carrier of a BRCA2 mutation after 2 of his daughters were diagnosed with ovarian cancer. He subsequently developed an invasive high-grade lobular carcinoma. (Right) Tumors arising in BRCA2 mutation carriers exhibit allelic loss of the remaining wild-type BRCA2 gene in their cancer and possible loss of BRCA2 expression. The normal ducts show expression of BRCA2 protein by IHC whereas the tumor has lost reactivity.

(Left) Germline BRCA2 mutations increase the risk of fallopian tube cancers. A high incidence of early neoplastic lesions are found at the fimbriated ends of the tubes. (Right) About 7% of ovarian carcinomas are due to BRCA2
mutations. The majority are high-grade serous carcinomas with psammoma body calcifications. Other types such as endometrioid, clear cell, and papillary occur but are unusual. After oophorectomy, ~4% of women develop primary peritoneal carcinomas.

(Left) It may be difficult to distinguish metastases from primary carcinomas in women at high risk for both breast and ovarian cancers. In this core needle biopsy of a breast mass, the papillary architecture and psammoma bodies favor metastatic ovarian serous carcinoma. A metastasis was confirmed by positivity for pax-8 and WT1. (Right) BRCA2 germline mutations also increase the risk of other types of cancers, such as early onset (before age 55) prostate cancer, as seen here.

**Hereditary Diffuse Gastric Cancer**

> Table of Contents > Part I - Overview of Syndromes > Section 2 - Syndromes > Hereditary Diffuse Gastric Cancer

Hereditary Diffuse Gastric Cancer

Joel K. Greenson, MD
This high-power image shows signet ring cells 🔄 surrounding a benign gastric gland 🔄. This signet ring cell carcinoma in situ is diagnostic of hereditary diffuse gastric cancer (HDGC). (Courtesy F. Carneiro, MD.)
This high-power view shows disorganized gastric surface epithelium with vacuolated cells. This vacuolization is often seen in hereditary diffuse gastric cancer and has been called globoid change.

TERMINOLOGY
Abbreviations
- Hereditary diffuse gastric cancer (HDGC)

EPIDEMIOLOGY
Prevalence
- 10% of gastric cancers have familial clustering
  - Of these, 1-3% represent HDGC
- 1st described in Maori families from New Zealand, but syndrome is seen in all ethnic groups
  - Large clusters in New Zealand and Canada
  - Asian countries with high incidence of sporadic gastric carcinoma seem to have low incidence of HDGC
    - Reason for this is unknown

GENETICS
E-Cadherin/CDH1 Gene
- Mutation in CDH1 gene in 30-40% of patients who fit clinical definition of HDGC
  - Autosomal dominant
    - Cumulative risk of gastric cancer at age 80 years is 67% for men and 83% for women
    - Lifetime risk of lobular breast carcinoma in women is 39-60%
    - Increased risk of prostate cancer in men
    - Increased risk of signet ring cell colorectal cancer in both men and women
  - Cell-cell adhesion protein that acts as tumor suppressor gene
    - Mutations typically cause truncation of protein and loss of function
  - 2nd hit that inactivates good copy of the gene appears to be promoter methylation
    - May be important mechanism in sporadic diffuse gastric cancer
    - May be “drugable” target
MICROSCOPIC FINDINGS

Endoscopic Biopsies

- Classic lesion is the presence of signet ring cell carcinoma in situ
  - Signet ring cells within basement membrane of glands with pagetoid spread
  - May also see vacuolization of foveolar epithelium, called globoid change
    - Globoid change by itself is not specific for HDGC
- 1 study has shown that immunohistochemical staining for E-cadherin is negative in 77% of signet ring cell carcinoma foci in HDGC (some foci do stain positively)
- If unsure about pathology, best to have case reviewed by a pathologist who has experience with HDGC cases

Resection Specimens

- Multiple foci of signet ring cell carcinoma
  - Some studies suggest most tumors are found at antral transition zone; others refute this, finding most lesions in fundus and body
  - Some patients have hundreds of small in situ lesions whereas others have only 1 or 2
    - May need to take hundreds of sections to find small in situ lesions
    - May be easier to identify these subtle changes with PAS stain
    - There are documented cases of patients with CDH1 mutations whose prophylactic gastrectomy specimen did not show any carcinoma despite totally embedding entire stomach

CLINICAL IMPLICATIONS AND ANCILLARY TESTS

Major Clinical Criteria

- 2 or more cases of gastric cancer in 1st- or 2nd-degree relatives with ≥ 1 diffuse gastric cancer in a patient < 50 years of age
- 3 or more cases of gastric cancer in 1st- or 2nd-degree relatives at any age with at least 1 documented case of diffuse gastric cancer
- Only 30-40% of cases that fulfill these 2 major criteria will have CDH1 mutation, suggesting other genes may cause a similar syndrome

Minor or Additional Clinical Criteria

- Diffuse gastric cancer in patient < 40 years of age without family history
- Diffuse gastric cancer and lobular breast cancer in 1 patient, or 1 patient with diffuse gastric cancer and family member with lobular breast cancer or signet ring colon cancer
- Patients who fulfill these clinical criteria should undergo sequencing of their CDH1 gene
  - Some variability among experts regarding these clinical criteria as some would test a single patient < 45 years with diffuse gastric cancer and no family history
  - > 100 mutations have been reported that lead to HDGC, so entire gene must be sequenced
  - ≥ 1 group of physicians recommends waiting until 16 years to test children of affected families

ASSOCIATED NEOPLASMS

Lobular Carcinoma of Breast

- Strong evidence that suggests association with HDGC

Signet Ring Cell Carcinoma of Colon

- Both sexes
- Uncommon tumor should raise question of Lynch syndrome or HDGC

Prostatic Adenocarcinoma

- Weak evidence that suggests association with HDGC
  - Likely unrelated given frequency of prostate cancer

CANCER RISK MANAGEMENT

Endoscopic Surveillance

- Early lesions are not evident endoscopically
  - Not very effective as number of biopsies needed to ensure adequate sampling is too high
    - 1 study found over 1,750 mucosal biopsies would be needed to have a 90% chance of finding an in situ lesion
  - Up to 25% of patients who test positive for CDH1 mutation refuse gastrectomy
    - Offered endoscopy with biopsy every 6 months

Prophylactic Total Gastrectomy

- Treatment of choice to prevent gastric cancer
- Procedure has low mortality rate but high morbidity
- In New Zealand, recommended after age 20 in known carriers
  - Others recommend gastrectomy 5 years earlier than earliest known cancer in individual family
  - Risk of advanced disease is < 1% at age 20 years, 4% at age 30 years, but between 21% and 46% at age 50 years

SELECTED REFERENCES

Hereditary Hyperparathyroidism-Jaw Tumor Syndrome

> Table of Contents > Part I - Overview of Syndromes > Section 2 - Syndromes > Hereditary Hyperparathyroidism-Jaw Tumor Syndrome
Hereditary Hyperparathyroidism-Jaw Tumor Syndrome
Vania Nosé, MD, PhD
Axial bone CT shows a large, well-demarcated left maxillary ossifying fibroma with mixed calcific and soft tissue density components. Note that the mass obstructs both sides of the nose. 
Nonossifying fibroma shows a large, well-demarcated maxillary mass with mixed calcification and fibrosis. Note that the mass obstructs 1 side of the nose and compresses the eye.

**TERMINOLOGY**

**Abbreviations**
- Hyperparathyroidism (HPT)
- Hyperparathyroidism-jaw tumor (HPT-JT) syndrome

**Synonyms**
- Familial isolated hyperparathyroidism (FI-HPT)
- Familial cystic parathyroid adenomatosis
- Familial primary hyperparathyroidism with multiple ossifying jaw fibromas

**Definitions**
- Autosomal dominant disorder characterized by parathyroid hyperplasia, adenoma, or carcinoma, ossifying fibromas of jaw bones, hamartomas, renal cysts, and tumors including Wilms tumor, resulting from inactivating mutations in HRPT2 gene
  - 15% of HPT-JT develop parathyroid carcinoma

**EPIDEMIOLOGY**

**Incidence**
- Currently unknown
- 1st described in 1990; to date, ~40 affected families have been reported
- Primary hyperparathyroidism is a common endocrine syndrome, but >90% are sporadic
- 10% of HPT are familial and include
  - HPT-JT
  - FI-HPT
  - Familial hypocaliuric hypercalcemia
  - Multiple endocrine neoplasia (MEN) syndromes

**GENETICS**
Molecular Genetics
- Most cases are due to inactivating mutation of HRPT2 tumor suppressor gene on 1q25-q31
  - Germline inactivating mutation of HRPT2 gene can be demonstrated in > 1/2 of cases
- Somatic mutation of HRPT2 is uncommon in sporadic parathyroid adenomas
- In contrast, mutations of HRPT2 are frequently seen in apparently sporadic cases of parathyroid carcinoma
  - Some 20% of patients with apparently sporadic parathyroid cancer may harbor germline HRPT2 mutations, suggesting that such cases may in fact represent undiagnosed HPT-JT
  - Recent studies suggest that dysregulation of several microRNAs may contribute to the pathogenesis of parathyroid cancers harboring HRPT2 mutation
- Germline HRPT2 mutation is a rare cause of familial isolated primary hyperparathyroidism, but in some cases, genetic cause remains unknown
- HRPT2 gene encodes the protein parafibromin, which consists of 531 amino acids and has weak homology to yeast protein Cdc73p
  - Mutations in HRPT2 are scattered throughout coding region, and most are predicted to cause inactivation of protein product
  - Parafibromin is also thought to either promote or inhibit cell growth and proliferation depending on signals within cell
  - Parafibromin is found throughout the body and is likely involved in gene transcription
  - In human cell lines, endogenous parafibromin represses expression of MYC proto-oncogene
  - Parafibromin appears to be essential/vital for progression of mammalian embryonic development
  - Homozygous parafibromin null mice die in utero, and conditional knockout of parafibromin in adult mice results in cachexia and death

ETIOLOGY PATHOGENESIS
Mutations of HRPT2 Gene on 1q25-q31
- Mutations of the parafibromin gene HRPT2 have been found in > 1/2 of families with HPT-JT
  - Encodes protein parafibromin
    - These mutations were predicted to inactivate parafibromin protein
- Germline HRPT2 mutations have been identified in subset of patients with mutation-positive carcinomas thought to be sporadic
  - HRPT2 gene was 1st implicated in development of sporadic parathyroid carcinoma

CLINICAL IMPLICATIONS AND ANCILLARY TESTS
Image Findings
- Ossifying fibroma
  - Radiography: Well-demarcated, expansile mass with central soft tissue density area surrounded by ossified rim
  - Bone scan: Increased uptake by affected bones

Clinical Presentation
- Hyperparathyroidism
  - Develops in late adolescence in 80% of patients
  - More aggressive course with severe hypercalcemia and higher incidence of parathyroid carcinoma
- Jaw tumors
  - Well-demarcated osseous lesion (ossifying fibroma) of mandible or maxilla
  - Other features reported include renal cysts, Wilms tumor, and papillary thyroid carcinoma

Serologic Testing
- Blood test measuring ionized calcium and intact parathormone (iPTH)

Treatment
- Medical therapy
  - Calcimimetics are useful for patients with primary hyperparathyroidism who are poor surgical candidates or have nonlocalizable tumors or inoperable disease
- Surgery
Cornerstone of treatment for primary hyperparathyroidism

- Surgical approach in HPT-JT is controversial because of increased risk of parathyroid cancer, but subtotal parathyroidectomy with close postoperative biochemical monitoring for recurrence is currently recommended over prophylactic total parathyroidectomy.
- Subtotal parathyroidectomy is indicated in familial syndromes such as MEN1 and familial isolated primary hyperparathyroidism (FIHP).
- En bloc resection is recommended as primary treatment for parathyroid carcinoma.
- Bilateral neck exploration with excision of adenoma is classic approach, although minimally invasive surgery guided by noninvasive imaging and intraoperative PTH monitoring is gaining favor in nonfamilial cases.

Prognosis

- Majority of patients with adenoma can be cured by surgery.
- Guarded, once parathyroid carcinoma is confirmed.

ASSOCIATED NEOPLASMS

Parathyroid

- Parathyroid involvement may include parathyroid hyperplasia, parathyroid adenomas, cystic parathyroid adenomas, and carcinomas.
- Hyperparathyroidism
  - Familial disease usually involves multiple glands.
  - Hyperplasia
    - Parathyroid hyperplasia may be chief cell or oxyphil cell hyperplasia.
  - Parathyroid adenomas may be multiple.
    - Familial cases with histopathological features similar to those observed in sporadic cases.
    - Parathyroid adenomas affect 1 or more glands.
    - Mean age at diagnosis is 32 years.
  - Parathyroid carcinoma
    - Higher incidence of parathyroid carcinoma in HPT-JT.
    - Parathyroid carcinoma is present in ~ 15% of families with HPT-JT.
    - Invasive growth.
    - Capsular invasion beyond thickened capsule.
    - Thick fibrous bands present.
    - Invasion of vessels outside thickened capsule and perineural invasion.
    - Cellular monotony is common, but occasional tumors have pronounced pleomorphism.
    - Macronucleoli.
    - Increased Ki-67 proliferative index and mitosis.
    - Presence of necrosis.
    - Should always be considered when evaluating parathyroid pathology in patients with HPT-JT.
- Familial disease is typically multigland whereas sporadic HPT tends to only affect 1 gland.
- Parathyroid adenomas associated with HPT-JT syndrome are usually negative for immunoexpression of parafibromin.

P.I(2):84

- Lack of parafibromin staining offers promise as a marker of parathyroid malignancy.

Ossifying Fibroma of Jaw

- Present in ~ 30% of affected family members.
- Gross pathology shows classic appearance of tumor with central pink-yellow area of fibrous tissue surrounded by pale yellow, dense, peripheral ossified tissue.
- Microscopically, tumor is densely cellular fibrous and ossifies beginning at periphery.
- Tumor composed of dense, relatively avascular fibroblast-rich stroma and irregular spicules of woven bone with osteoblastic rimming.
- No malignant predisposition.

Renal Diseases

- Renal cysts
  - Multiple cysts.
  - Polycystic renal disease.
- Renal hamartomas.
- Renal cortical adenomas.
Renal failure

Wilms Tumor

- Has occasionally been reported in families with HPT-JT, including occurrences in adults

Other Associated Malignant Neoplasms

- Papillary renal cell carcinoma
- Mixed epithelial stromal tumor of kidney
- Testicular germ cell tumor
- Prostate carcinoma
- Pancreatic carcinoma
- Thyroid carcinoma with oncycytic cells
- Uterine adenosarcoma

Other Associated Benign Diseases

- Benign uterine diseases
- Leiomyomas
- Adenomyosis
- Endometrial hyperplasia

CANCER RISK MANAGEMENT

Screening

- No definitive guidelines for surveillance
- Annual screening with serum calcium, phosphorus, and parathormone levels should begin at 10-12 years of age
- If test results are abnormal, imaging of parathyroid glands is indicated
- If HPT-JT is diagnosed, family members should undergo molecular testing and imaging studies
- Strong association with HRPT2 mutation and familial and sporadic parathyroid cancer
- Screening for subclinical jaw lesions is indicated as an adjunct to determining who has inherited HPT-JT
- Subset of patients positive for somatic mutation of HRPT2 were also positive for a germline mutation of the same gene
  - Suggests that a subset of patients with apparent sporadic carcinoma carried germline mutations of HRPT2 and might have HPT-JT or a forme fruste of the syndrome
  - Patients with carcinoma, therefore, should have jaw and kidney imaging studies
- Baseline evaluation of renal function test with reassessment every 1-2 years is suggested
- Imaging evaluation of renal masses or cysts is suggested

SELECTED REFERENCES


P.I(2):85
Gross and Microscopic Features

(Left) Gross image shows the classic appearance of an ossifying fibroma with central pink-yellow area of fibrous tissue surrounded by pale yellow, dense, peripheral ossified tissue. (Right) Typical ossifying fibroma exhibits a dense, avascular, fibroblast-rich stroma and irregular spicules of woven bone with osteoblastic rimming.

(Left) Gross photograph shows a large parathyroid adenoma that had grown down into the mediastinum. Parathyroid carcinomas are generally larger than adenomas, but they can show overlap in size. Parathyroid carcinomas, unlike adenomas, show unequivocal invasion. (Right) Chief cell parathyroid adenoma shows a rim of normal parathyroid tissue. Parathyroid adenomas are often composed of chief cells or mixtures of cell types, but can be composed of oncocytic or clear cells.
(Left) Oxyphil cells (10-20 µm in diameter) are larger than chief cells (10 µm in diameter) and have abundant eosinophilic granular cytoplasm. Oxyphil cell adenomas comprise ~3-6% of parathyroid adenomas. (Right) Oxyphilic parathyroid carcinoma shows multiple mitotic figures, which can be seen in both parathyroid adenomas and carcinomas but are more common in carcinomas.

Hereditary Leiomyomatosis and Renal Cell Carcinoma

> Table of Contents > Part I - Overview of Syndromes > Section 2 - Syndromes > Hereditary Leiomyomatosis and Renal Cell Carcinoma
Hereditary Leiomyomatosis and Renal Cell Carcinoma
Gladell P. Paner, MD
This photograph shows a cluster of leiomyomas in the skin. The nodules are reddish-brown and can be painful. Multiple cutaneous leiomyomas are the most prominent feature of HLRCC. (Courtesy C. Ko, MD.)
H&E shows RCC in HLRCC with papillary architecture. This RCC is characterized by high-grade nuclei with a large inclusion-like nucleolus producing a cytomegalovirus inclusion-like appearance.

**TERMINOLOGY**

**Abbreviations**
- Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)

**Synonyms**
- Multiple cutaneous and uterine leiomyomatosis syndrome
- Reed syndrome

**Definitions**
- Autosomal inherited disorder characterized by development of multiple cutaneous and uterine smooth muscle tumors and renal cell carcinoma (RCC) linked to fumarate hydratase (FH) mutation

**EPIDEMIOLOGY**

**Age Range**
- Smooth muscle tumors and RCC develop at younger age in patients with HLRCC than in those with sporadic onset
  - Males: By age 35, nearly all will have cutaneous leiomyomas
  - Females: By age 45, risk for cutaneous leiomyomas is > 70%
    - Uterine leiomyomas: Mean age at diagnosis: 30 years (range: 18-53 years)
- Median age of patients with RCC: 42-44 years
- Younger than in sporadic RCCs with papillary or tubulopapillary architectures

**Gender**
- Risk of disease is greater in men vs. women
  - However, number of cutaneous tumors is more numerous in women
  - Renal tumor: M:F = 1.1:1

**Incidence**
- Rare; FH mutation predisposing to HLRCC has been described in ~ 180 families worldwide
CLINICAL IMPLICATIONS

Clinical Presentation
- Most patients initially present with multiple skin lesions due to smooth muscle tumors
  - Usually multiple, involving limbs and trunk
  - Sometimes itchy, painful; can be disfiguring
- Gynecologic symptoms at reproductive age due to uterine smooth muscle tumors
  - Metrorrhagia, menorrhagia, pelvic pain, and fertility problems

GENETICS

FH Mutation
- FH in chromosome 1q42-1q44
- Mutation found in 76-100% of families with clinical manifestation of HLRCC
- Heterozygous germline mutation
  - Majority are missense (~ 58%); nonsense (~ 11%) or frameshift (~ 18%) mutations
  - Splice site mutations, in-frame deletions or insertions, exon 7 duplications, exon 1 deletions, and whole gene deletion also reported
- Mutations of 2 alleles seen in associated tumors (“2-hit” hypothesis)
  - FH suggested as a tumor suppressor gene
- > 100 different FH germline mutations have been reported
- FH gene encodes an enzyme in Krebs cycle that catalyzes hydration of fumarate to L-malate
  - Mutation causes accumulation of fumarate and succinate
  - Mutation causes aberrant stabilization and overexpression of hypoxia inducible factor 1 (HIF1) transcription factor
    - HIF1 regulates transcription of genes important for vascularization, glucose transport, and glycolysis, all of which are important for tumor growth
    - Somewhat similar mechanism with inactivation of VHL in hereditary clear cell RCC, which causes nondegradation and accumulation of HIF1
- Unrelated biallelic mutations of FH result in fumarate hydratase (FH) deficiency (fumaric aciduria)
  - Rare recessive syndrome with severe neurological symptoms, muscle hypotonia, and microcephaly
  - Marked decrease in FH activity results in metabolic crises and infant death
  - Symptoms not seen in HLRCC
  - Unclear why manifestations are completely different

Comparative Genomic Hybridization
- 27% of HLRCC renal tumors show gains in Chr 2, 7, and 17 and losses in 13q12.3-q21.1, 14, 18, and X
  - Gains in Chr 7 and 17 are common in sporadic papillary renal cell carcinoma

CLINICAL IMPLICATIONS AND ANCILLARY TESTS

FH Mutation Testing
- Usually by direct sequencing of FH coding region
  - Reveals genetic alterations in ~ 90% of families suspected for HLRCC
- If clinically highly suspicious and initial test is negative, additional methods such as multiplex ligation probe amplification (MLPA) are recommended

ASSOCIATED NEOPLASMS

Smooth Muscle Tumors
- Cutaneous leiomyomas (piloleiomyomas)
  - With age, eventually up to 100% of men and 80% of women will develop them
  - Originate from hair follicle arrector pili muscles
  - Size range: 2 mm to 4 cm
  - Vast majority are benign, with rare reports of leiomyosarcoma
  - Histologic hallmark of inclusion-like orangeophilic nucleolus with perinuclear clearing
- Uterine smooth muscle tumors
  - With age, up to 77% of women will develop uterine leiomyomas
  - Usually multiple (up to 20)
  - Size range: 1-8.5 cm
  - Grossly shows firm, solid, white-tan, whorled cut surface; similar in appearance to sporadic tumors
  - Mostly benign (leiomyomas)
    - Fascicles of spindle cells with elongated, blunt-edged nuclei
    - Can show increased atypia, multinucleation, &/or mitotic activity (up to 6 per HPF)
Histologic hallmarks of nuclei with inclusion-like orangeophilic nucleoli with perinuclear clearing
- Uterine leiomyosarcomas have been reported in 6 cases from HLRCC families

RCC
- Risk of developing RCC is lower and often manifests later than smooth muscle tumors
  - Seen in ~20-25% of FH mutation-positive families
- 6.5x greater risk than general population; higher in younger patients
  - Risk is 230x greater in patients 15-29 years old and 45x increase in patients 30-44 years old
  - Youngest patient reported was 11 years old
- When symptomatic, patients with renal tumor present with back pain, fatigue, and weight loss; discovery after work-up for suspicion of HLRCC after cutaneous lesion manifestation is not uncommon
- Usually involves 1 person in FH mutation-positive family
- Macroscopy
  - Tumors are predominantly unilateral and solitary, unlike other RCCs in hereditary setting
- Microscopy
  - Most RCCs in HLRCC were previously classified as papillary RCC (PRCC) type 2 and collecting duct carcinoma (CDC) but now considered as a different type of RCC
  - Variable architecture that includes papillary (most common), tubulopapillary, tubular, solid, and mixed
    - Papillae are thick with abundant collagen
    - Cells are large, high grade with abundant eosinophilic cytoplasm
    - Nuclei pseudostratification is common and may resemble rosettes
    - Mitoses common (2-6/10 HPF)
    - May have focal clear cell area
    - Histologic hallmark of nuclei with inclusion-like orangeophilic nucleoli with perinuclear clearing, resembling cytomegalovirus cytopathic change
    - Nuclear features are widespread, detected in almost all cells, including in foci of clear cells if present
  - Mucicarmine stain is negative for mucin, unlike in CDC
- Immunohistochemistry
  - CK7(-), unlike in PRCC
  - CD10(-), CK20(-), and TFE3(-)
  - HMWK (34bE12)(-), unlike in CDC
- Aggressive, most present with higher stage (≥pT3a)
  - Frequent metastasis to lymph nodes and involvement of adrenal glands
  - Most aggressive RCC among hereditary renal tumors
- Rare reports of concurrent clear cell RCC in bilateral cases; unclear if associated or incidental

Other Tumors
- Rarely reported
- P.I(2):88

- Adrenal gland adenomas, breast tumor, bladder tumor, brain tumor, lymphoid malignancy, basal cell carcinomas, thyroid tumors, ovarian cystadenomas

CANCER RISK MANAGEMENT
Diagnosis
- Proposed practical criteria for diagnosis
  - If clinical features are suggestive, genetic counseling and molecular testing should be performed for
    - Individual with multiple cutaneous leiomyomas, ≥1 histologically confirmed
    - Individual with leiomyoma and family history of HLRCC
    - Individual with ≥1 tubulopapillary RCCs showing large inclusion-like nucleolus and perinucleolar clearing
  - All family members of a person with germline FH mutation should be tested
Surveillance
- Currently, no consensus
  - Lifelong clinical surveillance warranted in individuals who are at risk
Diagnostic Pathology: Familial Cancer Syndromes

- No established standard for age of surveillance for RCC, but ideally should start at earliest age due to aggressive nature
  - For renal tumors, baseline renal ultrasound and abdominal CT scan with contrast or MR at age 20 years, then annual MR or semiannual ultrasound
  - For uterine tumors, annual gynecologic ultrasound at age 20 years
  - Dermatologic examination for lesions suspicious for cutaneous leiomyomas

Treatment

- Smooth muscle tumors
  - Surgical excision for solitary skin tumors
  - Myomectomy desired for smaller uterine tumors to retain fertility

- Renal cell carcinomas
  - Radical surgery preferred, even if small in size because of its aggressive nature
    - This approach is in contrast to renal tumors in other hereditary settings that are usually observed until a certain size is reached
  - Chemotherapy using inhibitors for HIF1-activated targets is being tried
    - LDHA inhibition has been shown to cause increase apoptosis in FH-deficient cells in xenograft mouse model, suggesting a possible therapeutic strategy

SELECTED REFERENCES


Lehtonen Modified Criteria for Diagnosis of HLRCC

<table>
<thead>
<tr>
<th>Major Criterion</th>
<th>Minor Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presence of multiple cutaneous leiomyomas (histopathologically confirmed) indicates high likelihood of HLRCC</td>
<td>HLRCC can be suspected when an individual meets ≥ 2 of the following criteria</td>
</tr>
<tr>
<td></td>
<td>Surgical treatment of severely symptomatic uterine leiomyomas before age 40</td>
</tr>
<tr>
<td></td>
<td>Type 2 papillary or collecting duct renal cell carcinoma before age 40</td>
</tr>
<tr>
<td></td>
<td>1st-degree family member who meets criteria for</td>
</tr>
</tbody>
</table>
Occurrence of severely symptomatic uterine leiomyomas before age 40 in 2nd-degree paternal family members may also be relevant.

(Left) Low-power view shows RCC in HLRCC with predominant papillary architecture. These RCCs were previously classified as papillary RCC type 2 (eosinophilic type) or collecting duct carcinoma and are now considered to be distinct. The neoplastic papillae have thick stalks and are lined by stratified high-grade tumor cells with eosinophilic cytoplasm. (Right) H&E shows RCC in HLRCC exhibiting tubular growth. The cells in the tubules and papillae have similar cytologic features.

(Left) Hallmark of RCC is the presence of large nuclei with inclusion-like orangeophilic nucleolus and perinucleolar clearing, resembling cytomegalovirus cytopathic change. This feature is seen diffusely in the tumor. Nuclear stratification is common, and nuclei may form pseudorosettes. (Right) Low-power view shows RCC in HLRCC with focal tubulocystic area adjacent to a papillary structure. Both papillae and tubulocystic areas exhibit similar characteristic nuclear features.
H&E shows cutaneous leiomyoma consisting of fascicles of smooth muscle cells. These lesions are thought to arise from pili erector muscle of the skin. Eventually, up to 100% of men and 80% of women with HLRCC will develop cutaneous leiomyomas. (Courtesy C. Ko, MD.) (Right) Graphic image shows uterus in HLRCC with leiomyomas at submucosal, intramural, and subserosal sites. HLRCC patients are at high risk for early onset, multiple, atypical, &/or cellular leiomyomas.

Hereditary Multiple Exostosis

Hereditary Multiple Exostosis

Vania Nosé, MD, PhD
Osteochondroma arising from the proximal femur is shown. The osteochondromas grow in a direction away from the joint. The cartilaginous cap is irregular with areas of thick cartilage alternating with thinner areas.
The cartilaginous cap of osteochondromas is composed of hyaline cartilage with cellularity comparable with an actively growing skeleton. The cartilage undergoes endochondral ossification.

**TERMINOLOGY**

**Abbreviations**
- Hereditary multiple exostosis (HME)
- Multiple hereditary osteochondromatosis (MHO)

**Synonyms**
- Multiple cartilaginous exostoses

**Definitions**
- HME is characterized by multiple exostoses
- Autosomal dominant condition caused by mutations in 1 of the EXT genes
- ≥ 2 osteochondromas of juxtaepiphyseal region of long bones are required for diagnosis

**EPIDEMIOLOGY**

**Age Range**
- Median age at diagnosis is 3 years
- Nearly all affected individuals are identified by age 12
- Most patients are in their 2nd decade of life at time of diagnosis

**Site**
- Typically arises in appendicular skeleton
  - Distal femur, proximal tibia, proximal humerus
- Can involve flat bones, such as ilium and scapula

**Gender**
- Male predominance

**Incidence**
- Prevalence ranges from 0.9 to 2 per 100,000 live births
- Sporadic osteochondromas are ≥ 6x more common than MHO
ETIOLOGY/PATHOGENESIS

Histogenesis
- Mutation in 1 of the EXT genes detected in 85-90% of cases
  - EXT1 (8q24.11-q24.13)
    - > 80 different mutations in EXT1
    - Accounts for 50-76% of families with hereditary multiple exostosis
  - EXT2 (11p11-p12)
    - 21-50% of families have mutation in EXT2
  - EXT3 (19p)
    - Rare
  - De novo mutations
    - In ~ 10% of affected individuals

Molecular Genetics
- Germline alterations in EXT1 (located at 8q24) and EXT2 (located at 11p11-p12) are involved in hereditary multiple osteochondromas
  - Loss of wild-type alleles has been reported in MHO and rare cases of sporadic osteochondroma
- Most of these mutations are predicted to result in truncated or nonfunctional protein
- No definitive proof of linkage to EXT3 gene (located on 19p)
- Contiguous gene deletion syndromes
  - Deletion of EXT1 and TRPS1 genes: Langer-Giedion syndrome
    - Multiple osteochondromas with craniofacial dysmorphism and mental retardation
  - Deletion of EXT2 and ALX4: Potocki-Shaffer syndrome
    - Multiple osteochondromas, enlarged parietal foramina, craniofacial dysostosis, and mental retardation
- Function of gene products of EXT1 and EXT2
  - Proteins exostosin-1 (EXT1 gene) and exostosin-2 (EXT2 gene) are localized to endoplasmic reticulum and catalyze heparan sulphate polymerization
    - These 2 proteins are hypothesized to be essential for fibroblast growth factor and Indian hedgehog signaling within normal growth plate

CLINICAL IMPLICATIONS

Clinical Presentation
- HME is characterized by multiple osteochondromas near diaphyses of the extremities, ribs, scapulae that undergo ossification
- Disorder can be associated with mild short stature
- HME can be diagnosed at birth
- 60% have positive family history of multiple osteochondromas
- Multiple slowly enlarging firm lesions present for many years
- Arises from surface of bone

Diagnosis
- Presence of multiple exostoses in an individual (average: 6)
- EXT1 phenotype is more severe than that associated with EXT2
  - Patients with EXT1 mutations have more exostoses, more limb malalignment, and more pelvic and flat bone involvement than EXT2 mutations
- Family history

Prognosis
- Malignant transformation of osteochondroma to chondrosarcoma occurs in 0.5-5% of MHO patients
  - Rarely, osteosarcoma and dedifferentiated chondrosarcoma have also been reported
- Patients may show deformities of forearm, inequality in limb length, varus or valgus angulation of knee, deformity of ankle, and disproportionate short stature

Associated Malignant and Benign Neoplasms
- < 5% malignant transformation to chondrosarcoma or other sarcomas
  - Chondrosarcoma has predilection for proximal femur or axial skeleton
    - Seldom occurs before age 10 and rare after 50
- Osteochondromas and multiple exostosis

Cancer Risk Management
MACROSCOPIC FINDINGS
General Features
- Generally similar to sporadic osteochondroma
- Arises from surface of bone
- Outer layer consists of thin sheath of fibrous tissue that overlies pearly gray-white cartilaginous cap
  - Cartilaginous cap is of varying thickness
  - Ranging from < 2.5 to several cm in depth
  - Base of cartilage cap undergoes enchondral ossification and merges with areas that have appearance of cancellous bone

MICROSCOPIC FINDINGS
General Features
- Overall architecture recapitulates that of disorganized growth plate
- Chondrocytes exhibit minimal cytologic atypia and no mitotic activity
- Peripheral cap of hyaline cartilage
  - Cellularity of cartilage decreases from deep to superficial layer
  - Chondrocytes are arranged in vague columns
- Newly formed trabeculae at base of cartilage mimics primary spongiosa of normal growth plate

SELECTED REFERENCES

IMAGE GALLERY
(Left) The overall architecture of an osteochondroma recapitulates that of a disorganized growth plate. The cartilage undergoes endochondral ossification. (Center) The cartilaginous cap of an osteochondroma is composed of hyaline cartilage. The cellularity of cartilage decreases from deep to superficial layer. (Right) The columns of chondrocytes mimic the zone of hypertrophy of the growth plate.

Hereditary Cutaneous Melanoma

> Table of Contents > Part I - Overview of Syndromes > Section 2 - Syndromes > Hereditary Cutaneous Melanoma
Hereditary Cutaneous Melanoma
Christine J. Ko, MD
Clinical photograph shows a large melanoma with variegated color, jagged border, and irregular surface, all of which are concerning clinical signs. (Courtesy J. Hall, MD.)
This melanoma from the back of a 16-year-old girl is composed of atypical epithelioid cells with several mitotic figures. (Courtesy C. Cockerell, MD.)

TERMINOLOGY

Definition of Hereditary Cutaneous Melanoma
- ≥ 3 blood relatives with cutaneous melanoma in areas with high sun exposure
- ≥ 2 blood relatives with cutaneous melanoma in areas with low sun exposure

EPIDEMIOLOGY

Incidence of Hereditary Cutaneous Melanoma
- 5-7% of cutaneous melanoma patients are from high-risk families
  - In individuals with multiple relatives with cutaneous melanoma
    - Percentage increases to ~54%
  - In individuals with multiple primary cutaneous melanomas
    - Percentage increases to ~15%

Hereditary vs. Sporadic Cutaneous Melanoma
- Most cutaneous melanoma is sporadic
  - Likely secondary to somatic mutations
    - May be induced by ultraviolet light, especially with intermittent sun exposure and sunburn
- Up to 10% of cases of cutaneous melanoma
  - Secondary to germline mutations
  - Mutations are currently detectable in up to 40% of families with suspected hereditary cutaneous melanoma

Age
- Mean age at presentation with cutaneous melanoma: 34 years

GENETICS

CDKN2A Mutations (Tumor Suppressor Gene on 9p21)
- In 20-40% of cutaneous melanoma kindreds; present in 0.2-2% of all cutaneous melanoma patients
Melanoma penetrance
- 30% by age 50 years
- 67% by age 80 years

Lifetime risk of cutaneous melanoma
- 53% in Europe
- 75% in United States
- 91% in Australia

Risk of CDKN2A mutation carriage
- ~50% risk if relative with known CDKN2A mutation
- 50% risk if 3 or more relatives with cutaneous melanoma
- 45% risk if 1 relative with multiple cutaneous melanomas
- 20-45% risk if 2 or more relatives with cutaneous melanoma
- 10-20% risk if multiple primary cutaneous melanomas and no family history of cutaneous melanoma
- ~20% risk if affected by cutaneous melanoma and pancreatic cancer
- <1% if early onset of 1 cutaneous melanoma

Mutations are generally inactivating
- Often missense leading to loss of function of p16INK4A
- Sometimes affect both p16INK4A and p14ARF
- Less commonly, deletions, insertions, and splice site mutations affect p14ARF alone

Gene transcripts of CDKN2A
- p16INK4A
  - Part of retinoblastoma pathway
  - Physiologic targets include CDK4 and CDK6
  - Thought to cause senescence in melanocytes and melanocytic nevi
- p14ARF
  - Part of p53 pathway
  - Function is to block HDM2-mediated degradation of p53

Linkage to 1p36 and 1p22
- 1p36
  - Multiple cutaneous melanomas and dysplastic nevi may be seen

CDK4 Mutations (Oncogene on 12q14)
- CDK4 functions in retinoblastoma pathway
- Mutations in exon 2, codon 24 disrupts binding to p16INK4A

BAP1 Mutations
- Associated with ocular melanoma
- Rarely, kindreds with ocular melanoma also have increased risk of cutaneous melanoma
- Unusually, may be seen in hereditary cutaneous melanoma kindreds
- Cutaneous melanomas
  - Uniquely nevoid

Genes With Low Associated Risk of Cutaneous Melanoma
- MC1R (melanocortin-1 receptor gene)
  - Risk of cutaneous melanoma
    - Increased 2-4x
  - Can alter risk of cutaneous melanoma for CDKN2A mutation carriers
  - Associated with red hair, Fitzpatrick skin type I, freckling
  - Associated with BRAF-mutant cutaneous melanomas

- Other genes with low associated risk of cutaneous melanoma
  - Many of these genes found in genome-wide association studies
  - Examples include
    - OCA2, TYR, TYRP1, TPCN2, ASIP, GSTM1, VDR

- Genes associated with other hereditary syndromes, with slightly increased risk of cutaneous melanoma
  - BRCA1, BRCA2
  - PS3
  - RB1
  - WRN
  - PTEN
Inheritance
- Autosomal dominant

Genotype-Phenotype Correlation
- CDKN2A mutations
  - Also associated with pancreatic cancer
    - Increased lifetime risk of 11-25%
  - Mutations in p14ARF function
    - Associated with astrocytoma

CLINICAL IMPLICATIONS AND ANCILLARY TESTS

Clinical Presentation
- Familial atypical multiple mole-melanoma syndrome
  - Mutations in CDKN2A and CDK4 genes may be found
  - Increased risk of cutaneous melanoma and pancreatic cancer
- Xeroderma pigmentosum
  - Mutations in XPA, XPB/ERCC3, XPC, XPD/ERCC2, XPE/DDB1, XPF/ERCC4, XPG/ERCC5, POLH
  - Sun sensitivity (can be extreme)
  - High risk of cutaneous melanoma, basal cell carcinoma, and squamous cell carcinoma
- Examples of other syndromes with occasional development of cutaneous melanoma
  - Hereditary breast and ovarian cancer syndrome
    - BRCA1 and BRCA2 mutations
    - Increased risk of breast and ovarian cancers
    - Risk of cutaneous melanoma appears to be increased in patients < age 65
  - Li-Fraumeni syndrome
    - Mutations in P53
    - Most common cancers include osteosarcoma, other sarcomas, leukemia, breast cancer, adrenal cortical carcinoma, and brain cancer
    - Increased risk of cutaneous melanoma, but exact quantification of risk is unknown
  - Hereditary retinoblastoma
    - RB1 mutations
    - Increased risk of retinoblastoma, osteosarcoma, cutaneous melanoma, and other sarcomas
  - Werner syndrome
    - Mutations in WRN
    - Premature aging with increased risk of cancer, including cutaneous melanoma

Clinical Risk Factors
- Cutaneous melanoma in 1 first-degree relative
  - 2.5-3x increased risk of cutaneous melanoma than general population
- Cutaneous melanoma in a parent and a sibling
  - 9x increased risk of cutaneous melanoma than general population
- CDKN2A mutation carrier
  - 75-100x greater risk of cutaneous melanoma than general population
- Degree/amount of sun exposure
  - Presence of extensive sun damage to skin
  - Prior history of skin cancers
- Geographic location
- Number of nevi, especially if > 50
  - Number of nevi with atypical features
    - Size > 6 mm, irregular/ill-defined borders, irregular color
- Very fair skin with inability to tan
- Presence of many freckles
- Hair color, especially red or blonde
- Eye color, especially blue
- Genetic mutations and modifier genes

ASSOCIATED NEOPLASMS
Malignant Melanoma
- Cutaneous
• Ocular (uveal tract)
  o Increased risk only in certain families (linked to 9p12.32)
  o No increased risk in families with CDKN2A mutations

Dysplastic Melanocytic Nevi (Atypical Melanocytic Nevi, Clark Nevi)
• Originally described in kindreds with increased risk of cutaneous melanoma
• Subsequently described in individuals with no increased risk of cutaneous melanoma
• Controversial on many levels
  o Definition not universal
    ▪ Clinical vs. histopathologic: Clinically atypical nevi are not necessarily histopathologically atypical, and vice versa
  o Clinically dysplastic melanocytic nevi
    o Size > 6 mm
    o Irregular color
    o Irregular borders
    o Asymmetric
    o History of change
    o Presence of elevated and flat (papular and macular) components
  o Histopathologic criteria for dysplastic melanocytic nevi
    o Include cytologic and architectural criteria
    o Cytologic criteria
      ▪ Nuclear size
      ▪ Pleomorphism
    o Architectural features
      ▪ Single melanocytes vs. nests
      ▪ Nest size
      ▪ Distribution of nests
      ▪ Bridging of rete
      ▪ Pagetoid scatter
      ▪ Fibroplasia, sometimes lamellar
      ▪ Extension of junctional component past dermal component
      ▪ Lymphocytic infiltrate

Pancreatic Cancer
• Average age is 5.8 years younger than patients affected by sporadic pancreatic cancer

Astrocytoma
• Linked to mutations in CDKN2A (p14ARF)

Breast Carcinoma
• Possible 4x increased risk in families with CDKN2A mutations

CANCER RISK MANAGEMENT

Photoprotection
• Sunscreen, sun protective clothing, avoidance of sunburn

Skin Examination
• Head-to-toe examination (including scalp and genitalia)
  o Baseline at age 10 years
  o Repeat every 6-12 months
  o May increase frequency during puberty or pregnancy
  o May use dermoscopy or other modalities
  o Monthly self-examination of skin
• Baseline photography may be helpful

Suspicious Lesions
• Prompt excision and histopathologic evaluation

Education
• On photoprotection and characteristics of melanoma

Pancreatic Cancer Surveillance
• Multimodal screening
  o Endoscopic ultrasound, computed tomography, endoscopic retrograde cholangiopancreatography, and magnetic resonance imaging

SELECTED REFERENCES

Image Gallery
Associated Lesions

(Left) Clinical photograph of a melanoma, superficial spreading type, shows darkly pigmented areas surrounding a central area of regression. (Courtesy J. Wu, MD.) (Right) This melanoma is composed of large melanocytes with mild dermal inflammation and scattered melanophages. (Courtesy S. Dadras, MD.)
This is a multicolored, irregularly bordered, asymmetric melanocytic nevus that mimics a melanoma. (Courtesy J. Hall, MD.) Mildly atypical compound melanocytic nevus shows a proliferation of small nests and a few single cells along the dermal-epidermal junction with focal bridging across rete ridges. The dermal component is composed of small, relatively uniform-appearing cells that show dispersion (maturation) with dermal descent. (Courtesy D. Cassarino, MD.)

Glioblastoma multiforme typically has an irregular, contrast-enhancing rim around a dark, necrotic center. (Courtesy P. Burger, MD.) Ductal pancreatic adenocarcinoma typically features small to medium-sized glands with haphazard growth embedded in a dense desmoplastic stroma. (Courtesy M. Mino-Kenudson, MD.)
Hereditary Neuroblastoma

Undifferentiated neuroblastoma shows cells with scant cytoplasm with round and hyperchromatic nuclei. The differential diagnosis should include other small blue round cell tumors.
Fluorescence in situ hybridization (FISH) of this neuroblastoma shows marked amplification of MYCN, demonstrated by numerous green dots in the neuroblastoma cells.

TERMINOLOGY

Abbreviations
- Neuroblastoma (NB)
- Ganglioneuroblastoma (GNB)

Definitions
- Malignant tumor derived from primordial neural crest cells that usually presents in childhood
  - NB is less differentiated
  - GNB is moderately differentiated, showing variable cytodifferentiation into ganglion cells

EPIDEMIOLOGY

Incidence
- Hereditary NB is rare
- Prevalence of NB in the general population 1:7,500 to 1:10,000
- Inherited cases represent ~ 2-3.5% of new cases
- Overall risk to siblings is ~ 0.2%
- Familial NBs are thought to have an earlier median age at diagnosis than those with sporadic NB
- Age at diagnosis in other 40% is extremely variable
- Most cases (> 60%) of hereditary NB are diagnosed before 1 year of age

GENETICS

Genetic Changes
- NB harbors a variety of genetic changes
  - Gain of genetic material from 17q
  - Loss of heterozygosity at 1p36 and 11q
  - Mutations on PHOX2B
  - High frequency of MYCN (N-myc) amplification
Anaplastic lymphoma kinase (ALK) is a frequent target of genetic alteration in advanced NB.

**Heterogeneous Etiology**
- Autosomal dominant
- Mutations on PHOX2B on 4p12
- ALK mutations
- MYCN amplification
  - Suggests a possible oligogenic model in which 2 loci have a synergistic effect on NB

**PHOX2B**
- Heterozygous mutations in PHOX2B found in 1 of 8 families cosegregating for NB
- PHOX2B found as a candidate gene because of reported increased risk of NB individuals with congenital central hypoventilation syndrome (due to de novo PHOX2B mutations)
  - Patients with this syndrome have increased risk (5-10%) of NB, GNB, or ganglioneuroma

**ALK**
- ALK locus, centromeric to the MYCN locus, was identified as a recurrent target of copy number gain and gene amplification
- Germline mutations in ALK gene explain most hereditary NBs
  - Activating mutations can also be somatically acquired
- DNA sequencing of ALK revealed 8 novel missense mutations in up to ~35% of NB
- Heritable mutations of ALK are main cause of familial NB
- Germline or acquired activation of this cell-surface kinase is a tractable therapeutic target for this lethal pediatric malignancy

**CLINICAL IMPLICATIONS AND ANCILLARY TESTS**

**Clinically Relevant Pathologic Features**
- **Gross appearance**
  - Cystic degeneration and calcification can be seen
- **Microscopy**
  - Small round blue cells with very scant cytoplasm
  - Homer Wright rosettes or pseudorosettes
  - Ganglionic differentiation
- **Mitotic-karyorrhectic index (MKI), applicable for stroma-poor tumors**
  - Count of cells undergoing mitosis or karyorrhexis (per 5,000 cells)
- **Adverse factors**
  - Older age at diagnosis
  - Advanced stage of disease (except IV-S)
  - High histologic grade of tumor
  - Diploid DNA value
  - MYCN oncogene amplification
  - Cytogenetic abnormalities of chromosomes 1 and 17
  - Pattern of urinary catecholamine excretion
  - Increased levels of ferritin NSE, LDH, creatine kinase BB, or chromogranin-A
  - Abnormalities in ganglioside composition
  - Lack of high-affinity nerve growth factor receptors

**ASSOCIATED NEOPLASMS**

**Neuroblastoma**
- Patients with familial NB have a 20% risk of developing bilateral adrenal and multifocal primary NBs

**Ganglioneuroma**
- Patients with familial NB have increased risk of developing benign tumors as ganglioneuromas

**CANCER RISK MANAGEMENT**

**Screening**
- Urinary catecholamines
  - NB could be detected by screening at age of 6 months
    - Evidence of improvement in survival of children with screen-detected NB
    - Associated with favorable biological features
    - Lack of MYCN amplification
• Urinary homovanillic acid and vanillylmandelic acid  
  o Increased in > 95% of cases of NB  
  o Due to clinical heterogeneity of hereditary NB and possibility of a later age at presentation, a prolonged period of time screening may be necessary  
• Lactate dehydrogenase  
  o > 1,500 IU/L associated with worse clinical outcome  
• Ferritin  
  o > 142 ng/mL associated with worse clinical outcome  
• Neuron-specific enolase (NSE)  
  o > 100 ng/mL associated with worse clinical outcome  

High Importance of Cytogenetics  
• MYCN amplification is associated with worse prognosis  
• Loss of heterozygosity of 1p and 11q associated with worse prognosis  
• Activating mutations of ALK receptor tyrosine kinase confer sensitivity to ALK inhibition with small molecules, providing a molecular rationale for targeted therapy of this disease  

Prognosis  
• 5-year survival based on stage at time of diagnosis  
  o Stage I: > 90%  
  o Stage II: 70-80%  
  o Stage III: 40-70%  
  o Stage IV  
    ▪ < 1 year old: > 60%  
    ▪ 1-2 years old: 20%  
    ▪ > 2 years old: 10%  
  o Stage IV-S: > 80%  

SELECTED REFERENCES  

Image Gallery  
Imaging, Microscopic, and Gross Features
(Left) Posterior bone scan shows calvarial metastasis of a neuroblastoma in a small child. (Right) This is a focus of metastatic neuroblastoma in a core biopsy specimen of bone. The marrow has been extensively replaced by sheets of metastatic small round cell tumor and shows no areas with normal trilineage hematopoiesis.

(Left) Axial T2-weighted MR shows a left adrenal mass, which proved to be a neuroblastoma. It was widely metastatic; the liver was filled with multiple high-signal nodular lesions, with little normal remaining hepatic parenchyma. (Right) This specimen of a liver shows diffuse involvement and extensive replacement by multiple deposits of metastatic neuroblastoma. There are several foci of hemorrhage.
Schwannian stroma in an NB is often present as thin septa composed of spindled cells, sometimes with wavy nuclei. The Schwann cell component can be demonstrated by immunohistochemistry for S100 protein. The neuroblastomatous component of this intermixed ganglioneuroblastoma (GNB) is predominantly mature ganglion cells. The ganglion cells are present in clusters in this tumor, differing from the pattern in maturing GNB in which they are present as single cells.

Microscopic Features and Ancillary Tests

Homer Wright rosettes are composed of neuroblasts surrounding a central core of neurites (cytoplasmic processes). These can be found in varying numbers in poorly differentiated NBs but are not wholly specific. Small foci of schwannian stroma are also seen. Low-power view of a poorly differentiated neuroblastoma shows thin septa composed of schwannian stroma. Pale, eosinophilic neuropil is seen in places between the nodules or nests of neuroblastoma cells.
(Left) In this bone marrow trephine specimen, there is diffuse immunoreactivity for neuroblastoma antigen (NB84) in metastatic deposits of neuroblastoma that extend between bony trabeculae. (Right) Synaptophysin immunostain shows granular pattern. Although synaptophysin is not specific, it can be used for differential diagnosis of other small round blue cell tumors like lymphoma, rhabdomyosarcoma, or Ewing sarcoma. NBs are also positive for chromogranin and CD56.

(Left) Immunohistochemical staining for ALK1 in neuroblastoma shows strong membranous staining. Activating mutations in ALK gene have been reported in neuroblastoma and provide a potential therapeutic target. (Right) FISH of a neuroblastoma shows marked amplification of MYCN demonstrated by numerous red dots. This finding predicts poor prognosis, although the amount of amplification does not relate to outcome.

Hereditary Pancreatic Cancer Syndrome
This medium-power image from a patient with hereditary pancreatitis shows chronic pancreatitis with scar and atrophy of the acinar units. (Courtesy M. Bronner, MD.)
This image shows PanIN-2 from a patient with hereditary pancreatitis. Note the enlarged nuclei on the surface compared to the bland nuclei. (Courtesy M. Bronner, MD.)

**TERMINOLOGY**

**Abbreviations**
- Familial pancreatic cancer (FPC)
- Familial atypical multiple mole melanoma syndrome (FAMMM)
- Hereditary pancreas cancer syndromes (HPCS)

**Definitions**
- FPC is defined as a group of families with 2 or more close relatives with pancreatic cancer, but who do not fulfill criteria of any other cancer syndromes
- HPCS are well-defined syndromes that have an increased risk of pancreatic neoplasms
  - Multiple endocrine neoplasia type 1 (MEN1), von Hippel-Lindau disease, neurofibromatosis type 1, tuberous sclerosis, hereditary breast and ovarian, FAMMM, Peutz-Jeghers, and hereditary pancreatitis are all HPCS

**EPIDEMIOLOGY**

**Prevalence**
- Up to 10% of pancreatic carcinomas have a familial component
  - Known genetic syndromes account for < 20% of this group
    - Most causes of FPC are still unknown
    - Mutations in ATM and PALLD genes have been identified in small kindreds of FPC patients
  - The more family members affected, the higher the relative risk of pancreatic cancer to individuals within that family
  - Cigarette smoking is a synergistic environmental cofactor

**GENETICS**

**Autosomal Dominant**
- Although most genes/syndromes have yet to be defined, those that have been identified tend to be autosomal dominant with 60-80% penetrance
Carcinomas tend to occur at an earlier age in each successive generation and also increase in aggressiveness.

ETIOLOGY/PATHOGENESIS

Histogenesis

- Given the wide variety of genes and syndromes involved, there is not much consistency in what has been described.
  - Patients with hereditary pancreatitis and FAMMM seem to develop multifocal pancreatic intraepithelial neoplasias (PanINs) as precursor lesions.
  - Patients with other forms of FPC develop multiple intraductal papillary mucinous neoplasms.
- Invasive carcinomas arise an average of 12 years earlier in familial cases compared to sporadic cases, and they have a worse prognosis.

CANCER RISK MANAGEMENT

Surveillance

- No clear-cut agreement on the best method to follow in patients at risk for FPC.
  - Endoscopic ultrasound (with fine-needle aspiration of lesions, if present) and MR cholangiopancreatography are thought to be the 2 best modalities for initial screening.
  - There is little agreement on the age at which screening should start.

- For patients with Peutz-Jeghers syndrome, screening is recommended to start between 25 and 30 whereas 35 years is the recommended starting age for hereditary pancreatitis and 40-50 years for FPC (10 years prior to the youngest family member's age at diagnosis of cancer).

- There is no agreement on minimal findings that should prompt surgical intervention.

Surgery

- Patients with lesions showing high-grade dysplasia/PanIN-2-3 are offered total pancreatectomy, but this is a very morbid procedure.

SELECTED REFERENCES


### Tables

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Gene(s)</th>
<th>Tumor(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEN1</td>
<td>MEN1</td>
<td>Pancreatic endocrine neoplasms</td>
</tr>
<tr>
<td>von Hippel-Lindau (VHL) disease</td>
<td>VHL</td>
<td>Serous cystadenomas, pancreatic endocrine neoplasms</td>
</tr>
<tr>
<td>Tuberous sclerosis (TSC)</td>
<td>TSC1, TSC2</td>
<td>Pancreatic endocrine neoplasms (TSC2 mutations)</td>
</tr>
<tr>
<td>Hereditary breast and ovarian cancer syndrome</td>
<td>BRCA2, PALB2, BRCA1</td>
<td>Adenocarcinoma</td>
</tr>
<tr>
<td>Familial atypical multiple mole melanoma syndrome</td>
<td>P16/CDKN2A</td>
<td>Adenocarcinoma</td>
</tr>
<tr>
<td>Peutz-Jeghers syndrome</td>
<td>STK11</td>
<td>Adenocarcinoma</td>
</tr>
<tr>
<td>Lynch syndrome</td>
<td>MLH1, PMS2, MSH2, MSH6</td>
<td>Adenocarcinoma</td>
</tr>
<tr>
<td>Hereditary pancreatitis</td>
<td>PRSS1, PRSS2, SPINK1, CFTR</td>
<td>Adenocarcinoma</td>
</tr>
<tr>
<td>Familial adenomatous polyposis</td>
<td>APC, MYH</td>
<td>Adenocarcinoma (ampullary)</td>
</tr>
</tbody>
</table>

**Relative Risk of Pancreatic Cancer**

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Relative Risk (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Family history: 1 first-degree relative affected</td>
<td>1.5-1.75</td>
</tr>
<tr>
<td>Family History: 2 first-degree relatives affected</td>
<td>6</td>
</tr>
<tr>
<td>Family history: 3 first-degree relatives affected</td>
<td>14-32</td>
</tr>
<tr>
<td>Cigarette smoking and family history of pancreatic cancer</td>
<td>3.7-8.2</td>
</tr>
<tr>
<td>Hereditary breast and ovarian cancer</td>
<td>4-13</td>
</tr>
<tr>
<td>Familial atypical multiple mole melanoma</td>
<td>13-22</td>
</tr>
<tr>
<td>Peutz-Jeghers syndrome</td>
<td>36-132</td>
</tr>
<tr>
<td>Hereditary pancreatitis</td>
<td>53-87</td>
</tr>
<tr>
<td>Lynch syndrome</td>
<td>4.5</td>
</tr>
<tr>
<td>Familial adenomatous polyposis</td>
<td>4.5</td>
</tr>
<tr>
<td>Diabetes &gt; 20 years</td>
<td>2</td>
</tr>
</tbody>
</table>

**Hereditary Papillary Renal Cell Carcinoma**

> Table of Contents > Part I - Overview of Syndromes > Section 2 - Syndromes > Hereditary Papillary Renal Cell Carcinoma

Hereditary Papillary Renal Cell Carcinoma

Gladell P. Paner, MD
Kidney shows multifocal PRCCs. Upper pole PRCC is dark red-brown due to diffuse hemorrhage, and lower pole PRCC has yellow discoloration due to histiocytic infiltrates. These changes are common in PRCC.
PRCC type 1 shows well-formed papillae lined by cuboidal cells with amphophilic cytoplasm. Nuclei are usually low grade. Note hemosiderin pigment-laden histiocytes and red blood cells from hemorrhage.

**TERMINOLOGY**

**Abbreviations**
- Hereditary papillary renal cell carcinoma (HPRCC)
- Papillary renal cell carcinoma (PRCC)

**Definitions**
- Autosomal dominant hereditary disease characterized by development of multiple type 1 PRCCs related to germline MET (c-MET) mutation

**EPIDEMIOLOGY**

**Age Range**
- PRCC typically develops between 45 and 63 years
  - Somewhat late onset for hereditary renal cancer syndrome; however, tumor development as early as 2nd or 3rd decade may occur

**Gender**
- More common in men (M:F = 2.4:1)

**Ethnicity Relationship**
- No known ethnic relationship
  - Most cases encountered in Caucasian families; possibly biased by general population ethnic distribution

**Incidence**
- Rare, only ~30 families with MET mutation described worldwide
  - 1 study did not find MET mutation in 59 clinic-based PRCC cases, including a subset with bilateral &/or multifocal tumors
  - PRCC represents 5% of familial renal cancers in National Institute of Health (NIH) database
- Vast majority of PRCC are sporadic tumors; 2nd most common type of renal epithelial tumor
MET mutation also rarely detected in some PRCC type 1 without known family history of PRCC type 1

**ETIOLOGY/PATHOGENESIS**

**Genetics**

- Mutation in MET proto-oncogene
  - Gene located in Chr 7q31.1-34
  - MET is receptor for hepatocyte growth factor (HGF) or scatter factor (SF)
  - Most are germline missense mutations
  - Mutation occurs in glycine-rich subdomain adjacent to ATP binding site or in activation loop of tyrosine kinase domain
    - Results in constitutive activation of receptor
  - MET overexpression is frequently observed in HPRCC
    - Suggested as potential therapeutic target
  - Penetrance suggested to be high

- HPRCC cytogenetics
  - Chr +7 detected in HPRCC tumors; similar to sporadic tumors
  - No Chr -3p detected

**CLINICAL IMPLICATIONS**

**Clinical Presentation**

- Diagnosis in index patients from families with HPRCC not different from sporadic PRCCs
  - Renal cancers often detected incidentally
  - When symptomatic, may present with hematuria, abdominal pain, &/or mass
  - Suspicion for HPRCC raised by history of multiple family members with renal cancers
  - Subsequent radiologic screening may identify affected family members with asymptomatic renal cancers

- Renal cancers can be lethal if not detected and treated at early stage
- Estimated prevalence of renal tumors is 1,100-1,300 microscopic papillary tumors in a kidney

**MET Proto-Oncogene Mutation Screening**

- Not advocated to be performed in every case of PRCC because HPRCC is rare
  - 1 study screened 59 patients with PRCC that included 22% with bilateral &/or multifocal tumors and no MET mutation was identified

- Testing should be performed only if there is clinical suspicion of the disease
  - Unusually young age of onset, positive family history, bilateral &/or multifocal PRCCs

- Testing can be performed on blood samples (lymphocytes)

**ASSOCIATED NEOPLASMS**

**PRCC Type 1**

**Macroscopy**

- Bilateral and multifocal tumors in > 80% of cases of HPRCC
- Reported number of PRCCs ranges from 1-26
- HPRCC tumors have similar gross appearance to sporadic PRCC
  - Well circumscribed with fibrous pseudocapsule
  - Hemorrhages are common and cause red or dark brown discoloration
  - Intratumoral collections of histiocytes may produce yellow streaks or contrasts

**Microscopy**

- Predominant histology of PRCC type 1 in HPRCC is similar to those in sporadic type
  - Papillary architecture with fibrovascular core that occasionally contains foamy histiocytes
  - May also have tubular or tubulopapillary architecture; may impart solid appearance when predominant
  - Tumor cells are small with scant to modest amount of basophilic or amphophilic cytoplasm
- Admixed areas of clear cells present in > 90% of tumors, more common than in sporadic PRCCs
  - Amount of clear cells varies from 1-70%
  - PRCC lacks delicate vasculature in clear cell RCC
  - Electron microscopy detects intracytoplasmic lipid and glycogen, unlike in usual PRCC cells

**Immunohistochemistry**

- AMACR(+), CK7(+), and EMA(+)

P.I(2):103
- Suggested to be more aggressive than sporadic PRCC
  - Patients typically survive into 7th decade of life

PRCC Type 2
- HPRCC with mixture of PRCC types 1 and 2 reported; association not established as in type 1
- Suggested that some PRCC type 1 classified before 1997 are perhaps type 2

Papillary Adenoma
- Small (≤ 5 mm) tumor nodule in renal parenchyma with papillary, tubular, or tubulopapillary architectures
- Similar cytology to PRCC type 1
  - Distinguished from PRCC type 1 by size criteria
- Like PRCC, multiple adenomas are present in kidney
- Similar genetic and immunophenotypic profiles to PRCC type 1
- Benign tumor with no metastatic potential

Other Tumors
- No known extrarenal manifestations, in contrast to most other hereditary renal cancer syndromes

CANCER RISK MANAGEMENT

Management
- Observation can be performed for smaller tumors
  - No standard size cut-off for therapeutic intervention; some follows 3 cm as cut-off, similar to criterion used for VHL disease
- Nephron-sparing surgery prioritized to preserve renal function
- Radical surgery if tumor is large or kidney is extensively involved
- Treatment with MET inhibitors (e.g., SK1363089 or ARQ197) in phase 2 trials shows promising results

Surveillance
- Lifelong clinical surveillance of affected family members should be performed
- Baseline radiographic examination of kidneys to detect asymptomatic tumor
- Regular follow-up to detect new tumor and careful monitoring for progression of smaller tumors

SELECTED REFERENCES

Hereditary Paraganglioma/Pheochromocytoma Syndromes
Graphic shows paraganglia and neuroendocrine tissues symmetrically distributed along the paravertebral axis in the abdomen, including the organ of Zuckerkandl and the adrenal medulla.
This pheochromocytoma (PCC) has the characteristic alveolar pattern (zellballen) with variably sized nests of tumor cells surrounded by thin-walled vessels and thin bands of fibrous tissue.

**TERMINOLOGY**

**Abbreviations**
- Hereditary paraganglioma/pheochromocytoma (PGL/PCC) syndromes
- Paraganglioma (PGL)
- Pheochromocytoma (PCC)

**Definitions**
- PCCs and PGLs are neuroendocrine tumors that arise in adrenal medulla or extraadrenal sympathetic and parasympathetic paraganglia
  - Occur sporadically or as part of different hereditary tumor syndromes
  - Tumors arising within adrenal medulla are known as PCCs; histologically identical tumors arising elsewhere are termed PGLs
- Hereditary PGL/PCC syndromes are characterized by presence of PGL &/or PCC that occur as part of a familial syndrome
  - > 30% of PCCs and PGLs are currently believed to be caused by germline mutations and several novel susceptibility genes have recently been discovered
    - RET, VHL, NF1, SDHA, SDHB, SDHC, SDHD, SDHAF2, KIF1Bβ, TMEM127, and MAX have been associated with hereditary PCC or PGL
- Hereditary PGL/PCC syndromes should be considered in all individuals with PGL or PCC with the following findings
  - Multiple tumors, including bilateral tumors
  - Multifocal with multiple synchronous or metachronous tumors
  - Early onset (age < 40 years)
  - Family history of such tumors
- Familial PGL/PCC syndrome is term restricted to tumors from germline mutations in SDHx genes
Simplex cases: Many individuals with a hereditary PGL/PCC syndrome may present with solitary tumor of head or neck, thorax, abdomen, adrenal, or pelvis and no family history of the disorder

In PGL/PCC that appear to be sporadic based on the absence of a family history, rate of occult germline mutation is said to be ~12% and ranges from 7.5-24%

 Syndromes Characterized by Susceptibility to PCC and PGL
- Most tumors were known to be associated with multiple endocrine neoplasia type 2 (MEN2), von Hippel-Lindau disease (VHL), and neurofibromatosis type 1 (NF1)
- More recently, mutations in genes encoding different subunits of succinate dehydrogenase (SDH) complex have been linked to familial PGL/PCC syndrome (PGL1, 2, 3, and 4)
- Small fraction is associated with other syndromes (e.g., Carney triad, Carney-Stratakis syndrome, MEN1)
- Several other genes have recently been added to the list (associated with unknown hereditary PGL/PCC)
  - Kinesin family member 1B (KIF1B)
  - EGL-9 homolog 1 (EGLN1), also termed PHD2
  - Transmembrane protein 127 (TMEM127)
  - MYC-associated factor X (MAX)

GENETICS
MEN2
- Autosomal dominant syndrome caused by mutation of RET proto-oncogene
- Activating RET mutation predisposes to PCC, which is often bilateral and recurrent
  - Low risk of malignancy
- MEN2 prevalence is estimated at 1:30,000
- MEN2 often suspected on basis of family history; individuals with PCC infrequently present as simplex cases

Clinically, can be divided into 3 types: MEN2A (55% of all cases), MEN2B (5-10%), and familial medullary thyroid carcinoma (FMTC, 35-40%)
- MEN2A and MEN2B patients have almost 100% risk of developing medullary thyroid carcinoma
- ~50% of individuals with MEN2A and MEN2B develop PCC
- Subtype FMTC has medullary thyroid carcinoma as its only feature

Familial PGL/PCC Syndromes
- Germline mutations in SDHx genes give rise to familial PGL/PCC syndrome, sometimes only referred to as familial PGL
- Prevalence of PGL/PCC syndrome is unknown, but a review of ~13% of all PGL/PCC cases gives an estimate of 1:50,000 to 1:20,000; majority represented by PGL1 and PGL4
- Associated with germline mutations in genes encoding subunits of SDH enzyme complex in context of familial PGL syndromes; PGL1, PGL2, PGL3, and PGL4 caused by mutations in SDHD, SDHAF2, SDHC, and SDHB genes, respectively
  - PGL2 is caused by mutations in SDHAF2/SDHS, which encodes for a molecule that is an accessory to the function of the SDH enzyme and its SDHA subunit
- Mutations were recently found in SDHA subunit in a limited number of patients with PGL &/or PCC
- SDHB mutations in particular may also predispose to thyroid and renal cancer, and possibly other tumors
  - Patients harboring SDHB mutation are at increased risk of malignancy
- Genotype-phenotype correlation
  - People with SDHB, SDHD, and SDHC mutations can develop PCCs or PGLs anywhere in paraganglia
    - Genotype-phenotype correlations guiding diagnostic testing and patient care
    - Germline mutations in SDHB are strongly associated with extraglandular sympathetic PGL
    - Chromaffin tumors in people with germline SDHB mutations are 6x more likely to be extraglandular than chromaffin tumors in general
    - PGL in people with germline SDHB mutation are more likely to become malignant than sporadic PGL or in those with germline SDHD and SDHC mutations
    - SDHB mutations also predict shorter survival
    - Up to 50% of people with malignant extraglandular PGL have a germline SDHB mutation PGL
    - People with a germline SDHD mutation are more likely to develop head and neck and abdominal PGL compared with people with a germline SDHB mutation
    - Germline SDHC mutations appear to be primarily associated with head and neck PGL

von Hippel-Lindau Syndrome (VHL)
- Autosomal dominant disorder caused by mutation of VHL
Features include retinal angiomas, central nervous system hemangioblastomas, clear cell renal cell carcinoma, pancreatic endocrine tumors, endolymphatic sac tumors, renal, pancreatic and epididymal cysts, and PCCs.

- Occurs in ~ 1/36,000 individuals
- ~ 10-26% of VHL patients develop PCC or PGL, but risk varies between families
  - Frequency of PCC in individuals with VHL is 10-20%
- Mean age of onset of PCC in VHL is ~ 30 years
  - PCCs occur in only 6-9% of individuals with VHL type 1
  - Prevalence of PCC rises to 40-59% in individuals with VHL type 2
  - In type 2C VHL, PCCs are sole manifestation of the syndrome (simplex cases)
- VHL mutations predispose to unilateral or bilateral PCCs and, much less frequently, to sympathetic or parasympathetic PGLs
  - ~ 50% of PCCs are bilateral
- PCCs in VHL secrete primarily norepinephrine and normetanephrine

NF1
- Autosomal dominant disorder caused by mutation of NF1
- Major features of NF1 include neurofibromas, café au lait spots, iris hamartomas, and axillary and inguinal freckling
- Gastrointestinal stromal tumors (GISTs) and carcinoid tumors may also occur
- PCCs and PGLs are not among most common manifestations of NF1 but occur in 0.1-5.7% of patients
- PCCs occur in 20-50% of individuals with NF1 and hypertension
- NF1-associated PCCs and PGLs typically have characteristics similar to those of sporadic tumors, with a relatively late mean age of onset and ~ 10% risk of malignancy
- Up to 84% of PCC are unilateral
- Extraadrenal sympathetic PGL can occur
- 95% of patients with NF1 had PCC and 6% had PGL; all PGLs were sympathetic
- 14% of patients displayed bilateral PCC
- 9% developed malignant disease

Carney Triad (CT)
- Rare multitumoral syndrome of unknown etiology
  - Some SDH-deficient GISTs are driven by classical SDH mutations, but precise mechanisms of tumorigenesis in those associated with Carney triad remain unknown

Carney-Stratakis Syndrome
- Mutations in SDHB, SDHC, and SDHD can give rise to Carney-Stratakis syndrome, characterized by dyad of PGLs and GISTs
- 100% of patients had PGL and 1 patient also presented with unilateral PCC, with a mean age of 33 years at presentation
- PGLs occur in head and neck, thorax, and abdomen
- Multiple PGLs, which could be both sympathetic and parasympathetic, were seen in 73% of patients
None of the tumors were malignant

MEN1

- Caused by mutations in MEN1 gene
- MEN1 gene is a 10-exon gene that encodes 610-amino acid protein, menin
- Mutation spectrum
  - > 1,300 different mutations of MEN1 gene have been characterized
  - Penetration of MEN1 is high: 45% by age 30, 82% by age 50, 96% by age 70
  - Spread over entire coding and intronic sequence
    - > 60% truncating mutation, 20% missense mutation, 10% frame deletions or insertions, 10% others
  - Most are inactivating
- Function is unknown; may act as regulator of gene transcription, cell proliferation, apoptosis, and genome stability
- No cases of PGL and only 7 cases of PCC in MEN1 syndrome have been reported in the literature
  - Reported tumors were unilateral in all cases and malignant in 1 case

Other Genes Involved in PGL/PCC

- Several other genes have recently been added to the list (associated with unknown hereditary PGL/PCC)
  - Kinesin family member 1B (KIF1B); EGL-9 homolog 1 (EGLN1), also termed PHD2; transmembrane protein 127 (TMEM127); and MYC-associated factor X (MAX)
- No specific syndrome has been attributed yet, but patients with germline KIF1Bβ mutations seem to be predisposed to at least PCCs and neuroblastomas
  - Ganglioneuroma, leiomyosarcoma, and lung adenocarcinoma have also been reported in a family with KIF1Bβ mutations
- Only 1 PGL patient, suffering from recurrent PGL and erythrocytosis, has been reported to have a germline mutation in EGLN1
  - Presentation with sympathetic PGL and a recurrent tumor was diagnosed 3 years later, but no metastases have been reported
- So far, no specific syndrome has been described for TMEM127
  - TMEM127 mutations were identified in 2% of the cases considered sporadic, all of which had PCC
  - 96% of patients have PCC and 39% have bilateral PCC
- MAX mutations segregate with disease in families with PCC, but no specific syndrome has been described yet
  - Usually bilateral tumors, early age of onset, &/or familial antecedents with the disease
  - Notably, 25% of patients showed metastasis at diagnosis, suggesting that MAX mutations are associated with high risk of malignancy
  - So far, no studies on PGLs have been reported

CLINICAL IMPLICATIONS AND ANCILLARY TESTS

Immunohistochemistry

- SDHA and SDHB are important surrogate markers to triage patients for genetic testing
  - Identifying the ~15% of PGL/PCC associated with mitochondrial complex 2 dysfunction, immunohistochemistry for SDHB is a vital tool for triaging genetic testing
    - Yield is particularly high in extraadrenal PCC/PGL
- SDHB immunoreexpression is lost in PGL and PCC with SDHA, SDHB, SDHC, and SDHD mutation
- SDHA protein is lost when SDHA is mutated
- Endothelial cells and sustentacular cells serve as intrinsic positive controls
- Any PGL/PCC should be considered potentially hereditary until this possibility is excluded
- High rate of malignant behavior of SDHB mutated PGL/PCC is emphasized and recognition of SDHB mutation should lead to more aggressive surgery and surveillance
  - Particularly if compared to tumors arising in MEN2 and VHL syndrome
    - More commonly bilateral but have a low risk of metastasis

Diagnosis/Testing

- Molecular genetics
  - Diagnosis/testing
    - Diagnosis based on physical examination, family history, imaging studies, biochemical testing, and molecular genetic testing
    - SDHD, SDHC, and SDHB: 3 nuclear genes responsible for hereditary PGL/PCC syndromes, encode 3 of 4 subunits of mitochondrial enzyme succinate dehydrogenase (SDH)
      P.I(2):107
- 4th nuclear gene, SDHAF2 (a.k.a. SDH5) encodes a protein that appears to be required for flavination of another SDH subunit, SDHA
- Molecular genetic testing for disease-causing variants in SDHD, SDHC, and SDHB is clinically available
  - MEN1 mutational analysis should be undertaken in
    - Index case with ≥ 2 MEN1-associated endocrine tumors
    - Asymptomatic 1st-degree relative
    - 1st-degree relative of MEN1 mutation carrier
    - In patient with suspicious or atypical MEN1
    - Genetic counseling useful for individuals and families with nonclassic MEN1 presentations

ASSOCIATED NEOPLASMS

MEN2
- MEN2A: Characterized by medullary thyroid carcinoma, PCC, and hyperparathyroidism
- MEN2B: Lacks hyperparathyroidism but includes mucocutaneous neuromas &/or diffuse ganglioneuromatosis of gastroenteric mucosa, slender body habitus, joint laxity, and skeletal malformations

Familial PGL/PCC Syndromes
- SDHB mutations in particular may predispose to thyroid and renal cancer, and possibly other tumors
- GIST

VHL Syndrome
- Retinal angiomas, central nervous system hemangioblastomas, clear cell renal cell carcinoma, pancreatic endocrine tumors, endolymphatic sac tumors, renal, pancreatic, and epididymal cysts, and PCCs

NF1
- Neurofibromas, café au lait spots, iris hamartomas, and axillary and inguinal freckling
- Optic nerve glioma, duodenal neuroendocrine tumors, bone lesions

Carney Triad
- Extraadrenal sympathetic PGL, gastric stromal sarcoma, and pulmonary chondroma

Carney-Stratakis Syndrome
- Association of PGLs and GISTs (dyad)

Other Genes Involved in PGL/PCC
- Ganglioneuroma, leiomyosarcoma, and lung adenocarcinoma have also been reported in a family with KIF1Bβ mutations

CANCER RISK MANAGEMENT

RET-Associated PGL/PCC
- Activating mutations predispose to PCCs, which are often bilateral (63%), and only 3% are malignant
- PGL are rare in MEN2

VHL-Associated PGL/PCC
- VHL mutations predispose to unilateral or bilateral PCCs: Bilateral in 44%, and only 3% were malignant
- In VHL patients with PGL/PCC, 90% had PCC and 19% had PGL

NF1-Associated PGL/PCC
- PCCs and PGLs not among most common tumors in NF1; occur in up to 6% of patients with NF1
- NF1-associated tumors with similar characteristics as sporadic tumors
- ~ 10% are malignant

SDHx-Associated PGL/PCC
- Prevalence of PGL/PCC in this syndrome is unknown, but presently represent ~ 15% of all PGL/PCC
  - 92% are PGL
- Frequently parasympathetic, multifocal in > 55%

PGL1 (SDHD)
- Mutations in SDHD (PGL1) demonstrate parent-of-origin effects and generally cause disease only when mutation is inherited from father
- Individual who inherits SDHD mutation from his/her mother has low but not negligible risk of developing disease
- Individual who inherits SDHD mutation from his/her father is at high risk of manifesting PGL and, to lesser extent, PCCs

PGL2 (SDHAF2)
- All parasympathetic PGL and no metastases

PGL3 (SDHC)
Diagnostic Pathology: Familial Cancer Syndromes

- Rare and associated with parasympathetic PGL (93%); 17% multiple
- PGL4 (SDHB)
  - Malignancy associated with SDHB mutation
  - Higher morbidity and mortality than mutations in other SDHx genes
  - 78% are PGL, 25% are unilateral PCC

Genetic Counseling
- Hereditary PGL/PCC syndromes are inherited in autosomal dominant manner
- Mutations in SDHD (PGL1) demonstrate parent-of-origin effects and generally cause disease only when mutation is inherited from father
- Each child of individual with hereditary PGL/PCC syndrome has 50% chance of inheriting disease-causing mutation
- Individual who inherits SDHD mutation from his/her mother has low but not negligible risk of developing disease
- Individual who inherits SDHD mutation from his/her father is at high risk of manifesting PGL and, to lesser extent, PCC
- Prenatal testing for pregnancies at increased risk is possible for families in which disease-causing mutation is known

Patient Evaluation
- Includes detailed family history, including specific knowledge of any relatives with unexplained or incompletely explained sudden death
  P.I(2):108

- Personal medical history for following symptoms of catecholamine excess: Sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, palpitations, pallor, and anxiety
  - Paroxysmal symptoms that may be triggered by changes in body position, increases in intraabdominal pressure, some medications, exercise, or micturition in case of urinary bladder PGLs
    - Urinary bladder PGLs may also be accompanied by painless hematuria
  - Head and neck PGLs may present as enlarging masses that are asymptomatic or associated with symptoms of mass effects from size and location of tumors
    - Associated symptoms may include unilateral hearing loss, pulsatile tinnitus, cough, hoarseness of voice, pharyngeal fullness, swallowing difficulty, pain, and problems with tongue motion
- Physical examination directed toward signs suggestive of PGL/PCC
  - Sympathetic PGLs and PCCs: Documentation of elevated blood pressure, tachyarrhythmias or other arrhythmias, and palpable abdominal masses
  - Head and neck PGLs: Head and neck masses

SELECTED REFERENCES

Image Gallery
Diagrammatic Features of Paraganglia and Paraganglioma

(Left) Graphic shows paraganglia in head, neck, and upper thorax that are associated with arteries or cranial nerves. They include aortic and carotid bodies and jugulotympanic, vagal, and laryngeal paraganglia. (Right) Axial graphic shows glomus bodies along the course of the inferior tympanic nerve (branch of Jacobsen) on the cochlear promontory. Glomus tympanicum tumors arise from this normal cellular collection. Also note the cochlea.
(Left) Graphic shows a vascular glomus tympanicum PGL pedunculating off the cochlear promontory into the inferior middle ear cavity. The bony floor of the middle ear cavity is intact. The pulsatile tumor mass is behind the lower tympanic membrane. (Right) A glomus jugulare paraganglioma is centered in the jugular foramen with superolateral extension into the middle ear. The main arterial supply for this vascular tumor is the ascending pharyngeal artery.

(Left) Lateral graphic depicts a carotid body paraganglioma at the carotid bifurcation, splaying the ICA and ECA. The main arterial feeder is the ascending pharyngeal artery. The vagus and hypoglossal nerves are in close proximity. (Right) Axial graphic depicts a glomus vagale paraganglioma, located in the nasopharyngeal carotid space. The mass is seen interposed between and displacing the internal carotid artery and jugular vein (inset).

P.II(2):110

Pheochromocytoma
Cross section of the adrenal from a patient with multiple endocrine neoplasia type 2A (MEN2A) reveals diffuse medullary expansion, and a well-defined nodule representing a pheochromocytoma (PCC). This graphic shows a MEN2-associated PCC and associated adrenal medullary hyperplasia, which is characteristically present in adrenal glands of MEN2 patients.

Some PCCs show a mosaic-like pattern of cells that have amphophilic to slightly eosinophilic cytoplasm mixed with scattered often large cells with granular basophilic cytoplasm. Some PCCs show a mosaic-like pattern of often large cells with granular basophilic cytoplasm admixed with cells that have amphophilic to slightly eosinophilic cytoplasm.
Some PCCs lack the organoid pattern and instead may show a diffuse growth pattern. Such PCCs are formed by small cells with ample eosinophilic cytoplasm with occasional bizarre cells. (Right) This tumor from a patient with hereditary familial paraganglioma (PGL) syndrome has a solid, patternless component with large sheets of tumor cells. There is cellular pleomorphism and mitoses. P.I(2):111

(Left) Coronal graphic shows glomus jugulare PGL centered in the jugular foramen with superolateral extension into the middle ear. The ascending parapharyngeal artery is feeding this vascular tumor. (Right) Graphic of part of the mitochondrial respiratory chain complex II shows the relationship between the succinate ubiquinone oxidoreductase subunits (SDHA → SDHD). Inactivating mutations result in hereditary PGL.
This highly vascular glomus jugulare PGL is underneath an intact mucosa and shows groups of neoplastic cells interspersed between the vascular channels. (Right) SDHB immunostaining reveals maintenance of immunoreactivity in a PGL in a MEN2-associated hereditary PGL patient, without SDHB or SDHD mutation. The staining is coarsely granular as the protein is localized in the mitochondria.

This picture shows a PGL with the characteristic alveolar patterns with variably sized nests of tumor cells surrounded by thin-walled vessels. This tumor has a solid component with large sheets of tumor cells. (Right) PCCs and other PGLs without mutations of SDHx genes show immunoreactivity of tumor cell cytoplasm for SDHB protein. The immunoreactivity is granular because the protein is localized to mitochondria.
Hereditary Prostate Cancer

H&E shows Gleason 3 + 3 = 6 prostate cancer. Majority of prostate cancers are diagnosed as low-grade, organ-confined disease with an indolent course.
Anterior bone scan shows multiple bony metastases with relative sparing of distal appendicular skeleton. Only < 5% of prostate cancer are diagnosed with metastasis.

**TERMINOLOGY**

**Abbreviations**
- Sporadic prostate cancer (SPC)
- Familial prostate cancer (FPC)
- Hereditary prostate cancer (HPC)

**Definitions**
- **FPC**
  - Affected individuals with ≥ 1 first-degree relative who also has prostate cancer
- **HPC**
  - Subtype of FPC with consistent passage of susceptibility gene via Mendelian inheritance
  - Despite strong evidence for existence of prostate cancer susceptibility genes, no definitive example has been identified so far
  - Clinical criteria for diagnosis of HPC proposed by Carter et al
    - Family with prostate cancer in ≥ 3 first-degree relatives
    - Family with prostate cancer in 3 successive generations from paternal or maternal side
    - Family with 2 first-degree relatives with prostate cancer at age ≤ 55 years
    - Diagnosis of HPC requires any 1 of these 3 criteria

**EPIDEMIOLOGY**

**Incidence**
- Prostate cancer is leading cause of cancer mortality and 2nd cause of cancer morbidity in men in the USA
  - Estimated that there will be 238,590 prostate cancer diagnosed in the USA in 2013
- ~ 5-10% of prostate cancer patients can be accounted for by genetic susceptibility
- Identification of true prevalence of FPCs or HPCs difficult due to the very high occurrence rate of prostate cancer
Family History as Risk Factor
- ~10-15% of prostate cancer patients have at least 1 relative who also has prostate cancer
- Risk is greater for men with affected brothers than for men with affected fathers
- Risk ↑ with number of relatives affected
  - Risk is higher with first-degree than with second-degree relatives affected
  - Risk is higher with 2 than with 1 first-degree relative affected
- Concordance between monozygotic twins of 27% vs. 7% between dizygotic twins

Age Range
- Peak occurrence of prostate cancer overall is at 65-75 years and median age is 67 years
  - HPC diagnosed ~6 to 7 years earlier than SPC
  - Estimated that prostate cancer attributable to high-risk susceptibility alleles is 43% for men diagnosed ≤ 55 years, 34% for men ≤ 70 years, and 9% for men ≤ 85 years old

ETIOLOGY/PATHOGENESIS
Risk Factors
- Major risk factors for prostate cancer are age, ethnicity (black), and family history

Genetics
- Several candidate genes proposed, with BRCA2 so far being the most consistently replicated in studies
- BRCA2-associated prostate cancer
  - Hereditary breast and ovarian cancer syndrome (HBOC) P.J[2]:113
    - Caused by inherited mutation in BRCA2, and manifests clinically with mutation in the other allele (Knudson “2-hit” hypothesis)
    - In women, mutations confer up to 87% lifetime risk of breast cancer and up to 54% risk of ovarian cancer
    - In men, mutations confer 7% risk of breast cancer
    - Also increase risk for prostate cancer, pancreatic cancer, and melanoma
      - BRCA2 carriers have cumulative risk for prostate cancer of 16% vs. 3.8% for noncarriers
      - Seems to contribute to a very small minority of prostate cancer risk with prevalence rate of only <1%
- Other candidate genes
  - Studies show conflicting results

CLINICAL IMPLICATIONS
Clinical Presentation
- Pre-radical prostatectomy PSA level higher in HPC than in FPC and SPC
- Clinical features and long-term oncological outcomes are similar post-radical prostatectomy in patients with FPC, HPC, and SPC
- Some studies suggest BRCA-associated prostate cancers have a more aggressive phenotype

PATHOLOGICAL FEATURES
Gross and Microscopic Features
- So far, no differences have been described in gross or microscopic features of tumors in FPC, HPC, and SPC
- Multifocality, a common trait for familial tumors in general, is frequent in sporadic prostate cancers

CANCER RISK MANAGEMENT
BRCA2 Mutation
- In men not selected for family history, BRCA2 contributes to a very small minority of prostate cancer risk (<1%)
- Unclear benefit of screening for this mutation in men

SELECTED REFERENCES

Tables

<table>
<thead>
<tr>
<th>Family History</th>
<th>Relative Risk (%)</th>
<th>Absolute Risk (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>Father with prostate cancer at age ≥ 60 years</td>
<td>1.5</td>
<td>12</td>
</tr>
<tr>
<td>1 brother with prostate cancer at age ≥ 60 years</td>
<td>2</td>
<td>15</td>
</tr>
<tr>
<td>Father with prostate cancer at age &lt; 60 years</td>
<td>2.5</td>
<td>20</td>
</tr>
<tr>
<td>1 brother with prostate cancer at age &lt; 60 years</td>
<td>3</td>
<td>25</td>
</tr>
<tr>
<td>2 affected male relatives*</td>
<td>4</td>
<td>30</td>
</tr>
<tr>
<td>≥ 3 affected male relatives</td>
<td>5</td>
<td>35-45</td>
</tr>
</tbody>
</table>

*Father and brother, 2 brothers, a brother and a maternal grandfather or uncle, or a father and a paternal grandfather or uncle; from Bratt O et al.

Predisposition to Prostate Cancer in Patients With Positive Family History

<table>
<thead>
<tr>
<th>Locus</th>
<th>Gene</th>
<th>Attributable Risk (%)</th>
<th>Age</th>
</tr>
</thead>
<tbody>
<tr>
<td>1q23-q25 (HPC1)</td>
<td>RNASEL</td>
<td>4-13</td>
<td>Early</td>
</tr>
<tr>
<td>1q42.2-43 (PCAP)</td>
<td>PCTA-1</td>
<td>40-50</td>
<td>Early</td>
</tr>
<tr>
<td>8q24</td>
<td>Unknown</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>8q24</td>
<td>HapC</td>
<td>11-31</td>
<td>-</td>
</tr>
<tr>
<td>8q24</td>
<td>POU5FIP1</td>
<td>21</td>
<td>-</td>
</tr>
<tr>
<td>13q12</td>
<td>BRCA2</td>
<td>5%</td>
<td>Early</td>
</tr>
<tr>
<td>17p11 (HPC2)</td>
<td>ELAC2</td>
<td>0.5-4</td>
<td>Early</td>
</tr>
<tr>
<td>Xq27-28 (HPCX)</td>
<td>Unknown</td>
<td>16</td>
<td>-</td>
</tr>
</tbody>
</table>

Hereditary Renal Epithelial Tumors, Others
Kidney shows multiple renal oncocytomas (ROs). A possible 4th tumor is present encased within the larger RO. RO is characterized by tumor cells with abundant eosinophilic cytoplasm and uniform round nuclei (inset).
Graphic shows heterogeneous, vascular, expansile RCC from the renal cortex, invading the renal vein and IVC. Tumor is multicentric, as is the case in up to 5% of sporadic RCCs (and higher for familial cases).

TERMINOLOGY

Abbreviations
- Clear cell renal cell carcinoma (CCRCC)
- Papillary renal cell carcinoma (PRCC)
- Chromophobe renal cell carcinoma (CHRCC)
- Renal oncocytoma (RO)

Definitions
- Familial renal tumor
  - Families with ≥ 2 members within 2 generations with renal tumor and no evidence of known hereditary renal tumor syndrome
  - Reported mostly in CCRCC and also in ROs, PRCC, and CHRCC
- Familial renal oncocytoma (FROS)

FAMILIAL RENAL ONCOCYTOMA

Definition
- Familial renal tumor with affected individuals predisposed to develop bilateral and multifocal ROs

General Features
- Rare, described in ~30 families
- Between 2 and 4 affected family members
- Patient age: 38-83 years old (median: 49, mean: 55)
  - Younger onset than in sporadic renal oncocytoma
- More common in males (M:F = 4:1)
- Partial or complete loss of Chr 1 most frequent
  - Chromosomal changes less frequently observed compared to sporadic ROs
- Most ROs detected incidentally or by screening of affected family members
- For unclear reason, some patients develop renal insufficiency that progresses into end-stage kidney disease
Some affected individuals have pulmonary cysts; association unclear

Renal Tumor

- Has benign outcome; no reported malignant transformation
- Not known if affected individuals have predisposition for renal oncocytosis or hybrid oncocytic tumor

CONSTITUTIONAL CHROMOSOME 3 TRANSLOCATION

Definition

- Hereditary renal tumor characterized by Chr 3 translocation and predisposition for CCRCC

Synonym

- Familial non-VHL, nonpapillary, CCRCC

General Features

- Rare, so far 13 different constitutional translocations identified
  - 7 translocations associated with familial disease
    - t(3;8)(p14;q24), t(2;3)(q35;q21), t(3;6)(q12;q15), t(2;3)(q33;q21), t(1;3)(q32;q13.3), t(3;8)(p13;q24), and t(3;8)(p14;q24.1)
    - Candidate genes: FHIT, TRC8, DIRC1, DIRC2, DIRC3, HSPBAP1, LSAMP, NORE1, KCNIP4, and FBXW7
- Affected individuals predisposed to multifocal and bilateral CCRCC
- Lifetime risk in some families: > 80%; however, in absence of family history, Chr 3 translocation carriers are not at high risk of developing CCRCC
- Between 2 and 5 affected family members
- Patient age: 9-92 years old (median: 54, mean: 53)
  - Younger onset than sporadic CCRCC
- M:F = 1.8:1
- “3-hit” model of tumorigenesis proposed
  - Germline Chr 3 translocation
  - P.I(2):115
  - Nondisjunctional loss of derivative chromosome carrying 3p segment
  - Somatic mutation in remaining 3p allele of ≥ 1 CCRCC tumor suppressor gene (e.g., VHL)
- No known extrarenal manifestations, including those encountered in VHL
  - Few affected individuals (3%) also developed breast cancer
- Annual surveillance not recommended unless there is personal or family history of clear cell RCC &/or tumor suppressor gene mutation

Renal Tumor

- CCRCC

FAMILIAL CLEAR CELL RCC

Definition

- Familial renal tumor with predisposition for clear cell RCC and with no identifiable genetic factor

General Features

- Currently, a diagnosis of exclusion of other hereditary causes of CCRCC
  - Exclude von Hippel-Lindau disease, chromosome 3 translocation, Birt-Hogg-Dubé syndrome, and tuberous sclerosis complex
- Rare, so far ~ 70 families with familial CCRCC reported with no identifiable genetic factor
- Perhaps has a multigenic inheritance mechanism
- More common in males (M:F = 1.9:1)
- Later onset, compared to other familial renal tumors
  - 1 family member develops CCRCC between 50 to 70 years
- Most patients present with solitary tumor
- Suggested management dependent on size to renal tumor; observation if < 3 cm (similar to VHL patients)
  - Conservative surgery, such as partial nephrectomy or enucleation if amenable

Renal Tumor

- CCRCC

HEREDITARY HYPERPARATHYROIDISM-JAW TUMOR SYNDROME

Definition

- Hereditary autosomal dominant disorder characterized by functional parathyroid neoplasm and ossifying fibroma of jaw with increased risk for renal and uterine tumors

General Features
Diagnostic Pathology: Familial Cancer Syndromes

- Very rare; largest study involved 19 affected family members
  - Patient age range: 3-63 years old
- Autosomal dominant inheritance
- Tumor suppressor gene identified as CDC73 or HRPT2 located at Chr 1q25-31 and encodes for parafibromin protein
- No germline mutations in MEN1
- Parathyroid neoplasm often functional parathyroid adenoma that can be multifocal
  - ~ 15% may have parathyroid carcinoma
- ~ 75% may have uterine neoplasm, such as adenofibromas, leiomyomas or adenomyosis, or adenosarcomas
- ~ 15% may have renal tumors
- Patients may also have renal hamartomas or polycystic kidney disease

Renal Tumor
- PRCC
- Wilms tumor
- Renal cortical adenoma
- Benign epithelial cysts

PAPILLARY THYROID CARCINOMA WITH ASSOCIATED NEOPLASIA
Definition
- Inherited renal tumor syndrome characterized by papillary thyroid cancer, nodular thyroid disease, and renal tumor

General Features
- Rare, ~ 5% of papillary thyroid carcinoma overall has familial association
- Autosomal dominant inheritance with age-dependent penetrance
- Women more affected than men
- Linked to Chr 1q21
- Specific gene not yet identified; potential candidates include NRAS and NTRK1
- No germline mutations in MET proto-oncogene present

Renal Tumor
- PRCC
- Multifocal papillary adenomas
- Renal oncocytoma reported in 1 patient

FAMILIAL NONCLEAR CELL RCC
General Features
- Familial renal tumor with no identifiable genetic factor, also described with PRCC and CHRCC
- 1 report from NIH of 68 affected individuals with familial renal tumor included
  - 54% CCRCC (familial CCRCC)
  - 16% RO (familial RO)
  - 12% PRCC
  - 4% CHRCC

SELECTED REFERENCES
P.I(2):116
15. Malchoff CD et al: Familial papillary thyroid carcinoma is genetically distinct from familial adenomatous polyposis coli. Thyroid. 9(3):247-52, 1999

### Hereditary or Familial Renal Tumor Syndromes

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Gene</th>
<th>Chromosome</th>
<th>Product</th>
<th>Renal Tumor</th>
</tr>
</thead>
<tbody>
<tr>
<td>von Hippel-Lindau</td>
<td>VHL</td>
<td>3p25-26</td>
<td>pVHL</td>
<td>Clear cell RCC and clear cell tumorlets</td>
</tr>
<tr>
<td>Hereditary papillary RCC</td>
<td>MET</td>
<td>7q31</td>
<td>MET</td>
<td>Papillary RCC type 1</td>
</tr>
<tr>
<td>Hereditary leiomyomatosis and renal cancer</td>
<td>FH</td>
<td>1q42-43</td>
<td>Fumarate hydratase</td>
<td>Papillary RCC, NOS (mostly classified as papillary RCC type 2 previously)</td>
</tr>
<tr>
<td></td>
<td>FLCN or BHD</td>
<td>17p11.2</td>
<td>Folliculin</td>
<td>Hybrid oncocytic tumor, renal oncocytoma, renal oncocytosis, chromophobe RCC, and clear cell RCC</td>
</tr>
<tr>
<td>Birt-Hogg-Dubé</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Familial oncocytoma</td>
<td></td>
<td>Unknown</td>
<td>Unknown</td>
<td>Renal oncocytoma (association with renal oncocytosis or hybrid oncocytic tumor not known)</td>
</tr>
<tr>
<td>Tuberous sclerosis</td>
<td>TSC1</td>
<td>9q34</td>
<td>Hamartin</td>
<td>Angiomyolipoma, clear cell RCC, benign epithelial cyst, and renal oncocytoma</td>
</tr>
<tr>
<td>Succinate dehydrogenase B-associated hereditary paraganglioma/pheochromocytoma</td>
<td>TSC2</td>
<td>16p13.3</td>
<td>Tuberin</td>
<td>RCC, NOS (mostly classified as renal oncocytoma previously)</td>
</tr>
<tr>
<td>Constitutional chromosome 3</td>
<td></td>
<td>1p36</td>
<td>SDHB</td>
<td>Clear cell RCC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| translocation | candidate genes:  
| | *FHIT*,  
| | *TRC8*,  
| | *DIRC1*,  
| | *DIRC2*,  
| | *DIRC3*,  
| | *HSPBAP1*,  
| | *LSAMP*,  
| | *NORE1*,  
| | *KCNIP4*,  
| | *FBXW7*  
| Familial clear cell RCC | Unknown | Unknown | Clear cell RCC  
| Hereditary hyperparathyroidism-jaw tumor syndrome | Unknown | 1q25-31 | Parafibromin  
| |  
| Papillary thyroid carcinoma with associated neoplasia | Unknown;  
| | potential candidate genes:  
| | *NRAS*,  
| | *NTRK1*  
| | 1q21 | Unknown | Papillary RCC and papillary adenoma; possibly renal oncocyoma  

P.I(2):117

Image Gallery  
Associated Neoplasms

(Left) CCRCC typically shows tumor cells with optically clear cytoplasm because of lipid and glycogen contents. Tumor cells are arranged in solid nests separated by intricate meshwork of delicate vasculatures imparting a chicken-wire appearance. (Right) Kidney section shows multiple small CCRCCs. Multifocal and bilateral CCRCCs are common in hereditary RCCs such as VHL and in constitutional Chr 3 translocation patients. Familial CCRCC tends to present with solitary tumor.
Kidney with multiple papillary adenomas (PAs) is seen in papillary thyroid carcinoma with associated neoplasia. PAs exhibit simple papillae lined by small cuboidal cells with low-grade nuclei. Cytology resembles PRCC type 1 cells and is distinguished only by size (> 5 mm). (Right) Tc-99m MIBI shows parathyroid adenoma inferior to the inferior pole of the right thyroid lobe. Activity is also evident in salivary glands. Gross specimen shows encapsulated brown-tan parathyroid adenoma.

Coronal bone CT demonstrates a very large, bilobed, ossifying fibroma with a large maxillary antral portion and smaller component extending into the buccal space. Peripheral ossification of the maxillary component is noted. (Right) Coronal graphic illustrates a left thyroid lobe differentiated thyroid carcinoma with metastatic nodal disease in the left paratracheal chain and superior mediastinum.

Howel-Evans Syndrome/Keratosis Palmares and Plantares With Esophageal Cancer

Howel-Evans Syndrome/Keratosis Palmares and Plantares With Esophageal Cancer

Christine J. Ko, MD
Clinical photograph shows plantar keratoderma. The histopathology of keratoderma is characterized by marked hyperkeratosis. (Courtesy L. Milstone, MD.)
Hematoxylin & eosin shows squamous cell carcinoma (SCC) of the esophagus. It has the same features as SCC elsewhere. Note the abnormal keratinization in the keratin “pearl” (Courtesy E. Montgomery, MD.)

**TERMINOLOGY**

**Synonyms**
- Tylosis with esophageal cancer
- Tylosis-esophageal cancer, tylosis esophageal cancer
- Focal nonepidermolytic palmoplantar keratoderma with carcinoma of esophagus
- Tylosis = palmoplantar keratoderma

**EPIDEMIOLOGY**

**Incidence**
- Unclear
- Originally described in 2 United Kingdom families in 1958
  - These 2 families possibly related
- Also described in other countries (e.g., North America, India, Germany)

**GENETICS**

**Inheritance**
- Autosomal dominant
- Linkage to chromosome 17q25
  - Missense mutations in RHBDF2 gene

**CLINICAL IMPLICATIONS AND ANCILLARY TESTS**

**Cutaneous Findings**
- Palmoplantar keratoderma
  - Distribution
    - May affect palms only, soles only, or both
    - May be accentuated on weight-bearing areas of soles
    - May be exacerbated by friction
May be diffuse
- Age at presentation
  - Typically between ages 6 and 12 (type A)
  - Early childhood presentation (before age 5) termed type B, with more benign course
  - Rarely present at birth
- Worsens with friction
  - e.g., heavy footwear
  - e.g., manual labor
  - May or may not be associated with hyperhidrosis
- Squamous cell carcinoma
  - May develop in areas of tylosis
  - Often presents as ulcerated area
- Rare findings
  - Follicular papules on body
  - Sparse hair

Gastrointestinal Symptoms/Findings
- Gastroesophageal reflux disease
- Esophageal ulcers
  - Ulcers
  - Strictures
- Esophageal squamous cell carcinoma

Oral Findings
- Mucosa
  - Oral leukoplakia
- Teeth
  - Premature loss
  - Poor dental enamel

ASSOCIATED NEOPLASMS

Esophageal Cancer
- United Kingdom kindreds
  - Developed at mean age of 45
  - Estimated 95% chance of carcinoma by age 65
- American kindred
  - Developed later (6th, 7th decades)

CANCER RISK MANAGEMENT

Esophageal Cancer
- No clear guidelines
- Estimated 70% of those with palmoplantar keratoderma ultimately develop esophageal carcinoma
- Screening has been recommended from age 20

Bronchial Cancer
- Unclear prevalence (much lower than esophageal cancer)
- No clear screening guidelines

Squamous Cell Carcinoma of the Skin
- Unclear prevalence
- Frequent skin examination
- Biopsy of any ulcerated areas

DIFFERENTIAL DIAGNOSIS
Focal Palmoplantar and Oral Mucosa Hyperkeratosis Syndrome
- Inheritance
  - Autosomal dominant
- Clinical findings
  - Palmoplantar keratoderma
  - Oral leukoplakia of gingiva
- Associations
  - No association with esophageal cancer
Acquired Tylosis as Paraneoplastic Phenomenon
- Acquired later in life (not inherited)
- Clinical findings
  - Palmoplantar keratoderma
  - Internal carcinoma
    - e.g., bronchogenic
- Family history
  - Negative for esophageal/bronchogenic cancer or tylosis

Dyskeratosis Congenita
- Inheritance
  - Often X-linked recessive
- Genetics
  - Often mutation in DKC1 gene that encodes dyskerin
- Clinical findings
  - Oral leukoplakia
  - Palmoplantar keratoderma
  - Nail dystrophy
  - Reticulated hyperpigmentation of skin
  - Bone marrow failure
- Associations
  - Increased risk of squamous cell carcinoma of
    - Oropharynx
    - Esophagus
    - Bronchus
    - Rectum
    - Cervix/vagina
  - Increased risk of
    - Myelodysplasia, acute myelogenous leukemia
    - Hodgkin disease
    - Gastrointestinal adenocarcinomas

Hidrotic Ectodermal Dysplasia
- Inheritance
  - Autosomal recessive
- Genetics
  - Mutation in GJB6 gene that encodes connexin 30
- Clinical findings
  - Alopecia
  - Nail dystrophy
  - Clubbing of fingers
  - Palmoplantar keratoderma

Pachyonychia Congenita
- Inheritance
  - Autosomal dominant
- Genetics
  - Secondary to mutations in KRT6/16/17 genes
- Clinical findings
  - Palmoplantar keratoderma
  - Thickened nails
  - Oral leukoplakia
  - Some types associated with steatocystoma multiplex

Other Palmoplantar Keratodermas
- Inherited but isolated (no other findings)
  - Examples
    - Unna-Thost syndrome
    - Vörrner syndrome
- Inherited and associated with other specific findings
  - Examples
    - Richner-Hanhart syndrome (oculocutaneous tyrosinemia)
- Olmsted syndrome (mutilating with periorificial plaques)
- Carvajal syndrome (cardiomyopathy)

SELECTED REFERENCES

Juvenile Polyposis Syndrome

Gross photograph shows multiple juvenile polyps. The larger polyps are pedunculated and multilobulated whereas the smaller ones are sessile and smooth. (Courtesy A. Srivastava, MD.)
Juvenile polyps have marked stromal expansion and cystically dilated crypts. The stroma is edematous and inflamed whereas the cysts are filled with inspissated mucin. (Courtesy A. Srivastava, MD.)

TERMINOLOGY
Abbreviations
- Juvenile polyp (JP)
- Juvenile polyposis syndrome (JPS)

Definitions
- Hamartomatous polyp
  - May occur sporadically (most juvenile polyps are nonsyndromic)
    - 90% of all polyps found in children
    - 20-50% may have > 1 polyp
    - No increase in cancer risk in sporadic JP
  - May be manifestation of inherited familial polyposis syndrome
    - Patients with JPS have increased risk of colorectal carcinoma
- Diagnostic criteria for JPS (any 1 of the following 3)
  - > 5 juvenile polyps (most patients have 50-200)
  - Presence of at least 1 JP outside of colon
  - Any number of polyps in patient with positive family history

EPIDEMIOLOGY
Incidence
- 1 in 100,000 worldwide

Age
- Typically presents in 1st decade of life

Inheritance
- 75% of cases show autosomal dominant inheritance
- 25% of cases appear de novo in patients without family history
GENETICS
Specific Mutations
- Germline mutations in SMAD4 (DPC4) gene on 18q21 present in 20-30% of JPS patients
  - Exon 9 deletion is most common abnormality
  - Patients with SMAD4 germline mutations are more likely to have polyps in upper gastrointestinal tract and positive family history
  - Significant proportion with SMAD4 mutation may also have hereditary hemorrhagic telangiectasia
    - Recent study found that 81% of JPS patients with SMAD4 mutations had hereditary hemorrhagic telangiectasia and another 14% were suspected of having it
- Germline mutations in BMPR1A gene on 10q23 present in similar proportion of JPS cases (20-30%)
- Germline mutations in ENG may also lead to JPS in unknown proportion of patients
  - Data suggest early childhood onset of polyps with ENG mutations
  - Also associated with hereditary hemorrhagic telangiectasia similar to SMAD4 mutations
- All 3 genes involved with transforming growth factor-β (TGF-β) pathway
- Older literature suggests PTEN mutations were also found in juvenile polyposis, but recent studies suggest these cases are better classified as Cowden/PTEN-hamartoma tumor syndrome instead of JPS

CLINICAL IMPLICATIONS
Presentation
- Hematochezia
- Anemia
- Diarrhea
- Prolapse

Juvenile Polyposis Coli
- Most common inherited form
- Present clinically in 1st decade of life
- Polyps confined to colon

Generalized Juvenile Polyposis
- Diffuse involvement of gastrointestinal tract
- Colon, stomach, and small intestine involved

Gastric Juvenile Polyposis
- Rare form of disease
- Polyps confined to stomach
- Patients may present with protein-losing enteropathy and mimic Cronkhite-Canada syndrome

Juvenile Polyposis of Infancy
- Rare
- Usually associated with death in infancy due to protein-losing enteropathy
- Initially thought to be autosomal recessive due to lack of family history, but recent studies have found large de novo chromosome 10 deletions containing both the BMPR1A and PTEN genes in affected individuals

Associated Manifestations
- Present in 2/3 of JPS patients
  - Hydrocephalus and mental retardation
  - Pulmonary arteriovenous malformation
  - Cleft palate and polydactyly
  - Malrotation of gut
  - Meckel diverticulum

ASSOCIATED NEOPLASMS
Colorectal Adenocarcinoma
- Mean age of developing cancer reported to be between 35 and 43 years
- Risk of developing colon cancer increases to 68% at age 60

Gastric Adenocarcinoma
- Associated with SMAD4 mutations and severe gastric polyposis

Small Intestinal and Pancreatic Adenocarcinoma
- Rare reports of duodenal, ampullary, and pancreatic adenocarcinoma in patients with JPS

CANCER RISK MANAGEMENT
Genetic Testing
Diagnostic Pathology: Familial Cancer Syndromes

- Direct sequencing of SMAD4 and BMPR1A will identify about 40-50% of cases
- Multiplex ligation probe-dependent amplification (MLPA) can pick up another 4-5% of cases by identifying large deletions and duplications in either SMAD4 or BMPR1A

Screening
- In suspected patients, endoscopic screening generally starts at ~ age 15 and consists of upper and lower endoscopy as well as small bowel imaging with either capsule endoscopy or MR enterography
- In known JPS patients, screening endoscopy should be done annually

Surgery
- If patients are symptomatic or endoscopic surveillance is not feasible due to number of polyps, then surgery may be needed
- Patients who develop dysplasia or have a high prevalence of colon cancer in their families typically have a total colectomy
  - Continued surveillance is still required after colectomy to remove polyps in rectal cuff

MACROSCOPIC FINDINGS

Gross Features
- Most patients have > 50 polyps
- Most polyps are pedunculated (> 2/3)
- Sessile polyps are infrequent, usually smaller in size, and often with smooth surface
- Size is variable, but most measure ~ 1.0 cm in greatest dimension
- Larger lesions are multilobulated and show surface ulceration
- Gross appearance may resemble adenomas
- Cut surface in larger polyps is soft, gelatinous due to mucin-filled cysts

MICROSCOPIC FINDINGS

Histologic Features
- Epithelial component in colonic polyps
  - Surface erosion or ulceration
  - Granulation tissue cap may be present
  - Markedly dilated cysts
    - Cysts filled with mucin or distended with crypt abscesses
    - Epithelium lining cysts is of variable height and may be completely flattened
  - Hyperplastic regenerative changes may be present
  - Random sections from grossly normal mucosa in colectomy specimens may show early “incipient” JP with cystically dilated and inflamed crypts
  - Dysplasia or carcinoma may be present
  - Crypt:stroma ratio in polyps is higher in patients with SMAD4 mutations as compared to those with BMPR1A mutations
- Stromal component in colonic polyps
  - Marked expansion of lamina propria
  - Loose edematous and inflamed (neutrophils or lymphoid follicles) stroma
    - Degree of inflammation is variable
    - Mucin extravasation from ruptured cysts accentuates inflammatory response
  - Hemorrhage and hemosiderin deposits present in larger polyps with torsion injury
  - Smooth muscle proliferation may be present in larger pedunculated polyps
    - Must distinguish from Peutz-Jeghers polyp
  - Ganglioneuromas have been described previously, but these cases were probably PTEN-hamartoma/Cowden syndrome, not JPS
  - Polyps from patients with BMPR1A have been reported to have a higher stroma:crypt ratio than those from patients with SMAD4 mutations
- Gastric polyps
  - Cystic epithelial component lined by foveolar-type epithelium
  - Variable degree of inflammation
  - Polyps resemble hyperplastic polyps or those seen in Cronkhite-Canada syndrome
    - Difficult to separate various hamartomatous gastric polyps without clinical information
- Dysplasia and carcinoma
  - Not present in sporadic juvenile polyps


P.I(2):124

Gastric polyps
- Cystic epithelial component lined by foveolar-type epithelium
- Variable degree of inflammation
- Polyps resemble hyperplastic polyps or those seen in Cronkhite-Canada syndrome
  - Difficult to separate various hamartomatous gastric polyps without clinical information

Dysplasia and carcinoma
- Not present in sporadic juvenile polyps
May be present in larger (> 1 cm) polyps in syndromic patients

- Pathologist must be wary of overinterpreting reactive atypia due to inflammation
- Prevalence of dysplasia ranges from 8-20%
- Higher incidence of dysplastic change present in polyps with villous architecture
- JPS patients may have adenomas as well as juvenile polyps
- Adenocarcinomas are more common in distal colon and rectum
- Carcinoma involving stomach or small bowel is rare

**Differential diagnosis**

- **Inflammatory polyposis**
  - Small polyps are identical to inflammatory pseudopolypos
  - Biopsies of flat mucosa to rule out idiopathic inflammatory bowel disease may be warranted in some cases
- **Peutz-Jeghers polyposis (PJP)**
  - Pedunculated juvenile polyps with prolapse-type changes may mimic those seen in PJP
  - Lobules in PJP are separated by compact smooth muscle bundles, unlike disarrayed proliferation seen in some juvenile polypos
  - Epithelial component in PJP is arranged in distinct lobular configuration
  - Musc chuckaneous manifestations typical of PJP not seen in juvenile polyposis
- **PTEN-hamartoma tumor syndrome/Cowden syndrome**
  - Polyps may be indistinguishable, but stroma in Cowden more fibrotic and less inflamed
- **Cronkhite-Canada syndrome (CCS)**
  - Polyps may be very similar to JPS
  - Ectodermal manifestations (onychodystrophy, alopecia, hyperpigmentation) diagnostic of CCS
- **Hereditary mixed polyposis syndrome**
  - Patients get juvenile polypos, serrated polyps, and adenomas
  - Easily confused with JPS since patients with JPS often have adenomas
  - Autosomal dominant inheritance
  - Increased risk of colon cancer
  - No extraintestinal manifestations

**SELECTED REFERENCES**

P.I(2):125

Image Gallery
Microscopic Features

(Left) This low-power view shows a small juvenile polyp from a resection specimen. There is cystic dilatation of glands without much in the way of stroma. (Right) This low-power view of a larger juvenile polyp shows the overall lobular growth pattern with an ulcerated surface. This polyp has abundant stroma as well as cystically dilated glands.

(Left) Hematoxylin & eosin shows a juvenile polyp with marked cystic change and crypt abscess formation. The stromal inflammation in such polyps may be in the form of neutrophils, lymphoid follicles, or both. (Courtesy A. Srivastava, MD.) (Right) Larger pedunculated juvenile polyps may undergo prolapse and show a prominent smooth muscle proliferation that may be mistaken for a Peutz-Jeghers polyp. (Courtesy A. Srivastava, MD.)
Regenerative changes in juvenile polyps may mimic serrated or adenomatous polyps. Prominent hyperplastic regenerative change is present in this juvenile polyp with inflamed granulation tissue on the surface. (Courtesy A. Srivastava, MD.)

Adenoma-like regenerative changes are seen in this sporadic juvenile polyp in a 4-year-old child. Juvenile polyps in syndromic patients may harbor truly dysplastic foci or even carcinoma. (Courtesy A. Srivastava, MD.)

Li-Fraumeni Syndrome/Li-Fraumeni-Like Syndrome

Susan C. Lester, MD, PhD
David G. Hicks, MD
Breast cancer is the most common malignancy associated with LFS and occurs at a median age of 33 years. The majority are poorly differentiated but positive for hormone receptors.
Over 1/2 of breast carcinomas occurring in women with LFS overexpress HER2. This is much higher than breast cancers in general (~ 20%).

**TERMINOLOGY**

**Abbreviations**
- Li-Fraumeni Syndrome (LFS)
- Li-Fraumeni-Like (LFL) syndrome

**Synonyms**
- LFS
  - Sarcoma family syndrome of Li and Fraumeni
  - Sarcoma, breast, leukemia, and adrenal gland (SBLA) syndrome
  - Online Mendelian Inheritance in Man (OMIM) #151623

**Definitions**
- LFS
  - Constellation of tumor types occurring in patients and kindreds
    - 0-10 years: Brain tumors, adrenal cortical carcinomas, soft tissue sarcomas, and leukemia
    - 11-20 years: Bone sarcomas
    - > 20 years: Breast cancers and brain tumors
  - Autosomal dominant inheritance
  - Classic LFS criteria
    - Individual (proband) diagnosed with sarcoma before age 45
    - 1st-degree relative with any cancer before age 45
    - 1st- or 2nd-degree relative with any cancer before age 45, or sarcoma at any age
  - ~ 70-80% of individuals with classic LFS criteria carry a germline TP53 mutation
- LFL syndrome
  - Birch definition requires following 3 criteria
- Patient diagnosed with any childhood cancer or sarcoma, brain tumor, or adrenal cortical carcinoma before age 45
- 1st- or 2nd-degree relative with sarcoma, leukemia, breast cancer, brain tumor, or adrenal cortical carcinoma, or leukemia at any age
- 1st- or 2nd-degree relative with any cancer diagnosed before age 60
  - Eeles definition
    - 2 first- or second-degree relatives with sarcoma, leukemia, breast cancer, brain tumor, or adrenal cortical carcinoma at any age
  - ~ 40% of individuals with LFL carry a germline TP53 mutation

**EPIDEMIOLOGY**

**Population Incidence**
- TP53 germline mutations
  - 1/5,000 to 1/25,000 individuals
  - A population in southeastern Brazil has 1/300 incidence
    - Due to specific mutation R337H (c.1010G > A, p.Arg337His)
    - Lifetime risk of ~ 50-60% for cancer
    - High incidence of childhood adrenal cortical carcinomas
    - Also increased risk for thyroid cancer and renal cancer; these cancers are not typical of LFS in other kindreds

**Incidence Among Women With Breast Carcinoma**
- TP53 germline mutations are associated with ~ 1% of breast carcinomas in women < 40 years of age
- Responsible for ~ 3% of all breast cancers due to a germline mutation

**Modifiers of Risk**
- Increased sensitivity to ionizing radiation
- Radiation exposure may increase risk of malignancy

**GENETICS**

**TP53 Gene**
- Located on 17p13.1
  - 20 kb, 11 coding exons, 393 amino acids
- Belongs to a family of growth-regulating genes
- Autosomal dominant inheritance
  - Lifetime risk higher and age of onset earlier in women than in men
- Types of germline TP53 mutations
  - Majority of cases (~ 75%) are missense mutations
    - Most are within central DNA binding domain: 85% in exons 5 through 8
    - Altered protein can have a dominant-negative effect: Abnormal protein interferes with function of wild-type protein
    - Unlike other recessive germline tumor suppressor genes, 2/3 of tumors in individuals with missense mutations retain the wild-type allele
    - Retention likely due to lower selective pressure to lose wild-type protein
  - Minority of cases are null mutations
    - May be due to nonsense mutations, splice mutations, deletions, or insertions
    - Results in nonfunctional protein
    - Loss of wild-type allele is necessary to alter normal P53 function
    - Acts like other recessive tumor-suppressor genes: Majority of tumors exhibit loss of the wild-type allele

- 535 germline mutations in 532 families have been reported
  - TP53 Mutation Database is maintained by the International Agency for Research on Cancer (IARC) and is updated each year

**Function of TP53 Protein**
- Central role in cell cycle control, DNA replication, DNA repair, and apoptosis
  - Binds to double-stranded DNA
  - Transactivation function for promoter sequences
- Activated in response to various stress signals
- Loss of function is thought to suppress a mechanism of protection against accumulation of genetic alterations
  - Cell cycle arrest allows repair of genetic damage prior to DNA replication and fixation of mutations
Terminally damaged cells undergo apoptosis

**Li-Fraumeni-Like Syndrome**

- Individuals who fulfill some but not all criteria for LFS
- ~20-40% carry germline TP53 mutations
- Others due to mutations in BRCA2, Fanconi genes (BRIP1, PALB2, and RAD51C), and DNA mismatch repair genes
- In the past, some cases of LFL were attributed to CHEK2 germline mutations
  - Most common tumor associated with CHEK2 is early-onset breast carcinoma
  - Full spectrum of tumors associated with LFS is not seen

**CLINICAL IMPLICATIONS AND ANCILLARY TESTS**

**Population to be Screened**

- When strict criteria are met, TP53 mutations are found in 60-80%
- If less strict criteria are used (LFL), TP53 mutations are found in 15-35%

**Chompret Criteria for Screening**

- Individual (proband) must have 1 of the following tumors before age 46: Soft tissue sarcoma, osteosarcoma, premenopausal breast cancer, brain tumor, adrenal cortical carcinoma, leukemia, or lepidic pattern of lung adenocarcinoma, and at least 1 of 3 criteria listed below
  - At least 1 first- or second-degree relative with an LFS tumor before age 56 or with multiple tumors
    - Breast cancer is not included if proband has breast cancer
  - Proband has multiple tumors (not including breast cancers), 2 of which belong to LFS tumors and 1st of which occurred before age 46
  - Proband has adrenal cortical carcinoma or choroid plexus tumor, irrespective of family history
- 30% of individuals fulfilling these criteria have a germline TP53 mutation

**Genetic Testing**

- DNA sequencing is gold standard for identifying TP53 mutations
- Sequence analysis of exons 2 through 11 detects ~95% of mutations
- Deletions of the gene, promoter region, or exon 1 may be present in ~1% of families
- Duplications, inversions, large deletions, and mutations in noncoding regions may not be detected by standard sequence analysis

**Immunohistochemistry for p53**

- TP53 protein degrades rapidly and has 20-minute half-life
  - Some mutant forms of p53 cannot transcriptionally activate MDM2
  - Loss of this negative feedback loop results in p53 accumulation
- Immunohistochemistry does not detect normal levels of p53 in nontumor cells
  - Increased p53 protein is also not seen in normal cells of individuals with germline mutations
- Many antibodies to p53 are available
  - Target different epitopes on the protein
  - May detect only wild-type protein, mutant protein, or both
- Increased p53 protein is only associated with ~2/3 of mutations
  - Some mutant forms of p53 have half-lives of up to 4 hours
  - Strong diffuse (>10-20%) immunoreactivity is a specific, but not sensitive, test for p53 mutations
- Weak &/or focal p53 positivity may be present when mutations are absent

**ASSOCIATED NEOPLASMS: TP53**

**Any Tumor**

- <20% of affected individuals develop a cancer in childhood
- >90% of affected individuals develop some type of tumor by age 70
  - 80% are breast, sarcoma, brain, or adrenal tumors
  - 7-20% of individuals with multiple primary tumors have LFS
- Risk for malignancy is 100x greater than for unaffected individuals
- Penetrance varies with type of mutation
- Individuals with cancer have greater risk of developing 2nd cancer
  - 15% have 2 cancers, 4% have 3 cancers, 2% have 4 cancers
  - Increased risk if 1st cancer occurred at early age
  - Radiation treatment for 1st cancer may elevate risk
Breast Cancer
- Usually occurs 6-12 years after 1st cancer
- Most common malignancy in LFS (~33% of total)
- Increased risk for females starts at age 20 and continues into adulthood
  - 6% of women diagnosed before age 31 have a germline TP53 mutation
- ~55% of women will develop breast cancer by age 45 (average age at diagnosis is 33)
  - ~ 100% lifetime risk for women
  - ~ 2% per year will develop subsequent contralateral breast cancer
    - Overall, 25% will have multiple breast cancers
  - Breast cancer in men has not been reported
- ~55% of invasive carcinomas are positive for hormone receptors and HER2
  - This pattern is present in <20% of sporadic breast carcinomas
  - Least common pattern is negativity for both hormone receptors and HER2 (present in ~5%)
- Increased incidence of phyllodes tumor reported in LFS compared with general population

Soft Tissue Sarcoma
- 2nd most common malignancy in this syndrome (~20% of total)
  - Many types: Only Ewing sarcoma has not been associated with LFS
- Most commonly develop in childhood (<10 years of age)
  - 5-10% of children with sarcomas have a germline TP53 mutation
- Rhabdomyosarcoma most common in individuals <5 years of age
  - 9% of individuals with this sarcoma have LFS

Osteosarcoma
- ~15% of LFS tumors
  - 2-3% of persons with osteosarcoma have LFS
- Most commonly develop during adolescence
- 10% of individuals with an osteosarcoma diagnosed before age 20 have a germline TP53 mutation

Brain Tumors
- Often develop in childhood
  - 2-10% of children with brain tumors have LFS
- Smaller 2nd peak in incidence in 4th-5th decades
- Glioblastomas are most common type (13%)
  - Also astrocytomas and medulloblastomas
- Choroid plexus tumors in children are characteristic

Adrenal Cortical Carcinoma
- 80% of children with this carcinoma have LFS
  - Median age of onset is 3 years
  - Some are due to de novo mutations
- Cases in adults usually occur before 50 years of age

Hematologic Malignancies
- Include both lymphoma and leukemia

Other Cancers
- Lung cancer (lepidic pattern)
- Gastrointestinal cancers (colon, gastric, pancreatic)

CANCER RISK MANAGEMENT
Screening
- In USA, National Comprehensive Cancer Network (NCCN) has published screening guidelines
  - Children and adults should have yearly comprehensive physical examinations including skin and neurological assessment
  - Breast cancer
    - Breast self-exam (BSE) training and regular monthly BSE starting at age 18
    - Clinical breast exam, starting at age 20-25 years (or 5-10 years before earliest breast cancer in family, whichever 1st), 2x per year
    - Annual mammogram &/or MR when clinical breast exams start
    - Prophylactic mastectomy can be considered
  - Men and women should be screened for colorectal cancer every 2-5 years starting at age 25
  - Organ targeted surveillance may be performed depending on pattern of cancers in specific families

SELECTED REFERENCES

Image Gallery
Tumors Associated With Li-Fraumeni Syndrome

(Left) The majority of breast carcinomas associated with Li-Fraumeni syndrome (LFS) are positive for ER and PR.
(Right) Immunohistochemical studies for p53 detect mutant forms that do not undergo normal degradation, allowing the protein to accumulate in the nucleus. Mutant forms that do undergo degradation or mutations that result in a truncated protein will not be detected. Overall, immunohistochemistry probably detects ~2/3 of tumors with mutations.

(Left) Soft tissue sarcomas are the 2nd most common type of tumor associated with LFS (~20%). All types (except Ewing sarcoma) occur. Rhabdomyosarcoma (seen here) is most common in affected children < 5 years of age. Overall, 9% of individuals with this tumor have a germline TP53 mutation. (Right) Approximately 15% of tumors associated with LFS are osteosarcomas. These are the most common type of tumor to be diagnosed in adolescents with this syndrome.
There are 2 peaks for brain tumors in LFS: Childhood and in the 4th and 5th decades. Choroid plexus carcinomas, such as this example, are frequently seen in children. (Courtesy P. Burger, MD.) (Right) This adrenal cortical carcinoma displaces the normal adrenal gland. In 80% of children with this tumor, a germline TP53 mutation will be present. Mutations at codons 152, 158, and 337 are particularly common. A few cases are due to de novo mutations.

Lynch Syndrome
Colon cancer from a Lynch syndrome patient shows a large number of tumor-infiltrating lymphocytes (TILs). These TILs are often seen in Lynch syndrome cancers.

This Lynch syndrome adenoma has a large number of adenoma-infiltrating lymphocytes. Although not specific, these lymphocytes are a marker of Lynch syndrome.

TERMINOLOGY

Synonyms
- Hereditary nonpolyposis colorectal cancer (HNPCC) (old term for Lynch syndrome)

EPIDEMIOLOGY

Prevalence
- Lynch syndrome is most common heritable cause of cancer
- ~3% of all colorectal cancers (CRCs)

GENETICS

Lynch Syndrome
- Autosomal dominant
- Mutations in genes coding for mismatch repair proteins (MLH1, PMS2, MSH2, MSH6)
  - Mutation in EPCAM (a gene immediately adjacent to MSH2) leads to epigenetic silencing of MSH2
  - Immunostains for MSH2 and MSH6 will be negative, implying an MSH2 mutation, but sequencing will not find MSH2 mutation

Constitutional Mismatch Repair-Deficiency (CMMR-D) Syndrome
- Autosomal recessive (very rare)
  - Patient inherits a mutated copy of mismatch repair gene from each parent (biallelic mutation)
  - Early childhood cancers (lymphoma/leukemia plus Lynch-associated solid tumors)
  - Café au lait spots similar to neurofibromatosis type 1

CLINICAL IMPLICATIONS AND ANCILLARY TESTS

Clinical Features
- Multiple epithelial cancers occur at average age of ~20 years younger than expected
Several guidelines have been proposed to help identify patients who should be tested for Lynch syndrome
  - Amsterdam criteria II
    - At least 3 relatives with a Lynch-associated cancer
    - 2 or more successive generations affected
    - 1 or more relatives diagnosed before age 50
    - 1 should be a 1st-degree relative of the other 2
    - Familial adenomatous polyposis must be excluded
  - Revised Bethesda guidelines
    - CRC diagnosed prior to age 50
    - Presence of synchronous or metachronous CRC or other Lynch-associated tumor, regardless of age
    - CRC with histologic features suggestive of microsatellite instability (MSI) in patients < age 60
    - CRC diagnosed in 1 or more 1st-degree relatives with a Lynch-associated tumor, with 1 of the cancers diagnosed prior to age 50
    - CRC diagnosed in 2 or more 1st-degree or 2nd-degree relatives with Lynch-associated tumors, regardless of age

Neither of these guidelines is foolproof; hence, many studies recommend testing all CRCs for Lynch syndrome

Immunohistochemistry (IHC)
  - Immunostains for MLH1, PMS2, MSH2, and MSH6 have become fairly routine
    - 5-10% false-negative rate, as protein may be antigenic but still not function due to mutation
    - Advantage of IHC over microsatellite instability (MSI-H) testing is that IHC reveals which gene is mutated

Microsatellite Instability
  - Mutations in proofreading genes lead to replication errors in DNA
    - These replication errors can be detected in short DNA repeats called microsatellites
    - ~ 95% of all Lynch syndrome colorectal cancers have MSI-H
      - Can be tested easily using formalin-fixed paraffin-embedded tissue
      - Need both normal and neoplastic tissue for comparison
  - MSI-H is also seen in 10-15% of sporadic colon cancers (not specific for Lynch syndrome)
    - Sporadic tumors often have BRAF V600E mutations &/or methylation of MLH1
    - Neither of these are present in Lynch tumors

ASSOCIATED NEOPLASMS
Gastrointestinal Tract Tumors
  - Colorectal cancer
    - 80% lifetime risk
    - Histologic features are often characteristic
      - Increased numbers of tumor-infiltrating lymphocytes and a Crohn-like reaction around edge of tumor
      - More likely to be well or poorly differentiated
      - More likely to have mucinous differentiation and lack dirty necrosis
      - More often right sided
      - More likely to have a circumscribed growth pattern and to exhibit histologic heterogeneity
  - Adenocarcinoma of stomach, small bowel, appendix, ampulla, and biliary tree
    - May share some of histologic features listed above for colon cancers

Nongastrointestinal Tract Tumors
  - Endometrium
    - 40-60% lifetime risk
    - Endometrioid carcinomas with mucinous differentiation, histologic heterogeneity, dedifferentiation, and increased host response
  - Ovaries
    - 4-12% lifetime risk
    - Clear cell and endometrioid carcinomas
  - Adrenal
    - As many as 5% of adrenal cortical carcinomas may be associated with Lynch syndrome
  - Prostate
Lynch patients have 2x the risk of prostate cancer as general population

- Kidney, ureters, bladder
  - Urothelial carcinomas
    - MSH2 mutations may selectively increase risk of bladder cancers compared to other mismatch repair gene mutations

- Skin
  - Sebaceous neoplasms and multiple keratoacanthomas = Muir-Torre syndrome
  - Café au lait spots in CMMR-D syndrome

- Brain
  - Glioblastoma in Turcot syndrome variant of Lynch syndrome

- Leukemia/lymphoma
  - Occurs in patients with CMMR-D

CANCER RISK MANAGEMENT

Surveillance Endoscopy
- Every 1-2 years starting between ages 20 and 25

Surgery
- Prophylactic colectomy is an option, but most patients opt for colonoscopic surveillance

SELECTED REFERENCES

<table>
<thead>
<tr>
<th>Mutation/DNA Abnormality</th>
<th>IHC Staining Pattern</th>
<th>Additional Testing/Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>MLH1</td>
<td>Negative stains for MLH1 and PMS2</td>
<td>BRAF wild type, negative for methylation, MLH1 sequence</td>
</tr>
<tr>
<td>MSH2</td>
<td>Negative stains for MSH2 and MSH6</td>
<td>Sequence MSH2; if normal, look for EPCAM mutation</td>
</tr>
<tr>
<td>MSH6</td>
<td>Negative stain for MSH6</td>
<td>Sequence MSH6</td>
</tr>
<tr>
<td>PMS2</td>
<td>Negative stain for PMS2</td>
<td>Sequence PMS2</td>
</tr>
<tr>
<td>EPCAM</td>
<td>Negative stains for MSH2 and MSH6</td>
<td>After MSH2 sequence is normal, sequence EPCAM, possible IHC for EPCAM</td>
</tr>
</tbody>
</table>

Image Gallery
Microscopic Features and Molecular Tests
Lynch syndrome tumor shows well-differentiated adenoma-like glands. Increased numbers of tumor-infiltrating lymphocytes and a Crohn-like reaction around edge of tumor suggest Lynch syndrome. The Lynch-associated tumors are likely to be circumscribed and to exhibit histologic heterogeneity. Poorly differentiated colon cancer from Lynch syndrome patient shows large numbers of tumor-infiltrating lymphocytes.

Well-differentiated Lynch syndrome colon cancer shows mucinous differentiation on the right. Even focal mucinous differentiation can be a tip-off that the patient may have Lynch syndrome. Well-differentiated Lynch syndrome colon cancer shows mucinous differentiation. Lynch syndrome-associated tumors are more likely to have mucinous differentiation and lack dirty necrosis.
(Left) Image shows the typical appearance of microsatellite stable (MSS), non-Lynch syndrome colon cancer with abundant dirty necrosis. Dirty necrosis is much more common in non-Lynch microsatellite stable tumors. (Right) PCR gel electrophoresis shows extra bands in the tumor lanes of specimens 1, 2, 3, 4, and 5, indicating microsatellite instability. Note identical patterns in normal and tumor samples in specimens 6, 7, and 8, indicating microsatellite stability. (Courtesy S. Gruber, MD.)

P.I(2):133

(Left) This MSS colorectal carcinoma shows strong nuclear staining for MLH1. Note the dirty necrosis typical of MSS carcinomas. Immunostains for PMS2, MSH2, and MSH6 were also positive. (Right) Immunohistochemical stain for PMS2 shows nuclear staining for PMS2 in inflammatory cells but no staining in the tumor cells. Stains for MLH1, MSH2, and MSH6 were positive in the tumor. This patient had a mutation in PMS2.
Medium-power view shows a sebaceous adenoma, a type of neoplasm seen in patients with Muir-Torre syndrome, a variant of Lynch syndrome. (Right) Immunostain for MSH2 shows positive nuclear staining in lymphocytes but negative staining in the nuclei of the sebaceous adenoma, indicative of a deficient mismatch repair protein in the neoplastic cells. This is consistent with Muir-Torre syndrome due to an MSH2 mutation.

This pedigree shows a family with Lynch syndrome and a patient whose DNA is sequenced in the next image. Note the autosomal dominant inheritance pattern. The age of cancer onset is younger in successive generations. (Right) This DNA sequencing chromatograph from the patient in the previous pedigree chart shows a frame-shift mutation in MSH2.

Melanoma/Pancreatic Carcinoma Syndrome

Melanoma/Pancreatic Carcinoma Syndrome

Christine J. Ko, MD
Clinical photograph of a nodular-type melanoma shows a darkly pigmented elevated lesion with irregular borders on the chest. (Courtesy J. Wu, MD.)
Low-power examination of a nodular melanoma shows a large, expansile dermal nodule with irregular pigmentation and areas of epidermal thinning and necrosis. (Courtesy S. Dadras, MD.)

TERMINOLOGY
Definition
- Hereditary melanoma
  - In geographic areas with high sun exposure: ≥ 3 affected blood relatives
  - In geographic areas with lower sun exposure: ≥ 2 affected blood relatives

EPIDEMIOLOGY
Incidence of Hereditary Cutaneous Melanoma
- 5-7% of cutaneous melanoma patients are from high-risk families

Incidence of Hereditary Pancreatic Cancer
- Considered to be low (1-3%), but possibly up to 10% of pancreatic cancer has a familial basis

GENETICS
CDKN2A Mutations
- Splice sites or ankyrin repeats 3 and 4 tend to be affected
- Lifetime risk of melanoma: ~75%
- Lifetime risk of pancreatic cancer may be close to 20%
- Mutations are generally inactivating

Inheritance
- Generally autosomal dominant

CLINICAL IMPLICATIONS AND ANCILLARY TESTS
Clinical Presentation
- Familial atypical multiple mole-melanoma syndrome
  - Increased risk of cutaneous melanoma and pancreatic cancer
  - Patients may have > 100 atypical melanocytic nevi
Some kindreds have cutaneous melanoma and pancreatic cancer without increased numbers of atypical melanocytic nevi

Clinical Risk Factors
- Number of relatives affected by melanoma or pancreatic cancer
- CDKN2A mutation carrier
- Number of nevi, especially if > 50
- Very fair skin with inability to tan
- Presence of many freckles
- Hair color, especially red or blonde
- Eye color, especially blue
- Degree/amount of sun exposure
  - Presence of extensively sun-damaged skin

ASSOCIATED NEOPLASMS

Malignant Melanoma
- Cutaneous Dysplastic Melanocytic Nevi (Atypical Melanocytic Nevi, Clark Nevi)
  - Originally described in kindreds with increased risk of cutaneous melanoma
  - Subsequently described in individuals with no increased risk of cutaneous melanoma
  - Clinically dysplastic melanocytic nevi
    - Size often > 6 mm, irregular color, irregular borders, asymmetric, may have history of change, may have elevated (papular) and flat (macular) components
  - Histopathologic criteria for dysplastic melanocytic nevi
    - Atypical cytology &/or disordered architecture
      - Single melanocytes, irregular nests, bridged rete, pagetoid scatter, fibroplasia

Pancreatic Cancer
- Cumulative lifetime risk: 11-17%
- Average age is 5.8 years younger than patients affected by sporadic pancreatic cancer

Breast Cancer
- Risk is higher in kindreds without multiple atypical melanocytic nevi

CANCER RISK MANAGEMENT

Photoprotection
- Sunscreen, sun protective clothing, avoidance of sunburn

Avoidance of Other Carcinogens
- Cigarette smoking increases pancreatic cancer risk

Skin Examination
- Head-to-toe examination (including scalp and genitalia)
  - Baseline at age 10 years
  - Repeat every 6-12 months
  - May increase frequency during puberty or pregnancy
  - May use dermoscopy
  - Monthly self-examination of skin
- Baseline photography may be helpful

Suspicious Lesions
- Prompt excision and histopathologic evaluation

Education
- On photoprotection and characteristics of melanoma

Pancreatic Cancer
- Suggested age to initiate screening
  - 10 years before youngest age of diagnosis of pancreatic cancer in a given family or age 50 years
- Screening is controversial
  - Multimodal screening
    - Endoscopic ultrasound
    - Computed tomography, magnetic resonance imaging
    - Endoscopic retrograde cholangiopancreatography

DIFFERENTIAL DIAGNOSIS
Disorders With Chronic Pancreatic Inflammation

- Familial pancreatic cancer
  - Generally not associated with melanoma
  - Families with ≥ 2 first-degree relatives with confirmed exocrine pancreatic cancer
  - Exclusion of other inherited tumor syndromes with associated pancreatic cancer
    - Examples includes melanoma/pancreatic carcinoma syndrome, hereditary breast and ovarian cancer, hereditary pancreatitis
  - Mutations in BRCA2, PALB2, and ATM in some families
- Hereditary pancreatitis
- Cystic fibrosis

Other Hereditary Tumor Syndromes With Increased Risk of Pancreatic Cancer

- Peutz-Jeghers syndrome
- Hereditary breast and ovarian cancers
- Li-Fraumeni syndrome
- Hereditary nonpolyposis colorectal carcinoma
- Familial adenomatous polyposis

Hereditary Multiple Melanoma

- Some kindreds with hereditary melanoma have no associated risk of pancreatic cancer

SELECTED REFERENCES


IMAGE GALLERY

(Left) This poorly differentiated pancreatic adenocarcinoma is composed of single and clustered tumor cells. (Courtesy M. Mino-Kenudson, MD.) (Center) Clinical photograph of an atypical compound nevus shows a central papular area surrounded by an irregular macular periphery. (Courtesy P. Duray, MD.) (Right) Severely atypical compound nevus exhibits a junctional proliferation of atypical melanocytes, with fused rete ridges. (Courtesy S. Dadras, MD.)

Multiple Endocrine Neoplasia Type 1
Over 30% of MEN1 patients develop pituitary adenoma. Coronal graphic shows a small microadenoma that enlarges the right side of the pituitary gland and deviates the infundibulum toward the left.
Graphic shows a small hypervascular lesion in the pancreatic body with regional lymph node metastases. Pancreatic gastrinomas and insulinomas are commonly observed in MEN1 patients.

TERMINOLOGY
Abbreviations
- Multiple endocrine neoplasia type 1 (MEN1)

Synonyms
- Wermer syndrome
- Multiple endocrine adenomatosis type 1

Definitions
- Rare autosomal dominant disease resulting in proliferative lesions of multiple endocrine organs involving mainly parathyroid, endocrine pancreas/duodenum, and pituitary glands

EPIDEMIOLOGY
Etiology
- Caused by mutations in MEN1 gene

Pathogenesis
- MEN1 gene is a 10 exon gene that encodes 610-amino acid protein menin
- Function is unknown; may act as regulator of gene transcription, cell proliferation, apoptosis, and genome stability

Incidence
- 1:20,000-50,000

Age
- Penetrance increases with age

Gender
- 1:1 sex distribution

GENETICS
MEN1 Gene
- Located on chromosome 11q13
- Consists of 10 exons and encodes menin

**Mutation Spectrum**
- > 1,300 different mutations of MEN1 gene have been characterized
- Penetrance of MEN1 mutations is high: 45% by age 30, 82% by age 50, 96% by age 70
- Spread over entire coding and intronic sequence
  - > 60% truncating mutation, 20% missense mutation, 10% in frame deletions or insertions, 10% others
- Most are inactivating mutations, consistent with those expected in tumor suppressor gene
  - Precise role of menin in tumor suppression remains elusive
- Clinical recommendation cannot be based on genotype
  - Truncating mutations: Increased risk of pancreatic endocrine tumor
  - Frameshift mutations in exon 2: Increased incidence of pituitary tumor
- 5-25% of patients with MEN1 may not harbor germline mutation in MEN1 gene-coding region
  - Whole or partial deletions or mutations in promoter region

**Testing**
- MEN1 mutational analysis should be undertaken in
  - Index case with 2 or more MEN1-associated endocrine tumors
  - Asymptomatic 1st-degree relative
  - 1st-degree relative of MEN1 mutation carrier
  - Patients with suspicious or atypical MEN1
- Genetic counseling useful for individuals and families with nonclassic MEN1 presentations

**P.I(2):137

**ASSOCIATED NEOPLASMS**

**Presentation**
- Hyperparathyroidism (HPT)
  - Present in > 90% of MEN1 patients
    - Occurs at younger ages (19 years) than sporadic counterpart (50 years)
  - Percentage of patients who develop biochemical evidence of hyperparathyroidism increases with age
    - 43% and 94% at age 20 and 50 years, respectively
  - Most are asymptomatic, severe cases with “moans, groans, bones, and stones” as hallmarks of hypercalcemia
  - Multiglandular disorder
  - High recurrence rate
- Pituitary tumors
  - Found in 10-60% of MEN1 patients; mean age 38
  - Initial clinical manifestation of MEN1 in 10% and 20% of familial and sporadic cases, respectively
  - MEN1 pituitary adenomas tend to be larger and more aggressive than sporadic counterparts
  - Prolactinomas (PRL) (60%), growth hormone (GH) secreting adenoma (10%), adrenocorticotropic hormone (ACTH) secreting (5%), and nonsecreting adenomas (15%)
    - Women with PRL adenoma: Major clinical signs are amenorrhea, infertility, galactorrhea
    - Men with PRL adenoma: Hypogonadism
    - GH adenoma: Acromegaly
    - ACTH-secreting adenoma: Cushing disease
- Endocrine pancreatic/duodenal tumors
  - Familial Zollinger-Ellison syndrome (ZES)
    - Most frequent clinical manifestation related to duodenal &/or pancreatic gastrinoma observed in MEN1 patients
    - Initial symptoms, such as abdominal pain or gastroesophageal reflux disease, caused by gastric acid hypersecretion
    - Severe complications include bleeding, perforation, and esophageal strictures
    - In 90% of MEN1 patients with ZES, lesions are often multiple, small, and located in duodenum
  - Insulinomas
    - 2nd most frequent pancreatic tumor in setting of MEN1
Hypoglycemia

- Glucagonoma, VIPoma, and other pancreatic endocrine tumors
  - Occur in < 5% of MEN1 patients
  - ~ 80% of glucagonomas and 40% of VIPomas are malignant
  - Glucagonomas induce necrolytic migratory erythema associated with diabetes mellitus, which is secondary to abnormal glucagon secretion
  - VIPomas induce classical Verner-Morrison syndrome associated with watery diarrhea, hypokalemia, and achlorhydria

- Nonfunctioning pancreatic endocrine tumors
  - 20-40% of MEN1 patients
  - When misdiagnosed, often discovered after local compression &/or hepatic metastases

Others

- Adrenal cortical lesions
  - Observed in 20-40% of MEN1 patients
  - Often detected about 7 years after diagnosis of MEN1
  - Most are adenomas and may produce aldosterone and cortisol
  - Often small, benign, and nonfunctional
  - Surgery for lesions < 3 cm

- Gastric ECLomas
  - Thought to originate from proliferation of enterochromaffin-like (ECL) cells in gastric mucosa
  - Often small and multiple
  - Can be treated with endoscopic polypectomy if lesion is < 1 cm
  - Good prognosis

- Thymic and bronchial neuroendocrine tumor
  - Observed in 5-10% of MEN1 patients
  - Thymic carcinoids are predominantly in males
  - Poor prognosis with local invasion, recurrence, and distant metastasis

- Cutaneous proliferations
  - Present in 40-80% of MEN1 patients
  - Nodular lipomas (30%)
  - Collagenomas (5%)
  - Angiofibromas are multiple and often on face (75%)

- Soft tissue tumors
  - Esophageal leiomyoma
  - Renal angiomyolipoma
  - Malignant gastrointestinal stromal tumors

- Central nervous system tumors
  - Spinal ependymomas, meningioma, and astrocytoma have been described in MEN1 cases

CLINICAL DIAGNOSIS

Basis for MEN1 Diagnosis

- Diagnosis of MEN1 may be established by 1 of 3 criteria

  - Clinical
    - Occurrence of 2 or more primary MEN1-associated endocrine tumors: Parathyroid adenoma, enteropancreatic tumor, and pituitary adenoma

  - Familial
    - Occurrence of 1 MEN1-associated tumor in 1st-degree relative of patient with clinical diagnosis of MEN1

  - Genetic
    - Identification of germline MEN1 mutation in an individual who may be asymptomatic and has not yet developed serum biochemical or radiological abnormalities is indicative of tumor development

Diagnostic Criteria

- Presence of ≥ 2 of the following
  - Primary hyperparathyroidism with multiglandular hyperplasia &/or adenoma or recurrent primary hyperparathyroidism
  - Duodenal &/or pancreatic endocrine tumors, gastric enterochromaffin-like tumors
Both functioning and nonfunctioning or multisecreting tumor
- Anterior pituitary adenoma
  - Functioning (GH-secreting tumor, prolactinoma)
  - Nonfunctioning or multisecreting
- Adrenal cortical tumor
  - Both functioning and nonfunctioning
- Thymic &/or bronchial endocrine tumors (foregut carcinoids)
  - 1st-degree relative with MEN1

ANCILLARY TESTS
Immunohistochemistry
- Pituitary adenoma can express 1 or several hormones
  - Prolactin, ACTH, HGH, LH, FSH, TSH
- Pancreatic endocrine tumor can express 1 or several hormones
  - Insulin, gastrin, glucagon, pancreatic polypeptide, VIP, somatostatin, or serotonin

CANCER RISK MANAGEMENT
Screening
- Optimal screening age, test, and frequencies not established, but recommend starting annual biochemical test by 5 years
  - For known carriers of MEN1 mutations
    - Glucose, insulin, prolactin, and IGF-1 levels
- Finding of MEN1 in a patient has important implications for family members
  - 1st-degree relatives have 50% risk of developing disease and can often be identified by MEN1 mutational analysis
- Serologic tests
  - Starting at age 8: PTH and calcium levels
  - Starting at age 20: Fasting serum gastrin, pancreatic polypeptide, VIP, and glucagon

Treatment
- Pituitary adenoma
  - Medical and surgical treatment for prolactin or GH-producing tumors
- Endocrine pancreatic/duodenal tumors
  - Surgery in most cases
- Hyperparathyroidism
  - Total parathyroidectomy with autotransplantation or subtotal resection

Prognosis
- MEN1 patients have decreased life expectancy, and outcomes of current treatments are not as successful due to
  - Multiple tumors
    - Tumors may be larger, more aggressive, and resistant to treatment
  - Concurrency of metastases
- Same prognosis for pituitary adenoma in MEN1 as in sporadic counterparts
- Malignancy of duodenal and pancreatic endocrine tumors
  - Gastrinomas > 40%, glucagonoma > 80%, VIPoma > 40%, nonfunctioning tumor > 70%
- Prognosis for MEN1 patients might be improved by presymptomatic tumor detection

SELECTED REFERENCES

<table>
<thead>
<tr>
<th>Tumor</th>
<th>Age</th>
<th>Biochemical Test</th>
<th>Imaging Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parathyroid</td>
<td>8</td>
<td>Calcium, PTH</td>
<td></td>
</tr>
<tr>
<td>Pituitary</td>
<td>5</td>
<td>Prolactin, IGF-1</td>
<td>MR every 3 years</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>Frequency</td>
<td>Markers</td>
<td>Imaging/Other Measures</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-----------</td>
<td>----------------------------------</td>
<td>-------------------------------------------------------------</td>
</tr>
<tr>
<td>Insulinoma</td>
<td>5</td>
<td>Fasting glucose, insulin</td>
<td></td>
</tr>
<tr>
<td>Gastrinoma</td>
<td>20</td>
<td>Gastrin</td>
<td></td>
</tr>
<tr>
<td>Other pancreatic endocrine tumors</td>
<td>&lt; 10</td>
<td>Chromogranin-A, pancreatic polypeptide, glucagon, VIP</td>
<td>MR, CT, or EUS annually</td>
</tr>
<tr>
<td>Adrenal cortical tumors</td>
<td>&lt; 10</td>
<td></td>
<td>MR or CT annually</td>
</tr>
<tr>
<td>Thymic and bronchial carcinoid</td>
<td>15</td>
<td></td>
<td>CT or MR every 1-2 years</td>
</tr>
</tbody>
</table>


Image Gallery

Pituitary, Parathyroid, and Pancreatic Pathology Features

(Left) Gross image shows a pituitary macroadenoma that extends upward into the suprasellar cistern and laterally into the cavernous sinus. Pituitary adenomas are found in 10-60% of MEN1 patients. (Right) Pituitary adenomas are usually arranged in a solid pattern that is formed by a homogeneous population of cells with no nuclear pleomorphism. The nuclei exhibit neuroendocrine cell features with finely dispersed chromatin and small distinct nucleoli.

(Left) The usual finding in specimens from patients with MEN1 and parathyroid hyperplasia is an uneven enlargement...
of the parathyroid glands. In this thyroid specimen, 2 attached parathyroid glands show hyperplasia. The parathyroids are markedly enlarged and of different sizes. (Right) Parathyroid from a patient with primary hyperparathyroidism in MEN1 setting shows nodular hyperplasia with nodules composed of chief cells and oncocytic cells.

(Left) Two distinct pancreatic endocrine cell proliferations in a patient with MEN1 are shown side by side. The lesion on the left has irregular borders, and the lesion on the right is well demarcated and larger. (Right) The smaller pancreatic endocrine lesion present in this field is uniformly positive for glucagon (microadenoma) whereas the larger lesion shows a pattern of immunostaining similar to that of a normal island, indicating hyperplasia.

Multiple Endocrine Neoplasia Type 2/Familial Medullary Thyroid Carcinoma
The adrenal gland from a patient with multiple endocrine neoplasia type 2A (MEN2A) shows diffuse medullary expansion as well as a well-defined nodule.
Bilateral medullary thyroid carcinoma from a patient with MEN2A shows both nodules to be well circumscribed with a pink-tan cut surface.

TERMINOLOGY

Abbreviations

- Multiple endocrine neoplasia type 2 (MEN2)
  - Multiple endocrine neoplasia type 2A (MEN2A)
  - Multiple endocrine neoplasia type 2B (MEN2B)
- Familial medullary thyroid carcinoma (FMTC)

EPIDEMIOLOGY

Incidence

- MEN2
  - Overall incidence is 1 in 30,000 live births
    - Hereditary medullary thyroid carcinoma (MTC) accounts for 25% of all MTC
- MEN2A
  - Unknown; estimated 1.25-7.5 per 10 million per year
  - Prevalence is 1 per 35,000
- MEN2B
  - Comprises about 5% of cases of MEN2
- FMTC
  - Comprises about 10-20% of cases with MEN2
- Overall incidence of MTC in patients with familial disease is 25%
  - This group represents ~ 5% of all thyroid tumors and ~ 15% of all thyroid cancer-related deaths

Age

- MEN2A
  - In late adolescence or early adulthood
  - Peak incidence of medullary carcinoma in these patients is in 4th decade
- **MEN2B**
  - Patients usually develop medullary carcinoma early in life, diagnosed in infancy or early childhood
- **FMTC**
  - Inherited medullary carcinoma without associated endocrinopathies
    - Similar to other types of thyroid cancers, peak incidence is between age 40 and 50 years

**Gender**
- **MEN2**
  - F:M = 1:1

**GENETICS**

**RET Proto-Oncogene**
- Maps to chromosome 10q11.2 and encodes a receptor tyrosine kinase called “rearranged during transfection”
  - Tyrosine kinase plays integral role in transducing signals for growth and differentiation in tissues derived from neural crest
- **MEN2A**: RET mutation in > 98% of cases
- **MEN2B**: RET mutation in 100% of cases
- **FMTC**: RET mutation in > 85% of cases
- **MEN2** is caused by gain-of-function mutations that produce constitutively active protein or ↓ substrate specificity
- In contrast, loss-of-function mutations are associated with a subset of Hirschsprung disease (HSCR)
- Pathologic allelic variants: Major disease-causing mutations are nonconservative gain-of-function substitutions located in 1 of 6 cysteine codons in extracellular domain of encoded protein
  - Include codons 609, 611, 618, and 620 in exon 10 and codons 630 and 634 in exon 11
  - All of these variants have been identified in families with MEN2A, and some have been identified in families with FMTC
    - Mutations in these sites have been detected in 98% of families with MEN2A
  - ~95% of all individuals with MEN2B have single-point mutation at codon 918 in exon 16
  - P.I(2):141

- 2nd point mutation at codon 883 in exon 15 has been found in 3-5% of individuals with MEN2B
- For families in which MEN2A and HSCR cosegregate, models to explain how same mutation can cause gain of function and loss of function have been proposed

**Genotype-Phenotype Correlations**
- 1st clear genotype-phenotype associations to be found in inherited neoplasia syndromes: RET genotype- and MEN2-phenotype correlations
- Most striking observation: Gain-of-function mutations affected several hotspot codons, with great majority mutating cysteine residues in exons 10 and 11
- Notably, mutations of codon 634 in exon 11 are highly associated with full-blown phenotype of MEN2A, i.e., with high prevalence of pheochromocytoma and hyperparathyroidism
  - Associated fulminant course with p.C634R, which is associated with higher probability of having metastases at diagnosis of MTC than other codon 634 mutations
  - Although 25% of FMTC kindreds harbor a mutation in codon 634 (most commonly p.C634Y), p.C634R mutations are virtually absent in this subtype
  - Codon 634 mutations are also associated with development of cutaneous lichen amyloidosis (36%)
- **RET germline** p.M918T mutations are associated only with MEN2B
  - Somatic mutations at this codon are frequently observed in MTC in individuals with no known family history of MTC
    - Overrepresented in individuals with sporadic MTC who have particular germline RET variant, c.2439C/T
- Genotype-phenotype correlations suggest that exon 10 codon mutations, in particular at codons 609 and 611, have incidence of MTC in 77%, pheochromocytoma in 17%, and HPT in 3%
- Mutations involving cysteine codons 609, 618, and 620 in exon 10 of RET are associated with MEN2A or FMTC cosegregating with HSCR
- Mutations at codons 768, 804, and 891 are associated with FMTC and in rare families with MEN2A
- Mutations in codons 790 or 804 may be associated with papillary thyroid carcinoma (PTC) as well as MTC
  - 40% of family members with p.V804M mutation had concomitant medullary and PTC
American Thyroid Association Guidelines Task Force has classified mutations based on risk for aggressive MTC. These mutations may be used in predicting phenotype and recommendations for age at which to perform prophylactic thyroidectomy and to begin biochemical screening for pheochromocytoma and hyperparathyroidism.

**Clinical Implications and Ancillary Tests**

**Presentation**
- MEN2A, FMTC, and MEN2B can all be diagnosed based on clinical features.
- With advances of RET testing, genotype-specific risks, and management, molecular genetic testing is virtually mandatory.
  - Most often used to distinguish sporadic from hereditary MTC.
- **MEN2A**
  - Diagnosed clinically by occurrence of ≥ 2 specific endocrine tumors (MTC, pheochromocytoma, or parathyroid adenoma/hyperplasia) in single individual or in close relatives.
  - Makes up ~70-80% of cases of MEN2.
  - ~100% of individuals with MEN2A develop MTC.
  - 10-60% develop pheochromocytoma and 10-30% develop hyperparathyroidism.
- **MEN2B**
  - Diagnosed clinically by presence of mucosal neuromas of lips and tongue, as well as medullated corneal nerve fibers, distinctive facies with enlarged lips, asthenic “Marfanoid” body habitus, and MTC.
  - Comprises ~5% of cases of MEN2.
  - Characterized by early development of aggressive form of MTC associated with C-cell hyperplasia (CCH).
  - 50% develop pheochromocytoma.
  - 60-90% have ganglioneuromatosis.
  - Presence of mucosal neuromas is identified early in life.
  - ~100% have asthenic “Marfanoid” body habitus.
- **FMTC**
  - Historically, operationally diagnosed in families with ≥ 4 cases of MTC in absence of pheochromocytoma or parathyroid adenoma/hyperplasia.
  - Because RET mutation accounts for all clinical subtypes of MEN2, FMTC may be viewed as MEN2A with reduced organ-specific penetrance.
  - Comprises 10-20% of cases of MEN2.
  - MTC is the only clinical manifestation of FMTC.

**Laboratory Tests**
- MTC: In provocative testing, plasma calcitonin concentration is measured before (basal levels) as well as 2 and 5 minutes after intravenous administration of calcium (stimulated level).
  - Other calcitonin secretagogues, e.g., pentagastrin, are also used.
  - Reference levels for basal calcitonin vary across laboratories: <10 pg/mL for adult males and <5 pg/mL for adult females are typically considered normal.
  - Basal or stimulated calcitonin level of ≥ 100 pg/mL is indication for surgery.
  - Caution should be used when interpreting calcitonin levels in children younger than 5 years.

**Immunohistochemistry**
- MTC: Calcitonin, calcitonin gene-related peptide (CGRP), chromogranin, and CEA.
- Pheochromocytoma (PCC): Neuroendocrine markers; RET staining is not helpful to distinguish MEN2-associated PCC from sporadic counterpart.

**Imaging Features**
- May be used in predicting phenotype and recommendations for age at which to perform prophylactic thyroidectomy and to begin biochemical screening for pheochromocytoma and hyperparathyroidism.
MR is more sensitive than CT in detection of pheochromocytoma

- 18F-fluorodopamine positron emission tomography (PET) is best overall imaging modality in localization of pheochromocytomas
- Postoperative parathyroid localizing studies with Tc-99m sestamibi scintigraphy may be helpful if HPT recurs
- For preoperative adenoma localization, 3D single-photon emission CT may also be used

### ASSOCIATED NEOPLASMS

#### Precursor Lesions
- **Neoplastic C-cell hyperplasia (NCCH)**
  - NCCH is precursor lesion in hereditary MTC
  - Clusters should have > 50 C cells
  - a.k.a. C-cell carcinoma in situ or medullary carcinoma in situ
  - These lesions harbor germline RET mutations
  - Postulated that CCH progresses to medullary microcarcinoma (MMC) and eventually to MTC
  - Found in vicinity of medullary carcinomas
  - Distinguishing CCH from MMC or intrathyroid spread of MTC may be difficult

- **Adrenal medullary hyperplasia (AMH)**
  - Common in multiple endocrine neoplasia 2A and 2B; absent or very rare in other pheochromocytoma/paraganglioma syndromes
  - Adrenals removed for pheochromocytoma should be carefully examined for additional nodules as a clue to presence of MEN2
  - AMH may present with signs of catecholamine excess or be discovered incidentally after adrenalectomy for pheochromocytoma
  - Adrenal medulla normally confined to central region (“body”) of gland
    - AMH often identifiable by gross extension of gray medullary tissue into alae and tail
    - Nodules often superimposed on diffuse hyperplasia

#### Medullary Thyroid Carcinoma
- Often presents as painless “cold” nodule
  - Up to 50% have nodal metastases
  - Up to 20% may present with distant metastases
  - Symptoms of carcinoid and Cushing syndromes may be present
- Typically at junction of upper and middle 1/3 of lobe
  - Hereditary tumors are usually multicentric and bilateral
    - Sporadic tumors tend to present as solitary mass ± lymph node involvement
  - Always associated with C-cell hyperplasia in MEN2

#### Pheochromocytoma
- ≥ 30% of PCCs/paraganglioma are hereditary tumors
  - ~ 1/3 of these are MEN2 patients
  - Occult germline mutations of susceptibility genes are common in patients with apparently sporadic pheochromocytomas
- Affected by genotype
  - Multiple tumors or tumors presenting in children suggest hereditary disease
    - Sporadic tumors are solitary, usually in adults
  - Tumors with RET mutations are almost always intraadrenal

#### Parathyroid Hyperplasia and Adenoma
- 20-30% of MEN2A are associated with parathyroid hyperplasia or adenoma
- Almost never initial presentation of MEN2A
  - In contrast, hyperparathyroidism is common presentation in MEN1 (> 80%)

#### Ganglioneuroma of Gastrointestinal Tract
- ~ 40% of MEN2B-affected individuals have diffuse intestinal ganglioneuromatosis

#### Mucosal Neuroma
- May be identified in infancy and early childhood
- On palate, anterior dorsal surface of tongue, or pharynx
- Neuromas in eyelids

#### CANCER RISK MANAGEMENT

### Genetic Testing, MEN2
- RET is the only gene known to be associated with MEN2
- RET molecular genetic testing is indicated in all individuals with diagnosis of MTC, clinical diagnosis of MEN2, or primary CCH
Algorithm for testing is summarized in most recent American Thyroid Association MTC Practice Guidelines
  - Young age of onset, significant CCH, &/or multifocal disease suggest inherited disorder
  - All individuals with MTC, regardless of other features or family history, and those with clinical
    P.I(2):143

  features suspicious for MEN2 &/or with family history suspicious of MEN2 should be offered germline RET testing for exons 10, 11, and 13-16

- MEN2A: 98% of families have RET mutation in exon 10 or 11
- Families with FMTC: RET mutation in > 85%
- Individuals with features suggestive of MEN2B: Mutation analysis or sequencing of exons 16 and 15 to detect
  p.M918T and p.A883F mutations
  - If mutation negative, testing for p.V804M in exon 14 followed by sequencing of entire RET coding region should be performed
  - Although isolated p.V804M mutation is associated with FMTC, p.V804M co-occurring with 2nd RET variant seems to result in MEN2B
  - This strategy will detect > 98% of mutations in individuals with MEN2B
- RET molecular genetic testing may be warranted in subsets of individuals presenting with apparently isolated adrenal pheochromocytoma
  - Other differential diagnoses, such as VHL and succinate dehydrogenase-associated pheochromocytoma, should also be considered
  - Testing algorithms for genes associated with paraganglioma and pheochromocytoma have been proposed based on age of onset, location, laterality, malignancy, and family history
  - Unexpected germline RET mutations are rarely (if ever) found in head and neck paraganglioma in absence of other features of MEN2 or family history of MEN2 phenotype

- Other clinical presentations may prompt consideration of genetic testing
  - Exon 10 sequencing should be considered in individuals with HSCR
  - Differential diagnosis in persons with intestinal ganglioneuromatosis should include MEN2B, and RET testing may be considered
  - Rarely, germline RET mutation may not be detected in family with clinical diagnosis of MEN2A, MEN2B, or FMTC

Genetic Testing, FMTC
- Germline point mutation in RET gene on chromosome 10q11.2 is responsible for hereditary MTC

Testing of Relatives at Risk
- At-risk relatives should be periodically screened for
  - MTC with neck ultrasound examination and basal &/or stimulated calcitonin measurements
  - HPT with albumin-corrected calcium or ionized calcium
  - PCC with measurement of plasma or 24-hour urine metanephrine and normetanephrine
- RET molecular genetic testing should be offered to probands with any MEN2 subtype and to all at-risk kindreds when a germline RET mutation has been identified in an affected family member
- American Society of Clinical Oncologists identifies MEN2 as group 1 disorder, i.e., well-defined hereditary cancer syndrome for which genetic testing is considered part of standard management for at-risk family members
- RET molecular genetic testing should be performed as soon as possible after birth in all children known to be at risk for MEN2B
- In families with MEN2A or FMTC, molecular genetic testing should be offered to at-risk children by age 5 years, as MTC has been documented in childhood

SELECTED REFERENCES
Tables

Components of Multiple Endocrine Neoplasia Syndromes Type 2

<table>
<thead>
<tr>
<th>Pathology</th>
<th>FMTC</th>
<th>MEN2A</th>
<th>MEN2B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medullary thyroid carcinoma</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>C-cell hyperplasia</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Pheochromocytoma</td>
<td>0%</td>
<td>10-60%</td>
<td>50%</td>
</tr>
<tr>
<td>Hyperparathyroidism</td>
<td>0%</td>
<td>10-30%</td>
<td>0%</td>
</tr>
<tr>
<td>Lichen amyloidosis</td>
<td>0%</td>
<td>0%</td>
<td>&lt; 10%</td>
</tr>
<tr>
<td>“Marfanoid” habitus</td>
<td>0%</td>
<td>0%</td>
<td>100%</td>
</tr>
<tr>
<td>Mucosal neuromas</td>
<td>0%</td>
<td>0%</td>
<td>70-100%</td>
</tr>
<tr>
<td>Intestinal ganglioneuromatosis</td>
<td>0%</td>
<td>0%</td>
<td>60-90%</td>
</tr>
<tr>
<td>Thick corneal nerves</td>
<td>0%</td>
<td>Rare</td>
<td>60-90%</td>
</tr>
</tbody>
</table>

Familial medullary thyroid carcinoma (FMTC), multiple endocrine neoplasia type 2A (MEN2A), multiple endocrine neoplasia type 2B (MEN2B).

Differential Diagnosis of Micromedullary Thyroid Carcinoma

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Sporadic</th>
<th>Familial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multifocality</td>
<td>Rare (~ 10%)</td>
<td>Frequent (~ 90%)</td>
</tr>
<tr>
<td>Bilaterality</td>
<td>Rare (~ 10%)</td>
<td>Common (~ 70%)</td>
</tr>
<tr>
<td>Physiologic CCH</td>
<td>Common (~ 55%)</td>
<td>Rare (~ 10%)</td>
</tr>
<tr>
<td>Neoplastic CCH</td>
<td>Rare (~ 15%)</td>
<td>Frequent (90%)</td>
</tr>
</tbody>
</table>

ATA Recommendations for Prophylactic Thyroidectomy Depending on RET Mutation

ATA Risk Level Based Recommended Age for Prophylactic Thyroidectomy on RET Mutation

| Codons 838, 918, 922              | Within 1st year of life |
| Codons 768, 790, 791, 804, 891    | Consider surgery before age 5 years; may delay surgery up to 10 years if normal serum calcitonin, normal neck ultrasound, family history of less aggressive tumor |
| Codons 609, 611, 618              | Consider surgery before age 5 years; may delay surgery up to 10 years if |
normal serum calcitonin, normal neck ultrasound, family history of less aggressive tumor

Codon 634  Before age 5 years


Image Gallery
Gross and Microscopic Features in MEN2

(Left) Total prophylactic thyroidectomy plus thymectomy from a patient with a family history of MEN2 with RET mutation. The entire thyroid submitted for histological examination showed C-cell hyperplasia and 2 microscopic foci of medullary thyroid carcinoma. (Right) Calcitonin staining shows a normal distribution of C cells within a section of the mid portion of the thyroid lobes, indicating lack of C-cell hyperplasia.

(Left) C-cell hyperplasia is identified by H&E in a patient with MEN2 syndrome. C cells are also present surrounding an entire thyroid follicle. (Right) Specimen from a patient with MEN2 syndrome, who underwent prophylactic thyroidectomy, shows C-cell hyperplasia highlighted by calcitonin immunostaining. Heritable medullary thyroid carcinoma is preceded by C-cell hyperplasia (neoplastic C-cell hyperplasia).
A patient with family history of MEN2B with RET mutation had a prophylactic thyroidectomy, which showed C-cell hyperplasia and 2 foci of medullary thyroid carcinoma. Calcitonin immunostain highlights the focus of a micromedullary carcinoma. (Right) Double immunostaining section of a medullary thyroid carcinoma in a child with MEN2B shows cytoplasmic staining for calcitonin and nuclear staining for TTF-1.

Clinical, Gross, and Microscopic Features

(Left) This young patient with multiple endocrine neoplasia type 2B displays marked thickening of the lips and tongue due to ganglioneuromatosis. This patient also had a medullary thyroid carcinoma diagnosed at a young age. (Right) S100 immunostain from an intestinal biopsy in a patient with MEN2B shows proliferation of neuromatous fibers in MEN-associated intestinal ganglioneuromatosis.
Hyperparathyroidism in MEN2A is typically mild; it may range from a single adenoma to mild hyperplasia and rarely to severe hyperplasia. Coronal graphic displays the typical anatomic relationships of the paired superior and inferior parathyroid glands (view from behind). (Right) Hyperparathyroidism in MEN2A is typically mild; it may be a single adenoma or hyperplasia. This gross photograph shows mildly enlarged parathyroid glands.

Parathyroid glands in patients with MEN2A with primary hyperparathyroidism show nodular hyperplasia growth pattern. This photomicrograph shows clear (water-clear) cells, chief cells, and oxyphil cells intermixed with scattered fat cells. (Right) Parathyroid hyperplasia and neoplasia are frequently seen in patients with MEN2A. This photomicrograph of a parathyroid hyperplasia demonstrates a diffuse proliferation of mitochondrion-rich oxyphil cells (right).

Features of Pheochromocytoma
This adrenal gland shows both MEN2-associated adrenal medullary hyperplasia and pheochromocytoma. Adrenal medullary hyperplasia is characteristic of MEN2. (Right) Axial contrast-enhanced CT shows a large, well-circumscribed, moderately enhancing right adrenal pheochromocytoma with a hypodense area of necrosis.

Hyaline globules are present in some paragangliomas (PGLs) and pheochromocytomas (PCCs), especially in PCC/PGLs in patients with MEN2. (Right) Chromogranin-A immunostain shows granular immunoreactivity in the nests of neuroendocrine cells of a paraganglioma in a patient with MEN2A.
Pheochromocytomas in MEN2 patients show granular cytoplasmic immunoreactivity for the SDHB protein. The stain is usually coarsely granular, as this protein is localized to the mitochondria. Immunohistochemistry for Ki-67 proliferative marker usually shows a low proliferative index in pheochromocytomas associated with MEN2. This field shows an unusually high proliferative index for a MEN2-associated pheochromocytoma.

**MYH-Associated Polyposis**

Medium-power view of a tubular adenoma from a patient with > 20 adenomas and multiple hyperplastic polyps. The
adenomas in MYH polyposis are identical to sporadic adenomas.

Endoscopic view shows a stomach that is carpeted with fundic gland polyps. Patients with MYH can have gastric findings similar to those of patients with familial adenomatous polyposis (FAP). (Courtesy E. Stoffel, MD.)

**TERMINOLOGY**

**Abbreviations**
- Mut Y homologue (MYH)
- MYH-associated polyposis (MAP)

**EPIDEMIOLOGY**

**Prevalence**
- $< 1$ in 10,000
- Mean age at diagnosis is 45, with a reported age range of 12-68 years
  - Risk of colorectal cancer (CRC) is 80% at age 70 with 50% of patients found to have CRC at time of polyposis diagnosis
  - Patients tend to be older than familial adenomatous polyposis (FAP) patients but slightly younger than typical CRC patients
    - May have right-sided CRC in younger patient suggestive of Lynch syndrome

**GENETICS**

**MYH Gene**
- Base excision repair gene
  - Biallelic germline mutations in MYH lead to G:C to T:A transversions in somatic genes (i.e., APC, KRAS)
    - Oxidation of guanine is normally repaired by MYH
    - Oxidated guanine binds to adenine instead of cytosine, hence the G:C to T:A transversions
    - Somatic mutations in APC gene leads to polyposis similar to FAP
- Autosomal recessive
  - 1-2% of population carry a single deleterious mutation
  - Parents of affected patient are both carriers
Unclear if carriers have an increased rate of colon cancer
- Some reports have found slightly increased risk (1.5-2.1 relative risk) of CRC, whereas other studies have failed to show this

CLINICAL IMPLICATIONS AND ANCILLARY TESTS

Clinical Profile
- Multiple adenomas but typically not in overwhelming numbers as seen in FAP
- Easy to miss diagnosis since there is no family history and patients have fewer polyps at an older age than typical FAP patients

Genetic Testing
- In patients without a family history of polyposis, need to test for both FAP and MAP as 30% of FAP cases arise de novo
- 2 common mutations in MYH gene account for 80% of cases (especially in people of Northern European descent)
  - Most cost-effective method currently is to sequence APC gene and test for the 2 common MYH mutations
    - If this fails to identify mutations, then sequencing MYH will be necessary
  - If patients are not of Northern European descent, may be more cost effective to sequence MYH from the start
- Can measure G:C to T:A transversion in tumor DNA, especially in APC and KRAS genes
- MAP carcinomas are typically microsatellite stable (as opposed to Lynch cancers that are unstable)

ASSOCIATED NEOPLASMS
Identical to FAP
- Multiple adenomas and increased risk of CRC
  - Up to 42% of MAP patients have 10-100 polyps, similar to attenuated FAP
  - Up to 29% will have > 100 adenomas and resemble classic FAP
  - May have unicryptal or microadenomas
  - May also have serrated polyps (hyperplastic polyps and sessile serrated adenomas have been reported)
- Extracolonic neoplasms
  - 18-25% have duodenal adenomas
    - 4% lifetime risk of duodenal carcinoma
  - Fundic gland polyps similar to FAP
  - Congenital hypertrophy of retinal pigment epithelium, dermal cysts, osteomas, dental abnormalities, and desmoids have also been reported
    - Prevalence of these lesions may be lower than in FAP, but given rarity of syndrome, good data do not exist
  - Ovarian, bladder, and skin cancers have been reported (which can be suggestive of Lynch syndrome)

CANCER RISK MANAGEMENT

Surveillance
- Patients with known MYH mutations should have colonoscopic surveillance beginning between ages 20 and 30
  - If no polyps are found, may continue surveillance every 3-5 years
  - If polyps are found, may go to annual surveillance
- Upper tract endoscopic surveillance is recommended beginning at age 30-35 years
  - If no polyps are found, may continue surveillance every 3-5 years
  - If polyps are found, annual surveillance may be recommended

Surgery
- When polyps become too numerous, prophylactic colectomy with ileoanal anastomosis is treatment of choice

SELECTED REFERENCES
4. Lefevre JH et al: MYH biallelic mutation can inactivate the two genetic pathways of colorectal cancer by APC or MLH1 transversions. Fam Cancer. 9(4):589-94, 2010
Neurofibromatosis Type 1

In neurofibromatosis type 1 (NF1), asymmetric deformities occur secondary to tissue overgrowth and plexiform/diffuse neurofibromas. Involvement of the orbit and ocular adnexa may be prominent.
Plexiform neurofibroma is a hallmark of NF1. This eyelid example demonstrates the characteristic multinodular appearance resulting from multiple nerve fascicle involvement.

**TERMINOLOGY**

**Abbreviations**
- Neurofibromatosis type 1 (NF1)

**Synonyms**
- von Recklinghausen disease

**Definitions**
- Genetic syndrome resulting from germline mutations in NF1 gene encoding for neurofibromin

**EPIDEMIOLOGY**

**Incidence**
- ~ 1 in 2,500-3,000 births (1 of the most common inherited syndromes)
- Occurs in all races and geographic regions

**GENETICS**

**NF1 Gene**
- Located in chromosome region 17q11.2
- Ubiquitously expressed, but levels highest in nervous system
- Encodes for neurofibromin, a tumor suppressor GTPase-activating protein that negatively regulates RAS
  - Constitutive activation of MAPK and AKT/mTOR signaling pathways
  - Also may regulate cAMP levels, which affect central nervous system manifestations
- Mosaicism or “segmental” neurofibromatosis manifests as involvement of an isolated anatomical region
- Penetration is ~ 100% with appropriate follow-up although manifestations are variable between individuals and within families

**Genetic Modifiers**
- Modifier genes identified in mice and families with NF1
  - Associated with disease severity
Affect predisposition to peripheral nerve and central nervous system tumors

NF1-Associated Tumors

- Loss of heterozygosity in NF1 is a feature of associated tumors
- Haploinsufficient cells in tumor microenvironment (macrophages/microglia, mast cells) also contribute to tumorigenesis

CLINICAL IMPLICATIONS AND ANCILLARY TESTS

Diagnostic Criteria (NIH 1991)

- 2 or more of the following features
  - Café au lait macules (≥ 6), with a diameter of 0.5 cm in children, or 1.5 cm after puberty
  - Cutaneous or subcutaneous neurofibromas (≥ 2) or plexiform neurofibroma
  - Freckling of the axillary or groin region
  - Glioma of the optic pathways
  - Lisch nodules identified by slit-lamp examination (≥ 2)
  - Dysplasias of skeletal system (sphenoid wing, long bone bowing, pseudoarthrosis)
  - Diagnosis of NF1 in a 1st-degree relative

NONNEOPLASTIC MANIFESTATIONS

Ophthalmic

- Lisch nodules: Nodular, hamartomatous aggregates of melanin-containing cells on surface of iris, usually asymptomatic

P.II(2):151

Central Nervous System

- Unknown bright objects (UBOs): Asymptomatic focal areas of ↑ T2 signal on MR
  - May represent localized myelin abnormalities/edema
- Macrocephaly, cognitive disabilities, developmental delays, and behavioral disturbances

Skin

- Café au lait spots: One of the earliest manifestations
- Axillary/inguinal (intertriginous skin) freckling

Musculoskeletal

- Sphenoid wing dysplasia/hypoplasia, scoliosis, pseudoarthrosis, bowing of long bones

Cardiovascular System

- Cerebral arteriopathy (Moyamoya disease)
- Pulmonary artery stenosis

ASSOCIATED NEOPLASMS

Central Nervous System

- Pilocytic astrocytoma
  - Most frequent central nervous system neoplasm in NF1
  - Predilection for optic pathways (15-20% of children with NF1)
  - May also occur in brainstem and anywhere along neuraxis
- Diffuse astrocytomas
  - Grades II-IV
  - Usually develop after childhood years
  - Aggressive as sporadic counterparts
- Indeterminate astrocytomas
  - Subset of low-grade astrocytomas in patients with NF1 difficult to classify
  - May demonstrate phenotypic or ultrastructural evidence of neuronal differentiation
- Glioneuronal tumors
  - Gangliogliomas and dysembryoplastic neuroepithelial tumors previously reported in NF1

Peripheral Nervous System

- Neurofibroma
  - Localized neurofibroma
    - Cutaneous, soft tissue or intraneural
    - Low cellularity
    - Variable contents of Schwann cells, perineurial cells, fibroblasts, mast cells, and axons
  - Diffuse neurofibroma
    - May develop in patients with NF1 but is not exclusive for the syndrome
    - Usually large cutaneous plaques infiltrating dermis &/or subcutis
May arise in internal organs

- **Cellular neurofibroma**
  - Areas of increased cellularity and even limited fascicular architecture
  - Lack pronounced atypia and mitotic activity
  - Differential diagnosis with low-grade MPNST challenging, particularly when associated with plexiform neurofibroma

- **Atypical neurofibroma**
  - Degenerative nuclear atypia
  - Lacks hypercellularity and mitotic activity

- **Plexiform neurofibroma**
  - Complex neoplasms that by definition involve multiple peripheral nerve fascicles or a large plexus
  - Characteristic “worm-like” gross appearance
  - Deep/large plexiform neurofibromas essentially restricted to patients with NF1
  - Propensity for malignant degeneration

- **Massive soft tissue neurofibroma**
  - Large neoplasm displaying prominent soft tissue infiltration, often containing hypercellular, round cell areas, and pseudo-meissnerian corpuscles
  - Usually benign, but some contain a plexiform neurofibroma component with a propensity for malignant degeneration
  - Arises only in patients with NF1

- **Rare findings in neurofibroma include presence of melanin pigment, metaplasia, and glandular differentiation**

- **Malignant peripheral nerve sheath tumor (MPNST)**
  - Afflicts 8-13% of patients with NF1
  - Usually aggressive, high-grade spindle cell neoplasms
  - Differentiation is predominantly schwannian but may also be perineurial
  - Presence of heterologous elements relatively more common in NF1 setting (skeletal muscle, cartilaginous, osseous, angiosarcomatous, glandular or smooth muscle)
  - “Low-grade MPNST” applied to tumors arising in transition from neurofibroma, usually in patients with NF1
    - Hypercellularity, nuclear enlargement (“~ 3x the size of a neurofibroma nucleus), and hyperchromasia
    - Mitotic activity may also be present but is not required for diagnosis

Other
- **Pheochromocytoma:** Usually unilateral but may be bilateral in NF1
- **Glomus tumor**
  - Recently recognized component of NF1
  - NF1-biallelic inactivation, mitotic recombination not uncommon
- **Intestinal ganglioneuromatosis (involving primarily the submucosal plexus)**
- **Gastrointestinal stromal tumor (GIST)**
  - Lacks KIT mutations in contrast to sporadic GIST
- **Gastrointestinal schwannoma**
  - More common in NF1 than NF2
  - Loss of heterozygosity in NF1 gene
- **Neuroendocrine neoplasms (carcinoid tumors)**
- **Juvenile myelomonocytic leukemia (JMML)**
  - 100x < risk in children with NF1
- **Breast carcinoma**
  - P.I(2):152
    - Increased risk and earlier age of occurrence in women with NF1
- **Rhabdomyosarcoma**

**MOLECULAR BIOLOGY**

**Central Nervous System**
- NF1-associated gliomas demonstrate complete NF1 inactivation
- Haploinsufficient stromal components (e.g., microglia) also required in mouse models of NF1-associated low-grade glioma
• Development of high-grade glioma requires losses in additional tumor suppressors (e.g., TP53, PTEN)

Peripheral Nerve
• Haploinsufficient microenvironment cell components (e.g., mast cells) important for neurofibroma formation in some NF1 mouse models
• Nonmyelinating Schwann cell progenitors and Dsh(+) Schwann cell precursors are candidate cells of origin of plexiform neurofibromas in mouse models
• Neural crest-derived cutaneous neural stem cell/progenitor candidate cell of origin for cutaneous neurofibroma
• Malignant peripheral nerve sheath tumors in addition to NF1 loss develop oncogene amplification (e.g., EGFR) and tumor suppressor loss (e.g., P16, TP53)

DIFFERENTIAL DIAGNOSIS
Neurofibromatosis Type 2 (NF2)
• Mutations in the NF2 gene encoding for merlin/schwannomin
• Gliomas, café au lait spots, and neurofibromas may present in patients with NF2 although at a lower frequency and number than in those with NF1
• Ependymoma, meningioma, and multiple schwannomas are not a feature of NF1

Noonan Syndrome
• Results from mutations in various components of the RAS/MAPK signaling pathway
  o PTPN11, KRAS, SOS1, NRAS, and RAF1
• Distinctive facial features, developmental delay, short stature, congenital heart disease, café au lait spots
• Tumor predisposition lower than NF1

Legius Syndrome
• Results from loss-of-function SPRED1 mutations leading to ↑ RAS-MAPK pathway activity
• Mild NF1-like phenotype
  o Café au lait spots, macrocephaly
  o Lack Lisch nodules, bone abnormalities, gliomas, and peripheral nerve sheath tumors

Constitutional Mismatch Repair-Deficiency Syndrome
• Homozygous or compound heterozygous mutations in mismatch repair genes
• Multiple cancers, including gliomas, colon cancer
• May be associated with clinical features of NF1 (e.g., café au lait spots)

McCune-Albright Syndrome
• Somatic mutations in GNAS1 gene resulting in increased cAMP signaling
• May have café au lait spots (unilateral) but no axillary freckling
• Polyostotic fibrous dysplasia

Proteus Syndrome
• Somatic (mosaic) activating mutations in AKT1 in most cases
• Localized tissue overgrowth clinically mimicking plexiform neurofibroma; scoliosis, hyperostoses, “cerebriform” connective tissue nevus, and epidermal nevi; monomorphic parotid gland adenomas, ovarian cystadenomas

Familial Café Au Lait Spots
• Rare autosomal dominant disorder
• Lack neurofibromas and noncutaneous manifestations of NF1

Multiple Endocrine Neoplasia Type 2B (MEN2B)
• Caused by genetic alterations in RET proto-oncogene
• Develop pheochromocytomas but also mucosal neuromas (not neurofibromas)
  o Diffuse and extensive involvement of all intestinal layers by ganglioneuromatosis is relatively specific to MEN2B

SELECTED REFERENCES
P.I(2):153

Image Gallery
Systemic Manifestations

(Left) NF1 syndrome is caused by germline mutations in the gene encoding for neurofibromin, a tumor suppressor protein that works by activating RAS GTPase function. Neurofibromin loss leads to constitutive RAS signaling and altered cAMP levels, resulting in a variety of neoplasms and other manifestations, particularly affecting the nervous system. (Right) Multiple café au lait spots represent an important cutaneous manifestation of NF1. (Courtesy K. Yohay, MD.)

(Left) Lisch nodules are asymptomatic nodular proliferations of pigmented cells involving the anterior surface of the iris in NF1 patients. They represent an important diagnostic criterion that is relatively easy to identify by ophthalmologic examination. (Right) Lisch nodules are composed of melanin-containing cells that form superficial aggregates in the iris. They usually do not affect vision and have no malignant potential.
NF1 is 1 of several syndromes characterized by the development of pheochromocytomas. Although these tumors are usually solitary/unilateral, multiple tumors may develop in a subset of patients. (Right) Both sporadic and NF1-associated pheochromocytomas are characterized by variably sized nodules of large cells with ample basophilic to amphophilic cytoplasm. A rich microvascular network is a constant feature.

Central Nervous System

Hyperintensities on T2-weighted MR images are a frequent finding in NF1 patients. These are referred to as unknown bright objects and may represent focal abnormalities in myelin. (Right) A small increase in glial cell number and even mild atypia are not uncommon in the setting of NF1. It is essential to identify these findings in central nervous system specimens because of the propensity of patients with NF1 to develop infiltrating gliomas of all grades.
The central nervous system hallmark of NF1 is multiple involvement of the optic pathways by low-grade gliomas. These may affect the optic nerve proper as well as the chiasm. (Right) The overwhelming majority of optic pathway gliomas are pilocytic astrocytomas. In this NF1-associated case, areas of tissue compaction, degenerative atypia, and Rosenthal fibers are evident. The tumors grow slowly and may even be followed without treatment in most cases.

Although pilocytic astrocytoma is the most frequent glioma in patients with NF1, all astrocytic subtypes may potentially develop, including high-grade astrocytomas as seen in this example. Heterogeneous contrast enhancement is evident. (Right) High-grade astrocytomas in patients with NF1 are graded using similar criteria as in sporadic tumors. Parenchymal infiltration, atypia, and mitotic activity are not subtle in this anaplastic (WHO grade III) astrocytoma.

Peripheral Nervous System
Numerous cutaneous neurofibromas afflict a significant proportion of patients with NF1. They are characterized by sessile or pedunculated growths. An associated café au lait spot is also present in this NF1 patient. (Courtesy K. Yohay, MD.) Most neurofibromas are paucicellular tumors characterized by wavy, delicate eosinophilic collagen bundles colorfully referred to as “shredded carrots.” A variable myxoid stroma may be identified in almost all neurofibromas.

Some neurofibromas are characterized by areas of increased cellularity and nuclear atypia. Such areas deserve particular attention when occurring in plexiform neurofibromas of NF1 patients. Distinction from a low-grade MPNST may be difficult. (Right) Well-circumscribed schwannian nodules may occur in neurofibromas. Although these nodules within neurofibroma are sometimes interpreted as hybrid benign nerve sheath tumors, the predominant architecture in NF1 is usually neurofibroma.
Rarely, melanin/pigment may be observed in neurofibroma examples, particularly diffuse tumors in the setting of NF1. Hybrid benign nerve sheath tumors may be more frequent in syndrome settings. This section from a patient with NF1 contains large hyalinized vessels and numerous foamy macrophages, features that are more frequently encountered in schwannomas. However, more classic features of neurofibroma were present in other fields.

P.I(2):156

The main diagnostic attributes of plexiform neurofibroma are evident on gross examination and low magnification, particularly a nodular or worm-like pattern of growth imparted by expansion of multiple peripheral nerve fascicles. Such tumors also demonstrate cellular complexity, including Schwann cells, perineurial cells, fibroblasts, mast cells, and peripheral nerve axons. Neurofibromas, including the plexiform variant, contain a myxoid stroma stained by Alcian blue.
Diffuse neurofibromas are usually characterized by large, superficial, plaque-like growths enveloping multiple cutaneous adnexa. Although relatively frequent in patients with NF1, these neurofibromas are not exclusive to the syndrome. Complex neurofibromas with diffuse components demonstrating dermal/subcutaneous infiltration as well as plexiform expansion of individual peripheral nerve fascicles are not uncommon in patients with NF1.

Pseudo-meissnerian corpuscles are characteristic of diffuse neurofibromas and may be present in variable amounts. They are intensely immunoreactive with antibodies directed against S100 protein. The massive soft tissue neurofibroma is a particular subtype limited to patients with NF1. It is characterized by diffuse infiltration of adipose tissue and other soft tissue elements. In addition, it may have areas of closely packed round cells.

Malignant Peripheral Nerve Sheath Tumor
Malignant peripheral nerve sheath tumor (MPNST) is the prototypical malignancy afflicting patients with NF1 syndrome. A suspicious finding on gross examination is the presence of necrosis. MPNST may arise de novo or from a preexisting, usually plexiform, neurofibroma. MPNSTs are usually high-grade spindle cell malignancies. The neoplastic cells may be arranged in fascicles and resemble fibrosarcoma. Mitotic activity is variable but usually evident.

The morphologic variability of MPNST is wide, and pleomorphism may be marked in some NF1-associated and sporadic examples. Some tumors may contain epithelioid cells with well-defined borders. S100, a ubiquitous Schwann cell marker, is characteristically weaker in areas of MPNST, or altogether negative. This is a useful distinguishing feature from cellular schwannoma. However, the latter is not typically NF1 associated.
Strong nuclear immunoreactivity for p53 in a variable number of neoplastic cell nuclei is frequent in MPNST in contrast with benign neurofibromas. (Right) p16 immunoreactivity is frequently lost in MPNST. p16 represents an important tumor suppressor that is frequently inactivated by gene mutations/deletions in MPNST. p16 loss at the gene or protein level may suggest malignant degeneration of neurofibromas in NF1 patients.

**Neurofibromatosis Type 2**

Bilateral schwannomas involving the vestibular branch of CN8 are a hallmark of neurofibromatosis type 2 (NF2). They
present as a cerebellopontine angle mass and may be multiple.

**Schwannomas** are the most common neoplasms affecting patients with NF2. They are composed of a solid proliferation of neoplastic Schwann cells and may contain characteristic Verocay bodies.

**TERMINOLOGY**

**Abbreviations**
- Neurofibromatosis type 2 (NF2)

**Definitions**
- Inherited tumor predisposition syndrome caused by germline mutations in the NF2 gene encoding for merlin/schwannomin

**EPIDEMIOLOGY**

**Incidence**
- 1 in 33,000 to 40,000 births
- Similar proportion of male and female patients

**GENETICS AND MOLECULAR BIOLOGY**

**NF2 Gene Encodes for Merlin**
- Inherited in 1/2 of patients and new germline mutation in remaining 1/2
- Located in chromosomal region 22q12.2
- Merlin associates with cell junctional complexes and participates in contact-dependent inhibition
- More severe phenotype in patients with frameshift or nonsense mutations
- Germline mosaicism occurs in 20-30% of patients without family history

**CLINICAL IMPLICATIONS AND ANCILLARY TESTS**

**Nonneoplastic Manifestations**
- Ophthalmic: Posterior subcapsular cataracts, retinal hamartomas, and epiretinal membranes
- Central nervous system: Glial microhamartomas
- Peripheral nervous system: Polyneuropathy
- Skin: Café au lait spots but at a lesser frequency than NF1; also hairy cutaneous plaques
Musculoskeletal: Scoliosis

Classification Criteria

- Manchester criteria (1992)
  - Bilateral vestibular schwannoma or
  - NF2 in 1st-degree relative plus unilateral vestibular schwannoma or any 2 of the following: Neurofibroma, meningioma, glioma, schwannoma, posterior subcapsular lens opacity or
  - Unilateral vestibular schwannoma plus any 2 of the following: Neurofibroma, meningioma, glioma, schwannoma, posterior subcapsular lens opacity or
  - ≥ 2 meningiomas plus unilateral vestibular schwannoma or any 2 of the following: Neurofibroma, glioma, schwannoma, or cataract

- Baser criteria (2011)
  - Manifests an effort to incorporate genetic information into clinical classifications

ASSOCIATED NEOPLASMS

Schwannoma

- Similar histologic features as sporadic tumors
  - Compact Antoni A areas alternating with loose Antoni B areas
  - Verocay bodies, hyalinized vessels, hemosiderin deposition
  - S100, SOX10, and pericellular collagen IV immunoreactivity; EMA limited to perineurium and neurofilament protein to rare entrapped axons
  - Features occurring more frequently in NF2-associated schwannomas include whorl formation, multiple tumors involving a single nerve, and juxtaposition to meningioma
  - Mosaic pattern of INI1 immunostaining in majority of syndrome-associated schwannomas
  - Bilateral vestibular schwannomas are a hallmark of NF2 (90-95% of patients)
  - Plexiform schwannomas may occur in NF2 but are not specific to the syndrome
    - Nodular Schwann cell proliferation favoring cutaneous and mucosal sites
    - May be multiple

Neurofibroma

- Relatively rare in NF2 compared to NF1 but may contribute to clinical diagnosis if other criteria present

Meningioma

- Intracranial meningiomas found in ~ 1/2 of NF2 patients
- Skull base involvement is less frequent than in sporadic tumors
- “Saltatory growth”: Periods of growth followed by quiescence
- Relatively high frequency of fibroblastic, transitional, and grade II meningiomas in NF2 patients but also histologic heterogeneity
- Meningioangiomatosis
  - Growth of meningothelial-like cells into superficial cortical vessels and leptomeninges
  - Associated with seizures
  - EMA(+) or EMA(−), collagen rich (Masson trichrome)

Ependymoma

- Cervical cord and cervicomedullary junction are favored sites in NF2
- Majority of NF2-associated ependymomas are low grade and asymptomatic
- Associated with a relatively high rate of truncating NF2 mutations

Other

- Conventional MPNST and MPNST ex-schwannomas reported in NF2 but very rare
- Some malignant neoplasms may be irradiation-induced
- Nonpendymal glial neoplasms may occur

SELECTED REFERENCES


Baser Criteria for Neurofibromatosis Type 2

<table>
<thead>
<tr>
<th>Feature</th>
<th>Present Age ≤ 30 Years</th>
<th>Present Age &gt; 30 Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>NF2 in 1st-degree relative</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Vestibular schwannoma (unilateral)</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Vestibular schwannoma (2nd)</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Meningioma</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Meningioma (2nd)</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Cutaneous schwannoma(s)</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Neoplasm of cranial nerves</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Mononeuropathy</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Cataract(s)</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>

Points are added: ≥ 6 = definite NF2; 4-5 = NF2 mutational analysis required for diagnosis; < 4 = NF2 unlikely.

Molecular, Imaging, and Microscopic Features

(Left) NF2 is associated with loss of the tumor suppressor merlin. Merlin has numerous important cellular functions,
including participation in intercellular junctions, contact dependent growth inhibition (through integrins, CD44), cytoskeleton dynamics, and modulation of signaling pathways, including those downstream from receptor tyrosine kinases (RTK) and YAP. (Right) In addition to neoplasms, patients with NF2 may develop a variety of nonneoplastic disorders, such as severe scoliosis.

(Left) Meningioangiomatosis afflicts some patients with NF2. It is a hamartomatous-like lesion associated with seizures and is characterized by a cortical proliferation of spindle cells, particularly surrounding small vessels. An association with an overlying meningioma may be present in some instances. (Right) Perivascular collagen deposition is a diagnostically useful feature of meningioangiomatosis that may be demonstrated with histochemical stains such as Masson trichrome.

(Left) Another nonneoplastic brain lesion afflicting patients with NF2 is the glial hamartoma, characterized by clusters of glial-like hyperchromatic cells with nuclear atypia and hyperchromasia. Multinucleated cells may also be present. They tend to arise in cerebral cortex and basal ganglia and lack mitotic activity and potential for neoplastic change. (Right) Glial hamartomas in NF2 patients show strong S100 labeling but lack expression of other neuronal and glial markers.

P.I(2):161

Schwannoma
Bilateral vestibular schwannomas are pathognomonic of NF2, presenting as enhancing masses in the cerebellopontine angle. Age of presentation is variable; candidate patients may be monitored for years before this characteristic manifestation presents. Compact proliferations of spindle cells characterize the Antoni A pattern of schwannomas. Mitotic activity is usually low and the potential for spontaneous malignant degeneration is negligible.

Bland spindle cells represent the main component of sporadic and NF2-associated schwannomas. These usually aggregate in compact areas known as Antoni A. Diagnostic Verocay bodies are not always identifiable, and in such instances, immunohistochemistry may be required for confirmation. Antoni B patterns are relatively paucicellular in contrast to Antoni A patterns. They contain variable mixtures of Schwann cells with clear cytoplasm and foamy histiocytes.
Plexiform schwannomas form multinodular masses usually involving superficial locations. Unlike plexiform neurofibromas, which are closely associated with NF1, most plexiform schwannomas are sporadic but may affect NF2 patients, as in this example. (Right) Whorls resembling those encountered in meningiomas may be more frequent in NF2-associated schwannomas than in sporadic tumors. IHC may help in their distinction, particularly in small biopsies. P.II(2):162

Meningioma

(Left) Meningiomas are the 2nd most common neoplasms in patients with NF2. They are usually dura-based and demonstrate strong, homogeneous contrast enhancement after administration of gadolinium in T1-weighted MR sequences. (Right) The cytologic features of meningiomas are evident in intraoperative smears. They include “flat” cells with ample eosinophilic cytoplasm containing bland oval nuclei. Intercellular borders are usually indistinct.
The most frequent meningioma subtype is meningotheliomatous, characterized by bland cells with indistinct borders and oval nuclei. This subtype occurs at a lesser frequency in NF2 patients compared to sporadic tumors. One of the most useful features for grading meningiomas is the number of mitotic figures per 10 high-power fields. Most meningiomas are low grade (WHO grade I), but the whole grading spectrum (I-III) may affect patients with NF2.

The combination of multiple meningiomas and schwannomas is characteristic of patients with NF2. Juxtaposition of schwannomas and meningiomas (i.e., collision tumors) represents a characteristic feature of patients with NF2. Histologically, these NF2-associated tumors may demonstrate morphologic overlap. However, the presence of wavy nuclei and Verocay bodies indicate schwannoma whereas psammoma bodies are usually limited to meningiomas.

Ependymoma
The intraparenchymal CNS neoplasm afflicting patients with NF2 is ependymoma, which has a predilection for the cervical cord/cervicomedullary junction. These tumors are well demarcated and demonstrate contrast enhancement. Perivascular pseudorosettes are frequent in ependymomas. They are composed of anuclear perivascular zones containing numerous neoplastic glial cell processes.

This intramedullary neoplasm in a patient with NF2 contains bland oval nuclei, but the pseudorosettes are inconspicuous, making identification of ependymoma difficult. A high index of suspicion is required in spinal cord tumors originating in patients with NF2. In some ependymomas, diagnosis is straightforward and possible at low magnification. In this NF2-associated ependymoma, perivascular pseudorosettes are abundant.
The glial nature of ependymoma may be confirmed by immunolabeling with anti-GFAP antibodies. Although the reactivity of individual cells varies, pseudorosettes show intense immunoreactivity. (Right) A dot-like pattern of immunoreactivity for EMA is a diagnostically useful property of ependymoma. Although it may resemble an artifact at first glance, it corresponds to microlumina containing microvilli at the ultrastructural level.

Peutz-Jeghers Syndrome

Low-power view of a Peutz-Jeghers polyp shows arborizing bands of smooth muscle.
Higher power view shows benign glands trapped within muscle bundles. Care must be taken not to overinterpret this as cancer.

**TERMINOLOGY**

**Abbreviations**
- Peutz-Jeghers syndrome (PJS)

**Definitions**
- PJS is characterized by
  - Pigmented melanotic lesions around lips, oral cavity, and genitals
  - Hamartomatous polyposis of gastrointestinal (GI) tract
  - Increased risk of cancers in the GI tract, pancreas, gynecologic tract, testis, breast, lung, and thyroid
  - Autosomal dominant inheritance
    - 25% of cases appear de novo

**EPIDEMIOLOGY**

**Prevalence**
- Exact prevalence is unknown; estimates range from 1 in 8,500 to 1 in 300,000 live births
- No gender or racial predominance

**GENETICS**

LKB1 Gene
- Also known as STK11
- Serine-threonine kinase that is thought to behave like a tumor suppressor gene
- Important in controlling cell proliferation
- Regulates mTOR pathway
  - Clinical trials using mTOR pathway inhibitors (rapamycin analogues) for chemoprevention are currently underway in PJS patients and have shown promising early results

**CLINICAL IMPLICATIONS AND ANCILLARY TESTS**

Clinical Presentation
- Pigmentation of lips and oral and genital mucosa seen in infancy and early childhood
  - Lips most common site (> 95%)
  - Pigmentation may fade with age
- GI tract symptoms
  - Abdominal pain due to obstruction/intussusception
    - Polyps arise in stomach (50%), small bowel (65%), and colon (50%)
  - Anemia due to occult or frank GI tract bleeding
    - Hematemesis in patients with gastric and duodenal polyposis
  - Prolapse of rectal polyps
- Associated skeletal abnormalities
  - Club foot and scoliosis

Diagnostic Criteria
- ≥ 2 histologically confirmed Peutz-Jeghers polyps (PJPs)
  - Even patients with only a single PJP seem to have an increased risk of cancer
- Any number of PJPs in a patient with a family history of PJS
- Any number of PJPs in a patient with mucocutaneous pigmentation
- Mucocutaneous pigmentation in a patient with a family history of PJS

Genetic Testing
- Sequencing the LKB1 gene identifies a mutation in 50-70% of cases
  - Need to look for both protein-truncating mutations as well as large deletions
- Gene inactivation theorized in cases that test negative

ASSOCIATED NEOPLASMS
GI Tract Neoplasms
- Adenocarcinoma of small bowel
  - Cumulative risk: 13%
- Adenocarcinoma of colon
  - Cumulative risk: 39%
  - Mean age of diagnosis: ~ 46 years
- Adenocarcinoma of pancreas
  - Cumulative risk: 36% (100x risk in general population)
- Adenocarcinoma of stomach
  - Cumulative risk: 29%

Other Neoplasms
- Carcinoma of breast
  - Absolute risk: ~ 54%
- Ovarian sex cord tumors with annular tubules
- Adenoma malignum of cervix
- Mucinous tumors of ovaries and fallopian tubes
  - Absolute risk: 10%
- Bronchioalveolar carcinomas of lung
- Testicular sex cord and Sertoli cell tumors
  - Absolute risk: 9%
- Papillary thyroid cancer
- Overall cumulative cancer risk: 93% at age 65

MICROSCOPIC FINDINGS
Hammartomatous Polyps
- Polyps classically have arborizing bands of smooth muscle with a papillary architecture
  - Best seen in small bowel polyps; stomach and colon polyps may lack classic features and thus can be difficult to diagnose
- Epithelium is nonneoplastic and has a lobular growth pattern
  - Epithelium frequently is trapped in bands of smooth muscle; do not overinterpret this finding as carcinoma
  - Dysplasia has hardly ever been found in PJPs, suggesting that cancer may arise by a different mechanism

CANCER RISK MANAGEMENT
Endoscopic Surveillance
- Baseline upper and lower endoscopy at age 8, to be repeated every 2-3 years
- Endoscopic removal of small polyps
  - Surgery may be necessary for obstructing polyps or intussusception

Radiologic Surveillance
- Transvaginal ultrasound, serum CA-125, and Pap smears annually beginning between age 20 and 25 for gynecologic (GYN) tumors
- Endoscopic ultrasound, abdominal CT, and CA-19-9 every 1-2 years starting between age 25 and 30 for pancreas tumors
- Mammography or MR annually starting at age 25 for breast cancer

SELECTED REFERENCES

IMAGE GALLERY

(Left) Adenoma malignum of the cervix in Peutz-Jeghers syndrome (PJS) shows bland infiltrative glands without a desmoplastic response. (Courtesy A. Srivastava, MD.) (Center) Ovarian sex cord tumor with annular tubules in PJS shows circumscribed nests of tumor cells containing hyaline material. (Right) A Sertoli cell tumor of the testis shows nests and cords of tumor cells with abundant pink cytoplasm and a hyalinized stroma with foci of calcification. (Courtesy E. Oliva, MD.)

PTEN-Hamartoma Tumor Syndromes

> Table of Contents > Part I - Overview of Syndromes > Section 2 - Syndromes > PTEN-Hamartoma Tumor Syndromes

PTEN-Hamartoma Tumor Syndromes
Vania Nosé, MD, PhD
Gross photograph of thyroid adenomatous nodules shows multiple well-circumscribed and unencapsulated nodules compressing the adjacent uninvolved thyroid parenchyma.

One of the major criteria for the diagnosis of PHTS is the presence of follicular carcinoma. A follicular cell proliferation present in this young patient with Cowden syndrome shows capsular invasion.

**TERMINOLOGY**

**Abbreviations**
- Phosphatase and tensin homolog (PTEN) deleted on chromosome 10
- PTEN-hamartoma tumor syndrome (PHTS)
- Cowden syndrome (CS)
- Cowden disease (CD)
- Multiple hamartoma syndrome (MHAM)
- Bannayan-Riley-Ruvalcaba syndrome (BRRS)
- PTEN-related Proteus syndrome (PRPS)

**Syndromes**
- PHTS includes
  - Cowden syndrome
  - Bannayan-Riley-Ruvalcaba syndrome
  - PTEN-related Proteus syndrome and Proteus-like syndrome
  - Autism with macrocephaly

**Definition**
- PHTS is a complex disorder caused by germline inactivating mutations of PTEN tumor suppressor gene, which maps to 10q23.3
- PHTS is primarily composed of the Cowden and Bannayan-Riley-Ruvalcaba syndromes
  - Several other syndromes have been linked with PTEN mutations including PTEN-related Proteus syndrome, Proteus-like syndrome, and autism with macrocephaly
- Cowden syndrome
  - Clinical manifestations of Cowden syndrome includes hamartomatous tumors in multiple organ systems and an increased risk for malignancy
Affected individuals usually have macrocephaly, trichilemmomas, and papillomatous papules and present by late 20s.

Multiple hamartoma syndrome with a high risk for benign and malignant tumors of thyroid, breast, and endometrium.

Lifetime risk of developing breast cancer is 25-50%; reports up to 85%
- Average age of diagnosis between 38 and 46 years
- ~ 50% of women have benign breast conditions: Ductal hyperplasia, intraductal papillomatosis, adenosis, lobular atrophy, fibroadenomas, fibrocystic change, &/or densely fibrotic hyalinized nodules

Increased incidence of both multifocality and bilateral involvement has been observed for both benign and malignant breast disorders.

~ 2/3 of CS patients develop thyroid lesions involving follicular cells
- Includes multinodular goiter, multiple adenomatous nodules, follicular adenoma, follicular carcinoma, and, less frequently, papillary thyroid carcinoma
- Usually follicular, rarely papillary, but no medullary thyroid cancer has been reported
- Risk of thyroid cancer in affected individuals ranges from 3-35% in large case series
- ~ 70x increased incidence of nonmedullary thyroid cancer relative to the general population

Risk for endometrial cancer, although not well defined, may approach ~ 13-28%

- Bannayan-Riley-Ruvalcaba syndrome
  - Congenital disorder characterized by macrocephaly, lipomas, intestinal hamartomatous polyposis, vascular hamartomatous lesions, and pigmented macules of glans penis
  - Although diagnostic criteria for CS have been established for more than a decade, there are no agreed upon international criteria for the diagnosis of BRRS
  - Rate of occurrence and histologic types of thyroid lesions in BRRS have not been widely reported P.J(2):167

but have appeared similar to those seen in CS, suggesting a single entity

- PTEN-related Proteus syndrome
  - Complex, highly variable disorder involving congenital malformations and hamartomatous overgrowth of multiple tissues as well as connective tissue nevi, epidermal nevi, and hyperostoses
  - There have been reports of PTEN mutations in some patients with phenotypic similarities to Proteus syndrome (PS)
    - Somatic activating mutations in AKT1 oncogene have been delineated as the genetic cause of PS
  - Proteus-like syndrome
    - Undefined but refers to individuals with significant clinical features of PS who do not meet the diagnostic criteria for PS

EPIDEMIOLOGY
Incidence
- Estimated ~ 1 in 200,000-250,000 people

Familial
- Only 10-50% of individuals with Cowden syndrome have an affected parent
- Each child of an affected individual has a 50% chance of inheriting mutation and developing PHTS

Lifetime Risk of Developing Cancer
- Lifetime risks for a variety of cancers are increased in patients with PTEN mutations
  - Thyroid: 3-35%
  - Breast: 25-85%
  - Endometrium: 13-28%
  - Now extending to
    - Colorectal cancer: 9-13%
    - Kidney cancer: 13-34%
    - Melanoma: 6%

GENETICS
PTEN
- PTEN is a tumor suppressor gene located on 10q23.3
- Up to ~ 80% of cases of that met criteria for Cowden syndrome and a small percentage of cases of Cowdenlike syndrome result from mutations in PTEN gene
  - In PTEN sequencing-negative and clinically positive Cowden syndrome, ~ 10% have large deletions and ~ 10% have promoter mutations
PTEN mutation
- Initially reported that up to 83% of individuals meeting clinical criteria for Cowden syndrome had a detectable PTEN mutation
  - Overestimate attributable to the highly selected nature of earlier Cowden syndrome cohorts
- More recent estimates are that germline PTEN mutations are found in ~ 20-34% of individuals who meet clinical criteria for Cowden syndrome or who meet criteria for genetic testing

Function of PTEN is not entirely understood, but it is a major phosphatase for phosphoinositide-3,4,5-triphosphate
- By downregulating the levels of phosphoinositide-3,4,5-triphosphate, PTEN produces an inhibitory (tumor suppressor) effect on the PI3P/Akt pathway, an important carcinogenesis pathway
- Loss of PTEN function results in escape from programmed cell death and G1 arrest in cell cycle
- Proposed that PTEN has important activity both in cytoplasm and nucleus
  - Nuclear PTEN might be required for cell cycle arrest by downregulating cyclin-D1 and preventing phosphorylation of mitogen-activated protein kinase pathway
  - Cytoplasmic PTEN seems to be required for apoptosis by downregulating the phosphorylation of Akt and upregulating p27
- 75% of germline mutations result in truncated protein, lack of protein, or dysfunctional protein
- Protein produced from PTEN gene is a tumor suppressor, which means that it normally prevents cells from growing and dividing (proliferating) too rapidly or in an uncontrolled way

Other Loci
- In some patients who lack PTEN mutations, hypermethylation of the promoter of the KLLN (Killin) gene, leading to reduced expression of KLLN, has been described
  - KLLN gene, which is located on chromosome 10q23 and functions as a p53-regulated inhibitor of DNA synthesis, shares the same transcription site as PTEN gene
- Other patients have been reported with mutations in the succinate dehydrogenase (SDH) gene, subunits B and D
- Germline PIK3CA and AKT1 mutations have also been reported in phenotypic Cowden syndrome patients without PTEN, SDH, or KLLN mutations

Diagnosis
- Up to 85% of individuals who meet the diagnostic criteria for CS and 65% of individuals with a clinical diagnosis of BRRS have a detectable PTEN mutation
- Preliminary data suggest that up to 50% of individuals with Proteus-like syndrome and up to 20% of individuals with PTEN-related Proteus syndrome have PTEN mutations
- PTEN sequence analysis, deletion/duplication testing, and FISH testing are available on a clinical basis

Cowden syndrome
- Consensus diagnostic criteria for CS have been developed and are updated each year by the National Comprehensive Cancer Network (NCCN)
- Clinical criteria have been divided into 3 categories: Pathognomonic, major, and minor
  - Pathognomonic criteria
    - Adult Lhermitte-Duclos disease (LDD), defined as presence of a cerebellar dysplastic gangliocytoma
  - Mucocutaneous lesions
    - Acral keratoses
    P.I(2):168
    - Papillomatous lesions
    - Mucosal lesions
    - Trichilemmomas (facial)
  - Major criteria
    - Epithelial thyroid cancer (nonmedullary), especially follicular thyroid cancer
    - Macrocephaly (occipital frontal circumference ≥ 97th percentile)
    - Endometrial carcinoma
    - Breast cancer
  - Minor criteria
    - Other thyroid lesions (e.g., adenoma, adenomatous nodules, multinodular goiter)
    - Hamartomatous intestinal polyps
    - Fibrocystic disease of the breast
• Lipomas
• Fibromas
• Genitourinary tumors (especially renal cell carcinoma)
• Genitourinary malformation
• Uterine fibroids
• Intellectual disability
  o Operational diagnosis of CS: Made if an individual meets any of the following criteria
    ▪ Pathognomonic mucocutaneous lesions combined with 1 of the following
    ▪ ≥ 6 facial papules, of which ≥ 3 must be trichilemmoma
    ▪ Cutaneous facial papules and oral mucosal papillomatosis
    ▪ ≥ 6 palmarplantar keratoses
    ▪ Oral mucosal papillomatosis and acral keratoses
    ▪ ≥ 4 minor criteria
    ▪ 1 major and ≥ 3 minor criteria
    ▪ ≥ 2 major criteria

• BRRS
  o Diagnostic criteria for BRRS have not been set
  o Based heavily on the presence of the cardinal features
    ▪ Macrocephaly
    ▪ Hamartomatous intestinal polyposis
    ▪ Lipomas
    ▪ Pigmented macules of glans penis
  o ~ 60% of patients with BRRS have detectable PTEN mutation

• PTEN-related Proteus syndrome
  o Highly variable and appears to affect individuals in a mosaic distribution
    ▪ Somatic activating mutations in the AKT1 oncogene have been delineated as the genetic cause of Proteus syndrome
  o It is frequently misdiagnosed despite the development of consensus diagnostic criteria
  o Mandatory general criteria for diagnosis include mosaic distribution of lesions, progressive course, and sporadic occurrence
  o Rapidly progressive, asymmetric postnatal overgrowth of tissues, with hyperostoses, vascular malformations, dysregulation of fatty tissues (both atrophy and overgrowth), and skin manifestations, such as verrucous epidermal nevi or cerebriform connective tissue nevi
  o Specific criteria for diagnosis include
  o Connective tissue nevi (pathognomonic)
  o 2 of the following
    ▪ Epidermal nevus
    ▪ Disproportionate overgrowth (≥ 1)
    ▪ Limbs: Arms/legs; hands/feet/digits
    ▪ Skull: Hyperostoses
    ▪ External auditory meatus: Hyperostosis
    ▪ Vertebrae: Megaspondylodyplasia
    ▪ Specific tumors before end of 2nd decade
    ▪ Bilateral ovarian cystadenomas
    ▪ Parotid monomorphic adenoma
  o 3 of the following
    ▪ Dysregulated adipose tissue: Lipomas or regional absence of fat
    ▪ Vascular malformations (≥ 1): Capillary, venous, lymphatic
    ▪ Facial phenotype: Dolichocephaly, long face, minor downslanting of palpebral fissures &/or minor ptosis, low nasal bridge, wide or anteverted nares, open mouth at rest

• Proteus-like syndrome
  o Exceedingly rare asymmetric overgrowth syndrome
  o Undefined but describes individuals with significant clinical features of PS yet do not meet diagnostic criteria

Genetic Counseling
• PHTS is inherited in an autosomal dominant manner
• Because CS is likely underdiagnosed, actual proportion of simplex cases (defined as individuals with no obvious family history) and familial cases (defined as ≥ 2 related affected individuals) cannot be determined
• Majority of CS cases are simplex
Perhaps 10-50% of individuals with CS have an affected parent. Each child of an affected individual has a 50% chance of inheriting mutation and developing PHTS. Prenatal testing for pregnancies at increased risk is possible if disease-causing mutation in family is known.

CLINICAL IMPLICATIONS AND ANCILLARY TESTS

Clinical Testing

- Sequence analysis
  - Virtually all missense mutations in PTEN are believed to be deleterious
  - Early studies suggest that up to 85% of individuals who meet diagnostic criteria for CS and 65% of individuals with a clinical diagnosis of BRRS have a detectable PTEN mutation
  - More recently, it was found that ~25% of individuals who meet strict diagnostic criteria for CS have a pathogenic PTEN mutation, including large deletions. P.I(2):169
  - Data suggest that up to 50% of individuals with a Proteus-like syndrome and up to 20% of individuals with Proteus syndrome have PTEN mutations

- Deletion/duplication analysis
  - Southern blotting, real-time PCR, MLPA, and other methods of detecting gene copy number variation can each be used to detect large PTEN deletions and rearrangements that are not detectable by PCR-based sequence analysis

Management

- Treatment of manifestations
  - Treatment for benign and malignant manifestations of PHTS is same as for their sporadic counterparts
  - Topical agents (e.g., 5-fluorouracil), curettage, cryosurgery, or laser ablation may alleviate mucocutaneous manifestations of CS
  - Cutaneous lesions should be excised only if malignancy is suspected or symptoms (e.g., pain, deformity) are significant

- Surveillance
  - To detect tumors at the earliest, most treatable stages
    - For children (< 18 years): Yearly thyroid ultrasound and skin check with physical examination
    - For adults: Yearly thyroid ultrasound and dermatologic evaluation
    - For men and women: Colonoscopy beginning at age 35-40 years with frequency dependent on degree of polyposis identified; biennial (every 2 years) renal imaging (CT or MR preferred) beginning at age 40 years
    - For women beginning at age 30 years: Monthly breast self-examination
    - Annual breast screening (at minimum mammogram; MR may also be incorporated) and transvaginal ultrasound or endometrial biopsy
    - For those with family history of a particular cancer type at an early age: Consider initiating screening 5-10 years prior to youngest age of diagnosis in family

- Testing of relatives at risk
  - When PTEN mutation has been identified in a proband, molecular genetic testing of asymptomatic at-risk relatives can identify those who have familyspecific mutation and warrant ongoing surveillance

ASSOCIATED LESIONS AND BENIGN NEOPLASMS

Skin

- Multiple trichilemmomas, usually on face, are cutaneous hallmark of disease
  - Trichilemmomas show differentiation toward hair follicle infundibulum

- Mucocutaneous fibromas and neuromas
- Acral and palmoplantar keratoses
- Oral papillomas involving lips, gums, and tongue

Breast

- Benign lesions are often bilateral and multiple
  - Fibroadenoma
  - Adenosis
  - Apocrine cysts
  - Hamartomas

Thyroid
Diagnostic Pathology: Familial Cancer Syndromes

- Multiple adenomatous nodules are hallmark of disease
- Lymphocytic thyroiditis
- Multinodular hyperplasia
- C-cell hyperplasia

**Esophagus**
- Esophageal glycogen acanthosis is hallmark of CS
  - Abundant glycogen demonstrated on PAS stain ± diastase treatment
  - Pale, ballooned, and vacuolated squamous cells
  - Multiple nodular foci of squamous cell proliferation

**Stomach**
- Most often resemble hyperplastic polyps with prominent foveolar hyperplasia
  - Stromal smooth muscle proliferation may be prominent and mimic Peutz-Jeghers polyposis
  - Distinction from gastric polyps in juvenile polyposis difficult
  - Polyps may appear virtually identical to those described in patients with Cronkhite-Canada syndrome

**Colon**
- Hamartomatous stroma-rich polyps with cystically dilated glands
- Ganglioneuromatous polyps with proliferation of Schwann cells and ganglion cells in lamina propria
- Inflammatory polyps with prominent mucosal or submucosal reactive lymphoid aggregates
- Lipoma
- Colon adenomas may occur in patients with CS at young age
  - Isolated polyps in rectosigmoid colon may mimic mucosal prolapse

**Brain**
- Dysplastic gangliocytoma of the cerebellum, or adult Lhermitte-Duclos disease
  - Refers to a hamartomatous tumor of the cerebellar cortex that can occur in the setting of a PTEN mutation
- Cavernous hemangioma

**Soft Tissue**
- Characteristic disorganized overgrowth of mesenchymal elements (PTEN hamartoma of soft tissue)
- Vascular proliferations
- Hamartomas

P.I(2):170

**ASSOCIATED MALIGNANT NEOPLASMS**

**Breast Carcinoma**
- Age of diagnosis: 38-46 years
  - Occurs 10 years younger than general population
  - Male breast cancer also occurs

**Follicular Thyroid Carcinoma**
- Predominant thyroid tumor in PHTS

**Papillary Thyroid Carcinoma**
- Also reported to have greater risk than general population

**Endometrial Carcinoma**
- Increased risk of endometrial adenocarcinoma: 13-28% lifetime risk

**Renal Cancer**
- Increased risk of renal cancer

**Colorectal Adenocarcinoma**
- Risk of colorectal cancer was estimated at 10x higher that the general population

**Other Cancers Associated With PHTS**
- Glioblastoma
- Melanoma
- Merkel cell carcinoma
- Retinal glioma
- Lung cancer
- Liver cancer
- Pancreatic cancer
- Ovarian cancer
- Bladder cancer
- Liposarcoma

Other Cancers Rarely Associated With PHTS
- Ependymoma
- Medullary thyroid carcinoma
- Granulosa cell tumor
- Lipoblastoma

CANCER RISK MANAGEMENT

Breast
- Breast awareness, including prompt reporting to physicians of any changes
- Periodic breast self-exams starting at age 18 years
- Clinical breast exam every 6-12 months starting at age 25 years or individualized based on earliest known onset of breast cancer in the family
- Annual mammography and breast MR screening starting at age 30-35 years
  - Or 5-10 years before the earliest known breast cancer in the family
  - Or screening as an adjunct to mammography

Thyroid
- Baseline thyroid ultrasound at 18 years and consideration of repeating annually thereafter
- Monthly thyroid examination and palpation starting in adolescence

Uterus
- Surveillance for endometrial cancer starting at age 35-40 years
  - Or 5 years younger than the earliest familial endometrial cancer diagnosis

Kidney
- Annual urinalysis with cytology and renal ultrasound

Colon
- Consideration of baseline colonoscopy at age 35 years
  - Then every 5-10 years or more frequently if patient is symptomatic or polyps are noted

Other Tumors
- Given the high risk of malignancy, cancer surveillance is the major focus of medical management as per American Cancer Society guidelines
  - Annual comprehensive physical exam, starting at 18 years of age

SELECTED REFERENCES
Benign and Malignant Neoplasms Associated With PHTS

(Left) Multiple facial trichilemmomas are common in patients with Cowden syndrome/PHTS. Well-circumscribed epidermal proliferation with pale clear cells are reminiscent of the hair follicle infundibulum. (Right) Invasive ductal carcinomas present in patients with PHTS may demonstrate tubules and have intermediate- to high-grade nuclei or a prominent component of well-formed tubules, and may have rare or absent mitoses.

(Left) Hematoxylin & eosin shows hamartomatous colon polyps usually present in Cowden syndrome/PHTS. Disarray of normal crypt architecture and fibromuscular proliferation may mimic mucosal prolapse polyps. (Right) Hematoxylin & eosin shows ganglioneuromatous polyps, which may be seen in juvenile polyposis and Cowden syndrome. Schwann cell proliferation and numerous ganglion cells are present in the lamina propria in this polyp.
Multiple adenomatous thyroid nodules are usually present in patients with PHTS. These adenomatous nodules may be seen in the thyroid with follicular adenoma and follicular carcinoma. Note the adjacent thyroid follicles are compressed. (Right) Immunohistochemistry for PTEN in thyroid adenomatous nodules in patients with PHTS usually shows loss of immunoreactivity of the follicular cells. Endothelial cells maintain immunopositivity.

**Rhabdoid Predisposition Syndrome**

Fausto J. Rodríguez, MD
The cerebellopontine angle is a classic location for AT/RT. This patient had a constitutional Chr 22 abnormality with multiple congenital anomalies in addition to AT/RT. (Courtesy C. Specht, MD.)
Cytologic features of rhabdoid tumors at all sites include the presence of large, variably dyscohesive cells with eosinophilic cytoplasm and eccentric nuclei with prominent nucleoli.

**TERMINOLOGY**

**Synonyms**
- Formerly called familial posterior fossa brain tumor syndrome, though not all tumors arise in the posterior fossa.

**Definition**
- Genetic predisposition for development of rhabdoid tumors (atypical teratoid/rhabdoid tumor [AT/RT]) of the brain, renal rhabdoid tumors, and extrarenal rhabdoid tumors.

**EPIDEMIOLOGY**

Relatively Rare
- AT/RT represents 1-2% of pediatric brain tumors; 10% of brain tumors in infants with M:F ratio 1.6-2:1.
- Rhabdoid tumors represent < 3% of pediatric renal tumors.
- Median age at diagnosis of rhabdoid tumors is 6 months in patients with germline mutations vs. 18 months sporadically.

**GENETICS**

Germline Mutations in INI1
- Occur in ~ 1/3 of patients with rhabdoid tumors.
- Also known as SMARCB1, hSNF5, BAF47.
- Located in chromosome region 22q11.2.
- Encodes for a protein component of the ATP-dependent SWI-SNF chromatin-remodeling complex.
  - Protein product interacts with HIV-1 integrase.
- Classic tumor suppressor gene (i.e., inactivation through 2 hits leads to tumor formation).
- Frequency of germline mutations is highest in patients with multiple primary sites (~ 100%).
- Gonadal mosaicism in a subset.
  - Multiple affected siblings, unaffected parents.
Most mutations in rhabdoid tumors are deletions, nonsense, or frameshift and lead to complete gene inactivation. Rarely present in > 1 generation given the high penetrance and high mortality of the disease. Few, if any, additional somatic genetic alterations in rhabdoid tumors other than INI1 alterations.

Germline Mutation in SMARCA4/BRG1:
- Reported in a rare family with rhabdoid predisposition syndrome
- Encodes for another protein member of the SWI/SNF chromatin-remodeling complex
- Loss of heterozygosity in 2 sisters with rhabdoid tumors, INI1 protein preservation

CLINICAL IMPLICATIONS AND ANCILLARY TESTS:

Genetic Testing:
- Germline mutation testing and genetic counseling recommended in any patient/families with rhabdoid tumors/neoplasms associated with INI1 protein loss
- Irrespective of age: Patients with germline mutations as old as 22 years at presentation have been reported
- Prenatal DNA testing may be offered in families with documented mutation

ASSOCIATED NEOPLASMS:

Atypical Teratoid/Rhabdoid Tumor:
- Highly malignant neoplasm corresponding to WHO grade IV
- Composed of large cells with eccentric nuclei and macronucleoli arranged in nests or sheets
- Brisk mitotic activity and necrosis
- Variable small round blue cell component
- May predominate in younger patients
- Mesenchymal differentiation, arrangement in cords, myxoid stroma in a subset of cases
- Epithelial morphology with papillae and gland-like areas is rare
- Immunohistochemistry highlights a polypheotypic pattern of staining
  - EMA expression is most frequent, but cytokeratin, GFAP, neurofilament protein, and smooth muscle actin may also be expressed
- Cytoplasmic aggregates of intermediate filaments by electron microscopy
- Very few genetic alterations other than INI1 mutation
  - Loss of INI1 nuclear protein by immunohistochemistry with preservation in nonneoplastic elements is almost diagnostic
- Differential diagnosis includes choroid plexus carcinoma, CNS-PNET/medulloblastoma, epithelioid/rhabdoid glioblastoma, metastasis (melanoma, carcinoma)
  - Cribriform neuroepithelial tumor: Rare, nonrhabdoid intracranial tumor that also demonstrates INI1 protein loss but with a relatively favorable prognosis

Malignant Rhabdoid Tumors:
- Renal
  - Most frequent organ affected outside of the CNS
  - Germline INI1 mutations in almost all bilateral cases
  - Sheets of rhabdoid cells with extensive infiltration of renal parenchyma
  - Brisk mitotic activity, necrosis, vascular invasion, and extrarenal extension are common
  - Gene expression studies suggest origin from early progenitors with repression of neural development
  - Differential diagnosis includes renal medullary carcinoma, cellular mesoblastic nephroma, and clear cell sarcoma of kidney
- Extrarenal
  - May occur in deep soft tissue, skin, and viscera
  - Differential diagnosis includes melanoma, proximal variant of epithelioid sarcoma, rhabdomyosarcoma, extraskeletal myxoid chondrosarcoma, soft tissue myoepithelioma, and carcinoma

Schwannoma:
- Germline mutations in SMARCB1 are also responsible for a subset of patients with schwannomatosis
  - Mainly multiple schwannomas but also meningiomas in rare occasions
  - “Mosaic” pattern of INI1 protein loss by immunohistochemistry in syndrome-associated schwannomas suggests a milder phenotype compared to rhabdoid tumors
  - Mutations more likely to be nontruncating (e.g., splice site)
Rare families characterized by both rhabdoid tumors and schwannomatosis in different family members

Choroid plexus carcinomas and medulloblastomas have been reported in the setting of rhabdoid predisposition syndrome, but morphologic and immunophenotypic features overlap with AT/RT

Loss of SMARCB1 protein expression also described in epithelioid sarcoma, renal medullary carcinoma, pediatric sarcomas, hepatoblastomas, epithelioid malignant peripheral nerve sheath tumor (MPNST), and soft tissue myoepithelioma

CANCER RISK MANAGEMENT
Established Guidelines for Tumor Screening in Affected Families

Routine imaging (CNS MR, renal ultrasound) and feasible screening approaches in the 1st few years of life for mutation carriers

SELECTED REFERENCES
P.I(2):174
Atypical teratoid/rhabdoid tumors (AT/RT) form variably sized masses that may appear well circumscribed. Multiple foci of necrosis are not uncommon in these highgrade, extremely aggressive pediatric tumors. Despite their genetic predisposition being ascribed to the posterior fossa in early reports, they occur throughout the neural axis, including the supratentorial compartment. (Right) AT/RT architecture is variable and may demonstrate sheet-like arrangements of rhabdoid cells.

Rhabdoid tumors in all sites contain variable numbers of large eosinophilic cells with eccentric nuclei and macronucleoli. Cell borders are usually distinct. Single cell necrosis may be a feature. (Right) Mitotic activity is usually not subtle in AT/RT. These tumors are characterized by high proliferative rates and are among the most aggressive human malignancies. Cell to cell wrapping raises the differential with anaplastic medulloblastoma in the CNS.
Rhabdoid tumors may contain poorly differentiated areas of closely packed cells with high nuclear:cytoplasmic ratios lacking overt rhabdoid cytologic features, particularly when involving the CNS. A high index of suspicion is required when encountering a primitive neoplasm in a very young child. Careful search for rare rhabdoid cells and immunostaining documenting INI1 loss is helpful in the diagnosis. (Right) Necrosis is almost always present in rhabdoid tumors.

P.I(2):175

Ancillary Techniques

(Right) Rhabdoid tumors typically label with numerous immunohistochemical markers. Epithelial membrane antigen (EMA) is 1 of the most frequently expressed antigens in such tumors. (Right) Smooth muscle actin expression occurs in a subset of cases of AT/RT and other rhabdoid tumors, although with less frequency than EMA.
One of the most diagnostically useful immunohistochemical findings in malignant rhabdoid tumors is the loss of INI1 expression in neoplastic cells. Preservation of reactivity in nonneoplastic elements, including stromal and endothelial cells, is essential for interpretation. (Right) Whole chr 22 loss/22q deletion features a variety of neoplasms, particularly rhabdoid tumors (BCR = green, NF2 = red). (Courtesy A. Perry, MD.)

Rarely, AT/RT may lack INI1 mutations and instead have mutations in associated proteins such as SMARCA4. As this example demonstrates, histologic and other immunophenotypic findings are identical to INI1 mutant tumors. (Courtesy C. Giannini, MD.) (Right) Retained INI1 (SMARCB1) in an AT/RT containing SMARCA4 mutation, although this tumor demonstrated classic histologic and immunohistochemical features of AT/RT. (Courtesy C. Giannini, MD.)
Multiple schwannomas are the hallmark of schwannomatosis. The spinal nerves are frequently involved in these patients. (Courtesy J. Blakeley, MD.)
Many schwannomas in patients with schwannomatosis have features similar to sporadic tumors, including circumscription and a biphasic architecture of Antoni A and Antoni B areas.

**EPIDEMIOLOGY**

**Incidence**
- Affects ~1 in 40,000 individuals (similar incidence as neurofibromatosis type 2 [NF2])
- Similar incidence in males and females

**ETIOLOGY/PATHOGENESIS**

**Inheritance Pattern**
- 75-85% sporadic, 15-25% inherited

**Suppressor Gene**
- 40-50% of familial cases
- 8-10% of sporadic cases
- 4-hit hypothesis: (1) germline SMARCB1 mutation → loss of Chr 22 with remaining (2) SMARCB1 allele and (3) NF2 gene → loss of remaining (4) NF2 allele

**CLINICAL IMPLICATIONS**

**Clinical Presentation**
- Onset is usually in 2nd and 3rd decades
  - Wide range of ages at initial presentation (children < 10 years through senior patients)
- Multiple schwannomas, usually sparing vestibular nerve
  - Restricted to 1 anatomical region in 1/3 of patients
  - Unilateral vestibular schwannomas may occur at a low frequency and do not exclude the diagnosis
- Chronic pain is most common symptom, often debilitating
  - No clear relationship to tumor size, location, or burden
- Mood disorders, including depression and anxiety, are frequent
- Lack of family history in a majority of patients
- Meningiomas occur at a low frequency in schwannomatosis patients (~5%)
o Rare families with schwannomatosis, multiple meningiomas, and germline SMARCB1 mutation
o Preferential location in falx cerebri
o Usually solitary rather than multiple in schwannomatosis in contrast to NF2

- Ependymoma not a feature
- Ophthalmologic manifestations not present at a higher frequency in schwannomatosis (in contrast to NF2)

**Imaging Findings**

- Peripheral schwannoma location (89%)
  o Arms and legs most common
- Spinal schwannomas (74%)
- Intracranial schwannoma (nonvestibular) (9%)

**Diagnostic Criteria**

- Several clinical criteria proposed to distinguish schwannomatosis from NF2
  - Lack of bilateral vestibular schwannoma; lack of NF2 in 1st-degree relative; lack of germline NF2 mutation
- Recent proposals incorporate molecular testing

**Proposed Criteria for Schwannomatosis (2011 International Schwannomatosis Workshop)**

- Molecular diagnosis
  - Schwannomas or meningiomas (≥ 2 pathologically proven) and
  - ≥ 2 tumors with chromosome 22 loss of heterozygosity + 2 different NF2 mutations or schwannoma or meningioma + germline SMARCB1 mutation
- Clinical diagnosis

<table>
<thead>
<tr>
<th>P.I(2):177</th>
</tr>
</thead>
</table>
| o ≥ 2 schwannomas (not intradermal), 1 pathologically confirmed; no vestibular schwannomas on high-quality MR study or
| o Schwannoma, pathologically confirmed, or intracranial meningioma and 1st-degree relative with schwannomatosis |
- Possible schwannomatosis
  - ≥ 2 nonintradermal schwannomas without pathologic confirmation
- Excludes schwannomatosis
  - Patient with diagnostic criteria for NF2, germline NF2 mutation, 1st-degree relative with NF2, or multiple schwannomas in a prior irradiated field only

**MICROSCOPIC FINDINGS**

**Schwannomas**

- Histologic features similar to sporadic tumors
  - Compact Antoni A areas alternating with loose Antoni B areas, Verocay bodies, hyalinized vessels, and well-formed capsule
- Myxoid changes (“myxoid schwannoma”), intraneural growth, and peritumoral edema overrepresented in schwannomatosis-associated cases
- Nerve edema
- Rare schwannoma variants reported in schwannomatosis patients include plexiform, cellular, and neuroblastoma-like
- S100 and collagen IV (pericellular) positive by immunohistochemistry; EMA(-)
- Mosaic pattern of INI1 immunostaining (i.e., loss in a subset of neoplastic cells) in most schwannomatosis-associated schwannomas

**Neurofibromas**

- Neurofibromas, in addition to schwannomas, are a recognized feature of neurofibromatosis type 2
- Not usually a feature of schwannomatosis patients but previously reported in at least 2 patients

**Hybrid Tumors**

- Tumors with hybrid neurofibroma/schwannoma features overrepresented in syndrome-associated peripheral nerve tumors, particularly in schwannomatosis
- Neurofilament (+) axons in neurofibroma-like component in 1/2 of cases
- GLUT1/EMA (+) perineurial-like cells in neurofibromalike areas
- CD34(+) in Antoni B and neurofibroma-like areas, negative in Antoni A areas

**GENETICS AND MOLECULAR BIOLOGY**

**SMARCB1 Function**

- Tumor suppressor gene
Diagnostic Pathology: Familial Cancer Syndromes

- Other synonyms include INI1, BAF47, hSNF5
- Encodes for a component of the SWI/SNF protein complex
  - Chromatin-remodeling complex, ATP dependent
  - Interacts with HIV-1 integrase

Germline Mutations in SMARCB1
- Nontruncating, missense, or splice site in familial schwannomatosis (unlike atypical teratoid rhabdoid tumor)
- Mutations usually located at ends of SMARCB1
- Inherited in an autosomal dominant fashion, incomplete penetrance

SELECTED REFERENCES

Image Gallery
Microscopic Features

(Left) Classic schwannoma features that may be present in tumors from patients with schwannomatosis include a circumscribed architecture, a collagenous capsule of variable thickness , and microcysts . (Right) Syndrome-associated and sporadic schwannomas are characterized by the presence of compact areas rich in neoplastic Schwann cells, (Antoni A areas) , alternating with loose, macrophage-rich regions (Antoni B areas). Microcysts may be
frequent.

(Left) One of the diagnostic hallmarks of schwannoma is the Verocay body. This anuclear, process-rich, elongated structure is bordered by palisades of neoplastic Schwann cells. (Right) Antoni B areas in schwannomas are characterized by a loose stroma containing lipidized cells as well as macrophages. Delicate wisps of bland spindle cells are variably present, suggesting the schwannian nature of the neoplasm.

(Left) A collagenous capsule is typical of most schwannomas, including schwannomatosis-associated cases. However, capsule thickness is variable and may be altogether absent in areas. (Right) Cellular pleomorphism is a well-recognized feature of schwannomas and has no prognostic significance. Classically termed “ancient change,” it likely represents a degenerative phenomenon. Proliferative rates in these areas are typically low, compatible with a benign nature.

P.I(2):179

Microscopic Features
Many schwannomas in schwannomatosis patients contain classic features. However, the presence of benign nerve sheath tumors with mixed features, including compact Antoni A areas typical of schwannoma and juxtaposed to neurofibroma-like areas, occur at a relatively higher frequency in syndrome-associated tumors. (Right) Neurofibroma-like area in a schwannomatosis-associated benign nerve sheath tumor contains wavy nuclei in a loose stroma with associated collagen.

The presence of delicate collagen in a loose stroma imparts a neurofibroma-like appearance to this difficult-to-classify benign nerve sheath tumor. Classic schwannoma regions were also present, which justifies its interpretation as a hybrid tumor. (Right) Conspicuous myxoid change (i.e., myxoid schwannoma) is seen at an increased frequency in schwannomatosis-associated tumors. Compact, Antoni A areas may represent a minor component of these tumors.
The immunohistochemical hallmark of schwannoma is the expression of S100 protein in a diffuse and strong pattern. (Right) A mosaic pattern of INI1 immunostaining is found in most syndrome-associated schwannomas, including in schwannomatosis. Immunonegative cells alternate with immunopositive cells. This finding suggests that INI1 protein loss is partial in these tumors, compared with the uniform INI1 loss present in rhabdoid tumors.

Tuberous Sclerosis Complex
Subependymal giant cell astrocytomas (SEGAs) are characteristic of TSC, characterized by contrast-enhancing intraventricular masses near the foramen of Monro. A subtle cortical tuber is also present.

SEGAs are characterized by eosinophilic, large cells with prominent nucleoli, features particularly recognizable in smear preparations. Variable cytoplasmic processes are also present.

**TERMINOLOGY**

**Abbreviations**
- Tuberous sclerosis complex (TSC)

**Definitions**
- Inherited tumor predisposition syndrome resulting from mutations in TSC1 or TSC2 genes leading to mTOR pathway activation

**EPIDEMIOLOGY**

**Incidence**
- ~1:5,000-10,000
  - 2nd most common hereditary tumor syndrome involving the CNS

**GENETICS**

**Germline Mutations in TSC1 or TSC2**
- Encode for tumor suppressor part of protein complex that inhibits RHEB and regulates mTOR activation
  - TSC1 located in chromosome region 9q34 (encodes for hamartin)
  - TSC2 located in chromosome region 16p13.3 (encodes for tuberin)
  - RHEB is a small GTPase/homolog of RAS and is kept in an inactive state by TSC1/TSC2 complex
- mTOR is a key downstream mediator of PI3K/AKT activation
- Protein mTOR exists as part of 2 different multiprotein complexes
  - mTORC1 contains PRAS40, RAPTOR, and mLST8/GBL
    - Increases protein translation, cell growth, and survival
  - mTORC2 contains RICTOR, mSIN1, PROTOR, and mLST8
    - Functional role less understood than mTORC1 complex
Regulates metabolism and survival through activation of AKT
- Plays a role in cytoskeletal organization
  - Activation leads to increased protein translation
  - Effective pharmacologic inhibition by rapamycin and analogs
- Majority of patients (70-80%) have new “spontaneous” mutations and lack a family history
  - TSC1 and TSC2 mutation frequency similar in familial cases
  - Mutations in TSC2 more frequent than TSC1 in nonfamilial cases

CLINICAL IMPLICATIONS AND ANCILLARY TESTS

Diagnostic Criteria
- Definite TSC: 2 major features or 1 major + 2 minor
- Probable TSC: 1 major + 1 minor
- Possible TSC: 1 major or > 1 minor
- Major features: Cortical tuber, subependymal nodule, subependymal giant cell astrocytoma (SEGA), facial angiofibroma/forehead plaque, ungual/periungual fibroma, > 3 hypomelanotic macules, Shagreen patch, multiple retinal hamartomas, cardiac rhabdomyoma, renal angiomyolipoma/lymphangioleiomyomatosis (LAM)
- Minor features: White matter migration lines, transmantle cortical dysplasia, retinal patch, hamartomatous rectal polyps, gingival fibroma, dental pits, hypomelanotic clustered skin lesions, bone cysts, renal cysts, nonrenal hamartomas

NONNEOPLASTIC MANIFESTATIONS

Skin
- Hypomelanotic macules (“ash leaf spot”)
- Shagreen patch

Nervous System
- Epilepsy and mental retardation
- Cortical tubers
  - Localized cortical areas with abnormal development
    - Abnormal lamination, dysmorphic neurons, microcalcifications
  - Giant/balloon cells: Pale cytoplasm, variably immunoreactive with glial (S100, GFAP) and neuronal markers (synaptophysin, neurofilament)
- Cortical cytoarchitectural abnormalities may also be present outside tubers
- Subependymal nodules (“candle guttering lesions”)
  - Giant cells arranged in clusters and fascicles with mixed glial/neuronal phenotype

Retinal Hamartoma/Astrocytoma
- Small lesions involving nerve fiber layer of retina in ~ 50% of TSC patients
- Larger lesions may grow and cause retinal detachment
- Histologically similar to SEGA

Renal Cysts
- Usually asymptomatic
- TSC2/PKD1 contiguous gene syndrome: Coexisting TSC and autosomal dominant polycystic kidney disease (severe)

Micronodular Pneumocyte Hyperplasia
- Small nodules of bland type II pneumocytes

ASSOCIATED NEOPLASMS

Cutaneous Angiofibroma
- Previously known by misnomer “adenoma sebaceum”
- Dermal sclerosis
- Dilatation/proliferation of small vessels
- Stellate fibroblasts/multinucleated cells

Subependymal Giant Cell Astrocytoma
- Slow growth
- WHO grade I
- Mitotic activity rare to absent
- Microcalcifications in a subset, necrosis rare
- Pseudorosettes may be present and simulate ependymal neoplasms
- Composed of large cells with eosinophilic cytoplasm and macronucleoli
- Evidence of glial and neuronal differentiation by immunohistochemistry and electron microscopy
  - Consistent S100 expression, GFAP variable
  - Variable expression of synaptophysin, chromogranin, and neurofilament protein
- Excellent response to mTOR inhibitors in clinical trials

**Angiomyolipoma**
- Usually benign, but large tumors associated with risk for life-threatening bleeding
- Most common cause of mortality in TSC adult patients
- May be classic or epithelioid subtype
- May be a cause of LAM
- Partial response to mTOR inhibitors in some studies

**Lymphangioleiomyomatosis**
- Occurs in 30% of women with tuberous sclerosis
- Progressive pulmonary disorder involving lung
- Cystic changes, respiratory failure
- Lung biopsies demonstrate smooth muscle cells involving lymphatics, vessels, airways, and alveolar septa
- SMA(+), HMB-45(+)
- Majority of cases associated with tuberous sclerosis have TSC2 mutations (rather than TSC1) and loss of heterozygosity
- Loss of heterozygosity in TSC2 also frequent in sporadic LAM

**Cardiac Rhabdomyoma**
- ~50% of patients with TSC
- Most frequent initial imaging finding in TSC patients
- May cause cardiac arrhythmias but also may regress with age

**Pancreatic Neuroendocrine Tumor**
- Not part of diagnostic criteria, but recognized in rare TSC patients

**SELECTED REFERENCES**

P.I(2):182

**Image Gallery**

**Microscopic Features**
Numerous cortical abnormalities characterize the tuberous sclerosis complex. In this example, cortical disarray is present in a cortical tuber. (Right) Numerous abnormal pale cells are evident in this field. They have an ambiguous phenotype. A distinct cortical neuron is also present in this field, which serves as a good comparison.

Large, pale balloon cells are typical of cortical tubers associated with tuberous sclerosis and are present in variable numbers. Fine, particulate calcifications are also present in this example. (Right) Cortical tubers are distinctive lesions associated with tuberous sclerosis complex containing enlarged pale cells (giant/balloon cells) with an ambiguous, variable phenotype along glial and neuronal lines.
(Left) Dysplastic neurons are also frequent in tubers. In this example, there is abnormal pallor and uneven distribution of Nissl substance. Prominent gliosis, including Rosenthal fibers, was also present. (Right) In addition to abnormal neurons and pale cells, tubers are characterized by frequent gliosis. An immunohistochemical stain for GFAP is useful in highlighting reactive astrocytes and their characteristic stellate cytoplasmic processes.

Diagrammatic and Microscopic Features

(Left) The characteristic lesions of tuberous sclerosis in the CNS include cortical tubers, subependymal nodules identifiable in the walls of the lateral ventricles, and the low-grade neoplasm known as subependymal giant cell astrocytoma. (Right) SEGAs may be identified on smear preparations during intraoperative evaluations. They are characterized by large eosinophilic cells with round/oval nuclei and macronucleoli.
(Left) The large cells of subependymal giant cell astrocytoma may contain voluminous eosinophilic cytoplasm with a “glassy” quality. Mitotic activity in these tumors is rare to absent, in keeping with their low-grade nature. (Right) Aggregates of eosinophilic cells in a fibrillar stroma characterize this SEGA.

(Left) Not infrequently, subependymal giant cell astrocytomas may contain fields of spindle cells arranged in loose fascicles. Whorling may be present in low-power magnification. (Right) Coarse calcifications may be a feature of some subependymal giant cell astrocytomas, as in other CNS lesions associated with tuberous sclerosis.

P.I(2):184

Ancillary Techniques
A glial phenotype was ascribed early on to subependymal giant cell astrocytoma, which is reflected in its name. The most consistent glial marker in these tumors is S100, which typically demonstrates diffuse staining. However, this marker is not entirely specific for glial differentiation. (Right) GFAP, a more specific marker of glial differentiation, is usually positive in subependymal giant cell astrocytoma, although it is more variable in frequency and intensity.

In addition to glial markers, subependymal giant cell astrocytoma also labels with markers of neuronal differentiation, such as synaptophysin. Therefore, these tumors demonstrate differentiation along glial and neuronal lines. (Right) Subependymal giant cell astrocytomas usually have very low proliferative rates. In this example, the Ki-67 proliferation index is < 1%.
Subependymal giant cell astrocytoma is a tumor of the nervous system that is characterized by varying numbers of mast cells. Other tumors with increased number of mast cells include hemangioblastoma and neurofibroma. Mast cells may be identified by expression of KIT on immunohistochemical preparations.

Microscopic and Imaging Features

Astrocytic hamartomas represent the typical intraocular manifestation in tuberous sclerosis patients. They are characterized by slow growth and bland spindle cell cytology. They are frequently multiple in TSC. Histologic similarities with subependymal nodules/SEGA are a feature of retinal astrocytic lesions in tuberous sclerosis patients. Scattered microcalcifications were present in this example.
Renal manifestations are also typical of tuberous sclerosis complex, including numerous cysts as well as bilateral neoplasms that, in this case, were interpreted radiologically as probable angiomyolipomas. The prototypical neoplasm involving the kidney in tuberous sclerosis patients is angiomyolipoma, which contains spindle/eosinophilic cells as well as variable amounts of adipose tissue.

Tuberous sclerosis patients also frequently develop cutaneous angiofibromas. As the name implies, these benign growths contain variable amounts of small vessels and collagen deposition. Numerous thinwalled vessels are evident in cutaneous angiofibromas. Multinucleated stromal cells are also frequent and, despite their pleomorphic nature, should not be a cause for alarm in these benign tumors.
Abdominal lesions in von Hippel-Lindau (VHL) syndrome are varied and include bilateral renal cysts, renal tumors, particularly renal cell carcinoma (RCC), pancreatic cysts, and pheochromocytoma.
The characteristic neoplasm involving the CNS and retina in patients with VHL syndrome is hemangioblastoma, a vascularized tumor containing vacuolated stromal cells.

**TERMINOLOGY**

**Abbreviations**
- von Hippel-Lindau (VHL) syndrome

**Synonyms**
- von Hippel-Lindau disease
- Familial cerebelloretinal angiomatosis

**Definitions**
- Rare autosomal dominant genetic disease resulting from mutation in VHL tumor suppressor gene on chromosome 3p25.3
- Characterized by retinal and CNS hemangioblastomas, pheochromocytomas, pancreatic serous cystadenoma, café au lait spots, and renal cell carcinoma
  - If no family history, diagnosis requires 2 cardinal manifestations
    - Including retinal and CNS involvement
    - Excluding cysts
  - With positive family history
    - 1 cardinal manifestation, excluding cysts
- Member of phacomatosis familial cancer syndromes

**EPIDEMIOLOGY**

**Incidence**
- 1 case per 36,000 newborns
- 6,000-7,000 patients in United States

**Age**
- Age at diagnosis varies from infancy to 60-70 years

**Gender**
No predilection is noted

**GENETICS AND MOLECULAR BIOLOGY**

**Tumorigenesis**
- VHL gene encodes VHL protein, which is an E3 ubiquitin ligase
  - Major regulator of hypoxic response by targeting transcription factor hypoxia inducible factor (HIF) for degradation
- VHL disease demonstrates marked phenotypic variability and age-dependent penetrance
  - Genotype-phenotype associations in VHL disease form basis of clinical classification
- Presumed that clinical presentation reflects quantitative or qualitative altered VHL protein function

**Molecular Genetics**
- Autosomal dominant
- Germline mutation of VHL gene (3p25.3)
  - VHL mutation in 50% of sporadic renal cell carcinoma (RCC)
  - 2nd inactivating event predisposes to neoplasms
- VHL protein
  - Promotes destruction of hypoxia inducible factor 1 α (HIF-1α) via ubiquitin pathway
    - Loss of function leads to increased levels of vascular endothelial growth factor (VEGF)
  - HIF-independent regulation of primary cilium and apoptosis via NF-κB pathway
    - Loss of function promotes renal cysts

**Subtypes**
- **Classification**
  - Type 1: Caused by deletions or truncation mutations of VHL gene
  - Types 2A, B, C: Caused by missense point mutations
- **Genotype-phenotype correlations**
  - Type 1 VHL (truncating and exon deletions)
  - Type 2 VHL (missense mutations)
    - Low risk of pheochromocytoma
    - Type 2 VHL (missense mutations)
      - High risk of pheochromocytoma
      - Type 2A: Low risk of RCC
      - Type 2B: High risk of RCC
      - Type 2C: Familial pheochromocytoma without hemangioblastoma or RCC

**CLINICAL IMPLICATIONS AND ANCILLARY TESTS**

**Surgical Approaches**
- Nephron-sparing surgery
- Tumor resection when other organs affected
- Surgery for > 3 cm endocrine pancreatic tumor
- Adrenalectomy for pheochromocytoma

**Prognosis**
- Death due to renal cell carcinoma in 50%
  - Metastases to liver, lung, and bone
- Pheochromocytoma is cured after surgery
  - Metastatic pheochromocytoma has not been reported

**ASSOCIATED NEOPLASMS**

**Hemangioblastoma**
- Most common lesion associated with VHL disease
- Clinical, radiologic, and pathologic features similar in sporadic and VHL-associated tumors
- Cerebellum and spinal cord tumors are major central nervous system manifestations
  - Affect 60-84% of patients
- Benign vascular tumor, but may cause significant morbidity due to neurological deficits
- Clinically, patient can present with headaches, numbness, dizziness, weakness, pain in arms and legs, incontinence, or ataxia
- Retinal hemangioblastomas are typical ocular lesions of VHL disease
  - Previously referred to as hemangiomas, but histologically identical to CNS counterparts
  - Usually multifocal and bilateral
  - Clinically, patients present with painless loss of visual acuity or visual field
In advanced cases, can present with hemorrhage, leading to secondary glaucoma and loss of vision.

- **Histologic features**
  - Well-circumscribed tumors
  - Piloid gliosis with Rosenthal fibers is common in adjacent CNS parenchyma
  - Highly vascular with large and small thin-walled vessels
  - Absent to rare mitotic activity
  - Reticular type
    - Composed of small nests/sheets of vacuolated cells known as stromal or interstitial
    - Reticulin abundant and highlights small lobules and individual cells
  - Cellular type
    - Architecture characterized by larger lobules
    - Increased cytoplasm, vacuolation inconspicuous
    - Glioma-like areas expressing GFAP
    - Less reticulin
  - Nuclear pleomorphism may be present
  - Extramedullary hematopoiesis
  - Cystic changes and sclerosis variable
  - Metastatic renal cell carcinoma to hemangioblastoma very rare but reported

- **Histochemistry and immunohistochemistry**
  - Lipid in stromal cells may be highlighted by oil red O in frozen sections
  - Reticulin helpful in highlighting small lobules and individual cells in reticular type
  - Immunophenotype typically inhibin (+), NSE(+), GFAP(+/−)
  - EMA usually negative (very rarely positive), CD10(−), CK(−)
  - Low Ki-67 labeling index

- **Molecular cytogenetics**
  - Different cytogenetic profiles in reticular and cellular subtypes of hemangioblastoma by comparative genomic hybridization
    - Loss of chromosome 6 associated with cellular subtype
    - Loss of 19/19p more frequent in reticular variant

Renal Cell Carcinoma

- Patients with VHL disease are at high risk of developing multiple renal cysts and RCC, affecting 2/3 of VHL patients
- RCC is clear cell type, often multicentric &/or bilateral
- **Histology**
  - Sporadic and VHL-associated clear cell tumors are often indistinguishable
  - Tumors are usually surrounded by a thick fibrous capsule
  - Tumors in VHL patients are usually multicystic &/or solid
  - Typically VHL tumors have microcystic growth pattern
  - Composed of cells with cleared-out cytoplasm and small nuclei
  - Early lesion: Intratubular proliferation of clear cells

Pheochromocytoma

- Catecholamine-producing neuroendocrine tumor related to chromaffin cells that arise from adrenal medulla or extraadrenal chromaffin tissue (paraganglia)
- Pheochromocytoma associated with VHL is usually asymptomatic
- **Hallmark of type 2 VHL disease**
  - Patients with VHL disease are often very young (< 40 years)
  - Tumor is usually bilateral, multiple, or extraadrenal
    - Hypertension with headache and sweating is most common presentation
- **Histology**
  - VHL pheochromocytoma have distinct pathological features from multiple endocrine neoplasia type 2 (MEN2) pheochromocytomas
    - Presence of thick fibrous capsule
    - Myxoid and hyalinized stroma
    - Small to medium-sized tumor cells
    - Absence of cytoplasmic hyaline globules
    - Lack of nuclear atypia

P.I(2):188
Absence of adrenomedullary hyperplasia

Pancreatic Endocrine Tumor and Pancreatic Cysts
- Tumors present in 10% of VHL patients are usually multiple and well circumscribed
- Tumors in VHL patients are usually nonsecretory
- Endocrine pancreatic tumors are characterized by solid, trabecular, &/or glandular architecture
- Stomal collagen is usually present
- Most tumors have clear cells
- Marked nuclear atypia may be present
- Mitoses are rare

Other Associated Lesions
- Papillary cystadenoma of epididymis
- Endolymphatic sac tumor
- Papillary cystadenoma of broad ligament and mesosalpinx
- Cysts of pancreas, kidney, adrenal, testis, and ovary

DIFFERENTIAL DIAGNOSIS
Cystic Renal Diseases Associated With Renal Neoplasms
- Acquired cystic kidney disease
  - Cyst frequency proportional to duration of ESRD
  - Diverse array of RCCs
- Tuberous sclerosis complex/autosomal dominant polycystic kidney disease (ADPKD) contiguous gene syndrome
  - Diffusely cystic kidneys identical to ADPKD
  - Multiple and bilateral angiomyolipomas
  - Rarely, clear cell RCC
- Autosomal dominant polycystic kidney disease
  - Risk of RCC may be increased but controversial
  - Far more numerous cysts than in VHL

Tuberous Sclerosis Complex
- Angiomyolipomas common
- Renal cancer and renal cysts rare
- Rare pancreatic lesions
- Calcified cortical lesions (i.e., tubers), subependymal nodules, and subependymal giant cell astrocytoma

Neurofibromatosis Type 1
- May develop multiple pheochromocytomas, but CNS lesions are astrocytomas rather than hemangioblastomas

CANCER RISK MANAGEMENT
Early Diagnosis
- Improves prognosis of most VHL manifestations
  - Comprehensive screening program starting in childhood
  - Lifelong routine screening for hemangioblastomas (CNS and retinal), RCCs, and pheochromocytomas

SELECTED REFERENCES

Image Gallery

Imaging and Gross Features

(Left) Axial T1-weighted post-contrast MR shows 2 of several cerebellar hemangioblastomas, a finding that is so characteristic as to be diagnostic of VHL syndrome by itself. The presence of multiple cysts and tumors in other organs is also characteristic of this disorder. (Right) Axial CT shows innumerable pancreatic and renal cysts. Either the CNS or abdominal findings would be considered diagnostic of this disorder. A patient’s family history is also useful for corroboration.
(Left) Axial T2WI in a young man with multiorgan manifestations of VHL syndrome shows multiple pancreatic and renal cysts. (Right) Kidney from a patient with VHL disease shows multiple renal cysts within the renal parenchyma. There is a yellow well-circumscribed RCC with extensive hemorrhage.

(Left) This cut surface of a pancreas from a patient with VHL disease shows diffuse replacement of the normal architecture by variably sized cysts. The cysts are thin walled and have clear contents. (Right) Pancreas from a VHL syndrome patient shows a multicystic lesion with a cystadenoma. The cysts are derived from the pancreatic duct system, have a thin capsule, and are lined by a simple epithelium.

Renal Cell Carcinoma
This photomicrograph demonstrates an RCC in a patient with VHL syndrome with a predominantly solid component of the tumor. The tumor is composed of clear cells and is morphologically indistinguishable from sporadic RCC. (Right) RCC with a cystic component is usually present in patients with VHL syndrome. The tumor is predominantly cystic, and the cysts are lined by cells with clear cytoplasm and low-grade nuclei.

The cyst lining from a renal cyst in a patient with VHL syndrome is composed of clear cells with ample cytoplasm and irregular grade 2 nuclei. The cyst is surrounded by a thick fibrous capsule. (Right) Most of the RCCs in VHL syndrome patients are solid and cystic. The solid component is composed of cells with similar appearance to the cells lining the cystic spaces.
RCC in a patient with VHL syndrome shows a solid component of the tumor. The tumor cells are arranged in cords or trabeculae and are separated by thin fibrovascular stroma. The tumor cells are round to oval with irregular nuclei. (Right) RCC in patients with VHL disease shows decreased clusterin staining in comparison with RCC in non-VHL disease patients.

P.I(2):191

Pheochromocytoma and Pancreatic Features

(Left) Pheochromocytoma in association with VHL disease shows tumor cells arranged in a nested and trabecular arrangement. Tumor cells have ample cytoplasm and irregular nuclei. Note the absence of intracytoplasmic eosinophilic granules. (Right) Decreased clusterin staining in VHL syndrome pheochromocytoma is similar to the findings of decreased expression seen in VHL syndrome-associated RCC.
(Left) SDHA immunostain reveals preservation of the staining of the pheochromocytoma cells in VHL syndrome-associated tumors. (Right) SDHB staining in VHL-associated pheochromocytoma shows loss of immunostaining, which is accompanied by preservation of SDHA. This finding is similar to the immunoeexpression of these antigens in familial paraganglioma-pheochromocytoma syndromes (SDHB- and SDHD-associated pheochromocytomas).

(Left) Pancreas from a patient with VHL disease shows multiple thin-walled cysts of variable sizes. The cysts are filled with clear fluid, and there is extensive fibrosis of the pancreas. (Right) This photomicrograph of a pancreas from a patient with VHL disease shows multiple cysts lined by a single layer of cuboidal clear cells, surrounded by thick fibrous bands. There is residual pancreatic parenchyma.

Hemangioblastoma
Hemangioblastoma is the most frequently occurring tumor in VHL syndrome patients. Although they may also arise sporadically, the presence of multiple tumors is essentially pathognomonic of the disorder. The main locations involved are the cerebellum and spinal cord. (Right) Although named hemangiomas in the past, given their rich vascular supply, retinal tumors afflicting VHL syndrome patients are hemangioblastomas, histologically identical to tumors involving the CNS.

The reticular variant of hemangioblastoma is characterized by variable numbers of stromal cells containing prominent cytoplasmic microvacuoles. (Right) This hemangioblastoma developed in a VHL syndrome patient and demonstrates some attributes of the cellular variant, particularly a paucity of vacuolated cells and larger lobules. There are no significant clinical or pathologic differences between VHL syndrome-associated and sporadic hemangioblastomas.
An interesting histologic finding in a minority of hemangioblastomas is the presence of extramedullary hematopoiesis. This is characterized by variable clusters of large cells with prominent nucleoli and frequent mitotic figures. (Right) Hemangioblastomas contain a rich vascular supply, and are not uncommonly grossly mistaken for blood clots or vascular malformations. This particular example demonstrates congestion as well as a multinucleated megakaryocyte.

P.I(2):193

Hemangioblastoma and Endolymphatic Sac Tumor

(Left) Stromal cells contain variable amounts of intracytoplasmic lipid. In frozen section, an oil red O special stain may be particularly useful, since the characteristic microvacuolation of stromal cells may not be evident. (Right) A positive immunohistochemical reaction for inhibin is one of the most useful diagnostic features of hemangioblastoma, since most entities in the differential diagnosis are almost always negative.
A subset of hemangioblastomas may contain areas of glial differentiation and demonstrate overt immunoreactivity in neoplastic cells for glial markers such as GFAP. Reticulin stain is useful in the evaluation of hemangioblastomas, since it highlights small lobules and even individual cells. This pattern is particularly characteristic of the reticular variant.

Endolymphatic sac tumor is another rare neoplasm that may develop in patients with VHL disease. It is characterized by epithelial papillary structures, which may be easy to identify in smear preparations. Endolymphatic sac tumors are recognized by their epithelial cytologic and architectural features. Their epithelial phenotype may also be confirmed by immunohistochemistry. Strong EMA immunopositivity is present in this example.
Werner Syndrome/Progeria

This is a patient with Werner syndrome at age 15. Her face has a normal appearance without premature aging; her hair is not yet gray. (Courtesy International Registry of Werner Syndrome.)
This is the same Japanese patient with Werner syndrome at age 49. Her hair is gray, and she has prematurely aged facies. (Courtesy International Registry of Werner Syndrome.)

TERMINOLOGY

Synonyms
- Adult progeria
- Progeria of the adult
- Adult premature aging syndrome

Definitions
- Premature aging after puberty
- Predisposition to cancers

EPIDEMIOLOGY

Natural History
- Normal growth until puberty
- Clinical diagnosis usually made in 30s
- Death usually in 40s to 60s
  - Often secondary to atherosclerosis or cancer

Incidence
- United States
  - ~1 in 200,000 to 1 million
- Japan
  - ~1 in 20,000 to 40,000
  - Even higher in some communities with high rates of consanguinity

Ethnicity Relationship
- More common in Japanese people
- All races affected

Age Range
Onset of clinical findings after puberty

Gender
- M:F = 1:1

GENETICS

Mutation
- WRN (RecQ2) gene
  - Encodes Werner (RecQ DNA helicase) protein
    - Werner protein involved in DNA repair/maintenance; has exonuclease and helicase activities
    - Most mutations lead to abnormally truncated protein that cannot translocate to nucleus
  - Mutations in WRN also described in age-related cataracts
  - DNA methylation of this gene may be altered in patients without mutations in WRN

Inheritance
- Autosomal recessive
- Heterozygote relatives of affected individuals may have very mild findings

CLINICAL IMPLICATIONS AND ANCILLARY TESTS

Clinical Presentation
- Premature graying (canities)/hair loss
  - > 98% of cases in Japanese series (Takemoto et al)
  - Mean age: 20 years
- Thin, sclerodermoid skin
  - Mean age: 25 years
  - Most prominent sites
    - Face
    - Forearms
    - Hands
    - Legs
    - Feet
- Pigmentary changes of skin
  - Diffuse or with localized freckles/lentigines
- Nails
  - Dystrophic, atrophic, or hypoplastic
- Clavus/callus/hyperkeratoses
  - On soles of feet
  - Also over pressure points
    - Fingers
    - Toes
    - Ankles
    - Elbows
    - Sometimes ears
- Flat feet
- Skin ulcers
  - > 85% of cases in Japanese series (Takemoto et al)
  - Mean age: 33 years
  - May be progressive
  - Difficult to treat
  - May be complicated by osteomyelitis
- Bird-like facies
  - > 95% of cases in Japanese series (Takemoto et al)
  - Pinched expression
  - Thin
  - Prominent eyes
  - Beaked nose
  - Circumoral radial furrows
  - Taut lips (but normal aperture)
  - Protuberant teeth
- Micrognathia
- Short stature
  - Average height: 5 feet
- Thin extremities
- Calcification of Achilles tendon
  - > 85% of cases in Japanese series (Takemoto et al)
  - Segmental and flame-shaped pattern
- Thick trunk (central obesity)
- Abnormal voice
  - > 85% of cases in Japanese series (Takemoto et al)
  - May be hoarse
  - May be high and raspy
  - Mean age: 25 years
  - Secondary to laryngeal atrophy
- Cataracts, bilateral
  - > 75% of cases in Japanese series (Takemoto et al)
  - Mean age: 30 years
- Type 2 diabetes mellitus
  - ~ 60% in Japanese series of 185 patients
  - Mean age: 34 years
- Dyslipidemia
  - ~ 50% in Japanese series of 185 patients
- Hypogonadism
- Atherosclerosis
- Osteoporosis

Laboratory Findings
- Abnormal glucose
- Abnormal lipid panel
- Uric acid may be elevated

Imaging Findings
- Calcification of Achilles tendon

MICROSCOPIC FINDINGS

Skin
- Often epidermal, dermal, subcutaneous atrophy
- May see dermal calcifications
- Dermis may be hyalinized

ASSOCIATED NEOPLASMS

Epithelial and Nonepithelial
- Wide variety of neoplasms in Japanese series of 163 patients, but epithelial:nonepithelial ratio ~ 1:1
  - Epithelial (1 or 2 cases except where noted)
    - Thyroid cancer (4/163) most common
    - Lung cancer (3/163)
    - Pharyngeal cancer
    - Breast cancer
    - Gastric cancer
    - Hepatic cancer
    - Pancreatic cancer
    - Renal cancer
    - Bladder cancer
    - Colon cancer
    - Uterine cancer
  - Nonepithelial (1 or 2 cases except where noted)
    - Malignant fibrous histiocytoma (6/163)
    - Melanoma (6/163)
    - Meningioma (6/163)
    - Myelodysplastic syndrome (4/163)
    - Leiomyosarcoma
    - Malignant peripheral nerve sheath tumor
Osteosarcoma
Multiple myeloma

CANCER RISK MANAGEMENT
Screening
- As clinically indicated

DIFFERENTIAL DIAGNOSIS
Hutchinson-Gilford Progeria
- Premature aging from infancy
- Mutation in LMNA
- Severe atherosclerosis
  - Often causing death by puberty
  - Secondary to myocardial infarction, stroke
- Sclerotic skin, joint contractures, alopecia, growth impairment
- Generally lacks cataracts, hyperkeratoses, skin ulcers, diabetes mellitus

Atypical Werner Syndrome
- Heterozygous mutations in LMNA rather than WRN
- Phenotype similar to Werner syndrome
  - May be more severe
- Some suggest this could be categorized as late-onset Hutchinson-Gilford progeria

Acrogeria
- Onset from birth; normal lifespan
- Autosomal dominant or recessive inheritance
- Poikiloderma with marked atrophy of skin of hands/feet
- Prominent veins on trunk
- Dystrophic nails, normal scalp hair

Metageryia
- Onset from birth
- Autosomal recessive
- Poikiloderma
- Atrophic extremities
- Early-onset diabetes mellitus, atherosclerosis

Rothmund-Thomson Syndrome
- Autosomal recessive, RECQL4 mutation
- Cataracts develop in 1st 4 years of life
- Short stature
- Hypogonadism
- Telangiectasias of skin (poikiloderma)
- Increased risk of osteosarcoma, squamous cell carcinoma
- Generally lacks premature graying, sclerodermoid skin changes, osteoporosis, arteriosclerosis

Cockayne Syndrome
- Autosomal recessive, mutation in ERCC8 or ERCC6
- Onset after 1st year
- Short stature, bird-like facies, canities
- Photosensitivity, poikiloderma
- No increased risk of malignancy
- Neurologic degeneration (optic atrophy, deafness, unsteady gait, demyelination of nervous system); may lead to death

DIAGNOSTIC CRITERIA
Cardinal Signs/Symptoms
- Premature graying, hair loss
- Bilateral cataracts
- Characteristic skin findings
  - Tight, atrophic skin
  - Pigmentary alteration
  - Ulceration
May be related to ectopic calcification
- Atrophy
- Soft tissue calcification
- "Bird" facies
  - Pinched nasal bridge
  - Atrophy
- Abnormal voice

Further Signs/Symptoms
- Short stature
- Abnormal glucose/lipid levels
- Abnormal bones (osteoporosis)
- Malignant tumors
- Parental consanguinity or affected sibling
- Premature atherosclerosis
- Hypogonadism

Genetic Testing
- WRN mutation

Confirmed Diagnosis
- All cardinal signs or 3 cardinal signs plus WRN mutation

Suspected Diagnosis
- > 2 cardinal signs or 1-2 cardinal plus other signs

Exclusion
- Onset of signs before puberty (excluding short stature)

SELECTED REFERENCES

P.I(2):197

Image Gallery
Clinical Photographs
(Left) This is a patient with Werner syndrome at age 13. Her appearance is normal. (Courtesy J. Oshima, PhD.) (Right) This is the same patient with Werner syndrome at age 21. She does not yet have premature gray hair but does have short stature. (Courtesy J. Oshima, PhD.)

(Left) This is the same patient with Werner syndrome at age 36. She has a prematurely aged appearance with gray hair. (Courtesy J. Oshima, PhD.) (Right) This is the same patient with Werner syndrome at age 40.
Coronal T2WI MR shows whorled high signal intensity throughout a Wilms tumor (WT). The tumor fills the right side of the abdomen and extends across the midline.
H&E shows classic triphasic histology of WT composed of an admixture of blastemal, epithelial tubular, and stromal spindle cells. Blastemal cells are crowded small cells with abundant mitosis.

**TERMINOLOGY**

**Abbreviations**
- Wilms tumor (WT)

**Definitions**
- Include WT in genetic syndromes associated with WT1 and childhood overgrowth syndromes

**EPIDEMIOLOGY**

**Incidence**
- WT diagnosed in ~ 1 in 10,000 white children
  - Vast majority of WTs are sporadic (up to 99%)
  - Familial WT comprises ~ 2% of cases
  - Congenital anomalies seen in up to 9% with syndrome diagnosis in up to 17% of WT patients
  - Childhood overgrowth syndrome seen in ~ 4% of WT patients

**CLINICAL IMPLICATIONS**

**Prognosis of WT**
- High cure rate, with estimated survival of 90% for localized disease and 70% for advanced disease
- Early screening detection for WT in individuals with syndrome is mainly to reduce complication from extensive therapy of higher stage diseases

**Screening of WT**
- Genetic testing and surveillance recommended for children with > 5% risk for WT
- Screening up to age 5 years expected to detect up to 95% of tumors in patients with WT1 mutations

**WT1-ASSOCIATED SYNDROMES**

**General Features**
- Patients with WT diagnosed younger than sporadic cases (~ 1 year vs. 3-4 years)
- Higher likelihood for bilateral WT (38% vs. 5% for sporadic cases)
Screening for WT performed by renal ultrasound ~ 3 months until 5 years of age
WT frequently contains intralobar nephrogenic rests and often stromal predominant

WT Aniridia Genitourinary Malformations and Mental Retardation (WAGR) Syndrome
- Phenotype: Aniridia, ambiguous external genitalia (including cryptorchidism), and intellectual impairment
- High risk for renal failure, affecting ~ 40% by age 20 years
- Caused by microdeletions at Chr 11p13 that encompass WT1 and PAX6
- ~ 30% risk for WT

Denys-Drash Syndrome
- Phenotype: Ambiguous genitalia, diffuse mesangial sclerosis, and genitourinary abnormalities in male
  - Nephropathy presents as hypertension and proteinuria
- Caused by point mutation in zinc finger region of WT1 at Chr 11p13
- ~ 90% risk for WT

Frasier Syndrome
- Phenotype: Ambiguous genitalia, streak gonads, focal segmental glomerulosclerosis
- Caused by point mutation in WT1 intron 9 donor splice site at Chr 11p13
- Low risk for WT

OVERGROWTH SYNDROMES
General Features
- Heterogeneous, poorly defined, and overlapping group of genetic conditions with manifestations of overgrowth
  - Large size at birth, large head, excessive growth or rapid increase in weight or length
- Risk for WT evaluated per syndrome rather than on collective basis
- Screening for WT in Beckwith-Wiedemann syndrome (BWS) and isolated (idiopathic) hemihypertrophy (IHH) performed by renal ultrasound ~ 3 months until age 8 years (older than in WT1-associated syndromes due to later age of onset)

Beckwith-Wiedemann Syndrome (BWS)
- Phenotype: Organomegaly, large birth weight, macroglossia, omphalocele, hemihypertrophy, ear anomalies, and neonatal hypoglycemia
- Renal abnormalities such as nephromegaly, renal cysts, medullary sponge kidney, medullary dysplasia, hydronephrosis, and calculi formation
- Most caused by altered expression of imprinted genes (KCNQ1OT1, CDKN1C, LIT1, or H19 and IGF2) located at Chr 11p15.5
- < 10% results from germline CDKN1C mutation
- ~ 7-14% develop cancer, greatest risk at 1st decade of life
  - Most frequent is WT affecting up to 8% of cases
- Higher risk for bilateral WT (17%) and perilobar nephrogenic rest (60%) than in sporadic WT

Simpson-Golabi-Behmel Syndrome
- Phenotype: Coarse facial features, skeletal and cardiac abnormalities, accessory nipples, and possible intellectual abnormalities
- ~ 30% have renal abnormalities
- Majority (70%) caused by mutations or deletions of Glypican-3 (GPC3) at Chr Xq26
- ~ 9% develop WT

Isolated (Idiopathic) Hemihypertrophy (IHH)
- Phenotype: Asymmetrical growth with 1 body part larger than contralateral counterpart
- Hemihypertrophy can be associated with other syndromes such as BWS, but majority presents as isolated finding
- Abnormality in Chr 11p15 in 20-35% of cases
- ~ 3% develop WT

Perlman Syndrome
- Phenotype: Polyhydramnios, visceromegaly, facial dysmorphism, developmental delay, cryptorchidism, renal dysplasia, WT, and high infant mortality
- Unknown cause; GPC3 mutation suggested
- ~ 33% develop WT and nephroblastomatosis

SELECTED REFERENCES

### Conditions With Increased Risk of Wilms Tumor

<table>
<thead>
<tr>
<th>Conditions</th>
<th>Level of Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>WTI deletions (including WAGR syndrome)</td>
<td>High</td>
</tr>
<tr>
<td>Truncating and pathogenic missense WTI mutations (including Denys-Drash syndrome)</td>
<td>High</td>
</tr>
<tr>
<td>Familial Wilms tumor</td>
<td>High</td>
</tr>
<tr>
<td>Perlman syndrome</td>
<td>High</td>
</tr>
<tr>
<td>Mosaic variegated aneuploidy</td>
<td>High</td>
</tr>
<tr>
<td>Fanconi anemia D1/biallelic BRCA2 mutation</td>
<td>High</td>
</tr>
<tr>
<td>WTI intron 9 splice mutations (Frasier syndrome)</td>
<td>Moderate</td>
</tr>
<tr>
<td>Beckwith-Wiedemann syndrome caused by 11p15 uniparental disomy, isolated H19 hypermethylation or of unknown cause</td>
<td>Moderate</td>
</tr>
<tr>
<td>Simpson-Golabi-Behmel syndrome caused by GPC3 mutations/deletions</td>
<td>Moderate</td>
</tr>
<tr>
<td>Isolated hemihypertrophy</td>
<td>Low</td>
</tr>
<tr>
<td>Bloom syndrome</td>
<td>Low</td>
</tr>
<tr>
<td>Li-Fraumeni syndrome/Li-Fraumeni-like syndrome</td>
<td>Low</td>
</tr>
<tr>
<td>Hereditary hyperparathyroidism-jaw tumor syndrome</td>
<td>Low</td>
</tr>
<tr>
<td>Mulibrey nanism</td>
<td>Low</td>
</tr>
<tr>
<td>Trisomy 18</td>
<td>Low</td>
</tr>
<tr>
<td>Trisomy 13</td>
<td>Low</td>
</tr>
<tr>
<td>2q37 deletions</td>
<td>Low</td>
</tr>
</tbody>
</table>

*High risk (> 20%); moderate risk (5-20%); low risk (< 5%); screening for WT recommended for moderate- and high-risk conditions.*
Xeroderma Pigmentosum

Many photo-distributed lentigines are seen in this patient with xeroderma pigmentosum. (Courtesy K. Kraemer, MD.)
This patient with xeroderma pigmentosum has corneal clouding. (Courtesy K. Kraemer, MD.)

**TERMINOLOGY**

**Abbreviations**
- Xeroderma pigmentosum (XP)

**Synonyms**
- DeSanctis-Cacchione syndrome

**Definitions**
- Inherited disorder of nucleotide excision repair
- Characterized by photosensitivity and early onset of skin cancer and solar lentigines

**EPIDEMIOLOGY**

**Incidence**
- ~1 in 1 million in United States
- ~1 in 40,000 in Japan

**Ethnicity Relationship**
- More common in Japan
- More common in populations in which consanguinity is common

**Age Range**
- Evidence of photodamage of skin (solar lentigines)
  - As early as 1-2 years of age
- Median age of onset of nonmelanoma skin cancer: 9 years
- Mean age of presentation of hearing loss: 19 years
- Median age of onset of cutaneous melanoma: 22 years
- Often multiple primary cutaneous tumors by age 20 years
- XP variant
  - Later disease onset
    - Age 10-20 years
Natural History
- **Cause of death**
  - Skin cancer
    - 34% of patients
  - Neurologic degeneration
    - 31% of patients
  - Internal malignancy
    - 17% of patients
- **Median age at death, if no neurologic degeneration**
  - 37 years
- **Median age at death, if neurologic degeneration**
  - 29 years

**ETIOLOGY/PATHOGENESIS**

**Ultraviolet (UV) Light Action Spectrum**
- Inflammatory erythema of skin
  - 290-340 nm range

**GENETICS**

**Inheritance**
- Autosomal recessive

**Mutations**
- In genes involved in nucleotide excision repair
  - Results in high number of UV signature mutations (C to T or CC to TT)
- **Complementation groups**
  - Complementation is capacity of cells from 1 XP cell line to compensate for repair defects of another cell line when these 2 cell lines are fused
  - Groups A to G, defective nucleotide excision repair of UV light-induced damage
    - **Group A:** Mutation in XPA
    - **Group B:** Mutation in XPB/ERCC3
    - **Group C:** Mutation in XPC
    - **Group D:** Mutation in XPD/ERCC2
    - **Group E:** Mutation in XPE/DDB2
    - **Group F:** Mutation in XPF/ERCC4
    - **Group G:** Mutation in XPG/ERCC5

  - XP variant: Mutation in POLH (defective DNA polymerase) causing incorrect replication of DNA

  - **Genotype-phenotype correlations**
    - Complementation groups A, B, D, and G
      - Blistering burns with minimal sun exposure
      - More likely to have neurologic degeneration
    - Complementation groups C, E, and variant
      - Generally lack acute sunburns
      - Develop evidence of chronic sun damage, often by age 2 years, manifesting as freckling and lentigines
    - Complementation groups C, E, F, XP variant
      - Generally absent neurologic degeneration

**CLINICAL IMPLICATIONS AND ANCILLARY TESTS**

**Clinical Presentation**
- **Childhood onset of photosensitivity**
  - Manifests as blistering (sunburn) with minimal acute sun exposure or as early-onset lentigines
    - By age 18 months in 50% of patients
    - By age 4 years in 75% of patients
    - By age 15 years in 95% of patients
  - Chronic changes, primarily in sun-exposed areas
    - Poikiloderma (dyspigmentation with atrophy and telangiectasias), lentigines
    - Xerosis
    - Tumors
- **Eye changes**
Telangiectasias of conjunctiva
- Photophobia
- Cataracts
- Keratitis
- Corneal opacification and vascularization

- Neurologic in 25-30% of patients
  - Absent deep tendon reflexes
  - High-frequency sensorineural hearing loss
    - Especially in patients in complementation groups A and D
    - Hearing loss correlated with acute burning on minimal sun exposure
    - Mean age of presentation: 19 years
  - Cognitive impairment
  - Difficulty swallowing
  - Loss of ability to ambulate
  - Microcephaly
  - Abnormal electroencephalogram
  - Seizures

**Imaging Findings**
- Enlarged ventricles
- Cortical thinning

**ASSOCIATED NEOPLASMS**

**Nonmelanoma Skin Cancer**
- Carcinomas and sarcomas
  - Especially basal cell carcinoma and squamous cell carcinoma
  - Frequency compared to general population
    - 10,000x increase in XP patients < 20 years old

**Cutaneous Malignant Melanoma**
- 2,000x increase in XP patients < 20 years old compared to general population

**Ocular Cancer**
- 1,000x increase in XP patients < 20 years old compared to general population

**Tongue Cancer**
- 100,000x increase in XP patients < 20 years old compared to general population

**Internal Malignancy**
- 10-20x increase compared to general population
- Brain tumors
  - Medulloblastoma
  - Glioblastoma
- Central nervous system tumors
  - Spinal cord astrocytoma
- Carcinomas
  - Pulmonary
  - Uterine
  - Breast
  - Gastric
  - Renal cell
  - Testicular
- Leukemias

**Benign Neoplasms**
- Lentigines
- Conjunctival papilloma
- Actinic keratosis
- Keratoacanthoma
- Pyogenic granuloma
- Fibroma
- Multinodular thyroid
- Schwannoma

**CANCER RISK MANAGEMENT**

Ultraviolet Light Protection (From Sunlight and Artificial Light)
• Of skin and eyes
• From day 1 of life
• Methods include
  o Sunblock
  o Sunglasses
  o Protective clothing
  o Window tinting
  o Use of ultraviolet meters
• Oral vitamin D and calcium supplementation

Regular Examination
• Mucocutaneous
• Ocular
Avoidance of Other Carcinogens
• e.g., tobacco smoke
P.I(2):202

Possible Prophylaxis
• Oral retinoids
• T4 endonuclease V (bacterial DNA repair enzyme)

DIFFERENTIAL DIAGNOSIS

Trichothiodystrophy
• Mutations
  o XPB and XPD genes
• Autosomal recessive
• Similarities to xeroderma pigmentosum
  o Cognitive impairment
  o Photosensitivity
• Differences from xeroderma pigmentosum
  o Brittle hair
    ▪ Hair shaft with alternating light and dark bands
  o Ichthyosis
  o Absent lentigines
  o No increased risk of internal cancer or skin cancer

Cockayne Syndrome
• Mutations
  o XPB, XPD, and XPG genes for combined XP/Cockayne phenotypes
  o ERCC8 and ERCC6 genes
  o Rarely XPF
• Autosomal recessive
• Clinical features
  o Cachectic dwarfism
  o Premature aged appearance
  o Microcephaly
  o Similarities to xeroderma pigmentosum
    ▪ Photosensitivity
    ▪ Progressive mental degeneration
  o Differences from xeroderma pigmentosum
    ▪ Absent lentigines
    ▪ Retinal degeneration
    ▪ No increased risk of internal cancer or skin cancer in “pure” Cockayne phenotypes

• XP/Cockayne syndrome overlap
  o Mutations in XPB, XPD, and XPG genes for combined XP/Cockayne phenotypes
  o Solar lentigines
  o Increased skin cancers
  o Pigmentary retinal degeneration
  o Basal ganglion calcification

UV-Sensitive Syndrome
- Mutations
  - CSB and CSA genes
- Autosomal recessive
- Rarely reported syndrome
  - May be mild variant of Cockayne syndrome
    - Photosensitivity
    - Solar lentigines

**Bloom Syndrome**
- Mutations
  - BLM (RECQL3) gene
    - Results in chromosomal instability
    - Increased sister chromatid exchanges, breakage, and rearrangement
- Autosomal recessive
- Malar erythema, telangiectasias
- Café au lait macules
- Long face with prominent nose
- Short stature
- Diabetes mellitus
- Normal intelligence
- Reduced/absent fertility
- Recurrent infections
  - Respiratory
  - Gastrointestinal
- Malignancies
  - Leukemia
  - Lymphoma
  - Gastrointestinal adenocarcinoma

**Rothmund-Thomson Syndrome**
- Mutations
  - RECQL4 gene
    - Encodes DNA helicase
- Autosomal recessive
- Facial erythema, edema, vesicles
  - Eventuates in poikiloderma
- Sparse hair
- Hypoplastic nails
- Acral keratoses
- Short stature
- Normal intelligence
- Malignancies
  - Osteosarcoma (10-30% of patients)
  - Squamous cell carcinoma (< 5% of patients)

**SELECTED REFERENCES**
Lentigines are common on the sunexposed skin of patients with xeroderma pigmentosum. Histopathologically, there is an increase in basilar melanin pigment. (Right) The lesion labeled “15” is a malignant melanoma with a depth of 0.55 mm, on the leg of this patient with xeroderma pigmentosum. There are numerous surrounding lentigines. (Courtesy K. Kraemer, MD.)

Cutaneous melanoma can be seen in patients with xeroderma pigmentosum. Low-power examination shows pagetoid spread of a superficial spreading type of malignant melanoma. (Courtesy S. Dadras, MD.) (Right) High-power magnification shows prominent cytologic atypia and 2 adjacent mitoses within the dermal nests of this malignant melanoma. (Courtesy S. Dadras, MD.)
Cutaneous basal cell carcinomas are common in patients with xeroderma pigmentosum. Histopathologically, in this example of basal cell carcinoma, there are infiltrating islands of basaloid cells with peripheral palisading. (Right) Cutaneous squamous cell carcinoma is also common in patients with xeroderma pigmentosum. In this example of squamous cell carcinoma of the skin, there are large islands of atypical keratinocytes in the dermis.

**Part II - Diagnoses Associated With Specific Syndromes**

**Section 1 - Breast**

**Breast Carcinoma, Female**

- **Etiology/Pathogenesis**
  - ~27% of breast cancer is thought to be due primarily to hereditary factors
  - Only 5-10% due to highly penetrant germline mutations
  - ~10% of women diagnosed with breast cancer at < 45 years of age will have a germline mutation
  - Familial risk not explainable by known mutations is likely due to additive effect of multiple genes
  - Features in common
    - Autosomal dominant alleles
      - Inherited via females and males
      - Majority of identified genes are associated with DNA repair pathways
    - Breast cancers occur at earlier ages compared to sporadic cancers and are often multiple and bilateral
    - Risk of nonbreast cancers increased

- **Diagnostic Checklist**
  - BRCA1 (hereditary breast and ovarian cancer syndrome)
  - BRCA2 (hereditary breast and ovarian cancer syndrome)
  - TP53 (Li-Fraumeni syndrome)
  - CDH1 (familial gastric cancer and lobular breast cancer syndrome)
  - PTEN (Cowden syndrome)
  - CHEK2
  - ATM (ataxia-telangiectasia carriers)
Family history is a powerful tool for detecting highly penetrant genes responsible for breast cancer susceptibility. This pedigree is very suggestive of a germline mutation due to the presence of multiple affected family members and the development of cancers at a young age. Genetic testing could determine whether any of the currently recognized mutations are present or establish the significance of a yet undescribed mutation if it consistently maps to individuals with cancer.

ETIOLOGY/PATHOGENESIS

Hereditary Breast Cancer

- Long recognized that many women with breast cancer also have affected relatives
  - ~27% of breast cancer is thought to be due primarily to hereditary factors
    - Only 5-10% due to highly penetrant germline mutations
    - ~10% of women diagnosed with breast cancer at <45 years of age will have a germline mutation
  - Familial risk not explainable by known mutations is likely due to additive effect of multiple genes
    - Multiple low penetrance genes may increase risk in families
      - These genes may also modify clinical features of high penetrance genes
    - Genome-wide association studies are searching for this group of genes
  - It is unlikely that another highly penetrant gene such as BRCA1 or BRCA2 will be identified
  - Features common to all major germline mutations
    - Autosomal dominant alleles
      - Tumors occur when remaining wild-type allele is rendered nonfunctional
Inherited via both females and males
- Majority of identified genes are associated with DNA repair pathways
  - Act as tumor suppressor genes in normal cells to maintain DNA integrity and control proliferation
  - Relative tissue specificity for breast cancer has not been explained
- Breast cancers occur at earlier ages compared to sporadic cancers and are often multiple and bilateral
  - 1st mutation present at birth
  - Destabilization of genome increases likelihood of additional mutations

Risk of nonbreast cancers increased
- Features specific to certain germline mutations
  - Type of breast carcinoma
  - Risk of male breast cancer
    - Increased risk for some mutations (e.g., BRCA1 and BRCA2)
    - Not reported for other mutations (e.g., TP53)
  - Penetrance
    - > 95% lifetime risk for some mutations
    - Other genes have lower penetrance (20% or lower lifetime risk)
- Spectrum of nonbreast cancers
  - Types of other cancers vary according to gene and sometimes are different for specific mutations
- Founder mutations in ethnic populations
  - Some populations have very high incidences of specific mutations
- Homozygosity
  - Homozygosity for some mutations confers disease (e.g., BRCA2 & BRIP1: Fanconi anemia; ATM: Ataxia-telangiectasia)
  - Homozygosity for other mutations is likely lethal (e.g., BRCA1)

**CLINICAL ISSUES**

**Epidemiology**
- ~ 10-25% of women with breast cancer have a 1st-degree relative (parent, sister, daughter) with breast cancer
  - Having an affected 1st-degree relative increases risk by 2-3x
- Most common family history is a mother developing breast cancer after menopause
  - This history does not increase risk of breast cancer for daughter
  - Sporadic breast cancer in this age group is very common
- Familial patterns of breast cancer likely to be associated with germline mutations
  - Affected 1st-degree relatives (mother, sister, daughter)
  - Multiple affected relatives
  - Carcinomas occurring at an early age (premenopausal)
  - Multiple carcinomas (bilateral or ipsilateral)
  - Relatives with nonbreast cancers associated with specific germline mutations
    - Male breast cancer for BRCA2 and BRCA1
    - Ovarian, fallopian tube, or primary peritoneal cancers for BRCA1 and BRCA2
    - Sarcomas for TP53
  - Relatives with diseases due to homozygous mutations
    - Ataxia-telangiectasia for ATM
    - Fanconi anemia for BRCA2 and BRIP1

**BRCA1 (Hereditary Breast & Ovarian Cancer Syndrome)**
- Function
  - BRCA1 and BRCA2 code for large proteins
    - Proteins do not have sequence homology but do share many similar functions
  - BRCA1 and BRCA2 help maintain genomic stability
    - Direct role in regulation of DNA damage responses and repair and cell cycle checkpoints
    - Cells lacking BRCA1 & BRCA2 functional activity are prone to replication errors and genomic instability
Drives acquisition of mutations and chromosomal instability, contributing to tumor formation
- BRCA1 function is required for transactivation of the estrogen receptor (ER) gene promoter
- May explain why 90% of BRCA1-associated carcinomas are negative for ER

- Incidence: 0.1-0.3%
  - More common in some ethnic groups: Ashkenazi Jews, Finns, French Canadians
  - Mutation can be suspected in young patients (35% risk for a patient < 30 years of age with an ER-negative poorly differentiated cancer)

High penetrance: 40-90% lifetime risk
- Magnitude of risk can vary for different mutations and for different types of cancers
- Responsible for ~1/2 of cancers known to be due to a germline mutation (~2% of all breast cancers)

Breast cancer
- Mean age of onset is 44 years, but age can vary with specific mutations
- Risk of subsequent contralateral cancer is higher
- ~90% of BRCA1 cancers share same gene expression pattern with basal-type carcinomas defined by gene expression profiling
- Morphology of invasive carcinomas
  - Circumscribed growth pattern with pushing borders, dense lymphocytic infiltrate
  - High nuclear grade and high proliferative rate
- Medullary carcinomas are overrepresented: 13% of cases vs. <5% for all women
  - Majority of women with medullary carcinomas do not have BRCA1 mutations
  - Additional BRCA1 carcinomas have “medullary features” but not all criteria for classification as classic medullary carcinoma
- Tumor markers
  - Lack hormone receptor positivity
  - Lack overexpression of HER2: Both HER2 and BRCA1 are on long arm of chromosome 17, and loss of heterozygosity may affect both
  - 10-25% of women <50 years of age with a triple negative carcinoma will have a BRCA1 mutation

Other associated cancers
- Ovarian, fallopian tube, primary peritoneal (40-50% lifetime risk)
  - Usually high-grade serous carcinomas
  - ~80% of women with both breast and ovarian cancer will have a BRCA mutation
  - Average age of onset: 49-53 years (compared to 63 years in general population)
- Male breast cancer (1-5% lifetime risk, but ~1/2 risk of BRCA2)
- Pancreas, cervix, uterus

BRCA2 (Hereditary Breast & Ovarian Cancer Syndrome)
- Function
  - Although BRCA2 is not structurally related to BRCA1, both genes have very similar functions and regulatory roles
- Incidence: 0.1-0.7%
  - More common in some ethnic groups: Ashkenazi Jews, Icelandic populations
- High penetrance: 45-85% lifetime risk
  - Magnitude of risk can vary for different mutations and for different types of cancers
  - Responsible for ~1/2 of cancers known to be due to a germline mutation (~2% of all breast cancers)
- Breast cancer
  - Mean age of onset is 47 years but can vary with specific mutations
  - Group with luminal A or B by gene expression profiling
  - Majority are high grade
    - ER positive
    - HER2 negative
- Other associated cancers
  - Ovary, fallopian tube, primary peritoneal (10-20% lifetime risk)
    - Usual age of onset: 55-58 years (compared to 63 years in general population)
  - Male breast cancer: 5-10% lifetime risk; ~5-15% of cases are associated with BRCA2
    - Also increased risk of early onset aggressive prostate cancer
TP53 (Li-Fraumeni Syndrome)
- **Function**
  - Central role in cell cycle control, DNA replication, DNA repair, and apoptosis
- **Incidence:** 0.0025%
  - Population in southeastern Brazil has 1/300 incidence
- **High penetrance:** > 90% lifetime risk of breast cancer for women
  - Penetrance varies for different mutations
- **Breast cancer**
  - 1/3 of malignancies in affected families
    - Early onset: Average age at diagnosis is 33 years
    - ~ 55% of women will develop breast cancer by age 45
    - ~ 2-7% of women with breast cancer were diagnosed at < 30 years of age
    - Rare for breast cancer to be diagnosed after age 50
  - Most common type is ER positive and HER2 positive (~ 55%)
  - Male breast cancer has not been reported
- **Other associated cancers**
  - Sarcomas: Most occur in children < 10 years of age
    - However, Ewing sarcoma, gastrointestinal stromal tumor (GIST), desmoid tumor, and angiosarcoma have not been reported
  - Adrenal cortical carcinoma: Most occur in children around 3 years of age
  - Brain tumors: Occur in children or in 4th-5th decades

CDH1 (Familial Gastric Cancer and Lobular Breast Cancer Syndrome)
- **Function**
  - CDH1 encodes gene for E-cadherin
  - E-cadherin is a protein involved in cell-to-cell adhesion
  - Mutations interfere with function
    - 75-80% are truncating mutations, 20-25% are missense mutations, and 7% are large deletions
    - Loss of protein results in cells rounding up and single-cell infiltrative pattern due to lack of adhesion to adjacent cells
- **Incidence:** 0.005%
- **High penetrance:** ~ 40-50% lifetime risk for women
- **Breast cancer**
  - Women are at increased risk for lobular carcinoma
  - However, majority of women with lobular carcinomas do not have CDH1 germline mutations
  - Loss of E-cadherin prevents cell adhesion, resulting in single tumor cells with rounded contours
- **Other associated cancers**
  - 70-85% lifetime risk of developing gastric signet ring cell carcinoma in majority of families
    - Gastric carcinomas are more common than breast carcinomas in most affected families
    - Families developing only breast cancer have also been identified

PTEN (Cowden Syndrome)
- **Function**
  - Dual specificity phosphatase gene involved in control of proliferation signals and apoptosis
- **Incidence:** 0.0005%
- **High penetrance:** 25-50% lifetime risk of breast cancer for women
- **Breast cancer**
  - Early onset; most women diagnosed between 38 and 46 years of age
  - Men also at increased risk for breast cancer; magnitude of risk not yet determined
  - Other breast lesions include fibroadenomas and hamartomas
- **Other associated tumors**
  - Multiple hamartomas (including trichilemmomas)
  - Thyroid, and endometrial cancer

ATM (Ataxia-Telangiectasia Carriers)
Diagnostic Pathology: Familial Cancer Syndromes

- **STK11/LKB1 (Peutz-Jeghers Syndrome)**
  - **Function**
    - Serine/threonine kinase that regulates how cells respond to proliferation signals depending on ATP availability
  - **Incidence:** 0.001%
  - **High penetrance:** ~ 40% lifetime risk for women
  - **Breast cancer**
    - Early onset: 8% by age 40 and 32% by age 60
    - No reported specific histologic types
  - **Other associated lesions**
    - Hamartomatous gastrointestinal polyps (including small intestine) and skin pigmentation (lips and buccal mucosa)
    - Skin pigmentation (lips and buccal mucosa)
    - Ovarian cancer (sex cord stromal tumors are most common): ~ 20% risk
    - Increased risk of cancer of colon, stomach, pancreas, small intestine, thyroid, lung, uterus, ovary, and cervix

- **CHEK2**
  - **Function**
    - Cell cycle checkpoint gene involved in DNA repair
  - **Incidence:** 0.5%
  - **High penetrance:** ~ 40% lifetime risk for women
  - **Breast cancer**
    - Later onset
    - Increased risk for males
    - No reported specific histologic types; 70-80% are ER positive (similar to sporadic breast cancer)

**Genetic Testing**

- **Population to be tested**
  - American Society of Clinical Oncology recommends that patients with a > 10% mutation risk undergo testing for BRCA1 and BRCA2 mutations
    - This approach will detect 85% of mutation carriers
  - Patients meeting criteria for Li-Fraumeni syndrome or Li-Fraumeni-like syndrome have > 15% risk of having a mutation
  - Group of genes conferring a low increased risk for breast cancer has been identified
    - Genes functionally related to BRCA1 and BRCA2: BARD1, CHEK1, MRE11A, NBN, RAD50, RAD51D
    - Genes in the Fanconi anemia pathway: PALB2, RAD51C (FANCQ), BRIP1, RAD51B
    - Other genes: MUTYH, PMS2
    - For many of these genes, the risk of breast cancer is not yet clear
    - Limited information is available for variants of unknown significance
    - Testing for mutations in these genes may only be of value in selected cases
  - Individuals may undergo testing for rare genes in the following settings
    - Testing has excluded mutations in BRCA1, BRCA2, and TP53
    - Clinical setting is suggestive of a specific gene mutation
    - Mutation has been identified in the family
  - Counseling should occur before testing to ensure patient is aware of possible implications for individual and family

- **Predictive models**
Diagnostic Pathology: Familial Cancer Syndromes

- National Comprehensive Cancer Network issues clinical guidelines for identifying individuals with a high risk of BRCA1, BRCA2, TP53, or PTEN mutations

- BRCA1 and BRCA2
  - Multiple models available

- TP53
  - Classical Li-Fraumeni criteria
  - Chompret criteria

- PTEN
  - Available at http://www.lerner.ccf.org/gmi/ccscore/index.php

- Genetic testing
  P.II(1):6

- Full genome sequencing is required to detect all mutations
  - All testing for BRCA1 and BRCA2 mutations in the USA is performed by Myriad Genetics (Salt Lake City, Utah)
  - Full genome sequencing (or full exome sequencing) is commercially available and will likely decrease in cost to make testing for all genes possible in many individuals

- Limited sequence analysis can be used to detect the most likely mutation
  - Common mutations found in ethnic groups, e.g., 2 BRCA1 and 1 BRCA2 mutations comprise 90% of mutations found in Ashkenazi Jewish population
  - Hotspots for mutations within gene
  - Detection of a known mutation in a family

- Duplications, inversions, large deletions, and mutations in noncoding regions may not be detected by standard sequence analysis
  - 18% of genetic changes in BRCA1 and BRCA2 are not detected by standard testing
  - If a known mutation is not found in the initial test, additional testing may be performed
  - BRACAnalysis large rearrangement test (BART) detects some rearrangements
  - Account for 17% of deleterious mutations in individuals from the Near East/Middle East and 22% of deleterious mutations in individuals from Latin America/Caribbean
  - None of the current tests detect every deleterious change

- Variants of unknown significance (VUS)
  - Genetic polymorphism that has not yet been associated with an increased risk of cancer
  - Found in 3-7% of individuals tested for BRCA1 and BRCA2
  - > 1,500 identified
  - More frequent in minority ethnic populations; however, frequency has been decreasing as more individuals are studied
  - Must be identified in multiple individuals to determine clinical significance

- Testing families with a history of cancer
  - Most useful, begin testing individual with cancer
    - If multiple affected individuals are present within a kindred, testing can establish linkage between cancer(s) and mutation
  - Once a mutation is detected, other family members without cancer may choose testing
  - Analysis for specific mutation in other family members is considerably less expensive

Cancer Risk Management

- Chemoprevention
  - Tamoxifen reduces the risk of ER-positive cancer for women with a family history of breast cancer
    - However, risk of endometrial cancer and thrombosis is increased
  - Tamoxifen reduces risk of cancers for BRCA2 carriers but not for BRCA1 carriers
    - However, few women have been studied
  - Tamoxifen reduces risk of subsequent ipsilateral and contralateral cancer in breast cancer patients with BRCA1 and BRCA2 germline mutations
  - Benefit of chemoprevention for BRCA carriers without breast cancer is less clear (few studies)

- Screening
  - Clinical breast examination 2x yearly starting at age 25
    - Patient self-breast awareness with periodic breast examinations
Mammography at earlier age (10 years before age at which the youngest relative with cancer was diagnosed) or more frequently
MR screening more sensitive than mammography in young women with dense breasts
- However, lower specificity leads to greater numbers of biopsies for benign lesions
Screening, mammography, and MR may be staggered every 6 months to decrease the screening interval

Prophylactic surgery
- Women with BRCA1 & BRCA2 mutations are at increased risk for subsequent ipsilateral (~2-3% per year) and contralateral (~2-6%) cancer
- Recurrence rates are higher for women with very early onset cancer (< 42 years)
- Ipsilateral cancers are likely new primary cancers rather than true recurrences
- Recurrence does not alter survival, as 2nd cancers are likely found at an early stage
- Bilateral mastectomy reduces risk by 97%
  - Not all breast tissue can be removed in all patients with acceptable cosmetic results
  - Major benefit to women prior to development of breast cancer; limited or no benefit after breast cancer diagnosis with possible distant metastases
- Bilateral salpingo-oophorectomy for mutations associated with ovarian cancer
  - Reduces risk of ovarian and fallopian tube cancer by 70-96%
  - Reduces risk of breast cancer by 50% in premenopausal women, presumably due to decrease in hormone production
  - Reduces risk of ER(-) breast cancers for BRCA1 patients to a lesser degree; mechanism is unknown

SELECTED REFERENCES

Image Gallery
General Features

(Left) The majority of hereditary breast cancer genes are tumor suppressors. Proteins are expressed in normal cells. BRCA2 is shown here. When the normal allele is mutated, expression is lost, resulting in genomic instability and the formation of tumors. (Right) TP53 is an unusual member of this group, as mutations can cause either loss of function or gain of function. Many mutated forms fail to be degraded, resulting in protein accumulation in the nucleus.
(Left) Hereditary carcinomas arise at earlier ages as women are born with cells with the 1st alteration, leading to neoplasia. Breast tissue is often dense, making detection of tumor by mammography difficult. (Right) MR can be a useful technique for screening young high-risk women with dense breasts. This woman with a BRCA1 mutation has an area of clumped linear enhancement that proved to be DCIS that was not detected by screening mammography.

(Left) Patients with germline mutations are more likely to develop multiple cancers, either synchronously or metachronously. Prophylactic mastectomy is an effective method to reduce the risk of cancer. (Right) Male breast cancer is increased by some germline mutations (including BRCA2, BRCA1, PTEN, and CHEK2), but the risk is lower than that for females. Male risk is not increased by other germline mutations (TP53). The reason for this gender specificity is unknown.

P.II(1):8

BRCA1- and BRCA2-Associated Cancers
BRCA1-associated breast cancers typically have circumscribed borders. These cancers can be mistaken for benign lesions in young women. However, growth can be quite rapid. (Right) BRCA1 carcinomas have high-grade nuclei, and the cells grow in a syncytial pattern. There is typically a dense lymphocytic infiltrate. Almost all carcinomas are negative for ER, PR, and HER2. 10-25% of women under the age of 50 with this type of carcinoma will have a germline mutation.

Carcinomas associated with BRCA2 mutations are often poorly differentiated and have a high mitotic rate. These cancers are typically classified as luminal A or B by gene expression profiling. They do not have the distinctive histologic features associated with BRCA1 mutations. (Right) Unlike BRCA1 cancers, BRCA2 cancers are usually positive for estrogen receptors. Both types of carcinoma are almost always negative for HER2.
Women with BRCA1 and BRCA2 mutations are at increased risk for ovarian carcinomas, such as this papillary serous carcinoma. Approximately 80% of women with both breast and ovarian carcinoma will have a BRCA mutation. Women with BRCA1 and BRCA2 mutations may choose to undergo prophylactic salpingooophorectomy to reduce the risk of ovarian cancer. Early tumors are frequently found in the end of the fallopian tube. Patients remain at risk for primary peritoneal carcinomas.

TP53- and CDH1-Associated Breast Cancers

E-cadherin is a cell adhesion molecule normally expressed by breast epithelial cells. Lobular carcinomas lose expression of this protein. The majority of lobular carcinomas lose E-cadherin expression due to somatic mutations. Individuals with Li-Fraumeni syndrome are at increased risk for a wide variety of tumors throughout their lifetimes, including adrenal carcinomas, sarcomas (alveolar rhabdomyosarcoma pictured), brain tumors, and others.
Families with germline mutations of E-cadherin (CDH1) are at greater risk for gastric signet ring cell carcinomas rather than breast carcinomas. Both stomach and breast carcinomas have similar histologic appearances due to the loss of cell adhesion; however, the signet ring cells of gastric carcinomas typically have finely vacuolated cytoplasm.

Over 1/2 of TP53-associated carcinomas are positive for estrogen receptor and HER2 (shown here).

Individuals with germline E-cadherin (CDH1) mutations develop lobular carcinomas. Due to the loss of cell adhesion, the cells are rounded and infiltrate as single cells. Many lobular carcinomas have signet ring cells that typically have a single vacuole with a mucin droplet, rather than the foamy cytoplasm more typical of signet ring cell gastric carcinomas. (Right) 80% of children with adrenal cortical carcinoma (shown here) have germline TP53 mutations. The median age of onset is 3 years.

Breast Carcinoma, Male

- Male breast cancer (MBC)
- Accounts for ~ 1% of breast cancer cases
- In situ and invasive carcinoma occur
Male breast cancer (MBC) typically presents as an irregular firm mass close to skin, nipple, and chest wall. Invasion of these structures can occur early in the course of the disease.
Invasive ductal carcinoma of no special type is the most common histology seen in male breast cancer and is identical in appearance to carcinomas in females. The majority express hormone receptors.

**TERMINOLOGY**

**Abbreviations**
- Male breast cancer (MBC)

**ETIOLOGY/PATHOGENESIS**

**Environmental Exposure**
- Radiation exposure
  - Occupational exposure
  - Therapeutic chest wall radiation
- Electromagnetic field exposure
- Occupational exposure to gasoline and airline fuels

**Disorders Associated With Hormonal Imbalance**
- Klinefelter syndrome (XXY karyotype)
- Obesity
- Testicular disorders associated with hypogonadism
  - Mumps orchitis, cryptorchidism, testicular injury
- Liver disease
- Diabetes
- Hyperthyroidism
- Alcohol abuse

**Gynecomastia**
- Generally not considered to be MBC risk factor
  - Some studies have suggested a slight increased risk
    - May be attributed to fact that both conditions share similar risk factors (hormonal imbalance)
Genetics (Family History)
- 5-10% of all breast cancer is attributable to mutations in high penetrance breast cancer susceptibility genes
  - ~ 15-20% of MBC patients have family history of breast or ovarian cancer
  - Risk increased in cases of an affected sister (RR 2.25) or mother and sister (RR 9.73)
- High-risk breast cancer germline mutations associated with male breast cancer
  - BRCA1 (17q21) hereditary breast and ovarian cancer syndrome
    - For male BRCA1 mutation carrier, estimated lifetime risk for MBC is 1.8% (< 4% of MBC is associated with BRCA1)
    - Lower risk than for BRCA2 mutation carriers
  - BRCA2 (13q12.3) hereditary breast and ovarian cancer syndrome
    - For male BRCA2 mutation carrier, estimated lifetime risk for MBC is ~ 7% (compared with < 1% in general population)
    - There is a 60-75% chance of a BRCA2 mutation in a family with an MBC patient
    - Also associated with increased risk for prostate cancer, pancreatic cancer, and GI tract malignancies
  - PTEN (10q23.3) Cowden syndrome
- Moderate/low-risk breast cancer susceptibility gene associated with male breast cancer
  - CHEK2 (22q12.1)
- Klinefelter syndrome (47XXY karyotype)
  - Patients suffer hormonal imbalance (estrogen > testosterone)
  - Marked increased relative risk for MBC
    - Lobule formation may occur

CLINICAL ISSUES

Epidemiology
- Incidence
  - MBC accounts for < 1% of all breast cancer
    - ~ 1% of all cancers seen in men
    - 0.13% of all cancer deaths in men annually
    - Incidence has remained stable (2000-2005)
- Age
  - MBC tends to occur in slightly older age group compared to female breast cancer (FBC)
    - Mean age: 67 years (MBC) vs. 61 years (FBC)
    - Younger males may also be affected
  - Compared with sporadic MBC, median age of onset for familial MBC is typically younger

Presentation
- Majority present with painless firm mass
  - Located in the subareolar region
  - Tends to be located eccentrically in relationship to nipple
  - Fixation to skin &/or pectoralis muscle is common
- Less commonly presents as nipple discharge, bloody or serous
  - May be associated with papillary ductal carcinoma in situ (DCIS)
  - Rarely presents as Paget disease of nipple
- Diagnosis may be delayed
  - MBC is rare and is often not detected early
  - Cancers usually diagnosed at higher stages as compared to FBC

Treatment
- Surgical approaches
  - Majority of males will undergo mastectomy
    - Breast conservation is not relevant for cosmesis
  - Sentinel lymph node biopsy can be performed
- Adjuvant therapy
  - Management is similar to that for postmenopausal FBC
  - Adjuvant treatment based on TNM stage, tumor grade, hormone receptors, and HER2 status

Prognosis
- Similar to that for FBC of similar stage and grade
  - Mainly determined by TNM stage, tumor grade, and receptor status
Often more advanced at diagnosis compared with FBC
  o > 40% of MBC presents with stage III or IV disease at diagnosis, which adversely influences prognosis
  o Minimal breast tissue in males results in cancers being closer to skin and chest wall
    ▪ Invasion of these structures occurs earlier
    ▪ Increases likelihood of vascular invasion and nodal metastasis

**IMAGE FINDINGS**

**General Features**
- Radiographic examination can contribute to diagnosis of a mass lesion in a male patient
  o Abnormalities similar to those seen in FBC present in 80-90% of cases

**Mammographic Findings**
- Typically shows mass lesion that is "taller than wide"
  o Irregular spiculated margins
    ▪ Often coarse microcalcifications
- Unlike gynecomastia, lesions tend to be eccentric in relationship to nipple
  o Gynecomastia has a flame-shaped appearance extending symmetrically from the nipple

**Ultrasonographic Findings**
- Distinguishes solid masses from cysts
  o Useful in identifying solid masses that are more likely to be malignant

**MACROSCOPIC FEATURES**

**General Features**
- Majority are irregular, firm, gray to white masses
  o In situ component may appear grossly as partially cystic
- Fixation to skin or pectoralis muscle is common
- Rarely, scaling exudate of nipple due to Paget disease occurs
  o Typically not seen in pathology specimens as skin is cleansed prior to surgery

**Size**
- 1-5 cm (usually 2-2.5 cm)

**MICROSCOPIC PATHOLOGY**

**Histologic Features**
- Carcinoma in situ (DCIS, lobular carcinoma in situ [LCIS])
  o DCIS accounts for ~ 10% of all MBC
    ▪ LCIS is extremely rare in male patients
  o DCIS is microscopically similar to that seen in FBC
    ▪ All architectural patterns have been reported
    ▪ Greater incidence of papillary DCIS compared with FBC
    ▪ Less likely to see comedonecrosis in DCIS in MBC compared with FBC
- Invasive carcinoma
  o Invasive ductal carcinoma of no special type is most common
    ▪ Identical in appearance to that occurring in FBC
  o Special histologic types are unusual in MBC
    ▪ Papillary carcinomas are most common special type
    ▪ Invasive lobular carcinoma occurs rarely
    ▪ Other special histologic types (medullary, mucinous, tubular) are also very rare
  o Graded using same system as for FBC (Elston and Ellis modification of Scarff-Bloom-Richardson histologic grading)
    ▪ Carcinomas of grades 2 and 3 reported in 80% of cases

**ANCILLARY TESTS**

**Immunohistochemistry**
- Hormone receptors
  o Estrogen receptor (ER) positive in 90%
  o Progesterone receptor (PR) positive in 80%
- HER2
  o Overexpression occurs but less frequent than in FBC

**Molecular Genetics**
- Molecular analysis shows disease subtypes similar to those reported for FBC
  o Luminal subtype most common (90%)
DIFFERENTIAL DIAGNOSIS

Gynecomastia
- Nonneoplastic enlargement of male breast tissue due to hyperplasia of epithelium and stroma
  - Variety of etiologies linked to an imbalance in ratio of free androgens and estrogens
  - Can be seen in infants, during puberty, or in elderly
- Often bilateral
  - If unilateral or asymmetric, can raise concern for carcinoma

Myofibroblastoma
- Clinical presentation (elderly male, palpable mass) may overlap with MBC
  - Usually discrete, well-circumscribed mass lesion
- Uniform proliferation of spindle-shaped myofibroblasts with well-circumscribed borders
  - Oval nuclei, pale cytoplasm, mitotic figures rare
  - Hyalinized bands of dense collagen separate spindle cells into groups or clusters
  - Varying degree of adipose tissue seen in some lesions
- Rarely, an epithelioid variant can be encountered
  - Can mimic invasive lobular carcinoma
    - Lesional cells express ER, PR, and AR
    - Cells are negative for cytokeratin

Metastases
- Metastatic tumors to breast can mimic primary breast carcinoma
  - Need to integrate prior history, clinical and imaging findings, and compare with prior biopsy material, if available
  - Suspect when cancer has an unusual appearance, is negative for ER and PR, &/or lacks in situ carcinoma
- Immunohistochemical markers can be helpful
  - Breast carcinoma
    - Usually CK7(+)/CK20(-), but significant overlap with other tumor immunophenotypes (e.g., lung)
    - ER(+) (70-90%), PR(+) (60-70%)
    - GCDFP-15(+) (50-75%)
    - Mammmaglobin (+) (40-70%)
    - DCIS often present and can be supported by markers for myoepithelial cells
  - Lung adenocarcinoma
    - Usually CK7(+)/CK20(-)
    - TTF1(+) &/or NAPSIN-A(+) helpful
    - Very rare breast cancers are TTF1(+); often have a neuroendocrine (small cell) appearance
  - Prostate carcinoma
    - Treatment for prostate carcinoma can increase risk for breast cancer (orchiectomy, hormonal therapy)
    - Hyperplasia associated with hormonal changes can be difficult to distinguish from carcinoma in situ
    - If patient is receiving hormonal therapy, this treatment can also alter appearance of metastatic prostate cancer or breast cancer
    - Usually CK7(-), PSA(+), PAP(+)
    - Some prostate cancers are ER(+)
    - Although uncommon, some breast cancers are PSA(+)
    - PAP should be negative in breast cancer

SELECTED REFERENCES
P.II(1):13
(Left) This breast cancer was initially mistaken for gynecomastia due to the location directly behind the nipple. Most male cancers are eccentrically displaced from the nipple. (Right) Breast cancers arising in males and females are morphologically similar. The majority of male cancers are invasive carcinomas of no special type. These carcinomas are more likely to be higher grade compared with female breast cancer (FBC). Carcinoma in situ is rarely seen in males in isolation.

(Left) The risk for breast cancer is lower for males with germline mutations in BRCA1 as compared to BRCA2. This male BRCA1 carrier developed a highgrade invasive ductal carcinoma. (Right) Breast cancer arising in male BRCA2 mutation carriers are predominantly invasive ductal carcinomas of no special type. Earlier reports suggested a higher incidence of tubulolobular and pleomorphic lobular carcinoma with BRCA2. However, this has not been seen in more recent series.
Most MBCs express estrogen receptor \( \text{ER} \) and progesterone receptor \( \text{PR} \). HER2 overexpression and gene amplification are less common compared with FBC. (Right) BRCA2 mutation carriers are at increased risk for MBC and other tumors, such as prostate and pancreatic cancer. A 70-year-old BRCA2(+) man presented with a palpable mass and was diagnosed with invasive lobular carcinoma. He was found to have an elevated serum PSA and prostate cancer.

Section 2 - Blood and Bone Marrow
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Key Facts
- Relatives of patients with CLL demonstrate 8.5x increased risk of CLL

Clinical Issues
- 5-year survival (79%)
- Clinical staging systems: Rai (0-IV) and Binet (A-C) are best predictors of survival

Microscopic Pathology
- Lymph nodes
  - Vaguely nodular pattern with alternating dark zones of mature CLL cells and light zones (proliferation centers)
- Peripheral blood
  - Diagnosis requires persistent (> 1 month) peripheral blood lymphocytosis (> \( 5 \times 10^9 \) cells/L)
  - Mature-appearing lymphocytes with CLL immunophenotype in absence of other causes

Ancillary Tests
- Dim expression of slg (IgM or IgM + IgD or, rarely, IgG) with \( \kappa \) or \( \lambda \) light chain restriction
- Dim CD20(+), CD19(+), CD5(+), CD23(+), FMC7(-)
- Expression of T-cell-associated antigen ZAP70 is associated with Ig gene mutational status
- ZAP70 on > 30% of cells by flow cytometry has worse prognosis than ZAP70(-) cases
- ~ 50% of cases have abnormal karyotypes

Top Differential Diagnoses
- Follicular lymphoma, mantle cell lymphoma
- Hairy cell leukemia, monoclonal B lymphocytosis
Image shows peripheral blood involved by chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL). The lymphocytes have sparse cytoplasm, round to oval nuclei, and small to indistinct nucleoli.
Image shows peripheral blood involved by CLL/SLL. Admixed among the neoplastic lymphocytes are “smudge cells”, an artifact of slide preparation.

TERMINOLOGY

Abbreviations
- Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

Definitions
- Neoplasm of monomorphic, small round B cells in peripheral blood, bone marrow, lymph nodes, and spleen
- CLL/SLL cells usually coexpress CD5 and CD23
- SLL is used for nonleukemic cases in which tissue infiltrate has morphology and immunophenotype of CLL
- Prolymphocytes and paraimmunoblasts form proliferation centers in tissues

ETIOLOGY/PATHOGENESIS

Familial
- Relatives of patients with CLL demonstrate 8.5x increased risk of CLL

CLINICAL ISSUES

Presentation
- Lymphadenopathy, generalized
  - Occurs primarily in persons older than 50 years
  - Most patients are asymptomatic
  - Patients with SLL present with lymphadenopathy and often develop lymphocytosis
  - Patients with CLL present with lymphocytosis and fatigue and may develop lymphadenopathy
  - Organ infiltration → splenomegaly, hypersplenism, and peripheral cytopenias
  - Bone marrow becomes extensively infiltrated by neoplastic cells, resulting in severe anemia, thrombocytopenia, and neutropenia
  - Patients with CLL/SLL have significantly impaired immunologic activity
  - Autoimmunity frequently seen in CLL/SLL; up to 25% of patients develop Coombs (+) autoimmune hemolytic anemia
Red cell aplasia is rare occurrence
- Serum M component present in some patients

**Treatment**
- CLL/SLL not considered to be curable with available therapy
- Chemoimmunotherapy combinations of fludarabine, cyclophosphamide, and rituximab (FCR) result in complete response rate of 72%

**Prognosis**
- Median survival: 7.5 years
  - 5-year survival (79%)
  - 10-year survival (< 30%)
  - Clinical staging systems: Rai (0-IV) and Binet (A-C) are best predictors of survival

**MACROSCOPIC FEATURES**

**Lymph Node Features**
- Lymph nodes are enlarged, and cut surface usually shows diffuse replacement
- Necrosis is rare

**MICROSCOPIC PATHOLOGY**

**Histologic Features**
- **Lymph nodes**
  - Vaguely nodular pattern with alternating dark zones of mature CLL cells and light zones (proliferation centers)
  - Predominant cell is small lymphocyte with clumped chromatin, usually round nucleus, and occasionally small nucleolus
  - Mitotic activity usually very low
  - Proliferation centers contain continuum of small, medium, and large cells
  - Prolymphocytes are medium-sized cells with dispersed chromatin and small nucleoli
  - Paraimmunoblasts: Medium to large cells with round to oval nuclei, dispersed chromatin, central eosinophilic nucleoli
  - In some cases, cells show moderate nuclear irregularity (atypical cytology), which can lead to differential diagnosis of mantle cell lymphoma
  - Occasional cases show plasmacytoid differentiation
  - CLL/SLL can involve lymph nodes with interfollicular pattern, surrounding reactive follicles
- **Peripheral blood (PB)**
  - Mature-appearing lymphocytes with scant agranular cytoplasm and homogeneously condensed chromatin without nucleoli
  - Characteristic “soccer ball” chromatin pattern and numerous smudge cells
  - Proportion of prolymphocytes (larger cells with prominent nucleoli) in blood films usually < 2%
  - Prolymphocytes correlate with more aggressive disease course, P53 abnormalities, and trisomy of chromosome 12
  - Variant CLL with prolymphocytes (CLL/PL) is defined by > 10% but < 55% prolymphocytes
  - Diagnosis requires persistent (> 1 month) PB lymphocytosis (> 5 × 10^9 cells/L) of matureappearing lymphocytes
  - Circulating lymphocytes with CLL immunophenotype
- **Bone marrow (BM)**
  - Involvement may be nodular, interstitial, or diffuse
  - Proliferation centers are less common in bone marrow than in lymph nodes but can be found with extensive involvement
  - Paratrabecular aggregates are not typical
  - Advanced disease and bone marrow failure are associated with diffuse pattern of infiltration
  - Examination of bone marrow is essential for staging and helpful to monitor response to therapy

**Ancillary Tests**

**Immunohistochemistry**
- B-cell antigens (CD20, CD79a, and pax-5) are positive, but CD20 expression can be very weak (dim)
- Tumor cells characteristically express CD5 and CD23
- CD23 is particularly useful in distinguishing CLL/SLL from mantle cell lymphoma
  - Should be evaluated in every case, if possible
- Some cases of CLL may express CD23 only weakly or partially; some cases of mantle cell lymphoma can be dimly CD23(+)
  - Evaluation of cyclin-D1 or t(11;14) is suggested
- p53 is expressed in ~10% of cases

**Flow Cytometry**
- Dim expression of sIg (IgM or IgM + IgD or, rarely, IgG) with κ or λ light chain restriction
- Expression of CD19, CD20 (dim), and CD79a
- CD5(+), CD23(+), CD43(+)
- CD11c(+/-), CD10(-), FMC7(-)
- Expression of CD38 on >30% of cells is seen in ~1/2 of cases and reported to be associated with worse prognosis
- Expression of T-cell-associated antigen ZAP70 is associated with unmutated Ig variable genes
- Cases with ZAP70 on >30% of cells by flow cytometry have worse prognosis than ZAP70(-) cases

**Cytogenetics**
- ~50% of cases have abnormal karyotypes (conventional methods); FISH is more often abnormal
  - P.II(2):4
- Trisomy 12 reported in 1/3 of cases with cytogenetic abnormalities
  - Correlates with atypical histology and aggressive clinical course
- Cases with trisomy 12 have predominantly unmutated Ig variable region genes
  - Those with 13q14 abnormalities more often have mutations
- Abnormalities of 13q reported in up to 25% of cases; associated with longer survival
- Abnormalities of 11q23 are found in small subset of cases; associated with lymphadenopathy and aggressive course
- Deletions of 6q21 or 17p13 (TP53 locus) seen in 5% and 10% of cases, respectively
- P53 mutations or deletions are associated with worse prognosis regardless of IGH mutational status

**Molecular Genetics**
- Mutations in NOTCH1 and SF3B1 predict a poor prognosis

**DIFFERENTIAL DIAGNOSIS**

**Follicular Lymphoma**
- Follicles can enlarge and coalesce to form large, grossly visible masses
- Neoplastic lymphocytes are centrocytes and centroblasts
  - Positive for CD10, CD19, CD20, and CD22; bright monoclonal sIg
  - Positive for Bcl-6 by immunohistochemistry
  - CD5(-), CD11c(-), CD43(-)

**Mantle Cell Lymphoma**
- Lymphocytes intermediate in size with irregular nuclear contours
  - Positive for CD5, CD19, CD20, CD22, and CD43; moderate monoclonal sIg
  - CD10(-), CD23(-)
- Cyclin-D1 (+) by immunohistochemistry; t(11;14) (q13;q32) positive by conventional cytogenetics or FISH

**Hairy Cell Leukemia**
- Patients present with splenomegaly and pancytopenia
- Indented nuclei with abundant clear cytoplasm
- Lymphocytes are positive for CD11c (bright), CD19, CD20, CD22 (bright), CD25, and CD103
- CD5(-), CD10(-), CD23(-)
- Tartrate-resistant acid phosphatase stain is strongly positive in hairy cells

**Monoclonal B Lymphocytosis**
- Healthy adults who have absolute increase in monoclonal B lymphocytes
  - <5x 10^7/L B lymphocytes in peripheral blood
- Absence of lymphadenopathy or organomegaly, cytopenias, or disease-related symptoms
- May progress to frank CLL/SLL at rate of 1-2% per year

**DIAGNOSTIC CHECKLIST**

**Pathologic Interpretation Pearls**
- Dimming light during light microscopy is helpful in appreciating proliferation centers in histologic sections of lymph node
- Atypical immunophenotype occurs in ~10-20% of cases

SELECTED REFERENCES
9. Zanotti R et al: ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor. Leukemia. 21(1):102-9, 2007

P.II(2):5

Image Gallery
Microscopic and Immunohistochemical Features
(Left) This lymph node involved by CLL/SLL shows numerous proliferation centers (a.k.a. pseudofollicular growth centers or pseudofollicles). (Right) The proliferation center seen in this case of CLL/SLL is composed of small lymphocytes, prolymphocytes, and paraimmunoblasts.

(Left) CLL/SLL with an interfollicular pattern is characterized by darkly stained, reactive follicles surrounded by large proliferation centers. This pattern mimics marginal zone lymphoma. (Right) In this case of CLL/SLL (interfollicular pattern), an immunohistochemical stain demonstrates dim and variable CD20 expression in the neoplastic cells and bright CD20 expression in the central (nonneoplastic) follicle.
In this case of CLL/SLL (interfollicular pattern), the neoplastic cells are highlighted by aberrant staining for the T-cell-associated marker CD5. The central benign germinal center is negative for CD5. (Right) In this case of CLL/SLL (interfollicular pattern), the neoplastic cells show dim CD23 expression. The central benign germinal center contains many CD23(+) follicular dendritic cells.

Microscopic and Immunohistochemical Features

(Left) The central proliferation center seen in this case of CLL/SLL contains a continuum of small lymphocytes, prolymphocytes, and paraimmunoblasts. (Right) An immunohistochemical stain for CD3 highlights background T cells. No staining is seen in the nodules of neoplastic CLL/SLL cells.
Immunohistochemical stain for CD20 highlights CLL/SLL cells. The proliferation centers are more brightly positive than the neoplastic small lymphocytes. (Right) An immunohistochemical stain for CD23 highlights the vaguely nodular proliferation centers as well as the small neoplastic cells.

Immunohistochemical stain for CD5 shows weakly positive expression of CD5 in the neoplastic cells. Scattered reactive T cells are darkly stained. (Right) An immunohistochemical stain for cyclin-D1 is negative in the neoplastic cells of CLL/SLL. Endothelial cells are positive and serve as an internal control.

Microscopic and Immunophenotypic Features
(Left) This image shows peripheral blood involved by CLL/SLL. Characteristic features seen in this image include marked lymphocytosis and admixed smudge cells. (Right) Wright-Giemsa shows CLL with cytologically atypical morphology in this peripheral blood smear with a population of small and medium-sized cells, some with indented nuclei.

(Left) Representative immunophenotypic analysis of CLL by flow cytometry shows that the neoplastic cells express CD5, CD11c (partial), CD19, CD20, CD23, CD38, weak surface immunoglobulin M&D, and monotypic κ light chain. (Right) Image shows bone marrow involvement by CLL/SLL with a diffuse pattern. The entire bone marrow space between bone trabeculae is replaced by small lymphocytes.
Diffuse Large B-Cell Lymphoma

Terminology
- Diffuse proliferation of large neoplastic B cells
- Often involves nodal or extranodal sites
- Bone marrow involvement less common than in lower grade B-cell lymphomas
- Clinically, immunophenotypically and genetically heterogeneous

Etiology/Pathogenesis
- Most commonly sporadic; may be familial
  - Relatives of patients with diffuse large B-cell lymphoma (DLBCL) demonstrate a 10x increased risk of DLBCL

Microscopic Pathology
- Diffuse growth of large cells
- Usually express pan-B markers: CD20, CD22, CD79-a, pax-5
- GCB subgroup: > 30% CD10(+) or CD10(-), Bcl-6(+), MUM1(-)
- Proliferation fraction (Ki-67) usually high (> 30-40%)

Ancillary Tests
- Concurrent rearrangements of MYC and BCL2 &/or BCL6 (so-called double-hit or triple-hit lymphomas) indicate a poorer prognosis

Top Differential Diagnoses
- DLBCL subtypes
- Other lymphomas of large B cells
- Burkitt lymphoma
- Plasmablastic lymphoma
- Follicular lymphoma (grade 3B)
H&E stain shows a lymph node involved by diffuse large B-cell lymphoma (DLBCL). Typical centroblasts are large, noncleaved cells with vesicular chromatin and membrane-bound nucleoli.
H&E stain shows a lymph node involved by DLBCL. Almost all of the cells are immunoblasts with large nuclei (compared to a histiocyte nucleus) and a single, central, prominent nucleolus.

**TERMINOLOGY**

**Abbreviations**
- Diffuse large B-cell lymphoma (DLBCL)

**Synonyms**
- Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)

**Definitions**
- Diffuse proliferation of large neoplastic B cells
  - Nuclei of neoplastic B cells are either equivalent to or larger than nucleus of a macrophage or are at least 2x as large as nucleus of a normal B cell
- Clinically, immunophenotypically, and genetically heterogeneous
- Multiple variants and subgroups are recognized by 2008 WHO classification system
  - Common morphologic variants (centroblastic, immunoblastic, anaplastic)
  - Rare morphologic variants
  - Molecular subgroups
    - Germinal center B-cell-like (GCB)
    - Activated B-cell-like (ABC)
  - Immunohistochemical subgroups
    - CD5(+) DLBCL
    - GCB
    - Non-GCB

**ETIOLOGY/PATHOGENESIS**

**Sporadic**
- Largely unknown
May arise de novo (without a preceding disorder) or from an underlying, lower grade malignancy, such as follicular lymphoma (i.e., transformation).

Patients with an underlying immunodeficiency at increased risk of developing DLBCL (often in association with Epstein-Barr virus [EBV] infection)

Familial

- Relatives of patients with DLBCL demonstrate 10x increased risk of DLBCL.

CLINICAL ISSUES

Epidemiology

- Incidence
  - Predominantly disease of adults and elderly, but also occurs in children and young adults

Presentation

- Enlarging mass at nodal or extranodal sites
  - Gastrointestinal tract is a frequent extranodal site
  - Presenting symptoms may be related to mass effect
- ~ 50% of patients are at stage I or II at presentation; up to 1/3 present at stage IV
  - Bone marrow involvement occurs less frequently than in patients with low-grade B-cell lymphomas

Prognosis

- 5-year overall survival for patients with DLBCL ranges from 25-75%, depending on prognostic factors present at diagnosis

MICROSCOPIC PATHOLOGY

Histologic Features

- Diffuse growth pattern
  - Neoplasm replaces normal architecture with diffuse and usually dense lymphoid infiltrate
  - Sometimes present as vague nodules
  - Sclerosis is frequent in extranodal sites
- Centroblastic morphology
  - Typical: Medium to large cells (10-14 µm) with fine chromatin, 2-3 small nucleoli often closely apposed to nuclear membrane, and scant basophilic cytoplasm
  - Multilobated: Medium to large cells with lobated nuclei (> 3 lobes)
- Immunoblast morphology
  - Large lymphocyte with centrally located nucleolus and moderate basophilic cytoplasm
- Anaplastic morphology
  - Large to very large bizarre, pleomorphic cells, some resembling Reed-Sternberg cells or hallmark cells of anaplastic large cell lymphoma; may grow in cohesive pattern
- Polymorphic variant: Mixture of centroblasts, immunoblasts, multilobated cells, and cells with overlapping cytologic features
- Rare morphologic variants: Myxoid stroma or fibrillary matrix, pseudorosette formation, spindle-shaped, signet ring, cytoplasmic granules, cytoplasmic projections, intercellular junctions

ANCILLARY TESTS

Immunohistochemistry

- Pan B-cell antigens (+)
- GCB subgroup: > 30% CD10(+) or CD10(-), Bcl-6(+), MUM1(-)
- Bcl-2(+/-), CD30(-/+), CD5(-/+)
- Proliferation fraction (Ki-67) usually high (> 30-40%)

Cytogenetics

- t(14;18): 1 of the most frequent translocations; detected in 20-30% of cases
- Abnormalities involving chromosome 3q27 region (BCL6 gene) are seen in up to 30% of cases
- MYC translocations are identified in up to 10% of cases
- Concurrent rearrangements of MYC and BCL2 &/or BCL6 (so-called double-hit or triple-hit lymphomas) indicate a poorer prognosis

Gene Expression Profiling

- Expression microarray studies have identified molecular subgroups of DLBCL
  - GCB type: Gene expression profile similar to germinal center B cells
  - ABC type: Gene expression profile similar to activated peripheral B cells

DIFFERENTIAL DIAGNOSIS
**DLBCL Subtypes**

- **Primary DLBCL of central nervous system**
  - Recognized as distinct subtype in 2008 WHO classification
  - All primary or intraocular lymphomas are considered in this category
  - Bcl-6 and MUM1(+) in most cases
  - CD10(+) in up to 20% of cases
  - EBV(-) in immunocompetent patients
  - Patients may have sporadic systemic relapses, particularly in testes and breasts

- **Primary cutaneous DLBCL, leg type**
  - Not limited to lower extremities
  - Multiple tumors frequent, sometimes ulcerated
  - Large monotonous lymphoid cells (immunoblastic morphology)
  - No epidermotropism
  - Positive for CD20, Bcl-2, Bcl-6, MUM1, and FOXP1
  - CD10 usually negative

- **EBV(+) DLBCL in patients > 50 years old**
  - No history of chronic inflammation, immunodeficiency, or previous lymphoma
  - Believed to be related to senescence of immune system
  - Frequent extranodal involvement
  - EBV always positive (EBER and LMP1)
  - MUM1(+) in most cases
  - CD10 and Bcl-6 usually negative

**Other Lymphomas of Large B Cells**

- **Primary mediastinal (thymic) large B-cell lymphoma**
  - Young females
  - Anterosuperior mediastinal mass
  - Locally aggressive with local compressive effects
  - Large cells with pale cytoplasm (often is retraction artifact) and sclerosis (compartmentalization)
  - Thymic components, such as Hassall corpuscles, may be identified
  - Positive for pan-B-cell markers
  - CD30 often (+) but usually weak &/or focal (~ 75%)
  - CD23 (70%), Bcl-6, and MUM1 (most cases)

- **DLBCL associated with chronic inflammation**
  - History of longstanding chronic inflammation
  - Associated with EBV (EBER and LMP1 [-])
  - Pleural cavity, bone (especially femur), and periarticular joint tissues
  - CD30 may be positive

- **Lymphomatoid granulomatosis**
  - Patients may have underlying immunodeficiency disorder
  - Lung is most common site of involvement (almost essential for diagnosis)
    - Other extranodal sites: Skin, kidney, liver, and central nervous system
  - Angiocentric and angiodestructive polymorphic lymphoid infiltrate with necrosis
  - Positive for CD20, CD30 (variable), and EBV (LMP1 and EBER)

- **Anaplastic kinase (ALK)-positive large B-cell lymphoma**
  - Rare (~ 100 reported cases)
  - Immunoblastic/plasmablastic morphology
  - Intrasinusoidal growth pattern
  - Positive for ALK, EMA, CD138, Vs38c, and monotypic cytoplasmic light chain
  - Negative for CD20, CD30, EBV, and T-cell antigens (except for CD4)
  - ALK gene at 2p23 can be involved in translocations with
    - Clathrin (CTCL) gene on 17p23, resulting in CTCL-ALK fusion protein
    - Nucleophosmin (NPM) gene on 5q35, resulting in NPM-ALK fusion protein
    - Complex SEC31A-ALK fusion also reported

- **Plasmablastic lymphoma**
  - Large neoplastic cells, most of which resemble immunoblasts or plasmablasts
  - Plasma cell-associated markers expressed (CD138, CD38, Vs38c, and EMA)
Diagnostic Pathology: Familial Cancer Syndromes

- CD56 frequently positive
  - CD56 expression is rare in DLBCL
- Almost always negative for CD20 and pax-5
- CD45 (LCA) weak or negative
- Some cases positive for some T-cell markers, including CD4 and CD7
- EBV frequently positive (~75%)

- **Primary effusion lymphoma**
  - Serous effusions (pleural, pericardial, and peritoneal cavities) without tumor masses
  - Usually in context of HIV infection
  - Positive for CD45 (LCA) and plasma cell markers
  - Negative for B-cell markers
  - EBV infection common (EBER[+], LMP1[-])
  - Usually associated with human herpesvirus 8 (HHV8)

- **Burkitt Lymphoma**
  - Monomorphic medium-sized cells with multiple small nucleoli
  - Numerous mitoses and “starry sky” pattern
  - Characteristic immunophenotype: Positive for CD10, Bcl-6 (strong), and CD20; negative for Bcl-2
  - Ki-67 positive in virtually 100% of tumor cells (uniformly strong)
  - Chromosomal translocations involving MYC gene at 8q24 are characteristic

- **Follicular Lymphoma (Grade 3B)**
  - CD21, CD23, and CD35 highlights follicular dendritic cells in follicular areas

SELECTED REFERENCES

Image Gallery
Morphologic Features
(Left) H&E stain shows DLBCL involving a lymph node with a diffuse growth pattern and loss of normal nodal architecture. The neoplasm extends into the fibroadipose tissue. (Right) H&E stain shows DLBCL involving a lymph node with prominent, reactive capsular fibrosis.

(Left) H&E stain shows DLBCL composed of centroblasts and admixed small reactive lymphocytes and occasional eosinophils. (Right) This high-magnification view of DLBCL reveals an infiltrate composed of multilobated centroblasts. The tumor cells are large, and some have deeply lobated nuclei.
The immunoblastic variant of DLBCL is composed of a monotonous population of large cells with central prominent nucleoli. The anaplastic variant of DLBCL demonstrates markedly pleomorphic cells that are mostly large in size with irregular nuclei, vesicular chromatin, and distinct nucleoli. These tumor cells were positive for CD20 and CD30 and negative for CD10, CD5, and CD3.

Morphologic and Immunophenotypic Features

(Left) Image shows DLBCL (centroblastic variant) with marked sclerosis. The centroblasts are large with vesicular nuclear chromatin and cleaved nuclei. Sclerosis is frequently seen in cases of DLBCL involving extranodal sites and retroperitoneum. (Right) H&E stain of a touch imprint of DLBCL shows medium to large lymphoid cells, some with small nucleoli apposed to the nuclear membrane. Few multilobated cells are also seen.
(Left) Image shows a CD10(+) DLBCL. Almost all of the cells are immunoblasts with large nuclei and show cytoplasmic immunopositivity for CD10. (Right) A Bcl-6 stain shows subset positivity in this case of DLBCL. The expression of both CD10 and Bcl-6 is consistent with a germinal center cell phenotype. DLBCL cells, when positive for Bcl-6, usually show variable degrees of nuclear positivity. In contrast, Burkitt lymphoma cells are usually strongly and uniformly positive for Bcl-6.

(Left) Image shows a Bcl-2(+) DLBCL. Neoplasm replaces normal architecture with diffuse and usually dense lymphoid neoplastic cells that are strongly positive for Bcl-2. (Right) Nuclei of neoplastic B cells of DLBCL are equivalent to or larger than nucleus of a macrophage, or are at least 2x as large as nucleus of a normal B cell with high proliferative rate. The proliferation rate of this DLBCL is ~40-50% as measured by MIB-1 (Ki-67).

Differential Diagnosis
(Left) H&E stain shows the characteristic morphologic features of Burkitt lymphoma. The tumor cells are fairly monotonous with multiple small nucleoli. Admixed tingible-body macrophages impart a "starry sky" pattern at low magnification. (Right) Plasmablastic lymphoma is composed of large, pleomorphic tumor cells, some with features of immunoblasts. These tumor cells were positive for CD38, CD138, and CD10, and were negative for CD20 and pax-5.

(Left) Primary cutaneous DLBCL (leg type) is composed of large cells, some with immunoblastic features. This tumor extensively involved the dermis and subcutaneous tissue. (Right) H&E stain shows lymphomatoid granulomatosis involving the lung with characteristic features, including extensive necrosis and an angiocentric pattern of infiltration.
ALK(+) large B-cell lymphoma is composed of immunoblasts with a plasmacytic appearance. These tumor cells were focally positive for CD79a and ALK (cytoplasmic and coarsely granular) and negative for CD30. This tumor, which presented in the anterior mediastinum, is composed of large cells with pale cytoplasm and sclerosis (features of primary mediastinal large B-cell lymphoma). These cells were positive for CD20, CD30 (focal), and MUM1, and were negative for CD10.

Follicular Lymphoma

- Table of Contents > Part II - Diagnoses Associated With Specific Syndromes > Section 2 - Blood and Bone Marrow > Follicular Lymphoma

C. Cameron Yin, MD, PhD
Elizabeth Morgan, MD

Key Facts
Terminology
- B-cell neoplasm composed of germinal center B cells (centrocytes and centroblasts)

Etiology/Pathogenesis
- Overexpression of antiapoptotic Bcl-2 due to t(14;18) (q32;q21)
- Susceptibility locus at 6p21.3 and higher risk in 1stdegree relatives of patients with follicular lymphoma (FL)

Clinical Issues
- ~20% of non-Hodgkin lymphoma (NHL), 2nd overall, in USA and Western Europe
- Usually asymptomatic although disseminated at presentation
- Overall 10-year survival is up to ~80%

Microscopic Pathology
- Closely packed neoplastic follicles, fairly uniform in size and shape
- Neoplastic follicles composed of variable amounts of centrocytes and large centroblasts
- Grading has prognostic and therapeutic significance

Ancillary Tests
- B cells positive for Bcl-2, Bcl-6, and CD10
- Bcl-2(+) in 85-90% of FL grade 1 and grade 2; 50% in FL grade 3

Top Differential Diagnoses
- Reactive follicular hyperplasia
- Nodular lymphocyte predominant HL
- Mantle cell lymphoma
- Nodal marginal zone lymphoma
Gross photograph shows matted mesenteric lymph nodes involved by low-grade follicular lymphoma (FL). This specimen was obtained at time of autopsy.
FL involving the lymph node shows follicles throughout the cortex and medulla. The large number and random distribution of follicles supports the diagnosis of lymphoma.

**TERMINOLOGY**

**Abbreviations**
- Follicular lymphoma (FL)

**Synonyms**
- Follicle (germinal) center cell lymphoma
- Centroblastic/centrocytic lymphoma

**Definitions**
- B-cell neoplasm composed of germinal center B cells (centrocytes and centroblasts)
  - Follicular, follicular and diffuse, and diffuse growth patterns

**ETIOLOGY/PATHOGENESIS**
- t(14;18)(q32;q21) Resulting in Overexpression of Bcl-2
  - Bcl-2 is antiapoptotic and confers survival advantage
  - t(14;18) is considered initiating molecular event of FL
    - Insufficient to induce lymphomagenesis by itself
    - Other molecular changes necessary for development of lymphoma

**Germline Susceptibility Factors**
- Genotypic analysis has identified novel susceptibility locus at 6p21.3
  - Contains single gene, chromosome 6 open reading frame 15 (C6orf15)
- 4x increased lymphoma risk in 1st-degree relatives of patients with FL
- Association of single nucleotide polymorphisms of estrogen receptor gene with reduced risk of FL

**Imbalance of Other Proteins Involved in Apoptosis**
- Overexpression of cell death suppressor proteins BclxL and Mcl-1
- Decreased expression of cell death promoting proteins BAX and BAD
- Overexpression of inhibitors of apoptosis proteins (IAP)
Immunologic Microenvironment
- CD40L(+) T cells in secondary follicles inhibit FL cell death
- Follicular dendritic cells contribute to preventing apoptosis of FL cells

CLINICAL ISSUES
Epidemiology
- Incidence
  - ~ 20% of non-Hodgkin lymphoma (NHL); 2nd most common NHL in USA and Western Europe
  - Uncommon in Asia and underdeveloped countries
- Age
  - Median = 59 years
- Gender
  - M:F = 1:1.7

Site
- Cervical and inguinal lymph nodes are more frequently affected
- Commonly affected extranodal sites
  - Bone marrow, spleen, liver, and peripheral blood
- FL uncommonly arises at extranodal sites
  - Skin, gastrointestinal tract, thyroid gland, testis

Presentation
- Insidious onset
- Often asymptomatic at time of initial diagnosis
- Almost always disseminated (stages III-IV)

Natural History
- Indolent clinical course but frequent relapses
- Some cases progress to diffuse large B-cell lymphoma (DLBCL)

Treatment
- In the past, “watch and wait” strategy was usually employed for asymptomatic patients
- Chemotherapy is currently used upfront more often for patients with stages III-IV disease
  - Rituximab, cyclophosphamide, Adriamycin (doxorubicin), vincristine, and prednisone (R-CHOP)
  - Bulky disease or signs of progression necessitate chemotherapy
- Radiation has value for subset of patients with stages I and II disease

Prognosis
- Overall 10-year survival is up to ~ 80%
- Adverse prognostic factors summarized in FL International Prognostic Index 2 (FLIPI 2)
  - High serum β2-microglobulin
  - Bulky lymph nodes > 6 cm
  - Bone marrow involvement
  - Hemoglobin < 12 g/dL
  - Age > 60 years
- FLIPI 2 prognostic model stratifies patients into different prognostic risk groups
  - Model developed in post-rituximab era using prospective analysis
- Pathologic adverse prognostic factors include
  - High histologic grade and diffuse areas > 25% with predominance of large cells
    - These areas are designated as DLBCL
  - High proliferation index
  - Complex karyotype
  - del6q23-26; del17p and mutation of TP53

IMAGE FINDINGS
General Features
- Widespread lymphadenopathy; often small lymph nodes

MACROSCOPIC FEATURES
General Features
- Replacement of nodal parenchyma by “fish-flesh” tumor; ± nodularity

MICROSCOPIC PATHOLOGY
Histologic Features
Lymph node
- Partial or complete effacement of architecture
- Closely packed neoplastic follicles, fairly uniform in size and shape
- Follicles usually poorly circumscribed with faint or absent mantle zones
- “Cracking” artifact may surround neoplastic follicles
- Neoplastic follicles are composed of centrocytes and centroblasts
  - Cells randomly distributed throughout individual follicles, without polarity
  - Infrequent mitoses and absent or scanty tingible body macrophages
  - Centrocytes: Small to large with angulated, elongated, or twisted nuclei, with dark chromatin and scant cytoplasm
  - Centroblasts: Large cells with oval or multilobated nuclei, vesicular chromatin, 1-3 nucleoli, and moderate cytoplasm
- Diffuse areas with or without sclerosis
  - More frequent in mesenteric and retroperitoneal lymph nodes
  - Scattered interfollicular neoplastic lymphocytes are not considered diffuse growth pattern
  - Follicular dendritic cell meshworks are absent in diffuse areas

Bone marrow
- Paratrabecular aggregates of centrocytes and, less frequently, centroblasts in bone marrow
  - Aspirate smears may have scant lymphoma cells or are negative

Peripheral blood
- Marked leukemic involvement in 5-10% of patients
- Neoplastic cells have highly cleaved nuclei and are known as “buttock cells”
- Low-level involvement is detected by molecular methods in ~ 90% of patients

Liver
- Portal tracts are preferentially involved
- Large mass lesions usually indicate transformation to DLBCL

Spleen
- Preferential involvement of white pulp

Unusual morphologic variants of FL
- Floral variant
  - Mantle zone lymphocytes penetrate into neoplastic follicles, imparting irregular shapes
  - Better highlighted with follicular dendritic cell markers, e.g., CD21
  - Often grade 3
- Plasmacytic differentiation
  - Focal plasmacytic differentiation can occur rarely in FL, intrafollicular or interfollicular
  - Extreme degrees with intracytoplasmic inclusions appear as “signet ring cells”
- Marginal zone differentiation
  - Monocytoid cells with clear cytoplasm at periphery of neoplastic follicles
  - Has been correlated with poorer prognosis

Cytologic Features
- Diagnosis of FL can be established by FNA with ancillary support
  - In smears, aggregates of cells bound by follicular dendritic cells
  - Variable mixture of centrocytes and centroblasts
  - Usually, absence of tingible body macrophages

Grading of FL
- Grading has prognostic and therapeutic significance
- Most reliably performed on lymph node biopsy specimen
- System is based on mean number of centroblasts per high power field (HPF)
  - Count 10 HPFs and divide by 10
- Grade 1: 0-5 centroblasts/HPF
- Grade 2: 6-15 centroblasts/HPF
- Grade 3: > 15 centroblasts/HPF
  - Grade 3A: Centrocytes admixed with centroblasts
  - Grade 3B: Sheets of centroblasts with rare or no centrocytes
- Remember: Cutoff values are based on 40x objective and 18 mm field-of-view ocular
Many microscopes have larger field-of-view ocular
  ▪ 20 mm field-of-view ocular: Divide 10 HPF count by 12
  ▪ 22 mm field-of-view ocular: Divide 10 HPF count by 15

2008 WHO classification recommends lumping cases of FL grades 1-2 together as low grade
  o Minimal differences in outcome between patients with FL grade 1 vs. grade 2
  o Diffuse areas > 25% of grade 3 FL should be diagnosed as DLBCL

Histologic Discordance (Discrepant Histology) in Patients With FL
  • FL involving different lymph node groups may show different grades
    o Occurs in up to 1/3 of patients who undergo staging laparotomy
  • Lymph node can be involved by grade 3 FL or DLBCL with bone marrow showing grade 1 FL
    o Occurs in ~ 10-20% of patients with grade 3 FL or DLBCL
    o Low-grade bone marrow involvement does not affect prognosis

Reporting Pattern in FL
  • Most reliably performed on lymph node biopsy specimen
  • Follicular: > 75% follicular
  • Follicular and diffuse: 25-75% follicular
  • Focally follicular: 1-25% follicular
  • Diffuse: 0% follicular

Diffuse Follicular Lymphoma
  • Diffuse growth of small centrocytes with few or absent centroblasts
    o Immunophenotype: CD10(+), Bcl-6(+), Bcl-2(+)
    o IGH-BCL2 fusion gene or t(14;18)(q32;q21) present
  • Rare diagnosis; more common in core needle biopsy specimens
    o Extensive sampling may reveal focal follicular pattern

Intrafollicular Neoplasia/In Situ Follicular Lymphoma
  • Lymph node with widely spaced follicles of which a subset have Bcl-2(+) germinal centers
    o Bcl-2 expression by germinal centers is characteristically bright
    o Bcl-2(+) follicles have immunophenotype of FL and t(14;18)
    o Using histologic criteria alone, diagnosis of FL can be difficult or not possible
  • Patients with intrafollicular neoplasia may
    o Have FL elsewhere simultaneously or develop FL subsequently
    o Have other types of non-Hodgkin lymphoma or Hodgkin lymphoma simultaneously or subsequently
    o Not develop lymphoma on clinical follow-up

Clinically Aggressive B-Cell Lymphoma
  • FL transformation to more clinically aggressive B-cell lymphomas occurs in ~ 30% of FL patients
  • Usually transforms into DLBCL
    o Accounts for most disease-related deaths
  • Transformed tumor less often resembles Burkitt lymphoma (BL) or tumor with features intermediate between BL and DLBCL
  • Transformation is commonly associated with
    o Resistance to therapy and median survival ~ 1 year
    o Inactivation of TP53 or P16; activation of MYC

Pediatric FL
  • Localized disease, usually involves neck lymph nodes
  • Extralymph nodes also affected: Testes, Waldeyer ring
  • High histological grade; usually with large follicles
  • Usually Bcl-2(-) and lacks t(14;18)(q32;q21) or IGH-BCL2
  • Most patients have good prognosis without disease progression

ANCILLARY TESTS
Immunohistochemistry
  • Monotypic surface Ig(+) ; pan-B-cell markers (+)  
  • CD10(+), Bcl-6(+)
    o CD10 and Bcl-6 more brightly expressed within follicles than in interfollicular regions
  • HGal(+), LMO2(+)
  • Bcl-2(+) in 85-90% of FL grade 1 and grade 2; 50% in FL grade 3
Bcl-2(+) is useful to distinguish FL from reactive follicles that are Bcl-2(-)  

- Follicular dendritic cell meshworks are present in follicles  
  - Variable expression of CD21, CD23, or CD35  
- CD23(+/-), IRF-4/MUM1(-)  
- FLs are usually CD5(-), CD43(-)  
  - Small subset (< 5%) can be CD5(+) or CD43(+)  
- CD2(-), CD3(-), CD4(-), CD7(-), CD8(-)  
- Proliferation rate of FLs assessed by Ki-67  
  - Percentage of Ki-67(+) cells correlates with grade  
    - Most low-grade FLs show low proliferation rate (< 20%)  
    - High-grade FLs show moderate to high proliferation rate (> 40%)  
  - Approximately 20% of low-grade FLs have moderate/high proliferation rate  
    - These FLs appear to behave more aggressively, similar to grade 3A FL  
- Grade 3 FLs  
  - Can be CD10(-), Bcl-2(-), IRF-4/MUM1(+)  

**Cytogenetics**  
- 80-90% of cases have t(14;18)(q32;q21)  
  - Juxtaposes BCL2 at 18q21 adjacent to IGH on derivative chromosome 14  
  - Is rarely (10%) the only karyotypic abnormality  
- Other common chromosomal aberrations in FL include  
  - Deletions of 1p, 6q, 10q, 17p  
  - Gains of 1, 6p, 7, 8, 12q, 18q, X  
- Complex karyotype correlates with poorer prognosis  

**In Situ Hybridization**  
- FISH can detect t(14;18)(q32;q21) in up to 90% of FL cases  
  - Large probes can detect multiple breakpoints  

**PCR**  
- Monoclonal IGH and Ig light chain gene rearrangements  
  - Variable regions of Ig genes undergo extensive and ongoing mutations  
  - Mutations can cause false-negative result when using PCR to assess for Ig gene rearrangements  
    - Multiple primer sets are therefore required for analysis  
- There are multiple breakpoints in BCL2 that must be individually assessed by PCR  
  - Major breakpoint cluster region (MBR): ~ 50-60% of FLs with t(14;18)  
  - Minor breakpoint cluster region (MCR): ~ 5-10% of FLs  
  - Intermediate cluster region (ICR): ~ 10-15% of FLs  
  - 5' breakpoint region: ~ 5% of FLs  

**Array CGH**  
- ~ 90% of FLs have abnormalities detected by CGH or array CGH  
  - Gains: 2p15, 7p, 7q, 8q, 12q, 18p, 18q  
  - Losses: 1p36, 3q, 6q, 9p, 11q, 13q, 17p  
- Abnormalities associated with worse prognosis  
  - Loss of 6q or 9p21  
  - Gain of chromosome X  
- Abnormalities associated with transformation to DLBCL  
  - Gains of 2, 3q, and 5  

**Molecular Genetics**  
- IGH-BCL2/t(14;18)(q32;q21) is insufficient to induce lymphomagenesis  
  - IGH-BCL2 fusion gene can be detected in blood of 50% of healthy individuals by using sensitive nested PCR methods  
- BCL6/3q27 rearrangement occurs in ~ 15% of FLs  
  - More common in grade 3B tumors  
- Inactivation of tumor suppressor genes TP53, P15, P16  
  - Occurs in FLs but is more common at time of transformation to DLBCL  
- MYC rearrangement is associated with transformation to DLBCL  

**Gene Expression Profiling**  
- Initial study from Leukemia/Lymphoma Molecular Profiling Project showed  
  - Host response in FLs has prognostic importance  
  - 2 gene expression profiles: Immune response (IR) 1 and IR2
• IR1: Good prognosis: Genes related to T cells and macrophages
  o These studies included FLs ± t(14;18)(q32;q21)
• IR2: Poor prognosis: Genes related to monocytes and dendritic cells
  o Other groups have shown importance of host response but emphasize different gene signatures
  • Recent studies have analyzed t(14;18)(+) FL and t(14;18)(-) FL separately
    o FL with t(14;18)(q32;q21)
      • Enriched germinal center B-cell genes
    o FL without t(14;18)(q32;q21)
      • Enriched activated B-cell-like, NF-κB, and proliferation genes

P.II(2):18

DIFFERENTIAL DIAGNOSIS
Reactive Follicular Hyperplasia (RFH)
• Children and young adults; patients with autoimmune disease
• Features that distinguish RFH from FL
  o Lymph node architecture preserved with follicles located mostly in cortex
  o Follicles vary in size and shape; widely spaced
  o Polarization of germinal centers into light and dark zones
  o Frequent mitoses and tingible body macrophages in germinal centers
  o Sharply demarcated mantle zones surround germinal centers
  o Immunophenotype: Polytypic B cells; Bcl-2(-)
  o No evidence of monoclonal Ig gene rearrangements

Progressive Transformation of Germinal Centers
• Partial lymph node replacement
• Nodules are 3-4x larger than background reactive follicles
• Small lymphocytes with mantle cell immunophenotype infiltrate and eventually replace germinal centers
• Immunophenotype: Polytypic B cells; Bcl-2(-)
• No evidence of monoclonal Ig gene rearrangements

Nodular Lymphocyte-Predominant Hodgkin Lymphoma
• Large, vague nodules
• Most cells in nodules are small round lymphocytes
  o Admixed with fewer LP ("popcorn") cells
• LP cells are CD20(+), CD45(+), CD10(-), Bcl-2(-)
• Small cells in tumor nodules are mostly reactive B cells
• CD4(+) and CD57(+) T cells commonly form rosettes around LP cells

Lymphocyte-Rich Classical Hodgkin Lymphoma
• Large vague nodules
• Most cells in nodules are small round lymphocytes
  o Admixed with Hodgkin and Reed-Sternberg (HRS) cells
  o HRS cells are CD15(+), CD30(+), CD45/LCA(-)
• No evidence of monotypic B cells or monoclonal Ig gene rearrangements

Mantle Cell Lymphoma (MCL)
• Usually MCL completely effaces lymph node architecture
  o Nodular pattern can resemble FL
• MCL cells are small with irregular nuclear contours; no centroblasts
• Hyalinized blood vessels and histiocytes with eosinophilic cytoplasm are common
• Immunophenotype
  o Monotypic B-cell population
  o CD5(+), CD43(+), cyclin-D1 (+)
• Detection of t(11;14)(q13;q32) by cytogenetics, FISH, or PCR

Nodal Marginal Zone Lymphoma
• Partial effacement of lymph node architecture with marginal zone expansion
• Neoplastic lymphocytes include small lymphocytes, lymphocytes with monocytoid nuclei, and large cells
  o Frequent plasmacytic differentiation
  o Neoplastic lymphocytes colonize and may replace germinal centers
• Bcl-2(-) in residual centrocytes of germinal centers
• Bcl-2(+) in marginal zone lymphocytes
- **Immunophenotype**
  - Monotypic B-cell population; Bcl-2(+)
  - CD5(-), CD10(-), cyclin-D1 (-), Bcl-6(-)
  - No evidence of t(14;18)(q32;q21)

SELECTED REFERENCES
5. Gradowski JF et al: Follicular lymphomas with plasmacytic differentiation include two subtypes. Mod Pathol. 23(1):71-9, 2010
8. Carlotti E et al: Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood. 113(15):3553-7, 2009

Image Gallery

**Microscopic Features**

*(Left) Image shows follicular lymphoma (FL) involving lymph node. The follicles are composed of numerous centrocytes and fewer centroblasts, supporting grade 2. *(Right) FL, grade 3A, follicular pattern is shown. The follicles are composed of many centroblasts, but centrocytes are also present.*
(Left) H&E shows FL, grade 3B, replacing a lymph node. The neoplastic follicles are composed of numerous large cells, many of which are consistent with centroblasts. (Right) FL, grade 3B is shown, replacing a lymph node. The architecture is replaced by neoplastic follicles composed of numerous centroblasts. In this neoplastic follicle, mitotic figures and tingible body macrophages are seen. No small centrocytes are noted.

(Left) FL, low grade, involves a retroperitoneal lymph node. This field shows sclerosis that is associated with the neoplastic lymphoid infiltrate. (Right) FL with plasmacytic differentiation involves a lymph node. Scattered plasma cells admixed with centrocytes are noted. Flow cytometric immunophenotyping demonstrated a population of CD10(+) B cells, and FISH revealed the IgH/BCL2 fusion gene.

Microscopic and Immunohistochemical Features
Initial sections of this core needle biopsy revealed FL with a diffuse growth pattern. Subsequent deeper levels of the block showed rare follicles. The diagnosis of FL was further confirmed by reactivity of the neoplastic cells with CD10, Bcl-6, and Bcl-2. (Right) Image shows diffuse FL involving lymph node. The neoplasm had a diffuse growth pattern and was composed predominantly of centrocytes, supporting grade 1. The proliferation rate was less than 5%.

The floral variant of FL involving lymph node is depicted. The fused or fragmented follicles have the appearance of flower petals. (Right) Immunohistochemical stain for Bcl-2 reveals a single positive germinal center showing intrafollicular neoplasia. A nearby hyperplastic germinal center is Bcl-2(-). Routine histologic examination revealed a benign-appearing germinal center with a predominance of small centrocytes.
Fine needle aspiration of a lymph node from a patient with FL, grade 2, shows aggregates of monotonous lymphoid cells bound by follicular dendritic cells. (Right) Fine needle aspiration of a lymph node from a patient with FL, grade 2, demonstrates a mixture of centrocytes and centroblasts.

Immunohistochemical Features

(Left) pax-5 immunohistochemistry highlights B lymphocytes in neoplastic follicles as well as in interfollicular areas in this FL involving a lymph node. (Right) Immunohistochemical stain for Bcl-2 from a lymph node involved by FL shows that the neoplastic cells are positive. In this case, the neoplastic cells stained more strongly than small reactive T cells, which are also Bcl-2(+).
FL involves a lymph node. Immunostain for CD21 highlights follicular dendritic cells within follicles. CD21 is very useful in establishing the presence of follicles. (Right) Immunohistochemical stain for CD10 in a case of FL shows that the neoplastic cells are strongly positive within neoplastic follicles and faintly positive in interfollicular areas.

(Left) Immunostain for Bcl-6 highlights germinal center B cells within follicles as well as within interfollicular B cells in a case of FL. The reactivity is stronger in germinal centers than in interfollicular regions. (Right) FL assessed for Bcl-6 by immunohistochemistry highlights germinal center B cells within follicles as well as within interfollicular B cells. The difference in intensity of expression is attributable to the microenvironment.

Immunohistochemical Features and Ancillary Techniques
Immunohistochemical stain for Ki-67 in a case of FL grade 3A, shows a germinal center with a proliferation rate of 40-50%. There is usually a good correlation between the grade of FL and the proliferation rate. Paradoxically, high proliferation rate (~60%) is seen in a neoplastic follicle in a case of FL grade 2. Histological cases of low-grade FL associated with high Ki-67 appear to behave more aggressively than those with a low proliferation rate.

Flow cytometric immunophenotyping of a lymph node fine aspirate specimen from a patient with FL reveals that the lymphoma cells express CD19 and CD10. In this example, the lymphocytes expressing κ outnumber the few lymphocytes expressing λ.
Real-time PCR assesses for the IgH/BCL2 fusion gene involving the major breakpoint cluster region. Threshold [1], negative control [2], high positive control [3] and low positive amplification [4] are highlighted. (Courtesy S. Chen, MD.) (Right) FISH was performed on a fixed, paraffin-embedded tissue section of FL using dual-fusion probes for Bcl-2 (red [5]) and IgH (green [6]). The t(14;18)(q32;q21)/IgH-BCL2 fusion gene is a yellow signal [7]. P.II(2):23

Follicular Lymphoma Involving Extranodal Sites

(Left) Image shows FL involving the testis in a 6-year-old boy. Most of the testis is replaced by tumor nodules, but a seminiferous tubule [8] can be seen in the field. Most children with FL have a clinically indolent course even when the lymphoma is grade 3. (Right) The anti-CD21 antibody highlights follicular dendritic cells within a neoplastic follicle in FL involving the testis in a 6-year-old boy. A seminiferous tubule [9] is present and can be seen at the upper right corner of this image.
Bone marrow core biopsy specimen is involved by FL. The neoplasm has a purely paratrabecular pattern, which is highly suggestive of FL. Bone marrow core biopsy specimen involved by FL is shown. In many patients with this pattern of involvement, flow cytometry or molecular studies are negative for a monotypic B-cell population or t(14;18) (q32;q21) because the lymphoma cells are not aspirated.

A peripheral blood smear from a patient with FL demonstrates leukemic involvement by centrocytes with deeply cleaved nuclei, so-called buttock cells. A core needle biopsy of liver involved by FL shows expansion of a portal tract. The lymphoid infiltrate is composed mostly of centrocytes.

Hodgkin Lymphoma

CHL (95% of HL) is a lymphoid neoplasm composed of neoplastic Hodgkin and Reed-Sternberg (HRS) cells in a reactive inflammatory background

- Composed of 4 subtypes: NSCHL, MCCHL, LRCHL, and LDCHL

NLPHL (5% of HL) is a lymphoid neoplasm composed of neoplastic lymphocyte-predominant (LP) cells in a reactive inflammatory background

Key Facts

Terminology

- CHL (95% of HL) is a lymphoid neoplasm composed of neoplastic Hodgkin and Reed-Sternberg (HRS) cells in a reactive inflammatory background

Etiology/Pathogenesis
• HRS cells arise from late germinal center B cells
  o Demonstrate many defects in B-cell differentiation
  o Utilize antiapoptotic mechanisms to survive
• LP cells arise from centroblastic-stage germinal center B cells and demonstrate frequent BCL6 abnormalities
• Familial factors
  o Familial HL accounts for ~ 4.5% of all HL
  o Specific HLA haplotypes have been associated with HL risk
  o Genome-wide association studies have also identified several susceptibility loci

Microscopic Pathology
• Both CHL and NLPHL are characterized by the presence of (typically) few, scattered neoplastic cells in a background of numerous reactive inflammatory cells
• Neoplastic HRS cells include bilobed or multilobated Reed-Sternberg forms and mononuclear Hodgkin cells, which display large eosinophilic nucleoli and abundant slightly basophilic cytoplasm

Image shows the cut surface of a lymph node from a patient with NSCHL. Note the nodular appearance and the intervening bands of fibrosis. The texture upon bisecting such lymph nodes is often described as gritty.
Image shows a bisected lymph node from a patient with nodular lymphocyte-predominant HL (NLPHL). There are multiple nodules of variable size throughout the lymph node parenchyma. (Courtesy P. Lin, MD.)

TERMINOLOGY

Abbreviations
- Hodgkin lymphoma (HL)
- Classical Hodgkin lymphoma (CHL)

Definitions
- CHL (95% of HL) is a lymphoid neoplasm composed of neoplastic Hodgkin and Reed-Sternberg (HRS) cells in a reactive inflammatory background
  - Composed of 4 subtypes that demonstrate distinct features
    - CHL, nodular sclerosis subtype (NSCHL) (70% CHL): Neoplastic HRS cells and reactive inflammatory cells form nodules surrounded by fibrous bands
    - CHL, mixed cellularity subtype (MCCHL) (20-25% CHL): Neoplastic HRS cells and reactive inflammatory cells form diffuse or interfollicular pattern
    - CHL, lymphocyte-rich subtype (LRCHL) (4-5% CHL): Neoplastic HRS cells are surrounded by small, reactive lymphocytes in a nodular or diffuse pattern
    - CHL, lymphocyte-depleted subtype (LDCHL) (< 1% CHL): Neoplastic HRS cells may be scant, frequent or pleomorphic in a variably fibrotic background depleted of small lymphocytes

- Nodular lymphocyte-predominant HL (NLPHL) (5% of HL) is a lymphoid neoplasm composed of neoplastic lymphocyte-predominant (LP) cells in a reactive inflammatory background

ETIOLOGY/PATHOGENESIS

CHL
- HRS cells
  - Arise from late germinal center or early postgerminal center B cells
  - Have undergone immunoglobulin (Ig) gene rearrangements with somatic mutations
  - In some cases, crippling (e.g., nonsense) Ig mutations occur but cells do not undergo apoptosis
  - Lack B-cell antigen receptors
• HRS cells lose much of the normal B-cell phenotype
  o Severe impairment of transcription factor networks regulating B-cell gene expression
    ▪ Low or undetectable levels of transcription factors: OCT2, BOB1, PU.1, and early B-cell factor-1 (EBF1)
    ▪ Because EBF1 also suppresses expression of myeloid and T-cell genes, low level of EBF1 expression in HRS may contribute to aberrant expression of T-cell markers or myeloid markers
    ▪ Numerous B-cell genes are inactivated by epigenetic silencing (e.g., promoter hypermethylation) including CD19
    ▪ Deregulated expression of NOTCH1, activated B-cell factor 1 (ABF1), and inhibitor of differentiation and DNA binding 2 (ID2) inhibit overall B-cell development
• HRS cells utilize antiapoptotic mechanisms to achieve survival
• Microenvironment plays a critical role
  o Reactive cellular infiltrate is induced, in part, by HRS cells, which produce a variety of cytokines, chemokines, and growth factors
    ▪ Protects HRS cells from apoptosis
    ▪ Suppresses T-cell and NK-cell immune response against HRS cells
• Notes about subtypes
  o NSCHL: HRS cells have increased production of IL-13, which may be responsible for broad bands of birefringent collagen
  o LDCHL: May represent progression from other types of CHL
• Infectious agents
  P.II(2):25
  o Epstein-Barr virus (EBV) likely plays a role in pathogenesis of HL but is only found in a proportion of cases
    ▪ NSCHL: EBV expression detected in HRS cells in ~ 20% of cases
    ▪ MCCHL: EBV expression detected in HRS cells in ~ 75% of cases
    ▪ LRCHL: EBV expression intermediate between NSCHL and MCCHL
    ▪ LDCHL: EBV expression common, particularly in patients with HIV infection
    ▪ No other associated viruses have been identified
• Primary immunodeficiencies
  o CHL has been reported in patients with ataxiatelangiectasia and Wiskott-Aldrich syndrome
• Secondary immunodeficiencies
  o Patients with HIV infection have an increased risk of HL
  o CHL may develop in the post-transplant setting (particularly after renal transplant) and is almost always EBV associated
• Familial factors
  o Familial HL accounts for ~ 4.5% of all HL
  o Specific HLA haplotypes have been associated with HL risk
  o Genome-wide association studies have also identified several susceptibility loci
NLPHEL
• LP cells are clonal with rearranged, somatically mutated Ig variable region genes that are functional, indicating that normal counterpart is likely antigenselected germinal center B lymphocytes
• No association with latent EBV infection
• IGH-BCL6 translocations have been found in a subset of NLPHEL cases
• BCL6 rearrangements are frequent in NLPHEL
• Aberrant somatic hypermutations in several genes including PAX5, PIM1, RHOH/TTF, and MYC have been identified
• NLPHEL is associated with progressive transformation of germinal centers (PTGC), which may precede or occur concurrently with NLPHEL, although diagnosis of PTGC alone does not increase risk of subsequent development of NLPHEL
• Several NLPHEL families have been identified
  o Whole exome sequencing and linkage studies revealed truncating germline mutation in NPAT gene in a family of 4 cousins with NLPHEL

CLINICAL ISSUES
Epidemiology
Incidence
- HL accounts for ~20-30% of all lymphomas in USA and Europe
- CHL accounts for 95% of HL (NSCHL > MCCHL > LRCHL > LDCHL)
  - NSCHL is more frequent in developed countries compared to developing countries
- NLPHEL accounts for 5% of HL

Age
- NSCHL: Peak incidence at 15-34 years of age
- MCCHL, LRCHL, LDCHL, NLPHEL: Older age group than peak of NSCHL (≥30-50 years)

Gender
- NSCHL: Slightly more prevalent in women
- MCCHL, LRCHL, LDCHL, NLPHEL: M:F ≥2:1

Site
- NSCHL: Mediastinal or cervical lymph nodes
- MCCHL: Cervical or supraclavicular lymph nodes (mediastinal involvement uncommon); spleen
- LRCHL: Peripheral lymph nodes, especially supradiaphragmatic; may involve Waldeyer ring, unlike other forms of CHL
- LDCHL: Retroperitoneal or abdominal lymph node involvement more frequent than peripheral lymph node involvement
- CHL generally spreads to contiguous structures
  - Involvement of lymphoid structures on both sides of diaphragm or at extranodal sites beyond site of contiguous spread (including bone marrow) is an indication of advanced stage disease
- NLPHEL: Cervical, axillary, or inguinal lymph nodes most common
  - Bone marrow involvement often indicates more aggressive behavior/transformation

Presentation
- B symptoms common in NSCHL, MCCHL, and LDCHL
- LDCHL often presents at advanced stage
- NLPHEL often presents with asymptomatic lymphadenopathy

Treatment
- Chemotherapy ± radiation
- Autologous stem cell transplantation following high-dose chemotherapy may be considered in relapsed/refractory disease

Prognosis
- CHL
  - With modern therapy, all subtypes at similar stages have a similar prognosis
    - >90% survival at 5 years in patients with early stage disease
    - Adverse prognostic factors: Advanced stage, massive mediastinal involvement, older age (>45 years), male gender
- NLPHEL
  - >80% 10-year survival
  - Indolent course but frequent relapses that are responsive to therapy
  - Large cell lymphoma may coexist with or follow NLPHEL
    - Diffuse large B-cell lymphoma (DLBCL): Good prognosis if localized
    - T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL): Poorer prognosis

MICROSCOPIC PATHOLOGY
Histologic Features
- Both CHL and NLPHEL are characterized by the presence of (typically) few, scattered neoplastic cells in a background of numerous reactive inflammatory cells
- CHL
  - Neoplastic HRS cells include bilobed or multilobated Reed-Sternberg forms and mononuclear Hodgkin cells, which display large eosinophilic nucleoli and abundant slightly basophilic cytoplasm
    - Presence of a classic Reed-Sternberg cell (≥2 nuclear lobes/nuclei with ≥1 nucleolus in each lobe/nucleus) is required at initial diagnosis
    - Once a diagnosis of CHL has been rendered, diagnostic Reed-Sternberg cells do not have to be present to make diagnosis at a secondary site or on subsequent biopsy
  - Some HRS cells are pyknotic, so-called mummified forms
  - NLPHEL
Diagnostic Pathology: Familial Cancer Syndromes

- Lymph node architecture effaced by neoplastic nodules surrounded by broad, birefringent collagen bands
- Nodules are composed of inflammatory cells (eosinophils, histiocytes, neutrophils, and plasma cells) and admixed HRS cells
- HRS cells may show retraction artifact in formalin-fixed tissue sections, so-called lacunar cells
- Neutrophilic or eosinophilic abscesses may occur
- Syncytial variant: Confluent aggregates of HRS cells and fewer collagen bands (may mimic large cell lymphoma or metastatic carcinoma)

  o **MCCHL**
    - Complete or partial effacement of lymph node architecture; interfollicular pattern can occur
    - Thick fibrous bands not present; otherwise similar to NSCHL
    - Histiocytes can be singly scattered or present as illdefined or epithelioid granulomas

  o **LRCHL**
    - Commonly nodular pattern in lymph node but may rarely show diffuse architecture
    - Nodules are composed of expanded mantle zones (small lymphocytes) with underlying loose follicular dendritic cell (FDC) meshworks; nodules may contain eccentrically located germinal centers
    - HRS cells are located within nodules (outside of germinal centers, if present)
    - Few histiocytes, plasma cells uncommon, rare to no eosinophils or neutrophils

  o **LDCHL**
    - Lymph node architecture is usually diffusely effaced
    - Generalized depletion of small lymphocytes
    - Eosinophils, neutrophils, and plasma cells are usually scant or absent
    - 3 morphologic patterns: (1) diffuse fibrosis with scant HRS cells admixed with few or abundant fibroblasts, fibrillary stroma, and scant lymphocytes; (2) reticular or sarcoma-like with abundant HRS cells, including pleomorphic, bizarre (sarcomatous) cells; (3) mixed cellularity-like with numerous HRS cells
    - ± coagulative necrosis, sinusoidal invasion, or disordered nonbirefringent fibrillary fibrosis
    - If nodular sclerosing fibrosis is present, process is classified as NSCHL

  o Bone marrow involvement
    - Often patchy with discrete focal lesions composed of a polymorphous infiltrate of lymphocytes, histiocytes, plasma cells, and eosinophils with few HRS cells
    - Commonly associated with fibrosis
    - Multiple levels (step sections) should be performed when evaluating for marrow involvement of CHL if lesions not apparent on initial sections
    - Clinically often manifests as cytopenias

  o **NLPHE**
    - Neoplastic LP cells are large with a variety of morphologic appearances, and are typically confined within expanded, intact FDC meshworks
    - Multilobated “popcorn” cells with vesicular chromatin, multiple small nucleoli, and scant cytoplasm
    - Multinucleated or mummified cells
    - Round cells without multilobation
    - Some forms may be morphologically indistinguishable from HRS cells
    - Background is composed predominantly of small lymphocytes as well as histiocytes (eosinophils and neutrophils rare)

  o Low-magnification view shows complete or partial effacement of lymph node architecture
    - Classical nodular pattern is most common (expansile nodules composed mostly of small lymphocytes and fewer histiocytes; usually no reactive follicles)
    - Serpiginous nodular pattern demonstrates confluent irregular nodules
    - Nodular pattern with extranodular LP cells (most commonly seen at recurrence)
    - Nodular pattern with T-cell-rich background
    - THRLBCL-like (i.e., with diffuse areas indistinguishable from THRLBCL), but with at least 1 typical nodule
Diagnostic Pathology: Familial Cancer Syndromes

- Adjacent reactive follicular hyperplasia with PTGC may preceed or be adjacent to NLPHL
- Large cell lymphoma may coexist with or follow NLPHL
  - Sheets of large cells outside of the NLPHL nodules indicates transformation to DLBCL
  - Scattered large cells in a diffuse architecture may indicate transformation to THRLBCL, although there is no consensus on pathologic criteria to distinguish between NLPHL with diffuse (THRLBCL-like) areas vs. evolving transformation to THRLBCL
  - Incorporation of clinical criteria (such as marrow or liver involvement or elevated LDH) may be needed to diagnose transformation to THRLBCL
- Bone marrow involvement
  - Uncommon
  - If present, consider progression to THRLBCL
- Fibrosis in up to 40% of cases with recurrence

Cytologic Features
- CHL
  - HRS cells in inflammatory background can be appreciated in fine needle aspiration smears
  - Must confirm morphologic impression with immunohistochemical stains performed on cell block
  - Difficult to subtype
- Features of NLPHL on fine needle aspiration are not well documented
  - Would be difficult to distinguish from THRLBCL given absence of architectural information

ANCILLARY TESTS

Immunohistochemistry
- CHL: HRS cells
  - Express CD30 (> 95% of cases) and CD15 (70-80%) with characteristic membranous pattern with accentuation in Golgi area
  - Express pax-5 (dim); variably express CD20 (often heterogeneous) and CD79a (~ 10-20%)
  - Express Ki-67, p53, MUM1, CCL17, fascin (+/1), Bcl-2 (+/-)
  - Variable expression of T-cell antigens in up to 15% of cases
  - No expression of CD45/LCA, EMA, immunoglobulin, clusterin
  - Rare expression of OCT2, BOB1; no expression of PU.1
  - Background CD4(+) T cells form rosettes around HRS cells
- NLPHL: LP cells
  - Express CD20, CD22, CD79a, OCT2, BOB1, PU.1
  - Express CD45/LCA, Ki-67, BCL6, EMA (50% of cases), MUM1 (50% of cases)
  - Express IgD in 25% of cases (typically younger patients)
  - Negative for CD30, CD15, Bcl-2, T-cell antigens
  - Small population of follicular T-helper cells (positive for CD3, CD4, CD57, PD.1) form rosettes around LP cells
  - Nodules demonstrate intact FDC meshworks as highlighted by immunohistochemical studies for CD21, CD23, or CD35

Flow Cytometry
- Will not detect HRS or LP cells
- Polytypic B cells (useful to exclude involvement by B-cell non-Hodgkin lymphoma)
- T cells with normal immunophenotype; possibly increased CD4:CD8 ratio in CHL

Cytogenetics
- NLPHL: Abnormalities of chromosome 3q27 (BCL6 locus) involved in up to 60% of cases

In Situ Hybridization
- Expression of EBV-encoded mRNA (EBER) can be detected by in situ hybridization in CHL (not present in NLPHL)

Molecular Genetics
- Monoclonal Ig gene rearrangements shown by singlecell PCR of HRS cells; difficult to isolate single HRS in routine practice; therefore, PCR often polyclonal (reflecting background B cells) unless abundant HRS cells present (i.e., syncytial variant)

DIFFERENTIAL DIAGNOSIS

NSCHL
- Other types of CHL
- NLPHL
- Primary mediastinal large B-cell lymphoma

P.II(2):28
• B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and CHL
• Anaplastic large cell lymphoma (ALCL), ALK(+), or ALK(-)
• Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS)
• Metastatic carcinoma
• Primary myelofibrosis

MCCHL
• Other types of CHL
• PTCL, NOS
• THRLBCL
• Infectious mononucleosis lymphadenopathy

LRCHL
• Other types of CHL
• NLPHL
• THRLBCL
• Small B-cell lymphomas
• Reactive paracortical immunoblastic hyperplasia

LDCHL
• Other types of CHL, particularly post therapy
• ALCL, ALK(+), or ALK(-)
• PTCL, NOS
• Metastatic carcinoma
• Metastatic melanoma
• Sarcoma

NLPHL
• NSCHL, nodular LRCHL
• THRLBCL
• Follicular lymphoma
• PTGC
• Reactive lymphoid hyperplasia

SELECTED REFERENCES

Tables

Characteristics of Classical Hodgkin Lymphoma Subtypes
### Clinical Features

<table>
<thead>
<tr>
<th>Subtype</th>
<th>Frequency</th>
<th>M:F</th>
<th>Median Age</th>
<th>Preferential Sites</th>
<th>B Symptoms</th>
<th>Histopathologic Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSCHL</td>
<td>70%</td>
<td>1:1</td>
<td>15-34 years</td>
<td>Mediastinal and cervical nodes</td>
<td>~40%</td>
<td>Architecture: Broad collagen bands surround cellular nodules; Cytologic features: Lacunar cells and mummified cells</td>
</tr>
<tr>
<td>MCCHL</td>
<td>20-25%</td>
<td>2:1</td>
<td>38 years</td>
<td>Peripheral nodes, spleen</td>
<td>Common</td>
<td>Architecture: Diffuse or interfollicular growth patterns; Cytologic features: Frequent HRS cells admixed with cellular inflammatory background</td>
</tr>
<tr>
<td>LDCHL</td>
<td>&lt;1%</td>
<td>4:1</td>
<td>57 years</td>
<td>Retroperitoneal and abdominal nodes, spleen, and bone marrow</td>
<td>Common</td>
<td>Architecture: Diffuse fibrosis, reticular and mixed cellularity-like variants diffuse; Cytologic features: Many HRS cells in background depleted of mantle zones surrounding small lymphocytes</td>
</tr>
<tr>
<td>LRCHL</td>
<td>4-5%</td>
<td>2:1</td>
<td>30-50 years</td>
<td>Peripheral nodes</td>
<td>Rare</td>
<td>Architecture: Nodular growth pattern; rarely; Cytologic features: Few HRS cells in mantle zones</td>
</tr>
</tbody>
</table>

### Special Markers

<table>
<thead>
<tr>
<th>Subtype</th>
<th>EBER Association</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSCHL</td>
<td>20%</td>
</tr>
<tr>
<td>MCCHL</td>
<td>70%</td>
</tr>
<tr>
<td>LDCHL</td>
<td>75%</td>
</tr>
<tr>
<td>LRCHL</td>
<td>40%</td>
</tr>
</tbody>
</table>

### Image Gallery: Microscopic Features of NSCHL

(Left) A diagnostic Reed-Sternberg cell is at the center of the image in a background of small lymphocytes, eosinophils, and few plasma cells. (Right) Hodgkin and Reed-Sternberg (HRS) cells have a dysregulated B-cell program and do not express CD20 in this example. In some cases, CD20 expression is present in HRS cells, but in a heterogeneous (weak, variable) pattern. A few small B cells in this field do express the B-cell marker CD20 (internal positive control).
CD15 is expressed in HRS cells. There is a strong staining pattern in the Golgi region. The small B cells in the background are strongly positive for pax-5. The HRS cells (in this case, a multinucleated Reed-Sternberg cell) weakly express pax-5.

The HRS cells do not express the leukocyte common antigen (CD45), but the small lymphocytes in the background do express CD45. The HRS cells strongly express CD30.

Microscopic Features
Low magnification view of a lymph node from a patient with NLPHL demonstrates an expanded nodule with a motheaten appearance due to the presence of large neoplastic LP cells in a background of small lymphocytes. Staining with CD21 demonstrates that the nodules in NLPHL are enmeshed in expanded, intact follicular dendritic cell (FDC) meshworks.

Several lymphocyte predominant (LP) cells with multilobulated nuclei and multiple small, basophilic nucleoli are present in a background of small lymphocytes. CD45 expression is present in a membranous pattern in the multiple LP cells seen in the center of the field, as well as in the small lymphocytes in the background.
(Left) CD20 highlights frequent small B cells in the background. The large LP cells are also CD20 positive. Note that the cells encircling the central LP cell do not express CD20 because they are follicular T-helper cells. (Right) The large, irregular LP cells show nuclear staining for pax-5. In this field, there are only a few reactive B cells, which are also strongly positive for pax-5.

P.II(2):31

Microscopic Features

(Left) H&E stain shows bone marrow involvement by CHL. Note the focal, patchy pattern of involvement. In cases of suspected marrow involvement by CHL, multiple levels (step sections) should be performed to ensure adequate evaluation. (Right) High magnification of the marrow biopsy demonstrates a large aggregate of histiocytes, lymphocytes, eosinophils, plasma cells, and rare HRS cells. Normal marrow is at the periphery.
(Left) Image shows a touch imprint of a lymph node involved by MCCHL. Scattered HRS cells are present in a mixed background of small lymphocytes, eosinophils, and neutrophils. (Courtesy C. Yin, MD, PhD.) (Right) Image shows a touch imprint of a lymph node involved by LRCHL. Large HRS cells are present in a background of numerous small lymphocytes. (Courtesy S. Wang, MD.)

(Left) Image shows DLBCL arising from NLPHL. The sheets of large cells are diagnostic of transformation. NLPHL was identified in other parts of the lymph node. (Courtesy P. Lin, MD.) (Right) This image shows THRLBCL arising from NLPHL. CD20 highlights the neoplastic large cells and rare small reactive B lymphocytes. Note that the B cells are markedly depleted in comparison with typical NLPHL. Many small T cells and histiocytes are also present. (Courtesy P. Lin, MD.)

Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia

Qian-Yun Zhang, MD, PhD

Key Facts

> Table of Contents > Part II - Diagnoses Associated With Specific Syndromes > Section 2 - Blood and Bone Marrow > Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia

Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia

- LPL/WM is characterized by clonal expansion of small mature B lymphocytes with variable plasmacytoid differentiation

- LPL/WM is characterized by clonal expansion of small mature B lymphocytes with variable plasmacytoid differentiation
WM is found in significant subset of patients with LPL and is defined as LPL with bone marrow involvement and IgM monoclonal protein.

**Etiology/Pathogenesis**
- Up to 20% of WM patients have 1st-degree relatives with WM or closely related B-cell disorder
- Somatic mutation of MYD88, predicting an amino acid change L265P is seen in ~90% of WM

**Clinical Issues**
- Bone marrow is primary site
- Typically IgM monoclonal paraprotein

**Microscopic Pathology**
- Blood and bone marrow show spectrum of lymphocytes, plasmacytoid lymphocytes, and plasma cells
- Bone marrow reveals combination of paratrabecular, nonparatrabecular lymphoid nodules, and diffuse &/or interstitial infiltrate
- Mast cells often increased; most prominent within particles on aspirate smears

**Ancillary Tests**
- Usually express IgM, CD19, CD20, CD22, CD79a
- Negative for CD5, CD10, CD23, CD43, and CD103
- Deletion 6q is reported in 40-50% of patients
- MYD88 mutation status helpful in differential diagnosis

Rouleaux and a plasmacytoid lymphocyte are evident on this peripheral blood smear from a patient with Waldenström macroglobulinemia.
Spectrum of small lymphocytes, a plasmacytoid lymphocyte, and a plasma cell (1 with a mast cell), in this bone marrow aspirate are characteristic of lymphoplasmacytic lymphoma.

**TERMINOLOGY**

**Abbreviations**

- Lymphoplasmacytic lymphoma (LPL)
- Waldenström macroglobulinemia (WM)

**Definitions**

- LPL/WM is characterized by clonal expansion of small mature B lymphocytes with variable plasmacytoid differentiation
- WM is found in significant subset of patients with LPL and is defined as LPL with bone marrow (BM) involvement and IgM monoclonal protein

**ETIOLOGY/PATHOGENESIS**

**Etiology**

- Mature B cell; evidence indicates memory B cell is likely cell of origin

**Pathogenesis**

- Genetic factors
  - Up to 20% of WM patients have 1st-degree relatives with WM or closely related B-cell disorder
  - Patients with familial history of WM or plasma cell disorder are diagnosed at younger age and with greater bone marrow involvement
  - Recent data demonstrate somatic mutation of MYD88, predicting an amino acid change L265P in ~90% of WM
    - MYD88 mutation triggers IRAK-mediated NF-κB signaling, thus driving NF-κB-dependent prosurvival signaling
  - Chronic immune stimulation
    - WM risk is elevated among individuals with autoimmune disorders and those with hepatitis, human immunodeficiency virus infection, and rickettsiosis
Predisposition
- Monoclonal gammopathy of unknown significance (MGUS) of IgM type is associated with significantly increased risk to
  - WM
  - Non-Hodgkin lymphomas
  - Chronic lymphocytic leukemia
  - Light chain amyloidosis

CLINICAL ISSUES
Epidemiology
- Incidence: 3 per 1 million people each year
- Mean age at diagnosis: 65 years
- Male predominance
Site
- Bone marrow is primary site
- Blood, lymph nodes, and extranodal sites are often involved
Presentation
- 20-30% of patients are asymptomatic at diagnosis
- Anemia-related symptoms: Fatigue, shortness of breath, and chest pain
- Thrombocytopenia-related bleeding tendency
- Constitutional symptoms including weight loss and night sweats
- Splenomegaly and adenopathy
- Hyperviscosity occurs in up to 20% of patients

Laboratory Tests
- CBC
  - Anemia and thrombocytopenia
  - Lymphocytosis
- Cryoglobulin test is positive in subset of cases
- Serum/urine protein electrophoresis (SPEP/UPEP)
  - Typically IgM monoclonal paraprotein
  - Rarely IgG or IgA

Treatment
- Not standardized; many options have been used in different practices
- Radiation for localized disease
- “Watch and wait” policy for asymptomatic patients
- Initiation of therapy is considered in patients with
  - Constitutional symptoms such as fever, fatigue, night sweats, weight loss
  - Hyperviscosity
  - Severe neuropathy
  - Amyloidosis
  - Symptomatic cryoglobulinemia
  - Cold agglutinin disease
  - Evidence of disease transformation
- Various combinations of chemotherapy for symptomatic patients
  - Rituximab in combination with purine analogue &/or alkylating agent
  - Cyclophosphamide/doxorubicin/vincristine/prednisone plus rituximab (R-CHOP)
  - Newer agents such as thalidomide or bortezomib are being investigated in clinical trials
- Plasmapheresis to reduce amount of circulating IgM
- Splenectomy for chemotherapy-resistant patients
- Stem cell transplantation
  - Autologous stem cell transplantation (ASCT) is feasible, safe, and associated with significant cytocoreduction in relapsed or refractory patients
  - Allogeneic stem cell transplantation is used only in patients with advanced and refractory disease for whom no other options are available

Prognosis
- Median survival: 50-60 months
Transformation to large cell lymphoma can occur
6q deletion does not appear to affect clinical outcome
Adverse prognostic factors
- Age > 65 years
- Presence of constitutional symptoms
- Anemia &/or thrombocytopenia
- Decreased albumin level
- Increased β-2-microglobulin level

**MICROSCOPIC PATHOLOGY**

**Histologic Features**
- **Blood**
  - May show lymphocytosis with spectrum of lymphocytes, plasmacytoid lymphocytes, and plasma cells
  - Rouleaux formation of red blood cells
  - Cold agglutinin and cryoglobulin may be present
- **Bone marrow**
  - Involved in almost all cases
  - Often, combination of paratrabecular, nonparatrabecular lymphoid nodules, and diffuse &/or interstitial infiltrate
  - Infiltrate composed predominantly of small lymphocytes with variable number of plasmacytoid lymphocytes and plasma cells
  - Pseudointranuclear (Dutcher bodies) and intracytoplasmic inclusions (Russell bodies) are most prominent on core biopsy section
  - Mast cells often increased; most prominent within particles on aspirate smears
  - May have amyloid
- **Lymph node**
  - Neoplastic cells infiltrate paracortex and hilum with patent or dilated sinuses
  - May have preserved architecture or attenuated germinal centers
  - Infiltrate consists of monotonous small lymphocytes with variable number of plasmacytoid lymphocytes and plasma cells
  - Increased mast cells and hemosiderin

**ANCILLARY TESTS**

**Immunohistochemistry**
- Helpful in assessing architecture or when flow is not available

**Flow Cytometry**
- Identify monoclonal B- and plasma cell populations
- Characteristics of lymphoma cells
  - Usually express IgM, CD19, CD20, CD22, CD79a
  - Presence of cytoplasmic immunoglobulin
  - Typically negative for CD5, CD10, CD23, CD43, and CD103
  - Variable CD25, CD11c, and CD38

**Cytogenetics**
- No specific abnormalities
- Most frequent finding of deletion 6q is reported in 40-50% of patients
- t(9;14)(p13;q32) is occasionally seen in LPL

**PCR**
- IGH gene rearranged
- Biased VH3 and VH3-23 usage
- MYD88 mutation identified in > 90% of WM

**DIFFERENTIAL DIAGNOSIS**

Marginal Zone Lymphoma (MZL)
- Mucosa-associated lymphoid tissue (MALT) lymphoma
LPL/WM can rarely involve extranodal sites, creating difficulty in differential diagnosis.

- IgM paraprotein is rare.
- Often exhibits characteristic monocytoid B cells, lymphoepithelial lesions, reactive follicles.
- Translocations of t(11;18)(q21;q21) API2-MALT1, t(14;18)(q32;q21) IGH-MALT1, t(1;14)(p22;q32) BCL10-IGH are seen.
- MYD88 mutation uncommon.

### Nodal MZL
- Can involve bone marrow, and LPL/WM can rarely involve lymph node, raising differential diagnosis between the 2 diseases.
- Primarily a nodal-based disease.
- Monocytoid lymphoid B cells prominent.
- IgM paraprotein only seen in minority of patients.
- MYD88 mutation uncommon.

### Splenic marginal zone lymphoma (SMZL)
- Splenomegaly prominent.
- May have villous lymphocytes in peripheral blood.
- Sinusoidal infiltration pattern on bone marrow core biopsy.
- Deletion 7q usually associated with SMZL.
- Minor subset exhibits MYD88 mutation.
- Spleen histology is diagnostic.

### IgM Monoclonal Gamopathy of Undetermined Significance (IgM MGUS)
- Serum M protein < 30 g/L.
- Bone marrow clonal plasma cells < 10%.
- No end-organ damage.
- No evidence of B-cell lymphoma or other M-protein producing disease.
- Subset exhibits MYD88 mutation; positive rate varies depending on study.

### Other B-Cell Chronic Lymphoproliferative Disorders
- Expression of CD5, CD23 helpful to exclude chronic lymphocytic leukemia/small lymphocytic lymphoma.
- Expression of CD5, cyclin-D1, and cytogenetic finding of t(11;14) helpful to exclude mantle cell lymphoma.
- Expression of CD10 and cytogenetic findings of t(14;18) helpful to exclude follicular lymphoma.
- Histology features also helpful in differential diagnosis.

### Diagnostic Checklist
**Clinically Relevant Pathologic Features**
- Based on combination of following findings:
  - Presence of spectrum lymphocytes, plasmacytoid lymphocytes, and plasma cells.
  - Flow cytometric study demonstrates monoclonal B cells with typical immunophenotype and monoclonal plasma cells.
  - Monoclonal paraprotein by SPEP/UPEP

### Selected References

540
P.II(2):35

Image Gallery
Microscopic Features and Differential Diagnosis

(Left) Increased mast cells (darkly stained cells) within bone marrow aspirate particles, although not specific, are highly characteristic of lymphoplasmacytic lymphoma. (Right) Nonparatrabecular lymphoid aggregate on bone marrow core biopsy is depicted here. Bone marrow involvement by lymphoplasmacytic lymphoma usually exhibits mixed diffuse, paratrabecular, nonparatrabecular nodular, and interstitial patterns.

(Left) At high power, lymphoplasmacytic lymphoma is shown to be composed of small mature lymphocytes, plasma cells, and rare scattered large cells. Note the Dutcher body. (Right) Low-power view of lymphoplasmacytic lymphoma and Waldenström macroglobulinemia involving lymph node shows a diffuse pattern of growth with patent sinuses that contain histiocytes. (Courtesy P. Lin, MD.)
Mantle Cell Lymphoma

> Table of Contents > Part II - Diagnoses Associated With Specific Syndromes > Section 2 - Blood and Bone Marrow > Mantle Cell Lymphoma

C. Cameron Yin, MD, PhD
Elizabeth Morgan, MD

Key Facts

Terminology
• Clinically aggressive B-cell lymphoma associated with t(11;14)(q13;q32) and cyclin-D1 overexpression

Etiology/Pathogenesis
• Reports of familial MCL are rare

Clinical Issues
• Elderly people; male predominance
• Most patients present with clinical stage III/IV disease
• B symptoms, lymphadenopathy, extranodal involvement
• Currently considered incurable with median survival of 2-5 years

Microscopic Pathology
• Architectural effacement by lymphoma with nodular, diffuse, or mantle zone growth pattern
• Monotonous population of small to medium-sized cells with variably irregular nuclear contours

Ancillary Tests
• Immunohistochemistry: Cyclin-D1(+)
• Flow cytometry: CD5(+), CD19(+), CD20(+), CD43(+/-), FMC-7(+), CD10(-), CD23(-)
• Cytogenetics: t(11;14)(q13;q32) or CCND1-IGH (FISH)
• Gene expression profiling
  o Unique profile
  o Proliferation predicts prognosis

Top Differential Diagnoses
• Chronic lymphocytic leukemia/small lymphocytic lymphoma
• Follicular lymphoma
• Nodal marginal zone B-cell lymphoma
Image shows mantle cell lymphoma (MCL) with a nodular and diffuse pattern associated with hyalinized blood vessels. Hyalinized blood vessels are a common feature in MCL.
Cyclin-D1 immunostain shows nuclear expression in the cells of MCL. As demonstrated here, the nuclei often show cell-to-cell variation in the intensity of cyclin-D1 expression.

TERMINOLOGY
Abbreviations
- Mantle cell lymphoma (MCL)

Synonyms
- Centrocytic lymphoma
- Lymphocytic lymphoma, intermediate grade of differentiation
- Intermediate lymphocytic lymphoma

Definitions
- Clinically aggressive B-cell lymphoma usually composed of monomorphic small to medium-sized cells and associated with t(11;14)/CCND1-IGH

ETIOLOGY/PATHOGENESIS
- t(11;14)(q13;q32)
  - Juxtaposes CCND1 at 11q13 with IGH at 14q32 and results in cyclin-D1 overexpression, Rb phosphorylation, and release of E2F
  - Facilitates cell cycle progression from G1 to S phase

Familial
- Reports of familial MCL are rare

CLINICAL ISSUES
Presentation
- Median age: 6th-7th decades; male predominance
- Most patients present with Ann Arbor clinical stage III/IV; B symptoms in 40-50%
- Lymphadenopathy, generalized
- Extranodal sites are common, particularly GI tract, bone marrow, spleen, peripheral blood

Treatment
Aggressive chemotherapy ± stem cell transplantation
HyperCVAD chemotherapy regimen used at many medical centers

Prognosis
Currently considered incurable; median survival: 2-5 years

MICROSCOPIC PATHOLOGY

Histologic Features
- Architectural effacement by monomorphic lymphoid proliferation with vaguely nodular, diffuse, or mantle zone growth pattern
- Monotonous population of small to mediumsized lymphoid cells with variably irregular nuclear contours, condensed chromatin, and scant cytoplasm
  - Rare variant has relatively abundant “monocytoid” cytoplasm
- Hyalinized blood vessels, “naked” germinal centers, and benign histiocytes with eosinophilic cytoplasm frequently seen
- 2 aggressive variants of MCL are recognized by 2008 WHO classification
  - Blastoid: Cells resemble lymphoblasts, small to intermediate in size, with immature chromatin and high mitotic rate (≥ 10/10 high-power field [HPF], x 400)
  - Pleomorphic: Heterogeneous population of cells, including large cells, often with prominent nucleoli and high mitotic rate
- Liver: MCL preferentially involves portal tracts
- Spleen: MCL preferentially replaces white pulp
- Bone marrow: MCL has nonparatrabecular and paratrabecular pattern
- Peripheral blood: Overt leukemia in ~ 10% of patients, but occasional MCL cells are common (in ~ 75% of patients)

ANCILLARY TESTS

Immunohistochemistry
- Cyclin-D1 overexpression is almost constant feature
- Rare cyclin-D1(-) variants described, but this entity is controversial

Flow Cytometry
- CD5(+), CD19(+), CD20(+), CD22(+), CD79b(+), FMC-7(+), SOX11(+/−), and monotypic Ig
- Bcl-2(+), CD11c(+/−)
- CD3(−), CD10(−), CD23(−), CD43(+/−)
- Rare cases have atypical immunophenotype: CD5(−) or CD10(+) or CD23(+) (dim ~ 10%)

Cytogenetics
- Numerous methods can be used for demonstrating t(11;14)(q13;q32)
  - FISH is convenient because it can be performed on fixed tissue sections
  - Conventional cytogenetics if fresh material available

Molecular Genetics
- PCR detects 1 major breakpoint (MTC) in 30-50% of cases

Gene Expression Profiling
- MCL has proliferation signature that can be used to divide patients into prognostic subgroups

DIFFERENTIAL DIAGNOSIS

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Proliferation centers; mixture of small lymphocytes, prolymphocytes, and paraimmunoblasts
- Cells express dim surface Ig, CD5, and CD23, but not cyclin-D1

Follicular Lymphoma
- Sharply circumscribed nodules composed of centrocytes and centroblasts
- Cells express CD10 but not CD5, CD43, or cyclin-D1

Nodal Marginal Zone B-Cell Lymphoma
- Neoplastic B cells ± monocytoid cytoplasm; reactive germinal centers are common; CD5(-) and cyclin-D1(-)

Lymphoblastic Lymphoma
- Mimics classic blastoid variant of MCL
- Younger patients; TdT(+) and cyclin-D1(-)

Diffuse Large B-Cell Lymphoma
- Mimics pleomorphic blastoid variant of MCL
- CD5(-) and cyclin-D1(-)
Reactive Follicular Hyperplasia
- Thinner mantle zones composed of small, round, mature lymphocytes surrounding prominent germinal centers
- No evidence of monoclonality

Castleman Disease, Hyaline Vascular Type
- Large localized mass in young person
- Architecture not entirely effaced
- Hyaline-vascular follicles, “onion skin” lymphocytes concentrically layered around germinal centers

SELECTED REFERENCES

Image Gallery
Microscopic and Immunohistochemical Features

(Left) The case of mantle cell lymphoma (MCL) shown in this image demonstrates a completely diffuse pattern of growth. (Right) H&E shows MCL with a nodular pattern. This pattern, in part, resembles follicular lymphoma at lowpower magnification, but the neoplastic nodules lack centroblasts.

(Left) Image shows MCL with a mantle zone pattern. In this pattern, the neoplasm surrounds reactive germinal
centers. (Right) A case of MCL shows “naked” reactive germinal centers and many benign histiocytes with eosinophilic cytoplasm (so-called pink histiocytes). Pink histiocytes are a helpful clue for the diagnosis of MCL but are not specific.

(Left) Smear of a lymph node prepared at the time of a frozen section shows MCL. In addition to the neoplastic lymphoid cells, a benign pink histiocyte is shown in this field. (Right) Cyclin-D1 immunostain shows nuclear expression in the cells of MCL. This immunostain is helpful for recognizing MCL at extranodal sites, especially in small biopsy specimens.

P.II(2):39

Microscopic and Immunohistochemical Features

(Left) MCL involving bone marrow is illustrated. In this case, the neoplastic cells had relatively abundant “monocytoid” cytoplasm mimicking marginal zone lymphoma. However, the neoplastic cells expressed cyclin-D1, and conventional cytogenetics showed the t(11;14)(q13;q32). (Right) Wright-Giemsa stain shows a case of MCL in the leukemic phase. The neoplastic lymphocytes of MCL often show variation in size and shape in a blood smear, as seen in this case.
(Left) Image shows MCL involving the liver. The neoplasm fills a portal tract and infiltrates sinusoids. (Right) CD20 immunostain highlights MCL cells within a portal tract and sinusoids of this liver biopsy.

(Left) MCL involving the colonic mucosa is shown. MCL has a tropism for the gastrointestinal tract and commonly involves this site at the time of diagnosis. However, GI symptoms occur in only 10-20% of patients. (Right) Schematic of the cell cycle shows the G1 to S transition and the role of cyclin-D1-cyclin-dependent kinase complexes. Some of the genes of interest in the pathogenesis of MCL are also shown.

Myeloid Neoplasms

Myeloid Neoplasms

Qian-Yun Zhang, MD, PhD

Key Facts

Terminology
- AML, MDS, and JMML are clonal hematopoietic neoplasms
- Blasts/blast equivalents comprise > 20% of nucleated PB &/or BM cells in AML
- MDS exhibits dysplasia in 1 or more lineages
- JMML is characterized by proliferation of myelomonocytic cells

Etiology/Pathogenesis
- AML develops with accumulation of multiple genetic hits
  - Class I and class II mutations
RAS signaling pathway mutations
- Initiating mutation or transforming event is unknown in MDS
- In JMML, mutations lead to constitutive activation of RAS pathway and cell proliferation
- Increased incidence of JMML is seen in many constitutional syndromes; underscores the need to rule out the syndromes in any JMML patient

Clinical Issues
- Symptoms related to bone marrow failure
- AML may have extramedullary involvement
- Liver and spleen are almost always involved in JMML

Microscopic Pathology
- Assess circulating leukemic cells
- Assess dysplasia in all 3 lineages in MDS
- Predominantly neutrophils and monocytes with immature forms and minimal dysplasia in JMML

Bone marrow aspirate smear is from a patient with acute myeloid leukemia without maturation. A subset of blasts contains cytoplasmic granules, indicative of myeloid differentiation.
Cytochemical myeloperoxidase stain is positive in a subset of blasts\[\rightarrow\] in this bone marrow aspirate smear from a patient with acute myeloid leukemia without maturation.

**TERMINOLOGY**

**Synonyms**
- Acute myeloid leukemia
- Acute myelogenous leukemia

**Definitions**
- Clonal hematopoietic neoplasms
- Acute myeloid leukemia (AML)
  - Blasts/blast equivalents comprise > 20% of nucleated peripheral blood (PB) &/or bone marrow (BM) cells
- Myelodysplastic syndrome (MDS)
  - Heterogeneous group of molecularly distinct entities
  - Variable degree of ineffective hematopoiesis due to simultaneous proliferation and apoptosis
  - < 20% blasts in PB and BM
  - Cytopenia of PB, hypercellular BM
  - Dysplasia in 1 or more lineages
  - Increased risk for AML
- Juvenile myelomonocytic leukemia (JMML)
  - Clonal hematopoietic disorder of childhood
  - Characterized by proliferation of myelomonocytic cells

**ETIOLOGY/PATHOGENESIS**

**Constitutional Disorders Predispose to Hematologic Malignancy**
- Down syndrome (DS)
  - 10-20x increased risk for AML
  - > 500x increased risk for acute megakaryoblastic leukemia
• Fanconi anemia (FA)
  o 10% of patients develop leukemia; majority are AML with a median age of 11-14 years at diagnosis
  o 600x increased risk for AML
  o 5,000x increased risk for MDS
  o Up to 80% of patients develop BM failure
  o Mutations in at least 15 FA genes located on various chromosomes
  o DNA cross-link repair defect

• Bloom syndrome (BS)
  o ~15% of patients develop MDS and leukemia, particularly AML and acute lymphoblastic leukemia (ALL)
  o BLM gene encodes DNA helicase that allows unwinding of DNA for repair
  o Mutations in BLM gene result in DNA repair defect

• Diamond-Blackfan anemia (DBA)
  o 3-4% of patients develop hematologic malignancy, particularly AML
  o Mutations in genes coding for ribosomal subunits, most frequently RPS19, preventing subunit from being incorporated into ribosome
  o Free subunits bind MDM2, a ubiquitin ligase that otherwise targets p52 for degradation, leading to increase in p53, thus favoring apoptosis

• Neurofibromatosis type 1 (NF1)
  o Increased risk for leukemia, particularly JMML
  o Increased risk for AML with monosomy 7
  o Increased risk for monosomy 7 syndrome
  o Neurofibromin 1 (NF1) is a negative regulator of RAS signaling pathway
  o Mutations in NF1 result in activated RAS pathway, thus enhanced cell proliferation, survival, and suppressed apoptosis

• Noonan, Noonan-like syndrome (NS)
  o Predisposes to JMML
  o Mutations in PTPN11 and CBL genes
  o PTPN11 encodes SHP-2 protein, which controls phosphorylation of specific RAS pathway inhibitors
    o Mutations in PTPN11 lead to sustained activation of RAS pathway
  o CBL plays a role in internalization and degradation of tyrosine kinase receptor dimers once the growth factor signal terminates
  P.II(2):41

  o Mutations in CBL result in failure of degradation, thus sustained activation of receptors

• Severe congenital neutropenia (SCN)
  o Increased risk for AML, particularly patients on chronic recombinant human granulocyte colony stimulating factor therapy
  o Mutation of granulocyte colony stimulating factor (G-CSF) receptor gene strongly associated with AML development

• Familial platelet disorder with propensity to develop myeloid malignancy (FPD/AML)
  o Increased risk for acute leukemia, particularly AML
  o RUNX family of proteins binds to core-binding factor beta to form core-binding factor complex
    o Plays major role in myeloid and lymphoid development and maturation
    o Mutations of RUNX1 gene lead to aberrant hematopoiesis and ultimately leukemia

• CCAAT/enhancer binding protein alpha (CEBPA)-dependent familial AML
  o Increased risk for AML with the following features
    o Particularly AML M1, M2 morphology subtypes
    o Auer rods
    o CD7 expression
    o Normal karyotype
  o Onset age varies from 4-46 years old
  o Complete penetrance
  o CEBPA is a member of leucine zipper transcription factors
    o Regulates myeloid differentiation by inducing granulocytic development
  o CEBPA encodes 2 transcription products: 42 kDa long form and 30 kDa short form
    o Short form has inhibitory function
• Mutations lead to preferential production of 30 kDa short form; result in suppressed CEBPA function and increased risk for AML
  o CEBPA-dependent AML should be suspected in any family with autosomal dominant pattern of AML, particularly M1 and M2 morphology subtype
• Familial monosomy 7
  o Increased risk of MDS (most often) and AML (often with preceding MDS)
  o Median age at onset is 8 years
  o Equal incidence between males and females
  o Exact mechanism unknown
  o Results in deregulated growth in hematopoietic cells at various levels of differentiation, including multilineage progenitors
• Childhood monosomy 7
  o Increased risk for JMML, followed by MDS
  o Median age at onset is 3 years
  o M:F = 3-10:1

Familial Leukemia
• Multiple reports of acute leukemia in family members
• Mutations in genes responsible for maintaining telomere length are proposed
• May result from additive interactions of complex genetic and environmental factors, as well as common variants in metabolic enzymes

Environmental Exposures
• Radiation
• Chemotherapy
• Benzene

Molecular Bases of Leukemogenesis in AML
• Accumulation of multiple genetic hits
• Class I and class II mutations
  o Class I: Pro-proliferation signals
    ▪ e.g., FLT3, KIT; encode receptor tyrosine kinase upstream of RAS pathway
    ▪ e.g., JAK2; encodes component of JAK/STAT pathway
  o Class II: Impairment of cellular maturation
    ▪ e.g., PML-RARA, CEBPA, RUNX1-RUNX1T1
• RAS signaling pathway mutations
  o NRAS mutations are more common than KRAS mutations in hematologic malignancies
  o NF1 mutations are present in rare hematologic malignancies
    P.J(2):42
  o RAS and NF1 mutations are overrepresented in AML with monocytic differentiation

Molecular Bases of Pathogenesis of MDS
• Initiating mutation or transforming event is unknown
• Clonal hematopoietic stem cell disease leads to ineffective hematopoiesis and apoptosis
• Clonal evolution with additional mutations leads to transformation to high-grade MDS and AML

Molecular Bases of Pathogenesis of JMML
• Mutations in various genes of RAS/MAPK signaling pathway are characteristic and lead to constitutive activation of RAS pathway and cell proliferation
  o Inactivating mutation in NF1 gene in 10-15% of cases
  o Inactivating mutation in CBL gene
  o Activating mutations in NRAS, KRAS in 25-30% of cases
  o Activating mutations in PTPN11 in ~ 35% of cases
  o CBL and RAS/PTPN11 mutations are mutually exclusive
• Increased incidence of JMML is seen in the following syndromes; underscores the needs to rule out the syndromes in any JMML patient
  o Noonan syndrome
    ▪ 50% of patients with Noonan syndrome have PTPN11 mutation
  o Neurofibromatosis type 1
    ▪ Patients with NF1 have 200-500x increased risk for JMML
  o Childhood monosomy 7
• 6-24% of children with JMML have monosomy 7 at diagnosis

CLINICAL ISSUES

Epidemiology

Incidence

- AML
  - Age-adjusted incidence: 3.4 cases per 100,000 individuals
  - ~ 10,000 new cases in USA each year

- MDS
  - Annual incidence of > 30/100,000 among those aged > 70 years
  - Precedes or is related to majority of AML in elderly
  - Overall slight male predominance: M:F = 1.8:1
  - Exception is MDS del(5q), which has a female predominance

- JMML
  - 1.3 per million children 0-14 years of age per year
  - M:F = 2:1

Age

- AML
  - All ages affected; median age: 63 years
  - 80% of adult acute leukemias are AML; incidence increases with age
  - AML with myelodysplasia-related changes is more prevalent in older adults
  - AML with recurrent genetic abnormalities (e.g., t[15;17], t[8;21], inv[16]/t[16;16], t[9;11]) are more prevalent in younger age groups

- MDS
  - Primarily a disease of elderly patients
  - Median age: 70 years in Western countries
  - Median age: ~ 10 years younger in Asian countries
  - Only ~ 10% of MDS patients are < 50 years old
  - Rare in children

- JMML
  - 75% of cases occur in children < 3 years of age
  - Median age at diagnosis: 2 years

Presentation

- Symptoms related to bone marrow failure
  - Anemia: Fatigue, pallor, weakness
  - Thrombocytopenia: Bleeding, petechiae
  - Neutropenia: Recurrent infections

- Extramedullary involvement
  - Skin lesions
  - Gingival hyperplasia
  - Myeloid sarcomas

- JMML
  - May present with hepatosplenomegaly; liver and spleen are almost always involved
  - Skin, lymph nodes, and respiratory tract are common sites of involvement
  - Café au lait spots, tumor of CNS, and malignant tumor of peripheral nerve sheath raise suspicion of NF1
  - Abnormal face, short stature, webbed neck, cardiac defects, thoracic skeletal abnormalities, and bleeding diatheses raise suspicion of NS

Treatment

- AML
  - Chemotherapy is the mainstay of treatment
  - Radiation may be used for local control of disease
  - Bone marrow transplantation

- MDS
  - WHO prognostic scoring system (WPSS)-based riskadapted treatment strategy
  - Low-risk patients may be monitored
  - Intermediate- or high-risk patients may choose
    - Azacytidine and its derivative decitabine to reverse effects of hypermethylation
Lenalidomide as immunomodulation and antiangiogenesis to induce apoptosis, particularly for MDS with 5q-

- JMMI
  - Resistant to essentially all chemotherapy
  - Stem cell transplantation (SCT) is curative
  - RAS pathway inhibitors are in development or clinical trials

### Prognosis

- AML
  - Highly dependent on genetic profile
    - Cytogenetics
    - Molecular genetics
  - Other factors affect prognosis
    - Prior chemotherapy &/or radiation history
    - Underlying hematopoietic neoplasm (e.g., MDS)
    - Increasing age (> 60 years old)
    - Elevated LDH
    - Performance status
  - Overall aggressive disease with high mortality and high relapse rate

- MDS
  - International prognostic scoring system (IPSS)
    - Based on number of cytopenia(s), % BM blasts, and cytogenetic abnormalities
    - Useful for predicting survival and risk of transformation to AML
  - WHO prognostic scoring system (WPSS)
    - Categorizes patients based on unil- or multilineage cytopenia, dysplasia, % BM blasts, cytogenetic findings, and transfusion dependency
    - Useful at diagnosis and during the course of disease evaluation in adult patients
    - Particularly helpful for identification of very low risk group
    - Better prediction for survival and probability of leukemic evolution than IPSS
  - Age at diagnosis is a major risk factor for survival
  - Bone marrow fibrosis shifts patient to more advanced risk group

- JMMI
  - 5-year event-free survival after SCT is ~ 50%
    - Leading cause of death is leukemic relapse
  - Median survival without SCT is 1 year
  - Age > 2 years at diagnosis, high fetal hemoglobin (HbF), and low platelet count correlate with worse prognosis
  - JMMI developing in patients with Noonan syndrome may regress spontaneously

### Macroscopic Features

#### General Features

- Myeloid sarcomas
  - Soft fleshy whitish or yellowish mass with variable foci of necrosis

### Microscopic Pathology

#### Peripheral Blood

- Cytopenia
  - Anemia
  - Thrombocytopenia
  - Neutropenia
- Circulating leukemic cells
- Assess for dysplasia in neutrophils and platelets
- JMMI often present with leukocytosis with median WBC count of 25,000-30,000/µL
  - Predominantly neutrophils and monocytes with immature forms and minimal dysplasia
  - Blasts < 20%, typically < 5%
- Assess red blood cell morphology for evidence of disseminated intravascular coagulation

#### Bone Marrow Aspirate

- Enumeration of blasts or leukemic cells; % blasts based on morphology, not by flow cytometry
- Assess for dysplasia in all 3 lineages, require ≥ 10% of cell lineage
• JMML
  o Hypercellular with myeloid hyperplasia
  o Minimal dysplasia
  o Monocytic lineage accounts for 5-10% of all cells
  o Blasts < 20%

Bone Marrow Core Biopsy
• Assess hematopoietic architecture
• Assess relative proportion of each lineage
• Assess overall number and distribution of immature cells or leukemic cells
• Assess megakaryocytic dysplasia
• Evaluate any concurrent malignancy

Diagnostic Criteria
• JMML
  o Absolute monocytes in PB > 1,000/µL
  o < 20% blasts in PB and BM
  o Absence of BCR-ABL1 fusion
  o Plus 2 of the 5 following criteria
    ▪ Circulating myeloid precursors
    ▪ WBC > 10,000/µL
    ▪ Increased HbF for age
    ▪ In vitro granulocyte monocyte colony stimulating factor (GM-CSF) hypersensitivity of myeloid progenitors
    ▪ Clonal cytogenetic abnormality: Mutation in RAS, PTPN11, NF1, or CBL gene, or monosomy 7

ANCILLARY TESTS

Cytology
• Myeloperoxidase (MPO)
  o Positive MPO: Confirms myeloid lineage
  o Negative MPO: Does not exclude myeloid lineage
  o ~ 5% of acute monoblastic leukemias may be MPO positive
• Nonspecific esterase (NSE)
  o Positive NSE: Confirms monocytic lineage

Immunohistochemistry
• Useful if flow cytometry is inadequate or not performed
• Fewer antibodies available than flow cytometry
  o CD34 for blasts; use CD117 if blasts are negative for CD34
  o MPO or CD33 for myeloid lineage quantification and distribution, i.e., abnormal localization of immature precursors (ALIP)
  o CD71, glycophorin A, or hemoglobin A for erythroid lineage quantification and colony formation assessment
  o CD61 or CD42b for megakaryocytic lineage quantification, abnormal clustering or localization, and morphology
  o CD68: Myeloid and monocytic
  o Lysozyme: Monocytic

Flow Cytometry
• Should be performed in all new cases
• Establish leukemic cell lineage
• Determine % blasts in PB &/or BM
• Establish immunophenotype, particularly aberrant marker expression as “fingerprint” for future monitoring or for maturation pattern
• Blast markers
  o CD34: Not all blasts express CD34
  o CD117: Also stains promonocytes and mast cells
  o TdT: Stains a subset of AML
• Myeloid markers
MPO, CD33, CD13

Monocytic markers
  - CD14, CD36/CD64 coexpression, CD163, CD4 (weak), CD33 (bright)

Gain of abnormal antigens such as CD56, CD19, CD7, CD5 on myeloid or monocytic cells

Megakaryocytic markers
  - CD31, CD41, CD42b, CD61

Erythroid markers
  - Glycophorin A, hemoglobin A, CD71 (not specific)

Cytogenetics
- Essential for new cases
- Diagnostic: AML and MDS with recurrent clonal cytogenetic abnormalities
- Prognostic: Favorable, intermediate, and unfavorable risk groups for AML and MDS
- JMML
  - Normal karyotype in 65% of cases
  - Monosomy 7 in ~ 25% of cases

Molecular Genetics
- Perform as per institution, protocol requirements, anticipated minimal residual disease monitoring
- Karyotypically normal AML should be evaluated for FLT3, NPM1, and CEBPA mutations
- JMML should be evaluated for RAS, NF1, PTPN11, or CBL mutations

FISH
- Cryptic cytogenetic abnormalities
- Prognostic: Favorable, intermediate, and unfavorable risk groups for MDS

DIFFERENTIAL DIAGNOSIS

Acute Lymphoblastic Leukemia (ALL)
- Typically has smaller blasts with scant cytoplasm
- Immunophenotype reveals lymphoid lineage

Therapy-Related Myeloid Neoplasm
- Exhibits dysplasia
- History of chemotherapy for other malignancy

Chronic Myelomonocytic Leukemia (CMML)
- Has monocytosis and should be differentiated from JMML
- Typically diagnosed in older patient population

Chronic Myeloid Leukemia (CML)
- Rarely CML arises in young patients and should be differentiated from JMML
- Exhibits predominantly granulocytic lineage proliferation
- Translocation 9;22 is diagnostic of CML

Atypical Chronic Myeloid Leukemia (aCML)
- May exhibit slightly increased monocytes and should be differentiated from JMML
- Typically seen in elderly patients
- Reveals predominantly granulocytic proliferation with significant dysplasia

DIAGNOSTIC CHECKLIST

Clinically Relevant Pathologic Features
- CEBPA-dependent AML should be suspected in any family with autosomal dominant pattern of AML, particularly M1 and M2 morphology subtype
- Rule out related syndromes in any JMML patient

SELECTED REFERENCES

Image Gallery
Microscopic Features and Immunophenotype

(Left) Bone marrow aspirate smear shows a case of AML that is tricky/difficult to diagnose because of the markedly increased erythroid precursors ▶ admixed with myeloid blasts ◀. Such cases raise the possibility of acute erythroid leukemia vs. MDS. (Courtesy K. Reichard, MD.) (Right) Auer rods are a hallmark feature of a myeloid neoplasm ▶, representing compact linear aggregation of MPO granules. This patient was diagnosed with AML by other studies. (Courtesy K. Reichard, MD.)
Bone marrow core biopsy of AML without maturation exhibits hypercellular marrow with predominant blasts. On occasion, flow cytometry is suboptimal or unavailable. Immunohistochemical (IHC) stains can verify an acute leukemia using lineage-specific and blast markers. CD34 reveals > 20% blasts in this acute leukemia. (Courtesy K. Reichard, MD.)

Flow cytometric analysis of AML without maturation demonstrates coexpression of CD34 and CD33, indicative of both immaturity and myeloid differentiation. Peripheral blood smear demonstrates the typical cytology of monoblasts. They are large with round nuclei, variably prominent nucleoli, and abundant cytoplasm, which may contain fine azurophilic granules. (Courtesy K. Reichard, MD.)

Ancillary Techniques and Microscopic Features

Nonspecific esterase (NSE) stain reveals NSE(+) monoblasts. The myeloblasts are negative. (Right) Flow cytometric analysis of acute myelomonocytic leukemia (AMML) demonstrates 2 blast populations. The blasts in the green circle demonstrate expression of both CD36 & CD64, consistent with monocytic differentiation. The myeloblasts in the blue circle are negative for both monocytic markers; they are identified as myeloblasts by myeloid markers.
This peripheral blood smear is from a 56-year-old man with pancytopenia. The red cells show prominent anisopoikilocytosis with teardrop cells and small hypochromatic irregularly shaped poikilocytes. The platelets are mildly decreased in number and include hypogranular forms. (Right) Large and hypogranular platelets are another dysplastic finding in MDS blood films.

Dysgranulopoiesis in ≥ 10% of the myeloid lineage is the predominant finding in this bone marrow aspirate from a patient with MDS. Dysplastic features include irregular and abnormal nuclear segmentation and cytoplasmic hypogranulation. (Right) Dysplastic features in erythroid precursors in MDS include nuclear budding, hyperlobation, and megaloblastic changes. P.II(2):47

Microscopic Features and Immunohistochemical Stains
Blasts in MDS may be small and are particularly difficult to identify in poorly prepared or suboptimally stained smears. Some cases of refractory anemia with excess blasts may not have prominent dysplastic features.

Small dysplastic megakaryocytes with hypolobated and hyperchromatic nuclei are clustered together in this aspirate smear from the same patient.

MDS bone marrows are typically hypercellular with intact hematopoiesis. Immature myeloid precursors normally line the trabecular bone but are also clustered in intratrabecular areas termed abnormal localization of immature precursors (ALIP). Higher power examination shows dysmegakaryopoiesis with monolobated and small megakaryocytes. The erythroid and myeloid lineages show complete maturation, and sinuses are patent.
(Left) The same biopsy has an uneven distribution of CD34(+) blasts that are slightly increased (~ 5%) and fulfill minimum criteria for a diagnosis of refractory anemia with excess blasts. (Right) Disruption of the normal bone marrow architecture is illustrated with the hemoglobin A stain. The erythroid precursors are scattered without good colony formation.

P.II(2):48

Microscopic Features and Ancillary Techniques

(Left) Megakaryocytes are increased despite thrombocytopenia. The megakaryocytes are visualized by CD42b staining and include small cells. (Right) A CD34(+) blast population (red) was detected in the MDS marrow aspirate by flow cytometric (FCM) analysis. The blasts have abnormally bright CD34 expression. Blast percentages should be based on visual inspection of the bone marrow rather than FCM analysis because of hemodilution and erythroid cell lysis of FCM specimens.
Peripheral blood from an 11-month-old boy with hepatosplenomegaly, leukocytosis, and monocytosis shows an immature monocyte. Cytogenetic study revealed monosomy 7, supporting the diagnosis of juvenile myelomonocytic leukemia (JMML). Bone marrow core biopsy from the same patient shows trilineage hematopoiesis, occasional hypolobulated megakaryocytes, and left-shifted myeloid and erythroid precursors.

Monosomy 7 can be seen in JMML, childhood monosomy 7 syndrome, familial monosomy 7, MDS/AML ± associated syndromes or prior therapy history, and familial MDS/AML, among others. Monosomy 7 may occur as an isolated abnormality or concurrently with other abnormalities. Mutations of RAS pathway are frequently found and may play important roles in the pathogenesis of neurofibromatosis type 1, Noonan syndrome, and JMML.

Differential Diagnosis
(Left) Typical small uniform lymphoblasts (L1 blasts) are seen in this bone marrow smear from a 3-year-old boy with a new diagnosis of ALL. The blasts have scant cytoplasm. (Right) Bone marrow aspirate smear shows therapy-related myeloid neoplasm that developed after topoisomerase II inhibitor treatment for acute lymphoblastic leukemia. Note the myeloblasts. (Courtesy K. Foucar, MD.)

(Left) Peripheral blood from a 5-month-old girl with 11q23-associated AML is shown. Dysplastic neutrophils and immature cell are prominent. (Right) Wright stain of peripheral blood from a patient with CML shows leukocytosis, left shift, presence of blasts, basophilia, and frequent large platelets. There is no significant dysplasia. t(9;22) is diagnostic of chronic myeloid leukemia (CML).
(Left) Wright stain of bone marrow aspirate smear from a patient with atypical CML (aCML) shows abundant granulocytes and precursors. aCML typically exhibits significant dysplasia. Neutrophils demonstrated here show abnormal nuclear hypolobation and hypogranulation. (Right) Blood smear from a patient diagnosed with chronic myelomonocytic leukemia, type 2 (CMML-2) shows monocytosis with an occasional immature cell. CMML is usually seen in older patients.

Section 3 - Bone and Soft Tissue
Chondrosarcoma

> Table of Contents > Part II - Diagnoses Associated With Specific Syndromes > Section 3 - Bone and Soft Tissue > Chondrosarcoma

Chondrosarcoma
Matthew R. Lindberg, MD

Key Facts
Terminology
- Malignant cartilaginous matrix-producing tumor
- Secondary chondrosarcoma arises in association with a preexisting benign tumor or diseased bone
- Periosteal chondrosarcoma arises on bone surface

Etiology/Pathogenesis
- > 90% of cases are sporadic
  - Can also arise in the setting of a solitary nonsyndromic osteochondroma (rare)
- Enchondromatosis
  - May be sporadic (Ollier disease) or familial
  - Maffucci syndrome
- Hereditary multiple exostosis/osteochondromas
  - Asymmetric distribution of multiple exostoses or osteochondromas
- Wilms tumor
  - Rare cases documented of Wilms tumor of the kidney and chondrosarcoma occurring in the same patient

Clinical Issues
- Conventional intramedullary chondrosarcoma accounts for > 90% of all chondrosarcomas
- Chondrosarcomas arising in osteochondroma and periosteal chondrosarcoma are rare

Macroscopic Features
- Neoplastic hyaline cartilage is blue or gray-tan and glistening

Microscopic Pathology
- Infiltration of preexisting bone is important histologic finding and distinguishes chondrosarcoma from a benign cartilaginous tumor
The gross appearance of chondrosarcoma varies with the grade and constitution of the tumor. Most cases show a glassy cut surface that is blue-gray to tan-white. (Courtesy A. Hough, MD.)
This image shows the classic low-power appearance of a conventional chondrosarcoma: Sheets and lobules of atypical cartilage demonstrating extensive intertrabecular bone infiltration and destruction.

TERMINOLOGY
Definitions
- Malignant cartilaginous matrix-producing tumor of bone
  - Primary chondrosarcoma arises in medullary cavity (i.e., conventional type) or on surface (i.e., periosteal/juxtacortical type) of bone
  - Secondary chondrosarcoma arises in association with preexisting benign tumor (e.g., enchondroma, osteochondroma) or diseased bone (e.g., radiation, Paget disease)
  - Chondrosarcoma with dedifferentiation contains areas of high-grade noncartilaginous sarcoma adjacent to traditional areas of conventional chondrosarcoma

ETIOLOGY/PATHOGENESIS
Sporadic
- > 90% of cases
- Can also arise in the setting of a solitary nonsyndromic osteochondroma (rare)

Enchondromatosis
- May be sporadic (Ollier disease) or familial
  - Familial cases occur predominantly in men and appear to show autosomal dominant transmission
- Asymmetric distribution of multiple enchondromas
  - Marked variability in size, location, number, and age at onset of lesions
- Maffucci syndrome
  - Enchondromatosis associated with soft tissue hemangiomas
- Risk of malignant transformation in these benign lesions is 35-40%

Hereditary Multiple Exostosis/Osteochondromas (HME/HMO)
- Autosomal dominant
- Asymmetric distribution of multiple exostoses or osteochondromas
Localization of lesions to surface of bone distinguishes this condition from enchondromatosis

Risk of malignant transformation is 5-25%

### Wilms Tumor

- Rare cases documented of Wilms tumor of the kidney and chondrosarcoma occurring in the same patient

### CLINICAL ISSUES

#### Site

- **Sporadic**
  - Can arise in any bone derived from endochondral ossification
  - Most originate in pelvis, especially ilium, followed by proximal femur, proximal humerus, distal femur, and ribs
    - In long bones, chondrosarcoma usually involves metaphysis or diaphysis
  - Infrequently develops in small bones of hands and feet (1% of chondrosarcoma)
  - Chondrosarcomas of cranium usually involve skull base

- **Hereditary**
  - Arise in a preexisting enchondroma or osteochondroma in syndromic patients

#### Presentation

- **Sporadic**
  - Patients present with pain, enlarging mass, and, infrequently, fracture
  - Symptoms often present for a long time
    - P.II(3):3
  - Skull base tumors frequently cause headache, diplopia, and cranial nerve palsies

- **Hereditary**
  - Worsening of clinical symptoms related to preexisting growths/lesions
  - Sudden, increased rate of growth in preexisting enchondroma or osteochondroma after puberty

#### Treatment

- Aggressive curettage for low-grade (grade 1/3) chondrosarcomas
  - Especially if tumor is located in appendicular skeleton
- High-grade chondrosarcomas (grades 2/3 and 3/3) require wide surgical resection
  - Include dedifferentiated tumors
- Radiation has been used to treat unresectable tumors
  - Frequently used for tumors arising in spine or skull base
- Chondrosarcomas arising in pelvis are treated with resection regardless of grade because local recurrence in this region is very difficult to treat
- Prophylactic removal of osteochondromas if possibility of morbidity is low

#### Prognosis

- Histologic grade is the single most important prognostic factor
  - Applies to both sporadic type and those arising in the setting of enchondromatosis
  - Prognosis of chondrosarcoma arising in osteochondroma(tosis) is excellent unless there is dedifferentiation (i.e., component of high-grade noncartilaginous sarcoma)
- Grade 1 chondrosarcomas behave in a locally aggressive manner
  - Deaths usually result from local recurrence
  - Metastases are rare
  - 5-year survival for grade 1 chondrosarcoma is ~ 85%
- Grade 2 and grade 3 chondrosarcomas have much worse prognosis
  - 5-year survival rate is ~ 50%
- Dedifferentiated chondrosarcoma has dismal prognosis
  - Most patients die within 2 years of diagnosis
- Recurrent tumors may have increase in histologic grade
- Periosteal chondrosarcomas tend to recur locally, and metastases are rare

### IMAGE FINDINGS

#### Radiographic Findings

- Lytic with scattered radiodensities
- Densities often take the form of rings and arcs and irregular spiculations
  - Rings and arcs represent peripheral enchondral ossification and reactive bone formation
  - Spiculations caused by irregular calcification of matrix
• Low-grade tumors may contain significant areas of mineralization, bone expansion, endosteal scalloping, and thickening of cortex
• High-grade tumors have large radiolucent areas and cortical destruction, frequently with a significant soft tissue mass
  o Includes dedifferentiated tumors
• Permeation of cortex is rarely seen, except in most aggressive lesions
• Periosteal chondrosarcoma shows irregular mineralization on surface of bone

MR Findings
• MR is helpful in identifying extent of tumor
• Dark on T1-weighted images
• Bright on T2-weighted images
• In osteochondroma, a cartilage cap with a thickness of > 1.5-2 cm should raise suspicion of possible malignant transformation
  o Thickened cap is not diagnostic for malignancy
• In periosteal chondrosarcoma, there is a T2 bright mass arising on surface of bone with areas of mineralization

CT Findings
• Unmineralized and mineralized components of tumor are clearly delineated in intramedullary and surface lesions

Bone Scan
• Avid technetium uptake on bone scan

MACROSCOPIC FEATURES
General Features
• Low-grade tumors fill medullary cavity, expand bone, scallop endosteal surface, and produce cortical thickening
• High-grade tumors destroy cortex and form a soft tissue mass that is frequently well delineated by raised periosteum
• Neoplastic hyaline cartilage is gray-tan and glistening
  o Has lobulated architecture that may be accentuated by thin, fibrous septa
• Mineralized portions of matrix appear as scattered, punctate, chalk-like deposits
• Regions of prominent endochondral ossification are seen as hard, ivory areas of bone formation
• Myxoid matrix is translucent, gray, and mucinous or watery
• In chondrosarcoma arising in osteochondroma, cartilage cap is thick and frequently shows cystic changes
• In sporadic periosteal chondrosarcoma, a large (usually > 5 cm) gray, glistening mass is attached to surface of bone
  o May contain gritty areas corresponding to calcification and ossification
  o Tumor scallops the underlying cortex and can invade into medullary cavity
• Areas of dedifferentiation may appear tan-white and firm or fleshy

Size
• Usually large (≥ 10 cm)

MICROSCOPIC PATHOLOGY
Histologic Features
• Infiltrative growth pattern encasing preexisting trabecular bone
• Neoplastic matrix is either hyaline or myxoid
  o Fibrocartilage is rare, and elastic cartilage is not found
• Hyaline matrix is homogeneous and usually basophilic
  o Occasionally, it may be pink
• Myxoid matrix is frothy or bubbly
  o Almost always basophilic
• Cartilage may mineralize or undergo endochondral ossification
• Neoplastic chondrocytes vary in size
  o Have moderate amounts of eosinophilic cytoplasm, occasionally vacuolated
• Tumor cells in hyaline cartilage are round to oval and confined to lacunar spaces
• Tumor cells in myxoid areas are bipolar or stellate and arranged singly or in cords and strands

478
Cytoplasmic processes of neighboring cells come in close or direct contact with one another and form a complex cellular network.

- Tumor cells do not form tight cohesive nests or clusters.
- Neoplastic cells demonstrate varying degrees of cytologic atypia.
- May contain foci of enchondroma.
- Chondrosarcoma arising in osteochondroma is usually low grade.
  - Diagnosis of chondrosarcoma in osteochondroma is somewhat subjective
    - Cartilage cap has nodular appearance with fibrous septae delineating lobules
    - Infiltration into stalk is unequivocal evidence of malignant transformation.
  - In periosteal chondrosarcoma, hyaline-type cartilaginous tumor is seen on surface of bone
    - Usually low to intermediate grade with areas of calcification and ossification.
    - Distinguishing periosteal chondroma from periosteal chondrosarcoma is also often subjective.
    - Chondrosarcoma shows more cellularity, atypia, invasion of underlying cortex, and, sometimes, infiltration into underlying medullary cavity.
  - Dedifferentiated chondrosarcoma shows abrupt transition from (most commonly) low-grade chondrosarcoma to high-grade pleomorphic sarcoma.

**ANCILLARY TESTS**

**Molecular Genetics**
- Isocitrate dehydrogenase genes IDH1 and IDH2 are mutated in many chondrosarcomas.
  - Primary chondrosarcoma: 38-70%.
  - Secondary chondrosarcoma: 86%.
  - Periosteal chondrosarcoma: 100%.

**DIAGNOSTIC CHECKLIST**

**Pathologic Interpretation Pearls**
- On core biopsy, it can be impossible to differentiate between enchondroma and low-grade chondrosarcoma.
  - In these instances, radiographic features of tumors should be correlated with histology.
  - In difficult cases, open biopsy should target interface between tumor and normal bone.
  - Best area to identify infiltrative growth pattern that is diagnostic of chondrosarcoma.
- In tubular bones, this distinction is not crucial as both enchondroma and low-grade chondrosarcoma can be treated with thorough curettage.

**SELECTED REFERENCES**

### Tables

#### Enchondroma vs. Low-Grade Chondrosarcoma

<table>
<thead>
<tr>
<th></th>
<th>Enchondroma</th>
<th>Low-Grade Chondrosarcoma</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain</td>
<td>Not attributed directly to neoplastic cartilage</td>
<td>Pain attributed to neoplastic cartilage</td>
<td>May be difficult to assess due to proximity of enchondromas to joints</td>
</tr>
<tr>
<td></td>
<td>(more often related to pathologic fracture)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histologic</td>
<td>In long bones, generally low cellularity and</td>
<td>Increased cellularity, double-nucleated chondrocytes, myxoid change, and chondrocyte necrosis</td>
<td>Cytologic and histologic features may overlap; degree of overlap is even more apparent in patients with multiple enchondromas (endochondromatosis)</td>
</tr>
<tr>
<td>features</td>
<td>absence of chondrocyte atypia; lacks myxoid</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>change and chondrocyte necrosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mitotic</td>
<td>Absence</td>
<td>Low level</td>
<td>Mitotic activity is extremely rare in enchondromas</td>
</tr>
<tr>
<td>activity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Growth pattern</td>
<td>Lacks infiltration</td>
<td>Infiltrative</td>
<td>This feature is diagnostic of low-grade chondrosarcoma</td>
</tr>
</tbody>
</table>

### Image Gallery

Gross, Imaging, and Microscopic Features
Conventional chondrosarcoma shows a nodular intramedullary proliferation of cartilage that often breaches the cortex and extends into the adjacent soft tissue. (Courtesy A. Hough, MD.) (Right) This image of a large exophytic chondrosarcoma arising in an osteochondroma of the pelvis reveals the production of chondroid matrix, which characteristically shows a “snowstorm” appearance on radiograph. The base portion of the tumor is seen proximally.

(Left) A cartilaginous neoplasm demonstrating infiltration of normal trabecular or cortical bone &/or invasion of the marrow cavity is diagnostic of chondrosarcoma. Note the rounded pushing border present at the leading edge of the tumor. (Right) Infiltrative soft tissue extension by a cartilaginous neoplasm is also diagnostic of a chondrosarcoma. Note the involvement of fibroadipose tissue and skeletal muscle.
(Left) Low-grade (grade 1) chondrosarcoma often demonstrates very low cellularity and an absence of pleomorphism, thereby making histologic distinction from a benign enchondroma challenging. However, atypical cytologic changes such as chondrocyte binucleation, formation of small nucleoli, and myxoid degeneration of the matrix may be seen. (Right) Clustering of chondrocytes may be identified in chondrosarcoma. However, this finding can be seen in benign cartilaginous tumors as well.

Microscopic Features

(Left) Intermediate-grade (grade 2) chondrosarcoma displays a greater degree of cellularity than low-grade examples but lacks significant nuclear pleomorphism. With the exception of cartilaginous tumors in the small bones of the hands and feet, this increase in cellularity usually favors a chondrosarcoma over enchondroma. (Right) Intermediate-grade chondrosarcoma may show prominent myxoid degeneration of the matrix, leading to potential difficulty in identification.
In some chondrosarcomas, the cartilaginous matrix is prominently dark blue-purple rather than light blue-gray. This change in color is often seen in more cellular (grade 2) chondrosarcomas. High-grade (grade 3) chondrosarcoma demonstrates not only an increase in cellularity but also an increase in nuclear pleomorphism. Mitotic figures are often readily seen in higher grade tumors as well.

Dedifferentiation in a chondrosarcoma is marked by the presence of a generally high-grade noncartilaginous sarcoma immediately adjacent to a more conventional hyalin type chondrosarcoma component. In most cases, the conventional chondrosarcoma component is histologically low grade. Chondrocyte necrosis is a common finding in chondrosarcoma and is represented by loss of nuclear staining, leading to the appearance of purely pink cells within lacunae.

Chordoma

Primary malignant tumor of bone with a phenotype that recapitulates notochord and usually arises within bones of axial skeleton

Etiology/Pathogenesis
Benign notochordal cell tumor (BNCT) thought to be a precursor lesion to chordoma

Clinical Issues
- Accounts for ~5% of primary malignant bone tumors
- Usually diagnosed between 4th and 8th decades
- Virtually restricted to axial skeleton

Image Findings
- Destructive
- Lytic
- Invariably extends into soft tissues, forming a sizable, well-defined mass; may show calcifications

Macroscopic Features
- Gelatinous and lobulated
- Well delineated from surrounding tissues
- Dedifferentiated component is solid and fish fleshlike in appearance

Microscopic Pathology
- Histologically, chordoma is classified into 3 groups: Conventional chordoma, chondroid chordoma, and dedifferentiated chordoma
  - Chondroid chordoma can mimic chondrosarcoma
  - Dedifferentiated chordomas contain high-grade sarcomatous areas and have worst prognosis

Chordomas classically occur in the midline of the body, and one of the more common locations (~35% of cases) is at the base of the skull in the region of the clivus.
This image shows the classic histologic appearance of a conventional chordoma: Nests and cords of plump eosinophilic cells, clear cells, and physaliferous cells within a myxoid stroma.

**TERMINOLOGY**

**Definitions**
- Primary malignant tumor of bone with a phenotype that recapitulates notochord and usually arises within bones of axial skeleton
- Chondroid chordoma: Tumor with areas of conventional chordoma and regions resembling low-grade hyaline-type chondrosarcoma
- Dedifferentiated chordoma: Tumor with areas of conventional chordoma juxtaposed to high-grade sarcoma

**ETIOLOGY/PATHOGENESIS**

**Sporadic and Familial**
- Thought to arise from notochordal remnants
- Benign notochordal cell tumor (BNCT) may be a precursor lesion to chordoma
- Variety of genetic abnormalities can be identified in sporadic and familial tumors
  - Familial tumors (familial chordoma) have been associated with upregulation of T-brachyury, a nuclear transcription factor
  - Appears to be increased incidence of chordoma in patients with tuberous sclerosis

**CLINICAL ISSUES**

**Epidemiology**
- **Incidence**
  - Accounts for ~5% of primary malignant bone tumors
- **Age**
  - Wide range: 30-70 years
    - Generally earlier in familial chordoma (30-50 years)
  - Only 5% of tumors develop in patients < 20 years
- Tumors in children usually arise in skull base and are often a part of tuberous sclerosis complex (TSC)
  
  - Gender
    - Men affected more frequently than women

**Site**

- Virtually restricted to axial skeleton
  - Rare cases reported to arise outside axial skeleton
- Most (~ 50%) arise in sacrococcygeal region
- ~ 35% arise in skull base
- ~ 15% arise in mobile spine
- Chondroid chordoma usually arises in skull base
- Dedifferentiated chordoma usually arises in sacrococcygeal region
  - Dedifferentiation is most often seen in recurrences

**Presentation**

- Depends on site of origin
  - Skull base: Diplopia, headaches, cranial nerve palsies
  - Mobile spine: Pain, neurologic symptoms
  - Sacrum: Pain, constipation, incontinence, bladder dysfunction, erectile dysfunction

**Treatment**

- Standard of care is surgery ± radiation therapy
  - No effective chemotherapy is currently available

**Prognosis**

- Affected by tumor location, size, and resectability
- Sacral chordomas have best prognosis and longest overall survival because they are most likely to be resected with negative margins
  - Local recurrences for sacrococcygeal tumors are common after incomplete excision
  - 5- and 10-year survival rates range from 60-95% and 40-60%, respectively
- In mobile spine, 5-year survival rate is ~ 55%, with local recurrence rate ranging from 62-75%

- Primarily due to difficulty in achieving complete resection
- In skull base, factors such as large size, female gender, and age > 40 years are associated with a worse outcome
  - In a series in which patients were treated with surgery and radiation, 46% developed local progression with median follow-up of 69 months
  - Others have reported a 5-year local control rate of 59%
- No apparent difference in overall survival for patients with chondroid chordomas (controversial)
- Dedifferentiated chordoma has worst prognosis of all chordomas
  - Usually rapidly fatal with systemic spread occurring in ~ 90% of cases
- Rate of metastatic spread of chordoma varies widely
  - Range: < 5-43% (highest for dedifferentiated chordoma)
- Common sites of dissemination include lung, skin, and bone

**IMAGE FINDINGS**

**Radiographic Findings**

- Lytic and destructive
- Invariably extends into soft tissues, forming a sizable, well-defined mass; may show calcifications
- In sacrum, soft tissue component is characteristically anterior
  - May displace the rectum and extend along sacral nerve roots into sciatic notch
- Sacral tumors are notoriously difficult to see on conventional radiographs

**MR Findings**

- Extremely bright on T2-weighted images; may show lobulated pattern
- Foci of calcification are frequently seen
- Soft tissue extent is better seen

**CT Findings**

- Has water content and appears radiolucent
- Bone destruction
- Calcifications may be seen
MACROSCOPIC FEATURES

General Features
- Soft, tan-gray, gelatinous, and lobulated
- Well delineated from surrounding tissues
- Dedifferentiated component is solid and fish flesh-like in appearance

Size
- Tumors in skull base are smallest, usually 2-5 cm in diameter
- Sacral tumors can be very large, usually > 10 cm

MICROSCOPIC PATHOLOGY

Histologic Features
- Histologically, chordoma is classified into 3 groups: Conventional chordoma, chondroid chordoma, and dedifferentiated chordoma
  - Familial and sporadic cases have similar findings
- Conventional chordoma has lobular growth pattern, infiltrates marrow space, encases preexisting bony trabeculae, and usually breaches the cortex, forming a well-demarcated soft tissue mass
  - Composed of large epithelioid cells arranged in cohesive nests and cords
  - One tumor cell may wrap or “hug” another
  - Nuclei are of moderate size, darkly staining, and may contain a small nucleolus or pseudoinclusions
  - Most cells have eosinophilic or clear cytoplasm (the latter due to ≥ 1 large intracytoplasmic vacuoles)
  - Physaliferous cells contain numerous small intracytoplasmic vacuoles that impart a “bubbly” appearance to cytoplasm

- Physaliphorous cells are not pathognomonic of chordoma, as other types of tumors may have similar-appearing cells and some chordomas may lack them
- In some tumors, physaliphorous cells have a large single cytoplasmic vacuole that causes them to mimic adipocytes
  - Pleomorphism and spindling of tumor cells may be present
  - Mitotic activity is usually limited
    - Foci of necrosis are common, especially in larger tumors
  - Extracellular stroma is myxoid, frothy, basophilic
- Chondroid chordoma contains areas of conventional chordoma as well as chondroid regions
  - Chondroid regions merge with or abruptly abut conventional component
  - Chondroid areas are composed of neoplastic cells distributed individually in lacunar-like spaces
    - Neoplastic cells are surrounded by solid-appearing hyalinized matrix similar in appearance to hyaline cartilage
  - Quantity of chondroid component is variable
    - In some tumors, chondroid areas may be so abundant as to make it difficult to distinguish chordoma from chondrosarcoma
- Dedifferentiated chordoma is composed of a high-grade sarcoma juxtaposed with conventional chordoma
  - Sarcoma is usually a high-grade, undifferentiated pleomorphic sarcoma
  - Dedifferentiation results from ongoing cumulative mutations in conventional chordoma cells
- In some tumors, areas of benign notochordal cell tumor may be seen adjacent to chordoma, suggesting malignant transformation

ANCILLARY TESTS

Immunohistochemistry
- Conventional chordoma typically expresses epithelial markers, including keratins and epithelial membrane antigen (EMA)
- Vast majority show nuclear expression of brachyury
- Most tumors show variable expression of S100
- Variable numbers also stain with antibodies to carcinoembryonic antigen (CEA) and glial fibrillary acidic protein (GFAP)
- Immunohistochemical stain can be very helpful in distinguishing chondrosarcoma from chordoma, especially on a small biopsy
  - Chondrosarcomas are negative for epithelial markers (particularly keratin) and brachyury

Molecular Genetics
Some familial cases may show similar genetic alterations as sporadic cases.

**Electron Microscopy**
- Neoplastic cells in conventional chordoma have villous-like surface projections, abundant cytoplasmic glycogen, and mitochondria-rough endoplasmic reticulum complexes.
- Contain cytoplasmic processes that wrap around adjacent cells.
- Cells have well-developed desmosomes, intracytoplasmic lumina, and tonofilaments.

**DIFFERENTIAL DIAGNOSIS**

**Metastatic Adenocarcinoma**
- Mucinous adenocarcinoma can mimic chordoma on small biopsy sample.
  - Immunohistochemical stains are helpful as adenocarcinomas are S100 protein positive and brachyury negative.

**Chondrosarcoma**
- On small biopsies, especially from skull base, it can be difficult to distinguish chordoma from myxoid chondrosarcoma.
  - Immunohistochemical stains for keratins and brachyury are helpful as chondrosarcoma is negative for those markers.
  - Both tumors stain for S100 protein.

**Benign Notochordal Cell Tumor**
- Contains cells with abundant clear cytoplasm (adipocyte-like) or eosinophilic cytoplasm.
- Has same immunohistochemical profile as chordoma.
- Unlike chordoma, BNCTs are usually confined to bone and lack extracellular myxoid matrix histologically.
- Radiographically, chordoma is lytic whereas BNCT is sclerotic and does not show contrast enhancement.

**SELECTED REFERENCES**

Sagittal T1 MR image shows near-complete involvement of the clivus with expansile low-signal tumor and the classic “thumb” of chordoma focally compressing the pons. Axial CECT shows a large lytic lesion destroying the majority of the sacrum and extending into the adjacent soft tissues. Sacral tumors can be large at presentation, as this one was.

This gross photograph shows the standard macroscopic features of a conventional chordoma. Most tumors are generally well circumscribed, tan-gray, focally hemorrhagic &/or myxoid, and demonstrate a nodular architecture. (Courtesy A. Hough, MD.) At low magnification, most chordomas demonstrate prominent lobularity with large nodules of tumor divided by thick fibrous septae.
Chordoma cells that contain a single large cytoplasmic vacuole often resemble mature adipocytes and, when extensive, may potentially lead to confusion with an adipocytic neoplasm. This microscopic field demonstrates numerous clear chordoma cells and somewhat resembles adipose tissue. Note, however, that there is also a large number of conventional eosinophilic tumor cells to help support a diagnosis of chordoma.

Microscopic Features

Some chordoma cells contain numerous tiny intracytoplasmic vacuoles that give the cell a “bubbly” appearance. These cells are known as physaliferous cells. The number of physaliferous cells varies widely from tumor to tumor and even from 1 microscopic field to another. This image shows a dramatic and abrupt demarcation between conventional chordoma and a sheet of physaliferous cells. In general, however, physaliferous cells are not usually numerous.
It is not uncommon for occasional chordoma cells to display nuclear hyperchromasia, enlargement, &/or pleomorphism. Within the context of otherwise conventional morphology, this finding is not prognostically significant. Similarly, mitotic figures are usually not prominent in chordomas. Tumor necrosis is a common finding in chordomas. Most often, it is localized and patchy; however, in larger tumors, it can be extensive.

Although most chordoma tumor cells are epithelioid, a spindled morphology may be seen occasionally. In a limited biopsy sample, this finding may raise the possibility of a myxoid chondrosarcoma of bone. Some chordomas demonstrate foci in which the tumor cells form a solid sheet of cells without the characteristic myxoid stroma. This morphology is usually not diffuse, however, and more conventional areas are often present elsewhere.

Microscopic and Immunohistological Features
This chordoma contained a few cellular areas composed of spindled tumor cells without well-developed myxoid stroma. Importantly, these areas did not show features of frank sarcoma that would suggest dedifferentiation. Chondroid chordomas show areas of conventional chordoma associated with a hyaline-type chondroid matrix. Depending on the extent of the chondroid portion, this variant may be difficult to distinguish from a chondrosarcoma.

A dedifferentiated chordoma contains areas of conventional chordoma (not shown in this image) juxtaposed to areas that have the appearance of a cellular &/or pleomorphic spindle cell sarcoma. (Courtesy M. Gokden, MD.) Most chordomas demonstrate strong diffuse expression of epithelial antigens, particularly keratins. Epithelial membrane antigen (EMA) is also commonly expressed but may show a more patchy staining pattern.
The expression of S100 protein in chordomas is often less strong and diffuse than that seen for keratins. Importantly, care must be taken as chondrosarcomas can also show expression of this marker. (Right) Chordoma is one of very few tumors that express T-brachyury, a nuclear transcription factor found in notochordal cells and tumors that have a notochordal phenotype. Only nuclear staining is considered positive. (Courtesy M. Gokden, MD.)

Malignant Peripheral Nerve Sheath Tumor

Terminology
- Sarcoma arising from a nerve or benign nerve sheath tumor or showing nerve sheath cellular differentiation

Etiology/Pathogenesis
- 50% of cases are associated with NF1
- 10% of cases are associated with radiation

Clinical Issues
- Mostly adults (20-50 years)
- Most (70%) arise in major nerve trunks
- Local recurrence: > 40%
- Metastasis: 30-60%
- 5-year survival: 15-34%

Microscopic Pathology
- Mostly high-grade sarcomas
- Spindle cell MPNST (80%)
  - Long fascicles of closely spaced hyperchromatic spindle cells
  - Small round blue cells
  - Pleomorphic cells
  - Extensive necrosis with perivascular preservation
- Epithelioid MPNST (5%)
- Heterologous differentiation (15%)

Ancillary Tests
- S100: 50-60% (usually focal)

Top Differential Diagnoses
- Synovial sarcoma
- Cellular schwannoma
- Atypical neurofibroma
- Malignant melanoma
At low magnification, malignant peripheral nerve sheath tumor (MPNST) classically shows a marbled or tapestry pattern of alternating regions of high and low cellularity.
Although some cases of MPNST can show monomorphic nuclear cytology, most examples show at least focal nuclear hyperchromasia and pleomorphism, as well as a brisk mitotic rate.

**TERMINOLOGY**

**Abbreviations**
- Malignant peripheral nerve sheath tumor (MPNST)

**Synonyms**
- Neurofibrosarcoma, malignant schwannoma, neurogenic sarcoma

**Definitions**
- Sarcoma arising from a nerve or benign nerve sheath tumor or showing nerve sheath differentiation
  - Arises from a nerve or benign nerve sheath tumor, or
  - Shows histological evidence of nerve sheath differentiation in patient with neurofibromatosis type 1 (NF1), or
  - Shows histological plus immunohistochemical or ultrastructural evidence of nerve sheath differentiation in patient without NF1

**ETIOLOGY/PATHOGENESIS**

**Genetic Predisposition**
- 50% of cases are associated with NF1
  - Lifetime incidence: 2-16%
- 40% of cases are sporadic

**Environmental Exposure**
- 10% of cases are associated with radiation

**Molecular Pathogenesis**
- NF1 caused by germline mutation of NF1 tumor suppressor gene
  - Somatic loss of 2nd NF1 allele required for tumorigenesis
Malignant transformation in both NF1-associated and sporadic MPNST often involves INK4A and TP53 and their downstream pathways.

**CLINICAL ISSUES**

**Epidemiology**

- **Incidence**
  - Rare: 5-10% of soft tissue sarcomas
- **Age**
  - Mostly adults (20-50 years)
    - Wide age range: 10-70 years
    - Average age in NF1: 30 years
    - Average age in sporadic MPNST: 40 years
- **Gender**
  - M ~ F

**Site**

- Common sites: Thigh, buttock, trunk, upper arm, retroperitoneum, head and neck
  - Mostly deep seated
  - Central body axis more common in NF1
- Most (70%) arise in major nerve trunks
  - Sciatic nerve most common
  - Brachial plexus, sacral plexus, paraspinal nerves

**Presentation**

- Painful mass
- Neurological deficit in some

**Treatment**

- Surgical approaches
  - Wide excision/resection
  - Amputation
- Adjuvant therapy
  - Radiation
- Drugs
  - Generally poor response to chemotherapy

**Prognosis**

- Poor
  - Local recurrence: > 40%
  - Metastasis: 30-60%
    - Lungs, bone, pleura most common
  - > 60% die of disease
  - 5-year survival: 15-34%
  - NF1 patients have worse overall prognosis
    - Probably due to higher incidence of large central axis tumors

**IMAGE FINDINGS**

**General Features**

- Morphology
  - Large heterogeneous mass
  - Fusiform mass within major nerve trunk

**MACROSCOPIC FEATURES**

**General Features**

- Similar to other soft tissue sarcomas
  - Pseudoencapsulated
  - Gray-tan
  - Firm to fleshy
  - Necrosis and hemorrhage common
- Fusiform or eccentric mass when arising in major nerve trunk
- Coexisting neurofibroma in some
  - Solitary or plexiform
Size
- Most > 5 cm
- Sometimes very massive

MICROSCOPIC PATHOLOGY

Histologic Features
- Wide spectrum of cytoarchitectural patterns
  - Mostly high-grade sarcomas
    - High mitotic rate and necrosis
    - Only ~ 15% are low grade
  - Nerve sheath differentiation
    - Nuclear palisading is uncommon (15%), usually focal
    - Tactoid differentiation with whorling or Wagner-Meissner-like features
  - Intraneural tumors
    - Plexiform architecture
    - Microscopic extension within nerve fascicle
  - Tumors arising from preexisting benign nerve sheath tumor
    - Neurofibroma most common, transitional areas, usually in NF1 patients
    - Schwannoma, ganglioneuroma, ganglioneuroblastoma, or pheochromocytoma; very rare
    - Diffuse sarcomatous proliferation with no evidence of nerve or nerve sheath origin
  - Spindle cell MPNST (80%)
    - Long fascicles of uniform, closely spaced, hyperchromatic spindle cells
    - Alternating cellular fascicles and hypocellular areas ("tapestry" or "marbled" pattern)
    - Storiform arrays
    - Small round blue cells
    - Pleomorphic cells
      - Multinucleated giant cells
    - Extensive necrosis with perivascular preservation
    - Hemangiopericytoma-like vascular pattern in some
  - Epithelioid MPNST (5%)
    - Multinodular architecture
    - Cords and clusters in some
    - Large epithelioid cells
      - Abundant eosinophilic cytoplasm
      - Large vesicular nuclei with macronucleoli
      - Clear cytoplasm in some
    - Often mixed with spindle cells
  - Heterologous differentiation (15%)
    - Osseous and osteosarcomatous
    - P.II(3):16
      - Chondroid and chondrosarcomatous
      - Rhabdomyosarcomatous (malignant triton tumor)
      - Angiosarcomatous
      - Glandular
      - Neuroepithelial (rosettes)

Cytologic Features
- Spindle cells
  - Hyperchromatic nucleus with dispersed coarse chromatin
  - Tapered and wavy nuclei in well-differentiated tumors
  - Very brisk mitotic activity in high-grade tumors
- Epithelioid cells
  - Abundant eosinophilic or clear cytoplasm
  - Vascular nucleus with prominent inclusion-like nucleolus

ANCILLARY TESTS

Immunohistochemistry
- S100 protein (+) in about 60%, usually focal
- Nestin (+) in 50-80%
- SOX10(+) in ~ 30%, usually focal
Cytogenetics
- Complex structural and numeric chromosomal abnormalities
  - Frequent loss of NF1 at 17q11
  - Frequent loss of TP53 at 17q13

**DIFFERENTIAL DIAGNOSIS**

**Monophasic or Poorly Differentiated Synovial Sarcoma**
- Nuclei have softer, less coarse chromatin
- Usually has lower mitotic rate
- TLE1(+)
  - MPNST rarely (2%) positive
- Usually cytokeratin (+) and EMA(+)
  - MPNST usually negative
- Usually S100(-)
- t(X:18) identified ~ 90% of cases
  - SSX gene on chromosome X fuses to SS18 gene (formerly termed SYT) on chromosome 18

**Cellular Schwannoma**
- Usually located in retroperitoneum, pelvis, posterior mediastinum, gastrointestinal tract
- Exclusively Antoni A areas; often lacks Verocay bodies
- Focal necrosis and mitotic figures may be present
- Lacks malignant cytological atypia
- Strong, diffuse S100 staining
  - MPNST usually has only focal staining

**Atypical Neurofibroma**
- Large, hyperchromatic spindle cells
- Degenerated (smudged) chromatin
- Low mitotic rate and generally low cellularity
- Usually retains cytarchitectural features of neurofibroma
  - Edematous fibrillary or myxoid matrix with collagen bundles (“shredded carrots” pattern)

**Malignant Melanoma**
- Spindle cell/sarcomatoid melanoma
  - May have clustered or thèque-like areas
  - Diffusely S100(+)
    - MPNST often focally S100(+) (60% of cases)
  - Usually HMB-45(-) and Melan-A (-)
- Epithelioid melanoma
  - Amelanotic melanoma may be indistinguishable from epithelioid MPNST
  - Usually HMB-45(+) and Melan-A (+)
    - MPNST is negative for these markers

**Clear Cell Sarcoma (CCS)**
- Predilection for acral extremities
- Multinodular, vaguely nested architecture
- Uniform epithelioid and spindle cells
- Diffuse S100, HMB-45, and Melan-A staining in most
- t(12:22) (~90% of cases)
  - EWSR1 gene on chromosome 22 fuses to ATF1 gene on chromosome 12
  - Variant t(2;22) (CREB1-EWSR1) identified in gastrointestinal forms of CCS

**Ewing Sarcoma**
- Usually a primary bone tumor but may present as soft tissue primary
  - MPNST is exceedingly rare as primary bone tumor
- Small round blue cell tumor
  - Often with glycogenated (clear) cytoplasm
  - Diffusely CD99(+), usually S100(-)
    - MPNST sometimes CD99(+) but usually weak/focal and nonmembranous
  - Several balanced translocations and fusions involving EWSR1 gene (on chromosome 22) identified in Ewing sarcoma
    - t(11;22), EWSR1-FLI1 (90% of cases)
    - t(21;22), EWSR1-ERG (5-10% of cases)
    - Others including t(2;22), t(7;22), t(17;22)
Embryonal Rhabdomyosarcoma

- Small round blue cells and spindle cells
- Scattered rhabdomyoblasts
- S100(-), desmin (+), and myogenin (+)

SELECTED REFERENCES


Image Gallery
Microscopic Features

(Left) Some cases of MPNST demonstrate a marked fascicular growth pattern with a herringbone architecture, similar to what is often seen in adult-type fibrosarcoma, fibrosarcomatous dermatofibrosarcoma protuberans, and other morphologically similar cellular spindle cell sarcomas. (Right) In the less cellular regions of an MPNST, the tumor cells exhibit typical features of neural derivation, including thin, elongated, and buckled nuclei with tapered ends.
A characteristic but underappreciated feature of many MPNSTs is an accentuation of tumor cells around the stromal blood vessels. Sometimes, the tumor cells will proliferate and appear to "herniate" into the lumen of the vessel. In some cases of MPNST, the perivascular tumor cells are so prominent that they may resemble true glands or epithelial islands, leading to potential confusion with biphasic synovial sarcoma.

Coagulative necrosis is a common finding in MPNST and may range from scattered foci to extensive zones. Within geographic zones of necrosis, it is common to see viable tumor cells around stromal blood vessels (peritheliomatous pattern), resembling “islands in an ocean.” Although not a typical finding in most cases, MPNST may show diffuse infiltration of peritumoral fat in a honeycomb fashion, mimicking the growth of dermatofibrosarcoma protuberans.
Myxoid stromal change is common in MPNST. In some cases, this change is extensive, and it can be difficult to distinguish this tumor from myxofibrosarcoma, myxoid dermatofibrosarcoma protuberans, and others. Areas of more conventional morphology are helpful in these cases. (Right) Diffuse nuclear pleomorphism and anaplasia are not common findings in MPNST and can make the diagnosis very difficult. Demonstration of origin from a nerve or a benign nerve sheath tumor is helpful.

Rare cases of MPNST contain a small round blue cell morphology that mimics a variety of round cell sarcomas or even a hematolymphoid process. The diagnosis usually requires demonstration of areas of more conventional MPNST morphology. (Right) Occasionally, MPNST will contain structures suggestive of neural origin such as cellular whorls; Verocay-like palisading, tactoid bodies; and fibrillar rosettes.
Demonstration of origin from a nerve (either microscopically or grossly/intraoperatively) by a spindle cell sarcoma is diagnostic of MPNST. Importantly, origin from a nerve seen histologically must be distinguished from simple neural/perineural invasion, which is seen in a variety of malignancies. Demonstration of a spindle cell sarcoma arising in association with a benign nerve sheath tumor (usually a neurofibroma) is also diagnostic of MPNST.

P.II(3):19

**Variant Microscopic Features**

In some cases of MPNST, residual nerve trunks/fibers can be identified that are almost completely replaced by tumor yet are still recognizable enough to clinch the diagnosis. Expression of S100 protein in MPNST is characteristically focal and patchy and is seen only in up to 60% of cases. Strong, diffuse expression of this antigen is very uncommon in conventional spindle cell MPNST and should raise the possibility of a cellular schwannoma.
A small subset of MPNST cases contain heterologous elements such as rhabdomyoblasts. (Such cases are also known as a malignant triton tumor.) These elements are morphologically distinct but do not appear to affect the prognosis. Other heterologous elements that can be identified in MPNST include histologically benign or malignant cartilage, bone, and vascular structures. Glands and squamous islands are exceptional findings.

Epithelioid MPNST is a less common variant of MPNST; it is generally composed of large nodules of epithelioid cells divided by fibrous septae. Large nucleoli and a variably prominent myxoid stroma are common features. A rhabdoid morphology may also be seen. Characteristically, epithelioid MPNST is diffusely positive for S100 protein, unlike conventional MPNST in which S100 staining is focal or negative. Melanocytic markers (e.g., HMB-45) are negative.

Melanotic Neuroectodermal Tumor of Infancy

<table>
<thead>
<tr>
<th>Terminology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rare, fast-growing, pigmented neoplasm of likely neural crest origin</td>
</tr>
<tr>
<td>Clinical Issues</td>
</tr>
<tr>
<td>Most present in 1st year of life</td>
</tr>
<tr>
<td>Commonly involve craniofacial sites</td>
</tr>
</tbody>
</table>
Maxilla: 69%
- Rapidly enlarging expansile mass
- Elevated urinary vanillylmandelic acid may be present

Microscopic Pathology
- 3 distinct components
  - Clusters of small round neuroblastic cells
  - Primitive gland-like structures
  - Fibrocollagenous stroma

Top Differential Diagnoses
- Primitive neuroectodermal tumor
  - Sheets of small to medium round blue cells
  - Characteristic t(11;22)
- Neuroblastoma
  - Sheets and lobules of small round hyperchromatic cells
- Congenital epulis
  - Characteristic location in labial aspect of dental ridge
  - Protruding round or ovoid nodule
- Alveolar rhabdomyosarcoma
  - Aggregates and nests of poorly differentiated small hyperchromatic cells
  - Characteristic immunohistochemical and cytogenetic findings

Clinical photo shows a maxillary expansion with an intact overlying mucosa in a child. The clinical features of the melanotic neuroectodermal tumor may mimic an eruption cyst. (Courtesy J. Hille, MDS, DDS.)
The neuroblastic small cells separated by a fibrocollagenous stroma demonstrate an alveolar pattern of growth. Epithelial cells with abundant eosinophilic cytoplasm and melanin pigment are scattered.

**TERMINOLOGY**

**Abbreviations**
- Melanotic neuroectodermal tumor of infancy (MNTI)

**Synonyms**
- Retinal anlage tumor
- Melanotic progonoma

**Definitions**
- Rare, fast-growing, pigmented neoplasm of likely neural crest origin

**ETIOLOGY/PATHOGENESIS**

**Disputed Histogenesis**
- Neural crest (neuroectodermal) origin

**Familial Setting**
- Reports of familial cases: Unknown gene

**CLINICAL ISSUES**

**Epidemiology**
- **Age**
  - Most present in 1st year of life (> 90%)

**Site**
- Most MNTI cases arise in maxilla, although occurrence in other intraosseous and extraosseous anatomic locations has been described, including the skull, brain, epididymis, testis, skin, and mediastinum
- Most involve craniofacial sites
  - Upper and lower jaw
    - Maxilla: 69%
    - Mandible: 6%
Skull: 11%

Presentation
- Rapidly enlarging, firm, expansile mass
- Intact overlying mucosa
- Erosion into adjacent bone
- Nontender
- Bluish discoloration

Laboratory Tests
- Elevated urinary vanillylmandelic acid may be present

Treatment
- Complete local excision
  - Local recurrence rate: 10-15%
  - Usually recurs in 1st postoperative year

Prognosis
- Benign to intermediate clinical course
  - Recurrence rate: 10-15%
  - Metastatic spread in < 5%

MACROSCOPIC FEATURES

Gross Features
- Firm
- Well circumscribed
- Gray to blue-black cut surface

MICROSCOPIC PATHOLOGY

Predominant Pattern/Injury Type
- Glandular/alveolar
  - Spaces lined by cuboidal pigmented epithelial cells
  - Small neuroblastic cells found within spaces
- Solid
  - Background of fibrocollagenous stroma

Predominant Cell/Compartment Type
- Dual population of cells
  - Flat to cuboidal pigmented epithelial cells
  - Small neuroblastic cells
  - Fibrocollagenous stroma

Microscopic Features
- Biphasic cell population of large epithelioid cells with intracellular melanin granules and smaller, round, neuroblast-like cells in a variably vascularized fibrous stroma
- 3 distinct components
  - Clusters of small round neuroblastic cells
    - Small round hyperchromatic nuclei
    - Scant cytoplasm
    - Arranged in small islands and cords
    - Crush artifact frequently encountered
  - Primitive gland-like structures
    - Larger cells with round vesicular nuclei
    - Abundant cytoplasm with melanin granules
    - Alveolar or glandular arrangements
  - Fibrocollagenous stroma

DIFFERENTIAL DIAGNOSIS

Primitive Neuroectodermal Tumor
- Sheets of small to medium round blue cells
- Frequent mitoses and foci of necrosis
- Characteristic t(11;22)

Neuroblastoma
- Predominantly located in retroperitoneum
Sheets and lobules of small round hyperchromatic cells
Homer Wright rosettes

Congenital Epulis
- Characteristic location in labial aspect of dental ridge
- Protruding round or ovoid nodule
- Microscopically resembles adult granular cell tumor
  - Polygonal cells with abundant eosinophilic cytoplasm
  - Lack pseudoepitheliomatous hyperplasia

Alveolar Rhabdomyosarcoma
- More commonly located in extremities
- Aggregates and nests of poorly differentiated small hyperchromatic cells
- Separated by fibrous septae
- Characteristic immunohistochemical and cytogenetic findings

SELECTED REFERENCES

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Reactivity</th>
<th>Staining Pattern</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE1/AE3</td>
<td>Positive</td>
<td>Cell membrane &amp; cytoplasm</td>
<td>Epithelial cells</td>
</tr>
<tr>
<td>HMB-45</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>Epithelial cells</td>
</tr>
<tr>
<td>Mart-1</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>Neuroblastic and epithelial cells</td>
</tr>
<tr>
<td>NSE</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>Frequently expressed by neuroblastic cells and epithelial cells</td>
</tr>
<tr>
<td>Synaptophysin</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>Neuroblastic cells and variably expressed in epithelial cells</td>
</tr>
<tr>
<td>CD57</td>
<td>Positive</td>
<td>Cell membrane &amp; cytoplasm</td>
<td>Neuroblastic cells and epithelial cells</td>
</tr>
</tbody>
</table>

P.II(3):22

Image Gallery
Clinical, Imaging, and Microscopic Features

(Left) Clinical photograph shows a huge mass extending toward parietal squama superiorly and in the upper neck inferiorly behind the displaced left ear. The overlying skin looks normal. (Right) Axial bone CT shows the most common appearance, location, and age for melanotic neuroectodermal tumor: Maxillary expansion with osteolysis.
and adjacent soft tissue changes in an infant.

(Left) High-power view of this nest of small neuroblastic round cells highlights the scant amount of cytoplasm and the small nucleoli with dispersed salt-and-pepper chromatin. Mitotic figures are rarely observed. (Right) Dense fibrous stroma is shown with scattered small neuroblastic cells arranged individually and in nests in this melanotic neuroectodermal tumor of infancy (MNTI). Note that the pigment deposition is minimal.

(Left) A mixture of pigmented epithelial cells and small neuroblastic cells separated by dense fibrocollagenous stroma show an alveolar pattern of growth in this MNTI. Note the crush artifact in the small hyperchromatic small cells. (Right) Dense fibrous stroma is shown with scattered small neuroblastic cells arranged individually and in cords with pigment deposition in this MNTI. Note the lack of a prominent epithelial component in this field.

P.II(3):23

Imaging, Gross, and Microscopic Features
CT shows a maxillary expansion with osteolysis and adjacent soft tissue changes in an infant. These are the most common appearance, location, and age for melanotic neuroectodermal tumor. (Courtesy J. Hille, MDS, DDS.)

Gross specimen of a melanotic neuroectodermal tumor of infancy in the maxilla of a young child shows a dark pigmented area in one side of the specimen corresponding to an area of heavy pigment deposition.

Immunohistochemical staining for NSE shows strong cytoplasmic reactivity in both the epithelial and small neuroblastic cellular components. (Right) Immunohistochemical staining for Melan-A shows a finely granular cytoplasmic reactivity predominantly in the small neuroblastic cellular component. This figure also shows rare immunopositivity in the epithelial cells.
(Left) Immunohistochemical reactivity for HMB-45 is observed in the cytoplasm of the epithelial cells. The other makers for these cells are keratins, vimentin, NSE, and epithelial membrane antigen. (Right) Immunohistochemical staining for synaptophysin shows strong cytoplasmic reactivity in both the epithelial and small neuroblastic cellular components.

Osteosarcoma

> Table of Contents > Part II - Diagnoses Associated With Specific Syndromes > Section 3 - Bone and Soft Tissue > Osteosarcoma
Osteosarcoma
Matthew R. Lindberg, MD

Key Facts
Terminology
- High-grade malignant tumor in which neoplastic cells produce bone

Etiology/Pathogenesis
- Primary osteosarcomas arise de novo without a known predisposing condition
- Secondary osteosarcomas arise within a diseased bone
  - Paget disease of bone
  - Radiation exposure
  - Chemotherapy
  - Trauma
  - Foreign body
  - Certain genetic abnormalities
- Hereditary retinoblastoma: Germline mutation in RB1 gene
- Li-Fraumeni syndrome: Germline mutation in TP53
- Rothmund-Thomson syndrome
  - Skin lesions, photosensitivity, hypogonadism, psychomotor retardation, and various skeletal abnormalities

Clinical Issues
- Most patients are young, between 10 and 20 years
- Distal femur > proximal tibia > proximal humerus

Microscopic Pathology
- Admixture of 2 elements in varying proportions
  - High-grade sarcoma with epithelioid, plasmacytoid, fusiform, ovoid, small round cells, clear cells, mono- or multinucleated giant cells, or spindle cells
  - Bone matrix produced directly by tumor
Coronal T1WI C+ MR of an osteosarcoma of the distal femur shows a very destructive bone lesion with a large soft tissue mass.
Conventional osteosarcoma demonstrates sheets of malignant osteoblasts intimately associated with the production of pink, lace-like osteoid and neoplastic bone.

**TERMINOLOGY**

**Synonyms**
- Osteogenic sarcoma

**Definitions**
- High-grade malignant tumor in which neoplastic cells directly produce bone

**ETIOLOGY/PATHOGENESIS**

**Neoplastic Process**
- Primary osteosarcomas arise de novo without a known predisposing condition
- Secondary osteosarcomas arise within a diseased bone
  - Paget disease of bone
  - Radiation exposure
  - Chemotherapy
  - Trauma
  - Foreign body (e.g., orthopedic implants)
  - Certain genetic abnormalities

**Genetic Susceptibility**
- Hereditary retinoblastoma: Germline mutation in RB1 gene
- Li-Fraumeni syndrome: Germline mutation in TP53
- Rothmund-Thomson syndrome
  - Skin lesions, photosensitivity, hypogonadism, psychomotor retardation, and various skeletal abnormalities

**CLINICAL ISSUES**

**Epidemiology**
- Incidence
Most common primary malignant tumor of bone; exclusive of hematopoietic malignancies
- Accounts for ~ 20% of primary bone sarcomas

**Age**
- Most patients are young, between 10 and 20 years
  - Females usually younger than males, probably due to earlier skeletal development
- 2nd peak occurs in patients > 50 years (usually secondary osteosarcoma)

**Gender**
- More common in males than females (1.3:1)

**Site**
- Most commonly arises in long tubular bones
  - Distal femur > proximal tibia > proximal humerus
    - 50% of cases located in knee region
- In older individuals, pelvis and axial skeleton are most common locations
- < 10% occur in mandible and craniofacial bones

**Presentation**
- Progressively enlarging painful mass
  - Pain is deep seated and frequently noted months prior to diagnosis
  - Intensity of pain increases over time, eventually producing unremitting discomfort
- May appear as visible and palpable mass
- Overlying skin may be warm, erythematous, edematous, and cartographed by prominent engorged veins
  - Ulceration of skin secondary to pressure ischemia can occur
- Large tumors may restrict range of motion
- May cause joint effusions when tumor involves epiphysis or periarticular structures
- Patients with advanced cases may have weight loss and cachexia
- In 5-10% of cases, heralding event is pathologic fracture through tumor

**Laboratory Tests**
- Elevated serum alkaline phosphatase

**Treatment**
- Surgical approaches
  - Limb salvage; complete excision with wide negative margins is optimal
    - Biopsy tract is often removed with tumor
  - Amputation necessary if major vessels and nerves compromised, if tumor involves region that cannot be reconstructed, or if pathologic fracture or surgical intervention has contaminated large volumes of tissue
- Adjuvant therapy
  - Preoperative chemotherapy often administered
    - May diminish tumor in size
    - Tumor often undergoes more extensive mineralization and develops a more developed pseudocapsule facilitating excision
    - Chemotherapeutic efficacy can be determined by histologic assessment of amount of necrosis induced in tumor
    - Tumor-induced necrosis of ≥ 90% considered good response and important prognostic indicator
- Drugs
  - Cisplatin, high-dose methotrexate, ifosfamide
- Radiation
  - Definitive treatment used for unresectable tumors because of size &/or site
  - Definitive radiation may be used to treat tumors in patients with widely metastatic disease who are considered incurable
  - Adjuvant radiation may be used if surgical excision is associated with positive margins

**Prognosis**
- Relapse-free survival rates reported to vary from 50-80% (median: ~ 70%)
- Of conventional osteosarcoma subtypes, chondroblastic variant has been shown to be associated with a poor preoperative chemotherapy response

**IMAGE FINDINGS**
Radiographic Findings
- Permeative and destructive lesion
- Centered around metaphysis of long bones (very rarely epiphysis)
- Poorly defined with a lack of sclerotic rim
- Mixed lytic and blastic mass transgressing cortex and forming large soft tissue components
  - 90% extend into soft issue
- Visible matrix present in 90% of cases
  - Periphery of lesion usually less mineralized than central area
- Soft tissue components may have fine "cloud-like" pattern of radiodensity
- In some instances, tumor is entirely lytic or sclerotic
  - Entirely lytic appearance is characteristic of telangiectatic variant
- Lower grade lesions tend to be more mineralized
- Periosteal reaction
  - Reactive woven bone is deposited between cortex and periosteum elevated by tumor
  - Appears either as multiple layers (onion skin) or radiating (sunburst) appearance
  - Codman triangle: Term used to describe periosteal reaction at diaphyseal end of tumor at angle created by cortex and elevated periosteum
- Rarely, imaging appears deceptively benign
- < 10% of lesions are diaphyseal

MR Findings
- Heterogeneous metaphyseal mass
- MR helpful in detecting skip lesions in same or adjacent bone
- Osteoid shows low signal on all sequences
- T1WI: Nonosteoid portions of tumor are near isointense to skeletal muscle
- Fluid sensitive sequences: Tumor appears heterogeneous

CT Findings
- Useful in defining bone matrix
- Useful when planning surgery and delineating extent of tumor

Bone Scan
- Increased activity in primary tumor and metastasis

MACROSCOPIC FEATURES
General Features
- Intramedullary
- Usually centered in metaphysis, but can involve any portion of bone
- Tumors containing abundant mineralized bone are tan-white and hard
- Nonmineralized cartilaginous components are glistening and gray
  - May be mucinous if matrix is myxoid, or more rubbery if hyaline in nature
- Areas of hemorrhage and cystic change
  - When extensive, produce a friable, bloody, and spongy mass (telangiectatic osteosarcoma)
- Tumor usually destroys overlying cortex and forms eccentric or circumferential soft tissue component displacing periosteum peripherally
- Dislodged periosteum becomes sharp interface between mass and bordering skeletal muscle and fat
- Layer of reactive bone at proximal and distal regions where periosteum 1st lifted from cortex
- Growth into joint space may occur
  - Growth may occur through synovium, via extension along cortical surface, or through tendoligamentous and joint capsule insertion sites
- Open growth plates often function as effective barriers to advancing tumors
  - Penetration of physis and invasion through epiphysis to base of articular surface occurs in some cases
- Skip metastases appear as intramedullary firm, ovoid, tan-white nodules located adjacent to or far from main mass
- Variants of osteosarcoma confined to surface of bone occur but are uncommon

MICROSCOPIC PATHOLOGY
Histologic Features
- Admixture of 2 elements in varying proportions
High-grade sarcoma with epithelioid, plasmacytoid, fusiform, ovoid, small round cells, clear cells, monon multuninucleated giant cells, or spindle cells
- Bone matrix produced directly by tumor
  - Mineralized (bone) and unmineralized (osteoid)
- Nuclei are hyperchromatic, and central or eccentric in position
  - Brisk mitotic activity and prominent nucleoli are common
  - Degree of atypia variable but frequently severe
  - Numerous mitoses, commonly including atypical forms
- Cytoplasm is eosinophilic and variable in volume
- Tumor cells intimately related to surface of neoplastic bone
  - Tumor cells diminish in size and appear less atypical as they are surrounded and imprisoned by matrix
    - In heavily mineralized portions of tumor, neoplastic cells lack atypia
    - This phenomenon is referred to as normalization
- Neoplastic bone is woven in architecture and varies in quantity
  - Deposited as primitive, disorganized trabeculae producing coarse, lace-like pattern or broad, large sheets formed by coalescing trabeculae
  - Bone is frequently mineralized
  - In some instances, neoplastic bone uses preexisting trabeculae as a scaffold
  - Neoplastic lamellar bone is very rare
- Bone is eosinophilic or basophilic and may have pagetoid appearance caused by haphazardly deposited cement lines
- Neoplastic cartilage, when present, is usually hyaline, but may be predominately myxoid, particularly in tumors arising in jaw bones
- Malignant chondrocytes demonstrate severe cytologic atypia
- Fibroblastic foci manifest as cytologically malignant spindle cells arranged in a herringbone or storiform pattern without direct bone formation

ANCILLARY TESTS
Immunohistochemistry
- Immunoprofile is nonspecific and of minimal help in diagnosis
- May be positive for keratin and epithelial membrane antigen
- Cartilaginous areas are positive for S100
- CD99 is frequently positive

Molecular Genetics
- Virtually all osteosarcomas contain clonal chromosomal aberrations
- Aberrations are complex, comprising abundance of numerical and structural alterations
- No specific translocation has been identified in conventional osteosarcoma

DIFFERENTIAL DIAGNOSIS
Fibrosarcoma (Malignant Fibrous Histiocytoma)
- Fibrosarcoma lacks tumor bone directly abutted by neoplastic cells
- Distinction between intraosseous fibrosarcoma and osteosarcoma is frequently an academic one
  - Chemotherapeutic regimens are similar
Fracture Callus
- Bone is rimmed by osteoblasts
P.II(3):27
- Fracture site shows fibrocartilage, a finding not seen in either osteosarcoma or chondrosarcoma
- Atypical mitotic figures are not seen
- Radiographic features frequently assist in making this distinction
Osteoblastoma
- Distinction between osteoblastoma-like osteosarcoma and aggressive osteoblastoma is often challenging
- Features supporting diagnosis of osteosarcoma include
  - Infiltration of preexisting bony trabeculae
  - Large size (> 5 cm)
  - Atypical mitotic figures
  - Prominent and abundant lace-like tumor bone deposition
- Osteoblastoma typically shows interconnecting trabeculae of tumor bone lined by plump osteoblasts
Chondrosarcoma
- In chondroblastic osteosarcomas and some gnathic osteosarcomas, bone may be scarce
- Extensive sampling will generally reveal foci of bone
- Cartilaginous tumor with marked atypia, particularly in 2nd and 3rd decades of life, is highly suspicious for osteosarcoma
- Presence of IDH1 or IDH2 mutations supports diagnosis of chondrosarcoma

Dedifferentiated Chondrosarcoma
- Characterized by presence of low-grade cartilage juxtaposed to high-grade sarcoma (dedifferentiated component)
- Rarely, dedifferentiated component may be osteosarcoma

Myositis Ossificans
- Both soft tissue and parosteal myositis ossificans may be mistaken for osteosarcoma
- Distinct zonal pattern is characteristic of myositis ossificans and is not seen in osteosarcoma
  - Grossly and on imaging, periphery of lesion is mineralized whereas center lacks mineralization
  - Microscopically, central portion of lesion shows granulation tissue/nodular fasciitis-like appearance whereas periphery shows woven bone lined by osteoblasts, with outermost layer of lamellar bone in mature lesions

Giant Cell Tumor
- May show reactive woven bone formation around periphery
- Unlike osteosarcoma, bone in giant cell tumor is lined by osteoblasts and not atypical tumor cells

Metastatic Carcinoma
- Metastatic breast and prostate carcinoma may evoke robust osteoblastic reaction
- Appropriate immunohistochemical studies assist in making this distinction

Ewing Sarcoma
- Small cell variant of osteosarcoma may mimic Ewing sarcoma
- In > 95% of cases, FISH will demonstrate rearrangement of EWSR1 gene

Aneurysmal Bone Cyst
- May mimic telangiectatic osteosarcoma
- Cells in cyst wall not severely atypical

**DIAGNOSTIC CHECKLIST**

Pathologic Interpretation Pearls
- At least focal bone production by malignant cells is necessary to render diagnosis of osteosarcoma
- Ancillary tests do not help in identifying bone
- Distinction between bone and nonosseous collagen may be difficult, and at times arbitrary
- Delicate lace-like deposition of mineralized eosinophilic matrix is highly suggestive of neoplastic bone

Assessment of Chemotherapy Effect
- Complete (grade 4) or near complete (grade 3) > 90% necrosis of tumor is associated with survival advantage
- Assessment of necrosis should be performed by histologically evaluating a central slice of tumor and sampling remaining halves
- Extent of necrosis on preoperative chemotherapy may be used to alter postoperative regimen

**SELECTED REFERENCES**
P.II(3):28

Image Gallery
Gross, Imaging, and Microscopic Features

(Left) Osteosarcoma most commonly arises in the region of the knee (distal femur shown here). This gross photograph shows the characteristic metadiaphyseal origin of this destructive tumor as well as foci of soft tissue extension. (Courtesy A. Hough, MD.) (Right) This anteroposterior radiograph of an osteosarcoma of the left femur shows an extensive and impressive periosteal reaction. This particular pattern is described as a sunburst pattern.

(Left) Osteosarcoma is a highly permeative neoplasm. This image shows the malignant cells and neoplastic woven bone growing between and around normal host mature trabecular bone. (Right) Malignant osteoblasts directly associated with the production of osteoid or woven (immature) bone is characteristic of osteosarcoma. Osteoid is classically depicted as very thin seams of glassy pink material that insinuate between individual neoplastic cells ("filigree pattern").
(Left) Foci of neoplastic bone production vary widely in size, shape, and distribution from 1 tumor to the next. Mineralized foci demonstrate a purple or blue glassy appearance. (Right) Osteosarcomas treated by specific chemotherapy regimens often show areas in which the infiltrating malignant cells are eliminated, leaving behind the neoplastic bone they had produced. Note that the overall permeative relationship with the host trabecular bone is retained.

P.II(3):29

**Microscopic Features**

(Left) As bone is produced, the neoplastic cells may become entrapped within it and will show a reduction in size and loss or decrease in cytologic atypia. This phenomenon has been described as normalization. (Right) Although the majority of osteosarcomas are osteoblastic (bone forming), some tumors demonstrate areas of malignant cartilage (chondroblastic osteosarcoma). Note the increased peripheral cellularity and presence of osteoid.
(Left) Some areas within an osteosarcoma may demonstrate a spindled and fascicular morphology (fibroblastic osteosarcoma). Neoplastic bone formation in these areas may be very focal or absent. (Right) This image shows a giant-cell-rich osteosarcoma. In these tumors, the osteoclastlike giant cells are often numerous and can lead to diagnostic confusion with other entities, such as malignant giant cell tumor and metastatic carcinoma containing giant cells.

(Left) This image shows an osteosarcoma with a prominent population of plump epithelioid malignant osteoblasts. This cellular morphology may mimic a metastatic osteoblastic carcinoma. Note the osteoid production. (Right) Most osteosarcomas contain hemorrhagic foci; however, in some cases these hemorrhagic and cystic changes are extensive (telangiectatic osteosarcoma). This variant resembles an aneurysmal bone cyst.

Rhabdomyosarcoma

Matthew R. Lindberg, MD

Key Facts

Terminology
- Malignant mesenchymal neoplasm that shows variable differentiation toward skeletal muscle
- Most common subtypes include embryonal (including botryoides), alveolar, spindle cell, sclerosing, and pleomorphic

Clinical Issues
Rhabdomyosarcomas (RMS) are most frequent soft tissue sarcomas in children and young adults
- Embryonal RMS (ERMS) subtype is most common
- Site varies depending on subtype; however, head and neck and extremities are common
- Multimodality approach to therapy (surgery, chemo, and radiation)
- Main prognostic parameters are histologic type, disease stage, and site
  - Pleomorphic and sclerosing subtypes are most aggressive

Macroscopic Features
- Tan-white fleshy to firm fibrous cut surface with hemorrhage, necrosis
- Botryoid variant of ERMS grows exophytically from mucosal surface

Microscopic Pathology
- Varies widely by subtype
- Rhabdomyoblasts most common in embryonal and spindle cell subtypes
- Wreath-like giant cells seen in ARMS

Ancillary Tests
- Desmin diffusely positive in most cases of RMS
- Myogenin and MYOD1 focally to diffusely positive

At low magnification, embryonal rhabdomyosarcoma (ERMS) characteristically shows a mixture of both hypercellular and hypocellular areas.
ERMS is generally composed of primitive spindled to ovoid cells with eosinophilic cytoplasm. Nuclear pleomorphism &/or anaplasia may be focal or diffuse.

TERMINOLOGY
Abbreviations
- Rhabdomyosarcoma (RMS)

Definitions
- Malignant mesenchymal neoplasm that shows variable differentiation toward skeletal muscle
- Most common subtypes include embryonal, alveolar, spindle cell, sclerosing, and pleomorphic

ETIOLOGY/PATHOGENESIS
Genetic Events
- Alveolar rhabdomyosarcoma (ARMS) has characteristic balanced translocations
  - t[2;13](q35;q14), PAX3-FOXO1
    - Most common (60% of cases)
  - t[1;13](p36;q14), PAX1-FOXO1
    - Approximately 15% of cases
- Embryonal and other subtypes of RMS do not show reproducible translocations

Genetic Associations
- Certain inherited diseases increase the risk of developing RMS
  - Li-Fraumeni syndrome
  - Neurofibromatosis type 1 (NF1)
  - Beckwith-Wiedemann syndrome
  - Costello syndrome
  - Noonan syndrome

CLINICAL ISSUES
Epidemiology
- Incidence
RMS is most frequent soft tissue sarcoma in children and young adults

- Embryonal rhabdomyosarcoma (ERMS) is most common subtype (60-70% of RMS)
- ARMS is 2nd most common subtype (30% of RMS)
- Spindle cell, sclerosing, and pleomorphic subtypes are much less common

**Age**
- Mostly children and adolescents
  - ERMS generally affects younger population than ARMS
- Most cases of RMS in adults are pleomorphic, spindle cell, and sclerosing subtypes
- Very rare cases of RMS are congenital

**Gender**
- M = F
  - Pleomorphic subtype more common in men

**Site**
- Embryonal subtype
  - Head and neck (particularly orbital and parameningeal sites)
  - Genitourinary region (bladder, prostate, paratesticular soft tissue)
  - Other sites including vagina, retroperitoneum, pelvis, biliary tract
  - Much less frequent involvement of trunk and limbs than ARMS
- Alveolar subtype
  - Most common in deep soft tissue of the extremities
  - Also head and neck, trunk, pelvis, retroperitoneum, perineum
- Pleomorphic subtype
  - Deep soft tissues of the extremities (particularly thigh)
  - Also abdomen, retroperitoneum, other sites
- Spindle cell subtype
  - Most common in head and neck region (50% of cases)
  - Paratesticular region
  - Retroperitoneum, extremities, vulva, other sites
- Sclerosing subtype
  - Extremities and head and neck sites are most common

**Presentation**
- Suddenly enlarging mass
  - Local symptoms pertaining to site of origin (e.g., deafness, proptosis in head and neck, or urinary retention in genitourinary sites)
- Most are painful, but may be painless

**Treatment**
- Multimodality approach
- Childhood RMS is generally sensitive to both chemotherapy and radiation therapy
- Complete resection is recommended, if possible

**Prognosis**
- Main prognostic parameters are histologic type, disease stage, and site
- Favorable sites are head and neck (nonparameningeal), genitourinary (nonbladder, nonprostate), and bile duct
- Botryoid and spindle cell variants in children and adolescents have better prognosis
  - Spindle cell subtype in adults is more clinically aggressive
- ERMS has significantly better prognosis than ARMS
- Pleomorphic subtype shows an aggressive clinical course with frequent metastases
- Sclerosing subtype also has a poor prognosis (often unresectable)

**MACROSCOPIC FEATURES**

**General Features**
- Varies in size (usually large)
- Tan-white fleshy to firm fibrous cut surface
- Margins usually infiltrative
- May contain hemorrhage, cystic degeneration, necrosis
- Botryoid RMS (variant of ERMS)
Exophytic, polypoid tumor arising from underneath a mucosal surface

More circumscribed margins

Gelatinous cut surface

MICROSCOPIC PATHOLOGY

Histologic Features

- Embryonal subtype
  - Wide variety of patterns
    - Often loose fascicles and sheets of spindled, stellate, &/or ovoid cells with hyperchromatic or vesicular nuclei
  - Variable cellularity and myxoid stroma
  - Rhabdomyoblasts variable in number
    - Cells with eccentric nuclei and variable amounts of eosinophilic cytoplasm
    - Cytoplasmic cross-striations may be visible
    - Varying shapes (strap cells, tadpole cells, spider cells)
  - Mitoses usually easily discernible
  - Necrosis
  - Botryoid RMS characteristically shows a tightly packed cellular layer of tumor cells (cambium layer) closely abutting the overlying epithelial surface
    - Often contains loose myxoid stroma and may be of relatively low cellularity
  - Anaplastic variant of ERMS shows marked nuclear anaplasia
    - Tumors with sheets of anaplastic cells rather than focal or scattered anaplasia associated with worse prognosis
    - Atypical mitotic figures
    - More conventional areas of ERMS are often present

- Alveolar subtype
  - Poorly differentiated round cells with hyperchromatic, relatively monomorphic nuclei and scanty cytoplasm
    - Nuclear anaplasia is very rare

P.II(3):32

- Sheets and nests of tumors cells separated by variably thick fibrous septae
  - Central necrosis and loss of cellular cohesion in tumor nests gives the tumor an alveolar appearance
  - Rare clear cell appearance
  - Rhabdomyoblasts can be present, but are less frequent than in ERMS
  - Multinucleated giant cells are characteristic, when present
    - Nuclei are arranged at periphery of giant cell (wreath cell)
  - Solid variant of ARMS lacks alveolar growth pattern but has similar cytromorphology to conventional ARMS
    - Solid sheets of neoplastic cells
    - Foci of more conventional ARMS may be present
    - More likely to be translocation negative

- Pleomorphic subtype
  - Densely cellular
  - Morphology is that of an undifferentiated pleomorphic sarcoma
    - Marked nuclear pleomorphism and anaplasia
    - Sheet-like, fascicular, or storiform growth patterns
    - Tumor cells have eosinophilic cytoplasm
    - Atypical mitotic figures and necrosis are common
  - Pleomorphic rhabdomyoblasts may be present

- Spindle cell RMS
  - Elongated spindled cells growing in a predominantly fascicular pattern
    - May have storiform foci
  - Nuclei can be vesicular or hyperchromatic
  - Mitoses common
    - Atypical figures more common in adult cases
  - Variable number of rhabdomyoblasts (spindled or polygonal)
  - Variable amounts of intervening collagen
No round cell or pleomorphic areas
Necrosis may be seen

- **Sclerosing subtype**
  - Hyalinized or sclerotic stroma
    - Can mimic osteoid or chondroid matrix (if myxoid)
  - Pseudovascular, microalveolar, cord-like, single cell strand patterns
  - Some areas are solid or fascicular
  - Composed of small round blue cells and spindle cells with scant eosinophilic or clear cytoplasm
  - Rhabdomyoblasts are rare

- **Mixed embryonal and alveolar RMS**
  - Presence of focal alveolar pattern is associated with reduced survival
  - Tumors with any evidence of alveolar features (morphologic or molecular) behave like and should be classified as ARMS

- **Post-chemotherapy RMS**
  - Cells often appear more differentiated
    - Larger, more mature rhabdomyoblasts are often evident
    - Possibly residual, better differentiated component is left after selective destruction of undifferentiated tumor cells
  - Fibrosis, myxoid changes, and necrosis are common

### ANCILLARY TESTS

#### Immunohistochemistry

- Desmin diffusely positive in most cases of RMS
  - Expression is more likely to be less diffuse or focal in embryonal and pleomorphic RMS
  - Perinuclear dot-like expression pattern in sclerosing RMS
- Myogenin and MYOD1 variably positive
  - Nuclear expression is specific for RMS
    - Cytoplasmic staining is nonspecific and should be disregarded
  - Expression in ARMS is characteristically strong and diffuse
    - Expression is usually more focal in other subtypes
  - MYOD1 is more likely to be expressed in sclerosing RMS than myogenin
- Variable positivity for smooth muscle actin
- H-caldesmon (-), S100(-)

#### Molecular Genetics

- Almost all RMS show regions of loss of heterozygosity (LOH)
- Most frequent LOH at chromosome 11
  - 80% of ERMS
  - Both long and short arms
  - LOH at 11p15.5 considered hallmark of ERMS
  - Genes located in 11p15.5 region include those encoding proteins involved in growth regulation
    - Subject to genomic imprinting (parent of origin-specific gene expression)
      - e.g., IGF2 (paternally expressed) and CDKN1C (maternally expressed)
  - Genetic alterations can lead to disruption of imprinted gene expression and cause disease
- ERMS lack PAX3/7-FOXO1 fusions characteristic of ARMS

### DIFFERENTIAL DIAGNOSIS

#### Embryonal RMS

- **Fetal rhabdomyoma**
  - Lacks mitoses, nuclear pleomorphism, necrosis
- **MPNST and malignant triton tumor**
  - Occur more commonly in adults
  - Desmin and myogenin expression limited to rhabdomyosarcomatous component, if present
- **Infantile fibrosarcoma**
  - Most occur congenitally or in first 2 years of life
  - Characteristic t(12;15) with NTRK3-ETV6 fusion
  - Does not express myogenic markers

#### Alveolar RMS

- **Ewing sarcoma**
  - Soft tissue examples typically occur in older age group than ARMS
  - Strong, diffuse membranous expression of CD99
  - Presence of t(11;22) (FLI1-EWSR1) or variants
- Desmoplastic small round cell tumor
  P.II(3):33
  - Keratin (+), desmin (+), myogenin (-)
  - Presence of t(11;22) (WT1-EWSR1)
- Leukemia/lymphoma
  - Absence of wreath cells
  - Expression of hematopoietic markers (e.g., CD45, CD3, CD20, TdT)
- Malignant extrarenal rhabdoid tumor
  - Predominantly infants
  - Prominent nucleoli are common
  - Loss of nuclear INI-1 by immunohistochemistry
  - Cytokeratin (+), desmin (-), myogenin (-)
- Neuroblastoma
  - NB84 (+), desmin (-), myogenin (-)
  - Infants and young children, often in characteristic locations (follows distribution of sympathetic ganglia)

### Pleomorphic RMS
- Pleomorphic leiomyosarcoma
  - Smooth muscle actin (+), desmin (+), H-caldesmon (+), myogenin (-)
  - Often shows better differentiated areas with typical cytoarchitectural features of leiomyosarcoma (fascicular bundles, cigar-shaped nuclei)
- Undifferentiated pleomorphic sarcoma
  - Lacks expression of myogenic markers
  - Distinction is largely academic prognostically
- Malignant triton tumor
  - Contains areas of conventional MPNST
  - Helpful to demonstrate origin from nerve, benign nerve sheath tumor, or within the setting of NF1

### Spindle Cell RMS
- Low-grade myofibroblastic sarcoma
  - No rhabdomyoblasts
  - Myogenin (-)
- Leiomyosarcoma
  - Intersecting fascicular architecture with cytologic features of smooth muscle differentiation (cigar-shaped nuclei)
  - Strong smooth muscle actin (+) and H-caldesmon (+); myogenin (-)
- Inflammatory myofibroblastic tumor
  - Prominent stromal inflammatory component, particularly plasma cells
  - ALK1 expression in most cases

### Sclerosing RMS
- Extraskeletal osteosarcoma
  - Usually highly pleomorphic
  - Negative for myogenic markers
- Angiosarcoma
  - Expresses vascular markers (CD31, CD34, ERG, etc.)
- Sclerosing epithelioid fibrosarcoma
  - Very similar histologically
  - Younger age group
  - May express MUC4; negative for myogenic markers

### SELECTED REFERENCES

### Tables

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Reactivity</th>
<th>Staining Pattern</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Desmin</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td></td>
</tr>
<tr>
<td>CD56</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td></td>
</tr>
<tr>
<td>Actin-sm</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>Variable positivity</td>
</tr>
<tr>
<td>WT1</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>Some tumors display cytoplasmic rather than nuclear staining</td>
</tr>
<tr>
<td>Myogenin</td>
<td>Positive</td>
<td>Nuclear</td>
<td>Cytoplasmic staining not diagnostic</td>
</tr>
<tr>
<td>MYOD1</td>
<td>Positive</td>
<td>Nuclear</td>
<td>Cytoplasmic staining not diagnostic</td>
</tr>
<tr>
<td>CD99</td>
<td>Positive</td>
<td>Cell membrane</td>
<td>Some tumors</td>
</tr>
<tr>
<td>AE1/AE3</td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caldesmon</td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD34</td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S100</td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Image Gallery

**Microscopic Features**

(Left) Some cases of embryonal RMS (ERMS) are very cytologically bland and may be confused with a benign lesion, such as fetal rhabdomyoma. Detection of mitotic activity, nuclear pleomorphism, &/or necrosis is helpful. (Right) Rhabdomyoblasts are commonly seen in embryonal and most other subtypes of RMS and are helpful in making the diagnosis. Depending on the morphology, they may be referred to as “strap cells” or “tadpole cells,” among other terms.
The botryoid variant of ERMS occurs in a mucosal location and often gives the macroscopic impression of a polyp or “bunch of grapes.” Another typical finding is a cambium layer, which is an increase in tumor cell density directly beneath the epithelium. (Right) Alveolar RMS is composed of relatively monomorphic small round cells with minimal cytoplasm arranged in nests divided by fibrous septae. Many nests typically show a central loss of cellular cohesion.

Another characteristic finding in alveolar RMS is the multinucleated giant cell with peripherally arranged nuclei (wreath cells). Although diagnostically useful when present, this cell type is usually very focal or completely absent. (Right) A small subset of cases of alveolar RMS are composed predominantly or exclusively of sheets of neoplastic cells without the usual nested and “pseudoalveolar” growth pattern. This is known as the solid variant of alveolar RMS.

P.II(3):35
Spindle cell RMS is composed of spindled neoplastic cells arranged in fascicles and loose storiform arrays. Rhabdomyoblasts are generally present but are often focal. These tumors have a predilection for the head and neck region. (Right) Pleomorphic RMS is usually characterized by diffuse cytologic anaplasia and is often impossible to distinguish from other pleomorphic sarcomas without IHC. Notably, pleomorphic RMS most commonly occurs in older adults.

(Left) Some pleomorphic RMS show sheets of large, eosinophilic rhabdoid cells with prominent cytoplasmic inclusions. Immunohistochemistry is usually necessary to distinguish this tumor from other similar malignancies. (Right) The sclerosing subtype of RMS shows small hyperchromatic cells within a sclerotic to myxochondroid stromal matrix. The sclerosis may be so prominent that it mimics a vascular neoplasm (particularly angiosarcoma) or other sclerosing malignancy.
Desmin is expressed to some degree in essentially all forms of RMS and is a good screening marker. One particular subtype (sclerosing RMS) is known to show a characteristic perinuclear dot-like pattern of expression.

Myogenin (MYO D1) is a specific marker of skeletal muscle derivation and is helpful in confirming a diagnosis of RMS. Expression may be very focal to diffuse. Most importantly, only nuclear expression is significant.

Schwannoma

Encapsulated, benign peripheral nerve sheath tumor composed predominantly of Schwann cells

Clinical Issues
- Common between 20 and 50 years
- Affects males and females equally
- Surgical excision is curative

Macroscopic Features
- Typically presents as eccentric mass loosely attached to underlying nerve

Microscopic Pathology
- Hallmark: Variable amounts of hypercellular Antoni A and hypocellular Antoni B areas
- Spindle cells in short fascicles in Antoni A areas
- Loose matrix with cystic change and inflammatory cells in Antoni B areas
- Bland nuclear features in most instances; degenerative nuclear atypia in “ancient” schwannoma
- Cellular schwannoma may mimic MPNST
- Plexiform schwannoma usually seen in children
- Epithelioid schwannoma may be mistaken for smooth muscle tumor
- Melanotic psammomatous schwannoma often associated with Carney complex
- Schwannomas in NF2 and schwannomatosis are similar to sporadic tumors
- Microcystic/reticular schwannoma has predilection for visceral location

Ancillary Tests
- Diffuse, strong S100 positivity is characteristic
Schwannoma is a common soft tissue neoplasm that occurs most often in the superficial extremities and characteristically shows areas of varying cellularity with a prominent vascular background.
Schwannoma is classically described as having both cellular (Antoni A) and hypocellular (Antoni B) regions. Antoni B zones often contain degenerative changes.

TERMINOLOGY
Definitions
- Encapsulated, benign peripheral nerve sheath tumor composed predominantly of Schwann cells

ETIOLOGY/PATHOGENESIS
Molecular Aberrations
- Somatic NF2 gene mutations present in most tumors
- Bilateral vestibular schwannomas occur in setting of germline NF2 gene mutations

CLINICAL ISSUES
Epidemiology
- Incidence
  - 90% are sporadic
  - 10% are syndromic
    - ~3% with neurofibromatosis type 2 (NF2)
    - 2% with schwannomatosis
    - 5% with multiple meningiomas
    - Rarely in association with neurofibromatosis type 1 (NF1)
- Age
  - All ages
  - Common between 20 and 50 years
- Gender
  - Affects males and females equally

Site
- Head & neck
- Upper and lower extremities
• Deep-seated tumors occur in mediastinum and retroperitoneum

Presentation
• Slow growing
• Painless mass
  o Large tumors may be painful
• Cystic tumors may show fluctuation in size

Treatment
• Surgical excision is curative

Prognosis
• Excellent

Multiple Schwannoma Syndromes
• Neurofibromatosis type 2
  o Autosomal dominant condition
  o Incidence is ~ 1:30,000-40,000
  o Inactivating germline mutations of NF2 gene on chromosome 22
  o Bilateral vestibular schwannomas are characteristic
  o Schwannomas involving other cranial nerves may be present
  o CNS tumors, such as meningioma, ependymoma, and gliomas, are also part of disease spectrum
  o Schwannomas in NF2 resemble their sporadic counterparts

• Schwannomatosis
  o Not associated with germline mutations in NF1 or NF2 genes
  o Autosomal dominant inheritance with incomplete penetrance
  o Both sexes affected equally
  o Patients do not develop bilateral vestibular schwannomas or CNS tumors as seen in NF2
  o Locus of disease has been mapped to chromosome 22 proximal to NF2 gene
  o Morphology similar to sporadic schwannomas

MACROSCOPIC FEATURES
General Features
• Surrounded by true capsule consisting of epineurium
P.II(3):37

  • Eccentric mass loosely attached to underlying nerve
  • Small tumors may be fusiform in shape and mimic neurofibroma
  • Dumbbell-shaped tumors occur in vertebral canal, usually in posterior mediastinum
  • Cut surface is pink, white-yellow
  • Large tumors may show cystic change, hemorrhage, or calcification

Size
• Variable

MICROSCOPIC PATHOLOGY
Histologic Features
• Uninodular mass with fibrous capsule
• Hallmark: Variable amounts of hypercellular Antoni A and hypocellular Antoni B areas

  • Antoni A
    o Spindle cells in short fascicles
    o Plump nuclei, indistinct cytoplasmic borders
    o Intranuclear vacuoles in some tumors
    o Nuclear palisading or whorling
    o Verocay bodies
      • Compact rows of palisaded nuclei separated by fibrillary processes

  • Antoni B
    o Spindle or oval cells
    o Loose matrix with cystic change and inflammatory cells
    o Large vessels with thick hyalinized walls and luminal thrombi

• Benign epithelial structures and glands may be present in rare instances

Cytologic Features
• Bland nuclear features in most instances

Variants
• “Ancient” schwannoma
  o Marked nuclear atypia of degenerative type
  o Usually seen in deep-seated large tumors of long duration
  o Cystic change, hemorrhage, calcification, and hyalinization present
  o Lacks mitotic activity
  o Behavior is similar to ordinary schwannoma

• Cellular schwannoma
  o Composed almost exclusively of hypercellular Antoni A areas, which lack Verocay bodies
  o More common in mediastinum and retroperitoneum
  o Encapsulated tumors; some may be multinodular or plexiform in architecture
  o Long sweeping fascicles of spindle-shaped cells
  o Mitotic activity is generally low (< 4/10 HPF)
  o Small foci of necrosis may be present
  o Diffuse strong S100 positivity distinguishes cellular schwannoma from malignant peripheral nerve sheath tumors (MPNSTs)

• Plexiform schwannoma
  o Usually involves skin
  o Infrequent in deeper locations
  o Encapsulated tumors with multinodular or plexiform architecture
  o Often more cellular than ordinary schwannoma
  o Association with neurofibromatosis is weak (unlike plexiform neurofibroma, which is almost pathognomonic of NF1)

• Epithelioid schwannoma
  o Small round Schwann cells with eosinophilic cytoplasm and sharp cell borders
  o Arranged in clusters, cords, or as single cells
  o Stroma is collagenous or myxoid
  o Foci of typical schwannoma may be present
  o Degenerative nuclear atypia may be seen
  o Lacks mitotic activity
  o Immunostains for S100 and type IV collagen are positive

• Melanotic psammomatous schwannoma
  o Distinctive tumor of adults (average age ~ 33 years) that often arises in spinal or autonomic nerves near midline
  o ~ 50% of patients have evidence of Carney complex (cardiac myxoma, spotty pigmentation, endocrine overactivity, acromegaly, or sexual precocity)
  o Multiple tumors may be present in 20% of patients
  o Pigmentation may be heavy and mask underlying tumor morphology
  o Syncytial arrangement of spindle to ovoid cells with prominent nucleoli and intranuclear inclusions
  o Psammoma bodies are present in most cases
  o Tumors express not only S100 but also HMB-45
  o Difficult to predict behavior since bland-appearing tumors have also been known to metastasize
  o Overall, metastasis occurs in ~ 26% of cases

• Neuroblastoma-like schwannoma
  o Schwann cells are round and small in this variant and cluster around large collagen cores
  o Mimics rosettes seen in neuroblastoma

• Pseudoglandular schwannoma
  o Prominent cystic change
  o Cystic spaces are lined by small round tumor cells
  o Mimics epithelial neoplasm

• Microcystic/reticular schwannoma
  o Anastomosing strands of spindle cells in myxoid, fibrillary, or collagenous matrix
  o Predilection for visceral location
  o Mimics reticular perineurioma

• Malignant transformation in schwannomas
  o Extremely rare
  o Malignant change in schwannomas usually resembles epithelioid MPNST
ANCILLARY TESTS
Immunohistochemistry
- Diffuse, strong S100 positivity is characteristic
- LEU-7 and GFAP may be positive in some tumors

Electron Microscopy
- Transmission
  - Almost exclusively composed of Schwann cells
  - Basal lamina with electron-dense material lines surface of Schwann cells
  - Flat invaginated nucleus and attenuated cell processes
  - Increased lysosomes in Schwann cells in Antoni B areas

DIFFERENTIAL DIAGNOSIS

Leiomyoma
- Nuclear palisading is also seen in smooth muscle tumors and may mimic schwannoma
- Leiomyomas lack Antoni A and Antoni B areas
- Leiomyomas are positive for desmin and smooth muscle actin and are negative for S100

MPNST
- Cellular schwannomas may be mistaken for MPNST
- Plexiform schwannomas are also cellular and may be mistaken for MPNST arising in plexiform neurofibroma
- MPNSTs show greater nuclear atypia, necrosis, and only focal S100 positivity, unlike benign schwannoma variants, which are diffusely S100 positive

Malignant Melanoma
- Melanotic schwannomas may be mistaken for melanoma due to coexpression of S100 and HMB-45
- Melanotic schwannomas do not have degree of nuclear atypia or mitotic activity seen in malignant melanoma
- Psammoma bodies are present in melanotic schwannoma but not in metastatic melanomas

DIAGNOSTIC CHECKLIST

Pathologic Interpretation Pearls
- Encapsulated tumor with alternating hypercellular and hypocellular areas with diffuse strong S100 positivity

SELECTED REFERENCES

Tables
Microscopic Features
A common finding in schwannomas is the formation of Verocay bodies within the cellular Antoni A zones, defined as palisading rows of nuclei around a pink fibrillary core. It is important to note, however, that nuclear palisading can be seen in a variety of other tumors and is therefore nonspecific. In some cases of schwannoma, Verocay bodies may be prominent and extensive. However, in other cases, they may be focal or even absent.

Schwann cell nuclei are generally small, elongated, and wavy or “buckled,” similar to what is seen in other neural tumors, although larger, rounder nuclei are not uncommon. Of note, prominent nuclear pleomorphism and mitotic activity are not features of this neoplasm. The interface between Antoni A and Antoni B areas is often quite abrupt in many cases of schwannoma and is a helpful clue to at least suggest the diagnosis.
Thick, hyalinized blood vessels are common in schwannoma, particularly in Antoni B zones. This finding is in no way pathognomonic, but it should prompt consideration of diagnosis. Antoni B zones in schwannoma typically contain a variety of degenerative changes including hyalinized vessels, xanthomatosus (foamy) and chronic inflammation, and cystic stromal degeneration. Some tumors may appear to completely lack Antoni A zones.

P.II(3):40

Variant Microscopic Features

Schwannoma is 1 of the few encapsulated soft tissue neoplasms. Note the thick fibrous capsule overlying the main tumor. A common finding in Antoni B areas is the presence of enlarged, hyperchromatic, “smudgy” nuclei, which may be focal or extensive. Although alarming at first, this change is a degenerative phenomenon and should not suggest malignancy. Furthermore, mitoses are rare to nonexistent in these tumors, supporting their benign nature.
The degenerative, “smudgy” quality of the nuclei is better appreciated at higher magnification. This finding has also been described as “ancient change.” A subset of schwannomas are composed almost entirely (> 90%) of Antoni A areas and are classified as cellular schwannomas. This variant can simulate a malignant peripheral nerve sheath tumor, but other typical features of schwannoma (e.g., small size, encapsulation, strong S100 protein expression) are often present.

Many cellular schwannomas (particularly visceral cases) demonstrate a lymphocytic cuff at the periphery, which is often patchy. This finding can be very useful in suggesting a diagnosis of schwannoma in difficult cases with unusual morphologies. An epithelioid morphology can also be seen in some cases of schwannoma and may be focal or extensive (epithelioid schwannoma). The epithelioid Schwann cells often cluster together in small aggregates.

Microscopic Features
In some cases of epithelioid schwannoma, the cells may be larger than usual with prominent nucleoli, similar to epithelioid malignant peripheral nerve sheath tumor. Importantly, the former contain few, if any, mitoses. (Right) Plexiform schwannomas contain many features of ordinary or cellular schwannoma but show a unique multinodular growth pattern. They are also more likely to occur in cutaneous locations and have no association with neurofibromatosis.

Pseudoglandular schwannoma is a rare variant that may be mistaken for an epithelial neoplasm. Fortunately, they often contain more conventional areas of schwannoma, and they may show a peripheral lymphocytic cuff. (Right) Melanotic psammomatous schwannoma is an unusual variant associated with Carney complex. In contrast to conventional schwannoma, this tumor contains extensive melanin pigmentation and often shows psammomatous calcifications.
(Left) An interesting but rare variant of schwannoma demonstrates the formation of hyalinized rosettes, similar to what is seen in neuroblastoma. As in other schwannoma variants, this tumor may show areas of conventional morphology. (Right) Strong and diffuse cytoplasmic and nuclear expression of S100 protein is a highly characteristic and reliable finding in schwannoma and all of its morphologic variants. This strong expression is uncommon in malignant neural tumors.

Section 4 - Head and Neck

Squamous Cell Carcinoma, Head and Neck

Vania Nosé, MD, PhD

Key Facts

Terminology
- Malignant neoplasm characterized by squamous cell differentiation arising from squamous epithelium

Etiology/Pathogenesis
- Genetic
  - Dyskeratosis congenita
  - Fanconi anemia
  - Xeroderma pigmentosum
  - Bloom syndrome
- Iron deficiency (Plummer-Vinson syndrome) associated with elevated risk of squamous cell carcinoma (SCC)
- Tobacco use, alcohol consumption, gastroesophageal reflux, chronic inflammation, nickel exposure
- Oncogenic viruses: Human papillomavirus (HPV) and Epstein-Barr virus (EBV)

Microscopic Pathology
- SCC is generally divided into multiple categories
  - Histologic categories: In situ, superficially invasive, or deeply invasive
  - Histologic grade includes well-, moderately, and poorly differentiated SCC
  - Divided into keratinizing and nonkeratinizing

Top Differential Diagnoses
- Nasal cavity SCC
  - Schneiderian papillomas
  - NUT midline carcinoma
- Tongue and laryngeal SCC
  - Pseudoepitheliomatous hyperplasia
  - Necrotizing sialometaplasia
  - Radiation changes
Coronal view through the mid oral cavity shows a lateral dorsal squamous cell carcinoma (SCC) that has grown into the deep muscles of the tongue and into the cortical bone of the mandible.
Well-differentiated SCC shows basement membrane violation with islands of malignant cells arising from the overlying epithelium invading into the lamina propria as a single or a group of cells with focal keratinization.

**TERMINOLOGY**

**Abbreviations**
- Squamous cell carcinoma (SCC)

**Synonyms**
- Epidermoid carcinoma (general for head and neck carcinomas)
- Sinonasal carcinoma
- Transitional carcinoma
- Respiratory epithelial carcinoma
- Cylindrical cell carcinoma

**Definitions**
- Malignant neoplasm characterized by squamous cell differentiation arising from squamous epithelium

**ETIOLOGY/PATHOGENESIS**

**Genetic Predisposition for Head and Neck Squamous Cell Carcinoma**
- Dyskeratosis congenita
  - TERT, TERC, DKC1, TINF2, and other genes involved in telomere maintenance
  - Squamous cell carcinoma of head and neck and squamous cell carcinoma of tongue
  - Other manifestations
    - Skin cancer, anorectal carcinoma, gastric carcinoma, lung carcinoma, colonic carcinoma, esophageal carcinoma, Hodgkin lymphoma, and retinoblastoma, among others
- Fanconi anemia
  - 13 separate genes (FANCx) comprise the Fanconi anemia pathway
  - Squamous cell carcinoma of head and neck
  - Other manifestations
    - Short stature
- Eye abnormalities
- Wilms tumor
- Hematologic neoplasms: Cumulative incidence of hematologic malignancy is 25% by age 45; predominantly myeloid malignancies, acute myeloid leukemia, and other hematopoietic abnormalities; 500X increased risk of acute myeloid leukemia (AML), 5,000X increased risk of myeloplastic syndrome (MDS)
- Solid tumors as squamous cell carcinoma (esophagus, anogenital, and cervix)
- Hepatocellular carcinoma
- Brain tumors
- Breast cancer susceptibility

- Xeroderma pigmentosum (XP)
  - Genes involved in nucleotide excision repair of ultraviolet light-induced damage: XPA-XPG
  - Squamous cell carcinoma of tongue (100,000X increase in XP patients; disease manifests 20 years earlier than in general population)
- Other manifestations
  - Carcinomas and sarcomas of skin
  - Melanomas
  - Ocular cancer
  - Brain tumors (medulloblastomas and glioblastomas)
  - Spinal cord astrocytomas
  - Carcinomas of lung, uterus, breast, stomach, kidney, and testicular
  - Leukemias
  - Multiple benign tumors

- Bloom syndrome
  - BLM: Tumor-suppressor gene that belongs to family of RecQ DNA helicase
  - Squamous cell carcinoma of head and neck
- Other manifestations
  - Up to 50% of patients will develop a malignancy
  - Hematolymphoid malignancies predominant in the first 2 decades of life
  - Carcinomas predominant after first 2 decades of life and arise in varied sites, including skin, head and neck, lung, uterus, breast, and gastrointestinal tract, including esophagus (both squamous cell carcinoma and adenocarcinoma), stomach, and colon
  - Medulloblastoma
  - Wilms tumor
  - Osteosarcoma

- Other syndromes

Environmental Exposure
- Laryngeal SCC
  - Tobacco use (e.g., cigarette, cigar, pipe, smokeless)
  - Alcohol consumption: Independent of tobacco but multiplicative if both are used
    - Maté drinking is a suggested risk factor
  - Gastroesophageal reflux or laryngopharyngeal reflux (chronic inflammation as a mutagen)
  - Radiation exposure (therapeutic and environmental)
  - Occupational factors/exposures
  - Protective effect by high intake of fruits and vegetables

- Tongue SCC
  - Tobacco use
  - Alcohol consumption
  - Nutritional deficiencies
    - Iron deficiency (Plummer-Vinson syndrome) associated with elevated risk of SCC
  - Betel quid (a.k.a. paan): Combination of betel leaf and 1 or more other ingredients (e.g., areca palm nuts, slaked lime, tobacco)
  - Radiation exposure (ultraviolet and therapeutic)

- Nasal
  - Nickel exposure
  - Textile dust
Infectious Agents

- **Tongue SCC**
  - Oncogenic virus: HPV, high-risk type associated with development of tonsil and base of tongue cancer
    - Relationship to oral SCC is not as convincing
  - Can develop from area of leukoplakia or erythroplakia
  - Malignant transformation of severe dysplasia or carcinoma in situ
- **Laryngeal SCC**
  - HPV, human herpesvirus 8 (HHV-8), EBV may have a minor causative role
- **Nasal and sinonasal SCC**
  - HPV

Developmental

- **Nasal SCC**: May develop from sinonasal (schneiderian) papilloma
  - Majority transform to keratinizing SCC
  - Majority arise in association with inverted-type sinonasal papilloma

CLINICAL ISSUES

Presentation

- Depending on location of head and neck SCC
  - Glottic tumors: Hoarseness is earliest symptom
  - Supraglottic &/or hypopharyngeal tumors: Dysphagia, changes in phonation, foreign body sensation in throat, and odynophagia
  - Subglottic tumors: Dyspnea and stridor most common
  - Tracheal tumors: Dyspnea, stridor, cough, and hemoptyis
  - Neck mass (lymph nodes) more common in transglottic tumors
  - Tongue: Difficulty eating and swallowing, sore that does not heal, dentures that fit poorly, loose teeth
  - Nasal cavity: Unilateral obstruction, nonhealing sore, rhinorrhea, epistaxis, mass, or pain
  - Maxillary sinus: Early symptoms often confused with sinusitis resulting in delay in diagnosis; with progression of disease, grouped in 5 categories

MACROSCOPIC FEATURES

General Features

- Gross findings vary depending on origin and location of tumor

MICROSCOPIC PATHOLOGY

Histologic Features

- SCC is generally divided into multiple categories
  - Histologic categories:
    - Squamous cell carcinoma in situ
    - Squamous cell carcinoma, superficially invasive
    - Squamous cell carcinoma, deeply invasive
  - Histologic grade includes well-, moderately, and poorly differentiated SCC
    - Grade 1 (well differentiated): Resembles normal squamous epithelium but shows invasion
    - Grade 2 (moderately differentiated): Easily identified nuclear pleomorphism, loss of polarity, disorganization, increased mitotic activity, usually less keratinization
    - Grade 3 (poorly differentiated): Immature cells predominate, high nuclear to cytoplasmic ratio, limited keratinization, numerous typical and atypical mitoses
  - Keratinization: Absent or present and divided into
    - Squamous cell carcinoma, keratinizing
Squamous cell carcinoma, nonkeratinizing

Variants of SCC
- Verrucous carcinoma
- Basaloid SCC
- Spindle cell squamous carcinoma
- Adenosquamous carcinoma
- Papillary SCC
- Lymphoepithelial carcinoma
- Acantholytic squamous cell carcinoma (pseudoglandular or adenoid)
- Carcinoma cuniculatum

ANCILLARY TESTS

Cytogenetics
- Molecular genetics of oral SCC
  - Loss of heterozygosity commonly noted at 3p (FHIT), 9p (CDKN2A), 17p (TP53)
  - Mutations in TP53, a tumor suppressor gene, increases with tobacco smoking
  - Overexpression of cyclooxygenase-2 (COX-2) may play a future role for targeted molecular therapy
- Molecular genetics of laryngeal SCC
  - TP53 mutations are early event in SCC but not a prognostic marker
  - EGFR may be amplified, but it is not overexpressed
  - Cytogenetics and comparative genomic hybridization show +3q21-29 and -3p
  - CCND1 is amplified and overexpressed; expression is lower in metastatic tumors
  - MMP13 expression and MMP14 overexpression are associated with advanced tumors
  - Losses at 8p, 9q, and 13 are more frequent in metastatic than in primary tumors

DIFFERENTIAL DIAGNOSIS

Nasal Cavity SCC
- Schneiderian papillomas
- NUT midline carcinoma
- Sinonasal undifferentiated carcinoma (SNUC)

Tongue SCC
- Pseudoepitheliomatous hyperplasia
- Necrotizing sialometaplasia
- Radiation changes

Laryngeal SCC
- Pseudoepitheliomatous hyperplasia (PEH)
- Radiation changes
- Squamous papilloma
- Necrotizing sialometaplasia

SELECTED REFERENCES
P.II(4):5
Squamous cell carcinoma can arise from nasal cavity and paranasal sinus. This coronal graphic illustrates the anatomic separations of the maxillary sinus from the nasal cavity, ethmoid sinus, and orbit. (Right) This coronal graphic illustrates the presence of a lobular inverted papilloma centered at the middle meatus. The lesion enters the maxillary sinus via an enlarged infundibulum. This may be a precursor lesion of SCC.

Basic anatomic landmarks of the larynx are used in accurate classification and separation of specific tumors into location and stage. The vocal cords are used to separate tumors into supraglottic, glottic, and subglottic regions, one of the most useful staging parameters. Extension into cartilage or across membranes also changes tumor stage. A large supraglottic tumor fills the laryngeal side of the epiglottis with expansion into thyroid cartilage and bone.
The oropharynx, highlighted in purple, includes the base of tongue (posterior 1/3), vallecula, tonsil, tonsillar fossa and pillars, inferior surface of the soft palate and uvula, and posterior wall of the pharynx. (Right) This oropharyngeal SCC is large and extends from the base of tongue to vallecul, involves the oropharynx and nasopharynx, and extends into the posterior nasal cavity. SCC of the tongue may be associated with dyskeratosis congenita and xeroderma pigmentosum.

P.II(4):6

Nasal Cavity Squamous Cell Carcinoma

(Left) Coronal graphic demonstrates a tumor involving the maxillary sinus with extension into bone. This squamous cell carcinoma may develop from a sinonasal papilloma and be associated with a few familial syndromes. (Right) Patients with hereditary retinoblastoma develop diverse neoplasms and may also develop an SCC of nasal cavity. This is a typical microscopic feature of nonkeratinizing SCC formed by sheets of basaloid cells with sharply defined borders. No stromal reaction is seen in the tumor.
Most of the SCC of nasal cavity and paranasal sinuses are of the well-differentiated keratinizing type and may be 1 of the neoplasms occurring in patients with hereditary retinoblastoma. This picture shows widened and downwardly growing rete, marked dysplastic cellular changes, and, focally, violation of the basement membrane by tumor cells.

This picture illustrates p16 positivity in an SCC. HPV, high-risk type, may be associated with development of head and neck SCC.

Nonkeratinizing SCC originates from the surface epithelium, invades into the submucosa as broad bands of neoplastic epithelium growing down, and very frequently invades adjacent bone. (Right) A sinonasal, invasive, keratinizing welldifferentiated SCC shows a nest of carcinoma cells within the bone and is associated with marked desmoplastic reaction.

Oropharyngeal Squamous Cell Carcinoma
SCC of head and neck may be associated with dyskeratosis congenita (DC) and Fanconi anemia. SCC of tongue is seen in patients with xeroderma pigmentosum (XP) and DC. This picture illustrates a keratinizing invasive SCC of tongue in a patient with DC. (Right) An invasive nonkeratinizing SCC may show only focal keratinization (< 10% of the tumor). Note that the basement membrane is violated and cells are present in lamina propria.

This invasive, keratinizing, well-differentiated SCC shows islands of malignant epithelial cells invading into deeper tissues with extensive keratin pearl formation and formation of a large mass of keratin. (Right) Higher magnification of a well-differentiated SCC shows violation of the basement membrane by groups of malignant epithelial cells associated with inflammatory cell infiltrate. Dyskeratotic cells are seen throughout. A keratin pearl is present.
Endolymphatic Sac Tumor

Endolymphatic Sac Tumor

Machiya Nishino, MD, PhD
Vania Nosé, MD, PhD

Key Facts
Terminology
- Rare, slowly growing, locally invasive but nonmetastasizing papillary neoplasm arising from endolymphatic sac within temporal bone

Clinical Issues
- Association with von Hippel-Lindau (VHL) disease
- Presentation: Meniere-like clinical syndrome of hearing loss, tinnitus, & vertigo; aural fullness; facial nerve dysfunction

Microscopic Pathology
- Papillary, tubular, &/or cystic structures lined by single layer of cuboidal/columnar cells with pale eosinophilic to clear cytoplasm

Ancillary Tests
- Positive: Cytokeratins (CK7, CK8, CK19, CAM5.2, 34bE12), vimentin, vascular endothelial growth factor (VEGF)
- Negative: CK10/13, CK20, chromogranin, synaptophysin

Top Differential Diagnoses
- Middle ear adenoma/carcinoid tumor
  - a.k.a. neuroendocrine adenoma of middle ear
- Ceruminous gland adenoma/adenocarcinoma
- Meningioma
- Paraganglioma
- Heterotopic or primary choroid plexus papillomas of cerebellopontine angle (CPA)
- Metastatic carcinoma
Axial graphic of temporal bone shows the typical appearance of endolymphatic sac tumor. The tumor is vascular, shows a tendency to fistulize the inner ear, and contains bone fragments within the tumor matrix.
Endolymphatic sac tumors typically show a papillary architecture with fibrovascular cores and a single row of eosinophilic cuboidal epithelium. Nuclei are ovoid with fine chromatin.

**TERMINOLOGY**

**Abbreviations**
- Endolymphatic sac tumor (ELST)

**Synonyms**
- Endolymphatic sac papillary tumor
- Papillary adenoma of endolymphatic sac
- Adenoma/adenocarcinoma of temporal bone
- Low-grade adenocarcinoma of endolymphatic sac
- Aggressive papillary cystadenomas of endolymphatic sac
- Heffner tumor

**Definitions**
- Rare, slowly growing, locally invasive but nonmetastasizing papillary neoplasm arising from endolymphatic sac within temporal bone

**ETIOLOGY/PATHOGENESIS**

**Genetic Predisposition**
- von Hippel-Lindau (VHL) disease
  - Prevalence: 1 in 39,000 people
  - Autosomal dominant inheritance
  - Germline mutation in VHL tumor suppressor gene on chromosome 3p25
    - VHL protein (pVHL): E3 ubiquitin ligase that marks certain proteins (e.g., alpha subunits of hypoxia-inducible factors [HIF]) for degradation
  - Somatic inactivation or loss of remaining wild-type VHL allele leads to characteristic manifestations
    - Retinal & central nervous system hemangioblastomas
    - Pheochromocytoma
Renal cysts & renal cell carcinoma
Pancreatic cysts, cystadenomas, carcinomas, & islet cell tumors
Epididymal papillary cystadenoma (men)
Female adnexal tumor of probable wolffian origin (FATWO)
ELST

- 2 types of VHL disease based on absence/presence of pheochromocytoma
  - Type 1 VHL: Pheochromocytoma absent
  - Type 2 VHL: Pheochromocytoma present

- ~ 10% of patients with ELSTs have VHL disease
  - Conversely, ~ 15% of patients with VHL disease have radiographically detectable ELSTs

**Histogenesis**

- Endolymphatic sac
  - Endolymph-filled, neuroectodermally derived, nonsensory component of membranous labyrinth
  - Paddle-shaped structure consisting of complex network of interconnecting tubules
  - Connected to utricular & saccular ducts by endolymphatic duct

- Specific precursor lesions for ELSTs: Not well characterized

**CLINICAL ISSUES**

**Epidemiology**

- **Incidence**
  - ELSTs are detected by MR or CT in ~ 15% of patients with VHL disease
  - 60% of VHL patients with vestibulocochlear symptoms may have microscopic ELSTs that are not visible by MR or CT imaging studies
  - Compared to sporadic cases, ELSTs in VHL patients are associated with the following (some features may be due to increased screening by imaging in VHL patients)
    - Younger patients
    - Less advanced
    - Bilateral tumors (30% of VHL patients with ELSTs have bilateral tumors)

- **Age**
  - 2nd-8th decades of life
  - Rare pediatric cases have been reported

- **Gender**
  - 2x female predominance among VHL patients

- **Site**
  - Posteromedial region of petrous portion of temporal bone (site of normal endolymphatic sac)

- **Presentation**
  - VHL patients with evidence of ELST by imaging may show following symptoms
  - Meniere-like clinical syndrome of hearing loss in 95%, tinnitus in 92%, & vertigo in 62%
    - Hearing loss: Usually irreversible; mean age of onset: 22 years
      - Typically sensorineural rather than conductive hearing loss
      - Acute & clinically significant in 43%
      - Subacute & progressive (over 3-6 months) in 43%
      - Gradual hearing loss in 14%
  - Aural fullness in 29%
  - Facial nerve dysfunction in 8%

- **Laboratory Tests**
  - VHL patients should undergo serial audiologic tests & high-resolution imaging studies for early detection of small ELSTs
  - Conversely, all patients with ELSTs should be screened for other signs & symptoms of VHL disease

- **Treatment**
  - Early & complete surgical resection: Relieves hearing & vestibular symptoms, prevents permanent neurologic deficits

- **Prognosis**
  - Slowly growing tumor with potential for local destruction & extension into vital structures
  - Invasion into posterior cranial fossa and brain can result in meningitis and death

**IMAGE FINDINGS**
CT and MR Findings
- Contrast-enhancing lytic lesion
- Typically 4-6 cm in greatest dimension
- Location: Posteromedial aspect of petrous portion of temporal bone
- Radiographic differential diagnosis includes inflammatory, cystic, & neoplastic lesions involving temporal bone

Angiography Findings
- Well-vascularized lesion with tumoral blush

MACROSCOPIC FEATURES
Size
- Variable; can measure up to several cm

MICROSCOPIC PATHOLOGY
Histologic Features
- Architecture: Papillary, tubular, &/or cystic structures lined by single layer of epithelial cells
  - Cystic structures may contain eosinophilic colloidlike fluid, resembling thyroid follicles
  - Variously cellular stroma ± small blood vessels ± fibrosis
  - Hemorrhage, hemosiderin, cholesterol clefts, & chronic inflammatory cells may be present

Cytologic Features
- Cuboidal to columnar cells with pale eosinophilic to clear cytoplasm
- Typically uniform, ovoid nuclei ± intranuclear pseudoinclusions
- Finely granular chromatin

Ancillary Tests
Histochemistry
- Periodic acid-Schiff (PAS) - diastase
  - Reactivity: PAS(+)/diastase-sensitive glycogen globules
  - Staining pattern
    - Intracytoplasmic

Immunohistochemistry
- Positive: Cytokeratins (CK7, CK8, CK19, CAM5.2, 34bE12), vimentin, vascular endothelial growth factor (VEGF)
  - Weak &/or focal: S100 (nuclear and cytoplasmic), CD34, neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), and epithelial membrane antigen (EMA)
- Negative: CK10/13, CK20, chromogranin, synaptophysin

Molecular Genetics
- In patients with germline mutations in VHL, fluorescence in situ hybridization (FISH) can show loss of remaining wild-type VHL allele (genetic “second hit” leading to tumor formation) in ELSTs

Electron Microscopy
- Scant microvilli, luminal glycocalyx, intercellular junctions, and basement membrane formation
- Abundant cytoplasmic glycogen, filaments, rough endoplasmic reticulum, & few secretory granules

SELECTED REFERENCES

Tables

<table>
<thead>
<tr>
<th>Tumor</th>
<th>Site</th>
<th>Architecture</th>
<th>Cytology</th>
<th>IHC: Positive</th>
<th>IHC: Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>ELST</td>
<td>Petrous portion of temporal bone</td>
<td>Papillary, tubular, cystic</td>
<td>Cuboidal to columnar cells; pale eosinophilic to clear cytoplasm; and CAM5.2, synaptophysin, chromogranin, various cytokeratins including CK7, CK20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor Type</td>
<td>Site</td>
<td>Histologic Description</td>
<td>Immunohistochemistry</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------------------</td>
<td>-------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Middle ear adenoma (neuroendocrine adenoma of middle ear [NAME])</td>
<td>Middle ear cavity of temporal bone</td>
<td>Glandular, trabecular, cords, single cells</td>
<td>Luminal cells (pankeratin, CAM5.2, CK7); basal cells (pankeratin, CAM5.2, synaptophysin, chromogranin)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ceruminous adenoma</td>
<td>External auditory canal, outer portion</td>
<td>Glandular and cystic</td>
<td>Luminal cells (pankeratin, EMA, CK7); basal cells (pankeratin, EMA, CK5/6, p63, S100, CD117)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningioma</td>
<td>Jugular foramen and internal auditory canal region of temporal bone</td>
<td>Infiltrative lobules and nests with whorled, syncytial pattern</td>
<td>Pankeratin, CAM5.2, EMA, S100 (weak)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paraganglioma</td>
<td>Middle ear (glomus tympanicum paraganglioma) or jugular foramen (glomus jugulotympanicum paraganglioma) regions of temporal bone</td>
<td>Ball-like clusters of tumor cells (“zellballen” architecture)</td>
<td>Chromogranin, Pankeratin synaptophysin, NSE, CD56; S100 and GFAP positive in sustentacular cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choroid plexus papilloma</td>
<td>Extraventricular tumors can occur at the cerebellopontine angle</td>
<td>Papillary, tubular, glandular</td>
<td>Pankeratin, vimentin; variable staining with transthyretin, S100, GFAP, synaptophysin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metastatic carcinoma</td>
<td>Variable</td>
<td>Variable</td>
<td>Distinguishing markers include TTF-1 (thyroid or</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
(Left) This low-magnification view highlights the papillary architecture of endolymphatic sac tumors (ELSTs) with their branching fibrovascular cores and single layer of cuboidal epithelium. (Right) Another low-magnification view of an ELST demonstrates the characteristic papillary architecture.

(Left) A glandular structure with colloid-like material in the lumen is shown. The epithelium is cuboidal with pale cytoplasm and uniform, ovoid nuclei. (Right) The papillae of this ELST is lined by columnar epithelium with pale eosinophilic cytoplasm. Mast cells can occasionally be seen in the fibrovascular cores. Nuclei are ovoid with fine chromatin, variably prominent nucleoli, and scattered intranuclear pseudoinclusions.
A portion of the temporal bone is shown in the lower left corner. The cytoplasm of ELSTs ranges from clear to pale eosinophilic. (Right) High-magnification image shows the cuboidal to columnar epithelium characteristic of ELSTs. Occasional intranuclear pseudoinclusions are present.

Section 5 - Endocrine
Adrenal Cortex
Adrenal Cortical Adenoma

> Table of Contents > Part II - Diagnoses Associated With Specific Syndromes > Section 5 - Endocrine > Adrenal Cortex
> Adrenal Cortical Adenoma

Vania Nosé, MD, PhD

Key Facts

Terminology
- Benign neoplasm arising from adrenal cortical cells with cortisol hypersecretion

Etiology/Pathogenesis
- Associated with syndromes
  - Multiple endocrine neoplasia 1 (MEN1)
  - McCune-Albright syndrome
  - Carney complex
  - Beckwith-Wiedemann syndrome
  - Congenital adrenal hyperplasia
  - Carney triad
- Sporadic

Microscopic Pathology
- Smooth pushing borders without well-defined fibrous capsule
- Clear cytoplasm that is finely vacuolated due to intracytoplasmic lipid droplets
- Cells are larger than in normal adrenal and have pleomorphic nuclei
- Nuclei are single, round/oval, with chromatin margination and single dot-like nucleolus
- Mixed pattern with oxyphilic and clear cells
- Mixed composition of pale-staining lipid-rich cells and cells with lipid-poor compact cytoplasm

Ancillary Tests
- Positive for adrenal cortical markers, such as inhibin and Melan-A
- Adenomas and carcinomas are monoclonal

Top Differential Diagnoses
- Pheochromocytoma
This cross section of an adrenal gland shows classical features of aldosterone-producing tumor. A round, small, well-circumscribed mass has the characteristic yellow cut surface.
High-magnification view of an aldosterone-secreting adenoma shows a nesting pattern (one of the characteristic patterns), as well as large lipid-rich cells, which are usually the predominant cell type.

**TERMINOLOGY**

**Abbreviations**
- Adrenal cortical adenoma (ACA)

**Synonyms**
- Cortisol-producing adrenocortical adenoma
- Aldosterone-producing adrenal adenoma
- Cushing syndrome
- Functional and nonfunctional adrenal adenoma

**Definitions**
- Benign neoplasm arising from adrenal cortical cells ± hormone hypersecretion

**ETIOLOGY/PATHOGENESIS**

**Syndromes Associated With Adrenal Cortical Adenoma**
- Multiple endocrine neoplasia 1 (MEN1)
- McCune-Albright syndrome
- Carney complex
- Beckwith-Wiedemann syndrome
- Congenital adrenal hyperplasia
- Carney triad

**Sporadic**
- Most ACA cases are considered sporadic

**CLINICAL ISSUES**

**Epidemiology**
- Incidence
  - True incidence is unknown
According to some literature, incidence of adrenal cortical adenomas is low if incidentalomas are excluded.

- **Typically unilateral, solitary, and benign**

### Age
- Can occur in any age group

### Gender
- Slight female predilection

#### Presentation
- **Nonfunctional, detected more often by imaging studies**
- **Most common presentation is associated with hormonal production**
  - **Glucocorticoid**
    - Weight gain (central obesity)
    - Supraclavicular and dorsocervical fat pads
    - Facial rounding (moon face) and plethora
    - Easy bruising and poor wound healing
    - Purple striae and hirsutism
    - Proximal muscle weakness
    - Osteoporosis
  - **Mineralocorticoid**
    - Hypertension and hypokalemia
  - **Androgens**
    - Virilization in women
    - Excess testosterone in men
  - **Estrogens**
    - Gynecomastia in men
    - Menstrual irregularities in women

#### Treatment
- **Surgical unilateral adrenalectomy**

### IMAGE FINDINGS

#### MR Findings
- Homogeneous
- Signal intensity less than fat but greater than muscle
- Similar intensity to liver on T1 and T2

#### CT Findings
- Well defined with smooth borders, homogeneous
  
P.II(5):3

- Attenuation values less than normal adrenal tissue
- May enhance after contrast administration

### MACROSCOPIC FEATURES

#### General Features
- Generally solitary, unilateral, and unicentric
- Rarely bilateral (contralateral adenoma is sometimes nonhyperfunctional)
- Cross section: Yellow, golden yellow, or brown
- Geographic or mottled zones of dark pigmentation may be present
  - Due to lipid depletion of neoplastic cells as well as lipofuscin accumulation
- Necrosis, coarse lobulation, and cystic changes are rare (as compared to carcinomas)
- When diffusely dark brown or black: Black adenoma

#### Size
- Average diameter: 3.6 cm (range: 1.5-6 cm)
- Usually < 50 g
- If > 100 g, considered carcinoma until proven otherwise

### MICROSCOPIC PATHOLOGY

#### Histologic Features
- Smooth pushing borders without well-defined fibrous capsule
- Broad fields of pale-staining, lipid-rich cells with uniform nuclei
Architectural patterns are cells in nesting or alveolar arrangement with delicate intersecting vasculature and areas of short cords. Distinct cell borders mimicking cells of normal adrenal. Mixed pattern with oxyphilic and clear cells. Mixed composition of pale-staining lipid-rich cells and cells with lipid-poor compact cytoplasm. May have areas of lipomatous or myelolipomatous metaplasia. Mitotic figures are very rare. Some may have degenerative features: Fibrosis, organizing fibrin-rich thrombi within sinusoids, dystrophic calcification, or even metaplastic bone. Myxoid changes are rare; however, when present, they should prompt suspicion of borderline or malignant tumor.

Cytologic Features
- Clear or eosinophilic cytoplasm which, at higher magnification, is finely vacuolated due to intracytoplasmic lipid droplets.
- Cells are larger than in normal adrenal and have pleomorphic nuclei.
- Nuclei are single, round/oval, with chromatin margination and single dot-like nucleoli. Intranuclear inclusions may be present.

ANCILLARY TESTS
Serologic Testing
- According to the European Network for the Study of Adrenal Tumors (ENSAT), tests should be performed when a functional adenoma is suspected:
  - Fasting blood glucose
  - Potassium
  - Cortisol
  - ACTH
  - 24-hour urinary free cortisol
  - Fasting serum cortisol at 8 am following 1 mg dose of dexamethasone at bedtime
  - Adrenal androgens (e.g., dehydroepiandrosterone sulfate [DHEAS], androstenedione, testosterone, 17-OH progesterone)
  - Serum estradiol in men and postmenopausal women

Immunohistochemistry
- Used to confirm diagnosis, to differentiate from pheochromocytoma, or when tumors occur in unusual locations in abdomen or spinal canal.

Electron Microscopy
- Abundant amount of intracytoplasmic lipid droplets
- Some may have little or no lipid
- Abundant smooth endoplasmic reticulum
- Mitochondria can be prominent with cristae that have tubular or vesicular profile (similar to normal cells of zona fasciculata).

Cytogenetics
- Genetic background is poorly understood.
- Adenomas and carcinomas both appear to be monoclonal.
- Mean number of comparative genomic hybridization (CGH) changes in carcinomas is 7.6 (range: 1-15) whereas adenomas have a mean of 1.1 changes (range: 0-4)
- Chromosomal loci implicated in adrenal cortical tumorigenesis include:
  - Activation of oncogenes on chromosomes 5 and 12
  - Inactivation of tumor suppressor genes on chromosome arms 1p and 17p.

DIFFERENTIAL DIAGNOSIS
Adrenal Cortical Carcinoma
- Differentiation is based on numerous morphological criteria, including...
Capsular invasion, lymphovascular invasion, invasion into adjacent structures, presence of necrosis, mitosis, and metastases

- Weight and size of tumor
- Clinical symptoms specific for each hormone will help in differential; carcinomas are usually nonfunctional

Pheochromocytoma
- Negative for inhibin, Melan-A, and positive for chromogranin

Metastatic Carcinoma
- Most metastatic carcinomas to adrenal are originally from lung or kidney
- Immunohistochemistry differentiates these tumors
  - Negative for inhibin and Melan-A and positive for cytokeratin

**DIAGNOSTIC CHECKLIST**

Pathologic Interpretation Pearls
- Unilateral
- Solitary
- Usually benign neoplasms
- Cross section: Yellow or golden yellow
- Geographic or mottled zones of dark pigmentation may be present
- Smooth pushing borders
- Broad fields of pale-staining, lipid-rich cells with uniform nuclei
- Clear cytoplasm that is finely vacuolated due to intracytoplasmic lipid droplets
- Mixed cell population with small compact eosinophilic cells and pale-staining lipid-rich cells
- Positive for inhibin and Melan-A
- Negative for cytokeratin and chromogranin

**SELECTED REFERENCES**

### Immunohistochemistry

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Reactivity</th>
<th>Staining Pattern</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhibin</td>
<td>Positive</td>
<td>Cell membrane &amp; cytoplasm</td>
<td>Helps to discriminate from pheochromocytoma</td>
</tr>
<tr>
<td>Mart-1</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td></td>
</tr>
<tr>
<td>Melan-A103</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td></td>
</tr>
<tr>
<td>Chromogranin-A</td>
<td>Negative</td>
<td></td>
<td>Helps to discriminate from other epithelial tumors</td>
</tr>
<tr>
<td>CK7</td>
<td>Negative</td>
<td></td>
<td>Helps to discriminate from other epithelial tumors</td>
</tr>
<tr>
<td>CK20</td>
<td>Negative</td>
<td></td>
<td>Helps to discriminate from other epithelial tumors</td>
</tr>
<tr>
<td>AE1/AE3</td>
<td>Negative</td>
<td></td>
<td>Helps to discriminate from other epithelial tumors</td>
</tr>
<tr>
<td>EMA</td>
<td>Negative</td>
<td></td>
<td>Helps to discriminate from other epithelial tumors</td>
</tr>
<tr>
<td>CD10</td>
<td>Negative</td>
<td></td>
<td>Helps to discriminate from renal cell carcinoma</td>
</tr>
<tr>
<td>Hep-Par1</td>
<td>Negative</td>
<td></td>
<td>Helps to discriminate from hepatocellular carcinoma</td>
</tr>
<tr>
<td>HMFG</td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCC</td>
<td>Negative</td>
<td></td>
<td>Helps to discriminate from renal cell carcinoma</td>
</tr>
<tr>
<td>HMB-45</td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Differential Diagnosis of Adrenal Cortical Adenoma

<table>
<thead>
<tr>
<th>Neoplasm</th>
<th>Inhibin</th>
<th>Melan-A</th>
<th>ChromoSyn</th>
<th>Hep-Par1</th>
<th>CD10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenal cortical adenoma</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>Pheochromocytoma</td>
<td>Negative</td>
<td>Negative</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
<td>Positive</td>
</tr>
<tr>
<td>Renal cell carcinoma</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
<td>Positive</td>
</tr>
</tbody>
</table>

Chromo: Chromogranin; Syn: Synaptophysin.

### Criteria for Differentiation Between Adenoma and Carcinoma

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Adenoma</th>
<th>Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hormonal production</td>
<td>Often functional</td>
<td>Usually nonfunctional</td>
</tr>
<tr>
<td>Gross</td>
<td>Weight &lt; 50 g</td>
<td>Weight &gt; 100 g</td>
</tr>
<tr>
<td>Tumor gross color</td>
<td>Variable</td>
<td>Variable; does not differentiate</td>
</tr>
<tr>
<td>Circumscription</td>
<td>Well circumscribed</td>
<td>Invasive</td>
</tr>
<tr>
<td>Hemorrhage</td>
<td>Absent</td>
<td>Frequent</td>
</tr>
<tr>
<td>Necrosis</td>
<td>Absent</td>
<td>Frequent</td>
</tr>
<tr>
<td>Capsular invasion</td>
<td>Absent</td>
<td>Usually present</td>
</tr>
<tr>
<td>Invasion into adjacent tissues</td>
<td>Absent</td>
<td>Usually present</td>
</tr>
<tr>
<td>Intratumoral fibrosis</td>
<td>May be present</td>
<td>May be present</td>
</tr>
<tr>
<td>Myxomatous degeneration</td>
<td>May be present</td>
<td>May be present</td>
</tr>
<tr>
<td>Cytology</td>
<td>May have cytologic atypia</td>
<td>Cytologic atypia present</td>
</tr>
<tr>
<td>Histology</td>
<td>Atypia may be present</td>
<td>Atypia present</td>
</tr>
<tr>
<td>Necrosis</td>
<td>Necrosis absent</td>
<td>Present; confluent necrosis</td>
</tr>
<tr>
<td>Mitosis</td>
<td>Rare</td>
<td>&gt; 5/50 HPF</td>
</tr>
<tr>
<td>Venous invasion</td>
<td>Absent</td>
<td>Present</td>
</tr>
</tbody>
</table>
### Adrenal Cortical Lesions Associated With Syndromes

<table>
<thead>
<tr>
<th>Adrenal Pathology</th>
<th>Syndromes Associated With Adrenal Pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenal cortical adenoma</td>
<td>MEN1, McCune-Albright syndrome, Beckwith-Wiedemann syndrome, congenital adrenal hyperplasia, Carney complex, Carney triad</td>
</tr>
<tr>
<td>Adrenal cortical carcinoma</td>
<td>MEN1, Beckwith-Wiedemann syndrome, Li-Fraumeni syndrome</td>
</tr>
<tr>
<td>Macronodular hyperplasia</td>
<td>MEN1, McCune-Albright syndrome, Beckwith-Wiedemann syndrome, congenital adrenal hyperplasia</td>
</tr>
<tr>
<td>Primary pigmented adrenocortical disease (PPNAD)</td>
<td>Carney complex</td>
</tr>
</tbody>
</table>

*P.II(5):6*

**Image Gallery**

**Gross and Microscopic Features**

(Left) Cross section from a cortisol-secreting adenoma shows the typical round, well-circumscribed golden yellow appearance. This tumor has foci of dark discoloration that can be attributed to an old hemorrhage, an area of lipid depletion of the tumor cells, or increased lipofuscin pigment. (Right) The tumor cells in cortisol-producing adrenal adenomas are arranged in a solid pattern with cytoplasmic lipofuscin pigment, gradation in cell size, and a varying amount of lipid.
Adrenal cortical adenoma in Cushing syndrome has a yellow-orange surface and mottled zones of dark pigmentation due to accumulation of lipofuscin and lipid depletion of the neoplastic cells. This cortisol-producing adrenal cortical adenoma is composed of large cells with eosinophilic cytoplasm and enlarged hyperchromatic nuclei. Some cells show a prominent intranuclear inclusion.

Close view of adenoma highlights the mottled zones of dark pigmentation. These areas are composed of lipid-depleted cells and cells with accumulation of lipofuscin pigment. Note the marked atrophy of the residual adrenal cortex. Cortisol-secreting adrenal cortical adenomas are usually composed of cells with eosinophilic cytoplasm with enlarged hyperchromatic nuclei, some with prominent nucleoli. The cytoplasm contains pigmented granular lipofuscin.
This well-circumscribed adenoma has a homogeneous yellow cut surface, and there is marked atrophy of the attached adrenal cortex. Adrenal cortical adenomas can be present in patients with MEN1 syndrome, McCune-Albright syndrome, Carney complex, and Beckwith-Wiedemann syndrome. This view of an adrenal cortical adenoma shows a sharp demarcation between the normal adrenal parenchyma, contrasting with the pushing borders of the adenoma.

Cross section through an adrenal mass shows the classic canary-yellow color of an aldosterone-secreting adenoma. Another characteristic of these tumors is the pushing borders. High-magnification view of an aldosterone-producing adenoma has the characteristic spironolactone bodies, which are small intracytoplasmic eosinophilic inclusions with a laminated appearance surrounded by a clear halo, which appear in patients treated with spironolactone.
This photomicrograph of an aldosterone-secreting adenoma shows lipomatous metaplasia intermixed with tumoral cells, which are arranged in a diffuse architecture. Central degenerative changes can be seen in large tumors. (Right) The tumor cells in this cortisol-producing adrenal cortical adenoma are present within the central vein. There is an associated fibrin thrombus within the lumen, compressing the adjacent normal adrenal cortex.

Microscopic Features

(Left) Low-power magnification shows a well-circumscribed corticoadrenal neoplasm. A thick fibrous capsule can be seen. (Right) High magnification shows an adrenal cortical adenoma that secretes sex steroids. This picture shows eosinophilic cells with abundant cytoplasm that resemble the cells in the zona reticularis.
(Left) High-power photomicrograph shows eosinophilic cells with abundant cytoplasm, characteristic of a sex-steroid-producing adenoma. (Right) This photomicrograph of an aldosterone-secreting adenoma has several characteristic features seen in these tumors. Lipomatous metaplasia is intermixed with tumoral cells in a diffuse architecture or different morphological patterns and may coexist as nesting pattern and cords.

(Left) The tumor cells are arranged in short cords or clusters. Individual tumor cells contain abundant lipid, which appears as numerous clear vacuoles. There is variation in nuclear size. (Right) The tumor cells are arranged in a solid pattern with a gradation in tumor cell size and a varying amount of lipid. There is a mixture of oncocytic cells and clear cells in this adrenal cortical adenoma.

P.II(5):9

Immunohistochemical Features
This picture shows positivity for synaptophysin, which is 1 of the characteristics of adrenal cortical neoplasms. There is positive cytoplasmic staining in this case of sex steroid-producing adrenal cortical adenoma. (Right) Immunoreactivity for α-inhibin as well as for Melan-A is sensitive but not specific for adrenal cortical tumors. This photomicrograph illustrates that the tumor cells have variably intense cytoplasmic granular immunopositivity for MART-1.

Synaptophysin is present in adrenal cortical tumors in a moderately weak membranous and cytoplasmic pattern. This positivity is usually less intense than in pheochromocytoma. (Right) Immunoreactivity for α-inhibin as well as for Melan-A is sensitive but not specific for adrenal cortical tumors. The tumor cells have variably intense cytoplasmic granular immunopositivity for inhibin. In contrast with other epithelial tumors, the tumor cells are negative for cytokeratin and EMA.
Immunohistochemistry for Ki-67 reveals a low proliferative index in the benign cortisol-secreting adrenal cortical adenomas. These findings correlate with a very low mitotic index. (Right) Immunohistochemistry in adrenal cortical adenoma is characteristically negative for chromogranin. The tumor cells in these tumors are also negative for CK7, CK20, AE1/AE3, S100, and CD10, aiding in the differential diagnosis with other epithelial neoplasms.

Adrenal Cortical Carcinoma

Vania Nosé, MD, PhD

Key Facts

Terminology

- Malignant epithelial neoplasm of adrenal cortical cells

Etiology/Pathogenesis

- Familial
  - Beckwith-Wiedemann syndrome
  - Li-Fraumeni syndrome
  - Multiple endocrine neoplasia 1
  - Carney complex
  - Congenital adrenal hyperplasia

- Sporadic

Clinical Issues

- Bimodal age distribution
- Overall 5-year survival: 70%

Macroscopic Features

- Bulky tumors with red-brown and fleshy, firm appearance
  - 3-40 cm
  - Usually > 200 g

Microscopic Pathology

- No single feature is diagnostic of carcinoma
- Multiple systems used for diagnosis (Weiss, Hough, van Slooten)

Ancillary Tests

- Positive for inhibin, Melan-A, calretinin, and SF1

Top Differential Diagnoses

- Adrenal cortical adenoma, metastatic tumors, renal cell carcinoma, and pheochromocytoma
This adrenal cortical carcinoma presented as an irregularly shaped, bulky, unilateral mass. The cut surface shows extensive regressive changes, necrosis, hemorrhage, fibrosis and degeneration, and calcification.
Adrenal cortical carcinoma metastatic to lung exhibits tumor cells with abundant, granular, oncocytic cytoplasm with round, uniform, hyperchromatic nuclei. Nuclear pleomorphism can be seen among tumor cells.

**TERMINOLOGY**

**Abbreviations**
- Adrenal cortical carcinoma (ACC)

**Synonyms**
- Adrenocortical carcinoma

**Definitions**
- Malignant epithelial neoplasm of adrenal cortical cells

**ETIOLOGY/PATHOGENESIS**

**Possible Multistep Process**
- Adrenal cortical hyperplasia and adenoma may represent precursor lesions

**Syndrome Association**
- Beckwith-Wiedemann (autosomal dominant)
  - Gene locus includes IGF2 and P57/KIP2 genes
  - Involves chromosome 11p15.5 in ~ 80% of cases
- Li-Fraumeni syndrome (autosomal dominant)
  - Germline mutations in tumor suppressor gene TP53 (17p13.1)
- Multiple endocrine neoplasia 1 (MEN1)
  - MEN1 gene in chromosome 11q13
- Carney complex
  - PRKAR1A in chromosome 17q22-24
  - 2p15-16
- Congenital adrenal hyperplasia
  - Autosomal recessive
- Lynch syndrome
CLINICAL ISSUES

Epidemiology

- Incidence
  - 1-2 cases per 1 million people
  - Comprises ~3% of endocrine neoplasms
  - No gender or ethnicity predilection

- Age
  - Bimodal age distribution
    - Primary peak: 60-70 years
    - Secondary peak: Early childhood

Presentation

- Nonfunctional tumors are detected more often as radiographic techniques improve
- Most common presentation is associated with hormone oversecretions
  - Glucocorticoid
    - Cushing syndrome
    - Central obesity
    - Moon facies
    - Protein wasting, striae, and skin thinning
    - Muscle atrophy, osteoporosis
    - Diabetes, hypertension, gonadal dysfunction
    - Psychiatric disorders
  - Mineralocorticoid
    - Hypertension and hypokalemia
  - Androgens
    - Virilization in women
    - Excess testosterone in men
  - Estrogens
    - Very rare, yielding gynecomastia in men
    - Menstrual irregularities in women

- Mass
  - Flank pain due to compressive symptoms

Laboratory Tests

- Serum or urinary hormone quantification
  - Hormones may not be bioactive
  - May require special methods for detection
  - Deoxycorticosterone, hydroxyprogesterone
  - Androstenedione, estrogens
  - Urine 17-ketogenic steroids or 17-ketosteroids may be elevated
  - Dehydroepiandrosterone sulfate (DHEAS)

P.II(5):11

- Dexamethasone suppression test

Treatment

- Options, risks, complications
  - Complications due to pituitary-hypothalamus-adrenal axis suppression

- Surgical approaches
  - Complete, radical surgical resection is treatment of choice

- Drugs
  - Mitotane
    - May help prolong recurrence-free survival after radical surgery
    - Can be used after incomplete resection or for metastatic disease
    - In patients not eligible for surgery
  - Chemotherapy regimens reported
    - Etoposide, doxorubicin, cisplatin, and mitotane
    - Streptozotocin and mitotane
    - Failure possibly due to high rate of multidrug resistance protein 1 (MDR1) gene expression

- Radiation
  - Radiotherapy can help control residual disease
Diagnostic Pathology: Familial Cancer Syndromes

Prognosis
- Overall 5-year survival: 50-70%
- Disease-free 5-year survival: 30%
- Dependent on age and stage
  - Children have better prognosis than adults
  - Stage 1 and stage 2 tumors have better prognosis than stage 3 or stage 4
- Majority of cases present with stage 4 disease
- Key prognostic factor is feasibility of complete tumor resection
- Local recurrence is frequent
- Nearly 40% have distant metastases at presentation
  - Most common metastases to liver, lung, lymph nodes, and bone

IMAGE FINDINGS
Radiographic Findings
- Inhomogeneous masses with irregular borders and necrosis
- Usually show low tumor fat content
  - Distinctly different from adenomas, which have high fat content

MR Findings
- Carcinoma tends to be large (> 5 cm)
- Irregular or invasive borders
- Decreased intracellular lipid and macroscopic fat
- Signal heterogeneity and necrosis
- Vena cava extension/invasion may be seen

CT Findings
- Heterogeneous, enhancing large mass
- Typically > 5 cm
- Frequently with displacement or invasion of adjacent organs
- Calcifications present in 30% of cases

PET Scan
- Helpful in determining distant metastases

MACROSCOPIC FEATURES
General Features
- Bulky tumors with red-brown and fleshy, firm appearance
- Typically unilateral
  - If bilateral, consider contralateral metastasis

Sections to Be Submitted
- Sample foci of hemorrhage &/or necrosis
- Usually 1 section per cm, up to 15 sections

Size
- Range: 3-40 cm (mean: 12 cm)

Weight
- Usually > 200 g
- Can be 10-5,000 g

MICROSCOPIC PATHOLOGY
Histologic Features
- May resemble normal adrenal
- Patternless sheets or nests of cells
- Broad trabeculae and fine sinusoids
- Myxoid change may be present
- Necrosis may be absent or abundant
- In children, these features may not indicate malignancy
- Benign cortical tumors with oncocytic change can have some of these features

Cytologic Features
- Cells have clear to eosinophilic cytoplasm
- Nuclei range from bland to highly atypical
- Variable mitotic rate
ANCILLARY TESTS

Cytology
- Unable to separate benign from malignant adrenal cortical lesions
- High nuclear pleomorphism, chromatin irregularities, and prominent nucleoli favor carcinoma
- FNA can be diagnostic for metastatic tumors

Histochemistry
- Reticulin
  - Reactivity: Quantitative changes in ACC with extensive loss and disruption of fibers
  - Staining pattern
    - Detect the presence of reticulin fiber disruptive changes

Immunohistochemistry
- Positive for inhibin, Melan-A, calretinin, synaptophysin, CD99, steroidogenic factor-1 (SF1)

Molecular Genetics
- Adrenocorticotrophic hormone-cAMP-protein kinase A and Wnt pathways are implicated
- Overexpression of IGF2
- Somatic mutations of TP53 or RB
- Low expression of P57, H19, and MYC

Electron Microscopy
- Features of steroidogenesis
  - Abundant rough and smooth endoplasmic reticulum
  - Many mitochondria
  - Intracytoplasmic lipid droplets

DIFFERENTIAL DIAGNOSIS

Adrenal Cortical Adenoma
- Tends to be smaller and weigh < carcinoma
- Often lacks mitotic figures, necrosis, and invasion
- Diagnosis of pediatric adrenal cortical tumors is difficult

Metastatic Tumors
- More likely to be bilateral
- Glandular, squamous, or small cell histology

Hepatocellular Carcinoma
- Confirm biopsy site
- Trabecular pattern, bile pigment, glandular arrangement
- Positive keratin, CEA, and Hep-Par1

Renal Cell Carcinoma
- Pseudoalveolar pattern
- Extravasated erythrocytes
- Clear cytoplasm, prominent cell borders
- Positive for keratin, CD10, and EMA

Pheochromocytoma
- Different radiographic appearance, especially with scintigraphic studies
- Nested and zellballen pattern
- Basophilic cytoplasm, bizarre, isolated, atypical nuclei
- Positive for chromogranin, synaptophysin, and CD56 in paraganglia cells
- S100 protein positive sustentacular cells

DIAGNOSTIC CHECKLIST

Distinction Between Benign and Malignant Adrenal Cortical Neoplasms
- No single feature is diagnostic of carcinoma
- Multiple systems used for diagnosis (Weiss, Hough, van Slooten)
- Most significant histologic features
  - High nuclear grade (analogous Fuhrman grade 4)
  - > 5 mitotic figures/50 HPF
  - Atypical mitotic figures
  - < 25% of tumor cells with clear/vacuolated cytoplasm
  - Diffuse architecture (> 1/3 of tumor)
  - Confluent tumor necrosis
  - Venous invasion (of smooth muscle-walled vessels)
  - Sinusoidal invasion (no smooth muscle in vessel wall)
**Capsular invasion**

**Acellular, fibrous connective tissue bands**

**STAGING**

Recently Adopted AJCC and UICC Staging Systems

- Stage 1: Confined to gland, ≤ 5 cm
- Stage 2: Confined to gland, > 5 cm
- Stage 3: Extends beyond gland but not into adjacent organs
- Stage 4: Distant metastases or adjacent organ involvement

**SELECTED REFERENCES**


**Immunohistochemistry**

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Reactivity</th>
<th>Staining Pattern</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vimentin</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td></td>
</tr>
<tr>
<td>Inhibin</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>Nondiscriminating between adenoma and carcinoma</td>
</tr>
<tr>
<td>Melan-A103</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>Nondiscriminating between adenoma and carcinoma</td>
</tr>
<tr>
<td>Calretinin</td>
<td>Positive</td>
<td>Nuclear &amp; cytoplasmic</td>
<td></td>
</tr>
<tr>
<td>SF1</td>
<td>Positive</td>
<td>Nuclear</td>
<td></td>
</tr>
<tr>
<td>CK-PAN</td>
<td>Equivocal</td>
<td>Cytoplasmic</td>
<td>&lt; 5% of tumor cells are reactive</td>
</tr>
</tbody>
</table>

**Histologic Criteria for Distinguishing Benign From Malignant Adrenal Cortical Neoplasms**

<table>
<thead>
<tr>
<th>Weiss Criteria</th>
<th>van Slooten System</th>
</tr>
</thead>
<tbody>
<tr>
<td>High nuclear grade; Fuhrman criteria</td>
<td>Histologic criteria and weight used</td>
</tr>
<tr>
<td>&gt; 5 mitoses/50 HPF</td>
<td>Extensive regressive changes (necrosis, hemorrhage, fibrosis, calcification)/5.7</td>
</tr>
<tr>
<td>Atypical mitotic figures</td>
<td>Loss of normal structure/1.6</td>
</tr>
<tr>
<td>&lt; 25% of tumor cells are clear cells</td>
<td>Nuclear atypia (moderate to marked)/2.1</td>
</tr>
<tr>
<td>Diffuse architecture (&gt; 33% of tumor)</td>
<td>Nuclear hyperchromasia (moderate to marked)/2.6</td>
</tr>
<tr>
<td>Necrosis</td>
<td>Abnormal nucleoli/4.1</td>
</tr>
<tr>
<td>Venous invasion (smooth muscle in wall)</td>
<td>Mitotic activity (≥ 2/10 HPF)/9.0</td>
</tr>
<tr>
<td>Sinusoidal invasion (no smooth muscle in wall)</td>
<td>Vascular or capsular invasion/3.3</td>
</tr>
<tr>
<td>Capsular invasion</td>
<td></td>
</tr>
</tbody>
</table>
**Presence of 3 or more criteria highly correlates with malignant behavior.**

**Histologic index > 8 correlates with malignant behavior.**

### System of Hough for Distinguishing Benign From Malignant Adrenal Cortical Neoplasms

<table>
<thead>
<tr>
<th>Histologic Criteria/Value</th>
<th>Nonhistologic Criteria/Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diffuse growth pattern/0.92</td>
<td>Tumor mass &gt; 100 g/0.60</td>
</tr>
<tr>
<td>Vascular invasion/0.92</td>
<td>Urinary 17-ketosteroids (10 mg/g creatinine/24 h)/0.50</td>
</tr>
<tr>
<td>Tumor cell necrosis/0.69</td>
<td>Response to ACTH (17-hydroxysteroids increased 2x after 50 mg ACTH IV)/0.42</td>
</tr>
<tr>
<td>Broad fibrous bands/1.00</td>
<td>Cushing syndrome with virilism, virilism alone, or no clinical manifestations/0.42</td>
</tr>
<tr>
<td>Capsular invasion/0.37</td>
<td>Weight loss (10 lb/3 months)/2.00</td>
</tr>
<tr>
<td>Mitotic index (1/10 HPF)/0.60</td>
<td></td>
</tr>
<tr>
<td>Pleomorphism (moderate and marked)/0.39</td>
<td></td>
</tr>
</tbody>
</table>

*Mean histologic index of malignant tumors is 2.91, indeterminate tumors 1.00, and benign tumors 0.17.*

---

Image Gallery

Imaging, Gross, and Microscopic Features

(Left) Radiologic image shows a large left adrenal gland mass pushing the kidney down and compressing the adjacent spleen. The interior is mottled and shows mixed intensity. (Right) Adrenal cortical carcinomas tend to appear grossly as large solid masses in the suprarenal region, typically measuring > 5 cm. Focal areas of necrosis and hemorrhage are usually present.
Cytologic diagnosis of adrenal cortical carcinoma can be challenging. The degree of polymorphism and nuclear irregularity shown in this cytology favors carcinoma, confirmed on histological examination. (Right) This adrenal cortical carcinoma (ACC) shows an alveolar and solid pattern composed of relatively uniform small round cells with clear cytoplasm. The differential diagnosis of this morphological variant includes metastatic carcinomas, such as renal cell carcinoma or hepatocellular carcinoma.

(Left) High-magnification view of an ACC shows a tumor composed of slightly pleomorphic round cells with both clear and eosinophilic cytoplasm. An atypical mitotic figure and a multinucleated giant cell are indicated. (Right) This picture shows an ACC composed of small, compact eosinophilic cells, some with prominent nucleoli intermixed with scattered, bizarre multinucleated cells. Several mitotic figures, including atypical mitoses, are present in this field.

Microscopic Features
(Left) Hematoxylin & eosin shows small trabeculae composed of neoplastic cells with a high nuclear to cytoplasmic ratio. Mitotic figures are noted, including an atypical form. (Right) High magnification shows cells in a trabecular arrangement separated by thin fibrovascular bands. Scattered large bizarre multinucleated cells intermixed with small cells may be present.

(Left) Small cells with a high nuclear to cytoplasmic ratio are juxtaposed with larger cells. Intracellular and extracellular eosinophilic globules can be seen in adrenal cortical carcinoma cells. (Right) Low magnification view shows an area of juxtaposition between an adrenal cortical carcinoma composed of small uniform cells and the residual normal adrenal tissue. Tumor invasion of a large intraparenchymal vessel is shown.
(Left) Viable tumor and necrosis are depicted. Tumor necrosis is an important histologic criterion in all schemes for differentiation between benign and malignant adrenal cortical neoplasms. (Right) This tumor invades a vessel wall and is composed of small, uniform cells with clear cytoplasm. Atypical cells with large irregular nuclei and a large bizarre multinucleated cell are also shown.

Beckwith-Wiedemann Syndrome

(Left) The adrenal cortical cells in children with Beckwith-Wiedemann syndrome are composed by a mixture of small cells and large polyhedral cells with markedly enlarged nuclei, also observed at a low magnification. (Right) Adrenal cortical cytomegaly is usually present in children with Beckwith-Wiedemann syndrome. The adrenal cortical cells are composed of a mixture of large polyhedral cells with markedly enlarged nuclei and small cells with small round nuclei.
(Left) H&E shows the interface between 2 distinct areas of an adrenal cortical carcinoma. One area of the tumor is made up of sheets of small, compact round cells with scant cytoplasm. There is a sharp contrast in the cell size of the 1st component compared to the 2nd component. (Right) Adrenal cortical carcinoma in a child with Beckwith-Wiedemann syndrome shows that the tumor is composed of large cells with nuclear pleomorphism, prominent nucleoli, and numerous mitotic figures.

(Left) H&E shows metastatic adrenal cortical carcinoma to lung parenchyma. The tumor mass is composed of small, compact eosinophilic cells and is surrounded by lung parenchyma. (Right) Extensive lymphovascular invasion may be present in adrenalectomy specimens of pediatric adrenal cortical carcinoma. Immunohistochemistry for CD99 in this photomicrograph highlights the intravascular tumor in a child with Beckwith-Wiedemann syndrome producing steroids.

Tumor Staging Graphics
(Left) Coronal graphic demonstrates T1 disease. The primary tumor is ≤ 5 cm in greatest dimension, without invasion of adjacent organs, including kidney or inferior vena cava. (Right) Coronal graphic demonstrates T2 disease. The primary tumor is > 5 cm in greatest dimension, without invasion of adjacent organs, including kidney or inferior vena cava.

(Left) Coronal graphic demonstrates T3 disease. The primary tumor may be any size, with local invasion beyond the adrenal capsule, shown in the superolateral margin, but no involvement of adjacent organs such as the kidney. (Right) Coronal graphic demonstrates T4 disease. The primary tumor can be any size, with local invasion beyond the confines of the adrenal capsule and into adjacent organs, including the kidney. Direct extension into the inferior vena cava is seen.
Pathogenesis

Pathogenesis

Primary Pigmented Nodular Adrenocortical Disease

> Table of Contents > Part II - Diagnoses Associated With Specific Syndromes > Section 5 - Endocrine > Adrenal Cortex

Primary Pigmented Nodular Adrenocortical Disease

Vania Nosé, MD, PhD

Key Facts

Terminology

- Rare cause of ACTH-independent Cushing syndrome that may occur sporadically or in autosomal dominant familial form associated with CNC
- Characterized by bilateral adrenocortical hyperplasia

Etiology/Pathogenesis

- All genetic events lead to constitutive activation of cAMP/PKA pathway, which results in hyperglucocortisolism and adrenocortical hyperplasia

Clinical Issues

- Corticotropin-independent Cushing syndrome
- Familial form as part of CNC; sporadic cases are rare

Macroscopic Features

- Small to normal-sized adrenal glands with multiple small pigmented nodules; similar in both forms

Microscopic Pathology

- Nodules are composed of cells with compact eosinophilic cytoplasm and abundant brown, granular pigment (lipofuscin)
- Findings are similar in familial and sporadic cases

Top Differential Diagnoses

- Cushing syndrome caused by primary cortisol-producing adrenocortical adenoma
- Corticotropin (ACTH)-independent bilateral macronodular adrenal hyperplasia (AIMAH)
- Cushing disease
- Malignant melanoma
These bilateral adrenal glands show pigmented nodules that are jet black to gray-brown. These nodules are usually small, however, some are macronodules resulting from a confluence of smaller nodules.
The intranodular cells in primary pigmented nodular adrenocortical disease (PPNAD) have lipid-depleted, compact, eosinophilic cytoplasm. Some have abundant, finely granular cytoplasmic lipofuscin pigment with focal accumulation of pigment.

**TERMINOLOGY**

**Abbreviations**
- Primary pigmented nodular adrenocortical disease (PPNAD)

**Synonyms**
- Primary pigmented nodular adrenal disease
- Isolated or sporadic primary pigmented nodular adrenocortical disease (iPPNAD)
- PPNAD associated with Carney complex (C-PPNAD)
- Adrenocortical dysplasia
- Bilateral micronodular hyperplasia

**Definitions**
- Rare form of primary bilateral adrenal disease that is often associated with adrenocorticotropic hormone (ACTH)-independent Cushing syndrome (CS)
- Characterized by bilateral micronodular adrenocortical hyperplasia
- Can be inherited in autosomal dominant manner associated with Carney complex (CNC)
- Nonfamilial, or isolated or sporadic (iPPNAD) forms also exist

**ETIOLOGY/PATHOGENESIS**

**Etiology**
- Unknown
- Familial
  - Can occur in familial form, inherited as autosomal dominant trait when associated with CNC
    - Known genetic heterogeneity in CNC
    - PPNAD is the most frequent endocrine manifestation of CNC, occurring in about 1/4 of patients
Sporadic
- Can occur as nonfamilial isolated or sporadic form (iPPNAD)

Autoimmune origin
- May result from adrenal-stimulating antibodies, which stimulate corticotropin receptor sites in adrenal cortex

Genetic Abnormality
- Disorder has been mapped to genomic loci on chromosomes 2q15-16 and 17q22-24
- Inactivating mutations of PRKAR1A gene on 17q22-24 have been reported in most patients with CNC
- Inactivating mutations of phosphodiesterase 11A (PDE11A) located at 2q31-2q35 have been identified in sporadic PPNAD
- Despite the known genetic heterogeneity in CNC, in most cases, PPNAD in its sporadic or isolated forms (iPPNAD) is caused by inactivating heterozygous mutations of PRKAR1A gene
  - Polypyrimidine tract mutation of PRKAR1A gene leading to a probable mild alteration of PRKAR1A mRNA splicing
  - Compared with mutations described for PRKAR1A gene, exon 7 IVS del([-]7 → [-]2) has a low penetrance and is almost exclusively associated with iPPNAD
- Strong genotype-phenotype correlation in CNC &/or PPNAD for PRKAR1A mutation

Pathogenesis
- All genetic events lead to constitutive activation of cAMP/PKA pathway, which results in hyperglucocortisolism and adrenocortical hyperplasia

CLINICAL ISSUES

Epidemiology
- Age
  - Patients with PPNAD in both sporadic and familial forms usually present in late childhood/early adulthood

Gender
- Slight female predominance

Presentation
- Most patients with PPNAD also have a multiple neoplasia syndrome within CNC
- PPNAD in its sporadic or isolated forms is rare
- Familial form as part of CNC: Autosomal dominant
  - In addition to PPNAD, which is the most common endocrine manifestation, CNC patients have
    - Myxomas
    - Spotty skin pigmentation
    - Cutaneous abnormalities
    - Schwannomas
    - Testicular tumors, including Leydig cell tumor and large cell calcifying Sertoli cell tumors
    - Mammary myoid fibroadenoma
    - Pituitary macroadenoma
    - Psammomatous melanotic schwannoma
- Sporadic or isolated corticotropin-independent Cushing syndrome (iPPNAD)
  - Establishing diagnosis of PPNAD can be challenging, particularly when PPNAD is the only manifestation of disease; a few signs are
    - Weight gain
    - Fatigue
    - Muscle weakness
    - Moon face
    - Facial flushing
    - Buffalo hump

Laboratory Tests
- Plasma cortisol is usually moderately elevated without diurnal rhythm
- Plasma ACTH is low or undetectable
- Hypercortisolism is resistant to high-dose dexamethasone suppression test (HDDST), metyrapone stimulation, and corticotropin-releasing hormone stimulation

Treatment
Diagnostic Pathology: Familial Cancer Syndromes

- Surgical approaches
  - Bilateral adrenalectomy is treatment of choice for PPNAD in patients with Cushing syndrome

Prognosis
- Most tumors are slow growing without malignant potential
- Life span is decreased in patients with CNC due to increased incidence of sudden death caused by heart myxoma or its complications

IMAGE FINDINGS
CT Findings
- Bilateral irregular adrenal margins with nodules
- Size of adrenal can be normal

MACROSCOPIC FEATURES
General Features
- Small to normal-sized adrenal glands
  - Rarely, slight increase in adrenal gland size
- Multiple small cortical nodules, 0.1-0.3 cm in diameter involving both glands
- Nodules may be pigmented, either brown or black
  - Some nodules may be pale to bright yellow

MICROSCOPIC PATHOLOGY
Histologic Features
- Nodules composed of cells with compact eosinophilic cytoplasm and abundant brown, granular pigment (lipofuscin)
- Cell nuclei are vesicular and may contain prominent eosinophilic nucleoli
- Intervening cortical tissue is atrophic

ANCILLARY TESTS
Serologic Testing
- Elevated basal cortisol
- Low ACTH
- High 24-hour urinary free cortisol
- Nonsuppressed cortisol after HDDST suggests ACTH-independent Cushing syndrome

Immunohistochemistry
- Increased expression of glucocorticoid receptor

Molecular Genetics
- PPNAD in its sporadic or isolated forms (iPPNAD) is caused by inactivating heterozygous mutations of PRKAR1A gene, encoding regulatory subunit type I-α of the cAMP-dependent protein kinase A (PKA)
  - Compared with other mutations described for the PRKAR1A gene, exon 7 IVS del([-]7 → [-]2) has a low penetrance and is almost exclusively associated with iPPNAD
- Loss of heterozygosity of PRKAR1A gene or nonsense mutation
- Mutations of PDE11A and PDE8B genes

DIFFERENTIAL DIAGNOSIS
Corticotropin (ACTH)-Independent Bilateral Macronodular Adrenal Hyperplasia (AIMAH)
- Associated with tumefactive enlargement of both adrenal glands
- Also associated with bilateral adrenocortical nodules, but nodules are much larger
- Associated with markedly enlarged adrenal glands
- Marked distortion of cortical architecture composed of lipid-rich cells with some lipid-depleted cells showing atrophy between nodules

Cushing Syndrome Caused by Primary Cortisol-Producing Adrenocortical Adenoma
- Patient presents with Cushing syndrome
- Lab: High cortisol, low ACTH
- Well-demarcated tumor lesion inside adrenal gland
- Gross: Single tumor nodule with expansile appearance, adjacent to grossly normal adrenal gland

Cushing Disease
- ACTH-dependent hypercortisolism caused by pituitary adenoma
- Lab: High cortisol, high ACTH
- MR shows mass in anterior pituitary gland
- Diffuse enlargement of adrenal cortex
Microscopically, diffuse adrenocortical hyperplasia without pigment deposition

Metastatic Malignant Melanoma

- Both diseases involve both adrenal glands
  - Immunohistochemistry for S100, HMB-45, Melan-A can readily separate both diseases

**DIAGNOSTIC CHECKLIST**

**Pathologic Interpretation Pearls**

- Adrenal glands usually normal in size
- Scattered small pigmented nodules ranging from light gray, gray-brown, dark brown, to jet black
- Histologically, pigmented nodules are round or oval; sporadic and familial forms have similar findings
- Unencapsulated nodules of mixed lipid-rich and lipid-depleted adrenocortical cells with expansile borders
- Intracytoplasmic pigment is lipofuscin

**SELECTED REFERENCES**

1. Almeida MQ et al: Activation of cyclic AMP signaling leads to different pathway alterations in lesions of the adrenal cortex caused by germline PRKAR1A defects versus those due to somatic GNAS mutations. J Clin Endocrinol Metab. 97(4):E687-93, 2012
5. Libør et al: Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype. J Clin Endocrinol Metab. 96(1):E208-14, 2011

**Image Gallery**

Clinical and Microscopic Features
In addition to PPNAD, which is the most common endocrine manifestation, CNC patients have the characteristic findings of spotty skin pigmentation in the mucocutaneous regions around eyes and lips. (Courtesy J.A. Carney, MD.)

The normal adrenal gland architecture in PPNAD is replaced by multiple nodules, most of which are unencapsulated but some with a thin fibrous capsule. The adjacent adrenal is atrophic.

Low power of an adrenal gland from a patient with PPNAD shows a nodule composed of cells with lipid-depleted cytoplasm containing a small amount of finely granular lipofuscin pigment. Lipomatous metaplasia is also present. (Right) Intranodular cells in PPNAD have lipid-depleted cytoplasm with finely granular to focally coarse cytoplasmic lipofuscin. The pigmented nodule cells may have pleomorphic nuclei and prominent nucleoli.
The lipid-depleted, compact, and eosinophilic cells in PPNAD may have abundant, finely granular, cytoplasmic, orange-brown lipofuscin pigment with focal globular pigment formation. Cytologically, the cells are uniform, although occasional binucleated or cells with enlarged nuclei and prominent nucleoli can be seen. The lipid-poor eosinophilic cytoplasm may contain a finely granular, orange-brown lipofuscin pigment with focal globular pigment.

**Adrenal Medulla**

**Adrenal Medullary Hyperplasia**

Vania Nosé, MD, PhD

Key Facts

**Terminology**
- Increase in mass of adrenal medullary cells and expansion of these cells into areas of gland where they are not normally present

**Etiology/Pathogenesis**
- Adrenal medullary hyperplasia is a precursor of pheochromocytomas in MEN2 syndrome
- AMH is common in multiple endocrine neoplasia 2A and 2B
  - Absent or very rare in other pheochromocytoma/paraganglioma syndromes

**Macroscopic Features**
- Adrenal medulla normally confined to central region (body) of gland
  - Medullary hyperplasia often identifiable by gross extension of gray medullary tissue into alae and tail
- Patients with MEN2 syndromes usually have diffuse and nodular hyperplasia involving both glands
- Nodules are gray to tan and may compress adjacent cortex

**Microscopic Pathology**
- Nodules can occur with little or no diffuse hyperplasia
- Histology shows medullary hyperplasia composed of proliferation of cells containing normal cellular architecture
  - As opposed to nests of cytologically atypical polygonal cells that characterize pheochromocytoma
This adrenal gland from a patient with multiple endocrine neoplasia type 2A (MEN2A) shows diffuse medullary expansion, characteristic of adrenal medullary hyperplasia, and a well-defined nodule.
Adrenal medullary hyperplasia in a patient with MEN2 syndrome shows medullary cells within the adrenal cortex. The presence of hyaline granules is usually present in MEN2.

**TERMINOLOGY**

**Abbreviations**
- Adrenal medullary hyperplasia (AMH)

**Definitions**
- Increase in mass of adrenal medullary cells and expansion of these cells into areas of gland where they are not normally present
- Benign change in adrenal gland characterized by disproportionate enlargement of medulla compared with cortex
  - Considered an adrenal cortex to medulla ratio of < 10:1
- Arbitrarily, lesions of < 1 cm in diameter are called adrenal medullary hyperplasia
  - It should be expected that majority of these are early lesions and, if left in situ, would grow to a pheochromocytoma
- Increased cell number in sympatoadrenal or parasympathetic paraganglia

**ETIOLOGY/PATHOGENESIS**

**Familial Medullary Hyperplasia**
- Known to be a precursor lesion of MEN2 syndromes
- Other predisposing genetic syndromes are not typically associated with adrenal medullary hyperplasia
  - Identification of adrenal medullary hyperplasia has been considered to be diagnostic of MEN2 syndrome
  - Recently, there was a report of bilateral diffuse adrenal medullary hyperplasia in a patient with SDHB mutation

**Hyperplasia Associated With Genetic Disorders**
- Bilateral adrenal medullary hyperplasia was first described in 1966
  - Its significance was not understood until identification of RET proto-oncogene
Now, the association of AMH and MEN2 syndromes is well established

- Adrenal medullary hyperplasia is a precursor of pheochromocytomas in MEN2 syndrome
  - AMH is common in multiple endocrine neoplasia 2A and 2B (MEN2A and MEN2B)
- AMH is known to be absent or very rare in other pheochromocytoma/paraganglioma syndromes
  - Report of bilateral diffuse adrenal medullary hyperplasia in a patient with SDHB mutation
- AMH and hyperplasia of extraadrenal sympathetic paraganglia in Beckwith-Wiedemann syndrome (BWS) noted by Beckwith in 1969 description
  - Now seems less consistent than cortical abnormalities
- Mature chromaffin cell nodules (sometimes present in fetuses with BWS) suggest extraadrenal paraganglia developing within adrenals

As Precursor Lesion

- Because of the link between RET mutations and adrenal medullary hyperplasia, it is hypothesized that medullary hyperplasia is a precursor lesion that will eventually develop into pheochromocytoma given enough time
  - Similar pattern of progression from hyperplasia to malignancy is seen in other endocrine tumors, such as medullary thyroid cancer and adrenal cortical tumors

Sporadic Adrenal Medullary Hyperplasia

- Sporadic AMH reported in different settings
  - In patients with cystic fibrosis
    - P.II(5):29
  - In infants dying of sudden infant death syndrome (SIDS)
  - Cushing syndrome
  - In sporadic forms of Beckwith-Wiedemann syndrome
  - Other rare causes

Compensatory Physiological Hyperplasia

- Extensively documented in parasympathetic paraganglia; mostly carotid body, sometimes vagal
  - Presumed association with hypoxia: Occurs in humans and animals living at high altitude; also reported in lung disease, cystic fibrosis, and cyanotic heart disease
  - Controversial association of hyperplastic paraganglia with SIDS

CLINICAL ISSUES

Presentation

- AMH may present with signs of catecholamine excess or be discovered incidentally after adrenalectomy for pheochromocytoma
- Hyperplasia of extraadrenal paraganglia usually studied in autopsy series of patients dying from other causes

MACROSCOPIC FEATURES

General Features

- Patients with MEN2 syndromes usually have diffuse and nodular hyperplasia involving both glands
  - Characteristically in these patients, medullary hyperplasia involves the tail
- Nodules are gray to tan and may compress adjacent cortex
- Adrenal medulla normally confined to central region (body) of gland
  - AMH often identifiable by gross extension of gray medullary tissue into alae and tail
  - Nodules often superimposed on diffuse hyperplasia
  - Mild diffuse hyperplasia may require morphometry for confirmation (usually not done in practice)
- On gross examination, as well as radiologic imaging, medullary hyperplasia has poorly defined nodules
  - Unlike pheochromocytoma, which usually presents as an enlarged adrenal nodule arising from medulla
  - Hyperplasia of other paraganglia usually not identifiable macroscopically

Size

- Morphometrically calculated weight of 1 normal adrenal medulla: 0.3-0.5 g (~ 10% of total adrenal weight)
  - AMH often begins as diffuse ↑ in volume and weight
- Carotid body weight ↑ with age
  - Average normal combined weight in adults: < 15 mg (> 30 mg suggests hyperplasia)

MICROSCOPIC PATHOLOGY

Histologic Features

- Shows medullary hyperplasia composed by proliferation of cells containing normal cellular architecture
  - As opposed to nests of cytologically atypical polygonal cells that characterize pheochromocytoma
In MEN2-associated medullary hyperplasia, hyaline globules may be present.

Hyperplastic medullary cells may show various growth patterns: Alveolar, diffuse or solid, and trabecular.

Sometimes, hyperplastic cells are arranged in small nests separated by thin fibrous tissue.

Presence of adrenal medullary tissue in tail indicates presence of adrenal medullary hyperplasia.

Classic AMH shows diffuse medullary expansion with increasing atypia and superimposed nodules.

Adrenal medullary nodules can occur with little or no diffuse hyperplasia.

Medulla does not represent > 1/3 of gland thickness, with cortex on each side comprising the other 2/3.

However, significant cortical atrophy, usually due to exogenous steroid administration, alters ratio and can mimic medullary hyperplasia.

Careful evaluation of cortical anatomy and cytology is required before diagnosis of AMH.

Normal carotid body is divided by thick fibrous septa into variable number of lobes.

Lobes are further divided by thin septa into lobules.

Lobules contain clusters (zellballen) of chief cells with peripheral sustentacular cells.

Carotid body hyperplasia at high altitude:

- ↑ number of lobes and larger lobes with ↑ cellularity caused by chief cell hyperplasia.

Studies variably report proportionate or disproportionate ↑ of sustentacular cells, especially in hyperplasia unrelated to high altitude.

ANCILLARY TESTS

Immunohistochemistry:

- Neuroendocrine markers highlight medullary cells.
  - Chromogranin-A
  - Synaptophysin
  - Neuron-specific enolase (NSE)
  - CD56
  - S100 stain identifies sustentacular cells.

- SDHA and SDHB immunostains help identify SDHx-associated inherited cases.

DIFFERENTIAL DIAGNOSIS

Pheochromocytoma:

- Distinction between AMH and pheochromocytoma can be challenging.
  - Cutoff of 1 cm to differentiate pheochromocytoma from hyperplastic nodule is arbitrary.
    - Some pheochromocytomas may be < 1.0 cm.
    - Benign adrenal nodules in patients with MEN2B can be monoclonal.
    - Both AMH and pheochromocytoma are often monoclonal.
    - Best to consider nodular hyperplasia and small pheochromocytomas as part of continuum of same disease process.

- Presence of unilateral vs. bilateral disease may be helpful in distinguishing AMH from pheochromocytoma (PCC).
  - Unilateral AMH has been reported in isolated and familial AMH.

- Altered macroscopic appearance and histology probably more meaningful.

- Pheochromocytomas have the characteristic alveolar pattern (zellballen) with variably sized nests of tumor cells surrounded by thin-walled vessels and thin bands of fibrous tissue.

- Some pheochromocytomas lack the organoid pattern and instead may show a diffuse growth pattern.

- Some pheochromocytomas show a mosaic-like pattern of often large cells with granular basophilic cytoplasm admixed with cells that have amphophilic to slightly eosinophilic cytoplasm.

- Some pheochromocytomas are formed by small cells with ample eosinophilic cytoplasm with occasional bizarre cells.

Metastatic Carcinoma:

- Can be distinguished by characteristic morphological features.
- Distinguished by immunohistochemical profile.
  - Positivity for chromogranin, synaptophysin, NSE, and CD56 in AMH.
  - Characteristic positivity for S100 in sustentacular cells, when present, helps identifying AMH.

DIAGNOSTIC CHECKLIST

Pathologic Interpretation Pearls.
- Adrenals removed for pheochromocytoma should be carefully examined for additional nodules as clue to presence of MEN2

SELECTED REFERENCES

Image gallery
Gross and Microscopic Features

(Left) Familial medullary hyperplasia is most commonly present in patients with MEN2A and MEN2B and associated with pheochromocytoma. The involvement is usually bilateral, diffuse, and nodular, and often extends to both alae and the tail of the adrenal gland. (Right) The hyperplastic medullary cells may show various growth patterns: Alveolar, solid, or trabecular. This example of adrenal medullary hyperplasia shows an alveolar growth pattern.
(Left) This photomicrography shows an area of adrenal medullary hyperplasia in a patient with MEN2 with a mixed alveolar-trabecular growth pattern. Note the presence of hyaline granules, usually present in MEN2. (Right) In areas of adrenal medullary hyperplasia, the hyperplastic cells may be arranged in small nests of cells, or as single cells, separated by thin fibrous tissue.

(Left) Patients with MEN2 syndrome may have diffuse and nodular adrenal medullary hyperplasia. This picture shows medullary cells within the adrenal cortex. The presence of hyaline granules is usually present in MEN2. (Right) H&E shows that diffuse adrenal medullary hyperplasia has cells arranged in cords and is composed of medullary cells with ample granular basophilic cytoplasm and small nuclei. There is mild nuclear pleomorphism.

**Neuroblastoma**

- Table of Contents > Part II - Diagnoses Associated With Specific Syndromes > Section 5 - Endocrine > Adrenal Medulla > Neuroblastoma
- Neuroblastoma
- Vania Nosé, MD, PhD
- Key Facts
- Terminology
  - Malignant tumor derived from primordial neural crest cells
- Etiology/Pathogenesis
  - Hereditary
    - Inherited cases represent ~ 2-3.5% of new cases
    - Heterozygous mutations in the PHOX2B on 4p12
o ALK mutations
o MYCN amplification
- Patients with familial NB have 20% risk of developing bilateral adrenal and multifocal primary tumors

Clinical Issues
- 85% of patients < 5 years of age
- 4th most common malignant tumor in children
- Follows distribution of sympathetic ganglia
- About 2/3 have metastases on presentation

Microscopic Pathology
- International Neuroblastoma Pathology Committee (INPC) classification
  o Undifferentiated NB
  o Poorly differentiated NB
  o Differentiating NB
  o Nodular ganglioneuroblastoma (GNB)
  o Intermixed GNB

Diagnostic Checklist
- Worse prognosis
  o MYCN amplification
  o Loss of heterozygosity of 1p and 11q

Neuroblastoma (NB) can arise anywhere along the sympathetic chain from the cervical region through the mediastinum and abdomen, including the adrenal gland, to the inferior pelvis.
Gross image shows a large mass arising from the adrenal gland and compressing the upper pole of the kidney. NB is often grossly hemorrhagic with areas of necrosis.

**TERMINOLOGY**

**Abbreviations**

- Neuroblastoma (NB)
- Ganglioneuroblastoma (GNB)

**Synonyms**

- Peripheral neuroblastic tumor
- Schwannian stroma-poor neuroblastic tumor

**Definitions**

- Malignant tumor derived from primordial neural crest cells
  - NB is less differentiated
  - GNB is moderately differentiated, showing variable cytodifferentiation into ganglion cells

**ETIOLOGY/PATHOGENESIS**

**Developmental Anomaly**

- Derived from primordial neural crest cells
  - Migrate from spinal cord to adrenal medulla and sympathetic ganglia

**Hereditary**

- Inherited cases represent ~ 2-3.5% of new cases
  - Heterogeneous etiology
    - Autosomal dominant
    - ALK mutations
    - MYCN amplification
    - Heterozygous mutations in the PHOX2B on 4p12
    - Found in 2 people with nonsyndromic NB
• Suggests a possible oligogenic model in which 2 loci have a synergistic effect on NB
  o Patients with familial NB have 20% risk of developing bilateral adrenal and multifocal primary tumors
  o Patients may have associated ganglioneuroma

CLINICAL ISSUES
Epidemiology
  • Incidence
    o 4th most common malignant tumor in children
    o Usually sporadic
      ▪ Some autosomal dominant familial cases have been seen
  • Age
    o Most cases of familial NB are diagnosed before 1 year of age
    o 1/2 of patients diagnosed by 2 years of age
    o 85% of patients < 5 years of age
    o ~ 20-30% congenital (some detected on ultrasound during pregnancy)
  • Ethnicity
    o Less common in African Americans (very low incidence in “Burkitt lymphoma belt” in Africa)

Site
  • Follows distribution of sympathetic ganglia
    o Abdomen (54%)
      ▪ Adrenal (36%)
      ▪ Extraadrenal (18%)
    o Thorax (14%)
    o Neck (5%)
    o Pelvis (5%)
    o Unknown/others (22%)

Presentation
  • Depends on age of patient, location of tumor, and associated clinical syndromes
  • Most have nonspecific symptoms
    o e.g., fever, weight loss, diarrhea, anemia, hypertension
  • Fetuses may have hydrops
  • Palpable mass
  • ~ 2/3 have metastasis on presentation
  • “Blueberry muffin” baby
  P.II(5):33
    o Blue-red cutaneous lesions in infants
  • Opsoclonus/myoclonus syndrome (dancing eyes, dancing feet)

Laboratory Tests
  • Urine catecholamine metabolites and dopamine have been used for screening
  • Lactate dehydrogenase
    o > 1,500 IU/L associated with worse clinical outcome
  • Ferritin
    o > 142 ng/mL associated with worse clinical outcome
  • Neuron-specific enolase (NSE)
    o > 100 ng/mL associated with worse clinical outcome

Natural History
  • Some cases undergo spontaneous regression, including stage IV-S
    o Most in children < 1 year of age

Treatment
  • Low risk
    o Surgery or observation alone
  • Intermediate risk
    o Surgery and adjuvant chemotherapy
  • High risk
    o Induction chemotherapy
    o Delayed tumor resection
• Radiation of primary site
• Myeloablative chemotherapy with stem cell recovery

• Metastases
  o Bone
  o Lymph nodes
  o Liver
  o Skin

Prognosis
• 5-year survival based on stage at time of diagnosis
  o Stage I: > 90%
  o Stage II: 70-80%
  o Stage III: 40-70%
  o Stage IV
    ▪ < 1 year old: > 60%
    ▪ 1-2 years old: 20%
    ▪ > 2 years old: 10%
  o Stage IV-S: > 80%

• Adverse factors
  o Older age at diagnosis
  o Advanced stage of disease (except IV-S)
  o High histologic grade of tumor
  o Diploid DNA value
  o MYCN oncogene amplification
  o Cytogenetic abnormalities of chromosomes 1 and 17
  o Pattern of urinary catecholamine excretion
  o Increased levels of ferritin, NSE, LDH, creatine kinase BB or chromogranin-A
  o Abnormalities in ganglioside composition
  o Lack of high affinity nerve growth factor receptors

IMAGE FINDINGS
General Features
• Extensive radiographic evaluation is required to determine extent of disease and identify metastatic foci
• Calcifications often seen in central portion of tumor

Bone Scan
• Radiolabeled metaiodobenzylguanidine (MIBG) incorporates into catecholamine-secreting cells and can detect neuroblastoma

MACROSCOPIC FEATURES
General Features
• Color and consistency depend on amount of stroma present (stroma-poor vs. stroma-rich tumors) and presence of hemorrhage and necrosis
• Usually solitary masses
• Cystic degeneration and calcification can be seen

P.II(5):34

MICROSCOPIC PATHOLOGY
Histologic Features
• Neuroblasts
  o Small round blue cells with very scant cytoplasm
• Homer Wright rosettes or pseudorosettes (uncommon)
  o Nuclei grouping in ring-like structures around central cores of tangled neuritic cell processes
• Ganglionic differentiation
  o Cells are enlarged
  o Increased eosinophilic or amphophilic cytoplasm
  o Vesicular chromatin pattern
  o Must have synchronous differentiation of cytoplasm and nucleus
• Neuropil
  o Fibrillar eosinophilic matrix
• Mitotic-karyorrhectic index (MKI), applicable for stroma-poor tumors
  o Count of cells undergoing mitosis or karyorrhexis (per 5,000 cells)
Low: < 100 cells
Intermediate: 100-200 cells
High: > 200 cells

International Neuroblastoma Pathology Committee (INPC) Classification
- a.k.a. Shimada classification
- **Undifferentiated NB**
  - No ganglionic differentiation
  - No neuropil
  - No or minimal schwannian stroma
  - Often requires immunohistochemistry for accurate diagnosis
- **Poorly differentiated NB**
  - < 5% of tumor cells showing ganglionic differentiation
  - Most cells appear undifferentiated
  - Neuropil background
  - No or minimal schwannian stroma
- **Differentiating NB**
  - > 5% of tumor cells showing ganglionic differentiation
  - More abundant neuropil
  - Usually more prominent schwannian stroma
    - Must be < 50%
- **Nodular GNB**
  - Grossly identifiable nodules will be neuroblastoma
  - Abrupt demarcation between stroma-poor neuroblastoma and stroma-rich component
  - Fibrous pseudocapsule often seen surrounding NB component
  - > 50% schwannian stroma
- **Intermixed GNB**
  - Microscopic nests of neuroblastoma within schwannian stroma
  - > 50% schwannian stroma
- Do not classify post-treatment resections
  - “Neuroblastoma with treatment effect” is sufficient
- May classify metastatic disease if resection/biopsy is pretreatment

ANCILLARY TESTS

**Immunohistochemistry**
- NSE
- NB84(+) in almost all NBs
  - Not specific; occasionally positive in other small round cell tumors
- S100 protein
- Other useful positive immunostains include
  - Chromogranin
  - Synaptophysin
  - Protein gene product 9.5 (PGP9.5)
  - CD56

**Cytogenetics**
- MYCN
  - Amplification is associated with worse prognosis
  - Usually seen in advanced disease
- DNA ploidy
  - Near-diploidy or tetraploidy is associated with worse prognosis
  - Hyperdiploidy is associated with better prognosis
- Loss of heterozygosity of 1p and 11q
  - Both associated with worse prognosis
- TrkA (high-affinity nerve growth factor receptor)
  - Increased expression associates with better prognosis

**Electron Microscopy**
- Wide range of cytologic differentiation
- Dense core of neurosecretory granules
  - Found in elongated cell processes
  - 100 nm in diameter
Dense core surrounded by clear halos and delicate outer membranes

**DIFFERENTIAL DIAGNOSIS**

**Ganglioneuroma**
- Differs from intermixed GNB in having single cells instead of nests of cells within schwannian stroma

**Ewing Sarcoma/Primitive Neuroectodermal Tumor (PNET)**
- Usually older patients
- Cells have finely stippled chromatin and glycogen-filled cytoplasm
- CD99 positivity
- Specific gene fusions, most commonly EWSR1-FLI1

**Alveolar Rhabdomyosarcoma**
- Cells with more pleomorphism and abundant cytoplasm
- Immunoreactivity for muscle markers (desmin, myogenin)
- t(1;13) or t(2;13) with PAX-FOXO1 fusion

**Lymphoma**
- Lymphoid immunomarkers (CD45, CD3, CD20)

**SELECTED REFERENCES**


**Favorable vs. Unfavorable Histology in Neuroblastic Tumors**
<table>
<thead>
<tr>
<th>Classification</th>
<th>Subclass</th>
<th>MKI</th>
<th>Age at Diagnosis</th>
<th>Histologic Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuroblastoma (NB)</td>
<td>Undifferentiated</td>
<td>Any MKI</td>
<td>Any age</td>
<td>Unfavorable histology</td>
</tr>
<tr>
<td></td>
<td>Poorly differentiated</td>
<td>High MKI</td>
<td>Any age</td>
<td>Unfavorable histology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Low or intermediate MKI</td>
<td>&gt; 1.5 years</td>
<td>Unfavorable histology</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>&lt; 1.5 years</td>
<td>Favorable histology</td>
</tr>
<tr>
<td></td>
<td>Differentiating</td>
<td>High MKI</td>
<td>Any age</td>
<td>Unfavorable histology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Intermediate MKI</td>
<td>&gt; 1.5 years</td>
<td>Unfavorable histology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Low MKI</td>
<td>&gt; 5 years</td>
<td>Unfavorable histology</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>&lt; 5 years</td>
<td>Favorable histology</td>
</tr>
<tr>
<td>Ganglioneuroblastoma (GNB)</td>
<td>Nodular</td>
<td>*</td>
<td>&lt; 5 years</td>
<td>Unfavorable or favorable histology</td>
</tr>
</tbody>
</table>

*The determination of favorable vs. unfavorable histology in nodular GNB is based on the NB component. Mitosis-karyorrhexis index (MKI).*

**Neuroblastoma Staging System**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Localized confined tumor; complete gross excision; ipsilateral and contralateral nodes negative</td>
</tr>
<tr>
<td>IIA</td>
<td>Unilateral tumor; incomplete gross excision; identifiable ipsilateral and contralateral nodes negative</td>
</tr>
<tr>
<td>IIB</td>
<td>Unilateral tumor ± complete gross excision; identifiable ipsilateral nodes positive, identifiable ipsilateral and contralateral nodes negative</td>
</tr>
<tr>
<td>III</td>
<td>Tumor infiltrating across midline without positive nodes or unilateral tumor with positive contralateral nodes</td>
</tr>
<tr>
<td>IV</td>
<td>Distant metastases to nodes, bone, bone marrow, liver, skin, &amp;/or other organs not stage IV-S</td>
</tr>
<tr>
<td>IV-S</td>
<td>Localized primary tumor (stages 1 or 2) with metastases limited to liver, skin, &amp;/or bone marrow</td>
</tr>
</tbody>
</table>

P.11(5):36

Image gallery
Clinical, Gross, and Microscopic Features
(Left) Child has bilateral orbital masses, clinically presenting with proptosis and ecchymosis. (Right) This is a typical appearance of a nodular ganglioneuroblastoma (GNB). The hemorrhagic nodule is stroma-poor NB whereas the tan, fleshy rim is either ganglioneuroma or intermixed GNB. The diagnosis of nodular GNB requires gross visible nodules.

(Left) This is a GNB from the mediastinum. This image depicts a tumor with a tan firm cut surface, but the gross appearance of GNB depends on how much of the tumor is neuroblastic. (Right) This specimen of liver shows diffuse involvement and extensive replacement by multiple deposits of metastatic NB. There are several foci of hemorrhage.
Undifferentiated NB shows cells with scant cytoplasm with round and hyperchromatic nuclei. The differential diagnosis should include other small blue round cell tumors. The mitotic-karyorrhectic index (MKI) is determined by counting the number of mitoses and karyorrhectic cells per 5,000 tumor cells. MKI counts should be averaged over the entire tumor and not assessed in only the worst-looking areas.

Microscopic Features

(Left) Low-power view of a poorly differentiated NB shows thin septa composed of schwannian stroma. Pale, eosinophilic neuropil is seen in places between the nodules or nests of neuroblastoma cells. (Right) This nodular GNB shows the pushing border between the stroma-poor NB component and the ganglioneuroma component. Even with this histologic picture, a grossly visible nodule is required to diagnose nodular GNB.
(Left) This intermixed GNB shows well-defined nests of maturing neuroblasts, ganglion cells, and neuropil within a schwannian stroma. (Right) This is a focus of metastatic NB in a core biopsy specimen of bone. The marrow has been extensively replaced by sheets of metastatic small round cell tumor and shows no areas with normal trilineage hematopoiesis.

(Left) Mature ganglion cells are characterized by abundant eosinophilic to amphophilic cytoplasm, eccentric nuclei, and prominent nucleoli. Nissl substance may or may not be present. Focally, these cells are admixed with a schwannian stroma. (Right) High-power view of a GNB highlights the maturing ganglion cells in a background of neuropil. The neuropil is composed of a dense tangle of fibrillary, eosinophilic cytoplasmic processes.

Microscopic Features
(Left) In intermixed-type GNB, at least 50% of the tumor must be schwannian stroma. This is characterized by spindled, wavy cells in bundles of varying densities. (Right) This section from an intermixed GNB could be mistaken for a maturing ganglioneuroma (GN). In maturing GN, the tumor is mainly composed of schwannian stroma, and individual neuroblastic cells merge into the schwannian stroma instead of forming distinct nests.

(Left) Low-power view of an intermixed GNB shows maturing ganglion cells →, neuroblasts ←, and neuropil → admixed with schwannian stroma ↑. (Right) At least 50% of the tumor must be composed of schwannian stroma to make the diagnosis of intermixed GNB. This is characterized by spindled, wavy cells in bundles of varying cellularity. The Schwann cells demonstrate nuclear immunoreactivity for S100 protein.
A typical intermixed GNB is seen in this image. The tumor is composed of a mixture of maturing ganglion cells and neuroblasts, and abundant schwannian stroma. (Right) This is an example of differentiating NB, in which > 5% of the neuroblasts show differentiation with increased cytoplasm and vesicular nuclei.

Ancillary Techniques

NSE IHC staining in NBs shows strong diffuse cytoplasmic positivity. NSE is a sensitive marker for NB, although nonspecific. Immunohistochemistry for synaptophysin shows membranous staining. Although not specific, it can be used for differential diagnosis of other small round blue cell tumors of childhood, such as lymphoma, rhabdomyosarcoma, or Ewing sarcoma. These tumors are also positive for chromogranin and CD56.
In this bone marrow trephine specimen, there is diffuse immunoreactivity for NB antigen (NB84) in metastatic deposits of NB that extend between bony trabeculae. (Right) Immunohistochemical staining for ALK1 in NB shows strong membranous staining. Activating mutations in the ALK gene have been reported in NB and provide a potential therapeutic target.

Fluorescence in situ hybridization (FISH) of NB shows marked amplification of N-Myc (multiple confluent green dots). The degree of N-Myc amplification, higher or lower, is not correlated with a worse outcome. (Right) Deletion of 1p might be seen on 70-80% of NB. Here, red dots represent the chromosome 1 centromere, and the green dot represents 1p36 (only 1 chromosomal copy is present).

**Pheochromocytoma/Paraganglioma**

- Use of term pheochromocytoma restricted to adrenal medulla
- Malignancy is defined by documentation of metastases to sites where normal paraganglia are not present

**Etiology/Pathogenesis**
At least 30% of PCCs are hereditary; at least 10 susceptibility genes are now known. Most attributable to mutations in RET, VHL, NF1, SDHA, SDHB, SDHC, SDHD, SDHAF2, KIF1B, TMEM127, and MAX. SDHx mutations account for up to 80% of familial PCC/PGL aggregations, 30% of pediatric tumors, and ~50% of malignant tumors. SDHB mutation associated with extraadrenal abdominal location, high probability of metastasis, and poor prognosis.

**Clinical Issues**
- Identification of patients with hereditary PCC involves clinical assessment, biochemical testing, and pathology leading to directed genetic testing.

**Microscopic Pathology**
- Classic pattern is small nests (zellballen) of neuroendocrine cells with interspersed small blood vessels.

**Ancillary Tests**
- Immunohistochemistry for SDHB and SDHA can triage patients for appropriate genetic testing.

The typical pheochromocytoma has a gray-pink cut surface with areas of hemorrhage, which distinguishes it from the yellow-brown of adrenal cortex.
Pheochromocytomas in patients with multiple endocrine neoplasia type 2 (MEN2) syndromes may have numerous hyaline globules that are particularly conspicuous in pheochromocytomas of these patients.

**TERMINOLOGY**

**Abbreviations**
- Pheochromocytoma (PCC)
- Paraganglioma (PGL)

**Definitions**
- Normal paraganglia consist of neural crest-derived neuroendocrine cells associated with sympathetic and parasympathetic nerves
- Adrenal medulla and organ of Zuckerkandl are major sympathetic paraganglia; others are microscopic
- Carotid bodies are major parasympathetic paraganglia; others are microscopic
- PCC and PGL are catecholamine-secreting tumors of neural crest origin that arise from the adrenal medulla or extraadrenal sympathetic paraganglia, respectively
- World Health Organization definitions of 2004 arbitrarily established terminology for tumors of paraganglia to eliminate previous inconsistent usage
  - PCC: Neuroendocrine tumor arising from chromaffin cells of adrenal medulla
  - Similar tumors in other locations are extraadrenal PGL (often abbreviated in practice to just PGL)
    - Sympathetic (sympathoadrenal) PGLs arise in vicinity of sympathetic chains and along sympathetic nerve branches in pelvic organs and retroperitoneum
    - Parasympathetic PGL (a.k.a. head and neck PGL [HNP]) arise mainly from branches of vagus and glossopharyngeal nerves in head and neck, sometimes mediastinum
    - PCC is an intraadrenal sympathetic PGL

**ETIOLOGY/PATHOGENESIS**

**Hereditary PCC/PGL**
- Over the last decade, extensive genetic heterogeneity of these tumors came to light with identification of multiple susceptibility genes
Most striking feature is genetic diversity

- ≥ 1/3 of PCCs/PGLs are hereditary
  - These mutations account for ≥ 1/3 of PCC and PGL
    - Highest inheritable proportion of any known human tumor
  - Occult germline mutations of susceptibility genes common in patients with apparently sporadic tumors
  - ≥ 10 susceptibility genes now established

- Most attributable to mutations in RET, VHL, NF1, SDHA, SDHB, SDHC, SDHD, SDHAF2, KIF1B, TMEM127, and MAX
- Most recently identified hereditary forms of PCC and PGL are SDHx, transmembrane-encoding gene, TMEM127, and MYC-binding partner, MAX
  - Greater understanding of molecular signals transduced by these genes and their respective mutants has advanced our understanding of kinase signaling pathways, hypoxia regulation, and link between metabolic disruptions and cell growth

- Multiple endocrine neoplasia type 2 ( MEN2)
  - Autosomal dominant syndrome caused by mutation of RET proto-oncogene
  - Activating RET mutations predispose to PCCs, which are often recurrent and bilateral but typically have a low risk of malignancy
  - PCC are bilateral in 50-80% of cases but are almost always benign

- Familial PGL/PCC syndromes
  - PGL syndromes encompass a group of inherited syndromes which involve mutations in the genes that encode components of the succinate dehydrogenase (SDH) mitochondrial enzyme complex 2
    - SDH is composed of 4 subunits: A, B, C, and D
  - Germline mutations in SDHx genes give rise to familial PCC/PGL syndrome, sometimes only referred to as familial PGL
  - Associated with germline mutations in genes encoding subunits of SDH enzyme complex in context of familial PGL syndromes
    - PGL1, PGL2, PGL3, and PGL4 caused by mutations in the SDHD, SDHAF2, SDHC, and SDHB genes, respectively
    - Familial PGL syndrome, PGL2, is caused by mutations in SDHAF2/SDH5, which encodes for a molecule that is an accessory to the function of the SDH enzyme and its SDHA subunit
    - SDHA-related PGLs are rare and are caused by loss-of-function mutation in SDHA

- Carney triad
  - Mean age of presentation of PGL/PCC: 28 years
    - Only 16% present with PCC

- von Hippel-Lindau syndrome (VHL)
  - Autosomal dominant disorder caused by mutation of VHL
  - About 10-26% of VHL patients develop PCC or PGL, but risk varies between different families
  - Frequency of PCC in individuals with VHL is 10-20%
  - Mean age of onset of PCC in VHL: ~ 30 years

- Neurofibromatosis type 1 (NF1)
  - Autosomal dominant disorder caused by mutation of NF1
  - PCCs occur in 20-50% of individuals with NF1 and hypertension
  - NF1-associated PCCs and PGLs typically have characteristics similar to those of sporadic tumors, with a relatively late mean age of onset and about 10% risk of malignancy
  - Gangliocytic duodenal PGL may occur in patients with NF1
  - Approximately 84% of PCC are unilateral

- Carney-Stratakis dyad
  - Inherited predisposition to gastrointestinal stromal tumor (GIST) and PGL caused by inactivating germline mutations in SDHB, SDHC, or SDHD
  - Only rare cases reported to be associated with PCC

- Most recently identified hereditary forms of PCC and PGL are transmembrane-encoding gene, TMEM127, and MYC-binding partner, MAX
  - So far, no specific syndrome has been described for TMEM127
  - MAX mutations occur in families with PCC, but no specific syndrome has been described yet

Sporadic PCC/PGL
Majority of PCCs appear to arise sporadically
- Only occasionally harbor somatic mutations except for NF1, which is mutated in > 25% of sporadic tumors
  - Germline mutations in known susceptibility genes may be seen in up to 16% of sporadic-appearing cases
- Changes in copy number of hereditary susceptibility genes may be present

Environmental Influences
- High-altitude PGL in people and cattle living in mountainous areas of some countries
  - Mostly carotid PGL

CLINICAL ISSUES

Site
- ~98% of sympathetic PGLs are located in abdomen or pelvis; 90% are adrenal PCCs
- Most parasympathetic PGLs are carotid, jugulotympanic, or vagal

Presentation
- Depends on tumor location
  - Sympathoadrenal PCCs/PGLs usually cause signs and symptoms of catecholamine excess
  - Tumors with SDHB gene mutation are more likely than other sympathoadrenal PCCs/PGLs to be clinically silent
  - Parasympathetic PGLs are usually clinically silent mass lesions
- Hereditary PCC/PGL often found after other stigmata point to hereditary tumor syndrome (usually MEN2, VHL, NF1)
- Gastrointestinal stromal tumors are important component of several new syndromes with mutated SDHx
- Variants of some hereditary syndromes can cause only PCC/PGL (VHL type 2C)
- Mutations of some genes (e.g., TMEM127) cause hereditary but nonsyndromic PCC/PGL (no associated abnormalities)
- Affected by genotype
  - Sporadic tumors solitary, usually in adults
  - Multiple tumors or tumors presenting in children suggest hereditary disease
  - Tumors with RET or NF1 mutations almost always intraadrenal
  - Abdominal PGL or combination of sympathetic and parasympathetic PCC/PGL suggests SDHx mutation
- SDHD- and SDHAF2-related PGL show parent-of-origin dependent expression; tumor development only with paternal inheritance
- Identification of patients with hereditary PCC/PGL involves clinical assessment, biochemical testing, and pathology leading to directed genetic testing

Laboratory Tests
- Plasma metanephrine and normetanephrine more sensitive than corresponding catecholamines for tumor detection
  - Methoxytyramine: New marker sometimes produced by clinically nonfunctional tumors, especially with SDH mutations
- PCC can be adrenergic or noradrenergic; extraadrenal PGL almost always noradrenergic; HNP can lack ability for catecholamine biosynthesis
- Genotype affects biochemical function
  - Noradrenergic PCC raises suspicion of VHL

Treatment
- Complete surgical excision is only cure
- Unresectable primary tumors and metastases can have long doubling time; watchful waiting often a viable option

Prognosis
- Most patients with metastases eventually die from complications of excess catecholamines or destructive local growth

Malignancy
- World Health Organization 2004 defines malignancy by presence of metastasis
  - Must be to sites where normal paraganglia are not present to avoid confusion with new primary tumor
- Currently, no generally accepted histological criteria to predict whether primary PCC or PGL will metastasize
Extensive local invasion alone is a poor predictor of metastasis. The predictive value of tumor size is controversial. Risk of metastasis and prognosis vary with tumor location and genotype. Approximately 10% of metastasis for PCCs, > 20% for PGLs. Best predictor of metastasis is the presence of SDHB mutation (>30%). After metastases occur, the worst prognosis is for tumors caused by SDHB mutation. Metastases can develop years or decades after resection of the primary tumor. Currently recommended that no PCC/PGL be signed out as benign; all patients receive lifelong follow-up.

**Image Findings**

**General Features**

- Anatomic imaging
  - MR: Very intense T2-weighted image (light bulb sign) is classic but not always present
  - Contrast-enhanced CT
- Functional imaging
  - More specific because based on specific aspects of tumor phenotype
  - More sensitive for small tumors or metastases in bone
  - Efficacy of different functional imaging techniques varies according to tumor genotype

**Macroscopic Features**

- Cut surface usually pink-gray to tan, distinguishes PCCs from yellow-gold of most adrenal cortical tumors
- Occasional tumors show patchy or diffuse brown pigmentation
- Cystic degeneration and necrosis sometimes present
- Medullary hyperplasia, when present, may indicate hereditary form of the disease

**Microscopic Pathology**

**Histologic Features**

- Classic pattern is small nests (zellballen) of neuroendocrine cells (chief cells) with interspersed small blood vessels
- Numerous variant and combined patterns exist, including diffuse growth, large zellballen, spindle cells, cell cords
- Sustentacular cells variably present, best seen with IHC
  - Possibly nonneoplastic cell type induced or attracted by tumor-derived factors
- Cavernous blood vessels sometimes prominent, especially in HNP

**Cytologic Features**

- Tumor cells smaller or larger than normal chromaffin cells, inconspicuous or large nucleoli
- Nuclear pseudoinclusions, embracing cells, extracellular hyaline globules variably present
- Basophilic, amphophilic, or clear cytoplasm
  - Clear cytoplasm particularly likely in parasympathetic PGL
- Extreme pleomorphism and hyperchromasia can be seen in benign tumors
- Mitoses usually rare

**Ancillary Tests**

**Immunohistochemistry**

- Generic neuroendocrine markers chromogranin (CgA or CgB) and synaptophysin are usually positive in chief cells; keratins are usually negative
  - Parasympathetic PGL can be negative for CgA and positive for CgB
- Sustentacular cells stain for S100
- Tyrosine hydroxylase (TYH) identifies ability to synthesize catecholamines; can be negative, especially in parasympathetic PGL
  - Elevated metanephrine after resection of TYH(-) PGL suggests 2nd primary, not metastasis
- SDHB and SDHA important new surrogate markers to triage patients for genetic testing
  - SDHB protein lost in PCC/PGL with SDHA, SDHB, SDHC, or SDHD mutations; SDHA protein lost only when SDHA is mutated
  - Sustentacular and endothelial cells serve as intrinsic positive controls for SDHB

**Molecular Genetics**

- Major genes causing hereditary PCCs/PGLs are RET (causes MEN2A and MEN2B), VHL, NF1, SDHx
SDHx mutations account for up to 80% of familial PCC/PGL aggregations, 30% of pediatric tumors, > 40% of malignant tumors.

**Gene Expression Profiling**
- Tumors with VHL or SDHx mutations have hypoxia-associated gene expression profile
- Tumors with RET and NF1 mutations characterized by expression of genes that mediate kinase signaling, translation initiation, protein synthesis, anabolic functions of activated RAS
  - Sporadic tumors or those with other mutations often segregate with 1 or other gene profile cluster

**DIFFERENTIAL DIAGNOSIS**

### Adrenal Cortical Carcinoma
- Synaptophysin immunoreactivity present in both cortical and medullary tumors and should not be used in this differential diagnosis
- Chromogranin (-), TYH(-), inhibin (+)

### Other Neuroendocrine Tumors (NETs)
- Neuroendocrine carcinomas and carcinoids, pancreatic endocrine tumors, medullary thyroid carcinoma
- Chromogranin and keratins are positive
- TYH usually negative but positive in some intestinal neuroendocrine tumors
- Tissue-specific hormones (e.g., calcitonin in medullary thyroid carcinoma, serotonin in intestinal NETs) are helpful but some can be produced ectopically in PCC/PGL

### Hepatocellular Carcinomas
- Absence of neuroendocrine markers, presence of keratins &/or tissue-specific markers

### Renal Cell Carcinoma (RCC)
- Absence of neuroendocrine markers, presence of keratins &/or CD10, RCC, and other tissue-specific markers

### Alveolar Soft Part Sarcomas
- Absence of neuroendocrine markers, presence of soft tissue-specific marker: TFE3

### Glomus Tumors and Glomangiomas
- Location: Outside adrenal
- Presence of neuroendocrine markers, S100, GFAP

### Squamous Cell Carcinomas
- Absence of neuroendocrine markers, presence of keratins &/or p63

### SELECTED REFERENCES

### Tables

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Gene (Chromosome)</th>
<th>Adrenal</th>
<th>Other sympathhetic</th>
<th>Head &amp; Neck</th>
<th>Other Tumors</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEN2A and MEN2B</td>
<td>RET (10q11)</td>
<td>+++</td>
<td>+/-</td>
<td>+/-</td>
<td>Medullary thyroid carcinoma, parathyroid adenoma (MEN2A only)</td>
</tr>
<tr>
<td>VHL</td>
<td>VHL (3p25-26)</td>
<td>+++</td>
<td>++</td>
<td>+/-</td>
<td>RCC, hemangioblastoma, endolymphatic sac tumor, neuroendocrine tumor (carcinoid), pancreatic endocrine tumor</td>
</tr>
<tr>
<td>NF1</td>
<td>NF1 (17q11.2)</td>
<td>+++</td>
<td>+/-</td>
<td>+/-</td>
<td>Neurofibroma, gastrointestinal stromal tumor (GIST), neuroendocrine tumor (carcinoid)</td>
</tr>
<tr>
<td>PGL1</td>
<td>SDHD (11q23)</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td></td>
</tr>
<tr>
<td>PGL2</td>
<td>SDHAF2 (assembly factor for SDH complex)</td>
<td>+/-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGL3</td>
<td>SDHC (1q21-23)</td>
<td>+/-</td>
<td>+/-</td>
<td>+++</td>
<td>GIST</td>
</tr>
<tr>
<td>PGL4</td>
<td>SDHB (1p36)</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>RCC, GIST</td>
</tr>
<tr>
<td>SDHA related</td>
<td>SDHA</td>
<td>+</td>
<td></td>
<td></td>
<td>GIST</td>
</tr>
<tr>
<td>Carney-Stratakis dyad</td>
<td>SDHB, SDHC, or SDHD</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>GIST</td>
</tr>
<tr>
<td>Familial pheochromocytoma</td>
<td>TMEM127</td>
<td>+</td>
<td>+/-</td>
<td>+/-</td>
<td></td>
</tr>
<tr>
<td>--------------------------</td>
<td>----------</td>
<td>----</td>
<td>-----</td>
<td>-----</td>
<td></td>
</tr>
<tr>
<td>2q</td>
<td>(membrane protein involved in protein trafficking)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAX related</td>
<td>MAX</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KIF1Bβ related</td>
<td>KIF1Bβ</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GIST: Gastrointestinal stromal tumor; RCC: Renal cell carcinoma.

P.II(5):45

Image gallery
Associated Tumors and Lesions

(Left) Neurofibromatosis (NF) is characterized by involvement of the neural crest and bony dysplasia. This axial graphic depicts sphenoid dysplasia with arachnoid cyst, optic nerve glioma, buphthalmos, and multiple plexiform NFs. PCC occurs in 20-50% of NF1 patients. (Right) Patients with NF1 may develop duodenal gangliocytic parangangioma (PGL). S100 stain shows staining of sustentacular cells, which sometimes have conspicuous cytoplasmic processes.

(Left) Graphic representation of abdominal lesions in von Hippel-Lindau (VHL) syndrome shows multiple bilateral renal cysts, renal tumors, pancreatic cysts, and pheochromocytoma (PCC). PCC or PGL occurs in about 10-26% of VHL patients. (Right) Endolymphatic sac tumors typically show a papillary architecture with fibrovascular cores.
and a single row of columnar epithelium with pale eosinophilic cytoplasm. These tumors are usually present in VHL syndrome.

(Left) Gross photograph shows a small intestinal gastrointestinal stromal tumor (GIST). These tumors may be associated with pheochromocytomas &/or paragangliomas in some familial PGL/PCC syndromes. (Right) GISTs associated with paragangliomas in some syndromes are negative for SDHB, with preservation of SDHA. Pediatric GISTs may have the same phenotype.

Gross and Imaging Features

(Left) Gross image shows the cut surface of a well-circumscribed adrenal pheochromocytoma with a central area of necrosis and with hemorrhage. Note small amount of residual adrenal cortex. (Right) Axial CECT shows a large, well-circumscribed, moderately enhancing right adrenal pheochromocytoma with a hypodense area of necrosis.
This graph shows both adrenal medullary hyperplasia and MEN2 pheochromocytoma. Adrenal medullary hyperplasia is characteristic of MEN2. (Right) This adrenal gland shows both MEN2-associated adrenal medullary hyperplasia and a pheochromocytoma. Adrenal medullary hyperplasia is characteristic of MEN2.

(Left) This adrenal gland shows both MEN2-associated pheochromocytoma and adrenal medullary hyperplasia, which is characteristic of MEN2. The cut surface is gray-pink, which distinguishes it from the yellow adrenal cortex. (Right) Gross photograph shows the cut surface of a well-circumscribed adrenal pheochromocytoma with an area of hemorrhage. The gross appearance of pheochromocytomas is variable and may mimic other tumors. Small residual adrenal cortex is present.

P.II(5):47

Variant Microscopic Features
The classic histologic pattern of pheochromocytoma is a small zellballen cellular arrangement. The group of cells is surrounded by a thin fibrovascular core. The cells have both eosinophilic and pale cytoplasm. The growth of this PCC is patternless with thin fibrous septae, but lacking the zellballen cellular arrangement. There is marked variability in cell size, with scattered pleomorphic cells surrounded by tumor cells with clear cytoplasm.

Hyaline globules are particularly conspicuous in pheochromocytomas of patients with MEN2. Pheochromocytoma may contain cells with ample basophilic, amphophilic, or clear cytoplasm. This figure highlights the characteristic basophilic granular cytoplasm of some of these tumors.
A mitotic figure is present in this malignant pheochromocytoma with a diffuse pattern, lacking the classic zellballen pattern. This tumor is composed of compact eosinophilic cells, which may be associated with more aggressive behavior. Although the classic histologic pattern of pheochromocytoma is a zellballen pattern, numerous variants and combined patterns exist, including diffuse growth, large zellballen, spindle cells, and cell cords. Note the mitotic figure.

SDHB and SDHA Immunohistochemical Features

(Left) Familial PCCs in syndromes other than those with mutations of SDHx genes show maintained coarse granular immunoreactivity of tumor cell cytoplasm for SDHB. Patients with VHL may have decreased or even absent immunoreactivity of SDHB. (Right) Familial PCCs without mutations of SDHx genes but with other inherited familial pheochromocytoma show coarse granular immunoreactivity of tumor cell cytoplasm for SDHA and SDHB proteins.
Familial pheochromocytomas without mutations of SDHx genes and with other mutations show coarse granular immunoreactivity of tumor cell cytoplasm for SDHB protein. (Right) Tumor cells in PCC with mutations of the SDHA, SDHB, SDHC, or SDHD genes are negative for SDHB protein whereas sustentacular cells and endothelial cells serve as intrinsic positive controls.

(Left) Pheochromocytomas and other paragangliomas without mutations of SDHx genes show immunoreactivity of tumor cell cytoplasm for SDHB protein. The staining is coarsely granular because the protein is localized to mitochondria. (Right) Tumor cells in PCC with mutations of the SDHA gene are negative for SDHA protein. Rare cases have been reported. The sustentacular cells and endothelial cells serve as intrinsic positive controls.

P.II(5):49

Ancillary Techniques
Chromogranin-A immunostain shows granular immunoreactivity in the neuroendocrine cell nests between cavernous blood vessels in a carotid PGL. Note the negativity of the endothelial cells for this marker. Chromogranin-A immunostain may show great variability of staining in pheochromocytomas. There is variable granular immunoreactivity in the neuroendocrine cell nests.

Synaptophysin immunostain shows granular immunoreactivity in the nests of neuroendocrine cells of a pheochromocytoma in a patient with MEN2A. Synaptophysin immunostain shows homogeneous, finely granular immunoreactivity throughout the tumor, with less variability in staining in the neuroendocrine cells of a pheochromocytoma in a patient with MEN2A.
S100 stain shows nuclear and cytoplasmic staining of sustentacular cells, which sometimes have conspicuous cytoplasmic processes. The chief cells are usually negative for this marker but sometimes may show weak staining.

A high Ki-67 labeling index is unusual in PCC/PGL and, when present, may be associated with aggressive tumor behavior. This carotid PGL showed angioinvasion and soft tissue infiltration. (Courtesy A. Tischler, MD.)

Paraganglioma

Syndromes characterized by susceptibility to pheochromocytoma and paraganglioma
- Multiple endocrine neoplasia type 2 (MEN2)
- von Hippel-Lindau (VHL) disease
- Neurofibromatosis type 1 (NF1)
- Mutations in genes encoding different subunits of SDH complex have been linked to familial pheochromocytoma/paraganglioma (PCC/PGL) syndrome (PGL1, 2, 3, and 4)
- Small fraction associated with other syndromes, including Carney triad, Carney-Stratakis syndrome, and MEN1
- Several other genes, such as KIF1B, EGLN1/PHD2, TMEM127, and MAX have recently been added to list

Clinical Issues
- Up to 50% of people with malignant extraadrenal PGLs have a germline SDHB mutation

Macroscopic Features
- Multifocal, bilateral, with multiple synchronous or metachronous tumors

Microscopic Pathology
- Histological features of familial paragangliomas are similar to those of tumors that occur sporadically

Ancillary Tests
- SDHB immunostain is decreased &/or absent in tumors of patients with SDHB or SDHD mutation
This coronal graphic shows a highly vascular glomus tympanicum paraganglioma extending out of the cochlear promontory, filling the middle ear cavity, and subtly expanding into the bony floor.
This highly vascular glomus tympanicum paraganglioma shows nests of tumor cells intermixed with vascular channels. These richly vascularized tumors may show large hemorrhagic areas.

**TERMINOLOGY**

**Abbreviations**
- Paraganglioma (PGL)

**Synonyms**
- Hereditary paraganglioma/pheochromocytoma (PGL/PCC) syndromes

**Definitions**
- **Pheochromocytomas (PCCs)** and PGLs are neuroendocrine tumors that arise in adrenal medulla or extraadrenal sympathetic and parasympathetic paraganglia
- **PGLs** arise from neuroendocrine tissues symmetrically distributed along paravertebral axis from their predominant location at base of skull and neck to pelvis
- **Paragangliomas** are classified by location and secretory status
  - Sympathetic: Hypersecrete catecholamines
    - Arise from chromaffin cells of paraganglia along the sympathetic chains and are usually located in the chest, abdomen, or pelvis
  - Parasympathetic: Do not hypersecrete catecholamines
    - Arise from the glomera that are distributed along parasympathetic nerves in the head, neck, and upper mediastinum and are therefore also referred to as head and neck PGLs
- **Pheochromocytomas** are catecholamine-secreting PGLs confined to adrenal medulla
  - a.k.a. adrenal chromaffin tumors
    - Another term for any sympathetic (catecholamine-secreting) neuroendocrine cell/tumor regardless of location
    - Chromaffin refers to brown-black color that results from oxidization and polymerization of catecholamines contained in cells/tumors by chromium salts, such as potassium dichromate
- Occurs sporadically or as part of different hereditary tumor syndromes
> 30% of PCCs and PGLs are currently believed to be caused by germline mutations, and several novel susceptibility genes have recently been discovered

- Genes RET, VHL, NF1, SDHA, SDHB, SDHC, SDHD, SDHAF2, KIF1B, TMEM127, and MAX have been associated with hereditary PCC or PGL
- Hereditary PGL/PCC syndromes should be considered in all individuals with PGL or PCC with the following findings
  - Multiple tumors, including bilateral tumors
  - Recurrent PGLs and PCCs
  - Early onset (age < 40 years)
  - Multifocal with multiple synchronous or metachronous tumors
  - Family history of such tumors

- Simplex cases: Many individuals with a hereditary PGL/PCC syndrome may present with solitary tumor of head or neck, thorax, abdomen, adrenal, or pelvis and no family history of the disorder

**ETIOLOGY/PATHOGENESIS**

**Inherited**

- Most attributable to mutations in RET, VHL, NF1, SDHA, SDHB, SDHC, SDHD, SDHAF2, KIF1B, TMEM127, and MAX
- Syndromes characterized by susceptibility to pheochromocytoma and paraganglioma
  - Multiple endocrine neoplasia type 2 (MEN2), von Hippel-Lindau (VHL) disease, and neurofibromatosis type 1 (NF1)
  - Small fraction associated with other syndromes, including Carney triad, Carney-Stratakis syndrome, and MEN1

- Mutations in genes encoding different subunits of succinate dehydrogenase (SDH) complex have been linked to familial PCC/PGL syndrome (PGL1, 2, 3, and 4)

**Multiple Endocrine Neoplasia Type 2 (MEN2)**

- Autosomal dominant syndrome caused by mutation of RET proto-oncogene
- Mean age at PCC presentation: 36 years
- Clinically, it can be divided into 3 types: MEN2A (55% of all cases), MEN2B (5-10%), and familial medullary thyroid carcinoma (FMTC, 35-40%)
- ~ 50% of individuals with MEN2A and MEN2B develop PCC
- Activating RET mutations predispose patients to PCCs, which are often recurrent and bilateral, but typically have a low risk of malignancy
- PCCs are bilateral in 50-80% of cases but are almost always benign
- PGLs very rare in MEN2, and only a few cases of sympathetic and parasympathetic PGL have been described

**PGL/PCC Syndromes**

- Germline mutations in the SDHx genes give rise to familial PCC/PGL syndrome, sometimes only referred to as familial PGL
- Hereditary PGL/PCC syndromes caused by mutation in 1 gene encoding 3 of 4 subunits of SDH are within differential diagnosis for all individuals with PGL and PCC
- Prevalence of PCC/PGL syndrome is unknown, but a review of ~ 13% of all PCC/PGL cases gives an estimate of 1:50,000 to 1:20,000

**VHL Syndrome**

- Autosomal dominant disorder caused by mutation of VHL
- ~ 10-26% of VHL patients develop PCC or PGL, but risk varies between different families
  - Frequency of PCC in individuals with VHL is 10-20%
- Mean age of onset of PCC in VHL: ~ 30 years
- VHL mutations predispose to unilateral or bilateral PCCs and, much less frequently, to sympathetic or parasympathetic PGLs
- ~ 5% of VHL-related catecholamine-secreting tumors become malignant, most commonly extraadrenal sympathetic PGL
- Mean age at diagnosis of PCC/PGL: 29 years

**Neurofibromatosis Type 1 (NF1)**

- Autosomal dominant disorder caused by mutation of NF1
- PCCs and PGLs are not among most common manifestations of NF1 but occur in 0.1-5.7% of patients
- PCCs occur in 20-50% of individuals with NF1 and hypertension
Diagnostic Pathology: Familial Cancer Syndromes

- Gangliocytic PGL of duodenum occurs in patients with NF1
- NF1-associated PCCs and PGLs typically have characteristics similar to those of sporadic tumors, with a relatively late mean age of onset and ~ 10% risk of malignancy
- Up to 84% of PCCs are unilateral

Carney Triad
- Extremely rare disorder that primarily affects young women
- Mean age at presentation with PGL/PCC: 28 years
  - ~ 85-90% present with PGL, including both sympathetic and parasympathetic tumors, and 10-15% present with PCC
- Metastasis occurs in ~ 1% of patients

Carney-Stratakis Syndrome
- Inherited predisposition to gastrointestinal stromal tumor (GIST) and PGL that is caused by inactivating germline mutations in SDHB, SDHC, or SDHD
  - Association of PGL and GISTS (dyad)
- PGLs occur in head and neck, thorax, and abdomen
- 100% had PGL and 1 patient also presented with unilateral PCC

Other Syndromes
- MEN1: No cases of PGL and only 7 cases of PCC in MEN1 syndrome have been reported in the literature
- Several other genes have recently been added to list of genes associated with unknown hereditary PGL/PCC
  - Kinesin family member 1B (KIF1B)
  - EGL 9 homolog 1 (EGLN1), also termed PHD2
  - Transmembrane protein 127 (TMEM127)
  - MYC-associated factor X (MAX)
- No specific syndrome has been attributed yet, but patients with germline KIF1Bβ mutations seem to be predisposed to at least PCCs and neuroblastomas
  - Ganglioneuroma, leiomyosarcoma, and lung adenocarcinoma have also been reported in a family with KIF1Bβ mutations
- Only 1 PGL patient, suffering from recurrent PGL and erythrocytosis, has been reported to have a germline mutation in EGLN1
  - Presentation with sympathetic PGL and a recurrent tumor was diagnosed 3 years later, but no metastases have been reported
- So far, no specific syndrome has been described for TMEM127
  - TMEM127 mutations were identified in 2% of cases considered sporadic, all of which had PCC
  - 96% of patients have PCC, and 39% have bilateral PCC
- MAX mutations segregate with disease in families with PCC, but no specific syndrome has been described yet
  - Usually bilateral tumors, early age of onset, &/or familial antecedents with disease
  - Notably, 25% of patients showed metastasis at diagnosis, suggesting that MAX mutations are associated with high risk of malignancy
  - So far, no studies on PGLs have been reported

CLINICAL ISSUES

Epidemiology
- Incidence
  - Annual incidence has been reported to be 2-10 per million
  - Prevalence is unknown but has been estimated to be between 1:6,500 and 1:2,500 in the United States
  - Autopsy series have revealed a higher prevalence of ~ 1:2,000, suggesting that many tumors remain undiagnosed
- Age
  - Tumors may occur in all ages but have the highest incidence between 40 and 50 years, with an approximately equal sex distribution

Presentation
- Diagnosis of PGL and PCC is based on physical examination, imaging studies, biochemical testing, and pathology findings
Clinical presentation, including localization, malignant potential, and age of onset varies depending on genetic background of tumors

- Symptoms of PGL/PCC result from either
  - Mass effect
  - Catecholamine hypersecretion: Sustained/paroxysmal elevations in blood pressure, headache, episodic sweating, palpitations, pallor, and anxiety

- PCCs and sympathetic PGLs are very similar histologically as well as functionally: Produce large amounts of catecholamines, mainly adrenaline and noradrenaline
  - Tumors usually cause hypertension, which may be either paroxysmal or sustained

- Up to 10% of patients have minor or no signs of clinical symptoms
- Increasing number of tumors are incidentally found during imaging studies
- Parasympathetic PGLs are histologically similar to PCCs and sympathetic PGLs, but parasympathetic PGLs are usually not functional and many patients are nonsymptomatic

- Majority of PCCs and PGLs are benign
- Malignancy is defined as presence of distant metastases and occurs in 5-13% of PCCs
  - Most common sites for metastasis are bone, liver, and lung
  - Prognosis of malignant PCC and PGL is poor, with a 5-year mortality rate > 50%

Laboratory Tests

- Catecholamines hypersecreted by PGL/PCC can be epinephrine (adrenaline), norepinephrine (noradrenaline), or dopamine
- When a catecholamine-secreting tumor is suspected, plasma &/or 24-hour urinary fractionated metanephrine or catecholamines are evaluated for catecholamine hypersecretion
- Measurement of fractionated metanephrine concentrations in plasma or urine is preferred
- False-positive results may be reduced by follow-up testing for plasma chromogranin-A &/or urine fractionated metanephrine levels
- Secretion of norepinephrine with little or no epinephrine suggests extraadrenal PGL or PCC associated with von Hippel-Lindau syndrome

Treatment

- Treatment of manifestations
  - For secretory tumors including PCC: Antagonism of catecholamine excess followed by surgery
  - For nonsecretory head and neck PGL: Surgical resection
  - PGL/PCCs identified in SDHB-mutation-positive individuals require prompt resection due to high risk of malignant transformation

IMAGE FINDINGS

General Features

- MR/CT
  - PGLs may be identified anywhere along paravertebral axis from head to pelvis, including paraortic sympathetic chain and urinary bladder
  - Common sites of neoplasia are near renal vessels and in organ of Zuckerkandl
  - Multiple tumors can be present

MACROSCOPIC FEATURES

General Features

- Fairly well circumscribed, tan, rubbery-firm mass with fibrous pseudocapsule

MICROSCOPIC PATHOLOGY

Histologic Features

- Inherited tumors are similar to sporadically occurring tumors
- Classic pattern is small nests of cells (zellballen) with interspersed small blood vessels
  - Numerous other patterns and combined patterns: Diffuse growth, large zellballen, spindle cells, cell cords
- Tumor cells smaller or larger than normal chromaffin cells, inconspicuous or large nucleoli

ANCILLARY TESTS

Immunohistochemistry

- Features similar to those of sporadic tumors
  - Chromogranin and synaptophysin (neuroendocrine markers) positive; keratins usually negative
- SDHA and SDHB are important surrogate markers to triage patients for genetic testing
SDHB immunostain is decreased &/or absent in tumors of patients with SDHB, SDHC, or SDHD mutation
SDHA immunostain is decreased/absent in tumors of patients with SDHA mutation

DIFFERENTIAL DIAGNOSIS
Sporadic PGL/PCC
- Sporadic tumors constitute majority of PCCs and PGLs
- Patients are generally somewhat older at onset
- Patients with sporadic PGLs/PCCs have a lower rate of multiple tumors than do those with familial disease
- Rate of inherited mutations in patients with negative family history has been reported to be 11-24%
- Of patients with apparently sporadic PCC or PGL, 73% have PCC, and 29% have PGL (9% sympathetic and 20% parasympathetic PGL)
- Bilateral PCC was seen in 6% of patients and multiple PGLs in only 1%
- Average age at presentation: 48 years
- 9% of patients had malignant disease
- Negative for mutations in RET, VHL, SDHB, SDHC, and SDHD and showed no clinical signs of NF1 syndrome

SELECTED REFERENCES
P.II(5):54
(Left) Graphic shows paraganglia and neuroendocrine tissues symmetrically distributed along the paravertebral axis from the base of the skull to the pelvis, including the adrenal medulla. (Right) Graphic shows paraganglia in head, neck, and upper thorax that are associated with arteries or cranial nerves. They include aortic and carotid bodies and jugulotympanic, vagal, and laryngeal paraganglia.

(Left) Graphic shows paraganglia and neuroendocrine tissues symmetrically distributed along the paravertebral axis in the abdomen, including the organ of Zuckerkandl and the adrenal medulla. (Right) Axial T2WI MR with fat suppression shows a large glomus vagale paraganglioma as a hyperintense right carotid space mass with subtle internal flow voids. Internal carotid artery on the anterior surface is shown.
(Left) This richly vascularized paraganglioma shows vascular channels interspersed with nests of paraganglioma cells. In this picture, the classic zellballen paraganglioma features are missing. (Right) This photomicrograph shows an intact squamous epithelium subtended by a nested neoplastic proliferation associated with a rich vascularized network and fibrous proliferation.

P.II(5):55

Paraganglia and Paraganglioma

(Left) This coronal graphic shows a highly vascular glomus tympanicum paraganglioma filling a portion of the middle ear cavity without involving adjacent structures and bone. (Right) This axial graphic shows glomus bodies along the course of the inferior tympanic nerve (branch of Jacobsen) on the cochlear promontory. Glomus tympanicum tumors arise from this normal cellular collection. Also note the cochlea.

631
(Left) This coronal graphic shows a glomus jugulare paraganglioma centered in the jugular foramen with superolateral extension into the middle ear. The ascending parapharyngeal artery is feeding this vascular tumor. (Right) This coronal graphic shows a large glomus jugulare paraganglioma arising from the jugular foramen, engulfing the jugular vein and CN9-12, and infiltrating the adjacent skull base.

(Left) This lateral graphic depicts a carotid body paraganglioma at the carotid bifurcation, splaying the ICA and ECA. The main arterial feeder is the ascending pharyngeal artery. The vagus and hypoglossal nerves are in close proximity. (Right) Lateral common carotid angiogram in late arterial phase demonstrates intense tumor blush between the external and internal carotid arteries.

Microscopic Features
(Left) This highly vascular paraganglioma underneath an intact mucosa shows scattered and nested neoplastic cells interspersed around vascular channels. (Right) This paraganglioma shows the classic zellballen nested cellular arrangement with variably sized nests of tumor cells. The small nests are surrounded by a thick fibrous vascular tissue.

(Left) The characteristic alveolar pattern (zellballen) with variably sized nests of tumor cells surrounded by thin-walled vessels is seen in this metastasizing paraganglioma from an SDHB mutation-positive patient. (Right) This photomicrograph shows the characteristic alveolar pattern (zellballen) with a nest of tumor cells surrounded by vessels and thick fibrous bands.
Some PGLs lack the typical pattern of small nests (zellballen) of neuroendocrine cells with interspersed small blood vessels and instead may show a diffuse growth pattern, as in this case. (Right) This high-power view of a paraganglioma shows an alveolar pattern with variably sized nests of tumor cells surrounded by thin-walled vessels. Focally, this tumor has a solid, patternless component with large sheets of tumor cells.

Gross, Microscopic, and Immunohistochemical Features

(Left) This gross cut surface of a liver from a patient with a hereditary SDHB-associated malignant middle ear paraganglioma shows multiple well-circumscribed, firm, pale pink metastatic nodules. This patient also had metastases to the pancreas. (Right) SDHB immunostaining reveals loss of immunoreactivity in a patient with SDHB-associated hereditary middle ear paraganglioma. The patient presented with metastatic disease.
A smear from a cardiac paraganglioma shows a homogeneous population of cells with pale eosinophilic cytoplasm and round to oval nuclei with regular nuclear membranes and stippled chromatin. Minute nucleoli can be identified in this picture. A metastatic focus of a malignant paraganglioma shows a high proliferative index by Ki-67 stain, as depicted in this photograph. The original paraganglioma had a lower proliferative index when compared with the metastases.

Chromogranin-A immunostain shows granular immunoreactivity in the neuroendocrine cell nests between cavernous blood vessels in a carotid PGL. Note the negativity of the endothelial cells for this marker. S100 stain in a duodenal gangliocytic paraganglioma of a patient with NF1 shows nuclear and cytoplasmic staining of sustentacular cells, which sometimes have conspicuous cytoplasmic processes.
(Left) Underneath an intact mucosa, the characteristic alveolar pattern (zellballen) with variably sized nests of tumor cells surrounded by thin-walled vessels is seen in this paraganglioma. (Right) SDHB immunostaining reveals maintenance of immunoreactivity in a paraganglioma in a patient with a MEN2-associated hereditary paraganglioma, without SDHB or SDHD mutation.

(Left) Cytokeratin stains the overlying epithelium but is negative in the paraganglioma cells. The tumor is composed of variably sized tumor cells in a solid arrangement. (Right) Neuroendocrine markers highlight the paraganglioma cells. The usual neuroendocrine markers include synaptophysin (shown), chromogranin, CD56, and NSE, among others.
High-power view shows an intact mucosa and a paraganglioma in the submucosa with the characteristic alveolar pattern (zellballen) with variably sized nests of tumor cells surrounded by thin-walled vessels. Chromogranin-A immunostain shows granular immunoreactivity in the neuroendocrine cell nests between cavernous blood vessels in a middle ear paraganglioma. The endothelial cells are negative for this marker.

SDH Paraganglioma

Pheochromocytomas and other paragangliomas without mutations of SDHx genes show immunoreactivity of tumor cell cytoplasm for SDHB protein. The staining is coarsely granular as the protein is localized to mitochondria. This graphic of part of the mitochondrial respiratory chain complex II shows the relationship between the succinate ubiquinone oxidoreductase subunits (SDHA → SDHD). Inactivating mutations result in hereditary paraganglioma.
(Left) Immunostaining for SDHA is preserved in the cytoplasm of paragangliomas of patients with an SDHB or SDHD mutation. This stain is used as a control for the SDHB stain. Note the granular brown deposits present in the cytoplasm of the tumor cells. (Right) SDHB immunostaining reveals the near-complete loss of immunoreactivity in a paraganglioma in a patient with SDHB mutation. Only endothelial cells display immunoreactivity.

(Left) Immunostaining for SDHA is preserved in the cytoplasm of paragangliomas in patients with an SDHB or SDHD mutation. SDHA can be used as a control for the SDHB stain. Note the granular brown deposits present in the cytoplasm of the tumor cells. (Right) SDHB immunostaining reveals maintenance of granular cytoplasmic immunoreactivity in a patient with MEN2-associated paraganglioma, without SDHB or SDHD mutation.

Pancreas
Pancreatic Endocrine Tumor

Vania Nosé, MD, PhD

Key Facts
Etiology/Pathogenesis
- Precursor lesions: Neuroendocrine cell proliferations in both ducts and islets in familial pancreatic NETs in patients with MEN1 and VHL
- Familial PETs are associated with MEN1, VHL, TS, and NF1 syndromes
• MEN1: 80% have PETs
  o 50% are gastrin-producing and 20% are insulin-producing tumors
  o Development of multiple, small PETs, often microadenomas, associated with foci of nesidioblastosis or ductuloinsular complexes
• VHL: Benign cysts and microcystic or serous adenomas, which occur in 35-70% of VHL patients
  o There is association of nesidioblastosis and microadenomas with VHL
  o Up to 60% of the tumors contain clear cells or multivacuolated lipid-rich cells
• Tuberous sclerosis: Rare PETs
• NF1: Pancreatic somatostatinomas are more rare than those of duodenal origin
• Majority of PETs are nonsyndromic (sporadic)

Clinical Issues
• 2-4% of clinically detected pancreatic neoplasms
• Body and tail most common
• Clinical syndromes related to excessive or inappropriate hormone or biogenic amine production
• Behavior depends on tumor size, functional status, hormone produced, and extent of local invasion
  o > 2 cm, > 2 mitoses/10 HPF, > 2% Ki-67
• Multifocal tumors more common in MEN1 and less frequently in VHL

Two distinct pancreatic endocrine cell proliferations are shown in a case of MEN1. The lesion on the left side of this figure has irregular borders, and the lesion on the right side is well demarcated and larger.
The smaller pancreatic endocrine lesion is uniformly positive for glucagon (microadenoma), whereas the larger lesion shows a pattern of distribution of glucagon similar to a normal islet, indicating hyperplasia.

**TERMINOLOGY**

**Abbreviations**
- Pancreatic endocrine tumor (PET)

**Synonyms**
- Pancreatic neuroendocrine tumor (PNET)
- Pancreatic endocrine neoplasm (PEN)
- Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

**Definitions**
- Functional or nonfunctional neoplasm arising from endocrine cells of pancreas
- PETs can be classified as sporadic or inherited
- WHO classifies PETs into 3 broad categories
  - Well-differentiated endocrine tumors
    - Benign: Confined to pancreas; no angioinvasion, no perineural invasion, < 2 cm, < 2 mitoses/10 HPF, < 2% Ki-67 proliferative index
    - Uncertain: Confined to pancreas; 1 or more of the following features: > 2 cm, 2-10 mitoses/10 HPF, > 2% Ki-67 proliferative index, angioinvasion, perineural invasion
  - Well-differentiated endocrine carcinomas: Gross local invasion, metastases
  - Poorly differentiated endocrine carcinoma (small cell carcinoma): High-grade malignancy, > 10 mitoses/10 HPF
- Endocrine microadenoma (< 0.5 cm)
  - Nonfunctional, discovered incidentally (surgery, radiographic, autopsy)
  - Pancreatic head affected most commonly
  - Often coexpress > 1 peptide
  - Multiple microadenomas are present in MEN1 syndrome
ETIOLOGY/PATHOGENESIS

Syndromic

- Associated with multiple endocrine neoplasia type 1 (MEN1), von Hippel-Lindau (VHL), tuberous sclerosis (TS), and neurofibromatosis type 1 (NF1) syndromes
- PETs associated with syndromes are associated with characteristic genetic abnormalities
- MEN1
  - MEN1 gene
  - 80% of cases have PETs
    - PETs are diagnosed clinically in ~ 80% of patients with MEN1
    - This number approaches 100% in autopsy studies
  - Patients with MEN1 have a unique profile of hormonal function: 50% are gastrin-producing and 20% are insulin-producing tumors
    - In MEN1, duodenal gastrin-producing NETs are more common than those arising in pancreas
  - MEN1 involvement of pancreas initially involves development of multiple small PETs, often microadenomas, associated with foci of nesidioblastosis or ductuloininsular complexes
  - Presence of peliosis in islets and adenomas is a curious feature
  - Islet dysplasia, defined as normal-sized or slightly enlarged islets containing cells with mild cytologic atypia
    - Readily confirmed by immunohistochemistry that shows loss of normal spatial and quantitative arrangement of the 4 main cell types
  - Once islet dysplasia attains a size of 0.5 mm, it is classified as microadenoma; islet dysplasia is most frequently associated with MEN1
  - MEN1 is diagnosed in ~ 25% of patients who have a gastrinoma and in ~ 5% of those who have an insulin-producing PET
  - In contrast to sporadic PETs, those associated with MEN1 tend to present at an earlier age (30-50 years), P.II(5):61
    - have a higher rate of postoperative recurrence, and are a common cause of death in these patients
  - MEN1-associated PETs display a wide variety of molecular abnormalities including chromosomal loss, chromosomal loss with duplication, mitotic recombination, or point mutation of the wild-type MEN1 allele
  - Similar to their sporadic counterparts, they exhibit inter- and intratumoral genetic heterogeneity indicating chromosomal instability
- VHL
  - VHL gene
  - Pancreatic pathology in VHL usually takes the form of benign cysts and microcystic or serous adenomas
    - Occur in 35-70% of VHL patients
    - Occur in young patients, are multiple, and located anywhere in the pancreas
    - Tumors are said to be functionally inactive, although immunohistochemistry does show focal positivity for pancreatic polypeptide, somatostatin, glucagon, &/or insulin in 30-40% of cases
    - Initially reported to not be associated with either microadenomas (endocrine cell foci, 0.5 cm in diameter) or nesidioblastosis; however, there is association of these findings with VHL
    - VHL-associated PETs tend to be arranged in trabeculae, glandular configurations, and solid foci
    - Characteristically, up to 60% of the tumors contain clear cells or multivacuolated lipid-rich cells in varying proportions
    - There are no data on VHL genotypic predisposition to PETs
    - Pancreatic tumors in patients with this disorder have been documented to exhibit loss of heterozygosity of normal VHL allele
- Tuberous sclerosis (TS)
  - TSC1 and TSC2 genes
  - Rare PETs have been reported in patients with TS
    - It is not clear if this is a causal or a casual association
  - Malignant PETs have been described in children
  - Functional PETs have been reported to produce both insulin and gastrin
- TSC1 (hamartin) is highly expressed in normal islet cells; loss of this tumor suppressor is speculated to have an etiologic role in these lesions

- **NF1**
  - NF1 gene
  - Somatostatinomas of pancreas are rarer than those of duodenal origin
    - 16x less common than duodenal somatostatinomas
  - Duodenal somatostatinomas occur in NF1 patients
    - NF1 accounted for 48% of duodenal somatostatinomas reported in the literature
  - Occasional NF1 patients may have pancreatic gastrinoma, insulinoma, and nonfunctioning PET

**Precursor Lesions**
- Although no precursor lesions have so far been described in sporadic PNETs, there is evidence of neuroendocrine cell proliferations in both ducts and islets as precursor lesions of familial PNETs in patients with MEN1 and VHL
- Pancreatic neuroendocrine cell ductular proliferations, a distinct phenomenon called nesidioblastosis or ductuloinsular complexes, is seen in both MEN1 and VHL
  - However, these changes may also be found in several other conditions, including chronic pancreatitis and ductal obstruction
- Alterations in islets of Langerhans, including islet hyperplasia and islet dysplasia, is seen only in setting of inherited pancreatic NETs
- Islet dysplasia refers to slightly enlarged islets (< 0.5 mm) that contain neuroendocrine cells arranged in trabeculae that display mild atypia and show loss of normal spatial and quantitative arrangement of normal 4 main cell types
  - Islet dysplasia is most frequently associated with MEN1

- Pancreatic neuroendocrine microadenoma is when an islet cell dysplasia attains a size > 0.5 mm
- Microadenoma > 5 mm is classified as PNET
- Pancreatic microadenomatosis, the presence of multiple pancreatic neuroendocrine microadenomas, is linked to MEN1 syndrome and also seen in association with VHL disease
  - At molecular level, microadenomas in MEN1 syndrome show loss of MEN1 wild-type allele, proving their neoplastic nature
  - Pancreatic microadenomatosis has also been described in a patient with oculofaciocardiodental syndrome
- Characteristically, VHL-related NETs contain clear cells or multivacuolated lipid-rich cells in varying proportions
- Ductuloinsular complexes and islet hyperplasia/dysplasia are precursor premalignant lesions since they may give rise to the development of pancreatic neuroendocrine microadenomas and NETs in the setting of familial disease
- In addition to ductuloinsular complexes, islet dysplasia, and microadenomas, peliotic change of islets can also be seen in MEN1- or VHL-related lesions

**Sporadic**
- Majority of cases are nonsyndromic (sporadic)
- There are no defined precursor lesions in sporadic pancreatic NETs
- Somatic mutations of MEN1 gene are identified in ~ 20% of sporadic PETs and up to 68% harbor losses of 11q13 &/or more distal parts of long arm of chromosome 11

**CLINICAL ISSUES**

**Epidemiology**
- **Incidence**
  - 1-2% of clinically detected pancreatic neoplasms
    - 1 per 100,000 people per year (USA)
    - 2-4 per million people per year for insulinoma
    - Asymptomatic type found in up to 1.5% of autopsies
  - ~ 20% of PET are MEN1 associated
  - Relative increase due to more sensitive diagnostic approaches
- **Age**
  - Peak: 30-60 years (mean: 50 years)
  - Syndrome-associated tumors (MEN1) tend to occur earlier (10-30 years)
Diagnostic Pathology: Familial Cancer Syndromes

- Gender
  - Equal distribution
    - Exception for somatostatinoma: F > M (2:1)
    - Exception for gastrinoma: M > F (1.2:1)

Site
- Entire pancreas may be affected; most common sites are body and tail
  - Somatostatinomas: More common in head
  - Gastrinoma: Head, duodenum, gastric antrum, and peripancreatic soft tissues
  - Glucagonoma: Tail most common
  - Vasoactive intestinal peptide (VIP)-oma: Most common in tail

Presentation
- Functional: Clinical syndromes related to excessive or inappropriate hormone or biogenic amine production
  - ~ 60%
  - Ectopic hormone: Gastrin, vasoactive intestinal peptide, pancreatic polypeptide (PP), and neurotensin
  - Pancreatic hormone: Insulin, glucagon, somatostatin
    - Insulinoma syndrome (~ 25%)
      - Whipple triad includes the following 3 characteristics
      - Symptoms of hypoglycemia
      - Plasma glucose levels < 3.0 mmol/L
      - Relief of symptoms with administration of glucose
    - Glucagonoma syndrome
      - Skin rash (necrolytic migratory erythema): 70% of patients
      - Rash usually starts in groin/perineum and migrates to distal extremities
      - Associated with angular stomatitis, cheilitis, atrophic glossitis, alopecia, onycholysis, vulvovaginitis, and urethritis
      - Marked weight loss (65%), mild diabetes mellitus (glucose intolerance) (50%), anemia (33%), diarrhea, depression (20%), deep vein thrombosis (12%)
  - Somatostatinoma syndrome
    - Nonspecific findings, although diabetes mellitus, hypochlorhydria, gallbladder disease (cholelithiasis), diarrhea, steatorrhea, anemia, and weight loss may be present
    - Markedly elevated somatostatin serum/tumor levels define the syndrome
  - Gastrinoma syndrome (~ 15%)
    - Zollinger-Ellison syndrome
    - Increased gastrin results in gastric or duodenal ulcers, resulting in abdominal pain, diarrhea, vomiting, and weight loss
    - 25% of patients are found to have MEN1 syndrome
  - VIPoma syndrome
    - a.k.a. Verner-Morrison syndrome
    - VIP excess produces voluminous watery diarrhea, hypokalemia, achlorhydria, and metabolic acidosis
    - Accounts for 80% of diarrheagenic tumors
- Nonfunctional: Inactive, nonsyndromic, incidentally discovered
  - ~ 40%
  - May have elevated hormone levels, but not a distinct syndrome
  - Large abdominal mass, abdominal or back pain, obstructive symptoms, pancreatitis
  - Jaundice may develop in large tumors located in head of pancreas
  - Large tumors are usually nonfunctional

Laboratory Tests
- Insulinoma
  - Elevated plasma insulin and proinsulin concentrations by radioimmunoassay
  - Combined measures of insulin, proinsulin, C-peptide, and blood glucose help exclude factitious hyperinsulinaemia
- Glucagonoma
  - Elevated fasting plasma glucagon concentration (usually 10-20x)
  - Tolbutamide or arginine stimulation tests may be used
- ~20% will also have increased plasma gastrin levels
- Somatostatinoma
  - Elevated plasma somatostatin levels
- Gastrinoma
  - Secretin stimulation test (measures evoked gastrin levels)
  - 3 separate elevated fasting gastrin levels
  - Gastric acid secretion and pH

**Treatment**

- Options, risks, complications
  - Multidisciplinary approach is mandatory
  - Before surgery, important to separate MEN1-associated tumors from solitary, nonsyndrome-associated, and malignant tumors
  - Management of hormone production is critical
- Adjuvant therapy
  - Usually employed for high-stage, malignant, &/or metastatic tumors
  - Includes chemoembolization for liver metastases

**Prognosis**

- Routine morphologic examination does not always predict behavior
  - Locally infiltrative disease, perineural and vascular invasion seen more often in malignant tumors
- Up to 30% of patients already have metastatic disease at diagnosis
  - ~65% will develop metastatic disease at some point during disease course
- Survival depends on tumor size, functional status, and extent of local invasion
  - Nonfunctional: 65% 5-year survival; 45% 10-year survival
  - Functional: 45% 5-year survival (except insulinoma)
- Tumor behavior is associated with functional status and specific hormone produced
  - Nonfunctional tumors are nearly all malignant (90%)
  - Insulinoma: Has best prognosis
    - Vast majority are benign (~8% malignant)
    - Early detection, as a result of symptoms while still small
  - Glucagonoma
    - ~60-70% have metastases at time of diagnosis
  - Somatostatinoma
    - Generally large at time of diagnosis
    - ~70% have metastases at time of diagnosis
- Adverse prognostic factors
  - Metastasis to regional lymph nodes &/or liver
  - Gross invasion into adjacent organs
  - Angiolympathic invasion and perineural invasion
  - Rule of 2: >2 cm, >2 mitoses/10 HPF, >2% proliferation index (Ki-67)
  - Necrosis
  - Functioning tumor (except insulinoma)

**IMAGE FINDINGS**

**Ultrasonographic Findings**

- Endoscopic ultrasonography: 20-65% sensitivity

**MR Findings**

- MR imaging: 25-60% sensitivity

Somatostatin Receptor Scintigraphy (SRS) &/or Positron Emission Tomography (PET)

- Somatostatin analogues attach with high-affinity binding to receptors overexpressed by tumors
- Allows for detection of very small tumors
- Gastrinoma, somatostatinoma, glucagonoma, and VIPoma are usually detected
- Insulinoma usually not detected

**MACROSCOPIC FEATURES**

**General Features**

- Vast majority are well demarcated, discrete/circumscribed, and solitary
  - Multifocal tumors more common in MEN1

**Size**

- Overall range: <0.5 up to 35 cm
- Microinsulinomas in MEN1 usually functionally silent, especially when there are multiple lesions
Size as it relates to functional status and hormone produced
- Functional: Usually < 2 cm
  - Insulinomas: < 2 cm
  - Somatostatinomas: Mean = 5-6 cm
  - Glucagonomas: Mean = 7 cm
- Nonfunctional: > 2 cm
- Microadenoma: < 0.5 cm but are nearly always nonfunctioning

MICROSCOPIC PATHOLOGY
Histologic Features
- Wide architectural and cytomorphologic appearance
  - Ribbon-like, trabecular, festooned, or gyriform
  - Solid, trabecular, glandular, tubuloacinar, or pseudorosette
- Cells are relatively uniform
- Lipid-rich, clear cell (in von Hippel-Lindau), oncocytic, and rhabdoid subtypes rare
- Nuclei show salt-and-pepper chromatin distribution
- Stroma and fibrosis are variably present
  - Amyloid seen in insulinoma
  - Psammoma bodies seen in somatostatinoma
- Invasion can be seen

Mitotic figures are usually sparse (< 2/10 HPF)
- Ki-67 required to document proliferation index

Well-Differentiated PET
- Functioning
  - Insulinoma (most common type): β-cell derived
    - Nonfunctioning and microtumors not encapsulated
    - Amyloid is unique to this tumor type (islet amyloid polypeptide [IAPP] or amylin)
  - Gastrinoma (2nd most common)
    - Many times, no primary tumor is identified in spite of having lymph node metastases
    - High risk of malignant behavior, irrespective of size
  - Glucagonoma (3rd most common): α-cell derived
    - Glucagonomas commonly occur in tail of pancreas or attached to surface of pancreas
  - VIPoma (4th most common)
    - Often react with other markers (growth hormone release hormone, α-human chorionic gonadotropin, pancreatic polypeptide)
  - Somatostatinoma (least common): δ-cell derived
    - Tend to have glands and psammoma bodies

Well-Differentiated Endocrine Carcinoma
- Functional or nonfunctional
- Gross local invasion (fat or organs)
- Regional lymph nodes (peripancreatic, coeliac, periaortic) involved first
- Metastases to liver

Poorly Differentiated Neuroendocrine Carcinoma
- Small cell variant: Diffuse sheet-like arrangements of cells, geographic necrosis, mitotic figures > 10/10 HPF
  - Resembles small cell carcinoma of lung
- Large cell neuroendocrine variant
  - Resembles large cell neuroendocrine carcinoma of lung

ANCILLARY TESTS
Immunohistochemistry
- Variety of neuroendocrine markers are positive
  - Synaptophysin, chromogranin, neuron-specific enolase
- Specific hormone products/prohormones can be found
  - Insulin, glucagon, somatostatin, gastrin, VIP, PP
- In addition to usual pancreatic peptides, others can also be seen
  - Adrenocorticotropic hormone (ACTH), parathyroid-like hormone, calcitonin, growth hormone releasing hormone, serotonin
SELECTED REFERENCES

Criteria for Clinicopathological Classification of Tumors of Endocrine Pancreas

<table>
<thead>
<tr>
<th>WHO Tumor Type</th>
<th>Criteria for Clinicopathological Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Well-differentiated endocrine tumor: Benign behavior</td>
<td>Confined to pancreas; &lt; 2 cm in diameter; &lt; 2 mitoses/10 HPF, Ki-67 proliferative index, no lymphovascular invasion</td>
</tr>
<tr>
<td>Well-differentiated endocrine tumor: Uncertain behavior</td>
<td>Confined to pancreas, and 1 or more of the following features: &gt; 2 cm in diameter; 2-10 mitoses/10 HPF, Ki-67 proliferative index, lymphovascular invasion, perineural invasion</td>
</tr>
<tr>
<td>Well-differentiated endocrine carcinoma</td>
<td>Gross local invasion &amp;/or metastases; low-grade malignant</td>
</tr>
<tr>
<td>Poorly differentiated endocrine carcinoma (small cell carcinoma)</td>
<td>High-grade malignant; &gt; 10 mitoses/10 HPF</td>
</tr>
<tr>
<td>Mixed endocrine-exocrine carcinoma</td>
<td>Malignant mixed neoplasm in which endocrine and exocrine cells are intimally admixed (each component comprises at least 1/3 of tumor)</td>
</tr>
</tbody>
</table>

P.II(5):65

Image gallery
Microscopic Features

(Left) In the pancreata of patients with MEN1, there are typically multiple small (< 5 mm) neuroendocrine tumors, a
finding that has been referred to as microadenomatosis. Note the irregular borders of the endocrine components.

(Right) Multiple pancreatic microadenomas (< 5 mm) seen in patients with MEN1 and NF are often accompanied by 1 or more macroadenomas (diameter > 5 mm), some of which may become insulinomas, as seen in this picture.

(Left) Islet dysplasia refers to slightly enlarged islets that contain neuroendocrine cells arranged in trabeculae that display mild atypia and show loss of the normal spatial distribution and numbers of the normal main cell types. This is usually present in patients with MEN1 and VHL. (Right) Immunohistochemistry for chromogranin-A in a pancreas of a patient with MEN1 shows a markedly enlarged islet. The pancreas also had multiple microadenomas, adenomas, and hyperplasia/dysplasia.

(Left) This pancreatic endocrine tumor in a 17-year-old boy with MEN1 was large and associated with islet cell hyperplasia. Note prominent nucleoli and mitoses. (Right) This photomicrograph from a liver in a 17-year-old boy with MEN1 shows metastases from the pancreatic endocrine tumor compressing the adjacent liver parenchyma. Metastases was present at diagnosis.

Parathyroid
Parathyroid Adenoma
Key Facts

Terminology
- Benign neoplasm of chief, oncocyctic, transitional, water-clear, or mixture of cells

Etiology/Pathogenesis
- Most are sporadic
- ~5-10% of cases of primary hyperparathyroidism are associated with familial syndromes
- Most common genetic syndromes
  - Hyperparathyroidism-jaw tumor syndrome (HPT-JT)
  - Familial isolated hyperparathyroidism (FIHP)
  - Multiple endocrine neoplasia types 1 and 2A (MEN1, MEN2A)
  - Familial hypocalciuric hypercalcemia (FHH)

Clinical Issues
- Often asymptomatic or vague symptoms, identified with serum calcium screening

Microscopic Pathology
- Parathyroid adenoma is composed of chief, oxyphilic, transitional, clear cells, or mixtures of cell types

Ancillary Tests
- Positive for chromogranin, synaptophysin, CAM5.2, and PTH; negative for TTF-1 and thyroglobulin
- Chromosome 11: Frequent loss in adenomas and frequent gain in carcinomas

Top Differential Diagnoses
- Parathyroid hyperplasia, parathyroid carcinoma, thyroid tumor

Parathyroid adenoma is a single enlarged parathyroid gland with a tan-yellow appearance. The surface is usually homogeneous and covered by a thin fibrous capsule.
Chief cell parathyroid adenoma shows a rim of normal parathyroid tissue. Rims of normal parathyroid tissue are identified in 50-60% of parathyroid adenomas.

**TERMINOLOGY**

**Abbreviations**
- Parathyroid adenoma (PTA)

**Definitions**
- Benign neoplasm composed of chief cells, oncocytic cells, transitional cells, water-clear cells, or a mixture of cell types generally affecting a single parathyroid gland

**ETIOLOGY/PATHOGENESIS**

**Sporadic Parathyroid Adenomas**
- Predisposing factors poorly understood; possible association with prior ionizing radiation

**Hereditary Parathyroid Adenomas**
- Hereditary hyperparathyroidism is less common than sporadic hyperparathyroidism
  - ~5-10% of cases of primary hyperparathyroidism are associated with familial syndromes
    - Study of this group has provided great insight into the genetic and molecular changes that underlie the neoplastic transformation of parathyroid tissue
  - Most common genetic syndromes associated with primary hyperparathyroidism are multiple endocrine neoplasia types 1 and 2A (MEN1, MEN2A), hyperparathyroidism-jaw tumor syndrome (HPT-JT), familial isolated hyperparathyroidism (FIHP), and familial hypocalciuric hypercalcemia (FHH)
  - HPT-JT
    - Autosomal dominant, inactivating mutations in HRPT2 (1q21-q31) tumor suppressor gene that encodes parafibromin
    - Hyperparathyroidism, fibroosseous jaw tumors, kidney cysts, hamartomas, and Wilms tumors
    - Parathyroid hyperplasia or adenoma and increased risk of parathyroid carcinoma
    - Germline HRPT2 mutations identified in subset of patients with mutation-positive carcinomas thought to be sporadic
Familial isolated hyperparathyroidism (FIHP)
- Autosomal dominant, 1% of primary hyperparathyroidism (parathyroid is only endocrine organ involved), adenoma or hyperplasia, and increased risk of parathyroid carcinoma
- Cause unknown in most families, but HRPT2, MEN1 gene, and area on chromosome 2 implicated

MEN1
- Autosomal dominant, high-penetrance germline mutation in MEN1 tumor suppressor gene (11q13) encoding menin protein
- Parathyroid adenomas and carcinomas occur in MEN1 but are less common than hyperplasia (multiglandular parathyroid disease)
- Other MEN1 features
  - Endocrine: Pituitary adenomas; neuroendocrine tumors of pancreas, duodenum, thymus and lung; gastrinomas; adrenal cortical adenomas and hyperplasia
  - Nonendocrine: Angiofibromas, collagenomas, café au lait macules, lipomas, gingival papules, meningiomas, ependymomas, leiomyomas

MEN2A
- Autosomal dominant, high-penetrance germline RET-activating proto-oncogene (10q11.2) mutation
- 20-30% of MEN2A is associated with parathyroid hyperplasia or adenomas; may also have medullary thyroid carcinoma &/or pheochromocytomas

Neonatal severe primary hyperparathyroidism

CLINICAL ISSUES

Epidemiology
- Incidence
  - Most common cause of primary hyperparathyroidism (80-85%), followed by P. II(5):67 parathyroid hyperplasia (15%) and carcinoma (1-2%)
  - Incidence has been increasing for 3 decades, attributable to introduction of automatic serum calcium screening
- Age
  - Any age, but most commonly in patients 50-60 years
  - Familial cases occur at younger ages (20-25 years)
- Gender
  - F:M = 3:1
  - Females and males equally affected in familial cases

Site
- Single parathyroid gland involved; lower parathyroids involved slightly more often than upper parathyroids
- 10% in other locations: Intrathyroidal, mediastinum, thymus, soft tissue behind esophagus & pharynx
- Exceptionally rare “double adenoma,” but asymmetric hyperplasia more common

Presentation
- Usually asymptomatic or vague symptoms of fatigue, weakness, gastrointestinal symptoms, depression
- Historical symptoms of nephrolithiasis and severe bone disease (osteitis fibrosa cystica) less common today

Treatment
- Surgical approaches
  - Bilateral neck exploration with excision of adenoma is the classic approach, although minimally invasive surgery guided by noninvasive imaging and intraoperative parathyroid hormone (PTH) monitoring is gaining favor in nonfamilial cases
  - Subtotal parathyroidectomy is indicated in familial syndromes, such as MEN1 and FIHP
  - Using a surgical approach in HPT-JT is controversial because of the increased risk of parathyroid cancer, but subtotal parathyroidectomy with close postoperative biochemical monitoring for recurrence is currently recommended over prophylactic total parathyroidectomy
  - Resection of single gland (parathyroid adenoma), often with assistance of intraoperative PTH monitoring
    - ≥ 50% drop in intraoperative PTH from baseline at 10 minutes after gland excision is helpful to ensure that abnormal gland(s) has been removed
  - Medical therapy with calcimimetics is useful for patients with primary hyperparathyroidism who are poor surgical candidates or have non-localizable tumors or an inoperable disease

IMAGE FINDINGS
Tc-99m sestamibi and ultrasound are commonly used to localize site of adenoma. May use computed tomography (CT), magnetic resonance (MR) imaging, etc.

**MACROSCOPIC FEATURES**

**Parathyroid Adenoma Macroscopic Features**
- Single enlarged gland: Usually 0.2 to > 1 g, tan to red-tan, encapsulated, ± rim of normal tissue
- Cystic change may occur in adenomas, particularly larger adenomas and in those with HPT-JT syndrome
- Parathyroid adenoma is ectopic in up to 10% (intrathyroidal, mediastinum, thymus, soft tissue behind esophagus and pharynx)
- Rare double adenomas (exercise caution as asymmetric hyperplasia is much more common)

**MICROSCOPIC PATHOLOGY**

**Histologic Features**
- Proliferation of parathyroid parenchymal chief cells, oxyphil cells, transitional cells, clear cells, or mixtures of cell types
- May have thin connective tissue capsule
- 50-60% have rim of normal parathyroid tissue
  - Rim more often identified in small adenomas
  - Rim often separated from adenoma by connective tissue capsule, but not always
  - Parathyroid parenchymal cells within rim are typically smaller than those within adenoma
  - Suppressed parathyroid parenchymal cells within rim have larger and more fat droplets than in adenoma cells, which have less lipid and more dispersed lipid than cells in the rim
  - Parathyroid hyperplasia can occasionally also have rims of normal tissue
- Fat cells sparse (scattered or nested) or absent
- Often a mixture of growth patterns: Follicular, acinar, cords, solid, rosette-like, but rarely papillae
- Scattered mitoses in up to 70% of adenomas (more in parathyroid carcinoma)
- No atypical mitoses
- Cysts and cystic change and degeneration common, especially in large adenomas and HPT-JT cases
- Parathyroid adenomas in MEN1 are histologically similar to sporadic parathyroid adenomas

**ANCILLARY TESTS**

**Frozen Sections**
- Assessing cellularity in small biopsies can be difficult
  - Cellularity is difficult to assess in small biopsies because it is variable within parathyroid glands and among glands within a single individual
  - Polar regions of parathyroid are more cellular than are central regions
  - Cellularity decreases with age and varies with gender, ethnicity, and body habitus
- Features helpful in differentiating parathyroid from thyroid
  - Parathyroid cells have well-defined cytoplasmic membranes (very helpful feature in differentiating parathyroid from thyroid)
  - Cytoplasmic lipid (fat droplets) common in parathyroid cell cytoplasm (not in thyroid)
  - Parathyroid cells are smaller and more vacuolated than thyroid cells
  - Parathyroid nuclei have rounder and denser chromatin than thyroid nuclei
  - Parathyroid lacks birefringent calcium oxalate crystals seen in thyroid
  - Parathyroid lacks colloid

**Immunohistochemistry**
- Positive for neuroendocrine markers chromogranin and synaptophysin
- Positive for keratin (CAM5.2 is most helpful keratin for neuroendocrine tumors)
- Negative for TTF-1, thyroglobulin, calcitonin (usually, but calcitonin can be variable in staining, thus panel of immunostains is often helpful)
- Positive for parathyroid hormone but less intense staining in adenomas compared to normal parathyroid or rim of normal parathyroid
- Increased p27 (cyclin-dependent kinase inhibitor protein) in parathyroid adenomas compared to carcinomas
- Adenomas are positive for p27, Bcl-2, and MDM2, and have low Ki-67 labeling index (< 4%)
- Carcinomas often low/absent p27, MDM2, and higher Ki-67 labeling index (> 4%)
- Parafibromin (encoded by HRPT2)
Loss of nuclear parafibromin in HRPT2-associated parathyroid carcinomas and adenomas

Sporadic adenomas are usually positive for parafibromin, and many carcinomas show loss of parafibromin

Parathyroid carcinomas in hemodialysis patients can show staining in parathyroid carcinomas and metastasis

Parafibromin immunostaining shows some promise, but reproducibility and variability in interpretation of this immunostain needs to be confirmed

Cytogenetics

- Chromosome 11: Frequent loss in adenomas and frequent gain in carcinomas

Molecular Genetics

- Study of uncommon familial syndromes has helped to define the pathophysiology of both familial and sporadic parathyroid neoplasms
  - Tumor suppressor genes MEN1 and HRPT2 were discovered through genetic analysis of kindreds with MEN1 and HPT-JT
  - Somatic mutations in MEN1 and HRPT2 are frequent events in the clonal development of sporadic parathyroid adenomas and carcinomas, respectively
- HRPT2 mutation (tumor suppressor gene, 1q21-q31, encodes parafibromin)
  - Germline HRPT2-inactivating mutation in HPT-JT syndrome-associated parathyroid adenoma or hyperplasia and increased risk of parathyroid carcinoma
  - Germline HRPT2 mutations have been identified in subset of patients with mutation-positive carcinomas (consider genetic testing in patients with parathyroid carcinoma)
  - Somatic HRPT2 mutations are common in sporadic parathyroid carcinomas and rare in sporadic adenomas
  - Strong association with HRPT2 mutation and familial and sporadic parathyroid cancer
- Cyclin-D1/CCND1 oncogene (11q13)
  - 5-8% of parathyroid adenomas have genetic alterations in cyclin-D1/CCND1 (parathyroid adenoma) gene
  - Cyclin-D1/CCND1 encodes cyclin-D1, a cell cycle regulator from G1 to S phase transition

P.II(5):69

- Cyclin-D1 protein overexpression observed in up to 40% of adenomas
- MEN1 mutation (tumor suppressor gene, 11q13, results in truncated menin protein)
  - Parathyroid adenomas and carcinomas occur in MEN1, but parathyroid hyperplasia occurs more commonly
  - Up to 40% of sporadic parathyroid adenomas have loss of 1 MEN1 allele, and 1/2 of these have inactivating mutation in 2nd allele
- RET mutation (proto-oncogene, 10q11.2)
  - Germline RET-activating mutation in MEN2A (95% mutation in exon 10 or 11, codon 634)
  - 30% of patients with MEN2A have parathyroid hyperplasia, but adenomas can also occur
  - RET mutation is generally not identified in sporadic parathyroid disease

DIAGNOSTIC CHECKLIST

Clinically Relevant Pathologic Features

- Often asymptomatic, identified by screening calcium
- Serum calcium elevated, but markedly elevated serum calcium (> 13 mg/dL) worrisome for carcinoma

Pathologic Interpretation Pearls

- Composed of chief, oxyphilic, transitional, clear, or mixtures of cell types
- Parathyroid (unlike thyroid) has well-demarcated cytoplasmic membranes, cytoplasmic lipid, round nuclei, and dense chromatin and lacks colloid and calcium oxylate crystals
- Normal parathyroid tissue shows significant variation in cellularity within and among glands
- Rims of normal tissue in 50-60% of adenomas, but can be seen in hyperplasia

SELECTED REFERENCES

### Tables

#### Parathyroid Adenoma vs. Carcinoma

<table>
<thead>
<tr>
<th>Feature</th>
<th>Parathyroid Adenoma</th>
<th>Parathyroid Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms</td>
<td>Usually asymptomatic or vague</td>
<td>Often symptomatic</td>
</tr>
<tr>
<td>Serum calcium</td>
<td>Elevated</td>
<td>Markedly elevated (&gt; 13 mg/dL)</td>
</tr>
<tr>
<td>Palpable mass</td>
<td>Unusual</td>
<td>Yes</td>
</tr>
<tr>
<td>Tumor size</td>
<td>Enlarged</td>
<td>Larger but may overlap</td>
</tr>
<tr>
<td>Invasion into adjacent structures</td>
<td>No (but can have irregular growth and cells in capsule due to degenerative features)</td>
<td>Yes</td>
</tr>
<tr>
<td>Fibrous bands</td>
<td>Can be present due to degenerative features</td>
<td>Yes</td>
</tr>
<tr>
<td>Perineural invasion</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Vascular invasion</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Growth pattern</td>
<td>Patterns of growth (follicular, acinar, etc.)</td>
<td>Monotonous, sheet-like growth</td>
</tr>
<tr>
<td>Cellular features</td>
<td>Often mixed cell types, can show endocrine atypia</td>
<td>Often monotonous cytomorphology, prominent nucleoli</td>
</tr>
<tr>
<td>Mitoses</td>
<td>Few, scattered</td>
<td>Yes, more numerous mitoses than adenomas</td>
</tr>
<tr>
<td>Proliferation markers (Ki-67/MIB-1)</td>
<td>Low</td>
<td>Moderate to high</td>
</tr>
</tbody>
</table>

#### Parathyroid and Thyroid Immunohistochemistry

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Keratin</th>
<th>TTF-1</th>
<th>PTH</th>
<th>Chro</th>
<th>Syn</th>
<th>Calcitonin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parathyroid cells and tumors</td>
<td>Positive (particularly low molecular weight keratins, e.g., CAM5.2)</td>
<td>Negative</td>
<td>Positive (but often not an overly robust stain)</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>Thyroid follicular cells and neoplasms</td>
<td>Positive</td>
<td>Positive (strong nuclear staining)</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td>Medullary thyroid carcinoma</td>
<td>Positive (particularly low molecular weight keratins, e.g., CAM5.2)</td>
<td>Positive (nuclear staining, may not be as strong as in follicular cells and neoplasms)</td>
<td>Negative</td>
<td>Positive</td>
<td>Positive</td>
<td>Positive</td>
</tr>
</tbody>
</table>

*Chro: Chromogranin; Syn: Synaptophysin.*

P.II(5):70

Image gallery

Gross and Microscopic Features
Parathyroid adenoma is a single enlarged parathyroid gland, usually 0.2 to > 1 g. The cut surface of a parathyroid adenoma is usually homogeneous tan-yellow to tan-red with focal areas of hemorrhage. Chief cell parathyroid adenoma shows adjacent rim of normal parathyroid tissue, a feature often identified in smaller rather than larger adenomas. The rim is often separated from the adenoma by connective tissue.

Oxyphil parathyroid adenoma shows a rim of normal parathyroid. Oxyphil adenomas are usually functional tumors and are associated with levels of serum calcium that are similar to those seen in chief cell adenomas. This chief cell parathyroid adenoma has a nested growth pattern and prominent vascularity. The nuclei are round. The cytoplasm of the chief cells is eosinophilic to amphophilic. The cells do not show significant nuclear pleomorphism or mitotic activity.
Varying degrees of cystic change can be seen in parathyroid adenomas. Cystic change is particularly common in larger parathyroid adenomas and those associated with hyperparathyroidism-jaw tumor syndrome (HPT-JT). HPT-JT is an autosomal dominant disorder caused by inactivating mutations in HRPT2 gene that encodes parafibromin. This clear (water-clear/wasserhelle) cell parathyroid adenoma is composed of large polyhedral cells with distinct plasma membranes and extensively vacuolated cytoplasm.

Microscopic Features

Oxyphil cells (10-20 μm) are larger than chief cells (10 μm) and have abundant eosinophilic granular cytoplasm. Oxyphil cell adenomas are uncommon, comprising approximately 3-6% of parathyroid adenomas. Foci of nuclear pleomorphism (endocrine atypia) can be seen in oxyphil cell adenomas. Well-defined cytoplasmic membranes of parathyroid cells help to differentiate parathyroid from thyroid.
Oxyphil adenomas are composed exclusively or predominantly (> 90%) of mitochondrion-rich oxyphil cells. Although originally thought to be nonfunctional, oxyphil adenomas are now recognized as usually functional tumors. This parathyroid chief cell adenoma is present within the thymus. Approximately 10% of parathyroid adenomas occur in unusual locations, such as intrathyroidal or within mediastinum, thymus, or soft tissues behind the esophagus and pharynx.

Parathyroid Carcinoma

Parathyroid Carcinoma
Vanía Nosé, MD, PhD
Lori A. Erickson, MD

Key Facts
Terminology
- Malignant parathyroid parenchymal neoplasm
Etiology/Pathogenesis
- Most parathyroid carcinomas are sporadic, but increased incidence in patients with HPT-JT
- HPT-JT: Autosomal dominant disorder of hyperparathyroidism, fibroosseous jaw tumors, kidney cysts, hamartomas, and Wilms tumors
- FIH: Autosomal dominant, accounts for 1% of primary hyperparathyroidism: Adenoma or hyperplasia
- MEN1: Autosomal dominant; only rare case of parathyroid carcinoma reported in MEN1
- MEN2A: 20-30% with MEN2A have parathyroid hyperplasia or adenoma with only rare reports of carcinoma

**Clinical Issues**
- Markedly elevated serum calcium (> 13 mg/dL), PTH, alkaline phosphatase
- HRPT2 mutations in familial and some sporadic, can be new germline mutation

**Microscopic Pathology**
- Require invasive growth with capsular, vascular, perineural, or invasion into adjacent structures
- Histologic features in sporadic and HPT-JT parathyroid lesions similar, but HPT-JT lesions may be cystic

**Ancillary Tests**
- Positive for chromogranin, synaptophysin, CAM5.2, PTH; negative for TTF-1, thyroglobulin, calcitonin
- Loss of parafibromin nuclear staining in many

Cut section of a parathyroid carcinoma shows a firm yellow-gray, nodular cut surface invading into adjacent structures. (Courtesy L. Erickson, MD.)
Parathyroid carcinoma is invading into the sternocleidomastoid muscle. Invasive growth is diagnostic of malignancy in parathyroid.

**TERMINOLOGY**

**Abbreviations**
- Parathyroid carcinoma (PC)

**Definitions**
- Malignant neoplasm of parathyroid parenchymal cells (chief cells, oxyphilic cells, transitional cells, water/clear cells, or mixtures of cell types)

**ETIOLOGY/PATHOGENESIS**

**Inherited**
- Most parathyroid carcinomas are sporadic but increased incidence in patients with hyperparathyroidism-jaw tumor syndrome (HPT-JT)

**HPT-JT**
- Autosomal dominant disorder of hyperparathyroidism, fibrousosseous jaw tumors, kidney cysts, hamartomas, and Wilms tumors
- Inactivating mutation tumor suppressor gene HRPT2 (1q21-q31) that encodes parafibromin
- Parathyroid hyperplasia, adenoma, or carcinoma
  - 15% with HPT-JT develop parathyroid carcinoma
- Germline HRPT2 mutations identified in a subset of patients with HRPT2 mutation-positive carcinomas

**Familial Isolated Hyperparathyroidism (FIH)**
- Autosomal dominant, accounts for 1% of primary hyperparathyroidism (parathyroid is only endocrine organ involved), adenoma, or hyperplasia
- Increased risk of parathyroid carcinoma has been reported but may be due to inclusion of HPT-JT cases
- Cause unknown in most families, but HRPT2 gene, MEN1 gene, and area on chromosome 2 implicated

**Multiple Endocrine Neoplasia Type 1 (MEN1)**
• Autosomal dominant, high penetrance, germline mutation in MEN1 tumor suppressor gene (11q13); results in truncated menin protein
• 20% of patients with primary parathyroid hyperplasia have MEN1, but only rare case of parathyroid carcinoma reported in MEN1
• Loss of heterozygosity and somatic MEN1 mutations identified in some parathyroid carcinomas
• Somatic MEN1 mutations occur in 15-20% of sporadic adenomas and occasionally in sporadic carcinomas

Multiple Endocrine Neoplasia 2A (MEN2A)
• 20-30% with MEN2A have parathyroid hyperplasia or adenoma (only rare reports of carcinoma)

Sporadic
• Predisposing factors poorly understood, possible association with prior ionizing radiation
• Reports of parathyroid carcinoma occurring in setting of secondary parathyroid hyperplasia

CLINICAL ISSUES
Epidemiology
• Incidence
  o 1-2% of primary hyperparathyroidism (parathyroid adenoma: 80-85%; parathyroid hyperplasia: 15%)
  o Reports: Up to 5% of hyperparathyroidism due to carcinoma in Italy and Japan
• Age
  o Middle-aged and older adults (mid 40s to mid 50s; 1 decade earlier than parathyroid adenomas)
• Gender
  o Males and females are equally affected (unlike adenomas, which are more frequent in females)

Site
• Arises in site of parathyroid gland

P.II(5):73

  o Similar to parathyroid adenomas, carcinomas can also occur in ectopic sites
  o Slightly more common in lower parathyroid glands

Presentation
• Most parathyroid carcinomas are functional and patients are symptomatic, but nonfunctional tumors occur
• Palpable neck mass (unusual for adenoma)
• Local recurrence of a parathyroid adenoma is worrisome for carcinoma but can be parathyromatosis

Laboratory Tests
• Extremely high serum calcium levels (> 13 mg/dL) more common in carcinoma
• Markedly elevated PTH levels (> 1,000 ng/L)
• High serum alkaline phosphatase activity (> 200 IU/L)

Natural History
• Usually recur 1st in neck then metastasize to cervical and mediastinal lymph nodes, lung, bone, and liver

Treatment
• Surgical approaches
  o First-line treatment is en bloc resection of parathyroid tumor and surrounding structures, usually ipsilateral thyroid lobe at 1st surgery (better local control and disease-free survival)
  o Risk progression associated with margin status
• Drugs
  o Inoperable parathyroid carcinoma management may include calcimimetics to control hypercalcemia and bisphosphonates to control bone resorption
  o Chemotherapy effectiveness unclear
  o Few reports of immunomodulating therapeutic approaches with vaccines
• Radiation
  o Patients treated with surgery and postoperative radiation may have lower risk of locoregional progression and improved cause-specific survival

Prognosis
• 5-year survival up to 85%, 10-year survival is 49%

IMAGE FINDINGS
General Features
• Tc-99m sestamibi scintigraphy or sonography identifies location but does not separate adenoma from carcinoma
• Mass noted on CT and MR, often no specific features

MACROSCOPIC FEATURES
Diagnostic Pathology: Familial Cancer Syndromes

General Features
- Firm tumors, may be adherent to or invasive into adjacent structures
  - Caution as large parathyroid adenomas, especially with cystic change, can become fibrotic and adhere to adjacent structures
  - May be grossly encapsulated and resemble adenomas

Size
- Large tumors (mean = 6.7 g, range from 1.5-27 g); larger than adenomas but overlap in size

MICROSCOPIC PATHOLOGY

Histologic Features
- Hypercellular parathyroid with invasive growth (invasion into adjacent structures, capsular, vascular, or perineural invasion)
- Capsular invasion of tumor beyond thickened capsule identified in 60%
- Fibrous bands common (up to 90%) but not specific
- Invasion of vessels in thickened capsule or surrounding soft tissue (most specific feature for carcinoma but seen in 15% of cases)
- Perineural invasion
- Solid growth pattern with sheets of cells or closely packed nests or trabecular growth but can show follicular or other growth patterns

ANCILLARY TESTS

Immunohistochemistry
- Positive for chromogranin and synaptophysin
- Positive for keratin (CAM5.2 most helpful keratin for neuroendocrine tumors)
- Positive for parathyroid hormone
- Negative for TTF-1, thyroglobulin, calcitonin (usually)
- Ki-67 (MIB-1) elevated > 4 (higher than in adenomas)
- p27 (cyclin-dependent kinase inhibitor protein) decreased expression in parathyroid carcinomas compared to adenomas
- Carcinomas often low/absent p27, MDM2, and higher Ki-67 labeling index
- Keratin 14 reported negative in oxyphil carcinomas and positive in oxyphil adenomas
- Parafibromin
  - HRPT2 encodes parafibromin
  - Loss of nuclear parafibromin in HRPT2-associated parathyroid carcinomas and adenomas
  - Sporadic parathyroid adenomas are usually positive for parafibromin whereas many carcinomas show loss of parafibromin
  - Parathyroid carcinomas in hemodialysis patients can show staining in primary and metastasis
  - Parafibromin shows some promise, but reproducibility and variability in interpretation need to be confirmed

Cytogenetics
- Loss of 1p and 13q relatively common in parathyroid carcinomas whereas loss of 11q (MEN1 gene location) most common abnormality in parathyroid adenoma
- Loss of chromosome 11 common in parathyroid adenoma; gain of chromosome 11 in carcinoma, particularly in those who died of disease
- Loss of heterozygosity on 13q (RB and BRCA2 gene location) in carcinomas, but specific abnormalities of RB or BRCA2 not identified by sequencing

Molecular Genetics
• HRPT2 mutation (tumor suppressor gene, 1q21-q31, encodes parafibromin)
  - Strong association HRPT2 mutation in familial and sporadic parathyroid cancer
    - HRPT2 mutation uncommon in sporadic adenomas but identified in 20% of sporadic cystic adenomas
  - 15% with HPT-JT (caused by germline HRPT2 inactivating mutation) develop parathyroid carcinoma
  - Germline HRPT2 mutations identified in a subset of patients with mutation-positive carcinomas
    - Consider genetic testing in patients with parathyroid carcinoma
• MEN1 mutation (tumor suppressor gene, 11q13, results in truncated menin protein)
  - Somatic MEN1 mutations in 15-20% of sporadic adenomas and some sporadic carcinomas
  - Loss of heterozygosity and somatic MEN1 mutations in some parathyroid carcinomas
  - Only a rare case of parathyroid carcinoma identified in MEN1
• RET mutation (proto-oncogene, 10q11.2)
  - Only rare case reports of parathyroid carcinomas in setting of MEN2A
• Cyclin-D1/CCND1 (11q13)
  - Genetic alterations in cyclin-D1/CCND1 (parathyroid adenoma) gene, 11q13, in 5-8% of parathyroid neoplasms
  - Loss of chromosome 11 frequent in parathyroid adenomas, and frequent chromosomal gain in parathyroid carcinomas in FISH studies
  - Cyclin-D1/CCND1 encodes cyclin-D1 (regulator of cell cycle progression from G1 to S phase), and cyclin-D1 overexpression observed in neoplastic parathyroid
    - Lack of definitive genotype-phenotype correlation limits utility

SELECTED REFERENCES

Image gallery
Microscopic Features
(Left) Parathyroid carcinoma shows a trabecular growth pattern. Parathyroid carcinomas usually have monotonous or trabecular growth. Other patterns of growth (follicular, acinar) are less common. The cytomorphology of the constituent cells is generally monotonous. (Right) Nested and acinar growth is shown in parathyroid carcinoma with a
Mitotic figure ➔. Mitoses are commonly identified in parathyroid carcinoma but can also be found in adenomas.

(Left) Parathyroid carcinoma shows mitotic figures ➔. Oxyphil carcinomas are usually functional and much larger than oxyphil adenomas. Similar to conventional parathyroid carcinomas, invasion is required to diagnose malignancy. (Right) Parathyroid carcinoma invades through the capsule ➔ into a vascular space ➔. (Courtesy L. Erickson, MD.)

(Left) Tumor thrombus is seen in a vessel within the thickened capsule of a parathyroid carcinoma. Vascular invasion is essentially diagnostic of malignancy in parathyroid. (Right) Parathyroid carcinoma ➔ is invading into the perithyroidal tissue (thyroid parenchyma ➔). Invasive growth, including invasion into adjacent structures, is diagnostic of malignancy in parathyroid carcinoma. (Courtesy L. Erickson, MD.)

Parathyroid Hyperplasia

Terminology

- Absolute increase in parathyroid parenchymal mass resulting from proliferation of chief, oxyphil, and transitional cells in multiple parathyroid glands in absence of recognized stimulus for parathyroid hormone (PTH) secretion

Etiology/Pathogenesis

Vania Nosé, MD, PhD
Lori A. Erickson, MD

Key Facts

Part II - Diagnoses Associated With Specific Syndromes > Section 5 - Endocrine > Parathyroid > Parathyroid Hyperplasia
- Hereditary hyperparathyroidism is less common than primary sporadic hyperparathyroidism
- Hyperparathyroidism jaw-tumor syndrome
  - Autosomal dominant, inactivating mutations in putative tumor suppressor gene HRPT2 that encodes parafibromin
- Multiple endocrine neoplasia type 1 (MEN1)
  - Autosomal dominant; germline mutation MEN1 tumor suppressor gene that encodes menin
- Familial isolated hyperparathyroidism
  - Autosomal dominant; parathyroid only endocrine organ involved; adenoma or hyperplasia, and suggested increased risk of parathyroid carcinoma
- Multiple endocrine neoplasia type 2A (MEN2A)
  - Autosomal dominant; germline RET-activating proto-oncogene mutation
- Calcium-sensing receptor (CASR) mutation
  - Inactivating CASR (3q13.3-21) mutation causes decreased calcium sensitivity of parathyroid and kidney and results in PTH-dependent hypercalcemia
  - Familial hypocalciuric hypercalcemia
  - Familial autosomal dominant hypoparathyroidism and familial hypocalcemia
  - Neonatal severe hyperparathyroidism

This picture shows 4 enlarged parathyroid glands with a great variability in glandular size (asymmetric hyperplasia), which can distinguish parathyroid hyperplasia from adenoma.
Asymmetric hyperplasia, a.k.a. pseudoadenomatous variant of hyperplasia with marked variation in extent of glandular involvement, is easily confused with adenoma or multiple adenomas.

**TERMINOLOGY**

**Synonyms**
- Nodular hyperplasia
- Primary parathyroid hyperplasia
- Secondary parathyroid hyperplasia
- Multiple adenomatosis

**Definitions**
- Absolute increase in parathyroid parenchymal mass resulting from proliferation of chief, oxyphil, and transitional cells in multiple parathyroid glands in absence of recognized stimulus for parathyroid hormone (PTH) secretion

**ETIOLOGY/PATHOGENESIS**

**Sporadic Primary Hyperparathyroidism**
- Etiology of sporadic primary hyperplasia is unclear

**Familial Hyperparathyroidism**
- Hereditary hyperparathyroidism is less common than primary sporadic hyperparathyroidism
- Most common hereditary hyperparathyroidism includes
  - Multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2A (MEN2A), familial hypocalciuric hypercalcemia, neonatal severe primary hyperparathyroidism, hyperparathyroidism-jaw tumor syndrome (HPT-JT), and familial isolated hyperparathyroidism
  - **MEN1**
    - Autosomal dominant due to germline mutation MEN1 tumor suppressor gene (11q13)
      - Encodes menin (truncated with MEN1 mutation)
      - Sporadic MEN1 cases due to new mutations
    - MEN1 equally affects females and males; no ethnic or geographic differences
Primary parathyroid hyperplasia (multiglandular parathyroid tumors) is the most common manifestation of MEN1. 90% of patients with MEN1 have primary parathyroid hyperplasia, and 20% of patients with primary parathyroid hyperplasia have MEN1. MEN1-associated hyperparathyroidism has onset of 20-25 years of age and affects males and females equally. Parathyroid adenomas and rare report of carcinoma in MEN1, but much less common than hyperplasia.

- **MEN2A**
  - Autosomal dominant, high penetrance, germline RET-activating proto-oncogene mutation (10q11.2)
  - 20-30% of MEN2A cases are associated with parathyroid hyperplasia (or adenomas; rare report of carcinoma)
  - MEN2A is diagnosed clinically by occurrence of at least 2 specific endocrine tumors
    - Medullary thyroid carcinoma, pheochromocytoma, or parathyroid hyperplasia/adenoma in individual or close relatives

- **HPT-JT**
  - Autosomal dominant, inactivating mutations in putative tumor suppressor gene HRPT2 (1q21-q31) that encodes parafibromin
  - Disorder of hyperparathyroidism, fibroosseous jaw tumors, kidney cysts, hamartomas, and Wilms tumors
  - Parathyroid hyperplasia or adenoma and increased risk of parathyroid carcinoma

- **Familial isolated hyperparathyroidism**
  - Autosomal dominant
  - 1% of primary hyperparathyroidism (parathyroid is only endocrine organ involved)
    - Adenoma or hyperplasia and suggested increased risk of parathyroid carcinoma (but may be due to inclusion of HPT-JT cases)

  - Cause is unknown in most families, but HRPT2 gene, MEN1 gene, and area on chromosome 2 have been implicated

- **Calcium-sensing receptor (CASR) mutation**
  - Inactivating CASR (3q13.3-21) mutation causes decreased calcium sensitivity of parathyroid and kidney and results in PTH-dependent hypercalcemia
  - CASRs detect extracellular calcium levels that regulate PTH release
    - Present in parathyroid, kidney, thyroid C cells, intestine, and bone
  - Neonatal severe primary hyperparathyroidism
    - Homozygous inactivating CASR mutations
    - Life-threatening disorder with markedly hypercellular, hyperplastic parathyroid glands
    - Autosomal recessive
  - Familial hypocalciuric hypercalcemia
    - Heterozygous inactivating CASR mutations in familial hypocalciuric hypercalcemia
  - Familial autosomal dominant hypoparathyroidism and familial hypocalcemia
    - Activating CASR mutations in familial autosomal dominant hypoparathyroidism and familial hypocalcemia
  - Hypocalciuric hypercalcemia
    - Caused by autoantibodies directed at CASR and can simulate familial hypocalciuric hypercalcemia

**Secondary Hyperparathyroidism**
- Secondary to numerous stimuli
  - Most commonly seen secondary to renal failure

**CLINICAL ISSUES**
**Epidemiology**
- **Incidence**
  - Primary parathyroid hyperplasia accounts for 15% of primary hyperparathyroidism (parathyroid adenomas, 80-85%; carcinomas, 1%)
  - Incidence increased in past 3 decades with increased calcium screening with multichannel autoanalyzer
  - Parathyroid hyperplasia occurs in 90% of patients with MEN1 and in 30% with MEN2A
20% of patients with primary parathyroid hyperplasia have MEN 1 or MEN2A.
Prevalence of 7% in autopsy study (patients had elevated serum calcium but no bone disease).

Age
Sporadic form typically presents in 5th decade but can manifest during a wide age range.
Familial cases occur earlier (often 20-25 years of age).

Presentation
Primary hyperparathyroidism (HPT) results from excessive secretion of parathyroid hormone from parathyroid tumors.
Most HPT cases are sporadic, but a minority of cases are associated with a familial syndrome.
HPT in its hereditary variants assumes special forms, has special associations, and requires special managements.
Familial hypocalciuric hypercalcemia (FHH) and neonatal severe primary hyperparathyroidism (NSHPT) reflect heterozygous and homozygous mutations, respectively, in the calcium-sensing receptor.
FHH represents mildest variant of HPT whereas NSHPT represents severest form of HPT.
Both FHH and NSHPT cause hypercalcemia from birth and atypical HPT that always and uniquely persists after subtotal parathyroidectomy.
HPT resulting from FHH and NSHPT is likely polyclonal and nonneoplastic.
In contrast, monoclonal or oligoclonal parathyroid neoplasia underlies most other HPT variants: MEN1, MEN2A, and HPT-JT.

Treatment
Surgical approaches
- Subtotal parathyroidectomy with 3 glands removed, leaving vascularized remnant of 4th gland, or
- Total parathyroidectomy with autotransplantation of portion of parathyroid gland into neck or forearm.

P.II(5):78
- Rapid intraoperative PTH measurements decrease risk of missing multiglandular disease and help confirm removal of diseased parathyroid gland(s).
- Difficult or impossible to differentiate primary hyperplasia from adenoma based only on intraoperative examination of 1 gland.
- Residual tissue may become hyperplastic, requiring additional surgery.
- Concurrent transcervical thymectomy is also suggested at time of parathyroidectomy.

MACROSCOPIC FEATURES
General Features
- Some reports indicate that 50% of cases show symmetric enlargement of all 4 glands; however, other studies report that in ~ 66% of cases, only 2 glands appear enlarged.
- Asymmetric hyperplasia or pseudoadenomatous variant of hyperplasia with marked variation in parathyroid glands size.
- Surgeons and pathologists must be cautious in evaluating parathyroid glands in relation to size and cellularity as these parameters can vary greatly within a single patient with parathyroid hyperplasia.
  - Asymmetrically enlarged gland can be misinterpreted as parathyroid adenoma.

MICROSCOPIC PATHOLOGY
Histologic Features
- Primary parathyroid hyperplasia histology.
- Increase in parenchymal cell mass of multiple parathyroid glands.
- Chief cell is predominant, but oxyphil, transitional, and clear cells may be present.
- Asymmetric hyperplasia or pseudoadenomatous variant of hyperplasia with marked variation in extent of glandular involvement is easily confused with adenoma or multiple adenomas.
  - Parathyroid hyperplasia in MEN1 usually involves increased numbers of chief cells that may have nodular or diffuse pattern.
  - MEN1-associated hyperplasia is often asymmetric.
  - Histologic features in HPT-JT-associated cases are similar to sporadic lesions, but HPT-JT cases are often cystic.
- Hyperplastic chief cells are arranged in cords, nests, sheets, or follicular structures.
- Scattered mitotic figures may be seen, but more mitoses and atypical mitoses are present in carcinoma.
- Cells show slight variation in size and shape.
  - Foci of endocrine atypia with pleomorphism and hyperchromasia (more common in adenomas).
Stromal fat is decreased, but regional variations in stromal fat are present even among glands in a single individual (pitfall in evaluating small biopsies)

Nodular or diffuse growth
- Nodular is most common pattern in primary hyperplasia
- Rim of normal parathyroid tissue can rarely be seen but this feature is more common in adenoma
- Fibrosis and hemosiderin, especially in markedly enlarged glands or glands with cystic degeneration
- Cystic change is uncommon but can be seen in markedly enlarged glands
- No capsular, vascular, or perineural invasion or invasion into adjacent structures

Primary parathyroid hyperplasia variants
- Clear (water-clear) cell hyperplasia
  - Multiple enlarged parathyroid glands associated with hyperplasia with parenchymal cells having abundant, vacuolated, clear cytoplasm
- Lipohyperplasia
  - Enlarged parathyroid glands with hyperparathyroidism, but abundant stromal fat of lipohyperplasia (or lipoadenoma) can be confused with normal parathyroid tissue

ANCILLARY TESTS

Immunohistochemistry
- Positive for PTH, chromogranin, and synaptophysin
- Positive for keratin (CAM5.2 most helpful keratin for neuroendocrine tumors)
- Negative for TTF-1, thyroglobulin, variable calcitonin
- Ki-67 lower in hyperplasia and adenomas than carcinomas

Molecular Genetics
- Parathyroid hyperplasia is often polyclonal, but monoclonality has been identified, particularly in nodular areas and in MEN1 (multiglandular parathyroid tumors)
- Somatic mutations in MEN1 and HRPT2 tumor suppressor genes are now recognized as frequent events in sporadic parathyroid adenomas and carcinomas, respectively
- Specific genetic abnormalities in idiopathic primary parathyroid hyperplasia are not as well defined as in hereditary forms of hyperparathyroidism
- CCND1/PRAD1 oncogene was discovered by analysis of sporadic parathyroid tumors
- RET mutation test became essential in management of MEN2A
- MEN1 test is less urgent because it rarely leads to a major patient benefit
- MEN1 germline mutation testing should be offered to index patients with MEN1 and their 1st-degree relatives
  - This includes relatives who are either asymptomatic or who have clinical manifestations of MEN1
- MEN1 germline mutation testing should be recommended in individuals with an atypical MEN1 phenotype, e.g., multigland hyperparathyroidism
- CASR test, perhaps the least urgent, has largely been unavailable
- Studies of familial isolated hyperparathyroidism and analysis of chromosomal loss and gain in P.II(5):79

parathyroid tumors suggest that other genes relevant to parathyroid neoplasia await identification

- Study of these syndromes has helped define the pathophysiology of both familial and sporadic parathyroid neoplasms
- HRPT2 mutation (tumor suppressor gene, 1q21-q31, encodes parafibromin)
  - Germline HRPT2-inactivating mutation in HPT-JT-associated hyperplasia, adenoma, and carcinoma
  - Strong association between HRPT2 mutations and familial and sporadic parathyroid cancer
  - Germline HRPT2 mutations identified in subset of patients with mutation-positive carcinomas
- MEN1 mutation (tumor suppressor gene, 11q13, results in truncated menin protein)
  - Primary parathyroid hyperplasia (multiglandular parathyroid tumors) is most common manifestation of MEN1 (90% of MEN1 cases have hyperplasia)
    - Autosomal dominant; germline mutation in MEN1 tumor suppressor gene (11q13)
    - Encodes menin
    - Sporadic MEN1 cases due to new mutations
    - Although classically referred to as parathyroid hyperplasia, recent studies demonstrated clonality (multiglandular parathyroid tumors)
  - Somatic MEN1 mutations occur in 15-20% of sporadic parathyroid adenomas and some sporadic parathyroid carcinomas
• RET mutation (proto-oncogene, 10q21)
  o RET germline activating proto-oncogene mutation in MEN2A
    ▪ Autosomal dominant, with high penetrance, 95% patients have mutation in exon 10 or 11, codon 634
    ▪ 20-30% of MEN2A associated with parathyroid hyperplasia or adenoma
  o RET mutation is generally not identified in sporadic parathyroid disease
• Cyclin-D1/CCND1
  o Encodes cyclin-D1, a cell cycle regulator from G1 to S phase
  o Cyclin-D1 overexpression has been observed in hyperplastic parathyroid glands, but lack of definitive correlation limits utility
• Familial isolated hyperparathyroidism
  o Cause is unknown in most cases, but HRPT2, MEN1 gene, and area on chromosome 2 have been implicated
• CASR mutation
  o Inactivating CASR (3q13.3-21) mutation causes decreased calcium sensitivity of parathyroid and kidney, resulting in PTH-dependent hypercalcemia
  o Familial hypocalciuric hypercalcemia
    ▪ Heterozygous inactivating CASR mutations
  o Familial autosomal dominant hypoparathyroidism and familial hypocalcemia
    ▪ Activating CASR mutations
  o Neonatal severe hyperparathyroidism
    ▪ Homozygous inactivating CASR mutations
  o CASR mutations are generally not seen in sporadic parathyroid disease

DIAGNOSTIC CHECKLIST
Clinically Relevant Pathologic Features
• 20% of primary hyperplasia cases are associated with MEN1
• Mild, nonspecific symptoms or asymptomatic and identified by screening serum calcium
Pathologic Interpretation Pearls
• Normal parathyroid has significant variation in cellularity in and among glands (use caution when evaluating small biopsies)
• Distinguishing parathyroid tissue from thyroid: Well-demarcated cytoplasmic membranes; lack colloid, lack cytoplasmic lipid; rounder nuclei; denser chromatin
• Symmetric enlargement of all 4 glands only in subset of cases; many show enlargement of < 4 glands
  o Be very cautious in attempting to diagnose multiple adenomas (most likely asymmetric hyperplasia)
• Rims of normal tissue occasionally are seen in parathyroid hyperplasia
• Be aware of parathyroid hyperplasia variants (lipohyperplasia and clear cell hyperplasia)

SELECTED REFERENCES
P.II(5):80
The graphic depicts normal parathyroid glands and their relationship to adjacent organs and structures.

The normal parathyroid gland is composed predominantly of chief cells and can show a significant variation in cellularity, even in a single patient. The normal parathyroid cellularity is variable, distributed unevenly, is high in children and infants, and decreases proportionally with age.

Parathyroid adenoma usually involves only 1 gland. The other parathyroid glands are normal in size. Asymmetric hyperplasia or pseudoadenomatous variant of hyperplasia with marked variation in extent of glandular involvement is easily confused with multiple adenomas. (Right) Parathyroid adenomas consist of a monomorphic proliferation of chief cells in a diffuse pattern. The diagnosis of adenoma is made by the involvement of 1 gland and by the presence of a rim of normocellular parathyroid.
A gross photograph of a parathyroid gland with multigland parathyroid hyperplasia shows a pale pink multilobulated outer surface. In contrast to a parathyroid adenoma, hyperplasia is characterized by heterogeneous enlargement of the 4 parathyroid glands. Parathyroid hyperplasia in MEN1 usually involves increased numbers of chief cells that may have a nodular or diffuse pattern. The nodular pattern is usually characteristic of parathyroid hyperplasia.

Microscopic Features of Parathyroid Hyperplasia

(Left) Low-power view of a parathyroid gland with parathyroid nodular hyperplasia shows the presence of multiple irregular nodules of chief cells with intermixed residual fat cells. (Right) Parathyroid hyperplasia in MEN1 has an increase in the parenchymal cell mass of multiple parathyroid glands. Chief cells are predominant, but oxyphil, transitional, and clear cells may also be present. Stromal fat is decreased, with marked variability within the gland.
Histologic features usually found in HPT-JT-associated parathyroid lesions include a cystic adenoma and parathyroid carcinoma. Parathyroid hyperplasia is not seen in patients with HPT-JT. Although foci of endocrine atypia with pleomorphism and hyperchromasia are more common in adenomas, they can be present in parathyroid hyperplasia.

Parathyroid hyperplasia in MEN1 has an increase in parenchymal cell mass. Chief cells are predominant, but oxyphil, transitional, and clear cells may also be present. Residual fat cells are present. (Right) High-power view of a parathyroid hyperplasia shows an increase in parenchymal cell mass with clear cells, chief cells, and a few oncocytic cells.

Pituitary

Pituitary Adenoma
Pituitary adenomas (PAs) may be sporadic or as part of an inherited tumor syndrome
  o Familial pituitary tumors are increasingly recognized
Pituitary adenomas may be associated with the following familial syndromes
  o Multiple endocrine neoplasia type 1 (MEN1)
  o McCune-Albright syndrome (MAS)
  o Familial isolated pituitary adenoma (FIPA)
  o Isolated familial somatotropinoma syndrome (IFS)
  o Carney complex (CC)
  o Genetic, epigenetic factors, hormonal stimulation, growth factors, and their receptors implicated in pituitary tumorigenesis

Clinical Issues
  o Occur in almost 20% of general population

Microscopic Pathology
  o Chromophobic, acidophilic, or basophilic cells
  o Architecture can predict cell type

Ancillary Tests
  o Immunohistochemistry is most valuable tool in classification of PAs
  o Immunopanel includes pituitary transcription factors, hormones, LMWK, and MIB-1
  o Total breakdown of normal acinar architecture on reticulin stain is diagnostic of PA

Gross image shows a pituitary macroadenoma that extends upward into the suprasellar cistern and laterally into the cavernous sinus. Pituitary adenomas are common findings in MEN1 syndrome patients.
This image shows an acidophilic pituitary adenoma composed of cells that exhibit bright cytoplasmic eosinophilia, associated with a familial growth hormone-producing adenoma.

TERMINOLOGY

Abbreviations
- Pituitary adenoma (PA)

Definitions
- Benign clonal epithelial neoplasms derived from adenohypophyseal cells
- Usually arise in sella turcica and, occasionally seen as ectopic lesion

ETIOLOGY/PATHOGENESIS

Etiology
- Genetic, epigenetic factors, hormonal stimulation, growth factors, and their receptors implicated in pituitary tumorigenesis

Pathogenesis
- Most adenomas are sporadic
- Hormone regulatory pathways
  - Hormonal stimulus or impaired feedback inhibition on hypothalamic-pituitary-target organ axes may underlie pathogenesis of PAs
    - Excess GHRH, CRH, TRH, or GnRH production
    - Target organ failure resulting in increased stimulation of hypothalamic-pituitary axes
- Somatic genetics
  - Pituitary gland is rarely affected by activating mutations of common oncogenes
  - Cell type-specific genetic changes are common
  - Epigenetically silenced tumor suppressors are found in sporadic PAs
  - Dysregulation of FGFRs may play important role in pathogenesis of PAs

Associated Syndromes
- Multiple endocrine neoplasia type 1 (MEN1)
Autosomal dominant disorder associated with germline mutation of MEN1 tumor suppressor gene that encodes menin

- **McCune-Albright syndrome (MAS)**
  - Mosaic mutations of GNAS gene (Gαs protein; Gsp)
  - Affected patients develop somatotroph hyperplasia or somatotroph PAs

- **Familial isolated pituitary adenoma (FIPA)**
  - Autosomal dominant disease with variable penetrance
    - 20% of patients affected by germline mutations in tumor suppressor aryl hydrocarbon receptor interacting protein (AIP)
    - No gene abnormality has been identified to date in majority of the FIPA families
  - Cyclin-dependent kinases inhibitor (CDKI) gene mutations have been described in a small number of other familial PAs
  - AIP mutation-positive patients have a characteristic clinical phenotype with usually young- or childhood-onset GH &/or PRL-secreting adenomas
    - It can be seen in cases with no apparent family history as well
  - Understanding tumorigenic process in AIP(+) and AIP(-) FIPA patients could result in better diagnostic and treatment options for both familial and sporadic cases

- **Isolated familial somatotropinoma syndrome (IFS)**
  - ~ 50% of IFS kindreds exhibit mutations in AIP gene

- **Carney complex (CC)**
  - Autosomal dominant disorder associated with germline mutations in PRKAR1A gene that encodes protein kinase-A regulatory subunit 1α

**MEN4**
- CDKN1B
- Rare reported cases of GH-producing pituitary adenoma associated with hyperparathyroidism

---

**CLINICAL ISSUES**

**Epidemiology**

- **Incidence**
  - Common, occurring in almost 20% of general population
  - Uncommon in pediatric population
    - When present, suggests familial syndrome
  - Constitute 10-25% of all intracranial neoplasms

- **Age**
  - Incidence increases with age in autopsy studies; > 30% of individuals 50-60 years of age have clinically undetected PAs
  - FIPA families comprise approximately 2% of pituitary adenomas and represent a clinical entity with homogeneous or heterogeneous pituitary adenoma types occurring within same kindred

**Presentation**

- **Hypersecretion of pituitary hormones**
  - Adrenocorticotropic (ACTH) excess presents with Cushing disease or Nelson syndrome
  - GH excess causes acromegaly, gigantism, or both
  - PRL excess presents with galactorrhea, amenorrhea, hypogonadism, and infertility
  - Thyrotropin (TSH) excess presents with hyperthyroidism and is sometimes associated with galactorrhea and hyperprolactinemia
  - Gonadotropin (FSH, LH) excess presents with gonadal dysfunction

- PAs present in 30-40% of MEN1 patients: PRL (20%), GH (10%)
- AIP mutations are usually associated with somatotropinomas, but prolactinomas, nonfunctioning pituitary adenomas, Cushing disease, and other adenoma types may occur
- PA in Carney complex is usually GH-producing adenoma
- Hypopituitarism due to compression of nontumorous anterior pituitary parenchyma
- Mass effects can be 1st sign, especially in clinically nonfunctioning adenomas

**Prognosis**

- Best prognosticator is classification of PAs based on hormone content and cell structure
- Some PA subtypes are usually associated with invasive or aggressive behavior
IMAGE FINDINGS

Radiographic Findings
- PAs are classified radiologically based on tumor size and degree of local invasion
  - Grade 1 (microadenomas) are intrapituitary lesions measuring up to 1 cm
  - Grade 2 (macroadenomas) are larger than 1 cm
  - Grade 3 PAs are locally invasive tumors associated with suprasellar extension and bone erosion
  - Grade 4 PAs involve extrasellar structures (bone, hypothalamus, cavernous sinus)

MACROSCOPIC FEATURES

General Features
- PAs are usually resected as multiple small pieces; majority of PAs exhibit soft white gross appearance

MICROSCOPIC PATHOLOGY

Histologic Features
- Solid, diffuse, trabecular, sinusoidal, papillary growth patterns are common
- Adenoma reveals breakdown of normal acinar architecture on Gordon-Sweet silver stain
  - This distinguishes neoplasia from hyperplasia that retains an acinar reticulin pattern
- Involvement of bone, posterior lobe, dura mater, or respiratory mucosa in invasive PAs

ANCILLARY TESTS

Immunohistochemistry
- General neuroendocrine markers (chromogranin-A, synaptophysin, and neuron-specific enolase [NSE])
- Other markers: LMWK (CAM5.2), MIB-1, p53
- Most valuable tool in determination of cellular differentiation and classification of PAs
  - Hormones: GH, PRL, TSH-β, FSH-β, LH-β, ACTH, α-subunit

DIFFERENTIAL DIAGNOSIS

Pituitary Hyperplasia
- Adenoma reveals total breakdown of normal acinar architecture on silver stain

Paraganglioma
- Sometimes PAs can be negative for keratins

Spindle Cell Oncocytoma/Pituicytoma
- Positive for TTF-1, galactin-3, vimentin, S100, and EMA

Metastatic Neuroendocrine Carcinoma
- Negativity for pituitary transcription factors (PIT-1, Tpit, SF1) and positivity for other transcription factors (CDX-2, TTF-1, etc.) favors metastatic neuroendocrine carcinoma

SELECTED REFERENCES

\[
\text{Immunohistochemical Classification of Pituitary Adenomas} \\
\begin{array}{|c|c|c|c|}
\hline
\text{Adenoma Type} & \text{Transcription Factor} & \text{Hormones} & \text{LMWK} \\
\hline
\text{GH-Producing Adenomas} & PIT-1 & GH, α-SU & Perinuclear \\
Densely granulated somatotroph adenoma & & & \\
Sprarsely granulated somatotroph & PIT-1 & GH & Fibrous bodies \\
\hline
\end{array}
\]
<table>
<thead>
<tr>
<th>Adenoma Type</th>
<th>Hormones Produced</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mammosomatotroph adenoma</td>
<td>GH, PRL, α-SU</td>
<td>AL</td>
</tr>
<tr>
<td>Mixed somatotroph and lactotroph adenoma</td>
<td>GH, PRL, α-SU</td>
<td>AL</td>
</tr>
<tr>
<td>Plurihormonal GH-producing adenoma</td>
<td>GH, PRL, α-SU, TSH-β</td>
<td>AL</td>
</tr>
<tr>
<td><em>PRL-Producing Adenomas</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sparsely granulated lactotroph adenoma</td>
<td>PRL (Golgi pattern)</td>
<td>AL</td>
</tr>
<tr>
<td>Densely granulated lactotroph adenoma</td>
<td>PRL (diffuse)</td>
<td>AL</td>
</tr>
<tr>
<td>Acidophil stem cell adenoma</td>
<td>PRL (diffuse), GH</td>
<td>AL</td>
</tr>
<tr>
<td></td>
<td>Fibrous bodies</td>
<td></td>
</tr>
<tr>
<td><em>TSH-Producing Adenoma</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyrotroph adenoma</td>
<td>TSH-β, α-SU</td>
<td>AL</td>
</tr>
<tr>
<td><em>ACTH-Producing Adenomas</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Densely granulated corticotroph adenoma</td>
<td>ACTH</td>
<td>AL</td>
</tr>
<tr>
<td>Sparsely granulated corticotroph adenoma</td>
<td>ACTH</td>
<td>AL</td>
</tr>
<tr>
<td>Crooke cell adenoma</td>
<td>ACTH</td>
<td>AL</td>
</tr>
<tr>
<td><em>Gonadotropin-Producing Adenoma</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gonadotroph adenoma</td>
<td>LH-β, FSH-β, α-SU</td>
<td>AL</td>
</tr>
<tr>
<td><em>Plurihormonal Adenomas</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Silent subtype 3 adenoma</td>
<td>Multiple</td>
<td>AL</td>
</tr>
<tr>
<td>Unusual plurihormonal adenoma, NOS</td>
<td>Multiple</td>
<td>AL</td>
</tr>
<tr>
<td><em>Hormone-Negative Adenoma</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Null cell adenoma</td>
<td>Absent</td>
<td>AL</td>
</tr>
</tbody>
</table>

(Left) The pituitary is composed of neuronal tissue forming the posterior pituitary (PL) and pituitary stalk, epithelial neuroendocrine tissue forming the anterior lobe (AL), and the cystic remnants of the intermediate lobe (IL). The anterior pituitary is composed of cells with production of diverse hormones. Normal distribution of cells is shown.
(inset). (Right) Pituitary adenomas demonstrate a breakdown of normal acinar architecture, highlighted by the loss of silver stain.

(Left) MR shows invasive pituitary adenoma with sphenoid sinus and cavernous sinus invasion. (Right) Cytoplasmic granularity gives 3 morphologically distinct cell types: Chromophobic, eosinophilic, and basophilic. This chromophobic pituitary adenoma is composed of cells that exhibit pale to light eosinophilic cytoplasm and small round nuclei.

(Left) Coronal graphic illustrates a large pituitary macroadenoma extending superiorly to compress the body of the chiasm, thus compressing the bulk of the crossing nasal retinal fibers. (Right) Normal corticotrophs exposed to elevated glucocorticoids undergo Crooke hyaline change, which is characterized by the accumulation of glassy pink material (keratin) in the cell cytoplasm.

**Pituitary Carcinoma**

> Table of Contents > Part II - Diagnoses Associated With Specific Syndromes > Section 5 - Endocrine > Pituitary

Pituitary Carcinoma

Vania Nosé, MD, PhD

Key Facts

Terminology

- Tumor of adenohypophysis exhibiting cerebrospinal &/or systemic metastases
- Conventional morphologic malignancy criteria (nuclear atypia, pleomorphism, mitotic activity, necrosis, hemorrhage, &/or dural invasion) are insufficient for diagnosis

Etiology/Pathogenesis
• Arise in transition from pituitary adenoma or de novo from previously normal adenohypophysial cells
• Inherited
  o Minority may be associated with familial syndromes
  o Multiple endocrine neoplasia 1 (MEN1)
  o Carney complex
  o Familial isolated pituitary adenoma (FIPA)
  o Isolated familial somatotropinoma (IFS) syndrome
  o McCune-Albright syndrome
  o In comparison to sporadic tumors, incidence of pituitary carcinoma is not increased in patients with syndromes
• Chromosomal gains were found in 4 cases
• Most common chromosomal gains (5, 7p, 14q)
• Point mutations in HRAS in carcinomas but not their adenoma precursors
• P53 mutations occasional

Clinical Issues
• 0.2% of operated adenohypophysial tumors
• De novo malignancy adenoma

Top Differential Diagnoses
• Metastatic carcinoma from other organs

Partial hepatectomy specimen on a patient with history of pituitary tumor shows infiltration of liver parenchyma by a neuroendocrine neoplasm, with immunoreactivity similar to the pituitary tumor.
Pituitary carcinoma shows a solid arrangement of pleomorphic cells with an eosinophilic cytoplasm, nuclear pleomorphism, irregular nuclear membranes, and prominent nucleoli.

**TERMINOLOGY**

**Abbreviations**
- Pituitary carcinoma (PC)

**Synonyms**
- Pituitary adenocarcinoma
- Adenocarcinoma of pituitary

**Definitions**
- Tumor of adenohypophysis exhibiting cerebrospinal &/or systemic metastases
  - Conventional criteria of malignancy, such as nuclear atypia, pleomorphism, mitotic activity, necrosis, hemorrhage, &/or dural invasion are insufficient criteria for diagnosis
  - Local extension into adjacent structures is not criteria for malignancy
- Brain invasion is also indicative of malignancy

**ETIOLOGY/PATHOGENESIS**

**Genetics**
- Inherited
  - Minority may be associated with familial syndromes
    - Multiple endocrine neoplasia 1 (MEN1)
    - Carney complex
    - Familial isolated pituitary adenoma (FIPA)
    - Isolated familial somatotropinoma (IFS) syndrome
    - McCune-Albright syndrome
    - In comparison to sporadic tumors, incidence of PC is not increased in patients with syndromes
  - Chromosomal gains were found in 4 cases
Most common chromosomal gains (5, 7p, 14q)
Chromosomal losses reported in 2 cases of PC comparative genomic hybridization (CGH)
Clonality studies (X-linked gene analysis) show primary, recurrent, and metastatic carcinoma to have same allelic pattern
Point mutations in HRAS in carcinomas but not their adenoma precursors
TP53 mutations are occasional

Pathophysiology
- Arise in transition from pituitary adenoma or de novo from previously normal adenohypophysial cells
- No evidence of pluripotent precursor cells involved in adenoma or carcinogenesis
- Invasion (e.g., dura) is common in adenomas, but malignant transformation is rare
- Latency from adenoma to carcinoma varies (longer latency for ACTH-secreting tumors > PRL)
- Spread to central nervous system by way of cerebrospinal fluid
- Direct infiltration of brain is rare
- Systemic metastases are hematogenous, associated with cavernous sinus/jugular vein involvement
- Lymph node metastases secondary to skull base and soft tissue involvement
- Unclear whether sellar surgery facilitates metastases

CLINICAL ISSUES
Epidemiology
- Incidence
  - Very rare; ~ 150 cases reported to date
  - 0.2% of operated adenohypophysial tumors
- Age
  - Adults; rarely adolescents
- Gender
  - Slight female predilection
Site
- Primary sellar; rarely ectopic
- Metastatic sites
  - Craniospinal leptomeninges
  - Systemic sites mainly liver, bone, lymph node, lung

Presentation
- Diagnosis based on metastasis, often from multiple recurring, invasive adenoma
- De novo malignancy in adenoma
- Interval to metastasis: 4 months to 30 years (mean: 10 years)
- Malignant transformation rare in ectopic adenoma
- Majority (75%) endocrinologically functional
  - Prolactin and ACTH most frequent, followed by GH and TSH
  - Presentations: Hyperprolactinemia, Nelson syndrome, Cushing disease, acromegaly, hyperthyroidism
  - Nonfunctioning PCs are rare
- Pituitary hormone levels do not permit distinction of adenoma from carcinoma except for PRL (marked increase: 10-30,000 ng/mL)
- Early features of aggressive behavior: Infiltration of dura, bone, cavernous sinus, and cranial nerves
- Clinical signs specific to site of metastasis

Treatment
- Multimodality therapies (surgery, external beam radiotherapy, radiosurgery, adjuvant pharmacologic, and chemotherapy)
- Temozolomide therapy efficacious
- Dopamine agonist response temporary in PRL cell carcinomas

Prognosis
- Poor; mortality 6% at 1 year and 80% within 8 years
- Overall mean survival: 2 years; range: 0.25-8 years
- Survival shorter in systemic vs. craniospinal metastases (1 vs. 2.6 years)
- Long-term survival with benign histology, but poor survival with anaplasia
• Loss of MGMT immunoreactivity and promoter methylation of gene associated with high response to temozolomide therapy

IMAGE FINDINGS
CT and MR Findings
• No features unique to PC
• Bone metastases are usually osteolytic but may be osteoblastic
  o Mimic meningioma when presenting as dura-based masses
• Invasive sellar primary often extending into parasellar structures
  o Cranial nerves in cavernous sinus often affected
• Brain infrequently involved by primary tumor
• Multifocal craniospinal deposits affect leptomeninges and nerve roots, often in cauda equina

MACROSCOPIC FEATURES
General Features
• Primary tumor of macroadenoma size (> 1 cm); all invasive
• Metastatic deposits may be single or multiple, nodular or diffuse
• Metastasis of PC indistinguishable from metastases of carcinomas of other organs

Size
• Metastatic deposits vary from minute focus to macroscopic
• Metastasis to spinal axis are usually relatively small (< 2 cm)
• Metastatic deposits, particularly to liver, can be large

MICROSCOPIC PATHOLOGY
Histologic Features
• No combination of histologic features diagnostic of carcinoma
  o Presence of invasion, cellular pleomorphism, mitosis, or necrosis are not sufficient for diagnosis of malignancy
  P.II(5):88
  o Diagnosis of PC is dependent upon demonstration of metastases
• Nuclear atypia, cellular pleomorphism, mitotic activity, or necrosis may be present
  o Also present to varying degrees in nonmetastasizing adenohypophysial tumors
• Most are not overtly malignant histologically or cytologically
• Mitotic activity is increased in carcinomas (up to 67%), but there is considerable overlap with adenomas
• Lack of acinar architecture on reticulin staining, such as adenomas

ANCILLARY TESTS
Immunohistochemistry
• Synaptophysin (+) in all tumors
• Chromogranin less often (+), usually (+) in glycoprotein-producing tumors
• All are hormone-producing tumors, even when clinically nonfunctional
• Ki-67 labeling index varies widely, up to 67%; often higher in metastases
• Topoisomerase-II, an indicator of proliferation rate, often exceeds 4%
• p27, cell cycle inhibitor widely expressed in normal pituitary, decreased in carcinomas
• p53 expressed in most PCs, staining in metastases higher than primary tumor
• VEGFR, related to angiogenesis, widely expressed
• Overexpression of HER2 rare

Electron Microscopy
• Does not distinguish adenoma from carcinoma

DIFFERENTIAL DIAGNOSIS
Metastatic Carcinoma From Other Organs
• Anaplasia more prominent in carcinoma
• Negative for pituitary hormones
  o Except for rare tumors secreting ACTH or GH
• Synaptophysin (+) only in neuroendocrine carcinomas
• Organ-specific markers positivity

Invasive Pituitary Adenoma
• Locally invasive tumor
• No metastases present
Histological features, immunohistochemical profile, electron microscopy, and proliferation markers cannot distinguish benign from malignant tumors

DIAGNOSTIC CHECKLIST

Clinically Relevant Pathologic Features
- History of pituitary adenoma or invasive pituitary adenoma is helpful

Pathologic Interpretation Pearls
- Disseminating lesions present in carcinoma often arise in infiltrating adenoma
- Local infiltration is not, in itself, an indicator of carcinoma
- Useful to compare histological appearance and immunohistochemical profile of metastatic focus with primary pituitary tumor
- No histological, immunohistochemical, or ultrastructural finding conclusively separates pituitary adenomas from carcinomas

GRADING

Grading System
- No suitable grading system exists

SELECTED REFERENCES
15. P.II(5):89

Image gallery

Microscopic Features
Smear from a liver nodule shows a highly cellular neoplasm composed of rare giant cells that are present in the background of a monotonous population of cells. The cells have scant cytoplasm and nuclei with a homogeneous appearance. Pituitary carcinoma metastatic to liver shows a solid arrangement of cells with mild atypia, cellular pleomorphism, apoptosis, and the presence of an atypical mitosis.

This low-power photomicrograph shows metastatic pituitary carcinoma in a liver. The tumor infiltrates the hepatic sinusoids and forms solid sheets of tumor cells with regular nuclei lacking pleomorphism. H&E from a liver with metastatic pituitary carcinoma shows diffuse infiltration of the hepatic sinusoids by tumor cells. There are apoptotic bodies present within the tumor.
ACTH immunostain of a smear from a liver tumor nodule shows positivity in the cytoplasm of scattered tumor cells. This immunopositivity was also present in the pituitary tumor of this patient. (Right) Immunohistochemistry for Ki-67 (MIB-1) in a pituitary carcinoma metastatic to liver shows a high proliferative index. p53 immunoexpression is often high and usually higher in metastatic sites than in the primary tumor.

Thyroid, Nonmedullary

Familial Thyroid Carcinoma

Vania Nosé, MD, PhD

Key Facts

Terminology

- Thyroid carcinoma derived from C cells or follicular cells, occurring in familial setting
- Familial follicular cell tumors are classified in 2 subgroups
  - Familial tumor syndromes characterized by predominance of nonthyroid tumors
  - Familial tumor syndromes characterized by predominance of nonmedullary thyroid carcinoma
- Familial medullary thyroid carcinoma occurs in 3 distinct settings
  - Multiple endocrine neoplasia 2A (MEN2A)
  - Multiple endocrine neoplasia 2B (MEN2B)
  - Medullary thyroid carcinoma only

Clinical Issues

- Presence of multiple benign nodules, high incidence of multifocality and bilateral disease, more aggressive behavior, and worse prognosis than sporadic thyroid cancer
- Incidence of familial medullary carcinoma is 25%
- Incidence of familial follicular cell tumors is ~ 5%

Microscopic Pathology

- Presence of lymphocytic thyroiditis, nodular hyperplasia, multiple follicular adenomas, multiple adenomatous nodules, follicular carcinoma, and PTC
- Presence of bilateral and multifocal PTC with local invasion and intrathyroid dissemination
- Familial PTC has no distinct histological characteristics
Gross cut surface of a thyroid from an 18-year-old woman with Cowden disease/PTEN hamartoma tumor syndrome shows multiple well-circumscribed nodules almost entirely replacing the thyroid parenchyma.
An encapsulated follicular carcinoma from a 12-year-old girl with Cowden syndrome shows complete capsular invasion. Follicular carcinoma is a major criterion for diagnosis of this syndrome.

TERMINOLOGY

Abbreviations
- Familial nonmedullary thyroid carcinoma (FNMTCT)
- Familial medullary thyroid carcinoma (FMTC)

Definitions
- Thyroid carcinoma occurring in familial setting
  - Can be syndrome-associated or nonsyndromic
- Familial thyroid carcinomas are divided into 2 subgroups: FNMTCT and FMTC
- FNMTCT or familial follicular cell tumors, derived from thyroid follicular cells
  - Further subdivided into 2 subgroups
    - Familial tumor syndromes characterized by predominance of nonthyroidal tumors
    - Familial tumor syndromes characterized by predominance of nonmedullary thyroid carcinoma
- FMTC, derived from thyroid calcitonin-producing C cells
  - Occurs in 3 distinct settings
    - Familial medullary thyroid carcinoma (medullary thyroid carcinoma-only syndrome)
    - Multiple endocrine neoplasia 2A (MEN2A)
    - Multiple endocrine neoplasia 2B (MEN2B)

ETIOLOGY/PATHOGENESIS

Familial Follicular Cell Tumors or Familial Nonmedullary Thyroid Carcinoma (FNMTCT)
- Rare tumors encompassing a heterogeneous group of diseases including both syndrome-associated and nonsyndromic tumors
- Familial tumor syndromes characterized by predominance of nonmedullary thyroid carcinoma
• PTEN-hamartoma tumor syndrome (PHTS): Cowden syndrome (CS) and Bannayan-Riley-Ruvalcaba syndrome (BRRS) are major entities composing PHTS
  ▪ Caused by germline mutations of PTEN gene and inherited in autosomal dominant fashion
  ▪ PTEN (phosphatase and tensin homolog deleted on chromosome 10) is tumor suppressor gene located on 10q23.3
• Familial adenomatous polyposis (FAP): Characterized by hundreds of adenomatous colonic polyps that develop during early adulthood
  ▪ Inherited autosomal dominant syndrome caused by germline mutations in adenomatous polyposis coli (APC) gene on chromosome 5q21
• Carney complex: Consists of myxomas, spotty pigmentation, and endocrine overactivity
  ▪ Autosomal dominant condition
  ▪ Most cases are classified as type 1 and are associated with mutation of protein kinase A regulatory subunit type 1α (PRKAR1A) gene, a probable tumor suppressor gene on chromosome 17q22-24
  ▪ Type 2 patients have mutation on chromosome 2p16, which may be regulator of genomic stability
• Werner syndrome: Rare premature-aging syndrome that begins in 3rd decade
  ▪ Autosomal recessive disease
  ▪ Caused by mutations in WRN gene on chromosome 8p11-p12
• Pendred syndrome: Most common hereditary syndrome associated with bilateral sensorineural deafness
  ▪ Also called deaf-mutism and goiter
  ▪ Autosomal recessive trait
  ▪ Result of mutations in SLC26A4 (PDS) gene, which encodes pendrin protein and is located on chromosome 7q21-34
  ▪ 100 mutations identified in PDS gene, and most are family specific

P.II(5):91

• Familial tumor syndromes characterized by predominance of nonmedullary thyroid carcinoma
  o Characterized by 3 or more 1st-degree relatives with follicular-derived nonmedullary thyroid carcinoma and occurs regardless of presence of another familial syndrome
  o Also includes
    ▪ Pure familial papillary thyroid carcinoma (PTC) ± oxyphilia: Mapped to chromosomal region 19p13
    ▪ Familial PTC (FPTC) with papillary renal cell carcinoma: Mapped to chromosomal region 1q21
    ▪ FNMTC type 1: Mapped to chromosome 2q21
    ▪ FPTC with multinodular goiter: Mapped to chromosomal region 14q

Familial Medullary Thyroid Carcinoma (FMTC)

• Refers to those neoplasms arising from calcitonin-producing C cells derived from neural crest
• MTCs occur in sporadic or hereditary (25% of cases) forms, as part of MEN2 syndrome, or as MTC-only syndrome
  o MEN2 syndrome consists of 3 variants: MEN2A, MEN2B, and FMTC
  o MEN2A is associated with pheochromocytoma and parathyroid hyperplasia
  o MEN2B is associated with marfanoid habitus, mucosal neuromas, ganglioneuromatosis, and pheochromocytoma
  o ~85% of all RET mutations responsible for FMTC are known
  o In majority of MEN2A and FMTC patients, RET mutations are clustered in 6 cysteine residues in RET cysteine-rich extracellular domain
  o Mutations have been detected in ~95% of MEN2A and ~85% of FMTC families
  o Somatic RET point mutations have been identified in ~50% of patients with sporadic MTC

CLINICAL ISSUES

Epidemiology

• Incidence
  o Thyroid cancer accounts for only 1% of all malignant tumors
    ▪ Advances in molecular genetics have confirmed presence of several familial cancer syndromes that have familial nonmedullary thyroid cancers (FNMTCs)
  o 5% incidence of FNMTC in 95% of patients with well-differentiated thyroid cancer
Familial forms of follicular cell-derived tumors are rare and encompass a heterogeneous group of diseases, including both syndrome-associated and nonsyndromic tumors.

- Thyroid neoplasia has been reported with increased frequency in familial syndromes, such as familial adenomatous polyposis (FAP), Cowden disease/PTEN-hamartoma tumor syndrome, Carney complex type 1, Werner syndrome, Pendred syndrome.
- Among nonsyndromic tumors, predominant neoplasm is nonmedullary thyroid carcinoma, although other neoplasms may occur with increased frequency.

Incidence of MTC in patients with familial disease is 25%.
- This group represents ~5% of all thyroid tumors and ~15% of all thyroid cancer-related deaths.

**Age**
- Familial follicular cell tumors or familial nonmedullary thyroid carcinoma.
  - Age of diagnosis varies, but tumors generally occur in younger patients as compared to their sporadic counterparts.
- Medullary thyroid carcinoma.
  - MEN2A syndrome or Sipple syndrome: In late adolescence or early adulthood; peak incidence of medullary carcinoma in these patients is in 4th decade. P.II(S):92.
  - MEN2B patients usually develop medullary carcinoma early in life, diagnosed in infancy or early childhood; males and females are equally affected.
  - Inherited medullary carcinoma without associated endocrinopathies: Similar to other types of thyroid cancers, peak incidence ranges from 40-50 years.

**Presentation:** FNMTC
- Syndrome-associated group.
  - Has increased prevalence of follicular cell-derived tumors within familial cancer syndrome, with preponderance of nonthyroidal tumors.
  - PTEN-hamartoma tumor syndrome.
    - >90% of individuals affected with CS manifest a phenotype by age 20 years.
    - By end of or during 3rd decade, almost all patients (99%) develop at least pathognomonic mucocutaneous lesions.
    - Affected individuals with CS develop both benign and malignant tumors in a variety of tissues, such as breast, uterus, and thyroid.
    - Thyroid pathologic findings in this syndrome typically affect follicular cells.
  - Familial adenomatous polyposis (FAP).
    - Extracolonic manifestations include osteomas, epidermal cysts, desmoid tumors, gastrointestinal tract polyps-hamartomas, congenital hypertrophy of retinal pigmented epithelium (CHRPE), hepatoblastomas.
    - Papillary thyroid carcinoma in 2-12% of FAP patients.
    - Young women with FAP are at particular risk of developing thyroid cancer; their chance of being affected is ~160x greater than that of normal individuals.
    - PTC occurs with frequency of ~10x greater than that expected for sporadic PTC.
  - Carney complex.
    - Characterized by skin and mucosal pigmentation, diverse pigmented skin lesions, nonendocrine and variety of endocrine neoplasias: Pituitary adenoma, pigmented nodular adrenal disease, Sertoli and Leydig cell tumors, and thyroid tumors.
    - Myxomas occur in heart, skin or soft tissue, external auditory canal, and breast.
  - Werner syndrome.
    - Elderly appearance with short stature, thin skin, wrinkles, alopecia, and muscle atrophy.
    - Age-related disorders (e.g., osteoporosis, cataracts, diabetes, peripheral vascular disease, or malignancy) are present in these patients.
    - Cardiac disease and cancer are most common causes of death in these patients.
    - Mutations of the WRN gene are specifically associated with malignancies such as melanoma, soft tissue sarcoma, osteosarcomas, and well-differentiated thyroid carcinoma.
  - Pendred syndrome: Thyroid disease in these patients may range from minimal enlargement to large multinodular goiter.
    - Most patients are euthyroid.
Familial tumor syndromes characterized by predominance of nonmedullary thyroid carcinoma (follicular cell-derived tumors)

- FNMTC is associated with multiple benign nodules, multifocality, bilateral disease, more aggressive clinical behavior, and worse prognosis than sporadic nonmedullary thyroid cancer
  - Diagnosed when ≥ 3 family members have nonmedullary thyroid cancer in absence of other known associated syndromes
  - Patients have shorter disease-free survival than do sporadic disease patients because of frequent locoregional recurrence
  - Individuals with FNMTC have increased risk of multifocal disease and are more likely to have intraglandular dissemination, local invasion, local or regional recurrence, and lymph node metastases
- Familial multinodular goiter (FMNG) syndrome (mapped to 14q)
  - Some patients may develop associated PTC
- Familial nonmedullary thyroid carcinoma type 1 (FNMTC1) syndrome (chromosomal region 2q21)
  - Characterized by PTC without any distinguishing pathologic features
- Familial PTC associated with papillary renal neoplasia syndrome (FPTC/PRN) (mapped to chromosomal region 1q21)
  - Includes not only PTC and expected benign thyroid nodules but also papillary renal neoplasia
- Familial papillary thyroid carcinoma (FPTC) (chromosomal region 19p13)
  - Characterized by multicentric tumors and multiple adenomatous nodules ± oxyphilia

Presentation: FMTC

- MEN2A syndrome or Sipple syndrome has bilateral medullary carcinoma or C-cell hyperplasia (CCH), pheochromocytoma, and hyperparathyroidism
  - Inherited in autosomal dominant manner, and males and females are equally affected
- MEN2B is associated with pheochromocytoma and alterations in nonendocrine tissue
  - Syndrome also has medullary carcinoma and pheochromocytoma, but only rarely hyperparathyroidism
  - Patients have unusual appearance, which is characterized by mucosal ganglioneuromas and marfanoid habitus
  - Inheritance is autosomal dominant as in MEN2A
- FMTC or inherited medullary carcinoma without associated endocrinopathies
  - Least aggressive form of medullary carcinoma
  - MTC usually develops in patients with no other clinical manifestations

MACROSCOPIC FEATURES
General Features
- Familial tumors have high incidence of multifocality, more likely to be bilateral

MICROSCOPIC PATHOLOGY
Histologic Features
- Familial tumor syndromes characterized by predominance of nonmedullary thyroid carcinoma
  - Most tumors are PTC and have no distinct morphological findings to differentiate them from sporadic counterparts
  - Mutations in patients with FNMTC syndromes have not been as well defined as in MTC
  - Familial thyroid cancers are more aggressive than sporadic thyroid cancer, with predisposition for lymph node metastasis, extrathyroidal invasion, and younger age of onset
- PTEN-hamartoma tumor syndrome
  - 2/3 of CS patients develop thyroid tumors; pathologic findings in this syndrome have been described as involving follicular cells
  - Majority of thyroid lesions occurring in PHTS are characteristically multicentric and bilateral; benign and malignant thyroid lesions are observed in PHTS
  - Multiple adenomatous nodules are characteristic, with multiple distinct well-circumscribed nodules, firm yellow-tan cut surface, diffusely involving thyroid gland
  - Follicular adenomas are very common, occur at earlier age, and usually are multicentric
  - Follicular carcinoma is a major criterion and an important feature in PTEN-hamartoma tumor syndrome; these tumors are more frequently multicentric
  - PTC and C-cell hyperplasia have rarely been associated with this entity
- Familial adenomatous polyposis (FAP)
  - Thyroid tumors in FAP patients occur almost exclusively in young females; the tumors are bilateral, multifocal, and well differentiated
  - Among patients with FAP who have synchronous PTC, > 90% exhibit histologic features of cribriform-morular variant (CMV), which focally shows typical nuclear features of PTC
  - Characteristic cribriform pattern with solid areas and spindle cell component, associated with marked fibrosis and morular areas
  - Characteristic PTC morphology is associated with follicular, papillary, trabecular, solid, spindle cell, and squamoid areas

- Carney complex
  - Thyroid is multinodular and has multifocal and bilateral thyroid disease
  - Lymphocytic thyroiditis, nodular hyperplasia, multiple follicular adenomas, characteristic multiple adenomatous nodules, follicular carcinoma, and PTC, usually present in ~ 15% of patients

- Werner syndrome
  - Patients present at younger age and have ~ 3x ↑ risk for developing follicular carcinoma and 6x ↑ risk for anaplastic thyroid carcinoma

- Pendred syndrome
  - Association of thyroid cancer and Pendred syndrome may be related to untreated congenital hypothyroidism and chronic stimulation by thyroid-stimulating hormone
  - Progression from thyroid goiter to cancer is uncommon, and risk is likely related to longstanding untreated hypothyroidism

ANCILLARY TESTS
Immunohistochemistry
- Immunostains of CMV-PTC show positivity for ER and PR, Bcl-2, E-cadherin, and galectin-3
- CMV-PTC is characterized by aberrant nuclear and cytoplasmic expression of β-catenin
- Immunostain for PTEN may be lost in cases of PHTS
- All other familial tumors have similar immunophenotype to sporadic thyroid tumor counterparts

Molecular Genetics
- Germline point mutation in RET gene on chromosome 10q11.2 is responsible for hereditary MTC
- Most patients with FAP-associated PTC have APC germline mutations
- Most patients with PHTS have germline mutations on gene PTEN
- Genetic inheritance of FNMTC remains unknown, believed to be autosomal dominant
  - Chromosomal regions involved: 14q, 2q21, 1q21, 19p13

DIFFERENTIAL DIAGNOSIS
Follicular Cell Carcinoma
- Sporadic follicular cell neoplasm
  - Comprises almost 95% of cases
  - Usually single and unilateral
  - Morphologically indistinguishable from tumor occurring in the familial setting

Medullary Thyroid Carcinoma
- Sporadic MTC
  - Accounts for up to 75% of all cases of medullary thyroid cancer
  - Females outnumber males by 3:2
  - Peak of onset is 40-60 years of age, mean: 50 years
  - 1/3 present with intractable diarrhea
  - Typically unilateral
  - No associated endocrinopathies (not associated with disease in other endocrine glands)

P.II(5):94

DIAGNOSTIC CHECKLIST
Clinically Relevant Pathologic Features
- Familial thyroid carcinoma has been shown to occur at younger age, be associated with presence of multiple benign nodules, have high incidence of multifocality and bilateral disease, have more aggressive clinical behavior, and have worse prognosis than its sporadic counterparts

SELECTED REFERENCES
11. Richards ML: Familial syndromes associated with thyroid cancer in the era of personalized medicine. Thyroid. 20(7):707-13, 2010

### Familial Follicular Cell Carcinoma Classification

| Syndrome | Histologic Subtype | Thyroid Involvement (%)
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>PTEN-hamartoma tumor syndrome (Cowden disease)</td>
<td>FTC associated with follicular adenomas, multiple adenomatous nodules, and C-cell hyperplasia</td>
<td>FTC, PTC, and ATC</td>
</tr>
<tr>
<td>Familial adenomatous polyposis (FAP)-hamartoma tumor syndrome</td>
<td>PTC with cribriform and morular pattern with sclerosis</td>
<td>FTC</td>
</tr>
<tr>
<td>Carney complex</td>
<td>FTC associated with follicular adenomas, multiple adenomatous nodules, and PTC</td>
<td></td>
</tr>
<tr>
<td>Werner syndrome</td>
<td>FTC</td>
<td></td>
</tr>
<tr>
<td>Pendred syndrome</td>
<td>FTC</td>
<td></td>
</tr>
<tr>
<td>Familial papillary thyroid carcinoma</td>
<td>PTC, usual variant</td>
<td></td>
</tr>
<tr>
<td>Familial papillary thyroid carcinoma with papillary renal cell neoplasia</td>
<td>PTC, usual variant</td>
<td></td>
</tr>
<tr>
<td>Familial nonmedullary thyroid carcinoma type 1</td>
<td>PTC, usual variant</td>
<td></td>
</tr>
<tr>
<td>Familial papillary thyroid carcinoma and multinodular goiter</td>
<td>PTC and nodular hyperplasia</td>
<td></td>
</tr>
</tbody>
</table>

**PTC: Papillary thyroid carcinoma; FTC: Follicular thyroid carcinoma; ATC: Anaplastic thyroid carcinoma.**

### Familial Follicular Cell Cancer in Familial Cancer Syndromes

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Inheritance</th>
<th>Gene</th>
<th>Gene Location</th>
<th>Thyroid Involvement (%)</th>
</tr>
</thead>
</table>

691
PTEN-hamartoma tumor syndrome   | Autosomal dominant | PTEN | 10q23.2 | 50
Familial adenomatous polyposis    | Autosomal dominant | APC  | 5q21   | 2-12
Carney complex                    | Autosomal dominant | PRKAR1-α | 2p12-17q22-60; 4-24  
Pendred syndrome                  | Autosomal recessive | SLC26A4 (pendrin) | 7q21-24 | 1
Werner syndrome                    | Autosomal recessive | WRN  | 8p11-p12 | 18

Image gallery
C-Cell Hyperplasia and Neoplasia

(Left) Total prophylactic thyroidectomy plus thymectomy from a patient with a family history of MEN2 with RET mutation shows a grossly normal thyroid. The entirely submitted specimen showed CCH and 2 foci of medullary thyroid carcinoma. (Right) Patient with family history of MEN2B with RET mutation had prophylactic thyroidectomy, which showed CCH and 2 foci of medullary thyroid carcinoma. Calcitonin stain highlights the focus of carcinoma.

(Left) C-cell hyperplasia is present in a patient with MEN2 syndrome, with C cells surrounding the entire thyroid follicle and replacing the follicular cells. (Right) Specimen from a patient with MEN2 syndrome who underwent
prophylactic thyroidectomy shows C-cell hyperplasia, with calcitonin-positive C cells surrounding the thyroid follicle. Heritable medullary thyroid carcinoma is preceded by C-cell hyperplasia (called neoplastic C-cell hyperplasia).

(Left) Fused transaxial FDG PET/CT shows a focal hypermetabolic mass in the right thyroid lobe in a patient with medullary thyroid cancer. (Right) Gross cut surface of both thyroid lobes from a patient with MEN2A shows 2 well-circumscribed white-yellow thyroid tumor nodules. Medullary thyroid carcinomas are usually firm and gritty, and familial medullary thyroid carcinomas are usually bilateral and with associated C-cell hyperplasia.

Familial Medullary Thyroid Carcinoma

(Left) H&E shows the characteristic histologic appearance of medullary thyroid carcinoma, a highly cellular tumor with a variable amount of fibrosis and amyloid deposition. (Right) Calcitonin immunostaining is usually strongly positive in the tumor cells whereas the areas of fibrosis or amyloid deposition are characteristically negative.
The characteristic histopathological features of medullary thyroid carcinoma are solid sheets and groups of round to polygonal tumor cells separated by thin fibrovascular cores. There is a variable amount of cytoplasm, and the medium-sized nuclei have minimal nuclear pleomorphism. Mitoses are usually rare. (Right) Medullary thyroid carcinoma from a patient with familial medullary thyroid carcinoma syndrome shows variable cytoplasmic immunostaining for calcitonin.

This photomicrograph of a Congo red-stained tumor shows extensive deposition of amyloid. Although amyloid is not essential for the diagnosis of medullary thyroid carcinoma, most of these tumors have at least some amyloid deposition. (Right) Congo red-stained medullary thyroid carcinoma under polarized light reveals the characteristic apple-green birefringence confirming amyloid deposition.

PTEN-Associated Thyroid Lesions
Gross cut surface of a thyroid from a 12-year-old patient with Cowden syndrome/PTEN-hamartoma tumor syndrome (PHTS) shows multiple well-circumscribed nodules and 1 encapsulated nodule. (Right) This photomicrograph of thyroid tissue from a patient with Cowden disease shows a well-encapsulated follicular adenoma. These lesions are usually present in association with multiple adenomatous nodules.

H&E of the thyroid from a patient with Cowden disease shows diffuse involvement by diversely sized adenomatous nodules. The larger nodule shows focal central degenerative changes. Note compressed intervening thyroid parenchyma. (Right) H&E of the thyroid from an 18-year-old woman with Cowden disease shows multiple well-circumscribed adenomatous nodules with a small amount of compressed residual thyroid parenchyma.
Immunohistochemistry for PTEN shows preservation of the staining in the follicular cells in a patient with no known genetic abnormalities of the PTEN gene. (Right) Immunohistochemistry for PTEN in a thyroidectomy specimen from an 18-year-old woman with PHTS/Cowden disease shows loss of staining of the follicular cells with preservation of staining of the endothelial cells.

Familial Adenomatous Polyposis (FAP) Features

(Left) This colectomy specimen from a 17-year-old girl with known thyroid tumor and familial adenomatous polyposis shows numerous polyps on the mucosal surface. This patient had multiple foci of cribriform-morular papillary thyroid carcinoma. (Right) This image shows congenital hypertrophy of the pigmented retinal epithelium. This condition is benign, and it is found in up to 2/3 of patients who have FAP.
(Left) Gross cut surface of a large PTC, cribriform-morular variant (CMV), shows irregular areas of fibrosis and a pale, soft, and friable tumor mass occupying most of the section. This variant usually has extensive fibrosis and a thick fibrous capsule. They are usually multiple and bilateral. (Right) This image shows the cytologic features of tumor cells typically seen in the cribriform-morular variant. The cells are cuboidal with basophilic cytoplasm and hyperchromatic nuclei. Note the absence of classic PTC nuclei.

(Left) Encapsulation is common in this variant of PTC. This particular example shows a thick fibrous band encapsulating the tumor. Note the papillary and cribriform architecture. Also shown are eosinophilic foci of sclerosis/hyalinization within the stroma. This focus of tumor was < 1 cm. (Right) This image shows a metastatic tumor focus in a lymph node, an unusual finding. The tumor deposit is largely cystic, though a small papillary structure with cribriform-appearing areas is present.

FAP-Associated Thyroid Tumors
This image demonstrates the solid pattern seen in cribriform-morular variant-papillary thyroid carcinoma (CMV-PTC). An area with the more common cribriform pattern is seen in the lower right-hand corner of the image. This photograph illustrates CMV-PTC and highlights the cribriform appearance of these types of tumors. This tumor shows areas of both cribriform pattern and solid pattern; however, this tumor has a predominantly cribriform architecture.

High-power H&E stain demonstrates the characteristic peculiar nuclear clearing (PNC) seen within some of the nuclei in CMV-PTC. These PNCs are characteristically found within squamous morules. A cribriform pattern tumor with focal solid areas and a spindle cell component is seen in this high magnification. The cells are spindled with basophilic cytoplasm and hyperchromatic nuclei with absence of typical PTC nuclei.
β-catenin immunostain shows the characteristic cytoplasmic and nuclear staining in CMV-PTC, as well as the cytoplasmic membrane staining in the adjacent compressed follicular cells. (Right) High-power image of β-catenin immunostain in CMV-PTC demonstrates characteristic nuclear and cytoplasmic staining resulting from aberrant accumulation within the nucleus. Note the negativity of the endothelial cells.

Follicular Carcinoma

> Table of Contents > Part II - Diagnoses Associated With Specific Syndromes > Section 5 - Endocrine > Thyroid, Nonmedullary > Follicular Carcinoma

Follicular Carcinoma
Vania Nosé, MD, PhD

Key Facts

Terminology
- Malignant epithelial tumor of thyroid showing evidence of follicular cell differentiation but lacking diagnostic features of papillary thyroid carcinoma

Etiology/Pathogenesis
- Familial follicular thyroid carcinoma (FTC) accounts for at least 5% of FTC in USA
- PTEN-hamartoma tumor syndrome (PHTS)
  - May be associated with multiple follicular adenomas and carcinomas
- Carney complex
  - 75% of patients develop multiple thyroid nodules
- Werner syndrome
  - Up to 3% of patients will have thyroid disease, usually FTC
-McCune-Albright syndrome
  - Associated with FTC and papillary thyroid carcinomas
- Li-Fraumeni syndrome
  - Unusual thyroid follicular cell tumors with marked nuclear pleomorphism

Macroscopic Features
- Usually multiple and bilateral in familial setting

Diagnostic Checklist
- Thyroid carcinoma in familial setting is usually multifocal and bilateral
- Familial cases are reportedly more aggressive than their sporadic counterparts and are usually associated with adenomatous nodules, multinodular hyperplasia, follicular adenomas, and lymphocytic thyroiditis
Photomicrograph depicts the classic “mushroom” sign, diagnostic of follicular thyroid carcinoma. The tumor cells are seen invading across the entire thickness of the fibrous capsule.
This image illustrates a hallmark in the diagnosis of follicular thyroid carcinoma. Vascular invasion is shown here with tumor cells present within a large capsular blood vessel.

**TERMINOLOGY**

**Abbreviations**
- Follicular carcinoma (FC)

**Synonyms**
- Follicular thyroid carcinoma
- Familial nonmedullary thyroid carcinoma
- Familial follicular thyroid carcinoma

**Definitions**
- Malignant epithelial follicular cell tumor of thyroid
  - Shows evidence of follicular cell differentiation
  - Lacks diagnostic features of papillary thyroid carcinoma
  - Occurs in a familial setting

**ETIOLOGY/PATHOGENESIS**

**Inherited Tumor Syndromes**
- Accounts for at least 5% of follicular thyroid carcinoma (FTC) in USA
- PTEN-hamartoma tumor syndrome (PHTS)
  - Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome (BRRS), Proteus syndrome, and Proteus-like syndrome
  - Germline mutation of PTEN gene transmitted in autosomal dominant fashion
  - Individuals may also develop multiple hamartomas of breast, colon, endometrium, brain, and ganglioneuromatous proliferations
    - Trichilemmomas
  - Affected individuals may develop benign and malignant tumors of breast, uterus, and thyroid
    - Breast cancer: Early onset; most women diagnosed between 38 and 46 years of age
May be associated with multiple follicular adenomas and carcinomas of the thyroid
- Thyroid tumors are associated with multiple thyroid nodules in a young patient
- Follicular thyroid carcinoma is a major diagnostic criteria for diagnosis of PHTS

* Carney complex
  - Autosomal dominant disorder caused by mutations in PRKAR1A gene
  - Carney complex includes cardiac myxomas, multiple endocrine neoplasms, and spotty cutaneous pigmentation
  - 75% of patients develop multiple thyroid nodules
    - ~5% of patients may present with follicular or papillary carcinoma

* Werner syndrome
  - Autosomal recessive
  - Caused by mutations in WRN gene
  - Age-related disorders are present early in patient's life including malignancies
    - Melanoma, soft tissue sarcoma, osteosarcoma
    - Up to 3% of patients will have thyroid disease, usually FTC

* McCune-Albright syndrome
  - Patients harbor postzygotic mutations in GNAS1 gene with mosaic distribution
  - Triad of café au lait skin pigmentation, polyostotic fibrous dysplasia, and hyperfunctioning endocrinopathies
  - Associated with precocious puberty, hyperthyroidism, GH excess, and Cushing syndrome
    - Associated with FTC and papillary thyroid carcinomas

* Li-Fraumeni syndrome
  - Caused by germline mutation of TP53
  - Development of diverse sarcomas and carcinomas at a young age
  - Unusual thyroid follicular cell tumors with marked nuclear pleomorphism

Preexisting Thyroid Disease
- Present in up to 15% of patients with FTC
- Dyshormonogenic goiter with chronic TSH stimulation may predispose to follicular neoplasms
- Associated with other thyroid tumors, mostly follicular adenoma
  - These tumors are identical histologically
  - Follicular adenoma may be the precursor of follicular carcinoma
    - Both harbor RAS, PTEN, and PIK3CA mutations
- Lymphocytic thyroiditis and FTC may coexist
- Association between lymphocytic thyroiditis and FTC remains unclear

CLINICAL ISSUES
Epidemiology
- Incidence
  - 10-20% of thyroid malignancies
- Age
  - Inherited syndrome-related FTC affects patients at earlier age than does sporadic FTC
    - Sporadic cases: 5th decade
- Gender
  - More common in women

Presentation
- Painless mass
- Slow growing
- Difficulty swallowing

Prognosis
- 70-80% cure rate if disease is confined to thyroid
- 20-30% recurrence when regional lymph node metastases are present
- 50-90% of patients who present with distant metastases will die

IMAGE FINDINGS
Ultrasonographic Findings
- In minimally invasive disease, usually a well-circumscribed nodule (> 1 cm)
- Cannot distinguish follicular adenoma from FTC
Carcinoma is usually associated with microcalcifications, hypoechochogenicity, irregular margins or absent halo sign, solid aspect, intranodular vascularization, and shape (taller than wide).

Scintigraphy

- Scan shows “cold” nodule

MACROSCOPIC FEATURES

General Features

- Round to ovoid encapsulated tumors, tan to light brown
- Usually multiple and bilateral in familial setting
- Minimally invasive tumors: Thick irregular fibrous capsule and grossly similar or indistinguishable from follicular adenoma
- Widely invasive carcinomas: Lack of capsule or extensive permeation of capsule

Size

- Round to ovoid encapsulated tumors 1-10 cm in diameter

Categories of Tumor

- Minimally invasive follicular carcinoma
- Widely invasive follicular carcinoma
- Oncocytic follicular carcinoma
  - This subtype was formerly called oxyphil or Hürthle cell carcinoma

MICROSCOPIC PATHOLOGY

Histologic Features

- Tumors arise in a background of multiple adenomatous nodules, nodular hyperplasia, &/or lymphocytic thyroiditis
- Follicular carcinoma in familial diseases may be an incidental finding within a thyroid with multiple nodules
- Follicular carcinoma in inherited syndromes tends to be
  - Smaller than sporadic tumors
  - Multiple
  - Bilateral
- Criteria for capsular invasion
  - Tumor bud has invaded beyond outer contour of capsule
  - Tumor bud still clothed by thin capsule; however, it has extended through outer capsular surface
  - Presence of satellite nodule with cytoarchitectural and cellular features identical to those of tumor cells
  - Classic mushroom-like bud that has totally transgressed fibrous capsule
- Criteria for vascular invasion
  - Blood vessels should be of larger caliber with an identifiable wall the size of a vein, and involved blood vessels must be located within or outside fibrous capsule (i.e., not within tumor)
  - Intravascular polypoid tumor growth must protrude into lumen, be covered by endothelium, and be attached to wall of vessel and associated with a thrombus
  - Clusters of epithelial cells floating in vascular lumen and unattached to wall are not considered vascular invasion
- Nodal status
  - Metastasis present or absent, ipsilateral vs. contralateral, number with metastases, size of largest metastatic deposit
  - Metastases are reportedly more frequent in familial cases

ANCILLARY TESTS

Molecular Genetics

- Mutations in PTEN, PRKAR1A, WRN, GNAS1, and TP53 genes
- Accumulation of additional mutations, such as TP53, may be associated with progression to poorly differentiated carcinomas
- Testing families with a history of cancer
  - Most useful to begin by testing the individual with cancer
    - If multiple affected individuals are present within a kindred, testing can establish linkage between the cancer(s) and the mutation
- Predictive models
DIFFERENTIAL DIAGNOSIS

Sporadic Follicular Carcinoma

- Usually single
- Usually unilateral
- Background thyroid with no other pathological findings
- Less aggressive than familial counterpart

DIAGNOSTIC CHECKLIST

Pathologic Interpretation Pearls

- Pathologist’s most important tasks are to
  - Demonstrate capsular or vascular invasion, as the diagnosis of FTC rests on identifying these
  - Differentiate between FTC and numerous variants of follicular adenoma and other benign or malignant neoplasms
  - Identify pathological characteristics of inherited tumor syndrome
- Thyroid carcinoma in familial setting is usually multifocal and bilateral
- Familial cases are reportedly more aggressive than their sporadic counterparts
- Familial cases are usually associated with other thyroid pathology: Adenomatous nodules, multinodular hyperplasia, follicular adenomas, and lymphocytic thyroiditis

SELECTED REFERENCES

P.II(5):103

Tables

<table>
<thead>
<tr>
<th>Lesion</th>
<th>Characteristic Findings</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dominant nodule in nodular hyperplasia</td>
<td>Follicles have different sizes and shapes; colloid ranges from pale to dark red, and these nodules have irregular fibrosis and pseudocapsule</td>
<td>Capsule in follicular carcinoma is thick and surrounds entire nodule; colloid is homogeneous and dark red in follicular carcinoma</td>
</tr>
<tr>
<td>Adenomatous nodule</td>
<td>Usually multiple and nonencapsulated</td>
<td>Follicular carcinoma may occur in association with adenomatous nodules</td>
</tr>
<tr>
<td>Follicular adenoma</td>
<td>Usually single and surrounded by thin capsule</td>
<td>Fibrous capsule in follicular adenoma is usually thinner than in follicular carcinoma</td>
</tr>
<tr>
<td>Follicular variant of papillary thyroid carcinoma</td>
<td>Follicular-patterned neoplasm with focal nuclear features of papillary thyroid carcinoma</td>
<td>Usually main differential diagnosis with follicular carcinoma</td>
</tr>
<tr>
<td>Poorly differentiated</td>
<td>Pattern of follicular cells is usually in</td>
<td>May show apoptosis, necrosis, and</td>
</tr>
<tr>
<td>Thyroid Carcinoma</td>
<td>Solid, trabecular, and insular pattern, and presents with rare follicles</td>
<td>High mitotic rate; has higher Ki-67 proliferative index, and some are positive for p53</td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Hyalinizing trabecular tumor</td>
<td>This benign thyroid tumor is well circumscribed but lacks a fibrous capsule; has trabecular growth pattern and rarely forms follicles</td>
<td>Positive for TTF-1 and thyroglobulin; however, HTT has characteristic membranous staining for Ki-67/MIB-1</td>
</tr>
<tr>
<td>Medullary thyroid carcinoma, follicular carcinoma, follicular patterned</td>
<td>Tumor cells in medullary thyroid carcinoma have ample eosinophilic granular cytoplasm and salt-and-pepper nuclei</td>
<td>Both tumors are positive for TTF-1; medullary thyroid carcinoma is positive for chromogranin, synaptophysin, calcitonin, and CEA</td>
</tr>
</tbody>
</table>

### Follicular Thyroid Carcinoma in Familial Setting

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Common Clinical Findings</th>
<th>Thyroid Pathology Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTEN-hamartoma tumor syndrome</td>
<td>Mucocutaneous lesions, breast carcinoma, endometrial carcinoma, thyroid carcinoma, macrocephaly, gastrointestinal hamartomas, lipomas, and other tumors</td>
<td>Follicular carcinoma associated with multiple adenomatous nodules and multiple follicular adenomas</td>
</tr>
<tr>
<td>Carney complex</td>
<td>Myxomas, spotty mucocutaneous pigmentation, psammomatous melanotic schwannoma, breast ductal adenoma, multiple endocrine neoplasms including PPNAD, GH-producing adenoma, thyroid carcinoma</td>
<td>Small percentage (about 5%) of patients with this syndrome may develop follicular carcinoma, usually associated with other thyroid nodules</td>
</tr>
<tr>
<td>Werner syndrome</td>
<td>Bilateral cataracts, characteristic dermatological findings, short stature, osteoporosis, multiple neoplasms at a younger age</td>
<td>Small percentage (about 3%) of patients with this syndrome develop follicular carcinoma</td>
</tr>
<tr>
<td>McCune-Albright syndrome</td>
<td>GH excess, Cushing syndrome, precocious puberty</td>
<td>Patients may develop follicular carcinoma and papillary thyroid carcinoma</td>
</tr>
<tr>
<td>Li-Fraumeni syndrome</td>
<td>Sarcomas, brain tumor, adrenal cortical carcinoma, breast cancer, other tumors at a young age; rarely involves thyroid</td>
<td>Patients develop many thyroid nodules with nuclear pleomorphism and may develop follicular carcinoma</td>
</tr>
</tbody>
</table>

*PPNAD = primary pigmented nodular adrenocortical disease.*

Image gallery
Gross, Diagrammatic, and Microscopic Features
Gross photograph shows a minimally invasive follicular carcinoma presenting as a single nodule in a sporadic setting. The tumor is grossly indistinguishable from a follicular adenoma. Thorough examination of the capsule is crucial to identify foci of capsular invasion. Gross cut surface of a thyroid from a 12-year-old patient with PTEN-hamartoma tumor syndrome shows multiple adenomatous nodules and a follicular carcinoma, confirmed by histopathology.

A schematic drawing illustrates the criteria necessary to interpret and diagnose a follicular neoplasm as follicular carcinoma based on capsular invasion. The follicular neoplasm is surrounded by a thick fibrous capsule with invasion on A, D, F, and G. Low-power photomicrograph shows multiple well-circumscribed adenomatous nodules and a follicular carcinoma. Full-thickness capsular invasion is easily recognizable. In this case, the patient has PTEN-associated thyroid disease.
(Left) Minimally invasive follicular carcinoma shows the point of invasion. There is tumor capsule invasion through the entire capsule thickness, invading a large blood vessel along the way. (Right) Follicular carcinoma with cytologically identical satellite nodules indicates true capsular invasion, even without demonstration of the point of capsular penetration.

Microscopic Features

(Left) Photomicrograph of a follicular carcinoma shows finger-like projections of the tumor protruding beyond the capsule into the surrounding thyroid parenchyma. (Right) High-power micrograph shows 2 groups of tumor cells in a vessel within the tumor capsule. The tumor cells are attached to the vessel wall. Endothelial cells can be seen lining both tumor thrombi.
(Left) Nuclear pleomorphism can be present to various degrees in follicular carcinoma. This case presents microfollicular architecture with a few large irregular nuclei that may show nucleoli. Colloid is present throughout the tumor. A mitotic figure is seen. (Right) High-power view of an FTC depicts pleomorphism and cellular atypia. The overall follicular architecture is preserved, but cells with pink granular cytoplasm and irregular large nuclei are present.

(Left) Follicular thyroid carcinoma in a familial setting is usually associated with other thyroid diseases. In this patient with PTEN hamartoma tumor syndrome, the follicular carcinoma was found in a thyroid with multiple adenomatous nodules and lymphocytic thyroiditis. (Right) Patients with familial syndromes involving the thyroid usually have associated lymphocytic thyroiditis. This field shows prominent lymphoid aggregates with germinal center and focal oncocytic follicular cell changes.

Thyroid, Medullary
C-Cell Hyperplasia

- An increase in C-cell population in thyroid due to reactive/physiologic or neoplastic process
For practical purposes, if C cells can be seen on H&E and confirmed by IHC, lesion should be reported as CCH

- Reactive/physiologic CCH
  - No clear malignant potential documented
  - Usually difficult to visualize on H&E stains

- Neoplastic CCH
  - Considered the precursor lesion to familial medullary thyroid carcinomas (MTC)

Clinical Issues
- 25-30% occur in context of multiple endocrine neoplasias (MEN2A and MEN2B) or familial MTC
- Prophylactic thyroidectomy appears to offer best chance of cure to patients with MEN2 and familial MTC
- Generally good prognosis with early detection and thyroidectomy
- 10-year survival rates of 74-100% reported for MMC

Microscopic Pathology
- Round and polygonal cells
- Slightly larger than adjacent follicular cells
- Granular to amphophilic cytoplasm
- Round nuclei, coarse granular or salt-and-pepper chromatin

Ancillary Tests
- C cells stain positively for calcitonin, chromogranin, synaptophysin, CRP, and CEA

The hyperplastic C cells in this photomicrograph surround almost the entire thyroid follicle. The C-cell proliferation has a diffuse pattern and the C cells have an ample blue granular cytoplasm.
The thyroid follicular cells are almost completely replaced by an increased number of C cells, highlighted by calcitonin immunostaining. The C cells surround the thyroid follicle in a diffuse pattern.

**TERMINOLOGY**

**Abbreviations**
- C-cell hyperplasia (CCH)

**Synonyms**
- C-cell proliferation

**Definitions**
- C cells produce calcitonin and are normally found at junction of upper and middle 1/3 of thyroid lobes bilaterally
- CCH is an increase in C-cell population in thyroid due to reactive/physiologic or neoplastic process
- Proposed diagnostic criteria include
  - > 50 C cells per low-power field (WHO 2004)
  - > 50 C cells in 3 low-power fields (100x)
  - > 40 C cells/cm²
  - For practical purposes, if C cells can be seen on H&E and confirmed by IHC, lesion should be reported as CCH
- Neoplastic CCH
  - Considered precursor lesion of familial medullary thyroid carcinomas (MTC)
    - Premalignant lesion; therefore, the term hyperplasia is a misnomer
  - Caused by mutations in RET protooncogene
  - Histopathology
    - Predominantly nodular or mixed nodular/diffuse
    - Usually easy to identify on conventional H&E
    - Cytomorphologically similar to medullary microcarcinomas
    - C-cell quantification not necessary for diagnosis
- Reactive/physiologic CCH
No clear malignant potential documented
Caused by stimuli external to C cell
Histopathology
- Predominantly diffuse
- Usually difficult to visualize on H&E stains
- Calcitonin stain improves detection

CLINICAL ISSUES
Presentation
- Neoplastic CCH
  - Most cases are sporadic
  - 25-30% occur in context of multiple endocrine neoplasias (MEN2A and MEN2B) or familial MTC
  - Incidence rising due to increase in prophylactic thyroidectomies
    - Patients with family history of MTC and elevated serum calcitonin
    - Carriers of mutations in RET gene
- Reactive CCH
  - May be associated with hyperparathyroidism, Hashimoto thyroiditis, multinodular goiter, hyperthyroidism, and subtotal thyroidectomy
  - Can be seen in vicinity of large tumors of follicular cell origin or lymphomas

Treatment
- Surgical approaches
  - Prophylactic thyroidectomy appears to offer best chance of cure to patients with MEN2 and familial MTC
  - Thyroidectomy recommended to prevent progression to medullary microcarcinoma (MMC)
    - Recommended age of prophylactic thyroidectomy depends on RET mutation

Prognosis
- Neoplastic CCH is premalignant lesion often associated with MMC
  - Generally good prognosis with early detection and thyroidectomy
  - 10-year survival rates of 74-100% reported for MMC
- Reactive CCH is unlikely to represent premalignant lesion

P.II(5):107
- Reports exist of MTC in patients thought to have reactive CCH, but with serum calcitonin > 50 pg/mL

IMAGE FINDINGS
General Features
- Due to diffuse nature or small size, CCH lesions may be easily overlooked on imaging studies

MACROSCOPIC FEATURES
General Features
- CCH is not usually grossly identified
- Associated MMC or MTC may be present as whitish, firm nodules typically in upper or middle 1/3 of lobe
- In at-risk patients who undergo thyroidectomy, entire gland should be submitted to identify areas of CCH

MICROSCOPIC PATHOLOGY
Histologic Features
- 4 histological patterns
  - Nodular: C-cell clusters between or filling a thyroid follicle
  - Diffuse: Cells are scattered between follicles
  - Solitary: Single focus of CCH
  - Multifocal: Foci of CCH throughout gland
- Hereditary and neoplastic CCH
  - More likely to be nodular, multifocal, and bilateral
  - Usually detectable on H&E sections
  - Presence of cytological atypia
  - Seen adjacent to medullary thyroid carcinoma
  - Usually bilateral
  - Can be nodular or diffuse
- Reactive and sporadic CCH
  - Tends to be solitary, diffuse, and unilateral
  - No cytologic atypia, not usually detectable on H&E stained sections
  - Usually unilateral and diffuse
Cytologic Features

- Round and polygonal cells
- Slightly larger than adjacent follicular cells
- Granular to amphophilic cytoplasm
- Round nuclei, coarse granular or salt-and-pepper chromatin

ANCILLARY TESTS

Immunohistochemistry

- C cells stain positively for calcitonin, chromogranin, synaptophysin, CRP, and CEA

Molecular Genetics

- RET mutation analysis in familial cases

DIFFERENTIAL DIAGNOSIS

Benign Entities

- Squamous metaplasia, remnants of thymus, solid cell nests, palpation thyroiditis, intrathyroid parathyroid tissue, tangentially cut follicles

Neoplastic Processes

- Intrathyroid spread of MTC, MMC, follicular-derived neoplasms

Micromedullary Thyroid Carcinoma

- < 1 cm
- Can be sporadic or familial
- Incidental finding in patients undergoing thyroidectomies for nodular disease
- Detected by routine calcitonin screening in patients with nodular disease

Medullary Thyroid Carcinoma With Intrathyroidal Spread

- May be seen multifocally in areas where C cells are absent

P.II(5):108

- Present in lymphovascular spaces, most prominent at periphery

Solid Cell Nests

- Can be associated with C cells; finding in normal thyroid
- Positive for p63, CD5, 34bE12, and CEA

Tangentially Cut Follicles

- Smaller cells with small pale cytoplasm
- Absence of immunexpression of chromogranin, synaptophysin, and calcitonin

Intrathyroid Parathyroid Tissue

- Small round nuclei
- Positive for PTH and negative for calcitonin and TTF-1

Palpation Thyroiditis

- Single or few follicles destroyed
- Presence of histiocytes and giant cells
- Random distribution throughout gland

DIAGNOSTIC CHECKLIST

Pathologic Interpretation Pearls

- Differentiation of nodular CCH from MMC represents a challenge
- Demonstration of breach of basement membrane and desmoplasia favor MMC

SELECTED REFERENCES


### Immunohistochemistry

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Reactivity</th>
<th>Staining Pattern</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>CK-PAN</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td></td>
</tr>
<tr>
<td>TTF-1</td>
<td>Positive</td>
<td>Nuclear</td>
<td></td>
</tr>
<tr>
<td>Chromogranin-A</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td></td>
</tr>
<tr>
<td>Synaptophysin</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td></td>
</tr>
<tr>
<td>Calcitonin</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td></td>
</tr>
<tr>
<td>CEA-M</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td></td>
</tr>
<tr>
<td>Thyroglobulin</td>
<td>Negative</td>
<td></td>
<td>Positive in sustentacular cells of intrathyroidal paraganglioma</td>
</tr>
<tr>
<td>S100</td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PTH</td>
<td>Negative</td>
<td></td>
<td>Used to differentiate from intrathyroidal parathyroid tissue</td>
</tr>
<tr>
<td>p63</td>
<td>Negative</td>
<td></td>
<td>Used in the differential diagnosis of solid cell nests</td>
</tr>
<tr>
<td>34bE12</td>
<td>Negative</td>
<td></td>
<td>Used in the differential diagnosis of solid cell nests</td>
</tr>
<tr>
<td>CD5</td>
<td>Negative</td>
<td></td>
<td>Used in the differential diagnosis of solid cell nests</td>
</tr>
</tbody>
</table>

### Reactive/Physiologic vs. Neoplastic C-Cell Hyperplasia

<table>
<thead>
<tr>
<th>Features</th>
<th>Reactive C-Cell Hyperplasia</th>
<th>Neoplastic C-Cell Hyperplasia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Detectable on H&amp;E stains</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Cytologic atypia</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Seen adjacent to medullary thyroid carcinoma</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Bilaterality</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Staining with NCAM</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Calcitonin reactivity</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>CEA reactivity</td>
<td>No</td>
<td>Yes/No</td>
</tr>
<tr>
<td>Chromogranin reactivity</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Synaptophysin reactivity</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

P.II(5):109

Image gallery

Microscopic and Immunohistochemical Features
Calcitonin stain highlights the normal C-cell distribution within the junction of the upper and middle 1/3 of the thyroid lobes. Normal C-cell population is characterized by < 50 calcitonin-positive cells per low-power field. (Right) An increased number of C cells can be seen adjacent to large thyroid nodules. The reactive C-cell proliferation is usually difficult to identify on H&E.

Low-power photomicrograph shows a thyroid from a patient with multiple endocrine neoplasia syndrome type 2. The C-cell proliferation is easily identified by H&E. In inherited syndromes, the C-cell hyperplasia usually precedes neoplasia. (Right) The C-cell proliferation in this field is easily identified at this magnification. This finding is usually seen in cases of neoplastic C-cell hyperplasia.
The thyroid follicular cells are almost completely replaced by an increased number of C cells, easily identified by H&E staining. The C cells have ample blue granular cytoplasm. (Right) C-cell hyperplasia highlighted by calcitonin staining shows the thyroid follicular cells replaced by an increased number of C cells that surround the entire follicle.

Medullary Thyroid Carcinoma

Vania Nosé, MD, PhD

Key Facts

Terminology
- Neuroendocrine tumor derived from C cells of thyroid
- MTCs measuring < 1 cm in diameter are called medullary microcarcinomas (MMC)

Etiology/Pathogenesis
- MTC is seen in setting of MEN2 and familial non-MEN MTC syndromes
- MEN2 is caused by mutations in RET gene
- Neoplastic C-cell hyperplasia (CCH) is precursor lesion in hereditary MTC

Clinical Issues
- 20-25% are hereditary
- Increased serum calcitonin and CEA levels
- RET gene mutation analysis
- In patients with hereditary MTC, recommended age for prophylactic thyroidectomy is according to RET mutations
- 5- and 10-year survivals of 60-80% and 40-70%, respectively

Microscopic Pathology
- In MEN2, age of transformation from CCH to MTC varies with different germline RET mutation

Ancillary Tests
- Positive for calcitonin and CEA

Diagnostic Checklist
- Desmoplasia and breaching of basement membrane helps differentiate CCH from MMC
- Finding CCH may serve as a morphological marker for MEN2-associated MTC
Bilateral medullary thyroid carcinoma from a patient with multiple endocrine neoplasia type 2A (MEN2A) shows the characteristic well-circumscribed cut surface. MEN-associated tumors are usually bilateral and multifocal.
This photomicrograph shows a thyroid from a patient with multiple neoplasia type 2. The C-cell hyperplasia is easily identified by H&E. In inherited syndromes, C-cell hyperplasia usually precedes neoplasia.

TERMINOLOGY

Abbreviations
- Medullary thyroid carcinoma (MTC)

Synonyms
- C-cell carcinoma
- Medullary carcinoma (MC) of thyroid
- Solid carcinoma with amyloid stroma
- Neuroendocrine carcinoma of thyroid

Definitions
- Neuroendocrine tumor derived from C cells of thyroid
- MTCs measuring < 1 cm in diameter are called medullary microcarcinomas (MMC)

ETIOLOGY/PATHOGENESIS

Genetic Predisposition
- Hereditary forms of MTC are transmitted as autosomal dominant traits, usually with high penetrance
- Multiple endocrine neoplasia type 2 (MEN2) syndrome and familial MTC (FMTC)-only syndrome are caused by mutations in RET gene
  - Commonly activating point mutations
  - Exon 10 codons 609, 611, 618, 620, and exon 11 codon 634 responsible for majority of MEN2A and of FMTC
    - MEN2A: Majority involve exon 11 codon 634
    - MEN2B: Majority is associated with exon 16 codon 918 mutation
  - Fusion genes with tyrosine kinase domain of RET also occur
    - RET chromosomal rearrangements also associated with papillary carcinoma (RET/PTC)
  - Somatic RET mutations also present in up to ~50% of sporadic MTCs
MTC is seen in setting of MEN2 syndromes and familial MTC-only syndrome
- **MEN2A**
  - MTC, parathyroid hyperplasia, pheochromocytoma, and pancreatic endocrine tumors
  - ~100% of individuals with MEN2A develop medullary thyroid carcinoma
- **MEN2B**
  - MTC, pheochromocytoma, mucosal and soft tissue tumors (notably neuromas), marfanoid body habitus
  - Characterized by early development of aggressive form of medullary thyroid carcinoma in ~100% of affected individuals
- **Familial MTC-only syndrome**
  - MTC not associated with other tumors
  - Comprises about 10-20% of MEN2 cases

Precursor Lesions
- **Neoplastic C-cell hyperplasia (NCCH)**
  - Precursor lesion in hereditary MTC
  - Clusters should have > 50 C cells
  - a.k.a. C-cell carcinoma in situ or medullary carcinoma in situ
  - These lesions harbor germline RET mutations
  - Postulated that CCH progresses to MMC and eventually to MTC
  - C-cell clusters surrounding or invading follicles
  - Found in vicinity of medullary carcinomas
  - Distinguishing CCH from MMC or intrathyroid spread of MTC may be difficult
- **Reactive C-cell hyperplasia**
  - Increase in number of C cells secondary to associated thyroid disorder (nodules, papillary or follicular carcinoma, inflammatory or autoimmune)
  - Lack pleomorphism, amyloid, fibrosis, or invasion of follicles
  - Difficult to visualize on H&E alone; requires calcitonin staining
- **Role of CCH in sporadic MTC remains unknown**

**CLINICAL ISSUES**

**Epidemiology**
- **Incidence**
  - 5-10% of all thyroid malignancies
  - 75-80% are sporadic
  - 20-25% are hereditary
  - Rising incidence due to calcitonin screening protocols and RET genetic testing
    - Increase in prophylactic thyroidectomies
    - Mostly MMC identified in familial cases
- **Age**
  - In sporadic cases: 50-60 years
  - Familial cases can present from early childhood
    - MTC in MEN2B: ~5 years
    - MTC in MEN2A: 25-30 years
    - MTC in FMTC: ~50 years
- **Gender**
  - 1:1 in familial cases

**Presentation**
- Often presents as painless “cold” nodule
- Up to 50% have nodal metastases
- Up to 20% may present with distant metastases
- Symptoms of carcinoid and Cushing syndromes may be present
- Large tumors may lead to dysphagia and upper airway obstruction
- Nonthyroid findings: Mucosal neuromas; parathyroid, adrenal, pituitary, and pancreatic tumors
- MTC tends to metastasize early: Liver, lungs, bone, soft tissue outside neck, brain, and bone marrow

**Laboratory Tests**
- Screening and monitoring tests are performed in patients at risk
- History or presence of multiple endocrine neoplasias
- Family history of MEN2 or familial MTC
- Genetic counseling is recommended to assess patient-specific risk
- Annual serum calcitonin screening should begin in children with MEN2B at 6 months, MEN2A at 3-5 years of age

- Increased serum calcitonin and CEA levels
- Abnormal pentagastrin-stimulated calcitonin response
- RET is the only gene associated with MEN2
- RET molecular genetic testing indicated in all individuals with
  - Diagnosis of MTC
  - Clinical diagnosis of MEN2
  - Primary C-cell hyperplasia
- RET gene mutation analysis
  - Most commonly exons 10, 11, 13, 14, and 16 in hereditary forms
  - Mutations in codons 768, 790, 791, and 804 may predispose to a milder form of MTC with low penetrance, late onset, and without family history
  - Most common somatic mutation in sporadic MTC is M918T
- MEN2A: ~ 100% of families have RET mutation in exon 10 or 11
- FMTC: Families have almost 100% RET mutation
- MEN2B: Individuals with features of this syndrome should have mutation analysis or sequencing of exons 15 or 16 to detect p.M918T and p.A883F mutations
- Rarely, germline RET mutation may not be detected in family with clinical diagnosis of MEN2A, MEN2B, or FMTC

**Treatment**

- Surgical approaches
  - Total thyroidectomy offers best chance of cure
  - Associated neck dissections considered for tumors > 1 cm
  - American Thyroid Association Guidelines Task Force has classified mutations based on risk for aggressive MTC
    - May be used in predicting phenotype and recommendations for age at which to perform prophylactic thyroidectomy and to begin biochemical screening for associated diseases
  - Prophylactic thyroidectomy
    - Primary preventive measure for individuals with identified germline RET mutation
    - Prophylactic thyroidectomy recommendations for specific RET germline mutations
      - Codons 883, 918, or 922: Thyroidectomy by 1 year of age
      - Codons 609, 611, 618, 620, 630, or 634: Thyroidectomy before 5 years of age
      - Codons 786, 790, 791, 804, or 891: Consider surgery before age of 5; may delay surgery up to 10 years
      - Other mutations: Thyroidectomy once stimulated calcitonin screening turns abnormal
  - Thyroidectomy for C-cell hyperplasia, before progression to micromedullary carcinoma, may allow surgery to be limited to thyroidectomy alone, sparing of lymph nodes
- Adjuvant therapy
  - Targeted tyrosine kinase, hormone therapy, chemotherapy, and anti-CEA treatments can be considered
- Radiation
  - For residual disease and palliation

**Prognosis**

- Considerable variation
- Overall 5- and 10-year survivals of 60-80% and 40-70%, respectively
- 10-year survival by tumor stage
  - Stage I: Near 100%, stage II: 98%, stage III: 81%, stage IV: 28%
- Better prognostic factors are tumor stage, young age, women, and familial forms
- Poor prognostic factors are necrosis, squamous metaplasia, < 50% calcitonin immunoreaction, and CEA reactivity in absence of calcitonin

**IMAGE FINDINGS**
Scintigraphic Scan

- “Cold” nodule on iodine scan

MACROSCOPIC FEATURES

General Features

- Typically at junction of upper and middle 1/3 of lobe
- Sporadic tumors tend to present as solitary mass ± lymph node involvement
- Hereditary tumors seen in MEN are usually multicentric and bilateral
- Usually not encapsulated but well circumscribed
- Firm, yellow-white, gritty cut surface

Size

- Ranges from grossly undetectable to large, replacing entire lobe
- Small tumors often seen in prophylactic thyroidectomy specimens from MEN2 patients

Sections to Be Submitted

- In high-risk patients (MEN2 and familial MTC) who undergo prophylactic thyroidectomy, entire gland should be submitted to identify MMC and C-cell hyperplasia
- Specimen should be serially sectioned and submitted as a whole from superior to inferior
- C cells are normally situated in upper and middle portions of lobes; submit apparently normal thyroid for histological examination
- Search for C-cell hyperplasia

MICROSCOPIC PATHOLOGY

Histologic Features

- MTC is diagnosed histologically when nests of C cells appear to extend beyond basement membrane and infiltrate and destroy thyroid follicles
- Finding C-cell hyperplasia may serve as a morphological marker for MEN2-associated MTC
- C-cell hyperplasia is diagnosed histologically by presence of increased number of diffusely scattered or clustered C cells
  - Immunohistochemistry for calcitonin expression may be performed as pathologic diagnosis adjunct
- In MEN2, age of transformation from CCH to MTC varies with different germline RET mutation
- Histologic appearance is quite variable
  - Most common morphology includes sheets, nests, trabeculae, or insular patterns
  - Cells are round, polygonal, or spindle-shaped, separated by thin fibrovascular cores
  - Cytoplasm can be clear, amphophilic, or eosinophilic
  - Nuclei are round to oval
  - Chromatin is fine, granular, and dispersed, typical of neuroendocrine tumors
  - Vacuoles with mucin have been frequently described
  - Psammoma-like concretions are occasionally seen
- May mimic other thyroid carcinomas (follicular, papillary, insular, anaplastic)
- 80% show calcitonin-positive amyloid in stroma

Histologic Variants

- Variants: Follicular, papillary, clear cell, oncocytic, small cell, giant cell, melanotic, paraganglioma-like and squamous cell
- Variant patterns of medullary thyroid carcinoma may resemble wide range of thyroid and extrathyroid tumors
- Staining for calcitonin is helpful in making distinction between MTC and other diverse tumors it may mimic

ANCILLARY TESTS

Cytology

- Aspirates are hypercellular with loosely cohesive to noncohesive cells
- Spindle, polygonal, or bipolar cells, often with eccentric nuclei

Histology: Familial Cancer Syndromes

- Hyperchromatic nuclei with granular chromatin and moderate pleomorphism
- Amyloid may be seen in 50-70%
- Multinucleated giant tumor cells are common

Histochemistry

- Congo red
  - Reactivity: Positive
  - Staining pattern
Amyloid shows light green birefringence with polarization

**Immunohistochemistry**
- Hallmark of MTC is positivity for calcitonin
- Tumor cells are also positive for neuroendocrine markers (chromogranin, synaptophysin) and CEA
- TTF-1 and low molecular weight keratins may be positive
- Progesterone receptor and S100 (in peripheral sustentacular cells) can be positive in MTC

**Cytogenetics**
- Identify rearrangements involving RET gene

**Molecular Genetics**
- RET gene sequencing is important to determine prognosis and timing of prophylactic thyroidectomy
  - Exons 10, 11, 13, 14, 15, and 16 cover 95% of cases

**Electron Microscopy**
- Transmission
  - Presence of neurosecretory granules confirms neuroendocrine origin of tumor
    - Electron dense, membrane bound
  - Amyloid material is detected as fine fibrillary material within parenchymal space

**DIFFERENTIAL DIAGNOSIS**

**Sporadic Medullary Thyroid Carcinoma**
- There is only 1 genetic differential diagnosis for MTC: MEN2
- Important for medical management of individual and his/her family to distinguish MTC + MEN2 from truly sporadic MTC
- Germline mutations in RET gene in individuals with apparent sporadic MTC: 6-9.5%
- Usually solitary mass
- Usually unilateral
- Not associated with C-cell hyperplasia
- Histological findings: Same as familial

**Intrathyroid Tumor**
- Metastatic neuroendocrine tumors
  - Can be positive for calcitonin and CEA in rare cases
  - Clinical and radiologic correlation may help in differential
- Paraganglioma
  - Negative for calcitonin; zellballen with S100-positive sustentacular cells
- Follicular carcinoma (FC)
  - Thyroglobulin is positive
  - Nuclear features: Neuroendocrine chromatin in MTC compared to dark dense nuclei in FC
- Undifferentiated carcinoma
  - Hemorrhage, necrosis, and high mitotic activity seen in undifferentiated carcinoma
  - Negative for calcitonin
- Papillary thyroid carcinoma
  - Intranuclear inclusions can be seen in both MTC and PTC
  - Nuclear features usually unique to PTC
  - PTC is calcitonin negative and thyroglobulin positive
- Hyalinizing trabecular tumor
  - Thyroglobulin positive, calcitonin negative
  - Hyaline material is not amyloid when stained by Congo red under polarized light
- Intrathyroid parathyroid tumors
  - PTH positive; calcitonin and thyroglobulin negative
  - Clear cytoplasm, defined cell border

**Tumor in Lymph Nodes**
- MTC metastatic to lymph nodes may be misdiagnosed as melanoma or metastatic neuroendocrine tumors
- Calcitonin and CEA immunostains should be performed in any suspicious case

**Benign Conditions**
- Amyloid goiter
  - May infiltrate fat, and Congo red is positive
  - Involves thyroid gland diffusely
  - Calcitonin stain is negative

**DIAGNOSTIC CHECKLIST**

**Pathologic Interpretation Pearls**
Finding C-cell hyperplasia may serve as a morphological marker for MEN2-associated MTC.

There is only 1 genetic differential diagnosis for MTC: MEN2.

Desmoplasia and breakage of follicular basement membrane helps differentiate C-cell hyperplasia from MMC.

### SELECTED REFERENCES

11. Richards ML: Familial syndromes associated with thyroid cancer in the era of personalized medicine. Thyroid. 20(7):707-13, 2010

### Differential Diagnosis of Medullary Thyroid Carcinoma by Immunohistochemistry

<table>
<thead>
<tr>
<th></th>
<th>MTC</th>
<th>PTC</th>
<th>PDC</th>
<th>ATC</th>
<th>PA/C</th>
<th>Para</th>
<th>Met C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytokeratin</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+/-</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Thyroglobulin</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>TTF-1</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+/-</td>
</tr>
<tr>
<td>Chromogranin</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+/-</td>
</tr>
<tr>
<td>Synaptophysin</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+/-</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Calcitonin</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PTH</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>S100</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**MTC**: Medullary thyroid carcinoma; **PTC**: Papillary thyroid carcinoma; **PDC**: Poorly differentiated carcinoma; **ATC**: Anaplastic thyroid carcinoma; **PA/C**: Parathyroid adenoma/carcinoma; **Para**: Paraganglioma; **Met C**: Metastatic carcinoma.
Pathological Features Distinguishing Familial From Sporadic Medullary Thyroid Carcinoma

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Familial Medullary Thyroid Carcinoma</th>
<th>Sporadic Medullary Thyroid Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross features</td>
<td>Multicentric and bilateral</td>
<td>Solitary mass; unilateral</td>
</tr>
<tr>
<td>Tumor characteristics</td>
<td>Small tumors in prophylactic thyroidectomy specimens</td>
<td>Usually large tumors</td>
</tr>
<tr>
<td>Microscopic features</td>
<td>Associated with neoplastic C-cell hyperplasia</td>
<td>Association with C-cell hyperplasia unknown</td>
</tr>
<tr>
<td>Lymph node metastases</td>
<td>May be present at time of diagnosis</td>
<td>Usually present at time of diagnosis</td>
</tr>
<tr>
<td>RET mutation</td>
<td>Present in majority of hereditary forms</td>
<td>May be present up to 50% of sporadic cases</td>
</tr>
</tbody>
</table>

Differential Diagnosis of Micromedullary Thyroid Carcinoma

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Familial</th>
<th>Sporadic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multifocality</td>
<td>Frequent (~ 90%)</td>
<td>Rare (~ 10%)</td>
</tr>
<tr>
<td>Bilaterality</td>
<td>Common (~ 70%)</td>
<td>Rare (~ 10%)</td>
</tr>
<tr>
<td>Physiologic C-cell hyperplasia</td>
<td>Rare (~ 10%)</td>
<td>Common (~ 55%)</td>
</tr>
<tr>
<td>Neoplastic C-cell hyperplasia</td>
<td>Frequent (~ 90%)</td>
<td>Rare (~ 15%)</td>
</tr>
</tbody>
</table>

Imaging and Microscopic Features

(Left) Coronal FDG PET shows hypermetabolic foci in an upper lumbar vertebra →, left sacroiliac region ←, and left lung ← in a patient with metastatic medullary thyroid cancer. Up to 20% of patients may have distant metastases at the time of presentation. (Right) Fused transaxial fludeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) shows a focal hypermetabolic mass ← in the right thyroid lobe in a patient with medullary thyroid cancer.
Unlike sporadic medullary thyroid carcinoma, MEN2 is frequently accompanied by C-cell hyperplasia. C cells are usually identified by calcitonin staining; however, in many cases of MEN2, C cells are easily identified by H&E. (Right) In MEN2 patients, foci of C-cell hyperplasia are typically present in the vicinity of the tumor as well as in the contralateral lobe. This photomicrograph shows calcitonin stain highlighting CCH adjacent to a medullary thyroid carcinoma.

(Left) FNA of an MTC shows a characteristic cellular specimen with clusters of loosely cohesive round to oval cells of variable sizes. Amyloid spheres can be seen in the background or associated with clusters of malignant cells. Colloid is absent. (Right) Thyroid FNA specimen immunocytological staining for calcitonin shows coarse granular cytoplasmic staining. The MTC cells in this case demonstrate the characteristic coarse neuroendocrine-type nuclear chromatin.

Gross and Microscopic Features and Ancillary Techniques
Total prophylactic thyroidectomy with portion of thymus from a patient with MEN2B and with mutation of the RET gene shows a grossly normal thyroid. However, on histological examination, C-cell hyperplasia and a small medullary thyroid carcinoma were present. Calcitonin-stained thyroid section from a prophylactic thyroidectomy from a patient with RET mutation and family history of MEN2B shows C-cell hyperplasia and medullary thyroid microcarcinoma.

Histological routine section reveals C-cell hyperplasia in a thyroid lobe of a patient with medullary thyroid carcinoma in the other lobe. Both were associated with MEN2 and RET mutation. C-cell hyperplasia can be easily identified on H&E section on heritable cases. C-cell hyperplasia highlighted by calcitonin staining shows the thyroid follicular cells replaced by an increased number of C cells.
This photomicrograph of a Congo red-stained tumor shows extensive deposition of dense amorphous material suggestive of amyloid. Although not essential for the diagnosis of medullary thyroid carcinoma, variable amounts of amyloid are commonly seen in these tumors. (Right) Congo red-stained medullary thyroid carcinoma under polarized light reveals the characteristic apple-green birefringence confirming amyloid deposition.

Microscopic Features and Ancillary Techniques

Medullary thyroid carcinoma presents as a proliferation of epithelial cells with high nuclear to cytoplasmic ratio and moderate atypia. C-cell clusters are shown surrounding and invading the follicular space. (Right) MTC extending into extrathyroidal fibroadipose tissue shows multiple nests of small cells with scant cytoplasm and regular round nuclei, associated with marked inflammatory infiltrate.
This micrograph depicts an unusually aggressive case of medullary thyroid carcinoma metastatic to ovary. A well-defined nodule of tumor cells with interspersed areas of amyloid deposition can be seen. Compressed normal ovarian parenchyma is present surrounding the tumor. (Right) Section of ovary stained for calcitonin highlights the neoplasm (positive staining) and confirms medullary thyroid carcinoma as the origin of this metastatic lesion.

(Left) Dual immunohistochemistry with chromogranin (red) and TTF-1 (brown) distinguishes the neuroendocrine-derived cells of a medullary thyroid carcinoma from the normal adjacent TTF-1-positive follicular cells. MTC cells have both TTF-1 and chromogranin positivity. The immunophenotypical distinction is especially important in cases with a follicular-patterned MTC morphology. (Right) Variable cytoplasmic calcitonin immunostaining is characteristic of MTC cells.

Section 6 - Gastrointestinal
Gastrointestinal Tract
Colon Adenoma

Joel K. Greenson, MD
Key Facts

Etiology/Pathogenesis
- High-fat/low-fiber diet, obesity, smoking, sedentary
- Adenoma prevalence in CRC patients' relatives: 30-40%
- Familial adenomatous polyposis
  - Many (100-1,000) adenomas, present/diagnosed at younger age, germline APC mutation
- Lynch syndrome
  - Fewer (< 10) adenomas, more/faster CRC progression
  - Adenomas often have increased numbers of adenoma-infiltrating lymphocytes

Clinical Issues
- 60-70% of endoscopically removed colorectal polyps
- Advanced adenoma
  - ≥ 1 cm, multiple (≥ 3), high-grade dysplasia, or any villous component
- 3-5% of adenomas contain invasive CRC at diagnosis
- High-grade dysplasia and villous component

Microscopic Pathology
- Proliferating, crowded, hypercellular, colonic tubules
- "Picket fence": Elongated, hyperchromatic nuclei
- Low-grade dysplasia: No architectural complexity
  - Nuclei retain basal orientation (basal cytoplasm)
- High-grade dysplasia: Significant polymorphism
  - Marked nuclear stratification and loss of polarity
  - Architectural complexity: Back-to-back, cribriform
- TA (70-90% adenomas): < 20-25% villous component
- TVA (10-25%): Between 20-25% and 75-80% villous
- VA (~5% of adenomas): > 75-80% villous component
  - > 30% have high-grade dysplasia, 2% have CRC
H&E shows a low-power view of an adenoma with crowded tubules of basophilic dysplastic epithelium overlying nonneoplastic tubules.
H&E shows a higher magnification view of a tubular adenoma (TA) with low-grade dysplasia. Note the “picket fence” arrangement of elongated hyperchromatic nuclei.

**TERMINOLOGY**

**Synonyms**
- Adenomatous polyp, intraepithelial neoplasia

**Definitions**
- Benign, premalignant (dysplastic), clonal (neoplastic) proliferation of colorectal epithelium
- Precursor lesions to colorectal carcinoma (CRC)
- Colorectal adenoma is by definition dysplastic
- Advanced adenomas
  - Any of following features
    - ≥ 1 cm, multiple (≥ 3), high-grade dysplasia, or any villous architecture
  - 3-5x ↑ CRC risk

**ETIOLOGY/PATHOGENESIS**

**Adenoma to Carcinoma Sequence**
- Monoclonal derivatives of mutated epithelial stem cell
  - Inherited or acquired genetic changes
  - May eventually produce malignant phenotype
  - Initiation: Inactivation of APC/\(\beta\)-catenin pathway
  - Step-wise accumulation of genetic mutations
    - Not always linear; occur over several years
- Aberrant crypt foci: Earliest recognizable alteration
  - Unicyclal adenomas can be found in familial adenomatous polyposis (FAP) patients
  - Adenomas grow in size by accelerated crypt fission
  - Early adenomas usually occupy mucosal surface
- Theories of histogenesis
Dysregulated proliferation zone (dysplastic cells)
  - Expansion upward to upper crypt/luminal surface
  - Highlighted with Ki-67 immunostain (MIB-1)
- Rate of proliferation exceeds cell loss
- Failed differentiation, cellular senescence/apoptosis
  - Altered expression of apoptotic genes TGFβ, BCL2
- Lack of phenotypic/morphologic maturation

Family History
- Adenoma prevalence in CRC patients' relatives: 30-40%

Genetic Syndromes
- Familial adenomatous polyposis
  - Many (100-1,000) adenomas, present/diagnosed at younger age, germline APC mutation
  - Presence of unicryptal adenomas diagnostic
- Lynch syndrome
  - Fewer (< 10) adenomas, more/faster CRC progression
  - Adenomas often have increased numbers of adenoma-infiltrating lymphocytes

Nutritional Factors
- Implicated in colorectal neoplasia (adenoma and CRC)
  - Diet high in animal fat, low in fruits/vegetables/fiber
  - High caloric intake, obesity, sedentary lifestyle
  - Excessive smoking, alcohol

CLINICAL ISSUES
Epidemiology
- Incidence
  - 60-70% of endoscopically removed colorectal polyps
  - Lifetime prevalence of adenoma: 30-50% (Western countries)
    - Lifetime prevalence of CRC: 6% (USA)
- Age
  - Prevalence ↑ with age: 20-30% by 50, 40-50% by 60
  - Nonsyndromic patients: Sharp increase at 40 years
    - CRC generally develops 1-2 decades later
- Gender
  - M:F = 2:1
- Ethnicity
  - Adenoma, CRC: ↑ prevalence in African Americans

Site
- 60-75% of adenomas, CRC: Distal to splenic flexure

Presentation
- Almost always asymptomatic, especially if < 1 cm
- Incidental at colonoscopy (screening or other reason)
- Overt or occult rectal bleeding (distal &/or > 1 cm)
- Bleeding risk increases with size and coexistent CRC
- Large polyps: Iron deficiency anemia, incontinence, prolapse, intussusception, partial bowel obstruction
- Cecal lesions mimic appendicitis (obstruct orifice)
- Large distal rectal VA: Watery diarrhea, hypokalemia
  - K+ not reabsorbed (no more epithelium distally)
  - Abnormalities correct after adenoma removal

Endoscopic Findings
- Most accurate method of detecting polyps of all sizes
  - Safe electrocautery for biopsy &/or polypectomy
  - Allows for immediate diagnosis and removal
  - Better than barium radiography (misses up to 50%)
Flexible sigmoidoscopy: Useful for distal neoplasms
  - Advanced adenoma in distal colon or rectum
    - Risk of proximal advanced adenoma: 11-12%
    - Follow-up with full colonoscopy
  - Small (< 1 cm) rectosigmoid adenoma
    - Risk of advanced proximal lesions: 0-7%
    - Decision for full colonoscopy individualized

Endoscopic surveillance guidelines
  - Baseline colonoscopy: Starting at age 50 unless in high-risk group, such as those with a family history of adenomas or colon cancers, FAP, Lynch syndrome, irritable bowel disease (IBD)

Gross findings at endoscopy
  - Redder than surrounding mucosa (lighter in melanosis coli)
  - Rarely multilobulated, filiform
  - Usually very friable, without architectural rigidity
  - Ulceration, depression, firmness: Possible CRC
  - Elevated sessile (no stalk) or pedunculated (long stalk of nonneoplastic tissue)
  - Larger, broad-based sessile lesions (usually VA)
    - Less well defined, harder to resect, tend to recur
  - Superficial, flat (nonprotruding), or depressed
    - Difficult to recognize; dyes may help
    - Mucosal erythema, subtle texture changes
    - Usually smaller, highlighted by formalin fixation
    - Often in HNPCC (right side, high-grade dysplasia, risk of synchronous or metachronous CRC)

Complications of endoscopy
  - Perforation (0.2%), significant bleeding (1%)
  - In 5-10% of patients, colonoscope is not easily/safely passed to cecum
    - Diverticulosis, pelvic surgery adhesions
  - ~25% adenomas < 5 mm are missed (single colonoscopy)
  - Right-sided and ileocecal valve lesions easily missed

Natural History
  - Well-established premalignant (CRC) precursors
    - ~1/2 of adenomas ↑ in size with time
    - Only some (5-10%) adenomas progress to CRC
      - Most small TA: Static, may even regress with time
      - 0.25% progress to CRC per year, usually slowly
      - 1% of advanced adenomas may progress per year
      - Estimated average of 10 years to transform to CRC
    - Endoscopic removal: Interruption of this sequence
      - Secondary prevention: ↓ CRC incidence by 70-90%
  - Evidence for adenoma → carcinoma sequence
    - Similar anatomic distribution, frequently coexist
    - Epidemiologic prevalence/risk factors correlate
    - Direct transition areas can be seen
    - Similar and sequential molecular defects
    - But adenomas not always found in CRC vicinity
      - CRC has overgrown precursor vs. de novo (rare)

Treatment
  - Complete removal (polypectomy) indicated for all
    - Regardless of size, dysplasia degree, villous component
    - Adequate margins evaluated at time of colonoscopy
    - Confirmed by pathology (when not piecemeal)

Incomplete removal (advanced adenoma) or invasion (in sessile polyp or with unfavorable histology)
  - Resection indicated (surgical or endoscopic mucosal)
  - Weigh relative risks: Procedure vs. metastasis risk

Surveillance (follow-up) intervals after polypectomy
  - Small, left-sided, hyperplastic polyps: 10 years
- 1-2 low-risk adenomas: 5-10 years
- Advanced adenomas, family history of CRC: 3 years
- > 10 adenomas (possible genetic syndrome): < 3 years
- Invasion in pedunculated adenoma: 0.5-1 year
  - If no unfavorable histologic features
- Inadequately removed adenoma: 2-6 months
- Large sessile adenoma: 2-6 months
- Negative follow-up: May revert to 5-year frequency

- Chemoprevention: Indirect, inconclusive evidence
  - Vitamins A, C, D, E, folate, calcium
  - Aspirin, NSAIDs, selective COX-2 inhibitors
  - May reduce incidence of adenomas (mixed results)

**Prognosis**

- 5-7% of adenomas: High-grade dysplasia at presentation
  - More if ≥ 1 cm, ≥ 75% villous, age > 60, multiplicity
  - Adenomas < 5 mm: 1% risk of high-grade dysplasia

- 3-5% of adenomas contain invasive CRC at diagnosis
  - Size of adenoma: Best predictor of carcinoma risk
    - > 2 cm: 10-20%; 1-2 cm: 5%; < 1 cm: < 1%
  - High-grade dysplasia and villous component
    - Both are more likely with ↑ adenoma size
    - Unclear if independent prognostic factors
    - 30% of villous adenomas (VAs) > 5 mm have invasive CRC

- Multiplicity of adenomas at colonoscopy
  - 1 adenoma: 30-50% sync./metachronous adenoma
    - ↑ risk: Larger lesions (advanced adenoma), CRC
  - 10-30% of patients have multiple (≥ 3) adenomas
    - Prevalence of multiple adenomas ↑ with age
    - 2x risk of villous component, high-grade dysplasia

**MICROSCOPIC PATHOLOGY**

**Histologic Features**

- Proliferating, crowded, hypercellular, colonic tubules
  - On surface (may have normal epithelium below)
  - Entire tubules replaced by dysplastic epithelium
  - No normal epithelial maturation toward surface
  - Mitotic activity extends upward (Ki-67 confirms)

- “Picket fence”: Elongated, hyperchromatic nuclei
  - Also described as pencillate, cigar-shaped
  - Varying architectural complexity, stratified nuclei (polarity loss), cell maturation, and mucin content
  - Goblet cells may be seen: “Dystrophic” goblet cells

- Cystic dilatation, acute/chronic inflammation, hemorrhage, erosion (especially at surface)
  - Rupture: Extravasated mucin (if pedunculated)

**Degree of Dysplasia**

- Low-grade dysplasia (mild, moderate)
  - Crowded crypts, arranged in parallel, no complexity
    - No back-to-back, cribriform, or budding tubules
  - Nuclei retain basal orientation (bottom 1/2)
  - Absent or minimal: Atypical mitoses, significant loss of polarity, pleomorphism

- High-grade dysplasia (severe, carcinoma in situ)
  - Significant polymorphism (cytologically malignant)
    - Rounded (heaped up) cells, ↑ nuclear:cytoplasm ratio
    - Nuclei: “Open” chromatin, prominent nucleoli
  - Marked nuclear stratification and loss of polarity
    - Lost basal orientation, extend to luminal 1/2
  - Increased and atypical mitoses
  - Architectural complexity: Irregular, back-to-back tubules, cribriforming, solid nests
    - No definite breach of basement membrane

- Reactive changes (especially on surface)
May occur in preexisting adenoma
- Focal loss of polarity, papillary tufting
- Do not overinterpret as high-grade dysplasia
  - Associated inflammation helps distinguish
- Interobserver variability among pathologists
  - Inconsistent interpretation of dysplasia grade

**Villous Component**
- Elongated leaf-like projections of dysplastic epithelium
  - Length > 2x thickness of normal colonic mucosa
  - Arbitrary definition, subjective, not reproducible
  - Problematic distinction from long, separate tubules
  - 35-75% of adenomas > 1 cm have villous component
- % of adenoma surface area with villi defines type
  - TA (70-90% adenomas): < 20-25% villous component
    - Maintains original tubular architecture of mucosa
    - Most pedunculated, 2-3% lifetime malignancy risk
    - Dysplastic tubules over normal epithelium below
  - TVA (10-25%): Between 20-25% and 75-80% villous
    - Intermediate risk of malignant degeneration
  - VA (~5% of adenomas): > 75-80% villous component
    - Typically sessile, with hair-like surface
    - > 30% have high-grade dysplasia
    - ~2% invasive CRC at diagnosis (15-25% lifetime)

**Intramucosal Carcinoma**
- Neoplastic cells extend through basement membrane into surrounding lamina propria of mucosa but not through muscularis mucosae
- Single cell infiltrates, small irregular tubules, marked expansion of back-to-back cribriform glands in mucosa
- Nuclei become more rounded (rather than oval)
- Not shown to have metastatic risk
  - General paucity of lymphatics in colorectal mucosa
  - Some argue against use of the term “carcinoma” in this setting and suggest “adenoma with high-grade dysplasia” if no invasion
    - Avoids clinical overinterpretation of malignancy

**Pseudoinvasion (Epithelial Misplacement)**
- Misplaced (herniated) epithelium in submucosa
  - Pedunculated polyps, especially right-sided
- Can be mistaken for invasive carcinoma
  - Lacks desmoplastic stromal reaction

**Flat or Depressed Adenoma**
- Dysplastic lesions without polypoid component
- Slightly raised edges, typically centrally depressed
- Higher prevalence in patients with FAP
- Difficult to identify endoscopically
  - Usually smaller than raised (elevated) adenomas
  - Inaccurate assessment of prevalence, natural history
- Different molecular defect than classic adenomas
  - ↑ rate of high-grade dysplasia, carcinoma
  - Resulting flat/depressed CRC, no residual adenoma
  - ↑ incidence and significance in Japan, east Asia

**Traditional Serrated Adenoma**
- 1-5% of colorectal adenomas
- Commonly left-sided; large (> 1 cm) in right colon
- Serrated/sawtooth luminal/surface contour
  - Pattern reminiscent of hyperplastic polyp
  - Papillary infolding, budding, surface nuclear tufting
• Obvious cytologic dysplasia
  o Crowded, pseudostratified, elongated nuclei
  o Hypereosinophilic cytoplasm, prominent nucleoli
  o Lack of surface maturation
• Prominent mitoses anywhere along crypt axes
• May have distinct molecular abnormalities
  o KRAS > BRAF mutations; common MSI, CIMP

Other Types of Adenoma
• Villomicroglandular adenoma
  o VA with closely packed small tubules at sides of villi
• Hypersecretory adenoma
  o Usually rectal VA associated with hypokalemia
  o Pale mucus-filled cells line dysplastic villi
• Clear cell adenoma
  o Focal clear cell change in otherwise classic adenoma
  o Minimal cytologic atypia
    • Basal nuclei, abundant pale foamy cytoplasm

DIFFERENTIAL DIAGNOSIS
Reactive/Regenerative Epithelium
• Epithelium matures toward surface
  o Acquires more cytoplasm, mucin
  o Nuclei become smaller, more basal
• Usually associated with active inflammation
• Mitoses limited to crypt bases

Invasive Carcinoma
• Adenoma has reached beyond muscularis mucosae
  o Into underlying submucosa
• Dysplastic tubules mixed with submucosal structures
  o Medium-sized vessels, large lymphatics, fat, ganglia
• Accompanied by desmoplastic stromal reaction
  o Necessary for diagnosis of submucosal invasion

DIAGNOSTIC CHECKLIST
Clinically Relevant Pathologic Features
• Dysplasia (adenomatous change) can also occur in
  o Other preexisting lesions (hamartomatous polyps)
  o Other epithelial polyps (hyperplastic polyps)
    • Resulting in mixed adenoma-serrated polyps
  o Inflammatory bowel disease (ulcerative colitis, Crohn colitis)
• Multiple adenomas may be part of genetic syndrome

Pathologic Interpretation Pearls
• Dysplastic colorectal epithelium considered invasive
  o When through muscularis mucosae into submucosa
  o Otherwise, no clinically significant risk of metastases
• Desmoplasia strongly suggests invasive carcinoma
  o Should be interpreted as such in pathology report
  o Even absent cytologically malignant epithelium
    • Raises concern that invasive carcinoma present
    • Perhaps not properly sampled
  o Unless history of prior biopsy in same area
    • Difficult to distinguish desmoplasia from changes of prior biopsy site

REPORTING CONSIDERATIONS
Key Elements to Report
• Key facts to be included in pathology report
  o Extent of villous component, degree of dysplasia
  o If multiple pieces of adenoma (piecemeal removal)
    • Indicate as such (1 or multiple polyps)
    • Margin cannot be adequately evaluated
    • Attempt to account for each polyp removed
Large pedunculated polyp, removed in single piece
- Bisect (or serially section) and properly orient
- Comment on dysplasia at cauterized margin
- Positive: Further removal &/or close follow-up
- Cautery may actually destroy residual adenoma

If invasive carcinoma is present (desmoplasia)
- Degree of differentiation
- Lymphovascular invasion, if present

Invasive carcinoma in pedunculated polyp
- Comment on any adverse histologic features
- Poor differentiation, < 1-2 mm to margin, lymphovascular invasion, tumor budding
- Any of these should prompt surgical resection
- Significant risk of recurrence &/or metastases
- Otherwise, complete polypectomy is curative if endoscopically and histologically confirmed
- Invasion of stalk not unfavorable (if clean margin)

SELECTED REFERENCES

Image Gallery
Microscopic Features

(Left) H&E shows high-grade dysplasia. Note significant polymorphism and increased nuclear:cytoplasmic ratio and rounded-up cells ➔. Marked nuclear stratification and extensive loss of polarity are also present ➔. (Right) Hematoxylin & eosin shows extensive high-grade dysplasia, which some would classify as intramucosal carcinoma. There is increased architectural complexity with irregular back-to-back glands, often in cribriform shapes ➔.
(Left) H&E shows extensive high-grade dysplasia in an adenoma with solid nests of dysplastic cells and back-to-back tubules. This would be classified as intramucosal carcinoma by some pathologists. (Right) H&E shows a tubulovillous adenoma (TVA) with some leaf-like villous projections of dysplastic epithelium. The dysplastic tissue occupies 25-75% of the adenoma, the rest consisting of tubular structures.

(Left) H&E shows a villous adenoma (VA), almost entirely composed of villi, elongated, leaf-like projections of dysplastic epithelium occupying >75-80% of the adenoma. (Right) H&E shows a VA with high-grade dysplasia. VAs are more likely to have high-grade dysplasia, evidenced here by extensive nuclear stratification and loss of polarity.

Microscopic Features
(Left) H&E shows a flat adenoma that is depressed in the center. Mucosa width that is narrower than surrounding normal mucosa is typical of flat adenomas, making them difficult to identify endoscopically. (Right) H&E shows adenoma with very low-grade dysplasia. Tubules are not extensively proliferating or crowded and are thus hard to recognize as dysplastic. Overall basophilia helps identify the enlarged, hyperchromatic, and stratified nuclei.

(Left) H&E shows an adenoma with squamous metaplasia. The dysplastic glandular epithelium of the adenoma differentiates into morules of squamous epithelium. (Right) H&E shows a tubular adenoma giving rise to an invasive adenocarcinoma. Typically arising from the base of the adenoma, invasive tubules elicit a desmoplastic stromal reaction once they have invaded past the muscularis mucosae into the submucosa.
(Left) H&E shows invasive carcinoma in a polyp biopsy. The presence of desmoplasia should raise concern for invasion, even if dysplastic tubules are not clearly seen invading the submucosa, as in this piecemeal specimen. (Right) H&E shows invasive adenocarcinoma arising from an adenoma at the head of a pedunculated polyp. Large vessels are present in the submucosa of the stalk. Invasive carcinoma is far from the cauterized polypectomy margin.

Esophageal Adenocarcinoma

Terminology

- Malignant epithelial tumor of esophagus with glandular differentiation
- Arises predominantly in lower 1/3 of esophagus in association with Barrett esophagus

Etiology/Pathogenesis

- Perhaps 5-10% of Barrett esophagus cases are familial
- Gastroesophageal reflux disease
- Obesity, smoking, alcohol

Clinical Issues

- Endoscopic treatment for early lesions (T1, intramucosal, or superficial submucosal invasion)
- Most rapidly increasing cancer in USA, especially among white males

Diagnostic Checklist

- Damaged muscularis mucosae duplicate and submucosal glands should be sought to determine invasion into submucosa
Gross pathology photograph shows an esophageal adenocarcinoma. The gastric folds are seen at the bottom of the field, and velvety background Barrett mucosa is readily identified.
Hematoxylin & eosin shows a focus of intramucosal adenocarcinoma adjacent to columnar epithelial dysplasia.

TERMINOLOGY
Abbreviations
- Esophageal adenocarcinoma (EAC)
Definitions
- Malignant epithelial tumor of esophagus with glandular differentiation
- Arises predominantly in lower 1/3 of esophagus in association with Barrett esophagus

ETIOLOGY/PATHOGENESIS
Risk Factors
- Male gender
- Gastroesophageal reflux disease
- Obesity, smoking, alcohol
Familial
- Perhaps 5-10% of Barrett esophagus cases are familial
  - May be several rare autosomal dominant susceptibility genes with incomplete penetrance

CLINICAL ISSUES
Epidemiology
- Incidence
  - > 15,000 new cases annually in USA
  - Most rapidly increasing cancer in USA, especially among white males
- Age
  - Average age at presentation: 65 years
- Gender
  - About 80% of cases are in men
Presentation
• Dysphagia &/or retrosternal pain or epigastric pain

Treatment
• Endoscopic treatment for early lesions (T1, intramucosal, or superficial submucosal invasion)
  o Photodynamic therapy
  o Laser treatments
  o Endoscopic mucosal resection
• Chemoradiation and surgery for high-stage lesions

Prognosis
• Dependent on stage (most tumors detected at high stage)
  o Overall 5-year survival (20%)
  o For pT1 cancers, 5-year survival (65-80%)
  o 5-year survival for intramucosal carcinomas (invading only lamina propria) (> 90%)

MACROSCOPIC FEATURES
General Features
• Lower 1/3 of esophagus
• Background Barrett esophagus often present

MICROSCOPIC PATHOLOGY
Histologic Features
• Gland forming as per any adenocarcinoma

DIFFERENTIAL DIAGNOSIS
Gastric Cardiac Adenocarcinoma
• Epidemiology and immunoprofiles (CK7[+], CDX2[±], CK20 variable) show extensive overlap; some lesions cannot be separated
• If Barrett esophagus is detected, cancers at esophagogastric junction are labeled as esophageal cancers

P.II(6):9
• If bulk of neoplasm is in stomach, lesion is regarded as gastric and staged as such
  o Gastric cancers are staged as N0, N1, and N2 whereas esophageal cancers are staged as N0 or N1

Other Adenocarcinomas
• Metastases from other sites, direct spread from lung cancers
• Clinical history and application of immunohistochemistry
  o Thyroid transcription factor-1 (TTF-1) for lung and thyroid

Barrett High-Grade Dysplasia
• Typically lacks nucleoli, necrosis in glands, and syncytial growth pattern
• Necrosis in glands, back-to-back glands, and nucleoli are features of early intramucosal adenocarcinoma

DIAGNOSTIC CHECKLIST
Pathologic Interpretation Pearls
• Remember that damaged muscularis mucosae duplicate, and submucosal glands should determine invasion into submucosa

SELECTED REFERENCES

Histologic Grading of Esophageal Adenocarcinoma

<table>
<thead>
<tr>
<th>Classification</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade X</td>
<td>Grade cannot be assessed</td>
</tr>
<tr>
<td>Grade 1</td>
<td>Well differentiated (&gt; 95% of tumor composed of glands)</td>
</tr>
<tr>
<td>Grade 2</td>
<td>Moderately differentiated (50-95% of tumor composed of glands)</td>
</tr>
<tr>
<td>Grade 3</td>
<td>Poorly differentiated (≤ 49% of tumor composed of glands)</td>
</tr>
</tbody>
</table>

(Left) Lower magnification H&E shows a contrasted background columnar epithelial dysplasia with the intramucosal carcinoma; the dysplasia lacks nucleoli in contrast to the invasive component. (Center) Hematoxylin & eosin shows the superficial portions of a deeply invasive adenocarcinoma. Note the well-developed desmoplasia. (Right) Hematoxylin & eosin shows an adenocarcinoma undermining squamous mucosa in the esophagus.

Esophageal Squamous Cell Carcinoma

Terminology
- Malignant epithelial neoplasm with squamous cell differentiation; manifested as keratinocyte-like cells that may contain intercellular bridges &/or keratinization

Etiology/Pathogenesis
- Plummer-Vinson syndrome
- Tylosis
- Celiac disease
- Tobacco, alcohol, others

Clinical Issues
- Varies by geography
- Uncommon in USA
  - 5 per 100,000 men, 1 per 100,000 women

Microscopic Pathology
- Appears as squamous cell carcinoma in other anatomic sites
Gross pathology photograph shows an esophageal squamous cell carcinoma (SCCa) in the upper 1/3 of the esophagus. Most esophageal squamous carcinomas are identified in the middle 1/3.
Hematoxylin & eosin shows SCCa of the esophagus. It has the same features as SCCa elsewhere. Note the abnormal keratinization in the keratin “pearl”.

TERMINOLOGY
Abbreviations
- Squamous cell carcinoma (SCCa)

Definitions
- Malignant epithelial neoplasm with squamous cell differentiation
  - Manifested as keratinocyte-like cells that may contain intercellular bridges &/or keratinization

ETIOLOGY/PATHOGENESIS
Risk Factors
- Tobacco
  - Accounts for majority of risk in Western countries
  - Potentiates risk associated with alcohol
- Alcohol
  - Northwest France and northern Italy; well studied and potentiated by tobacco use
- Nutrition
  - Nitrosamines in pickled or moldy foods
  - Vitamin deficiencies
- Ingestion of hot beverages: Thermal injury
  - Classic example: Mate tea in South America, consumed through a metal straw
- Human papillomavirus
  - Associated in endemic areas in China but rare in USA population
- Achalasia
- Prior corrosive ingestion
- Plummer-Vinson syndrome
  - Also called Paterson-Kelly syndrome or sideropenic dysphagia
Severe, long-term iron deficiency anemia with dysphagia due to esophageal webs

Genetic

- Tylosis
  - Also called focal nonepidermolytic palmoplantar keratoderma
  - Autosomal dominant skin disorder associated with familial early onset of esophageal SCCa
  - Abnormality localized to long arm of chromosome 17
    - Missense mutations in RHBDF2 gene thought to be the cause
- Celiac disease
  - Risk of SCCa due to iron deficiency anemia, similar to Plummer-Vinson syndrome
  - In Japanese alcoholics, associated with polymorphism in aldehyde dehydrogenase 2 (ALDH2) gene

CLINICAL ISSUES

Epidemiology

- Incidence
  - Varies by geography
    - Uncommon in USA: 5 per 100,000 men, 1 per 100,000 women
    - Normandy (northwest France) and Calvados (northern Italy): 30 per 100,000 men, 2 per 100,000 women
    - High-risk regions (China, Iran, Brazil, South Africa): > 100 per 100,000 men, 50 per 100,000 women
- Age
  - Rare before 30 years
  - Median age: 65 years
- Gender
  - Male predominance
- Ethnicity
  - In USA, 2-3x more common in African Americans than others

Presentation

- Difficulty swallowing

Treatment

- Combined radiation and chemotherapy followed by surgery

Prognosis

- Stage specific: Typically poor since patients present at high stage

MACROSCOPIC FEATURES

General Features

- Typically mass in midesophagus

MICROSCOPIC PATHOLOGY

Histologic Features

- Appears as squamous cell carcinoma in other anatomic sites
  - Abnormal keratinization, “paradoxical maturation,” squamous “pearls”
- Variants in esophagus
  - Basaloid: Appears as basaloid squamous carcinomas in other sites
  - Sarcomatoid variant often requires identification of in situ component to diagnose
  - Helpful to label with keratins and p63 to confirm

DIFFERENTIAL DIAGNOSIS

Pseudoepitheliomatous Hyperplasia

- Lacks “paradoxical maturation”
- Intact basal layer

Sarcomas and Spindle Cell Melanoma

- Sarcomas vanishingly rare in esophagus
- Immunohistochemistry for S100 protein for melanoma
- CD117 for gastrointestinal stromal tumor (very rare in esophagus)

Squamous Cell Carcinoma

- From lung with direct extension into esophagus
- Cannot be separated based on morphology or ancillary tests

SELECTED REFERENCES
Diagnostic Pathology: Familial Cancer Syndromes


IMAGE GALLERY

(Left) Hematoxylin & eosin shows an esophageal SCCa (mucosal biopsy) with keratinization. The left side of the field appears more basaloid. These subtypes have little impact on outcome, which depends on stage. (Center) Hematoxylin & eosin shows higher magnification of the focus of overt squamous differentiation in the same neoplasm. (Right) Hematoxylin & eosin shows an area of high-grade squamous dysplasia in the resection sample from the same patient. Note the nucleoli and lack of keratinization.

Gastric Adenocarcinoma

Table of Contents > Part II - Diagnoses Associated With Specific Syndromes > Section 6 - Gastrointestinal > Gastrointestinal Tract > Gastric Adenocarcinoma

Gastric Adenocarcinoma
Gregory Y. Lauwers, MD
Joel K. Greenson, MD

Key Facts
Terminology
- Early adenocarcinomas are invasive neoplasms limited to mucosa and submucosa, irrelevant of lymph node status
- Advanced adenocarcinomas are neoplasms invading muscularis propria and beyond

Etiology/Pathogenesis
- Helicobacter pylori
- Diet
- Bile reflux and bacterial overgrowth are implicated
- E-cadherin/CDH1 gene

Clinical Issues
- Decreasing incidence of distal adenocarcinomas
- Increasing incidence of cardial adenocarcinomas
- Currently, early adenocarcinomas are more commonly diagnosed
  - 90-100% survival at 5 years
- Endoscopic resection (mucosal or submucosal, depending on type and size)

Microscopic Pathology
- 2 main categories: Intestinal and diffuse
  - Intestinal type: Glandular or papillary structures of various degrees of differentiation
  - Diffuse type: Dyscohesive cells of plasmacytoid, histiocytic, or signet ring cell type

Top Differential Diagnoses
- Gastric dysplasia
- Gastric lymphoma
- Gastric xanthoma
Upper GI study shows a large fungating mass located along the lesser curve of the stomach. Endoscopic biopsy demonstrated a gastric adenocarcinoma.
Gross photograph shows a large fungating gastric adenocarcinoma (Borrmann type 2).

TERMINOLOGY
Definitions
- Primary invasive epithelial gastric neoplasm
  - Early adenocarcinomas: Limited to mucosa and submucosa, irrelevant of lymph node status
  - Advanced adenocarcinomas: Invading muscularis propria and beyond

ETIOLOGY/PATHOGENESIS
Environmental Exposure
- Diet
  - Dried and salted foods
  - Low consumption of fresh fruits and vegetables
- Smoking

Infectious Agents
- *Helicobacter pylori*
  - Category 1 carcinogen
  - Infection leads to chronic inflammation and metaplastic changes, precursors of adenocarcinoma
  - Infection early in life
  - Variable risks associated with different strains

Hereditary Diffuse Gastric Cancer
- E-cadherin/CDH1 gene

Previous Gastric Surgery
- Bile reflux and bacterial overgrowth are implicated

CLINICAL ISSUES
Epidemiology
- Incidence
  - Variable: 1.3 (Bangladesh) to 115 (Japan) per 100,000
    - Downward trend noticed in most industrialized nations
• Early gastric adenocarcinomas encountered more frequently; represent 25-50% of all newly diagnosed gastric cancers
  o Increasing for adenocarcinomas of cardia
  o Geographically restricted; common in West but rare in Asia
  o Association with Barrett esophagus, gastroesophageal reflux disease, and intestinal metaplasia is debated

• Age
  o Primarily disease of late adulthood (5th decade and older)
  o Earlier presentation in syndromic patients with hereditary diffuse gastric cancer or hereditary intestinal gastric cancer
    ▪ Look for multiple foci of early diffuse-type adenocarcinoma or signet ring cell carcinoma in situ in patients with hereditary diffuse gastric cancer

• Gender
  o M:F = 2:1

Presentation
• Abdominal pain
  o May mimic symptomatology related to peptic ulcer
• Anemia, vomiting, weight loss
• Young patients may present with intraabdominal dissemination and ascites
  o Females may present with metastatic ovarian lesions (Krukenberg tumors)

Endoscopic Findings
• Large polypoid mass
• Large ulcer
• Infiltrating with thickened gastric wall (linitis plastica)
• Early lesions may present as polyp, plaque, or mucosal erosion

Natural History
• Most early tumors progress to advanced carcinomas over months to years
• Lymphatic spread is common path of dissemination
• Transserosal coelomic extension common for diffuse-type adenocarcinomas with secondary ascites
  o Spread to ovaries produces Krukenberg tumor
• Hematogenous spread leads to liver and lung metastasis

Treatment
• Options, risks, complications
  o Endoscopic resection (mucosal or submucosal, depending on type and size)
• Surgical approaches
  o Gastrectomy
  o Associated with neoadjuvant and adjuvant therapies

Prognosis
• Early adenocarcinomas (T1) have good prognosis
  o > 90% survival at 5 years for mucosal tumors
    ▪ Rate of lymph node metastasis is 0-7%
  o 80% survival at 5 years for submucosal tumors
    ▪ Rate of lymph node metastasis is 8-25%
• Prognosis of advanced adenocarcinomas
  o T2: 65-81% survival at 5 years
  o T3: 35-44% survival at 5 years
  o T4: 16% survival at 5 years

MACROSCOPIC FEATURES
General Features
• Most cases diagnosed in antrum and antropyloric region
  o Preferentially on lesser curvature
• Multiple adenocarcinomas seen in 5% of patients
Size
• Microscopic to large bulky tumor several cm
  o Most early lesions measure 2-5 cm
30% of advanced adenocarcinomas are 6-10 cm

Gross Appearance of Early Gastric Cancer
- Protruded (type 1)
- Superficial (type 2) (80% of cases)
  - 2a (elevated type)
    - Lesion is 2x as thick as normal mucosa
  - 2b (flat type)
  - 2c (mimics benign ulcer)
    - Most common subtype
    - May require multiple biopsies
- Excavated (type 3)

Gross Appearance of Advanced Cancer
- Borrmann classification for gastric carcinomas
  - Polypoid carcinoma (type 1)
    - ~25% of cases
    - More common in corpus, often on greater curvature
  - Fungating carcinoma (type 2)
    - ~35% of cases
    - Frequently found in antrum, along lesser curvature
  - Ulcerated carcinoma (type 3)
    - ~25% of cases
    - More common in corpus, often on greater curvature
  - Diffusely infiltrative carcinoma (type 4)
    - ~15% of cases
    - Known as limitis plastica when it involves entire stomach

DIFFERENTIAL DIAGNOSIS
Gastric Dysplasia
- May be hard to distinguish from early intramucosal adenocarcinoma
- Absence of desmoplasia
- Limited cytoarchitectural anomalies

Gastric Lymphoma
- May mimic poorly differentiated intestinal and diffuse adenocarcinoma

P.II(6):14
- CD20 and CD45 (+); cytokeratin and CEA (-)

Gastric Xanthoma
- Foamy cytoplasm may mimic diffuse-type gastric cancer
- CD68(+), cytokeratin (-)

Whipple Disease
- May mimic diffuse-type gastric cancer
- Cytokeratin stain will be negative in Whipple disease
- CD68(+) stain in Whipple disease
- Bacteria (Tropheryma whipplei) observed on electron microscopy

SELECTED REFERENCES

<table>
<thead>
<tr>
<th>Clinical</th>
<th>Stage Category Definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary tumor (T)</td>
<td></td>
</tr>
<tr>
<td>TX</td>
<td>Primary tumor cannot be assessed</td>
</tr>
<tr>
<td>T0</td>
<td>No evidence of primary tumor</td>
</tr>
</tbody>
</table>
Carcinoma in situ: Intraepithelial tumor without invasion of lamina propria
T1 Tumor invades lamina propria, muscularis mucosae, or submucosa
T1a Tumor invades lamina propria
T1b Tumor invades submucosa
T2 Tumor invades muscularis propria
T3 Tumor invades lamina propria, muscularis mucosae, or submucosa
T3a Tumor invades lamina propria
T3b Tumor invades muscularis mucosae
T4 Tumor invades serosa (visceral peritoneum) or adjacent structures
T4a Tumor invades serosa (visceral peritoneum)
T4b Tumor invades adjacent structures

Regional Lymph Nodes (N)
NX Regional lymph node(s) cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in 1-2 regional lymph nodes
N2 Metastasis in 3-6 regional lymph nodes
N3 Metastasis in ≥ 7 regional lymph nodes
N3a Metastasis in 7-15 regional lymph nodes
N3b Metastasis in 16 or more regional lymph nodes

Distant Metastasis (M)
M0 No distant metastasis (no pathologic M0; use clinical M to complete stage group)
M1 Distant metastasis

A tumor may penetrate the muscularis propria with extension into the gastrocolic or gastrohepatic ligaments, or into the greater or lesser omentum, without perforation of the visceral peritoneum covering these structures. In this case, the tumor is classified T3. If there is perforation of the visceral peritoneum covering the gastric ligaments or the omentum, the tumor should be classified T4.

The adjacent structures of the stomach include the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, and retroperitoneum.

Intramural extension to the duodenum or esophagus is classified by the depth of the greatest invasion in any of these sites, including the stomach.

A designation of pN0 should be used if all examined lymph nodes are negative, regardless of the total number removed and examined.

Adapted from 7th edition AJCC Staging Forms.
(Left) From top to bottom, graphic shows the 4 types of advanced gastric adenocarcinoma in the Borrmann classification: Type 1 (polypoid), type 2 (fungating), type 3 (ulcerated), and type 4 (diffusely infiltrative). (Right) Graphic of the simplified endoscopic gross classification of early gastric adenocarcinoma shows 5 variants and subvariants, from top to bottom: Type 1 (polypoid), type 2a (elevated), type 2b (flat), type 2c (depressed), and type 3 (excavated).

(Left) Hematoxylin and eosin shows a well-differentiated papillary gastric adenocarcinoma. (Right) Hematoxylin and eosin shows a well-differentiated glandular adenocarcinoma. Cytologically, the tall clear neoplastic cells are consistent with gastric foveolar phenotype.
Hematoxylin and eosin shows a moderately differentiated adenocarcinoma, glandular type. The glandular structures are irregular but remain easily identifiable. (Right) Hematoxylin and eosin shows an example of moderately differentiated adenocarcinoma. In this example, smaller dyscohesive groups of tumor cells are seen invading the desmoplastic stroma.

Microscopic and Imaging Features

Hematoxylin and eosin shows an example of a poorly differentiated intestinal-type adenocarcinoma. This case displays a sheet-like pattern of growth with only rare glandular structures. (Right) Cytokeratin AE1/AE3 in the same case highlights the poorly formed glandular structures.
Contrast-enhanced CT through the level of the gastric antrum shows diffuse thickening of the stomach wall with lack of distensibility and narrowing of the lumen (linitis plastica). This appearance is typical for a diffusely infiltrating carcinoma. Hematoxylin and eosin shows a diffusely infiltrative adenocarcinoma. Sheets of dyscohesive tumors invade between the thick muscular fascicles of the muscularis propria.

Hematoxylin and eosin shows infiltrative diffuse-type tumor cells embedded in a thick desmoplastic stroma. Note that many assume a somewhat spindle-like appearance, and only rare signet ring cells are seen. Hematoxylin and eosin shows an infiltrative, diffuse-type adenocarcinoma with prominent mucin production. Note the clusters of tumor cells floating in the thick mucinous material.

Microscopic Features
Hematoxylin & eosin shows an “Indian file” infiltrative pattern in a case of diffuse-type adenocarcinoma. Caution should be exercised to not overlook a breast carcinoma metastatic to the stomach. (Right) Hematoxylin and eosin shows an early adenocarcinoma, diffuse type. The large mucin-rich cells should not be mistaken for a gastric xanthoma. Immunohistochemical stains, such as cytokeratin, can confirm the diagnosis.

High-power view of signet ring cells shows that the neoplastic cells are characterized by prominent mucin production; consequently, the nuclei are pushed to the side. (Right) Hematoxylin and eosin shows another histologic variant of a diffuse-type gastric adenocarcinoma. The cells in this example have a vaguely histiocytic appearance.
(Left) Hematoxylin and eosin shows another histologic pattern of a diffuse type of gastric adenocarcinoma with a plasmacytoid appearance. (Right) Hematoxylin and eosin shows an example of gastric adenocarcinoma with mixed glandular and diffuse carcinoma. About 10% of gastric adenocarcinomas belong in this mixed category.

Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor
Joel K. Greenson, MD
Elizabeth A. Montgomery, MD

Key Facts
Terminology
- Generally CD117(+) or KIT or PDGFRA mutation-driven mesenchymal tumors, usually of GI tract, with characteristic histologic features

Clinical Issues
- Molecular prognostication for GISTs
  - Not indicated for all cases
  - Best reserved for patients with advanced disease or disease refractory to treatment
- Both simple clinicopathologic features and molecular testing are prognostic
- Simple algorithms a function of size and mitotic counts
- Site is important risk factor
- 20-25% of gastric GISTs are malignant
- 40-50% of small intestinal GISTs are malignant
- Molecular analysis to determine likelihood of response to treatment
- KIT exon 11 (most common mutation type)
  - Complete remission (6%), partial response (61%), stable disease (25%), progressive disease (3%)
- KIT and PDGFRA wild type
  - Partial response (23%), stable disease (50%), progressive disease (19%)

Microscopic Pathology
- Uniform spindle cells or epithelioid cells arranged in lobules
- Nuclear pleomorphism is rare
- Eosinophilic cytoplasm
- Cytoplasmic vacuoles are common
Radiologic image shows a large gastrointestinal stromal tumor (GIST) \( \rightarrow \). The lesion compresses the liver but arises in association with the gastric wall \( \rightarrow \).
Hematoxylin & eosin shows low magnification of a gastric GIST that involved the muscularis propria of the gastric body. The lesion is lobulated and well marginated.

TERMINOLOGY
Abbreviations
- Gastrointestinal stromal tumor (GIST)

Synonyms
- Gastrointestinal smooth muscle tumors (used interchangeably in older literature)
- Gastrointestinal autonomic nerve tumor is now subsumed under GIST

Definitions
- Generally CD117(+) or KIT or PDGFRA mutation-driven mesenchymal tumors, usually of GI tract, with characteristic histologic features
  - Spindle cells
  - Epithelioid cells
  - Pleomorphic morphology (rare)
- Familial cases
  - Germline mutations of KIT gene, autosomal dominant
    - Relevant animal models are available for study
- Neurofibromatosis type 1 (NF1)
  - Interaction between KIT gene product and NF1 gene product
  - Tumors have CD117 immunolabeling but no KIT gene mutations
- Carney triad
  - Epithelioid gastric GISTs, paraganglioma, pulmonary chondroma
- Carney-Stratakis syndrome
  - Epithelioid gastric GISTs and paraganglioma
  - Germline mutations in succinate dehydrogenase (SDH) complex B, C, and D subunits

CLINICAL ISSUES
Epidemiology

- **Incidence**
  - 14.5 per million people in Sweden, 11 per million people in Iceland, ~4,500 new cases per year in USA
  - Clinically silent lesions (studied in gastroesophageal resections for carcinomas) are common (10%)
    - Suggests that most lesions remain clinically insignificant and do not progress

- **Age**
  - Median is 60 years; rare in children and young adults
    - Familial examples present in middle age
    - Carney-Stratakis and Carney triad cases may present in childhood
    - Mean age for NF1-associated lesions is 49 years

- **Gender**
  - No predilection in most series

- **Ethnicity**
  - Overrepresentation of malignant examples reported in African Americans

**Site**

- Stomach is most common site (60%)
- Jejunum and ileum (30%)
  - NF1-associated lesions tend to occur in small bowel
- Duodenum (5%)
- Colorectum (< 5%)
- Esophagus and appendix (rare)
- Primary extraintestinal (mesentery, omentum, retroperitoneum) is rare
  - Most lesions in these sites are metastases/direct spread from GI tract

**Presentation**

- Gastrointestinal bleeding
  - Most common presentation
- GI obstruction
- Abdominal pain
- Incidental
  - During surgery, imaging studies, or endoscopy

**Treatment**

- Surgical approaches
  - Complete resection regardless of site

- Drugs
  - Imatinib mesylate (Gleevec): Inhibits tyrosine kinases (such as c-kit)
  - Newer drugs
    - Used for acquired resistance to imatinib (attributed to secondary KIT or PDGFRA mutations)
      - or initial lack of response
    - Sunitinib malate (SU11248): Used for patients with KIT exon 9 mutations, others
    - Newer drugs in development

**Prognosis**

- Both simple clinicopathologic features and molecular testing are prognostic
  - Simple algorithms are function of size and mitotic counts
  - Site is important risk factor
    - 20-25% of gastric GISTs are malignant
    - 40-50% of small intestinal GISTs are malignant
- Small bowel criteria often applied for other sites of GISTs
- Molecular prognostication for GISTs
  - Not indicated for all cases
    - Best reserved for patients with advanced disease or disease refractory to treatment

**MACROSCOPIC FEATURES**

**General Features**

- Usually well-marginedated lesions with their epicenter in muscularis propria

**MICROSCOPIC PATHOLOGY**
Histologic Features
- Uniform spindle cells or epithelioid cells arranged in lobules
  - Nuclear pleomorphism is rare
  - Occasional cases show dedifferentiated pattern with bland areas and high-grade areas in same neoplasm
  - Some cases have multinucleated cells
- Eosinophilic cytoplasm
- Cytoplasmic vacuoles common
- Minimal inflammation
- Inconspicuous vessels
- Can have myxoid or myxochondroid background
- Some cases have cystic spaces
- “Skeinoid” fibers (coarse, wire-like, haphazardly arranged collagen bundles) in small bowel tumors
- Occasional extension into mucosa (poor prognostic factor)
- Tumor necrosis uncommon (poor prognostic factor)

ANCILLARY TESTS
Immunohistochemistry
- Usually CD117(+)
  - Newer relatively specific markers
    - Protein kinase C8
    - DOG1 (deleted on GIST-1)
  - Data accumulating on PDGFR-α antibodies

DIFFERENTIAL DIAGNOSIS
Solitary Fibrous Tumor
- Vanishingly rare in GI tract
- Spindle cell lesion, hemangiopericytoma-like vascular pattern
- CD34(+), Bcl-2(+), CD117(-)
- No KIT mutations

Schwannoma
- Usually in muscularis propria of stomach
- Prominent lymphoid cuff
- Intralesional lymphoplasmacytic inflammation
- S100(+), CD117(-)
- No KIT mutations

Fibromatosis
- Epicenter in mesentery with extension into muscularis propria
- Infiltrative growth pattern
- Pale cells, abundant collagen, prominent small vessels
- Usually CD34(-); some cases have cytoplasmic CD117, nuclear β-catenin (GISTs lack nuclear β-catenin)
- β-catenin and APC gene mutations
- No KIT mutations

 Leiomyoma
- Usually in esophagus or in association with colonic muscularis mucosae
- Brightly eosinophilic cells with blunt-ended nuclei
- Desmin (+), actin (+), CD117(-)
- No KIT mutations

Leiomyosarcoma
- Brightly eosinophilic cells with blunt-ended nuclei
- Perpendicularly oriented fascicles
- Nuclear pleomorphism
- Desmin (+), actin (+), CD117(-)
- No KIT mutations

Melanoma
- Metastases tend to spread to small bowel; occasional anal and esophageal primaries
- Typically more pleomorphic than GIST
• CD117 often positive, but also S100, other melanocytic markers
• About 20% of mucosal melanomas have KIT mutations and respond to treatment with imatinib

Clear Cell Sarcoma of GI Tract
• Usually in small bowel
• Lobules of uniform cells with prominent nucleoli
• S100(+), most CD117(-)
• t(12;22), EWS-ATF1 fusion, or EWS-CREB1 fusion

Inflammatory Fibroid Polyp
• Submucosal based
• Bland proliferating cells, numerous eosinophils
• CD34(+), CD117(-)
• PDGFRA mutations, no KIT mutations

DIAGNOSTIC CHECKLIST
Pathologic Interpretation Pearls
• If considering GIST diagnosis when confronted with pleomorphic mesenchymal neoplasm in GI tract, first consider alternative diagnoses

SELECTED REFERENCES
P.II(6):21

### Tables

**Clinical Prognostication for GISTs From Largest Series (Untreated With Imatinib)**

<table>
<thead>
<tr>
<th>Size</th>
<th>Mitoses/50 HPF</th>
<th>Metastases</th>
<th>Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gastric GISTs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 2 cm</td>
<td>≤ 5</td>
<td>None</td>
<td>None to negligible</td>
</tr>
<tr>
<td>&gt; 2 and ≤ 5 cm</td>
<td>≤ 5</td>
<td>2%</td>
<td>Low</td>
</tr>
<tr>
<td>&gt; 5 and ≤ 10 cm</td>
<td>≤ 5</td>
<td>4%</td>
<td>Low</td>
</tr>
<tr>
<td>&gt; 10 cm</td>
<td>≤ 5</td>
<td>12%</td>
<td>Intermediate</td>
</tr>
<tr>
<td>≤ 2 cm</td>
<td>&gt; 5</td>
<td>None</td>
<td>Low</td>
</tr>
<tr>
<td>&gt; 2 and ≤ 5 cm</td>
<td>&gt; 5</td>
<td>16%</td>
<td>Intermediate</td>
</tr>
<tr>
<td>&gt; 5 and ≤ 10 cm</td>
<td>&gt; 5</td>
<td>55%</td>
<td>High</td>
</tr>
<tr>
<td>&gt; 10 cm</td>
<td>&gt; 5</td>
<td>88%</td>
<td>High</td>
</tr>
<tr>
<td><strong>Small Bowel GISTs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 2 cm</td>
<td>≤ 5</td>
<td>None</td>
<td>None to negligible</td>
</tr>
<tr>
<td>&gt; 2 and ≤ 5 cm</td>
<td>≤ 5</td>
<td>4%</td>
<td>Low</td>
</tr>
<tr>
<td>&gt; 5 and ≤ 10 cm</td>
<td>≤ 5</td>
<td>24%</td>
<td>Intermediate</td>
</tr>
<tr>
<td>&gt; 10 cm</td>
<td>≤ 5</td>
<td>52%</td>
<td>High</td>
</tr>
<tr>
<td>≤ 2 cm</td>
<td>&gt; 5</td>
<td>50%</td>
<td>High</td>
</tr>
<tr>
<td>&gt; 2 and ≤ 5 cm</td>
<td>&gt; 5</td>
<td>73%</td>
<td>High</td>
</tr>
<tr>
<td>&gt; 5 and ≤ 10 cm</td>
<td>&gt; 5</td>
<td>85%</td>
<td>High</td>
</tr>
<tr>
<td>&gt; 10 cm</td>
<td>&gt; 5</td>
<td>90%</td>
<td>High</td>
</tr>
</tbody>
</table>

**Molecular Prognostication for GISTS**

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Site</th>
<th>Prognosis</th>
<th>Likelihood of Response to Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>KIT exon 9</td>
<td>Typical of small bowel GISTs</td>
<td>Not a prognostic marker</td>
<td>Poor response to imatinib, improved by high-dose treatment; sunitinib malate (SU11248) can be used</td>
</tr>
<tr>
<td>KIT exon 11 deletions and substitutions</td>
<td>Found in all sites</td>
<td>May indicate poor prognosis</td>
<td>Complete remission (6%), partial response (61%), stable disease (25%), progressive disease (3%)</td>
</tr>
<tr>
<td>KIT exon 11 duplications</td>
<td>Gastric</td>
<td>May indicate improved prognosis</td>
<td>Complete remission (6%), partial response (61%), stable disease (25%), progressive disease (3%)</td>
</tr>
<tr>
<td>KIT exon 13 mutations</td>
<td>All sites</td>
<td>May indicate poor prognosis in gastric GISTS</td>
<td>Partial response, all cases (rare)</td>
</tr>
<tr>
<td>KIT exon 17 mutations</td>
<td>Small bowel</td>
<td>No prognostic significance</td>
<td>Variable, depending on specific mutation</td>
</tr>
<tr>
<td>PDGFRA exon 12 deletions and substitutions</td>
<td>Gastric</td>
<td>May indicate good prognosis</td>
<td>Most respond to imatinib</td>
</tr>
<tr>
<td>PDGFRA exon 14 substitutions</td>
<td>Gastric</td>
<td>May indicate good prognosis</td>
<td>No data available</td>
</tr>
<tr>
<td>PDGFRA exon 18 deletions and substitutions</td>
<td>Gastric</td>
<td>May indicate good prognosis</td>
<td>Variable and mutation specific</td>
</tr>
<tr>
<td>KIT and PDGFRA wild type</td>
<td>Typical of NF1 and Carney triad</td>
<td>No prognostic significance</td>
<td>Partial response (23%), stable disease (50%), progressive disease (19%)</td>
</tr>
</tbody>
</table>
Microscopic Features

(Left) Hematoxylin & eosin shows a spindle cell gastric GIST. Even at this low magnification, paranuclear vacuoles, usually associated with benign behavior, are numerous. (Right) Hematoxylin & eosin shows a high-power view of the previous image. In addition to prominent paranuclear vacuoles, note the brightly eosinophilic fibrillary cytoplasm; both are reminiscent of smooth muscle differentiation. Such features led early pathologists to regard GISTs as smooth muscle neoplasms.

(Left) Hematoxylin & eosin shows a spindle cell gastric GIST with enhanced cellularity in comparison to the previous lesion. Such appearances are often associated with an unfavorable outcome. (Right) Hematoxylin & eosin shows higher magnification of the same neoplasm. The lesional cells are very uniform, a feature of tumors associated with characteristic mutations.
Hematoxylin & eosin shows an epithelioid gastric GIST. It has a lobulated appearance with chondroid areas. Hematoxylin & eosin shows an epithelioid GIST at intermediate magnification. There is a chondroid background, and the tumor cells have numerous cytoplasmic vacuoles. Epithelioid gastric GISTs such as this may be CD117 negative and have PDGFRA mutations.

Microscopic and Gross Features

Hematoxylin & eosin shows an epithelioid gastric GIST. This tumor has uniform epithelioid tumor cells with prominent vacuoles. There is minimal nuclear overlap. Patients whose tumors have such features typically have a favorable outcome. Hematoxylin & eosin shows the cytologic features of an epithelioid gastric GIST. The nuclei are uniform, and there is a chondromyxoid background.
Hematoxylin & eosin shows several tiny ("seedling") GISTs near the gastroesophageal junction. These were found incidentally in a resection performed for a separate gastric carcinoma. CD34 shows prominent staining in the small GISTs in the same patient. Such incidental tumors are common (~10% of esophagectomy samples contain them); since clinically evident GISTs are rare, few of these "seedling" lesions seem to progress.

CD117 shows labeling in "seedling" GISTs. A gross photograph shows a small intestinal GIST. The bulk of the tumor is in the muscularis propria, but the lesion has extended into the submucosa and was diagnosed by mucosal biopsy. Note the overlying mucosa, which is eroded in places.

Microscopic Features
(Left) Hematoxylin & eosin shows a small intestinal GIST at low magnification. The lesion has extended into the submucosa, and the overlying mucosa appears inflamed. (Right) Hematoxylin & eosin shows prominent “skeinoid” fibers in a small intestinal GIST. These are principally found in small bowel GISTs, where they are associated with a favorable outcome.

(Left) Hematoxylin & eosin shows nuclear pleomorphism in an extraintestinal epithelioid GIST. Nuclear pleomorphism is unusual in GISTs, and its presence should prompt other diagnostic considerations. (Right) Hematoxylin & eosin shows striking cytoplasmic vacuoles in an extraintestinal epithelioid GIST. Cases such as this should be addressed as diagnoses of exclusion with an appropriate immunolabeling panel.
(Left) Hematoxylin & eosin shows peculiar tumor giant cells and plasmacytoid features in a GIST, a variant pattern. Note that the background cells have rhabdoid appearances. (Right) Hematoxylin & eosin shows a palisaded pattern in a small intestinal GIST. This lesion displayed foci of individual tumor cell necrosis. The patient presented with liver metastases. This lesion proved lethal, as is the case in ~40% of small bowel GISTs.

P.II(6):25

Microscopic Features

(Left) Hematoxylin & eosin shows a smear prepared from an aspiration biopsy specimen of a malignant gastric GIST. There is a fragment of gastric mucosa. The lesional cells do not have diagnostic features; the diagnosis was made by performing immunohistochemistry on cell block material in this case. (Right) CD117 shows both Golgi zone and membranous labeling in this extraintestinal epithelioid GIST.
CD117 shows strong diffuse labeling in a gastric spindle cell GIST. This is the usual strong staining seen in the majority of such neoplasms. However, similar CD117 expression can be encountered in other tumors. (Right) CD117 shows a higher magnification view of membranous and cytoplasmic labeling in a gastric spindle cell GIST.

CD34 shows cytoplasmic labeling in a gastric spindle cell GIST. Approximately 80% of gastric GISTs express CD34, more than those of the small bowel (~60%). (Right) MART-1 shows aberrant labeling in an epithelioid gastric GIST, a common finding that should not be misinterpreted as melanoma. Of course, melanomas can express CD117, so caution must be used in interpreting immunolabeling patterns.

Hamartomatous Polyps of GI Tract

Hamartomatous Polyps of GI Tract
Joel K. Greenson, MD

Key Facts
Terminology
- Nonneoplastic tumor that contains disorganized normal tissues
Clinical Issues
- May present with hematochezia, anemia, diarrhea, prolapse, abdominal pain, obstruction, or intussusception
Top Differential Diagnoses
- Inflammatory pseudopolyps may be indistinguishable from small juvenile polyps (JP)
- Healed inflammatory polyps are often identical to CP
- Prominent smooth muscle proliferation of prolapse can mimic a PJP
- Reactive atypia in hamartomatous polyps may mimic adenoma/dysplasia, especially in JP

Low-power view of a Peutz-Jeghers polyp shows arborizing smooth muscle bundles.
H&E shows a small nondistinctive-appearing hamartomatous polyp from a patient with Cowden syndrome. These polyps often look like healed pseudopolyps or mucosal prolapse-type polyps.

**TERMINOLOGY**

**Definitions**
- Nonneoplastic tumor that contains disorganized normal tissues

**CLINICAL ISSUES**

**Presentation**
- Hamartomatous polyps may present with hematochezia, anemia, diarrhea, prolapse, abdominal pain, obstruction, or intussusception

**MICROSCOPIC PATHOLOGY**

**Histologic Features**
- **Cowden/PTEN-hamartoma syndrome polyps**
  - Polyps may be numerous; typically small and histologically indistinct
  - Colonic polyps may just look like focal crypt distortion or healed inflammatory pseudopolyps
  - Ganglioneuromas may be seen as well as adenomas
  - Some polyps may resemble juvenile polyps
    - Older literature on juvenile polyps mentions ganglioneuromas, but these likely represented misdiagnosed cases of Cowden/PTEN-hamartoma syndrome
  - May have glycogenic acanthosis in the esophagus
- **Juvenile polyps (JP)**
  - Polyps may be in stomach, small bowel, and colon
    - Must have > 5 JP in the colon to diagnose syndrome unless positive family history or patient has 1 polyp outside of colon
    - May have isolated colonic JP and not have the syndrome
  - Eroded or ulcerated surface with expanded lamina propria
    - Large pedunculated polyps may have secondary prolapse change that may mimic Peutz-Jeghers polyps (PJP)
Cystically dilated glands are histologic hallmark, but often not present in small polyps

- PJP
  - Polyps can be found in stomach, small bowel, and colon
    - Syndrome can be diagnosed with 2 PJP, but increased cancer risk found in patients with only a single PJP
  - Polyps have arborizing bands of smooth muscle
    - Epithelium is nonneoplastic and has a lobular arrangement around muscle bundles
    - Epithelium may be misplaced within muscle, mimicking invasive carcinoma
  - Small bowel polyps most likely to have characteristic histology
  - Dysplasia is not usually found in PJP
    - Carcinoma thought to arise via a different mechanism (expanded stem cell compartment in nonpolyoid mucosa)

**Differential Diagnosis**

**Inflammatory Pseudopolyps**

- May be indistinguishable from small juvenile polyps (JP)
  - Both may have eroded surface mucosa with hypercellular lamina propria
  - Small JP may not have the cystically dilated glands that are relied on to make diagnosis
- Healed inflammatory polyps are often identical to Cowden polyps (CP)
  - Without appropriate history, CP are extremely difficult to diagnose correctly

**Polypoid Prolapsing Mucosal Folds (Prolapse-Type Polyps)**

- These benign mucosal polyps are often seen at mouth of diverticulum
- Prominent smooth muscle proliferation of prolapse can mimic a PJP
  - May only be able to exclude PJP based on location at mouth of diverticulum
  - Presences of arborizing smooth muscle favors PJP, but may not be present in very small polyps
- Other prolapse phenomena may also mimic PJP

**Hyperplastic Polyps (Gastric)**

- Based on histology, gastric JP and PJP cannot reliably be differentiated from hyperplastic polyps

**Adenoma/Dysplasia**

- Reactive atypia in hamartomatous polyps may mimic adenoma/dysplasia, especially in JP
  - This can be a tricky diagnosis when lesion is eroded/ulcerated

**Invasive Adenocarcinoma**

- Epithelial misplacement in PJP can mimic invasive adenocarcinoma
  - Misplacement typically lacks desmoplastic stroma

**Selected References**

This hamartomatous polyp has abundant smooth muscle bundles surrounding benign mucosal islands. These features are characteristic of Peutz-Jeghers polyps. (Center) This small hamartomatous polyp has an ulcerated surface with benign dilated glands typical of a juvenile polyp. Identical findings could be seen in an inflammatory pseudopolyp. (Right) H&E shows a large juvenile polyp with cystically dilated glands and an expanded lamina propria.

Small Bowel Adenocarcinoma

Key Facts

Etiology/Pathogenesis
- Uncommon primary tumor, so pathologist should look for 1 of the following diagnoses when encountered: Crohn disease, celiac disease, polyposis syndromes

Clinical Issues
- Prognosis related to stage of disease
  - Overall 5-year survival: 30.5%
- ~2,400 new cases annually in USA
  - Most found in duodenum: 55%

Microscopic Pathology
- Nearly identical to colorectal carcinoma
- Arises from adenomas or dysplasia (Crohn disease)

Top Differential Diagnoses
- Metastatic adenocarcinoma
- Adenoma with high-grade dysplasia
- Ectopic pancreas
- Endometriosis
Hematoxylin & eosin shows an adenoma on the right and an invasive adenocarcinoma on the left. Note the presence of a more complex architecture and desmoplastic stroma on the left.
Hematoxylin & eosin shows a high-power view of adenocarcinoma. The overall appearance is very similar to colorectal carcinoma. Note the dirty necrosis.

TERMINOLOGY
 Definitions

- Invasive adenocarcinoma arising in small intestine

ETIOLOGY/PATHOGENESIS
 Risk Factors

- Crohn disease
- Celiac disease
  - Relative risk ↑ 10-80x
- Polyposis syndromes
  - Familial adenomatous polyposis (FAP)
    - Germline mutation in APC gene
    - Duodenal and ampullary adenomas
    - Duodenal adenocarcinomas
  - Lynch syndrome
    - Most common heritable cause of cancer
    - Small bowel and ampullary carcinomas
  - Peutz-Jeghers syndrome
    - Hamartomatous polyposis
    - Small bowel adenocarcinoma cumulative risk: 13%
  - Neurofibromatosis type 1

- Uncommon primary tumor, so pathologist should look for 1 of the above mentioned syndromes/diseases when encountered

Molecular Genetic Alterations

- In contrast to colorectal cancer, mutations in APC gene are not present
Mutations in TP53 and SMAD4

CLINICAL ISSUES

Epidemiology
- Incidence
  - ~2,400 new cases annually in USA
  - Average age-adjusted annual incidence of 3.9:1,000,000 persons
  - 2.4% of GI tract malignancies
  - M:F = 2:1

Site
- Duodenum (55%)
- Jejunum (18%)
- Ileum (13%)
- Not otherwise specified (14%)

Presentation
- Abdominal pain
- Obstruction
- Anemia
- GI bleeding
- Jaundice, cholestatic
  - Ampullary tumors
- Weight loss

Treatment
- Surgical approaches
  - Resection of primary tumor is mainstay of therapy
    - Segmental small bowel resection with wide excision of mesentery
    - Whipple resection for ampullary/duodenal tumors
- Adjuvant therapy
  - Chemotherapy similar to that given for colorectal cancer
    - Mixed results: Number of patients is too small

Prognosis
- Related to stage of disease
  - Overall 5-year survival: 30.5%
  - Median survival: 19.7 months
- Worse prognosis for duodenal tumors compared to rest of small bowel

DIFFERENTIAL DIAGNOSIS

Metastatic Adenocarcinoma
- Presence of preexisting adenoma or dysplasia suggests small bowel primary
- Pancreatic adenocarcinoma can grow out from ampulla and mimic duodenal/ampullary primary
  - May differentiate similarly to adenoma at surface

Adenoma With High-Grade Dysplasia
- Difficult to differentiate prolapse from invasion around ampulla
  - Desmoplasia is key to diagnosis

Ectopic Pancreas
- Small biopsy specimen that shows only ducts may be misinterpreted as neoplasm

Endometriosis
- Presence of characteristic stroma helps make diagnosis
- Look for ciliated epithelium; argues against neoplasm

SELECTED REFERENCES

Hepatobiliary and Pancreas
Ampullary Adenocarcinoma

[Left] Hematoxylin & eosin shows villiform high-grade dysplasia on the surface with invasive adenocarcinoma beneath. This small bowel carcinoma arose in the setting of Crohn disease and dysplasia. (Center) Hematoxylin & eosin shows a low-power view of invasive carcinoma arising in Crohn disease. Note the hypertrophic nerve trunk and fistula tract. (Right) Hematoxylin & eosin shows a higher power view of the hypertrophic nerve and an invasive carcinoma.
- Papillary carcinoma (noninvasive)
- Invasive papillary carcinoma
- Mucinous (colloid) carcinoma
- Adenosquamous carcinoma

Ancillary Tests
- Intestinal type is usually positive for CK20 and CDX2; often negative for CK7
- Pancreatobiliary type is usually positive for CK7; often negative for CK20 and CDX2

Diagnostic Checklist
- Intestinal type of histologic differentiation is associated with favorable outcome in comparison to pancreatobiliary type

From the luminal aspect of this resection specimen, the ampulla is replaced by a protruding tumor grossly involving the duodenal mucosa of the papilla and periampullary duodenum.
This ampullary adenocarcinoma consists of an exophytic white tumor involving the orifice of the common bile duct but not invading the pancreatic duct.

**TERMINOLOGY**

**Synonyms**
- Periampullary adenocarcinoma

**Definitions**
- Adenocarcinoma arising in ampullary region and periampullary duodenal adenocarcinoma are collectively termed ampullary adenocarcinoma
  - ~90% of all carcinomas of region

**ETIOLOGY/PATHOGENESIS**

**Genetics**
- Familial adenomatous polyposis
  - Biliary tract adenocarcinoma and dysplasia

**CLINICAL ISSUES**

**Epidemiology**
- **Incidence**
  - Relatively uncommon
    - ~0.2% of GI tract malignancies
    - Ampulla is most common site of small bowel adenocarcinoma
- **Age**
  - Most common in 7th-8th decades of life
  - Patients with familial adenomatous polyposis develop ampullary carcinoma at younger age than patients with sporadic cases
- **Gender**
  - Slightly more common in men (M:F = 1.48:1)

**Presentation**
Jaundice
- Weight loss
- Abdominal pain
- Distended, palpable gallbladder (Courvoisier sign)

Treatment
- Resection (Whipple procedure)
  - Resectability is ~60%
- Role of adjuvant chemoradiation therapy (5-FU based) is controversial

Prognosis
- 5-year survival rate after surgical resection is ~50%
  - Significantly better than that of pancreatic adenocarcinoma
  - Comparable to that of duodenal adenocarcinoma

MACROSCOPIC FEATURES
General Features
- Variable gross appearance
  - Intraampullary: Arises within ampulla itself
  - Peripapillary duodenal: Arises from duodenal mucosa surrounding ampulla
  - Mixed ampullary/duodenal
- Majority arise from preexisting adenomas
- May be exophytic, ulcerated, or mixture of both

Size
- Often small
  - ~20% are < 1 cm in diameter, and 75% are < 4 cm

MICROSCOPIC PATHOLOGY
Histologic Features
- Intestinal-type adenocarcinoma
  - Most common type (> 50%)
  - Histologically indistinguishable from tumors of colorectum
- Pancreatobiliary-type adenocarcinoma
  - 2nd most common type
  - Closely resembles primary tumors of pancreas or extrahepatic bile ducts
  - High-grade nuclear pleomorphism in presence of architecturally well-formed glands
  - Desmoplastic stroma
  - Perineural invasion is common
- Papillary carcinoma (noninvasive)
  - Exophytic tumor arising in intraampullary mucosa
  - Resembles similar papillary neoplasms of pancreas or bile ducts
  - Does not invade stroma
- Invasive papillary carcinoma
  - < 10% of ampullary adenocarcinomas
  - Complex, branching papillary structures with fibrovascular cores or micropapillae
  - Diagnosis is based on papillary architecture rather than cytologic appearance
- Mucinous (colloid) carcinoma
  - < 10% of ampullary adenocarcinomas
  - Consists predominantly (> 50%) of extracellular mucin pools with floating carcinoma cells
  - Often associated with adenomatous component
- Adenosquamous carcinoma
  - < 3% of ampullary carcinomas
  - Exhibits both glandular and squamous differentiation
  - Squamous component should be significant (> 25%), but focal glandular differentiation is sufficient for diagnosis
- Other rare histologic types
  - Signet ring cell carcinoma
  - Clear cell carcinoma
  - Adenocarcinoma with hepatoid differentiation
ANCILLARY TESTS
Immunohistochemistry
- CEA and CA19-9 positive
- Intestinal type
  - Positive for CK20 and CDX2; often negative for CK7
- Pancreatobiliary type
  - Positive for CK7; often negative for CK20 and CDX2

DIFFERENTIAL DIAGNOSIS
Distal Bile Duct Carcinoma
- Majority exhibit pancreatobiliary-type histology
- Fusiform growth pattern along bile duct

Pancreatic Adenocarcinoma
- Vast majority exhibit pancreatobiliary-type histology
- Pancreatic adenocarcinoma usually arises from main pancreatic duct; ampullary involvement represents peripheral extension
- No associated ampullary adenoma

DIAGNOSTIC CHECKLIST
Clinically Relevant Pathologic Features
- Important to distinguish ampullary from pancreatic or biliary adenocarcinoma because ampullary adenocarcinomas have better prognosis

Pathologic Interpretation Pearls
- Thorough sampling to rule out invasion is warranted in noninvasive papillary carcinomas

SELECTED REFERENCES

Image Gallery
Microscopic and Immunohistochemical Features

(Left) In the intestinal type, the tumor consists of columnar cells with stratified, elongated nuclei and a cribriform pattern with luminal necrosis. This type resembles colonic adenocarcinoma. (Right) Pancreatobiliary-type adenocarcinomas consist of well-formed tubules with a single layer of cuboidal to low-columnar cells in a background
of prominent desmoplastic stroma.

(Left) Pancreatobiliary-type adenocarcinoma often features nuclear pleomorphism and atypical mitoses within architecturally well-formed glands. (Right) This nerve is partially wrapped by malignant glands. Prominent perineural invasion is a characteristic feature of pancreatobiliary-type ampullary adenocarcinomas.

(Left) This pancreatobiliary-type adenocarcinoma shows infiltrating well-formed glands that strongly express CK7. These tumors also express moderate to intense marking with CEA and CA19-9. (Right) Pancreatobiliary-type ampullary adenocarcinoma demonstrates negative expression of CK20. This type is often negative for CK20 and CDX2. Conversely, intestinal-type adenocarcinoma usually stains positively with CK20 and CDX2 and is negative for CK7.

P.II(6):33

Variant Microscopic Features
Noninvasive papillary carcinomas of the ampulla are exophytic tumors resembling similar papillary neoplasms of the pancreas or bile ducts. They have a pushing border and no submucosal invasion. In some areas, this noninvasive papillary tumor exhibits enlarged nuclei with nuclear stratification, scattered mitoses, and micropapillary architecture.

This signet ring cell adenocarcinoma is associated with a large tubulovillous adenoma with high-grade dysplasia. The infiltrating component consists of clusters of single signet ring cells in a background of mucinous or desmoplastic stroma. Although pure signet ring cell carcinoma is rare in the ampulla, the presence of signet ring cells as a minor component is not uncommon.
This mucinous carcinoma shows a strip of malignant cells and a cluster of malignant cells with a cribriform pattern suspended in extracellular mucin pools. (Right) This adenosquamous carcinoma contains a component of keratinizing squamous cell carcinoma as well as a glandular component. The squamous component should be significant (>25%) to support the diagnosis of adenosquamous cell carcinoma.

**Hepatoblastoma**

- Table of Contents > Part II - Diagnoses Associated With Specific Syndromes > Section 6 - Gastrointestinal > Hepatobiliary and Pancreas > Hepatoblastoma

Hepatoblastoma
Grace E. Kim, MD
Joel K. Greenson, MD

**Key Facts**

- **Etiology/Pathogenesis**
  - Aberrant Wnt/β-catenin activation

- **Clinical Issues**
  - Most common malignant liver neoplasm in children
  - Typically presents with abdominal mass
  - Most patients have increased serum α-fetoprotein
  - Key prognostic factor of survival is tumor stage
    - May require preoperative chemotherapy before tumor is resectable

- **Microscopic Pathology**
  - Most common component is epithelial subtypes
    - Pure fetal epithelial histology is associated with favorable prognosis
    - Commonly embryonal and fetal epithelial patterns are seen together
    - Macrotabular is composed of fetal- or embryonal-type cells in wide trabeculae
    - Any amount of small undifferentiated cells often resembling neuroblasts is associated with poorer prognosis
  - Mixed hepatoblastoma (HB) is composed of epithelial and mesenchymal components
    - Mesenchymal component can be immature spindle cells to fibrous tissue
    - Osteoid-like and even teratoid elements can be found

- **Top Differential Diagnoses**
  - Normal liver parenchyma; positive nuclear &/or cytoplasmic β-catenin staining in HB
  - Hepatocellular carcinoma; presence of both fetal and embryonal cells is diagnostic of HB
Pure fetal histology consists of uniform polygonal cells that are smaller than normal hepatocytes, have round nuclei, no nucleoli, and clear cytoplasm. This pattern is clinically significant.
The amount of small undifferentiated cells (bottom right field) should be reported. In contrast, the fetal epithelial cells above have abundant cytoplasm with variable amounts of glycogen.

**TERMINOLOGY**

**Abbreviations**

- Hepatoblastoma (HB)

**Definitions**

- Predominantly pediatric liver tumor that histologically mimics developing fetal or embryonal liver

**ETIOLOGY/PATHOGENESIS**

**Genetics**

- Neoplasm: β-catenin mutation-associated Wnt pathway activation in 70-90%

**CLINICAL ISSUES**

**Epidemiology**

**Incidence**

- Constitutes 2.1% of all pediatric cancers among patients between 1 and 19 years of age
- Increased reporting in low-birth-weight infants but etiology is unknown

**Age**

- Most common malignant liver neoplasm in children
- 88% in children ≤ 5 years and 3% > 15 years
- Mean age at diagnosis: 19 months

**Gender**

- Male predominance
  - M:F = 3:2

**Site**

- 58% involve right lobe
- 27% involve both lobes

**Presentation**
Painless abdominal mass
Hepatomegaly

Laboratory Tests
Increased serum α-fetoprotein in 75-96% of patients
   Often ≥ 100,000 ng/mL
   Caveat: Neonates < 6 months of age normally have elevated α-fetoprotein
   Useful marker of response to therapy and recurrence

Treatment
Surgical resection
   Only 1/3 to 1/2 have resectable disease at presentation
   Preoperative chemotherapy converts > 50% of inoperable tumors to resectable tumors
Orthotopic liver transplant

Children's Oncology Group Staging System (Pretreatment Staging)
Stage I: Completely resected tumors with negative margins
Stage II: Grossly resected tumors with residual disease
   Microscopic positive margin
Stage III: Unresectable tumors
   Biopsy diagnosis, partially resected, macroscopic residual tumor, tumor rupture
   Positive abdominal lymph node
Stage IV: Tumors with metastasis to lungs, other organs, or sites distant from abdomen

Prognosis
   Tumor stage is key prognostic factor in survival
   90% event-free survival with primary complete resection of tumor
   < 70% event-free survival in those with nonmetastatic, unresectable tumor

Metastasis
   10-20% of patients have metastases at presentation
   Most frequently spread to lung but can involve bone, brain, eye, or ovaries

P.II(6):35

20-30% survival if there is metastatic disease at presentation

Conditions Associated With HB
   Familial adenomatous polyposis, Beckwith-Wiedemann, Li-Fraumeni, and Simpson-Golabi-Behmel syndromes
   Trisomy 18, glycogen storage disease types I-IV, and hemihypertrophy
   No known histologic features predict syndromic tumors

IMAGE FINDINGS
Radiographic Findings
   Solitary or multifocal mass
   Heterogeneous and hypervascular
   Calcification is frequently observed

MACROSCOPIC FEATURES
General Features
   Solitary or multifocal, coarsely lobulated, heterogeneous mass
   Fetal pattern areas resemble normal liver, light brown and moderately firm
   Embryonal and small cell patterns are softer, fleshy to gelatinous, gray-tan or pale pink
   Mesenchymal, osteoid-like areas are firm, fibrous, or calcified
   Teratoid, melanotic component may be dark brown or black
   Carefully search for vascular invasion

Size
   Large; can be > 15 cm

MICROSCOPIC PATHOLOGY
Histologic Features
   Epithelial patterns
   Fetal
   Uniform cells arranged in slender cords (2-3 cells thick) and thin trabeculae
   Fetal epithelial cells are smaller than normal hepatocytes
   Central round to oval nuclei, inconspicuous nucleolus, and abundant clear to pink cytoplasm
   with distinct membrane
   Alternating light and dark areas based on cytoplasmic glycogen content; may have fat
Low mitotic index (≤ 2 mitoses/10 high-power fields)

Crowded fetal (fetal with mitoses)
Similarities to pure fetal pattern, but cells are closely packed and have higher mitotic count (≥ 2 mitoses/10 high-power fields)
Slightly increased nuclear to cytoplasmic ratio, round nuclei, and eosinophilic cytoplasm
Intermixed with pure fetal pattern and merged into embryonal pattern; can be difficult to differentiate

Embryonal
Primitive cells in sheets, pseudorosettes, acini, or tubules
Small, angulated nuclei (larger than fetal nuclei) with coarse nuclear chromatin, prominent nucleoli, scant cytoplasm, indistinct membranes
Mitotic figures more frequent

Small undifferentiated
Can be difficult to recognize and diagnose
Resembles neuroblast, blastemal cells, or cells found in “small round blue cell” neoplasms
Grows in sheets, lacks cohesiveness, and is infiltrative
High nuclear to cytoplasmic ratio with almost no cytoplasm, hyperchromatic nuclei, inconspicuous nucleoli

Can have rhabdoid-like cells with eccentric cytoplasm
Variable mitotic rate
Extramedullary hematopoiesis occurs in fetal and embryonal patterns
Not useful to distinguish these epithelial patterns based on this finding alone

Mesenchymal component
Highly cellular primitive mesenchymal cells (immature spindle cells) with scant cytoplasm and elongated, plump nuclei
Collagenous stroma with loose fibrosis &/or mature fibrous tissue
Osteoid-like areas
Immunoreactive for cytokeratin and epithelial membrane antigen; a metaplastic phenomenon
Bone, cartilage, and rhabdomyoblasts

Teratoid component
Primitive neuroglia, ganglion cells, or melanin pigment
Can also show bone, cartilage, rhabdomyoblasts, squamous cells, and mucinous glands

Morphologic Classification
Epithelial HB (majority of HBs)
Epithelial patterns can occur alone or in combination with other epithelial patterns
Embryonal subtype alone or with fetal component
Squamous epithelium and mucinous glands can be part of an epithelial HB

Pure fetal histology HB
100% composed of fetal epithelial cells, not crowded fetal
Low mitotic index (≤ 2 mitoses/10 high-power fields)

Macrotrabecular HB
Fetal &/or embryonal cells in wide trabeculae, > 10 cells thick

Small undifferentiated or small cell anaplastic HB
For a diagnosis of pure small undifferentiated HB, > 70% of tumor must be composed of small undifferentiated cells
Any amount of small undifferentiated cells should be reported; provide percentage of small undifferentiated cells
May be located toward center of an embryonal region

Mixed HB
Both epithelial and mesenchymal elements

Mixed HB with teratoid (heterologous) features

Prognostic Factors
Stage IV associated with uniformly poor prognosis (39% 5-year, event-free survival)

Histology
Pure fetal epithelial HB is associated with excellent prognosis (100% 5-year, event-free survival)
Worse prognosis than pure fetal epithelial HB seen in
HB with any amount of small cell undifferentiated cells
Potentially macrotrabecular HB
α-fetoprotein < 100 ng/mL confers worse prognosis

ANCILLARY TESTS

Immunohistochemistry
- Nuclear β-catenin staining in epithelial and mesenchymal components (70% of HB)
- Positive in small undifferentiated cells
- Positive glypican-3 and Hep-Par1 staining in fetal and embryonal epithelial cells
- Positive glutamine synthetase staining in fetal and variably in embryonal cells
- INI1/BAF47 loss in some small undifferentiated cells, especially if rhabdoid phenotype

DIFFERENTIAL DIAGNOSIS

Normal Liver Parenchyma
- Must distinguish fetal epithelial cells of hepatoblastoma from normal hepatocytes, particularly near a margin
  - HB has nuclear &/or cytoplasmic immunoreactivity for β-catenin
  - Fetal cells are smaller than normal hepatocytes

Hepatocellular Carcinoma
- May be indistinguishable from macrotrabecular variant of HB
  - Biphasic pattern with both fetal and embryonal cells points to HB
  - Nuclear β-catenin and glypican-3 are more consistently positive in HB

DIAGNOSTIC CHECKLIST

Clinical Relevant Pathologic Features
- Stage I pure fetal HB cured by surgical resection alone
- Important to report any amount of small undifferentiated cells; confers worse prognosis

SELECTED REFERENCES

P.II(6):37

Image Gallery
Microscopic Features

(Left) Sheets and poorly formed nests of embryonal epithelial cells have angulated nuclei and less cytoplasm than fetal epithelial cells, which can often coexist within the same tumor. Embryonal cells have nuclear or cytoplasmic reactivity
to β-catenin and are diffusely positive for glypican-3. (Right) Macrotrabecular HB can mimic hepatocellular carcinoma at low power. Look for mesenchymal components or fetal epithelial pattern to assist in the diagnosis.

(Left) This HB shows embryonal epithelial cells merging into a focus of small undifferentiated cells. The latter have even less cytoplasm and are often dyscohesive. These cells look like neuroblasts or blastemal cells but have positive nuclear stain for β-catenin. Even a microscopic focus of small undifferentiated cells confers a poorer prognosis. (Right) This mixed HB has embryonal epithelial cells, spindled mesenchymal component, and a focus of osteoid-like tissue.

(Left) This mixed HB has neoplastic epithelial cells in cords, squamoid nests within dense fibrous stroma, and an osteoid-like focus. This is not considered a mixed HB with teratoid features because there is no neural or neuroectodermal differentiation. (Right) Immunohistochemical staining for β-catenin can be useful. The liver parenchyma shows membranous staining of normal hepatocytes whereas the hepatoblastoma shows nuclear staining in neoplastic cells.

Hepatocellular Carcinoma

Hepatocellular Carcinoma

Joel K. Greenson, MD
Joseph Misdraji, MD

Key Facts
Chronic viral hepatitis is leading cause of hepatocellular carcinoma (HCC) worldwide.

70-90% of HCC arises in cirrhosis.

Handful of hepatocellular adenomas and carcinomas reported in familial adenomatous polyposis.

In USA, annual incidence is ~4 per 100,000.

α-fetaprotein (AFP) is elevated in 70-90% of patients.

In USA, 5-year survival is 30-40% overall, but 75% for tumors < 5 cm.

Typically soft, bile-stained with hemorrhage and necrosis.

Can be solitary tumor, multiple discrete tumors, or small indistinct nodules throughout portion of liver.

Gross venous or bile duct invasion commonly occurs.

Grows as thickened hepatic plates separated by sinusoids without desmoplastic stroma.

Tumor cells resemble hepatocytes with polygonal shape, round vesicular nuclei, and prominent nucleoli.

Bile pigment in dilated canaliculi is helpful in distinguishing HCC from its mimics.

Positive for Hep-Par1, glypican-3, and CAM5.2 (CK8 and CK18).

Gross photograph shows a large bile-stained tumor nodule in a background of cirrhosis. This is a classic presentation of hepatocellular carcinoma.
Hepatocellular carcinoma is typically composed of neoplastic cells resembling hepatocytes with a high nuclear to cytoplasmic ratio, which are organized into thick, disordered trabeculae.

**TERMINOLOGY**

**Abbreviations**
- Hepatocellular carcinoma (HCC)

**Synonyms**
- Hepatoma

**Definitions**
- Primary malignant neoplasm of liver with hepatocytic differentiation

**ETIOLOGY/PATHOGENESIS**

**Developmental Anomaly**
- HCC can occur in patients with various congenital anomalies, including Alagille syndrome, ataxia-telangiectasia, Abernethy malformation, and bile salt export protein (BSEP) deficiency

**Environmental Exposure**
- Aflatoxin B1, a mycotoxin produced by fungi of Aspergillus genus that contaminates food, is major cause of HCC in China and southern Africa
- Alcoholic cirrhosis is major cause of HCC in Western populations
- Other exposures linked to HCC include anabolic steroids, Thorotrast, oral contraceptives, and smoking

**Infectious Agents**
- Chronic viral hepatitis (hepatitis B and hepatitis C) is leading cause of HCC worldwide

**Genetic Disorders**
- Handful of hepatocellular adenomas and carcinomas reported in familial adenomatous polyposis
- Increasing rate of hepatoblastomas in male infants

**Metabolic**
- Various metabolic disorders, including hemochromatosis, tyrosinemia, hypercitrullinemia, α-1-antitrypsin deficiency, and fructosuria, are associated with increased risk of HCC

**Cirrhosis**
70-90% of HCC arises in cirrhosis
Macronodular cirrhosis is more strongly associated with HCC than is micronodular cirrhosis

Progression of Benign Tumor
HCC can arise in preexisting hepatocellular adenoma

CLINICAL ISSUES
Epidemiology
Incidence
- Varies widely depending on geography in parallel with prevalence of hepatitis B, hepatitis C, and aflatoxin exposure
  - East Asia and southern Africa have highest incidence worldwide, up to 150 per 100,000
  - In USA, annual incidence is ~4 per 100,000
Age
- Incidence increases with advancing age and then falls off in elderly patients; however, average age varies depending on geography
  - In parts of world with high incidence, average age is 35 years
  - In USA, average age is 60 years
Gender
- Can occur in children, particularly in those with metabolic or genetic disorders

Presentation
Abdominal pain due to stretching of Glisson capsule
Malaise, weight loss, hepatomegaly

Decompensation of previously stable cirrhotic patient with jaundice and rapidly accumulating ascites
Fever, leukocytosis, and liver mass mimicking hepatic abscess
Increasingly, small asymptomatic tumors are being found during surveillance of cirrhotic patients

Laboratory Tests
- α-fetoprotein (AFP) is elevated in 70-90% of patients

Natural History
Metastasis occurs in 40-60% of patients
- Most common locations are lymph nodes in porta hepatis, celiac axis, and around pancreas
HCC has tendency for intravascular spread with involvement of hepatic and portal veins
  - Hematogenous spread most commonly occurs to lungs, but also adrenal glands, bone, stomach, heart, pancreas, kidney, spleen, and ovary
Tumor seldom breaches Glisson capsule; therefore, dissemination throughout peritoneal cavity is rare

Treatment
Surgical approaches
- Resection is possible if sufficient reserve liver function
- Transplantation is option if patient meets Milan criteria of single tumor < 5 cm, or < 4 tumors, none > 3 cm
Drugs
- Sorafenib
  - Tyrosine kinase inhibitor that has proven to be at least somewhat effective in advanced cases
Ablation therapy
- Radiofrequency or microwave ablation or direct percutaneous ethanol injections are options for small tumors
- Angiographic embolization of hepatic artery can infarct tumor and prolong survival

Prognosis
- Better prognosis associated with age < 50 years, female gender, resectable tumor, better differentiated tumor, low mitotic index, absence of vascular invasion, encapsulated tumor, and absence of cirrhosis
- In USA, 5-year survival is 75% for patients with tumors < 5 cm and 30-40% overall

MACROSCOPIC FEATURES
General Features
- Soft tumor that can be bile-stained, with variable hemorrhage and necrosis
- Can be solitary tumor, solitary tumor with satellite nodules, multiple discrete tumors, or multiple small indistinct nodules throughout portion of liver or entire liver
  - Pedunculated tumors are rare, more easily resected, and have better prognosis
Encapsulated tumors are rare, usually solitary tumors that arise in cirrhotic livers, and have better prognosis.

Gross venous or bile duct invasion may be seen and should be sought.

**MICROSCOPIC PATHOLOGY**

**Histologic Features**

**Architectural patterns**

- **Trabecular pattern:** Tumor cells grow as thickened hepatic plates separated by sinusoids without desmoplastic stroma.
- **Pseudoglandular or acinar pattern:** Tumor cells grow in solid nests with central degenerative changes.
- **Compact pattern:** Trabeculae grow compressed together.
- **Scirrhous pattern:** Resemble trabecular HCC but with abundant stroma.
- **Giant cell pattern:** Multinucleate giant cells.

P.II(6):40

Spindle cell pattern is often referred to as sarcomatoid HCC.

**Tumor cell morphology**

- Tumor cells resemble hepatocytes with polygonal shape, round vesicular nuclei, and prominent nucleoli.
- Inclusions can be seen in tumor cells, including Mallory hyaline, hyaline globules, and pale bodies.
- Clear cells may be present and even numerous due to accumulation of glycogen, water, or fat.
- Presence of bile pigment in dilated canaliculi is helpful in distinguishing HCC from its mimics.

**Cytologic Features**

- Neoplastic cells resemble hepatocytes but with enlarged nuclei, nuclear membrane irregularity, coarse chromatin, and prominent macronucleoli.
- May have dispersed cell pattern with numerous stripped, atypical nuclei.
- Tumor cells tend to be more monotonous with less anisonucleosis and higher nuclear to cytoplasmic ratio than benign hepatocytes.
- Thick, disordered plates or balls of neoplastic cells, focally lined by sinusoidal endothelial cells (“endothelial wrapping”).
- Large tissue fragments traversed by blood vessels.

**Fibrolamellar Variant**

- 5% of hepatocellular carcinomas.
- Arises in noncirrhotic livers.
- Affects both sexes equally, usually < 35 years of age.
- Better prognosis than conventional HCC; 5-year survival rate of ~50%.
- Grossly has lobular appearance with fibrous septa or central stellate scar.
- Nests and sheets of large, eosinophilic, polygonal tumor cells with vesicular nuclei and prominent nucleoli separated by fibrous stroma.

**ANCILLARY TESTS**

**Histochemistry**

- Reticulin.
  - Reactivity: Not applicable.
  - Staining pattern: Diminished or absent in sinusoids; may outline abnormally thick trabeculae as well.

**Immunohistochemistry**

- Positive for Hep-Par1, glypican-3, and CAM5.2 (CK8 and CK18).
- AFP staining is highly specific but insensitive (25%).
- Polyclonal CEA and CD10 demonstrate canalicular pattern.
- Sinusoidal capillarization demonstrated with CD34.

**DIFFERENTIAL DIAGNOSIS**

**Cholangiocarcinoma**

- Mucicarmine (+); expresses CK7, CK19, and CA19-9.
- Desmoplastic stroma.
- Mixed HCC/cholangiocarcinoma may show features of both.

**Metastatic Neuroendocrine Tumor**

- Prominent collagenous stroma; positive staining for neuroendocrine markers.

**Metastatic Adenocarcinoma**

- Mucicarmine (+); MOC-31(+), keratin profile not limited to 8 and 18.
Angiomyolipoma
Presence of adipose tissue and muscular arteries; HMB-45(+), Hep-Par1(-)

Renal Cell Carcinoma
History of renal cell carcinoma or renal tumor, no cirrhosis
Hep-Par1(-), pax-2(+), pax-8(+)

Hepatic Adenoma
Patient demographics differ; cirrhosis is absent, and trabeculae are at most 2 or 3 cells thick

Regenerative Nodule in Cirrhosis
Cytologically benign, absence of trabecular or pseudoglandular growth pattern
Portal tracts present in nodule
Intact reticulin

Dysplastic Nodule in Cirrhosis
Cytologic atypia and mild architectural abnormalities
Contains portal tracts, lacks invasion of portal tracts by tumor
Intact reticulin

GRADING
Edmondson and Steiner
Grade I (well differentiated): Small hepatocytic tumor cells arranged as trabeculae
Grade II (moderately differentiated): Larger tumor cells with abnormal nuclei and eosinophilic cytoplasm; pseudoglandular structures may be seen
Grade III (poorly differentiated): More frequent tumor giant cells
Grade IV (undifferentiated): Poorly differentiated tumor cells with hyperchromatic nuclei, little cytoplasm, and loss of trabecular architecture

SELECTED REFERENCES
P.II(6):41

Image Gallery
Gross and Microscopic Features

(Left) This large, multinodular hepatocellular carcinoma (HCC) arises in a background of cirrhosis. (Right) This hepatocellular carcinoma is unifocal, yellow-tan, and well circumscribed. The background liver is not cirrhotic.
This hepatocellular carcinoma arose in a background of hereditary hemochromatosis; note the rust-colored cirrhotic liver in the background. There is also central necrosis. (Right) This hepatocellular carcinoma is composed of a large central mass with small satellite tumor nodules. There is a background of cirrhosis.

This example of the diffuse pattern of HCC shows innumerable small white-tan nodules of a tumor in a background of cirrhosis. Careful inspection shows that 2 of these nodules represent gross venous invasion. (Right) A histologic section of a tumor shows venous invasion by HCC. A portal vein is distended and filled with trabeculae of hyperchromatic neoplastic cells. Note the adjacent accompanying bile duct.

Microscopic Features
The trabecular pattern of hepatocellular carcinoma is characterized by thickened trabeculae separated by sinusoids. In this focus, the trabeculae appear to be ~6-8 cells thick. (Right) This hepatocellular carcinoma is growing in a pattern of rounded trabeculae with central degenerative changes.

In the pseudoglandular pattern of hepatocellular carcinoma, dilated spaces in the centers of trabeculae mimic glands. (Right) This example of sarcomatoid hepatocellular carcinoma has extensive spindle cell change. Notice the interlacing of spindle cells with more compact epithelioid tumor cells.
These tumor cells in HCC contain pale eosinophilic inclusions (presumably fibrinogen) in the cytoplasm that are known as pale bodies. (Right) Mallory hyaline can be seen in hepatocellular carcinoma. In this tumor, many of the tumor cells contain an oval eosinophilic inclusion. Although Mallory hyaline in HCC can have the characteristic ropey appearance of alcoholic hyaline, it often is more globular and rounded.

Microscopic and Gross Features and Variants

(Left) The clear cell variant of hepatocellular carcinoma contains tumor cells with abundant glycogen in the cytoplasm, creating a clear appearance reminiscent of clear cell renal cell carcinoma. (Right) Metastatic renal cell carcinoma in the liver is easily mistaken for the clear cell variant of hepatocellular carcinoma. This patient had an identical renal tumor excised a few years prior to the development of this tumor in the liver.
This giant cell variant of hepatocellular carcinoma features striking multinucleated tumor giant cells. An area of more typical HCC is present at the periphery of the field. (Right) The scirrhous pattern of HCC has prominent stroma and may form a large central fibrous scar that can mimic focal nodular hyperplasia or the fibrolamellar variant of HCC. However, the other histologic features of fibrolamellar variant of HCC are absent.

The fibrolamellar variant of hepatocellular carcinoma typically has a lobular growth pattern and central scar. Also note the absence of cirrhosis in the background liver. (Right) Clinically, this fibrolamellar HCC in a young woman was thought to be focal nodular hyperplasia. Note the lobular growth pattern and central scar, which are typical of both focal nodular hyperplasia and fibrolamellar HCC.

Microscopic Features
Low-power view of fibrolamellar HCC shows cords of neoplastic hepatocytes separated by parallel arrays of collagenous stroma. High magnification of fibrolamellar HCC shows fibrous septae composed of parallel collagen fibers separating trabeculae of plump eosinophilic tumor cells.

In the fibrolamellar variant of HCC, the tumor cells are large, eosinophilic, and polygonal. They have large, vesicular nuclei with prominent nucleoli. The eosinophilic cytoplasm is due to large numbers of mitochondria.

Hep-Par1 immunohistochemical stain in hepatocellular carcinoma shows strong positive cytoplasmic staining.
Polyclonal CEA immunostain shows staining of bile canaliculi in hepatocellular carcinoma, producing a so-called canalicular pattern. This is in contrast to the pattern typical of ductal adenocarcinoma in which diffuse cytoplasmic staining is seen. (Right) CD34 in hepatocellular carcinoma stains the sinusoidal endothelium. The sinusoids in hepatocellular carcinoma become “capillarized” and thus express antigens normally found in capillary endothelium but not in normal sinusoidal endothelium.

P.II(6):45

Microscopic and Cytologic Features

(Left) Reticulin stain in hepatocellular carcinoma demonstrates an abnormal trabecular growth pattern with thickened, disorganized trabeculae. Reticulin is also frequently reduced in amount or even absent in HCC. (Right) Fine-needle aspiration (FNA) biopsy smear of HCC shows a trabecular growth pattern composed of thick trabeculae of neoplastic hepatocytes. Endothelial wrapping is present at the edges of the tumor.
(Left) Note the smooth contours of this group of HCC cells from an FNA created by endothelial wrapping. Note the increased nuclear density. (Right) This FNA biopsy smear of HCC shows a large cluster of neoplastic hepatocytes with traversing blood vessels typical of this tumor. A similar phenomenon occurs commonly in renal cell carcinoma.

(Left) This FNA smear of an HCC shows innumerable stripped atypical nuclei scattered throughout the slide. This pattern is not an uncommon one for HCC. (Right) In this air-dried preparation the malignant hepatocytes contain cytoplasmic inclusions, consistent with Mallory hyaline. Note that many of the inclusions appear round or more oval than they do in alcohol-related Mallory hyaline.

Pancreatic Ductal Adenocarcinoma

> Table of Contents > Part II - Diagnoses Associated With Specific Syndromes > Section 6 - Gastrointestinal > Hepatobiliary and Pancreas > Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma
Mari Mino-Kenudson, MD
Joel K. Greenson, MD
Key Facts
Terminology
  Adenocarcinoma arising in pancreatic ductal system
  Comprises 85-90% of all pancreatic neoplasms
Etiology/Pathogenesis
  Hereditary risk factors
Family history of pancreatic cancer
Hereditary pancreatitis
Peutz-Jeghers syndrome
Familial atypical multiple mole melanoma syndrome
BRCA2 and BRCA1 mutations

Clinical Issues
Most cases are unresectable at presentation
Nonspecific symptoms often mean delay in diagnosis

Macroscopic Features
Majority in head of pancreas
Poorly defined, firm mass with intense fibrotic reaction
Carcinoma may be difficult to distinguish from background pancreatitis

Microscopic Pathology
Small, haphazardly infiltrating glands embedded in dense desmoplastic stroma
Many histologic patterns and variants
Immunopositive for many antigens
Cytokeratins 7, 8, 18, 19
CEA, CA19-9, CA125, B72.3
MUC1, MUC4, MUC5AC, and MUC6 (25%)

This gross photograph shows the cut surface of a large pancreatic adenocarcinoma. The surface is firm, white, and gritty. Note the dilated pancreatic duct ➔.
Perineural invasion is a common feature of pancreatic ductal adenocarcinoma.

**TERMINOLOGY**

**Abbreviations**
- Pancreatic ductal adenocarcinoma (PDAC)

**Synonyms**
- Pancreatic adenocarcinoma
- Duct cell adenocarcinoma

**Definitions**
- Malignant epithelial neoplasm arising in pancreatic ductal system
- 85-90% of all pancreatic neoplasms
- Predominantly glandular differentiation

**ETIOLOGY/PATHOGENESIS**

**Hereditary Risk Factors**
- Family history of pancreatic cancer
- Hereditary pancreatitis
- Peutz-Jeghers syndrome
- Familial atypical multiple mole melanoma syndrome
- BRCA2 and BRCA1 mutations

**Medical Risk Factors**
- Chronic pancreatitis
- Diabetes mellitus
- Previous cholecystectomy or partial gastrectomy

**Environmental and Occupational Risk Factors**
- Cigarette smoking approximately doubles risk
- Diet high in meat, fat, nitrates, and pork products ↑ risk
- Obesity
- Chemicals (solvents, DDT, gasoline)
Occupational (coal gas workers, metal working, hide tanning, dry cleaning)

Precursor Lesions
- Pancreatic intraepithelial neoplasia

CLINICAL ISSUES
Epidemiology

Age
- Peak incidence in 7th and 8th decades
- Rare before age 40

Gender
- M > F (1.3:1)

Ethnicity
- More common in Maoris, native Hawaiians, and African Americans in the United States

Presentation
- Very nonspecific symptoms may result in delay in diagnosis
  - Epigastric pain radiating to the back
  - Weight loss
  - Painless jaundice
  - Signs of biliary obstruction

Disease associations
- Trousseau syndrome (migratory thrombophlebitis)
- Diabetes mellitus
- Sister Mary Joseph sign (palpable periumbilical nodules)
- Courvoisier sign (distended, palpable gallbladder)

Treatment
- Resection
  - Only 10-20% of cases are resectable at diagnosis
- Chemotherapy before resection, after resection, or both
  - Gemcitabine seems most promising

Prognosis
- Dismal
  - Overall 5-year survival is < 5%

IMAGE FINDINGS
General Features
- CT scan is most commonly used radiological method for diagnosis and staging
- Magnetic resonance angiography can be used to examine vascular anatomy and determine resectability
- Endoscopic ultrasound is also very reliable for diagnosis and staging
- ERCP/MRCP help visualize ductal system

MACROSCOPIC FEATURES
General Features
- Majority in head of pancreas
- Minority in body or tail
- Minority diffusely involves whole gland
- Solitary (majority) or multifocal
- Firm, solid, poorly defined, white-yellow mass
  - May have cystic degeneration
- Usually intense fibrotic reaction
  - May make carcinoma difficult to distinguish from background pancreatitis
- Pancreatic duct may be dilated
- May cause stenosis of common bile duct
- Tumors often grossly extend beyond pancreas

MICROSCOPIC PATHOLOGY
Histologic Features
- Invasive malignant glands
  - Range from very well-differentiated to very poorly differentiated
  - Glands grow in haphazard fashion and are very infiltrative
- Nuclear features
Nuclear crowding and overlapping
Nuclei vary in size, shape, and intracellular location from cell to cell within a given neoplastic gland
Loss of polarity
Irregular chromatin distribution
Irregular nuclear contour
Dense desmoplastic stroma
Fibroblasts and other inflammatory cells
Neoplastic tumor cells may represent only small component of tumor mass with rest made up of desmoplastic reaction
Mucin production
Perineural invasion is very common
Present in > 75% of cases
Angiolympathic invasion is common
Tumor may infiltrate larger blood vessels and cause thrombi
Tumor cells may grow along basement membrane of adjacent intact epithelium, such as in pancreatic ducts (cancerization), bile duct, and duodenum
Associated pancreatitis is common
Parenchymal atrophy
Fibrosis
Islet cell clustering (“pseudohyperplasia”)

ANCILLARY TESTS
Immunohistochemistry
Positive for cytokeratins 7, 8, 18, 19
Positive for CEA, CA19-9, CA125, B72.3
Positive for MUC1, MUC4, MUC5AC, and MUC6 (25%)
Positive for claudin-4, fascin, mesothelin, PSCA (60%), $100$ proteins
Loss of nuclear expression of p16 (> 90%) and SMAD4 (55%)
Overexpression of p53 (50-75%)

Histologic Patterns and Variants
Foamy gland pattern
Deceptively bland, benign-appearing cells with microvesicular cytoplasm
Mimics pancreatic intraepithelial neoplasm (PanIN), benign glands, or histiocytes
Clear cell pattern
P.II(6):48

Clear cytoplasm resembles renal cell carcinoma
Common focal finding in conventional ductal adenocarcinoma
Colloid carcinoma
Neoplastic epithelial cells suspended in large pools of extracellular mucin
Colloid component must comprise at least 80% of tumor
Almost always arises in association with intraductal papillary mucinous neoplasm (IPMN)
Signet ring cell carcinoma
At least 50% of tumor composed of infiltrating, noncohesive cells with intracytoplasmic mucin
Adenosquamous carcinoma
Squamous differentiation in at least 30% of entire lesion
Large duct adenocarcinoma
Composed of large, dilated, invasive glands, often with simple architecture
May simulate (dilated) PanIN
Microadenocarcinoma pattern
Small uniform cells arranged in microglandular structures
Represents a mixture of ductal adenocarcinoma, endocrine neoplasm, and acinar cell carcinoma
Medullary carcinoma
Poorly differentiated carcinoma with pushing rather than infiltrating borders
Associated with microsatellite instability, hereditary nonpolyposis colorectal cancer (HNPCC)
Undifferentiated carcinoma ± osteoclast-like giant cells
May have giant cell, spindle cell, or glandular component
Hepatoid carcinoma
Significant component demonstrates hepatocellular differentiation
DIFFERENTIAL DIAGNOSIS

Chronic Pancreatitis
- Often involves younger patients (< 40 years)
- Diffuse scarring of gland without a discrete mass
- Relatively preserved lobular architecture

Normal/Reactive Duct Changes
- Very well-differentiated tumors may mimic normal or reactive pancreatic ducts but can be distinguished by:
  - Small glands immediately adjacent to muscular arteries without intervening stroma or acini
  - Incomplete gland formation
  - Disorganized, haphazard growth of neoplastic glands
  - 4x variation in nuclear size within single gland

Ampullary/Periampullary Carcinomas
- Differentiation from PDAC is based on epicenter of mass grossly and presence of precursor lesions

Acinic Cell Carcinoma
- Highly cellular carcinoma with acinar, trabecular, &/or solid patterns
- Eosinophilic granular cytoplasm
- Basally located nuclei with single prominent nucleolus
- Positive for trypsin and chymotrypsin
- Negative for CK7

Neuroendocrine Neoplasms
- Nesting &/or trabecular patterns
- Often have hyalinized stroma
- Uniform nuclei with salt-and-pepper chromatin
- Positive for chromogranin, synaptophysin

DIAGNOSTIC CHECKLIST

Clinically Relevant Pathologic Features
- Perineural or angiolymphatic invasion in retroperitoneal soft tissue margin is underrecognised basis for surgical failure
  > 1/2 of patients have extrapancreatic nerve involvement in this area
- Lymph node metastases are present at time of surgery in 70-80% of patients

SELECTED REFERENCES
  P.II(6):49

Image Gallery

Microscopic Features
Ductal adenocarcinoma typically features small to medium-sized glands with haphazard growth embedded in dense desmoplastic stroma. Cytologic clues to the diagnosis of well-differentiated pancreatic adenocarcinoma include variation in nuclear size, haphazard arrangement of nuclei, irregular nuclear membranes, and mitoses.

Glands directly adjacent to a muscular artery are a clue to malignancy. Note the prominent mitoses and irregular nuclear membranes in these neoplastic glands. This photograph shows small infiltrating malignant glands directly adjacent to a muscular artery without intervening acinar parenchyma. This abnormal growth pattern is a sign of malignancy.
This well-differentiated malignant gland is present within the peripancreatic fat. The foamy gland pattern features well-formed glands with clear foamy cytoplasm. In this case, the tumor infiltrates the muscularis propria of the duodenum.

P.II(6):50

Microscopic Features

This foamy gland pattern features basally located round nuclei, microvesicular cytoplasm, and distinctive cytoplasmic condensation (brush border-like zone). The cytology is deceptively bland and mimics pancreatic intraepithelial neoplasm (PanIN) 1A. This high-power photograph of the foamy gland pattern shows a group of cells with microvesicular cytoplasm, raisinoid nuclei, and a low nuclear to cytoplasmic ratio. This pattern may mimic a collection of foamy histiocytes.
The mucinous or colloid pattern of pancreatic adenocarcinoma features neoplastic epithelium that is suspended in, or partially lines, large pools of extracellular mucin. A high-power view of the mucinous (colloid) pattern shows detached clusters of malignant cells floating in pools of mucin. Colloid carcinomas are almost always associated with intraductal papillary mucinous neoplasm, especially of the intestinal type.

A large component of the tumor cells have signet ring cell morphology in this signet ring cell variant of pancreatic ductal adenocarcinoma. This example of poorly differentiated adenocarcinoma lacks well-formed glands. The tumor is composed of sheets of poorly differentiated tumor cells as well as single malignant cells. Heterogeneous morphology, encompassing well, moderate, and poor differentiations, is often seen in pancreatic ductal adenocarcinoma.

Microscopic Features
(Left) This photograph shows extensive involvement of the duodenal lymphovascular spaces by pancreatic ductal adenocarcinoma. (Right) Ductal adenocarcinoma, large duct type, is characterized by cystically dilated neoplastic ducts that can mimic PanIN or branch-duct intraductal papillary mucinous neoplasm (IPMN). It can be differentiated from the latter based on the absence of low-grade epithelium in the duct lining.

(Left) This example of the medullary variant of pancreatic ductal carcinoma has well-defined borders and foci of necrosis. (Right) Medullary pancreatic carcinoma features a syncytial growth pattern containing poorly differentiated cells with scattered tumor-infiltrating lymphocytes.
This case of undifferentiated pancreatic ductal adenocarcinoma shows clusters of giant cells on the left and a poorly differentiated, spindled pattern on the right. The undifferentiated variant may or may not have giant cells.

This high-power photomicrograph highlights the numerous giant cells in this case of undifferentiated pancreatic ductal adenocarcinoma.

Section 7 - Genitourinary
Collecting System
Bladder Carcinoma

Bladder cancer is the 4th leading cause of cancer morbidity and 8th cause of cancer mortality in the USA. Disease of older adults with peak incidence in the 70s; rare in individuals younger than 45 years old. 3-4x more common in men than women. About 2x more common in whites than blacks.

Microscopic Pathology
- Urothelial CIS: Flat urothelial neoplasm with unequivocal high-grade cytology
- Low-grade PUCa: Papillae lined by urothelium with mild degree of distortion and low-grade dysplasia
- High-grade PUCa: Papillae lined by urothelium with moderate to high-grade cytology
- Inverted papillary urothelial carcinoma:
  - Endophytic rounded growth into lamina propria with regular outline and absent stromal reaction
- Invasive UCa
  - Irregular jagged nests, single cell infiltration, or tentacular finger-like projections
  - May show ↑ amount of cytoplasm and eosinophilia (squamoid change)
  - Stromal may have desmoplasia, retraction artifact, myxoid change, or pseudosarcomatous stroma

Variants include UCa with divergent differentiation, nested UCa, micropapillary UCa, plasmacytoid UCa, and lymphoepithelioma-like UCa among others.

Urothelial lineage-associated markers GATA3 and S100P help confirm UCa
CK7(+), CK20(+/-), HMWCK(+), and p63(+).
Low-power view shows urothelial carcinoma (UCa) extensively infiltrating the lamina propria. The invasive UCa nests are haphazard and show reactive desmoplastic response in the stroma.
Gross photograph shows a large polypoid mass of UCa at the posterior bladder wall. Most UCAs arise at the trigonal/bladder outlet area.

TERMINOLOGY

Synonyms
- Transitional cell carcinoma

Definitions
- In USA, > 90% of bladder carcinomas are urothelial carcinoma (UCa); < 10% are squamous cell carcinoma, adenocarcinoma, and small cell carcinoma

Flat urothelial neoplasm
- Urothelial dysplasia
  - Flat growth by urothelial cells thought to be neoplastic but cytologically falls below threshold for carcinoma in situ (CIS)
- Urothelial CIS
  - Flat growth by cytologically malignant urothelial cells that has not invaded through basement membrane

Papillary urothelial neoplasm
- Urothelial neoplasm with papillary growth on fibrovascular stalk in exophytic or endophytic manner

WHO/ISUP 2004 grading for papillary neoplasm
- Urothelial papilloma
- Papillary urothelial neoplasm of low malignant potential (PUNLMP)
- Papillary UCa (PUCa), low grade
- PUCa, high grade

Invasive UCa
- UCa that invades beyond the basement membrane

ETIOLOGY/PATHOGENESIS

Environmental Exposure
- Tobacco smoking with 2.5x higher risk
Chemicals such as arylamines (e.g., aniline, 2-naphthylamine, benzidine)

Other Possible Risk Factors
Chronic urinary tract infection, calculi, drugs (e.g., analgesics and cyclophosphamide)
Schistosomiasis is well-established risk factor for squamous cell carcinoma but may also increase risk for UCa

Model of Bladder Cancer Development and Progression (Dual Track Pathway)
Alterations in Chr 9 initiating event to either pathway
Hyperplasia/papillary pathway
70-80% transform to hyperplastic urothelium and progress to low-grade prostate carcinoma (PCa)
Linked to mutations in HRAS and FGFR3
Most tumors recur as PUCa, and ~15% become invasive UCa by alterations in PS3 and RB
Flat pathway
20-30% transform to CIS/dysplasia
Linked to alterations in PS3 and RB
Most tumors progress to invasive UCa

CLINICAL ISSUES
Epidemiology
Incidence
Bladder cancer is 4th leading cause of cancer morbidity and 8th cause of cancer mortality in USA
Age
Disease of older adults with peak incidence in 70s; rare in individuals younger than 45 years old
Urothelial papilloma and PUNLMP relatively more common in patients < 50 years old
Gender
3-4x more common in men than women
Ethnicity
About 2x more common in whites than blacks

Presentation
Hematuria, dysuria, and frequency
Advanced disease may present with abdominal pain and weight loss

Natural History
Most patients present with PUCa before or concurrently with CIS
Primary (de novo) or isolated CIS without prior or concurrent PUCa rare

Prognosis
For noninvasive urothelial neoplasm, dependent on grade
Urothelial papilloma: 0% recurrence
PUNLMP: 25-47% recurrence
Low-grade PUCa: 48-71% recurrence, < 5% progression and death
High-grade PUCa: 20% progression to invasive UCa
CIS: ~50% progress to invasive UCa in 5 years

For invasive UCa, dependent on stage
Locally advanced disease, even in absence of lymph node metastasis, is associated with poor prognosis
Estimated 5-year overall survival rates for pT3aN0, pT3bN0, and pT4aN0 disease are 64%, 49%, and 44%, respectively

Most variant morphology of UCa presents with higher stage; behavior may be similar to usual UCa when compared stage to stage

MACROSCOPIC FEATURES
General Features
Most common site is trigone/bladder outlet
More often multifocal
Noninvasive PUCa
Elevated or papillary lesion, which may increase in size and complexity with increasing grade
Inverted growth has more nodular appearance
Low or high-grade PUCa can be small or large; grading based on cytology; urothelial papilloma and PUNLMP generally < 2 cm

CIS
Mucosal erythema or discoloration
Invasive UCa
Papillary, polypoid, fungating, or ulcerating solid mass

MICROSCOPIC PATHOLOGY

Histologic Features

Urothelial CIS

Unequivocal high-grade cytology
Marked nucleomegaly, irregular nuclei, prominent nucleoli, coarse dark chromatin, and abundant mitosis
Cellular crowding and loss of polarity

Morphologic variations
- Clinging CIS: Denudation with few residual preserved CIS cells
- Pagetoid CIS: Individual malignant cells spread in adjacent benign urothelium
- Undermining CIS: Clusters of malignant cells covered by benign urothelium
May extend to involve von Brunn nests or cystitis cystica/glandularis in lamina propria

PUNLMP

Papillae lined by thickened urothelium with normal cytology and maintained polarity
Papillae with minimal branching

Low-grade PUCa
Papillae lined by urothelium with mild degree of architectural distortion and low-grade dysplasia
Pleomorphism is random
Mitosis may be present at base

High-grade PUCa
Papillae lined by urothelium with moderate to high-grade cytology
Nucleomegaly, irregular nuclei, prominent nucleoli, and coarse dark chromatin

Mitosis may be brisk and seen in all layers
Papillae exhibit architectural complexities, including branching, confluence, and fusion
May have epithelial denudation

Inverted papillary urothelial carcinoma
Endophytic rounded growth into lamina propria with regular outline and absent stromal reaction
Similar to exophytic PUCa, classified as PUNLMP, low or high grade based on cytologic atypia

Invasive UCa

Invasive epithelial features
- Irregular jagged nests, single cell infiltration, or tentacular finger-like projections
- May show ↑ amount of cytoplasm and eosinophilia (squamoid change) referred to as “paradoxical differentiation”
- Vast majority of invasive UCa exhibits high-grade cytology, notable exception in some variant morphologies

Stromal changes
- Desmoplasia, retraction artifact, myxoid change, pseudosarcomatous stroma, or no stromal response

Variant morphology of UCa

UCa with divergent differentiation
- UCa may exhibit glandular (i.e., adenocarcinoma) or squamous differentiation
- Squamous differentiation with cell bridges, keratinization, and keratin pearl formation
- Glandular differentiation includes enteric gland, mucinous gland, or signet ring cell formation
- Divergent differentiation can be extensive; surface CIS or PUCa that can be focal is clue for diagnosis

Nested UCa
Invasive UCa with deceptively benign appearance growing as infiltrating nests of bland-appearing malignant urothelial cells
At the surface, it closely resembles von Brunn nest proliferation
Unlike von Brunn nest, nested UCa shows more irregular nests with confluence and back-to-back pattern, and shows at least random pleomorphism
Most do not have surface CIS or PUCa component
Most present with (at least) muscle-invasive disease
Lymphovascular invasion common

Large-nested UCa

P. II(7):4
Invasive UCa consisting of large nests with pushing borders
Nests are typically more apart and connect to surface
Cells have low-grade cytology
Most have surface CIS or PUCa component

UCa with small tubules
Invasive UCa with predominance of tubular change
Similar to nested variant, composed of bland-appearing malignant urothelial cells
Nested UCa may have focal tubular change
May look like tubular nephrogenic adenoma or Gleason 3 prostatic adenocarcinoma

Microcystic UCa
Invasive UCa with small and large cysts (suggested to be at least 25%)
Cysts are lined by transitional or flattened cells and may have eosinophilic luminal secretions
Similar to nested variant, composed of bland-appearing malignant urothelial cells
Does not contain glandular cells
May resemble cystitis cystica at surface

Micropapillary UCa
Small nests or micropapillae in retraction-like spaces
Resembles micropapillary carcinoma of breast or ovary
Most exhibit high-grade cytology
Nuclei polarized exterior of nests
Multiple nests may be seen inside spaces
Surface PUCa may exhibit micropapillations or filiforms in layers of malignant urothelial cells

Plasmacytoid UCa
Invasive UCa characterized by infiltrative dyscohesive cells with eccentric nuclei that resemble plasma cells or poorly differentiated carcinoma
Tumor cells express plasma cell-associated marker CD138; a potential pitfall
Amount of plasmacytoid morphology varies in published series, although most report it to be at least 30%
Invasive tumor cells in single cells, cords (resembling lobular carcinoma), small nests, or solid sheets
May form a mass or is widely infiltrative in a limitis plastica-like spread
Has propensity to spread or recur in serosal spaces, such as in peritoneum presenting as carcinomatosis

Lymphoepithelioma-like carcinoma
Invasive UCa characterized by syncytium of poorly differentiated UCas in background of dense lymphoplasmacytic infiltrates
Resembles undifferentiated nasopharyngeal carcinoma; not EBV related

UCa with rhabdoid features
Exceedingly rare and occurs in association with poorly differentiated UCa
Characterized by plump oval to round cells with abundant cytoplasm and intracytoplasmic inclusion displacing nuclei
Rhabdoid cells are dyscohesive, infiltrating as single cells, in small nests, or as diffuse sheets

Lipid-rich UCa
Presence of large cells that contain multiple clear vacuoles, which indent nucleus to resemble lipoblasts or signet ring cells
Almost always admixed with conventional or other variants of UCa
Lipid-rich cells comprise 10-50% of tumor

Clear cell (glycogen-rich) UCa
Tumor cells with clear cytoplasm and may show solid alveolar growth to resemble clear cell renal cell carcinoma

Sarcomatoid UCa/carcinosarcoma
P.J(7):5
UCa containing admixture of epithelial and mesenchymal malignancies by morphology or immunophenotype
Epithelial component may include invasive UCa, CIS, or PUCa
Mesenchymal component often malignant spindle cells
Heterologous malignant mesenchymal elements may be present, such as bone (osteosarcoma), cartilage (chondrosarcoma), or skeletal muscles (rhabdomyosarcoma)

UCa with trophoblastic cells
- UCa may contain trophoblastic cells with associated production of βHCG, confirmed by immunohistochemistry &/or serum or urine assay
- ~35% of UCa may express βHCG, usually higher grade tumors, with more staining in more undifferentiated or anaplastic cells
- “Pure” choriocarcinoma may occur rarely in bladder; may arise from urothelial metaplasia
- Prognosis and treatment response to radiation poorer in UCa with βHCG expression

UCa with myxoid stroma and chordoid features
- UCa with abundant extracellular mucin in absence of glandular differentiation
- Tumor cells arranged in microcysts or small cellular aggregates
- Resembles extraskeletal myxoid chondrosarcoma, chordoma, and myxomatous yolk sac tumor

UCa with osteoclast giant cells
- Solid growth of mononuclear cells with evenly distributed osteoclast giant cells
- Mononuclear cells are plump with ovoid to round nuclei with vesicular chromatin, mostly exhibiting mild atypia

ANCILLARY TESTS
Immunohistochemistry
- Urothelial lineage-associated markers GATA3 and S100P help confirm UCa
- GATA3 is also expressed by breast ductal carcinoma, a subset of cervical carcinomas and paraganglioma
- UCa mostly CK7(+), CK20(+/-), HMCK(+), thrombomodulin (+), and p63(+)
- Uroplakin most specific for urothelial lineage; however suffers from low sensitivity, particularly in higher grade tumors
- Smoothelin shows differential strong expression in muscularis propria vs. muscularis mucosae and can be useful in staging of muscle-invasive disease

DIFFERENTIAL DIAGNOSIS
Poorly Differentiated Prostate Carcinoma
- May be difficult to distinguish from poorly differentiated UCa
- Relatively more monomorphic and does not usually exhibit marked pleomorphism
- May have associated glandular growth of cells with prominent nucleoli
- PSA, PAP, or PSMA (+)
- GATA3, p63, or HMWCK (-)

Gynecologic Carcinomas Involving Bladder
- Cervical squamous carcinoma
  - p63(+) and a subset is GATA3(+)
  - Lacks CIS or PUCA component in bladder surface
- Poorly differentiated uterine carcinomas
  - Often WT1(+), GATA3(-)

Pseudocarcinomatous Hyperplasia
- May simulate invasive UCa
- Often with prior radiotherapy or chemotherapy
- Squamoid changes present and associated with blood vessels and fibrin
- Mucosal hemorrhage common and diffuse radiation-induced atypia present (if patient has history)

Papillary Nephrogenic Adenoma
- May mimic PUCA
- Papillae lined by 1 or few layers of cells and with associated tubular proliferations
- Cells lack atypia and may exhibit hobnailing
- pax-2(+) and GATA3(-), or p63(-)

DIAGNOSTIC CHECKLIST
Clinically Relevant Pathologic Features
- Histologic type, including presence and amount of variant morphology
- Grade, most meaningful in noninvasive UCa
- Stage
  - In transurethral resection (TUR) specimens, diagnosis of high-grade UCa requires reporting of presence or absence of muscularis propria and status of involvement
  - Muscle should be specified if muscularis propria; reporting as “muscle present” is not appropriate
  - Repeat TUR is required if muscularis propria is not present for sampling adequacy
Margin status in cystectomy

SELECTED REFERENCES

P.II(7):6

Image Gallery
Papillary and Flat Urothelial Neoplasms

(Left) Urothelial papilloma shows papillae lined by normal-appearing urothelium, including presence of surface umbrella cells. The cells lack cellular atypia or mitoses. (Right) PUNLMP, in contrast to urothelial papilloma, shows increased thickness of urothelial cells with bland cytology. Nuclei are oblong, and tumor characteristically exhibits well-maintained cellular polarity from base toward the surface. Papillae with central fibrovascular core are often simple, delicate, and do not exhibit complex branching and fusion.

(Left) Low-grade PUCa shows tumor cells with nuclear rounding and mildly disordered cell polarity. Mitoses can be seen, usually at the base. (Right) High-grade PUCa shows tumor cells with unequivocal high-grade cytology. The nuclei are enlarged and more rounded and have irregular outlines and marked nucleomegaly. There is loss of the
normal perpendicular arrangement of cells toward the surface. Note that grading of papillary neoplasm is based on
cytomorphology of neoplastic cells.

(Left) UCa in situ shows cellular pleomorphism and presence of enlarged irregular hyperchromatic nuclei. There is
such marked disorganization of the neoplastic cells that, in some places, the nuclei overlap. Note presence of
prominent nucleoli and abundant mitoses. (Right) UCa in situ from the surface may extend downward to involve von
Brunn nests →. Recognition of this extension is important not to overcall as invasion into the lamina propria,
particularly in fragmented specimens.

P.II(7):7

Invasive Urothelial Carcinoma

(Left) Low-power view shows UCa with extensive invasion of the lamina propria. Recognition of the depth of invasion
in the bladder wall is important for staging of invasive UCa, including in transurethral resection specimens. (Right)
These invasive nests of UCa are irregular, variable in size, jagged, and surrounded by desmoplastic reaction. The
neoplastic cells have modest eosinophilic cytoplasm and exhibit pleomorphism, enlarged crowded nuclei, and brisk
mitotic activity.
Invasive UCa shows some smaller nests and individual infiltrating cells with abundant cytoplasm. This paradoxical differentiation or squamoid change, particularly if appreciated in single cells or small nests, is almost diagnostic for invasion. Note presence of stromal desmoplasia. (Right) Invasive UCa shows infiltrating larger and smaller nests and single cells. The invasive nests dissect in the desmoplastic stroma. Note that some of the cells have relatively more abundant cytoplasm.

UCa exhibits lymphovascular invasion (LVI). The tumor clusters follow the contour of blood vessels. Note presence of admixed hematopoietic cells in the lumen. UCa commonly exhibits retraction artifact and should be distinguished from LVI. (Right) GATA3 shows diffuse nuclear staining of UCa and is useful in distinguishing UCa from nonurothelial tumors in bladder and at metastatic sites. Ductal carcinoma of the breast and some cervical carcinomas may also express GATA3.

Staging, Immunohistochemistry, & Variant Morphologies
Diagnostic Pathology: Familial Cancer Syndromes

(Left) UCa shows invasion into the muscularis propria layer and is considered one of the crossroads for radical management. Identification of the presence of muscularis propria and reporting of status of involvement is warranted for staging adequacy. (Right) Low-power view of invasive UCa shows tumor infiltrating through the muscularis propria layer and into the perivesical soft tissue. Boundary between muscularis propria and perivesical tissue is often irregular, making staging of microscopic invasion at this site difficult.

(Left) CK20 shows diffuse full-thickness staining of urothelium in UCa in situ. In benign and reactive urothelium, CK20 staining is seen only at the surface umbrella cells or is absent. CD44 is often used to complement CK20, which shows full-thickness staining in reactive urothelium and only basal or absent staining in UCa in situ. (Right) p53 shows increased nuclear staining in UCa in situ. Diffuse staining (> 50% positive nuclei) is helpful, but may not always be present, in UCa in situ.
(Left) Low-power view shows UCa with glandular differentiation. Part of the tumor shows UCa with solid nests of polygonal malignant cells. In addition, there is adenocarcinoma characterized by glandular structures lined by tall columnar cells. (Right) Low-power view of invasive UCa with squamous differentiation shows prominent keratin production. Search for UCa component, particularly at the surface as in this case, is important to distinguish this tumor from pure squamous cell carcinoma.

P.II(7):9

Variant Morphologies

(Left) Nested UCa shows nests of bland-appearing cells that resemble a von Brunn nest proliferation. Distinction of this variant can be very difficult in superficial biopsy. Compared to von Brunn nests, nested UCa may show more irregular, tightly packed nests with confluence and fusion. Identification of muscularis propria invasion is key in making the diagnosis. (Right) Micropapillary UCa shows small nests of carcinoma cells within lacunar spaces that are often back-to-back.
Plasmacytoid UCa shows infiltrating dyscohesive individual tumor cell with abundant cytoplasm and off-centric nucleus mimicking plasma cells. Tumor cells may also express plasma-cell-associated marker CD138. This variant usually presents with higher stage and greater proclivity for extension into serosal surfaces. Sarcomatoid UCa shows presence of high-grade spindle cells. Heterologous elements (e.g., malignant bone, cartilage) may arise from this tumor.

Clear cell UCa shows neoplastic cells with clear cytoplasm mimicking clear cell renal cell carcinoma. Lymphoepithelioma-like carcinoma is characterized by presence of syncytium of poorly differentiated UCa cells in a background of dense lymphoplasmacytic infiltrates resembling undifferentiated carcinoma in nasopharynx. Tumor cells may be masked by the background infiltrates and mimic an inflammatory process. Epithelial markers can highlight the UCa cells.

Ureter Urothelial Carcinoma

Familial cases: Lynch syndrome or hereditary nonpolyposis colorectal cancer syndrome (HNPCC)
~6% lifetime increased risk of upper urinary tract cancer, greater for ureter than renal pelvis
Normal bladder cystoscopy and positive urine cytology suggest upper urinary tract cancer
Distribution of upper urinary tract cancer
Renal pelvis 36%, upper ureter 5%, mid ureter 7%, lower ureter 56%, and multifocal 22%
Up to ~6% will have contralateral ureteral cancer and ~17% will have concurrent bladder cancer

Microscopic Pathology
Classification similar to bladder or pelvicaliceal UCa (WHO, 2004); nonurothelial carcinoma variants rare in ureter

Gross image of a segment of an opened ureter shows an irregular sessile polypoid mass almost filling the ureteral lumina. Urothelial carcinoma (UCa) is relatively more common at the lower ureter.
High-grade ureteral UCa shows a complex papillary growth not invading the underlying stroma. Ureteral UCa may exhibit infiltrative or exophytic growths and cause symptoms related to urinary tract obstruction.

**TERMINOLOGY**

**Abbreviations**
- Urothelial carcinoma (UCa)

**Synonyms**
- Ureter transitional cell carcinoma

**Definitions**
- Carcinoma arising from ureteral urothelium
- Available clinicopathologic data similar with those for renal pelvicaliceal UCa; almost always lumped together in the literature as upper urinary tract cancer

**ETIOLOGY/PATHOGENESIS**

**Risk Factors**
- Similar to those in bladder cancer
  - Tobacco, long-term occupational exposure to aromatic carbons and phenacetin

**Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer Syndrome [HNPCC])**
- Autosomal dominant condition with increased risk of cancers of mainly colon, uterus, and upper urinary tract
- Due to inherited mutations in mismatch repair genes, most commonly MSH2 (~90%)
- ~6% Lifetime increased risk of upper urinary tract cancer in both ureter and renal pelvis; not established as a risk for bladder UCa
  - Higher incidence of ureter location of UCa in Lynch syndrome at ~50%

**CLINICAL ISSUES**

**Epidemiology**

**Incidence**
- Rare; estimated that there will be 2,710 new cases and 900 deaths from ureter and other urinary organ cancer in USA in 2013

**Age**
Range: 40s-90s with peak in 60s-70s; similar to bladder and pelvicaliceal UCa

Gender
More common in men, but lesser gender difference than in bladder UCa

Site
Distribution of upper urinary tract cancer
Renal pelvis 36%, upper ureter 5%, mid ureter 7%, lower ureter 56%, and multifocal 22%

Presentation
Hematuria, flank pain, irritative voiding symptoms, and weight loss
May have symptoms related to urinary tract obstruction

Endoscopic Findings
Papillary, sessile, or infiltrative tumor
Normal bladder cystoscopy and positive urine cytology suggest upper urinary tract cancer

Treatment
Surgical approaches
Ureterectomy, ± adjuvant therapy depending on stage

Drugs
Unlike in bladder cancer, intraluminal chemotherapy (e.g., BCG, thiotepa) and immunotherapy are sparsely used in ureter cancer and with no guidelines

Prognosis
Poor survival, similar to pelvicaliceal UCa
Stage is most important prognostic variable
T0: No evidence of primary tumor
T1: Tumor invades subepithelial connective tissue
P.II(7):11

T2: Tumor invades muscularis propria
T3: Tumor invades beyond muscularis propria into periureteric fat
T4: Tumor invades adjacent organ
N status (N1-N3): Stratified by size of nodal metastasis and number of positive nodes

UCa in ureter suggested to have worse prognosis than UCa in pelvicaliceal system
Some studies, however, showed that after adjustment for tumor stage, location for upper urinary tract cancer is no longer a predictor of cancer-specific survival

Up to ~6% of patients will have contralateral ureteral cancer and ~17% will have concurrent bladder cancer

IMAGE FINDINGS
CT Findings
May present with luminal mass and signs of ureteral obstruction (e.g., hydronephrosis)
Flat tumors may not be easily discernible, unless there is wall thickening or mass effect

MICROSCOPIC PATHOLOGY
Histologic Features
Classification similar to bladder or pelvicaliceal UCa (WHO, 2004)
Papillary urothelial neoplasms
Urothelial papilloma and papillary urothelial neoplasm of unknown malignant potential (PUNLMP) rare in ureter
Papillary UCa, low grade
Papillary UCa, high grade
Flat urothelial neoplasms
Urothelial dysplasia
UCa in situ
Invasive carcinoma, conventional UCa, and variants morphology
Squamous cell carcinoma, small cell carcinoma, adenocarcinoma, and sarcomatoid carcinoma rarer in ureter
Carcinoma may spread/infiltrate through ureteral wall or adventitial tissue without involving overlying ureteral mucosa
Potential pitfall for false-negative margin, particularly in frozen section ureteral margin

SELECTED REFERENCES

IMAGE GALLERY

(Left) Noninvasive high-grade ureteral papillary UCa shows regular boundary with underlying connective tissue. Note the relative closeness of ureteral muscularis propria to the surface. (Center) Invasive high-grade ureteral UCa shows infiltration into the ureter muscularis propria, which has smaller caliber bundles than those in the bladder proper. (Right) Cross section of a ureter shows a benign urothelial mucosa. However, deep in the wall are infiltrative nests of UCa, a feature that may present as a pitfall in margin assessment, particularly in frozen sections.

Genital Tract

Germ Cell Tumor

Terminology
- GCT: Group of tumors arising from germ cells that are capable of differentiating into embryonic and extraembryonic elements
- Pediatric GCTs: Most are pure GCTs and include mostly pure yolk sac tumor (YST) (~75% of childhood GCTs) and pure teratoma (TT)
- Postpubertal GCTs: Majority of GCTs arise in men 20-45 years old, with peak incidence in 30s
  - Most are pure classic seminoma (CS) (~30-45%), pure embryonal carcinoma (EC) (<5%), or MGCT (~30-40%)
- ITGCN: Considered precursor of most GCTs and common in postpubertal GCTs
- Clinically, GCTs are divided into SGCT and NSGCT with differing behavior and therapy

Etiology/Pathogenesis
- Familial GCTs: ~1.5% of TGCT patients have positive family history for GCT
  - Affected individuals' sons have 4-6x higher risk for TGCT, siblings have 8-10x higher risk for TGCT
- Postpubertal GCTs typically have 1 or more copies of Chr 12p or other forms of Chr 12 abnormalities

Microscopic Pathology
- Distinction of CS, EC, YST, TT, CC, SS, and components of MGCT are based mainly on morphologic assessment

Ancillary Tests
- Helpful immunostains: Oct3/4, CD117, CD30, α-fetoprotein, and Glypican-3
Photo shows MGCT with typical variegation. The cystic mucoid areas represent TT, the tan fleshy area represents seminoma, and hemorrhagic and necrotic areas represent EC. (Courtesy S. Shen, MD.)
MGCT shows admixture of TT with primitive neuroepithelium, and YST with variable patterns, including microcysts and seminoma with sheets and infiltrates of tumor cells with clear cytoplasm.

TERMINOLOGY

Abbreviations
- Germ cell tumor (GCT)

Definitions
- GCT: Group of tumors arising from germ cells that are capable of differentiating into embryonic and extraembryonic elements

Occurrence of testicular GCTs cluster in 3 age groups
- Pediatric GCTs
  - Occur mostly in infants and young children
  - Most are pure GCTs and include mostly pure yolk sac tumors (YST) (~75% of childhood GCTs) and pure teratomas (TTs)
- Postpubertal GCTs
  - Majority arise in men 20-45 years of age, with peak incidence in 30s
  - GCTs in this age group are pure or mixed: Pure classical seminoma (CS, ~30-45%), pure embryonal carcinoma (EC, < 5%), or mixed germ cell tumor (MGCT, ~30-40%)
  - YST, TT, and choriocarcinoma (CC) are more commonly encountered as component of MGCTs; pure form rare in adults
- Described familial GCT cases are mostly in this age group
- Older adult GCTs
  - Rare; majority are spermatocytic seminoma (SS) in patients with mean age of 53 years

From clinical standpoint, GCTs are divided into 2 groups
- Seminomatous GCT (SGCT)
  - Only pure CS
Nonseminomatous GCT (NSGCT)
Includes pure and mixed nonseminoma GCTs
Compared to NSGCT, SGCT usually arises in patients older by 10 years, is less likely to metastasize, is sensitive to radiotherapy, and responds better to chemotherapy
Response of NSGCTs with chemotherapy getting better with platinum-based regimens

Intratubular germ cell neoplasia (ITGCN)
Uncommitted neoplastic germ cells proliferating peripherally within seminiferous tubules
Considered precursor of most GCTs and common in seminiferous tubules of postpubertal GCTs; not seen in pediatric pure YST, pure TT, or SS

ETIOLOGY/PATHOGENESIS

Risk Factors
Family history, prior history of GCT, contralateral GCT, cryptorchidism, testicular dysgenesis syndrome, undescended testis (cryptorchidism), Klinefelter syndrome

Familial GCT
~1.5% of testicular GCT (TGCT) patients have positive family history for GCT
Sons of TGCT-affected individuals: 4-6x ↑ risk
Siblings of TGCT-affected individuals: 8-10x ↑ risk
Most affected families have 2 members with TGCT
However, no high-penetrance cancer susceptibility gene has been described so far
Hereditary GCT not yet firmly established

Cytogenetic Changes
Postpubertal GCTs typically have 1 or more copies of Chr 12p or other forms of Chr 12 abnormalities
Most common is isochromosome 12 (i[12p]) seen in ~80% of testicular GCTs
Pediatric GCTs are usually diploid

CLINICAL ISSUES

Epidemiology
Age
Postpubertal GCTs
Nonseminomatous GCT usually occurs in patients aged 25-35 years
CS occurs at ages ranging from 35-45 years (10 years older than NSGCT)

Ethnicity
Occurs 5x more often in white men than black men; 3x more often in white men than Asian men

Presentation
Typically a painless testicular mass
~10% present due to symptoms from distant metastasis

Laboratory Tests
α-fetoprotein elevated in YST
Borderline elevation of β-HCG in GCT with syncytiotrophoblasts and markedly high in CC (usually > 50,000 mIU/mL)
Serum LDH, α-fetoprotein, and β-HCG levels important in prognosis and are incorporated in AJCC TNM staging

Treatment
Decision is made based on stage and whether tumor is SGCT or NSGCT
SGCT: Radical orchiectomy and surveillance for stage I; radiotherapy, cisplatin-based, or multidrug chemotherapy depending on stage
NSGCT: Radical orchiectomy and retroperitoneal lymph node dissection for all stages; additional chemotherapy depending on stage

Prognosis
Depends on tumor type, stage, and therapy
In USA, overall survival is good (95%), attributed to advancement in therapy

MACROSCOPIC FEATURES

Classical Seminoma
Well-circumscribed homogeneous gray-white mass ± lobulations and usually devoid of necrosis or hemorrhages
May have punctate hemorrhages from syncytiotrophoblasts
Range: < 1-24 cm; mean: 5 cm

Embryonal Carcinoma
Usually poorly circumscribed and with variegated irregular surface exhibiting abundant necrosis and hemorrhage
Tumor usually presents smaller than CS

Yolk Sac Tumor
Homogeneous gray-white mass with gelatinous surface ± hemorrhage
“Pure CS-appearing” tumor in infants and young children

Teratoma
Often circumscribed solid &/or cystic mass
Cysts may contain keratinous debris or mucinous fluid
May have hairs, teeth, bone, or cartilage

Mixed Germ Cell Tumor
Variegated solid &/or cystic
Variation depends on components
NSGCT components usually associated with necrosis, hemorrhages, and cystic changes

MICROSCOPIC PATHOLOGY

Intratubular Germ Cell Neoplasia
Large atypical cells with large nucleus, nucleolomegaly, and prominent cytoplasmic membrane within
seminiferous tubules usually at periphery
P.II(7):14

Seminiferous tubules usually with thickened basement membrane, decreased or absent spermatogenesis, and
ITGCN cells admixed with mainly Sertoli cells

Classical Seminoma
Mainly solid growth but may exhibit interstitial and other rare patterns
Characteristically shows sheets of tumor cells compartmentalized by thin fibroconnective septae with occasional
lymphoplasmacytic infiltrates
Tumor cells have clear cytoplasm, prominent cytoplasmic border, regular nuclei, and large central nuclei; cells
typically do not overlap
≈30% may have granulomas

Embryonal Carcinoma
Mainly exhibits solid, glandular, or papillary growths
Characterized by large high-grade pleomorphic cells with indistinct cytoplasmic border, modest amphophilic
cytoplasm, large nuclei, and prominent irregular nucleoli; cells usually overlap
Hemorrhages and necrosis common

Yolk Sac Tumor
Variable patterns, including reticular (80%, micro- or macrocystic), endodermal sinus pattern (Schiller-Duval
bodies), solid, papillary, glandular-alveolar, parietal, enteric, hepatoid, spindled, myxomatous, and mixed
Bland cells with varied shape; can be cuboidal, columnar, flattened, or spindled
Clear to eosinophilic cytoplasm, overlapping border, and relatively regular nuclei with no to mild atypia

Teratoma
Mature teratoma
Mixture of ectodermal (e.g., epidermis, neuronal tissue), endodermal (e.g., gastrointestinal or
respiratory mucosa), and mesodermal (e.g., cartilage, bone) tissues

Immature teratoma
Presence of primitive endoderm, neuroectoderm, or mesoderm (undifferentiated spindle cells),
including blastemal cells
May have carcinomatous or sarcomatous transformation

Choriocarcinoma
Admixture of syncytiotrophoblasts (giant multinucleated cells) and cytotrophoblasts (smaller polygonal cells with
prominent membrane and uniform nuclei)
Hemorrhage is invariably present, forming pseudocystic hemorrhagic nodules
Lymphovascular invasion is common

Mixed Germ Cell Tumor
Combination of any CS, EC, YST, TT, or CC in varying proportions
Most common combinations are EC + TT and EC + CS, but any combination may occur
Usually exhibits hemorrhages and necrosis
YST and EC component are often intermingled (e.g., embryoid bodies, diffuse embryonal pattern)

Spermatocytic Seminoma
Hallmark is presence of 3 distinct cell types
Small lymphocyte-like cells: Scant cytoplasm with dark round nuclei
Intermediate cells: Most common, with modest cytoplasm and round nuclei with granular chromatin

Large cells: Nuclei with filamentous or “spireme” chromatin

ANCILLARY TESTS

Immunochemistry

PLAP: Positive in all GCT

Important immunostains include Oct3/4, CD117, CD30, α-fetoprotein, and Glypican-3

Oct 3/4: Positive in ITGCN, CS, and EC

β-HCG and human placental lactogen: Positive in CC (syncytiotrophoblasts)

SOX2: Positive in EC

Inhibin: Negative in GCT and positive in sex cord-stromal tumors

SELECTED REFERENCES


Tables

<table>
<thead>
<tr>
<th>Antibody</th>
<th>CS</th>
<th>EC</th>
<th>YST</th>
<th>SS</th>
<th>SCT</th>
<th>Melanoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oct3/4</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CD117</td>
<td>+</td>
<td>-</td>
<td>V</td>
<td>+</td>
<td>-</td>
<td>V</td>
</tr>
<tr>
<td>CD30 (BerH2)</td>
<td>V</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>α-fetoprotein</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Glypican-3</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PAN-CK (AE1/AE3)</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

V: Variable; CS: Classical seminoma; EC: Embryonal carcinoma; YST: Yolk sac tumor; SS: Spermatocytic seminoma; SCT: Sertoli cell tumor.

P.II(7):15

Image Gallery

Microscopic and Gross Features

(Left) ITGCN shows seminiferous tubules with no spermatogenesis and containing large atypical cells with abundant clear cytoplasm, prominent cell border, and large nuclei with nucleomegaly. ITGCN cells are more often at the periphery, intermingled with residual Sertoli cells. (Right) This gross photograph shows CS with no necrosis or hemorrhage. The tumor is well-circumscribed, bulging, tan, fleshy, and homogeneous. (Courtesy S. Shen, MD.)
Low-power view shows CS characterized by solid growth of clear cells separated by thin fibrovascular septae and with occasional lymphoplasmacytic infiltrates. (Right) High-power view of CS shows evenly spread clear cells with prominent cytoplasmic border and no significant overlapping. The nuclei are large with variably prominent nucleoli. However, CS may show increased mitosis and nuclear atypia (a.k.a. anaplastic seminoma [not shown]).

(Left) EC with a variegated cut surface, hemorrhage, and necrosis is shown. The tumor is poorly circumscribed. The rete testis and spermatic cord are more commonly involved in EC than in seminoma. (Courtesy S. Shen, MD.) (Right) EC shows solid sheet of high-grade pleomorphic cells with overlapping nuclei and brisk mitotic activity. Solid growth is the most common EC pattern. Morphologic diagnosis of EC is often straightforward due to the presence of these “angry-looking” cells.

Microscopic and Gross Features
(Left) High-power view of EC shows the pleomorphic high-grade cells with large variable nuclei, irregular outline, coarse chromatin, and prominent nucleoli. Other than the high-grade nuclei, notable differences from CS are the nuclear overlap and less distinct cell border. (Right) Large YST with relatively homogeneous, white, mucoid cut surface is shown. Focal hemorrhage is present. A gelatinous or myxoid appearance is common in pediatric YSTs that are histologically pure. (Courtesy S. Shen, MD.)

(Left) Low-power view of YST shows microcysts and focal solid area. Microcystic configuration is the most common pattern of YST. The cells vary from cuboidal to flat. YST typically shows variable pattern and cytomorphology. (Right) This image shows a Schiller-Duval body in YST characterized by a central vessel surrounded by a layer of tumor cells and a space created by another layer of tumor cells, giving a glomeruloid appearance. This pattern is the most specific pattern for YST. YST cells are typically bland appearing.
This mature TT shows a predominantly cystic mass with chalky keratin debris. Solid mucoid and gelatinous components are also present and frequently correlate microscopically with immature teratomatous components. Uninvolved testis is pushed to 1 side. (Courtesy S. Shen, MD.) (Right) Low-power view shows TT with mature elements, including cartilage, intestinal glands, and spindle cell mesenchymal stroma. In testicular TT, presence of immature elements has no prognostic bearing.

Microscopic and Immunohistochemical Features

(Left) Sarcomatous transformation in TT shows rhabdomyoblasts consisting of plump cells with abundant dense eosinophilic cytoplasm and eccentric atypical nuclei. (Right) CC shows a hemorrhagic cystic nodule with focal proliferation of mononuclear cells (cytotrophoblasts and intermediate trophoblasts) surrounded or “capped” by syncytiotrophoblasts. The latter are larger with dense eosinophilic cytoplasm and often multinucleate with smudgy nuclear chromatin.
MGCT consists of YST with polyvesicular vitelline pattern, EC consisting of glands and seminoma with clear cells. Note the abundant hyaline globules associated with YST. In postpubertal GCTs, YST is almost always seen as a component of MGCT. (Right) This high-power view shows an embryoid body in MGCT consisting of a central embryonic disc composed of EC cells and surrounded by YST cells creating an amniotic-like cavity.

(Left) Low power of MGCT shows diffuse embryoma pattern characterized by intimate admixture of YST & EC components. YST is seen wrapping around EC component. (Right) High-power view shows diffuse nuclear staining of Oct3/4 in EC cells. Oct3/4 is also positive in CS and is not expressed by the other GCTs. This marker is helpful in differentiating EC and CS from other tumors in testis that may exhibit solid growth, such as YST, SS, Sertoli cell tumor, and melanoma.

Prostate Carcinoma

Malignant neoplasm of acinar cell phenotype

~50% of PCa harbor TMPRSS2 and ETS gene fusion
SPOP mutation in TMPRSS2:ETS-negative PCa
Compelling evidence suggests familial predisposition to prostate cancer in some cases
Implicated genetic factors: BRCA2, ELAC2 on Chr 17p, RNASEL on Chr 1q25, MSR1 on Chr 8p22-23, NBS1 on Chr 5, and CHEK2 on Chr 22q

Microscopic Pathology
- Diagnosis based on constellation of architectural, nuclear, cytoplasmic, and intraluminal features
- Crowded uniform glands that infiltrate between preexisting benign glands
  - Small caliber, crowded clusters, rigid or “sharp” lumina, tinctorial staining of cytoplasm distinct from adjacent benign glands
- Nuclear enlargement and hyperchromasia with prominently enlarged &/or multiple and peripherally located nucleoli
- Luminal features, e.g., mucin, amorphous materials, and crystalloids
- Pathognomonic features for malignant glands
  - Glomerulations or collagenous micronodules
- Less differentiated tumors have poorly formed, fused, or large cribriform glands
- Poorly differentiated tumors may grow as infiltrative single cells or solid sheets
- Negative for basal cell markers (e.g., HMWCK, CK5/6, p63); overexpresses AMACR

Schematic diagram shows the modified Gleason grading system for PCa. The Gleason score is a powerful prognostic variable in predicting PCa behavior. This grading system is based purely on glandular architectural patterns, divided into 5 histologic categories or grades with decreasing differentiation. First developed in 1966 by Dr. Donald F. Gleason, it underwent refinements in 1974 and 1977 and had its latest modification by ISUP in 2005. This grading scheme is now universally accepted and recognized by the WHO and by the AJCC as the grading system of choice for PCa.

TERMINOLOGY
Abbreviations
Prostate carcinoma (PCa)

Synonyms
Prostatic adenocarcinoma

Definitions
Malignant neoplasm of acinar cell phenotype
≥ 95% of prostate carcinomas are acinar adenocarcinomas
Basis of epidemiologic, pathogenetic, and clinical features of PCas
< 5% of prostate carcinomas include urothelial carcinoma, small cell carcinoma, carcinoma with squamous differentiation, basal cell/adenoid cystic carcinoma, and sarcomatoid carcinoma

ETIOLOGY/PATHOGENESIS

Molecular Genetics
TMPRSS2 and ETS gene fusion
~50% of PCa patients harbor these recurrent gene fusions
ETS family of transcription factors include ERG, ETV1, ETV4, and ETV5
TMPRSS2:ERG gene fusion most common (~90%)
ERG brought under control of androgen-regulated promoter causing protein overexpression
In ~2/3 of cases, fusion results from deletion
Fusion may also occur by more complex rearrangement, such as translocation
Associated with blue-tinged mucin, cribriform pattern, intraductal spread, macronucleoli, and signet ring cells
Clinical significance not fully understood

PTEN mutation
P.II(7):19

Mutated in 20-40% of PCa, more often in advanced stage
Significant co-occurrence with TMPRSS2:ERG suggests a late genetic event or “second hit”

SPOP mutation
Mutated in 6-13% of PCa
Unlike PTEN, alterations occur in TMPRSS2:ERG(-) PCa, suggesting a different class of PCa

Other genes and molecular alterations
Most common chromosomal alterations in prostate cancer are losses at 1p, 6q, 8p, 10q, 13q, 16q, and 18q, and gains at 1q, 2p, 7, 8q, and Xq
Other genes implicated in PCa include tumor suppressor genes GSTP1, CDKN1B, NKX3-1, KLF6, RB, and TP53, and oncogenes MYC, BCL2, KIT, and STAT5
Mutations in androgen receptor gene may promote cancer growth at lower circulating androgen levels

Hereditary Prostate Cancer
Compelling evidence suggests familial predisposition to prostate cancer in some cases
Hereditary factor difficult to identify because PCa is so common
2x ↑ risk if 1 first-degree relative and 9x ↑ risk if 3 first-degree relatives are diagnosed with prostate cancer
High-risk alleles identified with either autosomal dominant or X-linked mode of inheritance
Implicated genetic factors include BRCA2, ELAC2 on Chr 17p, RNASEL on Chr 1q25, MSR1 on Chr 8p22-23, NBS1 on Chr 5, and CHEK2 on Chr 22q

Risk Factors
Older age, black race, and positive family history well established
Others include red meat diet, obesity, metabolic disease, environmental factors (e.g., exposure to cadmium, pesticides, rubber, textile, and chemicals), and vitamin D deficiency

CLINICAL ISSUES

Epidemiology
Incidence
Most common cause of cancer morbidity and 2nd cause of cancer mortality in men in USA
It is estimated that there will be 238,590 new cases of and 29,720 deaths from PCa in the USA in 2013
Age
PCa is a disease of older men and incidence increases dramatically with age
Incidence is remarkably low in men < 50 years old; ~ 60% of cases occur in men > 65 years old
Diagnosis rate peaks in men 65-74 years old
Median age at diagnosis: 67 years old
Ethnicity

Incidence rates highest in higher resource areas, such as USA, Canada, Australia, New Zealand, Western Europe, Scandinavia, and Caribbean

In USA, blacks have highest incidence rates, which is ~60% higher than in whites

Rates are much lower in Asian Americans, Native Americans, and Alaska Natives

Mortality rate is also highest in black Americans (54.9 per 100,000 men) and lowest in Asian Americans and Pacific Islanders

Presentation

Majority of PCa in USA are asymptomatic

Tumor detected due to early detection program

Main indication for needle biopsy are elevated serum PSA level and abnormal digital rectal examination

When symptomatic, presents with obstructive urinary symptoms, pelvic pain from local extension, and bone-related symptoms from metastasis

Natural History

Latent form of PCa extremely common; up to 80% of PCa in 9th decade

Most PCa patients die from other causes, most commonly from cardiovascular disease

Prognosis

Dependent on stage and Gleason grade

MACROSCOPIC FEATURES

General Features

Unlike most other visceral organ tumors, PCa often has no reliably distinguishable gross mass lesion

Grossly evident tumors are usually pT3, ≥ Gleason score (GS) 8, or ≥ 1 cm in size

Indurated yellow to yellow-tan homogeneous areas

More dense or firmer than surrounding benign spongy parenchyma

Typically lack necrosis or hemorrhage

Tumors usually in posterior or posterolateral aspect (peripheral zone [PZ]) of gland

Site

75-80% of PCas arise in PZ, and 15-25% arise in transition zone (TZ)

Multifocal tumors present in > 50% of PCas

MICROSCOPIC PATHOLOGY

Histologic Features

Diagnosis based on constellation of architectural, nuclear, cytoplasmic, and intraluminal features

Some individual features may also be seen in benign glands

Architectural features

Better differentiated tumors consist of compact or loose collections of well-formed glands

Small, crowded, uniform glands infiltrate between preexisting benign glands

Malignant glands usually differ in appearance from surrounding benign glands

Smaller caliber glands

Crowded or compact gland clusters

Rigid or “sharp” glandular lumina

May have periglandular clefts

Malignant glands should lack basal cells

Less differentiated tumors consist of poorly formed, fused, or large cribriform glands

Poorly differentiated tumors may grow as infiltrative single cells or solid sheets

Nuclear features

Nuclear enlargement and hyperchromasia

Prominently enlarged nucleoli

Single or multiple peripherally located nucleoli

Parachromatin clearing

Mitoses are rare; highly suggestive of malignancy if present

Apoptotic bodies (rare)

Nuclei commonly uniform, nonpleomorphic

Cytoplasmic features

Typically cuboidal to columnar cells with modest cytoplasm

Amphophilic, clear or pale granular cytoplasm

Taller cells with clear to pale pink cytoplasm and basally located nuclei more common in TZ
Intraluminal features

Blue mucin
- Usually prominent collection of wispy, blue-tinged intracellular mucin

Eosinophilic amorphous secretions
- Granular eosinophilic luminal material

Crystalloids
- Geometric bright eosinophilic rhomboid to prismatic structures with sharp edges, usually associated with eosinophilic amorphous secretions
- Present in up to 41% of PCas
- Seen in atypical adenomatous hyperplasia and uncommonly in benign glands
- Corpora amylacea are extremely rare in PCa, should strongly suggest benign glands
- Intraluminal necrosis may be present in high-grade tumors, highly indicative of malignancy

Pathognomonic features for malignant glands

Glomerulations
- Cribriform cellular luminal proliferations in otherwise well-formed glands attached to 1 pole

Collagenous micronodules (mucinous fibroplasia)
- Hyalinized eosinophilic material usually associated with abundant intraluminal blue mucin
- Often imparts an anastomosing epithelial pattern

Circumferential perineural or intraneural invasion
- Gland should completely surround nerve or be seen within nerve
- Benign glands may focally touch or indent a nerve; very rarely may be intraneural

Growth within adipose tissue
- Intraprostatic fat is exceedingly rare
- Indicates extraprostatic extension (EPE)

Morphologic Variants and Variations

Ductal adenocarcinoma
- Large glandular and papillary architecture lined by tall columnar cells, often with pseudostratified growth
- Often occurs admixed with acinar adenocarcinoma; requires > 80% ductal component for diagnosis
- ISUP 2005 consensus recommends grading as Gleason grade 4; if necrosis is present, grade 5

Atrophic variant
- PCa with glands lined by cells with scant cytoplasm, resembling atrophy
- Infiltrative growth, cytology of malignancy
- In contrast, benign atrophic glands typically have dense hyperchromatic nuclei and lobular growth

Pseudohyperplastic variant
- Large or dilated glands, with branching and papillary infolding, resembling hyperplasia
- Tall columnar cells with abundant pale to slightly granular cytoplasm and basally located nuclei
- Commonly with luminal eosinophilic amorphous secretions and may have crystalloids
- Diagnostic malignant nuclear features retained, in contrast to benign hyperplastic glands

Foamy gland (xanthomatous) variant
- PCa with abundant foamy cytoplasm
- Malignant nuclear features not always present, as nuclei may be small and pyknotic
- Presence of infiltrative pattern; may require immunostains

Mucinous (colloid) adenocarcinoma
- ≥ 25% of resected tumor shows extracellular mucin
- Intraluminal mucinous material does not qualify, and extraprostatic origin must be excluded

Signet ring cell variant
- ≥ 25% of resected tumor shows signet ring cell (arbitrary definition)
- Tumor cells contain optically clear vacuoles displacing nuclei and are widely infiltrative
- May be mucin-producing PCa (mucinous carcinoma with signet ring cells)

PCa with Paneth cell-like differentiation
- PCa containing neuroendocrine cells with bright eosinophilic cytoplasmic granules resembling Paneth cells of gastrointestinal tract

Other rarer variations

Lymphoepithelioma-like variant
- As in other organs, characterized by syncytial growth amid dense lymphocytic background

Oncocytic variant

841
PCa with abundant granular eosinophilic cytoplasm and ultrastructurally contains abundant mitochondria
PCa with stratified epithelium (PIN-like)
Glands lined by ≥ 2 layers of malignant cells

Key Elements to Report
- Gleason score
- Tumor quantity
  - Provide length in mm in biopsy
- Extraprostatic extension (EE)
- Margin status
- Perineural invasion
- Lymphovascular invasion
- Seminal vesicle invasion
- In biopsy
  - Atypical small acinar proliferation (ASAP)
  - High-grade prostatic intraepithelial neoplasia

ANCILLARY TESTS
- Immunohistochemistry
  - PCa should have no basal cells
  - Absent staining for basal cell markers HMWCK, CK5/CK6, or p63
  - Overexpress AMACR, in contrast to benign glands
  - Prostatic lineage specific marker such as PSA, PAP, and PSMA helpful for diagnosis at metastatic sites

DIFFERENTIAL DIAGNOSIS
- General Features
  - Given broad morphologic spectrum, differential diagnosis for PCa ranges from innocuous benign normal structures to secondary high-grade cancers
  - PCa most often mimicked by benign prostatic glandular lesions; difficulty enhanced in limited samples (e.g., biopsy)
  - Use of ancillary immunohistochemistry helpful in some scenarios
  - Pattern-based approach facilitates work-up and judicious selection of adjuvant stains

GRADING
- Gleason Grading System (GS)
  - Universally accepted grading system for PCa
  - Assessment of gland architecture at low/intermediate magnification: Classified into 5 basic grades
  - In resection specimens, GS is sum of primary and secondary Gleason grades
  - Primary grade is most prevalent grade and secondary is 2nd most common grade
  - International Society of Urological Pathology (ISUP) 2005 consensus conference proposed several modifications and guidelines
  - In needle biopsies, include tertiary pattern in Gleason score if it is higher than secondary grade
  - Similar rule applies for transurethral resection and enucleation (simple prostatectomy) specimens
  - In high-grade cancers, ignore lower grade if < 5% (e.g., 4 + 4, if pattern 3 is < 5%)
  - For cancers with more than 1 grade, include the higher grade even if it is < 5% (e.g., 3 + 4, even if grade 4 is < 5%)
  - Assign individual GS to all cores as an aggregate if submitted in 1 container; assign GS to each core separately designated (e.g., ink or separately submitted) by urologist
  - In radical prostatectomy, provide GS (primary and secondary grades); separately mention tertiary grade
  - Assign separate GS to dominant tumor(s) for multifocal tumors in radical prostatectomy
  - Individualized Gleason grading approach for some PCa morphologic variants and subtypes

Gleason pattern 1
- Circumscribed nodule of tightly packed, uniform, round to oval, well-formed glands, with no or minimal infiltration of adjacent parenchyma
- Using these strict criteria, exceedingly rare and controversial in current practice
  - Most described pre-immunohistochemistry were likely atypical adenomatous hyperplasia

Gleason pattern 2
- Nodular with minimal peripheral infiltration, less uniform and more loosely arranged glands
- Also very rare and typically found in TZ
- Usually incidental with associated higher grades, but occasionally secondary pattern in resection specimens
ISUP recommends that GS 3 or 4 should rarely, if ever, be diagnosed in needle biopsy specimens.

Architecture cannot be assessed in its entirety.

Poor reproducibility among experts.

Gleason pattern 3

Most common pattern

P.II(7):22

Predominantly well-formed, individual glands that infiltrate between benign ducts and acini.

Includes smaller but well-formed glands (microacini).

Glands typically smaller than in patterns 1 or 2.

Gleason pattern 4

Most commonly fused, poorly formed glands.

Tangentially sectioned grade 3 glands may mimic fused pattern 4 glands.

2nd most common pattern is cribriform structures with either regular or irregular outlines.

Uncommon “hypernephroid” pattern, consists of solid sheets of cells with optically clear cytoplasm.

Gleason pattern 5

Lacks glandular differentiation: Manifests as solid sheets, cords, or single infiltrative tumor cells.

Also includes solid, cribriform, or papillary structures with central comedo-type necrosis.

SELECTED REFERENCES


Tables

<table>
<thead>
<tr>
<th>Differential Diagnosis for Prostate Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Histologic Pattern</strong></td>
</tr>
<tr>
<td>Small glandular proliferation</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Atypical large glandular proliferation</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Infiltrative single cell pattern</td>
</tr>
<tr>
<td>---------------------------------</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Clear cell pattern</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Oncocytic pattern</td>
</tr>
<tr>
<td>Poorly to undifferentiated</td>
</tr>
<tr>
<td>carcinoma</td>
</tr>
<tr>
<td>Spindle cell pattern</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Small cell pattern</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Image Gallery
Gross and Microscopic Features

(Left) This transverse section of prostate shows multifocal PCa predominantly involving the left lobe with a dominant nodule at the posterolateral aspect and additional smaller tumor foci at the lateral aspect of the peripheral zone. (Right) Transverse section of the prostate shows the urethra pushed to the left due to prominent hyperplasia. The peripheral zone shows evidence of prominent atrophy and a carcinoma involving the posterolateral aspect.
Prominent nucleoli, as seen here, are characteristic of PCa, but they are not always required for the diagnosis. In addition, nuclei larger than the adjacent nuclei of benign glands and those with double nucleoli and with parachromatin clearing or mitosis are helpful features. PCa nuclei are typically homogeneous. Nuclear pleomorphism should suggest the possibility of a nonprostatic lesion.

PCa glands commonly show parachromatin clearing in the malignant nuclei. These nuclei also show a mild degree of nuclear variability and crowding not typically seen in PCa. PCa nuclei are usually very round and monotonous. Two carcinoma glands contain intraluminal mucin. PCa shows readily identifiable mitotic figures within the malignant glands. Mitotic figures are very rare in PCa; however, their presence is highly suggestive of adenocarcinoma.

Luminal and Pathognomonic Features
H&E shows PCa glands with multiple bright eosinophilic crystalloids in the lumina. The nuclei of these glands are enlarged with prominent nucleoli that are occasionally multiple and peripheral. Crystalloids are common, but not specific, in PCa. (Right) PCa glands contain eosinophilic amorphous secretions in the lumen. Focal crystalloids may be seen admixed with the eosinophilic secretions. Presence of these features warrants close examination of the harboring glands.

PCa glands contain blue mucin in the lumen. Sometimes these mucin may be thin and wispy and may not be easily discernible on scanning magnification. (Right) Collagenous micronodules (mucinous fibroplasia) is a pathognomonic feature of PCa. Early collagenous micronodules consist mostly of mucin with scant fibrous tissue and, with time, the fibrous deposits predominate. Despite the glands assuming a complex architecture because of the collagenous micronodule, these are typically assigned as GS 3 + 3 = 6.
(Left) H&E shows PCa with glomerulations characterized by intraluminal proliferation of cells that form a cribriform structure attached to 1 pole of the gland. Recent data suggests that glomerulations should be regarded as Gleason grade 4. (Right) High-power view shows PCa gland within a nerve. Intraneural and complete circumferential perineural invasion are pathognomonic features of PCa. Benign glands can be seen adjacent to a nerve and may resemble partial perineural invasion.

Gleason Grades 2 and 3

(Left) This GS 2 + 3 = 5 PCa consists of a circumscribed nodule of slightly irregular medium and large glands (Gleason grade 2)) and focally infiltrating glands (Gleason grade 3). (Right) Low-power view shows GS 3 + 3 = 6 PCa glands infiltrating between benign glands. PCa glands are smaller, haphazardly arranged, have different cytoplasmic tincture and some have rigid lumina. A well-formed gland should have a complete circumference of cells showing central lumina.
These GS 3 + 3 = 6 PCa glands have large nuclei and prominent nucleoli that can be multiple and peripheral. Nuclei of benign glands are smaller and the glands have > 1 layer of cells. (Right) H&E shows GS 3 + 3 = 6 PCa composed of individual infiltrating glands and microacini. One has to take into account that not all lumina may be visible on 1 plane of section. Tangentially sectioned glands (vs. ill-formed glands) are suggested by being few in numbers and scattered in between well-formed glands.

This GS 3 + 3 = 6 PCa shows periacini retraction spaces, which is a helpful diagnostic feature. The somewhat linear alignment of the PCa glands is also a helpful hint. These PCa glands consist of columnar cells with basally oriented nuclei. PCa nuclei are relatively homogeneous and very rarely exhibits marked pleomorphism. (Right) High-power view of GS 3 + 3 = 6 PCa shows glands with corpora amylacea. These concretions, while common in benign glands, are rare in PCa.

Gleason Grades 4 and 5
High-power view of Gleason grade 4 PCa shows ill-defined glands formed by aggregates of tumor cells that are unable to form a complete circumference and central lumina. These Gleason grade 4 PCa cribriform glands are larger and central lumina are compartmentalized by multiple cellular bridges. Cribriform PCa gland can be medium or large with an expansile, elongated, or branching shape. Most experts now assign Gleason grade 4 to any cribriform PCa gland that lacks necrosis.

This GS 4 + 4 = 8 PCa consists of multiple fused glands. Some lumina are separated by a single layer of cellular bridge that cannot be traced as an exclusive part of 1 gland. In contrast, tightly packed Gleason grade 3 glands can be individually outlined. H&E shows Gleason grade 4 PCa hypernephroid pattern consisting of solid growth of cells with clear cytoplasm that resemble clear cell RCC. The nuclei are often small and dark with inconspicuous nucleoli.
(Left) H&E shows Gleason grade 5 PCa consisting of cords and single infiltrative tumor cells. These high-grade PCa cells may resemble chronic inflammatory cells. Note that some of the cells exhibit vacuolation. (Right) This large cribriform PCa gland contains luminal necrosis and grading is bumped to Gleason grade 5. The lumen should unequivocally demonstrate necrotic tumor ghost cells. Luminal eosinophilic secretions and inflammatory debris can be mistaken for tumor cell necrosis.

Gleason Grade 5 and Intraductal Carcinoma

(Left) This Gleason grade 5 PCa gland shows comedonecrosis. The central lumen contains abundant necrotic tumor cells. (Right) This Gleason grade 5 PCa shows solid growth of poorly differentiated cells. This morphology should be distinguished from a poorly differentiated urothelial carcinoma. Morphologic distinction can be very difficult and often necessitate use of immunostains. Beware that poorly differentiated PCa may exhibit weak or absent PSA expression in up to 13% of cases.
HMWCK shows lack of staining in PCa glands. All atypical glands in a suspicious focus should have complete absence of basal cell staining. Adjacent benign gland shows HMWCK staining of the basal cells. (Right) This cocktail of AMACR (red) and basal cell markers p63 and HMWCK (brown) shows AMACR overexpression and complete absence of basal cell marker immunoreactivity in PCa glands. Benign glands in contrast show intact basal cells and no AMACR overexpression.

H&E shows intraductal carcinoma consisting of large expansile cribriform structures that are composed of cells with large nuclei and prominent nucleoli and has an intact basal cell layer. (Right) This antibody cocktail of AMACR (red) and basal cell markers p63 and HMWCK (brown) shows AMACR overexpression and basal cell marker staining. Intraductal carcinoma more often coexists with invasive glands and is considered to be a process succedent to PCa invasion.

P.II(7):28

Morphologic Variants and Variations
Duc
tal adenocarcinoma shows papillae lined by tall columnar cells with pale cytoplasm and elongated nuclei, exhibiting pseudostratification. Presence of tall columnar cell is a distinguishing feature for this variant. (Right) Pseudohyperplastic PCa shows medium to large dilated glands with papillary infolding, eosinophilic secretions, and few crystalloids. The cells have abundant cytoplasm and nuclei are usually aligned basally. This variant architecturally resembles benign hyperplasia.

(Left) Atrophic PCa shows acini lined by cells with attenuated cytoplasm. Features indicative of malignancy include malignant nuclear features (e.g., nucleomegaly, prominent nucleoli), nonlobular growth, luminal features of malignancy, and admixed typical PCa morphology. (Right) Foamy gland PCa shows cells with abundant xanthomatous cytoplasm and small to eosinophilic luminal secretions. Typical malignant nuclear features may not be present, making recognition as PCa difficult.
Mucinous (colloid) carcinoma is characterized by malignant cells floating in abundant extracellular mucin. This is distinct from the intraluminal mucin seen in more typical forms of PCa. When seen pure in biopsy, confirmation of prostatic origin by immunohistochemistry is necessary. (Right) PCa with Paneth cell-like differentiation shows occasional neuroendocrine cells with bright eosinophilic cytoplasmic granules resembling Paneth cells of the gastrointestinal tract.

Differential Diagnosis

H&E shows partial atrophy with relatively ample amount of pale to clear cytoplasm. In contrast to PCa, these glands are somewhat more lobular, more irregular, and lack nuclear and luminal features of malignancy. (Right) Simple atrophy shows nuclear crowding from loss of cytoplasmic volume. Unlike typical PCa, these atrophic glands are more irregular and angulated. Unlike atrophic PCa, these atrophic glands lack the nuclear and luminal features of malignancy.
Low-power view of AAH shows relatively well-circumscribed proliferation of variably sized acini. The glands at the central aspect are usually larger than in the periphery. Intraluminal proteinaceous material and crystalloids may occasionally be seen in AAH. Presence of both of these features in atypical glands compounds the diagnostic difficulty vs. PCa. Immunohistochemistry confirms presence of basal cells in AAH vs. PCa that can be focal or patchy.

PAH encountered in needle biopsy is shown. PAH is 1 of the main differential diagnoses for ASAP in needle biopsy. Diagnosis is relatively less challenging if the entire architecture is appreciated as in this case. Nephrogenic adenoma from the prostatic urethra may be sampled in needle biopsy and its tubules may mimic PCa. Distinction is confounded by the similar positivity for AMACR. Attention to single layer of hobnail cells at the surface similar to those in tubules is helpful.

Testicular Sertoli Cell Neoplasms

- Table of Contents > Part II - Diagnoses Associated With Specific Syndromes > Section 7 - Genitourinary > Genital Tract > Testicular Sertoli Cell Neoplasms
- Testicular Sertoli Cell Neoplasms
- Gladell P. Paner, MD
- Key Facts
- Terminology
  - Group of testicular neoplasms with Sertoli cell differentiation linked to syndromes such as Carney complex and Peutz-Jeghers syndrome
  - Most ILCHSCN described in Peutz-Jeghers syndrome
  - Most SCT and ~60% of LCCSCT are sporadic
Clinical Issues
- ILCHSCN: Benign course, but a subset may transform to invasive SCT or LCCSCT
- SCT: Majority benign; ~10% are malignant and may metastasize
- LCCSCT: Majority benign; ~20% malignant

Microscopic Pathology
- ILCHSCN: Seminiferous tubules with thickened basement membrane
  Expanded by large Sertoli cells with pale to eosinophilic cytoplasm and globular, eosinophilic basement membrane deposits
- SCT: Hallmark tubular growth of regular cuboidal or columnar cells with pale to pink cytoplasm that may be vacuolated
- LCCSCT: Large polygonal cells with abundant eosinophilic ground-glass cytoplasm associated with hallmark irregular or psammomatous calcifications

Ancillary Tests
- Inhibin (+), PLAP and OCT3/OCT4 (-)

Top Differential Diagnoses
- Leydig cell tumor
- Granulosa cell tumor
- Adenomatoid tumor

High-power view shows an intratubular large cell hyalinizing Sertoli cell neoplasia (ILCHSCN) in a Peutz-Jeghers syndrome testis, composed of large Sertoli cells admixed with basement membrane material.
Intermediate-power view shows Sertoli cell tumor (SCT) with small nested cords and tubular growths in a fibrous stroma. SCT grows in variable architectural patterns, with tubule formation being the most common.

TERMINOLOGY

Definitions

Group of testicular neoplasms with Sertoli cell differentiation linked to syndromes such as Carney complex and Peutz-Jeghers syndrome

Intratubular large cell hyalinizing Sertoli cell neoplasia (ILCHSCN): Intraseminiferous tubular neoplasia of large Sertoli cells admixed with globular basement membrane deposits

Subset may progress to invasive Sertoli cell tumor (SCT) or large cell calcifying SCT (LCCSCT)

SCT: Sex cord-stromal tumor exhibiting variable patterns and hallmark tubular growth

LCCSCT: Variant of SCT composed of large epithelioid cells with abundant eosinophilic cytoplasm and peculiar calcifications

Most ILCHSCN described in Peutz-Jeghers syndrome

Vast majority of SCT and ~60% of LCCSCT encountered as sporadic tumors

~40% of LCCSCT linked to syndromes

ETIOLOGY/PATHOGENESIS

Syndromes/Familial Sertoli Cell Neoplasms

Peutz-Jeghers syndrome

Mainly caused by mutations in STK11/LKB1

Autosomal dominant disorder characterized by multiple hamartomatous polyps and mucocutaneous pigments with higher risk for multiple visceral organ cancers (lifetime risk of 37-93%)

ILCHSCN, LCCSCT, and SCT described in patients with this syndrome

Carney complex

Autosomal dominant multiple neoplasia syndrome

Caused by mutations in PRKAR1A (45-80%)

LCCSCT is a component of this complex

CLINICAL ISSUES
Epidemiology

Incidence

SCT and LCCSCT are rare tumors

Age

SCT: ~30% occur in 1st decade of life
LCCSCT: Mostly prepubertal boys to young adult men; mean: ~30 years
ILCHSCN: < 15 years of age; mean: 6.8 years

Presentation

ILCHSCN may exhibit testicular enlargement but no discrete mass
SCT and LCCSCT may present as painless testicular mass or enlargement
LCCSCT has higher chance for bilaterality, particularly in Carney syndrome
Hormone-related symptoms, such as gynecomastia (most common), precocious puberty, or advanced skeletal maturation
Discovery of testicular tumors from other syndromic manifestations

Peutz-Jeghers syndrome
Mucocutaneous pigmentation, bowel obstruction, or intussusception from multiple gastrointestinal polyps
Carney complex
Spotty pigmentation of skin, cardiac or cutaneous myxomas, endocrinopathy, schwannomas

Testicular ultrasound of LCCSCT will show characteristic Christmas tree-like appearance

Laboratory Tests

High serum estradiol levels
Serum α-fetoprotein and β-HCG levels not elevated

Prognosis

ILCHSCN: Benign course, but a subset may transform to invasive SCT or LCCSCT

SCT: Majority benign; ~10% are malignant and may metastasize
LCCSCT: Majority benign; ~20% malignant

MACROSCOPIC FEATURES

General Features

ILCHSCN: Either testicular enlargement with no visible lesion or small ill-defined white lesions
SCT: Small (mean: 3.5 cm), well-circumscribed, homogeneous gray-white to yellow mass
LCCSCT: Usually small (< 4 cm), well-circumscribed, homogeneous gray-white to yellow mass with calcifications

MICROSCOPIC PATHOLOGY

Histologic Features

ILCHSCN: Expanded seminiferous tubules with thickened peritubular basement membrane
Tubules filled with large Sertoli cells with abundant pale to eosinophilic cytoplasm and globular, eosinophilic basement membrane deposits

SCT: Tubular (hallmark), microcystic, cords, and nests or solid growths
Nodular pattern on low-power view often separated by fibrous or acellular stroma
Tubules may be solid, hollow, or dilated
Regular cuboidal or columnar cells with bland round nuclei, occasional nucleoli, and pale to pink cytoplasm that may be vacuolated
Usually paucicellular, hyalinized, or fibrous stroma

LCCSCT: Nest, cords, and trabecular or focal tubular growth
Large polygonal cells with abundant eosinophilic “ground-glass” cytoplasm, nuclei with vesicular chromatin and variably prominent nucleoli
Hallmark calcifications that may be large, irregular, wavy, laminated, or psammomatous
Myxoid or fibromyxoid stroma

ANCILLARY TESTS

Immunohistochemistry

Inhibin (+), PLAP and OCT3/OCT4 (-)

DIFFERENTIAL DIAGNOSIS

Leydig Cell Tumor
Differential diagnosis for SCT and LCCSCT
Mainly solid growth of large round or polygonal cells with abundant eosinophilic cytoplasm
Granulosa Cell Tumor (GCT)
Differential diagnosis for SCT
Mainly microfollicular pattern and formation of Call-Exner bodies (eosinophilic material surrounded by palisading granulosa cells)

Adenomatoid Tumor
Differential diagnosis for SCT and LCCSCT
Located in testicular adnexa
Composed of gland-like or irregular spaces lined by cuboidal to flat bland cells
Calretinin (+) and WT1(+)

SELECTED REFERENCES
3. Young RH: Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems. Mod Pathol. 18 Suppl 2:S81-98, 2005

Image Gallery
Microscopic Features

(Left) SCT shows cords and tubules composed of polygonal cells with modest light eosinophilic cytoplasm and regular nuclei in a fibrous background. Note presence of cytoplasmic vacuolations, which is common in SCT. (Right) SCT is characterized by tubular formations that can be solid, hollow, or dilated. Dilated tubules are occasionally lined by more flattened cells and may ramify to resemble rete testis (retiform pattern). Note the presence of light eosinophilic secretions in tubular lumina.
High-power view shows SCT composed of polygonal cells with a modest amount of pale to light eosinophilic cytoplasm. Some of the tumor cells are also vacuolated. The nuclei usually do not exhibit prominent nucleoli, and mitosis is rare in > 80% of cases, particularly in the well-differentiated (tubule-forming) tumors. (Right) H&E shows SCT exhibiting a more solid growth. The tumor cells have abundant lipid-filled cytoplasmic vacuoles. Some of the vacuoles are multiple and large, which indents the nuclei.

A well-circumscribed LCCSCT is demarcated from the adjacent testis by a thick fibrous capsule. The tumor is composed of cords and nests of tumor cells with hyalinized or myxoid stroma. (Courtesy S. Shen, MD, PhD.) (Right) LCCSCT shows small nests and solid tubules of large polygonal cells with abundant eosinophilic cytoplasm in a myxoid stroma. Presence of calcifications is a hallmark for LCCSCT and can be marked. These calcifications may make the tumor notably gritty on sectioning.

Microscopic Features and Differential Diagnosis
(Left) High-power view of LCCSCT shows the characteristic large polygonal pink cells with bland nuclei. Note the dense calcifications and scattered neutrophils. (Right) H&E shows ILCHSCN composed of intratubular proliferations of large Sertoli cells and with dense eosinophilic basement membrane deposits. The deposits are denser at the peritubular area and may also form globules. The Sertoli cells have abundant eosinophilic cytoplasm, which can be fibrillary.

(Left) Low-power view shows an ILCHSCN adjacent to LCCSCT. ILCHSCN is an intratubular process that does not form a mass lesion. A subset of ILCHSCN may become invasive to form LCCSCT or SCT. (Right) Low-power view shows Leydig cell tumor with solid growth of polygonal cells with abundant eosinophilic cytoplasm. The tumor may also exhibit tubular or insular growths. The tumor cells are typically uniform with round to ovoid nuclei. Unlike LCCSCT, calcification is not a feature.
A GCT shows typical Call-Exner bodies characterized by central eosinophilic material and palisading tumor cells, resulting in a rosette appearance. The tumor cells have scant cytoplasm. (Courtesy S. Shen, MD, PhD.) Adenomatoid tumor shows variably sized tubules of cuboidal and flattened cells, and some may resemble vessels or signet ring cells. Unlike SCT, adenomatoid tumor is located in the testicular adnexa and expresses WT1 and calretinin.

Kidney

Angiomyolipoma

Gladell P. Paner, MD

Key Facts

Terminology

C-AML: Renal mesenchymal neoplasm putatively derived from PECs with typical triphasic components of dysmorphic blood vessels, fat, and spindle cells

E-AML: Renal mesenchymal neoplasm putatively derived from PECs consisting of polygonal cells

Etiology/Pathogenesis

> 90% of C-AML and ~75% of E-AML are sporadic

Up to 75% of TS patients will develop AML

Association of E-AML (~25%) to TS stronger

Clinical Issues

Age: 14-88 years old; median: 50 years

Younger for TS-associated AML (mean: 26 years)

TS-associated AML presents earlier, larger, multifocal or bilateral, and more symptomatic

Microscopic Pathology

C-AML: Usually triphasic pattern of dysmorphic vessels, fat, and spindle cells in 85% of cases

In 15%, fat or spindle cells may predominate (comprises 95% of tumor)

E-AML: Carcinoma-like or diffuse mixed epithelioid and plump spindle cell growths

Nuclei tend to be pleomorphic with brisk mitosis

Larger pleomorphic multinucleated cells present

Ancillary Tests

Melanocytic markers (+); epithelial markers (-)

Top Differential Diagnoses

C-AML: Sarcomatoid RCC or urothelial carcinoma, liposarcoma and smooth muscle tumors

E-AML: RCC
C-AML shows triphasic morphology composed of dysmorphic blood vessels, spindle cells, and fat. Proportion of these components vary so that 1 may predominate (e.g., leiomyomatous or lipoma-like AML).
E-AML shows carcinoma-like growth with epithelioid cells containing clear to granular cytoplasm separated by thin vasculatures and with pleomorphic nuclei, which may resemble high-grade clear cell RCC.

**TERMINOLOGY**

**Abbreviations**

Angiomyolipoma (AML)

**Synonyms**

Classic AML (C-AML): Renal PEComa, triphasic AML

**Definitions**

C-AML
Renal mesenchymal neoplasm putatively derived from perivascular epithelioid cells (PECs) with typical triphasic components of dysmorphic blood vessels, fat, and spindle cells

Epithelioid AML (E-AML)
Renal mesenchymal neoplasm putatively derived from PECs consisting mainly of polygonal cells

C-AML and E-AML are closely related to a family of PEC-derived visceral and soft tissue tumors e.g., PEComas, lymphangiomyomatosis, “sugar” tumor of lung, and cardiac rhabdomyomas

C-AML and E-AML often a spectrum

**ETIOLOGY/PATHOGENESIS**

**Sporadic AML**

> 90% of C-AML and ~75% of E-AML are sporadic

**Tuberous Sclerosis (TS)-Associated AML**

Genetic alterations in TSC1 or hamartin (Chr 9q34) and TSC2 or tuberin (Chr 16p13.3)

Up to 75% of TS patients will develop AML

Association of E-AML (~25%) to TS stronger

**CLINICAL ISSUES**

**Epidemiology**

Incidence

Uncommon, encountered in < 0.2% of population
**Age**

14-88 years old; median: 50 years
Younger for TS-associated AML (mean: 26 years)
E-AML younger than C-AML (mean: 39 vs. 52 years)

**Gender**

Higher female incidence shown by most studies

**Presentation**

~50% are incidental finding
~2/3 show signs of bleeding (e.g., hematuria, retroperitoneal hemorrhage) and ~1/5 has flank pain

**Natural History**

TS-associated AML presents earlier, larger, multifocal or bilateral, and more symptomatic than sporadic AML

**Treatment**

Conservative surgery for C-AML, such as partial nephrectomy, enucleation, or embolization
Expectant management suggested for radiographically typical AML
Surgical intervention for suspicion of malignancy, large size, hemorrhage, and intractable pain

**Prognosis**

Contemporary studies with C-AML shows benign outcome; retroperitoneal hemorrhage can be fatal
E-AML has malignancy potential with reported metastasis and deaths
Recurrence and metastasis varied from 5-49%
Reported mortality rates of 10-33%
Differences in aggressiveness influenced by varying diagnostic criteria and types of cases

**MACROSCOPIC FEATURES**

**General Features**

Solitary in 60% and multifocal in 40%

P.1l(7):35

Up to 100% of familial AMLs are multifocal/bilateral

**Size**

E-AML larger than C-AML
C-AML range from 1-30 cm; mean: 8.6 cm
E-AML range from 0.2-35 cm; mean: 5.6 cm
Familial larger than sporadic AMLs (mean: 13 vs. 5 cm)

**Gross Appearance**

C-AML
Unencapsulated and may bulge or extend to extrarenal fat (not a sign of malignancy)
Variable appearance depending on predominance of fat (lipoma-like) or spindle cells (leiomyoma-like)

E-AML
Unencapsulated and may extend outside of kidney
More solid with variable amount of hemorrhage, necrosis, or cystic degeneration

**MICROSCOPIC PATHOLOGY**

**Histologic Features**

C-AML
Usually triphasic pattern of dysmorphic vessels, fat, and spindle cells in up to 85% of cases
In 15%, fat or spindle cells may predominate (comprises 95% of tumor)
Vessels are ectatic, hyalinized with eccentric lumen
Spindle cells have granular cytoplasm, bland nuclei, rare mitosis, and appear to radiate from vessels
Fat cells are mature and may have nuclear atypia
Rarely, may have epithelial cysts lined by cuboidal or hobnail cells (AML with epithelial cells)

E-AML
Carcinoma-like growth
Cohesive nests, broad alveoli or sheets compartmentalized by vascular septae
Diffuse epithelioid and plump spindle cell growth
Cells have pale to granular eosinophilic cytoplasm
Nuclei tend to be atypical or pleomorphic
Brisk mitosis (> 5 per HPF) with atypical forms
Larger pleomorphic multinucleated cells present
Hemorrhages, necrosis, vascular invasion, and extrarenal extension not uncommon

864
ANCILLARY TESTS
Immunohistochemistry
- Melanocytic markers (HMB-45, MART-1, tyrosinase) (+); rare cells (+) in fat-predominant AML
- Epithelial markers (-); spindle cells actin (+)

DIFFERENTIAL DIAGNOSIS
C-AML
- Sarcomatoid spindle RCC or urothelial carcinoma
  - High grade, keratin (+), and melanocytic markers (-)
- Liposarcoma
  - Lacks dysmorphic vessels and MDM2 or CDK4 (+)
  - Smooth muscle tumors (leiomyoma or leiomyosarcoma)
    - So-called “capsuloma” likely fat-poor AML (HMB-45[+])
    - No dysmorphic vessels and melanocytic markers (-)

E-AML
RCC
- Clear cell RCC CAIX(+); melanocytic markers (-)

SELECTED REFERENCES

Image Gallery
Gross and Microscopic Features

(Left) Gross photograph of partial nephrectomy for C-AML shows variegated appearance because of varying admixture of spindle cells, fat, and vessels. This tumor protrudes into the perinephric fat, which is not uncommon for AML. (Right) Blood vessels in C-AML are abnormal (ectatic, thickened, and hyalinized). The epithelioid and spindle cells appear to arise from around the vessels or from perivascular epithelioid cells. Spindle cells merge with the fat component, which exhibits some atypia.
(Left) C-AML shows predominance of spindle cells (leiomyomatous AML). Tumor cells can be seen originating from around the vessels. In areas with prominent spindle cells, the tumor may have a hemangiopericytoma-like appearance. (Right) C-AML shows predominance of fat (lipoma-like AML) that may exhibit atypia. Careful search for abnormal vessels with spindle or epithelioid cells, as shown in this image, should be made. Lipoma-like AML may resemble a well-differentiated liposarcoma from the retroperitoneum.

(Left) Tuberous sclerosis patients may exhibit multiple and bilateral AMLs. As shown in this image, AML can be seen microscopically, incidentally in resected kidneys. Renal cysts are also common in tuberous sclerosis patients. (Right) E-AML shows diffuse epithelioid and plump spindle cell growth. Tumor cells show granular eosinophilic cytoplasm, and the nuclei exhibit some degree of pleomorphism. E-AML more often shows less prominent vascularity and rare fat cells. E-AML may resemble RCC.

P.II(7):37

Microscopic Features and Differential Diagnosis
E-AML shows admixture of epithelioid and spindle cells with granular eosinophilic cytoplasm. The nuclei are more variable with obvious nuclear atypia. This degree of nuclear atypia is greater than in usual clear cell RCC, which is the main differential diagnosis. This feature should raise suspicion for E-AML. Admixture of spindle cells and, occasionally, focal areas of abnormal vessels and fat may help in diagnosis.

MART-1 immunostain shows diffuse cytoplasmic immunoreactivity of the spindle cell component of C-AML. Other melanoma markers, such as HMB-45 and MITF are positive in AML. C-AML shows predominant spindle cells with absence of fat (leiomyomatous AML). Spindle cells may exhibit fascicular growth with elongated nuclei. These spindle cells are positive for smooth muscle markers. Most experts believe that the so-called capsulomas are likely fat-poor AMLs.
Sarcomatoid RCC contains spindle cells mimicking C-AML. Sarcomatoid spindle cells are high grade and may have brisk mitosis. Search, including by additional sampling, for differentiated area (in this case papillary RCC), may aid in diagnosis. (Right) Dedifferentiated liposarcoma contains an admixture of fat and spindle cells resembling E-AML. Lipoblasts, which show nuclear indentation by fat vacuoles and high-grade spindle cells, are helpful in diagnosis.

Clear Cell Renal Cell Carcinoma

Renal epithelial neoplasm composed of cells with optically clear cytoplasm in solid alveolar growth

Etiology/Pathogenesis

- Mostly sporadic; up to 90% have somatic inactivation of VHL at Chr 3p25-26
- PBRM1 on Chr 3p21 2nd frequently mutated gene
- Encountered in VHL, constitutional chromosome 3 translocation, familial CCRCC, and subset of Birt-Hogg-Dubé syndrome and tuberous sclerosis patients

Clinical Issues

- Most common renal epithelial neoplasm (~75%)
- 21-89 years (mean: 61); younger in VHL patients
- 5-year disease-specific survival: 76%; poorer behavior than papillary RCC and chromophobe RCC

Macroscopic Features

- Usually well circumscribed with golden-yellow cut surface due to lipid content

Microscopic Pathology

- Solid alveoli/nests separated by meshwork of delicate vessels forming characteristic “chicken-wire” pattern
- Occasionally, hemorrhage occurs within alveoli/nests, forming “blood lakes”
- Tumor cells typically have optically clear cytoplasm due to intracellular glycogen and lipid
- Occasionally, cells have eosinophilic granular cytoplasm; usually have higher grade nuclei
- CAIX diffusely (+), CD10(+), RCC(+), pax-2(+), and pax-8(+)
CCRCC shows typical golden-yellow cut surface due to abundant lipid content. This tumor pushes into the renal sinus fat and should be sampled thoroughly to search for possible invasion (pT3a).
CCRCC consists of optically clear cells arranged in solid alveolar nests surrounded by intricate vascular meshwork imparting a “chicken-wire” appearance. Occasionally, hemorrhage may occur within nests.

**TERMINOLOGY**

**Abbreviations**
- Clear cell renal cell carcinoma (CCRCC)

**Synonyms**
- Conventional RCC

**Definitions**
- Malignant renal epithelial neoplasm composed of cells with optically clear cytoplasm in solid alveolar growth

**ETIOLOGY/PATHOGENESIS**

**Sporadic CCRCC**
- Vast majority of CCRCC are sporadic tumors
- Up to 90% have somatic inactivation of VHL at Chr 3p25-26 by mutation, loss, or DNA methylation
- Leads to nondegradation of hypoxia-induced factor (HIF); usually degraded by VHL gene products
- Inactivating mutation of PBRM1 on Chr 3p21; 2nd most frequently mutated gene in CCRCC (~40%)

**Familial CCRCC**
- Familial predisposition for CCRCC and no identifiable genetic factor; diagnosis of exclusion
- Usually older onset and presents with solitary CCRCC, similar to sporadic CCRCC
- von Hippel-Lindau (VHL) disease
  - Virtually all patients have inactivation of VHL
  - CCRCC seen in up to 45% of VHL patients
  - Frequently multifocal and bilateral CRCCs
  - Multiple renal cysts and small “clear cell tumorlets” involved the renal parenchyma
  - At risk of developing up to 600 tumors per kidney
- Constitutional chromosome 3 translocation
  - Rare hereditary predisposition for bilateral and multifocal CCRCC due to Chr 3 translocation
CCRCC may occur in a subset of patients with Birt-Hogg-Dubé syndrome and tuberous sclerosis complex.

**CLINICAL ISSUES**

**Epidemiology**

**Incidence**

Most common renal epithelial neoplasm (~75%)

**Age**

21–89 years (mean: 61)
Younger in VHL patients (16–67 years, mean: 39)

**Gender**

M:F = 1.1:1

**Presentation**

Mostly encountered as incidental radiologic findings

Classic triad of abdominal mass, flank pain, and hematuria seen in only ~25% of patients

In VHL, discovered due to extrarenal symptoms

**Treatment**

**Surgical approaches**

Nephrectomy; partial is preferred, particularly if tumor is < 4 cm and not involving hilum

Robotic-assisted procedure gaining popularity

In VHL patients, conservative surgery performed if tumor reaches 3 cm in size

**Drugs**

For advanced-stage CCRCC; resistant to chemotherapy

Tyrosine kinase inhibitor as 1st option

Immunotherapy (IL-2) considered 1 of standards but its use is limited by side effects

Therapies targeting HIF or mammalian target of rapamycin (mTOR) pathways show promise

**Prognosis**

5-year disease-specific survival: 76%; poorer behavior compared to papillary RCC and chromophobe RCC

P.II(7):39

**MACROSCOPIC FEATURES**

**General Features**

Usually well circumscribed; can be cystic

Golden-yellow cut surface due to lipid content

May show hemorrhages, necrosis, or cystic change

Sarcomatoid change is firm white-tan and infiltrative

**Size**

1.3–15 cm (mean: 6.2)

**MICROSCOPIC PATHOLOGY**

**Histologic Features**

Solid alveoli/nests separated by meshwork of delicate vessels forming characteristic “chicken-wire” pattern

Occasionally, hemorrhage occurs within alveoli/nests, forming “blood lakes”

Tumor cells typically have optically clear cytoplasm due to intracellular glycogen and lipid

Occasionally, cells have eosinophilic granular cytoplasm; usually have higher grade nuclei

True papillae, if present, should be focal; breakdown of alveoli/nests may form pseudopapillae

**ANCILLARY TESTS**

Immunohistochemistry

CAIX diffusely (+), CD10(+), RCC(+), pax-2(+) and, pax-8(+)

CD117(-), ksp-cadherin (-), CK7(-), AMACR(-), and GATA3(-)

**DIFFERENTIAL DIAGNOSIS**

**Chromophobe RCC**

CCRCC with clear and eosinophilic cells mimic classic and eosinophilic chromophobe RCC, respectively

With prominent cytoplasmic membrane, perinuclear halo, wrinkled nuclei, and common binucleation

CD117(+), ksp-cadherin (+), CK7(+), and CAIX(-)

**MITF/TFE Translocation Carcinomas**

Usually younger patients with higher stage disease

TFE3 carcinomas: Prominent papillae, occasional psammoma calcifications, and clear cells with voluminous cytoplasm

TFEB carcinomas: Biphasic with nests of larger clear cells and central smaller cells clustered around nodules of hyaline materials
Epithelial markers focally (+) or (-), TFE3(+) or TFEB(+)

Clear Cell Papillary RCC
- Common in end-stage kidneys and often partly cystic
- Papillary and solid growths containing clear cells with low-grade nuclei aligned away from basal aspect
- CAIX(+), CK7(+) and AMACR(-)

Epithelioid Angiomyolipoma
- Higher grade, abundant mitosis, admixed plump spindle cells, and giant pleomorphic cells
- Epithelial markers (-) and melanocytic markers (+) (e.g., HMB45, MITF, and MART-1)

SELECTED REFERENCES

Image Gallery

Microscopic Features

(Left) CCRCC shows abundant hemorrhage within the central aspects of alveolar nests, creating multiple “blood lakes.” (Right) CCRCC is typically composed of tumor cells with optically clear cytoplasm due to abundant glycogen and fat content that are not preserved with processing. Few nuclei show prominent nucleoli visible on low-power view, consistent with Fuhrman nuclear grade (FNG) 3. Most of the nuclei are small without nucleoli, consistent with FNG 1. Grading is based on the highest nuclear grade present.
(Left) CCRCC shows FNG 4 nuclei characterized by marked pleomorphism and multinucleation. The high-grade nuclei increase the chance for recurrence and metastasis. (Right) CCRCC with eosinophilic cytoplasm retains the basic architecture of intricate vessels and solid alveolar nests. Cells in CCRCC with eosinophilic cytoplasm usually have higher grade nuclei. This tumor may resemble other renal tumors with eosinophilic cytoplasm; the intricate vasculature is a helpful distinguishing feature.

(Left) VHL patients’ kidneys harbor multiple microscopic “clear cell tumorlets,” seen here between normal renal tubules. The cytology of these cells is similar to that of CCRCC. It is debatable whether to consider these microscopic clear cell foci as CCRCC. (Right) A VHL patient’s kidney shows microcysts. These small cysts are lined by 1 or few layers of clear cells with low-grade nuclei. Management of VHL patients requires regular surveillance and intervention for renal masses that reach 3 cm in size.

P.II(7):41

Immunohistochemistry and Differential Diagnosis
(Left) CCRCC typically shows strong diffuse membranous staining with CAIX, a helpful marker in the differential diagnosis from most other renal tumors with pale or clear cytoplasm. (Right) Chromophobe RCC shows tumor cells with flocculent cytoplasm, prominent cell membrane (plant cell-like), perinuclear halo, koilocytoid nuclear atypia, and common binucleation. Unlike CCRCC, this tumor is diffusely CD117 and ksp-cadherin positive and CAIX negative.

(Left) TFE3 translocation carcinoma shows clear cells with abundant or voluminous cytoplasm. This tumor is more common in younger individuals and presents with higher stage. Diagnoses can be confirmed by TFE3 positivity. (Right) TFEB carcinoma shows dual population of cells consisting of larger clear cells arranged in nests surrounded by thin vessels and with central collections of smaller cells. This tumor occurs in younger individuals and can be confirmed by TFEB positivity.
Clear cell papillary RCC may show solid areas that may resemble CCRCC. However, clear cell papillary RCC shows tubules lined by clear cells with low-grade nuclei lined at the luminal aspect. This tumor is also CAIX(+), but unlike CCRCC, it is CK7(+). (Right) Epithelioid AML may exhibit a carcinoma-like growth and resemble CCRCC. Epithelioid AML usually shows nuclear pleomorphism with multinucleation and abundant mitosis. This tumor is pankeratin (-) and HMB45(+), unlike CCRCC.

Papillary Renal Cell Carcinoma

> Table of Contents > Part II - Diagnoses Associated With Specific Syndromes > Section 7 - Genitourinary > Kidney > Papillary Renal Cell Carcinoma

Gladell P. Paner, MD

Key Facts

Terminology

Renal epithelial neoplasm predominantly exhibiting papillary or tubulopapillary architectures

Etiology/Pathogenesis

Vast majority of PRCCs are sporadic tumors

Majority of PRCCs show Chr +7, +17, and -Y

Hereditary PRCC syndrome is characterized by development of multiple type 1 PRCCs related to a germline MET mutation

Clinical Issues

~10-15% of renal tumors; 2nd most common type

5-year survival rate is 82-90%; better than clear cell RCC but poorer than chromophobe RCC

Worse prognosis suggested for PRCC type 2 vs. type 1

Macroscopic Features

Well circumscribed with fibrous pseudocapsule

~40% multifocal; highest for sporadic renal tumors

Hemorrhage is common

Microscopic Pathology

Distinct papillary architectures with fibrovascular cores, usually with foamy histiocytes within the stalk

Tubulopapillary pattern common; ~50% with tubules

PRCC type 1: Smaller cells with few or modest amphophilic or basophilic cytoplasm, usually with low-grade nuclei

PRCC type 2: Larger cells with abundant eosinophilic cytoplasm, usually with higher grade nuclei

Ancillary Tests

AMACR(+), CK7(+), and EMA(+)
PRCC type 1 shows papillae lined by small cuboidal cells with amphophilic cytoplasm and low-grade nuclei. Papillae contain hemosiderin-laden histiocytes from an old hemorrhage, which is common in PRCC.
PRCC type 2 shows papillae lined by cells with abundant eosinophilic cytoplasm and nuclei with prominent nucleoli. Type 2 cells usually have higher grade nuclei. Foamy histiocytes are common in papillary cores.

**TERMINOLOGY**

**Abbreviations**
- Papillary renal cell carcinoma (PRCC)

**Synonyms**
- Chromophil renal cell carcinoma

**Definitions**
- Renal epithelial neoplasm predominantly exhibiting papillary or tubulopapillary architectures
- Published cut-off for papillae varies from 50-75%

**ETIOLOGY/PATHOGENESIS**

**Sporadic PRCC**
- Vast majority of PRCC are sporadic tumors
- Majority show Chr +7, +17, and -Y

**Hereditary PRCC Syndrome**
- Autosomal dominant; characterized by multiple type 1 PRCCs related to a germline MET mutation
- No associated extrarenal manifestations, unlike other renal tumor syndromes

**Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Syndrome**
- Some renal tumors previously classified as PRCC type 2
- Subsequently, renal tumors were identified to have unique features absent in PRCC (i.e., large inclusion-like nucleolus and perinucleolar clearing)

**CLINICAL ISSUES**

**Epidemiology**

**Incidence**
- ~10-15% of renal tumors; 2nd most common type

**Age**
- 22-83 years (mean: 62 years)
Gender
   More common in men (M:F = 1.8:1)
Presentation
   Majority of tumors detected incidentally
   Hematuria, flank pain, and abdominal mass
Treatment
   Nephrectomy, partial preferred if tumor is < 4 cm and does not involve the hilum
Prognosis
   5-year survival rate is 82-90%; better than clear cell RCC but poorer than chromophobe RCC
   Worse prognosis suggested for PRCC type 2 vs. type 1
MACROSCOPIC FEATURES
General Features
   Well circumscribed with fibrous pseudocapsule
   Multifocal in ~40%; highest for sporadic renal tumors
   Homogeneous tan to brown or variegated cut surface
   Hemorrhage is common and produces red to dark brown discoloration
   Collections of histiocytes cause yellowish streaks
   Sarcomatoid change: Firm white tan with infiltration
Size
   Range: 1.8-18 cm (mean: 6.7 cm)
MICROSCOPIC PATHOLOGY
Histologic Features
   Distinct papillary architectures with fibrovascular cores, usually with foamy histiocytes within the stalk
   Tubulopapillary pattern common; ~50% with tubules
   P. II(7):43
   Tubules may have intratubular cell proliferation (glomeruloid pattern)
   Tubular pattern may predominate and can be compacted (“solid variant”)
   Typing based on cell types
   PRCC type 1: Smaller cells with few or modest amphophilic or basophilic cytoplasm, usually with low-grade nuclei
   PRCC type 2: Larger cells with abundant eosinophilic cytoplasm, usually with higher grade nuclei
   PRCC mixed types 1 and 2: Mixture of cells seen in up to 24% of cases
   Psammomatous calcifications are occasionally present
   Hemorrhages, hemosiderin pigment deposits, necrosis, and cystic change are occasionally present
Grading
   Fuhrman grading system not applicable
   Grading based on nucleolar prominence proposed
ANCILLARY TESTS
Immunohistochemistry
   AMACR(+), CK7(+), and EMA(+)
DIFFERENTIAL DIAGNOSIS
Mucinous Tubular and Spindle Cell Carcinoma
   May resemble sarcomatoid PRCC type 1; also expresses AMACR, CK7, and EMA
   Contains mucinous stroma; can be abundant
   Spindle cells are low grade
   Cytogenetically does not harbor Chr +7, +17, and -Y
Collecting Duct Carcinoma
   May exhibit papillae (focal) and CK7 positivity
   Multinodular and infiltrative, centered at medulla
   High-grade cells, some have hobnail appearance
   Admixed invasive glands (adenocarcinoma) with marked stromal desmoplasia
Metanephric Adenoma
   Exhibits papillae, glomeruloid structures, and psammoma calcifications
   Tumor cells have scant cytoplasm with uniformly low-grade nuclei (primitive-appearing cells)
   WT1(+), CD57(+), and AMACR(-)
Clear Cell Papillary RCC
   Papillae lined by low-grade clear cells with nuclei aligned away from cell base
Cystic component common; often in end-stage kidneys
CK7(+), CAIX(+), and AMACR(-)

**MiTF/TFE Family Translocation Carcinomas**

- Usually in pediatric or young adult patients
- Papillae contain prominent clear cell component, sometimes with voluminous cytoplasm
- Epithelial marker is focally (+) or (-) and TFE3(+)

**SELECTED REFERENCES**


**Image Gallery**

**Gross and Microscopic Features**

(Left) PRCC shows a well-circumscribed tumor with solid, light-tan cut surface. Tumor may show pseudocapsule. Red-brown and yellow discoloration from hemorrhages and histiocytic infiltrates, respectively, are common in PRCC. (Right) PRCC type 1 is lined by cells with scant cytoplasm and low-grade nuclei imparting a basophilic appearance. PRCC type 1 papillae are usually lined by 1 layer or a few layers of cells with minimal stratification. PRCC type 1 cells resemble those in most papillary adenomas.
PRCC type 1 with predominant tubular growth imparts a solid appearance. Some tubules have glomeruloid pattern due to intratubular cellular proliferation. About 50% of PRCCs have tubular growth, and occasionally, it is predominate, as in this tumor. (Right) High-power view of PRCC type 2 shows cells with larger nuclei and occasional prominent nucleoli than in type 1. PRCC type 2 exhibits relatively more frequent cellular stratification. Papillary cores are thin and contain delicate vasculature.

PRCC shows mixed small cuboidal cells (type 1) and large eosinophilic cells (type 2). Admixture of these cells are encountered in ~1/4 of PRCC. PRCC type 2 is considered to have worse prognosis than type 1. Behavior of mixed PRCC types 1 and 2 is unclear. (Right) PRCC shows strong diffuse cytoplasmic immunoreactivity to AMACR. This immunostain is expressed in > 95% of PRCC and helps to distinguish it from most other renal tumors with papillary growth. PRCC and papillary adenoma are positive with AMACR.

Differential Diagnosis
Mucinous tubular and spindle cell carcinoma may exhibit focal papillation and resemble PRCC type 1. This tumor, however, exhibits prominent basophilic mucin in stroma. (Right) Mucinous tubular and spindle cell carcinoma also contains elongated tubular and spindle cells and may mimic a PRCC type 1 with sarcomatoid change. Unlike PRCC, this tumor contains abundant mucin in stroma, and the cells have bland-appearing nuclei unlike in sarcomatoid spindle cells, which are high grade.

Collecting duct carcinoma may exhibit papillary growth and mimic PRCC. Unlike PRCC, this tumor shows higher grade cells with hobnailing. Furthermore, collecting duct carcinoma also exhibits an infiltrative gland component. (Right) Metanephric adenoma shows papillary, tubulopapillary, and glomeruloid growth similar to PRCC. However, tumor cells have minimal cytoplasm (resembling primitive metanephric cells) and intervening paucicellular stroma.
TFE3 translocation carcinomas may exhibit papillary growth. The tumor contains high-grade clear cells that may have abundant (voluminous) cytoplasm. Translocation carcinoma is often seen in young adults and pediatric patients. Clear cell papillary RCC is characterized by papillae lined by clear cells with low-grade nuclei linearly placed away from the basal aspect of the cells. Cystic change is usual, and this tumor is more common in end-stage kidneys but may occur sporadically.

Renal Oncocytoma, Chromophobe, and Hybrid Oncocytic Tumors

Renal Oncocytoma, Chromophobe, and Hybrid Oncocytic Tumors

Gladell P. Paner, MD

Key Facts

Terminology

RO: Benign renal epithelial neoplasm characterized by eosinophilic cells, uniform nuclei, and small nests

Renal oncocytosis: Kidney involved by innumerable oncocytic nodules

CHRCC: Renal epithelial neoplasm characterized by prominent cytoplasmic membrane, flocculent cells, perinuclear clearing, and koiocytoid nuclei

HOT: Tumor with mixed RO and CHRCC cells

Etiology/Pathogenesis

BHD patients' renal tumors have higher proclivity for HOT (50%), CHRCC (34%), and oncocytosis (58%)

Clinical Issues

BHD renal tumors: Younger (37-67 years; mean: 51)

RO: Benign tumor & CHRCC: > 90% 5-year survival

Macroscopic Features

Multifocality/bilaterality common in familial tumors

Microscopic Pathology

RO: Small nests, tubulocystic with hyalinized stroma, and cells have eosinophilic granular cytoplasm, uniform nuclei, and occasional prominent nucleoli

CHRCC, classic type: Small/large solid nests and cells with pale cytoplasm, distinct cell membrane, perinuclear halo, binucleation, round to irregular (koilocytoid) nuclei with occasional large nucleoli

CHRCC, eosinophilic type: More dense eosinophilic granular cytoplasm

CHRCC, mixed type: Mixed pale and eosinophilic cells; pale cells usually at periphery

RO and CHRCC: CD117(+) and ksp-cadherin (+)
RO is characterized by tumor cells with eosinophilic granular cytoplasm in small nested growth and with round regular nuclei. Broad solid alveolar growth and high-grade irregular nuclei are not permissible in RO.
Classic CHRCC shows broad solid alveolar growth and tumor cells with pale or flocculent cytoplasm, prominent cell membrane (plant cell-like), perinuclear halo, koilocytoid nuclear atypia, and binucleation.

TERMINOLOGY

Abbreviations
- Renal oncocytoma (RO)
- Chromophobe renal cell carcinoma (CHRCC)
- Hybrid oncocytic tumor (HOT)

Definitions
- **RO**
  - Benign renal epithelial neoplasm characterized by eosinophilic cells, uniform nuclei, and small nests
- **Renal oncocytosis**
  - Kidney involved by innumerable oncocytic nodules
- **CHRCC**
  - Malignant renal epithelial neoplasm characterized by prominent cytoplasmic membrane, flocculent cells, perinuclear clearing, and koilocytoid nuclei
- **HOT**
  - Tumor with mixed RO and CHRCC cells

ETIOLOGY/PATHOGENESIS

Sporadic Tumors
- Vast majority of RO and CHRCC are sporadic

Cytogenetics
- **RO**: Loss of Chr 1 and Y and 11q23 alteration
- **CHRCC**: Multiple loss (Chr 1, 6, 10, 13, 17, 21 & Y)

Nonfamilial HOT uncommon and oncocytosis rare

Birt-Hogg-Dubé (BHD) Syndrome
- Autosomal dominant characterized by tumors of hair follicles, pneumothorax, and renal tumors
  - Alteration of folliculin (FLCN) at Chr 17p11.2
15-30% develop renal tumors with higher proclivity for HOT (50%), CHRCC (34%), and oncocytosis (58%)

**Familial Oncocytomas**
- Chr 1 loss; has fewer chromosomal instabilities
- RO often bilateral &/or multifocal

**Succinate Dehydrogenase B-Deficient Tumors**
- Association with RO initially reported; recent studies show different tumors from RO and common RCCs

**CLINICAL ISSUES**

**Epidemiology**

**Incidence**
- RO accounts for 6% of all renal tumors
- CHRCC 3rd most common renal tumor (~5%)

**Age**
- RO: 32-89 years (mean: 67); CHRCC: 27-82 (mean: 59)
- BHD renal tumors affect younger patients (37-67 years, mean: 51)

**Gender**
- RO: M:F = 3.1:1; CHRCC: M:F = 1.1:1
- Oncocytosis: M:F = 1:2.5; BHD renal tumors: M:F = 5:1

**Presentation**
- Mostly incidental (66-83%)
- Hematuria, flank pain, and abdominal mass

**Prognosis**
- RO: Benign tumor, no potential for metastasis
- CHRCC: 5- and 10-year survival > 90%

**MACROSCOPIC FEATURES**

**General Features**
- Familial tumors have higher tendency for multifocality and bilaterality
- BHD tumors are 73% multifocal and 62% bilateral, and 57% have associated renal oncocytosis
- Familial oncocytomas are 67% bilateral

**RO**
- Well circumscribed, homogeneous, mahogany brown, with central scarring in ~50%; few may have focal perinephric fat extension (not a sign of malignancy)

**Oncocytosis**
- Dominant nodules range from 2-10.5 cm, with multiple microscopic to small nodules
- Gross features depend on type (RO, CHRCC, or HOT)

**CHRCC**
- Well circumscribed with central scarring in ~20%
- Classic type: Beige or light yellow
- Eosinophilic type: Mahogany brown (resemble RO)
- Sarcomatoid change: Firm, white-tan with infiltration

**MICROSCOPIC PATHOLOGY**

**Histologic Features**

**RO**
- Small nests, tubulocystic with hyalinized stroma
- Large nests or diffuse pattern not permissible; “compact small nests” of RO may appear solid
- Cells have eosinophilic granular cytoplasms, uniform nuclei and occasional prominent nucleoli
- Some may have degenerate-appearing nuclei and smaller cells with less cytoplasm (oncoblasts)
- Mitosis rare; high-grade nuclei not allowed

**Oncocytosis**
- Dominant/larger tumors are RO, CHRCC, or HOT
- Smaller nodules from microscopic collections of few tumor cells to macroscopic visible lesions
  - Most have cells like RO, few like CHRCC or HOT
  - May percolate between tubules and glomeruli as irregular solid clusters or form tubules and cysts

**CHRCC**
- Classic type
  - Small/large solid nests; rare microcysts or tubules
Cells with flocculent pale cytoplasm and distinct cytoplasmic membrane (plant cell-like)
Perinuclear halo; round to irregular wrinkled dark nuclei (koilocytoid) with occasional large nucleoli
Binucleation common; may have large degenerative nuclei (like in RO)

Eosinophilic type
More dense eosinophilic granular cytoplasm
Mixed type (mixed pale and eosinophilic cells)
Pale cells usually at periphery of solid nests

HOT
Mixture of RO-like and CHRCC-like cells/areas
RO-like with high-grade nuclei excluded (categorized as unclassified RCC)

ANCILLARY TESTS
Immunohistochemistry
RO and CHRCC: CD117(+) and ksp-cadherin (+)
RO: CK7(-) or focal (+); classic CHRCC: CK7(+); eosinophilic CHRCC: CK7(+) or focal (+)

Electron Microscopy
Abundant mitochondria; microvesicles in CHRCC

DIFFERENTIAL DIAGNOSIS
Clear Cell RCC With Eosinophilic Cytoplasm
Solid alveolar nests with “chicken-wire" vasculatures
May have higher grade nuclei than RO (> Fuhrman nuclear grade 2 [FNG2])
CAIX diffusely (+); CD117/ksp-cadherin (-)

SELECTED REFERENCES

```
(Left) Gross photograph of RO shows typical central scar seen in “50% of cases. This finding, however, is not specific and can be seen in “20% of CHRCC, particularly in eosinophilic type. Both RO and eosinophilic CHRCC show mahogany brown appearance. (Right) Low-power view of RO shows nested growth that is more compact at periphery and loose toward the center (central scarring). This RO exhibits random degenerate nuclear atypia, appreciable even on low-power view, which is not uncommon in RO.
```
RO typically exhibits small nested growth. Diffuse solid or broad large alveolar growths should be excluded in RO. More compact growth of small nests, as seen in this image, may impart a diffuse or solid growth, and should be examined closely for outline of tight small nests of RO. (Right) RO shows round relatively regular nuclei. Presence of marked nuclear irregularity or atypia should prompt consideration of a diagnosis of RCC. Cytoplasm is eosinophilic and granular due to abundance of mitochondria.

Renal oncocytosis shows innumerable oncocytic nodules in the kidney. Some may be small and microscopic, as seen in this image. This minute oncocytic nodule is composed of low-grade cells with abundant eosinophilic cytoplasm and percolates between renal tubules. (Right) Gross photograph of CHRCC, eosinophilic type, shows well-circumscribed tumor with mahogany brown appearance similar to RO. Considerable overlap from gross to microscopic exists between RO and CHRCC, eosinophilic type.

P.II(7):49

Microscopic Features and Differential Diagnosis
Low-power view of CHRCC, classic type, shows the typical broad solid alveolar growth. There is paucity of vessels within the broad alveolar area, unlike in clear cell RCC. CHRCC, classic type, shows tumor cells with pale or flocculent cytoplasm and prominent cytoplasmic membrane imparting a plant cell-like appearance. Nuclei of CHRCC are innately atypical or pleomorphic despite its being a low-grade tumor. Thus, Fuhrman nuclear grading is not applicable in CHRCC.

CHRCC, eosinophilic type, demonstrates cells with abundant eosinophilic cytoplasm similar to RO. Unlike RO, nuclei exhibit koilocytoid atypia, perinuclear halo, and more frequent binucleation. CHRCC, eosinophilic type, may exhibit small nested growth similar to RO. Diagnosis can be made by nuclear features. Currently, there are no reliable immunohistochemical stains to distinguish these 2 tumors, and distinction is mainly morphologic.
HOT shows area of cells with more diffuse growth and relatively variable nuclei, consistent with CHRCC, and another area of cells in smaller nests with more uniform nuclei, consistent with RO. HOT is more frequently encountered in BHD and renal oncocytosis. (Right) Clear cell RCC with eosinophilic cytoplasm may resemble RO and CHRCC, eosinophilic type. Presence of “chicken-wire” vasculatures and nested growth are helpful futures for diagnosis of clear cell RCC.

Renal Urothelial Carcinoma

Familial cases: Lynch syndrome (a.k.a. HNPCC)
- Associated with inherited mutations in DNA mismatch repair genes, most commonly with MSH2 (~90%), but also observed in small numbers of MLH1, MSH6, PMS2, and EpCAM (TACSTD1)
- ~6% lifetime risk for upper urinary tract UCa
- 22x higher risk than general population

Clinical Issues
- Upper tract UCa accounts for ~5-10% of all UCa
- Mostly present with gross or microscopic hematuria (70-80%)
- ~17% has concurrent bladder cancer
- In up to ~25% of ureteroscopic biopsy, diagnosis cannot be made due to inadequate sampling

Macroscopic Features
- Papillary or polypoid mass involving or filling pelvicalyceal space
- Infiltrative mass may extensively involve kidney and mimic primary high-grade renal carcinoma

Microscopic Pathology
- Histologic classification similar to bladder UCa (WHO, 2004)
- Higher percentage of non-UCa and variant morphology (25%) than bladder
- Other morphologies may occur, e.g., small cell, micropapillary, plasmacytoid, lymphoepithelioma-like, and sarcomatoid carcinomas
- Intratubular growth by UCa (pTis) should not be interpreted as renal parenchymal invasion (pT3)
Bivalved resected kidney (coronal plane) shows a urothelial carcinoma (UcA) along the lower pole collecting system and is invading into the renal parenchyma with no extension into perinephric fat.
Low-power view shows a papillary UcA involving and filling the renal pelvis lumen. Despite its size, this tumor does not show invasion into the underlying structures, evident by the regular smooth boundary.

TERMINOLOGY

Abbreviations
Urothelial carcinoma (UcA)

Synonyms
Renal transitional cell carcinoma, pelvicaliceal UcA

Definitions
Carcinoma arising from pelvicaliceal urothelium

ETIOLOGY/PATHOGENESIS

Risk Factors
Similar to bladder cancer
- Tobacco exposure increases risk by 2.5-7x
- Long exposure to aromatic amines (e.g., benzidine, β-naphthalene) ↑ risk by 8.3x
  ~7 years of exposure, with latency of ~20 years to develop upper tract UcA

Familial Renal UcA
Lynch syndrome, a.k.a. hereditary nonpolyposis colorectal cancer (HNPCC) syndrome
- Autosomal dominant condition with increase risk for cancer of colon (most common: 63%), uterus (9%), upper urinary tract, stomach, ovary, biliary tract, pancreas, and brain
- Lifetime risk of cancer up to 80% by age 70 years
- Associated with inherited mutations in DNA mismatch repair genes
  - Most commonly with MSH2 (~90%), but also observed in small numbers of MLH1, MSH6, PMS2, and EpCAM (TACSTD1)
  - ~6% Lifetime risk for upper urinary tract UcA
- 22x higher risk than general population
- Younger median age of onset (56 years, or 10-15 years younger than sporadic cases)
- More likely to have bilateral disease than sporadic cases
Risk is higher for ureter than renal pelvis uCa; risk for bladder uCa not established
UCA s have more potential for high grade than in general population
Suspect hereditary upper tract uCa if
Patient < 60 years old
History of HNPCC-associated cancer
First-degree relative < 50 years of age with HNPCC-associated cancer
2 first-degree relatives with HNPCC-associated cancer
Suspected patients should undergo DNA testing for confirmation

CLINICAL ISSUES
Epidemiology
Incidence
Upper tract uCA accounts for ~5-10% of all uCA
Annual incidence of 2 new cases per 100,000 in Western countries
Age
Range: 40s to 90s; median: 69 years (similar to bladder uCA)
Gender
M:F = 2:1
Presentation
Gross or microscopic hematuria (70-80%)
Flank pain (20-40%)
Lumbar mass (10-20%)
Systemic symptoms, such as anorexia, weight loss, malaise, fatigue, fever, night sweats, or cough for metastasis
~17% have concurrent bladder cancer

Endoscopic Findings
Papillary or sessile mass; may fill renal pelvic cavity
In up to ~25% of ureteroscopic biopsies, diagnosis cannot be made due to inadequate sampling
Potential pitfall in diagnosis
Treatment
Surgical approaches
Radical nephroureterectomy (RNU) with excision of bladder cuff is gold standard therapy
Indicated for suspicion of infiltrating uCA on imaging, high-grade uCA, multifocality and noninvasive but > 2 cm tumor size
Prognosis
Dependent on stage (most consistent on multivariate analyses)
5-year specific survival is < 50% for pT2/pT3 and < 10% for pT4
Other important prognostic factors
Grade, tumor size, multifocality, lymphovascular invasion, hydronephrosis, and positive margin after RNU
Associated with poor prognosis are advanced age, ECOG performance status ≥ 1, body mass index ≥ 30, systemic symptoms, and previous/synchronous bladder cancer
Recurrence in bladder occurs in 22-47%
Recurrence in contralateral upper tract occurs in 2-6%
MACROSCOPIC FEATURES
General Features
Papillary or polypoid mass involving or filling pelvicalyceal space
Infiltrative mass may extensively involve renal parenchyma and mimic primary high-grade renal carcinoma
MICROSCOPIC PATHOLOGY
Histologic Features
Classification similar to bladder uCA (WHO, 2004)
Papillary urothelial neoplasms
Urothelial papilloma and papillary uCA of unknown malignant potential (PUNLMP) rare in renal pelvis
Papillary uCA, low grade
Papillary uCA, high grade
Flat urothelial neoplasms
Urothelial dysplasia
UcA in situ

Invasive carcinoma, conventional UcA and variants

Higher percentage of non-UcA and variant morphology (25%) than bladder

Most common variants: Squamous cell carcinoma (9.9%) and carcinomas with glandular differentiation (4.4%)

Other morphologies may occur, e.g., small cell, micropapillary, plasmacytoid, lymphoepithelioma-like, and sarcomatoid carcinomas

Intratubular growth by UcA (pTis) should not be interpreted as renal parenchymal invasion (pT3)

Involvement of renal parenchyma by UcA shows infiltrative, irregular nests in contrast to well-circumscribed mass common among renal cell carcinoma subtypes

Inverted growth of UcA suggested to be associated with Lynch syndrome

SELECTED REFERENCES


P.II(7):52

Image Gallery

Gross and Microscopic Features

(Left) Gross image shows a UcA involving the inferior pelvicaliceal system. At the upper aspect, the tumor shows a relatively regular and distinct boundary whereas at the inferior aspect, there is focal infiltration of the renal parenchyma. Distinction between renal UcA and primary renal cell carcinoma can often be made by gross examination alone. (Right) Low-power view shows a renal pelvis low-grade papillary UcA. It is not uncommon to see large papillary UcA with low-grade cytology in the renal pelvis.
This renal pelvis low-grade papillary UcA shows similar histology to low-grade UcA elsewhere in the GU tract. The tumor cells exhibit mild nuclear atypia with oval nuclei, vesicular chromatin, and mild cellular disorganization.

(Right) Low-power view shows a high-grade papillary UcA with necrosis in the renal pelvis and extending into the ureteropelvic portion. Note the adjacent peripelvic fat; infiltration of tumor into this fat is staged similar to renal parenchymal invasion.

(Left) Low-power view shows a high-grade noninvasive papillary UcA in the renal pelvis with delicate exophytic papillae containing fibrovascular cores. Similar to UcA elsewhere, grading of renal UcA is based entirely on cytomorphological features. (Right) High-grade papillary UcA shows fused papillae containing disorganized, large pleomorphic cells with nuclear rounding and frequent overlap. Nuclear chromatin is dense and mitosis is frequent. No invasion is present in this tumor.

Microscopic and Immunohistochemical Features
(Left) Invasive UCa to renal parenchyma is seen infiltrating between glomeruli. There are irregular nests and small cell clusters in a desmoplastic background. (Right) This noninvasive papillary UCa exhibits an endophytic growth characterized by a smooth, regular outline and no desmoplastic response. Inverted growth is suggested to be a feature of renal UCa in Lynch syndrome. Note the artifactual dyscohesion, which is not uncommon in nephrectomy specimens for UCa.

(Left) H&E shows UCa in situ involving the renal pelvis urothelium. There is cellular disorganization with nuclear pleomorphism and hyperchromaticity. (Right) Low-power view shows UCa in situ in the renal pelvis urothelium with extension within the collecting ducts. Note the outline of the tumor nests follows the contour of the native tubules with no desmoplastic reaction. This growth remains noninvasive (pTis) and should not be overstaged as renal parenchymal invasion (pT3).
Low-power view shows a high-grade UcA with squamous differentiation exhibiting abundant keratinization. In terms of proportion, variant morphology of UcA is more frequent (~25%) in the renal pelvis than in the bladder. GATA3 shows diffuse nuclear staining in this invasive renal UcA. GATA3 can be helpful in the distinction of UcA from renal carcinoma. Distinction between renal UcA and renal carcinoma has important prognostic and therapeutic implications.

Wilms Tumor

Malignant immature tumor of nephrogenic blastemal cell origin that may differentiate into epithelial or mesenchymal cells, recapitulating renal embryogenesis

Genes altered in Wilms tumor (WT) include WT1, CTNNB1, WTX, IGF2, and P53

Mutations in WT1 occur in 15-20% of SWT

WT1 considered not the predisposition gene in most FWT families

WT cases grouped into

- SWT, comprising up to 99% of cases
- FWT, comprising ~1-2% of cases

WT-associated syndromes, which include WT1-associated and overgrowth syndromes

Most common renal tumor of pediatric age group, accounting for 95% of tumors

Peak incidence at 2-3 years of age

Clinical outcomes excellent for both COG and SIOP therapies with > 90% overall survival

Classic histology of WT is a triphasic pattern composed of undifferentiated blastemal cells, epithelial cells, and stromal cells

Diffuse anaplasia considered a poor prognostic factor

WT1(+) in blastemal and epithelial but not stromal elements
H&E shows Wilms tumor (WT) with classic triphasic histology consisting of undifferentiated blastemal cells ➔, epithelial cells (tubules) ➔, and stromal cells ➔. Proportion of these 3 components in the tumor may vary.
Low-power view shows large nests of blastemal cells with serpentine growth. These are tightly packed undifferentiated cells with high nuclear to cytoplasmic ratio giving the appearance of small round blue cells.

**TERMINOLOGY**

**Abbreviations**
- Wilms tumor (WT)

**Synonyms**
- Nephroblastoma

**Definitions**
- Malignant immature tumor of nephrogenic blastemal cell origin that may differentiate into epithelial or mesenchymal cells, recapitulating renal embryogenesis

**ETIOLOGY/PATHOGENESIS**

**Gene Alterations in WT**
- **WT1**
  - Encodes a 55 kDa zinc finger transcription factor containing 4 carboxy-terminal zinc finger domains that mediate DNA binding
  - Localized at Chr 11p13
  - Transcript critical in early and late stages of genitourinary development
  - Mutations in WT1 common in sporadic WT and germline mutation consistently present in WT1-associated syndromes
- **CTNNB1**
  - Encodes an 88 kDa β-catenin protein
  - Functions as oncogene located at Chr 3p21
  - β-catenin is a main effector in Wnt/β-catenin signaling pathway
  - Mutations in CTNNB1 seen in ~15% of WT and majority are 3 nucleotide deletions or missense mutations that delete or mutate Ser45
- **WTX**
  - a.k.a. FAM123B or AMER1, which contributes to stabilization of β-catenin
Functions as tumor suppressor gene located at Chr Xq11.1
Altered in 7-29% of WT, with most (~2/3) carrying deletion of the entire WTX IGF2
Encodes an embryonic growth factor located at Chr 11p15
Loss of imprinting (LOI) occur in ~50% of WT, resulting in aberrant inactivation of IGF2
LOI found more often in perilobar nephrogenic rests (vs. WT1 mutations, which tend to be associated with intralobar nephrogenic rests)

**P53**
- Tumor suppressor gene located at Chr 17p13.1 and is the most frequently mutated gene in human cancers
- Altered in ~5% of WT by missense mutation
- Associated with diffusely anaplastic WT (AWT), detected in ~75% of cases

**Loss of Heterozygosity (LOH) in WT**
- LOH at Chr 1p and 16q are shown to be adverse prognostic factors in favorable histology Wilms tumor (FHWT)
  - Testing has sensitivity of 8% and specificity of 96%
  - Presence in FHWT requires more aggressive chemotherapy
  - Current Children Oncology Group (COG) guideline recommends LOH studies for Chr 1p and 16q in FHWT

**Other Significant Gene Abnormalities**
- Loss of Chr 4q and 14q specific for AWT
- Gain of Chr 1q and MYCN, and loss of Chr 16q, common in AWT and FHWT

**Sporadic WT (SWT)**
- Mutations in WT1 occur in 15-20% of SWT

**Familial WT (FWT)**
- WT1 not considered the predisposition gene in most FWT families
  - P.II(7):55

- 2 FWT genes mapped
  - FWT1 at Chr 17q12-q21
  - FWT2 at Chr 19q13.4
- Specific genes in these 2 regions have not yet been identified
- Lack of linkage in some families to FWT1 and FWT2 suggests the existence of at least 1 additional FWT gene

**WT-Associated Syndromes**
- ↑ risk for WT in syndromic settings
  - WT1-associated syndromes (WTS)
    - WAGR syndrome
      - Caused by microdeletions at Chr 11p13 that encompass WT1 and PAX6
    - Denys-Drash syndrome
      - Caused by point mutation in zinc finger region of WT1 at Chr 11p13
    - Frasier syndrome
      - Caused by point mutation in WT1 intron 9 donor splice site at Chr 11p13
  - Overgrowth syndromes (OGS)
    - Beckwith-Wiedemann syndrome
      - Most caused by altered expression of imprinted genes (KCNQ1OT1, CDKN1C, LIT1 or H19, and IGF2) located at Chr 11p15.5
    - Simpson-Golabi-Behmel syndrome
      - Majority (70%) caused by mutations or deletions of glypican-3 (GPC3) at Chr Xq26
    - Isolated (idiopathic) hemihypertrophy
      - Abnormality in Chr 11p15 in 20-35% of cases
    - Perlman syndrome
      - Unknown cause; GPC3 mutation suggested

**CLINICAL ISSUES**

**Epidemiology**

- 5th most common pediatric malignancy accounting for 6% of all pediatric renal cancers
- Estimated incidence of 7 in 1 million children < 16 years of age
- ~650 new cases diagnosed in USA per year
- Most common renal tumor of pediatric age group accounting for 95% of tumors
SWT comprises up to 99% of cases
FWT comprises ~1-2% of cases
Syndrome diagnosis seen in up to 17% of WT patients and OGS seen in ~4% of WT patients

Age
Peak incidence at 2-3 years of age
~75% occur in children < 5 years of age

Gender
Similar incidence in male and female

Presentation
Most commonly asymptomatic abdominal mass detected by relatives
Abdominal pain
Hematuria seen in ~20-30% of cases
Hypertension from renin overactivity seen in ~25% of cases
Subcapsular hemorrhage of tumor may cause rapidly enlarging abdominal mass, anemia, pain, and fever

Treatment
Surgical approaches
Surgeon has to completely remove the tumor without spillage and adequately assess extent of spread
Treatment approach differs for COG (includes National Wilms Tumor Study [NWTS]) followed mostly in USA, and the Société Internationale d'Oncologie Pédiatrique (SIOP) followed mostly in Europe
COG advocates resection 1st, followed by further therapy depending on stage and histology (i.e., favorable or unfavorable)
SIOP advocate neoadjuvant therapy followed by resection, and further therapy depends on stage, histology, and treatment response

Prognosis
Clinical outcomes excellent for both COG and SIOP therapies with > 90% overall survival
Most common site for metastasis is lungs

MACROSCOPIC FEATURES
General Features
Most are unilateral and unifocal tumors

MICROSCOPIC PATHOLOGY
Histologic Features
Classic histology of WT is a triphasic pattern composed of undifferentiated blastemal cells, epithelial cells, and stromal cells
Some WTs may have predominance of 2 or 1 components or may only have 2 (biphasic) or 1 (uniphasic) component
Blastemal cells
Tightly packed primitive cells with high nuclear to cytoplasmic ratio (round blue cells)
Nuclei have evenly spread chromatin and with indistinct nucleoli
Mitotically active and may show nuclear molding
Grow in small or large solid nests that can be serpiginous and infiltrative
Epithelial components
Variable, includes solid or hollow primitive or mature tubules, glomeruloid structures, and papillae
Rarely, focal mucinous cells and squamous cells may be present
Stromal components
Spindle cells that are commonly nondescript or with fibroblastic, smooth muscle, or skeletal differentiation
Often have myxoid background that resembles embryonic mesenchyme
Rarely, cartilage, bone, adipocytes, or neural elements
Anaplasia
Criteria for diagnosis (all 3 are nuclear features)
Markedly enlarged nuclei (at least 3x size of adjacent nuclei)
Nuclear hyperchromasia
Multipolar mitotic figure
Present in 5% of WT; more common in older children
Focal anaplasia
Clearly defined focus of anaplasia, without presence of anaplasia elsewhere
May have > 1 focus, but should be completely surrounded on all sides by nonanaplastic foci
Not considered a poor prognostic factor (i.e., considered favorable histology)

Diffuse anaplasia
Presence of anaplasia beyond above criteria for focal anaplasia
Considered a poor prognostic factor (unfavorable histology by COG)
Stage IA WT has 69% 10-year relapse-free survival vs. 91% for FWT
Correlates with p53 expression

Teratoid WT
Presence of extensive heterologous differentiation in WT, such as mucinous glands, cartilages, skeletal muscles
Tumor necrosis
Necrotic WT with < 1/3 viable area is considered completely necrotic; low-risk tumor (by SIOP)

ANCILLARY TESTS
Immunohistochemistry
WT1(+) in blastemal and epithelial but not stromal elements
pax-2 or pax-8(+)
Cytokeratin (+) in epithelial components
CK7 and CD57 may be positive in epithelial components
Desmin and CD56 may be positive in blastemal component

DIFFERENTIAL DIAGNOSIS
Small Round Blue Cell Tumors
Pediatric tumors in this morphologic group may occur in or at vicinity of kidney
Neuroblastoma, rhabdomyosarcoma, acute lymphoblastic lymphoma, poorly differentiated synovial sarcoma, and primitive neuroectodermal tumor (PNET)
Distinction can often be made with the use of ancillary immunohistochemistry

Immature Teratoma
May resemble teratoid WT
More organoid structural differentiation (vs. haphazard elements in teratoid WT)

Metanephric Adenoma
Primitive cells with high nuclear:cytoplasmic ratio arranged in papillae, tubules, or glomeruloid structures
May have stromal elements (metanephric adenofibroma)
Positive for WT1, similar to WT
Unlike WT, nuclei are bland and mitosis is rare and more common in adults

Papillary Renal Cell Carcinoma
Papillary and glomeruloid structures of type 1 tumors may resemble epithelial component of WT
AMACR(+), CK7(+), and WT1(-) unlike WT
More common in older patients (peak: 60s-70s)

Clear Cell Sarcoma of Kidney
Similar age group to WT and may resemble blastemal-predominant WT
Tumor cells with clearing and percolated by “chicken-wire” vasculatures
CD99(+), and WT1(-), unlike WT

SELECTED REFERENCES

TABLES

<table>
<thead>
<tr>
<th>Stage</th>
<th>Tumor Extent</th>
<th>Findings</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Tumor limited to kidney and completely excised</td>
<td>Tumor confined to kidney</td>
<td>40-45%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Renal capsule is intact or tumor not ruptured</td>
<td></td>
</tr>
</tbody>
</table>
### II Tumor extends beyond the kidney, but completely excised

- No invasion of lymphatic or veins of renal sinus
- Resection margin free of tumor
- Tumor with regional or local extension

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
<th>Probability</th>
</tr>
</thead>
<tbody>
<tr>
<td>II</td>
<td></td>
<td>20%</td>
</tr>
</tbody>
</table>

- Tumor penetrates capsule or perirenal tissue
- Tumor invades lymphatics or veins outside of kidney
- Resection margin free of tumor

### III Residual nonhematogenous tumor confined to abdomen

- Spillage from rupture before or during surgery
- Peritoneal implants
- Gross residual tumor in abdomen
- Microscopic or gross positive resection margin
- Positive lymph node involvement

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
<th>Probability</th>
</tr>
</thead>
<tbody>
<tr>
<td>III</td>
<td></td>
<td>20-25%</td>
</tr>
</tbody>
</table>

### IV Hematogenous metastasis

- Tumor deposits beyond stage III (i.e., lungs, liver, brain, or bone or distant lymph nodes)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
<th>Probability</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV</td>
<td></td>
<td>10%</td>
</tr>
</tbody>
</table>

### V Bilateral renal involvement

- Each side substages separately (e.g., stage V, substage II [right], substage I [left])

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>V</td>
<td></td>
</tr>
</tbody>
</table>

## Classification of WT After Neoadjuvant Therapy (SIOP)

<table>
<thead>
<tr>
<th>Risk Level</th>
<th>Tumor Histology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low-risk tumors</td>
<td>Cystic partially differentiated WT</td>
</tr>
<tr>
<td></td>
<td>Completely necrotic WT</td>
</tr>
<tr>
<td></td>
<td>Intermediate-risk tumors WT, epithelial type</td>
</tr>
<tr>
<td></td>
<td>WT, stromal type</td>
</tr>
<tr>
<td></td>
<td>WT, mixed type</td>
</tr>
<tr>
<td></td>
<td>WT, regressive type</td>
</tr>
<tr>
<td></td>
<td>WT, focal anaplasia</td>
</tr>
<tr>
<td>High-risk tumors</td>
<td>WT, blastemal type</td>
</tr>
<tr>
<td></td>
<td>WT, diffuse anaplasia</td>
</tr>
</tbody>
</table>

### Histological Criteria for WT Subtyping After Chemotherapy by SIOP

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Chemotherapy-Induced Changes (%)</th>
<th>Epithelium (%)</th>
<th>Stroma (%)</th>
<th>Blastema (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Completely necrotic</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Regressive</td>
<td>&gt; 66</td>
<td>0-33</td>
<td>0-33</td>
<td>0-33</td>
</tr>
<tr>
<td>Mixed</td>
<td>&lt; 66</td>
<td>0-65</td>
<td>0-65</td>
<td>0-65</td>
</tr>
<tr>
<td>Epithelial</td>
<td>&lt; 66</td>
<td>66-100</td>
<td>0-33</td>
<td>0-10</td>
</tr>
<tr>
<td>Stromal</td>
<td>&lt; 66</td>
<td>0-33</td>
<td>66-100</td>
<td>0-10</td>
</tr>
<tr>
<td>Blastemal</td>
<td>&lt; 66</td>
<td>0-33</td>
<td>0-33</td>
<td>66-100</td>
</tr>
</tbody>
</table>

P.II(7):58

Image Gallery
Microscopic Features
(Left) Low-power view shows WT, which typically has a well-defined border from the normal kidney parenchyma. WT with predominance of blastemal cells may exhibit more infiltrative growth with irregular boundary. (Right) H&E shows WT with epithelial structures amidst blastemal and stromal cells. The epithelial component is most often in the form of tubules, and may also form papillae or glomeruloid bodies. Mixed-type WT is considered an intermediate-risk tumor by SIOP working classification.

(Left) H&E shows epithelial component of WT with rosette-like structures or solid tubulopapillary formations. These structures contain cells with relatively regular hyperchromatic nuclei. Anaplasia is usually not appreciated in the epithelial component of WT. (Right) H&E shows well-differentiated hollow tubular epithelial structures in WT. Note the presence of abundant mitosis. Increased mitotic activity (excluding multipolar mitosis) is not considered a poor prognostic factor in WT.
(Left) WT shows presence of primitive glomeruloid structures consisting of large tubules with intraluminal papillary growths in a background of spindle cells in myxoid stroma. A nest of blastemal cells is present nearby. (Right) H&E shows WT with large solid nests of blastemal cells partly showing peripheral cellular palisading. These immature undifferentiated cells may predominate in WT (blastemal-type WT), which is considered a high-risk tumor by the SIOP working classification.

P.II(7):59

Microscopic Features

(Left) High-power view shows blastemal cells of WT. These cells typically have large overlapping nuclei, scant cytoplasm, and evenly distributed chromatin. Note the abundant mitoses. Blastemal cells of WT resemble other small round blue cell tumors that may occur in the kidney or extrarenal sites. (Right) H&E shows stromal cells and blastemal cells in WT. Stromal cells are often nondescript spindle cells. Sometimes these cells exhibit smooth muscle or skeletal muscle differentiation.
H&E shows WT with presence of a cluster of adipocytes in the stromal component. These fat cells exhibit atypia, including variability in size and multivacuolations. Rarely, the stromal component of WT may also contain other heterologous elements, such as cartilage, bone, or glial tissues (not shown). (Right) H&E shows WT with rhabdomyoblastic differentiation. The cells are focally spindled and some show dense eosinophilic cytoplasm with eccentric nuclei.

H&E shows WT with anaplasia, which is considered an unfavorable histology when diffuse. Features of anaplasia include markedly enlarged nuclei (3x in size compared to the rest of the tumor cells), hyperchromasia, and multipolar mitotic figures. (Courtesy S. Tickoo, MD.) (Right) Multipolar mitotic figures are considered a diagnostic feature of anaplasia in WT. Only diffuse, and not focal, anaplasia is used in making therapeutic decisions in WT. (Courtesy S. Tickoo, MD.)

P.II(7):60

Staging and Immunohistochemistry
Section shows WT involving the perinephric fat. This tumor is classified as stage II due to local extension of WT outside of the kidney with complete tumor resection (negative margin). (Right) Section shows WT seen within a large vessel. Note that the tumor follows the vessel contour. Involvement of a vessel in the renal sinus in a completely resected WT results in this tumor being classified as stage II. Stage and histology after resection are important pathologic variables that dictate subsequent therapy of WT.

Section shows WT with capsular rupture demonstrated by a tumor cell involving the inked capsule, which results in residual tumor in the abdomen. Tumor spillage of any degree before or during surgery is considered a stage III tumor. (Right) This WT shows abundant necrosis characterized by presence of tumor ghost cells (coagulative type necrosis). Note the focal viable cluster of blastemal cells. Completely necrotic WT after chemotherapy is considered a low-risk tumor (by SIOP).
WT1 shows diffuse nuclear positivity in WT. Blastemal and epithelial cells, and not the stromal cells, are usually positive for WT1 protein. Beware that metanephric adenoma may also be positive for WT1. (Right) pax-8 shows diffuse nuclear positivity in WT (pax-8 is nephric-lineage transcription factor crucial for kidney organogenesis). Expression of this protein is helpful in distinguishing WT from other nonrenal tumor mimics, particularly most other small round blue cell tumors.

Differential Diagnosis

H&E shows neuroblastoma with rosette formations, which have central neurophil surrounded by neuroblastic tumor cells (Homer Wright rosettes). This is in contrast to pseudorosettes, which have a central blood vessel. Unlike WT, neuroblastoma may exhibit cytoplasmic, and not nuclear, WT1 positivity. (Right) Low-power view shows teratoma giving rise to WT. Adjacent to WT are well-differentiated glands (including intestinal type glands), fat cells and skeletal muscles.
Metanephric adenoma shows tubulopapillary and glomeruloid growths of primitive-appearing cells with high nuclear to cytoplasmic ratio. Similar to WT, these tumor cells are positive for nuclear WT1. Unlike epithelial-predominant WT, the nuclei are more regular and lack mitotic figures. (Right) Papillary renal cell carcinoma type 1 shows papillae lined by cells with amphophilic cytoplasm. These tumors occur mostly in adults and are racemase (+) and WT1(-).

H&E shows “solid” variant of papillary renal cell carcinoma type 1 consisting of diffuse glomeruloid growth and may resemble epithelial-predominant WT. (Right) Clear cell sarcoma of the kidney may resemble blastemal or stromal component of WT. Clear cell sarcoma typically shows polygonal tumor cells with cytoplasmic clearing from mucopolysaccharide material and with presence of arborizing vasculatures. Unlike WT, clear cell sarcoma is negative for nuclear WT1.

Section 8 - Gynecology
Cervical Carcinoma

> Table of Contents > Part II - Diagnoses Associated With Specific Syndromes > Section 8 - Gynecology > Cervical Carcinoma
Cervical Carcinoma
Fabiola Medeiros, MD
Key Facts
Etiology/Pathogenesis
Peutz-Jeghers syndrome
  Caused by mutations of LKB1 (STK11) gene
  Cervix: Minimal deviation adenocarcinoma
  Ovary: Sex cord-stromal tumor with annular tubules (SCTATs)
  10% of MDAs (specifically the mucinous subtype) are associated with Peutz-Jeghers syndrome

Microscopic Pathology
  Minimal deviation mucinous adenocarcinoma
  Irregularly shaped glands that deeply infiltrate cervical wall
  Deceptively bland nuclear features

Minimal deviation adenocarcinoma shows deeply infiltrating mucinous glands.
Minimal deviation adenocarcinoma is composed of glands lined by tall columnar cells with abundant apical mucin and bland nuclei.

**TERMINOLOGY**

**Synonyms**

Minimal deviation adenocarcinoma (MDA) is also known as adenoma malignum

**Definitions**

Cervical carcinoma

Includes multiple types of epithelial tumors

Most common are squamous cell carcinomas and adenocarcinomas

MDA is a rare subtype of cervical adenocarcinoma

Can be subdivided in mucinous and endometrioid types

Particularly associated with Peutz-Jeghers syndrome (PJS)

**PJS**

Autosomal dominant disorder

Caused by mutations of LKB1 (STK11) gene

Mucocutaneous pigmentation

Hammartomatous gastrointestinal polyps

Increased cancer risk in multiple sites, including gastrointestinal, pancreas, breast, thyroid, lung, testis, and gynecologic

Gynecologic tumors

Cervix: Minimal deviation adenocarcinoma

Ovary: Sex cord-stromal tumor with annular tubules (SCTATs)

**ETIOLOGY/PATHOGENESIS**

Peutz-Jeghers Syndrome

Caused by germline mutations of LKB1 (STK11) gene

LKB1 is a serine-threonine kinase that functions as a tumor suppressor gene

LKB1 regulates mTOR pathway and plays a role in the control of cell proliferation
25% of cases are de novo

Minimal Deviation Adenocarcinoma
- Comprises 1-3% of cervical adenocarcinomas
- 10% of MDA (specifically the mucinous subtype) are associated with PJS
- Not associated with human papillomavirus (HPV) infection, unlike the majority of cervical adenocarcinomas

CLINICAL ISSUES
Presentation
- Most patients with MDA present with cervical discharge
- Vaginal bleeding is 2nd most common presentation
- Upon exam, a bulky cervix can be detected in most patients

Treatment
- Surgery is most important modality of treatment
- Chemotherapy and radiation are also employed

Prognosis
- Late detection in most cases leads to poor prognosis
- 1 study (Kuragaki et al) suggests that MDA with LKB1 mutations have worse prognosis than MDA without mutations

MACROSCOPIC FEATURES

Minimal Deviation Adenocarcinoma
- Barrel-shaped cervix
- Usually no discrete lesion
- Firm, expanded endocervical wall

MICROSCOPIC PATHOLOGY

Histologic Features
- Irregularly shaped glands that deeply infiltrate cervical wall
- Minimal or no stromal reaction
- Glands are lined by columnar cells with basal nuclei and abundant apical mucin
- Deceptively bland nuclear features, most cases have focal nuclear atypia
- Low mitotic rate
- Diagnosis on cervical biopsies is usually not possible as diagnosis relies primarily on identification of deeply infiltrative glands
- Conization is usually diagnostic

Cytologic Features
- Cytologic examination has low detection rate for MDA as cells show minimal cytologic atypia

ANCILLARY TESTS

Immunohistochemistry
- Minimal deviation mucinous adenocarcinoma
- Practically all cases positive for HIK1083, a marker for gastric mucin
- Vimentin and CEA positive in most cases, similar to usual-type cervical adenocarcinomas
- Most cases are negative for CA125, unlike usual-type cervical adenocarcinomas
- Immunoexpression of proliferation markers (Ki-67 and PCNA) tends to be moderate to high (> 50% of cells), unlike well-differentiated usual-type adenocarcinomas that have low proliferation index
- p53 overexpression is seen in some cases

SELECTED REFERENCES
2. Takatsu A et al: Clonality analysis suggests that STK11 gene mutations are involved in progression of lobular endocervical glandular hyperplasia (LEGH) to minimal deviation adenocarcinoma (MDA). Virchows Arch. 462(6):645-51, 2013

IMAGE GALLERY
Low-power view of minimal deviation adenocarcinoma shows infiltrative glands with irregular outlines. Minimal deviation adenocarcinoma is composed of glands lined by tall mucinous cells with abundant apical mucin and small, bland, basally located nuclei. Diligent search commonly leads to the identification of atypical nuclei focally within the tumor. Nuclei are enlarged, hyperchromatic, and irregular.

Endometrial Carcinoma

Key Facts
- **Etiology/Pathogenesis**
  - Lynch syndrome: Multiple-cancer disorder caused by germline mutations of mismatch repair genes MLH1, MSH2, MSH6, and PMS2
  - PTEN-hamartoma tumor syndrome (a.k.a. Cowden syndrome): Germline-inactivating mutations of PTEN tumor suppression gene
  - Peutz-Jeghers syndrome: Mutations in serine/threonine kinase STK11 gene

Clinical Issues
- Lynch syndrome: Increased risk for cancer of gastrointestinal tract, endometrium, ovaries, pancreatobiliary, urinary tract, brain, and skin. Women with synchronous endometrial and ovarian endometrioid adenocarcinomas are more likely to have Lynch syndrome. Lifetime risk for endometrial cancer is slightly higher than for colorectal cancer.

Ancillary Tests
- **Lynch syndrome**
  - Mismatch repair protein immunohistochemical expression using antibodies against MLH1, MSH2, MSH6, and PMS2
  - MLH1 promoter hypermethylation
  - Microsatellite instability (MSI)
  - Germline testing
Gross photograph of an endometrial adenocarcinoma, endometrioid type, shows a sessile polypoid lesion involving most of the endometrial cavity.
Endometrial adenocarcinoma, endometrioid type, shows cribriforming glands lined by columnar cells, similar to normal endometrial glands.

TERMINOLOGY

Synonyms
- Endometrial adenocarcinoma

Definitions
- Endometrial malignant neoplasms that comprise multiple subtypes
  - Endometrioid adenocarcinoma
  - Serous adenocarcinoma
  - Clear cell adenocarcinoma
  - Malignant mixed müllerian tumor (also known as carcinosarcoma)

ETIOLOGY/PATHOGENESIS

Genetic Predisposition
Syndromic
- Lynch syndrome (LS)
  - Autosomal dominant
  - Multiple-cancer disorder caused by germline mutations of mismatch repair genes MLH1, MSH2, MSH6, and PMS2
  - DNA mismatch repair genes excise errors occurring during DNA replication
  - Less common causes for LS are EPCAM deletions and germline MLH1 promoter hypermethylation

- PTEN-hamartoma tumor syndrome (PHTS) (a.k.a. Cowden syndrome [CS]) or PHTS/CS
  - Autosomal dominant
  - Germline-inactivating mutations of PTEN tumor suppression gene

- Peutz-Jeghers syndrome (PJS)
  - Autosomal dominant
  - Mutations in the serine/threonine kinase 11 (STK11) gene, also known as LKB1 gene
Sporadic

Endometrioid adenocarcinoma
Unopposed estrogen stimulation due to anovulation, exogenous estrogen, or obesity

Nonendometrioid adenocarcinoma
TP53 mutations in majority of cases
May be related to aging and radiation

CLINICAL ISSUES

Epidemiology

LS
Accounts for 2-3% of all endometrial cancers and 10% of endometrial cancers diagnosed before age 50
In women, lifetime risk for endometrial cancer (~ 60%) is slightly higher than for colorectal cancer (~ 54%)
Risk of endometrial cancer development varies with genetic alteration
21-57% for MLH1 and MSH2
17-26% for MSH6
15% for PMS2
Ratio of endometrial to colon cancer is higher for MSH6

PHTS/CS
Lifetime risk for endometrial cancer has been estimated to range from 5-42%, although it is not well defined
Recent study showed that PTEN-related endometrial cancer risk begins at age 25 and rises to 30% by age 60

PJS
Estimated 9% risk of endometrial cancer by age 65

Presentation

LS
Increased risk for cancer of gastrointestinal tract, endometrium, ovaries, pancreatobiliary, urinary tract, brain, and skin
Patients with synchronous colorectal and endometrial cancer should be investigated for LS

P.J[8]:5

Women with synchronous endometrial and ovarian endometrioid adenocarcinomas are more likely to have LS
Carcinomas of lower uterine segment appear to be more frequent in LS than in general population
Mean age at diagnosis of nonendometrioid tumors is lower in LS vs. sporadic cases

PHTS/CS
Multiple-cancer syndrome with hamartomatous growth in many organs
Hamartomas of the skin, mucous membranes, breast, thyroid, and endometrium
Cancers of the thyroid, breast, endometrium, colorectum and kidney; also melanoma
Frequent and multiple uterine leiomyomas

PJS
Hamartomatous gastrointestinal polyps and mucocutaneous pigmentation
Increased risk for multiple cancers including gastrointestinal, pancreatic, ovarian, cervical, and uterine

Treatment
Most experts recommend hysterectomy and bilateral salpingo-oophorectomy after childbearing is complete for patients with LS
No specific recommendations have been defined for PHTS/CS and PJS

Prognosis
Does not seem to differ for endometrial carcinomas arising in familial or sporadic settings

Surveillance
Transvaginal ultrasound and endometrial sampling after age 30 is recommended for patients with familial cancer syndromes with increased risk for endometrial cancer

MACROSCOPIC FEATURES

General Features
Synchronous endometrial and ovarian endometrioid adenocarcinomas
Carcinomas of lower uterine segment

MICROSCOPIC PATHOLOGY

Histologic Features
Both endometrioid and nonendometrioid histology
Higher incidence of high-grade nonendometrioid types than among general population, particularly with MSH2 mutations
As in colorectal cancer, tumor-infiltrating lymphocytes and peritumoral lymphocytes in endometrial carcinoma appear to be predictors of microsatellite instability (MSI)
Undifferentiated tumor histology, unlike colon cancer, has not been consistently associated with LS

LS

PHTS/CS and PJS

Data regarding histologic subtypes in PHTS/CS and PJS are limited

Cytologic Features

Cytopathologic examination is rarely employed for diagnosis of endometrial carcinoma
Detected tumor cells can be identified in cervical cytology and peritoneal fluid in some cases

ANCILLARY TESTS

Immunohistochemistry

Mismatch repair protein immunohistochemistry using antibodies against MLH1, MSH2, MSH6, and PMS2
Loss of nuclear staining is considered abnormal

Background nonneoplastic cells, particularly lymphocytes, are good internal positive controls
Concurrent loss of MLH1 and PMS2 expression indicates MLH1 gene abnormalities
When PMS2 mutations are present, only PMS2 expression is lost
Concurrent loss of MSH2 and MSH6 expression indicates MSH2 gene abnormalities
When MSH6 mutations are present, only MSH6 expression is lost
Immunohistochemical results are used to triage cases for germline testing
Screening test of choice in endometrial carcinoma as a significant proportion of LS-associated endometrial carcinomas are microsatellite low or microsatellite stable by MSI testing, particularly when MSH6 is mutated

Molecular Genetics

LS

MLH1 promoter hypermethylation
Methylation of MLH1 promoter is a sporadic cause of loss of MLH1 protein expression
When MLH1 promoter is methylated, there is no indication for germline testing
Performed in DNA extracted from paraffin-embedded tissues

MSI

Hallmark of defective mismatch repair
Can result from sporadic or germline loss of mismatch repair protein function
DNA is extracted from both tumor and nonneoplastic tissue
Normal tissue can be extracted from paraffin-embedded tissue or peripheral blood lymphocytes
Significant proportion of LS-associated endometrial carcinomas are microsatellite low or microsatellite stable by MSI testing, particularly when MSH6 is mutated
Less reliable as LS screening test in endometrial carcinoma compared to colorectal cancer

Germline testing

Mutational analysis by DNA sequencing of MLH1, MSH2, MSH6, and PMS2
Performed in DNA extracted from peripheral blood lymphocytes

PHTS/CS

Germline testing

PTEN sequencing analysis, large deletion/duplication analysis
Performed in DNA extracted from peripheral blood lymphocytes

PJS

Germline testing

STK11 gene sequencing analysis, large deletion/duplication analysis
Performed in DNA extracted from peripheral blood lymphocytes

DIFFERENTIAL DIAGNOSIS

Lynch Syndrome

Guidelines for identifying LS in women with gynecologic cancers are less defined than for colorectal cancer
Endometrial carcinoma may be 1st malignancy diagnosed in women with LS
Women with endometrial carcinoma before age 50 have a higher likelihood of having LS, but the tumor may develop later in life.

Patients with synchronous endometrioid uterine and ovarian adenocarcinomas are at increased risk for LS and should be screened by immunohistochemistry &/or MSI.

Patients with synchronous endometrial carcinoma and colorectal cancer should be screened by immunohistochemistry &/or MSI.

PTEN-Hamartoma Tumor Syndrome and Peutz-Jeghers Syndrome

Differential between sporadic and familial endometrial carcinoma in these syndromes relies primarily on nongynecologic manifestations and genetic testing.

SELECTED REFERENCES

P.II(8):7

Image Gallery

Microscopic Features and Ancillary Techniques

(Left) Endometrioid adenocarcinoma shows back-to-back glands lined by pseudostratified columnar cells with nuclear atypia. Despite the high frequency of nonendometrioid adenocarcinomas in Lynch syndrome, endometrioid adenocarcinomas are most common in absolute numbers. (Right) Serous adenocarcinoma is composed of broad papillae with cellular budding into intervening spaces. The cells are markedly atypical with pleomorphic nuclei and prominent nucleoli.
Clear cell adenocarcinoma shows tubulopapillary growth of polygonal cells with abundant clear cytoplasm and markedly pleomorphic nuclei. Typical of this tumor are nuclei polarized toward the lumen, known as hobnailing.

Carcinosarcoma consists of an admixture of carcinomatous gland-forming and sarcomatous chondroid components.

Immunohistochemistry for MSH2 is shown in an endometrioid adenocarcinoma in a patient with Lynch syndrome and germline MSH2 gene mutation. Tumor cell nuclei are negative, and infiltrating lymphocytes serve as an internal positive control. Microsatellite instability testing using a mononucleotide marker (BAT26) shows that the top tumor sample is microsatellite stable whereas the bottom tumor sample is microsatellite unstable.

Fallopian Tube Carcinoma

Fallopian Tube Carcinoma
Fabiola Medeiros, MD

Key Facts
Etiology/Pathogenesis
Germline BRCA1 and BRCA2 mutations with increased risk for breast and gynecologic cancers

Clinical Issues
Most tubal carcinomas are detected at early stages at risk-reducing bilateral salpingo-oophorectomy (RRSO)

Microscopic Pathology
Invasive or in situ tubal carcinoma is detected in ~ 5-7% of RRSO specimens
Majority are serous tubal intraepithelial carcinomas (STIC)
Ancillary Tests

p53 and Ki-67 (MIB-1) can be performed to confirm diagnosis of STIC

Serous intraepithelial carcinoma shows cellular stratification. Compare with the background normal tubal epithelium.
Serous intraepithelial carcinoma shows high nuclear:cytoplasmic ratio and pleomorphic nuclei.

**TERMINOLOGY**

**Abbreviations**
- Hereditary breast and ovarian cancer (HBOC)

**ETIOLOGY/PATHOGENESIS**

**Hereditary Breast and Ovarian Cancer**
- Caused by germline BRCA1 and BRCA2 mutations with increased risk for breast and gynecologic cancers, including ovary, fallopian tube, and peritoneum
- Germline mutations in other genes, such as genes involved in the Fanconi anemia-BRCA pathway, might be related to the development of fallopian tube cancer, but data is limited
- p53 signatures are believed to be precursor lesion for development of serous tubal intraepithelial carcinomas (STIC), which, in turn, represent in situ stage of invasive serous carcinoma

**CLINICAL ISSUES**

**Epidemiology**
- Up to 30% of women with unselected fallopian tube carcinoma were found to have germline BRCA1 and BRCA2 mutations in a recent study
- In situ tubal carcinoma can be detected before age 40 whereas most invasive tubal carcinomas occur in 50s and 60s
- Patients with fallopian tube carcinoma diagnosed before age 60, of Jewish decent, and with personal or familial history of breast or ovarian cancer are at increased risk of harboring BRCA1 or BRCA2 mutations

**Presentation**
- Most tubal carcinomas diagnosed in HBOC patients are detected at early stages at risk-reducing bilateral salpingo-oophorectomy (RRSO)
- Based on molecular genetic studies, a significant proportion of serous carcinomas involving the ovary and peritoneum are believed to arise from the fallopian tube epithelium

**Treatment**
- RRSO is recommended between ages 35 and 40, after childbearing is complete
Oral contraceptives decrease the risk of cancer development
Hormone replacement therapy has been shown to increase the risk of fallopian tube cancer
BRCA1- and BRCA2-related tumors have better response to platinum-based chemotherapy and increased sensitivity to poly ADP-ribose polymerase (PARP) inhibitors compared to sporadic carcinomas

Prognosis
As for ovarian carcinomas, HBOC tubal carcinomas have a better prognosis than the sporadic counterpart

MACROSCOPIC FEATURES
Gross Findings
Most RRSO specimens do not have a visible gross lesion
Majority of both in situ and invasive tubal carcinomas in RRSO specimens are found in the distal fimbria
Sectioning and extensively examining the fimbriated end (SEE-FIM) protocol describes how to submit fallopian tubes to optimize detection of microscopic carcinomas
Fimbriated end is amputated and longitudinally sectioned at 2-3 mm intervals

Remainder fallopian tube is transversely sectioned at 2-3 mm intervals
Bilateral fallopian tubes received as part of RRSO specimen should be fixed in formalin prior to sectioning

MICROSCOPIC PATHOLOGY
Histologic Features
Invasive or in situ tubal carcinoma is detected in ~ 5-7% of RRSO specimens
Majority are STIC
Characterized by marked cytologic atypia when compared with the background tubal epithelium
Cellular stratification and pseudostratification
Disorganization and loss of polarity
High nuclear:cytoplasmic ratio and loss of cilia
Nuclear enlargement and chromatin irregularities
Most invasive tumors are high-grade serous carcinomas
Some carcinomas show undifferentiated or endometrioid histology
Frozen section examination of RRSO specimen is not recommended unless a grossly visible suspicious lesion, such as a solid nodule, is present

ANCILLARY TESTS
Immunohistochemistry
p53 and Ki-67 (MIB-1) can be performed to confirm diagnosis of STIC
Microscopic foci of morphologically atypical tubal epithelium is expected to show strong and diffuse immunostaining for both p53 and Ki-67 to be diagnostic of STIC
p53 signature
Defined as strong and diffuse p53 immunoreaction in 12 or more consecutive tubal lining epithelial cells
To be considered a p53 signature, the focus in question should not demonstrate cytologic atypia
p53 signatures have been shown to harbor TP53 mutations by molecular genetic studies
Not recommended for diagnostic reporting

Molecular Genetics
DNA sequencing for germline mutations in BRCA1 and BRCA2 genes
Consider BRCA1 and BRCA2 mutational analysis in all patients diagnosed with fallopian tube carcinoma

SELECTED REFERENCES

IMAGE GALLERY
Serous intraepithelial carcinoma shows stratification, loss of polarity, and lack of cilia. The cells have high nuclear:cytoplasmic ratio, nuclear enlargement, and chromatin irregularities. (Center) p53 immunostain is positive in serous intraepithelial carcinoma and negative in the background benign epithelium. (Right) p53 immunostain in serous intraepithelial carcinoma shows diffuse and strong nuclear staining.

**Ovarian Carcinoma**

> Table of Contents > Part II - Diagnoses Associated With Specific Syndromes > Section 8 - Gynecology > Ovarian Carcinoma

**Fabiola Medeiros, MD**

**Key Facts**

**Clinical Issues**

- ~1 in 4 women with ovarian cancer has hereditary gene mutation related to cancer development
- Hereditary breast and ovarian cancer
  - 13-15% of women with invasive ovarian cancer harbor germline mutations of BRCA1 or BRCA2 genes
  - Lifetime risk for ovarian cancer: 35-60% for BRCA1, 12-25% for BRCA2
- Lynch syndrome
  - ~2-4% of ovarian cancers are believed to be associated with Lynch syndrome
  - Lifetime risk for ovarian cancer is estimated at 4-11%
- Peutz-Jeghers syndrome
  - Estimated 10x increased cancer incidence compared to general population

**Microscopic Pathology**

- Hereditary breast and ovarian cancer
  - Characteristically epithelial tumors
  - Most are high-grade serous carcinomas
  - Borderline tumors and mucinous carcinomas are uncommon
- Lynch syndrome
  - Characteristically epithelial invasive tumors
- Peutz-Jeghers syndrome
  - Patients are particularly at risk for sex cord-stromal tumors with annular tubules (SCTATs)
  - Up to 35% of women with SCTATs are found to have PJS
Gross photo shows an ovarian serous carcinoma forming a solid cystic mass.
High-grade serous carcinoma forms cleft-like spaces lined by large epithelial cells with marked nuclear atypia.

TERMINOLOGY
Definitions
- Hereditary breast and ovarian cancer
  - Germline BRCA1 and BRCA2 mutations with ↑ risk for breast and gynecologic cancers
- Lynch syndrome
  - Germline mismatch repair gene mutations leading to increased cancer risk, including colorectal and gynecologic
- Peutz-Jeghers syndrome
  - Germline STK11 mutations with increased risk of multiple cancers, such as gastrointestinal, pancreatic, and gynecologic

ETIOLOGY/PATHOGENESIS
Hereditary Breast and Ovarian Cancer (HBOC)
- Autosomal dominant
- Germline BRCA1 and BRCA2 mutations
  - BRCA1 and BRCA2 genes repair DNA damage through homologous recombination

Lynch Syndrome (LS)
- Autosomal dominant
- Germline mutations of MLH1, MSH2, MSH6, and PMS2 genes
  - DNA mismatch repair genes that excise errors occurring during DNA replication

Peutz-Jeghers Syndrome (PJS)
- Autosomal dominant
- Mutations in serine threonine kinase 11 (STK11) gene

Germline Mutations of Genes in Fanconi Anemia (FA)-BRCA Pathway
- RAD51C, RAD51D, BRIP1, among others
  - Monoallelic germline mutations of these genes have been identified in highly penetrant breast and ovarian cancer families lacking BRCA1/BRCA2 mutations
FA-BRCA pathway plays a role in homologous recombination, which mends double-stranded DNA breaks.

**CLINICAL ISSUES**

**Epidemiology**

~1 in 4 women with ovarian cancer has hereditary gene mutation related to cancer development.

Hereditary breast and ovarian cancer

- Account for majority of hereditary ovarian cancers
- 13-15% of women with invasive ovarian cancer harbor germline mutations of BRCA1 or BRCA2 genes
- Proportion of ovarian cancer that is hereditary varies with prevalence of founder mutations in each population
- In women of Ashkenazi decent, 35-40% of ovarian carcinomas are associated with BRCA1 or BRCA2 mutations
- Lifetime risk for ovarian cancer
  - 35-60% for BRCA1
  - 12-25% for BRCA2
- Average age of ovarian cancer onset
  - 50 years for BRCA1 mutation
  - 60 years for BRCA2 mutation
  - 63 years in general population
- Women with very early onset ovarian cancer (< 40 years old) are less likely to harbor BRCA1/BRCA2 mutations, unlike breast cancer

Lynch syndrome

- Approximately 2-4% of ovarian cancers are believed to be associated with Lynch syndrome
- Lifetime risk for ovarian cancer is estimated at 4-11%

Mean age at diagnosis of ovarian cancer is 42 years with 1/3 of patients < 40 years old

Peutz-Jeghers syndrome

- Estimated 10x ↑ cancer incidence compared to general population
- 1/2 of patients with ovarian tumors present at ≤ 22 years old

**Presentation**

Hereditary breast and ovarian cancer

- Patients are at risk for developing ovarian, fallopian tube, and primary peritoneal carcinomas

Lynch syndrome

- Cancers of gastrointestinal tract, endometrium, ovaries, hepatobiliary, urinary tract, brain, and skin
- Women with synchronous endometrial and ovarian endometrioid adenocarcinomas are more likely to have Lynch syndrome

Peutz-Jeghers syndrome

- Hamartomatous gastrointestinal polyps and mucocutaneous pigmentation
- Increased risk for multiple cancers including colon, pancreas, ovary, cervix, and uterus
- Ovarian sex cord-stromal tumors may lead to precocious puberty and infertility

**Treatment**

Hereditary breast and ovarian cancer

- Risk-reducing bilateral salpingo-oophorectomy (RRSO) in ages 35-40, after childbearing is complete
- RRSO has been shown to ↓ pelvic cancer risk by 80-95%
- After RRSO, patients still have estimated 4% risk of primary peritoneal cancer development
- Oral contraceptives have been shown to reduce ovarian cancer risk by 50% in patients choosing nonsurgical approach
- BRCA1/BRCA2-related ovarian cancers have better response to platinum-based agents compared to nonmutation carriers
- Increased sensitivity to poly ADP-ribose polymerase (PARP) inhibitors compared to sporadic carcinomas

Lynch syndrome

- Hysterectomy and bilateral salpingo-oophorectomy recommended after childbearing is complete

Peutz-Jeghers syndrome

- Tumors arising in PJS setting are treated in same manner as sporadic ovarian tumors of same histologic subtype

**Prognosis**

Hereditary breast and ovarian cancer

- BRCA1/BRCA2-related ovarian cancers have better prognosis than nonmutation carriers
Lynch syndrome and Peutz-Jeghers syndrome

Apparently, there are no prognostic differences between sporadic and hereditary ovarian tumors associated with these syndromes.

Surveillance

Hereditary breast and ovarian cancer

Transvaginal ultrasound and CA-125 are recommended every 6 months starting at age 30 or 5-10 years before earliest age at onset of ovarian cancer in patient’s family.

Lynch syndrome

No specific recommendations have been outlined for ovarian cancer.

Peutz-Jeghers syndrome

Annual transvaginal ultrasound starting at age 18-20.

MACROSCOPIC FEATURES

Hereditary Breast and Ovarian Cancer

2.5-17% of patients undergoing RRSO have occult ovarian, fallopian tube, or peritoneal carcinoma upon pathologic examination.

Extensive sampling of RRSO specimens should be performed including histopathologic examination of entire ovaries and fallopian tubes.

Ovaries should be transversely sectioned in 5 mm intervals along greater axis and all cross sections submitted.

P.II(8):12

MICROSCOPIC PATHOLOGY

Histologic Features

Hereditary breast and ovarian cancer

Characteristically epithelial tumors.

Most are high-grade serous carcinomas.

Solid pseudoendometrioid and transitional patterns, increased mitosis, and tumor-infiltrating lymphocytes may be associated with BRCA-related tumors but data is limited.

Borderline tumors and mucinous carcinomas are uncommon.

Ovaries and fallopian tubes should be scrutinized for occult microscopic carcinoma.

Lynch syndrome

Characteristically epithelial invasive tumors.

Histologic subtypes include serous, endometrioid, mucinous, and clear cell.

Higher proportion of endometrioid subtype than nonmutation carriers.

Peutz-Jeghers syndrome

Patients are particularly at risk for sex cord-stromal tumors with annular tubules (SCTATs).

SCTATs in PJS tend to be small, calcified, multifocal, and bilateral.

Up to 35% of women with SCTATs are found to have PJS.

Other histologic types have been described in PJS including granulosa cell tumors, Brenner tumors, dysgerminomas, and Sertoli cell tumors.

ANCILLARY TESTS

Immunohistochemistry and Molecular Genetics

Hereditary breast and ovarian cancer

DNA sequencing for germline mutations in BRCA1 and BRCA2 genes.

Current testing is limited by gene patents to a single company (Myriad Genetics).

Commercially available test includes sequencing of all coding exons and exon-intron boundaries as well as testing for common gene rearrangements.

Current sensitivity for BRCA1 and BRCA2 gene analysis is 90%.

Lynch syndrome

Experience with interpreting testing for somatic alterations by microsatellite instability (MSI) analysis and immunohistochemistry in ovarian cancer is limited compared with colorectal and endometrial cancers.

Paraffin-embedded tissue can be evaluated for immunohistochemistry for mismatch repair proteins MLH1, MSH2, MSH6, and PMS2.

MLH1 promoter hypermethylation

Germline mutation testing.
DNA sequencing of MLH1, MSH2, MSH6, and PMS2
Performed on DNA extracted from peripheral blood lymphocytes

Peutz-Jeghers syndrome
- Testing for germline alterations of STK11 gene
- STK11 alterations are found in 50-90% of individuals with a clinical diagnosis of PJS
- Majority of mutations are missense or truncating but up to 30% are large deletions
- Optimal testing includes both DNA sequencing and analysis for large deletions/duplications
- Performed on DNA extracted from peripheral blood lymphocytes

DIFFERENTIAL DIAGNOSIS
Hereditary Breast and Ovarian Cancer
- Women with breast and ovarian cancer should undergo genetic counseling and genetic testing for HBOC if indicated

Lynch Syndrome
- Guidelines for identifying LS in women with gynecologic cancers are less defined than for colorectal cancer
- Patients with synchronous endometrioid uterine and ovarian adenocarcinomas are at increased risk for LS and should be screened by immunohistochemistry &/or MSI analysis

SELECTED REFERENCES
P.II(8):13

Image Gallery
Microscopic Features

(Left) Solid pseudoendometrioid and transitional patterns, increased mitosis, and tumor-infiltrating lymphocytes may be associated with BRCA-related tumors. High-grade serous carcinomas are the prototypical ovarian tumors in hereditary breast and ovarian cancer. (Right) Solid areas of high-grade serous carcinoma show marked nuclear pleomorphism with numerous mitotic figures.
Endometrioid adenocarcinoma, FIGO grade 1, is characterized by confluent growth of glands lined by pseudostratified epithelium. Histologic subtypes of tumors that are seen in Lynch syndrome include serous, endometrioid, mucinous, and clear cell. FIGO grade 2 endometrioid adenocarcinoma is composed of both glandular and solid areas. Ovarian endometrioid adenocarcinomas occur frequently in patients with Lynch syndrome.

Sex cord-stromal tumor with annular tubules (SCTATs) occur in Peutz-Jeghers syndrome. Up to 35% of women with SCTATs are found to have Peutz-Jeghers syndrome. Sex cord-stromal tumor with annular tubules consist of pale Sertoli cells arranged around hyaline bodies. SCTATs in Peutz-Jeghers syndrome tend to be small, calcified, multifocal, and bilateral.

Section 9 - Nervous System

Astrocytoma

Astrocytomas represent primary CNS neoplasms demonstrating a phenotype similar to astrocytic glia.
Pilocytic astrocytoma (WHO grade I)
   Classic biphasic pattern with alternating compact (“piloid”) and loose (microcyst-rich) areas
   When affecting optic nerve, involves substance of nerve and extends into subarachnoid space
Subependymal giant cell astrocytoma (SEGA) (WHO grade I)
   Large eosinophilic cells with macronucleoli
Low-grade astrocytomas, subtype indeterminate
   Subset of NF1 gliomas difficult to classify; may have features of both pilocytic and diffuse astrocytomas
Diffuse astrocytoma (WHO grade II)
   Hypercellularity and atypia when compared to nonneoplastic brain
Anaplastic astrocytoma (WHO grade III)
   Increased cellularity compared to grade II and evident mitotic activity
Glioblastoma (WHO grade IV)
   Infiltrating astrocytoma with mitotic activity + necrosis &/or microvascular proliferation

Ancillary Tests
   GFAP(+), OLIG2(+), S100(+)
   NFP stains entrapped axons in diffuse astrocytomas; pilocytic astrocytomas more circumscribed
   Expression of neuronal markers (synaptophysin, neurofilament protein) frequent in SEGA
   Ki-67 labeling index generally increases with grade

Optic nerve gliomas are characterized by fusiform expansions of the optic nerve. When bilateral &/or multiple, they are essentially pathognomonic for neurofibromatosis (NF1) syndrome.
Almost all optic nerve gliomas in NF1 patients are pilocytic astrocytomas. The tumors involve the substance of the optic nerve proper, but also frequently extend into the leptomeninges.

**TERMINOLOGY**

**Abbreviations**
- Neurofibromatosis type 1 (NF1)
- Tuberous sclerosis complex (TSC)
- Subependymal giant cell astrocytoma (SEGA)

**Definitions**
- Astrocytomas represent primary CNS neoplasms demonstrating a phenotype similar to astrocytic glia

**ETIOLOGY/PATHOGENESIS**

**Neurofibromatosis Type 1**
- Results from germline inactivation of NF1 gene encoding for neurofibromin
- Pilocytic astrocytoma most frequent primary CNS tumor arising in neurofibromatosis type 1
- Diffuse gliomas grades II-IV may also develop, particularly after childhood years
- Subset of astrocytomas, particularly low grade, remain difficult to precisely classify using current WHO guidelines

**Neurofibromatosis Type 2**
- Results from germline inactivation of NF2 gene encoding for merlin
- Main glioma in NF2 is ependymoma, but astrocytomas may also rarely develop

**Noonan Syndrome**
- Combines facial features and cardiac abnormalities; associated with mutations in genes encoding for components of RAS signaling pathway
  - Mutation in PTPN11 most frequent (50%) but also caused by mutations in KRAS, SOS1, RAF1, and NF1
- May develop low-grade astrocytomas and glioneuronal tumors

**Turcot Syndrome**
- Defined as concomitant brain tumors in setting of familial colon cancer
- Germline heterozygous mutations in mismatch repair genes (MLH1, MSH2, MSH6, PMS1, PMS2) associated with Turcot syndrome and glioma development (Turcot type 1)
Germline mutations in APC associated with medulloblastoma/PNET (Turcot type 2)

Constitutional Mismatch Repair-Deficiency Syndrome
- Homozygous or compound heterozygous mutations in mismatch repair genes
- Multiple cancers, including gliomas, colon cancer
- May be associated with clinical features of NF1 (e.g., café au lait spots)

Li-Fraumeni Syndrome
- Associated with germline TP53 mutations
- Multiple cancers, including sarcomas, breast cancer, leukemias, adrenocortical carcinomas, choroid plexus tumors, and gliomas

Tuberous Sclerosis Complex
- Results from germline mutations in TSC1 or TSC2 genes
- Subependymal giant cell astrocytoma (SEGA) is a low-grade astrocytoma that develops almost exclusively in TSC

Melanoma Astrocytoma Syndrome
- Associated with germline mutations of chromosome region 9p21 (involving the CDKN2A gene or the P14 (ARF) specific exon 1-β)
- Cutaneous melanoma and high-grade astrocytomas (glioblastomas) in family members

P.II(9):3

CLINICAL ISSUES

Presentation
- Gradual visual loss main symptom in NF1 patients with optic nerve gliomas
- Seizures may be initial presentation in cortically based tumors
- Signs of increased intracranial pressure (headaches, nausea/vomiting) in posterior fossa or intraventricular tumors (e.g., SEGA)

Treatment
- Optic nerve gliomas (pilocytic astrocytomas) in NF1 children are usually observed without treatment
- Diffuse astrocytomas in NF1 may require additional treatment, although irradiation is avoided as much as possible
- High-grade astrocytomas (WHO grades III-IV) require treatment after surgery, usually irradiation + chemotherapy
- SEGAs in TSC respond to mTOR pathway inhibitors

Prognosis
- Prognosis of astrocytic neoplasms depends strongly on grade (WHO grades I-IV) and molecular alterations
- Pilocytic astrocytomas in NF1 may behave in a favorable fashion, particularly when involving optic pathways
  - May stabilize or even regress in absence of treatment
  - Pilocytic astrocytomas with anaplasia demonstrate variable outcome
  - Aggressive behavior in a subset of cases, although not as predictably poor as infiltrating high-grade astrocytomas
- High-grade astrocytomas in NF1 associated with poor outcome similar to sporadic tumors
- High-grade astrocytomas in Turcot may have a better outcome compared to sporadic tumors

IMAGE FINDINGS

MR Findings
- Pilocytic astrocytoma
  - Well demarcated, contrast enhancement, often cyst with enhancing mural nodule configuration
  - Predilection for optic nerve/pathways in young NF1 patients
  - Fusiform expansion of optic nerve
  - Bilateral optic nerve glioma almost pathognomonic for NF1
  - May also arise in brainstem, cerebellum, cerebral hemispheres, and spinal cord
- Diffusely infiltrating astrocytomas
  - Occur throughout neural axis in sporadic and syndrome associated settings
  - Diffuse astrocytomas (WHO grade II) form ill-defined, T2-hyperintense masses lacking contrast enhancement
  - Anaplastic astrocytomas may show variable contrast enhancement
  - Glioblastomas almost always enhance, and may show ring enhancement reflecting central necrosis
- SEGA
  - Arises in lateral ventricles near foramen of Monro
  - Additional CNS manifestations of tuberous sclerosis, e.g., subependymal nodules, cortical tubers, may be present
  - Presence of contrast enhancement and size distinguishes it from subependymal nodules
MICROSCOPIC PATHOLOGY

Histologic Features

Pilocytic astrocytoma (WHO grade I)

- Classic biphasic pattern with alternating compact (“piloid”) and loose (microcyst-rich) areas
- Rosenthal fibers and eosinophilic granular bodies characteristic

May contain hyalinized &/or glomeruloid microvasculature

Mitotic activity rare to absent

When affecting optic nerve, involves substance of nerve and extends into subarachnoid space

Pilomyxoid variant, characterized by monomorphous cells, myxoid background, and perivascular pseudorosettes, is associated with more aggressive clinical behavior

Pilocytic astrocytoma with anaplastic features

- Previously defined as pilocytic astrocytomas with brisk mitotic activity (≥ 4-5/10 HPF), hypercellularity, and atypia ± necrosis
- No WHO grade assignment yet
- Associated NF1 syndrome in 24%

SEGA (WHO grade I)

- Large eosinophilic cells with macronucleoli
- Vague fascicular formation, occasional perivascular pseudorosettes and microcalcifications
- Frequent mast cells
- Mitotic figures and necrosis rare to absent

Pleomorphic xanthoastrocytoma (WHO grade II)

- Circumscribed astrocytoma containing pleomorphic cells, xanthic change, fascicular architecture, and eosinophilic granular bodies
- Rare reports in NF1 patients, including curious occurrence in 2 NF1 siblings

Low-grade astrocytoma, subtype indeterminate

- Subset of NF1-associated astrocytoma remains difficult to classify
- May have features of both pilocytic and diffuse astrocytomas
- A subset demonstrates increased cytoplasmic size and macronucleoli

May demonstrate partial neuronal differentiation by immunohistochemistry &/or electron microscopy

Glioneuronal tumors

Dysembyroplastic neuroepithelial tumor (DNT)

- Cortical-based, multinodular, usually sporadic low-grade neoplasm strongly associated with chronic seizures
- Bland, round oligodendrogial-like cells, specific glioneuronal element between nodules
- Microcysts, “floating” neurons in mucin pools
- Occasionally occurs in NF1 patients

Ganglioglioma

- Biphasic neoplasm with neoplastic glial and neuronal components
- Neoplastic ganglion cells with atypia, binucleation
- Glial component may be pilocytic or diffuse

Rosette forming glioneuronal tumor

- Characterized by a component of small, uniform neurocytes and distinctive small, synaptophysin-positive neurocytic rosettes
- Variable glial component resembling pilocytic astrocytoma
- DNT-like areas may be present
- Predilection for the 4th ventricle
- Most often sporadic but reported in NF1 and Noonan patients

Diffuse astrocytoma (WHO grade II)

- Hypercellularity and atypia when compared to nonneoplastic brain
- Underlying axons &/or neurons evident on H&E or highlighted by immunohistochemistry
- Absent to very rare mitotic activity

Anaplastic astrocytoma (WHO grade III)

- Increased cellularity compared to grade II and evident mitotic activity

Glioblastoma (WHO grade IV)

- Infiltrating astrocytoma with mitotic activity + necrosis &/or microvascular proliferation
Presence of a sarcomatous component (i.e., gliosarcoma) previously described in NF1 and Turcot syndrome
Component of bizarre multinucleated giant cells described in several cases of Turcot syndrome
Other variants reported in NF1 include giant cell and adenoid

ANCILLARY TESTS

Immunohistochemistry
GFAP(+), Olig2(+), S100(+)
Neurofilament protein highlights entrapped axons in diffusely infiltrating astrocytomas; pilocytic astrocytomas are more circumscribed
Strong nuclear p53 immunostaining frequent in diffuse astrocytomas
Mutant IDH-1 (R132H) protein usually absent in NF1-associated infiltrating gliomas compared with sporadic counterparts
Expression of neuronal markers (synaptophysin, neurofilament protein) frequent in SEGA
Ki-67 labeling index generally increases with grade
Markers of mTOR pathway activation frequently immunopositive in SEGA as well as NF1-associated pilocytic and indeterminate astrocytomas

In Situ Hybridization
BRAF duplications present in majority of sporadic pilocytic astrocytomas, but only rarely in NF1-associated cases
CDKN2A and 10q deletions, as well as NF1 inactivation frequent in NF1-associated high-grade astrocytomas

Molecular Genetics
Homozygous NF1 gene inactivation is a feature of NF1-associated neoplasms including gliomas
Leads to RAS and mTOR pathway activation
Partial (heterozygous) NF1 loss in nonneoplastic stromal and hematopoietic cells (e.g., microglia) required for optic glioma development in model systems
CDKN2A homozygous deletions (~50%) and TP53 mutations (~35%) represent important somatic genetic events in sporadic glioblastoma
NF1 gene point mutations/deletions also occur in a subset (< 20%) of sporadic primary glioblastoma
Astrocytomas developing in Li-Fraumeni patients with germline TP53 mutations may develop secondary IDH1 mutation (R132C rather than R132H)

Gene Expression Profiling
Gene expression profiles separate NF1-associated and sporadic pilocytic astrocytomas despite histologic similarities
Gene expression profiles of SEGA include up-regulation of genes involved in tumorigenesis and downregulation of developmental genes, probably mediated by increased mTOR activity

DIFFERENTIAL DIAGNOSIS

Gliosis
Piloid gliosis is main nonneoplastic entity in differential diagnosis with pilocytic astrocytoma
Lacks biphasic architecture, microcysts, and eosinophilic granular bodies
Seen around slow-growing tumors in hypothalamic region, posterior fossa, and spinal cord
Also a feature of spinal cord cavities (syrinx)
Glial hyperplasia variably occurs in association with NF1
Glial clusters and perineuronal satellitosis described as nonneoplastic features of NF1 brains
Lacks hypercellularity, proliferation, and atypia of infiltrating glioma
Immunohistochemical stains (p53, Ki-67) may be helpful in distinction

Malignant Peripheral Nerve Sheath Tumor (MPNST)/Sarcoma
Associated malignancies in NF1 (MPNST and sarcoma) and Li-Fraumeni (sarcoma)
May involve CNS by direct extension from intracranial primaries or metastases from distant sites
Difficult to differentiate from gliosarcoma with a predominant sarcomatous component
Identification of a malignant, GFAP(+), reticulin-poor glial component required for diagnosis of gliosarcoma

Metastatic Carcinoma
Must be considered, particularly in Turcot syndrome
Cytokeratin (CAM5.2) positive, GFAP negative

Metastatic Melanoma
May be difficult to distinguish from high-grade glioma
Expression of specific melanocytic markers (e.g., Melan-A, HMB-45, tyrosinase) in addition to S100; GFAP negative
DIAGNOSTIC CHECKLIST

Clinically Relevant Pathologic Features
- Gliomas of optic nerve in NF1 patients are almost always pilocytic astrocytomas.
- NF1 patients may also develop unclassifiable and higher grade gliomas, particularly after the childhood years.

Pathologic Interpretation Pearls
- Think of SEGA and TSC when large cells with ample cytoplasm and macronucleoli are encountered in a mass from the lateral ventricle.

SELECTED REFERENCES
11. Wimmer K et al: Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet. 124(2):105-22, 2008
Pilocytic astrocytomas of the optic nerve frequently extend into the leptomeninges, although this finding should not be interpreted as reflecting more aggressive biology. (Right) Pilocytic astrocytomas of the optic nerve may demonstrate infiltrative behavior, which is identifiable in cross sections as increased cellularity of optic nerve fascicles. As in other anatomic sites, infiltration in pilocytic astrocytoma is not necessarily associated with more aggressive behavior.

Optic nerve gliomas in NF1 patients may be hypercellular, and on occasion may be associated with underlying, reactive meningotheial hyperplasia. It is important to not mistake the latter for meningioma in small, nonrepresentative biopsies. (Right) Hypercellular pilocytic astrocytoma of the optic nerve forms bland, ill-formed nests. Despite the increase in cellularity, almost no mitotic activity was present in this relatively large specimen.
NF1-associated pilocytic astrocytomas have similar histologic features as their sporadic counterparts, including frequent enlarged vessels with degenerative changes (e.g., mural hyalinization). Microvascular glomeruloid changes are often encountered in pilocytic astrocytomas. They are still compatible with WHO grade I CNS neoplasms despite their similarity to the florid microvascular proliferation typical of high-grade gliomas, particularly glioblastoma.

Low-Grade Astrocytomas

The cytologic features of pilocytic astrocytomas are best appreciated in smear preparations, which include bright, bipolar eosinophilic processes and delicate oval nuclei. The most characteristic architectural feature of NF1-associated or sporadic pilocytic astrocytoma is the compact piloid areas where Rosenthal fibers are relatively easy to find. The main differential diagnosis is with piloid gliosis, which may develop around a variety of slow-growing neoplasms.
Loose-textured areas rich in microcysts represent the other component of pilocytic astrocytomas. Monotonous, oligodendroglioma-like cells are a conspicuous feature of this cerebellar NF1-associated pilocytic astrocytoma. Oligodendroglioma-like areas often occur in pilocytic astrocytomas. Clues to the correct diagnosis in this case included the presence of focal piloid architecture elsewhere, cerebellar location, and characteristic imaging findings.

Eosinophilic granular bodies (EGBs) are also frequent, but not specific, acellular components of pilocytic astrocytoma. EGBs are typical of circumscribed, low-grade glial or glioneuronal neoplasms and are almost never encountered in diffuse gliomas. Multinucleated giant cells are also often present in pilocytic astrocytomas. Some NF1-associated pilocytic astrocytomas may contain hypercellular pleomorphic areas and rare mitoses.

Low-Grade Astrocytomas
The whole spectrum of pilocytic astrocytoma variants may occur in NF1 patients, including the WHO grade II pilomyxoid variant. In cytologic preparations, these tumors contain oval, monotonous cells in tight association with intratumoral vessels. Compared to conventional pilocytic astrocytomas, the pilomyxoid variant exhibits more monotonous cytologic and architectural features. A myxoid stroma and perivascular arrangement of cells are typical. EGBs are rare to absent.

GFAP expression is a feature of all pilocytic astrocytomas. In the pilomyxoid astrocytoma variant, it particularly stains around vessels, highlighting the characteristic perivascular processes. NF1 patients may develop other astrocytomas, including diffuse astrocytoma (grade II). These tumors contain hyperchromatic, “naked” nuclei with irregular nuclei membranes infiltrating underlying CNS parenchyma.
(Left) Post-contrast MR T1-weighted image shows a cyst with an enhancing mural nodule in an NF1 patient. Histologically, this tumor was a pleomorphic xanthoastrocytoma, a glioma subtype that may develop in NF1 patients on rare occasions. (Right) This NF1-associated pleomorphic xanthoastrocytoma contains large pleomorphic cells and scattered eosinophilic granular bodies, hallmarks of this glioma subtype.

P.II(9):9

Low-Grade Astrocytomas, Indeterminate

(Left) Although most low-grade astrocytomas in NF1 patients are pilocytic, a subset represent classification challenges. In this example, there is tissue infiltration, but also cytoplasmic eosinophilia and focal compact architecture elsewhere. (Right) In this NF1-associated low-grade astrocytoma, there is conspicuous parenchymal infiltration. However, bright eosinophilic cytoplasmic processes raise at least the possibility of pilocytic astrocytoma. Rosenthal fibers are absent.
Some low-grade astrocytomas in NF1 patients demonstrate architectural features of pilocytic astrocytoma, but additionally may show unusual cytologic features, including plump cytoplasmic processes and macronucleoli. Conspicuous macronucleoli represent an eye-catching feature of some NF1-associated low-grade astrocytomas. Although they may be reminiscent of ganglion cells, the eosinophilic cytoplasm and cell processes suggest glial differentiation.

Macronucleoli represent a remarkable ultrastructural feature of this low-grade indeterminate astrocytoma from a NF1 patient. A subset of low-grade NF1-associated astrocytomas in addition to immunohistochemical and ultrastructural features of glial differentiation may contain neurosecretory granules, as well as other ultrastructural evidence of neuronal differentiation.

Pilocytic Astrocytoma With Anaplasia
A small subset of pilocytic astrocytomas, including those originating in NF1 patients, may develop clinical &/or histologic malignant/anaplastic features. In this cerebellar pilocytic astrocytoma, a more ominous biology is anticipated by large size, rapid progression, multinodularity, and heterogeneous enhancement. (Right) Brisk mitotic activity present throughout the specimen is the main histologic feature of pilocytic astrocytomas that develop anaplastic features.

By definition, pilocytic astrocytomas with anaplasia must contain recognizable morphologic attributes of pilocytic astrocytoma, e.g., piloid cytoplasmic processes and Rosenthal fibers. Anaplastic features are ascribed by the presence of concurrent brisk mitotic activity. (Right) In this NF1-associated pilocytic astrocytoma with anaplastic features, there are concurrent features of pilocytic astrocytoma (granular bodies) and anaplasia (frequent mitoses).
A subset of pilocytic astrocytomas with anaplasia contain areas of necrosis, including pseudopalisading. The presence of necrosis in addition to brisk mitotic activity is associated with a greater potential for aggressive behavior in these tumors. An elevated Ki-67 labeling index in pilocytic astrocytomas with anaplasia confirms the proliferative activity that is characteristic of these tumors, whether sporadic or NF1 associated.

Low-grade glioneuronal tumors also develop in NF1 patients, albeit at a lower frequency. Diagnosis of dysembryoplastic neuroepithelial tumor (DNT) was made in this example based on bland, intracortical nodules. Intact specimens that preserve the lesion's architecture are optimal. Intracortical nodules of dysembryoplastic neuroepithelial tumor are acid mucopolysaccharide rich and are particularly highlighted by the Alcian blue special stain.
DNT is composed of bland, round, monotonous cells similar to those present in oligodendroglia. In contrast to oligodendroglia, intralesional neurons in DNT are often found in mucoid pools (“floating neurons”), lacking perineuronal satellitosis. Gangliogliomas represent glioneuronal tumors that also may arise in the setting of NF1. In addition to a glial component, they contain neoplastic ganglion cells.

Rosette-forming glioneuronal tumor is a distinctive neoplasm that may occasionally occur in the setting of inherited genetic syndromes, as in this patient with Noonan syndrome. This neoplasm has a distinctive predilection for the 4th ventricle region. The most distinctive feature of rosette-forming glioneuronal tumor is the presence of small rosettes with an eosinophilic fibrillar core surrounded by bland neurocytes. This example developed in a Noonan patient.

Subependymal Giant Cell Astrocytoma
Subependymal giant cell astrocytomas (SEGAs) appear as well-demarcated, contrast-enhancing lesions on post-contrast T1-weighted MR images. They arise in the lateral ventricle, almost always near the foramen of Monro. (Right) The neoplastic cells in SEGAs contain abundant eosinophilic cytoplasm, as well as large nuclei with prominent nucleoli. These tumors are low grade, and mitotic activity is scant or altogether absent. Necrosis is also rare in these tumors.

Dense cytoplasmic eosinophilia is a prominent feature of some SEGAs. A subset of the cells may also have more fusiform contours, and even be arranged in vague fascicles. The presence of large nuclei with macronucleoli raises the possibility of a neuronal tumor, and in fact these neoplasms show immunohistochemical and ultrastructural evidence of neuronal differentiation, at least in part. (Right) Nests embedded in fibrillary stroma may be identified in areas of most SEGAs.
Foci of microcalcification may be present in a subset of SEGAs. The large cells with ample cytology suggest the diagnosis, particularly when encountering an intraventricular neoplasm located near the foramen of Monro. Perivascular, fibrillar neoplastic cell processes may be present in SEGA. Given its uniform intraventricular location, ependymoma represents the main diagnostic consideration. However, the cells of SEGA are larger and the immunophenotype is distinct.

Subependymal Giant Cell Astrocytoma

Strong, uniform immunoreactivity for S100 is an almost universal feature of SEGA, including cytoplasmic and nuclear labeling. S100 is a sensitive (although not entirely specific) marker for glial differentiation in primary neoplasms of the central nervous system. GFAP expression is also frequent in SEGA and highlights perinuclear cytoplasm as well as cell processes. The presence of GFAP expression confirms that these neoplasms are indeed glial.
Immunohistochemical stain for GFAP is frequent in SEGA, although it is variable. In some cases, such as this example, convincing expression may be limited to a minority of neoplastic cells, in contrast to most diffuse astrocytomas. In addition to expressing glial markers, SEGA frequently demonstrates immunohistochemical evidence of neuronal differentiation, such as synaptophysin expression. This suggests a mixed glioneuronal phenotype.

SEGA is one CNS tumor type that frequently contains a component of mast cells. Mast cells may be recognized by strong CD117 (KIT) expression. General low proliferative activity is an important feature of SEGA. Mitotic activity is always difficult to find in these tumors, and the Ki-67 labeling index is very low, as demonstrated by this particular example. This explains in part its slow progression, even in subtotally resected cases.

High-Grade Astrocytomas
High-grade astrocytomas may also develop in NF1 patients, particularly after the childhood years. These tumors may arise anywhere in the neural axis and demonstrate aggressive imaging features, including heterogeneous contrast enhancement. (Right) Astrocytic neoplasm in an NF1 patient demonstrates hypercellularity, nuclear hyperchromasia, glial processes, and frequent mitotic figures, consistent with at least an anaplastic astrocytoma.

This patient with a family and personal history of cutaneous melanoma developed a large ring-enhancing mass that histologically proved to be a glioblastoma. (Right) Pseudopallisading necrosis is a frequent feature in high-grade brain parenchymal neoplasms, particularly glioblastoma. This example developed in a patient with a personal and family history of cutaneous melanoma. This combination of tumors is sometimes associated with germline CDKN2A gene mutations.
High-grade astrocytomas may develop in constitutional mismatch repair-deficiency syndrome. This patient had clinical features of NF1 but also microsatellite unstable colorectal cancer and lymphoma. A tripolar mitotic figure is evident, as well as entrapped neurons. (Right) This NF1-associated giant cell glioblastoma is characterized by large multinucleated glial cells. Multinucleated giant cells have also been described in glioblastomas associated with Turcot syndrome.

P.II(9):15

High-Grade Astrocytomas

(Left) Gliosarcoma in an NF1 patient contains a malignant spindle cell/mesenchymal component arranged in well-formed fascicles, a morphology that corresponds to fibrosarcoma. (Right) Reticulin shows a prominent pericellular pattern of staining in the malignant mesenchymal component of gliosarcoma. In addition, loss of GFAP expression in the sarcomatous component is another feature that may be demonstrated by immunohistochemistry, and required for the diagnosis.
This anaplastic astrocytoma developed in a patient with Li-Fraumeni syndrome. High-grade astrocytomas are also a feature of Li-Fraumeni syndrome, characterized by germline mutations in the tumor suppressor gene TP53.

A gemistocytic astrocytoma developing in a patient with Li-Fraumeni syndrome shows strong p53 labeling. Strong, uniform p53 immunostaining in most tumor cells is a frequently used, albeit imperfect surrogate for TP53 mutations.

This tumor developed in a patient with Turcot type 1 syndrome, associated with deficiency in mismatch repair enzymes. Mitotic activity was identifiable elsewhere, supporting a high-grade astrocytoma. (Right) This high-grade astrocytoma developing in a patient with Turcot type 1 syndrome demonstrates MSH6 loss by IHC in tumor cells, but not in vessels or other nonneoplastic elements. MSH2 was also lost (not shown). (Courtesy C. Giannini, MD.)

Choroid Plexus Tumors

- Spectrum of neoplasms arising in ventricular locations and with anatomic, morphologic, and immunophenotypic similarities with choroid plexus
- Etiology/Pathogenesis
  - Most are sporadic
Choroid plexus carcinomas are strongly associated with germline TP53 mutations.

- **Li-Fraumeni syndrome**: Most CNS neoplasms are astrocytomas, but some are also choroid plexus tumors (carcinoma > papilloma).
- **Rhabdoid predisposition syndrome**: Reported cases of choroid plexus carcinoma may in fact be atypical teratoid/rhabdoid tumors (AT/RT).
- **Aicardi syndrome**: Associated with choroid plexus papillomas and cysts.

**Microscopic Pathology**

- **Papilloma**: Papillary architecture with fibrovascular cores lined by cuboidal to columnar epithelium; mitotic activity rare to absent.
- **Atypical papilloma**: Mitotic activity ≥ 2 per 10 high-power fields.
- **Carcinoma**: Overtly malignant histology, brisk mitotic activity.

**Ancillary Tests**

- TP53 alterations associated with poorer prognosis in choroid plexus tumors in some studies.
- Notch pathway activation induces choroid plexus tumors in mice and is present in a subset of human choroid plexus tumors.

Choroid plexus carcinomas are malignant neoplasms that almost always develop in young children and demonstrate variable contrast enhancement. (Courtesy T. Vanegas, MD.)
Choroid plexus carcinomas usually have a papillary architecture and variable pleomorphism. This young patient developed a rhabdomyosarcoma, which strongly suggests Li-Fraumeni syndrome.

TERMINOLOGY
Definitions
- Spectrum of neoplasms arising in ventricular locations and with anatomic, morphologic, and immunophenotypic similarities with choroid plexus

ETIOLOGY/PATHOGENESIS
Sporadic Tumors
- Most choroid plexus tumors are sporadic, but choroid plexus carcinomas are strongly associated with germline TP53 mutations

Li-Fraumeni Syndrome
- Tumor predisposition syndrome most commonly secondary to germline TP53 mutations
- Most CNS neoplasms in Li-Fraumeni patients are astrocytomas (~60%)
- Also develop medulloblastomas and choroid plexus tumors (carcinomas > papillomas)

Rhabdoid Predisposition Syndrome
- Choroid plexus carcinomas reported in some patients, but there is morphologic and immunophenotypic overlap with atypical teratoid/rhabdoid tumors (AT/RT)

Aicardi Syndrome
- X-linked dominant sporadic syndrome occurring almost exclusively in females
- Agenesis of corpus callosum, chorioretinal lacunae, and infantile spasms
- Associated with choroid plexus papillomas and cysts

CLINICAL ISSUES
Epidemiology
Incidence
- Rare brain tumors overall (<1%)
- Relatively high proportion of brain tumors in infants

Presentation
Symptoms attributable to hydrocephalus and increased intracranial pressure

Prognosis
Varies from excellent (choroid plexus papilloma) to poor (choroid plexus carcinoma)

MICROSCOPIC PATHOLOGY

Histologic Features
Choroid plexus papilloma
- Papillary architecture with fibrovascular cores lined by cuboidal to columnar epithelium
- Pleomorphism, sheet-like growth, and necrosis are rare but may be present in isolation
- Mitotic activity rare to absent

Atypical choroid plexus papilloma
- Mitotic activity ≥ 2 per 10 high-power fields
- ↑ cellularity, nuclear pleomorphism, sheet-like growth, and necrosis may be present but not required for diagnosis

Choroid plexus carcinoma
- Overtly malignant histology
- Brisk mitotic activity
- Hypercellularity, pleomorphism, solid growth, and necrosis common
- Brain invasion may be present

ANCILLARY TESTS

Immunohistochemistry
- Cytokeratin and podoplanin expressed by choroid plexus tumors
- S100 protein and transthyretin also frequently expressed
- GFAP expression in a subset
- Frequent p53 immunopositivity in carcinomas
- Kir7.1 and stanniocalcin-1 expression in nonneoplastic choroid plexus and most choroid plexus tumors

Molecular Genetics
- TP53 alterations associated with poorer prognosis in choroid plexus tumors in some studies
- Notch pathway activation induces choroid plexus tumors in mice and is present in a subset of human choroid plexus tumors

DIFFERENTIAL DIAGNOSIS

Normal Choroid Plexus
- Cobblestone appearance, less cellularity than papilloma, microcalcifications

Cribiform Neuroepithelial Tumor
- Very rare low-grade intraventricular neoplasm with cribriform/trabecular architecture
- Surface EMA staining, INI1 loss

Ependymoma
- May have a papillary pattern (papillary or myxopapillary ependymoma)
- Prominent pseudorosettes, true rosettes
- Dot-like or surface EMA immunopositivity

Papillary Tumor of Pineal Region
- Similar morphologic and immunophenotypic features
- Pineal gland location not a feature of choroid plexus tumors
- Lacks Kir7.1 and stanniocalcin-1 positivity

Atypical Teratoid/Rhabdoid Tumor
- May have morphologic and immunophenotypic overlap with choroid plexus carcinoma
- INI1 protein loss

Metastatic Carcinoma
- Usually not an issue in children but main consideration in adult patients

GRADING
WHO Grades I-III
- Papilloma (WHO grade I), atypical papilloma (WHO grade II), and carcinoma (WHO grade III)

SELECTED REFERENCES

Image Gallery
Imaging and Microscopic Features

(Left) Choroid plexus neoplasms almost always arise within the ventricular system. This sagittal T1-weighted MR image shows a choroid plexus papilloma involving the 4th ventricle, a common location in adults. (Right) Choroid plexus tumors encompass a spectrum ranging from benign (grade I) to malignant (grade III). This grade I choroid plexus papilloma contains numerous papillae lined by cuboidal to columnar cells.

(Left) Distinctive fibrovascular cores are hallmarks of choroid plexus tumors. This choroid plexus papilloma has bland cytology and lacks mitotic activity and necrosis, which is consistent with a grade I neoplasm. (Right) This choroid...
plexus tumor has a more solid pattern of growth, which may be a feature of a subset of tumors. Mitotic activity is not subtle, which is consistent with an atypical choroid plexus papilloma, indicating a WHO grade II.

(Left) Keratin expression is a universal feature of choroid plexus neoplasms. Strong labeling with cytokeratin CAM5.2 is strongly supportive of the diagnosis in the right context. (Right) Choroid plexus tumors may also express a variety of markers. This example expresses S100, with a nuclear and cytoplasmic pattern.

Diagrammatic and Microscopic Features

(Left) Choroid plexus carcinomas are highly malignant neoplasms and may form huge, fleshy masses with associated edema and mass effect. (Right) Many choroid plexus carcinomas demonstrate cytologic features of malignancy, particularly nuclear enlargement, hyperchromasia, and pleomorphism. In this example, a papillary architecture is still evident.
A subset of choroid plexus papillomas may contain minimal atypia and are well differentiated at the architectural level. However, the presence of brisk mitotic activity in a choroid plexus neoplasm is very worrisome and consistent with a carcinoma. (Right) Sheets of coagulative necrosis are not uncommon in choroid plexus carcinomas. In combination with brisk mitotic activity, it strongly supports the diagnosis.

This tumor developed in a young patient after treatment for a choroid plexus carcinoma and had morphologic and immunophenotypic features of rhabdomyosarcoma. The combination of choroid plexus carcinoma and sarcoma in a young patient is strongly suggestive of a tumor predisposition syndrome, particularly Li-Fraumeni. (Right) Strong nuclear myogenin labeling confirmed the diagnosis of rhabdomyosarcoma in this young patient treated for choroid plexus carcinoma.

Ependymoma
Most frequent primary spinal cord neoplasm
Predilection for cervical cord/cervicomedullary junction in NF2 patients
NF2 ependymomas (when present) are multiple in most patients (58%)
Majority of NF2 patients are asymptomatic
Most NF2-associated ependymomas are indolent

Microscopic Pathology
Most histologic subtypes have been reported in NF2 patients, including myxopapillary, tanycytic, and anaplastic
Perivascular pseudorosettes are present in majority of ependymomas to variable extent
True ependymal rosettes
Usually sharp interface with CNS parenchyma

Ancillary Tests
Molecular genetics
Alterations in the NF2 gene in 76% of NF2-associated spinal ependymomas
Most mutations truncating (nonsense or frameshift)

As this T1-weighted MR shows, ependymomas in NF2 patients have a predilection for the cervical cord. Ependymomas form well-circumscribed masses, and most demonstrate contrast enhancement.
Among the main architectural features of ependymomas at low power are perivascular pseudorosettes, which impart an anuclear area around intratumoral vessels.

**TERMINOLOGY**

**Definitions**
- Circumscribed CNS neoplasm with dual glial and epithelial differentiation, properties resembling ependymal lining of ventricular system/central spinal cord canal

**CLINICAL ISSUES**

**Site**
- May arise anywhere in neuraxis
- Predilection for spinal cord (adults) and posterior fossa/supratentorial compartment (children)
- Most frequent primary spinal cord neoplasm in adults
- Predilection for cervical cord/cervicomedullary junction in patients with neurofibromatosis type 2 (NF2)

**Presentation**
- Present in ~1/3 to 1/2 of NF2 patients on imaging
- NF2-ependymomas (when present) are multiple in most patients (58%)
- Majority of NF2 patients are asymptomatic

**Treatment**
- Clinical follow-up is indicated for asymptomatic tumors in NF2
- Goal of surgery is complete surgical resection if feasible

**Prognosis**
- Most NF2-associated ependymomas are indolent
- Progression occurs in only a minority of patients

**IMAGE FINDINGS**

**MR Findings**
- Well-circumscribed neoplasms
- ↑ T2 signal, homogeneous contrast enhancement
- Heterogeneous enhancement in necrotic tumors
Associated cyst/spinal cord syrinx may be present
Leptomeningeal dissemination in a subset of cases (intracranial tumors)

**MICROSCOPIC PATHOLOGY**

**Histologic Features**
Subtypes include cellular, myxopapillary, papillary, clear cell, tanycytic, giant cell, and anaplastic
Most histologic subtypes have been reported in NF2 patients, including myxopapillary, tanycytic, and anaplastic
Perivascular pseudorosettes present in majority of ependymomas to variable extent
  - Gliarial processes surrounding vessels create an anuclear zone
  - More accentuated in ependymomas but may be present to a lesser extent in astrocytic and neuronal neoplasms
True ependymal rosettes
  - Well-defined lumina resembling ependymal linings
  - When large, known as ependymal canals
  - May be minute and recognized by EMA immunohistochemistry (dot-like pattern) or electron microscopy
  - Less frequent than pseudorosettes but essentially diagnostic in right context
Usually sharp interface with CNS parenchyma
  - Gliosis with Rosenthal fibers may be present
  - Infiltration is rare but may be found in supratentorial/recurrent &/or anaplastic tumors

**Cytologic Features**
  - Uniform, bland oval cells with relatively short processes
  - Aggregation/clinging of cells around vessels (pseudorosettes) is characteristic

**ANCILLARY TESTS**

**Molecular Genetics**
Alterations in *NF2* gene in 76% of NF2-associated spinal ependymomas
  - Most mutations truncating (nonsense or frameshift)

**Gene Expression Profiling**
Relevant subtypes cluster according to anatomic site and clinical behavior

**DIFFERENTIAL DIAGNOSIS**

**Schwannoma**
  - May coexist with ependymoma and meningioma in NF2 patients, usually extramedullary
  - S100(+) but EMA(-)

**Meningioma**
  - May coexist with schwannoma and ependymoma in NF2 patients
  - Extramedullary location
  - Membranous (rather than dot-like) EMA expression, GFAP negative

**Astrocytoma**
  - May also develop in NF2 patients
  - Most intramedullary tumors in NF2 are ependymomas
  - Strong index of suspicion, even in the absence of overt ependymal features

**Paraganglioma**
  - Clinical and histologic overlap with myxopapillary ependymoma in the filum terminale
  - Strong synaptophysin and chromogranin positivity

**Metastatic Carcinoma**
  - Rare in the spinal cord proper
  - Increased pleomorphism, strong cytokeratin expression

**GRADING**

**WHO Grades I-III**
  - Myxopapillary (WHO grade I), conventional (WHO grade II), anaplastic (WHO grade III)
  - Criteria for anaplasia: Brisk mitotic activity, often with microvascular proliferation and pseudopalisading necrosis
  - Adverse histologic factors may depend on anatomic site and be less significant in spinal cord tumors

**SELECTED REFERENCES**
1. Raghunathan A et al: Histological Predictors of Outcome in Ependymoma are Dependent on Anatomic Site Within the Central Nervous System. Brain Pathol. 23(5):584-94, 2013

Image Gallery
Diagrammatic and Microscopic Features

(Left) Ependymomas are well-circumscribed neoplasms that may develop anywhere along the neural axis but with a predilection for the spinal cord, particularly in adults and patients with NF2. Associated cystic changes are not uncommon. (Right) Perivascular pseudorosettes are frequent in ependymomas. They are composed of anuclear perivascular zones containing numerous neoplastic glial cell processes.

(Left) A more specific histologic feature of ependymoma is the presence of well-developed epithelial surfaces resembling the lining of the ventricular system and central canal of the cord. These surfaces may be conspicuous in some tumors and include ependymal rosettes as well as larger elongated ependymal canals. (Right) Among primary CNS neoplasms, ependymomas tend to be the most well circumscribed, and a sharp interface with brain parenchyma is seen in most cases.
Myxopapillary ependymoma is a distinctive subtype containing myxoid cuffs in pseudorosettes and stroma. These tumors have a predilection for the distal cord/filum terminale region and are assigned a grade I under the current WHO classification. Clear cell ependymoma is an ependymoma subtype characterized by the presence of round/oval nuclei and cytoplasmic clearing. The latter property raises the differential with oligodendroglial and neurocytic tumors.

Microscopic Features

Microvascular proliferation is a worrisome feature in ependymomas and usually 1 of the histologic properties ascribed to the anaplastic subtype (WHO grade III). The hallmark of anaplastic ependymoma is the presence of brisk mitotic activity. This particular example has at least 3 mitoses in a single high-power field.
The Ki-67 labeling index is very high in this ependymoma, consistent with its anaplastic histologic features. GFAP expression is variable in ependymomas but usually accentuated around vessels, highlighting perivascular pseudorosettes. This pattern of staining is not surprising since pseudorosettes are rich in GFAP-containing glial processes.

A useful immunohistochemical marker in the evaluation of ependymoma is epithelial membrane antigen, which stains with a characteristic paranuclear/intercellular dot-like pattern. This pattern of staining is attributed to microlumina rich in microvilli, which may be demonstrated by electron microscopy. Electron microscopy is still a useful ancillary technique in the diagnosis of ependymoma. Features include well-formed intercellular junctions and microlumina.

Medulloblastoma/CNS-PNET

Medulloblastoma/CNS-PNET
Fausto J. Rodríguez, MD
Key Facts
Terminology
Malignant embryonal neoplasms with predominant neuronal differentiation arising in CNS parenchyma (central nervous system primitive neuroectodermal tumor [CNS-PNET]) or cerebellum/4th ventricle region (medulloblastoma)
Etiology/Pathogenesis
Tumor predisposition syndromes associated with medulloblastoma/CNS-PNET include Gorlin syndrome, Turcot syndrome type 2, hereditary retinoblastoma, Li-Fraumeni syndrome
Majority of medulloblastomas and CNS-PNETs develop sporadically without a family history

Microscopic Pathology
- Desmoplastic/nodular: Pale nodules reflective of neuronal differentiation, and proliferative reticulin-rich internodular areas; frequent in Gorlin syndrome
- Classic: Prototypical embryonal round blue cell tumor
- Anaplastic/large cell: Characterized by nuclear enlargement (anaplastic) or large nuclei with macronucleoli (large); histologic marker of poor prognosis

CNS-PNET subtypes include cerebral neuroblastoma, ganglioneuroblastoma, medulloepithelioma, ependymoblastoma, ETANTR, undifferentiated, and nodular

Molecular subtypes of medulloblastoma and CNS-PNET separated based on gene expression profiles

Medulloblastomas form heterogeneous masses in the cerebellum with variable contrast enhancement on post-contrast T1-weighted MR images. Nodularity may be present.
Most medulloblastomas arise sporadically. A subset develop in the setting of tumor-predisposing syndromes. This tumor developed in a patient with Li-Fraumeni syndrome, characterized by germline TP53 mutations.

TERMINOLOGY

Abbreviations
Central nervous system primitive neuroectodermal tumor (CNS-PNET)

Definitions
Malignant embryonal neoplasms with predominant neuronal differentiation arising in CNS parenchyma (CNS-PNET) or cerebellum/4th ventricle region (medulloblastoma)
Unrelated to peripheral PNET/Ewing sarcoma
WHO grade IV

ETIOLOGY/PATHOGENESIS

Sporadic Tumors
Vast majority of medulloblastomas and CNS-PNET develop sporadically without a family history
Frequency of cancer predisposing syndrome higher in very young patients (< 3 years)

Gorlin Syndrome/Nevoid Basal Cell Carcinoma Syndrome
Caused by germline mutations in PTCH1 (most frequent), PTCH2, or SUFU, resulting in activation of sonic hedgehog signaling pathway
Patients develop numerous basal cell carcinomas, ovarian fibromas, and nonneoplastic manifestations (odontogenic keratocysts, calcification of the falx cerebri, skeletal abnormalities)
Cancer predisposing syndrome most strongly associated with medulloblastoma (~6% of medulloblastoma patients)

Turcot Syndrome Type 2
Caused by germline mutations in APC leading to activation of WNT signaling pathway
Patients may develop medulloblastomas and CNS-PNET

Hereditary Retinoblastoma
Patients may develop embryonal tumors involving CNS in addition to retinoblastoma (i.e., trilateral retinoblastoma)
Usually midline, ~80% centered in pineal gland (pineoblastoma) 
Remainder mostly in suprasellar region

Li-Fraumeni Syndrome
Autosomal dominant syndrome characterized by germline TP53 mutations 
Leads to development of a variety of neoplasms, including sarcomas, adrenocortical carcinomas, and brain tumors 
Astrocytomas and choroid plexus carcinomas more typical of syndrome, but medulloblastomas may also develop

CLINICAL ISSUES
Epidemiology
Age
Predominantly childhood neoplasms
~20-30% of medulloblastoma develop in adults (usually 2nd-3rd decades)
Site
Medulloblastoma
By definition, involves posterior fossa
Cerebellar vermis, cerebellar hemispheres > 4th ventricle
CNS-PNET
Cerebral hemispheres most frequently affected
Often near cerebral ventricles
Occasionally suprasellar region, brainstem, spinal cord

Presentation
Medulloblastoma
Ataxia, nausea, vomiting, headache
CNS-PNET
Symptoms secondary to mass effect, hydrocephalus
Treatment
Craniospinal irradiation and chemotherapy
Prognosis
Aggressive neoplasms with propensity for CSF dissemination
Potentially curable tumors with aggressive therapy (unlike high-grade astrocytomas)
Prognosis better for medulloblastoma than CNS-PNET

IMAGE FINDINGS
MR Findings
Relatively well-circumscribed tumors
Variable enhancement
Spinal MR usually performed to assess for CSF dissemination
MICROSCOPIC PATHOLOGY
Histologic Features
Medulloblastoma
Hypercellular neoplasm composed of cells with high nuclear:cytoplasmic ratios
Pathologic subtypes
Desmoplastic/nodular: Characterized by pale nodules reflective of neuronal differentiation, and proliferative reticulin-rich internodular areas; frequent in Gorlin syndrome
Medulloblastoma with extensive nodularity: May reside in desmoplastic nodular spectrum; affects young children and is associated with better prognosis; a significant proportion associated with Gorlin syndrome
Classic: Prototypical embryonal round blue cell tumor; most frequent medulloblastoma subtype
Anaplastic/large cell: Characterized by nuclear enlargement (anaplastic) or large nuclei with macronucleoli (large); histologic marker of poor prognosis
CNS-PNET
Heterogeneous group of neoplasms
Hypercellular neoplasms with increased mitotic activity
Relatively circumscribed neoplasms, but may infiltrate CNS parenchyma
Variable extent of neuronal and glial differentiation
Histologic subtypes
Cerebral neuroblastoma, ganglioneuroblastoma, medulloepithelioma, ependymoblastoma, embryonal tumor with abundant neuropil and true rosettes (ETANTR), undifferentiated, and nodular

ANCILLARY TESTS

Immunohistochemistry

Synaptophysin expression present in almost all medulloblastomas/CNS-PNET, although extent of staining variable
Other markers of neuronal differentiation (e.g., neurofilament protein, chromogranin, NeuN) may also be positive, but less consistent
GFAP may also be expressed
Usually around vessels or nodules in desmoplastic/nodular medulloblastoma variant

Gene Expression Profiling

4 distinct molecular subgroups of medulloblastoma recognized
WNT subgroup
Least frequent subgroup (~10%) but excellent prognosis (long term survival rates > 90%)
Classic histology in almost all
P.II(9):26

β-catenin mutations, monosomy 6; nuclear β-catenin immunolocalization

Sonic hedgehog (SHH) subgroup

Frequent in young children and adults, desmoplastic/nodular histology in a proportion (but not all)
Intermediate prognosis
9q deletions, PTCH1/SMO/SUFU mutations, GLI2 amplifications; SFRP1, YAP1 and GAB1 detectable by immunohistochemistry
SHH medulloblastomas with TP53 mutations have a high frequency of germline TP53 mutations

Group 3
Poor prognosis; mostly classic histology, but relatively high frequency of anaplastic/large cell histology
MYC amplification; NPR3 expression

Group 4
Most frequent subgroup (~35%), intermediate prognosis
Isochromosome 17q frequent

Medulloblastoma subgroups may currently be separated using special platforms in formalin-fixed paraffin-embedded tissues

PNET is a more heterogeneous group, but distinct from medulloblastoma
3 molecular subgroups of CNS-PNET also characterized by gene expression
Group 1 (primitive neural): Worst prognosis; LIN28 positive
Group 2 (oligo-neural): Intermediate prognosis; OLIG2 positive
Group 3 (mesenchymal): Better prognosis; LIN28/OLIG2 negative

DIFFERENTIAL DIAGNOSIS

Neurocytic Tumors

Central neurocytoma (intraventricular), extraventricular neurocytoma (hemispheric), and cerebellar liponeurocytoma
Better differentiated, low proliferation
Mitoses rare, low Ki-67 labeling index
Synaptophysin positive (as medulloblastoma/PNET) but also frequently NeuN positive

Lymphoma

Primary CNS lymphoma almost always large B cell
Usually afflicts elderly patients or develops in setting of immunosuppression
LCA(+), CD20(+)
Secondary CNS involvement by lymphoma usually superficial (leptomeninges)

Glial Neoplasms

May arise at any age and any location in the neuraxis
Poorly differentiated astrocytomas may be difficult to separate from CNS-PNET
High-grade oligodendrogliomas may resemble PNET and express neuronal markers
Mutant IDH1(+), OLIG2(+), 1p19q codeleted
In adults, high-grade gliomas may develop a PNET component
Usually high grade (III-IV)
Infiltrating glial and PNET components distinct
Anaplastic ependymoma: EMA(+), perivascular pseudorosettes, true ependymal rosettes

Atypical Teratoid Rhabdoid Tumor
Component of rhabdoid predisposition syndrome
May contain a predominant undifferentiated round blue cell component, particularly in very young patients
Polyphenotypic pattern by immunohistochemistry (EMA, GFAP, SMA, and CK [+])
INI1 loss in neoplastic cells

Metastasis
Metastatic embryonal tumors
- Retinoblastoma, neuroblastoma
- Small cell carcinoma
  Should be considered in adults

Pineoblastoma
Embryonal tumor that by definition arises in pineal gland region
Often grouped with CNS-PNET category, but more properly designated a pineal parenchymal tumor
May arise in setting of hereditary retinoblastoma (trilateral retinoblastoma)

Olfactory Neuroblastoma (Esthesioneuroblastoma)
Tumor of adults, cribriform plate involvement

SELECTED REFERENCES

Image Gallery
Diagrammatic, Gross, and Microscopic Features
Medulloblastomas generally form well-circumscribed masses that, by definition, are centered in the cerebellum/4th ventricle region. Although they may appear well circumscribed, they have a propensity for CSF dissemination. Therefore, not only intracranial imaging but also spinal imaging is recommended for appropriate evaluation. Medulloblastomas are highly cellular neoplasms and may demonstrate a gray-white appearance on gross cut surface examination.

Classic medulloblastoma represents the main histologic subtype, characterized by sheets of packed round cells with apoptotic bodies and mitotic activity. Nuclear size varies from small to moderate. Desmoplastic/nodular medulloblastoma is characterized by pale nodules alternating with a proliferative desmoplastic cellular infiltrate. Molecularly, they demonstrate sonic hedgehog activation and are overrepresented in Gorlin syndrome.
(Left) Nodules in the desmoplastic/nodular medulloblastoma variant are characterized by variable sizes and shapes. They may be ill defined or well circumscribed, appearing as an area of pallor as shown here. They reflect neuronal differentiation in any embryonal tumor. (Right) The nodules of the desmoplastic/nodular variant of medulloblastoma are reticulin poor, which contrasts with the dense pericellular reticulin of internodular areas.

Microscopic Features

(Left) The anaplastic variant of medulloblastoma is defined mainly on the basis of nuclear enlargement. Cell-to-cell wrapping, apoptotic bodies, and increased mitotic activity are frequent. (Right) The large cell variant is a unique variant of medulloblastoma recognized on the basis of cytologic features. The cells are large, round, and contain a prominent nucleoli. Areas of anaplastic and large cell medulloblastoma may coexist.
(Left) Synaptophysin expression is frequent in medulloblastomas and CNS-PNET. Strong expression is evident in this example, but it varies from strong to weak. (Right) GFAP expression may also be present in medulloblastomas and CNS-PNET, although to a limited extent. Labeling tends to be more frequent and stronger around intratumoral vessels ➔. GFAP expression is also frequent around the nodules of the nodular/desmoplastic variant of medulloblastoma.

(Left) Immunohistochemical staining for β-catenin demonstrates a membranous/cytoplasmic pattern in most medulloblastomas. When nuclear staining, it identifies the diagnostically favorable WNT subgroup. (Right) Nuclear INI1 labeling is a feature of all medulloblastomas. INI1 loss by neoplastic cells characterizes atypical teratoid rhabdoid tumor, which is an important entity in the differential diagnosis, particularly of the anaplastic/large cell variant. P.II(9):29

Imaging and Microscopic Features
CNS-PNETs represent malignant embryonal neoplasms usually developing in the supratentorial compartment. This example developed in a patient with familial adenomatous polyposis (i.e., Turcot type 2 syndrome). Supratentorial PNETs can arise in familial adenomatous polyposis (FAP) syndrome. This example has considerable nuclear variability and large cells with a ganglioid appearance.

Nuclear β-catenin staining (seen in this CNS-PNET in a patient with FAP), reflects activation of the WNT signaling pathway; this pathway is also operational in a subset of medulloblastomas. CNS-PNET are highly cellular neoplasms composed of sheets of cells with high nuclear:cytoplasmic ratios, frequent apoptotic bodies, and mitotic activity. They are analogous to medulloblastoma, although they are distinct at the molecular level.
Distinctive subtypes of CNS-PNET include the embryonal tumor with abundant neuropil and true rosettes (ETANTR), which, as the name implies, contains large areas of neuropil as well as distinctive rosettes with central lumina. (Right) A PNET component may be part, and a dominant feature, of high-grade gliomas with PNET components. Careful histologic and immunohistochemical analysis must be pursued in those tumors to identify the glial component.

Meningioma

> Table of Contents > Part II - Diagnoses Associated With Specific Syndromes > Section 9 - Nervous System > Meningioma

Meningioma
Fausto J. Rodríguez, MD

Key Facts
Etiology/Pathogenesis
- NF2 gene frequently inactivated in meningioma
- Multiple meningiomas represent a frequent component of the NF2 syndrome
- Rare families described with multiple schwannomas and meningiomas and with SMARCB1 germline mutations
- May occur in a subset of families lacking other tumor types (e.g., schwannomas)
- Subset of familial multiple spinal meningiomas associated with heterozygous SMARCE1 inactivating mutations and clear cell histology

Ancillary Tests
- Inactivating mutations in NF2 present in ~1/2 of meningiomas
- Oncogenic mutations in AKT1 and SMO present in a meningioma subset associated with activation of PI3K and sonic hedgehog pathways
- Combined TRAF7 and KLF4 mutations characterize secretory meningioma and are mutually exclusive with NF2 mutations

Top Differential Diagnoses
- Meningothelial hyperplasia
- Schwannoma
- Glioblastoma/gliosarcoma
- Metastatic carcinoma
- Mesenchymal neoplasms
  - Solitary fibrous tumor/hemangiopericytoma, dural sarcoma
Meningiomas are usually well-circumscribed neoplasms that arise in relation to the dura. They are well vascularized, which explains the typical contrast enhancement in imaging studies.
The prototypical histologic meningioma subtype is the meningotheliomatous, characterized by cohesive nests and indistinct cell borders. Whorls are conspicuous in this neurofibromatosis type 2-associated example.

TERMINOLOGY
Definitions
Neoplasm with differentiation along meningothelial (arachnoid) cell types, usually associated with dura

ETIOLOGY/PATHOGENESIS
Neurofibromatosis Type 2 (NF2)
- NF2 gene frequently inactivated in meningioma
- Multiple meningiomas represent a frequent component of NF2 syndrome

Schwannomatosis With Multiple Meningiomas
- Most schwannomatosis patients develop schwannomas only
- Rare families described with multiple schwannomas and meningiomas and with SMARCB1 germline mutations
- Meningiomas predominantly intracranial and located in falx cerebri

Familial Multiple Meningioma Disease
- Most meningiomas arise sporadically; familial in 1-5%, multiple in < 10%
- May occur in a subset of families lacking other tumor types (e.g., schwannomas)
- Germline mutation in SUFU (negative regulation of Hh signaling) with loss of heterozygosity identified in 1 family with multiple meningiomas
- Subset of familial multiple spinal meningiomas associated with heterozygous SMARCE1 inactivating mutations and clear cell histology

MICROSCOPIC PATHOLOGY
Histologic Features
- Frequent features include cohesive nests of cells with indistinct borders, nuclear grooves/inclusions, whorls, and psammoma bodies (i.e., concentric calcifications)
- Subtypes include meningothelial, fibrous (fibroblastic), transitional, psammomatous, angiomatous, microcystic, secretory, lymphoplasmacytic-rich, chordoid (WHO grade II), clear cell (WHO grade II), rhabdoid (WHO grade III), and papillary (WHO grade III)
NF2-associated meningiomas histologically similar to sporadic counterparts. May be associated with meningioangiomatosis in either sporadic or NF2-associated cases.

ANCILLARY TESTS

Cytogenetics

- Chromosome 22 loss most frequent alteration (~2/3 of cases)
  - Most frequent in fibroblastic, transitional, and psammomatous subtypes
  - Losses of 1p, 6q, 10, 14q, &/or 18q associated with atypical or anaplastic subtypes
  - Gains of 1q, 9q, 12q, 15q, 17q, &/or 20q also associated with atypical or anaplastic subtypes

Molecular Genetics

- Inactivating mutations in NF2 present in ~1/2 of meningiomas
- Oncogenic mutations in AKT1 and SMO present in a meningioma subset associated with activation of PI3K and sonic hedgehog pathways
- Combined TRAF7 and KLF4 mutations characterize secretory meningioma and are mutually exclusive with NF2 mutations

DIFFERENTIAL DIAGNOSIS

Meningothelial Hyperplasia

- Reactive proliferation associated with a variety of superficial CNS insults (hemorrhage, inflammation, neoplasms)
- Limited in size

Schwannoma

- Important differential with fibrous meningioma and predilection for cerebellopontine angle
- Smears poorly; S100(+), EMA(-)

Mesenchymal Neoplasms

- Solitary fibrous tumor more differentiated, ropy collagen; hemangiopericytoma, increased cellularity and more aggressive clinical behavior
  - CD34(+), EMA(-)
- Dural sarcomas usually high grade, overtly malignant with high cellularity, fascicular pattern of growth, brisk mitotic activity

Glioblastoma/Gliosarcoma

- Superficial high-grade gliomas may extend to dura
  - GFAP(+), usually EMA(-)

Metastatic Carcinoma

- Cytokeratin (+) whereas meningiomas are usually cytokeratin (-)

GRADING

WHO Grade I

- Low proliferative activity (< 4 mitoses per 10 high-power fields) and lack of brain invasion

WHO Grade II

- Increased mitotic activity (≥ 4 per 10 high-power fields) or ≥ 3 of the following: Hypercellularity, sheet-like growth, macronucleoli, small cell change, necrosis (in the absence of embolization) or brain invasion or chordoid/clear cell histologic subtypes

WHO Grade III

- ≥ 20 mitoses per 10 high-power fields or histologic malignancy (i.e., resembling carcinoma or sarcoma) or rhabdoid/papillary histologic subtypes

SELECTED REFERENCES


Image Gallery
Imaging and Microscopic Features

(Left) Meningiomas are the 2nd most common neoplasms in NF2 patients. They are usually dura-based, multiple in these patients, and demonstrate strong, homogeneous contrast enhancement after administration of gadolinium in T1-weighted MR sequences. (Right) Diagnostic properties of meningioma are usually evident on smear preparations, including flat cells and whorls with psammoma bodies.

(Left) Meningiomas are usually characterized by bland, flat cells with oval nuclei in smear preparations. In this specific example arising in a woman with NF2, Barr bodies are present. Barr bodies, representing the inactive X chromosome, are a cytologic feature supporting the female sex and often seen in meningiomas. (Right) The presence of whorls is 1 of the architectural hallmarks of meningioma. Numerous whorls are present in this meningioma arising in a patient with NF2.
Psammoma bodies represent peculiar calcifications with concentric arrangements occurring in the center of meningioma whorls. When numerous and occupying every field, the diagnosis of psammomatous meningioma may be appropriate. Most meningiomas are WHO grade I and demonstrate low proliferative rates. Ki-67/MIB1, which labels cells that are actively in the cell cycle, stains only rare nuclei in these tumors.

Microscopic Features

Meningiomas in NF2 patients are usually multiple and may arise in any anatomic site, including the orbit. Many intraorbital meningiomas develop in close relation to the optic nerve sheath. Increased mitotic activity may occur in a subset of meningiomas and represents an important criterion for grading. In this atypical meningioma (WHO grade II), mitotic activity is not subtle and exceeds 4 mitotic figures per 10 high-power fields.
The fibrous meningioma subtype is characterized by the presence of spindle cells. Bright, eosinophilic collagen bundles may be present, which raises the differential diagnosis to a variety of mesenchymal neoplasms, particularly solitary fibrous tumor. Most meningiomas, regardless of the subtype, express EMA, although the immunoreactivity is variable and usually not to the extent of epithelium. A linear/membranous pattern is common.

Clear cell meningioma is a unique subtype with more aggressive behavior. This tumor arose in a patient with a germline heterozygous SMARCE1 mutation, a recently recognized familial meningioma syndrome. These patients are predisposed to the development of clear cell meningiomas. Meningiomas associated with SMARCE1 mutations are of the clear cell type. PAS highlights glycogen.

Pineoblastoma

Malignant, high-grade embryonal neoplasm centered in pineal region

May arise in patients with RB1 germline mutations

Trilateral retinoblastoma: Bilateral retinoblastoma + intracranial/midline embryonal tumor
Intracranial tumor frequently (80%) in pineal region = pineoblastoma (“3rd eye”)

Clinical Issues
~40% of pineal parenchymal tumors

Microscopic Pathology
Sheets of tightly packed round cells with brisk mitotic activity, similar to other embryonal neoplasms

Ancillary Tests
Expresses same neuronal antigens that other PNETs and pineal parenchymal tumors express

Pineoblastomas are malignant neoplasms presenting as contrast-enhancing masses in the pineal region ➔. Associated hydrocephalus is a frequent finding.
Pineoblastomas are hypercellular, round blue cell tumors. Neuronal differentiation is reflected in the form of small Homer Wright rosettes.

TERMINOLOGY
Definitions
- Malignant, high-grade embryonal neoplasm centered in pineal region

ETIOLOGY/PATHOGENESIS
Syndrome Association
- Most pineoblastomas arise sporadically without syndrome association
- May arise in patients with RB1 germline mutations
- Also may develop in setting of Turcot type 2 (familial adenomatous polyposis) with associated APC mutations
- Rare report of pineoblastoma developing in a patient with germline DICER1 mutation and subsequent loss of heterozygosity

Trilateral Retinoblastoma Syndrome
- Bilateral retinoblastoma + intracranial/midline embryonal tumor, RB1 germline mutation
- Occurs in < 1% of patients with retinoblastoma
- Intracranial tumor frequently (~80%) in pineal region = pineoblastoma (“3rd eye”)
- 1 report of trilateral retinoblastoma in Peutz-Jeghers syndrome patient with germline LKB1/STK11 mutation

CLINICAL ISSUES
Epidemiology
- ~40% of pineal parenchymal tumors, ~20% of nonmedulloblastoma primitive neuroectodermal tumors (PNET) affecting CNS
- More common in children < 3 years of age

Presentation
- Pineal region mass with associated hydrocephalus, tectal plate compression, paralysis of vertical gaze

Prognosis
- Related to age (worse in young children)
- Poor in patients with trilateral retinoblastoma syndrome
IMAGE FINDINGS

MR Findings
- Heterogeneous enhancing mass

CT Findings
- Calcifications rare to absent

MICROSCOPIC PATHOLOGY

Histologic Features
- Sheets of tightly packed round cells with brisk mitotic activity, similar to other embryonal neoplasms
- Lack of pineocytomatous rosettes
- Homer Wright rosettes → acellular synaptophysin positive cores; Flexner-Wintersteiner rosettes → contain a central lumen, consistent with retinoblastic differentiation

ANCILLARY TESTS

Immunohistochemistry
- Expresses same neuronal antigens as other PNETs and pineal parenchymal tumors express (e.g., synaptophysin)
- GFAP usually negative (highlights entrapped astrocytes)
- High Ki-67 labeling index

Molecular Genetics
- Genomic imbalance lower in pineoblastomas compared with other CNS-PNET in single nucleotide polymorphism (SNP) array studies
  - Copy number gains in gene regions of PCDHGA3 (5q31.3) and FAM129A (1q25)
  - Copy number losses in gene region of OR4C12 (11p11.12)
- Cytogenetic alterations in RB1 and TP53 mutations are not a feature of sporadic pineoblastoma

DIFFERENTIAL DIAGNOSIS

Pineal Parenchymal Tumors
- Pineocytoma (WHO grade I) and pineal parenchymal tumor of intermediate differentiation (WHO grades II-III)
- Grading systems complex but based on mitotic activity and extent of differentiation (i.e., neurofilament protein expression)

Medulloblastoma/CNS-PNET
- Similar histology but distinct anatomic location and molecular features

Papillary Tumor of Pineal Region
- Epithelial morphology and keratin expression (CAM 5.2)

Germ Cell Tumors
- Mainly germinoma, but other patterns also possible
- Immunoreactivity for germ cell markers (PLAP, OCT4, SALL4, AFP)

Metastatic Carcinoma
- Important consideration in adults
- Expression of epithelial markers (keratin, EMA)

SELECTED REFERENCES


IMAGE GALLERY
Pineoblastomas may present as large masses with an epicenter in the pineal region and associated areas of heterogeneity. Brisk mitotic activity is an important histologic property of pineoblastoma that distinguishes it from other, better differentiated pineal parenchymal tumors. Necrosis may also be present. (Right) All pineal parenchymal tumors are characterized by the expression of neuronal markers, particularly synaptophysin.

Retinoblastoma

Key Facts

Etiology/Pathogenesis
- Loss or inactivation of both alleles of retinoblastoma gene (RB1 gene)
  - Knudson “2-hit” hypothesis

Clinical Issues
- Most common intraocular malignancy in children
- Average age at diagnosis: 18–24 months
- Up to 40% have genetic predisposition
- 2nd cancers common in patients with RB1 mutations
  - Osteosarcoma, soft tissue sarcoma, melanoma, Hodgkin lymphoma, breast carcinoma
- Leukocoria is most common clinical presentation

Image Findings
- Calcified intraocular mass
- Diagnosis often made by imaging only

Microscopic Pathology
- Small round blue cell tumor
- Variable appearance based on degree of differentiation
  - Flexner-Wintersteiner rosettes have central lumen
  - Fleurette shows photoreceptor differentiation
- Ischemic necrosis common
- Calcifications common

Top Differential Diagnoses
- Primitive neuroectodermal tumor (PNET)
- Leukemia/lymphoma
- Astrocytoma
- Medulloepithelioma
Retinoblastoma may have lobulated contours and extend through the limiting membrane into the vitreous. Punctate calcifications are characteristic.
Retinoblastoma is a cellular malignant neoplasm composed of cells with high nuclear:cytoplasmic ratios, forming sheets.

Abbreviations
- Retinoblastoma (RB)

Definitions
- Malignant embryonal neoplasm centered in the retina and demonstrating variable photoreceptor differentiation

ETIOLOGY/PATHOGENESIS

Developmental Anomaly
- Loss or inactivation of both alleles of retinoblastoma gene (RB1)
  - Located at 13q14
  - Tumor suppressor gene
- Knudson “2-hit” hypothesis
  - RB results from 2 independent mutations
  - 1st mutation may be either somatic (sporadic) or germinal (inherited)
  - 2nd mutation is sporadic

CLINICAL ISSUES

Epidemiology

Incidence
- Most common intraocular malignancy in children

Age
- Average age at diagnosis is 18-24 months
  - Younger in bilateral/familial cases

Gender
- No predilection

Ethnicity
- No predilection
Site
Sporadic RB is usually unilateral
Inherited RB is often bilateral
May include pineal tumor (so-called trilateral RB)
Quadrilateral RB is very rare and includes bilateral RB plus pineal and suprasellar tumors

Presentation
Leukocoria (white pupil)
Frequently noticed in photographs
Strabismus
Decreased visual acuity
Glaucoma
Red, painful eye
Up to 40% have genetic predisposition
5-10% have family history of RB
Remainder are new germline mutations

Treatment
Depends on tumor size, intraocular location, and histopathologic risk factors

Prognosis
If untreated, invariably fatal
Poor prognosis if direct scleral invasion or invasion of optic nerve
90% cure rate if noninvasive
2nd cancers common in patients with RB1 mutations
   Incidence is higher in inherited RB
Osteosarcoma, soft tissue sarcoma, melanoma, Hodgkin lymphoma, breast carcinoma

IMAGE FINDINGS
General Features
Calcified intraocular mass
Diagnosis often made by imaging only

MACROSCOPIC FEATURES
General Features
Creamy white appearance, calcifications and necrosis
Growth patterns
   Endophytic: Growth inward toward vitreous cavity
   Exophytic: Growth outward toward subretinal space and choroid
      Detaches retina; still may fill vitreous cavity
   Diffusely infiltrating: Thickens retina

MICROSCOPIC PATHOLOGY
Histologic Features
Small round blue cell tumor
Flexner-Wintersteiner rosettes
   Tumor cells surround central lumen that contains acid mucopolysaccharide
   Tumor nuclei are placed away from central lumen
Homer Wright rosettes
   Lack well-defined lumen
Fleurette
   Photoreceptor differentiation (well-differentiated RB, “retinocytoma” when completely made of fleurettes)
   Pattern resembles a fleur-de-lis
Ischemic necrosis common
Surrounds perivascular tumor cells
Calcifications common
May invade optic nerve and extend to brain or CSF
High-risk characteristics include anterior chamber involvement, massive posterior uveal invasion, postlaminar optic nerve invasion, and posterior uveal + optic nerve invasion

DIFFERENTIAL DIAGNOSIS
Primitive Neuroectodermal Tumor (PNET)
If in eye, would be considered metastatic/secondary extension

Leukemia/Lymphoma
- Immunohistochemical stains for lymphoid markers helpful

Astrocytoma
- Small round blue cell pattern generally not seen in astrocytoma; GFAP(+)

Medulloepithelioma
- Larger rosettes, tubular architecture
- May be benign or malignant; teratoid (i.e., containing heteroplastic elements) or nonteratoid

SELECTED REFERENCES

Image Gallery

Clinical and Other Features

(Left) Leukocoria, or white pupil, is a common presentation of retinoblastoma. This is frequently noticed in photographs. (Courtesy D. Shatzkes, MD.) (Right) Retinoblastoma forms variably sized masses on funduscopic examination. Tumors are usually white and fluffy. The optic nerve and macula are uninvolved. (Courtesy D. Dries, MD.)
Diagnostic Pathology: Familial Cancer Syndromes

(Left) Gross pathology shows the macroscopic appearance of the eye after exenteration. Retinoblastoma is a calcified mass that fills the vitreous cavity. (Courtesy B. Ey, MD.) (Right) Retinoblastomas may form large intraocular masses, which block the normal retinal light reflex. Necrosis is a frequent finding and may be identified on low magnification.

(Left) Axial CT shows a large, lobulated, partially calcified left intraocular mass, typical of retinoblastoma. (Right) Knudsen “2-hit” hypothesis refers to the sequence in which both copies of a tumor suppressor gene must be mutated for a tumor to develop. The 1st hit may be either inherited (germline, bottom) or sporadic (somatic, top). The 2nd hit is always sporadic (red chromosome contains a mutant copy of a tumor suppressor gene).

P.II(9):39

Microscopic Features
Sheets of small round blue cells make up this poorly differentiated retinoblastoma. This field could be mistaken for PNET if the location was not known. Necrosis and calcifications are very common in retinoblastoma. The necrosis is often seen around vascular spaces, as the tumor outgrows its blood supply. Calcifications are an important marker in radiologic studies.

Calcifications may be prominent in some examples and are a useful diagnostic finding in x-ray-based imaging studies. Flexner-Wintersteiner rosettes are seen in moderately differentiated retinoblastomas. They have central lumina filled with mucopolysaccharide, and the surrounding tumor cells have their nuclei located away from the lumina.
Homer Wright rosettes are less specific structures characterized by an anuclear center lacking lumina. They may be encountered in a variety of tumor types. Invasion of the optic nerve is a negative prognostic factor in retinoblastoma and must be carefully evaluated in all specimens. Extent of invasion is important and the lamina cribrosa represents an important landmark. Invasion beyond the lamina cribrosa is associated with an ominous prognosis.

Section 10 - Pulmonary
Adenocarcinoma, Lung

Key Facts
Terminology
  Malignant epithelial neoplasm with glandular differentiation
Etiology/Pathogenesis
  Close association with tobacco smoking
  Lung adenocarcinoma shows increased frequency and occurs at a younger age than general population in Bloom syndrome
  BRCA2
  Hereditary retinoblastoma
Macroscopic Features
  Peripheral or central tumors
  Varying size from 0.6 cm to > 10 cm
Microscopic Pathology
  Acinar
  Solid
  Papillary
  Micropapillary
  Mixed
Ancillary Tests
  EGFR by FISH
  Analysis of exons 18, 19, 20, and 21
Top Differential Diagnoses
  Adenocarcinoma from extrathoracic origin
  Atypical adenomatous hyperplasia (AAH)
Adenoid cystic carcinoma (ACC)
Fetal adenocarcinoma (monophasic pulmonary blastoma)
Papillary carcinoma of thyroid origin

High-power view shows a well-differentiated adenocarcinoma with an acinar growth pattern. The glands are irregular with nuclear atypia and scattered mitotic figures.
High-power view shows a true papillary carcinoma of the lung. Note the presence of true papillae. The nuclear characteristics of this tumor may mimic those seen in thyroid carcinomas.

TERMINOLOGY
Definitions
-Malignant epithelial neoplasm with glandular differentiation

ETIOLOGY/PATHOGENESIS
Environmental Exposure
-Close association with tobacco use

Association With Familial Syndromes
-Lung adenocarcinoma shows increased frequency and occurs at a younger age than the general population in Bloom Syndrome, hereditary retinoblastoma, and BRCA2

Etiology
-Tumor probably originates from endobronchial glands

CLINICAL ISSUES
Epidemiology
-Incidence
-Although more common in adults, adenocarcinomas also occur in younger individuals

Presentation
-Cough
-Weight loss
-Difficulty breathing
-Chest pain
-Cushing syndrome
Superior vena cava syndrome
Pancoast syndrome
Hemoptysis

Treatment
   Surgical approaches
      Segmentectomy, lobectomy, pneumonectomy
   Adjuvant therapy
      Chemotherapy, radiation therapy, or both
      Cases positive for epidermal growth factor receptor (EGFR) mutation may receive targeted treatment

Prognosis
   Depends on stage at time of diagnosis
   Patients with carcinomas positive for EGFR mutation may have better prognosis
   It is also possible that tumors with better differentiated histology have more favorable outcome
   It may also be related to other pulmonary function factors as well as other medical conditions

MACROSCOPIC FEATURES
General Features
   Peripheral or central tumors
      Tumors may show necrosis &/or hemorrhage
      Homogeneous tan surface
      Well-circumscribed but not encapsulated

Sections to Be Submitted
   Tumor in relation to pleural surface
      Pleural involvement crucial for staging tumors < 3 cm in size

Size
   Varying size from 0.6 cm to > 10 cm

MICROSCOPIC PATHOLOGY
Histologic Features
   Malignant glandular component

Predominant Pattern/Injury Type
   Acinar
   Solid
   Papillary
   Mixed
   Micropapillary

Predominant Cell/Compartment Type
   Epithelial

True Papillary Carcinoma
   Should be composed of at least 75% true papillae with fibrovascular cores
   This particular pattern is believed to be more aggressive
   Lymph node metastases in this pattern are commonly seen
   TTF-1(+) and thyroglobulin (-)

Papillary Carcinoma with Morular Component
   Similar criteria to true papillary carcinoma
   Presence of morular component in alveolar spaces
   Morules are of different sizes and always in intraalveolar location
   TTF-1(+) and thyroglobulin (-)

Micropapillary Carcinoma
   Composed of small micropapillae without fibrovascular cords
   This pattern is often seen in combination with true papillary carcinoma
   TTF-1(+) and thyroglobulin (-)

Hepatoid Adenocarcinoma
   Composed of cords of neoplastic cells resembling hepatic parenchyma
   This pattern is commonly placed among large cell carcinomas of lung
   TTF-1 may show focal positive staining

Warthin-Like Adenocarcinoma
   Prominent lymphoid component similar to tumors in salivary gland
Some cases of mucoepidermoid carcinoma may also display similar features
Glandular proliferation with cells producing mucin embedded in inflammatory background
TTF-1 may show positive staining

Adenomatoid Tumor-Like Adenocarcinoma
Blind appearance similar to true adenomatoid tumor
In some cases, can be confused with so-called alveolar adenoma
TTF-1 and keratin 7 positive

ANCILLARY TESTS
Histochemistry
Mucicarmine
  Reactivity: Positive
  Staining pattern
  Cytoplasmic
PAS-diastase
  Reactivity: Positive
  Staining pattern
  Cytoplasmic
EGFR by Fluorescent In Situ Hybridization (FISH)
Analysis of exons 18, 19, 20, and 21

DIFFERENTIAL DIAGNOSIS
Adenocarcinoma From Extrathoracic Origin
Immunohistochemistry positive for TTF-1; keratin 7 would favor lung origin in vast majority of cases

Atypical Adenomatous Hyperplasia (AAH)
  Lesion ≤ 0.5 cm in diameter
  Shares similar histological features with bronchioloalveolar carcinoma (BAC)
Adenoid Cystic Carcinoma (ACC)
  Shows characteristic double layer-forming glands
  Immunohistochemical studies show myoepithelial differentiation
Fetal Adenocarcinoma (Monophasic Pulmonary Blastoma)
  Presence of morules and embryonic-type glandular structures
  Presence of cytoplasmic mucin content in favor of adenocarcinoma
Papillary Carcinoma of Thyroid Origin
  Histologically, tumors with papillary pattern may show similar histological features
  Positive TTF-1 and negative staining for thyroglobulin favors primary lung cancer

DIAGNOSTIC CHECKLIST
Pathologic Interpretation Pearls
  Size of lesion separates carcinoma from AAH
  Cases designated as AAH are < 5 mm in diameter

GRADING
Low Grade
  Well-differentiated adenocarcinoma composed of easily identifiable glandular structures and arranged in back-to-back arrangement
  Absence of necrosis, increased mitotic activity, and nuclear atypia
  Glandular tumoral structures may be separated by extensive areas of collagenization
Intermediate Grade
  Moderately differentiated adenocarcinoma composed of identifiable glands
  Tumor may show more nuclear atypia and mitotic activity
  Glandular structures may show more disarray
High Grade
  Poorly differentiated adenocarcinoma may show solid areas with ↑ mitotic activity and nuclear atypia
  Necrosis and hemorrhage may be present

SELECTED REFERENCES

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Reactivity</th>
<th>Staining Pattern</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEA-M</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>Often negative in mucinous tumors</td>
</tr>
<tr>
<td>TTF-1</td>
<td>Positive</td>
<td>Nuclear</td>
<td></td>
</tr>
<tr>
<td>CD15</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>Often negative in poorly differentiated tumors</td>
</tr>
<tr>
<td>MOC-31</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>Some mesotheliomas may show focal positive staining</td>
</tr>
<tr>
<td>CK-PAN</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td></td>
</tr>
<tr>
<td>CK7</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td></td>
</tr>
<tr>
<td>Surfactant</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>Negative in many cases of primary lung origin</td>
</tr>
<tr>
<td>CDX-2</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td></td>
</tr>
<tr>
<td>EpCAM/BER-EP4/CD326</td>
<td>Positive</td>
<td>Cell membrane</td>
<td>Some mesotheliomas are positive</td>
</tr>
<tr>
<td>NAPSIN-A</td>
<td>Positive</td>
<td>Cell membrane</td>
<td>Positive in most well-differentiated tumors</td>
</tr>
<tr>
<td>PRP</td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mammaglobin</td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ERP</td>
<td>Negative</td>
<td></td>
<td>Some lung adenocarcinomas may be positive</td>
</tr>
<tr>
<td>CK20</td>
<td>Negative</td>
<td></td>
<td>Some lung adenocarcinomas may show weak positive staining</td>
</tr>
</tbody>
</table>

Image Gallery
Microscopic Features
Adenocarcinoma shows an acinar pattern of growth. The neoplastic glandular proliferation is composed of glands of different sizes in a back-to-back arrangement. Adenocarcinoma in which a nonmucinous component merges with a mucinous component shows cystic changes whereas the nonmucinous component reveals a more acinar component.

Adenocarcinoma shows predominantly a nonmucinous type of glandular epithelium. In focal areas, a nonmucinous type of proliferation merges with glands composed of a mucinous type of epithelium. This component may be subtle. High-power view shows a moderately differentiated adenocarcinoma revealing glandular structures with nuclear atypia and mitotic activity. The glands have a vague enteric type of differentiation, mimicking a metastasis from colon.

Adenocarcinoma is shown with comedo-like necrosis and with an acinar pattern that demonstrates a vague neuroendocrine morphology whereas in some areas it shows conventional glandular differentiation. Adenocarcinoma with the presence of numerous multinucleated giant cells is seen in this photomicrograph. Note the presence of atypical bizarre mitotic figures.

Microscopic Features
Moderately differentiated adenocarcinoma displays easily recognizable glandular structures of different sizes. The glands are separated by an inflammatory reaction. Some of the glands are collapsed and show more nuclear atypia. Adenocarcinoma involves the pleural surface. This particular feature is highly important in tumors < 3 cm in which pleural involvement will upgrade the pathologic staging of the tumor to a higher level (T2).

This poorly differentiated adenocarcinoma of lung has only focal areas with glandular differentiation. Most of the tumor has a predominantly solid growth pattern. Adenocarcinoma with prominent inflammatory changes is seen in this photomicrograph. These changes may be very extensive or may form abscess areas within the tumor.
(Left) Intermediate-power view of a poorly differentiated adenocarcinoma with vague glandular formation is shown. The presence of glandular differentiation in some poorly differentiated adenocarcinomas may be focal. (Right) Well-differentiated adenocarcinoma with an acinar growth pattern is composed of small glandular proliferation of different sizes. The glands are arranged in a haphazard pattern with fibrotic and inflammatory reaction.

P.II(10):7

Microscopic Features

(Left) High-power view of a well-differentiated adenocarcinoma is composed of malignant glands with low cuboidal epithelium. (Right) High-power view shows a micropapillary adenocarcinoma of the lung. Note that the micropapillae filling the alveolar spaces are devoid of fibrovascular cord, contrary to true papillae.
(Left) High-magnification view shows a papillary adenocarcinoma with morular component. Note the presence of the morules within the alveolar spaces, in contrast to those seen in monophasic blastomas, which are in the interstitium at the base of the glands. (Right) Immunohistochemical stain for TTF-1 with strong nuclear staining in the morular component of the tumor is shown. Note that adjacent neoplastic glands are also positive.

(Left) Moderately differentiated adenocarcinoma shows the malignant glandular proliferation admixed with areas of fibrosis and inflammatory reaction. (Right) FISH shows gene amplification of the characteristic EGFR mutation in a pulmonary adenocarcinoma.

Adenocarcinoma With Lepidic (Bronchioloalveolar) Predominant Pattern

Adenocarcinoma With Lepidic (Bronchioloalveolar) Predominant Pattern
Vania Nosé, MD, PhD
Cesar A. Moran, MD
Key Facts
Terminology
  Adenocarcinoma with a lepidic (bronchioloalveolar) predominant pattern
  Adenocarcinoma with no evidence of stromal, vascular, or pleural invasion
  In situ adenocarcinoma
Etiology/Pathogenesis
Adenocarcinoma with a lepidic pattern appears not to be associated with tobacco smoking
Risk of developing lung cancer is increased in
- Li-Fraumeni syndrome as compared with general population
- Peutz-Jeghers syndrome, with a cumulative cancer risk of 15% by age 60

Macroscopic Features
- Multinodular pattern: Extensive areas of lung parenchyma are involved in miliary fashion
- Diffuse pattern: No distinct tumor mass or nodule

Top Differential Diagnoses
- Atypical adenomatous hyperplasia (AAH)
  - Tumor nodule of < 0.5 cm in greatest dimension
- Metastatic adenocarcinoma
  - Immunohistochemical studies may be helpful in determining primary site
- Invasive adenocarcinoma
  - Adenocarcinoma with a lepidic pattern is a tumor with no lymphatic, pleural, or interstitial invasion
  - To rule out invasion, entire specimen has to be examined

Illustration of adenocarcinoma with a lepidic predominant pattern shows growth of neoplastic cells along alveolar structures without evidence of stromal, vascular, or pleural invasion.
Illustration of an adenocarcinoma with a lepidic predominant pattern highlights the absence of pleural involvement by the tumor. This is an important criterion for the diagnosis of BAC.

TERMINOLOGY

Abbreviations
- Adenocarcinoma with a lepidic predominant pattern (BAC)

Synonyms
- Adenocarcinoma in situ
- Minimally invasive adenocarcinoma
- Adenocarcinoma with a bronchioloalveolar carcinoma pattern

Definitions
- Lesion with relatively bland cytologic features that arises in periphery of lung and spreads along walls of distal air spaces
- A bronchioloalveolar carcinoma pattern of adenocarcinoma shows growth of neoplastic cells along preexisting alveolar structures (lepidic growth)
  - In situ adenocarcinoma
  - No evidence of stromal, vascular, or pleural invasion

ETIOLOGY/PATHOGENESIS

Environmental Exposure
- Adenocarcinoma with a lepidic (bronchioloalveolar) predominant pattern appears not to be associated with tobacco use

Association With Familial Syndromes
- BAC associated with familial tumor syndromes is rare
  - Risk of developing lung cancer is increased in
    - Li-Fraumeni syndrome, as compared with general population
    - Peutz-Jeghers syndrome, with a cumulative cancer risk of 15% by age 60
    - Xeroderma pigmentosum

CLINICAL ISSUES
Diagnostic Pathology: Familial Cancer Syndromes

**Epidemiology**
Incidence of true BAC is not high and may represent less than 10% of all lung carcinomas
Tumor can occur at any age

**Presentation**
Cough
Chest pain
Shortness of breath

**Treatment**
Surgical approaches
Wedge resection, lobectomy, or pneumonectomy

**Prognosis**
As currently defined, patients with BAC tumors ≤ 2 cm are expected to do well

**MACROSCOPIC FEATURES**
**General Features**
- Localized tumor mass
- Multinodular pattern: Extensive areas of lung parenchyma are involved in miliary fashion
- Diffuse pattern: No distinct tumor mass or nodule is present

**MICROSCOPIC PATHOLOGY**
**Histologic Features**
- Conventional type
  - Tumor cells are small and dark with hyperchromatic nuclei and scant cytoplasm
  - Tumor cells display prominent hobnail appearance and are devoid of nucleoli or mitotic figures

**DIFFERENTIAL DIAGNOSIS**
- Atypical Adenomatous Hyperplasia
  - Tumor nodule < 0.5 cm in greatest dimension
  - Histology very similar to BAC
- Metastatic Adenocarcinoma
  - Past or present history of adenocarcinoma outside of thoracic cavity
  - Immunohistochemical studies may be helpful in determining primary site
- Pulmonary Invasive Adenocarcinoma
  - BAC lacks presence of vascular, lymphatic, pleural, or interstitial involvement by tumor cells

**DIAGNOSTIC CHECKLIST**
**Clinically Relevant Pathologic Features**
- Noninvasive pattern
- Diagnosis of BAC cannot be achieved in biopsy specimens
- Histopathological examination of entire tumor is required for diagnosis of BAC
- Lymph node sampling is required to properly rule out metastatic disease

**Pathologic Interpretation Pearls**
- Alveolar wall lined by neoplastic cells
- Absence of pleural invasion
- Absence of interstitial invasion

**SELECTED REFERENCES**

### Immunohistochemistry

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Reactivity</th>
<th>Staining</th>
<th>Comment</th>
</tr>
</thead>
</table>

1000
### Pattern

<table>
<thead>
<tr>
<th>Antibody / Marker</th>
<th>Pattern</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>KERATIN-LMW</td>
<td>Positive</td>
<td>Cytoplasmic</td>
</tr>
<tr>
<td>CEA-M</td>
<td>Positive</td>
<td>Cytoplasmic</td>
</tr>
<tr>
<td>CK7</td>
<td>Positive</td>
<td>Cytoplasmic</td>
</tr>
<tr>
<td>TTF-1</td>
<td>Positive</td>
<td>Nuclear</td>
</tr>
<tr>
<td>NAPSIN-A</td>
<td>Positive</td>
<td>Cytoplasmic</td>
</tr>
<tr>
<td>CK20</td>
<td>Negative</td>
<td></td>
</tr>
<tr>
<td>CDX-2</td>
<td>Negative</td>
<td></td>
</tr>
<tr>
<td>GCDFP-15</td>
<td>Negative</td>
<td></td>
</tr>
</tbody>
</table>

Helpful in both mucinous and nonmucinous tumors

In some mucinous cases, stain may be negative

May show focal positive staining in tumor cells in some cases

May show focal positive staining in tumor cells in some mucinous tumors

**Image Gallery**

**Gross and Microscopic Features**

(Left) Gross photograph shows multiple small pulmonary nodules of different sizes. This represents the multinodular pattern of bronchioloalveolar cell carcinoma. (Right) Nodular (nonmucinous) pattern of adenocarcinoma with a lepidic predominant pattern is shown. The tumor is in a subpleural location without pleural or interstitial involvement.

(Left) H&E shows adjacent areas of normal lung parenchyma in a pneumonic type of adenocarcinoma with a lepidic...
predominant pattern. The alveoli are filled with fluid and numerous floating macrophages. (Right) This photomicrograph shows a characteristic adenocarcinoma with a lepidic predominant pattern. Note the absence of tumor infiltrating the interstitium. However, absence of pleural invasion must also be excluded for this diagnosis.

(Left) Adenocarcinoma with a lepidic predominant pattern is seen composed of cellular proliferation lining the alveolar walls. The cells are low to flat cuboidal with pyknotic nuclei and an absence of mitotic activity or nuclear atypia. Note the lack of interstitial involvement. (Right) Adenocarcinoma with a lepidic predominant pattern is shown, in which the alveolar walls are lined by cells displaying more nuclear atypia. However, the tumor cells do not show mitotic activity.

Microscopic Features

(Left) Predominantly alveolar pattern in adenocarcinoma is shown, in which malignant cells line the alveolar walls. Also note the presence of areas of normal lung parenchyma. (Right) Bronchioloalveolar cell carcinoma pattern shows a classical pattern of the lepidic growth. Note the presence of neoplastic cells lining the alveolar wall. Still, one is able to follow the “normal” architecture of the lung parenchyma.
Low power view of this adenocarcinoma shows extensive areas of lung parenchyma replaced with proteinaceous fluid filling the alveolar spaces. This pattern represents the so-called pneumonic pattern of adenocarcinoma. (Right) Pneumonic pattern of adenocarcinoma in which the alveoli are filled with edematous fluid is shown here with only focal areas of alveoli replaced by mucinous epithelium.

Closer view shows the pneumonic variant of adenocarcinoma with a lepidic predominant pattern. Note the presence of mucinous epithelium replacing the alveolar lining. (Right) Mucinous type of epithelium replaces the alveolar lining. The mucinous epithelium is composed of columnar cells with nuclei displaced toward the base. No cellular atypia or mitotic activity is present.

**Lymphangioleiomyomatosis**

- Unknown etiology
- Occurs in ~6% of tuberous sclerosis patients
- May share similar genetic relationship with tuberous sclerosis complex
Clinical Issues
Incidence
More common in premenopausal women
Rarely described in children
Microscopic Pathology
Cystic changes with smooth muscle proliferation
Spindle cell proliferation lining cystic structures
  In alveolar walls
  With focal clear cell change
Lacking atypia or mitotic activity
Ancillary Tests
Spindle cells are positive for SMA, HMB-45, and ER/PR
Top Differential Diagnoses
Tuberous sclerosis
  Distinction between sporadic and familial LAM may not be possible on histologic grounds
  Associated with numerous tumors, hamartomas, and cysts
Leiomyoma
  Usually forms a solid tumor mass
Leiomyosarcoma
LAM lacks atypia or mitotic activity

High-power view of the smooth muscle proliferation in lymphangioleiomyomatosis (LAM) is shown. Distinguishing between sporadic and tuberous sclerosis-associated LAM may not be possible on histologic grounds.
High-power magnification of LAM shows the classical presence of smooth muscle proliferation. The muscle proliferation is obvious and has obliterated the normal alveolar lining.

**TERMINOLOGY**

**Abbreviations**
- Lymphangioleiomyomatosis (LAM)

**Synonyms**
- Lymphangiomatosis

**Definitions**
- Nonneoplastic lung condition characterized by presence of immature muscle proliferation

**ETIOLOGY/PATHOGENESIS**

**Etiology**
- Unknown
- May share similar genetic relationship with tuberous sclerosis complex

**CLINICAL ISSUES**

**Epidemiology**

**Incidence**
- LAM occurs in ~2 cases per million patients
- May be underreported

**Age**
- More common in premenopausal women
- Rarely described in children

**Gender**
- Commonly affects women

**Presentation**
- Cough
- Shortness of breath
Chylous effusion
Pneumothorax
Hemoptysis

Treatment
No specific treatment
Possible treatments
  Hormonal manipulation
  Oophorectomy
  Lung transplantation

Prognosis
  Predominantly cystic lesions may have poor prognosis
  85% survival at 5 years
  70% survival at 10 years

IMAGE FINDINGS
General Features
  Bilateral multiple nodular and cystic changes in lung parenchyma
  Unilateral involvement is also possible

MACROSCOPIC FEATURES
General Features
  Multiple cysts with honeycomb appearance

MICROSCOPIC PATHOLOGY
Histologic Features
  Cystic changes
  Hemorrhage
  Spindle cell proliferation
    In alveolar walls
    Lining cystic structures
    With focal clear cell change
    Lacking atypia or mitotic activity
  Adjacent lung parenchyma may show type II pneumocyte hyperplasia

ANCILLARY TESTS
Immunohistochemistry
  Spindle cells are positive for SMA, HMB-45, and for ER/PR

DIFFERENTIAL DIAGNOSIS
Tuberous Sclerosis
  Tuberous sclerosis-associated LAM has similar features to sporadic tumors
  Such distinction may not be possible on histologic grounds alone
  It is important to obtain a clinical history of tuberous sclerosis

Leiomyoma
  Usually forms a tumor mass
  Unusual for leiomyoma to present with prominent cystic changes

Leiomyosarcoma
  LAM lacks atypia or mitotic activity

SELECTED REFERENCES

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Reactivity</th>
<th>Staining Pattern</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actin-sm</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>In muscle component</td>
</tr>
<tr>
<td>Desmin</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>In muscle component</td>
</tr>
<tr>
<td>HMB-45</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>More often in clear cells</td>
</tr>
<tr>
<td>IGF-1</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td></td>
</tr>
<tr>
<td>MMP-1</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td></td>
</tr>
<tr>
<td>ER</td>
<td>Positive</td>
<td>Nuclear</td>
<td>May be focal</td>
</tr>
<tr>
<td>PR</td>
<td>Positive</td>
<td>Nuclear</td>
<td>May be focal</td>
</tr>
<tr>
<td>S100</td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CK-PAN</td>
<td>Negative</td>
<td></td>
<td>Positive in alveolar cell and entrapped lung</td>
</tr>
</tbody>
</table>

(Left) Low-power view of lung parenchyma in LAM shows little change at this magnification. However, note the presence of cysts and the thickening of some of those cysts' walls. (Right) Higher magnification shows alternating normal alveolar structures and other cystic structures lined by smooth muscle proliferation in pulmonary lymphangioleiomyomatosis.
(Left) LAM shows areas of nonneoplastic vascular proliferation; some of the vessels contain fresh blood. Note the presence of muscle proliferation adjacent to the dilated vascular structures. (Right) This LAM shows a very subtle area of muscle proliferation adjacent to an alveolar space. In some cases, the presence of muscle may be only focal and can easily be missed in a cursory review.

(Left) An unusual feature that may be seen in some cases of LAM is the presence of pneumocyte hyperplasia. Such change may be in the form of small nodules that can raise the possibility of a malignant epithelial neoplasm. (Right) Low-power view of LAM shows 2 focal areas of muscle proliferation. Note that the rest of the pulmonary parenchyma appears to be within normal limits.

Microscopic Features
(Left) This LAM shows areas of congestion and hemorrhage with the presence of fresh blood. However, note that the alveolar wall has been replaced by a muscle proliferation, which also shows some clear cell changes. Due to the areas of hemorrhage and congestion, these areas can be missed. (Right) Hemorrhage and congestion in LAM can at times be very marked, and areas of muscle proliferation can be difficult to find. Muscle proliferation can be easily missed.

(Left) The presence of muscle proliferation must be separated from the normal muscle layers that surround normal airway structures. Note the difference between the muscle of LAM and the normal muscular layer around the airway. (Right) In some cases of LAM, the muscle proliferation can be marked and can actually mimic a smooth muscle tumor. The muscle proliferation in this case is extensive, destroying normal lung architecture.
Despite the presence of dilated alveolar spaces filled with fresh blood, smooth muscle proliferation is still visible. One additional feature that may be seen in most of the cases of LAM is the presence of hemosiderin-laden macrophages filling alveolar spaces, as shown here.

**Neuroendocrine Carcinoma, Lung**

- **Terminology**
  - Spectrum of neoplasms ranging from low- to high-grade malignancy
- **Etiology/Pathogenesis**
  - Patients with hereditary retinoblastoma syndrome have an increased risk of developing neuroendocrine lung tumors
- **Clinical Issues**
  - Paraneoplastic syndromes
- **Macroscopic Features**
  - Endobronchial or intraparenchymal tumor
  - 0.5 to > 10 cm in diameter
- **Microscopic Pathology**
  - Neuroendocrine pattern, mitotic activity, necrosis
  - Low-grade tumors: < 2 mitotic figures per 10 HPF; absence of necrosis
  - Intermediate-grade tumor: 3-10 mitotic figures per 10 HPF; comedo-like necrosis
  - High-grade tumors: > 10 mitotic figures per 10 HPF; necrosis is present
  - Large cell neuroendocrine carcinoma requires neuroendocrine pattern and positive staining with neuroendocrine markers (chromogranin-A, synaptophysin, CD56)
  - In small cell carcinoma, mitotic count of > 10 per 10 HPF applies only to resected specimens, not biopsy material
- **Ancillary Tests**
  - Chromogranin-A, CD56, synaptophysin
Graphic of a neuroendocrine carcinoma of the lung shows 1 of the usual locations of these tumors. The tumors are usually endobronchial and obstruct the bronchial lumen.
Low-power view of a low-grade endobronchial neuroendocrine carcinoma (carcinoid tumor) shows organized pattern of growth.

**TERMINOLOGY**

**Synonyms**
- Carcinoid tumor, atypical carcinoid, small cell carcinoma, large cell carcinoma

**Definitions**
- Spectrum of neoplasms ranging from low- to high-grade malignancy showing neuroendocrine differentiation

**ETIOLOGY/PATHOGENESIS**

**Etiology**
- Tumor is thought to be derived from Kulchitsky cells
- Patients with hereditary retinoblastoma syndrome have an increased risk of developing neuroendocrine lung tumors

**CLINICAL ISSUES**

**Presentation**
- Incidental finding
- Paraneoplastic syndromes
- Chest pain, cough, dyspnea, or hemoptysis

**Treatment**
- Surgical approaches
  - Low- and intermediate-grade tumor
- Adjuvant therapy
  - High-grade tumors

**Prognosis**
- **Low-grade neoplasms**
  - Survival rate at 5 years: > 75%
- **Intermediate-grade neoplasms**
  - Survival rate at 5 years: ~50%
High-grade neoplasms
Survival rate at 5 years: May be < 5%

MACROSCOPIC FEATURES
General Features
Endobronchial or intraparenchymal tumor
High-grade tumor may show extensive areas of necrosis
Size
0.5 to > 10 cm in diameter

MICROSCOPIC PATHOLOGY
Histologic Features
Low-grade tumors
< 3 mitotic figures per 10 high-power field (HPF)
Necrosis is absent
Intermediate-grade tumors
3-10 mitotic figures per 10 HPF
Comedo-like necrosis
High-grade tumors
> 10 mitotic figures per 10 HPF
Necrosis is present
Large cell neuroendocrine carcinoma requires neuroendocrine pattern and positive staining with neuroendocrine markers (chromogranin-A, synaptophysin, CD56)
Cells with prominent nucleoli
Neuroendocrine markers must be positive
Electron microscopic studies show neurosecretory granules
Comedo-like necrosis
Small cell carcinoma
Miotic figures > 10 per 10 HPF applies only to resected specimens
Neuroendocrine markers are not required for diagnosis

DIFFERENTIAL DIAGNOSIS
Low-Grade Neuroendocrine Carcinoma
< 3 mitotic figures and absence of necrosis
Well-organized growth pattern
Intermediate-Grade Neuroendocrine Carcinoma
Mitotic activity from 3-9 per 10 HPF and necrosis
Often a combination of well-organized nested pattern and diffuse pattern of growth
High-Grade Neuroendocrine Carcinoma
> 10 mitotic figures per 10 HPF, necrosis &/or hemorrhage (in resected specimens)
Positive neuroendocrine markers (synaptophysin, chromogranin-B, &/or CD56) in cases of large cell neuroendocrine carcinoma
In cases of small cell carcinoma, neuroendocrine markers may be negative
Carcinoid Tumorlet
These tumors are usually < 5 mm in diameter
Tumorlets and carcinoid tumors share same immunophenotype
Metastatic Neuroendocrine Carcinoma of Extrathoracic Origin
Clinical history of previous tumor is of utmost importance
Immunohistochemical study for TTF-1 may be helpful

Pulmonary Paraganglioma
- Paragangliomas and neuroendocrine tumors show positive staining for neuroendocrine markers
- Usually negative for keratin
- Generally do not show mitotic activity
- Usually show cells with macronuclei

Large Cell Carcinoma
- Must show neuroendocrine pattern and positive neuroendocrine markers

Large Cell Carcinoma With Neuroendocrine Differentiation
- Histology is that of conventional non-small cell carcinoma with positive neuroendocrine markers

Large Cell Carcinoma With Neuroendocrine Pattern
- Tumors show neuroendocrine histologic pattern but negative staining for neuroendocrine markers

DIAGNOSTIC CHECKLIST
Clinically Relevant Pathologic Features
- Mitotic rate

Pathologic Interpretation Pearls
- Neuroendocrine pattern
- Rosettes
- Necrosis
- Mitotic activity
- Positive neuroendocrine markers in large cell neuroendocrine carcinoma

P.II(10):18

NEUROENDOCRINE CARCINOMA, LUNG GRADING
Low-Grade Neuroendocrine Carcinoma (Carcinoid Tumor)
- Tumors with < 3 mitoses per 10 HPF and no necrosis

Intermediate-Grade Neuroendocrine Carcinoma (Atypical Carcinoid)
- Tumors with ≥ 3 but > 10 per 10 HPF and necrosis

High-Grade Neuroendocrine Carcinoma
- Small cell carcinoma
- Large cell neuroendocrine carcinoma
  - For large cell neuroendocrine carcinoma, neuroendocrine markers must be positive

SELECTED REFERENCES
### Immunohistochemistry

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Reactivity</th>
<th>Staining Pattern</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chromogranin-A</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>Strongly positive but not global</td>
</tr>
<tr>
<td>Synaptophysin</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>Diffuse positive staining</td>
</tr>
<tr>
<td>CD56</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>Diffuse staining</td>
</tr>
<tr>
<td>KERATIN-LMW</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>Diffuse staining</td>
</tr>
<tr>
<td>TTF-1</td>
<td>Positive</td>
<td>Nuclear</td>
<td>In most cases</td>
</tr>
<tr>
<td>CD57</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>In some cases</td>
</tr>
<tr>
<td>Bombesin</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>In some cases</td>
</tr>
<tr>
<td>LEU-7</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>In some cases</td>
</tr>
<tr>
<td>CK7</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>Diffuse positive staining</td>
</tr>
<tr>
<td>CDX-2</td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Molecular Features of Neuroendocrine Carcinomas

<table>
<thead>
<tr>
<th>Gene Alterations</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>RB gene; hereditary retinoblastoma</td>
<td>Well-differentiated and moderately differentiated carcinomas</td>
</tr>
<tr>
<td>11q deletion</td>
<td>Well-differentiated and moderately differentiated carcinomas</td>
</tr>
<tr>
<td>10q and 13q losses</td>
<td>Well-differentiated and moderately differentiated carcinomas</td>
</tr>
<tr>
<td>3q gain</td>
<td>Small cell carcinoma</td>
</tr>
<tr>
<td>10q-, 16q-, and 17p deletions</td>
<td>High-grade neuroendocrine carcinomas</td>
</tr>
<tr>
<td>LOH at 3p14.2-p21.3</td>
<td>More common in moderately differentiated carcinomas</td>
</tr>
</tbody>
</table>

P.11(10):19

Image Gallery

Low-Grade NE Carcinoma (Carcinoid Tumor)

(Left) H&E shows the nesting pattern in a low-grade neuroendocrine carcinoma. Note the well-organized growth and delicate bands of fibroconnective tissue separating the nests of tumor cells. (Right) Homogeneous cellular proliferation without nuclear atypia, necrosis, or hemorrhage is shown. Notice the well-organized pattern of growth, which is an important parameter in low-grade neuroendocrine lung tumors.
Tubular (glandular) pattern of a low-grade neuroendocrine carcinoma is shown. This glandular pattern at low-power view may mimic adenocarcinoma. (Right) Sheets of cells with a homogeneous pattern are shown in a low-grade neuroendocrine carcinoma. Note the absence of necrosis &/or hemorrhage. These features are highly important in low-grade tumors in helping to separate them from higher grade tumors.

H&E shows rosettes in a well-differentiated neuroendocrine carcinoma. Also important to note is the absence of mitotic activity &/or necrosis. (Right) Low-grade neuroendocrine carcinoma with prominent spindle cell growth pattern is shown. The tumor does not show necrosis, hemorrhage, or mitotic activity, which are not features of low-grade tumors.

Low-Grade NE Carcinoma (Carcinoid Tumor)
Well-differentiated neuroendocrine carcinoma shows glands composed of rather small cells without mitotic activity. This pseudoglandular architecture may be erroneously interpreted as adenocarcinoma. Thus, a careful cytological examination of the neoplastic cells is important. (Right) H&E shows glandular pattern of low-grade neuroendocrine carcinoma. This complex architecture may mimic a well-differentiated adenocarcinoma.

Well-differentiated neuroendocrine carcinoma shows subtle nesting pattern with spindle cell proliferation. This architectural pattern may be misinterpreted as sarcoma or other neoplasms of neuroectodermal origin, such as melanomas. (Right) Spindle cells without nuclear atypia or mitotic activity are shown. The pattern of growth mimics a neural neoplasm. A spindle cell pattern may also be seen in higher grade tumors.
Low-grade neuroendocrine carcinoma is shown with areas of metaplastic bone formation. Bone formation in neuroendocrine carcinomas is rare. This metaplastic change is rarely extensive. (Right) Closer view of the metaplastic bone formation in neuroendocrine carcinoma shows pseudoglandular arrangement of the neoplastic neuroendocrine cells.

P.II(10):21

Intermediate-Grade NE Carcinoma (Atypical Carcinoid)

(Left) Atypical carcinoid (AC) shows the characteristic nesting growth pattern of neuroendocrine carcinoma; however, the neoplastic cellular proliferation is composed of clear cells. The presence of extensive areas of clear cell change in neuroendocrine carcinomas is rare. (Right) Closer view shows neuroendocrine cellular proliferation composed predominantly of clear cells with small round and homogeneous nuclei. Nucleoli are inconspicuous.
H&E shows spindle cell neuroendocrine carcinoma with easily identifiable mitotic figures. The mitotic count in neuroendocrine carcinoma is the most important feature in the classification of these tumors. Sheets of neoplastic cells are shown in a disorganized pattern of growth. Nuclear atypia is evident and should prompt the search for mitotic activity.

Moderately differentiated neuroendocrine carcinoma shows extensive areas of necrosis with areas of viable tumor. It is very important to separate tumor necrosis from other possible causes of necrosis, such as necrosis secondary to needle biopsy. H&E shows well-organized pattern with rosettes and easily identifiable mitotic figures. Although the pattern is fairly organized, the presence of mitotic figures is the most important criterion for grading these tumors.

High-Grade NE Carcinoma, Small Cell Type
H&E shows predominantly solid pattern of growth of neoplastic cells with high mitotic activity and prominent nuclear atypia. (Right) H&E shows solid pattern of neoplastic cells admixed with numerous inflammatory cells, predominantly lymphocytes. In some cases, the inflammatory response may be very prominent. It is unusual to see this type of feature in small cell carcinomas.

H&E shows high-grade neuroendocrine carcinoma with extensive necrosis and sheets of neoplastic cells with a vague basaloid pattern. (Right) Closer view shows neoplastic cells in a high-grade neuroendocrine carcinoma. Note the absence of nucleoli, which is an important characteristic of these tumors. The features of small cell carcinomas in resected specimens may show better preservation than in biopsy specimens.
(Left) H&E shows extensive necrosis and clusters of neoplastic cells. The tumor cytology is that of small cells with scant cytoplasm and inconspicuous nucleoli. Often the presence of extensive areas of necrosis is more commonly seen in high-grade tumors. (Right) H&E shows classic small cell morphology of small cells with nuclear molding and prominent atypia. However, in this example, the presence of mitoses is not marked.

P.II(10):23

High-Grade NE Carcinoma, Large Cell Type

(Left) H&E shows large cell neuroendocrine carcinoma with necrosis and organoid pattern of growth. This pattern, however, may be seen in tumors that do not show positive neuroendocrine markers. (Right) Closer view shows neoplastic cells displaying nuclear atypia and prominent nucleoli. However, it is the positive staining for neuroendocrine markers that confirms the diagnosis of large cell neuroendocrine carcinoma.
High-power view shows larger cells with ample cytoplasm, round nuclei, and prominent nucleoli. These features are those of a non-small cell carcinoma. (Right) High-grade neuroendocrine carcinoma is shown with more conventional nesting pattern and absence of obvious necrosis. In some focal areas, there is a hint of comedo-like necrosis and the presence of larger pleomorphic cells.

High-grade neuroendocrine carcinoma is shown with a very organized pattern of growth. Necrosis is absent; however, note the presence of marked nuclear atypia, which should raise the suspicion of a higher grade neoplasm. (Right) High-grade neuroendocrine carcinoma shows the classic characteristics of prominent nuclear atypia and increased mitotic activity; however, necrosis is absent.

**Pleuropulmonary Blastoma**

- Embryonal tumor of lung and pleura with epithelial (benign) and mesenchymal (low- to high-grade malignant) components, presenting most often in early childhood
- 20% are familial and associated with other extrapulmonary lesions in same patient or family members

Vania Nosé, MD, PhD
Aliya N. Husain, MD

Key Facts
Terminology
Etiology/Pathogenesis
Heterozygous germline mutations in DICER1 have been identified in familial pleuropulmonary blastoma (PPB)

**Macroscopic Features**
- Type I: Peripheral- and pleural-based cysts, sometimes protruding from pleural surface, no solid nodules
- Type II: Both solid and cystic areas in varying proportions
- Type III: All solid, although areas of necrosis and cystic degeneration may be present

**Microscopic Pathology**
- PPB type I: Large cysts lined by single layer of cuboidal to flattened benign epithelium; within wall, there are areas of hypercellularity composed of small blue to spindled cells, often forming cambium-like layer
- PPB types II and III have variable amount of solid areas composed of higher grade sarcomatous components (which may be undifferentiated), rhabdomyosarcomatous, or chondrosarcomatous

This low-power view of solid type III pleuropulmonary blastoma (PPB) shows benign epithelial component in the upper right → overlying the malignant mesenchymal component ». 
Solid component of PPB illustrated here consists of malignant cartilage ➥, blastema ➥, and spindle cell undifferentiated sarcoma with atypical mitotic figure ➥.

TERMINOLOGY

Abbreviations
- Pleuropulmonary blastoma (PPB)

Synonyms
- Mesenchymal cystic hamartoma, malignant mesenchymoma, sarcoma arising in congenital cystic malformation

Definitions
- Embryonal tumor of lung and pleura with epithelial (benign) and mesenchymal (low- to high-grade malignant) components, presenting most often in early childhood
- A rare pediatric lung tumor that is often part of an inherited cancer syndrome
- PBBs consist of mesenchymal cells that are susceptible to malignant transformation and cysts lined by epithelial cells
- Sentinel disease in a familial tumor syndrome recently found to be associated with germline mutations in DICER1

ETIOLOGY/PATHOGENESIS

Genetic Abnormality
- 20% are familial and associated with other extrapulmonary lesions in same patient or family members
- Heterozygous germline mutations in DICER1 have been identified in familial PPB
  - Loss of DICER1 protein expression specifically in lung epithelium overlying mesenchymal component
  - Loss of DICER1 in epithelium of developing lung alters regulation of diffusible factors that promote mesenchymal proliferation
- Extrapulmonary lesions include cystic nephroma (most common), thyroid hyperplasia, rhabdomyosarcoma, Sertoli-Leydig-type tumors, and other embryonal tumors
- Variety of karyotypic abnormalities have been described; gain of chromosome 8, usually as trisomy 8, is very common
- Thus PPB may arise through a novel mechanism of non-cell-autonomous cancer initiation
CLINICAL ISSUES

Epidemiology

Incidence

Extremely rare tumor, estimated incidence of 0.35-0.65 cases per 100,000 births
Most common malignancy of lung presenting in early childhood

Age

Occurs almost exclusively in children, primarily in infants and toddlers
94% present in children < 6 years old
Rare beyond 12 years of age

Presentation

May be detected incidentally in utero or postnatally
Most common presentation is respiratory distress ± pneumothorax
May be solitary or multiple with additional lesions occurring synchronously or metachronously
In a subset of patients, overgrowth of cysts by mesenchymal cells → sarcoma formation

Treatment

Depends on type of PPB

PPB I (cystic): Complete surgical resection; adjuvant chemotherapy if resection is incomplete
PPB II (cystic and solid) and PPB III (solid): Complete surgical resection followed by adjuvant chemotherapy; radiation therapy for residual disease

P. II(10): 25

Close clinical follow-up for recurrence, metastasis, multifocal lesions, extrapulmonary lesions

Prognosis

5-year survival is 83% for type I and 42% for types II and III PPB
Type I may recur as higher grade (II or III) lesions
Metastases occur in 30% of types II and III lesions and may occur late
Sites of metastases include central nervous system and bone

Associated Tumors

Cystic nephroma (CN)

Multilocular CN is a benign kidney tumor and is part of a family of kidney neoplasms including cystic partially differentiated nephroblastoma and Wilms tumor
CN is rarely familial or bilateral, but it occurs in ~ 10% of families in which PPB is present

Medulloepithelioma

Embryonal rhabdomyosarcoma is the most common childhood sarcoma and is a component of familial PPB predisposition syndrome

Ovarian sex cord-stromal tumors (OSCST)

Primary ovarian neoplasms, particularly OSCST, are a manifestation of familial PPB syndrome and may be initial clinical presentation of DICER1 mutations within a family
OSCST is also present in PPB kindred

Multinodular hyperplasia

DICER1 mutations are associated with both familial multinodular goiter (MNG) and MNG with Sertoli-Leydig cell tumor (SLCT), independent of PPB

Nasal chondromesenchymal hamartoma (NCMH), an extremely rare benign tumor arising in sinonasal tract

IMAGE FINDINGS

General Features

Best diagnostic clue

Radiographically seen as unilocular or multilocular cyst, mixed cystic or solid lesion, or large solid mass often distorting contour of lung, located in periphery or protruding from pleura

MACROSCOPIC FEATURES

Subclassification

Based on gross morphology
Type I: Purely cystic
Type II: Solid and cystic
Type III: Purely solid

Gross Features

Type I: Peripheral- and pleural-based cysts, sometimes protruding from pleural surface, no solid nodules
Type II: Both solid and cystic areas in varying proportions
Type III: All solid, although areas of necrosis and cystic degeneration may be present
MICROSCOPIC PATHOLOGY

Histologic Features

PPB type I: Large cysts lined by single layer of cuboidal to flattened benign epithelium; within wall, there are areas of hypercellularity composed of small blue to spindled cells, often forming cambium-like layer

PPB types II and III have variable amount of solid areas composed of higher grade sarcomatous (which may be undifferentiated), rhabdomyosarcomatous, or chondrosarcomatous components

Primitive/sarcomatous component is vimentin (+); may be focal myogenic differentiation on IHC staining

ANCILLARY TESTS

In Situ Hybridization

Chromosome 8 copy number

Polysony of chromosome 8 is a feature of PPB

Chromosome 8 gains are present in all mesenchymal elements, including undifferentiated blastematous, rhabdomyoblastic, fibroblastic, and chondroblastic areas

Epithelial cells show no chromosome 8 gains

DIFFERENTIAL DIAGNOSIS

Congenital Pulmonary Airway Malformation Type 4 (CPAM 4)

PPB type I has areas very similar to CPAM 4; however, latter has no immature/malignant component

Cytogenetically, these are completely different lesions

Primary Sarcomas of Lung

Synovial sarcoma can be distinguished by being focally keratin (+) and EMA(+), and by diagnostic t(X;18)

Primary rhabdomyosarcoma of lung is very rare; many cases reported in older literature are probably PPB type III

DIAGNOSTIC CHECKLIST

Pathologic Interpretation Pearls

Cystic lesions need to be sampled extensively to differentiate benign CPAM 4 from low-grade malignant PPB I

PPB I may recur as PPB II or III

Margins of resection must be assessed

SELECTED REFERENCES


Tables

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Reactivity</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>TTF-1</td>
<td>Positive</td>
<td>In glandular component</td>
</tr>
<tr>
<td>EMA/MUC1</td>
<td>Positive</td>
<td>In glandular component</td>
</tr>
<tr>
<td>CEA-M</td>
<td>Positive</td>
<td>In glandular component</td>
</tr>
<tr>
<td>Chromogranin-A</td>
<td>Positive</td>
<td>In morules</td>
</tr>
<tr>
<td>p53</td>
<td>Positive</td>
<td>Scattered nuclei</td>
</tr>
<tr>
<td>Desmin</td>
<td>Positive</td>
<td>In muscle component</td>
</tr>
<tr>
<td>Myogenin</td>
<td>Positive</td>
<td>In muscle component</td>
</tr>
<tr>
<td>S100</td>
<td>Positive</td>
<td>In nerves and adipose tissue component</td>
</tr>
</tbody>
</table>

P.II(10):27

Image Gallery
Types of Pleuropulmonary Blastoma

(Left) CT scan of chest with type I PPB shows a pleural-based cystic lesion with no solid component. (Courtesy B. Shehata, MD.) (Right) This histologic section from a type I PPB shows the diagnostic cystic spaces lined by a single layer of epithelium. The walls contain densely cellular (blastomatous) tumor as well as loose hypocellular tissue. (Courtesy B. Shehata, MD.)
Diagnostic Pathology: Familial Cancer Syndromes

(Left) CT scan of type II PPB shows a large cyst in the center of the left lung field, with some solid component in its wall. Part of the lung is collapsed. (Courtesy B. Shehata, MD.) (Right) This histologic section of a type II PPB has cystic space to the right, which is lined by a single layer of cuboidal cells, beneath which is the solid cellular component of the tumor composed of primitive cells. In addition, there is a smaller cyst. (Courtesy B. Shehata, MD.)

(Left) High-power photomicrograph of a type III PPB shows a solid proliferation of malignant cells without any cyst formation. There is a blastomatous small cell component as well as focal cartilaginous differentiation. Note the atypical mitotic figure. (Right) FISH shows trisomy 8 (green dots) in many of the tumor cells of this pleuropulmonary blastoma. There is no evidence of trisomy 18 (red dots). (Courtesy B. Shehata, MD.)

Section 11 - Skin
Basal Cell Carcinoma

> Table of Contents > Part II - Diagnoses Associated With Specific Syndromes > Section 11 - Skin > Basal Cell Carcinoma

Basal Cell Carcinoma
Christine J. Ko, MD
David S. Cassarino, MD, PhD
Key Facts
Terminology
Low-grade malignancy of basal keratinocytes
Etiology/Pathogenesis
Related to sun exposure, radiation, immunosuppression
May have a genetically inherited component
May be derived from follicular stem cells

Clinical Issues
- Very common: Most common cancer in humans
- Prognosis usually excellent, most cases cured by excision
- More aggressive subtypes: Infiltrative, micronodular, desmoplastic, and basosquamous
- Most commonly treated by complete excision or electrodessication and curettage

Microscopic Pathology
- Proliferation of nodules, nests, and cords of small basaloid cells with peripheral palisading, stromal retraction artifact, and mucinous material
- Numerous mitotic and apoptotic figures
- Cells show enlarged hyperchromatic nuclei with inconspicuous nucleoli and scant amounts of eosinophilic cytoplasm

Top Differential Diagnoses
- Squamous cell carcinoma
- Actinic keratosis (on superficial shave biopsy)
- Follicular neoplasms (trichoepithelioma and trichoblastoma)
- Merkel cell carcinoma

Clinical photograph of a large facial basal cell carcinoma (BCC) shows areas of ulceration and granulation-like tissue surrounded by a raised border. (Courtesy S. Yashar, MD.)
High magnification of a nodular BCC shows a sheet-like proliferation of atypical basaloid cells with high N:C ratios and numerous apoptotic and mitotic figures.

TERMIOLOGY
Abbreviations
Basal cell carcinoma (BCC)
Synonyms
Basal cell epithelioma
Trichoblastic carcinoma (not well accepted)

ETIOLOGY/PATHOGENESIS
Multifactorial
Related to sun exposure (vast majority of cases)
Some cases may also be associated with radiation, immunosuppression (organ transplantation), burn scars
These cases tend to be more aggressive
May actually be derived from follicular stem cells (hence, “trichoblastic carcinoma”)
Genetics
Rare cases are associated with genetic syndromes including
Nevoid basal cell nevus (Gorlin) syndrome
Xeroderma pigmentosum
Basex-Dupré-Christol syndrome
Rombo syndrome
Genes implicated include PTCH1 (Gorlin syndrome), P53, SOX9, BMI1, BAX, RMRP

CLINICAL ISSUES
Epidemiology
Incidence
Extremely common: Most common cancer in humans when skin cancers are included
Accounts for 70% of primary cutaneous malignancies
Age
- Typically older adults
- Sporadic BCC is presenting at younger ages (3rd and 4th decades)
  - Risk factors include red hair and tanning bed use
  - If patient age < 20 years, should consider a genetic syndrome

Ethnicity
- Light-skinned individuals; rare in darker skin types

Site
- Most common in head and neck region (up to 80% of cases)
  - ~15% occur on trunk and shoulders
  - Very rare cases involve lips, breast, axillae, groin, inguinal region, and genitalia
- If on palms or soles, a genetic syndrome should be considered

Presentation
- Typically pearly, papular, plaque-like, or nodular lesion with surface telangiectasias
- Larger lesions often ulcerated with bleeding &/or overlying crusting
- Minority of cases are pigmented, more often in patients with darker skin types

Treatment
- Surgical approaches
  - Complete excision or electrocautery and curettage (ED&C)
  - Mohs micrographic surgery often used in facial cases or other high-risk cases
- Radiation
  - Radiation therapy is an option, particularly if there are comorbidities

Prognosis
- Usually excellent, cured by local excision
- More aggressive subtypes, including micronodular, infiltrative, desmoplastic, and basosquamous, have higher rate of recurrence and increased risk of metastasis
- Overall risk of metastasis estimated at 0.05%

MACROSCOPIC FEATURES
Size
- Variable, small (few mm) to large (several cm)

MICROSCOPIC PATHOLOGY
Histologic Features
- Any microscopic variant of BCC can be seen in Gorlin syndrome
  - There are not microscopic clues, per se, as to presence of a genetic syndrome
  - Proliferation of small basaloid cells with peripheral palisading in nodules, nests, &/or infiltrative cords
  - Overlying ulceration and serum crusting often present in large tumors
  - Particularly in ulcerated or eroded lesions, there is squamatization, with increased eosinophilic cytoplasm and sometimes formation of keratin
  - Stromal retraction artifact
    - Between tumor cells and stroma
  - Mucinous material may be present
  - Numerous mitotic and apoptotic figures present

Cytologic Features
- Oval nuclei with inconspicuous/small nucleoli and scant eosinophilic cytoplasm

Variants
- Superficial-multicentric: Superficial nests attached to epidermis separated by areas of uninvolved epidermis
- Nodular: Large, rounded, predominantly dermal-based nests with prominent peripheral palisading
- Micronodular: Predominantly dermal-based infiltrative proliferation of small nests
- Infiltrative: Small cords and nests, often deeply invasive
- Desmoplastic/sclerosing/morpheaform: Infiltrative strands and nests associated with dense sclerotic stroma
- Infundibulocystic: Cystic spaces containing keratinous material surrounded by ramifying cords of cells with pink cytoplasm
- Basosquamous/metatypical: Prominent areas of squamous differentiation (may mimic squamous cell carcinoma [SCC]), less peripheral palisading present
- Fibroepithelioma of Pinkus: Numerous small, anastomosing cords of basaloid cells attached to the epidermis
Rare variants include adenoid, clear cell, signet ring cell, plasmacytoid/myoepithelial, and BCC with neuroendocrine differentiation or sebaceous differentiation.

**ANCILLARY TESTS**

**Immunohistochemistry**

Not necessary in most cases except when unusual features present.

- **Basal cell carcinoma vs. trichoepithelioma and trichoblastoma**
  - BCC shows greater staining for Bcl-2, p53, and Ki-67.
  - BCC lacks CK20(+) cells.
  - CD10 tends to stain basaloid cells of BCC with only stromal staining in trichoepithelioma.
  - BCC often stains for androgen receptor; desmoplastic trichoepithelioma is generally negative.

- **BCC vs. SCC**
  - BCC is positive for BER-EP4; SCC generally negative.
  - CK-PAN, HMWCKs, and p63 positive in both tumors.

**DIFFERENTIAL DIAGNOSIS**

**Squamous Cell Carcinoma (SCC)**

- Most cases are easily separated; however, basosquamous type of BCC shows prominent squamous differentiation.
  - Usually, areas of more typical BCC are present, especially at periphery of tumor.
  - Overlying actinic keratosis or Bowen disease often seen in association with SCC.
  - BER-EP4 strongly positive in BCC, almost always negative in SCC.
  - Superficial shave biopsies of ulcerated/inflamed cases may be very difficult or impossible to accurately separate.

- **Actinic Keratosis (AK)**
  - Can be difficult to distinguish from superficial type of BCC on very superficial shave biopsies.
  - AK typically shows basilar budding of atypical squamous cells and overlying parakeratosis.
  - No mucinous stroma, peripheral palisading, or tumor-stromal retraction artifact should be seen.
  - Numerous apoptotic and mitotic figures favor BCC.

- **Follicular Neoplasms (Trichoepithelioma and Trichoblastoma)**
  - Dermal-based basaloid adnexal neoplasms, may be large and nodular (trichoblastoma).
  - Usually symmetric and well circumscribed at scanning magnification.
  - Typically lack the degree of cytologic atypia, mitoses, and apoptotic figures of BCC.
  - May show peripheral palisading, but mucinous stroma and tumor-stromal retraction artifact typically lacking in benign follicular neoplasms.
  - Papillary mesenchymal bodies may be evident.
  - Immunohistochemistry may be helpful.

- **Merkel Cell Carcinoma**
  - Nodular to sheet-like proliferation of highly atypical basaloid cells.
  - Mucinous stroma and tumor-stromal retraction artifact only rarely identified.
  - Peripheral palisading usually absent.
  - Nuclei typically show speckled (salt-and-pepper) chromatin pattern or nuclear clearing.
  - Perinuclear dot-like staining with CK20, pancytokeratin, and CAM5.2.
  - Positive immunoreactivity with neuroendocrine markers.

- **Sebaceous Carcinoma**
  - Can show prominent areas of basaloid differentiation.
  - Focal atypical clear/multivacuolated cells with nuclear indentations should be present.
  - Lacks peripheral palisading, mucinous stroma, or stromal retraction artifact.
  - Immunohistochemistry may be useful.
    - Androgen receptor is not necessarily helpful as it stains both sebaceous carcinoma and BCC.
    - CAM5.2 and CK7 (+/-); typically negative in BCC.
    - EMA often positive in clear cells, although it is often lost in poorly differentiated cases.
    - Strong BER-EP4 and Bcl-2 favor BCC, but they are positive in some sebaceous carcinomas.
    - Adipophilin is positive in sebaceous carcinoma and is negative in clear cell basal cell carcinoma.

**DIAGNOSTIC CHECKLIST**

**Clinically Relevant Pathologic Features**

- Aggressive behavior associated with certain subtypes, deep dermal/subcutaneous invasion, and perineural invasion.

**SELECTED REFERENCES**

Image Gallery

Microscopic Features

(Left) Low magnification shows a large nodular- and micronodular-type BCC with diffuse overlying ulceration and dense serum crusting. (Right) Histologic section of a micronodular-type BCC shows a proliferation of small nests of basaloid cells with a prominent retraction artifact in a somewhat sclerotic-appearing stroma.
(Left) Basosquamous-type BCC shows a proliferation of large, squamoid-appearing cells with abundant eosinophilic cytoplasm and focal mucin collections. (Right) Another example of basosquamous-type BCC shows traditional areas of BCC with peripheral palisading surrounding collections of larger, squamoid-appearing cells associated with follicular differentiation and focal keratinization.

(Left) Scanning magnification of a fibroepithelioma of Pinkus-type BCC is characterized by numerous small anastomosing cords of basaloid cells with multiple epidermal connections. (Right) Clear cell BCC is composed of large cells with abundant clear cytoplasm, and can mimic clear cell squamous cell carcinoma or sebaceous carcinoma in some cases. However, areas of more conventional-appearing BCC are often present, as are seen in the lower portion of this photomicrograph.

Microscopic and Immunohistochemical Features
Low-power view of a large pigmented nodular BCC shows prominent pigmentation throughout the nodule. High magnification of a nodular BCC shows a rare markedly enlarged, pleomorphic tumor cell with a macronucleolus.

Morpheaform (desmoplastic/sclerosing) BCC shows cords of atypical basaloid cells infiltrating a dense, desmoplastic stroma. High-power magnification of a plasmacytoid BCC shows dense eosinophilic cytoplasmic inclusions and displaced nuclei. These cases have been shown to exhibit myoepithelial differentiation.

P.II(11):7

Differential Diagnosis

(Left) Histologic section of a trichoblastoma shows a bland-appearing basaloid tumor in a fibromyxoid stroma lacking tumor-stromal retraction artifact (as in BCC). There is focal pigmentation and an area of calcification, findings typical of this neoplasm. (Right) High magnification shows a trichoblastoma with diffuse pigmentation. The lesion is composed of bland-appearing basaloid cells in anastomosing ribbons. Note the bland cytology and lack of mitotic or apoptotic figures.
Merkel cell carcinoma is typically composed of broad cords and sheet-like collections of highly atypical basaloid cells. There is scant stroma intervening between the neoplastic cells, and no tumor-stromal retraction, peripheral palisading, or mucinous material present. (Right) Nuclear clearing is often seen in Merkel cell carcinoma, a feature not seen in basal cell carcinoma. Note the numerous apoptotic and mitotic figures.

Squamous cell carcinoma can rarely show mucin production, as in this example of acantholytic SCC, but it is typically found within the center of a tumor island, not in the stroma (as in BCC). (Right) Infiltrative SCC with cord-like structures associated with a desmoplastic stroma can mimic desmoplastic/morpheaform BCC or, less likely, microcystic adnexal carcinoma.

Cutaneous Melanoma

Terminology
- Malignant tumor of melanocytes

Etiology/Pathogenesis
- Majority of melanomas are sporadic
Inherited predisposition to melanoma seen in minority of cases; may be associated with
- Multiple, clinically atypical melanocytic nevi (often > 50)
- Pancreatic cancer
- Germline mutations in CDKN2A and other genes, MC1R, BAP1
- Other syndromes, such as xeroderma pigmentosum

Clinical Issues
- Broad pigmented lesion, variegated colors, irregular borders
- Sites vary: Often back in men, legs in women
- Prognosis mainly dependent on depth of invasion in nonmetastatic lesions

Microscopic Pathology
- Microscopic features are not different in hereditary vs. sporadic melanomas
- Spread of atypical single cells and nests in epidermis
- Often abundant pagetoid scatter of atypical melanocytes into spinous layer
- Atypical melanocytes in dermis

Top Differential Diagnoses
- Severely atypical (dysplastic) melanocytic nevus
- Traumatized or special site melanocytic nevus
- Reed (pigmented spindle cell) nevus
- Spitz nevus

Clinical photograph shows a large melanoma with variegated color, jagged border, and irregular surface, all of which are concerning clinical signs. (Courtesy J. Hall, MD.)
Melanoma is seen with pagetoid spread overlying the invasive melanoma. This case was complicated by a preexisting intradermal melanocytic nevus. (Courtesy S. Dadras, MD.)

TERMINOLOGY
Synonyms
- Malignant melanoma
Definitions
- Malignant tumor of melanocytes

ETIOLOGY/PATHOGENESIS
Pathogenesis
- Environmental
  - > 85% of melanomas related to ultraviolet light-induced sporadic, activating mutations in BRAF and NRAS
- Genetics
  - Some melanomas have a genetic component with underlying germline mutations
  - Most common mutations are found in CDKN2A, a tumor suppressor gene
  - Other genetic disorders with DNA repair defects, such as xeroderma pigmentosum, can lead to accumulation of ultraviolet light-induced mutations at a young age, with development of melanoma at a young age

CLINICAL ISSUES
Epidemiology
Age
- Generally adults
  - Hereditary melanoma presents at a mean age of 34
  - Prepubertal melanoma is exceedingly rare
  - Presentation of melanoma in a young child, especially if not occurring within a large congenital nevus, should prompt consideration of a genetic syndrome (e.g., xeroderma pigmentosum)

Gender
Males and females have different site predilections

Ethnicity
- Typically affects ethnicities with fairer skin (especially red hair and skin types I/II)
- Linked to genetic risk; for example, red hair correlates with underlying MC1R mutations

Geographic distribution
- Highest incidence in Australia

Site
- Varies according to gender, on back (in men) and on legs (in women)
- Different types of melanoma associated with varying degrees of chronic sun exposure
  - Lentigo maligna type of melanoma in situ: Chronic sun exposure (e.g., face)
  - Acral melanoma: Generally non-sun-exposed sites (e.g., sole)
  - Superficial spreading melanoma: Often intermittently exposed areas (e.g., back)

Presentation

Patient
- Consider hereditary melanoma in a patient with
  - Multiple primary melanomas
  - Multiple clinically atypical nevi (often > 50)
  - > 2 or 3 first-degree relatives with cutaneous melanoma
  - Melanoma and a history of pancreatic cancer

Risk factors for melanoma
- Endogenous factors: Number of melanocytic nevi, skin/eye color, family/personal history of melanoma and other skin cancer, degree of sun damage of skin
- Environmental factors (e.g., tropical area)

Tumor
- Traditionally > 6 mm, but can be < 6 mm in diameter
- Variegated color with shades of tan, brown, black, blue-black, red (due to inflammation or vascular ectasia), gray and white (zones of regression)
- Irregular borders

Treatment
- Surgical approaches
  - Complete excision with margins dependent on depth of invasion

Prognosis
- Dependent on variables such as depth of invasion, ulceration

MICROSCOPIC PATHOLOGY

Histologic Features
- Features of melanoma, whether sporadic or in inherited familial cancer setting, are the same; any microscopic variant of melanoma can be seen in inherited melanoma syndromes
  - Exception is cutaneous melanomas associated with BAP1 mutations; these kindreds have risk of ocular melanoma
  - Melanoma composed of large, pleomorphic melanocytes; often with adjacent epithelioid nevus

Melanoma variants/subtypes
- Melanoma in situ (lentigo maligna is another term for melanoma in situ)
  - Limited to epidermis
- Lentigo maligna melanoma
  - Predominantly single-cell melanocytic proliferation in epidermis with dermal invasion
- Superficial spreading melanoma
  - Melanoma with large epidermal and dermal nests of atypical melanocytes
- Nodular melanoma
  - Melanoma with at least 1 dermal mitosis or
  - Melanoma with a junctional component that does not extend beyond 3 rete ridges of invasive portion
- Desmoplastic melanoma
  - Melanoma with a dermal component that has stromal desmoplasia and predominance of atypical spindled melanocytes, often with neurotropism
- Acral lentiginous melanoma
  - Melanoma occurring on hands or feet with single melanocytes predominating
Nevoid melanoma
   Melanoma that has histopathologic features mimicking melanocytic nevus
   Asymmetric, poorly circumscribed lesion with lateral expansion of large nests of atypical melanocytes
   Irregular distribution of nests, which can be confluent
   Increased numbers of single atypical melanocytes involving both rete ridges and suprapapillary plates
   May have abundant pagetoid spread of atypical melanocytes located in spinous layer
      Pagetoid spread at periphery of lesion (as opposed to only central focal spread in atypical and irritated nevi)
      Pagetoid spread may be so extensive as to cause so-called consumption of epidermis
   Clefts between nests and epidermis above
   Absence of maturation with depth
   Generally at least 1 dermal mitosis
   Necrosis
   Dermal melanocytes often display large, purplish nucleoli
   Sometimes dense but irregularly distributed inflammatory dermal infiltrate
   Melanin pigment may be located deep in dermal nests and be distributed asymmetrically within the entire lesion
   Perineural or vascular invasion may be present
   Up to 1/3 of melanomas may be associated with a melanocytic nevus
   Regression
      Absence of melanoma in epidermis or dermis with alteration of dermis (lymphocytic inflammation, melanophages, vascular alteration, fibroplasia)

Cytologic Features
   Cytoplasm
      Pink and granular or with dusty melanin
      Sometimes scant
   Nuclear hyperchromasia and pleomorphism
      Large eosinophilic or purple nucleoli
      Thick, irregular nuclear membranes
   Mitotic figures often present
   Occasional cytologic features include
      Balloon cell (sebocyte-like) cells
      Small cell size
      Signet ring shapes
      Rhabdoid
      Myxoid
      Clear cell

ANCILLARY TESTS
   Immunohistochemistry
      Ki-67 often shows elevated nuclear proliferative rate (> 10-15%)
      HMB-45 may stain the base of tumor

DIFFERENTIAL DIAGNOSIS
   Atypical (Dysplastic) Melanocytic (Clark) Nevus
      Should show symmetry and circumscription
      Can be difficult to assess on partial biopsy
      Bridging of nests across rete ridges
      Lamellar fibroplasia of papillary dermis
      Pagetoid upward scatter of melanocytes is not prominent
      If present, should be in center of lesion
      Dermal component typically small, nonatypical melanocytes in nests with maturation with depth; often located in center of junctional component
      Mitoses should be rare or absent
   Melanocytic Nevi Subjected to External Forces (Irritated/Traumatized)
      May show parakeratosis &/or serum
      Ki-67 low
   Spitz Nevus
      Hyperplastic (not atrophic) epidermis, lateral margins are sharply defined (no trailing off of single cells)
Composed of epithelioid and spindle-shaped cells, which may be atypical but are often monomorphic
Symmetric with circumscription
Can be difficult to assess on partial biopsy
Kamino bodies (amorphous pink globs) often present in the epidermis
Nests in epidermis may show clefting
Maturation with depth
If mitoses present, typically located in superficial portion of dermal component
May have gain of chromosome 11

Acral Nevus
- May have upward melanocytic scatter
- Generally small (< 6 mm diameter) with lateral circumscription
- Minimal melanocytic cytologic atypia
- Maturation of dermal component, if present

Genital Nevus
- May have similar histopathologic appearance to atypical (dysplastic) melanocytic nevus
- Generally symmetric, laterally circumscribed

Recurrent Nevus
- Usually any irregular junctional component delimited to epidermis above a scar
- Ideally, review of the preceding biopsy will show a banal melanocytic nevus

Nonmelanocytic Lesions
- Pagetoid scatter of nonmelanocytic cells can sometimes mimic melanoma
  - Paget disease of breast
  - Merkel cell carcinoma
  - Sebaceous carcinoma
  - Bowen disease
  - Pagetoid reticulosis
  - Clear cell papulosis
  - Pagetoid dyskeratosis

DIAGNOSTIC CHECKLIST

Pathologic Interpretation Pearls
Anatomic (Clark) levels of invasion
- I: Entirely intraepidermal
- II: Invasive into papillary dermis
- III: Expansion of papillary dermis (but confined to papillary dermis)
- IV: Invasion of reticular dermis
- V: Invasion of subcutaneous fat

Case summaries should include, at the least, tumor thickness, anatomic level, ulceration, margin assessment, mitotic index, invasion (perineural, vascular), tumor-infiltrating lymphocytes, regression

SELECTED REFERENCES

Image Gallery
Microscopic Features
Lentigo maligna (melanoma in situ) shows atypical melanocytes replacing the basilar layer in an atrophic epidermis, extending down the follicular epithelium. (Courtesy S. Dadras, MD.) Multifocal pagetoid scatter of atypical, epithelioid-shaped melanocytes is seen throughout all layers of the epidermis in a melanoma in situ.

The dermal component of this invasive melanoma fails to mature from the superficial to deeper dermis. Multiple mitoses are easily found. (Courtesy S. Dadras, MD.) Scanning magnification of a nodular melanoma shows a large nodule with broad areas of overlying ulceration and large areas of necrosis. (Courtesy S. Dadras, MD.)
Desmoplastic melanoma may resemble an inflamed scar on low-power examination. However, aggregates of lymphoid cells and prominent solar elastosis are usually identified and are helpful findings. (Courtesy S. Dadras, MD.) (Right) High-magnification examination of desmoplastic melanoma shows hyperchromatic, atypical spindle cells surrounded by abundant collagen bundles. (Courtesy S. Dadras, MD.)

**Cutaneous Squamous Cell Carcinoma**

Most cases are related to ultraviolet (UV) radiation

Previous radiation therapy implicated in some cases, usually associated with more aggressive SCC

Genetic component may be present, especially in SCC presenting in 1st or 2nd decades

Often the genetic defect is related to defective DNA repair (e.g., xeroderma pigmentosum, Muir-Torre syndrome)

**Clinical Issues**

Genetic syndrome should be considered in very young patients

Often arises in sun-damaged skin of elderly patients (usually head and neck) with preexisting actinic keratosis

Complete surgical excision is optimal and definitive therapy

Prognosis usually good in superficial and well-differentiated cases

Worse prognosis with poorly differentiated, deeply invasive, or aggressive subtypes

**Microscopic Pathology**

Proliferation of invasive atypical keratinocytes, often with areas of keratinization (keratin pearls) and squamous eddies

Degree of differentiation is variable, ranging from well to moderately to poorly differentiated

Multiple variants of differing malignant potential described

KA associated with certain genetic syndromes, e.g., Muir-Torre syndrome
This child with xeroderma pigmentosum is predisposed to multiple skin cancers, including squamous cell carcinoma (SCC) at a young age. Many lentigines cover the face. (Courtesy, K. Kraemer, MD.)
Keratoacanthoma (KA), a crateriform tumor considered by most to be a self-regressing subtype of squamous cell carcinoma, is sometimes associated with Muir-Torre syndrome. (Courtesy D. Cassarino, MD.)

TERMINOLOGY

Abbreviations
- Squamous cell carcinoma (SCC)

Synonyms
- Epidermoid carcinoma
- Sarcomatoid carcinoma, spindle cell carcinoma, carcinosarcoma, metaplastic carcinoma
- Acantholytic/adenoid/pseudoglandular SCC
- Verrucous carcinoma (well-differentiated variant)
- Keratoacanthoma (KA) (considered by some to be a well-differentiated, spontaneously regressing variant of cutaneous SCC)

Definitions
- Malignant tumor of squamous keratinocytes

ETIOLOGY/PATHOGENESIS

Environmental Exposure
- Most cases are related to ultraviolet (UV) radiation
- Some cases are likely related to chronic inflammation (e.g., SCC arising in burns, lupus, lichen planus)
- Other causes include previous radiation therapy and chronic wounds/scars, sometimes associated with more aggressive SCC
- HPV is associated with some cases
  - Especially verrucous carcinoma (low grade) and SCC in immunosuppressed patients (high grade)

Genetics
- Some cases with an underlying genetic predisposition
  - DNA repair defects in xeroderma pigmentosum lead to inability to repair mutations induced by UV radiation at an early age
  - Consider a genetic component in patients with SCC presenting in first 2 decades
Consider Muir-Torre syndrome or Ferguson-Smith disorder if multiple KAs, especially if age < 50 years

**CLINICAL ISSUES**

**Epidemiology**

**Age**
- Usually in elderly, especially solar-related lesions; however, can present in a wide age range (34-95 years)
- Rare in children/young adults
  - Consider a genetic syndrome (e.g., xeroderma pigmentosum; Ferguson-Smith disorder or Muir-Torre syndrome if multiple KA)

**Gender**
- Slightly more common in males, overall

**Presentation**
- Slow-growing papular, nodular, or plaque lesion
- Often arises in sun-damaged skin (head and neck tumors)
  - Vast majority of cases associated with preexisting actinic keratosis (AK)
- May be ulcerated or bleeding
- Ear canal and middle ear tumors may present with pain, hearing loss, and discharge

**Treatment**

**Surgical approaches**
- Complete surgical excision (especially with Mohs surgery) is optimal and definitive therapy

**Drugs**
- Topical chemotherapeutics or immunomodulators may be used in patients who are not surgical candidates

**Radiation**
- May be used for very advanced cases in which surgical therapy is not curative

**Prognosis**
- Usually excellent in most cases
- Worse prognosis with poorly differentiated, deeply invasive, or rare aggressive subtypes
- Site of tumor important for prognosis
  - Lip and ear tumors more aggressive, regardless of degree of differentiation

**MACROSCOPIC FEATURES**

**General Features**
- Papular to nodular or plaque-like lesion; can be exophytic, ulcerated, or hemorrhagic

**Size**
- Variable; can be small or large

**MICROSCOPIC PATHOLOGY**

**Histologic Features**
- Microscopic features, per se, do not point to a genetic syndrome
  - Exception would be the well-differentiated, crateriform, KA type composed of glassy keratinocytes
  - Associated with Ferguson-Smith disorder, Muir-Torre syndrome (especially if mature sebocytes are intermixed in the KA); if subungual, incontinentia pigmenti

**Proliferation of invasive atypical keratinocytes**
- Cells are present in nests, sheets, and infiltrative cords
- Often show areas of keratinization (keratin pearls) and squamous eddies
- Attachments to overlying epidermis in most cases
- Associated AK is very common; less likely, may be associated with SCC in situ (Bowen disease)
- Cytologically, cells show abundant eosinophilic cytoplasm and large nucleus with vesicular chromatin and prominent nucleoli
- Intercellular bridges (desmosomes) should be present on high-power examination
- Presence of dyskeratotic cells (apoptotic keratinocytes) is reliable sign of squamous differentiation
- If no definite squamous differentiation is present, immunohistochemistry should be used to confirm diagnosis

**Degree of differentiation is variable, ranging from well- to moderately to poorly differentiated**
- Amount of keratinization typically decreases and cytologic atypia increases with higher grades
- Mitotic figures are usually numerous, and atypical forms are found especially in moderately to poorly differentiated cases
Multiple variants of differing malignant potential described

Low-risk variants include well-differentiated SCC arising in AK, KA, verrucous carcinoma, and trichilemmal (variant of clear cell) carcinoma

Intermediate-risk variants include acantholytic (adenoid/pseudoglandular) and lymphoepithelioma-like carcinoma of skin (LELCS)

High-risk variants include spindle cell/sarcomatoid, basaloid, adenosquamous, and desmoplastic

Also radiation, burn scar, and immunosuppression-related SCCs

Rare variants of uncertain malignant potential include clear cell SCC, signet ring cell SCC, follicular SCC, papillary SCC, pigmented SCC, and SCC arising from adnexal ducts or cysts

Predominant Pattern/Injury Type

Epithelioid/squamous

ANCILLARY TESTS

Immunohistochemistry

Not necessary in well-/moderately differentiated cases but may be needed in poorly differentiated and spindle cell cases

P.II(11):14

Cytokeratins are most important markers, especially high molecular weight cytokeratins (HMWCKs)

HMWCKs are most sensitive markers for poorly differentiated and spindle cell/sarcomatoid SCC

Pan keratin can be lost in poorly differentiated and spindle cell cases

p63 is also a very sensitive marker and can be used in addition to HMWCK to confirm diagnosis

Vimentin may be positive in spindle cell/sarcomatoid cases

Negative staining for other markers, including

- S100, MART-1/Melan-A, and HMB-45 (melanoma)
- CD10, CD68, and CD99 (AFX)
- Actin-sm and desmin (leiomyosarcoma)
- BER-EP4, androgen receptor (AR), and D2-40 (BCC and sebaceous carcinoma)

DIFFERENTIAL DIAGNOSIS

Basal Cell Carcinoma (BCC)

Cells typically smaller, more hyperchromatic, and show peripheral palisading, mucinous stroma, and retraction artifact

BER-EP4 and AR are almost always positive in BCC, negative in SCC

Atypical Fibroxanthoma (AFX)

Usually a large nodular lesion in heavily sun-damaged skin (typically head and neck)

SCC is typically positive for HMWCKs and p63; AFX is negative for these markers and often CD10(+) and CD99(+)

Poorly Differentiated Carcinoma (Including Metastatic)

Clinical history and imaging studies are paramount, as immunohistochemistry may not be able to distinguish some cases from primary SCC

Adenocarcinomas may show varying degree of ductal/glandular differentiation (highlighted with markers such as EMA and CEA)

Pseudoepitheliomatous Hyperplasia

Can mimic SCC but does not show infiltrative features or high-grade cytologic atypia

Keratoacanthoma (KA)

Considered by many to be a well-differentiated variant of SCC that spontaneously regresses in most cases

Typically a large, crateriform (cup-like) lesion filled with abundant keratin

Cells are enlarged, with abundant glassy-appearing/hyalinized cytoplasm

Most cases regress, but giant KA and subungual KA can be aggressive

DIAGNOSTIC CHECKLIST

Clinically Relevant Pathologic Features

Degree of differentiation

Depth of invasion

Deeply invasive tumors have much higher rates of recurrence and metastasis

Perineural invasion

Tumors with perineural invasion have high rates of local recurrence and increased risk of metastasis

More concerning if diameter of nerve is > 0.1 mm

Location of tumor important (i.e., lip, mucosal lesions more aggressive)

SELECTED REFERENCES

Image Gallery

Microscopic Features

(Left) Scanning power examination of a relatively small KA shows a symmetric-appearing atypical squamous proliferation with a dilated, central keratin-filled crater and dense overlying parakeratosis. (Courtesy D. Cassarino, MD.) (Right) High magnification shows enlarged keratinocytes with abundant, glassy amphophilic-to-eosinophilic-staining cytoplasm. Note the numerous dyskeratotic cells in the foci of keratinization. (Courtesy D. Cassarino, MD.)
This well-differentiated SCC has some features mimicking a KA, including enlarged squamous cells with abundant glassy-appearing eosinophilic cytoplasm. However, this tumor lacks a central keratin-filled crater and shows infiltrating single atypical cells in the dermis. (Courtesy D. Cassarino, MD.) (Right) This well-differentiated SCC mimics a KA. This case arose on the ear and invaded deeply to abut the cartilage. (Courtesy D. Cassarino, MD.)

(Left) This is a subungual keratoacanthoma. Although such tumors can present in patients without a genetic syndrome, multiple such tumors should cause consideration of incontinentia pigmenti. (Right) High-grade invasive SCC shows a sheet-like proliferation of atypical and pleomorphic epithelioid and multinucleated cells with hyperchromatic nuclei, prominent nucleoli, and abundant glassy-appearing eosinophilic cytoplasm. P.II(11):16

Variant Microscopic Features
Acantholytic (adenoid) type of invasive squamous cell carcinoma shows scattered cystic spaces containing dyscohesive squamous cells. This variant of SCC may mimic adenocarcinoma (pseudoglandular SCC) or even angiosarcoma (pseudovascular SCC). High-power view of acantholytic SCC shows large epithelioid cells with dense eosinophilic cytoplasm and scattered dyskeratotic (apoptotic) cells. There is an associated heavy inflammatory cell infiltrate.

Higher power view of poorly differentiated myxoid SCC shows epithelioid to signet ring-like eosinophilic-staining cells with focal extracellular mucin. H&E section shows poorly differentiated infiltrating squamous cell carcinoma forming cords, mimicking ductal structures. There is an associated dense desmoplastic stroma.
Poorly differentiated infiltrating SCC associated with a sclerotic (desmoplastic) stroma is shown. This is a high malignant potential variant of SCC. (Right) Heavily inflamed invasive SCC with moderately differentiated tumor islands composed of basaloid to squamoid cells is surrounded by a sea of inflammatory cells, features suggestive of the lymphoepithelioma-like carcinoma of the skin (LELCS) variant.

Immunohistochemical Features

(Left) CK-PAN immunohistochemistry (IHC) shows only focal staining of a few scattered single cells in a case of poorly differentiated SCC. CK-PAN is much less sensitive than HMWCKs and p63 in identifying poorly differentiated and sarcomatoid SCC cases. (Right) CK903 (HMWCK) immunohistochemistry shows strong staining of an invasive, poorly differentiated SCC (with strong internal control staining of the overlying epidermis).
(Left) CK5/6 (HMWCK) IHC shows strong staining of the epidermis and scattered single cells in a poorly differentiated SCC. (Right) Higher power view of CK5/6 shows moderate to strong cytoplasmic staining of many of the tumor cells.

(Left) IHC stain for p63 in an lymphoepithelioma-like carcinoma of the skin (LELCS) shows strong and diffuse nuclear staining in islands of epithelial tumor cells. (Right) High-power view of p63 immunohistochemistry shows strong and diffuse nuclear staining of large, irregularly shaped nuclei in a poorly differentiated infiltrating SCC.

Sebaceous Carcinoma

> Table of Contents > Part II - Diagnoses Associated With Specific Syndromes > Section 11 - Skin > Sebaceous Carcinoma

Terminology
- Adnexal carcinoma that often lacks clear cell features in poorly differentiated cases

Etiology/Pathogenesis
- Strong association with MTS if patients have multiple sebaceous tumors

Clinical Issues
- Eyelids are most common site (~ 75% of cases)
- Mohs excision is effective in most cases
- Aggressive tumors with high incidence of metastasis (> 30%) and generally poor prognosis unless discovered early

Microscopic Pathology
Dermal-based infiltrative, nodular to sheet-like tumor
Often focal follicular &/or epidermal connections
Well-differentiated tumors show clear cell changes
Moderately and poorly differentiated tumors show few to rare clear cells
Often show basaloid or squamoid features
Mitotic figures are usually abundant
Areas of comedonecrosis are common
Ancillary Tests
EMA(+) in well-differentiated cases, but often lost in poorly differentiated tumors
AR(+) in most cases, including poorly differentiated
Top Differential Diagnoses
Clear cell squamous cell carcinoma (SCC)
Clear cell basal cell carcinoma (BCC)
Other primary cutaneous adnexal carcinomas
Metastatic carcinoma to the skin

Scanning magnification of a sebaceous carcinoma shows a very large nodular tumor in the dermis. Note the lack of epidermal attachments; however, there are focal entrapped follicular structures. 
Higher power examination of sebaceous carcinoma shows a proliferation of markedly atypical clear cells with numerous mitotic figures and abundant apoptotic cellular debris.

**TERMINOLOGY**

**Synonyms**
- Sebaceous adenocarcinoma

**Definitions**
- Malignant adnexal tumor of sebaceous cells
- Often lacks clear cell features in poorly differentiated cases and may show basaloid or squamoid features, leading to high incidence of misdiagnosis

**ETIOLOGY/PATHOGENESIS**

- Unknown in Most Cases
  - Some cases likely due to solar (UV) damage, as most occur on sun-damaged skin of elderly
  - Sporadic tumors may have loss of mismatch repair proteins, suggesting a defect in DNA mismatch repair

**Genetic**
- May be a marker of Muir-Torre syndrome (MTS)
- Genes implicated include MSH2 (majority of cases), MLH1, MSH6
- Encode mismatch repair proteins
- Mutations lead to microsatellite instability (MSI)
- MSI assays and immunohistochemistry can be used to screen for MTS

**CLINICAL ISSUES**

**Epidemiology**

- **Incidence**
  - Uncommon tumors, but 1 of the more common types of adnexal carcinoma

- **Age**
  - Most occur in elderly patients

- **Gender**
Females have slightly higher incidence

Site
Eyelids are by far the most common site (~75% of cases)
Remainder of cases occur in other head and neck sites, followed by trunk, extremities
Nonperiocular sebaceous carcinoma may be more likely than periocular carcinomas to be associated with MTS

Presentation
Nodular, firm, yellow-tan lesions
Often ulcerated

Treatment
Surgical approaches
Complete excision is necessary to ensure local removal
Mohs excision is reported to be effective in most cases
Sentinel lymph node biopsy may be useful for staging purposes

Prognosis
Aggressive tumors with high incidence of metastasis (>30% of cases) and generally poor prognosis unless discovered early

MACROSCOPIC FEATURES
General Features
Dermal-based firm, nodular lesion
Size
Usually 1-4 cm

MICROSCOPIC PATHOLOGY
Histologic Features
Dermal-based infiltrative, nodular to sheet-like tumor

Often with focal follicular &/or epidermal connections
Pagetoid involvement of epidermis may be seen in up to 30% of cases
Tumor consists of variably differentiated epithelioid cells
Clear cells often present but vary greatly in number
Well-differentiated tumors show prominent clear cell changes
Cells contain abundant cytoplasmic lipid, often producing multiple vacuoles and nuclear indentation
Nuclei are enlarged and vesicular or hyperchromatic staining, with prominent nucleoli
Moderately and poorly differentiated tumors show few to rare clear cells
May be composed predominantly of basaloid or squamoid cells
Show prominent cytologic atypia and pleomorphism
Mitotic figures, including atypical forms, are usually abundant
Areas of necrosis, with comedonecrosis pattern, are common
Lymphovascular invasion present in significant percentage of cases
Tumor-infiltrating lymphocytes may be a marker of defective mismatch repair

Cytologic Features
Enlarged, epithelioid cells with abundant cytoplasm and hyperchromatic or vesicular nuclei with enlarged nucleoli
Clear cells usually show cytoplasmic vacuoles and nuclear indentation
Cells can also be basaloid (common) or squamoid (rare)

ANCILLARY TESTS
Histochemistry
Sudan black B and oil red O (need frozen tissue)
Reactivity: Positive
Staining pattern
Cytoplasmic staining
Periodic acid-Schiff
Reactivity: Usually negative (indicating lack of glycogen)

Immunohistochemistry
EMA: Positive in most well-differentiated cases, but is often negative in poorly differentiated tumors
Negative in BCC, but often shows at least focal staining in SCC
Often highlights ductal structures in other adnexal carcinomas (i.e., porocarcinoma and hidradenocarcinoma), but not in sebaceous carcinoma
Androgen receptor (AR) is positive (nuclear staining) in most cases, including poorly differentiated carcinomas. SCC and most other primary cutaneous carcinomas are negative for AR. AR is often positive in BCC (> 60% of cases) and some metastatic carcinomas to the skin. Adipophilin is often positive in most cases. HMWCK (i.e., CK5/6 and CK903/34BE12) and p63 are typically strongly and diffusely positive. Help to exclude metastatic tumors (most of which are negative for both of these markers) but do not distinguish from other primary cutaneous tumors. D2-40 (podoplanin) is positive in a subset of cases, especially in more basaloid sebaceous carcinomas. Can also highlight areas of lymphovascular invasion. Other markers that may be positive include CAM5.2, BER-EP4, CK7 (~ 50% of cases), and CD10 (~ 50%). Negative for CEA-M, CK20, GCDFP-15, renal cell carcinoma antigen (RCA), TTF-1, S100. Loss of staining for MLH1, MSH2, &/or MSH6 may be seen, regardless of whether patient has MTS.

Molecular Genetics
MTS is defined as 1 sebaceous tumor and 1 internal organ malignancy. Genes include MSH2 (90% of cases), MLH1, MSH6. Mutations lead to loss of mismatch repair capabilities. Can be identified directly through PCR for specific mutations or indirectly through MSI studies. MSI studies are less sensitive than PCR.

Differential Diagnosis
Squamous Cell Carcinoma (SCC)
SCC with clear cell features can be difficult to distinguish from sebaceous carcinoma in some cases. Often associated with overlying actinic keratosis or SCC in situ (Bowen disease). Clear cells in SCC are due to either degenerative changes or glycogen accumulation. Lack cytoplasmic lipid and nuclear indentations. PAS (without diastase) is positive in cases with cytoplasmic glycogen (negative in sebaceous carcinoma). Areas of squamous eddies and keratinization typically present (only rarely seen in sebaceous carcinoma). Sebaceous carcinoma is usually diffusely positive for EMA (weak/focal in SCC) and AR (negative in SCC).

Basal Cell Carcinoma (BCC)
Most cases are not difficult to distinguish from sebaceous carcinoma. Some cases of BCC are predominantly clear cell, but typically show at least focal areas of more conventional BCC with peripheral palisading and mucinous stroma. BCC is usually negative with EMA and only focally positive with AR.

Other Primary Cutaneous Adnexal Carcinomas
Porocarcinoma and hidradenocarcinoma with clear cell features. Porocarcinoma shows multiple epidermal attachments, whereas hidradenocarcinoma is a dermal-based tumor typically lacking epidermal connections. Both tumors show at least focal ductal differentiation. May be highlighted by EMA and CEA. Sebaceous carcinoma is usually diffusely positive for EMA and AR.

Metastatic Carcinomas to Skin
Metastatic carcinomas with clear cell features should be considered in the differential, especially if no epidermal or follicular connections are identified. Metastatic clear cell renal cell carcinoma (RCC) is the most likely consideration. Prominent capillary-type vasculature present. Cells are typically relatively low-grade appearing. Show uniform cytoplasmic clearing. IHC: Positive for RCC antigen, pax-8, CD10 (positive in ~ 50% of sebaceous carcinomas); EMA is positive in both RCC and sebaceous carcinoma.

Diagnostic Checklist
Pathologic Interpretation Pearls
Well-differentiated cells with cytoplasmic lipid, often producing multiple vacuoles and nuclear indentation. Poorly differentiated cells often basaloid.

Selected References

Image Gallery
Microscopic Features

(Left) Scanning magnification view shows an atypical cellular, nodular, basloid-appearing proliferation with large areas of comedonecrosis. (Right) High magnification of an area of comedonecrosis is surrounded by atypical clear to basloid cells with apoptotic bodies and mitoses. Some of the cells show clear cytoplasmic vacuoles.
Sebaceous carcinoma shows areas of squamous differentiation adjacent to more typical areas with clear cell differentiation. (Right) Invasive poorly differentiated sebaceous carcinoma with squamoid features shows markedly enlarged, atypical, and pleomorphic-appearing cells. Note the overlying epidermal ulceration with serum crusting and neutrophils. Scattered cells show nuclear indentations by cytoplasmic vacuoles.

High magnification shows a sebaceous carcinoma with abundant red blood cells, some of which appear to be within the cytoplasm of the atypical clear cells. However, the abundant vascularity of renal cell carcinoma is lacking. Note the central atypical mitotic figure. (Right) High magnification shows nests and atypical single pagetoid clear cells in the epidermis. Pagetoid involvement may be present in a minority of cases, and it may rarely be entirely in situ.

Ancillary Techniques
High magnification shows a sebaceous carcinoma composed of atypical clear to basaloid cells with mitoses. Many of the cells show multiple small to large clear cytoplasmic vacuoles. (Right) Strong immunohistochemical staining for EMA, often positive in well-and moderately differentiated tumors, highlights the cytoplasmic membrane and intracytoplasmic vacuoles.

CK7 may be positive, but only in approximately 50% of cases. It often shows patchy, moderate to strong cytoplasmic staining, as in this case. (Right) Androgen receptor (AR) immunohistochemistry is positive in most cases and shows moderate, diffuse nuclear staining in the majority of the tumor cells.
D2-40 (podoplanin) is positive in some cases of sebaceous carcinoma, especially basaloid variants. This case shows strong cytoplasmic staining of many of the basaloid and spindled cells without significant staining of the well-differentiated clear cells. (Right) Diffuse nuclear staining for p53 is seen in this example of sebaceous carcinoma. p53 and Ki-67 are usually elevated in sebaceous carcinomas, and Bcl-2 is lost, compared with sebaceous adenomas and sebaceomas.

**Differential Diagnosis**

(Left) Low magnification shows a large sebaceous adenoma. The tumor is a well-circumscribed, fusing lobular proliferation with superficial holocrine necrosis (recapitulating normal sebaceous glands), composed of bland clear cells surrounded by a thin layer of basaloid cells. (Right) High magnification of a sebaceous adenoma shows the bland cytologic appearance of the mature sebocytes and surrounding basaloid cells. Note the prominent intracytoplasmic lipid vacuoles.
Sebaceoma shows well-circumscribed lobules of predominantly basaloid cells with a smaller population of bland-appearing mature sebaceous cells. (Right) High magnification of an atypical sebaceoma shows a predominantly basaloid population of enlarged, moderately atypical cells with nuclear hyperchromasia surrounding several large clear cells with abundant, multivacuolated cytoplasm. Several mitotic figures are seen, but these can be quite numerous in some sebaceomas.

Clear cell BCC shows uniform cytoplasmic clearing without the vacuoles and nuclear indentations seen in sebaceous carcinoma. Note the focal retraction artifact and adjacent areas of conventional-type BCC. (Right) Hidradenocarcinoma is another malignant adnexal tumor that often shows clear cell features. However, the cells lack cytoplasmic vacuoles and nuclear indentations. In addition, a few ductal structures are often seen, which are rare in sebaceous carcinoma.

Part III - Syndromes by Organ Location
Section 1 - Breast
Breast

<table>
<thead>
<tr>
<th>Gene</th>
<th>Germline Mutations Associated With Increased Risk of Breast Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Population % of Hereditary Risk by Age Type of Other Involvement Comments</td>
</tr>
<tr>
<td></td>
<td>70 years</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Gene</td>
<td>Frequency (Penetrance)</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>BRCA1 (17q21)</td>
<td>0.1-0.3% ~ 50% (~ 2% of all cancers)</td>
</tr>
<tr>
<td>BRCA2 (13q12.3)</td>
<td>0.1-0.7% ~ 50% (~ 2% of all cancers)</td>
</tr>
<tr>
<td>TP53 (17p13.1) Li-Fraumeni syndrome</td>
<td>0.0025% 3% (&lt; 1% &gt; 90%) of all cancers</td>
</tr>
<tr>
<td>CDH1 (16q22.1) Familial gastric cancer and lobular breast cancer syndrome</td>
<td>0.005% ~ 0.2-1% ~ 40-50%</td>
</tr>
<tr>
<td>PTEN (10q23.3) Cowden syndrome</td>
<td>0.0005% ~ 0.3% 50-85%</td>
</tr>
<tr>
<td>ATM (11q22-q23) ataxia-telangiectasia heterozygotes</td>
<td>0.5% &lt; 1% ~ 30%</td>
</tr>
<tr>
<td>Gene</td>
<td>Incidence</td>
</tr>
<tr>
<td>------------</td>
<td>-----------</td>
</tr>
<tr>
<td><strong>CHEK2</strong></td>
<td>0.5%</td>
</tr>
<tr>
<td>(22q12.1)</td>
<td></td>
</tr>
<tr>
<td><strong>STK11/LKB1</strong></td>
<td>0.001%</td>
</tr>
<tr>
<td>(19p13.3) Peutz-Jeghers syndrome</td>
<td></td>
</tr>
<tr>
<td><strong>BRIP1</strong></td>
<td>0.1%</td>
</tr>
<tr>
<td>(FANCJ or BACH1) (17q22.2)</td>
<td></td>
</tr>
<tr>
<td><strong>PALB2/FANC N</strong></td>
<td>0.1%</td>
</tr>
<tr>
<td>(16p12.1)</td>
<td></td>
</tr>
<tr>
<td><strong>RAD51C</strong></td>
<td>~ 0.3%</td>
</tr>
<tr>
<td>(17q25.1)</td>
<td></td>
</tr>
<tr>
<td><strong>BARD1</strong></td>
<td>~ 0.5%</td>
</tr>
<tr>
<td>(2q34-q35)</td>
<td></td>
</tr>
<tr>
<td><strong>RAD50</strong></td>
<td>~ 0.3%</td>
</tr>
<tr>
<td>(5q31)</td>
<td></td>
</tr>
<tr>
<td><strong>NBN</strong></td>
<td>~ 0.2%</td>
</tr>
<tr>
<td>(8q21)</td>
<td></td>
</tr>
<tr>
<td><strong>MRE11A</strong></td>
<td>~ 0.1%</td>
</tr>
<tr>
<td>(11q21)</td>
<td></td>
</tr>
<tr>
<td><strong>MUTYH</strong></td>
<td>~ 0.1%</td>
</tr>
<tr>
<td>(1p34.1)</td>
<td></td>
</tr>
</tbody>
</table>
**BRCA1 and BRCA2**

<table>
<thead>
<tr>
<th>Feature</th>
<th>BRCA1</th>
<th>BRCA2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chromosome</td>
<td>17q21</td>
<td>13q12.3</td>
</tr>
<tr>
<td>Gene size</td>
<td>81 kb</td>
<td>84 kb</td>
</tr>
<tr>
<td>Protein size</td>
<td>1,863 amino acids</td>
<td>3,418 amino acids</td>
</tr>
<tr>
<td>Function</td>
<td>Tumor suppressor: Role in double-stranded DNA repair, transcriptional regulation</td>
<td>Tumor suppressor: Role in double-stranded DNA repair, transcriptional regulation</td>
</tr>
<tr>
<td>Mutations</td>
<td>&gt; 1,000</td>
<td>&gt; 1,000</td>
</tr>
<tr>
<td>Incidence of mutations in population</td>
<td>~ 0.1-0.3%</td>
<td>~ 0.1-0.7%</td>
</tr>
<tr>
<td>Groups with increased incidence</td>
<td>Ashkenazi Jews (2 mutations), Finns, French Canadians, others</td>
<td>Ashkenazi Jews (1 mutation), Icelandic, others</td>
</tr>
<tr>
<td>Risk of breast cancer by age 70</td>
<td>40-90%</td>
<td>45-85%</td>
</tr>
<tr>
<td>Risk of ovarian cancer</td>
<td>40-50%</td>
<td>10-20%</td>
</tr>
<tr>
<td>Risk of male breast cancer</td>
<td>1.8%</td>
<td>7%</td>
</tr>
<tr>
<td>Age of onset of female breast cancer</td>
<td>44 years</td>
<td>47 years</td>
</tr>
<tr>
<td>Age of onset of ovarian cancer</td>
<td>49-53 years</td>
<td>55-58 years</td>
</tr>
<tr>
<td>Proportion of families with breast cancer due to a single gene</td>
<td>~ 50%</td>
<td>~ 50%</td>
</tr>
<tr>
<td>Proportion of families with breast and ovarian cancer</td>
<td>80%</td>
<td>15%</td>
</tr>
<tr>
<td>Proportion of families with female and male breast cancer</td>
<td>&lt; 4%</td>
<td>75%</td>
</tr>
<tr>
<td>Other associated cancers</td>
<td>Prostate, pancreas, cervix, uterus</td>
<td>Prostate, pancreas, stomach, bile duct, gallbladder, melanoma</td>
</tr>
<tr>
<td>Alterations in sporadic breast cancer</td>
<td>Mutations very rare (&lt; 5%) inactivation may occur by methylation</td>
<td>Mutations very rare (&lt; 5%)</td>
</tr>
</tbody>
</table>

**Pathologic Features of Breast Cancers**

<table>
<thead>
<tr>
<th>Feature</th>
<th>BRCA1</th>
<th>BRCA2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histologic type</td>
<td>Many medullary or “medullary-like” (high nuclear grade, syncytial growth pattern, pushing borders, lymphocytic infiltrate)</td>
<td>Many lobular or with lobular features</td>
</tr>
<tr>
<td>DCIS</td>
<td>Absent or scant</td>
<td>Common</td>
</tr>
<tr>
<td>Grade</td>
<td>&gt; 95% poorly differentiated</td>
<td>Majority moderately to poorly differentiated</td>
</tr>
<tr>
<td>Hormone receptors</td>
<td>70-80% negative</td>
<td>&gt; 80% positive (but may be at low levels)</td>
</tr>
<tr>
<td>HER2</td>
<td>&gt; 95% negative</td>
<td>&gt; 95% negative</td>
</tr>
<tr>
<td>TP53 mutations</td>
<td>&gt; 90% of cancers</td>
<td>30-65% of cancers</td>
</tr>
<tr>
<td>Molecular type</td>
<td>Majority basal-like</td>
<td>Majority “luminal B,” HER2</td>
</tr>
</tbody>
</table>
# Section 2 - Blood and Bone Marrow

## Blood and Bone Marrow

> Table of Contents > Part III - Syndromes by Organ Location > Section 2 - Blood and Bone Marrow > Blood and Bone Marrow

### Hereditary Syndromes With Blood and Bone Marrow Abnormalities and Predisposition to Myeloid Neoplasms

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Affected Gene(s)</th>
<th>Clinical Features</th>
<th>Peripheral Blood Manifestations</th>
<th>Bone Marrow Manifestations</th>
<th>Incidence of MDS/AML</th>
<th>Inheritance Pattern</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone Marrow Failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Congenital amegakaryocytic thrombocytopenia</td>
<td>MPL (encodes thrombopoietin receptor)</td>
<td>No syndromic malformations/dysmorphism, evolution to bone marrow failure</td>
<td>Severe thrombocytopenia, progression to pancytopenia</td>
<td>Absent or markedly reduced megakaryocytes (may be relatively normal in number at early age/initial presentation), progression to marrow aplasia</td>
<td>Lower than other bone marrow failure syndromes</td>
<td>AR</td>
</tr>
<tr>
<td>Diamond-Blackfan anemia</td>
<td>Mutations in genes encoding several ribosomal subunit proteins (25% of cases: RPS19)</td>
<td>40% with congenital manifestations such as cardiac and renal defects, hypertelorism, short stature, radial ray abnormalities</td>
<td>Isolated severe macrocytic anemia and reticulocytopenia</td>
<td>Erythroid maturation arrest (only rare erythroblasts) 1% , increased hematogones, other lineages preserved, normal marrow cellularity</td>
<td>Poorly defined (some report ≤ 1%)</td>
<td>AD (highly variable penetrance); also sporadic</td>
</tr>
<tr>
<td>Dyskeratosis congenita</td>
<td>Mutations in telomere maintenance genes: TERT, TERC, DKC1, TINF2</td>
<td>Variable findings, classically oral leukoplakia, abnormal nails, reticulate hyperpigmentation in 1st decade, and progression to bone marrow failure in 2nd decade, carcinoma</td>
<td>Gradual development of pancytopenia, reticulocytopenia</td>
<td>Aplastic anemia (in up to 85% of patients)</td>
<td>3-5%</td>
<td>AD, AR, and X-linked recessive</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>Risk/Features</td>
<td>Initial Sustained</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Severe congenital neutropenia</strong></td>
<td>Mutations in <em>ELANE</em>, causing misfolding of the encoded protein (neutrophil elastase) and granulocyte apoptosis; <em>HAX1</em>, causing uncontrolled mitochondrial-dependent apoptosis; and WAS, causing increased activity (gain of function)</td>
<td>Usually no syndromic malformations/dysmorphism, highly susceptible to infection</td>
<td>Isolated, profound neutropenia presenting at birth/infancy</td>
<td>Sustained myeloid aplasia with maturation arrest (few myeloblasts and promyelocytes)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Shwachman-Diamond syndrome</strong></td>
<td>Mutations in <em>SBDS</em> (ribosomal biogenesis; mitotic spindle stabilization)</td>
<td>Exocrine pancreatic insufficiency (failure to thrive, malabsorption, steatorrhea, deficiency of fat-soluble vitamins), skeletal abnormalities including short stature</td>
<td>Initially neutropenia (may be intermittent), 25% progress to pancytopenia</td>
<td>Initially only 10% granulocytic abnormalities, variable myeloid left-shift/hypoplasia, 25% develop eventual marrow aplasia</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DNA Damage Repair Deficiency</strong></td>
<td>Mutations in genes encoding the Fanconi anemia pathway; proteins encoded by these genes sense DNA abnormalities damage and initiate DNA repair</td>
<td>Up to 75% demonstrate low birth weight/short stature, hypoplastic or absent thumbs &amp;/or radii, pigmentation, or ear, cardiac, renal, neurologic, endocrine, and gastrointestinal abnormalities</td>
<td>Thrombocytopenia initially normocellular progressing to hypercellular; incidence of hematologic malignancy (compare to normal population)</td>
<td>25% AR and cumulatively X-linked recessive</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Fanconi anemia**

**Thrombocytopenia**

**Hypoplasia**

**Malignancy**

**Incidence**

**Normal population**
(most frequently mutated: \textit{FANCA})

\begin{tabular}{|l|l|}
\hline
n, 600x increased risk of AML and 5,000x increased risk of MDS) \\
\hline
\end{tabular}

\textit{AD: Autosomal dominant; AML: Acute myeloid leukemia; AR: Autosomal recessive; MDS: Myelodysplastic syndromes.}

P.III(2):3

Image Galley
Microscopic Features

(Left) Congenital amegakaryocytic thrombocytopenia is characterized by absent or markedly reduced megakaryocytes. Other lineages are unaffected, and early in the disease course, bone marrow cellularity is normal. (Courtesy D. Czuchlewski, MD.) (Right) Bone marrow aspirate smear from a patient with Diamond-Blackfan anemia shows only scattered erythroid elements within a background of adequate granulopoiesis. (Courtesy D. Czuchlewski, MD.)

(Left) The majority of patients with dyskeratosis congenita develop aplastic anemia. Bone marrow core biopsy will
reveal marked hypocellularity as shown here. (Courtesy D. Czuchlewski, MD.) (Right) Bone marrow aspirate from a 2 year old with severe congenital neutropenia shows a so-called maturation arrest picture with a paucity of late-stage granulocytes. (Courtesy D. Czuchlewski, MD.)

(Left) The bone marrow appearance of Shwachman-Diamond syndrome can be variable, but cases may show hypoplastic &/or left-shifted myelopoiesis, as in this 1-year-old girl. (Courtesy D. Czuchlewski, MD.) (Right) A bone marrow clot section from a 6-year-old girl with new onset pancytopenia shows moderate hypocellularity. The patient progressed to fulminant bone marrow failure and aplasia in the setting of Fanconi anemia. (Courtesy D. Czuchlewski, MD.)

Section 3 - Bone and Soft Tissue

Bone and Soft Tissue

Molecular and Cytogenetic Findings in Bone and Soft Tissue Tumors

<table>
<thead>
<tr>
<th>Histologic Type</th>
<th>Translocation or Rearrangement</th>
<th>Fusion Gene or Other Feature</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aggressive angiomyxoma</td>
<td>t(12q15)</td>
<td>HMGA2</td>
<td>&gt; 20%</td>
</tr>
<tr>
<td>Alveolar soft part sarcoma</td>
<td>t(X;17)(p11;q25)</td>
<td>ASPL-TFE3 fusion</td>
<td>&gt; 90%</td>
</tr>
<tr>
<td>Aneurysmal bone cyst</td>
<td>t(16;17)(q22; p13)</td>
<td>CDH11-USP6 fusion</td>
<td>20%</td>
</tr>
<tr>
<td></td>
<td>t(17p13.2)</td>
<td>USP6</td>
<td>&gt; 50%</td>
</tr>
<tr>
<td>Angiomatoid fibrous histiocytoma</td>
<td>t(12;22)(q13;q12)</td>
<td>EWSR1-ATF1 fusion</td>
<td>Unknown</td>
</tr>
<tr>
<td>Bizarre parosteal osteochondromatous proliferation</td>
<td>t(12;16)(q13;p11)</td>
<td>FUS-ATF1 fusion</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>t(2;22)(q33;q12)</td>
<td>EWSR1-CREB1 fusion</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>t(1;17)(q32;q21)</td>
<td>Unknown</td>
<td>Breakpoint in 1q23 present in 100% of lesions</td>
</tr>
<tr>
<td></td>
<td>t(1;17)(q42;q23)</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>Tumor Type</td>
<td>Chromosome/Translocation</td>
<td>Fusion/Translocation</td>
<td>% Fusions</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>--------------------------</td>
<td>----------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Clear cell sarcoma of soft parts</td>
<td>t(12;22)(q13;q12)</td>
<td>EWSR1-ATFI fusion</td>
<td>&gt; 75%</td>
</tr>
<tr>
<td>Clear cell sarcoma (gastrointestinal)</td>
<td>t(2;22)(q33;q12)</td>
<td>EWSR1-CREBI fusion</td>
<td>Unknown</td>
</tr>
<tr>
<td>Chondromyxoid fibroma</td>
<td>Deletion 6q</td>
<td>Unknown</td>
<td>&gt; 75%</td>
</tr>
<tr>
<td>Dermatofibrosarcoma protubera and variants</td>
<td>t(17;22)(q21;q13)</td>
<td>COL1A1-PDGFB fusion</td>
<td>&gt; 75%</td>
</tr>
<tr>
<td>Desmoplastic fibroblastoma</td>
<td>t(2;11)(q31;q12)</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>Desmoplastic small round cell tumor</td>
<td>t(11;22)(p13;q12)</td>
<td>EWSR1-WT1 fusion</td>
<td>&gt; 95%</td>
</tr>
<tr>
<td>Endometrial stroma sarcoma</td>
<td>t(2;22)(q33;q12)</td>
<td>EWSR1-FLI1 fusion</td>
<td>&gt; 80%</td>
</tr>
<tr>
<td>Epithelioid hemangioendothelioma</td>
<td>t(6;7)(p21;p22)</td>
<td>JAZF1-JIAZ1 fusion</td>
<td>30%</td>
</tr>
<tr>
<td>Epithelioid sarcoma</td>
<td>t(10;14)(p13;q24)</td>
<td>Gene for VEGF-related protein at 14q24</td>
<td>Unknown</td>
</tr>
<tr>
<td>Ewing sarcoma/primary neuroectodermal tumor</td>
<td>t(11;22)(q24;q12)</td>
<td>EWSR1-FLI1 fusion</td>
<td>&gt; 75%</td>
</tr>
<tr>
<td>Extraskeletal myxoid chondrosarcoma</td>
<td>t(9;22)(q22;q12)</td>
<td>TAFII68-NR4A3 fusion</td>
<td>&lt; 10%</td>
</tr>
<tr>
<td>Fibromatosis</td>
<td>t(7;17)(p15;q21)</td>
<td>JAZF1-JIAZ1 fusion</td>
<td>30%</td>
</tr>
<tr>
<td>Fibromyxoid sarcoma, low grade</td>
<td>t(9;17)(q22;q11)</td>
<td></td>
<td>10-20% and 50%, respectively</td>
</tr>
<tr>
<td>Fibromyxoid sarcoma, high grade</td>
<td>t(7;16)(q32-34;p11.2)</td>
<td>APC mutation or inactivation and β-catenin</td>
<td>96%</td>
</tr>
<tr>
<td>Fibrosarcoma, infantile</td>
<td>t(11;16)(p11;p11)</td>
<td>FUS-CREB3L1fusion</td>
<td>Rare</td>
</tr>
<tr>
<td>Gastrointestinal stromal tumor</td>
<td>t(12;15)(p13;q26)</td>
<td>ETV6-NTRK3 fusion</td>
<td>&gt; 75%</td>
</tr>
<tr>
<td>Giant cell tumor, diffuse type (PVNS)</td>
<td>t(1;2)(p13;q37)/t(1p13)</td>
<td>KIT, PDGFRA, SDHB</td>
<td>&gt; 90%</td>
</tr>
<tr>
<td>Inflammatory myofibroblastic tumor</td>
<td>2p23 rearrangement, numerous</td>
<td>ALK fusions with various genes</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>t(1;2)(q22;p23)</td>
<td>TPM3-ALK fusion</td>
<td>Unknown</td>
</tr>
<tr>
<td></td>
<td>t(2;19)(p23;p13)</td>
<td>TPM4-ALK fusion</td>
<td>Unknown</td>
</tr>
<tr>
<td>Genetic Findings in Benign and Intermediate Soft Tissue Tumors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Histologic Type</strong></td>
<td><strong>Translocation or Rearrangement</strong></td>
<td><strong>Fusion Gene or Other Feature</strong></td>
<td></td>
</tr>
<tr>
<td>Adipose tumors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipoma</td>
<td>t(3;12)(q27-28;q15), <em>HMGA2</em></td>
<td><em>HMGA2-LPP</em> fusion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>rearrangements at 12q15</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Diagnostic Pathology: Familial Cancer Syndromes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Leiomyosarcoma</strong></td>
</tr>
<tr>
<td>Lipoblastoma</td>
</tr>
<tr>
<td>Lipoma</td>
</tr>
<tr>
<td>Typical lipoma</td>
</tr>
<tr>
<td>Spindle cell or pleomorphic Lipoma</td>
</tr>
<tr>
<td>Liposarcoma</td>
</tr>
<tr>
<td>Dedifferentiated</td>
</tr>
<tr>
<td>Spindle cell</td>
</tr>
<tr>
<td>Myxoid/round cell</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Pleomorphic</td>
</tr>
<tr>
<td>Malignant rhabdoid tumor</td>
</tr>
<tr>
<td>Malignant peripheral nerve sheath tumor</td>
</tr>
<tr>
<td>Myxofibrosarcoma</td>
</tr>
<tr>
<td>Myxoinflammatory fibroblastic sarcoma</td>
</tr>
<tr>
<td>Osteochondroma</td>
</tr>
<tr>
<td>Osteosarcoma</td>
</tr>
<tr>
<td>Rhabdomyosarcoma</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Schwannoma and perineurioma</td>
</tr>
<tr>
<td>Subungual exostosis</td>
</tr>
<tr>
<td>Synovial sarcoma</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Tumor Type</td>
</tr>
<tr>
<td>----------------------------------</td>
</tr>
<tr>
<td>Spindle cell and pleomorphic lipoma</td>
</tr>
<tr>
<td>Hibernoma</td>
</tr>
<tr>
<td>Lipoblastoma</td>
</tr>
<tr>
<td>Chondroid lipoma</td>
</tr>
<tr>
<td>Cellular angiofibroma</td>
</tr>
<tr>
<td>Chondroma of soft tissue</td>
</tr>
<tr>
<td>Desmoplastic fibroblastoma</td>
</tr>
<tr>
<td>Fibroma of tendon sheath</td>
</tr>
<tr>
<td>Fibromatosis</td>
</tr>
<tr>
<td>Sporadic deep</td>
</tr>
<tr>
<td>In familial adenomatous polyposis</td>
</tr>
<tr>
<td>Leiomyoma</td>
</tr>
<tr>
<td>Cutaneous hereditary</td>
</tr>
<tr>
<td>Uterine</td>
</tr>
<tr>
<td>Nerve sheath tumors</td>
</tr>
<tr>
<td>Neurofibroma</td>
</tr>
<tr>
<td>Perineurioma</td>
</tr>
<tr>
<td>Sclerosing perineurioma</td>
</tr>
<tr>
<td>Schwannoma</td>
</tr>
<tr>
<td>Mammary-type myoepiblastoma</td>
</tr>
<tr>
<td>Myoepithelioma</td>
</tr>
<tr>
<td>Plexiform fibrohistiocytic tumor</td>
</tr>
<tr>
<td>Solitary fibrous tumor</td>
</tr>
<tr>
<td>Tenosynovial giant cell tumor</td>
</tr>
</tbody>
</table>

**Familial Cancer Syndromes With Bone and Soft Tissue Tumors**

<table>
<thead>
<tr>
<th>Bone and Soft Tissue Tumor</th>
<th>Familial Cancer Syndromes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chondrosarcoma</td>
<td>Hereditary multiple exostosis</td>
</tr>
<tr>
<td></td>
<td>Li-Fraumeni syndrome</td>
</tr>
<tr>
<td></td>
<td>Hereditary retinoblastoma</td>
</tr>
<tr>
<td>Chordoma</td>
<td>Familial chordoma</td>
</tr>
<tr>
<td></td>
<td>Tuberous sclerosis</td>
</tr>
<tr>
<td>Soft tissue tumor and sarcoma</td>
<td>Basal cell nevus syndrome</td>
</tr>
<tr>
<td></td>
<td>Li-Fraumeni syndrome</td>
</tr>
<tr>
<td></td>
<td>Hereditary retinoblastoma</td>
</tr>
<tr>
<td></td>
<td>Multiple hereditary exostosis</td>
</tr>
</tbody>
</table>
Familial adenomatous polyposis  
Renal carcinoma with leiomyomas  
von Hippel-Lindau syndrome  
Werner syndrome  
Familial melanoma

Osteosarcoma  
Li-Fraumeni syndrome  
Hereditary retinoblastoma

Rhabdomyosarcoma  
Li-Fraumeni syndrome  
Beckwith-Wiedemann syndrome  
Neurofibromatosis type 1  
Hereditary retinoblastoma  
Costello syndrome  
Werner syndrome

Malignant peripheral nerve sheath tumor  
Li-Fraumeni syndrome  
Familial melanoma  
Neurofibromatosis type 1  
Neurofibromatosis type 2  
Carney complex  
Multiple endocrine neoplasia 1  
Werner syndrome

Ossifying fibroma  
Hyperparathyroidism-jaw tumor syndrome

Image Galley  
Diagrammatic Features

(Left) Graphic shows a chordoma of the clivus extending into the sphenoid sinus. The tumor has a gray translucent appearance and expands and erodes the bone, causing focal destruction of the bony cortex. These tumors may be associated with familial chordoma or with tuberous sclerosis.  
(Right) Bilateral schwannomas involving the vestibular branch of cranial nerve 8 are a hallmark of neurofibromatosis type 2, present as a cerebropontine angle mass, and may be multiple.
(Left) Chondrosarcoma with a tan-gray glistening appearance fills the medullary cavity of the proximal diaphysis, greater trochanter, and base of the femoral neck. It can be present in hereditary multiple exostosis, Li-Fraumeni syndrome, and hereditary retinoblastoma. (Right) Graphic shows bilateral spinal nerve root and branchial plexus neurofibromas in NF1. There is lobulated tortuous expansion of the cervical nerve roots with widening of the neural foramina.

(Left) Graphic depicts a nonossifying fibroma in a patient with hyperparathyroidism-jaw tumor syndrome, presenting as a large maxillary mass. Note that the mass obstructs one side of the nose and compresses the eye. (Right) Graphic depicts osteosarcoma arising from the lateral area of C5. The firm, pink, solid mass has transgressed the cortex and extended into the soft tissues. These tumors may be present in Li-Fraumeni syndrome, Werner syndrome, and hereditary retinoblastoma.

Section 4 - Head and Neck
Head and Neck

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Familial Cancer Syndromes With Head and Neck Neoplasms</th>
<th>Head and Neck Tumor</th>
<th>Other Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dyskeratosis congenita</td>
<td><em>TERT, TERC, DKCI, TINF2;</em></td>
<td>SCCa of head and neck, SCCa of</td>
<td>Skin cancer, anorectal carcinoma, gastric</td>
</tr>
<tr>
<td>Syndrome</td>
<td>Genes Involved</td>
<td>Characteristics</td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Fanconi anemia</td>
<td>13 separate genes SCCa of head and neck</td>
<td>Short stature, eye abnormalities, Wilms tumor and other solid tumors, SCCa of cervix; hematologic neoplasms (by age 45, cumulative incidence of hematologic malignancy is 25%; median diagnosis age: 11-14 years); predominantly myeloid malignancies, acute myeloid leukemia, and other hematopoietic abnormalities, (600x increased risk of AML; 5,000x increased risk of MDS); solid tumors such as SCCa (esophageal, anogenital), hepatocellular carcinoma, brain tumors; breast cancer susceptibility</td>
<td></td>
</tr>
<tr>
<td></td>
<td>“Fanconi anemia pathway”: FANCx</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XP</td>
<td>Genes involved in nucleotide excision repair of ultraviolet light-induced damage (XPA-XPG)</td>
<td>SCCa of tongue (increase 100,000x in XP patients &lt; 20 years compared to general population)</td>
<td></td>
</tr>
<tr>
<td>Bloom syndrome</td>
<td>BLM (a tumor-suppressor gene belonging to the family of RecQ DNA helicase)</td>
<td>Up to 50% of patients will develop a malignancy; ~10% of patients have ≥ 2 primary cancers, with fewer patients reported to have 3, 4, or even 5 primary neoplasms; hematolymphoid malignancies predominant in the first 2 decades of life; carcinomas predominant after the first 2 decades of life and arise in varied sites, e.g., skin, head and neck, gastrointestinal tract (including esophagus [both squamous cell carcinoma and adenocarcinoma], stomach, and colon), lung, uterus, and breast; medulloblastoma, Wilms tumor, osteogenic sarcoma</td>
<td></td>
</tr>
<tr>
<td>Retinoblastoma</td>
<td>RB</td>
<td>Carcinoma of nasal cavity; Retinoblastoma; 2nd cancers common in patients with RB mutations (i.e., osteosarcoma, leiomyosarcoma, fibrosarcoma, chondrosarcoma, rhabdomyosarcoma, Ewing sarcoma, melanoma, pinealoblastoma, Hodgkin lymphoma, breast carcinoma)</td>
<td></td>
</tr>
<tr>
<td>NF2</td>
<td>NF2</td>
<td>Vestibular schwannoma: Bilateral vestibular schwannomas a hallmark of NF2 (90-95% of patients); Plexiform schwannoma (features occurring more frequently in NF2-associated schwannomas include whorl formation, multiple tumors involving a single nerve, and juxtaposition to meningioma), neurofibroma, meningoma,</td>
<td></td>
</tr>
<tr>
<td>Basal cell nevus PTTCH1 syndrome (Gorlin syndrome)</td>
<td>Odontogenic cysts, dentigerous cysts</td>
<td>ependymoma, conventional MPNST and MPNST ex-schwannomas reported in NF2 but very rare</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>-------------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Triggers that should prompt evaluation for Gorlin syndrome: Odontogenic keratoctyes if age &lt; 20 years old, basal cell carcinoma if age &lt; 20 years old, palmar or plantar pits, lamellar calcification of falx cerebri, medulloblastoma, desmoplastic, characteristic facies with broad nasal root (and hypertelorism), numerous tumors, including basal cell carcinoma, medulloblastoma, meningoma, ovarian fibroma, cardiac fibroma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPTH-jaw tumor HRPT2 syndrome</td>
<td>Fibroma of the jaw, ossifying fibroma of the jaw</td>
<td>Hyperparathyroidism develops late in adolescence in &gt; 80% of patients: Parathyroid hyperplasia, adenoma, and carcinoma; renal cysts, hamartomas, and cortical adenomas; Wilms tumor; testicular germ cell tumor; papillary thyroid carcinoma, and other neoplasms</td>
<td></td>
</tr>
<tr>
<td>FAP APC</td>
<td>Juvenile nasopharyngeal angiofibroma</td>
<td>≥ 100 colorectal adenomas (classical FAP), fundic gland polyps, antral adenomas, gastric cancer (rare), hepatoblastomas in male infants, hepatic adenomas and hepatocellular carcinomas, pancreatic adenocarcinoma and intraductal mucinous neoplasms of pancreas, adenocarcinoma of gallbladder, fibromatosis, multiple osteomas, congenital hypertrophy of the retinal pigmented epithelium, cribriform-morular variant of papillary thyroid carcinoma</td>
<td></td>
</tr>
</tbody>
</table>

AML: Acute myeloid leukemia; FAP: Familial adenomatous polyposis; HPTH: Hyperparathyroidism; MDS: Myelodysplastic syndrome; MPNST: Malignant peripheral nerve sheath tumor; NF2: Neurofibromatosis type 2; SCCa: Squamous cell carcinoma; XP: Xeroderma pigmentosum.

P.III(4):3

Image Galley
Diagrammatic, Clinical, and Gross Features
Bilateral schwannomas involving the vestibular branch of cranial nerve 8 are a hallmark of neurofibromatosis type 2, present as a cerebellopontine angle mass. These may be multiple. (Right) Squamous cell carcinoma on the posterior lateral border of the tongue in a patient with dyskeratosis congenita presents as an exophytic, firm, indurated mass with rolled borders. (Courtesy S. Muller, DMD.)

Axial graphic shows retinoblastoma with lobulated tumor extending through the limiting membrane into the vitreous. Punctate calcifications are characteristic. Hereditary retinoblastoma patients may develop carcinoma of the nasal cavity. (Right) Lateral graphic of the mandible (buccal cortex removed) illustrates features of a classic keratocytic odontogenic tumor, splaying roots of the 1st and 2nd molar teeth, displacing the inferior alveolar nerve.
Nonossifying fibroma shows a large, well-demarcated maxillary mass with mixed calcification and fibrosis. Note that the mass obstructs 1 side of the nose and compresses the eye in a patient with hyperparathyroidism-jaw tumor syndrome. (Right) Multiple thyroid tumors in a patient with familial adenomatous polyposis show white firm nodules in both thyroid lobes. The patient also had a juvenile nasopharyngeal angiofibroma.

## Salivary Glands

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Gene</th>
<th>Inheritance</th>
<th>Familial Cancer Syndromes</th>
<th>Salivary Gland Neoplasms</th>
<th>Other Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSS and FC</td>
<td>CYLD</td>
<td>AD</td>
<td>Basal cell adenoma, membranous type</td>
<td>Dermal cylindroma, trichoepithelioma, and eccrine spiradenoma</td>
<td></td>
</tr>
<tr>
<td>VHL</td>
<td>VHL</td>
<td>AD</td>
<td>Mucoepidermoid carcinoma</td>
<td>Retinal and central nervous system hemangioblastoma; pheochromocytoma; renal cysts and renal cell carcinoma; pancreatic cysts, cystadenoma, carcinoma, and islet cell tumor; hepatic cysts; papillary cystadenoma of epididymis (men) and broad ligament (women); FATWO; endolymphatic sac tumor</td>
<td></td>
</tr>
<tr>
<td>AT</td>
<td>ATM</td>
<td>AR</td>
<td>Mucoepidermoid carcinoma and acinic cell carcinoma</td>
<td>Cerebellar ataxia-telangiectasia; hematolymphoid malignancies (B-cell lymphoma, ALL, chronic lymphocytic leukemia); gastric cancer (associated with IgA-deficient men); medulloblastoma; basal cell carcinoma; glioma; uterine cancer; ovarian dysgerminoma; heterozygotes show increased risk for breast cancer in younger women, colorectal cancer, gastric cancer, and T-cell ALL</td>
<td></td>
</tr>
<tr>
<td>RB</td>
<td>RB1</td>
<td>AD</td>
<td>Mucoepidermoid carcinoma</td>
<td>Osteosarcoma; pinealoblastoma; melanoma, nasal cavity cancers; leiomyosarcoma; fibrosarcoma; chondrosarcoma; rhabdomyosarcoma; Ewing sarcoma; leukemia and lymphoma; malignant</td>
<td></td>
</tr>
</tbody>
</table>
phyllodes tumor; some tumors may be due in part to radiation therapy for retinoblastoma


1 Strong etiologic association of membranous type of basal cell adenoma with BSS and FC based on multiple reports.

2 Etiologic association with VHL disease is unclear; single case from authors' institution.

3 Etiologic association with AT is unclear; 2 case reports in literature.

4 Etiologic association with RB is unclear; 1 case report in literature.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Case Reports of Salivary Gland Neoplasms With Familial Clustering</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Affected Family Members (Age in Years at Diagnosis)</td>
</tr>
<tr>
<td></td>
<td>Comment</td>
</tr>
<tr>
<td><strong>Pleomorphic Adenoma</strong></td>
<td></td>
</tr>
<tr>
<td>Ahn MS et al (1999)</td>
<td>Sister (51), sister (age N/A)</td>
</tr>
<tr>
<td>Klausner RD and Handler SD (1993)</td>
<td>Brother (11), sister (15)</td>
</tr>
<tr>
<td>Hayter JP and Robertson JM (1990)</td>
<td>Brother (27), brother (29)</td>
</tr>
<tr>
<td>Cameron JM (1959)</td>
<td>Father (51), son (21), daughter (21)</td>
</tr>
<tr>
<td>Warthin Tumor</td>
<td>Twin brothers (45, 47)</td>
</tr>
<tr>
<td>Gallego et al (2010)</td>
<td>Mother (73), son (51)</td>
</tr>
<tr>
<td>Russo et al (1999)</td>
<td>3 brothers (ages N/A)</td>
</tr>
<tr>
<td>Talmi et al (1994)</td>
<td>Mother (76), son (57)</td>
</tr>
<tr>
<td>Noyek et al (1980)</td>
<td>3 brothers (ages N/A)</td>
</tr>
<tr>
<td>Skerlavay et al Brother (69), brother (1976)</td>
<td>Twin brothers (45, 47)</td>
</tr>
<tr>
<td><strong>Acinic Cell Carcinoma</strong></td>
<td></td>
</tr>
<tr>
<td>Delides et al (2005)</td>
<td>Father (89), son (64), Son (64) with bilateral acinic cell carcinoma; other conditions in family include pituitary adenoma, oncocytic adenoma of parotid, Warthin tumor</td>
</tr>
<tr>
<td>Depowski et al Father (35), daughter (1999)</td>
<td>Family of 3 brothers (ages N/A)</td>
</tr>
<tr>
<td><strong>Mucoepidermoid Carcinoma</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Low-Grade Neuroendocrine Carcinoma</strong></td>
<td></td>
</tr>
</tbody>
</table>

1079
Tumors in siblings were composed primarily of cells with neuroendocrine differentiation, admixed with ductal and myoepithelial cells; histology of mother's tumor not reported; other conditions in family include vestibular schwannoma, sensorineural hearing loss, amelogenesis imperfecta

Other conditions in family include trichoepitheliomas, eccrine spiradenomas, cylindromas

Likely EBV related, but suspect additional genetic predisposition; other conditions in family include uterine cervical cancer, nasopharyngeal carcinoma, malignant neck mass (NOS) in maternal grandfather

EBV: Epstein-Barr virus; N/A: Not available. Case reports of salivary gland neoplasms showing familial clustering (without a known germline mutation) are summarized in this table.

<table>
<thead>
<tr>
<th>Tumor</th>
<th>Locus</th>
<th>Implicated Gene(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pleomorphic adenoma</td>
<td>8q12 translocations [t(3;8)p21;q12 is most common]</td>
<td>Fusion transcripts involving PLAG1</td>
</tr>
<tr>
<td>Carcinoma ex pleomorphic adenoma</td>
<td>12q14-15 translocations [t(9;12)(p12-22;q13-15) is most common]</td>
<td>Fusion transcripts involving HMGA2 (also known as HMGIC)</td>
</tr>
<tr>
<td>Mammary analogue secretory carcinoma</td>
<td>t(12;15)(p13;q25)</td>
<td>ETV6-NTRK3 fusion</td>
</tr>
<tr>
<td>Mucoepidermoid carcinoma</td>
<td>t(11;19)(q21;p13) and losses of 2q, 5p</td>
<td>MECT1-MAML2 fusion (MECT1 is also known as CRTC1, TORC1, and WAMTP1)</td>
</tr>
<tr>
<td>Warthin tumor</td>
<td>12p, 16p</td>
<td></td>
</tr>
<tr>
<td>Adenoid cystic carcinoma</td>
<td>t(6;9)(q22-23;p23-24); LOH at 6q23-q25; and loss of 12q12-q13</td>
<td>MYB-NFIB fusion</td>
</tr>
<tr>
<td>Acinic cell carcinoma</td>
<td>Deletions of 6q; loss of Y; trisomy 8; and LOH at 4p, 5q, 6p, 17p</td>
<td></td>
</tr>
<tr>
<td>Polymorphous low-grade adenocarcinoma</td>
<td>12q12-q13, 12q22, or 12p12.3 translocations</td>
<td></td>
</tr>
<tr>
<td>Salivary duct carcinoma</td>
<td>LOH at 9p21, 6q, 17p, 17q</td>
<td></td>
</tr>
</tbody>
</table>

LOH: Loss of heterozygosity. This table summarizes cytogenetic changes that have been observed in salivary gland neoplasms. Most of these cases represent somatic mutations in sporadic salivary gland tumors and are included here for reference.
(Left) This basal cell adenoma, membranous type, was resected from the parotid gland of a patient with multiple dermal cylindromas. The tumor has multinodular architecture and is encased by dense fibrous stroma. (Right) Another area of the basal cell adenoma shows dense collagen bands and multiple tumor nodules. Within the nodules are nests of basaloid cells that are surrounded by eosinophilic hyaline material and arranged in a jigsaw puzzle-like pattern.

(Left) On higher magnification, this membranous-type basal cell adenoma shows drop-like eosinophilic hyaline material of variable sizes and shapes in addition to the rim of basement membrane-like material separating the nests of basaloid cells. (Right) The basaloid cells in the centers of the nests are larger with fine chromatin; those at the periphery appear smaller with hyperchromatic nuclei. Peripheral palisading of the tumor cells is seen.
(Left) This Romanowsky-stained, air-dried smear from a fine-needle aspiration of basal cell adenoma shows a sheet of medium-sized basaloïd cells with a peripheral rim of hyaline material. (Right) Other areas of the smear showed multiple droplets of magenta-colored extracellular matrix material surrounded by basaloïd tumor cells.

P.III(4):7

Microscopic Features

(Left) In addition to basal cell adenoma in the parotid gland, this patient had multiple cutaneous cylindromas. This low-power view shows multiple nodules of basaloïd cells in the dermis. (Right) This cylindroma from the same patient shows a typical jigsaw puzzle-like pattern (lower left) in addition to a more diffuse pattern that overlaps with eccrine spiradenoma.
Higher magnification highlights the hyaline droplets and peripheral palisading of the basaloid cells. The upper portion of the tumor shows cords of basaloid cells and increased stromal hyalinization. A sweat duct lumen is present. (Right) The basaloid cytology and peripheral palisading of the tumor cells are highlighted. The tumor nests are separated by hyaline material and appear identical to the membranous-type basal cell adenoma in the patient’s parotid.

This low-grade mucoepidermoid carcinoma was resected from the parotid gland of a patient with von Hippel-Lindau disease. On low magnification, a cystic space lined by epidermoid and mucous cells is present. A prominent lymphoid infiltrate is present. Parotid parenchyma is present at the top of the image. (Right) Multiple mucocytes are supported by sheets of epidermoid/intermediate cells with a transitional or squamous metaplastic appearance.

Section 5 - Endocrine
Adrenal Cortex

<table>
<thead>
<tr>
<th>Clinical Settings Associated With Cytomegalic Cells</th>
<th>Diffusely Scattered Cytomegalic Cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>Focal Cytomegalic Cells (Variably Present)</td>
<td>Beckwith-Wiedemann syndrome</td>
</tr>
<tr>
<td>Extensive hemolysis</td>
<td>X-linked congenital adrenal hypoplasia</td>
</tr>
<tr>
<td>Rhesus isoimmunization</td>
<td></td>
</tr>
<tr>
<td>Congenital lupus erythematosus</td>
<td></td>
</tr>
<tr>
<td>Erythropoietic purpura</td>
<td></td>
</tr>
</tbody>
</table>
Nonimmune hydrops
Trisomy 13 and 18
Diaphragmatic hernia
Ectopic adrenal tissue
Intrauterine viral infections

<table>
<thead>
<tr>
<th>Neoplasm</th>
<th>Differential Diagnosis of Adrenal Cortical Adenoma</th>
<th>Immunohistochemistry of Adrenal Cortical Adenomas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenal cortical adenoma</td>
<td>Inhibin Positive Melan-A Positive ChromograninA Synaptophysin Par1 Positive (57%)</td>
<td>Antibody Reactivity Staining Pattern Comment</td>
</tr>
<tr>
<td>Pheochromocytoma</td>
<td>Inhibin Negative Melan-A Negative ChromograninA Positive Synaptophysin Par1 Negative</td>
<td>Inhibin Positive (57%) Cell membrane and cytoplasm Helps to differentiate from pheochromocytoma</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>Inhibin Negative Melan-A Negative ChromograninA Negative Synaptophysin Par1 Negative</td>
<td>Mart-1 Positive Cytoplasmic Helps to differentiate from other epithelial tumors</td>
</tr>
<tr>
<td>Renal cell carcinoma</td>
<td>Inhibin Negative Melan-A Negative ChromograninA Negative Synaptophysin Par1 Negative</td>
<td>Melan-A103 Positive Cytoplasmic Helps to differentiate from other epithelial tumors</td>
</tr>
</tbody>
</table>

**Clinical Features Suggesting Familial Adrenal Cortical Carcinoma**

**Personal History**
- Metachronous ACC
- Bilateral ACC
- Multiple primary tumors in other organs
- Other rare cancers

**Family History**
- Family history of ACC
- Family history of known hereditary cancer susceptibility syndromes
- Unusually high number of family members affected with cancer
- Family history of other rare cancers

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Reactivity Staining Pattern</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhibin</td>
<td>Positive</td>
<td>Cell membrane and cytoplasm</td>
</tr>
<tr>
<td>Mart-1</td>
<td>Positive</td>
<td>Cytoplasm</td>
</tr>
<tr>
<td>Melan-A103</td>
<td>Positive</td>
<td>Cytoplasm</td>
</tr>
<tr>
<td>Chromogranin-A</td>
<td>Negative</td>
<td>Helps to differentiate from pheochromocytoma</td>
</tr>
<tr>
<td>CK7</td>
<td>Negative</td>
<td>Helps to differentiate from other epithelial tumors</td>
</tr>
<tr>
<td>CK20</td>
<td>Negative</td>
<td>Helps to differentiate from other epithelial tumors</td>
</tr>
<tr>
<td>AE1/AE3</td>
<td>Negative</td>
<td>Helps to differentiate from other epithelial tumors</td>
</tr>
<tr>
<td>EMA</td>
<td>Negative</td>
<td>Helps to differentiate from other epithelial tumors</td>
</tr>
<tr>
<td>CD10</td>
<td>Negative</td>
<td>Helps to differentiate from renal cell carcinoma</td>
</tr>
<tr>
<td>Hep-Par1</td>
<td>Negative</td>
<td>Helps to differentiate from hepatocellular carcinoma</td>
</tr>
<tr>
<td>HMFG</td>
<td>Negative</td>
<td></td>
</tr>
<tr>
<td>RCC</td>
<td>Negative</td>
<td>Helps to differentiate from renal cell carcinoma</td>
</tr>
<tr>
<td>HMB-45</td>
<td>Negative</td>
<td></td>
</tr>
</tbody>
</table>
Other congenital defects

*ACC:* Adrenal cortical carcinoma.

### Criteria for Differentiation Between Adenoma and Carcinoma

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Adenoma</th>
<th>Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hormone production</td>
<td>Often functional</td>
<td>Usually nonfunctional</td>
</tr>
<tr>
<td>Gross</td>
<td>Weight &lt; 50 g</td>
<td>Weight &gt; 100 g</td>
</tr>
<tr>
<td>Tumor gross color</td>
<td>Variable</td>
<td>Variable; does not differentiate</td>
</tr>
<tr>
<td>Circumscription</td>
<td>Well circumscribed</td>
<td>Invasive</td>
</tr>
<tr>
<td>Hemorrhage</td>
<td>Absent</td>
<td>Frequent</td>
</tr>
<tr>
<td>Necrosis</td>
<td>Absent</td>
<td>Frequent</td>
</tr>
<tr>
<td>Capsular invasion</td>
<td>Absent</td>
<td>Usually present</td>
</tr>
<tr>
<td>Invasion into adjacent tissues</td>
<td>Absent</td>
<td>Usually present</td>
</tr>
<tr>
<td>Intratumoral fibrosis</td>
<td>May be present</td>
<td>May be present</td>
</tr>
<tr>
<td>Myxomatous degeneration</td>
<td>May be present</td>
<td>May be present</td>
</tr>
<tr>
<td>Cytology</td>
<td>May have cytologic atypia</td>
<td>Cytologic atypia present</td>
</tr>
<tr>
<td>Histology</td>
<td>Atypia may be present</td>
<td>Atypia present</td>
</tr>
<tr>
<td>Necrosis</td>
<td>Necrosis absent</td>
<td>Present; confluent necrosis</td>
</tr>
<tr>
<td>Mitosis</td>
<td>Rare</td>
<td>&gt; 5/50 HPF</td>
</tr>
<tr>
<td>Venous invasion</td>
<td>Absent</td>
<td>Present</td>
</tr>
</tbody>
</table>

### Adrenal Cortical Tumor as Part of Inherited Tumor Syndromes

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Gene</th>
<th>Chromosomal Location</th>
<th>Adrenal Pathology</th>
<th>% Adrenal Involvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Li-Fraumeni</td>
<td><em>TP53</em></td>
<td>17p13</td>
<td>ACC</td>
<td>6.5-9.9%</td>
</tr>
<tr>
<td>Beckwith-Wiedemann</td>
<td><em>CDKN1C/NSD1</em></td>
<td>11p15.5</td>
<td>ACA, ACC, NH</td>
<td>1.0%</td>
</tr>
<tr>
<td>MEN1</td>
<td><em>MEN1</em></td>
<td>11q13</td>
<td>ACA, ACC</td>
<td>45-55%</td>
</tr>
<tr>
<td>Carney complex</td>
<td><em>PRKAR1A</em></td>
<td>2p16</td>
<td>PPNAD, ACA</td>
<td>~ 100%</td>
</tr>
<tr>
<td>McCune-Albright</td>
<td><em>GNAS1</em></td>
<td>20q13.2</td>
<td>NH, ACA</td>
<td></td>
</tr>
<tr>
<td>Congenital adrenal hyperplasia</td>
<td><em>CYP21</em></td>
<td>6p21.3</td>
<td>NH, ACA, ACC</td>
<td></td>
</tr>
<tr>
<td>NF1</td>
<td><em>NF1</em></td>
<td>17</td>
<td>ACC</td>
<td></td>
</tr>
<tr>
<td>FAP</td>
<td><em>APC</em></td>
<td>5q21-22</td>
<td>ACA, functional or nonfunctional; ACC</td>
<td>7.4-13%</td>
</tr>
<tr>
<td>HNPCC</td>
<td><em>MLH1, MSH2, MSH6, PMS2</em></td>
<td>Multiple</td>
<td>ACC</td>
<td></td>
</tr>
</tbody>
</table>

ACA: Adrenal cortical adenoma; ACC: Adrenal cortical carcinoma; FAP: Familial adenomatous polyposis; HNPCC: Hereditary nonpolyposis colon cancer; MEN1: Multiple endocrine neoplasia type 1; NF1: Neurofibromatosis type 1; NH: Nodular hyperplasia; PPNAD: Primary pigmented nodular adrenal disease.

### Pathology Findings and Syndromes Involving Adrenal Cortex

<table>
<thead>
<tr>
<th>Adrenal Pathology</th>
<th>Syndrome Associated With Pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenal cortical adenoma</td>
<td>MEN1, McCune-Albright Syndrome, Beckwith-Wiedemann syndrome, congenital adrenal hyperplasia, Carney complex</td>
</tr>
<tr>
<td>Adrenal cortical carcinoma</td>
<td>MEN1, Beckwith-Wiedemann syndrome, Li-Fraumeni syndrome Carney complex</td>
</tr>
<tr>
<td>Primary pigmented adrenal cortical disease</td>
<td>MEN1, McCune-Albright syndrome, Beckwith-Wiedemann syndrome, congenital adrenal hyperplasia</td>
</tr>
<tr>
<td>Macronodular hyperplasia</td>
<td>MEN1, McCune-Albright syndrome, Beckwith-Wiedemann syndrome, congenital adrenal hyperplasia</td>
</tr>
</tbody>
</table>

1085
**MEN1: Multiple endocrine neoplasia 1.**

P.III(5):4

**Image Galley**

**Gross Features of Adrenal Cortical Lesions**

(Left) Sections of the adrenal gland with primary pigmented adrenal nodular disease in a patient with Carney complex may appear almost unremarkable, with the exception of rare pigmented micronodules. The outer surface may have a micronodular contour. (Right) Sections of the adrenal gland are studded with pigmented micronodules and occasional macronodules that are due to confluence of smaller nodules. The outer surface has an irregular micronodular contour.

(Left) This coronal graphic demonstrates an adrenal cortical adenoma. The tumor is < 5 cm in greatest dimension, without invasion of kidney or other adjacent organs. (Right) Cross section of a cortisol-secreting adrenal cortical adenoma shows the typical round, well-circumscribed golden-yellow appearance. This tumor also has an area of dark discoloration that can be attributed to an old hemorrhage.
A cross section through an adrenal mass shows the classic “canary yellow” color of an aldosterone-producing adenoma. Another characteristic of these tumors is the pushing borders. This cross section shows classical findings in aldosterone-producing tumors. A round, small, and well-circumscribed mass has pushing borders. Also seen is hyperplasia of the zona glomerulosa located at the nontumoral adrenal gland, frequently present in aldosterone-secreting adenomas.

Gross Features of Adrenal Tumors

This well-circumscribed adrenal cortical adenoma demonstrates a mottled appearance with areas of dark discoloration due to the compact eosinophilic cytoplasm of the tumor cells by lipid depletion and increased lipofuscin pigment. Note the marked atrophy of the adjacent adrenal cortex. (Right) Adrenal cortical adenoma in Cushing syndrome has a yellow-orange cut surface and mottled zones of dark pigmentation due to lipofuscin accumulation and depletion of lipid.
Adrenal cortical carcinomas tend to be large, usually > 5 cm with irregular and invasive borders, and are usually unilateral. This graphic shows direct extension into the vena cava. (Right) Adrenal cortical carcinoma tends to appear grossly as a large solid mass in the suprarenal region. Focal areas of necrosis and hemorrhage are present.

(Left) This pediatric adrenal cortical carcinoma has a yellow, pink to light-brown variegated cut surface with extensive areas of necrosis, degenerative changes, and hemorrhagic areas. (Right) This adrenal cortical carcinoma presented as an irregular shaped, bulky, unilateral mass and has a light-brown variegated cut surface. Note also extensive necrosis, degenerative changes, hemorrhage, and calcification.

### Adrenal Medulla

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Gene</th>
<th>Tumors in Paranglia</th>
<th>Associated Neoplasms</th>
<th>Relative Frequency of PCC/PGL (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Familial PGL 1</td>
<td>SDHD</td>
<td>Multiple H&amp;N PGL</td>
<td>Thyroid</td>
<td>5-6</td>
</tr>
<tr>
<td>Familial PGL 2</td>
<td>SDHAF2</td>
<td>Multiple H&amp;N PGL</td>
<td>Unknown</td>
<td>&lt; 1</td>
</tr>
<tr>
<td>Familial PGL 3</td>
<td>SDHC</td>
<td>Multiple PGL</td>
<td>Unknown</td>
<td>1</td>
</tr>
<tr>
<td>Familial PGL 4</td>
<td>SDHB</td>
<td>Single PGL</td>
<td>Renal cell carcinoma</td>
<td>6-8</td>
</tr>
<tr>
<td>Familial SDHA-related</td>
<td>SDHA</td>
<td>Predominant extraadrenal PGL</td>
<td>GIST</td>
<td>Rare</td>
</tr>
<tr>
<td>-----------------------</td>
<td>------</td>
<td>-----------------------------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>Carney-Stratakis syndrome</td>
<td>SDHB, SDHC, SDHD</td>
<td>Predominant extraadrenal PGL</td>
<td>GIST</td>
<td>Rare</td>
</tr>
<tr>
<td>MEN2</td>
<td>RET</td>
<td>Predominant adrenal Pheo</td>
<td>Medullary thyroid carcinoma, 5-6 parathyroid adenoma or hyperplasia</td>
<td>5-6</td>
</tr>
<tr>
<td>von Hippel-Lindau</td>
<td>VHL</td>
<td>Predominant adrenal Pheo</td>
<td>Renal cell carcinoma, hemangioblastomas</td>
<td>9-12</td>
</tr>
<tr>
<td>Neurofibromatosis type 1</td>
<td>NF1</td>
<td>Predominant adrenal Pheo</td>
<td>Neurofibroma, glioma, other tumors</td>
<td>1-2</td>
</tr>
<tr>
<td>Familial Pheo 2q</td>
<td>TMEM127</td>
<td>Predominant adrenal Pheo</td>
<td>Unknown</td>
<td>1.7-2</td>
</tr>
<tr>
<td>Familial MAX-related</td>
<td>MAX</td>
<td>Predominant adrenal Pheo</td>
<td>Unknown</td>
<td>1.2</td>
</tr>
<tr>
<td>Familial KIF1B-related</td>
<td>KIF1B</td>
<td>Predominant adrenal Pheo</td>
<td>Neuroblastoma, medulloblastoma</td>
<td>Rare</td>
</tr>
<tr>
<td>Familial PHD2-related</td>
<td>PHD2</td>
<td>Unknown</td>
<td>Erythrocytosis</td>
<td>Rare</td>
</tr>
</tbody>
</table>

GIST: Gastrointestinal stromal tumor; H&N: Head and neck; PGL: Paraganglioma; Pheo: Pheochromocytoma.

Image Galley

Adrenal Medullary Hyperplasia and Pheochromocytoma

(Left) Adrenal medullary hyperplasia in a patient with MEN2 syndrome shows medullary cells within the adrenal cortex. The presence of hyaline granules is usually present in MEN2. (Right) Bilateral adrenal medullary hyperplasia is a precursor of pheochromocytomas and was initially described in patients with MEN2A and MEN2B syndromes. This figure shows medullary adrenal hyperplasia composed of large cells with basophilic granular cytoplasm.
Abdominal lesions in von Hippel-Lindau are varied and include bilateral renal cysts, renal tumors, particularly renal cell carcinoma, pancreatic cysts, and pheochromocytoma. (Right) This pheochromocytoma has the characteristic alveolar pattern (zellballen) with variably sized nests of tumor cells surrounded by thin-walled vessels and thin bands of fibrous tissue.

Some pheochromocytomas lack the organoid pattern and instead may show a diffuse growth pattern composed of small cells with ample eosinophilic cytoplasm with occasional bizarre cells. (Right) Some pheochromocytomas show a mosaic-like pattern of often large cells with granular basophilic cytoplasm admixed with cells that have amphophilic to slightly eosinophilic cytoplasm.

### Pancreas

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Reactivity</th>
<th>Staining Pattern</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synaptophysin</td>
<td>Positive</td>
<td>Cell membrane &amp; cytoplasm</td>
<td>Nearly every tumor cell is positive; SPT and ACC may be focally positive</td>
</tr>
<tr>
<td>PGP9.5</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>Nearly every tumor cell is positive</td>
</tr>
<tr>
<td>NSE</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>Very low specificity</td>
</tr>
<tr>
<td>CD56</td>
<td>Positive</td>
<td>Cell membrane &amp; cytoplasm</td>
<td>Usually accentuated on cell membrane</td>
</tr>
<tr>
<td>Chromogranin-A</td>
<td>Positive</td>
<td>Cytoplasmic</td>
<td>Granular reactivity, a reflection of neurosecretory granules; less staining in less granulated tumors; SPT</td>
</tr>
</tbody>
</table>
### Criteria for the Clinicopathological Classification of Tumors of the Endocrine Pancreas

<table>
<thead>
<tr>
<th>WHO Tumor Type</th>
<th>Criteria for Clinicopathological Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Well-differentiated endocrine tumor: Benign behavior</td>
<td>Confined to pancreas; &lt; 2.0 cm in diameter; &lt; 2 mitoses/10 HPF, &lt; 2% Ki-67 proliferative index; no lymphovascular invasion; no perineural invasion</td>
</tr>
<tr>
<td>Well-differentiated endocrine tumor: Uncertain behavior</td>
<td>Confined to pancreas and 1 or more of the following features: &gt; 2.0 cm in diameter; 2-10 mitoses/10 HPF, &gt; 2% Ki-67 proliferative index; lymphovascular invasion, perineural invasion</td>
</tr>
<tr>
<td>Well-differentiated endocrine carcinoma</td>
<td>Gross local invasion &amp;/or metastases; low-grade malignant</td>
</tr>
<tr>
<td>Poorly differentiated endocrine carcinoma (small cell carcinoma)</td>
<td>High-grade malignant; &gt; 10 mitoses/10 HPF</td>
</tr>
<tr>
<td>Mixed endocrine-exocrine carcinoma</td>
<td>Malignant mixed neoplasm in which endocrine and exocrine cells are intimately admixed (each component comprises at least 1/3 of tumor)</td>
</tr>
</tbody>
</table>


---

### Comparison of Different Features of Endocrine Pancreatic Tumors and Their Differential Diagnoses

<table>
<thead>
<tr>
<th>Clinical Features</th>
<th>Solid Pseudopapillary Neoplasm</th>
<th>Pancreatic Endocrine Neoplasm</th>
<th>Acinar Cell Carcinoma</th>
<th>Pancreatoblastoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Young adults</td>
<td>50-70 years; younger in MEN1</td>
<td>50-60 years</td>
<td>Children &lt; 10 years</td>
</tr>
<tr>
<td>Gender</td>
<td>Female</td>
<td>Equal gender distribution</td>
<td>Slight male predominance</td>
<td>Slight male predominance</td>
</tr>
<tr>
<td>Gross</td>
<td>Circumscribed; variegated, hemorrhagic, solid, and cystic</td>
<td>Circumscribed, usually solid</td>
<td>Circumscribed, soft with abundant hemorrhage</td>
<td>Circumscribed and lobulated, soft and fleshy</td>
</tr>
<tr>
<td>Microscopic</td>
<td>Pseudopapillae, necrosis, polygonal epithelial cells with eosinophilic to clear cytoplasm, uniform, round to oval nuclei with grooves, intracytoplasmic and extracytoplasmic hyaline globules</td>
<td>Trabecular, nested pattern; densely hyalinized stroma; cells are polygonal with amorphophilic cytoplasm; round to oval, uniform in sizeeosinophilic and shape of nuclei; classic coarsely stippled salt-and-</td>
<td>Tumor is arranged in cellular lobules separated by bands of collagenized stroma; acinar formation; granular cytoplasm; uniform cells</td>
<td>Lighter- and darker-staining cells, reflecting different cell types of pancreatoblastoma; acinar formation and squamoid corpuscles; hypercellular stromal</td>
</tr>
</tbody>
</table>
Cytology

<table>
<thead>
<tr>
<th>Cytology Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Papillary fragments; cytoplasmic vacuoles, nuclear grooves</td>
</tr>
<tr>
<td>Cellular, monotonous, small or medium-sized cells; granular chromatin and plasmacytoid morphology</td>
</tr>
<tr>
<td>Prominent acinar formation, cells with granular cytoplasm</td>
</tr>
<tr>
<td>Primitive stromal elements, squamoid corpuscles</td>
</tr>
</tbody>
</table>

Positive IHC markers

<table>
<thead>
<tr>
<th>Positive IHC markers</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-catenin, progesterone receptor, CD10, cyclin-D1</td>
</tr>
<tr>
<td>Chromogranin, synaptophysin, CD56</td>
</tr>
<tr>
<td>Trypsin, chymotrypsin</td>
</tr>
<tr>
<td>Markers of acinar, endocrine, and ductal differentiation</td>
</tr>
</tbody>
</table>

Pancreatic Tumor as Part of Inherited Tumor Syndrome

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Gene</th>
<th>Pancreatic Pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multiple endocrine neoplasia 1</td>
<td>MEN1</td>
<td>Islet cell hyperplasia, nesidioblastosis, and dysplasia; pancreatic endocrine tumors (e.g., Zollinger-Ellison syndrome, insulinoma, glucagonoma, VIPoma); usually associated with nesidioblastosis and microadenomas</td>
</tr>
<tr>
<td>von Hippel-Lindau syndrome</td>
<td>VHL</td>
<td>Pancreatic cysts and endocrine pancreatic tumors; usually functionally inactive with 30-40% with immunoreactivity of somatostatin, glucagon, or insulin; usually not associated with nesidioblastosis or microadenomas; presence of foamy and clear cell changes is characteristic of VHL-associated PET</td>
</tr>
<tr>
<td>Neurofibromatosis type 1</td>
<td>NF1</td>
<td>Somatostatinoma (in pancreas, duodenum, and periampullary region)</td>
</tr>
<tr>
<td>Tuberous sclerosis</td>
<td>TSC1 and TSC2</td>
<td>Benign and malignant pancreatic endocrine tumors, insulinoma</td>
</tr>
</tbody>
</table>

MEN1: Multiple endocrine neoplasia 1; PET: Pancreatic endocrine tumor; VHL: von Hippel-Lindau syndrome.

Genes Involved in Pancreatic Tumorigenesis

<table>
<thead>
<tr>
<th>Gene</th>
<th>% Sporadic Pancreatic Endocrine Tumor With Mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEN1</td>
<td>30% of sporadic PETs have MEN1 mutation; found in 55% of gastrin-producing tumors, 50% of VIP-producing tumors, and 7% of insulin-producing tumors</td>
</tr>
<tr>
<td>VHL</td>
<td>Not found to be involved in the development of sporadic tumors</td>
</tr>
<tr>
<td>NF1</td>
<td>Not found to be involved in the development of sporadic tumors</td>
</tr>
<tr>
<td>TSC1 and TSC2</td>
<td>Not found to be involved in the development of sporadic tumors</td>
</tr>
</tbody>
</table>

PET: Pancreatic endocrine tumor.

Image Galley

Diagrammatic and Microscopic Features
This graphic shows the anatomic relationship of the pancreas to the surrounding organs and vessels. A pancreatic endocrine tumor (PET) is shown in relationship to the lymph nodes seen along the upper border of the pancreas. (Right) Islet dysplasia refers to slightly enlarged islets that contain neuroendocrine cells arranged in trabeculae that display mild atypia and show loss of the normal spatial cellular distribution and numbers of the 4 cell types. This is usually present in patients with MEN1 and VHL.

Two distinct pancreatic endocrine cell proliferations are shown in a case of MEN1. The lesion on the left side of this figure has irregular borders, and the lesion on the right side is well demarcated and larger. (Right) The smaller pancreatic endocrine lesion is uniformly positive for glucagon (microadenoma) whereas the larger lesion shows a pattern of distribution of glucagon similar to a normal island, indicating hyperplasia.
In the pancreata of patients with MEN1, there are typically multiple small (< 5 mm) neuroendocrine tumors, a finding that has been referred to as microadenomatosis. Note the presence of a proliferation of endocrine cells within the acinar component. (Right) Touch imprint from a pancreatic neuroendocrine tumor shows a monotonous population of round cells with eosinophilic cytoplasm and a coarse, “salt and pepper” chromatin.

**Microscopic Features**

(Left) The round monotonous nuclei with a coarse chromatin support the diagnosis of a pancreatic endocrine neoplasm. Note the presence of small amounts of cytoplasm. (Right) This pancreatic endocrine tumor in a 17-year-old young man with MEN1 syndrome is a large tumor associated with islet cell hyperplasia and microadenomas. Note the prominent nucleoli and mitosis.
This well-differentiated PET with a prominent acinar pattern with multifocal intraluminal calcifications is associated with pancreatic cysts in a patient with von Hippel-Lindau (VHL). These tumors are usually inactive, 30-40% with immunoexpression of somatostatin, glucagon, or insulin. High-power view shows the characteristic small to medium-sized cells with an eosinophilic, slightly granular cytoplasm. There is focal fibrosis and a psammoma body.

A pancreatic endocrine neoplasm shows a prominent trabecular architecture. The monotonity of the cells suggests neuroendocrine cell differentiation. The presence of foamy and clear cell changes is characteristic of VHL-associated PET. Multiple pancreatic microadenomas (< 0.5 cm) seen in patients with MEN1 and neurofibromatosis are often accompanied by 1 or more macroadenomas (diameter > 5 mm), some of which may become insulinomas, as seen in this picture.

### Parathyroid

<table>
<thead>
<tr>
<th>Feature</th>
<th>Parathyroid Adenoma</th>
<th>Parathyroid Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms</td>
<td>Usually asymptomatic or vague symptoms</td>
<td>Often symptomatic</td>
</tr>
<tr>
<td>Serum calcium</td>
<td>Elevated</td>
<td>Markedly elevated (&gt; 13 mg/dL)</td>
</tr>
<tr>
<td>Palpable mass</td>
<td>Unusual</td>
<td>Yes</td>
</tr>
<tr>
<td>Tumor size</td>
<td>Enlarged</td>
<td>Larger, but may overlap</td>
</tr>
<tr>
<td>Invasion into adjacent</td>
<td>No (but can have irregular growth and</td>
<td>Yes</td>
</tr>
<tr>
<td>structures</td>
<td>cells in capsule due to degenerative</td>
<td></td>
</tr>
<tr>
<td></td>
<td>features</td>
<td></td>
</tr>
</tbody>
</table>
Fibrous bands & Can be present due to degenerative features & Yes
Perineural invasion & No & Yes
Vascular invasion & No & Yes
Growth pattern & Patterns of growth (follicular, acinar, etc.) & Monotonous, sheet-like growth
Cellular features & Often mixed cell types, can show “endocrine atypia” & Often monotonous cytomorphology, prominent nucleoli
Mitoses & Few, scattered & Yes, more mitoses than adenomas
Proliferation markers (Ki-67, MIB1) & Low & Moderate to high

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Differential Diagnosis: Parathyroid and Thyroid Immunohistochemistry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parathyroid cells and tumors</td>
<td>Keratin (particularly low molecular weight keratins, e.g., CAM5.2)</td>
</tr>
<tr>
<td>Parathyroid carcinomas</td>
<td>Positive</td>
</tr>
<tr>
<td>Thyroid follicular cells and neoplasms</td>
<td>Positive (nuclear staining; may not be as strong as in follicular cells and neoplasms)</td>
</tr>
<tr>
<td>Medullary thyroid carcinoma</td>
<td>Positive (particularly low molecular weight keratins, e.g., CAM5.2)</td>
</tr>
</tbody>
</table>

Differential Diagnosis of Parathyroid Carcinoma

<table>
<thead>
<tr>
<th>Tumor</th>
<th>Chromogranin</th>
<th>Synaptophysin</th>
<th>Parathyroid Hormone</th>
<th>Thyroglobulin</th>
<th>TTF-1</th>
<th>Calcitonin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parathyroid carcinoma</td>
<td>Positive</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td>Medullary thyroid carcinoma</td>
<td>Positive</td>
<td>Negative</td>
<td>Negative</td>
<td>Positive</td>
<td>Positive</td>
<td></td>
</tr>
<tr>
<td>Follicular, Hürthle, or papillary thyroid carcinoma</td>
<td>Negative</td>
<td>Negative</td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
<td></td>
</tr>
<tr>
<td>Metastatic carcinoma</td>
<td>Usually negative</td>
<td>Usually negative</td>
<td>Negative</td>
<td>Negative</td>
<td>Positive/negative</td>
<td>Negative</td>
</tr>
</tbody>
</table>

Differential Diagnosis of Tumors Secondarily Involving Parathyroid Tumor/Tissue Chromogranin Synaptophysin Cytokeratin TTF-1 Calcitonin Other
<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Gene</th>
<th>Locus</th>
<th>Parathyroid Pathology</th>
<th>Associated Tumors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multiple endocrine neoplasia 1</td>
<td>MEN1</td>
<td>11q13</td>
<td>Parathyroid hyperplasia (80%)</td>
<td>Pituitary adenoma, pancreatic endocrine tumors, carcinoid tumors, adrenal cortical tumors, Medullary thyroid carcinoma, pheochromocytoma, Ossifying fibromas of the jaw, renal cysts and renal carcinomas, Wilms tumor</td>
</tr>
<tr>
<td>Multiple endocrine neoplasia 2</td>
<td>RET</td>
<td>10q11.2</td>
<td>Parathyroid hyperplasia (30%)</td>
<td></td>
</tr>
<tr>
<td>Hyperparathyroidism-jaw tumor syndrome</td>
<td>HRPT2</td>
<td>1q25-q32</td>
<td>Cystic parathyroid adenoma; parathyroid carcinoma (15%)</td>
<td></td>
</tr>
<tr>
<td>Familial hypocalciuric hypercalcemia</td>
<td>CASR/heterozygous</td>
<td>3q13.3-q21</td>
<td>Parathyroid hyperplasia, mild</td>
<td></td>
</tr>
<tr>
<td>Neonatal severe primary</td>
<td>CASR/homozygous</td>
<td>3q13.3-q21</td>
<td>Parathyroid hyperplasia</td>
<td></td>
</tr>
<tr>
<td>Hyperparathyroidism</td>
<td></td>
<td></td>
<td>Parathyroid hyperplasia; parathyroid adenoma</td>
<td></td>
</tr>
<tr>
<td>Familial isolated hyperparathyroidism</td>
<td>CASR; HRPT2</td>
<td>3q13.3-q21; 1q25-q32</td>
<td>Parathyroid hyperplasia; parathyroid carcinoma</td>
<td></td>
</tr>
<tr>
<td>Familial hypercalcemic</td>
<td>CASR</td>
<td>3q13.3-q21</td>
<td>Parathyroid hyperplasia; parathyroid adenoma</td>
<td></td>
</tr>
</tbody>
</table>
This axial graphic at the thyroid level depicts the thyroid lobes and the isthmus in the anterior visceral space. The figure also shows 2 normal parathyroid glands in the area of the tracheoesophageal groove. (Right) Cut surface of a parathyroid adenoma shows a homogeneous yellow-orange surface, with focal areas of hemorrhage. A small rim of normal parathyroid is appreciated.

This graphic shows a parathyroid adenoma and a normal parathyroid gland. Parathyroid adenoma is a benign neoplasm and usually affects a single parathyroid gland. (Right) This smear of a parathyroid adenoma composed by oxyphil cells shows a monomorphic population of cells with abundant eosinophilic cytoplasm and round nuclei.
Chief cell parathyroid adenoma shows a rim of normocellular parathyroid tissue. Parathyroid adenomas are usually composed of chief cells. Cells in the rim are usually smaller than those within the adenoma. (Right) Chief cell adenoma with a nested growth pattern shows prominent vascularity. The nuclei are small, round, and dense. The cells show no nuclear pleomorphism or mitosis.

Gross and Microscopic Features of Parathyroid Lesions

Parathyroid hyperplasia is characterized by asymmetric hyperplasia with marked variation in extension of glandular involvement (pseudoadenomatous variant). The asymmetric hyperplasia is easily confused with adenoma or multiple adenomas. (Right) Parathyroid hyperplasia in MEN1 usually shows nodular growth pattern. The nodules are composed of populations of chief cells, which predominate, as well as nodules of oxyphil cells.
In primary parathyroid hyperplasia, ~50% of patients present with symmetric enlargement of all 4 parathyroid glands, as seen in this gross picture, which differs from asymmetric hyperplasia. (Right) Cystic change is particularly common in larger parathyroid adenomas and those associated with hyperparathyroidism-jaw tumor syndrome (HPT-JT). This picture illustrates a chief cell adenoma with cystic changes in a patient with HPT-JT.

![Gross picture of parathyroid adenoma with cystic changes.](image)

![Histological picture of chief cell adenoma with cystic changes.](image)

Cut surface of a parathyroid carcinoma shows a firm yellow nodular surface. Parathyroid carcinomas are usually larger than parathyroid adenoma and show unequivocal capsular invasion, vascular invasion, perineural invasion, or invasion into adjacent structures. (Courtesy L. Erickson, MD.) (Right) Parathyroid carcinoma is characterized by capsular and vascular invasion. This picture illustrates a parathyroid carcinoma tumor invading through the tumor capsule into the vascular space.

![Cut surface of parathyroid carcinoma.](image)

![Histological picture of parathyroid carcinoma with capsular and vascular invasion.](image)

---

### Thyroid, Nonmedullary

<table>
<thead>
<tr>
<th>Disease</th>
<th>Histological Subtype</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTEN hamartoma tumor syndrome (Cowden disease)</td>
<td>FTC associated with follicular adenomas, multiple adenomatous nodules, and C-cell hyperplasia</td>
</tr>
<tr>
<td>FAP hamartoma tumor syndrome</td>
<td>PTC with cribriform and morular pattern with sclerosis</td>
</tr>
</tbody>
</table>
Carney complex
Werner syndrome
Pendred syndrome

**Nonsynornic or Familial Tumor Syndrome with Preponderance of Nonmedullary Thyroid Carcinoma**

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Inheritance</th>
<th>Gene</th>
<th>Gene Location</th>
<th>Thyroid Involvement (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Familial PTC</td>
<td>Autosomal dominant</td>
<td>PTEN</td>
<td>10q23.2</td>
<td>50</td>
</tr>
<tr>
<td>Familial PTC with papillary renal cell neoplasia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Familial nonmedullary thyroid carcinoma type 1</td>
<td>Autosomal recessive</td>
<td>PRKAR1A</td>
<td>2p12-17q22-24</td>
<td>60; 4</td>
</tr>
<tr>
<td>Familial PTC and multinodular goiter</td>
<td>Autosomal recessive</td>
<td>SLC26A4 (pendrin)</td>
<td>7q21-24</td>
<td>1</td>
</tr>
<tr>
<td>Werner syndrome</td>
<td>Autosomal recessive</td>
<td>WRN</td>
<td>8p11-p12</td>
<td>18</td>
</tr>
</tbody>
</table>

**Distinct Characteristics of Familial Thyroid Carcinoma and Sporadic Carcinoma**

<table>
<thead>
<tr>
<th>Gross Characteristics</th>
<th>Familial</th>
<th>Sporadic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Usually multiple tumors</td>
<td>Usually single</td>
<td></td>
</tr>
<tr>
<td>Usually bilateral</td>
<td>Unilateral</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Microscopic Characteristics</th>
<th>Familial</th>
<th>Sporadic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Usually associated with a background of lymphocytic thyroiditis &amp;/or multinodular hyperplasia</td>
<td>Background thyroid usually uninvolved</td>
<td></td>
</tr>
<tr>
<td>Unique morphology in some familial cases: Cribriform morular thyroid carcinoma in familial adenomatous polyposis</td>
<td>All described variants occur</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lymph Node Metastases</th>
<th>Familial</th>
<th>Sporadic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Usually more frequent than sporadic cases</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

P.III(5):23

Image Galley

FAP and PTEN Hamartoma Tumor Syndrome
(Left) Gross cut surface of a cribriform morula variant of papillary thyroid carcinoma (CMV-PTC) in a patient with FAP shows irregular areas of fibrosis and a pale, soft, and friable tumor mass. These tumors are usually multiple and bilateral in a familial setting. (Right) Gross cut surface of a thyroid from an 18-year-old woman with PHTS/Cowden disease shows multiple well-circumscribed nodules almost entirely replacing the thyroid parenchyma with a small amount of residual noninvolved thyroid.

(Left) High-power H&E demonstrates the characteristic peculiar nuclear clearing (PNC) seen within some of the nuclei in CMV-PTC. These PNCs are characteristically found within squamous morules. (Right) This photomicrograph of a thyroid from an 18-year-old woman with PTEN hamartoma tumor syndrome (PHTS) shows multiple well-circumscribed, nonencapsulated, adenomatous nodules with a small amount of compressed residual thyroid parenchyma.
High power of β-catenin immunostain in CMV-PTC demonstrates characteristic nuclear and cytoplasmic staining resulting from aberrant accumulation within the nucleus. Note the negativity of endothelial cells for β-catenin.

Immunohistochemistry for PTEN in a thyroidectomy specimen from an 18-year-old woman with PHTS/Cowden disease shows loss of staining of the follicular cells with preservation of staining of the endothelial cells.

Section 6 - Gastrointestinal
Biliary Tract/Liver/Pancreas

<table>
<thead>
<tr>
<th>Type of Tumor</th>
<th>Possible Syndromes</th>
<th>Gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ampullary adenoma/carcinoma</td>
<td>FAP, MYH, Lynch, Peutz-Jeghers</td>
<td>APC, MYH, MSH1, MSH2, MLH1,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PMS2, LKB1</td>
</tr>
<tr>
<td>Pancreaticobiliary adenocarcinoma</td>
<td>FAP, Lynch, Peutz-Jeghers, juvenile cancer syndrome, familial atypical multiple mole melanoma syndrome, hereditary pancreatitis, Li-Fraumeni</td>
<td>APC, MSH1, MSH2, MLH1, PMS2, LKB1, SMAD4, BMPR1A, ENG, BRCA2, PALB2, BRCA1, P16/CDKN2A, PRSS1, PRSS2, SPINK1, CFTR, TP53, CHEK2, MEN1, VHL, TSC1, TSC2</td>
</tr>
<tr>
<td>Pancreatic endocrine tumor</td>
<td>Multiple endocrine neoplasia 1, von Hippel-Lindau disease, tuberous sclerosis</td>
<td></td>
</tr>
<tr>
<td>Hepatocellular adenoma/carcinoma</td>
<td>FAP, hemochromatosis, tyrosinemia, citrullinemia, α-1-antitrypsin deficiency, glycogen storage disease, Alagille, progressive familial intrahepatic cholestasis</td>
<td>APC, HFE, FAH, HPD, LAT, SLC25A13, ASS1, SERPINA1, G6PC, AGL, PYGL, JAG1, NOTCH2, ATP8B1, ABCB11, MDR3</td>
</tr>
<tr>
<td>Hepatoblastoma</td>
<td>FAP, Li-Fraumeni</td>
<td>APC, TP53, CHEK2</td>
</tr>
</tbody>
</table>

FAP: Familial adenomatous polyposis.

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Gene(s)</th>
<th>Inheritance Tumor Pattern</th>
<th>Other Manifestations</th>
</tr>
</thead>
</table>

P.III(6):3
<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Genes</th>
<th>Inheritance</th>
<th>Tissues and Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>FAP</td>
<td>APC</td>
<td>Autosomal dominant</td>
<td>Ampullary adenomas and adenocarcinomas, hepatoblastoma, hepatic adenoma, hepatocellular carcinoma, pancreatic and biliary tract adenocarcinomas, Multiple colonic adenomas and carcinomas, gliomas, desmoids, CHRPE, osteomas and jaw cysts, adrenal cortical neoplasms, papillary thyroid carcinoma, cribriform-morular variant, parathyroid and pituitary adenomas</td>
</tr>
<tr>
<td>Peutz-Jeghers syndrome</td>
<td>LKB1</td>
<td>Autosomal dominant</td>
<td>Ampullary, biliary, and pancreatic adenocarcinomas Hamartomatous polyps of the GI tract, adenocarcinoma of the colon, ovarian sex cord tumor with annular tubules, adenoma malignum of cervix, mucinous tumors of ovaries and fallopian tubes, breast carcinoma, bronchioalveolar carcinomas of the lung, testicular sex cord and Sertoli cell tumors, papillary thyroid carcinoma</td>
</tr>
<tr>
<td>Juvenile polyposis</td>
<td>SMAD4, BMPR1A, ENG</td>
<td>Autosomal dominant</td>
<td>Pancreatic adenocarcinoma Hamartomatous polyps of the GI tract and adenocarcinoma of the stomach, small intestine, and colon</td>
</tr>
<tr>
<td>Multiple endocrine neoplasia 1</td>
<td>MEN1</td>
<td>Autosomal dominant</td>
<td>Pancreatic endocrine neoplasms Endocrine neoplasms of the parathyroid and pituitary glands, adrenal cortical neoplasms, thymic and bronchial carcinoids, esophageal leiomyomas, renal angiomyolipomas, GISTs, spinal ependymomas, meningioma, astrocytoma, lipomas, collagenomas, and angiofibromas</td>
</tr>
<tr>
<td>von Hippel-Lindau disease</td>
<td>VHL</td>
<td>Autosomal dominant</td>
<td>Pancreatic serous cystadenomas, pancreatic endocrine neoplasms, pancreatic endocrine neoplasms (TSC2 mutations) CNS hemangioblastomas, renal cell carcinomas, pheochromocytomas, café au lait spots</td>
</tr>
<tr>
<td>Tuberous sclerosis</td>
<td>TSC1, TSC2</td>
<td>Autosomal dominant</td>
<td>Pancreatic endocrine neoplasms (TSC2 mutations) Angiomyolipomas, angiofibromas, astrocytomas, lymphangioleiomyomatosis, renal cysts, retinal hamartomas, cardiac rhabdomyoma, hypomelanotic skin macules, periungual fibromas, cortical tubers</td>
</tr>
<tr>
<td>Hereditary breast and ovarian cancer</td>
<td>BRCA2, PALB2, BRCA1</td>
<td>Autosomal dominant</td>
<td>Pancreatic and biliary tract adenocarcinomas Breast, ovarian, fallopian tube, peritoneal, prostate, stomach, cervical, and endometrial carcinomas</td>
</tr>
</tbody>
</table>
## Familial atypical multiple mole melanoma syndrome (FAMMM)

**Gene**: **P16/CDKN2A**

- **Type**: Autosomal dominant
- **Tumor Type**: Pancreatic adenocarcinoma
- **Possible Syndromes**: Melanomas and dysplastic nevi

## Lynch syndrome

**Genes**: **MLH1, PMS2, MSH2, MSH6**

- **Type**: Autosomal dominant
- **Tumor Type**: Ampullary, biliary, and pancreatic adenocarcinomas
- **Possible Syndromes**: Colonic adenomas and adenocarcinomas; carcinomas of the endometrium, ovaries, adrenal cortex, prostate, bladder, renal pelvis, and ureter; glioblastomas; and sebaceous neoplasms

## Hereditary pancreatitis

**Genes**: **PRSS1, PRSS2, SPINK1, CFTR**

- **Type**: Autosomal dominant
- **Tumor Type**: Pancreatic adenocarcinoma
- **Possible Syndromes**: Pancreatitis

## Hemochromatosis

**Gene**: **HFE**

- **Type**: Autosomal recessive
- **Tumor Type**: Hepatocellular carcinoma
- **Possible Syndromes**: Iron overload can lead to endocrine dysfunction, heart failure, arthritis, and cirrhosis of the liver

## Tyrosinemia

**Genes**: **FAH, HPD, TAT**

- **Type**: Autosomal recessive
- **Tumor Type**: Hepatocellular adenoma and carcinoma
- **Possible Syndromes**: Failure to thrive, liver and renal failure, skin and ocular lesions

## Citrullinemia

**Genes**: **SLC25A13, ASS1, SERPINA1**

- **Type**: Autosomal recessive
- **Tumor Type**: Hepatocellular carcinoma
- **Possible Syndromes**: Liver dysfunction, hyperammonemia

## Glycogen storage disease

**Genes**: **G6PC, AGL, PYGL**

- **Type**: Autosomal recessive
- **Tumor Type**: Hepatocellular adenoma and carcinoma
- **Possible Syndromes**: Hypoglycemia, muscle disease, liver disease

## Li-Fraumeni syndrome

**Genes**: **TP53, CHEK2**

- **Type**: Autosomal dominant
- **Tumor Type**: Hepatoblastoma, pancreatic and biliary adenocarcinoma
- **Possible Syndromes**: Breast carcinoma, osteosarcoma, and other soft tissue sarcomas; leukemias; adrenal cortical carcinoma; brain tumors

## Alagille syndrome

**Genes**: **JAG1, NOTCH2**

- **Type**: Autosomal dominant
- **Tumor Type**: Hepatocellular carcinoma
- **Possible Syndromes**: Bile duct paucity, pulmonic stenosis, butterfly vertebrae, abnormal facial features

## Progressive familial intrahepatic cholestasis (Byler disease)

**Genes**: **ATP8B1, ABCB11, MDR3**

- **Type**: Autosomal recessive
- **Tumor Type**: Hepatocellular carcinoma
- **Possible Syndromes**: Cholestatic liver disease

---

**CHRPE**: Congenital hypertrophy of retinal pigment epithelium; **FAP**: Familial adenomatous polyposis; **GIST**: Gastrointestinal stromal tumor.

## Colon/Rectum

### Familial Neoplasia of the Colon and Rectum

<table>
<thead>
<tr>
<th>Type of Tumor</th>
<th>Possible Syndromes</th>
<th>Gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenoma</td>
<td>FAP, MYH-associated polyposis, Lynch syndrome, juvenile polyposis, hereditary mixed polyposis, Cowden/PTEN hamartoma syndrome (possible association), serrated polyposis</td>
<td><strong>APC, MYH, MLH1, PMS2, MSH2, MSH6, SMAD4, ENG, CRAC1, BMPR1A, PTEN</strong></td>
</tr>
</tbody>
</table>
Serrated polyp

(previously known as giant hyperplastic polyposis)

Serrated polyposis (previously known as giant hyperplastic polyposis), hereditary mixed polyposis, MYH-associated polyposis

Hereditary mixed polyposis

Unknown, possibly CRAC1 for hereditary mixed polyposis, MYH

CRAC1 possible gene involved

Adenomas, hamartomatous polyps, and serrated polyps

Juvenile polyposis, Cowden/PTEN hamartoma syndrome

SMAD4, BMPR1A, ENG, PTEN

Adenocarcinoma

FAP, MYH-associated polyposis, Lynch syndrome, juvenile polyposis, hereditary mixed polyposis, Cowden/PTEN hamartoma syndrome (possible association), serrated polyposis, Peutz-Jeghers syndrome, Li-Fraumeni syndrome

APC, MYH, MLH1, PMS2, MSH2, MSH6, SMAD4, ENG, CRAC1, BMPR1A, PTEN, LKB1, TP53

FAP: Familial adenomatous polyposis.

P.III(6):5

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Gene</th>
<th>Inheritance Pattern</th>
<th>Tumor</th>
<th>Other Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>FAP</td>
<td>APC</td>
<td>Autosomal dominant</td>
<td>Adenomas and adenocarcinomas of the GI tract</td>
<td>Gastric fundic gland polyps with and without dysplasia, pancreaticobiliary tract adenocarcinomas, fibromatosis (Gardner syndrome), hepatoblastomas, hepatic adenomas, hepatocellular carcinomas, osteomas (Gardner syndrome), supernumerary teeth, congenital hypertrophy of retinal pigment epithelium, epidermal inclusion cysts of face and scalp, papillary thyroid carcinoma (cribriform morular variant), adrenal cortical neoplasms, pancreatic islet cell neoplasms, parathyroid and pituitary adenomas, medulloblastomas (Turcot syndrome), nasopharyngeal angiofibromas</td>
</tr>
</tbody>
</table>
| MYH-associated polyposis | MYH | Autosomal recessive | Adenomas and adenocarcinomas of the GI tract | Gastric fundic gland polyps with and without dysplasia, fibromatosis, osteomas, supernumerary teeth, congenital hypertrophy of retinal pigment epithelium, epidermal inclusion cysts of face and scalp; ovarian, bladder, and skin cancers that may mimic Lynch syndrome have been reported; given the rarity of the MYH, it is unknown whether all of
<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Gene(s)</th>
<th>Inheritance Pattern</th>
<th>Lesions Associated with FAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lynch syndrome (HNPCC)</td>
<td>MLH1, PMS2, MSH2, MSH6</td>
<td>Autosomal dominant</td>
<td>Adenomas, adenocarcinomas of the GI tract, the lesions associated with FAP can be seen</td>
</tr>
<tr>
<td>Peutz-Jeghers syndrome</td>
<td>LKB1</td>
<td>Autosomal dominant</td>
<td>Hamartomatous polyps and adenocarcinomas of the GI tract</td>
</tr>
<tr>
<td>Juvenile polyposis</td>
<td>SMAD4, BMPR1A, ENG</td>
<td>Autosomal dominant</td>
<td>Hamartomatous polyps and adenocarcinomas of the GI tract</td>
</tr>
<tr>
<td>Cowden/PTEN hamartoma syndrome</td>
<td>PTEN</td>
<td>Autosomal dominant</td>
<td>Hamartomatous polyps, adenomas, and adenocarcinomas of the GI tract</td>
</tr>
<tr>
<td>Serrated polyposis</td>
<td>Unknown</td>
<td>Both autosomal dominant and recessive patterns reported</td>
<td>Serrated polyps, adenomas, adenocarcinomas of the colon and rectum</td>
</tr>
<tr>
<td>Hereditary mixed polyposis</td>
<td>CRAC1?</td>
<td>Autosomal dominant?</td>
<td>Adenomas, serrated polyps, and juvenile polyps as well as adenocarcinomas of the GI tract</td>
</tr>
<tr>
<td>Li-Fraumeni syndrome</td>
<td>TP53</td>
<td>Autosomal dominant</td>
<td>Adenocarcinomas of the colon and rectum</td>
</tr>
<tr>
<td>Bloom syndrome</td>
<td>BLM</td>
<td>Autosomal recessive</td>
<td>Adenocarcinomas of the GI tract and squamous cell carcinoma of the esophagus</td>
</tr>
<tr>
<td>Hereditary diffuse gastric</td>
<td>CDHI</td>
<td>Autosomal dominant</td>
<td>Signet ring cell carcinoma of the colon and rectum</td>
</tr>
</tbody>
</table>

*FAP: Familial adenomatous polyposis; HNPCC = familial nonpolyposis colorectal cancer.*
### Esophagus/Stomach/Small Bowel

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Familial Esophageal, Gastric, and Small Intestinal Tumors by Syndromes</th>
<th>Other Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tylosis (type A nonepidermolytic palmoplantar keratoderma)</td>
<td>Rhbdf2</td>
<td>Autosomal dominant</td>
</tr>
<tr>
<td>Familial Barrett esophagus</td>
<td>Unknown gene or genes</td>
<td>Thought to be autosomal dominant with incomplete penetrance</td>
</tr>
<tr>
<td>Familial adenomatous polyposis</td>
<td>ApC</td>
<td>Autosomal dominant</td>
</tr>
<tr>
<td>MYH polyposis</td>
<td>MYH</td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td>Hereditary diffuse gastric cancer</td>
<td>CdH1</td>
<td>Autosomal dominant</td>
</tr>
<tr>
<td>Germline KIT mutation</td>
<td>KIT</td>
<td>Autosomal dominant</td>
</tr>
<tr>
<td>Carney-Stratakis syndrome</td>
<td>Sdh subunits B, C, D</td>
<td>Autosomal dominant</td>
</tr>
<tr>
<td>Germline platelet-derived growth factor-a mutation Neurofibromatosis type 1</td>
<td>Pdgfra</td>
<td>Autosomal dominant</td>
</tr>
</tbody>
</table>
dysplasia, pheochromocytomas, glomus tumors, carcinoid tumors, gastrointestinal schwannomas, juvenile myelomonocytic leukemia, breast cancer, rhabdomyosarcoma

Colonic adenomas and adenocarcinomas; carcinomas of the endometrium, ovaries, adrenal cortex, prostate, bladder, renal pelvis, ureter, and biliary tract; glioblastomas, and sebaceous neoplasms

Adenocarcinoma of the colon and pancreas, ovarian sex cord tumor with annular tubules, adenoma malignum of cervix, mucinous tumors of ovaries and fallopian tubes, breast carcinoma, bronchioalveolar carcinomas of the lung, testicular sex cord and Sertoli cell tumors, papillary thyroid cancer

Adenocarcinoma of the colon and pancreas

Adenocarcinoma of the colon and pancreas

Familial Neoplasia of Esophagus, Stomach, and Small Intestine

<table>
<thead>
<tr>
<th>Type of Tumor</th>
<th>Possible Syndromes</th>
<th>Gene</th>
<th>Tests Available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenocarcinoma of Familial Barrett esophagus (arising in Barrett mucosa)</td>
<td>Tylosis</td>
<td>RHBDF2</td>
<td>Sequencing of RHBDF2</td>
</tr>
<tr>
<td>Squamous cell carcinoma of the esophagus</td>
<td>FAP, MYH polyposis, gastric APC or MYH adenocarcinoma and GAPPS (most fundic gland polyps are sporadic and associated with gastric acid suppression</td>
<td>Sequence FAP gene first; if normal, look for 2 common mutations in MYH gene; gene for GAPPS is unknown</td>
<td></td>
</tr>
</tbody>
</table>
Gastric adenoma

- therapy); multiple polyps with dysplasia should raise issue of polyposis
- FAP or MYH polyposis (most are sporadic)
- APC or MYH

Diffuse gastric cancer

- HDGC or Lynch syndrome
- CDH1 (E-cadherin) for HDGC, MLH1, MSH2, MSH6, or PMS2 for Lynch syndrome
- CDH1 gene mutation in 30-40% of HDGC, presence of signet ring cell carcinoma in situ diagnostic of HDGC; loss of E-cadherin immunostaining in up to 77% of tumors in HDGC; loss of mismatch repair proteins in Lynch syndrome

Intestinal-type gastric cancer

- FAP, MYH polyposis, Peutz-Jeghers syndrome, juvenile polyposis, GAPPS
- APC, MYH, LKB1, SMAD4, BMPR1A, ENG

GIST

- Familial GIST, Carney-Stratakis syndrome (epithelioid GIST with parangangiomas), NF1
- KIT, PDGFRA, NF1, and succinate dehydrogenase gene complex
- Germline mutational analysis of KIT (usually exon 11), PDGFRA, NF1, or succinate dehydrogenase; loss of immunostaining for succinate dehydrogenase in Carney-Stratakis but not specific for the syndrome

Small intestinal adenoma (usually periampullary duodenum)

- FAP or MYH polyposis
- APC or MYH

Small intestinal adenocarcinoma

- FAP, MYH polyposis, Lynch syndrome, Peutz-Jeghers syndrome, juvenile polyposis, NF1
- APC, MYH, MLH1, MSH2, MSH6, PMS2, LKB1, SMAD4, BMPR1A, ENG, NF1
- Sequencing of all genes, immunostaining for MLH1, MSH2, MSH6, and PMS2 as well as microsatellite instability testing (Lynch)

FAP: Familial adenomatous polyposis; GAPPS: Gastric adenocarcinoma and proximal polyposis of the stomach; GIST: Gastrointestinal stromal tumor; HDGC: Hereditary diffuse gastric cancer; NF1: Neurofibromatosis type 1.

Section 7 - Genitourinary
Bladder

<table>
<thead>
<tr>
<th>Antibody</th>
<th>High-Grade Poorly Differentiated Carcinoma</th>
<th>Prostate Carcinoma</th>
<th>Urothelial Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSMA</td>
<td>&gt; 95% (best)</td>
<td></td>
<td>0%</td>
</tr>
<tr>
<td>PSA</td>
<td>68-94%</td>
<td></td>
<td>0%</td>
</tr>
<tr>
<td>PAP</td>
<td>78-95%</td>
<td></td>
<td>0%</td>
</tr>
<tr>
<td>p63</td>
<td>0-18%</td>
<td></td>
<td>70-75%</td>
</tr>
<tr>
<td>HMWCK (34bE12)</td>
<td>6-10%</td>
<td>65-100%</td>
<td></td>
</tr>
<tr>
<td>GATA3</td>
<td>0-3%</td>
<td></td>
<td>67%</td>
</tr>
</tbody>
</table>

1110
<table>
<thead>
<tr>
<th>Antibody</th>
<th>Normal Urothelium</th>
<th>Reactive Urothelium</th>
<th>Carcinoma In Situ</th>
</tr>
</thead>
<tbody>
<tr>
<td>CK20</td>
<td>Umbrella layer only</td>
<td>Umbrella layer only</td>
<td>Full-thickness urothelium</td>
</tr>
<tr>
<td>CD44</td>
<td>Basal layer only</td>
<td>Intermediate cells to full thickness</td>
<td>Basal layer only or loss of expression</td>
</tr>
<tr>
<td>p53</td>
<td>Rare cells; weak reactivity</td>
<td>Rare cells; weak reactivity</td>
<td>Diffuse, strong reactivity</td>
</tr>
</tbody>
</table>

### Urothelial Carcinoma-Associated Markers in Metastatic Setting

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Sensitivity for Urothelial Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>p63</td>
<td>60-90%</td>
</tr>
<tr>
<td>S100p</td>
<td>78-86%</td>
</tr>
<tr>
<td>GATA3</td>
<td>67%</td>
</tr>
<tr>
<td>CK7/CK20</td>
<td>65%</td>
</tr>
<tr>
<td>Thrombomodulin</td>
<td>49-69%</td>
</tr>
<tr>
<td>Uroplakin-3</td>
<td>57-60%</td>
</tr>
</tbody>
</table>

### 2010 AJCC Staging for Bladder Cancer

**Stage Definition**

**Primary Tumor (pT)**
- pT0  No evidence of primary tumor
- pTa  Noninvasive papillary carcinoma
- pTis Carcinoma in situ: “Flat tumor”
- pT1  Tumor involves subepithelial connective tissue
- pT2  Tumor invades muscularis propria
- pT2a Tumor invades superficial muscularis propria (inner half)
- pT2b Tumor invades deep muscularis propria (outer half)
- pT3  Tumor invades perivesical tissue
- pT3a Microscopically
- pT3b Macroscopically (extravesical mass)
- pT4  Tumor invades any of the following: Prostatic stroma, seminal vesicles, uterus, vagina, pelvic wall, abdominal wall
- pT4a Tumor invades prostatic stroma, uterus, vagina
- pT4b Tumor invades pelvic wall, abdominal wall

**Regional Lymph Nodes (pN)**
- N0  No lymph node metastasis
- N1  Single regional lymph node metastasis in the true pelvis (hypogastric, obturator, external iliac, or presacral lymph node)
- N2  Multiple regional lymph node metastasis in the true pelvis (hypogastric, obturator, external iliac, or presacral lymph node)
- N3  Lymph node metastasis to the common iliac lymph nodes

**Distant Metastasis (M)**
- M0  No distant metastasis
- M1  Distant metastasis

---

**Image Gallery**

Bladder Cancer Staging
Diagnostic Pathology: Familial Cancer Syndromes

(Left) Graphic image shows different pT stages of bladder cancer. Bladder cancer pT staging is defined by the level of invasion of bladder wall and adjacent structures. In the 2010 AJCC system, intraurethral extension into prostate was excluded from pT4a tumors, which now includes only transmural invasion into prostate. (Right) H&E shows urothelial carcinoma invading into the muscularis propria (MP) (pT2). MP is composed of large compact muscle bundles. Note presence of intra-MP fat.

(Left) Axial CECT shows a sessile mass in the bladder with enhancement greater than that of the bladder wall. The mass straddles the ureterovesical junction. The cervix is noted for orientation. (Right) Low-power view shows urothelial carcinoma infiltrating through the MP and extending into perivesical fat (pT3). The MP-perivesical fat boundary is usually irregular because of fat extension into MP, complicating assessment of microscopic perivesical tissue invasion.
Axial CECT shows a pelvic lymphadenopathy due to bladder cancer. (Right) H&E shows a pelvic lymph node involved by metastatic urothelial carcinoma. Metastatic foci can be discrete in a post-neoadjuvant setting in which there is shrinkage of tumor. It is important to document the number and location of positive nodes for pN substaging. Involvement of common iliac lymph node is staged as pN3. Size of lymph node metastasis is suggested to have prognostic significance. P.III(7):4

Immunohistochemical Features

(Left) H&E shows CIS with nuclear pleomorphism and prominent nucleoli. In some instances, distinction between CIS and reactive atypia can be difficult, necessitating use of ancillary immunostains (CK20, CD44, and p53). (Right) CK20 shows full-thickness staining of urothelium in CIS. In normal and reactive urothelium, CK20 is expressed only in the surface umbrella cell layer. When interpreting immunoreactivity in CIS, it is crucial to match the exact focus to the corresponding H&E stain.
Diagnostic Pathology: Familial Cancer Syndromes

(Left) CD44 in CIS shows staining in basal and few parabasal cells and with no staining in most cells. In reactive urothelium, CD44 staining extends to intermediate cells or is full thickness (not shown). Note the positive staining in lymphocytes, which serves as internal positive control. (Right) p53 shows diffuse (> 50%) nuclear staining in CIS. Full-thickness nuclear p53 staining is diagnostic of CIS. It is recommended that CK20, CD44, and p53 should be performed together as a panel.

(Left) Needle biopsy shows urothelial carcinoma involving prostate parenchyma highlighted by diffuse HMWCK staining. Prostate carcinoma is typically negative for HMWCK. (Right) Dual chromogen stain of AMACR (red) and prostatic basal cell markers (HMWCK and p63) (brown) shows nuclear p63 staining and some cytoplasmic AMACR staining in this urothelial carcinoma involving the prostate. Note the adjacent benign prostatic glands positive for basal cell markers and no AMACR staining.

P.III(7):5

Immunohistochemical Features
(Left) p63 shows diffuse nuclear staining in urothelial carcinoma. In the GU tract, p63 is helpful when distinguishing urothelial carcinoma from prostate or renal cell carcinomas, which are both p63 negative. (Right) GATA3 shows diffuse nuclear staining in urothelial carcinoma. Compared to p63, GATA3 is more urothelial lineage specific and is helpful in the metastatic setting. Other GATA3-positive tumors include ductal breast carcinoma and some uterine cervical carcinomas.

(Left) S100-pla shows nuclear and cytoplasmic positivity in urothelial carcinoma. S100-pla is generally not expressed in squamous cell carcinoma and like GATA3 is helpful when making a distinction from urothelial carcinoma. (Right) HMWCK shows strong diffuse cytoplasmic staining in urothelial carcinoma. HMWCK is helpful when distinguishing urothelial carcinoma from prostatic carcinoma. In the prostate, HMWCK is typically expressed only by prostatic basal cells, which are lost in prostate carcinoma.
(Left) Uroplakin-3 shows some plaque-like positivity in urothelial carcinoma. Uroplakin-3 is the most specific marker for urothelial lineage. However, sensitivity is not high and reactivity is often focal with this stain. (Right) Smoothelin shows differential staining between MP (strong and diffuse staining) and hyperplastic muscularis mucosae (MM) (weak to absent staining). Smoothelin can be helpful when distinguishing MP from hyperplastic MM in staging muscle-invasive urothelial carcinoma.

**Kidney**

<table>
<thead>
<tr>
<th>Conditions</th>
<th>Familial Renal Tumors</th>
<th>Renal Tumors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuberous sclerosis</td>
<td><em>TSC1</em> and <em>TSC2</em></td>
<td>Angiomyolipoma, clear cell RCC, benign epithelial cyst, and renal oncocytoma</td>
</tr>
<tr>
<td>von Hippel-Lindau</td>
<td><em>VHL</em></td>
<td>Clear cell RCC and “clear cell tumorlets”</td>
</tr>
<tr>
<td>Constitutional chromosome 3 translocation</td>
<td>Unknown; candidate genes: <em>FHIT</em>, <em>TRC8</em>, <em>DIRC1</em>, <em>DIRC2</em>, <em>DIRC3</em>, <em>HSPBAP1</em>, <em>LSAMP</em>, <em>NORE1</em>, <em>KCNIP4</em> and <em>FBXW7</em></td>
<td>Clear cell RCC</td>
</tr>
<tr>
<td>Familial clear cell RCC</td>
<td>Unknown</td>
<td>Clear cell RCC</td>
</tr>
<tr>
<td>Familial oncocytoma</td>
<td>Unknown</td>
<td>Renal oncocytoma (association with renal oncocytosis or hybrid oncocytic tumors unknown)</td>
</tr>
<tr>
<td>Birt-Hogg-Dubé</td>
<td><em>FLCN</em> or <em>BHD</em></td>
<td>Hybrid oncocytic tumors, renal oncocytoma, renal oncocytosis, chromophobe RCC, and clear cell RCC</td>
</tr>
<tr>
<td>Hereditary papillary RCC</td>
<td>Unknown; candidate genes: <em>MET</em>, <em>NRAS</em> and <em>NTRK1</em></td>
<td>Papillary RCC type 1</td>
</tr>
<tr>
<td>Papillary thyroid carcinoma with associated neoplasia</td>
<td>Unknown</td>
<td>Papillary RCC and papillary adenoma; possibly renal oncocytoma</td>
</tr>
<tr>
<td>Hereditary hyperparathyroidism-jaw tumor syndrome</td>
<td>CDC73 or HRPT2</td>
<td>Papillary RCC, Wilms tumor, cortical adenoma, and benign epithelial cyst</td>
</tr>
<tr>
<td>Succinate dehydrogenase B-associated hereditary paraganglioma/pheochromocytoma</td>
<td>SDHB</td>
<td>RCC, NOS (mostly classified as renal oncocytoma previously)</td>
</tr>
<tr>
<td>Familial Wilms tumor</td>
<td>FWT1, FWT2, and at least 1 unknown gene</td>
<td>Wilms tumor</td>
</tr>
<tr>
<td>WT1-associated Wilms tumor (WAGR, WT1)</td>
<td></td>
<td>Wilms tumor</td>
</tr>
<tr>
<td>Overgrowth syndromes (BWS, SGBS, IHH, and PS)</td>
<td>BWS: Most caused by altered expression of KCNQ1OT1, CDKNIC, LIT1 or H19, and IGF2 and CDKNIC mutation; SGBS: GPC3; IHH: Subset with Chr 11p15 abnormality; PS: Unknown, but GPC3 suggested</td>
<td>Wilms tumor</td>
</tr>
</tbody>
</table>

BWS: Beckwith-Wiedemann syndrome; DDS: Denys-Drash syndrome; FS: Frasier syndrome; IHH: Isolated hemihypertrophy; PS: Perlman syndrome; RCC: Renal cell carcinoma; SGBS: Simpson-Golabi-Behmel syndrome; WAGR: Wilms tumor, aniridia, genitourinary malformations, and mental retardation syndrome.

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Clear Cell RCC</th>
<th>Chromophobe RCC</th>
<th>MiTF/TFE Family Translocation-Associated Carcinoma</th>
<th>Papillary RCC</th>
<th>Angiomyolipoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>pax-2</td>
<td>+</td>
<td>+</td>
<td>+ (but often - in TFEB carcinoma)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>pax-8</td>
<td>+</td>
<td>+</td>
<td>+ (some focal +)</td>
<td>+ (diffuse)</td>
<td>-</td>
</tr>
<tr>
<td>CAIX</td>
<td>+ (diffuse)</td>
<td>- (rarely +)</td>
<td>- (usually)</td>
<td>ND</td>
<td>-</td>
</tr>
<tr>
<td>CK7</td>
<td>-</td>
<td>+ (rarely +)</td>
<td>+ (rarely focal +)</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>CD10</td>
<td>+ (membranous)</td>
<td>- (rarely +)</td>
<td>+</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Vimentin</td>
<td>+</td>
<td>- (rarely +)</td>
<td>ND</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Ksp-cadherin</td>
<td>+</td>
<td>+ (diffuse, occasionally patchy)</td>
<td>ND</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>CD117</td>
<td>+</td>
<td>+ (diffuse, often peripheral membranous accentuation)</td>
<td>+ (usually)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>AMACR</td>
<td>- (rarely focal +)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>EMA/MUC1</td>
<td>+</td>
<td>+ (rarely focal +)</td>
<td>+</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>PAN-CK (AE1/AE3)</td>
<td>+</td>
<td>- (rarely focal +)</td>
<td>+</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>TFE3/TFEB</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Parvalbumin</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Antibody</td>
<td>Renal Tumors With Papillary or Tubulopapillary Architecture</td>
<td>Renal Tumors With Granular/Eosinophilic Cytoplasm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------------------------------------</td>
<td>--------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Papillary RCC, Collecting Duct Carcinoma, Metanephric Adenoma, Mucinous Tubular and Spindle Cell Carcinoma, Clear Cell Papillary RCC</td>
<td>Clear Cell RCC, Eosinophilic Chromophobe RCC, Eosinophilic Oncocytoma, MitF/TFE Family Translocation-Associated Carcinoma, Angiomyolipoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CK7</td>
<td>+ (may be + in branching tubules or papillary structures)</td>
<td>+ (rarely +)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD10</td>
<td>-/+ (focal)</td>
<td>-/+</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCC</td>
<td>V</td>
<td>-/+</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMACR</td>
<td>-/+</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EMA/MUC1</td>
<td>+ (may be + in branching tubules or papillary structures)</td>
<td>+ (lost in renal medullary carcinoma)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT1</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HMWCK (34bE12)</td>
<td>+/-</td>
<td>+/-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD57</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INI1</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAIX</td>
<td>(+ perinecrotic -/+ (perinecrotic ND areas and papillary tips))</td>
<td>ND</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ND: No data; RCC: Renal cell carcinoma; V: Variable.
<table>
<thead>
<tr>
<th>Antibody</th>
<th>Wilms Tumor</th>
<th>Ewing Sarcoma/PNET</th>
<th>Small Cell Carcinoma</th>
<th>Lymphoma</th>
<th>Desmoplastic Small Round Cell Tumor</th>
<th>Synovial Sarcoma, Poorly Differentiated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vimentin</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>WT1</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>S100</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>V</td>
<td>-/+</td>
</tr>
<tr>
<td>FLI-1</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CD99</td>
<td>+/-</td>
<td>+</td>
<td>-</td>
<td>+/-</td>
<td>+/-</td>
<td>+/-</td>
</tr>
<tr>
<td>NSE</td>
<td>-</td>
<td>-</td>
<td>-/+</td>
<td>-</td>
<td>+</td>
<td>ND</td>
</tr>
<tr>
<td>HMWCK (34bE12)</td>
<td>-</td>
<td>+/-</td>
<td>+ (often dot-like)</td>
<td>-</td>
<td>-</td>
<td>-/+</td>
</tr>
<tr>
<td>EMA/MUC1</td>
<td>+/-</td>
<td>-</td>
<td>+/-</td>
<td>-</td>
<td>-</td>
<td>-/+</td>
</tr>
<tr>
<td>CD45 (LCA)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Chromogranin</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Desmin</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>pax-2</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>PAN-CK (AE1/AE3)</td>
<td>+ (in tubules)</td>
<td>+/- (focal)</td>
<td>+ (often dot-like)</td>
<td>+</td>
<td>+/-</td>
<td>+/-</td>
</tr>
<tr>
<td>ND: No data; PNET: Primitive neuroectodermal tumor; V: Variable.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Stage Definition**

*Primary Tumor (T)*

**TX** Primary tumor cannot be assessed

**T0** No evidence of primary tumor

**T1** Tumor ≤ 7 cm in greatest dimension, limited to kidney

**T1a** Tumor ≤ 4 cm in greatest dimension, limited to kidney

**T1b** Tumor > 4 cm but ≤ 7 cm in greatest dimension, limited to kidney
<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>T2</td>
<td>Tumor &gt; 7 cm in greatest dimension, limited to kidney</td>
</tr>
<tr>
<td>T2a</td>
<td>Tumor &gt; 7 cm but ≤ 10 cm in greatest dimension, limited to kidney</td>
</tr>
<tr>
<td>T2b</td>
<td>Tumor &gt; 10 cm, limited to kidney</td>
</tr>
<tr>
<td>T3</td>
<td>Tumor extends into major veins or perinephric tissues but not into ipsilateral adrenal gland and not beyond Gerota fascia</td>
</tr>
<tr>
<td>T3a</td>
<td>Tumor grossly extends into renal vein or its segmental (muscle-containing) branches, or tumor invades perirenal &amp;/or renal sinus fat but not beyond Gerota fascia</td>
</tr>
<tr>
<td>T3b</td>
<td>Tumor grossly extends into vena cava below diaphragm</td>
</tr>
<tr>
<td>T3c</td>
<td>Tumor grossly extends into vena cava above diaphragm or invades wall of vena cava</td>
</tr>
<tr>
<td>T4</td>
<td>Tumor invades beyond Gerota fascia (including contiguous extension into ipsilateral adrenal gland)</td>
</tr>
<tr>
<td>N0</td>
<td>No regional lymph node metastasis</td>
</tr>
<tr>
<td>N1</td>
<td>Metastasis in regional lymph node(s)</td>
</tr>
<tr>
<td>M0</td>
<td>No distant metastasis</td>
</tr>
<tr>
<td>M1</td>
<td>Distant metastasis</td>
</tr>
</tbody>
</table>

Regional Lymph Nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in regional lymph node(s)

Distant Metastasis (M)
M0 No distant metastasis
M1 Distant metastasis

Adapted from 7th edition AJCC Staging Forms (2010).

Image Galley
Kidney Cancer Staging

(Left) Renal cell tumors confined to the kidney and ≤ 7 cm in diameter are assigned stage pT1 (up to 4 cm, pT1a; 4-7 cm, pT1b). Tumors > 7 cm and confined to the kidney are regarded as pT2. (Right) The size criterion does not apply to tumors with extrarenal extension. Tumors with renal sinus or perirenal fat or renal vascular invasion are all assigned stage pT3a. Tumors directly invading the adrenal are considered pT4, and those with discontinuous adrenal invasion as pM1.
(Left) Low-power view shows RCC invading the renal sinus \( \rightarrow \) (pT3a). Renal sinus invasion occurs more often via the sinus vessels or by direct infiltration of adipose tissue. Renal sinus should be routinely sampled in nephrectomy specimens to assess for invasion, which significantly upstages small tumors. (Right) This clear cell RCC involves the adrenal gland. Direct contiguous extension into the adrenal is considered pT4 whereas discontinuous involvement is regarded as metastasis (pM1).

(Left) Axial CECT shows a large, centrally necrotic mass \( \rightarrow \) invading the posterior margin of the liver (T4). The mass completely engulfs the adrenal gland and has invaded the entire perirenal and pararenal spaces. The IVC \( \rightarrow \) is not invaded but is displaced anteriorly. (Right) This clear cell RCC has metastasized into a pulmonary hilar lymph node. Involvement of distant nonregional lymph nodes is regarded as M1. Diagnosis of metastatic clear cell RCC can often be made by morphology alone.

P.III(7):10

Immunohistochemical Features
(Left) pax-2 shows nuclear immunoreactivity in this collecting duct carcinoma. pax-2 is expressed by most RCC subtypes and is helpful in the metastatic setting. (Right) Needle core biopsy shows diffuse CAIX immunoreactivity in this clear cell RCC. Diffuse CAIX immunoreactivity is helpful in distinguishing clear cell RCC from its mimics such as eosinophilic chromophobe RCC and renal oncocytoma, which are usually negative. Clear cell papillary RCC also exhibits diffuse CAIX positivity.

(Left) AMACR shows strong diffuse cytoplasmic immunoreactivity in this papillary RCC. Mucinous tubular and spindle cell carcinoma is diffusely AMACR positive. Other renal tumors with papillae, such as clear cell papillary RCC and collecting duct carcinoma, show absent AMACR staining. Some metanephric adenoma, however, may express AMACR. (Right) This clear cell papillary RCC shows diffuse CK7 reactivity. This tumor is also positive for CAIX and negative for AMACR, in contrast to papillary RCC.
(Left) C-Kit (CD117) is diffusely immunoreactive in this chromophobe RCC. Renal oncocytoma is also diffusely positive with C-Kit and is not helpful to distinguish this tumor. Clear cell RCC with eosinophilic cytoplasm, however, is typically negative with this marker. (Right) CK7 shows cytoplasmic positivity in some chromophobe RCC cells. CK7 staining in chromophobe RCC can be diffuse or focal; diffuse staining may help distinguish from oncocytoma, which usually shows scattered or absent staining.

P.III(7):11

Immunohistochemical Features

(Left) CK-PAN shows scattered immunoreactivity in this translocation-associated RCC, where staining is often focal or absent. Lack of CK-PAN is a helpful when translocation-associated RCC is suspected. Clear cell RCC often shows diffuse staining with CK-PAN. (Right) This antibody to TFE3 shows diffuse nuclear positivity in this translocation-associated carcinoma. Specificity of this antibody is still not proven and FISH confirmation may be necessary for cases with atypical morphology.
Diagnostic Pathology: Familial Cancer Syndromes

(Left) This TFEB carcinoma shows diffuse MART-1 staining. Other melanocytic markers such HMB-45 and MITF are often positive in this tumor and are helpful when distinguishing from clear cell RCC, where these are generally negative. (Right) GATA3 shows nuclear positivity in this renal urothelial carcinoma. In contrast, renal carcinomas are often GATA3 negative. Note GATA3 positivity in some collecting tubules. GATA3 is a good compliment for pax-2/pax-8, which are positive in renal carcinoma.

(Left) WT1 shows diffuse nuclear reactivity in this Wilms tumor. WT1 immunoreactivity is usually seen in blastemal and epithelial components. Metanephric adenoma also exhibits nuclear WT1 positivity. (Right) This fat-poor angiomyolipoma shows diffuse nuclear positivity for MITF. Other melanocytic markers such as MART-1 and HMB-45 are also expressed by this tumor, which helps confirm the diagnosis. Immunoreactivity is usually present in the spindle cell component.

Prostate

<table>
<thead>
<tr>
<th>Structures</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peripheral zone (PZ)</td>
<td>Most common origin for prostate carcinoma (70-75%)</td>
</tr>
<tr>
<td></td>
<td>Most susceptible to inflammation and most common to undergo atrophy</td>
</tr>
<tr>
<td>Transition zone (TZ)</td>
<td>Uncommon site for benign prostatic hyperplasia (BPH)</td>
</tr>
<tr>
<td></td>
<td>Most common site for BPH and its myriad morphologic patterns</td>
</tr>
<tr>
<td></td>
<td>Common site for atypical adenomatous hyperplasia (AAH)</td>
</tr>
<tr>
<td>Location</td>
<td>Description</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Central zone (CZ)</td>
<td>Less commonly, site of origin of prostate carcinoma (15-20%), which tends to be lower grade.</td>
</tr>
<tr>
<td>Periurethral gland region</td>
<td>Relatively resistant to prostate carcinoma and inflammation. CZ glands mimic glands of BPH and prostatic intraepithelial neoplasia (PIN).</td>
</tr>
<tr>
<td>Corpora amylacea</td>
<td>Possible origin of uncommon pure primary urothelial carcinoma of prostate.</td>
</tr>
<tr>
<td>Intraluminal crystalloids</td>
<td>Common in prostate carcinoma but may also be seen in benign glands. Presence in benign glands not a risk factor for subsequent diagnosis.</td>
</tr>
<tr>
<td>Lipofuscin pigment</td>
<td>Common in prostate carcinoma but may also be seen in benign glands. Presence in benign glands not a risk factor for subsequent diagnosis.</td>
</tr>
<tr>
<td>Striated muscles in anterior fibromuscular stroma (AFS) and apical region</td>
<td>Benign glands may be seen admixed with striated muscles and thus are not necessarily an invasive or malignant feature.</td>
</tr>
<tr>
<td>Prostate capsule</td>
<td>Adenocarcinoma involving striated muscles at these sites does not constitute extraprostatic extension (EPE).</td>
</tr>
<tr>
<td>Nerve</td>
<td>Prostate capsule Although not a true capsule, serves as histologic boundary for organ-confined prostate cancer. Absent in base and not clearly defined in apex, complicating interpretation of EPE at these sites.</td>
</tr>
<tr>
<td>Prostatic urethra (PU)</td>
<td>Nerve Perineural glands not exclusively associated with carcinoma, unless glands completely circle or are present within a nerve. 1 of the pathways for EPE by carcinoma.</td>
</tr>
<tr>
<td>Seminal vesicle (SV)</td>
<td>Prostatic urethra (PU) May give rise to urothelial carcinoma (common), squamous carcinoma, adenocarcinoma of prostate, and primary carcinoma of urethra. Florid nephrogenic adenoma from this site may extend to prostate and mimic prostate carcinoma. Urothelial carcinoma of PU invading prostate may occur in patients with bladder urothelial carcinoma and should not be staged as pT4 bladder cancer.</td>
</tr>
<tr>
<td>Verumontanum</td>
<td>Seminal vesicle (SV) Rare site for primary malignancy. Secondary involvement by prostate carcinoma relatively more common and denotes higher tumor stage (pT3b). Pseudomalignant features of epithelium may be confused with malignancy in limited sample.</td>
</tr>
<tr>
<td>Ejaculatory duct (ED)</td>
<td>Verumontanum May undergo florid glandular hyperplasia, which may be confused with prostate carcinoma.</td>
</tr>
<tr>
<td>Cowper gland</td>
<td>Ejaculatory duct (ED) Involvement by cancer in needle biopsy should not be confused as SV involvement, which denotes higher tumor stage. Pseudomalignant features of epithelium may be confused with malignancy in limited sample. Distinction from SV is based on absence of distinct smooth muscle wall.</td>
</tr>
<tr>
<td></td>
<td>Cowper gland Resembles minor salivary gland tissue; may mimic low-grade prostate carcinoma.</td>
</tr>
</tbody>
</table>
Periprostatic adipose tissue
Involvement by prostate carcinoma constitutes EPE, including needle biopsy specimens
May be absent over large areas of prostatic surface in prostatectomy specimen, making evaluation of EPE difficult
May mimic prostate carcinoma with hypernephroid features
Involvement by carcinoma not always equivalent to EPE, since it may be present rarely within prostate

| Important Immunohistochemical Stains in Diagnosis of Prostate Carcinoma |
|-----------------------------|-------------|
| **Immunostain**              | **Rationale** |
| Basal cell-associated markers | Benign vs. malignant proliferation; complete absence of HMWCK (34bE12), CK5/6, p63, basalbasal cell layer is defining criterion for invasive prostate carcinoma |
| Prostate carcinoma-associated marker AMACR (p504S) | Benign vs. malignant proliferation; absence of basal cell-associated markers favors invasive prostate carcinoma |
| Epithelial lineage PAN-CK(AE1/AE3) | Identification of subtle infiltrating cells in post-treatment setting; in differential diagnosis of carcinoma vs. nonepithelial process or malignancy |
| Prostate lineage-specific marker PSA, PAP, PSMA | Prostatic vs. nonprostatic origin, e.g., Cowper gland, mesonephric remnant, nephrogenic adenoma, seminal vesicle vs. prostate cancer |

**Benign Mimics of Prostate Carcinoma**

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Seminal Vesicle</th>
<th>Ejaculatory Duct</th>
<th>Cowper Gland</th>
<th>Mesonephric Remnants</th>
<th>Verumontanum Hyperplasia</th>
<th>Nephrogenic Remnants</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSA/PAP</td>
<td>-/+</td>
<td>-/+</td>
<td>-/+</td>
<td>+/-</td>
<td>-/+</td>
<td>-/+</td>
</tr>
<tr>
<td>Basal cell marker</td>
<td>+ (basal cell)</td>
<td>+</td>
<td>-/+</td>
<td>+ (basal cell)</td>
<td>-/+</td>
<td>-/+</td>
</tr>
<tr>
<td>AMACR</td>
<td>-/NS</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+/NS</td>
<td>+/NS</td>
</tr>
</tbody>
</table>

NS: Nonspecific, frequently marks pigment. Mesonephric remnants are also positive for CD10, calretinin, and vimentin.

**Atypical Small Glandular Proliferations**

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Benign Glands</th>
<th>Postatrophic Hyperplasia and Atrophy</th>
<th>Prostatic Adenocarcinoma</th>
<th>Basal Cell Hyperplasia</th>
<th>Outpouching of High-Grade PIN</th>
<th>AAH (Adenosis) PIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal cell-associated markers</td>
<td>+</td>
<td>+ (patchy)</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+/- (patchy)</td>
</tr>
<tr>
<td>AMACR</td>
<td>-/+</td>
<td>-/+(rare)</td>
<td>+ (strong circumferential)</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

AAH: Atypical adenomatous hyperplasia; PIN: Prostatic intraepithelial neoplasia.

**Single/Individual Cell Patterns**

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Single/Individual Cell Patterns</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAN-CK (AE1/AE3)</td>
<td>Gleason Pattern 5 Prostate Carcinoma Post-Treatment Carcinoma Marked Inflammation Granulomatous Prostatitis</td>
</tr>
<tr>
<td>Basal cell marker</td>
<td>+</td>
</tr>
<tr>
<td>AMACR</td>
<td>-</td>
</tr>
</tbody>
</table>

2010 AJCC Pathologic Staging of Prostate Cancer
<table>
<thead>
<tr>
<th>Stage</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Tumor (pT)</strong>*</td>
<td></td>
</tr>
<tr>
<td>pT2</td>
<td>Organ confined</td>
</tr>
<tr>
<td>pT2a</td>
<td>Unilateral, 1/2 of 1 side or less</td>
</tr>
<tr>
<td>pT2b</td>
<td>Unilateral, involving &gt; 1/2 of side but not both sides</td>
</tr>
<tr>
<td>pT2c</td>
<td>Bilateral disease</td>
</tr>
<tr>
<td>pT3</td>
<td>Extraprostatic extension</td>
</tr>
<tr>
<td>pT3a</td>
<td>Extraprostatic extension or microscopic invasion of bladder neck</td>
</tr>
<tr>
<td>pT3b</td>
<td>Seminal vesicle invasion</td>
</tr>
<tr>
<td>pT4</td>
<td>Invasion of rectum, levator muscles, &amp;/or pelvic wall</td>
</tr>
<tr>
<td><strong>Regional Lymph Nodes (pN)</strong></td>
<td></td>
</tr>
<tr>
<td>pNX</td>
<td>Regional lymph nodes not sampled</td>
</tr>
<tr>
<td>pN0</td>
<td>No positive regional lymph nodes</td>
</tr>
<tr>
<td>pN1</td>
<td>Metastasis in regional lymph node(s)</td>
</tr>
<tr>
<td><strong>Distant Metastasis (M)</strong></td>
<td></td>
</tr>
<tr>
<td>M0</td>
<td>No distant metastasis</td>
</tr>
<tr>
<td>M1</td>
<td>Distant metastasis</td>
</tr>
<tr>
<td>M1a</td>
<td>Nonregional lymph node(s)</td>
</tr>
<tr>
<td>M1b</td>
<td>Bone(s)</td>
</tr>
<tr>
<td>M1c</td>
<td>Other site(s) with or without bone disease</td>
</tr>
</tbody>
</table>

*There is no pathologic pT1 classification.*

Adapted from 7th edition AJCC Staging Forms (2010).

Image Galley

Normal Anatomy and Histology

(Left) PU is divided into proximal PU and distal PU by a mid angulation at the verumontanum where the ED exits. TZ (blue) and CZ (magenta) encase proximal PU and ED, respectively. PZ (transparent) surrounds CZ and distal PU posteriorly. Nonglandular AFS (yellow) is situated anteriorly. (Right) McNeal model uses PU as key anatomic landmark and divides the prostate glandular component into PZ (green), CZ (orange), TZ (blue), and PUGR (white). The AFS (yellow) comprises the midanterior portion.
Coronal section of the prostate at the verumontanum shows the peripheral zone extending from posterior aspect, surrounding part of transition zone, and abutting the AFS. The central urethra is enveloped by the transition zone. (Right) The prostate “capsule” is not a true capsule but a condensation of fibromuscular tissue that is an inseparable component of the prostatic stroma. Periprostatic adipose tissues and nerves are present. Involvement of adipose tissue by prostatic carcinoma constitutes EPE.

Typical benign acini show columnar secretory cells with pale cytoplasm and round, regular, basally oriented nuclei, with indistinct nucleoli. Basal cells are situated internal to glandular basement membrane outline and contain scant cytoplasm. (Right) The lining of the prostatic duct is similar to that of the adjacent acini. On cross section, ducts and acini are not reliably distinguished unless the longitudinal dimension of the duct is appreciated.

Cancer Staging
Graphic shows examples of incidental T1 prostate carcinoma divided into T1a, < 5% tumor in tissue resected (TURP), T1b, > 5% tumor in tissue resected (TURP), and T1c, tumor identified by needle biopsy (e.g., because of elevated PSA). If unsuspected prostate carcinoma is identified in tissue submitted and is < 5%, then remainder of tissue should be submitted for histologic evaluation. (Right) pT2a shows tumor involving not more than 1/2 of 1 lobe of the prostate.

pT2b shows tumor involving more than 1/2 of 1 lobe of prostate. This pattern of tumor involvement is uncommon, since prostate carcinoma is usually located at the posterior aspect, and larger tumors tend to involve bilateral posterior sides (pT2c), even without anterior involvement. (Right) pT2c shows organ-confined tumor involving both lobes of the prostate. pT2 subdivisions may act as surrogate for estimating prostate carcinoma volume, which correlates with disease relapse.
EPE by prostate carcinoma indicates pT3 disease. Detection of EPE is most reliably made by histologic examination. DRE and radiographic studies are not sensitive in detecting EPE. (Right) EPE with tumor extension into periprostatic fat is shown, which is the most objective evidence for EPE. Intraprostatic fat is vanishingly rare; thus, fat involvement by prostate carcinoma is considered diagnostic for EPE. EPE most commonly occurs at the posterior and posterolateral aspects of prostate.

Cancer Staging

Mechanisms of SV involvement by prostate cancer include spread via (a) ejaculatory duct tissue into SV (green), (b) direct extra- (blue) or intraprostatic (red) spread into SV, or (c) noncontiguous metastasis to SV (purple). (Right) Prostate cancer involving the ED shows a tumor adjacent to ED epithelium. Prostate cancer may extend to SV via invasion through the wall and not within the lumen of ED. SV invasion is considered only when there is involvement of SV muscular wall.
(Left) pT4 prostate cancer shows tumor invading structures other than SV, such as the bladder, rectum, and anterior pelvic wall. This tumor extent is managed with radiotherapy or hormonal therapy. RP with lymph node dissection may be performed in selected patients (e.g., low volume, no fixation). (Right) Rectal biopsy shows poorly differentiated prostate carcinoma involving rectal mucosa. This, the highest pT stage, is confirmed histologically, and criteria for pT staging is fulfilled without removal of the tumor.

(Left) Axial CT shows retroperitoneal lymphadenopathy and sclerotic vertebral metastasis by prostate cancer. Staging pelvic CT or MR is performed for T3 or T4 or in localized prostate cancer with high nomogram probability for lymph node involvement. Due to false positivity, staging MR/CT is usually not performed if GS < 7 or PSA < 20 ng/mL.

(Right) Lymph node shows subcapsular metastatic prostate carcinoma. It is important to specify the number of nodes involved.

P.III(7):17

Immunohistochemical Features
PSA shows strong positive reaction in the prostatic acini whereas staining is negative in the SV epithelium. (Right) p63 shows nuclear positivity of basal cells in the benign gland. Carcinoma glands show absence of p63 staining. Complete absence of basal cell layer is defining criterion for invasive prostate carcinoma. All glands in the same atypical focus should similarly show complete absence of basal cells as some benign cancer mimics may have patchy basal cell staining.

Dual chromogen immunostain shows overexpression of AMACR (red) in carcinoma glands and basal cell markers (HMWCK and p63) (brown) positivity only in benign glands. AMACR staining in carcinoma is typically granular and circumferential. (Right) Dual chromogen immunostain shows overexpression of AMACR (red) and basal cell markers (brown) positivity in HGPIN glands. Carcinoma glands show AMACR overexpression. Benign glands show basal cell markers staining.
AMACR immunostain shows cytoplasmic staining in tubules of nephrogenic adenoma. Prostatic urethral nephrogenic adenoma may proliferate inward into the prostate and mimic a Gleason grade 3 acinar carcinoma, confounded by the similar AMACR staining. (Right) Bone biopsy shows foci of metastatic prostate carcinoma highlighted by PSMA staining. Prostate-lineage markers PSMA, PSA, and PAP have good sensitivity in the metastatic setting. Among these, PSMA is considered the most sensitive.

Renal Pelvis and Ureter

Diagnosis of Lynch (HNPCC) Syndrome Upper Urinary Tract UCa

<table>
<thead>
<tr>
<th>Examination</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical</td>
<td>Patient &lt; 60 years old</td>
</tr>
<tr>
<td></td>
<td>History of HNPCC-associated cancer (e.g., colon cancer, uterine cancer)</td>
</tr>
<tr>
<td></td>
<td>First-degree relative &lt; 50 years of age with HNPCC-associated cancer</td>
</tr>
<tr>
<td></td>
<td>2 first-degree relatives with HNPCC-associated cancer</td>
</tr>
</tbody>
</table>

| Pathologic | Upper tract UCa more often with inverted growth pattern (sensitivity and specificity of 0.82 for high frequency MSI [MSI-H]) |

- Immunohistochemical screening with antibodies against MLH1, MSH2, PMS2, and MSH6
- MSI testing by PCR using NCI consensus panel of 2 mononucleotide (BAT25 and BAT26) and 3 dinucleotide (D2S123, D5S346, and D17S250) markers

MSI phenotypes: MSI-H if size alterations or shifts observed in ≥ 2 markers, low MSI (MSIL) if only 1 marker shows instability, and microsatellite stable (MSS) if none of the markers show instability

HNPCC: Hereditary nonpolyposis rectal cancer; MSI: Microsatellite instability; NCI: National Cancer Institute; UCa: Urothelial carcinoma.
### Diagnostic Pathology: Familial Cancer Syndromes

<table>
<thead>
<tr>
<th>Marker</th>
<th>Expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>GATA3</td>
<td>+</td>
</tr>
<tr>
<td>CK7</td>
<td>+</td>
</tr>
<tr>
<td>CK20</td>
<td>+/-</td>
</tr>
<tr>
<td>HMWCK (34bE12)</td>
<td>+/-</td>
</tr>
<tr>
<td>Thrombomodulin</td>
<td>+/-</td>
</tr>
<tr>
<td>Uroplakin-3</td>
<td>+/-</td>
</tr>
<tr>
<td>pax-8</td>
<td>- (rarely focal +)</td>
</tr>
<tr>
<td>pax-2</td>
<td>- (rarely focal +)</td>
</tr>
<tr>
<td>RCC</td>
<td>+/-</td>
</tr>
<tr>
<td>Vimentin</td>
<td>+/-</td>
</tr>
<tr>
<td>INI1</td>
<td>+/-</td>
</tr>
</tbody>
</table>

#### 2010 AJCC Staging System for Renal Pelvis and Ureter Cancer

**Stage Definition**

*Primary Tumor (pT)*
- pTX: Primary tumor cannot be assessed
- pT0: No evidence of primary tumor
- pTa: Papillary noninvasive carcinoma
- pTis: Carcinoma in situ
- pT1: Tumor invades subepithelial connective tissue
- pT2: Tumor invades the muscularis
- pT3: For renal pelvis only: Tumor invades beyond muscularis into peripelvic fat or the renal parenchyma
  - For ureter only: Tumor invades beyond muscularis into periureteric fat
- pT4: Tumor invades adjacent organs or through the kidney into the perinephric fat

*Regional Lymph Nodes (pN)*
- pNX: Regional lymph nodes cannot be assessed
- pN0: No regional lymph node metastasis
- pN1: Metastasis in a single lymph node, ≤ 2 cm in greatest dimension
- pN2: Metastasis in a single lymph node, > 2 cm but not > 5 cm in greatest dimension; or multiple lymph nodes, none > 5 cm in greatest dimension
- pN3: Metastasis in a lymph node, > 5 cm in greatest dimension

*Distant Metastasis (M)*
- M0: No distant metastasis
- M1: Distant metastasis

Adapted from 7th edition AJCC Staging Forms (2010).

P.III(7):19

---

Image Galley

Staging and Immunohistochemical Features
(Left) Gross image shows urothelial carcinoma arising from upper renal pelvis and infiltrating into the renal parenchyma without involving the perinephric fat (pT3). Urothelial carcinoma shows an infiltrative border in contrast to most renal carcinomas. (Right) Low-power view shows adrenal cortex involved by urothelial carcinoma. Extension by renal urothelial carcinoma into adrenal or perinephric fat is considered pT4. Five-year specific survival of pT4 renal urothelial carcinoma is < 10%.

(Left) Gross photograph shows a segment of ureter thickened by invasive urothelial carcinoma. Ureteral urothelial carcinoma may present as obstruction that mimics a stricture. In this case, the tumor infiltrates full thickness of the wall and extends into the periureteric fat (pT3). (Right) p63 shows diffuse nuclear positivity in this infiltrating renal urothelial carcinoma. A portion of overlying benign urothelium similarly shows diffuse nuclear positivity, which serves as an internal control.
Diagnostic Pathology: Familial Cancer Syndromes

(Left) GATA3 shows nuclear positivity in this renal pelvis invasive urothelial carcinoma. Note the variability of staining, weaker in areas where there are squamoid features. (Right) pax-8 shows negative staining in urothelial carcinoma infiltrating the renal parenchyma. Renal tubules exhibit nuclear positivity and serve as internal control.

Combination of p63 and pax-8/pax-2 is helpful to distinguish urothelial carcinoma (p63+/pax-8 or pax-2[-]) from renal carcinoma (p63[-]/pax-8 or pax-2[+]).

**Testicle**

<table>
<thead>
<tr>
<th>Conditions</th>
<th>Gene</th>
<th>Testicular Tumors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Familial testicular GCT (female relatives with familial ovarian GCT)</td>
<td>Several genes implicated; KITLG, SPRY4, and BAK1 confirmed by genome-wide association studies</td>
<td>ITGCN and GCT (tumors reported are postpubertal types)</td>
</tr>
<tr>
<td>Peutz-Jeghers syndrome</td>
<td>STK11/LKB1</td>
<td>ILCHSCN, LCCSCT, and Sertoli cell tumor</td>
</tr>
<tr>
<td>Carney complex</td>
<td>PRKAR1A (mutations seen in 45-80%)</td>
<td>LCCSCT is a component of Carney complex</td>
</tr>
</tbody>
</table>

GCT: Germ cell tumor; ILCHSCN: Intraductular large cell hyalinizing Sertoli cell neoplasia; ITGCN: Intraductular germ cell neoplasia; LCCSCT: Large cell calcifying Sertoli cell tumor.

### Tumors With Diffuse Arrangement and Pale and Clear Cytoplasm

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Classic Seminoma</th>
<th>Spermatocytic Seminoma</th>
<th>Embryonal Yolk Sac Carcinoma</th>
<th>Testicular Tumors</th>
<th>Renal Cell Melanoma</th>
<th>Sertoli Lymphoma</th>
<th>Tumors With Diffuse Arrangement and Pale and Clear Cytoplasm</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD117</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-/+</td>
<td>V</td>
<td>-</td>
<td>CD117</td>
</tr>
<tr>
<td>OCT3/4</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>V</td>
<td>ND</td>
<td>OCT3/4</td>
</tr>
<tr>
<td>CD30</td>
<td>-/+ (rare BER-H2 focal cells)</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>V</td>
<td>ND</td>
<td>CD30</td>
</tr>
<tr>
<td>α-fetoprotein</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>ND</td>
<td>-</td>
<td>α-fetoprotein</td>
</tr>
<tr>
<td>Glypican-3</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Glypican-3</td>
</tr>
<tr>
<td>PAN-CK (AE1/AE3)</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+/-</td>
<td>+</td>
<td>-</td>
<td>PAN-CK (AE1/AE3)</td>
</tr>
<tr>
<td>CK7</td>
<td>V</td>
<td>ND</td>
<td>+</td>
<td>-/+</td>
<td>ND</td>
<td>V</td>
<td>CK7</td>
</tr>
<tr>
<td>EMA</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-/+</td>
<td>-</td>
<td>+</td>
<td>EMA</td>
</tr>
<tr>
<td>Inhibin (+ STC)</td>
<td>ND</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>Inhibin (+ STC)</td>
</tr>
<tr>
<td>Antibody</td>
<td>Embryonal Carcinoma</td>
<td>Seminoma</td>
<td>Yolk Sac Tumor</td>
<td>Sertoli Cell Tumor</td>
<td>Ret Testis Tumor</td>
<td>Metastatic Adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>---------------------</td>
<td>----------</td>
<td>---------------</td>
<td>-------------------</td>
<td>-----------------</td>
<td>---------------------------</td>
<td></td>
</tr>
<tr>
<td>OCT3/4</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>CD30 (BER-H2)</td>
<td>+</td>
<td>-/+ (rare focal cells)</td>
<td>Rarely +</td>
<td>-</td>
<td>V</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD117</td>
<td>-</td>
<td>+</td>
<td>-/+</td>
<td>-</td>
<td>-</td>
<td>V</td>
<td></td>
</tr>
<tr>
<td>Inhibin</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>EMA</td>
<td>-</td>
<td>-</td>
<td>-/+</td>
<td>-</td>
<td>V</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>SALL4</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>α-fetoprotein</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Calretinin</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-/+</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Chromogranin</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Glypican-3</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>- (+ in hepatocellular carcinoma)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Leydig Cell Tumor</th>
<th>Large Cell Calcifying Sertoli Cell Tumor, NOS</th>
<th>CarcinoidPlasmacytoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhibin</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>PLAP</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PAN-CK (AE1/AE3)</td>
<td>-/+</td>
<td>-/+</td>
<td>+/-</td>
</tr>
<tr>
<td>Vimentin</td>
<td>+</td>
<td>+</td>
<td>V</td>
</tr>
<tr>
<td>S100</td>
<td>V</td>
<td>+</td>
<td>V</td>
</tr>
<tr>
<td>Synaptophysin</td>
<td>V</td>
<td>ND</td>
<td>V</td>
</tr>
</tbody>
</table>

**ND: No data; STC: Syncytiotrophoblast; V: Variable.**

### 2010 AJCC Staging System for Testicular Cancer

**Stage Definition**

**Primary Tumor (pT)**
- **pTX**: Primary tumor cannot be assessed
- **pT0**: No evidence of primary tumor (e.g., histologic scar in testis)
- **pTis**: Intratubular germ cell neoplasia (carcinoma in situ)
- **pT1**: Tumor limited to the testis and epididymis without vascular/lymphatic invasion; tumor may invade into the tunica albuginea but not the tunica vaginalis
- **pT2**: Tumor limited to the testis and epididymis with vascular/lymphatic invasion, or tumor extending through the tunica albuginea with involvement of the tunica vaginalis
- **pT3**: Tumor invades the spermatic cord with or without vascular lymphatic invasion
- **pT4**: Tumor invades the scrotum with or without vascular/lymphatic invasion

**Regional Lymph Nodes (pN)**
- **pNX**: Regional lymph nodes cannot be assessed
- **pN0**: No regional lymph node metastasis
- **pN1**: Metastasis with a lymph node mass ≤ 2 cm in greatest dimension and ≤ 5 nodes positive, none > 2 cm in greatest dimension
pN2  Metastasis with a lymph node mass > 2 cm but not > 5 cm in greatest dimension; or > 5 lymph nodes positive, none > 5 cm; or evidence of extranodal tumor extension
pN3  Metastasis with a lymph node mass > 5 cm in greatest dimension

Distant Metastasis (M)
M0  No distant metastasis
M1  Distant metastasis
M1a  Nonregional nodal or pulmonary metastasis
M1b  Distant metastasis other than to nonregional lymph nodes or lung

Adapted from 7th edition AJCC Staging Forms (2010).

P.III(7):22

Image Galley
Normal Testicular Histoanatomy and Cancer Staging

(Left) Schematic diagram of testis and paratestis is shown. The testicular parenchyma is separated by fibrous septae. The tubules converge and exit to the rete testis, efferent ducts, epididymis, and vas deferens. (Right) Schematic diagram shows seminiferous tubule with spermatogenesis (spermatogonia, spermatocytes, spermatids, spermatozoa). Cellular maturation progresses from base to lumina. Sertoli cells and Leydig cells are also shown.

(Left) Seminiferous tubule (ST) shows spermatogenesis. The largest cell in a normal ST is the primary spermatocyte, usually situated about halfway toward the lumen. Primary spermatocytes have beaded (spireme) nuclear
chromatin. In ITGCN, large atypical cells with nucleoli are seen usually adjacent to basement membrane. Note the Leydig and Sertoli cells. (Right) Axial CECT shows a complex enhancing mass in the left scrotum, compatible with testicular cancer.

(Left) Longitudinal ultrasound shows a large seminoma, which has essentially replaced the testis. There is a thin crescent of normal remaining parenchyma. Despite its large size, it remains homogeneous without evidence of necrosis. (Right) Gross photograph of resected testis shows the seminoma to be uniform in texture without necrosis or hemorrhage, resulting in its homogeneous echogenicity on ultrasound. The testicular tunica is grossly uninvolved by tumor.
P.III(7):23

Testicular Cancer Staging

(Left) Embryonal carcinoma shows circumscribed variegated hemorrhagic tumor surrounded by a rim of normal testicular parenchyma. Primary tumor size is not a variable when staging testicular cancer. Staging is based on extent of invasion to surrounding structures and by lymphovascular invasion. (Right) Low-power view shows embryonal carcinoma invading the rete testis and into the spermatic cord (pT3). Invasion of the rete testis is suggested to be an adverse prognostic indicator.
Multiple tumor emboli are seen inside the vessel lumina. Note the tumor clusters follow the vessel contour. Presence of lymphovascular invasion upstages a testis-confined tumor from pT1 to pT2 and should be diligently searched in orchectomy specimens. (Right) Schematic drawing shows testicular lymphatic drainage. The primary pathway (yellow) follows the testicular veins. If tumor has invaded through the tunica vaginalis into the scrotal skin, the inguinal nodes may be involved.

(Left) Axial CECT in a patient with a right testicular carcinoma shows bulky retroperitoneal adenopathy. The right testis lymphatics drain to the aorto-caval nodes just inferior to the right renal hilum. (Right) This mixed germ cell tumor has metastasized into a retroperitoneal lymph node. Note presence of extranodal tumor extension. Size of nodal metastasis (pN1 ≤ 2 cm, pN2 = 2-5 cm, and pN3 > 5 cm) and presence of extranodal extension (pN2) are used in substaging pN status.

Immunohistochemical Features
PLAP shows cytoplasmic and membranous immunoreactivity in intratubular germ cell neoplasia (ITGCN). PLAP is generally not expressed in normal spermatocytes and has high sensitivity in highlighting presence of ITGCN. (Right) PLAP shows strong and diffuse immunoreactivity in this embryonal carcinoma. PLAP is immunoreactive in all germ cell tumors (GCTs) and is only helpful in testis when distinguishing GCTs from non-GCT tumors, particularly sex cord-stromal tumors.

OCT3/4 shows nuclear and some membranous positivity in this ITGCN. OCT3/4 is not expressed by normal spermatocytes. (Right) OCT3/4 shows diffuse immunoreactivity in this embryonal carcinoma. OCT3/4 can be positive in ITGCN, classic seminoma, and embryonal carcinoma. This marker is useful when distinguishing seminoma and embryonal carcinoma from other GCTs exhibiting solid growth, such as solid yolk sac tumor and spermatocytic seminoma.
CD117 is diffusely (+) in this classic seminoma. It is also immunoreactive in ITGCN and spermatocytic seminoma and is useful when distinguishing seminoma from embryonal carcinoma and solid yolk sac tumor, which are both negative for CD117. (Right) CD30 shows diffuse membranous immunoreactivity in this embryonal carcinoma (EC). CD30 is highly specific for EC and is often done to compliment CD117 when distinguishing EC from seminoma (CD30[-] and CD117[+]).

Immunohistochemical Features

(Left) Glypican-3 highlights yolk sac element in mixed germ cell tumor. Note the embryonal carcinoma component is completely negative. Glypican-3 may also be positive in some teratomas. (Right) HCG-β highlights a multinucleated syncytiotrophoblasts. HCG-β can be used to confirm diagnosis of choriocarcinoma and detect presence of syncytiotrophoblasts admixed in GCTs such as seminoma or embryonal carcinoma. Use of HCG-β is sometimes limited by its nonspecific background staining.
HPL in choriocarcinoma shows intense cytoplasmic reactivity in syncytiotrophoblasts. The large mononucleated (intermediate) trophoblasts usually show weaker cytoplasmic staining. Cytotrophoblasts are typically negative for HPL (not shown). (Right) Desmin shows cytoplasmic positivity in this rhabdomyosarcoma (RMS) arising from teratoma. Nonsarcomatous myogenic differentiation may also occur in teratoma after therapy and should be distinguished morphologically from RMS.

Inhibin shows occasional positivity in this Sertoli cell tumor. Inhibin is expressed by all sex cord-stromal tumors (SCSTs) and is often used to complement PLAP when distinguishing SCSTs from GCTs (inhibin [-] and PLAP[+]). (Right) Calretinin shows positivity in this Sertoli cell tumor. GCTs that also exhibit tubular features such as seminoma, yolk sac tumor, and embryonal carcinoma are negative for calretinin. Beware that calretinin is also expressed by paratesticular adenomatoid tumor.

Section 8 - Gynecology
Gynecologic Neoplasms
<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Tissue Affected</th>
<th>Genes/Tests</th>
<th>Tumor Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lynch syndrome</strong></td>
<td>Endometrium, ovaries</td>
<td>MLH1, MSH2, MSH6, PMS2</td>
<td>60% for endometrial cancer; 11% for ovarian cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Endometrioid, serous, clear cell, carcinosarcoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Tumor infiltrating lymphocytes; synchronous endometrial and ovarian endometrioid adenocarcinoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Immunohistochemistry for MLH1, MSH2, MSH6, and PMS2; MLH1 promoter hypermethylation; microsatellite instability testing; sequencing of MLH1, MSH2, MSH6, PMS2; PMS2 sequencing of BRCA1 and BRCA2; testing for gene rearrangements</td>
</tr>
<tr>
<td><strong>Hereditary breast and ovarian cancer</strong></td>
<td>Ovaries, peritoneum, fallopian tubes</td>
<td>BRCA1, BRCA2</td>
<td>Ovarian cancer: 35-60% for BRCA1, 12-25% for BRCA2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ovaries: Most are high-grade invasive serous carcinomas; fallopian tubes: Most are serous intraepithelial carcinomas</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Endometrial adenocarcinoma, uterine leiomyomas</td>
</tr>
<tr>
<td><strong>PTEN hamartoma tumor syndrome (Cowden syndrome)</strong></td>
<td>Uterus</td>
<td>PTEN</td>
<td>5-42% for endometrial cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Limited data</td>
</tr>
<tr>
<td><strong>Peutz-Jeghers syndrome</strong></td>
<td>Ovaries, cervix, endometrium</td>
<td>STK11 (LKB1)</td>
<td>Ovarian SCTAT, cervical minimal deviation adenocarcinoma, endometrial adenocarcinoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>SCTATs are small, calcified, multifocal, bilateral</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Limited data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>STK11 sequencing and large deletion analysis</td>
</tr>
<tr>
<td><strong>Germline mutations of Fanconi anemia-BRCA pathway and others</strong></td>
<td>Ovaries, potentially fallopian tubes and peritoneum</td>
<td>RAD51C, RAD51D, BRIP1, RAD50, NBN, MRE11A</td>
<td>Limited data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Limited data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Limited data</td>
</tr>
<tr>
<td><strong>Hereditary leiomyomatosis and renal cell carcinoma</strong></td>
<td>Uterus</td>
<td>Fumarate hydratase (FH)</td>
<td>77% for uterine leiomyoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Leiomyomas</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Multiple leiomyomas</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Limited data</td>
</tr>
<tr>
<td><strong>Hereditary esophageal-vulvar syndrome</strong></td>
<td>Vulva</td>
<td>Some limited associate data with Alport</td>
<td>Limited data</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Leiomyomas</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Multiple leiomyomas</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Limited data</td>
</tr>
</tbody>
</table>
von Hippel-Lindau syndrome
Mesosalpinx VHL and broad ligament

SCTAT: Sex cord-stromal tumors with annular tubules.

Limited data
Clear cell papillary cystadenoma

VHL sequencing and deletion/duplication analysis

(Left) In 5-7% of cases, risk-reducing salpingo-oophorectomies in patients with hereditary breast and ovarian cancer reveal high-grade serous carcinoma at the in situ stage, known as serous intraepithelial carcinomas. (Right) Sex cord-stromal tumor with annular tubules (SCTAT) is associated with Peutz-Jeghers syndrome.
Section 9 - Nervous System
Central Nervous System

<table>
<thead>
<tr>
<th>Syndromes</th>
<th>Gene(s)</th>
<th>Gene Regions</th>
<th>Cell Pathways</th>
<th>CNS Tumors</th>
<th>Non-CNS Tumors</th>
<th>Nonneoplastic Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurofibromatosis type 1</td>
<td>NFI</td>
<td>17q11. RAS/MAPK/PI3K/mTOR/cAMP</td>
<td>Astrocytic tumors (grade I-IV), glioneuronal tumors</td>
<td>Neurofibromas, Lisch nodules, pheochromocytoma, café au lait spots, skeletal dysplasias, juvenile myelomonocytic leukemia, retinal hamartoma, Abnormalities, café au lait spots (few), subcapsular cataract, choroidal hamartomas, Hyperviscosity, Hemangiomas, Hepatic angiomatosis, Hepatic angiomatosis, Renal cell carcinoma, Cysts of pancreas,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurofibromatosis type 2</td>
<td>NF2</td>
<td>22q12. Integrin, RAC/PAK, WNT, YAP/ Hippo, MAPK, PI3K, CRL4</td>
<td>Meningioma, ependymoma, glioma NOS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>von Hippel-Lindau</td>
<td>VHL</td>
<td>3p25. HIF (angiogenesis)</td>
<td>Hemangioblastoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Syndrome</td>
<td>Gene(s)</td>
<td>Chromosome(s)</td>
<td>Tumors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------</td>
<td>-----------</td>
<td>------------------------</td>
<td>------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gorlin syndrome</td>
<td>PTCH1, PTCH2, SUFU</td>
<td>9q22, 1p34, 10q24</td>
<td>Medulloblastoma, Basal cell carcinoma, Pheochromocytoma, Pancreatic endocrine tumors, Endolymphatic sac tumor, Papillary cystadenoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Turcot type 1 (Lynch)</td>
<td>MLH1, MSH2, MSH6, PMS2</td>
<td>3p, 2p, 7p</td>
<td>Astrocytic tumors (grade II-IV), GI carcinomas, Endometrium, Adrenal carcinoma, Osteomas, Sebaceous neoplasms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Turcot type 2 (familial adenomatous polyposis)</td>
<td>APC</td>
<td>5q21-q22</td>
<td>Medulloblastoma, FAP colorectal cancer, GI polyps, Desmoid tumor (fibromatosis), Papillary thyroid carcinoma (cribriform-morular variant)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Constitutional mismatch repair deficiency syndrome</td>
<td>MLH1, MSH2, MSH6, PMS2</td>
<td>3p, 2p, 7p</td>
<td>Astrocytic tumors (grade II-IV), Lymphoma + cancers associated with Turcot type 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuberous sclerosis complex</td>
<td>TSC1, TSC2</td>
<td>9q34, 16p13</td>
<td>Subependymal giant cell astrocytoma (SEGA), Angiomyolipoma, Angioleiomyomatosis, Subependymal nodules, Angiofibroma, Ungual fibroma, Macules, Nevi</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Li-Fraumeni syndrome</td>
<td>TP53</td>
<td>17p13</td>
<td>DNA damage response, Apoptosis, Cell cycle, Sarcomas, Osteosarcomas</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Syndrome</td>
<td>Genes/Proteins</td>
<td>Chromosome</td>
<td>Associated Tumors</td>
<td>Genetic Disease Model</td>
<td>Clinical Manifestations</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>----------------</td>
<td>------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>-------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Melanoma-astrocytoma syndrome</td>
<td>CDKN2A</td>
<td>9p21</td>
<td>Cell cycle (CDKs) (p16), DNA damage response (p14)</td>
<td>Astrocytic tumors</td>
<td>Breast carcinoma, adrenal cortical carcinoma, hematolymphoid medulloblastoma, choroid plexus tumors</td>
<td></td>
</tr>
<tr>
<td>Familial uveal melanoma</td>
<td>BAP1</td>
<td>3p21</td>
<td>DNA repair (BRCA1 pathway)</td>
<td>Astrocytic tumors, meningioma</td>
<td>Melanoma, pancreatic adenocarcinoma, atypical nevi, Uveal melanoma, renal cell carcinoma, mesothelioma, atypical melanocytic lesions</td>
<td></td>
</tr>
<tr>
<td>Rhabdoid predisposition syndrome</td>
<td>INI1</td>
<td>22q11.1</td>
<td>Chromatin dynamics</td>
<td>Atypical teratoid-rhabdoid tumor</td>
<td>Renal and extrarenal rhabdoid tumors</td>
<td></td>
</tr>
<tr>
<td>Hereditary retinoblastoma</td>
<td>RB1</td>
<td>13q14.2</td>
<td>Cell cycle (CDKs)</td>
<td>Pineoblastoma, PNET</td>
<td>Breast/endometrial carcinomas, keratoses, multiple thyroid nodules, intestinal polyps, intellectual disabilities</td>
<td></td>
</tr>
<tr>
<td>Cowden/Lhermitte-Duclos syndrome</td>
<td>PTEN</td>
<td>10q23.3</td>
<td>Cell cycle (CDKs)</td>
<td>Dysplastic gangliocytoma of cerebellum</td>
<td>Pulmonary valve stenosis, learning disabilities, pectus excavatum, characteristic facies</td>
<td></td>
</tr>
<tr>
<td>Noonan syndrome</td>
<td>PTPN11</td>
<td>12q24.1</td>
<td>Cell cycle (CDKs)</td>
<td>Pilocytic astrocytoma, glioneuronal tumors</td>
<td>Pulmonary agensis of corpus callosum, chorioretinal lacunae, infantile spasms</td>
<td></td>
</tr>
<tr>
<td>Aicardi syndrome</td>
<td>Unknown</td>
<td>X-linked</td>
<td>Unknown</td>
<td>Choroid plexus papilloma</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Pleuro-pulmonary</td>
<td>Dicer1</td>
<td>14q32.3</td>
<td>Cell cycle (CDKs)</td>
<td>Pineoblastoma</td>
<td>Pleuropulmonary Lung cysts, blastoma</td>
<td></td>
</tr>
</tbody>
</table>
(Left) The central nervous system hallmark of NF1 is multiple (bilateral) involvement of the optic pathways by low-grade gliomas. These may affect the optic nerve proper as well as the chiasm. (Right) The overwhelming majority of optic pathway gliomas are pilocytic astrocytomas. In this NF1-associated case, areas of tissue compaction, microcysts, and Rosenthal fibers are evident. The tumors grow slowly and may even be followed without treatment in most cases.

(Left) Although pilocytic astrocytoma is the most frequent glioma in patients with NF1, all astrocytic subtypes develop including high-grade astrocytomas, as seen in this example. Heterogeneous contrast enhancement is evident in...
High-grade astrocytomas in patients with NF1 are graded using similar criteria as in sporadic tumors. Parenchymal infiltration, atypia, and mitotic activity are present in this anaplastic (WHO grade III) astrocytoma.

Meningiomas are the 2nd most common neoplasms in patients with NF2. They are usually dura-based, multiple, and demonstrate strong, homogeneous contrast enhancement after administration of gadolinium in T1-weighted MR sequences. The cytologic features of meningiomas are evident in intraoperative smears. Features include “flat” cells with ample eosinophilic cytoplasm containing bland oval nuclei as well as whorls.

Imaging and Microscopic Features

Axial T1-weighted post-contrast MR shows 2 of several cerebellar hemangioblastomas, a finding that is so characteristic as to be diagnostic of VHL syndrome by itself. The presence of multiple cysts and tumors in other organs is also characteristic of this disorder. The characteristic neoplasm involving the CNS and retina in patients with VHL syndrome is hemangioblastoma, a vascularized tumor containing vacuolated stromal cells.
Subependymal giant cell astrocytomas (SEGAs) are typical of tuberous sclerosis complex, characterized by contrast-enhancing intraventricular masses near the foramen of Monro. A subtle cortical tuber is also present in this patient with tuberous sclerosis complex. SEGAs are characterized by colorful, large cells with prominent nucleoli, features particularly recognizable in smear preparations. Variable cytoplasmic processes and pleomorphism may also be present.

Choroid plexus carcinomas are malignant neoplasms that almost always develop in young children and demonstrate variable contrast enhancement. (Courtesy T. Vanegas, MD.) Choroid plexus carcinomas usually have a papillary architecture, at least in part, and variable pleomorphism. This young patient developed a rhabdomyosarcoma subsequently, which strongly suggests Li-Fraumeni syndrome.

Imaging, Diagrammatic, and Microscopic Features
The cerebellopontine angle is a classic location for AT/RT. These tumors may form large heterogeneous masses involving the posterior fossa, but they may also affect other CNS sites. (Courtesy C. Specht, MD.)

Atypical teratoid rhabdoid tumors contain variable proportions of rhabdoid cells, characterized by eccentric nuclei with nucleoli and eosinophilic cytoplasm. This patient had a constitutional chromosome 22 abnormality and multiple associated congenital anomalies.

Pineoblastomas are malignant neoplasms presenting as contrast-enhancing masses in the pineal region. Associated hydrocephalus is a frequent finding. Pineoblastomas may occur sporadically or in association with tumor predisposition syndromes such as familial retinoblastoma. (Right) Pineoblastomas are high-grade neoplasms composed of cells with high nuclear to cytoplasmic ratios. Cell-cell wrapping may be present as in other embryonal neoplasms.
The hallmark of CNS involvement by Cowden syndrome secondary to constitutional PTEN mutations is Lhermitte-Duclos disease, which has a characteristic gross/radiographic appearance (i.e., asymmetric expansion of cerebellar folia). (Right) Lhermitte-Duclos (or dysplastic gangliocytoma of the cerebellum) is characterized by replacement of the internal granular layer of the cerebellum by large, dysplastic ganglion cells, with relative architectural preservation.

### Eye

<table>
<thead>
<tr>
<th>Genetic Syndromes and Neoplasms Involving Eye and Ocular Adnexa</th>
<th>Eye Tumors</th>
<th>Extraocular Tumors</th>
<th>Nonneoplastic Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Neurofibromatosis type 1</strong></td>
<td>Optic nerve glioma (pilocytic astrocytoma), orbital and intraocular neurofibromas</td>
<td>Astrocytomas, gliioneural tumors, neurofibromas, MPNST, pheochromocytoma, carcinoid tumors, juvenile myelomonocytic leukemia</td>
<td>Lisch nodules, café au lait spots, skeletal, vasculopathy</td>
</tr>
<tr>
<td><strong>Neurofibromatosis type 2</strong></td>
<td>Orbital meningioma, orbital and intraocular schwannoma</td>
<td>Meningioma, schwannoma</td>
<td>Retinal hamartoma, skeletal abnormalities, café au lait spots (few), subcapsular cataract</td>
</tr>
<tr>
<td><strong>von Hippel-Lindau syndrome</strong></td>
<td>Hemangioblastoma</td>
<td>Renal cell carcinoma, pheochromocytoma, pancreatic endocrine</td>
<td>Cysts of pancreas, kidney, adrenal gland, testis</td>
</tr>
<tr>
<td><strong>RAS/MAPK/PI3K/mTOR/cAMP</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Optic nerve glioma (pilocytic astrocytoma)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Integrin, RAC/PAK, WNT, YAP/Hippo, MAPK, PI3K, CRL4</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Orbital meningioma, orbital and intraocular schwannoma</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hemangioblastoma</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Renal cell carcinoma, pheochromocytoma, pancreatic endocrine</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Syndrome</td>
<td>Gene(s)</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>----------------------------------</td>
<td>---------</td>
<td>-----------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Muir-Torre/McKee (Lynch)</td>
<td>MSH2, MLH1</td>
<td>Mismatch repair tumors, endolymphatic sac tumor, papillary cystadenoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Astrocytomas, GI carcinomas, endometrial and ovarian tumors, sebaceous neoplasms</td>
<td></td>
</tr>
<tr>
<td>Tuberous sclerosis complex</td>
<td>TSC1, TSC2</td>
<td>Giant cell astrocytoma/astrocytic hamartomas, Subependymal giant cell astrocytoma, astrocytoma, angiomylipoma, angiolipoma, rhabdomyoma, angiofibroma, nevi</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cortical tubers, subependymal nodules, angioleiomyoma, macules, nevi</td>
<td></td>
</tr>
<tr>
<td>Familial uveal melanoma</td>
<td>BAP1</td>
<td>Uveal melanoma, Astrocytoma, meningioma, renal cell carcinoma, mesothelioma, atypical melanocytic lesions</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>DNA repair (BRCA1 pathway)</td>
<td></td>
</tr>
<tr>
<td>Hereditary retinoblastoma</td>
<td>RB1</td>
<td>Retinoblastoma, (often bilateral) Pineoblastoma, CNS-PNET, retinoblastoma, bone and soft tissue sarcomas</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pineoblastoma, pleuropulmonary blastoma, Wilms tumor, sex cord-stromal tumors</td>
<td></td>
</tr>
<tr>
<td>Pleuropulmonary blastoma</td>
<td>DICE, R1</td>
<td>Medulloepithelioma, Lung cysts, Lung cysts, telangiectasias, cataracts, keratitis, cataracts, keratitis, CNS dysfunction</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Medulloepithelioma</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pleuropulmonary blastoma, Wilms tumor, sex cord-stromal tumors</td>
<td></td>
</tr>
<tr>
<td>Xeroderma pigmentosum</td>
<td>XPA-G, POLH</td>
<td>Multi Nucleotide excision DNA repair, Ocular surface squamous cell carcinoma (SCCa); basal cell carcinoma and melanoma (eyelids/conjunctiva)</td>
<td></td>
</tr>
<tr>
<td>Norrie disease</td>
<td>NDP</td>
<td>Pseudoglioma of retina, Cataracts, eye globe shrinkage; abnormalities</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pseudoglioma of retina</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cataracts, eye globe shrinkage; abnormalities</td>
<td></td>
</tr>
</tbody>
</table>
**MPNST: Malignant peripheral nerve sheath tumor.**

<table>
<thead>
<tr>
<th>Syndromes</th>
<th>Gene(s)</th>
<th>Gene Region</th>
<th>Nonneoplastic Ocular Manifestations</th>
<th>Extraocular Neoplasms</th>
<th>Other Nonneoplastic Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aicardi syndrome</td>
<td>Unknown</td>
<td>X-linked dominant</td>
<td>Chorioretinal lacunae</td>
<td>Choroid plexus papilloma</td>
<td>Agenesis of corpus callosum, infantile spasms</td>
</tr>
<tr>
<td>Ataxia-telangiectasia</td>
<td><em>ATM</em></td>
<td>11q22-23</td>
<td>Conjunctival telangiectasias</td>
<td>Hematolymphoid neoplasms, ovarian and breast carcinoma, smooth muscle tumors</td>
<td>Progressive ataxia, dermatitis, café au lait spots, hypogonadism, short stature, insulin resistance</td>
</tr>
<tr>
<td>WAGR</td>
<td>Multiple</td>
<td>11p</td>
<td>Aniridia</td>
<td>Wilms tumor, gonadoblastoma</td>
<td>Genitourinary anomalies, mental retardation</td>
</tr>
<tr>
<td>Gorlin syndrome</td>
<td><em>PTCH1</em> &gt; &gt; 9q22.3, 1p34.1, 10q24.32</td>
<td>Microphthalmos, cataracts, glaucoma, coloboma</td>
<td>Basal cell carcinoma, medulloblastoma</td>
<td>Odontogenic keratocysts, skeletal anomalies, calcification of falx cerebri, palmar/plantar pits</td>
<td></td>
</tr>
<tr>
<td>Fanconi anemia</td>
<td>Genes coding for Fanconi anemia core complex</td>
<td>Multiple</td>
<td>Microphthalmia</td>
<td>Hematolymphoid, solid tumors (e.g., SCCa)</td>
<td>Multiple congenital anomalies, endocrine dysfunction</td>
</tr>
<tr>
<td>Werner syndrome/progeria (RECQL2)</td>
<td><em>WRN</em></td>
<td>8p12</td>
<td>Cataracts</td>
<td>Epithelial and nonepithelial cancers</td>
<td>Premature aging, short stature, bird-like facies</td>
</tr>
</tbody>
</table>

P.III(9):7

Image Galley
Microscopic Features
A diagnostically important ocular manifestation of neurofibromatosis type 1 (NF1) is the Lisch nodule, an aggregate of pigmented cells in the anterior surface of the iris. (Right) Lisch nodules are composed of melanin-containing cells that form superficial aggregates in the iris. They usually do not affect vision and have no malignant potential.

Plexiform neurofibroma is a hallmark of NF1 and often affects the eyelid and orbital tissues. This eyelid example demonstrates the characteristic multinodular appearance resulting from multiple nerve fascicle involvement. (Right) Posterior subcapsular cataracts represent a hallmark of neurofibromatosis type 2 (NF2) and are incorporated in the clinical diagnostic criteria for the syndrome.
(Left) Meningiomas in NF2 patients are usually multiple and may arise in any anatomic site, including the orbit. Many intraorbital meningiomas develop in close relation to the optic nerve sheath. (Right) Glial hamartomas are characterized by benign glial proliferations involving the retina superficially. They may occur in the setting of NF2 or tuberous sclerosis complex (TSC). This particular example developed in an NF2 patient.

P.III(9):8

Microscopic Features

(Left) The typical intraocular manifestation of TSC is the astrocytic hamartoma/astrocytoma. This proliferation is characterized by slow growth and bland cytology, and it is frequently multiple in TSC but may form a dominant mass. (Right) Retinal astrocytic lesions in tuberous sclerosis patients are histologically similar to subependymal nodules/subependymal giant cell astrocytoma. Scattered microcalcifications were present in this example.
(Left) Uveal melanomas arise predominantly in the choroid and form well-circumscribed masses. Most uveal melanomas arise sporadically, but they may also develop in the setting of a tumor predisposition syndrome characterized by BAP1 mutations. (Right) The presence of epithelioid cells in uveal melanoma is a negative prognostic factor and is associated with class 2 (high-risk) tumors and BAP1 mutations. These cells contain ample cytoplasm, round nuclei, and macronuclei.

(Left) Retinoblastoma is a proliferative tumor with frequent necrosis, centered in the retina. It is the main tumor developing in patients with germline RB1 mutations and may be multiple &/or bilateral in these patients. (Right) Retinoblastoma is histologically a round blue cell tumor, highly cellular, and composed of sheets or nests of proliferative neoplastic cells.

P.III(9):9

Microscopic Features
Although named hemangiomas in the past, given their rich vascular supply, retinal tumors afflicting von Hippel-Lindau syndrome (VHL) patients are hemangioblastomas, histologically identical to tumors involving the CNS. The characteristic neoplasm involving the CNS and retina in patients with VHL syndrome is hemangioblastoma, a vascularized tumor containing vacuolated stromal cells. This particular example is intraocular in a VHL patient.

Patients with xeroderma pigmentosum (XP) are predisposed to neoplasms developing in sun-exposed areas. This excision of a bulbar conjunctival lesion in a child with XP demonstrates a well-differentiated squamous cell carcinoma. XP patients also develop basal cell carcinomas in a variety of cutaneous sites, including the eyelids, as this example shows.
Patients with alterations in genes encoding for mismatch repair enzymes are predisposed to a variety of superficial and visceral neoplasms. Sebaceous tumors characterize Muir-Torre syndrome. Sebaceous carcinomas frequently involve the eyelids. Medulloepithelioma is a distinct ocular neoplasm arising in the ciliary body. It is a recently recognized component of a tumor predisposition syndrome characterized by DICER1 mutations.

Peripheral Nervous System

<table>
<thead>
<tr>
<th>Feature</th>
<th>NF1</th>
<th>NF2</th>
<th>Schwannomatosis</th>
<th>Carney Complex</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence</td>
<td>1 in 2,500-3,000 births</td>
<td>1 in 30,000-40,000 births</td>
<td>1 in 30,000-40,000 births</td>
<td>Very rare</td>
</tr>
<tr>
<td>Geography/ethnic</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Inheritance</td>
<td>Familial ~ sporadic (autosomal dominant)</td>
<td>Familial ~ sporadic (autosomal dominant)</td>
<td>Sporadic &gt; familial (autosomal dominant)</td>
<td>Familial &gt; sporadic (autosomal dominant)</td>
</tr>
<tr>
<td>Gene</td>
<td>NF1</td>
<td>NF2</td>
<td>INI1 (SMARCB1, BAF47, hSNF5)</td>
<td>PRKAR1A</td>
</tr>
<tr>
<td>Gene location</td>
<td>17q11.2</td>
<td>22q12.2</td>
<td>22q11.23</td>
<td>17p22-24, 2p16</td>
</tr>
<tr>
<td>Protein</td>
<td>Neurofibromin</td>
<td>Merlin</td>
<td>SMARCB1 (SWI/SNF complex)</td>
<td>Regulatory R1 α-subunit of protein kinase A (PKA)</td>
</tr>
<tr>
<td>Pathway/cellular</td>
<td>RAS/MAPK/PI3K/mTOR/cAMP</td>
<td>Integrin, RAC/PAK, WNT, YAP/hippo, MAPK, PI3K, CRL4</td>
<td>Chromatin remodeling</td>
<td>cAMP</td>
</tr>
<tr>
<td>Mosaicism</td>
<td>Yes (“segmental neurofibromatosis”)</td>
<td>Yes</td>
<td>Yes (segmental No in 1/3)</td>
<td></td>
</tr>
<tr>
<td>Peripheral nervous system neoplasms</td>
<td>Neurofibromas (localized, diffuse, plexiform, massive soft tissue), intestinal ganglioneuromatosis, gastrointestinal schwannoma, benign hybrid nerve sheath tumor, Schwannomas &gt; &gt; Schwannomas, Melanotic schwannomas benign hybrid (cutaneous), benign nerve sheath hybrid nerve sheath tumor, neurofibromas (very rare, probably (very rare) post radiation)</td>
<td>Schwannomas, benign hybrid nerve sheath tumor, Schwannomas &gt; &gt; Schwannomas, Melanotic schwannomas benign hybrid (cutaneous), benign nerve sheath hybrid nerve sheath tumor, neurofibromas (very rare, probably (very rare) post radiation)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Central nervous system neoplasms</td>
<td>Astrocytomas (grade I-IV), indeterminate astrocytomas, glioneuronal tumors</td>
<td>Ependymomas &gt;, Meningiomas &gt;, Meningiomas &gt;, Meningiomas (rare)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other neoplasms</td>
<td>Pheochromocytoma, sarcomas (rhabdomyosarcoma), gastrointestinal stromal tumor, carcinoids, glomus tumor, juvenile myelomonocytic leukemia, breast carcinoma</td>
<td>Melanotic schwannomas (psammomatous)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonneoplastic nervous system manifestations</td>
<td>Macrocephaly, cognitive disabilities, developmental delays, and behavioral disturbances</td>
<td>Meningioangiomatosis, Neuropathic pain, microhamartoma, peripheral neuropathy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye manifestations</td>
<td>Lisch nodules</td>
<td>Posterior subcapsular cataract, retinal hamartoma, epiretinal membranes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cutaneous manifestations</td>
<td>Café au lait spots, intertriginous skin freckling</td>
<td>Hairy plaques, café au lait spots (rare)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skeletal manifestations</td>
<td>Sphenoid wing dysplasia/hypoplasia, scoliosis, pseudoarthrosis, bowing of long bones</td>
<td>Scoliosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endocrine manifestations</td>
<td>Increased catecholamines/hypertension (secondary to</td>
<td>Acromegaly, hyperprolactinemia, pigmented</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1161
<table>
<thead>
<tr>
<th>Cardiovascular/Cerebral arteriopathy manifestations (moyamoya disease), pulmonary artery stenosis</th>
<th>Differential diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pheochromocytoma</td>
<td>Noonan syndrome, Legius syndrome, constitutional mismatch repair syndrome, McCune-Albright syndrome, proteus syndrome, familial café au lait spots, MEN2B</td>
</tr>
<tr>
<td>Nodular adrenal cortical disease (Cushing disease) Cardiomyopathy</td>
<td></td>
</tr>
<tr>
<td>Schwanomatosis, NF2</td>
<td>Peutz-Jeghers, McCune-Albright syndrome, LEOPARD, Cowden disease and Bannayan-Ruvalcaba-Riley syndrome (PTEN hamartoma tumor syndromes)</td>
</tr>
<tr>
<td>Neurofibromatosis type 2</td>
<td></td>
</tr>
</tbody>
</table>

**MEN2B: Multiple endocrine neoplasia 2B; NF1: Neurofibromatosis type 1; NF2: Neurofibromatosis type 2.**

P.III(9):11

**DIAGNOSTIC CRITERIA**

**Neurofibromatosis Type 1**

NIH (1991)

2 or more of the following features

- Café au lait macules (≥ 6), with a diameter of 0.5 cm in children or 1.5 cm after puberty
- Cutaneous or subcutaneous neurofibromas (≥ 2) or plexiform neurofibroma
- Freckling of the axillary or groin region
- Glioma of the optic pathways
- Lisch nodules identified by slit-lamp examination (≥ 2)
- Dysplasias of skeletal system (sphenoid wing, long bone bowing, pseudoarthrosis)
- Diagnosis of NF1 in a 1st-degree relative

**Neurofibromatosis Type 2**

Manchester criteria (1992)

Any of the following

- Bilateral vestibular schwannoma
- NF2 in 1st-degree relative plus unilateral vestibular schwannoma or any 2 of the following
  - Neurofibroma
  - Meningioma
  - Glioma
  - Schwannoma
  - Posterior subcapsular lens opacity
- Unilateral vestibular schwannoma plus any 2 of the following
  - Neurofibroma
  - Meningioma
  - Glioma
  - Schwannoma
  - Posterior subcapsular lens opacity
- ≥ 2 meningiomas plus unilateral vestibular schwannoma or any 2 of the following
  - Neurofibroma
  - Glioma
  - Schwannoma
  - Cataract

**Baser Criteria-Additive scoring system**

Criteria

NF2 in 1st-degree relative → 2 points
Vestibular schwannoma (unilateral)
If present at age ≤ 30 years → 2 points
If present at age > 30 years → 1 point

Vestibular schwannoma (2nd)
If present at age ≤ 30 years → 4 points
If present at age > 30 years → 3 points

Meningioma(s)
If present at age ≤ 30 years → 2 points
If present at age > 30 years → 1 point

Cutaneous schwannoma(s)
If present at age ≤ 30 years → 2 points
If present at age > 30 years → 1 point

Neoplasm of cranial nerves
If present at age ≤ 30 years → 2 points
If present at age > 30 years → 1 point

Mononeuropathy
If present at age ≤ 30 years → 2 points
If present at age > 30 years → 1 point

Cataract(s)
If present at age ≤ 30 years → 2 points
If present at age > 30 years → 0 points

Points added
Points ≥ 6: Definite NF2
Points 4-5: NF2 mutational analysis required
Points < 4: NF2 unlikely

Schwannomatosis

Definite schwannomatosis
Age > 30 years plus 2 or more schwannomas (not dermal), at least 1 with histologic confirmation
Schwannoma (pathologically confirmed) plus 1st-degree relative who meets the above criteria

Possible schwannomatosis
Age < 30 years plus 2 or more schwannomas (not dermal), at least 1 with histologic confirmation
Age > 45 years plus 2 or more schwannomas (not dermal), at least 1 with histologic confirmation
Evidence of a schwanna (by radiology) and 1st-degree relative meeting the criteria for definite schwannomatosis

Must not have
NF2 by criteria
Vestibular schwannoma (by high-resolution MRI)
NF2 in 1st-degree relative
Germline NF2 mutation

International Schwannomatosis Workshop (2011)

Molecular diagnosis
Both
Schwannomas or meningiomas (≥ 2 pathologically proven)
≥ 2 tumors with chromosome 22 loss of heterozygosity + 2 different NF2 mutations
Or schwannoma or meningioma + germline SMARCB1 mutation

Clinical diagnosis
Both
≥ 2 schwannomas (not intradermal), 1 pathologically confirmed
No vestibular schwannomas on high-quality MR study
Or either
Schwannoma, pathologically confirmed
Intracranial meningioma and 1st-degree relative with schwannomatosis

Possible schwannomatosis
≥ 2 schwannomas (not intradermal) without pathologic confirmation

Any of the following excludes schwannomatosis
NF2 by criteria
Germline NF2 mutation
1st-degree relative with NF2
Multiple schwannomas in a prior irradiated field only

Image Galley
Diagrammatic, Imaging, and Microscopic Features

(Left) Expansion of numerous nerve roots by neurofibromas is typical of neurofibromatosis type 1. Many of these neurofibromas may be classified as plexiform neurofibromas, defined by involvement of multiple nerve fascicles.
(Right) Plexiform neurofibroma is a distinctive subtype defined by architectural features (i.e., involvement of multiple nerve fascicles) and demonstrates a multinodular pattern of growth. When large and deep, plexiform neurofibroma is almost pathognomonic of NF1.

(Left) Neurofibromas of all types may affect NF1 patients. The typical neurofibroma contains wavy neoplastic Schwann cells in a myxoid background and delicate collagen fibers. Mast cells are frequent. In the context of NF1, mast cells facilitate tumor growth by providing trophic signals to the Schwann cell component. (Right) Spinal neurofibromas often involve sensory ganglia in NF1. These entrapped ganglion cells are distributed singly and contain numerous satellite cells.
(Left) Malignant peripheral nerve sheath tumors (MPNST) represent the main malignancies afflicting NF1 patients. This large contrast-enhancing mass afflicting a patient with NF1 was characterized by sudden growth, which is a worrisome clinical feature. The histologic features were diagnostic of MPNST. (Right) MPNSTs are characterized by a cellular, fascicular pattern of growth. Mitotic activity is not subtle in this NF1-associated MPNST.

P.III(9):13

Microscopic Features

(Left) Well-circumscribed schwannomas of various sizes are evident in nerve roots in this patient with NF2 at autopsy. These schwannomas stand out as areas of pallor in a background of myelinated nerve fibers. (Right) In contrast to neurofibromas, schwannomas form well-circumscribed masses composed almost exclusively of neoplastic Schwann cells, as this NF2-associated example demonstrates. A sharp edge with associated nerve is typical, which facilitates surgical excision.
Schwannomas characterized by a predominance of myxoid stroma ("myxoid schwannomas") are not infrequent in the setting of schwannomatosis, as this example shows. (Right) Melanotic schwannoma is a distinctive, rare subtype characterized by prominent melanotic content, pleomorphism, and nuclear pseudoinclusions. On isolation, melanotic schwannomas raise an important differential diagnosis with melanocytic neoplasms of various grades.

Patients with melanotic schwannomas containing microcalcifications and psammoma bodies (psammomatous melanotic schwannoma) should be clinically evaluated for the possibility of Carney complex. A significant proportion of such tumors develop in the setting of this rare syndrome. (Right) Pericellular and perilobular collagen IV staining, identifying basal lamina typical of Schwann cells, is typical of melanotic schwannomas. A perilobular pattern may predominate.

Section 10 - Pulmonary
Lung

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Type of Tumor</th>
<th>Associated Neoplasms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuberous sclerosis</td>
<td>LAM</td>
<td>Major features: Cortical tuber, subependymal nodule, SEGA, facial angiofibroma/forehead plaque, ungual/periungal fibroma, &gt; 3 hypomelanotic macules, Shagreen patch, multiple retinal hamartomas, cardiac rhabdomyoma, renal</td>
</tr>
<tr>
<td>Syndrome/Mutation</td>
<td>Characteristics</td>
<td></td>
</tr>
<tr>
<td>-------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Carney triad</td>
<td>Pulmonary chondroma</td>
<td></td>
</tr>
<tr>
<td>Familial pleuropulmonary blastoma due to germline DICER1 mutation</td>
<td>Gastric stromal sarcomas, extraadrenal parangliomas, adrenal cortical neoplasms, esophageal tumors</td>
<td></td>
</tr>
<tr>
<td>Bloom syndrome</td>
<td>Lung adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>Breast-ovarian BRCA2</td>
<td>Lung adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>Li-Fraumeni</td>
<td>Lung adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>Peutz-Jeghers</td>
<td>Lung adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>Hereditary retinoblastoma</td>
<td>Early onset of small cell lung carcinoma; some non-small cell carcinoma</td>
<td></td>
</tr>
<tr>
<td>Xeroderma pigmentosum</td>
<td>Carcinoma, both adenocarcinoma and squamous cell carcinoma</td>
<td></td>
</tr>
</tbody>
</table>

Minor features: White matter migration lines, transmantle cortical dysplasia, retinal patch, hamartomatous rectal polyps, gingival fibroma, dental pits, hypomelanotic clustered skin lesions, bone cysts, renal cysts, nonrenal hamartomas

DICER1 mutations are associated with both familial multinodular thyroid hyperplasia and multinodular thyroid hyperplasia with Sertoli-Leydig cell tumor of the ovary, independent of PPB

Leukemias, both acute myeloid leukemia and acute lymphoblastic leukemia; carcinomas arise in varied sites including skin, head and neck, gastrointestinal tract including esophagus (both squamous cell carcinoma and adenocarcinoma), stomach and colon, lung, uterus and breast; medulloblastoma, Wilms tumor, osteogenic sarcoma

Carcinoma of breast, ovary, fallopian tubes and peritoneal; carcinoma of prostate, pancreas, gall bladder, bile duct, and stomach

Any childhood cancer or sarcoma, brain tumor, or adrenal cortical carcinoma before age 45; soft tissue sarcoma, osteosarcoma, premenopausal breast cancer, brain tumor, adrenal cortical carcinoma, leukemia

Pigmentation of lips and oral and genital mucosa; polyps arise in stomach, small bowel, and colon; adenocarcinoma of small bowel, colon, pancreas, stomach; carcinoma of breast; ovarian sex cord tumors with annular tubules, adenoma malignum of cervix, mucinous tumors of ovaries and fallopian tubes, testicular sex cord and Sertoli cell tumors, papillary thyroid carcinoma

Retinoblastoma, pineoblastoma/CNS-PNET; soft tissue and bone sarcomas including leiomyosarcoma, fibrosarcoma, rhabdomyosarcoma, pleomorphic sarcoma, liposarcoma/limomatous tumors; melanoma of skin; carcinomas of bladder, upper respiratory tract, and skin; tumors of the central nervous system/meningiomas

Skin carcinomas and sarcoma, especially basal cell carcinoma and squamous cell carcinoma; cutaneous malignant melanoma, ocular cancer, tongue cancer, brain tumors, and carcinoma of uterus, breast, stomach, kidney, and testis

LAM: Lymphangioleiomyomatosis; PNET: Primitive neuroectodermal tumor; PPB: Pleuropulmonary blastoma; SEGA: Subependymal giant cell astrocytoma.
One of the tumors associated with Carney triad is pulmonary chondroma. This gross picture of a pulmonary chondroma shows a cartilaginous cut surface appearance. (Courtesy J. A. Carney, MD.) Carney triad is a rare multitumoral syndrome composed by neoplasms of the stomach, lungs, paraganglionic system, adrenal cortex, and esophagus. The pulmonary chondroma is covered by a thin, fibrous pseudocapsule without entrapped epithelium and fat.

High-power magnification of lymphangioleiomyomatosis in a patient with tuberous sclerosis shows the classical presence of smooth muscle proliferation within the alveolar wall that has obliterated the normal alveolar lining. (Right) Familial pleuropulmonary blastoma (PPB) is associated with DICER1 mutation. This low-power view of solid type III PPB shows benign epithelial component at upper right overlying the malignant mesenchymal component.
Lung adenocarcinoma, lepidic pattern shows a classical pattern of lepidic growth, characteristically associated with Li-Fraumeni syndrome. Note the presence of neoplastic cells lining the alveolar wall. (Right) Well-differentiated adenocarcinomas seen in association with familial syndromes are similar to the sporadic tumors. The acinar growth pattern is composed of small glandular proliferation, arranged in a haphazard pattern with fibrotic and inflammatory stroma.

Section 11 - Skin

### Skin

#### Selected Cutaneous Neoplasms and Associated Hereditary Cancer Syndromes

<table>
<thead>
<tr>
<th>Cutaneous Neoplasm</th>
<th>Hereditary Cancer Syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal cell carcinoma</td>
<td>Gorlin syndrome (basal cell nevus syndrome), xeroderma</td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>Hereditary multiple melanoma, melanoma/pancreatic carcinoma</td>
</tr>
<tr>
<td>Malignant melanoma</td>
<td>Hereditary infundibulocystic basal cell carcinoma, xeroderma pigmentation, Werner syndrome</td>
</tr>
<tr>
<td>Sebaceous adenoma</td>
<td>Muir-Torre syndrome, Lynch syndrome</td>
</tr>
<tr>
<td>Sebaceoma</td>
<td>Muir-Torre syndrome, Lynch syndrome</td>
</tr>
<tr>
<td>Sebaceous carcinoma</td>
<td>Muir-Torre syndrome, Lynch syndrome</td>
</tr>
<tr>
<td>Trichilemmoma</td>
<td>Cowden syndrome</td>
</tr>
<tr>
<td>Fibrofolliculoma/trichodiscoma</td>
<td>Birt-Hogg-Dubé syndrome</td>
</tr>
<tr>
<td>Fibrous papule (angiofibroma)</td>
<td>Tuberous sclerosis, multiple endocrine neoplasia type 1, Birt-Hogg-Dubé syndrome</td>
</tr>
<tr>
<td>Leiomyoma</td>
<td>Reed syndrome</td>
</tr>
</tbody>
</table>

#### Selected Hereditary Cancer Syndromes With Skin Manifestations

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Common Skin Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gorlin syndrome (basal cell nevus syndrome)</td>
<td>Basal cell carcinoma, palmoplantar pitting</td>
</tr>
<tr>
<td>Muir-Torre syndrome</td>
<td>Sebaceous neoplasms</td>
</tr>
<tr>
<td>Lynch syndrome</td>
<td>Sebaceous neoplasms</td>
</tr>
<tr>
<td>Hereditary multiple melanoma syndrome</td>
<td>Melanoma, atypical nevi</td>
</tr>
<tr>
<td>Melanoma/pancreatic carcinoma syndrome</td>
<td>Melanoma, atypical nevi</td>
</tr>
<tr>
<td>Birt-Hogg-Dubé syndrome</td>
<td>Fibrofolliculoma/trichodiscoma, perifollicular fibroma, skin tags</td>
</tr>
</tbody>
</table>
Cowden syndrome (*PTEN*-hamartoma syndrome)  Trichilemmoma, verrucous keratosis, acral keratosis, oral papilloma, sclerotic fibroma, lipoma
Reed syndrome  Leiomyoma
Tuberous sclerosis  Angiofibroma, hypopigmented macule, collagenoma
Multiple endocrine neoplasia type 1  Angiofibroma, collagenoma, lipoma, hypopigmented macule
Multiple endocrine neoplasia type 2B  Mucosal > cutaneous neuroma
Multiple endocrine neoplasia type 2A  Lichen amyloidosis
Gardner syndrome (familial polyposis of colon)  Epidermoid cyst, pilomatrical cyst, desmoid tumor, fibroma
Hereditary breast/ovarian carcinoma  Melanoma
Beckwith-Wiedemann syndrome  Hemihyperplasia, abdominal wall defects, anterior ear lobe creases, posterior helical pits, nevus flammeus
Xeroderma pigmentosum  Skin cancers, lentigines, poikiloderma
Werner syndrome  Melanoma, skin atrophy
Howel-Evans syndrome  Palmoplantar keratoderma
Costello syndrome  Papillomas, palmoplantar keratoderma
Dyskeratosis congenita  Palmoplantar keratoderma, reticulate hyperpigmentation

Image Galley

Microscopic Features

(Left) This is a morpheaform basal cell carcinoma. Multiple basal cell carcinomas are seen in Gorlin syndrome. (Right) This verrucous keratosis has some features of trichilemmoma but does not have a truly lobular configuration with peripheral palisading and central clear/pale cells. This verrucous keratosis was removed from a patient with Cowden syndrome.
(Left) This is a sebaceous adenoma, which may be seen in the setting of Muir-Torre syndrome. The tumor may display loss of staining with mismatch repair proteins. (Right) There is prominent perifollicular fibrosis around the central hair follicle, compatible with a perifollicular fibroma. This particular lesion was removed from a patient with Birt-Hogg-Dubé syndrome.

(Left) This is a high-magnification view of a pilar leiomyoma. Such tumors can be seen in the setting of Reed syndrome. (Right) There are amorphous pink deposits and pigment incontinence in the papillary dermis below a hyperplastic epidermis, compatible with lichen amyloidosis. Lichen amyloidosis is sometimes seen in association with multiple endocrine neoplasia type 2A.

Part IV - Reference
Section 1 - Molecular Factors
Molecular Factors Index
P.IV(1):3

P.IV(1):4
# Molecular Factors Discussed

<table>
<thead>
<tr>
<th>Gene</th>
<th>Gene Location</th>
<th>Official Gene Symbol and Name</th>
<th>Chapter Term Found</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABCB11</td>
<td>2q24</td>
<td>ABCB11; ATP-binding cassette, subfamily B (MDR/TAP), member 11</td>
<td>Biliary Tract/Liver/Pancreas</td>
</tr>
<tr>
<td>ABF1</td>
<td>8q21</td>
<td>MSC; musculin</td>
<td>Hodgkin Lymphoma</td>
</tr>
<tr>
<td>AGL</td>
<td>1p21</td>
<td>AGL; amylo-alpha-1, Biliary Tract/Liver/Pancreas 6-glucosidase, 4-alpha-glucanotransferase</td>
<td></td>
</tr>
<tr>
<td>AIP</td>
<td>11q13.3</td>
<td>AIP; aryl hydrocarbon receptor interacting protein</td>
<td>Pituitary; Pituitary Adenoma</td>
</tr>
<tr>
<td>AKT1</td>
<td>14q32.32</td>
<td>AKT1; v-akt murine thymoma viral oncogene homolog 1</td>
<td>Meningioma; Neurofibromatosis Type 1; PTEN-Hamartoma Tumor Syndromes</td>
</tr>
<tr>
<td>ALDH2</td>
<td>12q24.2</td>
<td>ALDH2; aldehyde dehydrogenase 2 family</td>
<td>Esophageal Squamous Cell Carcinoma</td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Description</td>
<td>Tissues/Conditions</td>
</tr>
<tr>
<td>--------</td>
<td>------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>ALK</td>
<td>2p23</td>
<td>ALK; anaplastic lymphoma receptor tyrosine kinase (mitochondrial)</td>
<td>Bone and Soft Tissue; Diffuse Large B-Cell Lymphoma; Hereditary Neuroblastoma; Neuroblastoma</td>
</tr>
<tr>
<td>ALX4</td>
<td>11p11.2</td>
<td>ALX4; ALX homeobox 4</td>
<td>Hereditary Multiple Exostosis</td>
</tr>
<tr>
<td>AML1</td>
<td>21q22.3</td>
<td>RUNX1; runt-related transcription factor 1</td>
<td>Familial Acute Myeloid Leukemia</td>
</tr>
<tr>
<td>APC</td>
<td>5q21</td>
<td>APC; adenomatosis polyposis coli</td>
<td>Adrenal Cortex; Adrenal Cortical Neoplasms in Children; Astrocytoma; Biliary Tract/Liver/Pancreas; Bone and Soft Tissue; Central Nervous System; Colon Adenoma; Colon/Rectum; Esophagus; Familial Adenomatous Polyposis; Familial Nonmedullary Thyroid Carcinoma; Familial Thyroid Carcinoma; Gastrointestinal Stromal Tumor; Head and Neck; Hereditary Pancreatic Cancer Syndrome; Medulloblastoma/CNS-PNET; MYH-associated Polyposis; Pineoblastoma; Small Bowel Adenocarcinoma; Thyroid, Nonmedullary Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia</td>
</tr>
<tr>
<td>API2-MALT1</td>
<td>t(11;18)(q22;q21)</td>
<td>BIRC3-MALT1</td>
<td>Hereditary Multiple Melanoma</td>
</tr>
<tr>
<td>ASIP</td>
<td>20q11.2-q12</td>
<td>ASIP; agouti signaling protein</td>
<td>Bone and Soft Tissue</td>
</tr>
<tr>
<td>ASK1</td>
<td>6q22.33</td>
<td>ASK1; MAP3K5: mitogen-activated protein kinase kinase 5</td>
<td></td>
</tr>
<tr>
<td>ASPL-TFE3</td>
<td>t(X;17)(p11.2;q25)</td>
<td>ASPSCR1-TFE3</td>
<td></td>
</tr>
<tr>
<td>ASS1</td>
<td>9q34.1</td>
<td>ASS1; argininosuccinate synthase 1</td>
<td></td>
</tr>
<tr>
<td>ATG13</td>
<td>11p11.2</td>
<td>ATG13; autophagy related 13</td>
<td></td>
</tr>
<tr>
<td>ATM</td>
<td>11q22.3</td>
<td>ATM; ataxia telangiectasia mutated</td>
<td></td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Description</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>------------</td>
<td>------------------------------------------------------------------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>ATP8B1</td>
<td>18q21.31</td>
<td>ATP8B1; ATPase, aminophospholipid transporter, class I, type 8B, member 1</td>
<td>Carcinoma Syndrome; Salivary Glands</td>
</tr>
<tr>
<td>BACH1</td>
<td>21q22.11</td>
<td>BACH1; BTB and CNC homology 1, basic leucine zipper transcription factor 1</td>
<td>Breast; Breast Carcinoma, Female</td>
</tr>
<tr>
<td>BAK1</td>
<td>6p21.3</td>
<td>BAK1; BCL2-antagonist/killer 1</td>
<td>Familial Testicular Tumor; Testicle</td>
</tr>
<tr>
<td>BAP1</td>
<td>3p21.31-p21.2</td>
<td>BAP1; BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase)</td>
<td>Central Nervous System; Cutaneous Melanoma; Eye; Familial Uveal Melanoma; Hereditary Multiple Melanoma</td>
</tr>
<tr>
<td>BARD1</td>
<td>2q34-q35</td>
<td>BARD1; BRCA1 associated RING domain 1</td>
<td>Breast; Breast Carcinoma, Female</td>
</tr>
<tr>
<td>BAX</td>
<td>19q13.3-q13.4</td>
<td>BAX; BCL2-associated X protein</td>
<td>Basal Cell Carcinoma</td>
</tr>
<tr>
<td>BCL10-IGH</td>
<td>t(1;14)(p22;q32)</td>
<td>Lymphoplasmacytic Lymphoma/Waldenstörm</td>
<td></td>
</tr>
<tr>
<td>BCL2</td>
<td>18q21.3</td>
<td>BCL2; B-cell CLL/lymphoma 2</td>
<td>Colon Adenoma; Diffuse Large B-Cell Lymphoma; Familial Non-Hodgkin Lymphoma; Prostate Carcinoma</td>
</tr>
<tr>
<td>BCL6</td>
<td>3q27</td>
<td>BCL6; B-cell CLL/lymphoma 6</td>
<td>Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Hodgkin Lymphoma</td>
</tr>
<tr>
<td>BCR-ABL1</td>
<td>t(9;22)(q34;q11)</td>
<td>FLCN; folliculin</td>
<td>Myeloid Neoplasms</td>
</tr>
<tr>
<td>BHD</td>
<td>17p11.2</td>
<td>FLCN; folliculin</td>
<td>Hereditary Renal Epithelial Tumors, Others; Kidney</td>
</tr>
<tr>
<td>BLM</td>
<td>15q26.1</td>
<td>RECQL3; Bloom syndrome, RecQ helicase-like</td>
<td>Bloom Syndrome; Colon/Rectum; Head and Neck; Myeloid Neoplasms; Squamous Cell Carcinoma, Head and Neck; Xeroderma Pigmentosum</td>
</tr>
<tr>
<td>BMI1</td>
<td>10p11.23</td>
<td>BMI1; BMI1 polycomb ring finger oncogene</td>
<td>Basal Cell Carcinoma</td>
</tr>
<tr>
<td>BMPR1A</td>
<td>10q22.3</td>
<td>BMPR1A; bone morphogenetic protein receptor, type Juvenile Polyposis IA</td>
<td>Biliary Tract/Liver/Pancreas; Colon/Rectum; Esophagus; Juvenile Polyposis IA</td>
</tr>
<tr>
<td>BOB1</td>
<td>3q11.2-q13.1</td>
<td>GPR15; G protein-</td>
<td>Hodgkin Lymphoma</td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Diagnosis</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>------------</td>
<td>---------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>BRAF</td>
<td>7q34</td>
<td>BRAF; v-raf mouse sarcoma viral oncogene homolog B; Astrocytoma; Colon Adenoma; Costello Syndrome; Cutaneous Melanoma; Familial Nonmedullary Thyroid Carcinoma; Familial Uveal Melanoma; Hereditary Multiple Melanoma; Lynch Syndrome</td>
<td></td>
</tr>
<tr>
<td>BRCA1</td>
<td>17q21</td>
<td>BRCA1; breast cancer 1, early onset; Biliary Tract/Liver/Pancreas; Breast; Breast Carcinoma, Female; Breast Carcinoma, Male; Fallopian Tube Carcinoma; Familial Uveal Melanoma; Gynecologic Neoplasms; Hereditary Breast/Ovarian Cancer Syndrome: BRCA1; Hereditary Breast/Ovarian Cancer Syndrome: BRCA2; Hereditary Multiple Melanoma; Hereditary Pancreatic Cancer Syndrome; Ovarian Carcinoma; Pancreatic Ductal Adenocarcinoma; Pathology of Familial Tumor Syndromes</td>
<td></td>
</tr>
<tr>
<td>BRCA2</td>
<td>13q12.3</td>
<td>BRCA2; breast cancer 2, early onset; Biliary Tract/Liver/Pancreas; Breast; Breast Carcinoma, Female; Breast Carcinoma, Male; Fallopian Tube Carcinoma; Gynecologic Neoplasms; Hereditary Breast/Ovarian Cancer Syndrome: BRCA1; Hereditary Breast/Ovarian Cancer Syndrome: BRCA2; Hereditary Multiple Melanoma; Hereditary Pancreatic Cancer Syndrome; Hereditary Prostate Cancer; Li-Fraumeni Syndrome/Li-Fraumeni-Like Syndrome; Lung; Melanoma; Melanoma/Pancreatic Carcinoma Syndrome; Ovarian Carcinoma; Pancreatic Ductal Adenocarcinoma; Parathyroid Carcinoma; Pathology of</td>
<td></td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Description</td>
<td>Miscellaneous Diseases/Conditions</td>
</tr>
<tr>
<td>--------</td>
<td>------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>BRIP1</td>
<td>17q22.2</td>
<td>BRIP1; BRCA1 interacting protein C-terminal helicase 1</td>
<td>Familial Tumor Syndromes; Prostate Carcinoma; Wilms Tumor-Associated Syndromes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Breast; Breast Carcinoma, Female; Gynecologic Neoplasms; Li-Fraumeni Syndrome/Li-Fraumeni-Like Syndrome; Ovarian Carcinoma</td>
</tr>
<tr>
<td>CASR</td>
<td>3q13.3-21</td>
<td>CASR; calcium-sensing receptor</td>
<td>Familial Isolated Hyperparathyroidism; Parathyroid; Parathyroid Hyperplasia</td>
</tr>
<tr>
<td>CBFA2</td>
<td>21q22.3</td>
<td>RUNX1; runt-related transcription factor 1</td>
<td>Familial Acute Myeloid Leukemia</td>
</tr>
<tr>
<td>CBL</td>
<td>11q23.3</td>
<td>CBL; Cas-Br-M (murine) ecotropic retroviral transforming sequence</td>
<td>Myeloid Neoplasms</td>
</tr>
<tr>
<td>CCNA1</td>
<td>13q12.3-q13</td>
<td>CCNA1; cyclin-A1</td>
<td>Pituitary</td>
</tr>
<tr>
<td>CCND1</td>
<td>11q13</td>
<td>CCND1; cyclin-D1</td>
<td>Parathyroid Adenoma; Parathyroid Carcinoma; Parathyroid Hyperplasia; Pituitary; Plasma Cell Myeloma; Squamous Cell Carcinoma, Head and Neck</td>
</tr>
<tr>
<td>CCND1-IGH</td>
<td>t(11;14)(q13;q32)</td>
<td>CCND1-IGH; cyclin D3; CD19 molecule</td>
<td>Mantle Cell Lymphoma</td>
</tr>
<tr>
<td>CCND3</td>
<td>6p21</td>
<td></td>
<td>Plasma Cell Myeloma</td>
</tr>
<tr>
<td>CD19</td>
<td>16p11.2</td>
<td>CD19; CD19 molecule</td>
<td>Hodgkin Lymphoma</td>
</tr>
<tr>
<td>CDC73/HRPT2</td>
<td>1q25</td>
<td>CDC73; cell division cycle 73</td>
<td>Familial Isolated Hyperparathyroidism; Hereditary Renal Epithelial Tumors, Others; Kidney</td>
</tr>
<tr>
<td>CDH1</td>
<td>16q22.1</td>
<td>CDH1; cadherin 1, type 1</td>
<td>Breast; Breast Carcinoma, Female; Colon/Rectum; Esophagus; Gastric Adenocarcinoma; Hereditary Diffuse Gastric Cancer</td>
</tr>
<tr>
<td>CDH11</td>
<td>16q21</td>
<td>CDH11; cadherin 11, type 2</td>
<td>Bone and Soft Tissue</td>
</tr>
<tr>
<td>CDK4</td>
<td>12q14</td>
<td>CDK4; cyclin-dependent kinase 4</td>
<td>Bone and Soft Tissue; Hereditary Multiple Melanoma</td>
</tr>
<tr>
<td>CDKN1B</td>
<td>12p13.1-p12</td>
<td>CDKN1B; cyclin-dependent kinase inhibitor 1B</td>
<td>Pituitary; Pituitary Adenoma; Prostate Carcinoma</td>
</tr>
<tr>
<td>CDKN1C</td>
<td>11p15.5</td>
<td>CDKN1C; cyclin-dependent kinase inhibitor 1C</td>
<td>Adrenal Cortex; Adrenal Cortical Neoplasms in Children; Beckwith-Wiedemann Syndrome;</td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Description</td>
<td>Associated Syndromes</td>
</tr>
<tr>
<td>-------------</td>
<td>------------</td>
<td>------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>CDKN2A/P16</td>
<td>9p21</td>
<td>CDKN2A; cyclin-dependent kinase inhibitor 2A</td>
<td>Kidney; Rhabdomyosarcoma; Wilms Tumor; Wilms Tumor-Associated Syndromes; Astrocytoma; Biliary Tract/Liver/Pancreas; Central Nervous System; Cutaneous Melanoma; Cutaneous Melanoma; Familial Plasma Cell Myeloma; Familial Uveal Melanoma; Follicular Lymphoma; Hereditary Multiple Melanoma; Hereditary Pancreatic Cancer Syndrome; Melanoma/Pancreatic Carcinoma Syndrome; Neurofibromatosis Type 1; Pancreatic Endocrine Tumor; Squamous Cell Carcinoma, Head and Neck</td>
</tr>
<tr>
<td>CEBPA</td>
<td>19q13.1</td>
<td>CEBPA; CCAAT/enhancer binding protein (C/EBP), alpha</td>
<td>Familial Acute Myeloid Leukemia; Myeloid Neoplasms</td>
</tr>
<tr>
<td>CFTR</td>
<td>7q31.2</td>
<td>CFTR; cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7)</td>
<td>Biliary Tract/Liver/Pancreas; Hereditary Pancreatic Cancer Syndrome</td>
</tr>
<tr>
<td>CHEK1</td>
<td>11q24.2</td>
<td>CHEK1; checkpoint kinase 1</td>
<td>Breast Carcinoma, Female</td>
</tr>
<tr>
<td>CHEK2</td>
<td>22q12.1</td>
<td>CHEK2; checkpoint kinase 2</td>
<td>Biliary Tract/Liver/Pancreas; Breast; Breast Carcinoma, Female; Breast Carcinoma, Male; Li-Fraumeni Syndrome/Li-Fraumeni-Like Syndrome; Prostate Carcinoma</td>
</tr>
<tr>
<td>CLTC-ALK</td>
<td>t(2;17)(p23;q23)</td>
<td>CLTC-ALK; COL12A1; collagen, type XII, alpha 1</td>
<td>Bone and Soft Tissue; Bone and Soft Tissue</td>
</tr>
<tr>
<td>COL12A1</td>
<td>6q12-q13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COL1A1-PDGF</td>
<td>t(17;22)(q21;q13)</td>
<td>COL1A1-PDGF; COL4A5; collagen, type IV, alpha 5</td>
<td>Bone and Soft Tissue; Bone and Soft Tissue</td>
</tr>
<tr>
<td>COL4A5</td>
<td>Xq22</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COL6A3-CSF1</td>
<td>t(1;2)(p13;q37)</td>
<td>COL6A3-CSF1; CRAC1; colorectal adenoma and carcinoma 1</td>
<td>Bone and Soft Tissue; Colon/Rectum</td>
</tr>
<tr>
<td>CRAC1</td>
<td>15q13-q21</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTC1</td>
<td>17p13</td>
<td>CTC1; CTS telomere Dyskeratosis Congenita maintenance complex component 1</td>
<td></td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Description</td>
<td>Disease/Condition</td>
</tr>
<tr>
<td>--------</td>
<td>------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>CTCL</td>
<td>Xp11.2</td>
<td>TSPYL2; TSPY-like 2</td>
<td>Diffuse Large B-Cell Lymphoma</td>
</tr>
<tr>
<td>CTNNB1</td>
<td>3p21</td>
<td>CTNNB1; catenin (cadherin-associated protein), beta 1</td>
<td>Bone and Soft Tissue; Wilms Tumor</td>
</tr>
<tr>
<td>CXORF5</td>
<td>Xp22</td>
<td>OFD1; oral-facial-digital syndrome 1</td>
<td>Beckwith-Wiedemann Syndrome</td>
</tr>
<tr>
<td>CYLD</td>
<td>16q12.1</td>
<td>CYLD; cylindromatosis (turban tumor syndrome)</td>
<td>Birt-Hogg-Dubé Syndrome; Salivary Glands</td>
</tr>
<tr>
<td>CYP21</td>
<td>6p21.3</td>
<td>CYP21A2; cytochrome P450, family 21, subfamily A, polypeptide 2</td>
<td>Adrenal Cortex; Adrenal Cortical Neoplasms in Children</td>
</tr>
<tr>
<td>DICER1</td>
<td>14q32.13</td>
<td>DICER1; dicer 1, ribonuclease type III</td>
<td>Central Nervous System; Clinical Diagnosis and Management of Familial; Eye; Lung; Pineoblastoma; Pleuropulmonary Blastoma</td>
</tr>
<tr>
<td>DIRC1</td>
<td>2q33</td>
<td>DIRC1; disrupted in renal carcinoma 1</td>
<td>Hereditary Renal Epithelial Tumors, Others; Kidney</td>
</tr>
<tr>
<td>DIRC2</td>
<td>2q33</td>
<td>DIRC2; disrupted in renal carcinoma 1</td>
<td>Hereditary Renal Epithelial Tumors, Others; Kidney</td>
</tr>
<tr>
<td>DIS3L2</td>
<td>2q37.1</td>
<td>DIS3L2; DIS3 mitotic control homolog (S. cerevisiae)-like</td>
<td>Beckwith-Wiedemann Syndrome</td>
</tr>
<tr>
<td>DKC1</td>
<td>Xq28</td>
<td>DKC1; dyskeratosis congenita 1, dyskerin</td>
<td>Blood and Bone Marrow; Dyskeratosis Congenita; Head and Neck; Howel-Evans Syndrome/Keratosis Palmares and Plantares With Esophageal Cancer; Squamous Cell Carcinoma, Head and Neck</td>
</tr>
<tr>
<td>DND1</td>
<td>5q31.3</td>
<td>DND1; DND microRNA-mediated repression inhibitor 1</td>
<td>Familial Testicular Tumor</td>
</tr>
<tr>
<td>DOG1</td>
<td>11q13.3</td>
<td>ANO1; anoctamin 1, calcium activated chloride channel</td>
<td>Gastrointestinal Stromal Tumor</td>
</tr>
<tr>
<td>EBF1</td>
<td>5q34</td>
<td>EBF1; early B-cell factor 1</td>
<td>Hodgkin Lymphoma</td>
</tr>
<tr>
<td>EGFR</td>
<td>7p12</td>
<td>EGFR; epidermal growth factor receptor</td>
<td>Adenocarcinoma, Lung; Neurofibromatosis Type 1; Pituitary; Squamous Cell Carcinoma, Head and Neck</td>
</tr>
<tr>
<td>EGLN1/PHD2</td>
<td>1q42.1</td>
<td>EGLN1; egl-9 family hypoxia-inducible</td>
<td>Adrenal Medulla; Hereditary Paraganglioma/Pheochromocytoma</td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Description</td>
<td>Tumor Type</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
<td>-------------</td>
<td>------------</td>
</tr>
<tr>
<td>ELAC2</td>
<td>17p11.2</td>
<td>ELAC2; elaC ribonuclease Z 2</td>
<td>Paraganglioma; Hereditary Prostate Cancer; Prostate Carcinoma</td>
</tr>
<tr>
<td>ELANE</td>
<td>19p13.3</td>
<td>ELANE; elastase, neutrophil expressed</td>
<td>Blood and Bone Marrow</td>
</tr>
<tr>
<td>ENG</td>
<td>9q34.11</td>
<td>ENG; endoglin</td>
<td>Biliary Tract/Liver/Pancreas; Colon/Rectum; Esophagus; Juvenile Polyposis; Endometrial Carcinoma; Lynch Syndrome</td>
</tr>
<tr>
<td>EPCAM</td>
<td>2p21</td>
<td>EPCAM; epithelial cell adhesion molecule</td>
<td></td>
</tr>
<tr>
<td>ERCC6</td>
<td>10q11.23</td>
<td>ERCC6; excision repair cross-complementing rodent repair deficiency, complementation group 6</td>
<td>Werner Syndrome/Progeria; Xeroderma Pigmentosum</td>
</tr>
<tr>
<td>ERCC8</td>
<td>5q12.1</td>
<td>ERCC8; excision repair cross-complementing rodent repair deficiency, complementation group 8</td>
<td>Werner Syndrome/Progeria; Xeroderma Pigmentosum</td>
</tr>
<tr>
<td>ERG</td>
<td>21q22.3</td>
<td>ERG; v-ets erythoblastosis virus E26 oncogene homolog</td>
<td>Prostate Carcinoma</td>
</tr>
<tr>
<td>ETS</td>
<td>11q23.3</td>
<td>ETS; v-ets avian erythoblastosis virus E26 oncogene homolog</td>
<td>Prostate Carcinoma</td>
</tr>
<tr>
<td>ETV1</td>
<td>7p21.3</td>
<td>ETV1; ets variant 1</td>
<td>Prostate Carcinoma</td>
</tr>
<tr>
<td>ETV4</td>
<td>17q21</td>
<td>ETV4; ets variant 4</td>
<td>Prostate Carcinoma</td>
</tr>
<tr>
<td>ETV5</td>
<td>3q28</td>
<td>ETV5; ets variant 5</td>
<td>Prostate Carcinoma</td>
</tr>
<tr>
<td>ETV6-NTRK3</td>
<td>t(12;15)(p13;q25)</td>
<td>ETV6-NTRK3</td>
<td>Bone and Soft Tissue; Salivary Glands</td>
</tr>
<tr>
<td>EWSR1/EWS</td>
<td>22q12</td>
<td>EWSR1; EWS RNA-binding protein 1</td>
<td>Osteosarcoma</td>
</tr>
<tr>
<td>EWSR1-ATF1/EWS-ATF1</td>
<td>t(12;22)(q13;q12)</td>
<td>EWSR1-ATF1</td>
<td>Bone and Soft Tissue; Gastrointestinal Stromal Tumor; Malignant Peripheral Nerve Sheath Tumor</td>
</tr>
<tr>
<td>EWSR1-CREB1/EWS-CREB1</td>
<td>t(2;22)(q34;q12)</td>
<td>EWSR1-CREB1</td>
<td>Bone and Soft Tissue; Gastrointestinal Stromal Tumor; Malignant Peripheral Nerve Sheath Tumor</td>
</tr>
<tr>
<td>EWSR1-DDIT3/EWS-CHOP</td>
<td>t(12;22)(q13;q12)</td>
<td>EWSR1-DDIT3</td>
<td>Bone and Soft Tissue</td>
</tr>
<tr>
<td>EWSR1-E1AF</td>
<td>t(17;22)(q21;q12)</td>
<td>EWSR1-ETV4</td>
<td>Bone and Soft Tissue</td>
</tr>
<tr>
<td>EWSR1-ERG</td>
<td>t(21;22)(q22;q12) EWSR1-ERG</td>
<td>Bone and Soft Tissue; Malignant Peripheral Nerve Sheath Tumor</td>
<td></td>
</tr>
<tr>
<td>EWSR1-ETV1</td>
<td>t(7;22)(p21.3;q12) EWSR1-ETV1</td>
<td>Bone and Soft Tissue</td>
<td></td>
</tr>
<tr>
<td>EWSR1-FEV</td>
<td>t(2;22)(q36;q12) EWSR1-FEV</td>
<td>Bone and Soft Tissue</td>
<td></td>
</tr>
<tr>
<td>EWSR1-FLI1</td>
<td>t(11;22)(q24;q12) EWSR1-FLI1</td>
<td>Bone and Soft Tissue; Malignant Peripheral Nerve Sheath Tumor; Neuroblastoma; Rhabdomyosarcoma</td>
<td></td>
</tr>
<tr>
<td>EWSR1-NR4A3</td>
<td>t(9;22)(q22;q12) EWSR1-NR4A3</td>
<td>Bone and Soft Tissue</td>
<td></td>
</tr>
<tr>
<td>EWSR1-PBX1</td>
<td>t(1;22)(q23;q12) EWSR1-PBX1</td>
<td>Bone and Soft Tissue</td>
<td></td>
</tr>
<tr>
<td>EWSR1-WT1</td>
<td>t(11;22)(p13;q12) EWSR1-WT1</td>
<td>Bone and Soft Tissue</td>
<td></td>
</tr>
<tr>
<td>EWSR1-ZNF444</td>
<td>t(19;22)(q13;q12) EWSR1-ZNF444</td>
<td>Bone and Soft Tissue</td>
<td></td>
</tr>
<tr>
<td>EWSR1-ZSG</td>
<td>t(22;22)(q12;q12) EWSR1-PATZ1</td>
<td>Bone and Soft Tissue</td>
<td></td>
</tr>
<tr>
<td>EXT1</td>
<td>8q24.11 EXT1; exostosin 1</td>
<td>Bone and Soft Tissue; Hereditary Multiple Exostosis</td>
<td></td>
</tr>
<tr>
<td>EXT2</td>
<td>11p12-p11 EXT2; exostosin 2</td>
<td>Hereditary Multiple Exostosis; Hereditary Multiple Exostosis</td>
<td></td>
</tr>
<tr>
<td>EXT3</td>
<td>19p EXT3; exostoses (multiple) 3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FAH</td>
<td>15q25.1 FAH; fumarylacetoacetate hydrolase (fumarylacetoacetase)</td>
<td>Biliary Tract/Liver/Pancreas</td>
<td></td>
</tr>
<tr>
<td>FAM129A</td>
<td>1q25 FAM129A; family with sequence similarity 129, member</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FANCA</td>
<td>16q24.3 FANCA; Fanconi anemia, complementation group A</td>
<td>Blood and Bone Marrow; Fanconi Anemia</td>
<td></td>
</tr>
<tr>
<td>FANCB</td>
<td>Xp22.2 FANCB; Fanconi anemia, complementation group B</td>
<td>Fanconi Anemia</td>
<td></td>
</tr>
<tr>
<td>FANCC</td>
<td>9q22.3 FANCC; Fanconi anemia, complementation group C</td>
<td>Fanconi Anemia</td>
<td></td>
</tr>
<tr>
<td>FANCD1</td>
<td>13q12.3 BRCA2; breast cancer 2, early onset</td>
<td>Fanconi Anemia</td>
<td></td>
</tr>
<tr>
<td>FANCD2</td>
<td>3p26 FANCD2; Fanconi anemia, complementation group D2</td>
<td>Fanconi Anemia</td>
<td></td>
</tr>
<tr>
<td>FANCE</td>
<td>6p22-p21 FANCE; Fanconi anemia, complementation group E</td>
<td>Fanconi Anemia</td>
<td></td>
</tr>
<tr>
<td>FANCF</td>
<td>11p15 FANCF; Fanconi</td>
<td>Fanconi Anemia</td>
<td></td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Description</td>
<td>Disorder</td>
</tr>
<tr>
<td>--------</td>
<td>------------</td>
<td>------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>FANCG</td>
<td>9p13</td>
<td>complementation group F FANCG; Fanconi anemia, complementation</td>
<td>Fanconi Anemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>group F</td>
<td></td>
</tr>
<tr>
<td>FANCI</td>
<td>15q26.1</td>
<td>complementation group G FANCI; Fanconi anemia, complementation</td>
<td>Fanconi Anemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>group G</td>
<td></td>
</tr>
<tr>
<td>FANCI</td>
<td>17q22.2</td>
<td>BRIP1; BRCA1 breast cancer interacting protein C-terminal</td>
<td>Breast; Breast Carcinoma, Female; Fanconi Anemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>helicase 1</td>
<td></td>
</tr>
<tr>
<td>FANCL</td>
<td>2p16.1</td>
<td>complementation group L FANCL; Fanconi anemia, complementation</td>
<td>Fanconi Anemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>group L</td>
<td></td>
</tr>
<tr>
<td>FANCM</td>
<td>14q21.2</td>
<td>complementation group M FANCM; Fanconi anemia, complementation</td>
<td>Fanconi Anemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>group M</td>
<td></td>
</tr>
<tr>
<td>FANCN</td>
<td>16p12.2</td>
<td>PALB2; partner and localizer of BRCA2 Fanconi anemia, complementation</td>
<td>Breast; Fanconi Anemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>groups</td>
<td></td>
</tr>
<tr>
<td>FANCx</td>
<td>multiple</td>
<td>Fanconi anemia, complementation groups</td>
<td>Head and Neck; Squamous Cell Carcinoma, Head and Neck</td>
</tr>
<tr>
<td>FAP</td>
<td>2q23</td>
<td>activation protein, alpha FAP; fibroblast activation protein,</td>
<td>Esophagus</td>
</tr>
<tr>
<td></td>
<td></td>
<td>alpha</td>
<td></td>
</tr>
<tr>
<td>FBXW7</td>
<td>4q31.3</td>
<td>FBXW7; F-box and WD repeat domain containing 7, E3 ubiquitin</td>
<td>Hereditary Ren epithelial Tumors, Others; Kidney</td>
</tr>
<tr>
<td></td>
<td></td>
<td>protein ligase</td>
<td></td>
</tr>
<tr>
<td>FGFR2</td>
<td>10q26</td>
<td>FGFR2; fibroblast growth factor receptor 2 FGFR2; fibroblast</td>
<td>Pituitary</td>
</tr>
<tr>
<td></td>
<td></td>
<td>growth factor receptor 2</td>
<td></td>
</tr>
<tr>
<td>FGFR3</td>
<td>4p16.3</td>
<td>FGFR3; fibroblast growth factor receptor 3 FGFR3; fibroblast growth factor receptor 3</td>
<td>Bladder Carcinoma; Plasma Cell Myeloma</td>
</tr>
<tr>
<td>FH</td>
<td>1q42.1</td>
<td>FH; fumarate hydratase F; fumarate hydratase</td>
<td>Gynecologic Neoplasms; Hereditary Leiomyomatosis and Renal Cell</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Carcinoma/Reed Syndrome; Hereditary Ren epithelial Tumors, Others; Kidney</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FHIT</td>
<td>3p14.2</td>
<td>FHIT; fragile histidine triad FHIT; fragile histidine triad</td>
<td>Hereditary Ren epithelial Tumors, Others; Kidney; Squamous Cell</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Carcinoma, Head and Neck</td>
</tr>
<tr>
<td>FKHR</td>
<td>13q14.1</td>
<td>FOXO1; forkhead F; forkhead FOXO1; forkhead</td>
<td>Bone and Soft Tissue</td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>FLCN</td>
<td>17p11.2</td>
<td>FLCN; folliculin</td>
<td></td>
</tr>
<tr>
<td>FLT3</td>
<td>13q12</td>
<td>FLT3; fms-like tyrosine kinase 3</td>
<td></td>
</tr>
<tr>
<td>FNIP1</td>
<td>5q23.3</td>
<td>FNIP1; folliculin interacting protein 1</td>
<td></td>
</tr>
<tr>
<td>FUS-ATF1</td>
<td>t(12;16)(q13;p11.2)</td>
<td>FUS-ATF1</td>
<td></td>
</tr>
<tr>
<td>FUS-CREB3L1</td>
<td>t(11;16)(p11.2;p11.2)</td>
<td>FUS-CREB3L1</td>
<td></td>
</tr>
<tr>
<td>FUS-CREB3L2</td>
<td>t(7;16)(q34;p11.2)</td>
<td>FUS-CREB3L2</td>
<td></td>
</tr>
<tr>
<td>FUS-DDIT3</td>
<td>t(12;16)(q13;p11)</td>
<td>FUS-DDIT3</td>
<td></td>
</tr>
<tr>
<td>FUS-ERG</td>
<td>t(16;21)(p11.2;q2)</td>
<td>FUS-ERG</td>
<td></td>
</tr>
<tr>
<td>FWT1</td>
<td>17q12-q21</td>
<td>WT4; Wilms tumor 4</td>
<td></td>
</tr>
<tr>
<td>G6PC</td>
<td>17q21</td>
<td>G6PC; glucose-6-phosphatase, catalytic subunit</td>
<td></td>
</tr>
<tr>
<td>GATA2</td>
<td>3q21.3</td>
<td>GATA2; GATA binding protein 2</td>
<td></td>
</tr>
<tr>
<td>GATA3</td>
<td>10p15</td>
<td>GATA3; GATA binding protein 3</td>
<td></td>
</tr>
<tr>
<td>GJB6</td>
<td>13q12</td>
<td>GJB6; gap junction protein, beta 6, 30kDa</td>
<td></td>
</tr>
<tr>
<td>GLI2</td>
<td>2q14</td>
<td>GLI2; GLI family zinc finger 2</td>
<td></td>
</tr>
<tr>
<td>GNA11</td>
<td>19p13.3</td>
<td>GNA11; guanine nucleotide binding protein (G protein), alpha 11 (Gq class)</td>
<td></td>
</tr>
<tr>
<td>GNAQ</td>
<td>9q21</td>
<td>GNAQ; guanine nucleotide binding protein (G protein), q polypeptide</td>
<td></td>
</tr>
<tr>
<td>GNAS/GNAS1</td>
<td>20q13.3</td>
<td>GNAS; GNAS complex locus</td>
<td></td>
</tr>
<tr>
<td>GPC3</td>
<td>Xq26.1</td>
<td>GPC3; Glypican 3</td>
<td></td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome Location</td>
<td>Description</td>
<td>Related Tumors</td>
</tr>
<tr>
<td>------</td>
<td>---------------------</td>
<td>-------------</td>
<td>----------------</td>
</tr>
<tr>
<td>gr/gr</td>
<td>Yq11.2</td>
<td>genetic linkage region (no specific gene identified)</td>
<td>Tumor; Wilms Tumor-Associated Syndromes; Familial Testicular Tumor</td>
</tr>
<tr>
<td>GSTM1</td>
<td>1p13.3</td>
<td>GSTM1; glutathione S-transferase mu 1</td>
<td>Hereditary Multiple Melanoma</td>
</tr>
<tr>
<td>GSTP1</td>
<td>11q13</td>
<td>GSTP1; glutathione S-transferase pi 1</td>
<td>Prostate Carcinoma</td>
</tr>
<tr>
<td>H19</td>
<td>11p15.5</td>
<td>H19; imprinted maternally expressed transcript (non-protein coding)</td>
<td>Adrenal Cortical Carcinoma; Adrenal Cortical Neoplasms in Children; Beckwith-Wiedemann Syndrome; Kidney; Wilms Tumor; Wilms Tumor-Associated Syndromes</td>
</tr>
<tr>
<td>HAX1</td>
<td>1q21.3</td>
<td>HAX1; HCLS1 associated protein X-1</td>
<td>Blood and Bone Marrow</td>
</tr>
<tr>
<td>HER2</td>
<td>17q12</td>
<td>ERBB2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2</td>
<td>Breast Carcinoma, Female</td>
</tr>
<tr>
<td>HFE</td>
<td>6p21.3</td>
<td>HFE; hemochromatosis</td>
<td>Biliary Tract/Liver/Pancreas</td>
</tr>
<tr>
<td>HLA-DRA</td>
<td>6p21.3</td>
<td>HLA-DRA; major histocompatibility complex, class II, DR alpha</td>
<td>Familial Hodgkin Lymphoma</td>
</tr>
<tr>
<td>HMGA2/HMGIC</td>
<td>12q15</td>
<td>HMGIC; high mobility group AT-hook 2</td>
<td>Bone and Soft Tissue; Salivary Glands</td>
</tr>
<tr>
<td>HMGA2-LPP</td>
<td>t(3;12)(q28;q15)</td>
<td>HMGIC-LPP</td>
<td>Bone and Soft Tissue</td>
</tr>
<tr>
<td>HPD</td>
<td>12q24.31</td>
<td>HPD; 4-hydroxyphenylpyruvate dioxygenase</td>
<td>Biliary Tract/Liver/Pancreas</td>
</tr>
<tr>
<td>HRAS</td>
<td>11p15.5</td>
<td>HRAS; v-Ha-ras Harvey rat sarcoma viral oncogene homolog</td>
<td>Bladder Carcinoma; Costello Syndrome; Familial Nonmedullary Thyroid Carcinoma; Pituitary Carcinoma</td>
</tr>
<tr>
<td>HRPT2</td>
<td>1q25</td>
<td>CDC73; cell division cycle 73</td>
<td>Head and Neck; Hereditary Hyperparathyroidism-Jaw Tumor Syndrome; Hereditary Renal Epithelial Tumors, Others; Kidney; Parathyroid; Parathyroid Adenoma; Parathyroid Carcinoma; Parathyroid Hyperplasia</td>
</tr>
<tr>
<td>HSPBAP1</td>
<td>3q21.1</td>
<td>HSPBAP1; HSPB (heat shock 27kDa associated protein 1)</td>
<td>Hereditary Renal Epithelial Tumors, Others; Kidney;</td>
</tr>
<tr>
<td>ID2</td>
<td>2p25</td>
<td>ID2; inhibitor of</td>
<td>Hodgkin Lymphoma</td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Description</td>
<td>Cancers/Conditions</td>
</tr>
<tr>
<td>--------</td>
<td>------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>IDH1</td>
<td>2q33.3</td>
<td>DNA binding 2, dominant negative helix-loop-helix protein</td>
<td>Astrocytoma; Chondrosarcoma; Medulloblastoma/CNS-PNET; Osteosarcoma</td>
</tr>
<tr>
<td>IDH2</td>
<td>15q26.1</td>
<td>IDH2; isocitrate dehydrogenase 2 (NADP+), mitochondrial</td>
<td>Chondrosarcoma; Osteosarcoma</td>
</tr>
<tr>
<td>IGF2</td>
<td>11p15.5</td>
<td>IGF2; insulin-like growth factor 2</td>
<td>Adrenal Cortical Carcinoma; Adrenal Cortical Neoplasms in Children; Beckwith-Wiedemann Syndrome; Kidney; Rhabdomyosarcoma; Wilms Tumor; Wilms Tumor-Associated Syndromes</td>
</tr>
<tr>
<td>IGH</td>
<td>14q32.33</td>
<td>IGH; immunoglobulin heavy locus</td>
<td>Chronic Lymphocytic Leukemia; Plasma Cell Myeloma; Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia</td>
</tr>
<tr>
<td>IGH-BCL2</td>
<td>t(14;18)(q32;q21)</td>
<td>IGH-BCL2</td>
<td>Follicular Lymphoma</td>
</tr>
<tr>
<td>IGH-BCL6</td>
<td>t(3;14)(q27;q32)</td>
<td>IGH-BCL6</td>
<td>Hodgkin Lymphoma</td>
</tr>
<tr>
<td>IGH-MALT1</td>
<td>t(14;18)(q32;q21)</td>
<td>IGH-MALT1</td>
<td>Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia</td>
</tr>
<tr>
<td>IL10</td>
<td>1q31-q32</td>
<td>IL10; interleukin 10</td>
<td>Familial Non-Hodgkin Lymphoma</td>
</tr>
<tr>
<td>INK4A</td>
<td>9p21</td>
<td>CDKN2A; cyclin-dependent kinase inhibitor 2A</td>
<td>Bone and Soft Tissue; Malignant Peripheral Nerve Sheath Tumor</td>
</tr>
<tr>
<td>JAG1</td>
<td>20p12.1-p11.23</td>
<td>JAG1; jagged 1</td>
<td>Biliary Tract/Liver/Pancreas</td>
</tr>
<tr>
<td>JAK2</td>
<td>9p24</td>
<td>JAK2; Janus kinase 2</td>
<td>2 Myeloid Neoplasms</td>
</tr>
<tr>
<td>JAZF1-JJAZ1</td>
<td>t(7;17)(p15;q11)</td>
<td>JAZF1-JJAZ1</td>
<td>Bone and Soft Tissue</td>
</tr>
<tr>
<td>JAZF1-PHF1</td>
<td>t(6;7)(p21;p15)</td>
<td>JAZF1-PHF1</td>
<td>Bone and Soft Tissue</td>
</tr>
<tr>
<td>JUN</td>
<td>1p32-p31</td>
<td>JUN; jun proto-oncogene</td>
<td>Bone and Soft Tissue</td>
</tr>
<tr>
<td>KCNIP4</td>
<td>4p15.32</td>
<td>KCNIP4; Kv channel interacting protein 4</td>
<td>Hereditary Renal Epithelial Tumors, Others; Kidney</td>
</tr>
<tr>
<td>KCNQ1</td>
<td>11p15.5</td>
<td>KCNQ1; potassium voltage-gated channel, KQT-like subfamily, member 1</td>
<td>Adrenal Cortical Neoplasms in Children; Beckwith-Wiedemann Syndrome</td>
</tr>
<tr>
<td>KCNQ1OT1/LIT1</td>
<td>11p15</td>
<td>KCNQ1OT1; KCNQ1 opposite strand/antisense transcript 1 (non-protein coding)</td>
<td>Adrenal Cortical Neoplasms in Children; Beckwith-Wiedemann Syndrome; Kidney; Wilms Tumor; Wilms Tumor-Associated</td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome Location</td>
<td>Synonym(s)</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>---------------------</td>
<td>------------</td>
<td>-------------</td>
</tr>
<tr>
<td>KIF1B</td>
<td>1p36.2</td>
<td>kinesin family member 1B</td>
<td>Adrenal Medulla; Hereditary Paraganglioma/Pheochromocytoma Syndromes; Paraganglioma; Pheochromocytoma/Paraganglioma</td>
</tr>
<tr>
<td>KIT</td>
<td>4q11-q12</td>
<td>KIF1B; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog</td>
<td>Bone and Soft Tissue; Esophagus; Familial Gastrointestinal Stromal Tumor; Familial Testicular Tumor; Gastrointestinal Stromal Tumor; Myeloid Neoplasms; Neurofibromatosis Type 1; Prostate Carcinoma</td>
</tr>
<tr>
<td>KITLG</td>
<td>12q22</td>
<td>KITLG; KIT ligand</td>
<td>Familial Testicular Tumor; Testicle</td>
</tr>
<tr>
<td>KLF4</td>
<td>9q31</td>
<td>KLF4; Kruppel-like factor 4 (gut)</td>
<td>Meningioma</td>
</tr>
<tr>
<td>KLF6</td>
<td>10p15</td>
<td>KLF6; Kruppel-like factor 6</td>
<td>Prostate Carcinoma</td>
</tr>
<tr>
<td>KLHDC8B</td>
<td>3p21.31</td>
<td>KLHDC8B; kelch domain containing 8B</td>
<td>Familial Hodgkin Lymphoma</td>
</tr>
<tr>
<td>KLLN</td>
<td>10q23</td>
<td>KLLN; killin, p53-regulated DNA replication inhibitor</td>
<td>PTEN-Hamartoma Tumor Syndromes</td>
</tr>
<tr>
<td>KRAS</td>
<td>12p12.1</td>
<td>KRAS; v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog</td>
<td>Astrocytoma; Central Nervous System; Colon Adenoma; Costello Syndrome; Familial Nonmedullary Thyroid Carcinoma; Myeloid Neoplasms; MYH-associated Polyposis; Neurofibromatosis Type 1; Pancreatic Endocrine Tumor; Plasma Cell Myeloma</td>
</tr>
<tr>
<td>KRT16</td>
<td>17q21.2</td>
<td>KRT16; keratin 16</td>
<td>Howel-Evans Syndrome/Keratosis Palmares and Plantares With Esophageal Cancer</td>
</tr>
<tr>
<td>KRT17</td>
<td>17q21.2</td>
<td>KRT17; keratin 17</td>
<td>Howel-Evans Syndrome/Keratosis Palmares and Plantares With Esophageal Cancer</td>
</tr>
<tr>
<td>KRT6</td>
<td>12q13.13</td>
<td>KRT72; keratin 72</td>
<td>Howel-Evans Syndrome/Keratosis Palmares and Plantares With Esophageal Cancer</td>
</tr>
<tr>
<td>LIN28</td>
<td>1p36.11</td>
<td>LIN28; lin-28 homolog A</td>
<td>Medulloblastoma/CNS-PNET</td>
</tr>
<tr>
<td>LMNA</td>
<td>1q22</td>
<td>LMNA; lamin A/C</td>
<td>Werner Syndrome/Progeria</td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Description</td>
<td>Cancer Syndromes</td>
</tr>
<tr>
<td>------</td>
<td>------------</td>
<td>-------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>LSAMP</td>
<td>3q13.2-q21</td>
<td>LSAMP; limbic system-associated membrane protein</td>
<td>Hereditary Renal Epithelial Tumors, Others; Kidney;</td>
</tr>
<tr>
<td>MAF</td>
<td>16q22-q23</td>
<td>MAF; v-maf musculoaponeurotic fibrosarcoma oncogene homolog</td>
<td>Plasma Cell Myeloma</td>
</tr>
<tr>
<td>MAFB</td>
<td>20q11.2-q13.1</td>
<td>MAFB; v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog B</td>
<td>Plasma Cell Myeloma</td>
</tr>
<tr>
<td>MAX</td>
<td>14q23</td>
<td>MAX; MYC associated factor X</td>
<td>Adrenal Medulla; Hereditary Paraganglioma/Pheochromocytoma Syndromes; Paraganglioma; Pathology of Familial Tumor Syndromes; Pheochromocytoma/Paraganglioma</td>
</tr>
<tr>
<td>MC1R</td>
<td>16q24.3</td>
<td>MC1R; melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor)</td>
<td>Cutaneous Melanoma; Hereditary Multiple Melanoma</td>
</tr>
<tr>
<td>MCUL1</td>
<td>1q42.1</td>
<td>FH; fumarate hydratase</td>
<td>Bone and Soft Tissue</td>
</tr>
<tr>
<td>MDM2</td>
<td>12q15</td>
<td>MDM2; MDM2 oncogene, p53 E3 ubiquitin protein ligase homolog</td>
<td>Bone and Soft Tissue; Hereditary Retinoblastoma</td>
</tr>
<tr>
<td>MDM4</td>
<td>1q32</td>
<td>MDM4; Mdm4 p53 binding protein homolog</td>
<td>Hereditary Retinoblastoma</td>
</tr>
<tr>
<td>MDR1</td>
<td>7q21.12</td>
<td>ABCB1; ATP-binding cassette, sub-family B (MDR/TAP), member 1</td>
<td>Adrenal Cortical Carcinoma</td>
</tr>
<tr>
<td>MDR3</td>
<td>7q21.1</td>
<td>ABCB4; ATP-binding cassette, sub-family B (MDR/TAP), member 4</td>
<td>Biliary Tract/Liver/Pancreas</td>
</tr>
<tr>
<td>MECT1</td>
<td>19p13</td>
<td>MECT1; mucoepidermoid carcinoma translocated 1</td>
<td>Salivary Glands</td>
</tr>
<tr>
<td>MECT1-MAML2</td>
<td>t(11;19)(q21-22;p13)</td>
<td>MECT1-MAML2 translocation</td>
<td>Salivary Glands</td>
</tr>
<tr>
<td>MEK1</td>
<td>15q22.1-q22.33</td>
<td>MAP2K1; mitogen-activated protein kinase kinase 1</td>
<td>Costello Syndrome; Familial Nonmedullary Thyroid Carcinoma</td>
</tr>
<tr>
<td>MEK2</td>
<td>19p13.3</td>
<td>MEK2; mitogen-</td>
<td>Costello Syndrome; Familial</td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>------------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>MEN1</td>
<td>11q13</td>
<td>Activated protein kinase kinase 2 Nonmedullary Thyroid Carcinoma; Adrenal Cortex; Adrenal Cortical Carcinoma; Adrenal Cortical Neoplasms in Children; Biliary Tract/Liver/Pancreas; Familial Isolated Hyperparathyroidism; Hereditary Pancreatic Cancer Syndrome; Hereditary Paraganglioma/Pheochromocytoma Syndromes; Hereditary Renal Epithelial Tumors, Others; Multiple Endocrine Neoplasia Type 1; Pancreas; Pancreatic Endocrine Tumor; Parathyroid; Parathyroid Adenoma; Parathyroid Carcinoma; Parathyroid Hyperplasia; Pituitary; Pituitary Adenoma</td>
<td></td>
</tr>
<tr>
<td>MET</td>
<td>7q31</td>
<td>MET; met proto-oncogene (hepatocyte growth factor receptor) Familial Nonmedullary Thyroid Carcinoma; Hereditary Papillary Renal Cell Carcinoma; Hereditary Renal Epithelial Tumors, Others; Kidney; Papillary Renal Cell Carcinoma</td>
<td></td>
</tr>
<tr>
<td>MICB</td>
<td>6p21.3</td>
<td>MICB; MHC class I polypeptide-related sequence B Familial Hodgkin Lymphoma</td>
<td></td>
</tr>
<tr>
<td>MLH1</td>
<td>3p21.3</td>
<td>MLH1; mutL homolog 1 Adrenal Cortex; Adrenal Cortical Neoplasms in Children; Astrocytoma; Biliary Tract/Liver/Pancreas; Central Nervous System; Colon/Rectum; Endometrial Carcinoma; Esophagus; Eye; Gynecologic Neoplasms; Hereditary Pancreatic Cancer Syndrome; Lynch Syndrome; Ovarian Carcinoma; Renal Urothelial Carcinoma; Sebaceous Carcinoma</td>
<td></td>
</tr>
<tr>
<td>MMSET</td>
<td>4p16.3</td>
<td>WHSC1; Wolf-Hirschhorn syndrome candidate 1 Plasma Cell Myeloma</td>
<td></td>
</tr>
<tr>
<td>MPL</td>
<td>1p34</td>
<td>MPL; myeloproliferative leukemia virus oncogene Blood and Bone Marrow</td>
<td></td>
</tr>
<tr>
<td>MRE11A</td>
<td>11q21</td>
<td>MRE11A; MRE11 Ataxia-Telangiectasia; Breast;</td>
<td></td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Description</td>
<td>Cancer Types</td>
</tr>
<tr>
<td>----------</td>
<td>------------</td>
<td>----------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>MSH2</td>
<td>2p21</td>
<td>meiotic recombination 11 homolog A MSH2; mutS homolog 2</td>
<td>Breast Carcinoma, Female; Gynecologic Neoplasms Adrenal Cortex; Adrenal Cortical Neoplasms in Children; Astrocytoma; Biliary Tract/Liver/Pancreas; Central Nervous System; Colon/Rectum; Endometrial Carcinoma; Esophagus; Eye; Gynecologic Neoplasms; Hereditary Pancreatic Cancer Syndrome; Lynch Syndrome; Ovarian Carcinoma; Renal Urothelial Carcinoma; Sebaceous Carcinoma; Ureter Urothelial Carcinoma</td>
</tr>
<tr>
<td>MSH6</td>
<td>2p16</td>
<td>MSH6; mutS homolog 6</td>
<td>Adrenal Cortex; Adrenal Cortical Neoplasms in Children; Astrocytoma; Biliary Tract/Liver/Pancreas; Central Nervous System; Colon/Rectum; Endometrial Carcinoma; Esophagus; Gynecologic Neoplasms; Hereditary Pancreatic Cancer Syndrome; Lynch Syndrome; Ovarian Carcinoma; Renal Urothelial Carcinoma; Sebaceous Carcinoma; Ureter Urothelial Carcinoma</td>
</tr>
<tr>
<td>MSR1</td>
<td>8p22</td>
<td>MSR1; macrophage scavenger receptor 1</td>
<td>Prostate Carcinoma</td>
</tr>
<tr>
<td>MUTYH/MYH</td>
<td>1p34.1</td>
<td>MUTYH; mutY homolog</td>
<td>Breast; Breast Carcinoma, Female; Biliary Tract/Liver/Pancreas; Colon/Rectum; Esophagus; Familial Adenomatous Polyposis; Hereditary Pancreatic Cancer Syndrome; MYH-associated Polyposis; Pathology of Familial Tumor Syndromes</td>
</tr>
<tr>
<td>MYB-NFIB</td>
<td>t(6;9)(q22-23;p24)</td>
<td>MYB-NFIB</td>
<td>Salivary Glands Adrenal Cortical Carcinoma; Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Hereditary Hyperparathyroidism-Jaw Tumor Syndrome; Hodgkin Lymphoma; Medulloblastoma/CNS-PNET; Prostate Carcinoma</td>
</tr>
<tr>
<td>MYC</td>
<td>8q24</td>
<td>MYC; v-myelocytomatosis viral oncogene homolog</td>
<td>Adrenal Cortical Carcinoma; Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Hereditary Hyperparathyroidism-Jaw Tumor Syndrome; Hodgkin Lymphoma; Medulloblastoma/CNS-PNET; Prostate Carcinoma</td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Description</td>
<td>Conditions</td>
</tr>
<tr>
<td>--------</td>
<td>------------</td>
<td>------------------------------------------------------------------------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td>MYCN</td>
<td>2p24.3</td>
<td>MYCN; v-myc myelocytomatosis viral related oncogene, neuroblastoma derived</td>
<td>Hereditary Neuroblastoma; Neuroblastoma; Wilms Tumor</td>
</tr>
<tr>
<td>MYD88</td>
<td>3p22</td>
<td>MYD88; myeloid differentiation primary response 88</td>
<td>Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia</td>
</tr>
<tr>
<td>NBN/NBS1</td>
<td>8q21</td>
<td>NBN; nibrin</td>
<td>Breast; Breast Carcinoma, Female; Gynecologic Neoplasms; Ataxia-Telangiectasia; Prostate Carcinoma</td>
</tr>
<tr>
<td>NDP</td>
<td>Xp11.4</td>
<td>NDP; Norrie disease (pseudoglioma)</td>
<td>Eye</td>
</tr>
<tr>
<td>NF1</td>
<td>17q11.2</td>
<td>NF1; neurofibromin 1</td>
<td>Adrenal Cortex; Adrenal Cortical Neoplasms in Children; Adrenal Medulla; Astrocytoma; Bone and Soft Tissue; Central Nervous System; Clinical Diagnosis and Management of Familial; Esophagus; Eye; Familial Gastrointestinal Stromal Tumor; Gastrointestinal Stromal Tumor; Hereditary Paraganglioma/Pheochromocytoma Syndromes; Malignant Peripheral Nerve Sheath Tumor; Myeloid Neoplasms; Neurofibromatosis Type 1; Pancreas; Pancreatic Endocrine Tumor; Paraganglioma; Peripheral Nervous System; Pheochromocytoma/Paraganglioma; Schwannoma</td>
</tr>
<tr>
<td>NF2</td>
<td>22q12.2</td>
<td>NF2; neurofibromin 2</td>
<td>Astrocytoma; Bone and Soft Tissue; Central Nervous System; Clinical Diagnosis and Management of Familial; Ependymoma; Eye; Head and Neck; Meningioma; Neurofibromatosis Type 1; Neurofibromatosis Type 2; Peripheral Nervous System; Schwannoma; Schwannomatosis</td>
</tr>
<tr>
<td>NHP2</td>
<td>5q35.3</td>
<td>NHP2; NHP2 ribonucleoprotein</td>
<td>Dyskeratosis Congenita</td>
</tr>
<tr>
<td>NKX3-1</td>
<td>8p21.2</td>
<td>NKX3-1; NK3</td>
<td>Prostate Carcinoma</td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Function/Comment</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td>NMTC1</td>
<td>2q21</td>
<td>homeobox 1; NMTC1; Familial Nonmedullary Thyroid Carcinoma</td>
<td></td>
</tr>
<tr>
<td>NOLA2</td>
<td>5q35.3</td>
<td>NHP2; NHP2 ribonucleoprotein</td>
<td>Dyskeratosis Congenita</td>
</tr>
<tr>
<td>NOLA3</td>
<td>15q14-q15</td>
<td>NOP10; NOP10 ribonucleoprotein</td>
<td>Dyskeratosis Congenita</td>
</tr>
<tr>
<td>NORE1</td>
<td>1q32.1</td>
<td>RASSF5; Ras association (RalGDS/AF-6) domain family member 5</td>
<td>Hereditary Renal Epithelial Tumors, Others; Kidney</td>
</tr>
<tr>
<td>NOTCH1</td>
<td>9q34.3</td>
<td>NOTCH1; notch 1</td>
<td>Chronic Lymphocytic Leukemia; Hodgkin Lymphoma</td>
</tr>
<tr>
<td>NOTCH2</td>
<td>1p13-p11</td>
<td>NOTCH2; notch 2</td>
<td>Biliary Tract/Liver/Pancreas</td>
</tr>
<tr>
<td>NPAT</td>
<td>11q22-q23</td>
<td>NPAT; nuclear protein, ataxia-telangiectasia locus</td>
<td>Familial Hodgkin Lymphoma; Hodgkin Lymphoma;</td>
</tr>
<tr>
<td>NPM</td>
<td>5q35</td>
<td>NPM; nucleophosmin</td>
<td>Diffuse Large B-Cell Lymphoma</td>
</tr>
<tr>
<td>NRAS</td>
<td>1p13.2</td>
<td>NRAS; neuroblastoma RAS viral (v-ras) oncogene homolog</td>
<td>Costello Syndrome; Cutaneous Melanoma; Familial Nonmedullary Thyroid Carcinoma; Hereditary Renal Epithelial Tumors, Others; Kidney; Myeloid Neoplasms; Neurofibromatosis Type 1; Plasma Cell Myeloma</td>
</tr>
<tr>
<td>NSD1</td>
<td>5q35</td>
<td>NSD1; nuclear receptor binding SET domain protein 1</td>
<td>Adrenal Cortex; Adrenal Cortical Neoplasms in Children; Beckwith-Wiedemann Syndrome</td>
</tr>
<tr>
<td>NTRK1</td>
<td>1q22</td>
<td>NTRK1; neurotrophic tyrosine kinase, receptor, type 1</td>
<td>Hereditary Renal Epithelial Tumors, Others; Kidney</td>
</tr>
<tr>
<td>NTRK3-ETV6</td>
<td>t(12;15)(p13;q25)</td>
<td>NUTM1; NUT midline carcinoma, family member 1</td>
<td>Rhabdomyosarcoma; Squamous Cell Carcinoma, Head and Neck</td>
</tr>
<tr>
<td>NUT</td>
<td>15q14</td>
<td>NUTM1; NUT midline carcinoma, family member 1</td>
<td></td>
</tr>
<tr>
<td>OCA2</td>
<td>15q</td>
<td>OCA2; oculocutaneous albinism II</td>
<td>Hereditary Multiple Melanoma</td>
</tr>
<tr>
<td>OCT2</td>
<td>6q25.3</td>
<td>SLC22A2; solute carrier family 22 (organic cation transporter), member 2</td>
<td>Hodgkin Lymphoma</td>
</tr>
<tr>
<td>OLIG2</td>
<td>21q22.11</td>
<td>OLIG2;</td>
<td>Medulloblastoma/CNS-PNET</td>
</tr>
<tr>
<td>Gene</td>
<td>Location</td>
<td>Description</td>
<td>Cancer Type and Syndrome</td>
</tr>
<tr>
<td>------</td>
<td>----------</td>
<td>-------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>OR4C12</td>
<td>11p11.12</td>
<td>OR4C12; olfactory receptor, family 4, subfamily C, member 12</td>
<td>Pineoblastoma</td>
</tr>
<tr>
<td>P14/ARF</td>
<td>9p21</td>
<td>CDKN2A; cyclin-dependent kinase inhibitor 2A</td>
<td>Astrocytoma</td>
</tr>
<tr>
<td>P15</td>
<td>9p21</td>
<td>CDKN2B; cyclin-dependent kinase inhibitor 2B</td>
<td>Follicular Lymphoma</td>
</tr>
<tr>
<td>P57KIP2</td>
<td>11p15.5</td>
<td>CDKN1C; cyclin-dependent kinase inhibitor 1C</td>
<td>Adrenal Cortical Carcinoma</td>
</tr>
<tr>
<td>PALB2</td>
<td>16p12.2</td>
<td>PALB2; partner and localizer of BRCA2</td>
<td>Biliary Tract/Liver/Pancreas; Breast; Breast Carcinoma, Female; Hereditary Pancreatic Cancer Syndrome; Li-Fraumeni Syndrome/Li-Fraumeni-Like Syndrome; Melanoma; Melanoma/Pancreatic Carcinoma Syndrome</td>
</tr>
<tr>
<td>PAX1-FOXO1</td>
<td>t(13;20)(q14;p11)</td>
<td>PAX1-FOXO1; PAX3; paired box 3</td>
<td>Rhabdomyosarcoma</td>
</tr>
<tr>
<td>PAX3</td>
<td>2q35</td>
<td>PAX3; paired box 3</td>
<td>Bone and Soft Tissue</td>
</tr>
<tr>
<td>PAX3/7-FOXO1</td>
<td>t(2;13)(q35;q14) or t(1;13)(p36;q14)</td>
<td>PAX3-FOXO1; PAX7-FOXO1</td>
<td>Rhabdomyosarcoma</td>
</tr>
<tr>
<td>PAX3-FOXO1/PAX3-FKHR</td>
<td></td>
<td>PAX3-FOXO1</td>
<td>Bone and Soft Tissue; Rhabdomyosarcoma</td>
</tr>
<tr>
<td>PAX5</td>
<td>9p13</td>
<td>PAX5; paired box 5</td>
<td>Hodgkin Lymphoma</td>
</tr>
<tr>
<td>PAX6</td>
<td>11p13</td>
<td>PAX6; paired box 6</td>
<td>Wilms Tumor; Wilms Tumor-Associated Syndromes</td>
</tr>
<tr>
<td>PAX7-FOXO1/PAX7-FKHR</td>
<td>t(1;13)(p36;q14)</td>
<td>PAX7-FOXO1</td>
<td>Bone and Soft Tissue</td>
</tr>
<tr>
<td>PBRM1</td>
<td>3p21</td>
<td>PBRM1; polybromo 1</td>
<td>Clear Cell Renal Cell Carcinoma</td>
</tr>
<tr>
<td>PCDHGA3</td>
<td>5q31</td>
<td>PCDHGA3; protocadherin gamma subfamily A, 3</td>
<td>Pineoblastoma</td>
</tr>
<tr>
<td>PCTA-1</td>
<td>1q43</td>
<td>LGALS8; lectin, galactoside-binding, soluble, 8</td>
<td>Hereditary Prostate Cancer</td>
</tr>
<tr>
<td>PDE11A</td>
<td>2q31-2q35</td>
<td>PDE11A; phosphodiesterase 11A</td>
<td>Familial Testicular Tumor; Primary Pigmented Nodular Adrenocortical Disease;</td>
</tr>
<tr>
<td>PDE8B</td>
<td>5q13.3</td>
<td>PDE8B; phosphodiesterase 8B</td>
<td>Primary Pigmented Nodular Adrenocortical Disease</td>
</tr>
<tr>
<td>PDGFRA</td>
<td>4q12</td>
<td>PDGFRA; platelet-derived growth factor</td>
<td>Esophagus; Familial Gastrointestinal Stromal</td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Description</td>
<td>Tumor/Condition</td>
</tr>
<tr>
<td>--------</td>
<td>------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>PDS</td>
<td>7q31</td>
<td>receptor, alpha polypeptide SLC26A4; solute carrier family 26 (anion exchanger), member 4</td>
<td>Tumor; Gastrointestinal Stromal Tumor Familial Thyroid Carcinoma</td>
</tr>
<tr>
<td>PHD2</td>
<td>1q42.1</td>
<td>EGLN1; egl-9 family hypoxia-inducible factor 1</td>
<td>Adrenal Medulla; Hereditary Parangangioma/Pheochromocytoma Sydromes; Adrenomioma</td>
</tr>
<tr>
<td>PHOX2B</td>
<td>4p12</td>
<td>PHOX2B; paired-like homeobox 2b</td>
<td>Hereditary Neuroblastoma; Neuroblastoma</td>
</tr>
<tr>
<td>PIK3CA</td>
<td>3q26.3</td>
<td>PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha</td>
<td>Follicular Carcinoma; Pituitary; PTEN-Hamartoma Tumor Syndromes</td>
</tr>
<tr>
<td>PIM1</td>
<td>6p21.2</td>
<td>PIM1; pim-1 oncogene</td>
<td>Hodgkin Lymphoma</td>
</tr>
<tr>
<td>PKC</td>
<td>16p11.2</td>
<td>PKC; proline-rich transmembrane protein 2</td>
<td>Pituitary</td>
</tr>
<tr>
<td>PLAG1</td>
<td>8q12</td>
<td>PLAG1; pleiomorphic adenoma gene 1</td>
<td>Bone and Soft Tissue; Salivary Glands</td>
</tr>
<tr>
<td>PLAG1-HAS2</td>
<td>t(8;8)(q12;q24)</td>
<td>PLAG1-HAS2</td>
<td>Bone and Soft Tissue</td>
</tr>
<tr>
<td>PML-RARA</td>
<td>t(15;17)(q22;q21)</td>
<td>PML-RARA</td>
<td>Myeloid Neoplasms</td>
</tr>
<tr>
<td>PMS1</td>
<td>2q31.1</td>
<td>PMS1; PMS1 postmeiotic segregation increased 1</td>
<td>Astrocytoma</td>
</tr>
<tr>
<td>PMS2</td>
<td>7p22.2</td>
<td>PMS2; PMS2 postmeiotic segregation increased 2</td>
<td>Adrenal Cortex; Adrenal Cortical Neoplasms in Children; Astrocytoma; Biliary Tract/Liver/Pancreas; Breast Carcinoma, Female; Central Nervous System; Colon/Rectum; Endometrial Carcinoma; Esophagus; Gynecologic Neoplasms; Hereditary Pancreatic Cancer Syndrome; Lynch Syndrome; Ovarian Carcinoma; Renal Urothelial Carcinoma</td>
</tr>
<tr>
<td>POLH</td>
<td>6p21.1</td>
<td>POLH; polymerase (DNA directed), eta</td>
<td>Eye; Hereditary Multiple Melanoma; Xeroderma Pigmentosum</td>
</tr>
<tr>
<td>POU5F1P1</td>
<td>8q24.21</td>
<td>POU5F1B; POU class 5 homeobox 1B</td>
<td>Hereditary Prostate Cancer</td>
</tr>
<tr>
<td>PRAD1</td>
<td>11q13</td>
<td>CCND1; cyclin-D1</td>
<td>Parathyroid Hyperplasia</td>
</tr>
<tr>
<td>PRKAR1A</td>
<td>17q23-q24</td>
<td>PRKAR1A; protein kinase, cAMP-</td>
<td>Adrenal Cortex; Adrenal Cortical Carcinoma; Adrenal Cortical Carcinoma; Adrenal</td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Description</td>
<td>Tumor Syndromes</td>
</tr>
<tr>
<td>------</td>
<td>------------</td>
<td>-------------</td>
<td>----------------</td>
</tr>
<tr>
<td>PRSS1</td>
<td>7q34</td>
<td>PRSS1; protease, serine, 1 (trypsin 1)</td>
<td>Biliary Tract/Liver/Pancreas; Hereditary Pancreatic Cancer Syndrome</td>
</tr>
<tr>
<td>PRSS2</td>
<td>7q34</td>
<td>PRSS2; protease, serine, 2 (trypsin 2)</td>
<td>Biliary Tract/Liver/Pancreas; Hereditary Pancreatic Cancer Syndrome</td>
</tr>
<tr>
<td>PTAG</td>
<td>22q12.2</td>
<td>RHBDD3; rhomboid domain containing 3</td>
<td>Pituitary</td>
</tr>
<tr>
<td>PTCH1</td>
<td>9q22.3</td>
<td>PTCH1; patched 1</td>
<td>Basal Cell Carcinoma; Basal Cell Nevus Syndrome/Gorlin Syndrome; Central Nervous System; Eye; Head and Neck; Medulloblastoma/CNS-PNET</td>
</tr>
<tr>
<td>PTCH2</td>
<td>1p34.1</td>
<td>PTCH2; patched 2</td>
<td>Central Nervous System; Eye; Medulloblastoma/CNS-PNET</td>
</tr>
<tr>
<td>PTEN</td>
<td>10q23.31</td>
<td>PTEN; phosphatase and tensin homolog</td>
<td>Birt-Hogg-Dubé Syndrome; Breast; Breast Carcinoma, Female; Breast Carcinoma, Male; Carney Complex Including LAMB Syndrome; Central Nervous System; Colon/Rectum; Endometrial Carcinoma; Familial Nonmedullary Thyroid Carcinoma; Familial Thyroid Carcinoma; Follicular Carcinoma; Gynecologic Neoplasms; Hereditary Multiple Melanoma; Juvenile Polyposis; Neurofibromatosis Type 1; Pathology of Familial Tumor Syndromes; Prostate Carcinoma; PTEN-Hamartoma Tumor Syndromes; Skin; Thyroid,</td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Description</td>
<td>Cancer Types</td>
</tr>
<tr>
<td>--------</td>
<td>------------</td>
<td>----------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>PTPN11</td>
<td>12q24</td>
<td>PTPN11; protein tyrosine phosphatase, non-receptor type 11</td>
<td>Nonmedullary Astrocytoma; Central Nervous System; Costello Syndrome; Myeloid Neoplasms; Neurofibromatosis Type 1</td>
</tr>
<tr>
<td>PTTG</td>
<td>5q35.1</td>
<td>PTTG1; pituitary tumor-transforming 1</td>
<td>Pituitary</td>
</tr>
<tr>
<td>PU.1</td>
<td>11p11.2</td>
<td>SPI1; spleen focus forming virus (SFFV) proviral integration oncogene</td>
<td>Hodgkin Lymphoma</td>
</tr>
<tr>
<td>PVT1</td>
<td>8q24</td>
<td>PVT1; PVT1 oncogene (non-protein coding)</td>
<td>Familial Hodgkin Lymphoma</td>
</tr>
<tr>
<td>PYGL</td>
<td>14q21-q22</td>
<td>PYGL; phosphorylase, glycogen, liver</td>
<td>Biliary Tract/Liver/Pancreas</td>
</tr>
<tr>
<td>RAD50</td>
<td>5q31</td>
<td>RAD50; RAD50 homolog</td>
<td>Breast; Breast Carcinoma, Female; Gynecologic Neoplasms</td>
</tr>
<tr>
<td>RAD51B</td>
<td>14q23-q24.2</td>
<td>RAD51B; RAD51 paralog B</td>
<td>Breast Carcinoma, Female</td>
</tr>
<tr>
<td>RAD51C</td>
<td>17q22</td>
<td>RAD51C; RAD51 paralog C</td>
<td>Breast; Breast Carcinoma, Female; Gynecologic Neoplasms; Li-Fraumeni Syndrome/Li-Fraumeni-Like Syndrome; Ovarian Carcinoma</td>
</tr>
<tr>
<td>RAD51D</td>
<td>17q11</td>
<td>RAD51D; RAD51 paralog D</td>
<td>Breast Carcinoma, Female; Gynecologic Neoplasms; Ovarian Carcinoma</td>
</tr>
<tr>
<td>RAF1</td>
<td>3p25</td>
<td>RAF1; v-raf-1 murine leukemia viral oncogene homolog 1</td>
<td>Astrocytoma; Central Nervous System; Costello Syndrome; Neurofibromatosis Type 1</td>
</tr>
<tr>
<td>RAS</td>
<td>multiple</td>
<td>RAS; Rat sarcoma oncogene</td>
<td>Follicular Carcinoma; Myeloid Neoplasms; Pheochromocytoma/Paraganglioma; Pituitary</td>
</tr>
<tr>
<td>RB1/RB</td>
<td>13q14.2</td>
<td>RB1; retinoblastoma 1</td>
<td>Adrenal Cortical Carcinoma; Bladder Carcinoma; Bone and Soft Tissue; Bone and Soft Tissue; Central Nervous System; Eye; Head and Neck; Hereditary Multiple Melanoma; Hereditary Retinoblastoma; Neuroendocrine Carcinoma, Lung; Osteosarcoma; Parathyroid Carcinoma; Pineoblastoma; Pituitary; Plasma Cell Myeloma</td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Description</td>
<td>Diseases/ Syndromes</td>
</tr>
<tr>
<td>------</td>
<td>------------</td>
<td>-------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>RECQL4</td>
<td>8q24.3</td>
<td>RECQL4; RecQ protein-like 4</td>
<td>Prostate Carcinoma; Retinoblastoma; Salivary Glands</td>
</tr>
<tr>
<td>REL</td>
<td>2p13-p12</td>
<td>REL; v-rel reticulendotheliosis viral oncogene homolog; c-REL</td>
<td>Bloom Syndrome; Werner Syndrome/Progeria; Xeroderma Pigmentosum</td>
</tr>
<tr>
<td>RET</td>
<td>2p13-p12</td>
<td>RET; v-rel reticulendotheliosis viral oncogene homolog; c-REL</td>
<td>Familial Hodgkin Lymphoma; Adrenal Medulla; Adrenal Medullary Hyperplasia; C-Cell Hyperplasia; Familial Isolated Hyperparathyroidism; Familial Nonmedullary Thyroid Carcinoma; Familial Thyroid Carcinoma; Hereditary Paraganglioma/Pheochromocytoma Syndromes; Medullary Thyroid Carcinoma; Multiple Endocrine Neoplasia Type 2/Familial Medullary Thyroid Carcinoma; Neurofibromatosis Type 1; Paraganglioma; Parathyroid; Parathyroid Adenoma; Parathyroid Carcinoma; Parathyroid Hyperplasia; Pheochromocytoma/Paraganglioma; Thyroid, Medullary</td>
</tr>
<tr>
<td>RHBDF2</td>
<td>17q25.1</td>
<td>RHBDF2; rhomboid 5 homolog 2</td>
<td>Esophageal Squamous Cell Carcinoma; Esophagus; Howel-Evans Syndrome/Keratosis Palmares and Plantares With Esophageal Cancer</td>
</tr>
<tr>
<td>RHOH</td>
<td>4p13</td>
<td>RHOH; ras homolog family member H</td>
<td>Hodgkin Lymphoma</td>
</tr>
<tr>
<td>RMRP</td>
<td>9p21-p12</td>
<td>RMRP; RNA component of mitochondrial RNA processing endoribonuclease</td>
<td>Basal Cell Carcinoma</td>
</tr>
<tr>
<td>RNASEL</td>
<td>1q25</td>
<td>RNASEL; ribonuclease L (2',5'-oligoisoadenylate synthetase-dependent)</td>
<td>Hereditary Prostate Cancer; Prostate Carcinoma</td>
</tr>
<tr>
<td>RPS19</td>
<td>19q13.2</td>
<td>RPS19; ribosomal protein S19</td>
<td>Blood and Bone Marrow; Myeloid Neoplasms</td>
</tr>
<tr>
<td>RTEL1</td>
<td>20q13.3</td>
<td>RTEL1; regulator of Dyskeratosis Congenita</td>
<td></td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Description</td>
<td>Pathologies</td>
</tr>
<tr>
<td>------</td>
<td>------------</td>
<td>-------------</td>
<td>-------------</td>
</tr>
<tr>
<td>RUNX1</td>
<td>21q22.3</td>
<td>Telomere elongation helicase 1</td>
<td>Familial Acute Myeloid Leukemia; Myeloid Neoplasms</td>
</tr>
<tr>
<td>RUNX1-RUNX1T1</td>
<td>t(8;21)(22;22.3)</td>
<td>RUNX1; runt-related transcription factor 1</td>
<td>Myeloid Neoplasms</td>
</tr>
<tr>
<td>SBDS</td>
<td>7q11.21</td>
<td>SBDS; Shwachman-Bodian-Diamond syndrome</td>
<td>Blood and Bone Marrow</td>
</tr>
<tr>
<td>SDH/SDHx</td>
<td>multiple</td>
<td>Succinate dehydrogenase complex</td>
<td>Adrenal Medullary Hyperplasia; Familial Gastrointestinal Stromal Tumor; Paraganglioma; Pathology of Familial Tumor Syndromes; PTEN-Hamartoma Tumor Syndromes</td>
</tr>
<tr>
<td>SDHA</td>
<td>5p15</td>
<td>SDHA; succinate dehydrogenase complex, subunit A, flavoprotein</td>
<td>Adrenal Medulla; Hereditary Paraganglioma/Pheochromocytoma Syndromes; Paraganglioma; Pathology of Familial Tumor Syndromes; Pheochromocytoma/Paraganglioma</td>
</tr>
<tr>
<td>SDHAF2</td>
<td>11q12.2</td>
<td>SDHAF2; succinate dehydrogenase complex assembly factor 2</td>
<td>Adrenal Medulla; Hereditary Paraganglioma/Pheochromocytoma Syndromes; Paraganglioma; Pheochromocytoma/Paraganglioma</td>
</tr>
<tr>
<td>SDHB</td>
<td>1p36</td>
<td>SDHB; succinate dehydrogenase complex, subunit B, iron sulfur</td>
<td>Adrenal Medulla; Adrenal Medullary Hyperplasia; Esophagus; Hereditary Paraganglioma/Pheochromocytoma Syndromes; Hereditary Renal Epithelial Tumors, Others; Kidney; Paraganglioma; Pheochromocytoma/Paraganglioma</td>
</tr>
<tr>
<td>SDHC</td>
<td>1q21-23</td>
<td>SDHC; succinate dehydrogenase complex, subunit C, integral membrane protein</td>
<td>Adrenal Medulla; Esophagus; Hereditary Paraganglioma/Pheochromocytoma Syndromes; Paraganglioma; Pheochromocytoma/Paraganglioma</td>
</tr>
<tr>
<td>SDHD</td>
<td>11q23</td>
<td>SDHD; succinate dehydrogenase complex, subunit D, integral membrane protein</td>
<td>Adrenal Medulla; Esophagus; Hereditary Paraganglioma/Pheochromocytoma Syndromes; Paraganglioma</td>
</tr>
<tr>
<td>Gene/Mutation</td>
<td>Chromosome Location</td>
<td>Description</td>
<td>Associated Conditions</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------</td>
<td>-------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>SEC31A-ALK</td>
<td>t(2;4)(p23;q21.22)</td>
<td>Pheochromocytoma/Paraganglioma</td>
<td>Diffuse Large B-Cell Lymphoma</td>
</tr>
<tr>
<td>SERPINA1</td>
<td>14q32.1</td>
<td>SERPINA1: serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1</td>
<td>Biliary Tract/Liver/Pancreas</td>
</tr>
<tr>
<td>SF3B1</td>
<td>2q33.1</td>
<td>SF3B1: splicing factor 3b, subunit 1, 155kDa</td>
<td>Chronic Lymphocytic Leukemia</td>
</tr>
<tr>
<td>SHH</td>
<td>7q36</td>
<td>SHH: sonic hedgehog</td>
<td>Medulloblastoma/CNS-PNET</td>
</tr>
<tr>
<td>SHOC2</td>
<td>10q25</td>
<td>SHOC2; soc-2 suppressor of clear homolog</td>
<td>Costello Syndrome</td>
</tr>
<tr>
<td>SLC25A13</td>
<td>7q21.3</td>
<td>SLC25A13: solute carrier family 25 (aspartate/glutamate carrier), member 13</td>
<td>Biliary Tract/Liver/Pancreas</td>
</tr>
<tr>
<td>SLC26A4</td>
<td>7q31</td>
<td>SLC26A4: solute carrier family 26, member 4</td>
<td>Familial Nonmedullary Thyroid Carcinoma; Familial Thyroid Carcinoma; Thyroid, Nonmedullary</td>
</tr>
<tr>
<td>SMAD4</td>
<td>18q21.1</td>
<td>SMAD4; SMAD family member 4</td>
<td>Biliary Tract/Liver/Pancreas; Colon/Rectum; Esophagus; Juvenile Polyposis; Pancreatic Endocrine Tumor; Small Bowel Adenocarcinoma</td>
</tr>
<tr>
<td>SMARCA4/BRG1</td>
<td>19p13.2</td>
<td>SMARCA4; SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4</td>
<td>Rhabdoid Predisposition Syndrome</td>
</tr>
<tr>
<td>SMARCB1/INI1/BAF47/h SNF5</td>
<td>22q11</td>
<td>SMARCB1; SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1</td>
<td>Bone and Soft Tissue; Central Nervous System; Meningioma; Peripheral Nervous System; Rhabdoid Predisposition Syndrome; Schwannomatosis</td>
</tr>
<tr>
<td>SMARCE1</td>
<td>17q21.2</td>
<td>SMARCE1; SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member</td>
<td>Central Nervous System; Meningioma</td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Description</td>
<td>Associated Conditions</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
<td>----------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>SMO</td>
<td>7q32.3</td>
<td>SMO; smoothened, frizzled family receptor</td>
<td>Medulloblastoma/CNS-PNET; Meningioma</td>
</tr>
<tr>
<td>SOS1</td>
<td>2p21</td>
<td>SOS1; son of sevenless homolog 1</td>
<td>Astrocytoma; Central Nervous System; Costello Syndrome; Neurofibromatosis Type</td>
</tr>
<tr>
<td>SOX9</td>
<td>17q23</td>
<td>SOX9; SRY (sex determining region Y)-box 9</td>
<td>Basal Cell Carcinoma</td>
</tr>
<tr>
<td>SPINK1</td>
<td>5q32</td>
<td>SPINK1; serine peptidase inhibitor, Kazal type 1</td>
<td>Biliary Tract/Liver/Pancreas; Hereditary Pancreatic Cancer Syndrome</td>
</tr>
<tr>
<td>SPOP</td>
<td>17q21.33</td>
<td>SPOP; speckle-type POZ protein</td>
<td>Prostate Carcinoma</td>
</tr>
<tr>
<td>SPRED1</td>
<td>15q14</td>
<td>SPRED1; sprouty-related, EVH1 domain containing 1</td>
<td>Neurofibromatosis Type 1</td>
</tr>
<tr>
<td>SPRY4</td>
<td>5q31.3</td>
<td>SPRY4; sprouty homolog 4</td>
<td>Familial Testicular Tumor; Testicle</td>
</tr>
<tr>
<td>SRP72</td>
<td>4q11</td>
<td>SRP72; signal recognition particle 72kDa</td>
<td>Familial Acute Myeloid Leukemia</td>
</tr>
<tr>
<td>SS18/SYT</td>
<td>18q11.2</td>
<td>SS18; synovial sarcoma translocation, chromosome 18</td>
<td>Bone and Soft Tissue; Malignant Peripheral Nerve Sheath Tumor</td>
</tr>
<tr>
<td>SS18L1-SSX1</td>
<td>t(X;20)(p11.23;q13.3)</td>
<td>SS18L1-SSX1</td>
<td>Bone and Soft Tissue</td>
</tr>
<tr>
<td>SSX</td>
<td>multiple</td>
<td>synovial sarcoma, X</td>
<td>Malignant Peripheral Nerve Sheath Tumor</td>
</tr>
<tr>
<td>SSX1</td>
<td>Xp11.23</td>
<td>SSX1; synovial sarcoma, X breakpoint 1</td>
<td>Bone and Soft Tissue</td>
</tr>
<tr>
<td>SSX2</td>
<td>Xp11.22</td>
<td>SSX2; synovial sarcoma, X breakpoint 2</td>
<td>Bone and Soft Tissue</td>
</tr>
<tr>
<td>SSX4</td>
<td>Xp11.23</td>
<td>SSX4; synovial sarcoma, X breakpoint 4</td>
<td>Bone and Soft Tissue</td>
</tr>
<tr>
<td>STAT5B/STAT5</td>
<td>17q11.2</td>
<td>STAT5B; signal transducer and activator of transcription</td>
<td>Prostate Carcinoma</td>
</tr>
<tr>
<td>STK11/LKB1</td>
<td>19p13.3</td>
<td>STK11; serine/threonine kinase 11</td>
<td>Biliary Tract/Liver/Pancreas; Breast; Breast Carcinoma, Female; Cervical Carcinoma; Colon/Rectum; Endometrial Carcinoma; Esophagus; Familial Testicular Tumor; Gynecologic Neoplasms; Hereditary Pancreatic Cancer Syndrome; Ovarian</td>
</tr>
<tr>
<td>Gene</td>
<td>Location</td>
<td>Description</td>
<td>Conditions</td>
</tr>
<tr>
<td>------------</td>
<td>----------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>SUFU</td>
<td>10q24.32</td>
<td>SUFU; suppressor of fused homolog</td>
<td>Central Nervous System; Eye; Medulloblastoma/CNS-PNET; Meningioma</td>
</tr>
<tr>
<td>TACSTD1</td>
<td>2p21</td>
<td>EPCAM; epithelial cell adhesion molecule</td>
<td>Renal Urothelial Carcinoma</td>
</tr>
<tr>
<td>TAFII68-NR4A3</td>
<td>t(9;17)(q22;q11)</td>
<td>TAFII68-NR4A3</td>
<td>Bone and Soft Tissue</td>
</tr>
<tr>
<td>TAT</td>
<td>16q22.1</td>
<td>TAT; tyrosine aminotransferase</td>
<td>Biliary Tract/Liver/Pancreas</td>
</tr>
<tr>
<td>TCAB1</td>
<td>17p13.1</td>
<td>WRAP53; WD repeat containing, antisense to TP53</td>
<td>Dyskeratosis Congenita</td>
</tr>
<tr>
<td>TCF12-NR4A3</td>
<td>t(9;15)(q22;q21)</td>
<td>TCF12-NR4A3</td>
<td>Bone and Soft Tissue</td>
</tr>
<tr>
<td>TERC</td>
<td>3q26</td>
<td>TERC; telomerase RNA component</td>
<td>Blood and Bone Marrow; Dyskeratosis Congenita; Familial Acute Myeloid Leukemia; Head and Neck; Squamous Cell Carcinoma, Head and Neck</td>
</tr>
<tr>
<td>TERT</td>
<td>5p15.33</td>
<td>TERT; telomerase reverse transcriptase</td>
<td>Blood and Bone Marrow; Dyskeratosis Congenita; Familial Acute Myeloid Leukemia; Head and Neck; Squamous Cell Carcinoma, Head and Neck</td>
</tr>
<tr>
<td>TGFBR3-MGEA5</td>
<td>t(1;10)(p22;q24)</td>
<td>TGFBR3-MGEA5</td>
<td>Bone and Soft Tissue</td>
</tr>
<tr>
<td>TGFβ</td>
<td>19q13.1</td>
<td>TGFBR3-MGEA5; transforming growth factor, beta 1</td>
<td>Colon Adenoma</td>
</tr>
<tr>
<td>TINF2</td>
<td>14q12</td>
<td>TINF2; TERF1 (TRF1)-interacting nuclear factor 2</td>
<td>Blood and Bone Marrow; Dyskeratosis Congenita; Head and Neck; Squamous Cell Carcinoma, Head and Neck</td>
</tr>
<tr>
<td>TMEM127</td>
<td>2q11.2</td>
<td>TMEM127; transmembrane protein 127</td>
<td>Adrenal Medulla; Hereditary Paraganglioma/Pheochromocytoma Syndromes; Paraganglioma; Pheochromocytoma/Paraganglioma</td>
</tr>
<tr>
<td>TMPRSS2</td>
<td>21q22.3</td>
<td>TMPRSS2; transmembrane protease, serine 2</td>
<td>Prostate Carcinoma</td>
</tr>
<tr>
<td>TP53</td>
<td>17p13.1</td>
<td>TP53; tumor protein p53</td>
<td>Adrenal Cortex; Adrenal Cortical Carcinoma; Adrenal Cortical Neoplasms in Children; Astrocytoma; Basal Cell Carcinoma; Biliary</td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>TPCN2</td>
<td>11q13.3</td>
<td>TPCN2; two pore segment channel 2</td>
<td></td>
</tr>
<tr>
<td>TPM3-ALK</td>
<td>t(1;2)(q21.2;p23)</td>
<td>TPM3-ALK</td>
<td></td>
</tr>
<tr>
<td>TRAF7</td>
<td>16p13.3</td>
<td>TRAF7; TNF receptor-associated factor 7, E3 ubiquitin protein ligase</td>
<td></td>
</tr>
<tr>
<td>TRC8</td>
<td>8q24</td>
<td>TRC8; RNF139; ring finger protein 139</td>
<td></td>
</tr>
<tr>
<td>TRK</td>
<td>1q21-q22</td>
<td>NTRK1; neurotrophic tyrosine kinase, receptor, type 1</td>
<td></td>
</tr>
<tr>
<td>TRPS1</td>
<td>8q24.12</td>
<td>TRPS1; trichorhinophalangeal syndrome 1</td>
<td></td>
</tr>
<tr>
<td>TSC1</td>
<td>9q34</td>
<td>TSC1; tuberous sclerosis 1</td>
<td></td>
</tr>
</tbody>
</table>

**Gene Functions:**
- **TPCN2:** Hereditary Multiple Melanoma
- **TPM3-ALK:** Bone and Soft Tissue Meningioma
- **TRAF7:** Malignant Peripheral Nerve Sheath Tumor
- **TRC8:** Hereditary Renal Epithelial Tumors, Others; Kidney Tumors, Others; Kidney
- **TRK:** Familial Nonmedullary Thyroid Carcinoma
- **TRPS1:** Hereditary Multiple Exostosis
- **TSC1:** Angiomyolipoma; Astrocytoma; Biliary
<table>
<thead>
<tr>
<th>Gene/Protein</th>
<th>Chromosome</th>
<th>Description</th>
<th>Tumor Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSC2/PKD1</td>
<td>16p13.3</td>
<td>TSC2; tuberous sclerosis 2</td>
<td>Tract/Liver/Pancreas; Birt-Hogg-Dubé Syndrome; Central Nervous System; Eye; Familial Chordoma; Hereditary Pancreatic Cancer Syndrome; Hereditary Renal Epithelial Tumors, Others; Kidney; Pancreas; Pancreatic Endocrine Tumor; Tuberosclerosis Complex</td>
</tr>
<tr>
<td>TSHR</td>
<td>14q31</td>
<td>TSHR; thyroid stimulating hormone receptor</td>
<td>Angiomyolipoma; Astrocytoma; Biliary Tract/Liver/Pancreas; Birt-Hogg-Dubé Syndrome; Central Nervous System; Eye; Familial Chordoma; Hereditary Pancreatic Cancer Syndrome; Hereditary Renal Epithelial Tumors, Others; Kidney; Pancreas; Pancreatic Endocrine Tumor; Tuberosclerosis Complex</td>
</tr>
<tr>
<td>TYR</td>
<td>11q14.3</td>
<td>TYR; tyrosinase</td>
<td>Familial Nonmedullary Thyroid Carcinoma</td>
</tr>
<tr>
<td>TYRP1</td>
<td>9p23</td>
<td>TYRP1; tyrosinase-related protein 1</td>
<td>Hereditary Multiple Melanoma</td>
</tr>
<tr>
<td>ULK4</td>
<td>3p22.1</td>
<td>ULK4; unc-51 like kinase 4</td>
<td>Hereditary Multiple Melanoma</td>
</tr>
<tr>
<td>USB1/C16orf57</td>
<td>16q21</td>
<td>USB1; U6 snRNA biogenesis 1</td>
<td>Familial Plasma Cell Myeloma</td>
</tr>
<tr>
<td>USP6</td>
<td>17p13</td>
<td>USP6; ubiquitin specific peptidase 6 (Tre-2 oncogene)</td>
<td>Dyskeratosis Congenita</td>
</tr>
<tr>
<td>VDR</td>
<td>12q13.11</td>
<td>VDR; vitamin D (1,25-dihydroxyvitamin D3) receptor</td>
<td>Bone and Soft Tissue</td>
</tr>
<tr>
<td>VHL</td>
<td>3p25.3</td>
<td>VHL; von Hippel-Lindau tumor suppressor</td>
<td>Adrenal Medulla; Biliary Tract/Liver/Pancreas; Central Nervous System; Clear Cell Renal Cell Carcinoma; Clinical Diagnosis and Management of Familial; Endolymphatic Sac Tumor; Eye; Gynecologic Neoplasms; Hereditary Leiomyomatosis and Renal Cell Carcinoma/Reed Syndrome; Hereditary Pancreatic Cancer</td>
</tr>
<tr>
<td>Gene</td>
<td>Chromosome</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
<td>--------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>WAS</td>
<td>Xp11.4-p11.21</td>
<td>WAS; Wiskott-Aldrich syndrome</td>
<td></td>
</tr>
<tr>
<td>WNT</td>
<td>multiple</td>
<td>wingless-type family</td>
<td></td>
</tr>
<tr>
<td>WRN/RECQL2</td>
<td>8p12</td>
<td>WRN; Werner syndrome, RecQ helicase-like</td>
<td></td>
</tr>
<tr>
<td>WT1</td>
<td>11p13</td>
<td>WT1; Wilms tumor 1</td>
<td></td>
</tr>
<tr>
<td>WT1-EWSR1</td>
<td>t(11;22)(p13;q12)</td>
<td>WT1-EWSR1 genetic linkage region (no specific gene identified)</td>
<td></td>
</tr>
<tr>
<td>WT2</td>
<td>19q13.4</td>
<td>Rhabdomyosarcoma</td>
<td></td>
</tr>
<tr>
<td>WTX/FAM123B</td>
<td>Xq11.2</td>
<td>AMER1; APC membrane recruitment protein 1</td>
<td></td>
</tr>
<tr>
<td>XPA</td>
<td>9q22.3</td>
<td>XPA; xeroderma pigmentosum, complementation group A</td>
<td></td>
</tr>
<tr>
<td>XPA-XPG</td>
<td>multiple</td>
<td>xeroderm pigmentosum, complementation group A through G</td>
<td></td>
</tr>
<tr>
<td>XPB</td>
<td>2q21</td>
<td>ERCC3; excision repair cross-complementing rodent repair deficiency, complementation group 3</td>
<td></td>
</tr>
<tr>
<td>XPC</td>
<td>3p25</td>
<td>XPC; xeroderma pigmentosum, complementation</td>
<td></td>
</tr>
</tbody>
</table>

 Syndromes: Hereditary Paraganglioma/Pheochromocytoma Syndromes; Hereditary Renal Epithelial Tumors, Others: Kidney; Pancreas; Pancreatic Endocrine Tumor; Paraganglioma; Pheochromocytoma/Paraganglioma; Salivary Glands; von Hippel-Lindau Syndrome; Blood and Bone Marrow; Bloom Syndrome; Eye; Familial Nonmedullary Thyroid Carcinoma; Familial Thyroid Carcinoma; Follicular Carcinoma; Hereditary Multiple Melanoma; Thyroid, Nonmedullary; Werner Syndrome/Progeria; Beckwith-Wiedemann Syndrome; Denys-Drash Syndrome; Familial Wilms Tumor; Kidney; Wilms Tumor; Wilms Tumor-Associated Syndromes; Rhabdomyosarcoma; Familial Wilms Tumor; Kidney; Wilms Tumor; Wilms Tumor; Hereditary Multiple Melanoma; Xeroderma Pigmentosum; Eye; Head and Neck; Squamous Cell Carcinoma, Head and Neck; Hereditary Multiple Melanoma; Xeroderma Pigmentosum; Hereditary Multiple Melanoma; Xeroderma Pigmentosum; Hereditary Multiple Melanoma; Xeroderma Pigmentosum.
<table>
<thead>
<tr>
<th>Gene</th>
<th>Chromosome</th>
<th>Description</th>
<th>Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>XPD</td>
<td>19q13.3</td>
<td>group C ERCC2; excision repair cross-complementing rodent repair deficiency, complementation group 2</td>
<td>Hereditary Multiple Melanoma; Xeroderma Pigmentosum</td>
</tr>
<tr>
<td>XPE</td>
<td>11q12-q13</td>
<td>DDB1; damage-specific DNA binding protein 1</td>
<td>Hereditary Multiple Melanoma; Xeroderma Pigmentosum</td>
</tr>
<tr>
<td>XPF</td>
<td>16p13.12</td>
<td>ERCC4; excision repair cross-complementing rodent repair deficiency, complementation group 4</td>
<td>Hereditary Multiple Melanoma; Xeroderma Pigmentosum</td>
</tr>
<tr>
<td>XPG</td>
<td>13q33</td>
<td>ERCC5; excision repair cross-complementing rodent repair deficiency, complementation group 5</td>
<td>Hereditary Multiple Melanoma; Xeroderma Pigmentosum</td>
</tr>
</tbody>
</table>
Index

A

Acantholytic squamous cell carcinoma. See Squamous cell carcinoma, cutaneous.

Acinar cell carcinoma, comparison of different features of endocrine pancreatic tumors and their differential diagnoses (table), III(5):8

Acinic cell carcinoma
case reports of salivary gland neoplasms with familial clustering (table), III(4):4
molecular changes described in salivary gland tumors (table), III(4):5
pancreatic ductal adenocarcinoma vs., II(6):48
Acquired tylosis as paraneoplastic phenomenon, Howel-Evans syndrome vs., I(2):121
Acral keratoses, in PTEN-hamartoma tumor syndromes, I(2):169
Acral nevus, cutaneous melanoma vs., II(11):10
Acrogeria, Werner syndrome/progeria vs., I(2):196
Actinic keratosis
basal cell carcinoma vs., II(11):4
xeroderma pigmentosum associated with, I(2):201
Acute lymphoblastic leukemia (ALL), familial neoplasms vs., II(2):44
Acute myelogenous leukemia. See Acute myeloid leukemia.
Acute myeloid leukemia. See Acute myeloid leukemia, familial.
Acute myeloid leukemia, familial. See Familial acute myeloid leukemia.
Adenocarcinoma
from extrathoracic origin, lung adenocarcinoma vs., II(10):3
gastric. See Gastric adenocarcinoma polymorphous low-grade, molecular changes described in salivary gland tumors (table), III(4):5
Adenocarcinoma with lepidic (bronchioloalveolar) predominant pattern, II(10):8, II(10):9, II(10):10, II(10):11
differential diagnosis, II(10):9
etiology/pathogenesis, II(10):8
familial syndromes associated with, II(10):8
histologic features, II(10):8, II(10):9
immunohistochemistry, II(10):9
microscopic features, II(10):10, II(10):11
Adenoid squamous cell carcinoma. See Squamous cell carcinoma, cutaneous.
Adenoma malignum, cervical. See Cervical carcinoma.
Adenoma with high-grade dysplasia, small bowel adenocarcinoma vs., II(6):29
Adenoid/papillary, hamartomatous polyps of Gi tract vs., III(6):27
Adenomatoid tumor, testicular Sertoli cell neoplasms vs., II(7):31
Adenomatous hyperplasia, atypical adenocarcinoma with lepidic (bronchioloalveolar) predominant pattern vs., II(10):9
lung adenocarcinoma vs., II(10):3
Adenomatous polyposis coli. See Familial adenomatous polyposis.
Adenomyosis, hereditary hyperparathyroidism-jaw tumor syndrome associated with, I(2):84
Adenosis of breast, in PTEN syndrome associated with, I(2):216
Adenosquamous carcinoma
as variant of head and neck squamous cell carcinoma, III(4):4
in ampullary adenocarcinoma, II(6):31
Adrenal adenoma, functional and nonfunctional. See Adrenal cortical adenoma.
Adrenal cortex neoplasms
clinical settings associated with cytomegalic cells (table), III(5):2
gross features of adrenal cortical lesions, III(5):4
of adrenal tumors, III(5):5
pathology findings and syndromes involving adrenal cortical, III(5):3
adrenal cortical carcinoma vs., II(5):12
adrenal cortical lesions associated with syndromes (table), II(5):5
ancillary tests, II(5):3, II(5):4
as part of inherited tumor syndromes (table), III(5):3
criteria for differentiation between adenoma and carcinoma, II(5):5, III(5):3
Cushing syndrome due to, primary pigmented nodular adrenocortical disease vs., III(5):26
differential diagnosis, II(5):4
table, II(5):5, III(5):2
gross features, II(5):6, II(5):7
P. ii
immunohistochemical features, II(5):9
immunohistochemistry, II(5):5, III(5):2
in children. See Adrenal cortical neoplasms in children.
microscopic features, II(5):6, II(5):7, II(5):8
primary pigmented nodular adrenocortical disease vs., I(5):26
syndromes associated with, III(5):2
adrenal cortical adenoma vs., II(5):4
adrenal cortical lesions associated with syndromes (table), II(5):5
as part of inherited tumor syndromes (table), III(5):3
Beckwith-Wiedemann syndrome associated with, I(2):9
graphics, II(5):16
clinical features suggesting familial adrenal cortical carcinoma (table), III(5):2
criteria for differentiation between adenoma and carcinoma, III(5):5, III(5):3
criteria for distinguishing benign from malignant neoplasms
system of Hough, II(5):13
van Slooten system, II(5):13
Weiss criteria, II(5):13
cytologic features, II(5):12
differential diagnosis, II(5):12
distinction between benign and malignant adrenal cortical neoplasms, II(5):12
histologic features, II(5):12
image findings, II(5):11
immunohistochemistry, II(5):13
in children. See Adrenal cortical neoplasms in children.
Li-Fraumeni syndrome/Li-Fraumeni-like syndrome associated with, I(2):128
microscopic and other features, II(5):14
microscopic features, II(5):15
pheochromocytoma/paraganglioma vs., III(5):43
prognosis, II(5):11
staging recently adopted AJCC and UICC systems, II(5):12
tumor staging graphics, II(5):17
syndrome associated with, II(5):10
treatment, II(5):11
Adrenal cortical lesions, multiple endocrine neoplasia type 1 associated with, I(2):137
adrenal cortical tumor as part of inherited syndromes (table), II(5):20
associated neoplasms, II(5):19
clinical, gross, and graphic features, II(5):21
differential diagnosis, II(5):20
etiology/pathogenesis...
Beckwith-Wiedemann syndrome, II(5):18
Carney complex, II(5):18
congenital adrenal hyperplasia, II(5):18
familial adenomatous polyposis, II(5):18
hemihypertrophy, II(5):18
hereditary nonpolyposis colorectal cancer, II(5):18
Leach syndrome, II(5):18
Li-Fraumeni syndrome, II(5):18
McCune-Albright syndrome, II(5):18
multiple endocrine neoplasia type 1, II(5):18
neurofibromatosis type 1, II(5):18
microscopic features, II(5):21, II(5):22
microscopic features, variant, II(5):23
prognosis, II(5):19
Adrenal hyperplasia, congenital adrenal cortical adenoma associated with, II(5):2
adrenal cortical carcinoma associated with, II(5):10
adrenal cortical neoplasms in children as part of, II(5):18
adrenal cortical tumors as part of (table), III(5):3
Adrenal hyperplasia, corticotropin (ACTH)-independent bilateral macronodular, primary pigmented nodular adrenocortical disease vs., II(5):26
differential diagnosis, II(5):30
etiology/pathogenesis, II(5):28, II(5):29
as precursor lesion, II(5):28
compensatory physiological hyperplasia, II(5):29
familial medullary hyperplasia, II(5):28
hyperplasia associated with genetic disorders, II(5):28
sporadic adrenal medullary hyperplasia, II(5):28, II(5):29
gross and histopathologic features, II(5):31
microscopic features, II(5):7
microscopic pathology, II(5):29, II(5):30
multiple endocrine neoplasia type 2familial medullary thyroid carcinoma associated with, I(2):142
Adrenal neoplasia, hereditary syndromes associated with, I(1):3
Adrenal tumors, Lynch syndrome associated with, I(2):131
Adrenocortical disease, primary pigmented nodular. See Primary pigmented nodular adrenocortical disease.
Adrenocortical dysplasia. See Primary pigmented nodular adrenocortical disease.
Adult premature aging syndrome. See Werner syndrome/progeria.
Aflatoxin B1, hepatocellular carcinoma associated with, II(6):38
Aggressive papillary cystadenomas of endolymphatic sac. See Endolymphatic sac tumor.
Aicardi syndrome
choroid plexus tumors associated with, II(9):15
gene expression, human, II(9):15
variant, II(9):2
AIP gene mutations, pituitary adenomas associated with, III(5):16
Alagille syndrome, familial biliary tract, liver, and pancreas neoplasms in (table), III(6):3
gene expression, II(9):3
Alcohol abuse, male breast carcinoma associated with, II(1):10
Alcoholic cirrhosis, hepatocellular carcinoma associated with, II(6):38
Aldosteron-producing adrenal adenoma. See Adrenal cortical adenoma.
ALK gene mutations, hereditary neuroblastoma associated with, II(2):96
α-1-antitrypsin deficiency, familial biliary tract, liver, and pancreas neoplasms in (table), III(6):3
Ampullary adenocarcinoma, Lynch syndrome associated with, II(2):131
Aplastic anemia, isolated, dyskeratosis congenita associated with, II(2):32
Anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma, diffuse large B-cell lymphoma vs., II(2):10, II(2):13
Aneurysmal bone cyst
molecular and cytogenetic findings (table), III(3):2
osteosarcoma vs., II(3):27
Angiobroma
Birt-Hogg-Dubé syndrome associated with, I(2):13
cellular, genetic findings in benign tumors (table), III(3):3 (includes Bone and Soft Tissue and Bone and Soft Tissue)
cutaneous, tuberous sclerosis complex associated with, I(2):181
Angiomyointimal fibrous histiocytoma, molecular and cytogenetic findings (table), III(3):2
Angiomyolipoma, II(7):34, II(7):35, II(7):36, II(7):37
differential diagnosis, II(7):35, II(7):37
brothelioid, clear cell renal cell carcinoma vs., II(7):39, II(7):41
gross and microscopic features, II(7):36
hepatocellular carcinoma vs., II(6):40
microscopic features, II(7):36, II(7):37
microscopic pathology, II(7):35
prognosis, II(7):34
renal, multiple endocrine neoplasia type 1 associated with, II(2):137
sporadic AML, II(7):34
treatment, II(7):34
tuberous sclerosis complex associated with, I(2):181
tuberous sclerosis-associated AML, II(7):34
Angiomyxoma, aggressive, molecular and cytogenetic findings (table), III(3):2
Angiosarcoma, sclerosing rhabdomyosarcoma vs., II(3):33
Anorectal carcinoma, dyskeratosis congenita associated with, I(2):32
APC germline mutations
familial adenomatous polyposis associated with, I(2):38
familial thyroid carcinoma associated with, II(5):93
pineoblastoma associated with, II(9):34
Aplastic anemia, isolated, dyskeratosis congenita vs., I(2):32
Apocrine cysts, in PTEN-hamartoma tumor syndromes, I(2):169
Appendix adenocarcinoma, Lynch syndrome associated with, I(2):131
Astrocytoma, II(9):2, II(9):3, II(9):4, II(9):5, II(9):6, II(9):7, II(9):8, II(9):9, II(9):10, II(9):11, II(9):12, II(9):13, II(9):14, II(9):15
Primary adenocortical neoplasms
microscopic features, II(6):32
variant, II(6):33
microscopic pathology, II(6):30, II(6):31
Primary pigmented nodular adrenal cortical disease.
Diagnostic Pathology: Familial Cancer Syndromes

anaplastic astrocytoma, histologic features, II(9):4
ancillary tests, II(9):4, II(9):5
differential diagnosis, II(9):5
diffuse histologic features, II(9):4
image findings, II(9):3
neurofibromatosis type 1 associated with, II(2):151
ependymoma vs., II(9):21
etiology/pathogenesis, II(9):2
congenital mismatch repair-deficiency syndrome, II(9):2
P.iv

Li-Fraumeni syndrome, II(9):2
melanoma astrocytoma syndrome, II(9):2
neurofibromatosis type 1, II(9):2
neurofibromatosis type 2, II(9):2
Noonan syndrome, II(9):2
tuberous sclerosis complex, II(9):2
Turcot syndrome, II(9):2
familial uveal melanoma associated with, II(2):67
glioblastoma, histologic features, II(9):4
glioneuronal tumors graphics, II(9):11
histologic features, II(9):4
heriteditary cutaneous melanoma associated with, I(2):94
image findings, II(9):3
low-grade (graphics), II(9):6, II(9):7, II(9):8
low-grade, indeterminate graphics, II(9):9
histologic features, II(9):4
neurofibromatosis type 1 associated with, II(2):151
pilocytic familial chordoma associated with, I(2):43
histologic features, II(9):3, II(9):4
neurofibromatosis type 1 associated with, II(2):151
pilocytic, with anaplastic features graphics, II(9):10
histologic features, II(9):4
image findings, II(9):3
pleomorphic xanthoastrocytoma, histologic features, II(9):4
prognosis, II(9):3
retinal, in tuberous sclerosis complex, I(2):181
retinoblastoma vs., II(9):37
subependymal giant cell graphics, II(9):12, II(9):13
high grade (graphics), II(9):14, II(9):15
histologic features, II(9):4
image findings, II(9):3
tuberous sclerosis complex associated with, II(2):181
treatment, II(9):3

Ataxia-telangiectasia mutated (ATM) gene
function, II(1):5
germ line inactivation of, I(2):2
heterozygous carriers of mutations predisposed to cancers, II(2):2
mutations, risk of breast cancer associated with (table), III(1):2
Ataxia-telangiectasia syndrome, I(2):2, II(2):3
breast carcinoma in, II(1):5
differential diagnosis, II(2):3
generic tumor syndromes and nonneoplastic ocular manifestations (table), III(9):6
genetics, II(2):2
nonneoplastic manifestations, I(2):3
salivary gland neoplasms associated with (table), III(4):4
Ataxia-telangiectasia-like disorders, ataxia-telangiectasia syndrome vs., I(2):3
ATM gene. See Ataxia-telangiectasia mutated (ATM) gene.
Attenuated familial adenomatous polyposis, as variant of familial adenomatous polyposis, I(2):40
Atypical adenomatous hyperplasia adencarcinoma with lepidic (bronchioloalveolar) predominant pattern vs., II(10):9
lung adenocarcinoma vs., II(10):3
Atypical carcinoid tumor. See Neuroendocrine carcinoma of lung.
Atypical chronic myeloid leukemia (aCML), myeloid neoplasms vs., I(2):44
Atypical fibroxanthoma, cutaneous squamous cell carcinoma vs., II(11):14
Atypical melanocytic nevi. See Dysplastic melanocytic nevi (atypical melanocytic nevi, Clark nevi).
Atypical neurofibroma, malignant peripheral nerve sheath tumor vs., II(3):16
Atypical teratoid/rhabdoid tumor medulloblastoma/CNS-PNET vs., II(9):26
rhabdoid predisposition syndrome associated with, II(2):172, II(2):173
Atypical Werner syndrome, Werner syndrome/progeria vs., I(2):195
BAP1-associated tumor predisposition syndrome, in familial uveal melanoma, I(2):66
BARD1 gene mutations, risk of breast cancer associated with (table), III(1):2
Barrett esophagus, familial esophageal, gastric, and small intestinal tumors in (table), III(6):6
Barrett high-grade dysplasia, esophageal adenocarcinoma vs., II(6):9
basal cell nevus syndrome/Gorlin syndrome associated with, I(2):5
cutaneous squamous cell carcinoma vs., II(11):14
cytologic features, II(11):3
P.v
early onset, basal cell nevus syndrome/Gorlin syndrome vs., I(2):5
genetics, II(11):2
heriteditary infundibulocystic basal cell nevus syndrome/Gorlin syndrome vs., I(2):6
selected cutaneous neoplasms and associated hereditary cancer syndromes (table), III(11):2
histologic features, II(11):3
immunohistochemical features, II(11):6
microscopic features, II(11):5, II(11):6
prognosis, II(11):2, II(11):3
sebaceous carcinoma vs., II(11):20, II(11):23
treatment, II(11):2
variants, II(11):3
Basal cell epitheloma. See Basal cell carcinoma.
bone and soft tissue tumors associated with (table), III(3):4
criteria for diagnosis, I(2):6
diagnostic criteria for, I(1):12
differential diagnosis, I(2):5, I(2):6
genetic syndromes associated with CNS neoplasms (table), III(9):2
genetic tumor syndromes and nonneoplastic ocular manifestations (table), III(9):6
genetics, I(2):4
graphic, clinical, imaging, and microscopic features, I(2):7
head and neck neoplasms associated with (table), III(4):2
medulloblastoma/CNS-PNET associated with, II(9):24
selected cutaneous neoplasms and associated hereditary cancer syndromes (table), III(11):2
selected hereditary cancer syndromes with skin manifestations (table), III(11):2

B

BALK gene, familial testicular germ cell tumors associated with, I(2):64, I(2):65
Bannayan-Ruvalcaba-Riley syndrome Carney complex vs., I(2):21
diagnosis, I(2):168
in PTEN-hamartoma tumor syndromes, I(2):166, I(2):167
BAP1 gene mutations, hereditary cutaneous melanoma associated with, I(2):93
Basaloid squamous cell carcinoma, as variant of head and neck squamous cell carcinoma, II(4):4
BAX gene mutations, basal cell carcinoma associated with, II(11):2
Bazex-Dupré-Christol syndrome
basal cell nevus syndrome/Gorlin syndrome vs., I(2):5
selected cutaneous neoplasms and associated hereditary cancer syndromes (table), III(11):2
B-cell chronic lymphoproliferative disorders, lymphoplasmyacistic lymphoma/Waldenström
macroglobulinemia vs., II(2):3
B-cell lymphoma, aggressive, transformation of follicular lymphoma to, I(2):16
BCL2 gene overexpression, in follicular lymphoma, II(2):14
rearrangements, in diffuse large B-cell lymphoma, II(2):9
BCL6 gene abnormalities, diffuse large B-cell lymphoma associated with, I(2):9
adrenal cortical adenoma associated with, II(5):2
adrenal cortical carcinoma associated with, II(5):10, II(5):16
adrenal cortical neoplasms in children as part of, II(5):18, III(5):20
adrenal cortical tumors as part of (table), III(5):3
as Wilms tumor-associated syndrome, I(2):199
associated neoplasms, I(2):9
bone and soft tissue tumors associated with (table), III(3):4
clinical risk factors, I(2):9
criteria for diagnosis, (I(2):9
differential diagnosis, I(2):9, I(2):10
familial renal tumors in (table), III(7):6
genes, I(2):9, II(7):55
gross and microscopic features, I(2):11
hepatoblastoma associated with, II(6):35
increased risk of Wilms tumor in (table), I(2):199
rhabdomyosarcoma associated with, II(3):30
selected hereditary cancer syndromes with skin manifestations (table), III(11):2
Benign notochordal cell tumor, chordoma vs., III(3):10
β-catenin mutation-associated Wnt pathway activation, in hepatoblastoma, II(6):34
Bilateral micronodular hyperplasia. See Primary pigmented nodular adrenocortical disease.
Bile duct carcinoma, distal, ampullary adenocarcinoma vs., II(6):31
Bile duct neoplasms, hereditary breast/ovarian cancer syndrome: BRCA2 associated with, I(2):78
Biliary tract adenocarcinoma, Lynch syndrome associated with, I(2):131
Biliary tract neoplasms by syndromes (table), III(6):3
familial adenomatous polyposis associated with, I(2):39
familial neoplasia of biliary tract, liver, and pancreas, III(6):2
as hereditary or familial renal tumor syndrome, I(2):116
associated neoplasms, I(2):12, I(2):13
cancer risk management, I(2):13
colorectal carcinoma, I(2):13
renal cell carcinoma, I(2):13
diagnostic criteria, I(2):14
differential diagnosis, I(2):13, I(2):14
P.vi

familial renal tumors in (table), III(7):6
genetics, I(2):12
gross and microscopic features, I(2):15
renal oncocytoma, chromophobe, and hybrid oncocytic tumors associated with, II(7):46
selected cutaneous neoplasms and associated hereditary cancer syndromes (table), III(11):2
selected hereditary cancer syndromes with skin manifestations (table), III(11):2
Bizarre parosteal osteochondromatous proliferation, molecular and cytogenetic findings (table), III(3):2
AJCC Staging for Bladder Cancer (2010), I(2):7
bladder cancer staging (graphics), II(7):3
differential diagnosis, I(7):5
etiology/pathogenesis, II(7):2
environmental exposure, II(7):2
model of bladder cancer development and progression (dual-track pathway), II(7):2
other possible risk factors, II(7):2
high-grade poorly differentiated carcinoma (table), III(7):2
histologic features, II(7):3, II(7):4, II(7):5
clear cell (glycogen-rich) urothelial carcinoma, II(7):4
flat urothelial lesions with atypia (table), II(7):2
high-grade papillary urothelial carcinoma, II(7):3, II(7):4
invasive papillary urothelial carcinoma, II(7):4
inverted papillary urothelial carcinoma, II(7):4
large- and nested urothelial carcinoma, II(7):4
lipid-rich urothelial carcinoma, II(7):4
low-grade papillary urothelial carcinoma, II(7):3
lymphoepithelioma-like carcinoma, II(7):4
microcystic urothelial carcinoma, II(7):4
microcystic urothelial carcinoma, II(7):4
nested urothelial carcinoma, II(7):4
papillary urothelial neoplasm of low malignant potential (PUNLMP), II(7):3
plasmacytoid urothelial carcinoma, II(7):4
sarcomatoid urothelial carcinoma/carcinosarcoma, II(7):4, II(7):5
urothelial carcinoma in situ, II(7):3
urothelial carcinoma with divergent differentiation, II(7):4
urothelial carcinoma with myxoid stroma and chordoid features, II(7):5
urothelial carcinoma with osteoclast giant cells, II(7):5
urothelial carcinoma with rhabdoid features, II(7):4
urothelial carcinoma with small tubules, II(7):4
urothelial carcinoma with trophoblastic cells, II(7):5
variant morphology of urothelial carcinoma, II(7):4
immunohistochemistry (graphics), II(7):4
in Costello syndrome, cancer risk management, I(2):25
invasive urothelial carcinoma (graphics), II(7):7
papillary and flat urothelial neoplasms (graphics), II(7):6
prognosis, II(7):3
PTEN-hamartoma tumor syndromes associated with, I(2):170
staging immunohistochemistry, II(7):8
urothelial carcinoma-associated markers in metastatic setting, III(7):2
variant morphologies (graphics), II(7):8, II(7):9
Bladder neoplasms
AJCC Staging for Bladder Cancer (2010), III(7):2
bladder cancer staging (graphics), III(7):3
hereditary syndromes associated with, I(1):4
Lynch syndrome associated with, I(2):131
Werner syndrome/progeria associated with, I(2):195
BLM gene mutations, Bloom syndrome associated with, I(2):16
Blood and bone marrow neoplasms
Differential diagnosis, II(2):4
Mantle cell lymphoma vs., II(2):37
Diffuse large B-cell lymphoma. See Diffuse large B-cell lymphoma.
Follicular lymphoma. See Follicular lymphoma.
Hereditary syndromes associated with, (I①):5, I①:6
Hereditary syndromes with blood and bone abnormalities and predisposition to myeloid neoplasms
Microscopic features, III(2):3
Table, III(2):2
Mantle cell lymphoma. See Mantle cell lymphoma.
Bloom syndrome, II①:6, II①:17
Associated neoplasms, II①:17
Confirmation of diagnosis, II①:17
Cytogenetic testing, II①:17
Familial cancer syndromes with lung neoplasms (table), III①:10:2
Familial colon and rectum tumors by syndrome (table), III①:6:5
P.vii
Genetic predisposition for squamous cell carcinoma of head and neck, II①:4:2, II①:4:3
Genetics, I①:2:16
Head and neck neoplasms associated with (table), III①:4:2
Increased cancer risk, I①:2:17
Increased risk of Wilms tumor in (table), I①:2:199
Lung adenocarcinoma associated with, II①:10:2
Molecular testing, I①:2:17
Predisposition to hematologic malignancy, II①:2:40
Prenatal testing, I①:2:17
Xeroderma pigmentosum vs., I①:2:202
Bloom-Torre-Machacek syndrome. See Bloom syndrome.
BM11 gene mutations, basal cell carcinoma associated with, I11:2
BMPR1A germline mutations, in juvenile polyposis syndrome, I①:2:122
Bone and soft tissue neoplasms chondrosarcoma. See Chondrosarcoma.
Chordoid, chondrosarcoma vs., I①:3:5
Differential diagnosis, I①:3:10
Familial cancer syndromes with bone and soft tissue tumors (table), I①:3:4
Genetic findings in benign and intermediate soft tissue tumors (table), I①:3:3 (includes Bone and Soft Tissue and Bone and Soft Tissue), I①:3:4
Graphic features of, I①:3:5
Hereditary syndromes associated with, II①:1:5
Malignant peripheral nerve sheath tumor. See Malignant peripheral nerve sheath tumor.
Molecular and cytogenetic findings in (table), III①:3:2, III①:3:3 (includes Bone and Soft Tissue and Bone and Soft Tissue)
Osteosarcoma. See osteosarcoma.
Rhabdomyosarcoma. See Rhabdomyosarcoma.
Schwannoma. See Schwannoma.
Bone manifestations, of familial adenomatous polyposis, I①:2:39
Bone marrow failure syndrome inherited, dyskeratosis congenita vs., I①:2:32
With predisposition to myelodysplastic syndromes/acute myeloid leukemia, I①:2:34
Bowie disease, cutaneous melanoma vs., II①:11:10
BRAF gene mutations, familial uveal melanoma associated with, I①:2:66
Brain manifestations of familial adenomatous polyposis, I①:2:39, I①:2:40
PTEN-hamartoma tumor syndromes, I①:2:169
Brain tumors. See also Central nervous system neoplasms.
Fanconi anemia associated with, I①:2:71
Li-Fraumeni syndrome/Li-Fraumeni-like syndrome associated with, I①:2:128
Xeroderma pigmentosum associated with, I①:2:201
BRCAl gene characteristics, I①:2:72, III①:1:3
Function, I1:1:3
Protein function, I①:2:72, I①:2:73
BRCAl gene mutations
Fallopian tube carcinoma associated with, II①:8:9
Hereditary cutaneous melanoma associated with, I①:2:93
Male breast carcinoma associated with, II①:1:10
Pancreatic ductal adenocarcinoma associated with, II①:6:46
Risk of breast cancer associated with (table), III①:1:2, III①:1:3
BRCAl syndrome. See Hereditary breast/ovarian cancer syndrome (BRCAl).
Function, I1:1:4
Protein function, I①:2:77
BRCAl gene mutations
Fallopian tube carcinoma associated with, II①:8:9
Hereditary cutaneous melanoma associated with, I①:2:93
Hereditary prostate cancer associated with, I①:2:112, I①:2:113
Male breast carcinoma associated with, I①:2:10
Pancreatic ductal adenocarcinoma associated with, II①:6:46
Risk of breast cancer associated with (table), III①:1:2, III①:1:3
BRCAl syndrome. See Hereditary breast/ovarian cancer syndrome (BRCAl).
Breast cancer
Germline mutations associated with increased risk of breast cancer (table), I①:1:2
Hereditary syndromes associated with, I①:1:4
Li-Fraumeni syndrome/Li-Fraumeni-like syndrome associated with, I①:2:128
Melanoma/pancreatic carcinoma syndrome associated with, I①:2:135
Pathologic features associated with BRCAl and BRCAl2 (table), III①:1:3
Risk of, in Fanconi anemia, I①:2:71
Werner syndrome/progeria associated with, I①:2:195
Breast cancer 1 syndrome. See Hereditary breast/ovarian cancer syndrome (BRCAl).
Breast cancer 2 syndrome. See Hereditary breast/ovarian cancer syndrome (BRCAl2).
Cancer risk management, I①:1:6
Chemoprevention, I①:1:6
Prophylactic surgery, I①:1:6
Screening, I①:1:6
P.viii
Clinical issues
ATM (ataxia-telangiectasia carriers), I①:1:5
BRCAl (hereditary breast & ovarian cancer syndrome), I①:1:3, I①:1:4
BRCAl2 (hereditary breast & ovarian cancer syndrome), I①:1:4
CHEK2, I①:1:5
PTEN (Cowden syndrome), I①:1:5
STK11/LKB1 (Peutz-Jeghers syndrome), I①:1:5
TP53 (Li-Fraumeni syndrome), I①:1:4
Diagnostic Pathology: Familial Cancer Syndromes

differential diagnosis of tumors secondarily involving parathyroid (table), III(5):13
epidemiology, II(1):3
etiology/pathogenesis, II(1):2, II(1):3
features common to all major germline mutations, II(1):2, II(1):3
features specific to certain germline mutations, II(1):3
hereditary breast cancer, II(1):2, II(1):3
genetic testing, II(1):5, II(1):6
graphics
BRCA1- and BRCA2-associated cancers, II(1):8
general features, II(1):7
TP53- and CDH1-associated breast cancers, II(1):9
hereditary breast/ovarian cancer syndrome (BRCA1) associated with, II(2):73, I(2):74
hereditary breast/ovarian cancer syndrome (BRCA2) associated with, II(2):77, I(2):78
hereditary cutaneous melanoma associated with, I(2):94
lobular
hereditary diffuse gastric cancer associated with, I(2):81
neurofibromatosis type 1 associated with, II(2):151, I(2):152
Peutz-Jeghers syndrome associated with, I(2):165
PTEN-hamartoma tumor syndromes associated with, I(2):170
xeroderma pigmentosum associated with, I(2):201
ancillary tests, II(1):12
clinical issues, II(1):10, II(1):11
differential diagnosis, II(1):12
etiology/pathogenesis, II(1):10
 genetics (family history), II(1):10
hereditary breast/ovarian cancer syndrome (BRCA1) associated with, I(2):74
hereditary breast/ovarian cancer syndrome (BRCA2) associated with, I(2):78
image findings, II(1):11
macroscopic features, II(1):11
microscopic pathology, II(1):12
carcinoma in situ, II(1):12
invasive carcinoma, II(1):12
radiographic and microscopic features, II(1):13
Breast manifestations, of PTEN-hamartoma tumor syndromes, I(2):169
BRIP1 gene mutations, risk of breast cancer associated with (table), III(1):2
Bronchial cancer, in Howel-Evans syndrome/keratitis palmare and plantares with esophageal cancer, I(2):121
Bronchiectasis, in ataxia-telangiectasia syndrome, I(2):3
Bronchioalveolar carcinoma of lung, Peutz-Jeghers syndrome associated with, I(2):165
Bronchioalveolar-pattern adenocarcinoma. See Adenocarcinoma with lepidic (bronchioalveolar) predominant pattern.
Brooke-Spiegler syndrome
basal cell nevus syndrome/Gorlin syndrome vs., I(2):5
Birt-Hogg-Dubé syndrome vs., I(2):14
salivary gland neoplasms associated with (table), III(4):4
Bussey-Gardner polyposis. See Familial adenomatous polyposis.

C
Cancer susceptibility testing, I(1):11, I(1):12
Carcinoid tumor. See Neuroendocrine carcinoma of lung.
Carcinoid tumorlet, neuroendocrine carcinoma of lung vs., II(10):17
Carcinoma cuniculatum, as variant of head and neck squamous cell carcinoma, II(4):4
Carcinoma ex pleomorphic adenoma, molecular changes described in salivary gland tumors (table), III(4):5
Carcinomas in varied sites, Bloom syndrome associated with, I(2):17
Carcinosarcoma. See Squamous cell carcinoma, cutaneous.
Cardiac fibroma, associated with basal cell nevus syndrome/Gorlin syndrome, I(2):5
Cardiac rhabdomyoma, tuberous sclerosis complex associated with, I(2):181
Cardiofaciocutaneous syndrome,
Costello syndrome vs., I(2):25
Cardiovascular system manifestations, of neurofibromatosis type 1, I(2):151
adrenal cortical adenoma associated with, II(5):2
P. ix
adrenal cortical carcinoma associated with, II(5):10
adrenal cortical neoplasms in children as part of, II(5):18, II(5):20
adrenal cortical tumors as part of (table), III(5):3
ancillary tests, I(2):20
bone and soft tissue tumors associated with (table), III(3):4
classification based on dermatological and endocrine markers, I(2):20
cutaneous manifestations constituting 3% of manifestations, I(2):19
findings suggestive of but not diagnostic of, I(2):19, I(2):20
for clinical diagnosis, I(2):20
major diagnostic criteria, I(2):19
similar clinical and pathologic features, I(2):20
supplementary criteria, I(2):19
familial nonmedullary thyroid carcinoma associated with, I(2):60, II(5):92
familial nonmedullary thyroid carcinoma in familial cancer syndromes (table), III(5):22
familial sex cord-stromal tumors associated with, I(2):65
familial testicular tumors (table), III(7):20
familial thyroid carcinoma associated with, II(5):90
follicular thyroid carcinoma associated with, II(5):100, II(5):103
 genetics, I(2):18, I(2):59
macroscopic findings, I(2):19
atrial myxoma, I(2):19
large cell calcifying Sertoli cell tumor, I(2):19
primary pigmented nodular adenocortical disease, I(2):19
psammomatous melanotic schwannoma, I(2):19
microscopic findings, I(2):19
pituitary adenoma associated with, II(5):82, III(5):16
primary pigmented nodular adenocortical disease associated with, II(5):24
syndromes with genetic predisposition for peripheral nerve neoplasia (table), III(9):10
 testicular Sertoli cell neoplasms associated with, II(7):30
thyroid tumors in, II(5):93
tumors and lesions associated with (graphics), I(2):22, I(2):23
Carney triad
adrenal cortical adenoma associated with, II(5):2
familial cancer syndromes with lung neoplasms (table), III(10):2
familial gastrointestinal stromal tumor associated with, I(2):46, I(2):47
 genetics, I(2):105, I(2):106
hereditary paraganglioma/pheochromocytoma syndromes associated with, I(2):107
paraganglioma associated with, II(5):51
pheochromocytoma/paraganglioma associated with, II(5):40
Carney-Stratakis syndrome
familial esophageal, gastric, and small intestinal tumors in (table), III(6):6
familial gastrointestinal stromal tumor associated with, I(2):46, I(2):47
genetics, I(2):106
hereditary paraganglioma/pheochromocytoma syndromes associated with, I(2):107
paraganglioma associated with, II(5):51, II(5):52
pheochromocytoma/paraganglioma associated with, II(5):40
tumor distributions in major familial paraganglioma syndromes, II(5):44
CASR gene mutations
genetic testing, I(2):53
parathyroid hyperplasia associated with, II(5):79
Castlemain disease, hyaline vascular type, mantle cell lymphoma vs., II(2):37
CCD1 gene mutations, pituitary adenomas associated with, III(5):16
C-cell carcinoma. See Medullary thyroid carcinoma.
differential diagnosis, II(5):107, II(5):108
histologic features, II(5):107
immunohistochemical features, II(5):109
immunohistochemistry, II(5):108
incidence of medullary thyroid carcinoma and associated diseases in MEN2 (table), III(5):20
microscopic features, II(5):109
neoplastic as precursor lesion to medullary thyroid carcinoma, II(5):110
clinical issues, II(5):106
definition, II(5):106
histologic features, II(5):107
multiple endocrine neoplasia type 2/familial medullary thyroid carcinoma associated with, I(2):142
prognosis, II(5):106, II(5):107
reactive/physiologic as precursor lesion to medullary thyroid carcinoma, II(5):110
clinical issues, II(5):106
definition, II(5):106
histologic features, II(5):107
reactive/physiologic vs. neoplastic C-cell hyperplasia, II(5):108, II(5):20
treatment, II(5):106
CCNA1 gene mutations, pituitary adenomas associated with, III(5):16

PAR

parathyroid adenoma associated with, II(5):68
parathyroid carcinoma associated with, II(5):74
parathyroid hyperplasia associated with, II(5):79
CCND1 gene amplification, laryngeal squamous cell carcinoma associated with, II(4):4
CDC73 gene mutations
familial isolated hyperparathyroidism associated with, I(2):52
genetic testing, II(2):53
CDH1 gene, function, II(1):4
CDH1 gene mutations
breast cancer associated with (graphics), II(1):9
hereditary diffuse gastric cancer associated with, II(2):80
risk of breast cancer associated with (table), III(1):2
CDK4 mutations, in hereditary cutaneous melanoma, II(2):93
CDKN1B gene mutations, pituitary adenomas associated with, III(5):16
CDKN1C gene mutations, Beckwith-Wiedemann syndrome associated with, II(2):9
CDKN2A gene mutations
astrocytoma associated with, II(9):4
cutaneous melanoma associated with, II(11):8
familial plasma cell myeloma associated with, I(2):62
familial uveal melanoma associated with, I(2):66
hereditary cutaneous melanoma associated with, II(2):92, I(2):93
melanoma/pancreatic carcinoma syndrome associated with, I(2):134
CEBPA gene mutations
familial CEBPA mutation, I(2):34
CEBPA-dependent familial acute myeloid leukemia, predisposition to hematologic malignancy, II(2):41
Celiac disease, as risk factor for small bowel adenocarcinoma, II(6):28
Cell cycle and cell differentiation defects, associated with myelodysplastic syndromes/acute myeloid leukemia, I(2):35
Cellular immunity deficiency, in ataxia-telangiectasia syndrome, I(2):3
Cellular schwannoma, malignant peripheral nerve sheath tumor vs., I(3):16
Central nervous system degeneration, in ataxia-telangiectasia syndrome, I(2):3
Central nervous system manifestations neurofibromatosis type 1, I(2):151
neurofibromatosis type 2, I(2):158
tuberous sclerosis complex, I(2):181
Central nervous system neoplasms associated with basal cell nevus syndrome/Gorlin syndrome, I(2):5
astrocytoma. See Astrocytoma.
choroid plexus tumors, II(9):16, II(9):17, II(9):18, II(9):19
ependymoma, II(9):20, II(9):21, II(9):22, II(9):23
choroid plexus tumors vs., II(9):17
differential diagnosis, II(9):21
 genetic syndromes associated with CNS neoplasms (table), III(9):2
graphic features, III(9):5
hereditary syndromes associated with, I(1):4, I(1):5
imaging and microscopic features, II(9):3, III(9):4, III(9):5
medulloblastoma/CNS-PNET. See Medulloblastoma/CNS-PNET.
meningioma. See Meningioma.
multiple endocrine neoplasia type 1 associated with, I(2):137
pineoblastoma, II(9):34, II(9):35
differential diagnosis, II(9):35
hereditary retinoblastoma associated with, I(2):119
medulloblastoma/CNS-PNET vs., II(9):26
retinoblastoma, II(9):36, II(9):37, II(9):38, II(9):39
differential diagnosis, II(9):37
head and neck neoplasms associated with (table), III(4):2
salivary gland neoplasms associated with (table), III(4):4
xeroderma pigmentosum associated with, I(2):201
Centroblastic/centrocytic lymphoma. See Follicular lymphoma.
Centrocytic lymphoma. See Mantle cell lymphoma.
Ceruminous adenoma, endolumphatic sac tumor vs., II(4):10
Cervical carcinoma, II(8):2, II(8):3
cytologic features, II(8):3
etiology/pathogenesis, II(8):2
minimal deviation adenocarcinoma, II(8):2
Peutz-Jeghers syndrome, II(8):2
hereditary breast/ovarian cancer syndrome (BRCA1) associated with, I(2):74
histologic features, II(8):2, II(8):3
Peutz-Jeghers syndrome associated with, I(2):165

treatment, II(8):2
cervical squamous carcinoma, bladder carcinoma vs., I(7):7
CHEK2 gene, function, I(1):5
CHEK2 gene mutations
breast carcinoma associated with, I(1):5
risk of breast cancer associated with (table), I(1):2
Chemical exposure, pancreatic ductal adenocarcinoma associated with, II(6):46
Childhood monosomy 7, predisposition to hematologic malignancy, II(2):41
Diagnostic Pathology: Familial Cancer Syndromes

Cholangiocarcinoma, hepatocellular carcinoma vs., II(6):40

Cholecystectomy, previous, pancreatic ductal adenocarcinoma associated with, II(6):46

Chondroid chordoma, chondrosarcoma vs., II(3):5

Chondroma of soft tissue, genetic findings in benign tumors (table), III(3):3 (includes Bone and Soft Tissue and Bone and Soft Tissue)

Chondromyxoid fibroma

Chondrosarcoma vs., II(3):4

molecular and cytogenetic findings (table), III(3):2

dedifferentiated, osteosarcoma vs., II(3):27
differential diagnosis, II(3):4, II(3):5
clinical pathology (table), II(3):5

etiology/pathogenesis

Chondromyxoid fibroma


See also Familial chordoma.

Chordoid, chondrosarcoma vs., II(3):5
differential diagnosis, II(3):10

familial cancer syndromes with bone and soft tissue tumors (table), III(3):4

image findings, II(3):9

imaging and gross features, II(3):11

immunohistochemical features, II(3):13

microscopic features, II(3):11, II(3):12, II(3):13

microscopic pathology, II(3):9, II(3):10

prognosis, II(3):8, III(3):9

treatment, II(3):8

Choriocarcinoma, microscopic pathology, II(7):14

Choroid plexus, normal, choroid plexus tumors vs., II(9):17

Choroid plexus papilloma, endolymphatic sac tumor vs., II(4):10

Choroid plexus tumors, II(9):16, II(9):17, II(9):18, II(9):19
differential diagnosis, II(9):17

etiology/pathogenesis, II(9):16

Aicardi syndrome, II(9):16

Li-Fraumeni syndrome, II(9):16

rhabdoid predispersion syndrome, II(9):16

sporadic tumors, II(9):16

grading, II(9):17

graphic features, II(9):19

histologic features, II(9):16

imaging features, II(9):18

microscopic features, II(9):18, II(9):19

Chromophil renal cell carcinoma.

Chromophobe renal cell carcinoma. See Renal oncocytoma, chromophobe, and hybrid oncocytic tumors.

Chromosome 1 loss chromosome phel renal cell carcinoma associated with, II(7):46

renal oncocytoma associated with, II(7):46

Chromosome 1p

loss of heterozygosity

neuroblastaoma associated with, II(5):34

Wilms tumor associated with, II(7):54

losses, in prostate carcinoma, II(7):19

Chromosome 1q, gain of

in prostate carcinoma, II(7):19

Wilms tumor associated with, II(7):54

Chromosome 1q21, as possible site of gene for familial nonmedullary thyroid carcinoma, II(5):59

Chromosome 2p gains, in prostate carcinoma, II(7):19

Chromosome 2q15-16, primary

pigmented nodular adrenocortical disease associated with, II(5):24

Chromosome 2q37 deletion, increased risk of Wilms tumor in (table), II(2):199

Chromosome 3 translocation, constitutional

clear cell renal cell carcinoma associated with, II(7):38

familial renal tumors in (table), II(7):6


Chromosome 3p loss of heterozygosity, in oral squamous cell carcinoma, II(4):4

Chromosome 3p22.1 SNP, familial plasma cell myeloma associated with, II(2):62

Chromosome 3q27 abnormalities in diffuse large B-cell lymphoma, II(2):9

in Hodgkin lymphoma, II(2):27

Chromosome 4q, losses, Wilms tumor associated with, II(7):54

Chromosome 5 gains, in pituitary carcinoma, II(5):86

Chromosome 6 loss, chromophobe renal cell carcinoma associated with, II(7):46

Chromosome 6q losses, in prostate carcinoma, II(7):19

Chromosome 7 gains, in prostate carcinoma, II(7):19

Chromosome 7p gains, in pituitary carcinoma, II(5):86

Chromosome 8, gains, pleuropulmonary blastoma associated with, II(10):24

Chromosome 8p losses, in prostate carcinoma, II(7):19

Chromosome 8p23.1-p22, as possible site of gene for familial nonmedullary thyroid carcinoma, II(2):59

Chromosome 8q gains, in prostate carcinoma, II(7):19

Chromosome 9p loss of heterozygosity, in oral squamous cell carcinoma, II(4):4

Chromosome 10 loss, chromophobe renal cell carcinoma associated with, II(7):46

Chromosome 10q losses, in prostate carcinoma, II(7):19

Chromosome 11 loss of heterozygosity, in rhabdomyosarcoma, II(3):32

Chromosome 11p15.5, in Beckwith-Wiedemann syndrome, II(2):9

Chromosome 11q loss of heterozygosity, neuroblastaoma associated with, II(5):34

Chromosome 11q22-23, of ataxia-telangiectasia mutated (ATM) gene, II(2):2

Chromosome 11q23 alteration, renal oncocytoa associated with, II(7):46

Chromosome 13 loss, chromophobe renal cell carcinoma associated with, II(7):46

Chromosome 13q losses, in prostate carcinoma, II(7):19

Chromosome 14q gains, in pituitary carcinoma, II(5):86

Chromosome 14q32, as possible site of gene for familial nonmedullary thyroid carcinoma, II(2):59

Chromosome 16q

loss of heterozygosity, Wilms tumor associated with, II(7):54

losses in prostate carcinoma, II(7):19

Wilms tumor associated with, II(7):54

Chromosome 17 loss, chromophobe renal cell carcinoma associated with, II(7):46

Chromosome 17p loss of heterozygosity, in oral squamous cell carcinoma, II(4):4

Chromosome 17q22-24, primary

pigmented nodular adrenocortical disease associated with, II(5):24

Chromosome 18q losses, in prostate carcinoma, II(7):19

Chromosome 19p13.2
as possible site of gene for familial nonmedullary thyroid carcinoma, [I(2):59]
pure familial papillary thyroid carcinoma associated with, [I(2):58], [I(2):59]
Chromosome 21 loss, chromophobe renal cell carcinoma associated with, [II(7):46]
Chromosome 22 loss, in meningioma, [I(9):30]
Chromosome q14, loss of, Wilms tumor associated with, [II(7):54]
Chromosome Xq gains, in prostate carcinoma, [II(7):19]
Chromosome Y loss
chromophobe renal cell carcinoma associated with, [II(7):46]
renal oncocytoma associated with, [II(7):46]
Chronic lymphocytic leukemia, familial, [I(2):44], [I(2):45]
comparison of sporadic and familial CLL, [I(2):45]
genetics, [I(2):44], [I(2):45]
Chronic lymphocytic leukemia/small lymphocytic lymphoma, [II(2):2], [II(2):3], [II(2):4], [II(2):5], [II(2):6], [II(2):7]
ancillary tests, [II(2):3], [II(2):4]
differential diagnosis, [II(2):4]
histologic features, [II(2):2], [II(2):3]
immunohistochemical features, [II(2):5]
immunophenotypic features, [II(2):7]
mantle cell lymphoma vs., [II(2):37]
immunohistochemistry, [II(7):41]
metastatic to skin, sebaceous carcinoma vs., [II(11):20]
microscopic features, [II(7):40]
treatment, [II(7):38]
tumors with clear/light-staining cytoplasm (table), [III(7):6]
Clear cell papilosis, cutaneous melanoma vs., [II(11):10]
Clear cell renal cell carcinoma, [II(7):39], [II(7):41]
papillary renal cell carcinoma vs., [II(7):43], [II(7):45]
tumors with clear/light-staining cytoplasm (table), [III(7):6]
Clear cell papulosis, cutaneous melanoma vs., [II(11):10]
Clear cell renal cell carcinoma, [II(7):38], [II(7):39], [II(7):40], [II(7):41]
differential diagnosis, [II(7):39], [II(7):41]
etiology/pathogenesis, [II(7):38]
familial CCRC, [II(7):38]
sporadic CCRC, [II(7):38]
smoking, pancreatic ductal adenocarcinoma vs., [II(6):44]
Chronic myeloid leukemia
atypical, myeloid neoplasms vs., [II(2):44]
myeloid neoplasms vs., [II(2):44]
Chronic myelomonocytic leukemia, myeloid neoplasms vs., [II(2):44]
Chronic pancreatitis
pancreatic ductal adenocarcinoma associated with, [II(6):46]
pancreatic ductal adenocarcinoma vs., [II(6):48]
Cigarette smoking, pancreatic ductal adenocarcinoma associated with, [II(6):46]
Cirrhosis
dysplastic nodule in, hepatocellular carcinoma vs., [II(6):40]
hepatocellular carcinoma associated with, [II(6):38]
regenerative nodule in, hepatocellular carcinoma vs., [II(6):40]
Citrullinemia, familial biliary tract, liver, and pancreas neoplasms in (table), [III(6):3]
Clark nevi. See Dysplastic melanocytic nevi (atypical melanocytic nevi, Clark nevi).
Clear cell chondrosarcoma, chondrosarcoma vs., [II(3):4]
Clear cell papillary renal cell carcinoma
clear cell renal cell carcinoma vs., [II(7):39], [II(7):41]
papillary renal cell carcinoma vs., [II(7):43], [II(7):45]
tumors with clear/light-staining cytoplasm (table), [III(7):6]
Clear cell papulosis, cutaneous melanoma vs., [II(11):10]
Clear cell renal cell carcinoma, [II(7):38], [II(7):39], [II(7):40], [II(7):41]
differential diagnosis, [II(7):39], [II(7):41]
etiology/pathogenesis, [II(7):38]
familial CCRC, [II(7):38]
sporadic CCRC, [II(7):38]
immunohistochemistry, [II(7):41]
P.xiii
metastatic to skin, sebaceous carcinoma vs., [II(11):20]
microscopic features, [II(7):40]
treatment, [II(7):38]
tumors with clear/light-staining cytoplasm (table), [III(7):6]
with eosinophilic cytoplasm, renal oncocytoma, chromophobe, and hybrid oncocytic tumors vs., [II(7):47], [II(7):49]
Clear cell renal cell carcinoma, familial as hereditary or familial renal tumor syndrome, [II(2):116]
as hereditary renal epithelial tumor, [II(2):115]
familial renal tumors in (table), [III(7):6]
Clear cell sarcoma
Gl tract
gastrointestinal stromal tumor vs., [II(6):20]
molecular and cytogenetic findings (table), [III(3):2]
kidney, Wilms tumor vs., [II(7):56], [II(7):61]
malignant peripheral nerve sheath tumor vs., [II(3):16]
soft parts, molecular and cytogenetic findings (table), [III(3):2]
background, [I(1):10]
cancer susceptibility testing, [I(1):11], [I(1):12]
American Society of Clinical Oncology (ASCO), [I(1):11]
genetic counseling, [I(1):12]
special issues related to genetic testing research, [I(1):12]
clinical findings, [I(1):15]
diagnosis, [I(1):12], [I(1):13], [I(1):14]
established diagnostic criteria, [I(1):12], [I(1):13], [I(1):14]
basal cell nevus syndrome, [I(1):12]
Carcney complex, [I(1):13]
Li-Fraumeni syndrome, [I(1):13]
Lynch syndrome, [I(1):13]
neurofibromatosis type 1, [I(1):13]
von Hippel-Lindau syndrome, [I(1):12], [I(1):13]
features suggesting presence of familial cancer predisposition, [I(1):14]
future perspectives, [I(1):14]
identification of at-risk individuals, [I(1):10], [I(1):11]
introduction to hereditary cancer, [I(1):10]
Cockayne syndrome
Werner syndrome/progeria vs., [I(2):196]
xeroderma pigmentosum vs., [I(2):202]
Collecting duct carcinoma
involving kidney &/or renal pelvis, [III(7):18]
papillary renal cell carcinoma vs., [II(7):43], [II(7):45]
Colon adenocarcinoma, Peutz-Jeghers syndrome associated with, [I(2):165]
Colon adenoma, [II(6):2], [II(6):3], [II(6):4], [II(6):5], [II(6):6], [II(6):7]
adenoa to carcinoma sequence, [II(6):2]
differential diagnosis, [II(6):5]
endoscopic findings, [II(6):3]
family history, [II(6):2]
genetic syndromes in, [II(6):2]
unmicroscopic features, [II(6):6], [II(6):7]
 microscopic pathology, [II(6):4], [II(6):5]
degree of dysplasia, [II(6):4]
flat or depressed adenoma, [II(6):5]
histologic features, [II(6):4]
intramuscular carcinoma, [II(6):4]
other types of adenoma, [II(6):5]
pseudo invasion (epithelial misplacement), [II(6):4]
traditional serrated adenoma, [II(6):5]
villous component, [II(6):4]
natural history, [II(6):3]
nutritional factors, [II(6):2]
prognosis, [II(6):4]
reporting considerations, [II(6):5]
treatment, [II(6):3], [II(6):4]
Colon carcinoma
invasive, colon adenoma vs., [II(6):5]
signet ring cell, hereditary diffuse gastric cancer associated with, [I(2):81]
Werner syndrome/progeria associated with, [I(2):195]
Colon manifestations, of PTEN-hamartoma tumor syndromes, [I(2):169]
Colon polyps, hamartomatous, in PTEN-hamartoma tumor syndromes, [I(2):169]
Colorectal adenocarcinoma
juvenile polyposis syndrome associated with, [II(2):123]
PTEN-hamartoma tumor syndromes associated with, [II(2):170]
Colorectal carcinoma
dyskeratosis congenita associated with, [I(2):32]
in Birt-Hogg-Dubé syndrome, cancer risk management, [I(2):13]
Colorectal neoplasms
familial colon and rectum tumors by genetic testing, [II(1):11]
-
familial neoplasia of (table), III(6):4
hereditary nonpolyposis. See Lynch syndrome.
Lynch syndrome associated with, (I(2):131
Congenital adrenal hyperplasia
adrenal cortical adenoma.
Congenital adrenal hyperplasia
adrenal cortical carcinoma associated with, II(5):2
adrenal cortical neoplasms in children
as part of, II(5):10
adrenal cortical tumors as part of
(table), III(5):3
Congenital amegakaryocytic
thrombocytopenia, microscopic features, III(2):3
predisposition to myeloid neoplasms
(table), III(2):2
Congenital epulis, melanotic
Cutaneous neoplasms (table)
genetic syndromes associated with CNS
malignancies (table)
Constitutional mismatch repair
deficiency syndrome
astrocytoma associated with, II(9):2
0
Constitutional mismatch repair
deficiency syndrome
syndrome associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lynch syndrome associated with,
I(2):21
Lynch syndrome associated with
neoplasms associated with CNS
neoplasms (table), III(9):2
Lymphadenopathy, multiple
Cutaneous neoplasms.
Lymphoma, B-cell
Cutaneous neoplasms.
Lymphoma, large cell
Cutaneous neoplasms.
Lymphoma, lymphocytic
Cutaneous neoplasms.
Lymphoma, marginal zone
Cutaneous neoplasms.
Lymphoma, mantle cell
Cutaneous neoplasms.
Lymphoma, mantle-zone
Cutaneous neoplasms.
Lymphoma, nodal
Cutaneous neoplasms.
Lymphoma, nodose
Cutaneous neoplasms.
Lymphoma, non-Hodgkin
Cutaneous neoplasms.
Lymphoma, non-Hodgkin
Cutaneous neoplasms.
Lymphoma, non-Hodgkin
Cutaneous neoplasms.
Lymphoma, nodose
Cutaneous neoplasms.
Lymphoma, non-Hodgkin
Cutaneous neoplasms.
Lymphoma, nodose
Cutaneous neoplasms.
Lymphoma, non-Hodgkin
Cutaneous neoplasms.
Lymphoma, nodose
Cutaneous neoplasms.
Lymphoma, non-Hodgkin
Cutaneous neoplasms.
Lymphoma, nodose
Cutaneous neoplasms.
Lymphoma, non-Hodgkin
Cutaneous neoplasms.
Dyskeratosis congenita associated with DKC1 adenocarcinoma vs. Drash syndrome vs. morphologic features

Immunophenotypic features

Differential diagnosis

Ancillary tests

Diffuse large B cell lymphoma.

DNA damage repair deficiency syndromes, with predisposition to myelodysplastic syndromes/acute myeloid leukemia, I(2):34, I(2):35

DNA single-strand break repair defects, disorders associated with ataxia-telangiectasia syndrome vs., I(2):3

DND1 gene, familial testicular germ cell tumors associated with, I(2):65

Down syndrome, predisposition to hematologic malignancy, I(2):40

Duct cell adenocarcinoma. See Pancreatic ductal adenocarcinoma.


Associated neoplasms, I(2):31, I(2):32

Cancer risk management, I(2):32

Leukemia, I(2):32

Prevention, I(2):32

Squamous cell carcinoma, I(2):32

Clinical implications and ancillary tests, I(2):31

Diagnostic criteria, I(2):32

Differential diagnosis, I(2):32

Genetic predisposition for squamous cell carcinoma of head and neck, II(4):2

Genetics, I(2):30, I(2):31

P.xvi

E - cadherin/CDH1 gene. See CDH1 gene mutations.

Ectopic pancreas, small bowel adenocarcinoma vs., I(6):29

EGFR gene mutations, pituitary adenomas associated with, I(5):16

EGFR gene overamplification, in laryngeal squamous cell carcinoma, I(4):4

DLBCL. See Diffuse large B-cell lymphoma.

Endometrial carcinoma, I(4):8


Cytologic features, I(4):9

Diagnostic criteria, I(4):10

Differential diagnosis, I(4):7

Genetic predisposition, I(4):8

Histogenesis, I(4):8

Histologic features, I(4):9

Image findings, I(4):9

Microscopic features, I(4):11


Endometrial carcinoma, II(8):4, II(8):5

Ancillary techniques, I(8):7

Diagnostic diagnosis, I(8):6

Etiology/pathogenesis genetic predisposition, I(8):6

Histogenesis, I(8):5, I(8):6

Lynch syndrome associated with epidemiology, I(8):8

Genetic predisposition, I(8):8

Histologic features, I(8):5

Molecular genetics, I(8):6

Presentation, I(8):4, I(8):5

Risk associated with, I(2):131

Microscopic features, I(8):7

Peutz-Jeghers syndrome associated with epidemiology, I(8):8

Genetic predisposition, I(8):8

Histologic features, I(8):5

Molecular genetics, I(8):6

Presentation, I(8):5
PTEN-hamartoma tumor syndrome associated with
epidemiology, II(8):4
genetic predisposition, II(8):4
histologic features, II(8):5
increased risk with, I(2):170
molecular genetics, II(8):6
presentation, II(8):5
subtypes, II(8):4
Endometrial hyperplasia, hereditary hyperparathyroidism-jaw tumor syndrome associated with, I(2):84
Endometrial stroma sarcoma, molecular and cytogenetic findings
(table), III(3):2
Endometriosis pulmonary, Birt-Hogg-Dubé syndrome
vs., I(2):14
small bowel adenocarcinoma vs., II(6):29
Environmental/infectious etiology, of familial Hodgkin lymphoma, I(2):49
EPCAM gene mutations, Lynch syndrome associated with, I(2):130, I(2):131
Ependymoma, II(9):20, II(9):21, II(9):22, II(9):23
choroid plexus tumors vs., III(9):17
cytologic features, II(9):21
differential diagnosis, II(9):21
grading, II(9):21
P.xvii

histologic features, II(9):20
image findings, II(9):20
light and electron microscopy, II(9):23
microscopic features, II(9):22
neurofibromatosis type 2 associated with, II(2):159, I(2):163
treatment, II(9):20
Epidermoid carcinoma. See Squamous cell carcinoma, cutaneous; Squamous cell carcinoma, head and neck.
Epithelioid angiomylipoma clear cell renal cell carcinoma vs., II(7):39, II(7):41
tumors with clear/light-staining cytoplasm (table), III(7):6
Epithelioid fibrosarcoma, sclerosing, sclerosing rhabdomyosarcoma vs., II(3):33
Epithelioid hemangioendothelioma, molecular and cytogenetic findings (table), III(3):2
Epithelioid sarcoma, molecular and cytogenetic findings (table), III(3):2
Epstein-Barr virus diffuse large B-cell lymphoma positive for, II(2):9
familial Hodgkin lymphoma associated with, I(2):49
Esophageal adenocarcinoma, II(6):8, II(6):9
differential diagnosis, II(6):8, II(6):9
familial syndromes associated with (table), III(6):7
histologic grading, II(6):9
Esophageal carcinoma dyskeratosis congenita associated with, I(2):32
in Howel-Evans syndrome/keratosis palmares and plantares, with esophageal cancer, I(2):120, II(2):121
Esophageal glycogen acanthosis, in PTEN-hamartoma tumor syndromes, I(2):169
Esophageal manifestations, of PTEN-hamartoma tumor syndromes, I(2):169
Esophageal neoplasms familial esophageal tumors by syndromes (table), III(6):6
familial neoplasia of esophagus, stomach, and small intestine (table), III(6):7
hereditary syndromes associated with, I(1):4
leiomyoma, multiple endocrine neoplasia type 1 associated with, I(2):137
Esophageal squamous cell carcinoma, II(6):10, II(6):11
differential diagnosis, II(6):11
familial syndromes associated with (table), III(6):7
genetics, II(6):10
Ewing sarcoma alveolar rhabdomyosarcoma vs., III(3):32
malignant peripheral nerve sheath tumor vs., II(3):16
osteosarcoma vs., II(3):27
Ewing sarcoma/primitive neuroectodermal tumor (PNET) molecular and cytogenetic findings (table), III(3):2
neuroblastoma vs., II(5):34	small blue round cell tumors of kidney (table), III(7):8
Exostosis, hereditary multiple. See Hereditary multiple exostosis.
EXT1 gene mutations function of gene products, I(2):90, II(2):91
hereditary multiple exostosis associated with, I(2):90
Extraclonic neoplasms, MYH-associated polyposis associated with, I(2):149
Extraosseous plasmacytoma, plasma cell myeloma vs., II(2):53
Eye and ocular adnexa, genetic syndromes and neoplasms involving (table), III(9):6
Eye manifestations. See Ocular manifestations.

extraintestinal manifestations, I(2):39, I(2):40
familial biliary tract, liver, and pancreas neoplasms in (table), III(6):3
familial colon and rectum tumors by syndrome (table), III(6):3
familial colon and rectum tumors by syndrome (table), III(6):3
familial esophageal, gastric, and small intestinal tumors in (table), III(6):6
familial follicular cell carcinoma in, II(5):94
familial neoplasia of colon and rectum in (table), III(6):4
familial nonmedullary thyroid carcinoma associated with, I(2):60, II(5):92
familial nonmedullary thyroid carcinoma in familial cancer syndromes, III(5):22
familial thyroid carcinoma associated with, II(5):90, II(5):98

- gross, microscopic, and genetic features, I(2):41
- head and neck neoplasms associated with (table), III(4):2
- hepatoblastoma associated with, II(6):35
- hepatocellular carcinoma associated with, II(6):38

in hereditary pancreatic cancer syndrome (table), I(2):101

- macroscopic features, I(2):39
- melanoma/pancreatic carcinoma syndrome vs., I(2):135
- microscopic features, I(2):39
  - MYH-associated polyposis associated with, I(2):149

selected hereditary cancer syndromes with skin manifestations (table), III(11):2

- thyroid pathology in (graphics), III(5):23
- thyroid tumors in, II(5):93
- variants, I(2):40
- Familial atypical multiple mole melanoma syndrome

familial biliary tract, liver, and pancreas neoplasms in (table), III(6):3

in hereditary pancreatic cancer syndrome (table), I(2):101

- pancreatic ductal adenocarcinoma associated with, II(6):46
- Familial Barrett esophagus, familial esophageal, gastric, and small intestinal tumors in (table), III(6):6

Familial benign hypocalcic hypercalcemia, familial isolated hyperparathyroidism vs., I(2):54

- Familial café au lait spots, neurofibromatosis type 1 vs., I(2):152
- Familial CEPTA mutations, I(2):34
- Familial cerebelloretinal angiomatosis. See von Hippel-Lindau syndrome.

Familial chordoma, I(2):42, I(2):43

- bone and soft tissue tumors associated with (table), III(3):4
- genetics, I(2):42
- cancer risk management


- genetics, I(2):44, I(2):45
- sporadic chronic lymphocytic leukemia vs., I(2):45

Familial clear cell renal cell carcinoma as familial renal tumors (table), III(7):6

- as hereditary or familial renal tumor syndrome, I(2):116
- as hereditary renal epithelial tumor, I(2):115

Familial cylindromatosis, salivary gland neoplasms associated with (table), III(4):4

Familial cystic parathyroid adenomatosis. See Hereditary hyperparathyroidism-jaw tumor syndrome.

Familial follicular cell carcinoma classification, II(5):54

- in familial cancer syndromes, II(5):94

Familial follicular cell tumors, etiology/pathogenesis, II(5):90, II(5):91

Familial cell-derived carcinoma definitions, I(2):58

- type 1, genetics, I(2):58
- Familial follicular thyroid carcinoma. See Follicular thyroid carcinoma.


Familial gastrointestinal stromal tumor, I(2):46, I(2):47

- genetic syndromes associated with (table), I(2):47
  - syndromes/genetics, I(2):46, I(2):47
  - Carney triad, I(2):46, I(2):47
  - Carney-Stratakis syndrome, I(2):46
  - KIT germline mutations, I(2):46
  - neurofibromatosis type 1, I(2):47
  - platelet-derived growth factor receptor alpha (PDGFRA) germline mutations, I(2):46


- associated neoplasms, I(2):50
- cancer risk management, I(2):50
- categories of Hodgkin lymphoma, I(2):48

- environmental/infectious etiology, I(2):49

- genetics, I(2):49
  - microscopic features, I(2):51
  - sporadic Hodgkin lymphoma vs., I(2):50
  - Familial hypercalcemic hypercalcemia (table), III(5):13
  - Familial hypocalcic hypercalcemia, hyperparathyroidism in (table), III(5):13

See also Hereditary hyperparathyroidism-jaw tumor syndrome.

- associated conditions, I(2):53
- cancer risk management, I(2):53

- P.xix

clinical implications and ancillary tests, I(2):52, I(2):53
diagnosis, I(2):53
genetics, I(2):52
graphic and microscopic features, I(2):55

parathyroid adenoma associated with, II(5):66

parathyroid carcinoma associated with, II(5):72

parathyroid hyperplasia associated with, II(5):76, II(5):77

parathyroid pathology in (table), III(5):13

Familial isolated pituitary adenoma, pituitary adenoma associated with, I(5):82, III(5):16

Familial medullary hyperplasia, in etiology of adrenal medullary hyperplasia, I(5):28

Familial medullary thyroid carcinoma. See Multiple endocrine neoplasia type 2/familial medullary thyroid carcinoma.

Familial melanoma, bone and soft tissue tumors associated with (table), III(3):4

Familial monosomy 7, predisposition to hematologic malignancy, I(2):41

Familial multiple basoloid follicular hamartomas, basal cell nevus syndrome/Gorlin syndrome vs., I(2):6

Familial multiple meningioma disease, meningioma associated with, III(9):30

Familial nephroblastoma. See Familial Wilms tumor.

Familial nodular lymphocyte-predominant Hodgkin lymphoma, I(2):50

Familial nonclear cell renal cell carcinoma, as hereditary renal epithelial tumor, I(2):115


- genetics, I(2):56
- sporadic non-Hodgkin lymphoma vs., I(2):57


- associated neoplasms, I(2):60
- cancer risk management, I(2):60

clinical implications and ancillary tests, I(2):60
definitions, I(2):58
epidemiology, I(2):58
epidemiology/pathogenesis, II(5):90, II(5):91

genetics, I(2):58, I(2):59

familial papillary thyroid carcinoma (PTC) with multinodular goiter, I(2):59

familial papillary thyroid carcinoma (PTC) with papillary renal cell carcinoma, I(2):59

- other possible candidates, I(2):59
- pure familial PTC ± oxyphilia, I(2):59

- syndromes characterized by predominance of nonthyroidal tumors, I(2):58, I(2):59
- syndromes with predominance of nonendocrine thyroid carcinoma, I(2):59
- type 1 familial nonendocrine thyroid carcinoma, I(2):59

- in familial cancer syndromes, III(5):22

- microscopic features, I(2):61

presentation, III(5):92
### Familial Cancer Syndromes

<table>
<thead>
<tr>
<th>Genetic Syndrome</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hereditary renal epithelial tumor</td>
<td>Associated with FAP. See Familial adenomatous polyposis.</td>
</tr>
<tr>
<td>Familial primary hyperparathyroidism with multiple ossifying jaw fibromas</td>
<td></td>
</tr>
<tr>
<td>Familial pancreatic cancer, melanoma/pancreatic carcinoma syndrome vs., I(2):135</td>
<td></td>
</tr>
<tr>
<td>Familial multiple myeloma, I(2):62</td>
<td>Monoclonal gammopathy of undetermined significance or multiple myeloma, I(2):63</td>
</tr>
<tr>
<td>Familial aggregated renal cancer, I(2):69</td>
<td>Associated neoplasms, I(2):70</td>
</tr>
<tr>
<td>Familial renal cancer, I(2):69</td>
<td>Cancer risk management, I(2):71</td>
</tr>
<tr>
<td>Familial melanoma, I(2):70</td>
<td>Associated neoplasms, I(2):71</td>
</tr>
<tr>
<td>Familial melanoma, I(2):70</td>
<td>Dyskeratosis congenita vs., I(2):32</td>
</tr>
<tr>
<td>Familial melanoma, I(2):70</td>
<td>Genetic predisposition for squamous cell carcinoma of head and neck, I(2):42</td>
</tr>
<tr>
<td>Familial melanoma, I(2):70</td>
<td>Genetic tumor syndromes and nonneoplastic ocular manifestations (table), I(2):36</td>
</tr>
<tr>
<td>Familial melanoma, I(2):70</td>
<td>Head and neck neoplasms associated with (table), I(2):36</td>
</tr>
<tr>
<td>Familial melanoma, I(2):70</td>
<td>Increased risk of Wilms tumor (table), I(2):71</td>
</tr>
<tr>
<td>Familial melanoma, I(2):70</td>
<td>Predisposition to hematologic malignancy, I(2):40</td>
</tr>
<tr>
<td>Familial melanoma, I(2):70</td>
<td>Predisposition to myeloid neoplasms (table), I(2):41</td>
</tr>
<tr>
<td>Familial melanoma, I(2):70</td>
<td>FAP. See Familial adenomatous polyposis.</td>
</tr>
<tr>
<td>Familial melanoma, I(2):70</td>
<td>Fetal adenocarcinoma (monophasic pulmonary blastoma), lung adenocarcinoma vs., I(2):10</td>
</tr>
<tr>
<td>Familial melanoma, I(2):70</td>
<td>Fetal rhabdomyoma, embryonal rhabdomyosarcoma vs., I(2):32</td>
</tr>
<tr>
<td>Familial melanoma, I(2):70</td>
<td>FGFR2 gene mutations, pituitary adenomas associated with, I(2):5</td>
</tr>
<tr>
<td>Familial melanoma, I(2):70</td>
<td>FH gene mutations</td>
</tr>
<tr>
<td>Familial melanoma, I(2):70</td>
<td>Hereditary leiomyomatosis and renal cell carcinoma associated with, I(2):87</td>
</tr>
<tr>
<td>Familial melanoma, I(2):70</td>
<td>Testing for, I(2):87</td>
</tr>
</tbody>
</table>

---

**Subgroups, I(2):58**

Familial oncocytoma

as hereditary or familial renal tumor syndrome, I(2):116

familial renal tumors in (table), II(7):46

renal oncocytoma, chromophobe, and hybrid oncocytic tumors associated with, II(7):6

Familial pancreatic cancer, melanoma/pancreatic carcinoma syndrome vs., I(2):135

Familial papillary thyroid carcinoma (FPTC)


associated neoplasms, I(2):63

familial multiple myeloma, I(2):63

monoclonal gammopathy of undetermined significance or multiple myeloma, I(2):63

cancer risk management, I(2):63

myeloma susceptibility loci testing, I(2):63

test for M component in family members, I(2):63

clinical implications

familial aggregation of multiple myeloma, I(2):63

familial multiple myeloma or myeloma syndrome, I(2):63


genetic/environmental, I(2):62

genetics, I(2):62, I(2):63

putative autosomal dominant transmission of MM, I(2):62

transmission of MM, I(2):63

role of immune-mediated conditions, I(2):63

Familial platelet disorder, with propensity to develop myeloid malignancy, I(2):41

Familial platelet disorder/acute myeloid leukemia (FPD/AML) definition, I(2):34

familial acute myeloid leukemia associated with, I(2):36

Familial polyposis coli. See Familial adenomatous polyposis.

Familial posterior fossa brain tumor syndrome. See Rhabdoid predisposition syndrome.

Familial primary hyperparathyroidism with multiple ossifying jaw fibromas. See Hereditary hyperparathyroidism-jaw tumor syndrome.

Familial renal oncocytoma, as hereditary renal epithelial tumor, I(2):114

P.xx

Familial sex cord-stromal tumors, I(2):65

Familial somatotropinoma syndrome, isolated, pituitary adenoma associated with, I(2):82

Familial testicular germ cell tumors, I(2):64, I(2):65

familial sex cord-stromal tumors, I(2):65

familial testicular germ cell tumors, I(2):64, I(2):65

familial testicular tumors (table), I(2):67

genes implicated in (table), I(2):65

hereditary hyperparathyroidism-jaw tumor syndrome associated with, I(2):84


C-cell hyperplasia and neoplasia (graphics), I(2):95

differential diagnosis, I(2):93

distinct characteristics of familial thyroid carcinoma and sporadic carcinoma (table), I(3):22

epidemiology, I(2):91, I(2):92

etiology/pathogenesis, I(2):90, I(2):91

Carney complex, I(2):90

familial adenomatous polyposis, I(2):90

familial follicular cell tumors or familial nonmedullary thyroid carcinoma, I(2):90, I(2):91

familial medullary thyroid carcinoma, I(2):91

familial tumor syndromes characterized by predominance of nonmedullary thyroid carcinoma, I(2):90, I(2):91

Pendred syndrome, I(2):93

PTEN-hamartoma tumor syndrome, I(2):93

Werner syndrome, I(2):93

presentation

familial medullary thyroid carcinoma (FMTC), I(2):92

familial nonmedullary thyroid carcinoma (FNMTCTC), I(2):92

syndrome-associated group, I(2):92


cancer risk management, I(2):67

gene mutations, pituitary adenomas associated with, I(2):10

Fetal rhabdomyosarcoma vs.

Fetal adenocarcinoma (monophasic pulmonary blastoma), lung adenocarcinoma vs., I(2):10

Fetal rhabdomyoma, embryonal rhabdomyosarcoma vs., I(2):32

FGFR2 gene mutations, pituitary adenomas associated with, I(3):5

FH gene mutations

hereditary leiomyomatosis and renal cell carcinoma associated with, I(2):86, I(2):87

testing for, I(2):87
in familial cancer syndromes, II(5):94
Follicular cell carcinoma, familial thyroid carcinoma vs., II(5):93
Follicular cell-derived carcinoma, familial definitions, I(2):58
type 1, genetics, I(2):58
Follicular hyperplasia, reactive follicular lymphoma vs., II(2):18
mantle cell lymphoma vs., II(2):37
ancillary techniques (graphics), II(2):22
ancillary tests, II(2):17
chronic lymphocytic leukemia/small lymphocytic lymphoma vs., II(2):4
cytologic features, II(2):16
differential diagnosis, II(2):18
diffuse follicular lymphoma, II(2):16
etiology/pathogenesis, II(2):14
germ line susceptibility factors, II(2):14
imbalance of other proteins involved in apoptosis, II(2):14
immunologic microenvironment, II(2):14
t(14;18)(q32;q21) resulting in BCL2 overexpression, II(2):14
extranodal sites (graphics), II(2):23
 genetics, II(2):14
grade 3B, diffuse large B-cell lymphoma vs., II(2):10
grading, II(2):16
histologic discordance, II(2):16
histologic features, II(2):15, II(2):16, II(2):17
immunohistochemical features, II(2):20, II(2):21, II(2):22
intrafollicular neoplasia/in situ follicular lymphoma, II(2):16
mantle cell lymphoma vs., II(2):37
microscopic features, II(2):19, II(2):20
pediatric follicular lymphoma, II(2):17
prognosis, II(2):15
reporting pattern, II(2):16
transformation to aggressive B-cell lymphoma, II(2):16
treatment, II(2):15
Follicular neoplasms (trichoepithelioma and trichoblastoma), basal cell carcinoma vs., II(11):4, II(11):7
differential diagnosis, II(5):102
 table, II(5):103
differential diagnosis of tumors secondarily involving parathyroid (table), III(5):13
etiology/pathogenesis, II(5):100, II(5):101
inherited tumor syndromes, II(5):100
preexisting thyroid disease, II(5):101
gross and diagrammatic features, II(5):104
histological features, II(5):104
in familial cancers, (table), II(5):103
medullary thyroid carcinoma vs., II(5):113
microscopic features, II(5):105
microscopic pathology, II(5):102
parathyroid carcinoma vs. (table), III(5):12
PTEN-hamartoma tumor syndromes associated with, I(2):170
Fracture callus
chondrosarcoma vs., III(3):5
osteosarcoma vs., III(3):26, III(3):27
Frasier syndrome
as Wilms tumor-associated syndrome, I(2):138
Denys-Drash syndrome vs., I(2):27
P.xxi
familial renal tumors in (table), III(7):6
genetics, II(7):55
Fundic gland polyposis ± dysplasia, familial syndromes associated with (table), III(6):7
FWT1 gene mutations, familial Wilms tumor associated with, II(2):69
FWT2 gene mutations, familial Wilms tumor associated with, II(2):69

G
Gallbladder neoplasms, hereditary breast/ovarian cancer syndrome (BRCA2) associated with, I(2):78
Gangliocytoma of cerebellum, in PTEN-hamartoma tumor syndromes, I(2):169
Ganglioneuroma
gastrointestinal tract, multiple endocrine neoplasia type 2/familial medullary thyroid carcinoma associated with, I(2):142
hereditary neuropathoma associated with, I(2):97
hereditary paraganglioma/pheochromocytoma syndromes associated with, I(2):107
neuroblastoma vs., II(5):34
Ganglioneuromatosis, intestina,
genetics, II(7):55
neurofibromatosis type 1 associated with, I(2):151
Gardner syndrome. See also Familial adenomatous polyposis,
as variant of familial adenomatous polyposis, I(2):40
Gastrectomy, prophylactic total, for hereditary diffuse gastric cancer, I(2):81
differential diagnosis, II(5):13, II(5):14
endoscopic findings, II(5):12
etiology/pathogenesis, II(5):12
gastric adenocarcinoma and proximal polyposis (GAPPS) of the stomach,
familial esophageal, gastric, and small intestinal tumors in (table), III(6):6
graph and microscopic features, II(6):15
gross appearance advanced cancer, II(6):13
early gastric cancer, II(6):13
histologic grading, II(6):14
juvenile polyposis syndrome associated with, II(2):123
Lynch syndrome associated with, II(2):131
Peutz-Jeghers syndrome associated with, II(2):165
prognosis, II(6):13
radiologic features, II(6):16
TNM classification, II(6):14
treatment, II(6):13
Gastric adenoma, familial syndromes associated with (table), III(6):7
Gastric cancer hereditary diffuse. See Hereditary diffuse gastric cancer.
type, familial syndromes associated with (table), III(6):7
Gastric carcinoma dyskeratosis congenita associated with, II(2):32
xeroderma pigmentosum associated with, II(2):201
Gastric cardiac adenocarcinoma, esophageal adenocarcinoma vs., II(6):8, II(6):9
Gastric dysplasia, gastric adenocarcinoma vs., II(6):13
Gastric lymphoma, gastric adenocarcinoma vs., II(6):13, II(6):14
Gastric neoplasms familial adenomatous polyposis associated with, II(2):39
familial gastric tumors by syndromes (table), III(6):6
familial neoplasia of esophagus, stomach, and small intestine (table), III(6):7
hereditary breast/ovarian cancer syndrome (BRCA2) associated with, II(2):78
hereditary syndromes associated with, II(1):4
Li-Fraumeni syndrome associated with, II(2):128
Lynch syndrome associated with, II(2):131
Peutz-Jeghers syndrome associated with, II(2):165
small bowel adenocarcinoma. See Small bowel adenocarcinoma.
Gastrointestinal schwannoma, neurofibromatosis type 1 associated with, II(2):151
Gastrointestinal smooth muscle tumors. See Gastrointestinal stromal tumor.
P.xxiii
clinical prognostic for GISTs from largest series, II(6):21
familial, II(2):46, II(2):47
familial syndromes associated with (table), III(6):7
gross features, II(6):23
malignant, multiple endocrine neoplasia type 1 associated with, II(2):137
molecular and cytogenetic findings (table), III(3):2
molecular prognostic for, II(6):21
neurofibromatosis type 1 associated with, II(2):151
prognosis, II(6):19
GATA2 gene mutations familial acute myeloid leukemia associated with, II(2):35, II(2):36
familial GATA2 mutation, II(2):34
recently described GATA2 mutation in Emberger syndrome, II(2):34
in MonoMAC syndrome, II(2):34
Generalized basoloid follicular hamartoma syndrome, basal cell nevus syndrome/Gorlin syndrome vs., II(2):6
Genetic risk assessment of at-risk individuals, I(1):11
Genetic testing
American Society of Clinical Oncology (ASCO)
clinical utility of genetic testing, I(1):11
indications for testing, I(1):11
familial adenomatous polyposis, II(2):40
familial isolated hyperparathyroidism associated with, II(2):53
genetic counseling, I(1):12
hereditary breast/ovarian cancer syndrome (BRCA1), II(2):73
hereditary breast/ovarian cancer syndrome (BRCA2), II(2):77
juvenile polyposis syndrome, II(2):123
Li-Fraumeni syndrome/Li-Fraumeni-like syndrome, II(2):129
MEN1 gene mutation, II(2):136
multiple endocrine neoplasia type 2/familial medullary thyroid carcinoma associated with, II(2):142, II(2):143
Peutz-Jeghers syndrome, II(2):164
rhabdoid predisposition syndrome, II(2):172
special issues related to genetic testing research, I(1):12
Genital nevus, cutaneous melanoma vs., II(11):10
Genitalia, in Denys-Drash syndrome, II(2):26
Genitourinary neoplasms associated with basal cell nevus syndrome/Gorlin syndrome, II(2):5
bladder carcinoma. See Bladder carcinoma.
germ cell tumor. See Germ cell tumor.
hereditary syndromes associated with, I(1):3, I(1):4
prostate carcinoma. See Prostate carcinoma.
renal. See Renal neoplasms.
testicular Sertoli cell neoplasms, II(7):30, II(7):31, II(7):32, II(7):33
ureter urothelial carcinoma, II(7):10, II(7):11
etiology/pathogenesis, II(7):12
cytogenetic changes, II(7):12
familial germ cell tumor, II(7):12
risk factors, II(7):12
gross and histologic features, II(7):15, II(7):16, II(7):17
immunohistochemical features, II(7):17
key immunohistochemical reactivity and differential diagnosis (table), II(7):14
macrogenic features classical seminoma, II(7):13
embryonal carcinoma, II(7):13
mixed germ cell tumor, II(7):13
teratoma, II(7):13
yolk sac tumor, II(7):13
microscopic pathology, II(7):13, II(7):14
choriocarcinoma, II(7):14
classical seminoma, II(7):14
embryonal carcinoma, II(7):14
intraductal germ cell neoplasia, II(7):13, II(7):14
mixed germ cell tumor, II(7):14
spERMATOCYTIC SEMINOMA, II(7):14
teratoma, II(7):14
yolk sac tumor, II(7):14
pineoblastoma vs., II(9):35
treatment, II(7):13
Germinal centers, progressive
transformation of, follicular lymphoma
vs., II(2):18
Giant cell tumor
diffuse type, molecular and cytogenetic
findings (table), III(3):2
osteosarcoma vs., II(9):31
Giall neoplasms,
medulloblastoma/CNS-PNET vs.,
II(9):26
Glioblastoma
as subtype of astrocytoma, II(9):4
in Turcot syndrome, Lynch syndrome
associated with, I(2):131
meningioma vs., II(9):31
PTEN-hamartoma tumor syndromes
associated with, I(2):170
Glioneuronal tumors
as subtype of astrocytoma, II(9):4
neurofibromatosis type 1 associated
with, II(2):151
Glinosarcoma, meningioma vs., II(9):31
Glinois, astrocytoma vs., II(9):5
Gliomangiomatosis,
pheochromocytoma/paraganglioma
vs., II(5):43
P.xxiv

Glomus tumor
neurofibromatosis type 1 associated
with, II(2):151
pheochromocytoma/paraganglioma
vs., II(5):43
Glucagonoma
in well-differentiated pancreatic
docrine tumor, II(5):64
laboratory tests, II(5):63
multiple endocrine neoplasia type 1
associated with, I(2):137
prognosis, II(5):63
Glucagonoma syndrome, in
presentation of pancreatic endocrine
tumor, II(5):62
Glycogen storage disease types I-IV
familial biliary tract, liver, and pancreas
neoplasms in (table), III(6):3
hepatoblastoma associated with,
II(6):35
GNA11 gene mutations, familial uveal
melanoma associated with, I(2):66
GNAQ gene mutations, familial uveal
melanoma associated with, I(2):66
GNAS gene mutations, pituitary
adenomas associated with, II(5):16
GNAS1 gene mutations, follicular
carcinoma associated with, II(5):102
Gonadal malignancies, in Denys-Drash
syndrome, cancer risk management,
I(2):27
Gonadoblastoma, Denys-Drash
syndrome associated with, I(2):27
Gorlin-Goltz syndrome. See Basal cell
evenus syndrome/Gorlin syndrome.
Granulosa cell tumor, testicular Sertoli
cell neoplasms vs., II(7):31
Gynecologic carcinomas involving
bladder, bladder carcinoma vs., II(7):5
Gynecologic neoplasms
cervical carcinoma, II(8):2, II(8):3
hereditary breast/ovarian cancer
syndrome (BRCA1) associated with,
I(2):74
Peutz-Jeghers syndrome associated
with, I(2):165
dometrioidal carcinoma, II(8):4, II(8):5,
II(8):6, II(8):7
fallopian tube carcinoma, II(8):8, II(8):9
hereditary breast/ovarian cancer
associated with, II(8):8
hereditary breast/ovarian cancer
syndrome (BRCA1) associated with,
I(2):74
hereditary breast/ovarian cancer
syndrome (BRCA2) associated with,
I(2):78
familial cancer syndromes with
gynecologic manifestations (table),
II(8):2
hereditary syndromes associated with,
I(1):5
microscopic features, II(8):3
ovarian carcinoma. See Ovarian
carcinoma.
Gynecomastia, male breast carcinoma
vs., II(1):12
endolymphatic sac tumor, II(4):8,
familial cancer syndromes with head
and neck neoplasms (table), III(4):2
graphic, clinical, and gross features,
III(4):3
hereditary syndromes associated with,
II(1):5
squamous cell carcinoma, II(4):2,
Helicobacter pylori, gastric
adenocarcinoma associated with,
II(6):12
Hemangioblastoma, von Hippel-Lindau
syndrome associated with, I(2):187,
I(2):192, I(2):193
Hematologic neoplasms. See also Blood
and bone marrow neoplasms.
Fanconi anemia associated with,
I(2):71
Li-Fraumeni syndrome/Li-Fraumeni-like
syndrome associated with, I(2):128
Hematolymphoid malignancies
Bloom syndrome associated with,
I(2):17
differential diagnosis of tumors
secondarily involving parathyroid
(table), III(5):13
in ataxia-telangiectasia syndrome,
I(2):3
Hemihyperplasia, isolated, Beckwith-
Wiedemann syndrome vs., I(2):9
Hemihypertrophy
adrenal cortical neoplasms in children
as part of, II(5):18
hepatoblastoma associated with,
II(6):35
isolated (idiopathic)
as Wilms tumor-associated syndrome,
I(2):199
familial renal tumors in (table), III(7):6
 genetics, II(7):55
 increased risk of Wilms tumor in
 (table), I(2):199
Hemihypoplasia, Beckwith-Wiedemann
syndrome vs., I(2):10
Hemochromatosis, familial biliary tract,
liver, and pancreas neoplasms in
(table), III(6):3
Hepatic adenoma, hepatocellular
carcinoma vs., II(6):40
Hepatobiliary neoplasms
ampullary adenocarcinoma, II(6):30,
associated familial neoplasia (table),
III(6):2
differential diagnosis, II(6):31
Lynch syndrome associated with,
I(2):131
by syndromes (table), III(6):3
familial neoplasia of biliary tract, liver,
and pancreas, II(6):2
hepatoblastoma. See Hepatoblastoma.
hepatocellular carcinoma. See
Hepatocellular carcinoma.
hepatoblastoma, II(6):34, II(6):35,
II(6):36, II(6):37

H
H19 gene abnormalities
adrenal cortical carcinoma associated
with, II(5):12
Beckwith-Wiedemann syndrome
associated with, I(2):9
Hairy cell leukemia, chronic
lymphocytic leukemia/small
lymphocytic lymphoma vs., II(2):4
Hamartomas
in PTEN-hamartoma tumor syndromes,
I(2):169
cystic, mesenchymal See
Pleuripulmonary blastoma.
nasal chondromesenchymal,
pleuripulmonary blastoma associated
with, II(10):25
Hamartomatous polyp
in Peutz-Jeghers syndrome, I(2):165
gastrointestinal tract, III(6):26,
II(6):27
Head and neck manifestations, of
familial adenomatous polyposis,
I(2):40
Head and neck neoplasms

Diagnostic Pathology: Familial Cancer Syndromes

adrenal cortical neoplasms in children vs., II(5):20
associated familial neoplasia (table), III(6):2
Beckwith-Wiedemann syndrome associated with, I(2):9
Children’s Oncology Group Staging System, II(6):34
conditions associated with, II(6):35
differential diagnosis, II(6):36
genetics, II(6):34
mesenchymal component, II(6):36
metastasis, II(6):34, II(6):35
microscopic features, II(6):37
morphologic classification, II(6):36
prognostic factors, II(6):36
teratoid component, II(6):36
adrenal cortical adenoma vs., II(5):5, III(5):2
adrenal cortical carcinoma vs., II(5):12
architectural patterns, II(6):39, II(6):40
associated familial neoplasia (table), III(6):2
cytologic features, II(6):40
graphics, II(6):45
differential diagnosis, II(6):40
differential diagnosis of tumors secondarily involving parathyroid (table), III(5):13
etiology/pathogenesis, II(6):38
cirrhosis, II(6):38
developmental anomaly, II(6):38
environmental exposure, II(6):38
genetic disorders, II(6):38
infectious agents, II(6):38
metabolic, II(6):38
progression of benign tumor, II(6):38
Fanconi anemia associated with, I(2):71
fibrolamellar variant, II(6):40
grading, Edmondson and Steiner, II(6):40
gross features, II(6):41, II(6):43
hepatoblastoma vs., II(6):36
histologic features, II(6):39, II(6):40
pseudocarcinoma/paraganglioma vs., II(5):43
treatment, II(6):39
tumor cell morphology, II(6):40
variants (graphics), II(6):43
Hepatoma. See Hepatocellular carcinoma.
associated neoplasms, I(2):73, II(2):74, II(1):4
BRCA1-related cancers (graphics), I(2):75
calculating risk, I(2):73
cancer risk management, I(2):74
chemoprevention, I(2):74
prophylactic surgery, I(2):74
screening, I(2):74
fallopian tube carcinoma associated with, II(8):8
familial biliary tract, liver, and pancreas neoplasms in (table), III(6):3
familial cancer syndromes with gynecologic manifestations (table), III(8):2
gene testing, I(2):73
mutations, I(2):72, I(2):73
in hereditary pancreatic cancer syndrome (table), I(2):101
in ovarian carcinoma, II(8):10, II(8):11, II(8):12
incidence, II(1):3
lifetime risk, II(1):4
melanoma/pancreatic carcinoma syndrome vs., I(2):135
microscopic features, II(1):8
modifiers of risk, I(2):76
selected hereditary cancer syndromes with skin manifestations (table), III(11):2
associated lesions (graphics), I(2):95
associated neoplasms, I(2):94
cancer risk management, I(2):94
clinical implications and ancillary tests, I(2):93
clinical risk factors, I(2):93
epidemiology, I(2):92
genetics, I(2):92, I(2):93
hereditary vs. sporadic cutaneous melanoma, I(2):92
Hereditary diffuse gastric cancer, I(2):80, I(2):81
associated neoplasms, I(2):81
cancer risk management, I(2):81
endoscopic surveillance, I(2):81
prophylactic total gastrectomy, I(2):81
clinical implications and ancillary tests, I(2):81
familial colon and rectum tumors by syndrome (table), III(6):5
familial esophageal, gastric, and small intestinal tumors in (table), III(6):6
familial syndromes associated with (table), III(6):7
mutations, II(2):80
microscopic features, I(2):80
Hereditary esophageal-vulvar syndrome: familial cancer syndromes with gynecologic manifestations (table), III(8):2
as hereditary or familial renal tumor syndrome, I(2):116
as hereditary renal epithelial tumor, I(2):115
associated neoplasms, I(2):83, I(2):84
bone and soft tissue tumors associated with (table), III(3):4
cancer risk management, I(2):84
clinical implications and ancillary tests, I(2):83
familial renal tumors in (table), III(7):6
gross and microscopic features, I(2):85
head and neck neoplasms associated with (table), III(4):2
hyperparathyroidism in (table), III(5):13
increased risk of Wilms tumor in (table), I(2):199
molecular genetics, I(2):82, I(2):83
mutations of HRPT2 gene on 1q25-q31, I(2):83
parathyroid adenoma associated with, II(5):66
parathyroid carcinoma associated with, II(5):72
parathyroid hyperplasia associated with, II(5):76
Diagnostic Pathology: Familial Cancer Syndromes

Hereditary infundibulocystic basal cell carcinoma
basal cell nevus syndrome/Gorlin syndrome vs., I(2):6
selected cutaneous neoplasms and associated hereditary cancer syndromes (table), III(11):2
ancillary tests, I(2):87
as hereditary or familial renal tumor syndrome, I(2):116
associated neoplasms, I(2):87, I(2):88
cancer risk management, I(2):88
diagnosis, I(2):88
surveillance, I(2):88
treatment, I(2):88
comparative genomic hybridization, I(2):87
familial cancer syndromes with gynecologic manifestations (table), III(8):2
familial renal tumors in (table), III(7):6
genetics, I(2):86, I(2):87
in etiology of papillary renal cell carcinoma, II(7):42
Lehtonen Modified Criteria for diagnosis of, I(2):88
selected cutaneous neoplasms and associated hereditary cancer syndromes (table), III(11):2
selected hereditary cancer syndromes with skin manifestations (table), III(11):2
familial renal tumors in (table), III(7):6
genetics, I(2):86, I(2):87
in etiology of papillary renal cell carcinoma, II(7):42
Lehtonen Modified Criteria for diagnosis of, I(2):88
selected cutaneous neoplasms and associated hereditary cancer syndromes (table), III(11):2
selected hereditary cancer syndromes with skin manifestations (table), III(11):2
tumors in (graphics), I(2):89
Hereditary mixed polyposis syndrome familial colon and rectum tumors by syndrome (table), III(6):5
familial neoplasia of colon and rectum in (table), III(6):4
juvenile polyposis syndrome vs., (I(2):124
Hereditary multiple exostosis, I(2):90, I(2):91
bone and soft tissue tumors associated with (table), III(3):4
diagnosis, I(2):91
histogenesis, I(2):90
malignant and benign neoplasms associated with, I(2):91
molecular genetics, I(2):90, I(2):91
Hereditary multiple exostosis/osteochondromas, as etiology of chondrosarcoma, II(3):2
Hereditary multiple melanoma melanoma/pancreatic carcinoma syndrome vs., I(2):135
selected cutaneous neoplasms and associated hereditary cancer syndromes (table), III(11):2
selected hereditary cancer syndromes with skin manifestations (table), III(11):2

P.xxvii

ancillary tests (graphics), I(2):99
associated neoplasms, I(2):97
cancer risk management, I(2):97
high importance of cytogenetics, I(2):97
prognosis, I(2):97
screening, I(2):97
clinical implications and ancillary tests, I(2):97
genetics, I(2):96
imaging, microscopic and gross features, I(2):98
Hereditary nonpolyposis colorectal cancer. See Lynch syndrome.
Hereditary pancreatic cancer syndrome, I(2):100, I(2):101
cancer risk management, I(2):100, I(2):101
genetics, I(2):100
histogenesis, I(2):100
relative risk of pancreatic cancer, I(2):101
syndromes and associated genes in (table), I(2):101
Hereditary pancreatitis familial biliary tract, liver, and pancreas neoplasms in (table), III(6):3
in hereditary pancreatic cancer syndrome (table), I(2):101
melanoma/pancreatic carcinoma syndrome vs., I(2):135
pancreatic ductal adenocarcinoma associated with, II(6):46
as hereditary or familial renal tumor syndrome, I(2):116
associated neoplasms, I(2):103
cancer risk management, I(2):103
clinical implications and ancillary tests, I(2):103
familial renal tumors in (table), III(7):6
teiology of papillary renal cell carcinoma, II(7):42
genetics, I(2):102
genetic counseling, I(2):107
genotype-phenotype correlation, I(2):108
patient evaluation, I(2):107
clinical and genetic features of (table), III(5):6
clinical implications and ancillary tests, I(2):106
genotype-phenotype correlation, I(2):108
graphic features
paraganglia and paraganglioma, I(2):109
paraganglioma, I(2):111
pheochromocytoma, I(2):110
paraganglioma associated with, II(5):51
syndromes characterized by susceptibility to pheochromocytoma and paraganglioma, I(2):104
Hereditary prostate cancer, I(2):112, I(2):113
cancer risk management, I(2):113
family history as risk factor, I(2):112
effects on lifetime risk, I(2):113
predisposition to prostate cancer in patients with positive family history, I(2):113
genetics, I(2):112, I(2):113
prostate carcinoma associated with, II(7):19
associated neoplasms (graphics), I(2):117
constitutional chromosome 3 translocation, I(2):114, I(2):115
familial clear cell renal cell carcinoma, I(2):115
familial nonclear cell renal cell carcinoma, I(2):115
familial renal oncocytoma, I(2):114
hereditary hyperparathyroidism-jaw tumor syndrome, I(2):115
hereditary or familial renal tumor syndromes (table), I(2):116
papillary thyroid carcinoma with associated neoplasia, I(2):115
associated neoplasms, I(2):119
bone and soft tissue tumors associated with (table), III(3):4
familial cancer syndromes associated with lung neoplasms (table), III(10):2
genetic syndromes and neoplasms involving eye and ocular adnexa (table), III(9):6
genetic syndromes associated with CNS neoplasms (table), III(9):2
 genetics, I(2):118
Knudson “2-hit” hypothesis, I(2):119
lung adenocarcinoma associated with, I(10):2
medulloblastoma/CNS-PNET associated with, II(9):24
bone and soft tissue-related hereditary syndromes, I(1):5
breast, I(1):4
central nervous system, I(1):4, I(1):5
docrine system, I(1):3
Diagnostic Pathology: Familial Cancer Syndromes

gastrointestinal tract, I(1):4
gynecologic system, I(1):5
head and neck, I(1):5
introduction, I(1):3
lung, I(1):5
skin, I(1):4
P.xviii

Hidrotic ectodermal dysplasia, Howel-Evans syndrome/keratosis palmares and plantares, with esophageal cancer vs., I(2):121
HLAG loci, associated with susceptibility to classical Hodgkin lymphoma (CHL), I(2):49
ancillary tests, II(2):27
characteristics of subtypes (table), II(2):28
classical (CHL)
cytologic features, II(2):27
definition, II(2):24
etiology/pathogenesis, II(2):24, II(2):25
microscopic pathology, II(2):26
clinical issues, II(2):25, II(2):26
differential diagnosis, II(2):27, II(2):28
histologic features, II(2):26, II(2):27
lymphocyte-depleted subtype (LDCHL)
differential diagnosis, II(2):28
microscopic pathology, II(2):26
lymphocyte-rich subtype (LRCHL)
differential diagnosis, II(2):28
follicular lymphoma vs., II(2):18
microscopic pathology, II(2):26
microscopic features, II(2):30, II(2):31
mixed cellularity subtype (MCHL)
differential diagnosis, II(2):28
microscopic pathology, II(2):26
nodular lymphocyte-predominant (NLPHL)
cytologic features, II(2):27
defifferential diagnosis, II(2):28
etiology/pathogenesis, II(2):25
follicular lymphoma vs., II(2):18
microscopic pathology, II(2):26, II(2):27
nodular sclerosis subtype (NSCHL)
differential diagnosis, II(2):27, II(2):28
microscopic features, II(2):29
Hormonal imbalance, disorders associated with, male breast carcinoma associated with, II(1):10
Hornstein-Knickerberg syndrome. See Birt-Hogg-Dubé syndrome.
Howel-Evans syndrome/keratosis palmares and plantares, associated with esophageal cancer, I(2):120, I(2):121
associated neoplasms, I(2):120
cancer risk management, I(2):121
bronchial cancer, I(2):121
esophageal cancer, I(2):121
squamous cell carcinoma of skin, I(2):121
clinical implications and ancillary tests, I(2):120
differential diagnosis, I(2):121
familial esophageal, gastric, and small intestinal tumors in (table), III(6):6
genetics, I(2):120
selected hereditary cancer syndromes with skin manifestations (table), III(11):2
Hogera-Hreidarsson syndrome. See Dykeratosis congenita.
HRAS gene mutations, Costello syndrome associated with, I(2):24
familial isolated hyperparathyroidism associated with, I(2):52
genetic testing, I(2):53
hereditary hyperparathyroidism-jaw tumor syndrome associated with, I(2):82
parathyroid adenoma associated with, I(2):56
parathyroid carcinoma associated with, I(2):54
hyperparathyroidism associated with, I(2):79
Human papillomavirus, cutaneous squamous cell carcinoma associated with, I(2):11
Hutchinson-Gilford progeria, Werner syndrome/progeria vs., I(2):195
Hyalinizing trabecular tumor, medullary thyroid carcinoma vs., I(2):113
Hyperparathyroidism
heritable hyperparathyroidism (table), III(5):13
incidence of medullary thyroid carcinoma and associated diseases in MEN2 (table), III(5):20
multiple endocrine neoplasia type 1 associated with, I(2):137
prognosis, I(5):63
Insulinoma
in well-differentiated pancreatic endocrine tumor, I(5):64
laboratory tests, I(5):63
multiple endocrine neoplasia type 1 associated with, I(2):137
prognosis, I(5):63
Insulinoma
in presentation of pancreatic endocrine tumor, I(5):62
Intestinal ganglioneuromatosis incidence of medullary thyroid carcinoma and associated diseases in MEN2 (table), III(5):20
neurofibromatosis type 1 associated with, I(2):151
Intestinal neoplasms. See Gastrointestinal neoplasms.
Intrathyroid parathyroid tissue, C-cell hyperplasia vs., I(5):108
Intrathyroid parathyroid tumors, medullary thyroid carcinoma vs., I(5):113
Intratubular germ cell neoplasia, I(7):13, I(7):14
Invasive adenocarcinoma, hamartomatous polyps of GI tract vs., I(6):27
Invasive colon carcinoma, colon adenoma vs., I(6):5

IDH1 and IDH2 gene mutations astrocytoma associated with, I(9):4
chondrosarcoma associated with, I(3):4
IGF2 gene abnormalities adrenal cortical carcinoma associated with, I(5):12
Beckwith-Wiedemann syndrome associated with, I(2):9
Wilms tumor associated with, I(7):54
IGM monoclonal gammapathy of undetermined significance, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia vs., I(2):34
Infantile fibrosarcoma, embryonal rhabdomyosarcoma vs., I(3):32
Inflammatory fibroid polyp, gastrointestinal stromal tumor vs., I(6):20
Inflammatory myofibroblastic tumor molecular and cytogenetic findings (table), III(3):2
spindle cell rhabdomyosarcoma vs., I(3):33
Inflammatory polyposis, juvenile polyposis syndrome vs., I(2):124
Inflammatory pseudopolyps, hamartomatous polyps of GI tract vs., I(6):26
IN1 germline mutations, in rhabdoid predisposition syndrome, I(2):172
Insulinoma
in well-differentiated pancreatic endocrine tumor, I(5):64
laboratory tests, I(5):63
multiple endocrine neoplasia type 1 associated with, I(2):137
prognosis, I(5):63
Insulinoma
in presentation of pancreatic endocrine tumor, I(5):62
Intestinal ganglioneuromatosis incidence of medullary thyroid carcinoma and associated diseases in MEN2 (table), III(5):20
neurofibromatosis type 1 associated with, I(2):151
Intestinal neoplasms. See Gastrointestinal neoplasms.
Intrathyroid parathyroid tissue, C-cell hyperplasia vs., I(5):108
Intrathyroid parathyroid tumors, medullary thyroid carcinoma vs., I(5):113
Intratubular germ cell neoplasia, I(7):13, I(7):14
Invasive adenocarcinoma, hamartomatous polyps of GI tract vs., I(6):27
Invasive colon carcinoma, colon adenoma vs., I(6):5
Invasive papillary carcinoma, in ampullary adenocarcinoma, II(6):31
Invasive pituitary adenoma, pituitary carcinoma vs., II(5):88
Invasive pulmonary adenocarcinoma, adenocarcinoma with lepidic (bronchioalveolar) predominant pattern vs., II(10):9
Ionizing radiation, hypersensitivity to, in ataxia-telangiectasia syndrome, I(2):2
Islet dysplasia, as precursor of pancreatic endocrine tumor, II(5):61
Isolated aplastic anemia, dyskeratosis congenita vs., I(2):32
Isolated familial somatotropinoma syndrome, pituitary adenoma associated with, I(5):82, II(5):16
Isolated hemihyperplasia, Beckwith-Wiedemann syndrome vs., I(2):9
Isolated (idiopathic) hemihypertrophy as Wilms tumor-associated syndrome, I(2):199
familial renal tumors in (table), I(2):199
Isolated ophalmolele, Beckwith-Wiedemann syndrome vs., I(2):10

K

KCNQ1 gene, Beckwith-Wiedemann syndrome associated with, I(2):9
KCNQ1OT1 gene, Beckwith-Wiedemann syndrome associated with, I(2):9
Keratoacanthoma
cutaneous squamous cell carcinoma vs., II(11):14
xeroderma pigmentosum associated with, I(2):201
Keratosis palmaris and plantares. See Howel-Evans syndrome/keratosis palmaris and plantares, with esophageal cancer. P.xxx

KIF1B gene mutations
hereditary
paragangioma/pheochromocytoma syndromes associated with, I(2):106
pheochromocytoma/paragangioma associated with, II(5):40
Kinesin family of genes, hereditary paragangioma/pheochromocytoma syndromes associated with, I(2):106
KIT gene mutations
familial gastrointestinal stromal tumor associated with, I(2):46, I(2):47
familial testicular germ cell tumors associated with, I(2):65
gastrointestinal stromal tumor vs., II(6):18
molecular prognostication for GISTs, II(6):21
KITLG gene, familial testicular germ cell tumors associated with, I(2):64, I(2):65
KLHDC8B disruption, familial Hodgkin lymphoma associated with, I(2):49
Klinefelter syndrome, male breast carcinoma associated with, II(1):10
KLNN gene, PTEN-hamartoma tumor syndromes associated with, I(2):167
Knudson “2-hit” hypothesis, for hereditary retinoblastoma, I(2):119

L

Lamb syndrome. See Carney complex, including Lamb syndrome.
Large B-cell lymphomas diffuse. See Diffuse large B-cell lymphoma.
medulloblastoma/CNS-PNET vs., I(9):26
other, diffuse large B-cell lymphoma vs., II(2):9, II(2):10
Large cell calcifying Sertoli cell tumor familial sex cord-stromal tumors associated with, I(2):65
tumors with oxyphilic cytoplasm (table), II(7):20
Large cell carcinoma
neuroendocrine carcinoma of lung vs., II(10):17
with neuroendocrine differentiation, neuroendocrine carcinoma of lung vs., II(10):17
with neuroendocrine pattern, neuroendocrine carcinoma of lung vs., II(10):17
Laryngeal squamous cell carcinoma
differential diagnosis, II(4):4
etiology/pathogenesis environmental exposure in, II(4):3
infectious agents in, II(4):3
infectious agents in etiology/pathogenesis, II(4):3
Legius syndrome, neurofibromatosis type 1 vs., I(2):152
Leiomyoma
classic angiomylipoma vs., II(7):35
esophageal, multiple endocrine neoplasia type 1 associated with, I(2):137
gastrointestinal stromal tumor vs., II(6):20
gene mutations in benign tumors (table), III(3):3 (includes Bone and Soft Tissue and Bone and Soft Tissue) hereditary hyperparathyroidism-jaw tumor syndrome associated with, I(2):84
lymphangiomyomatosis vs., II(10):13
schwannoma vs., II(3):38
Leiomyosarcoma
classic angiomylipoma vs., II(7):35
gastrointestinal stromal tumor vs., II(6):20
hereditary paragangioma/pheochromocytoma syndromes associated with, I(2):107
lymphangiomyomatosis vs., II(10):13
molecular and cytogenetic findings (table), III(3):2
pleomorphic, pleomorphic rhabdomyosarcoma vs., II(3):33
spindle cell rhabdomyosarcoma vs., II(3):33
Werner syndrome/progeria associated with, I(2):195
Lentigines, xeroderma pigmentosum associated with, I(2):201, I(2):203
LEOPARD syndrome
Carney complex vs., I(2):21
Costello syndrome vs., I(2):25
Leukemia
acute myeloid. See Myeloid neoplasms.
alveolar rhabdomyosarcoma vs., II(3):33
Bloom syndrome associated with, I(2):17
differential diagnosis, II(2):4
mantle cell lymphoma vs., II(2):37
chronic myeloid leukemia atypical, myeloid neoplasms vs., II(2):44
myeloid neoplasms vs., II(2):44
chronic myelomonocytic leukemia, myeloid neoplasms vs., II(2):44
familial chronic lymphocytic leukemia, II(2):44, II(2):45
comparison of sporadic and familial CLL, II(2):45
genetics, I(2):44, II(2):45
familial platelet disorder/acute myeloid leukemia (FPD/AML) definition, I(2):24
familial acute myeloid leukemia associated with, I(2):36
haired cell leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma vs., II(2):4
P.xxx

hereditary syndromes associated with, I(1):6
in dyskeratosis congenita, cancer risk management, I(2):32
juvenile myelomonocytic, neurofibromatosis type 1 associated with, I(2):151
lymphocytic chronic. See Familial chronic lymphocytic leukemia.
### Diagnostic Pathology: Familial Cancer Syndromes

<table>
<thead>
<tr>
<th>Page</th>
<th>Topic</th>
</tr>
</thead>
</table>

### Lipoblastoma, molecular and cytogenetic findings (table), III(3):2

<table>
<thead>
<tr>
<th>Page</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>I(2):131</td>
<td>retinoblastoma vs., II(9):37 xeroderma pigmentosum associated with, I(2):201</td>
</tr>
</tbody>
</table>

### Leydig cell tumor testicular Sertoli cell neoplasms vs., II(7):31 tumors with oxyphilic cytoplasm (table), III(7):20 |

### Lichen amyloidosis, incidence of medullary thyroid carcinoma and associated diseases in MEN2 (table), III(5):20 |


Lymphocytic lymphoma, intermediate grade of differentiation. See Mantle cell lymphoma.
Lymphocytic thyroiditis, in PTEN-hamartoma tumor syndromes, (I):2;169 Lymphoepithelial carcinoma as variant of head and neck squamous cell carcinoma, (II):4;4 case reports of salivary gland neoplasms with familial clustering (table), (III):4;4 Lymphoma

M
Malignant mesenchymoma. See Pleuropulmonary blastoma.
selected hereditary cancer syndromes with skin manifestations (table), III(1):2
clinical features, II(3):22
differential diagnosis, II(3):21
gross features, II(3):23
imaging features, II(3):23
immunohistochemistry, II(3):21
microscopic features, II(3):22, II(3):23
radiologic features, II(3):22
Malignant progonoma. See Melanotic neuroectodermal tumor of infancy.
MEN1 gene mutations
genetic testing, I(2):53
hereditary
paraganglioma/pheochromocytoma syndromes associated with, I(2):106
involved in pancreatic tumorigenesis, I(5):9
multiple endocrine neoplasia type 1 associated with, I(2):136
pancreatic endocrine tumor associated with, I(5):60
parathyroid adenoma associated with, I(5):68, II(5):69
parathyroid carcinoma associated with, II(5):74
parathyroid hyperplasia associated with, II(5):79
pituitary adenomas associated with, I(5):16
testing for, I(2):136
MEN2 gene, hereditary
paraganglioma/pheochromocytoma syndromes associated with, I(2):104, I(2):105
Meningioma, II(9):30, II(9):31, II(9):32, II(9):33
basal cell nevus syndrome/Gorlin syndrome associated with, II(2):5
differential diagnosis, II(9):31
endolymphatic sac tumor vs., II(4):10
ependymoma vs., II(9):21
etiology/pathogenesis, II(9):30
familial multiple meningioma disease, II(9):30
neurofibromatosis type 2, II(9):30
schwannomatosis with multiple meningiomas, II(9):30
grading, II(9):31
imaging and pathological features, II(9):32
microscopic features, II(9):33
neurofibromatosis type 2 associated with, I(2):159, I(2):162
Werner syndrome/progeria associated with, I(2):195
Meningothelial hyperplasia, meningioma vs., II(9):31
Merkel cell carcinoma
basal cell carcinoma vs., II(11):4, II(11):7
cutaneous melanoma vs., II(11):10
PTEN-hamartoma tumor syndromes associated with, I(2):170
Mesenchymal cystic hamartoma. See Pleuropulmonary blastoma.
Mesenchymal neoplasms, meningioma vs., II(9):31
Mesothelioma, familial uveal melanoma associated with, I(2):67
MET proto-oncogene mutations
hereditary papillary renal cell carcinoma associated with, I(2):102
screening for, I(2):103
Metagener, Werner syndrome/progeria vs., I(2):196
Metanephrin adenoma
papillary renal cell carcinoma vs., II(7):43, II(7):45
Wilms tumor vs., II(7):56, II(7):61
Metastases
adrenal cortical carcinoma vs., II(5):12
medulloblastoma/CNS-PNET vs., II(9):26
to breast, male breast carcinoma vs., II(1):12
Metastatic adenocarcinoma adenocarcinoma with lepidic (bronchioalveolar) predominant pattern vs., II(10):9
cordoma vs., II(3):10
esophageal adenocarcinoma vs., II(6):9
hepatocellular carcinoma vs., II(6):40
cellular adenocarcinoma vs., II(6):29
testicular tumors with glandular/tubular pattern (table), II(7):20
P.xxxvi
Metastatic carcinoma
adrenal cortical adrenocarcinoma vs., II(5):4
adrenal medullary hyperplasia vs., II(5):30
astrocytoma vs., II(9):5
dementia sac tumor vs., II(4):10
ependymoma vs., II(9):21
metastases vs., II(9):31
osteosarcoma vs., II(3):27
parathyroid carcinoma vs. (table), III(5):12
pineblasto
carcinoma vs., II(9):35
pituitary carcinoma vs., II(5):88
to skin, sebaceous carcinoma vs., II(11):20
Metastatic melanoma
astrocytoma vs., II(9):5
malignant, primary pigmented nodular adrenocortical disease vs., II(5):26
Metastatic neuroendocrine carcinoma of extrathoracic origin, neuroendocrine carcinoma of lung vs., II(10):17
Metastatic neuroendocrine tumors hepaticellular carcinoma vs., II(6):40
medullary thyroid carcinoma vs., II(5):113
Micromedullary thyroid carcinoma
C-cell hyperplasia vs., II(5):107
differential diagnosis (table), I(2):144, II(5):114
Micronodular pneucoyte hyperplasia, in tuberous sclerosis complex, I(2):181
Microsatellite instability, in Lynch syndrome, I(2):130
Middle ear adenoma, endolymphatic sac tumor vs., II(4):10
Minimal deviation adenocarcinoma.
See Cervical carcinoma.
Minimally invasive adenocarcinoma.
See Adenocarcinoma with lepidic (bronchioalveolar) predominant pattern.
MIFT/TFE translocation carcinomas clear cell renal cell carcinoma vs., II(7):39, II(7):41
papillary renal cell carcinoma vs., II(7):43, II(7):45
tumors with clear/light-staining cytoplasm (table), III(7):6
Mixed germ cell tumor
macroscopic features, II(7):13
microscopic pathology, II(7):14
MLH1 gene mutations
Lynch syndrome associated with, I(2):130, I(2):131
sebaceous carcinoma associated with, II(11):18
Monoclonal B lymphocytosis, chronic lymphocytic leukemia/small lymphocytic lymphoma vs., II(2):4
Monoclonal gammapathy of undetermined significance (MGUS)
familial plasma cell myeloma associated with, I(2):63
plasma cell myeloma vs., II(2):53, II(2):59
Monoclonal immunoglobulin deposition diseases, plasma cell myeloma vs., II(2):53
MonoMAC syndrome
familial acute myeloid leukemia associated with, I(2):36
GATA2 mutation in, I(2):34
Monosomy 7
aplastic anemia/myelodysplasia associated with, I(2):35, I(2):36
childhood or familial, predisposition to hematologic malignancy, II(2):41
Mosaic variegated aneuploidy, increased risk of Wilms tumor in (table), II(1):199
MRE11A gene mutations, risk of breast cancer associated with (table), III(1):2
MRE11A/RAD50/NBS1 complex, required for activation of ataxia-telangiectasia, I(2):2
MSH2 gene mutations, sebaceous carcinoma associated with, II(11):18
MSH6 gene mutations
Diagnostic Pathology: Familial Cancer Syndromes

Lynch syndrome associated with, II(10):25
sebaceous carcinoma associated with, II(11):18
Mucin (colloid) carcinoma, in
ampullary adenocarcinoma, II(6):31
Mucinous tubular and spindle cell
carcinoma, papillary renal cell
carcinoma vs., II(7):43, II(7):45
Mucinous tumors of ovaries and
fallopian tubes, Peutz-Jeghers
syndrome associated with, II(2):165
Mucocutaneous fibromas and
neuromas, in PTEN-hamartoma tumor
syndromes, II(2):169
Mucocutaneous fibromatosis, (table), III(4):4
Mucocutaneous fibromatosis, (table), III(4):5
Mucosa-associated lymphoid tissue
(MALT) lymphoma, lymphoplasmacytic
lymphoma/Waldenström
mucoglandular adenomatosis vs., II(2):34
Mucosal neoplasm
incidence of medullary thyroid
carcinoma and associated diseases in
MEN2 (table), III(5):20
multiple endocrine neoplasia type 2/familial medullary thyroid carcinoma
associated with, II(2):142
Muir-Torrey syndrome
selective oncogenes and neoplasms
involving eye and ocular adnexa (table), III(9):6
selected cutaneous neoplasms and
associated hereditary cancer
syndromes (table), III(11):2
selective hereditary cancer syndromes
with skin manifestations (table), III(11):2
Mulliken nanism, increased risk of
Wilms tumor in (table), II(2):199
Multinodular hyperplasia
in PTEN-hamartoma tumor syndromes,
II(2):169
P.xxiv
pleuropulmonary blastoma associated
with, II(10):25
Multinodular thyroid, xeroderma
pigmentosum associated with, II(2):201
Multiple adenomatosis. See
Parathyroid hyperplasia.
Multiple cartilaginous exostoses. See
Hereditary multiple exostosis.
Multiple cutaneous and uterine
leiomyomatosis syndrome. See
Hereditary leiomyomatosis and renal
cell carcinoma.
Multiple endocrine adenomatosis type
1. See
Multiple endocrine neoplasia type 1.
medullary thyroid carcinoma associated with, II(5):110
diagnosis, II(5):92
Multiple endocrine neoplasia type 4, pituitary adenoma associated with,
II(5):82, III(5):16
Multiple menigioma disease, familial, meningioma associated with, II(9):30
Multiple meningioma syndromes, genetic syndromes associated with CNS
neoplasms (table), III(9):2
Multiple myeloma. See Familial plasma cell myeloma; Plasma cell myeloma.
Musculoskeletal manifestations neurofibromatosis type 1, I(2):151
neurofibromatosis type 2, I(2):158
Musculoskeletal neoplasms, associated with basal cell nevus syndrome/Gorlin
syndrome, I(2):5
MUTYH gene mutations, risk of breast cancer associated with (table), III(1):2
MYC abnormalities
adrenal cortical carcinoma associated with, II(5):12
diffuse large B-cell lymphoma associated with, II(2):9
MYC dysregulation, in plasma cell myeloma, II(2):52
MYCN gene gain
neuroblastoma associated with, II(5):34
Wilms tumor associated with, II(7):54
MYD88 gene mutations, lymphoplasmaclaymphoma/Waldenström
macroglobulinemia associated with, II(2):32
Mycoplasma pneumoniae pneumonia
myelodysplastic syndrome, Werner syndrome/progeria associated with,
I(2):195
constitutional disorders predisposing to hematologic malignancies, II(2):40,
II(2):41
differential diagnosis, II(2):44, II(2):49
environmental exposures, II(2):41
microscopic features
and ancillary techniques, II(2):46, II(2):48
and immunohistochemical stains, II(2):47
and immunophenotype, II(2):45
microscopic pathology, II(2):43, II(2):44
bone marrow aspirate, II(2):43
bone marrow core biopsy, II(2):43
diagnostic criteria, II(2):43
peripheral blood, II(2):43
special testing, II(2):43, II(2):44
molecular bases of leukemogenesis in AML, II(2):41, II(2):42
molecular bases of pathogenesis in juvenile myelomonocytic leukemia 
(JMML), II(2):42
in myelodysplastic syndrome (MDS), II(2):42
progression, II(2):42, II(2):43
treatment, II(2):42
MYH gene mutations, MYH-associated polyposis associated with, II(2):148
MYH-associated polyposis, II(2):148, II(2):149
associated neoplasms, I(2):149
familial colon and rectum tumors by syndrome (table), III(6):5
familial esophageal, gastric, and small intestinal tumors in (table), III(6):6
familial neoplasia of colon and rectum in (table), III(6):4
molecular and genetic findings, II(2):148
Myoepithelioma, genetic findings in benign tumors (table), III(3):4
Myofibroblastic sarcoma, low-grade, spindle cell rhabdomyosarcoma vs.,
III(3):33
Myofibroblastic tumor, inflammatory
molecular and cytogenetic findings (table), III(3):2
spindle cell rhabdomyosarcoma vs.,
III(3):33
Myxofibrosarcoma
male breast carcinoma vs., II(1):12
mammary, genetic findings in benign tumors (table), III(3):4
Myositis ossificans, osteosarcoma vs.,
III(3):27
Myxofibrosarcoma, molecular and cytogenetic findings (table), III(3):3
(includes Bone and Soft Tissue and Bone and Soft Tissue)
Myxoid chondrosarcoma, extraskeletal, molecular and cytogenetic findings 
(table), III(3):2
Myxoinflammatory fibroblastic sarcoma, molecular and cytogenetic findings 
(table), III(3):3
(includes Bone and Soft Tissue and Bone and Soft Tissue)
N
NAME syndrome (nevi, atrial myxoma, myxoid neurofibroma, and ephelides).
See Carney complex, including Lamb syndrome.
Nasal chondromesenchymal hamartoma, pleuropulmonary blastoma associated with, II(10):25
Nasal squamous cell carcinoma differential diagnosis, II(4):4
etiology/pathogenesis
developmental issues, II(4):3
environmental exposure, II(4):3
infectious agents, II(4):3
graphics, II(4):6
NBN gene mutations, risk of breast cancer associated with (table), III(1):2
Necrotizing sialometaplasia
laryngeal squamous cell carcinoma vs., II(4):4
tongue squamous cell carcinoma vs., II(4):4
Neonatal severe primary hyperparathyroidism (table), III(5):13
Neoplastic C-cell hyperplasia. See C-cell hyperplasia, neoplastic.
P.xxix
Nephroblastoma. See Wilms tumor.
Nephrotic syndrome
in Denys-Drash syndrome, I(2):26, I(2):27
in infants, Denys-Drash syndrome vs., I(2):27
Nervous system neoplasms. See
Central nervous system neoplasms.
adrenal cortical neoplasms in children vs., II(5):20
alveolar rhabdomyosarcoma vs.,
III(3):33
ancillary techniques, II(5):39
Beckwith-Wiedemann syndrome associated with, I(2):9
clinical and gross features, II(5):36
developmental anomaly, II(5):32
differential diagnosis, II(5):34
favorable vs. unfavorable histology, II(5):35
International Neuroblastoma Pathology Committee Classification, II(5):34
melanotic neuroectodermal tumor of infancy vs., II(3):21
microscopic features, III(5):36, III(5):37, II(5):38
microscopic pathology, II(5):34
prognosis, II(5):33
staging system, II(5):35
treatment, II(5):33
Neurocytic tumor, medulloblastoma/CNS-PNET vs., I(2):96
Neuroectodermal tumors
Ewing sarcoma/primitive neuroectodermal tumor (PNET)
molecular and cytogenetic findings (table), III(3):2
neuroblastoma vs., II(5):34
small blue round cell tumors of kidney (table), III(7):8
primitive neuroectodermal tumor (PNET), retinoblastoma vs., I(2):90
Neuroendocrine carcinoma
high-grade, neuroendocrine carcinoma of lung vs., I(2):17
intermediate-grade, neuroendocrine carcinoma of lung vs., I(2):17
low-grade
case reports of salivary gland neoplasms with familial clustering (table), III(4):4
neuroendocrine carcinoma of lung vs., II(10):17
differential diagnosis, II(10):17
etiology/pathogenesis, II(10):16
grading, II(10):18
graphics
high-grade NE carcinoma, large cell type, II(10):23
high-grade NE carcinoma, small cell type, II(10):22
intermediate-grade NE carcinoma (atypical carcinoid), II(10):21
low-grade NE carcinoma (carcinoid tumor), II(10):19, II(10):20
histologic features, II(10):16, II(10):17
high-grade tumors, II(10):16
intermediate-grade tumors, II(10):16
large cell neuroendocrine carcinoma, II(10):16
low-grade tumors, II(10):16
small cell carcinoma, II(10):16
immunohistochemistry, II(10):18
molecular features, II(10):18
predominant cell/compartment type, II(10):17
predominant pattern/injury type, II(10):17
small blue round cell tumors of kidney (table), III(7):8
testicular tumors with oxyphilic cytoplasm (table), III(7):8
Neuroendocrine carcinoma of thyroid. See Medullary thyroid carcinoma.
Neuroendocrine tumors
neurofibromatosis type 1 associated with, I(2):151
other, I(2):151
pheochromocytoma/paraganglioma vs., II(5):43
pancreatic, tuberous sclerosis complex associated with, I(2):181
pancreatic ductal adenocarcinoma vs., II(6):48
Neuroepithelial tumor, cribiform, choroid plexus tumors vs., II(9):17
Neurofibroma
atypical malignant peripheral nerve sheath tumor vs., II(3):16
neurofibromatosis type 1 associated with, I(2):151
cellular, neurofibromatosis type 1 associated with, I(2):151
diffuse, neurofibromatosis type 1 associated with, I(2):151
genetic findings in benign tumors (table), III(3):3 (includes Bone and Soft Tissue and Bone and Soft Tissue) in schwannomatosis, I(2):177
massive soft tissue, neurofibromatosis type 1 associated with, I(2):151
neurofibromatosis type 1 associated with, I(2):151
neurofibromatosis type 2 associated with, I(2):159
plexiform, neurofibromatosis type 1 associated with, I(2):151
P.xl
Neurofibroma/schwannoma hybrid tumors, in schwannomatosis, I(2):177
adrenal cortical neoplasms in children as part of, II(5):18, II(5):20
adrenal cortical tumors as part of (table), III(5):3
as risk factor for small bowel adenocarcinoma, II(6):28
associated neoplasms, I(2):151, I(2):152
astrocytoma associated with, II(9):2
bone and soft tissue tumors associated with (table), III(3):4
central nervous system (graphics), I(2):154
diagnostic criteria for, I(1):13, I(2):150, III(9):11
differential diagnosis, I(2):152
familial esophageal, gastric, and small intestinal tumors in (table), III(6):6
familial gastrointestinal stromal tumor associated with, I(2):47
genetic syndromes and neoplasms involving eye and ocular adnexa (table), III(9):6
genetic syndromes associated with CNS neoplasms (table), III(9):2
genetics, I(2):150
genetic modifiers, I(2):150
NF1 gene, I(2):150
NF1-associated tumors, I(2):150
graphics
central nervous system, I(2):154
malignant peripheral nerve sheath tumor, I(2):157
peripheral nervous system, I(2):155, I(2):156
systemic manifestations, I(2):153
hereditary paraganglioma/pheochromocytoma syndromes associated with, I(2):107
malignant peripheral nerve sheath tumor (graphics), I(2):157
molecular biology, I(2):152
nonneoplastic manifestations, I(2):150, I(2):151
cardiovascular system, I(2):151
central nervous system, I(2):151
musculoskeletal, I(2):151
ophthalmic, I(2):150
skin, I(2):151
pancreatic endocrine tumor associated with, II(5):61
Neurofibrosarcoma. See Malignant peripheral nerve sheath tumor.
Neurogenic sarcoma. See Malignant peripheral nerve sheath tumor.
Neutropenia, severe congenital dyskeratosis congenita vs., I(2):32
microscopic features, III(2):3
predispension to hematologic malignancy, I(2):41
pancreatic tumors as part of (table), III(5):9
paraganglioma associated with, II(5):51
peripheral nervous system (graphics), I(2):155, I(2):156
pheochromocytoma/paraganglioma associated with, II(5):40
predispension to hematologic malignancy, II(2):40
rhabdomyosarcoma associated with, I(3):30
syndromes with genetic predisposition for peripheral nerve neoplasia (table), III(9):10
systemic manifestations (graphics), I(2):153
tumor distributions in major familial paraganglioma syndromes, II(5):44
tumor syndromes with genetic predisposition for peripheral nerve neoplasia (table), III(9):10
von Hippel-Lindau syndrome vs., I(2):188
associated neoplasms, I(2):158, I(2):159
bone and soft tissue tumors associated with (table), III(3):4
classification criteria, I(2):158
Baser criteria, I(2):158, I(2):159
Manchester criteria, I(2):158
diagnostic criteria, III(9):11
Baser criteria-additive scoring system, III(9):11
Syndromes with genetic predisposition
involving eye and ocular adnexa (table), III(9):6
genetic syndromes associated with CNS neoplasms (table), III(9):2
genetics and molecular biology, I(2):158
graphics
ependymoma, I(2):163
meningioma, I(2):162
molecular, imaging, and microscopic features, I(2):160
schwannoma, (I2):161
head and neck neoplasms associated with (table), III(4):2
meningioma associated with, III(9):30
multiple schwannoma syndromes, II(3):36
neurofibromatosis type 1 vs., I(2):152
nonneoplastic manifestations, I(2):158
syndromes with genetic predisposition for peripheral nerve neoplasia (table), III(9):10
Neurofibrosarcoma. See Malignant peripheral nerve sheath tumor.
Neurogenic sarcoma. See Malignant peripheral nerve sheath tumor.
Neutropenia, severe congenital dyskeratosis congenita vs., I(2):32
microscopic features, III(2):3
predispension to hematologic malignancy, I(2):41
neurofibromatosis type 1 associated with, I(2):150
plochromocytoma/paraganglioma associated with, II(5):40
NF1-associated paraganglioma/pheochromocytoma, risk management, I(2):107
NF1-associated tumors, I(2):150
NF2 gene, encodes for Merlin, I(2):158
NF2 gene mutations ependymoma associated with, I(2):21
meningioma associated with, II(9):30
schwannoma associated with, II(3):36
NF-KB pathway mutations, in plasm cell myeloma, I(2):52
Nijmegen breakage syndrome, ataxia-telangiectasia syndrome vs., I(2):3
Nodal marginal zone lymphoma follicular lymphoma vs., II(2):18
lymphoplasmacytic
lymphoma/Waldenström macroglobulinemia vs., II(3):34
mantle cell lymphoma vs., II(3):37
Nodular hyperplasia. See Parathyroid hyperplasia.
Nodular lymphocyte-predominant Hodgkin lymphoma, follicular lymphoma vs., I(2):18
NOL2A gene, dyskeratosis congenita associated with, I(2):30
NOL3A gene, dyskeratosis congenita associated with, I(2):30
Nonmelanocytic lesions, cutaneous melanoma vs., II(11):10
Noonan syndrome astrocytoma associated with, II(9):2
Costello syndrome vs., I(2):25
genetic syndromes associated with CNS neoplasms (table), III(9):2
neurofibromatosis type 1 vs., I(2):152
predisposition to hematologic malignancy, I(2):40, I(2):41
rhabdomyosarcoma associated with, II(3):30
Norrie disease, genetic syndromes and neoplasms involving eye and ocular adnexa (table), III(9):6
NOTCH1 gene mutations, chronic lymphocytic leukemia/small lymphocytic lymphoma associated with, II(2):4
Notochordal cell tumor, benign, chordoma vs., II(3):10
NUT midline carcinoma, nasal cavity squamous cell carcinoma vs., II(4):4
O
Obesity male breast carcinoma associated with, I(1):10
pancreatic ductal adenocarcinoma associated with, II(6):46
Occupational exposure, pancreatic ductal adenocarcinoma associated with, II(6):46
Ocular manifestations ataxia-telangiectasia syndrome, I(2):3
genetic tumor syndromes and nonneoplastic ocular manifestations (table), III(9):6
microscopic features, III(9):7, III(9):8, II(9):9
of familial adenomatous polyposis, I(2):39
Ocular neoplasms, xeroderma pigmentosum associated with, I(2):201
Odontogenic keratocyst, basal cell nevus syndrome/Gorlin syndrome associated with, I(2):5
Olfactory neuroblastoma (esthesioneuroblastoma), medulloblastoma/CNS-PNET vs., II(9):26
Omphalolele, isolated, Beckwith-Wiedemann syndrome vs., I(2):10
Oncocytoma, familial as hereditary or familial renal tumor syndrome, I(2):116
familial renal tumors in (table), III(7):6 renal oncocytoma, chromophobe, and hybrid oncocytic tumors associated with, II(7):46
Oncocytoma. See Renal oncocytoma, chromophobe, and hybrid oncocytic tumors.
Ophthalmic manifestations neurofibromatosis type 1, I(2):150
neurofibromatosis type 2, I(2):158
Oral papillomas, in PTEN-hamartoma tumor syndromes, I(2):169
Oropharyngeal squamous cell carcinoma, II(4):7
Ossifying fibroma familial cancer syndromes with bone and soft tissue tumors (table), III(3):4
of jaw, hereditary hyperparathyroidism-jaw tumor syndrome associated with, I(2):84
Osteoblastoma, osteosarcoma vs., II(3):27
Osteochondromas hereditary multiple exostosis associated with, I(2):91
molecular and cytogenetic findings (table), III(3):3 (includes Bone and Soft Tissue and Bone and Soft Tissue)
Osteogenic sarcoma. See Osteosarcoma.
Bloom syndrome associated with, I(2):17
differential diagnosis, II(3):26, II(3):27
etiology/pathogenesis genetic susceptibility, II(3):24
neoplastic process, II(3):24
extraskeletal, sclerosing rhabdomyosarcoma vs., II(3):33
familial cancer syndromes with bone and soft tissue tumors (table), III(3):4
gross features, II(3):28
image findings, II(3):25, II(3):26
imaging features, II(3):28
Li-Fraumeni syndrome associated with, I(2):128
P.xlii

microscopic features, II(3):28, II(3):29
molecular and cytogenetic findings (table), III(3):3 (includes Bone and Soft Tissue and Bone and Soft Tissue)
prognosis, II(3):25
treatment, II(3):25
Werner syndrome/progeria associated with, I(2):195
Osteosclerotic myeloma (POEMS syndrome), plasma cell myeloma vs., II(2):53
differential diagnosis, II(8):12
germline mutations of genes in Fanconi anemia-BRCA pathway, II(8):10, III(8):2
hereditary breast and ovarian cancer in ancillary tests, II(8):12
epidemiology, II(8):10
etiology/pathogenesis, II(8):10
macroscopic features, II(8):11
microscopic pathology, II(8):12
presentation, II(8):11
prognosis, II(8):11
surveillance, II(8):11
treatment, II(8):11
hereditary breast/ovarian cancer syndrome (BRCA1) associated with, I(2):74
hereditary breast/ovarian cancer syndrome (BRCA2) associated with, I(2):78
Lynch syndrome in ancillary tests, II(8):12
epidemiology, II(8):10, II(8):11
etiology/pathogenesis, II(8):10
microscopic pathology, II(8):12
presentation, II(8):11
prognosis, II(8):11
surveillance, II(8):11
treatment, II(8):11
microscopic features, II(8):13
Peutz-Jeghers syndrome in ancillary tests, II(8):12
epidemiology, II(8):11
etiology/pathogenesis, II(8):10
microscopic pathology, II(8):12
presentation, II(8):11
surveillance, II(8):11
treatment, II(8):11
PTEN-hamartoma tumor syndromes associated with, I(2):170
Ovarian fibroma/fibrosarcoma, basal cell nevus syndrome/Gorlin syndrome associated with, I(2):5
Ovarian neoplasia, hereditary syndromes associated with, I(1):5
Ovarian sex cord-stromal tumors pleuropulmonary blastoma associated with, II(10):25
with annular tubules, Peutz-Jeghers syndrome associated with, I(2):165
Ovarian tumors
Lynch syndrome associated with, I(2):131
mucinous, Peutz-Jeghers syndrome associated with, I(2):165

P
PS3 gene abnormalities, Wilms tumor associated with, II(7):54
PS3 gene mutations
basal cell carcinoma associated with, II(11):2
hereditary cutaneous melanoma associated with, I(2):93
PF53 pathway mutations, in plasma cell myeloma, II(2):52
PS5 gene abnormalities, adrenal cortical carcinoma associated with, II(5):12
Pachyonychia congenita, Howel-Evans syndrome/keratosis palmare and plantares, with esophageal cancer vs., I(2):121
Paget disease of breast, cutaneous melanoma vs., II(11):10
Pagetoid dyskeratosis, cutaneous melanoma vs., II(11):10
Pagetoid reticulosis, cutaneous melanoma vs., II(11):10
Palplantar keratodermas, other, Howel-Evans syndrome/keratosis palmare and plantares, with esophageal cancer vs., I(2):121
Palplantar keratoses, in PTEN-hamartoma tumor syndromes, I(2):169
Palplantar pits, basal cell nevus syndrome/Gorlin syndrome associated with, I(2):5
Palpation thyroiditis, C-cell hyperplasia vs., III(5):108
Pancreas
ectopic, small bowel adenocarcinoma vs., III(6):29

I(2):10

Pancreas neoplasms as part of inherited tumor syndromes (table), III(5):9 by syndromes (table), III(6):3 familial adenomatous polyposis associated with, I(2):39
familial neoplasia of biliary tract, liver, and pancreas, III(6):2
genes involving pancreatic tumorgenesis (table), III(5):9
graphic and microscopic features, III(5):10
hereditary breast/ovarian cancer syndrome (BRCA1) associated with, I(2):74
hereditary breast/ovarian cancer syndrome (BRCA2) associated with, I(2):78
hereditary syndromes associated with, I(1):4
P.xliii

immunohistochemistry, III(5):8
microscopic features, III(5):10, III(5):11
Werner syndrome/progeria associated with, I(2):195
Pancreatic adenocarcinoma. See Pancreatic ductal adenocarcinoma.
Pancreatic cancer, familial, melanoma/pancreatic carcinoma syndrome vs., I(2):135
Pancreatic cancer syndrome, hereditary, I(2):100, I(2):101
Pancreatic carcinoma
hereditary cutaneous melanoma associated with, I(2):94
hereditary hyperparathyroidism-jaw tumor syndrome associated with, I(2):84
melanoma/pancreatic carcinoma syndrome associated with, I(2):135
PTEN-hamartoma tumor syndromes associated with, I(2):170
Pancreatic carcinoma syndrome. See Melanoma/pancreatic carcinoma syndrome.

ampullary adenocarcinoma vs., II(6):31
ancillary tests, II(6):47, II(6):48
differential diagnosis, II(6):48
image findings, II(6):47
juvenile polyposis syndrome associated with, I(2):123
Peutz-Jeghers syndrome associated with, I(2):165
risk factors, II(6):46
environmental and occupational, II(6):46
hereditary, II(6):46
medical, II(6):46
Pancreatic ductal changes, normal/reactive, pancreatic ductal adenocarcinoma vs., II(6):48
associated familial neoplasia (table), III(6):2
classification, II(5):60
comparison of different features of endocrine pancreatic tumors and their differential diagnoses (table), III(5):8
criteria for clinicopathological classification, II(5):64, III(5):8
differentiation, pancreatic duodenal tumors, multiple endocrine neoplasia type 1 associated with, I(2):137
multiple endocrine neoplasia type 1, II(5):60, II(5):61
neurofibromatosis type 1, II(5):61
precursor lesions, II(5):61, II(5):62
sporadic, II(5):62
tuberous sclerosis, II(5):61
von Hippel-Lindau syndrome, II(5):61
hereditary syndromes associated with, I(1):3
microscopic features, II(5):65
microscopic pathology, II(5):63, III(5):64
poorly differentiated neuroendocrine carcinoma, II(5):64
well-differentiated endocrine carcinoma, II(5):64
well-differentiated PET, II(5):64
multiple endocrine neoplasia type 1 associated with, I(2):137
presentation functional, II(5):62
gastrinoma syndrome, II(5):62
glucagonoma syndrome, II(5):62
nonfunctional, II(5):62
somatostatinoma syndrome, II(5):62
VIPoma syndrome, II(5):62
prognosis, II(5):63
tuberous sclerosis complex associated with, I(2):181
Pancreatic neuroendocrine cell ductular proliferation, as precursor of pancreatic endocrine tumor, II(5):61
Pancreatic neuroendocrine microadenoma, as precursor of pancreatic endocrine tumor, II(5):62
Pancreatic duct carcinomas. See Pancreatic endocrine tumor.
Pancreatitis, chronic pancreatic ductal adenocarcinoma associated with, II(6):46
Pancreatic ductal adenocarcinoma vs., II(6):48
Pancreatitis, hereditary familial biliary tract, liver, and pancreas neoplasms in (table), III(6):3
in hereditary pancreatic cancer syndrome (table), I(2):101
melanoma/pancreatic carcinoma syndrome vs., I(2):135
Pancreatic ductal adenocarcinoma associated with, II(6):46
Pancreatobiliary-type adenocarcinoma associated familial neoplasia (table), III(6):2
in ampullary adenocarcinoma, II(6):30, II(6):31
Pancreatoblastoma, comparison of different features of endocrine pancreatic tumors and their differential diagnoses (table), III(5):8
Paperoid adenoma endolymphatic sac. See Endolymphatic sac tumor.
hereditary papillary renal cell carcinoma associated with, I(2):103 nephrogenic, bladder carcinoma vs., II(7):5
Papillary carcinoma in ampullary adenocarcinoma, II(6):31
P.xlv
invasive, in ampullary adenocarcinoma, II(6):31
of thyroid origin, lung adenocarcinoma vs., I(10):3
Papillary cystadenomas of endolymphatic sac, aggressive. See Endolymphatic sac tumor.
clear cell
clear cell renal cell carcinoma vs., II(7):39, II(7):41
papillary renal cell carcinoma vs., II(7):43, II(7):45
differential diagnosis, II(7):43, II(7):45
typing, II(7):42
hereditary leiomyomatosis and renal cell carcinoma syndrome, II(7):42
hereditary PRCC syndrome, II(7):42
sporadic PRCC, II(7):42
familial nonmedullary thyroid carcinoma associated with, I(2):60
growing, II(7):43
gross and microscopic features, II(7):44
hereditary hyperparathyroidism-jaw tumor syndrome associated with, I(2):84
type 1, II(7):43
hereditary papillary renal cell carcinoma associated with, II(7):43
type 2, II(7):43
hereditary papillary renal cell carcinoma associated with, II(7):103
invasive, in ampullary adenocarcinoma
clinical implications and ancillary tests, II(10):12
familial renal tumors in (table), III(7):6
Papillary renal cell carcinoma, hereditary, I(2):102, II(2):103
hereditary familial renal tumor syndrome, II(2):116
associated neoplasms, II(2):103
cancer risk management, II(2):103
clinical implications and ancillary tests, II(10):12
familial renal tumors in (table), III(7):6
Papillary renal carcinoma, II(7):42
Papillary squamous cell carcinoma, variant of head and neck squamous cell carcinoma, II(4):4
Papillary thyroid carcinoma differential diagnosis of tumors secondarily involving parathyroid (table), III(5):13
medullary thyroid carcinoma vs., II(5):113
parathyroid carcinoma vs. (table), III(5):12
Peutz-Jeghers syndrome associated with, I(2):165
PTEN-hamartoma tumor syndromes associated with, II(2):170
with associated neoplasia, familial renal tumors in (table), III(7):6
Papillary thyroid carcinoma, familial pure familial papillary thyroid carcinoma, genetics, I(2):58, II(2):59
with multidirectional goiter, genetics, I(2):59
with papillary renal cell carcinoma, genetics, II(2):59
Papillary thyroid carcinoma with associated neoplasia as hereditary or familial renal tumor syndrome, II(2):116
as hereditary renal epithelial tumor, II(2):115
Papillary tumor of pineal region choroid plexus tumors vs., II(9):17
pineoblastoma vs., II(9):35
Paraganglioma, II(5):50, II(5):51
See also Hereditary paraganglioma/pheochromocytoma
syndromes; Pheochromocytoma/paraganglioma.
classification, II(5):50
diagnostic, imaging, and histopathological features, II(5):54
differential diagnosis, II(5):53
dysplastic sac tumor vs., II(4):10
ependymoma vs., II(9):21
Carney triad, II(5):51
Carney-Stratakis syndrome, II(5):51, II(5):52
inherited, II(5):50, II(5):51
multiple endocrine neoplasia types 2, II(5):51
neurofibromatosis type 1, II(5):51
other syndromes, II(5):52
paraganglioma/pheochromocytoma
syndromes, II(5):51
von Hippel-Lindau syndrome, II(5):51
paraganglioma/pheochromocytoma
graphic and imaging of paraganglia and paraganglioma, II(5):55
gross and immunohistochemical features, II(5):57
hereditary syndromes associated with, I(1):3
medullary thyroid carcinoma vs., II(5):113
pituitary adenoma vs., II(5):84
pulmonary, neuroendocrine carcinoma of lung vs., II(10):17
SDH paraganglioma (graphics), II(5):59
ancillary tests, II(5):68, II(5):69
differential diagnosis between adenoma and carcinoma (table), III(5):12
familial isolated hyperparathyroidism associated with, II(2):53
gross features, II(5):70
hereditary hyperparathyroidism-jaw tumor syndrome associated with, II(2):83
hereditary parathyroid adenomas, II(5):66
microscopic features, II(5):70, II(5):71
microscopic pathology, II(5):67, II(5):68
parathyroid adenoma vs. carcinoma, II(5):69
parathyroid and thyroid immunohistochemistry, II(5):69
P.xlv
sporadic, familial isolated hyperparathyroidism vs., II(2):53
treatment, II(5):67
Parathyroid and thyroid immunohistochemistry, II(5):12
Parathyroid carcinoma, II(5):72, II(5):73, II(5):74, II(5):75
ancillary tests, II(5):74
Diagnostic Pathology: Familial Cancer Syndromes

differential diagnosis, III(5):12
between adenoma and carcinoma
(table), III(5):12
etiology/pathogenesis, II(5):72
familial isolated hyperparathyroidism
associated with, I(2):53
hereditary hyperparathyroidism-jaw
tumor syndrome associated with,
I(2):83
microscopic features, II(5):75
microscopic pathology, III(5):73, II(5):74
treatment, II(5):73
Parathyroid gland, anatomy and
pathology (graphics), III(5):14
Parathyroid hyperplasia, II(5):76,
II(5):77, II(5):78, II(5):79, II(5):80,
II(5):81
ancillary tests, II(5):78, II(5):79
familial isolated hyperparathyroidism
associated with, I(2):53
graphic and gross features, II(5):80
hereditary hyperparathyroidism-jaw
tumor syndrome associated with,
I(2):83
histological features
of normal parathyroid, adenoma and
carcinoma, II(5):80
of parathyroid hyperplasia, II(5):80
microscopic pathology, II(5):78
syndromes associated with, II(5):76,
II(5):77
treatment, II(5):77, II(5):78
Parathyroid hyperplasia and adenoma,
multiple endocrine neoplasia type
2/familial medullary thyroid carcinoma
associated with, I(2):142
Parathyroid lesions, gross and
microscopic features, III(5):15
Parathyroid neoplasms
differential diagnosis of tumors
secondarily involving parathyroid
(table), III(5):13
hereditary syndromes associated with,
I(1):3
Parathyroid tissue, intrathyroid, C-cell
hyperplasia vs., II(5):108
Parotid neoplasms, associated with
Birt-Hogg-Dubé syndrome, I(2):13
Parotid oncocytoma, associated with
Birt-Hogg-Dubé syndrome, I(2):13
Pathology of familial tumor syndromes,
I(1):13, I(1):14
pathologic findings in familial tumor
pathology reporting, I(1):3
practical guide to pathological
recognition of hereditary syndromes,
I(1):2
recognition of morphological
syndromes known to be associated
I(1):6
bone and soft tissue-related hereditary
syndromes, I(1):5
breast, I(1):4
central nervous system, I(1):4, I(1):5
docrine system, I(1):3
gastrointestinal tract, I(1):4
gynecologic system, I(1):5
head and neck, I(1):5
introduction, I(1):3
lung, I(1):5
skin, I(1):4
PAX1-FOXO1 genes,
rhabdomyosarcoma associated with,
I(3):30
PAX3-FOXO1 genes,
rhabdomyosarcoma associated with,
I(3):30
PBRM1 gene mutations, clear cell renal
carcinoma associated with, II(7):38
PDE11A gene mutations
familial testicular germ cell tumors
associated with, I(2):65
primary pigmented nodular
adrenocortical disease associated with,
II(5):24
PDGFRA mutations
familial gastrointestinal stromal tumor
associated with, I(2):46, I(2):47
gastrointestinal stromal tumor vs.,
II(6):18
PDGFRA substitutions, molecular
prognostic for GISTs, II(6):21
Pendred syndrome
familial follicular cell carcinoma in,
II(5):94
familial nonmedullary thyroid
carcinoma associated with, II(5):92
familial nonmedullary thyroid
carcinoma in familial cancer syndromes
(table), III(5):22
familial thyroid carcinoma associated
with, II(5):90
genetics, I(2):59
thyroid tumors in, II(5):93
Periampullary adenocarcinoma. See
Ampullary adenocarcinoma.
Perifollicular fibroma, associated with
Birt-Hogg-Dubé syndrome, I(2):13
Perineuroma
genetic findings in benign tumors
(table), III(3):4
molecular and cytogenetic findings
(table), III(3):3 (includes Bone and Soft
Tissue and Bone and Soft Tissue)
Peripheral nerve sheath tumor,
malignant. See Malignant peripheral
nerve sheath tumor.
Peripheral nervous system
manifestations, of neurofibromatosis
type 2, I(2):158
Peripheral nervous system neoplasms
graphic, imaging, and microscopic
features, III(9):12
P.xlvi
hereditary syndromes associated with,
I(1):4
microscopic features, III(9):12, III(9):13
syndromes with genetic predisposition
for peripheral nerve neoplasia (table),
III(9):10
Peripheral neuroblastic tumor. See
Neuroblastoma.
Peritoneal carcinoma
hereditary breast/ovarian cancer
syndrome (BRCA1) associated with,
I(2):74
hereditary breast/ovarian cancer
syndrome (BRCA2) associated with,
I(2):78
Perlmutter syndrome
as Wilms tumor-associated syndrome,
I(2):199
Beckwith-Wiedemann syndrome vs.,
I(2):10
familial renal tumors in (table), III(7):6
genetics, II(7):55
increased risk of Wilms tumor in
(table), I(2):199
Peutz-Jeghers syndrome, I(2):164,
I(2):165
as risk factor for small bowel
adenocarcinoma, II(6):28
associated neoplasms, I(2):165
breast carcinoma in, II(1):5
cancer risk management, I(2):165
diagnostic testing, I(2):165
radiologic surveillance, I(2):165
Carney complex vs., I(2):21
cervical carcinoma associated with,
II(8):2
diagnostic criteria, I(2):164
familial biliary tract, liver, and pancreas
neoplasms in (table), III(6):3
familial cancer syndromes with
gynecologic manifestations (table),
III(8):2
familial cancer syndromes with
urothelial neoplasms (table), III(10):2
familial colon and rectum tumors by
syndrome (table), III(6):5
familial esophageal, gastric, and small
intestinal tumors in (table), III(6):6
familial sex cord-stromal tumors
associated with, I(2):65
familial testicular tumors (table),
III(7):20
genetic testing, I(2):164
genetics, I(2):164
hamartomatous polyps in, I(2):165
in endometrial carcinoma, II(8):4,
II(8):5, II(8):6, II(8):7
in hereditary pancreatic cancer
syndrome (table), I(2):101
in ovarian carcinoma, II(8):10, II(8):11,
II(8):12
melanoma/pancreatic carcinoma
syndrome vs., I(2):135
microscopic findings, I(2):165

32
pancreatic ductal adenocarcinoma associated with, II(6):46
polyposis in, juvenile polyposis syndrome vs., I(2):124
testicular Sertoli cell neoplasms associated with, II(7):30
Pharyngeal neoplasms, Werner syndrome/progeria associated with, I(2):195
Pheochromocytoma. See also Hereditary parangangioma/pheochromocytoma syndromes;
adrenal cortical carcinoma vs., II(5):12
adrenal cortical neoplasms in children vs., II(5):20
adrenal medullary hyperplasia vs., II(5):30
hereditary syndromes associated with, I(1):3
in multiple endocrine neoplasia type 2 familial medullary thyroid carcinoma, I(2):142, I(2):147
incidence of medullary thyroid carcinoma and associated diseases in MEN2 (table), III(5):20
multiple endocrine neoplasia type 2 multiple endocrine neoplasia type 2 familial medullary thyroid carcinoma associated with, I(2):142
neurofibromatosis type 1 associated with, I(2):151
See also Hereditary parangangioma/pheochromocytoma syndromes; Paraganglioma. ancillary techniques, II(5):49
associated tumors and lesions (graphics), II(5):45
differential diagnosis, II(5):43
etiology/pathogenesis, II(5):40, II(5):41
Carney triad, II(5):41
Carney-Stratakis dyad, II(5):41
environmental influences, II(5):41
familial PGL/PCC syndromes, II(5):40, II(5):41
hereditary PCC/PGL, II(5):40, II(5):41
multiple endocrine neoplasia type 2 in
II(5):40
neurofibromatosis type 1, II(5):41
sporadic PCC/PGL, II(5):41
von Hippel-Lindau syndrome, II(5):41
gross and imaging features, II(5):46
paraganglioma associated with, II(5):51
SDHB and SDHA immunohistochemical features, II(5):48
sporadic, paraganglioma vs., II(5):53
tumor distributions in major familial paraganglioma syndromes, II(5):44
variant microscopic features, II(5):47
World Health Organization definitions of 2004, II(5):40
PHOX2B gene mutations, hereditary neuroblastoma associated with, I(2):96
PKD3CA gene mutations, pituitary adenomas associated with, III(5):16
P.xlvii
Pineal parenchymal tumors, pineoblastoma vs., II(9):35
Pineal region papillary tumor choroid plexus tumors vs., II(9):17
pineoblastoma vs., II(9):35
Pineoblastoma, II(9):34, II(9):35
ancillary tests, II(9):34, II(9):35
differential diagnosis, II(9):35
etiology/pathogenesis syndrome association, II(9):34
trilateral retinoblastoma syndrome, II(9):34
hereditary retinoblastoma associated with, I(2):119
medulloblastoma/CNS-PNET vs., II(9):26
Pituitary adenocarcinoma. See Pituitary carcinoma.
as part of inherited tumor syndromes (table), III(5):16
differential diagnosis, II(5):84
etiology/pathogenesis, II(5):82
hormone regulatory pathways, II(5):82
somatic genetics, II(5):82
syndromes associated with, II(5):82
genetic abnormalities (table), III(5):16
graphic, imaging, and microscopic features, II(5):85
graphic and microscopic features, II(5):17
immunohistochemical classification, II(5):84
invasive, pituitary carcinoma vs., II(5):88
differential diagnosis, II(5):88
genetics, II(5):86
grading, II(5):88
microscopic features, II(5):89
prognosis, II(5):87
treatment, II(5):87
Pituitary hyperplasia, pituitary adenoma vs., II(5):84
Pituitary neoplasms
graphic and microscopic features, II(5):19
hereditary syndromes associated with, I(1):3
microscopic features, II(5):18, III(5):19
multiple endocrine neoplasia type 1 associated with, I(2):137
PKC gene mutations, pituitary adenomas associated with, III(5):16
See also Familial plasma cell myeloma.
ancillary techniques (graphics), II(2):58
ancillary tests, II(2):52, II(2):53
differential diagnosis, II(2):53, II(2):59
environmental exposure, II(2):50
familial. See Familial plasma cell myeloma.
flow cytometry, II(2):58
immunohistochemical stains, II(2):57, II(2):58
laboratory features, II(2):54
microscopic pathology, II(2):52
prognosis, II(2):52
proposed pathogenesis, II(2):50
 treatment, II(2):51
Werner syndrome/progeria associated with, I(2):195
WHO Classification of Tumors of Plasma Cell Neoplasms (2008), II(2):50, II(2):53
Plasmablastic lymphoma, diffuse large B-cell lymphoma vs., II(2):10, II(2):13
Plasmacytoma solitary, of bone, or extramedullary, plasma cell myeloma vs., II(2):53
testicular tumors with oxyphilic cytoplasm (table), III(7):20
Plasmacytosis, reactive polyclonal, plasma cell myeloma vs., II(2):53
Pleomorphic adenoma case reports of salivary gland neoplasms with familial clustering (table), III(4):4
molecular changes described in salivary gland neoplasms (table), III(4):5
Pleomorphic sarcoma, undifferentiated, pleomorphic rhabdomyosarcoma vs., III(3):33
associated tumors, II(10):25
differential diagnosis, II(10):26
familial cancer syndromes with lung neoplasms (table), III(10):2
genetic abnormalities in etiology, II(10):24
genetic syndromes and neoplasms involving eye and ocular adnexa (table), III(9):6
genetic syndromes associated with CNS neoplasms (table), III(9):2
histologic features, II(10):25
immunohistochemistry, II(10):26
prognosis, II(10):25
subclassification, II(10):25
treatment, II(10):24, II(10):25
types of (graphics), II(10):27
PMS2 gene mutations, Lynch syndrome associated with, I(2):130, I(2):131
Pneumocyte hyperplasia, micronodular, in tuberous sclerosis complex, I(2):181
Polyoid prolapsing mucosal folds (prolapse-type polyps), hamartomatous polyps of GI tract vs., II(6):27
Polyposis
familial adenomatous. See Familial adenomatous polyposis.
hereditary mixed polyposis syndrome familial colon and rectum tumors by syndrome (table), III(6):5
familial neoplasia of colon and rectum in (table), III(6):4
juvenile polyposis syndrome vs., I(2):124
juvenile. See Juvenile polyposis syndrome.
P.xlviii

familial colon and rectum tumors by syndrome (table), III(6):5
familial neoplasia of colon and rectum in (table), III(6):4
serrated
familial colon and rectum tumors by syndrome (table), III(6):5
familial neoplasia of colon and rectum in (table), III(6):4
Poorly differentiated carcinoma, cutaneous squamous cell carcinoma vs., II(11):14
Poorly differentiated prostate carcinoma, bladder carcinoma vs., II(7):5
Porocarcinoma, sebaceous carcinoma vs., II(11):20
Prenatal testing, for Bloom syndrome, I(2):17
Primary diffuse large B-cell lymphoma central nervous system, diffuse large B-cell lymphoma vs., I(2):9, I(2):13
leg type, diffuse large B-cell lymphoma vs., I(2):9
Primary effusion lymphoma, diffuse large B-cell lymphoma vs., II(2):10
Primary parathyroid hyperplasia. See Parathyroid hyperplasia.
adrenal cortical lesions associated with syndromes (table), II(5):5
clinical and microscopic features, II(5):27
differential diagnosis, II(5):26
genetic abnormality in etiology of, II(5):24
presentation, II(5):25
prognosis, II(5):25
Primary sarcoma of lung, pleuropulmonary blastoma vs., II(10):26
Primitive neuroectodermal tumor (PNET)
melanotic neuroectodermal tumor of infancy vs., II(3):21
retinoblastoma vs., II(9):37
PRKARIA gene mutations
Carney complex associated with, I(2):18
follicular carcinoma associated with, II(5):102
pituitary adenomas associated with, III(5):16
primary pigmented nodular adenocortical disease associated with, II(5):24, II(5):26
Progeria of adult. See Werner syndrome/progeria.
Progressive familial intrahepatic cholestasis, familial biliary tract, liver, and pancreas neoplasms in (table), III(6):3
Progressive transformation of germinal centers, follicular lymphoma vs., II(2):18
Prophylactic surgery for hereditary breast/ovarian cancer syndrome (BRCA1), I(2):74
for hereditary breast/ovarian cancer syndrome (BRCA2), I(2):78
Prostate cancer, hereditary, I(2):112, I(2):113
benign mimics of (table), III(7):13
differential diagnosis, II(7):21
graphics, II(7):29
table, II(7):22
differential diagnosis of tumors secondarily involving parathyroid (table), III(5):13
epidemiology, II(7):19
etiology/pathogenesis, II(7):18, II(7):19
hereditary prostate cancer, II(7):19
molecular genetics, II(7):18, II(7):19
risk factors, II(7):19
Gleason Grading System, II(7):21, II(7):22
grade 5: immunohistochemistry and intraductal carcinoma, II(7):27
grades 1 and 2 (graphics), II(7):25
grades 4 and 5 (graphics), II(7):26
schematic diagram of modified Gleason Grading System, II(7):18
gross features, II(7):23
hereditary breast/ovarian cancer syndrome (BRCA1) associated with, I(2):74
hereditary breast/ovarian cancer syndrome (BRCA2) associated with, I(2):78
hereditary diffuse gastric cancer associated with, I(2):81
hereditary hyperparathyroidism-jaw tumor syndrome associated with, I(2):84
immunohistochemistry (graphics), III(7):17
important immunohistochemical stains in diagnosis of (table), III(7):12
luminal and pathognomonic features, II(7):24
Lynch syndrome associated with, I(2):131
microscopic features, II(7):23
microscopic pathology, II(7):20, II(7):21
architectural features, II(7):20
cyttoplasmic features, II(7):20
intraluminal features, II(7):20
key elements to report, II(7):21
morphologic variants and variants, II(7):20, II(7):21
nuclear features, II(7):20
pathognomonic features for malignant glands, II(7):20
morphologic variants and variants, II(7):20, II(7):21
atrophic variant, II(7):20
ductal adenocarcinoma, II(7):20
foamy gland (xanthomatos) variant, II(7):20, II(7):21
graphics, II(7):28
lymphoepithelioma-like variant, II(7):21
mucinous (colloid) adenocarcinoma, II(7):21
oncocytic variant, II(7):21
PCa with Paneth cell-like differentiation, II(7):21
PCa with stratified epithelium (PIN-like), II(7):21
P.xlix

pseudohyperplastic variant, II(7):20
signet ring cell variant, II(7):21
poorly differentiated, bladder carcinoma vs., II(7):5
single/individual cell patterns (table), III(7):13
staging
AIJC Pathologic Staging of Prostate Cancer (2010), III(7):13
graphics, III(7):15, III(7):16
Prostate gland
atypical small glandular proliferations, III(7):13
normal anatomy and histology (graphics), III(7):14
significance of normal histoanatomic structures in prostate pathology (table), III(7):12
Proteus syndrome
neurofibromatosis type 1 vs., I(2):152
PTEN-related diagnosis, I(2):168
in PTEN-hamartoma tumor syndromes, I(2):167
Pseudoepheliphomatous hyperplasia
cutaneous squamous cell carcinoma vs., II(11):14
esophageal squamous cell carcinoma vs., III(6):11
laryngeal squamous cell carcinoma vs., II(4):4
tongue squamous cell carcinoma vs., II(4):4
Pseudoglandular squamous cell carcinoma. See Squamous cell carcinoma, cutaneous.
PTEN gene mutations, pituitary adenomas associated with, III(5):16
PTCH1 gene mutations
basal cell carcinoma associated with, II(11):2
basal cell nevus syndrome/Gorlin syndrome associated with, II(2):4, II(2):5
PTEN gene, function, II(1):5
PTEN gene mutations
familial nonmedullary thyroid carcinoma associated with, I(2):58
familial thyroid carcinoma associated with, II(5):93
follicular carcinoma associated with, II(5):102
hereditary cutaneous melanoma associated with, I(2):93
prostate carcinoma associated with, II(7):18, II(7):19
PTEN-hamartoma tumor syndromes associated with, II(2):167
risk of breast cancer associated with (table), III(1):2
associated lesions and benign neoplasms, II(2):169
graphics, II(2):171
associated malignant neoplasms, II(2):170
Bannayan-Riley-Ruvalcaba syndrome, II(2):166, II(2):167
cancer risk management, II(2):170
breast, II(2):170
colon, II(2):170
kidney, II(2):170
other tumors, II(2):170
thyroid, II(2):170
uterus, II(2):170
clinical implications and ancillary tests, II(2):168, II(2):169
Cowden syndrome in, II(2):166
diagnosis, II(2):167, II(2):168
familial cancer syndromes with gynecologic manifestations (table), III(8):2
familial colon and rectum tumors by syndrome (table), III(6):5
familial colonic and rectal adenomatosis (table), III(5):94
familial neoplasia of colon and rectum in (table), III(6):5
familial nonmedullary thyroid carcinoma associated with, II(2):60, II(5):92
familial nonmedullary thyroid carcinoma in familial cancer syndromes, III(5):22
familial thyroid carcinoma associated with, II(5):90, II(5):97
follicular thyroid carcinoma associated with, II(5):100, II(5):103
genetic counseling, I(2):168
in endometrial carcinoma, II(8):4, II(8):5, II(8):6, II(8):7
juvenile polyposis syndrome vs., I(2):124
lifetime risk of developing cancer, I(2):167
PTEN-related Proteus syndrome in, II(2):167, II(2):168
selected hereditary cancer syndromes with skin manifestations (table), III(11):2
syndromes included in, II(2):166
thyroid pathology in (graphics), III(5):23
thyroid tumors in, II(5):93
PTTG gene mutations, pituitary adenomas associated with, III(5):16
Pulmonary conditions, lymphangioleiomyomatosis. See Lymphangioleiomyomatosis.
Pulmonary cysts, associated with Birt-Hogg-Dubé syndrome, I(2):13
Pulmonary endometriosis, Birt-Hogg-Dubé syndrome vs., II(2):14
Pulmonary invasive adenocarcinoma, adenocarcinoma with lepิดic (bronchioloalveolar) predominant pattern vs., II(10):9
Pulmonary neoplasms adenocarcinoma with lepидic (bronchioloalveolar) predominant pattern, II(10):8, II(10):9, II(10):10, II(10):11
lung adenocarcinoma. See Lung adenocarcinoma.
P.I.
pleuropulmonary blastoma. See Pulmonary adenocarcinoma.
Pulmonary parangangioma, II(2):117
Pure familial papillary thyroid carcinoma (PTC), genetics, I(2):58, II(2):59
Pyogenic granuloma, xeroderma pigmentosum associated with, I(2):201

R
RAD50 gene mutations, risk of breast cancer associated with (table), III(3):4
RAD51C gene mutations, risk of breast cancer associated with (table), III(1):2

Radiation, ionizing, hypersensitivity to, in ataxia-telangiectasia syndrome, I(2):2
Radiation changes
laryngeal squamous cell carcinoma vs., II(4):4
tongue squamous cell carcinoma vs., II(4):4
Radiation exposure, male breast carcinoma associated with, II(1):10
Radiation therapy, cutaneous squamous cell carcinoma associated with, II(1):12
RAS gene mutations, pituitary adenomas associated with, III(5):16
RB1 gene mutations, adrenal cortical carcinoma associated with, II(5):12
RB pathway mutations, in plasma cell myeloma, II(2):52
RB1 gene mutations
hereditary cutaneous melanoma associated with, I(2):93
hereditary retinoblastoma associated with, I(2):118
pineoblastoma associated with, III(9):34
pituitary adenomas associated with, III(5):16
retinoblastoma associated with, II(9):36
Reactive follicular hyperplasia follicular lymphoma vs., II(2):18
mante cell lymphoma vs., II(2):37
Reactive polyclonal plasmacytosis, plasma cell myeloma vs., II(2):53
Reactive/regenerative epithelium, colon adenoma vs., II(6):5
Recurrent nevus, cutaneous melanoma vs., II(11):10
Reed syndrome. See Hereditary leiomyomatosis and renal cell carcinoma.
Regenerative nodule in cirrhosis, hepatocellular carcinoma vs., II(6):40
Renal angiomyolipoma, multiple endocrine neoplasia type 1 associated with, I(2):137
Renal carcinoma
PTEN-hamartoma tumor syndromes associated with, I(2):170
with leiomyomas, bone and soft tissue tumors associated with (table), III(3):4
Renal cell carcinoma
adrenal cortical adenoma vs., III(5):5, III(5):2
adrenal cortical carcinoma vs., III(5):12
adrenal cortical neoplasms in children vs., III(5):20
carcinomas involving kidney &/or renal pelvis, III(7):18
clear cell. See Clear cell renal cell carcinoma.
epithelioid angiomyolipoma vs., II(7):35
familial nonclear cell renal cell carcinoma, as hereditary renal epithelial tumor, I(2):115
familial uveal melanoma associated with, I(2):67
hepatocellular carcinoma vs., II(6):40
hereditary leiomyomatosis and renal cell carcinoma associated with, II(2):87
in Birt-Hogg-Dubé syndrome, cancer risk management, II(2):13
and leiomyomatosis. See Hereditary leiomyomatosis and renal cell carcinoma.
papillar. See Papillary renal cell carcinoma.
pheochromocytoma/paraganglioma vs., II(5):43
testicular tumors with diffuse arrangement and pale and clear cytoplasm (table), III(7):20
xeroderma pigmentosum associated with, I(2):201
Renal cysts
Birt-Hogg-Dubé syndrome associated with, I(2):13
hereditary hyperparathyroidism-jaw tumor syndrome associated with, I(2):84
in tuberous sclerosis complex, I(2):181
Renal diseases, hereditary
hyperparathyroidism-jaw tumor syndrome associated with, I(2):84
Renal features, in Denys-Drash syndrome, I(2):26, I(2):27
Renal neoplasms
AJCC Staging System for Kidney Cancer (2010), III(7):8
angiomyolipoma. See Angiomyolipoma.
cystic renal diseases associated with, von Hippel-Lindau syndrome vs., I(2):188
familial renal tumors (table), III(7):6
hereditary syndromes associated with, I(1):3, I(1):4
immunohistochemistry (graphics), III(7):10, III(7):11
Lynch syndrome associated with, I(2):131
papillary renal cell carcinoma. See Papillary renal cell carcinoma.
renal oncocytopma, chromophobe, and hybrid oncotypic tumors. See Renal oncotypic, chromophobe, and hybrid oncotypic tumors. 
P.Ii
renal tumors
with clear/light-staining cytoplasm (table), III(7):6, III(7):7
with granular/eosinophilic cytoplasm (table), III(7):7
with papillary or tubulopapillary architecture (table), III(7):7
renal urothelial carcinoma, II(7):50, II(7):51, II(7):52, II(7):53
small blue round cell tumors of kidney (table), III(7):8
staging (graphics), III(7):9
Werner syndrome/progeria associated with, I(2):195
Wilms tumor. See Wilms tumor.
Renal oncocytopma, chromophobe, and hybrid oncotypic tumors, II(7):46, II(7):47, II(7):48, II(7):49
chromophobe renal cell carcinoma clear cell renal cell carcinoma vs., II(7):39, II(7):41
histologic features, II(7):47
macroscopic features, II(7):47
tumors with clear/light-staining cytoplasm (table), III(7):6
differential diagnosis, II(7):47, II(7):49
etiology/pathogenesis, II(7):46
Birt-Hogg-Dubé syndrome, II(7):46
familial oncotypomas, II(7):46
sporadic tumors, II(7):46
succinate dehydrogenase B-deficient tumors, II(7):46
gross and microscopic features, II(7):48 macroscopic features, II(7):46, II(7):47
microscopic features, II(7):48, II(7):49
oncotypic histologic features, II(7):47
macroscopic features, II(7):47
renal oncocytopma
histologic features, II(7):47
macroscopic features, II(7):47
Renal PEComa. See Angiomyolipoma.
Renal pelvis and ureter carcinomas involving kidney &/or renal pelvis, III(7):18
diagnosis of Lynch syndrome upper urinary tract urothelial carcinoma, III(7):18
staging
AJCC Staging System for Renal Pelvis and Ureter Cancer (2010), III(7):18
staging and immunohistochemistry (graphics), III(7):19
Renal rhabdoid tumors, malignant, rhabdoid predisposition syndrome associated with, I(2):172, I(2):173
Renal transitional carcinoma. See Renal urothelial carcinoma.
Renal urothelial carcinoma, II(7):50, II(7):51, II(7):52, II(7):53
classification similar to bladder UcA, II(7):51
etiology, II(7):50
familial renal UcA, II(7):50
risk factors, II(7):50
gross and microscopic features, II(7):52
immunohistochemical features, II(7):53
microscopic features, II(7):52, II(7):53
prognosis, II(7):51
treatment, II(7):51
Respiratory epithelial carcinoma. See Squamous cell carcinoma, head and neck.
Respiratory infections, in ataxia-telangiectasia syndrome, I(2):3
RET gene mutations
ATA age recommendations for prophylactic thyroidectomy depending on (table), I(2):144, III(5):21
familial thyroid carcinoma associated with, II(5):93
multiple endocrine neoplasia type 2familial medullary thyroid carcinoma associated with, I(2):140, I(2):141
parathyroid adenoma associated with, II(5):69
parathyroid carcinoma associated with, II(5):74
parathyroid hyperplasia associated with, II(5):79
pheochromocytoma/paraganglioma associated with, II(5):40
testing for, in medullary thyroid carcinoma, II(5):111, II(5):113
RET-associated paraganglioma/pheochromocytoma, risk management, I(2):107
Rete testis tumor, tumors with glandular/tubular pattern (table), II(7):20
Retinal anlage tumor. See Melanotic neuroectodermal tumor of infancy.
Retinal glioma, PTEN-hamartoma tumor syndromes associated with, I(2):170
Retinal hamartoma/astrocytoma, in tuberous sclerosis complex, I(2):181
Retinoblastoma, II(9):36, II(9):37, II(9):38, II(9):39
See also Hereditary retinoblastoma.
clinical and other features, II(9):38
differential diagnosis, II(9):37
epidemiology, I(2):118
etiology/pathogenesis, II(9):36
head and neck neoplasms associated with (table), III(4):2
histologic features, II(9):37
microscopic features, II(9):39
microscopic findings, I(2):119
prognosis, II(9):36
salivary gland neoplasms associated with (table), III(4):4
Retinoblastoma syndrome, trilateral, pineoblastoma associated with, II(9):34
Retinoblastoma/retinocytoma, hereditary retinoblastoma associated with, I(2):119
Revesz syndrome. See Dyskeratosis congenita.
P.Iii
ancillary tests (graphics), I(2):175
associated neoplasms, I(2):172, I(2):173
cancer risk management, I(2):173
choroid plexus tumors associated with, II(9):15
diagrammatic and microscopic features, I(2):174
genetic syndromes associated with CNS neoplasms (table), III(9):2
genetics, I(2):172
Rhabdoid tumors, malignant extrarenal, alveolar
rhabdomyosarcoma vs., II(3):33
Rhabdomyoma
cardiac, tuberous sclerosis complex associated with, I(2):181
fetal, embryonal rhabdomyosarcoma vs., II(3):32
alveolar
melanotic neuroectodermal tumor of infancy vs., II(3):21
neuroblastoma vs., II(5):34
Costello syndrome associated with, I(2):24
differential diagnosis, II(3):32, II(3):33
embryonal, malignant peripheral nerve sheath tumor vs., II(3):16
etiology/pathogenesis genetic associations, II(3):30
genetic events, II(3):30
familial cancer syndromes with bone and soft tissue tumors (table), III(3):4
immunohistochemistry, II(3):33
in Costello syndrome, cancer risk management, I(2):25
microscopic features, II(3):34, II(3):35
microscopic pathology, III(3):31, II(3):32
alveolar subtype, II(3):31, II(3):32
embryonal subtype, II(3):31
mixed embryonal and alveolar subtype, II(3):32
pleomorphic subtype, II(3):32
post-chemotherapy RMS, II(3):32
sclerosing subtype, II(3):32
spindle cell subtype, II(3):32
molecular and cytogenic findings (table), III(3):3 (includes Bone and Soft Tissue and Bone and Soft Tissue) primary, pleuropulmonary blastoma vs., II(10):26
prognosis, II(3):31
treatment, II(3):31
RHBDF2 gene mutations, esophageal squamous cell carcinoma associated with, II(6):10
RMRP gene mutations, basal cell carcinoma associated with, II(11):2
Rombo syndrome
basal cell nevus syndrome/Gorlin syndrome vs., I(2):5
selected cutaneous neoplasms and associated hereditary cancer syndromes (table), III(11):2
Rothmund-Thomson syndrome
Werner syndrome/progeria vs., I(2):196
xeroderma pigmentosum vs., II(2):202
RT11 gene, dyskeratosis congenita associated with, I(2):30
RUNX1 gene mutations, familial acute myeloid leukemia associated with, I(2):35
S
Salivary duct carcinoma, molecular changes described in salivary gland tumors (table), III(4):5
Salivary gland neoplasms case reports with familial clustering (table), III(4):4
familial cancer syndrome with (table), III(4):4
hereditary syndromes associated with, I(1):1
microscopic features, II(4):6, II(4):7
molecular changes described in, III(4):5
Sarcoma, arising in congenital cystic malformation. See Pleuropulmonary blastoma.
Sarcoma, breast, leukemia, and adrenal gland syndrome. See Li-Fraumeni syndrome/Li-Fraumeni-like syndrome.
Sarcoma, familial cancer syndrome of Li and Fraumeni. See Sarcoma family syndrome of Li and Fraumeni.
Sarcomas alveolar soft part, pleochromocytoma/paraganglioma vs., II(5):43
bone, hereditary retinoblastoma associated with, I(2):119
clear cell sarcoma
GI tract
gastrointestinal stromal tumor vs., II(6):20
molecular and cytogenic findings (table), III(3):2
kidney, Wilms tumor vs., II(7):56, II(7):61
malignant peripheral nerve sheath tumor vs., II(3):16
soft parts, molecular and cytogenic findings (table), III(3):2
esophageal squamous cell carcinoma vs., II(6):11
Ewing sarcoma. See Ewing sarcoma.
fibromyxoid, low-grade, molecular and cytogenic findings (table), III(3):2
fibrosarcoma. See Malignant fibrous histiocytoma.
gliosarcoma, meningioma vs., II(9):31
P.liii
leiomyosarcoma. See Leiomyosarcoma.
liposarcoma
classic angiomylipoma vs., II(7):35, II(7):37
molecular and cytogenic findings (table), III(3):3 (includes Bone and Soft Tissue and Bone and Soft Tissue)
PTEN-hamartoma tumor syndromes associated with, I(2):170
myofibroblastic sarcoma, low-grade, spindle cell rhabdomyosarcoma vs., II(3):33
myofibrosarcoma, molecular and cytogenic findings (table), III(3):3 (includes Bone and Soft Tissue and Bone and Soft Tissue)
myoinflammatory fibroblastic sarcoma, molecular and cytogenic findings (table), III(3):3 (includes Bone and Soft Tissue and Bone and Soft Tissue)
osteosarcoma. See Osteosarcoma.
primary, of lung, pleuropulmonary blastoma vs., II(10):26
soft tissue and bone, hereditary retinoblastoma associated with, I(2):119
Sarcomatoid carcinoma. See Squamous cell carcinoma, cutaneous.
Sarcomatoid spindle renal cell carcinoma, classic angiomyolipoma vs., II(7):35, II(7):37
Schneiderian papillomas, nasal cavity squamous cell carcinoma vs., II(4):4
Schwannian stroma-poor neuroblastic tumor. See Neuroblastoma.
cellular, malignant peripheral nerve sheath tumor vs., II(3):16
differential diagnosis, II(3):38
ependymoma vs., II(9):21
gastrointestinal, neurofibromatosis type 1 associated with, I(2):151
gastrointestinal stromal tumor vs., II(6):19
genetic findings in benign tumors (table), III(3):4
in schwannomatosis, I(2):177
malignant. See Malignant peripheral nerve sheath tumor.
meningioma vs., II(9):31
molecular features, II(3):39, II(3):41
variant, II(3):40
microscopic pathology, II(3):37, II(3):38
molecular aberrations in etiology, II(3):36
molecular and cytogenic findings (table), III(3):3 (includes Bone and Soft Tissue and Bone and Soft Tissue)
multiple schwannoma syndromes, II(3):36
neurofibromatosis type 2 associated with, I(2):158, I(2):159, I(2):161
rhabdoid predisposition syndrome associated with, I(2):172, I(2):173
variants, II(3):37, II(3):38
Differential diagnosis

Cutaneous melanoma vs. basal cell carcinoma vs. neuroblastoma-like schwannoma

Ancillary tests

SDHx

Associated with pheochromocytoma/paraganglioma syndromes associated with, I(2):81

Beckwith-Wiedemann syndrome vs.

Familial renal tumors in (table), III(7):6

Genetics and molecular biology

Baser et al (2006), III(9):11


Syndromes associated with

Risk syndromes associated with familial colon and rectum tumors by Serrated polyposis, III(7):20

Parathyroid hyperplasia. See Parathyroid hyperplasia.

Risk syndromes associated with familial colon and rectum tumors by Serrated polyposis, III(7):20

Sex cord-stromal tumors in (table)

Sertoli cell tumor familial sex cord-stromal tumors associated with, I(2):65

Peutz-Jeghers syndrome associated with, I(2):165

tumors with diffuse arrangement and pale and clear cytoplasm (table), III(7):20

tumors with glandular/tubular pattern (table), III(7):20

Seminoma, spermatogenic key immunohistochemical reactivity for GCTs and differential diagnosis (table), III(7):14

P. liv
tumors with diffuse arrangement and pale and clear cytoplasm (table), III(7):20

tumors with glandular/tubular pattern (table), III(7):20

Seminoma, spermatogenic key immunohistochemical reactivity for GCTs and differential diagnosis (table), III(7):14

tumors with diffuse arrangement and pale and clear cytoplasm (table), III(7):20

Sertoli cell tumor familial sex cord-stromal tumors associated with, I(2):65

Peutz-Jeghers syndrome associated with, I(2):165

tumors with diffuse arrangement and pale and clear cytoplasm (table), III(7):20

tumors with glandular/tubular pattern (table), III(7):20

tumors with oxyphilic cytoplasm (table), III(7):20

Severe congenital neutropenia dyskeratosis congenita vs., I(2):32
microscopic features, III(2):3

Predisposition to hematologic malignancy, II(2):41

Predisposition to myeloid neoplasms (table), III(2):2

Sex cord-stromal tumors familial, I(2):65

Ovarian pleuropulmonary blastoma associated with, I(10):25

with annular tubules, Peutz-Jeghers syndrome associated with, I(2):165

SF3B1 gene mutations, chronic lymphocytic leukemia/small lymphocytic lymphoma associated with, II(2):4

Shwachman-Diamond syndrome dyskeratosis congenita vs., I(2):32
microscopic features, III(2):3

Predisposition to myeloid neoplasms (table), III(2):2

Signet ring cell carcinoma colon, hereditary diffuse gastric cancer associated with, I(2):81

In ampullary adenocarcinoma, I(6):31

Simpson-Golabi-Behmel syndrome as Wilms tumor-associated syndrome, I(2):199

Beckwith-Wiedemann syndrome vs.

Familial renal tumors in (table), III(7):6

Genetics, III(7):55

Hepatoblastoma associated with, III(6):35

Increased risk of Wilms tumor in (table), I(2):199

Single nucleotide polymorphism, at 3p22.1, familial plasma cell myeloma associated with, I(2):62

Sinonasal squamous cell carcinoma. See also Nasal squamous cell carcinoma.

Infectious agents in etiology/pathogenesis, I(4):3

Skin manifestations

Ataxia-telangiectasia syndrome, I(2):3

Familial adenomatous polyposis, I(2):39

Neurofibromatosis type 1, I(2):151

Neurofibromatosis type 2, I(2):158

PTEN-hamartoma tumor syndromes, I(2):169

Tuberous sclerosis complex, I(2):181

Skin neoplasms associated with basal cell nevus syndrome/Gorlin syndrome, I(2):5

Associated with Birt-Hogg-Dubé syndrome, I(2):12, I(2):13

Basal cell carcinoma. See Basal cell carcinoma.

Cutaneous melanoma. See Cutaneous melanoma.

Cutaneous squamous cell carcinoma. See Squamous cell carcinoma.

Dyskeratosis congenita associated with, I(2):32

Hereditary syndromes associated with, I(1):4

Lynch syndrome associated with, I(2):131

Microscopic features, III(11):3

Nonmelanoma, xeroderma pigmentosum associated with, I(2):201

Sebaceous carcinoma. See Sebaceous carcinoma.

Selected cutaneous neoplasms and associated hereditary cancer syndromes (table), III(11):2

Selected hereditary cancer syndromes with skin manifestations (table), III(11):2

Skin papillomas, Costello syndrome associated with, I(2):24

Skin tag (achrocordon), associated with Birt-Hogg-Dubé syndrome, I(2):13
SMAD4 gene mutations, small bowel adenocarcinoma associated with, II(6):28
SMAD4 germ line mutations, in juvenile polyposis syndrome, II(2):122
Small bowel adenocarcinoma, II(6):28, II(6):29
differential diagnosis, II(6):29
familial syndromes associated with, (table), III(6):7
juvenile polyposis syndrome associated with, II(2):123
Lynch syndrome associated with, II(2):131
molecular genetic alterations, II(6):28
Peutz-Jeghers syndrome associated with, II(2):165
risk factors, II(6):28
Piv
Small bowel adenoma, familial syndromes associated with (table), III(6):7
Small bowel neoplasms
familial adenomatous polyposis associated with, I(2):39
familial neoplasia of esophagus, stomach, and small intestine (table), III(6):7
familial small intestinal tumors by syndromes (table), III(6):6
Small cell carcinoma. See Neuroendocrine carcinoma of lung.
Small round blue cell tumors, Wilms tumor vs., II(7):56
Small round cell tumor, desmoplastic alveolar rhabdomyosarcoma vs., II(3):32, II(3):33
molecular and cytogenetic findings (table), III(3):2
small blue round cell tumors of kidney (table), III(7):8
SMARCA4/BRG1 germline mutations, in rhabdoid predisposition syndrome, I(2):172
SMARCB1 gene, function of, I(2):177
SMARCB1 germline mutations, in schwannomatosis, I(2):176, II(2):177
Smooth muscle tumors
classic angiomyolipoma vs., II(7):35
hereditary leiomyomatosis and renal cell carcinoma associated with, I(2):87
Soft tissue manifestations of familial adenomatous polyposis, I(2):39
PTEN-hamartoma tumor syndromes, I(2):169
Soft tissue neoplasms, hereditary syndromes associated with, I(1):5
Soft tissue sarcomas
familial cancer syndromes with bone and soft tissue tumors (table), III(3):4
hereditary retinoblastoma associated with, I(2):119
Li-Fraumeni syndrome/Li-Fraumeni-like syndrome associated with, I(2):128

Soft tissue tumors
familial cancer syndromes with bone and soft tissue tumors (table), III(3):4
multiple endocrine neoplasia type 1 associated with, I(2):137
Solid cell nests, C-cell hyperplasia vs., III(5):108
Solid tumors
Fanconi anemia associated with, I(2):71
in ataxia-telangiectasia syndrome, I(2):3
Solitary fibrous tumor gastrointestinal stromal tumor vs., II(6):19
genetic findings in benign tumors (table), III(3):4
Solitary plasmacytoma of bone, plasma cell myeloma vs., II(2):53
Somatostatinoma
laboratory tests, II(5):63
prognosis, II(5):63
Somatostatinoma syndrome, in presentation of pancreatic endocrine tumor, II(5):62
Somatotropinoma syndrome, isolated familial, pituitary adenoma associated with, III(5):82
Sotos syndrome, Beckwith-Wiedemann syndrome vs., I(2):10
SOX9 gene mutations, basal cell carcinoma associated with, II(11):2
Spermatocytic seminoma
key immunohistochemical reactivity for GCTs and differential diagnosis (table), I(2):7:14
microscopic pathology, II(7):14
tumors with diffuse arrangement and pale and clear cytoplasm (table), III(7):20
Spindle cell carcinoma. See Squamous cell carcinoma, cutaneous.
Spindle cell melanoma, esophageal squamous cell carcinoma vs., II(6):11
Spindle cell squamous cell carcinoma, as variant of head and neck squamous cell carcinoma, II(4):4
Spitz nevus, cutaneous melanoma vs., II(11):10
Splenic marginal zone lymphoma, lymphoplasmacytic lymphoma/Waldenström macroglobulinemia vs., II(2):34
SPOP gene mutations, prostate carcinoma associated with, II(7):19
Sporadic chronic lymphocytic leukemia, familial chronic lymphocytic leukemia vs., I(2):45
Sporadic Hodgkin lymphoma, familial Hodgkin lymphoma vs., I(2):50
Sporadic medullary thyroid carcinoma, medullary thyroid carcinoma vs., II(5):113
Sporadic non-Hodgkin lymphoma, familial non-Hodgkin lymphoma vs., I(2):57

Sporadic parathyroid adenoma, familial isolated hyperparathyroidism vs., I(2):53
SPRY4 gene, familial testicular germ cell tumors associated with, I(2):64, I(2):65
Squamous cell carcinoma
basal cell carcinoma vs., III(11):4
II(11):7
esophageal squamous cell carcinoma vs., III(6):11
Fanconi anemia associated with, I(2):71
pheochromocytoma/paraganglioma vs., III(5):43
acantholytic, as variant of head and neck squamous cell carcinoma, II(4):4
differential diagnosis, II(11):14
etiology/pathogenesis
environmental exposure, II(11):12
genetics, II(11):13
immunohistochemical features, II(11):17
in Howel-Evans syndrome/keratosis palmare and plantares, with esophageal cancer, I(2):121
P.liv
microscopic features, II(11):15
microscopic features, variant, II(11):16
prognosis, II(11):13
sebaceous carcinoma vs., II(11):20
treatment, II(11):12
Squamous cell carcinoma, esophageal, II(6):10, II(6):11
differential diagnosis, II(6):11
familial syndromes associated with (table), III(6):7
genetics, II(6):10
II(4):7
cytogenetics and molecular genetics, II(4):4
differential diagnosis, II(4):4
etiology/pathogenesis, II(4):2, II(4):3
developmental, II(4):3
environmental exposure, II(4):3
genetic predisposition for head and neck SCC, II(4):2, II(4):3
infectious agents, II(4):3
genetic predisposition for, II(4):2, II(4):3
Bloom syndrome, II(4):2, II(4):3
dyskeratosis congenita, II(4):2
Fanconi anemia, II(4):2
eroderma pigmentosum, II(4):2
xeroderma pigmentosum, II(4):2
graphics of head and neck, II(4):5
histologic categories, II(4):4
histologic grades, II(4):4
nasal cavity squamous cell carcinoma (graphics), II(4):6
poorly differentiated, small blue round cell tumors of kidney (table), III(7):8

T

t(1;13)(p36;q14), in rhabdomyosarcoma, II(3):30
t(2;3)(q11.2;p21.21), associated with familial Hodgkin lymphoma, II(2):49
t(2;13)(q35;q14), in rhabdomyosarcoma, II(3):30
t(11;14)(q13;q32), in Mantle cell lymphoma, II(2):36
t(14;18), in diffuse large B-cell lymphoma, II(2):9
t(14;18)(q32;q21) in follicular lymphoma, II(2):17
resulting in BCL2 overexpression, in follicular lymphoma, II(2):14
Tamoxifen, for hereditary breast/ovarian cancer syndrome (BRCA1), II(2):74
Tangentially cut follicles, C-cell hyperplasia vs., II(5):108
TCAB1 gene, dyskeratosis congenita associated with, I(2):30
Telomerase complex, as possible site of gene for familial nonmedullary thyroid carcinoma, II(2):59
Telomere maintenance mutations, in familial acute myeloid leukemia, II(2):35
Temporal bone adenoma/adenocarcinoma. See Endolympathic sac tumor. P.lvi

Tenosynovial giant cell tumor, genetic findings in benign tumors (table), III(3):4
Teratoid/rhabdoid tumor, atypical medulloblastoma/CNS-PNET vs., II(9):26
rhabdoid predisposition syndrome associated with, I(2):172, I(2):173
Teratoma immature, Wilms tumor vs., II(7):56
macroscopic features, II(7):13
microscopic pathology, II(7):14
TERC gene mutations

dyskeratosis congenita associated with, I(2):30
familial acute myeloid leukemia associated with, I(2):35
squamous cell carcinoma of head and neck associated with, II(4):2
TERT gene mutations
dyskeratosis congenita associated with, I(2):30
familial acute myeloid leukemia associated with, I(2):35
squamous cell carcinoma of head and neck associated with, II(4):2
Testicular disorders, male breast carcinoma associated with, II(1):10
Testicular neoplasms

AJCC Staging System for Testicular Cancer (2010), III(7):21
cancer staging (graphics), III(7):22, III(7):23
familial testicular tumors (table), III(7):20
hereditary syndromes associated with, I(1):4
immunohistochemistry (graphics), III(7):24, III(7):25
normal testicular histoanatomy (graphics), III(7):22
tumors with diffuse arrangement and pale and clear cytoplasm (table), III(7):20
tumors with glandular/tubular pattern (table), III(7):20
tumors with oxyphilic cytoplasm (table), III(7):20
xeroderma pigmentosum associated with, I(2):201
Testicular Sertoli cell neoplasms, II(7):30, II(7):31, II(7):32, II(7):33
differential diagnosis, II(7):30, II(7):33
syndromes/familial Sertoli cell neoplasms, II(7):30
Testicular tumors. See Familial sex cord-stromal tumors; Familial testicular germ cell tumors.

THEM127 gene, pheochromocytoma/paraganglioma associated with, II(5):40, II(5):41
Therapy-related myeloid neoplasm, myeloid neoplasms vs., II(2):44
Thrombocytopenia, congenital amegakaryocytic microscopic features, II(2):3
predisposition to myeloid neoplasms (table), II(2):2
Thrombocytopenia absent radii, dyskeratosis congenita vs., I(2):32
Thymic and bronchial neuroendocrine tumor, multiple endocrine neoplasia type 1 associated with, I(2):137
Thyroid and parathyroid immunohistochemistry, III(5):12
Thyroid carcinoma cribriform morular, hereditary syndromes associated with, I(1):3
familial. See Familial thyroid carcinoma. familial nonmedullary thyroid carcinoma associated with, II(2):60
follicular. See Follicular thyroid carcinoma.
medullary. See Medullary thyroid carcinoma. nonmedullary. See Familial nonmedullary thyroid carcinoma.
pure familial papillary thyroid carcinoma (PTC), genetics, I(2):58, I(2):59
with oncocytic cells, hereditary hyperparathyroidism-jaw tumor syndrome associated with, I(2):84
Thyroid carcinoma with oxyphilia, genetics, I(2):59
Thyroid cysts, Birt-Hogg-Dubé syndrome associated with, I(2):13
Thyroid neoplasms
Birt-Hogg-Dubé syndrome associated with, I(2):13
C-cell hyperplasia. See C-cell hyperplasia.
hereditary syndromes associated with, I(1):3
Werner syndrome/progeria associated with, I(2):195
Thyroid nodules
Birt-Hogg-Dubé syndrome associated with, I(2):13
in PTEN-hamartoma tumor syndromes, I(2):169
Thyroid pathology in familial adenomatous polyposis and PTEN-hamartoma tumor syndromes, III(5):23
Thyroidectomy, prophylactic, ATA age recommendations for, depending on RET mutation (table), I(2):144, III(5):21
Thyroiditis, palpation, C-cell hyperplasia vs., II(5):108
TINF2 gene mutations
dyskeratosis congenita associated with, I(2):30
squamous cell carcinoma of head and neck associated with, II(4):2
TMEM127 gene mutations, hereditary paraganglioma/pheochromocytoma syndromes associated with, I(2):106
TMPRSS2 and ETS gene fusion, prostate carcinoma associated with, II(7):18
TMPRSS2:ERG gene fusion, prostate carcinoma associated with, II(7):18
Tongue neoplasms, xeroderma pigmentosum associated with, I(2):201
Tongue squamous cell carcinoma differential diagnosis, II(4):4
P.Iviii

etiology/pathogenesis
environmental exposure in, II(4):3
infectious agents in, II(4):3
Tooth manifestations, of familial adenomatous polyposis, I(2):39
TP53 gene, function of, I(2):127, II(1):4
TP53 gene mutations
adrenal cortical carcinoma associated with, II(5):12
breast cancer associated with (graphics), II(1):9
choroid plexus tumors associated with, II(9):17
follicular carcinoma associated with, II(5):102
laryngeal squamous cell carcinoma associated with, II(4):4
Li-Fraumeni syndrome/Li-Fraumeni-like syndrome associated with, I(2):127
malignant peripheral nerve sheath tumor associated with, II(3):16
oral squamous cell carcinoma associated with, II(4):4
pituitary carcinoma associated with, II(5):86
risk of breast cancer associated with (table), III(1):2
small bowel adenocarcinoma associated with, II(6):28
Transitional carcinoma. See Squamous cell carcinoma, head and neck.
renal. See Renal urothelial carcinoma.
Transitional cell carcinoma. See Bladder carcinoma; Ureter urothelial carcinoma.
Trichilemmomas, in PTEN-hamartoma tumor syndromes, I(2):169
Trichoblastoma, basal cell carcinoma vs., II(11):4, II(11):7
Trichoepithelioma, basal cell carcinoma vs., II(11):4
Trichothiodystrophy, xeroderma pigmentosum vs., I(2):202
Trilateral retinoblastoma syndrome, pineoblastoma associated with, II(9):34
Triphasic angiomyolipoma. See Angiomyolipoma.
Trisomy 13, increased risk of Wilms tumor in (table), I(2):199
Trisomy 18
hepatoblastoma associated with, II(6):35
increased risk of Wilms tumor in (table), I(2):199
TSC1 and TSC2 genes
involved in pancreatic tumorigenesis, III(5):9
pancreatic endocrine tumor associated with, II(5):61
ancillary tests (graphics), I(2):184
as hereditary or familial renal tumor syndrome, I(2):116
associated neoplasms, I(2):181
astrocytoma associated with, II(9):2
Birt-Hogg-Dubé syndrome vs., I(2):13, I(2):14
bone and soft tissue tumors associated with (table), III(3):4
diagnostic criteria, I(2):180
familial biliary tract, liver, and pancreas neoplasms in (table), III(6):3
familial cancer syndromes with lung neoplasms (table), III(10):2
familial renal tumors in (table), III(7):6
genetic syndromes and neoplasms involving eye and ocular adnexa (table), III(9):6
genetic syndromes associated with CNS neoplasms (table), III(9):2
genetics, I(2):180
graphic and microscopic features, I(2):183
in hereditary pancreatic cancer syndrome (table), I(2):101
lymphangiomyomatosis vs., I(10):13
nonneoplastic manifestations, I(2):181
pancreatic endocrine tumor associated with, II(5):61
pancreatic tumors as part of (table), III(5):9
selected cutaneous neoplasms and associated hereditary cancer syndromes (table), III(11):2
selected hereditary cancer syndromes with skin manifestations (table), III(11):2
von Hippel-Lindau syndrome vs., I(2):188
Tuberous sclerosis-associated angiomyolipoma, I(7):34
Turcot syndrome. See also Familial adenomatous polyposis.
as variant of familial adenomatous polyposis, I(2):40
astrocytoma associated with, II(9):2
hereditary syndromes associated with CNS neoplasms (table), III(9):2
Turcot syndrome type 2, medulloblastoma/CNS-PNET associated with, II(9):24
Tylosis as paraneoplastic phenomenon, acquired, Howel-Evans syndrome/keratosis palmaris and plantares, with esophageal cancer vs., I(2):121
with esophageal cancer. See Howel-Evans syndrome/keratosis palmaris and plantares, with esophageal cancer.
Tyrosinemia, familial biliary tract, liver, and pancreas neoplasms in (table), III(6):3

U
Ultraviolet-sensitive syndrome, xeroderma pigmentosum vs., I(2):202
Ureteral neoplasms
TSC1 and TSC2 genes
see also
Urothelial carcinoma
See Bladder carcinoma, histologic features.
carcinomas involving kidney &/or renal pelvis, III(7):18
classic angiomylipoma vs., II(7):35
Costello syndrome associated with, (I:2):24
Lynch syndrome associated with, (I:2):131
renal. See Renal urothelial carcinoma.
ureteral, II(7):10, II(7):11
Urothelial lesions with atypia, flat (table), III(7):2
Uterine adenosarcoma, hereditary hyperparathyroidism-jaw tumor syndrome associated with, (I:2):84
Uterine carcinoma poorly differentiated, bladder carcinoma vs., II(7):5
xeroderma pigmentosum associated with, (I:2):201
Uterine disease, benign, hereditary hyperparathyroidism-jaw tumor syndrome associated with, (I:2):84
Uterine neoplasms hereditary breast/ovarian cancer syndrome (BRCA1) associated with, (I:2):74
hereditary syndromes associated with, (I:1):5
Werner syndrome/progeria associated with, (I:2):195
Uterine smooth muscle tumors, hereditary leiomyomatosis and renal cell carcinoma associated with, (I:2):87
Uveal melanoma epidemiology, (I:2):66
Genetic syndromes and neoplasms involving eye and ocular adnexa (table), III(9):6
Genetic syndromes associated with CNS neoplasms (table), III(9):2
Genetics, (I:2):66

V
Verrucous carcinoma as variant of head and neck squamous cell carcinoma, (II:4):4
well-differentiated variant. See Squamous cell carcinoma, cutaneous.
VHL gene mutations clear cell renal cell carcinoma associated with, (II:7):38
endolymphatic sac tumor associated with, (II:4):8, (II:4):10
involved in pancreatic tumorigenesis, III(5):9
Pancreatic endocrine tumor associated with, (II:5):61
pheochromocytoma/paraganglioma associated with, (II:5):40
VHL germline mutations hereditary paraganglioma/pheochromocytoma syndrome associated with, (I:2):105
in von Hippel-Lindau syndrome, (I:2):186
VHL-associated paraganglioma/pheochromocytoma, risk management, (I:2):107
VIPoma in well-differentiated pancreatic endocrine tumor, (I:5):64
multiple endocrine neoplasia type 1 associated with, (I:2):137
VIPoma syndrome, in presentation of pancreatic endocrine tumor, (II:5):62
Viral hepatitis, hepatocellular carcinoma associated with, (II:6):38
as hereditary or familial renal tumor syndrome, (I:2):116
bone and soft tissue tumors associated with, (table), III(3):4
clear cell renal cell carcinoma associated with, (II:7):38
differential diagnosis, (I:2):188
endolymphatic sac tumor, (I:2):193
familial biliary tract, liver, and pancreas neoplasms in (table), III(6):3
familial cancer syndromes with gynecologic manifestations (table), III(8):2
familial renal tumors in (table), III(7):6
geneic predisposition to endolymphatic sac tumor, (I:2):4
Genetic syndromes and neoplasms involving eye and ocular adnexa (table), III(9):6
genetic syndromes associated with CNS neoplasms (table), III(9):2
Genetics, (I:2):66

W
WAGR syndrome
as Wilms tumor-associated syndrome, (I:2):198
Denys-Drash syndrome vs., (I:2):27
familial renal tumors in (table), III(7):6
geneic tumor syndromes and nonneoplastic ocular manifestations (table), III(9):6
genetics, (I:2):55
Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. See Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.
Warthin tumor case reports of salivary gland neoplasms with familial clustering (table), III(4):4
molecular changes described in salivary gland tumors (table), III(4):5
Werner syndrome. See Multiple endocrine neoplasia type 1.
Werner syndrome, atypical, Werner syndrome/progeria vs., (I:2):195
associated neoplasms, (I:2):195
bone and soft tissue tumors associated with, (table), III(3):4
clinical photographs, (I:2):197
diagnostic criteria, (I:2):196
familial follicular cell carcinoma in, (II:5):94
familial nonmedullary thyroid carcinoma associated with, (I:2):60, (II:5):92
familial nonmedullary thyroid carcinoma in familial cancer syndromes, III(5):22
familial thyroid carcinoma associated with, (II:5):90
follicular thyroid carcinoma associated with, (II:5):100, (II:5):103
genetic tumor syndromes and nonneoplastic ocular manifestations (table), III(9):6
Genetics, (I:2):59, (I:2):194
selected cutaneous neoplasms and associated hereditary cancer syndromes (table), III(11):2
selected hereditary cancer syndromes with skin manifestations (table), III(11):2
thyroid tumors in, II(5):93
Whipple disease, gastric adenocarcinoma vs., II(6):14
adrenal cortical neoplasms in children vs., II(5):20
Beckwith-Wiedemann syndrome associated with, I(2):9
Bloom syndrome associated with, I(2):17
classification after neoadjuvant therapy (SIOP), II(7):57
differential diagnosis, II(7):56, II(7):61
etiology/pathogenesis, II(7):54, II(7):55
familial WT, II(7):54, II(7):55
gene alterations, II(7):54
loss of heterozygosity, II(7):54
other significant gene abnormalities, II(7):54
sporadic WT, II(7):54
syndromes associated with WT, II(7):55
hereditary hyperparathyroidism-jaw tumor syndrome associated with, I(2):84
histologic criteria for subtyping after chemotherapy by SIOP, II(7):57
histologic features, II(7):56
anaplasia, II(7):56
blastemal cells, II(7):56
epithelial components, II(7):56
stromal components, II(7):56
teratoid WT, II(7):56
tumor necrosis, II(7):56
immunohistochemistry, II(7):60
in Denys-Drash syndrome, cancer risk management, I(2):27
in etiology of chondrosarcoma, II(3):2
microscopic features, II(7):58, II(7):59
nonsyndromic, Beckwith-Wiedemann syndrome vs., I(2):10
small blue round cell tumors of kidney (table), III(7):8
staging (graphics), II(7):60
staging system (COG), II(7):57
syndromic, Beckwith-Wiedemann syndrome vs., I(2):10
treatment, II(7):55
Wilms tumor, aniridia, genitourinary abnormalities, and mental retardation. See WAGR syndrome.
Wilms tumor, familial, I(2):68, I(2):69
cancer risk management, I(2):69
familial renal tumors in (table), III(7):6
genetics, I(2):68, I(2):69
increased risk of Wilms tumor in (table), I(2):199
associated syndromes, I(2):198
conditions with increased risk of Wilms tumor, I(2):199
overgrowth syndromes, I(2):199
Wnt pathway activation, β-catenin mutation associated, in hepatoblastoma, II(6):34
WRAP53 gene mutations, dyskeratosis congenita associated with, I(2):30
WRN gene mutations
follicular carcinoma associated with, II(5):102
hereditary cutaneous melanoma associated with, I(2):93
Werner syndrome/progeria associated with, I(2):194
WT1 gene mutations
Denys-Drash syndrome associated with, I(2):26
familial Wilms tumor associated with, I(2):68
Wilms tumor associated with, I(7):54
WTX gene mutations, Wilms tumor associated with, II(7):54

X
associated lesions (graphics), I(2):203
associated neoplasms, I(2):201
cancer risk management, I(2):201, I(2):202
differential diagnosis, I(2):202
familial cancer syndromes with lung neoplasms (table), III(10):2
genetic predisposition for squamous cell carcinoma of head and neck, II(4):2
genetic syndromes and neoplasms involving eye and ocular adnexa (table), III(9):6
genetics, I(2):200, I(2):201
head and neck neoplasms associated with (table), III(4):2
selected cutaneous neoplasms and associated hereditary cancer syndromes (table), III(11):2
selected hereditary cancer syndromes with skin manifestations (table), III(11):2
ultraviolet light action spectrum in etiology, I(2):201

Y
Yolk sac tumor
key immunohistochemical reactivity for GCTs and differential diagnosis (table), II(7):14
macroscopic features, II(7):13
microscopic pathology, II(7):14
tumors with diffuse arrangement and pale and clear cytoplasm (table), III(7):20
tumors with glandular/tubular pattern (table), III(7):20

Z
Z
Zinsser-Cole-Engman syndrome. See Dyskeratosis congenita.